PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Al-Zoubi, AM; Efimova, EV; Kaithamana, S; Martinez, O; El-Idrissi, MEA; Dogan, RE; Prabhakar, BS				Al-Zoubi, AM; Efimova, EV; Kaithamana, S; Martinez, O; El-Idrissi, MEA; Dogan, RE; Prabhakar, BS			Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN PROTEIN; GENE-EXPRESSION; FACTOR RECEPTOR; FAMILY MEMBERS; SERPIN CRMA; CELL-DEATH; PATHWAYS; INHIBITION; ENCODES; VIRUSES	We identified a novel cDNA (IG20) that is homologous to cDNAs encoding a protein differentially expressed in normal and neoplastic cells (DENN-SV) and human MADD (MAPK-activating death domain-containing protein). Furthermore, we show that the above variants most likely result from alternative splicing of a single gene. Functional analyses of these variants in permanently transfected HeLa cells revealed that IG20 and DENN-SV render them more susceptible or resistant to tumor necrosis factor alpha (TNF-alpha)-induced apoptosis, respectively. All variants tested could interact with TNF receptor 1 and activate ERK and nuclear factor KB. However, relative to control cells, only cells expressing IG20 showed enhanced TNF-alpha -induced activation of caspase-8 and -3, whereas cells expressing DENN-SV showed either reduced or no caspase activation. Transfection of these cells with a cDNA encoding CrmA maximally inhibited apoptosis in HeLa-IG20 cells. Our results show that IG20 can promote TNF-alpha -induced apoptosis and activation of caspase-8 and -3 and suggest that it may play a novel role in the regulation of the pleiotropic effects of TNF-alpha through alternative splicing.	Univ Illinois, Dept Microbiol & Immunol MC 790, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol MC 790, Rm E-709,Bldg 935, Chicago, IL 60612 USA.			Martinez, Osvaldo/0000-0001-7335-4342				Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cunningham SJ, 1996, THESIS U TEXAS MED B; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Krajcsi P, 1998, SEMIN CELL DEV BIOL, V9, P351, DOI 10.1006/scdb.1998.0244; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; OBrien DP, 1997, MOL CELL BIOL, V17, P3477, DOI 10.1128/MCB.17.7.3477; Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898-6568(98)00018-7; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; VAN AD, 1996, SCIENCE, V274, P787; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Walter U, 2000, EUR J IMMUNOL, V30, P1224, DOI 10.1002/1521-4141(200004)30:4<1224::AID-IMMU1224>3.0.CO;2-B; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	27	51	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47202	47211		10.1074/jbc.M104835200	http://dx.doi.org/10.1074/jbc.M104835200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577081	hybrid			2022-12-27	WOS:000172768500072
J	Borggrefe, T; Davis, R; Bareket-Samish, A; Kornberg, RD				Borggrefe, T; Davis, R; Bareket-Samish, A; Kornberg, RD			Quantitation of the RNA polymerase II transcription machinery in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; IDENTIFICATION; MEDIATOR; PROTEINS; DOMAIN; GENOME	TAP tags and dot blot analysis have been used to measure the amounts of RNA polymerase II transcription proteins in crude yeast extracts. The measurements showed comparable amounts of RNA polymerase II, TFIIE, and TFIIF, lower levels of TBP and TFIIB, and still lower levels of Mediator and TFIIH. These findings are consistent with the presumed roles of the transcription proteins, but do not support the idea of their recruitment in a single large complex to RNA polymerase II promoters. The approach employed here can be readily extended to quantitative analysis of the entire yeast proteome.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu			NIGMS NIH HHS [GM 36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Kornberg RD, 1998, COLD SPRING HARB SYM, V63, P229, DOI 10.1101/sqb.1998.63.229; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Puig O, 1998, YEAST, V14, P1139; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315	24	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47150	47153		10.1074/jbc.M109581200	http://dx.doi.org/10.1074/jbc.M109581200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591727	hybrid			2022-12-27	WOS:000172768500065
J	Musgrove, EA; Hunter, LJK; Lee, CSL; Swarbrick, A; Hui, R; Sutherland, RL				Musgrove, EA; Hunter, LJK; Lee, CSL; Swarbrick, A; Hui, R; Sutherland, RL			Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(KP1) association with cyclin E-Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; C-MYC; TRANSCRIPTION FACTOR; ECTOPIC EXPRESSION; DEPENDENT KINASES; S-PHASE; PROGRESSION; ACTIVATION; P27(KIP1); GROWTH	Long-term growth inhibition, arrest in G(1) phase and reduced activity of both cyclin D1-Cdk4 and cyclin E-Cdk2 are elicited by progestin treatment of breast cancer cells in culture. Decreased cyclin expression, induction of p18(INK4c) and increased association of the CDK inhibitors p21(WAF1/Cip1) and p27(Kip1) with cyclin E-Cdk2 have been implicated in these responses. To determine the role of decreased cyclin expression, T-47D human breast cancer cells constitutively expressing cyclin D1 or cyclin E were treated with the progestin ORG 2058. Overexpression of cyclin E had only a modest effect on growth inhibition. Although cyclin E expression was maintained during progestin treatment, cyclin E-Cdk2 activity decreased by similar to 60%. This was accompanied by p27(Kip1) association with cyclin E-Cdk2, indicating that both cyclin E down-regulation and p27(Kip1) recruitment contribute to the decrease in activity. In contrast, overexpression of cyclin D1 induced progestin resistance and cell proliferation continued despite decreased cyclin E-Cdk2 activity. Progestin treatment of cyclin overexpressing cells was associated with increased p27(Kip1) association with cyclin E-Cdk2. Thus the ability of cyclin D1 to confer progestin resistance does not depend on sequestration of p27(Kip1) away from cyclin E-Cdk2, providing evidence for a critical function of cyclin D1 other than as a high-capacity "sink" for p27(Kip1). These data indicate that regulation of cyclin D1 is a critical element of progestin inhibition in breast cancer cells and suggest that breast cancers overexpressing cyclin D1 may respond poorly to progestin therapy.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Musgrove, EA (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	e.musgrove@garvan.org.au	Swarbrick, Alexander/E-6107-2010; Sutherland, Robert L/A-8378-2008	Swarbrick, Alexander/0000-0002-3051-5676; 				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; HARLOW E, 1986, ANTIBODIES LAB MANUA; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; JIANG W, 1993, ONCOGENE, V8, P3447; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; KEYOMARSI K, 1994, CANCER RES, V54, P380; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen KE, 1999, CANCER RES, V59, P2297; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Pacilio C, 1998, CANCER RES, V58, P871; Pelosio P, 1996, ANN ONCOL, V7, P695; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rose PG, 1996, NEW ENGL J MED, V335, P640, DOI 10.1056/NEJM199608293350907; Scott KA, 1997, BRIT J CANCER, V76, P1288, DOI 10.1038/bjc.1997.550; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soni R, 2001, JNCI-J NATL CANCER I, V93, P436, DOI 10.1093/jnci/93.6.436; SUTHERLAND RL, 1988, CANCER RES, V48, P5084; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; vanDiest PJ, 1997, AM J PATHOL, V150, P705; Veronesi U, 1995, OXFORD TXB ONCOLOGY, P1243; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	53	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47675	47683		10.1074/jbc.M106371200	http://dx.doi.org/10.1074/jbc.M106371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590147	hybrid			2022-12-27	WOS:000172768500130
J	Scaffidi, P; Bianchi, ME				Scaffidi, P; Bianchi, ME			Spatially precise DNA bending is an essential activity of the Sox2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG DOMAIN; SRY; PROTEIN; BINDING; ENHANCER; ACTIVATION; DEPENDS; COMPLEX; OCT-3; GENES	Sox proteins, a subclass of high mobility group box proteins, govern cell fate decisions by acting both as classical transcription factors and architectural components of chromatin. We aimed to demonstrate that the DNA bending activity of Sox proteins is essential to regulate gene expression. We focused on mouse Sox2, which participates in the transactivation of the Fgf4 (fibroblast growth factor (4) under bar) gene in the inner cell mass of the blastocyst. We generated six substitutions in the high mobility group box of Sox2. One mutant showed a reduced DNA bending activity on the Fgf4 enhancer (46 degrees instead of 80 degrees), which resulted in more powerful transactivation compared with the wild type protein. We then selected two single-base mutations in the Fgf4 enhancer that make the DNA less bendable by the Sox2 protein. Again, a different DNA bend (0 degrees and 42 degrees instead of 80 degrees) resulted in a different activation of transcription, but in this case reduced bending corresponded to decreased transcription. We found that the opposite effect on transcription of similar DNA bending angles is due to a 20 degrees difference in the relative orientation of the DNA bends, proving that a correct three-dimensional geometry of enhanceosome complexes is necessary to promote transcription.	San Raffaele Sci Inst, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, Fac Med, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Bianchi, ME (corresponding author), San Raffaele Sci Inst, Via Olgettina 58, I-20132 Milan, Italy.		Bianchi, Marco Emilio/K-3417-2018; Scaffidi, Paola/GRS-9019-2022	Bianchi, Marco Emilio/0000-0002-5329-6445; Scaffidi, Paola/0000-0002-3642-4193				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; Collignon J, 1996, DEVELOPMENT, V122, P509; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; Engelhorn M, 1998, MOL MICROBIOL, V30, P431, DOI 10.1046/j.1365-2958.1998.01078.x; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	26	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47296	47302		10.1074/jbc.M107619200	http://dx.doi.org/10.1074/jbc.M107619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584012	hybrid			2022-12-27	WOS:000172768500084
J	Volpicelli, LA; Lah, JJ; Levey, AI				Volpicelli, LA; Lah, JJ; Levey, AI			Rab5-dependent trafficking of the m4 muscarinic acetylcholine receptor to the plasma membrane, early endosomes, and multivesicular bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; RAB GTPASES; CELL LINE; ENDOCYTOSIS; INTERNALIZATION; SUBTYPE; STIMULATION; COMPLEXES; NEURONS; STORAGE	The m4 subtype of muscarinic acetylcholine receptor regulates many physiological processes and is a novel therapeutic target for neurologic and psychiatric disorders. However, little is known about m4 regulation because of the lack of pharmacologically selective ligands. A crucial component of G protein-coupled receptor regulation is intracellular trafficking. We thus used subtype-specific antibodies and quantitative immunocytochemistry to characterize the intracellular trafficking of m4. We show that following carbachol stimulation, m4 co-localizes with transferrin, and the selective marker of early endosomes, EEA1. In addition, m4 intracellular localization depends on Rab5 activity. The dominant negative Rab5S34N inhibits m4 endocytosis initially following carbachol stimulation, and reduces the size of m4 containing vesicles. The constitutively active Rab5Q79L enhances m4 intracellular distribution, even in unstimulated cells. Rab5Q79L also produces strikingly enlarged vacuoles, which by electron microscopy contain internal vesicles, suggesting that they are multivesicular bodies. m4 localizes both to the perimeter and interior of these vacuoles. In contrast, transferrin localizes only to the vacuole perimeter, demonstrating divergence of m4 trafficking from the pathway followed by constitutively endocytosed transferrin. We thus suggest a novel model by which multivesicular bodies sort G protein-coupled receptors from a transferrin-positive recycling pathway to a nonrecycling, possibly degradative pathway.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University	Levey, AI (corresponding author), Emory Univ, Sch Med, Dept Neurol, Woodruff Mem Res Bldg, Atlanta, GA 30322 USA.		Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030454] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30454] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; Bernard V, 1999, J NEUROSCI, V19, P10237; BERNHEIM L, 1992, P NATL ACAD SCI USA, V89, P9544, DOI 10.1073/pnas.89.20.9544; BURRY RW, 1993, J NEUROSCI RES, V36, P241, DOI 10.1002/jnr.490360302; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Felder CC, 2001, LIFE SCI, V68, P2605, DOI 10.1016/S0024-3205(01)01059-1; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLYNN DD, 1995, J NEUROCHEM, V64, P1888; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GHOSH RN, 1994, J CELL SCI, V107, P2177; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Koenig JA, 1996, MOL PHARMACOL, V49, P351; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krudewig R, 2000, J NEUROCHEM, V74, P1721, DOI 10.1046/j.1471-4159.2000.0741721.x; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Rodman JS, 2000, J CELL SCI, V113, P183; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P5184, DOI 10.1073/pnas.74.11.5184; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Szekeres PG, 1998, J NEUROCHEM, V70, P1694; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155	31	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47590	47598		10.1074/jbc.M106535200	http://dx.doi.org/10.1074/jbc.M106535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590149	hybrid			2022-12-27	WOS:000172768500119
J	Girardi, ACC; Degray, BC; Nagy, T; Biemesderfer, D; Aronson, PS				Girardi, ACC; Degray, BC; Nagy, T; Biemesderfer, D; Aronson, PS			Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase TV in the renal proximal tubule.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; BRUSH-BORDER; REGULATORY PROTEIN; APICAL MEMBRANE; SODIUM-CHANNEL; CELL; EZRIN; CD26; PHOSPHORYLATION; EXPRESSION	In an attempt to identify proteins that assemble with the apical membrane Na+-H+ exchanger isoform NHE3, we generated monoclonal antibodies (in-Abs) against affinity-purified NHE3 protein complexes isolated from solubilized renal microvillus membrane vesicles. Hybridomas were selected based on their ability to immunoprecipitate NHE3. We have characterized in detail one of the m-Abs (1D11) that specifically co-precipitated NHE3 but not villin or NaPi-2. Western blot analyses of microvillus membranes and immunoelectron microscopy of kidney sections showed that mAb 1D11 recognizes a 110-kDa protein highly expressed on the apical membrane of proximal tubule cells. Immunoaffinity chromatography was used to isolate the antigen against which mAb 1D11 is directed. N-terminal sequencing of the purified protein identified it as dipeptidyl peptidase IV (DPPIV) (EC 3.4.14.15), which was confirmed by assays of DPPIV enzyme activity. We also evaluated the distribution of the NHE3-DPPIV complex in microdomains of rabbit renal brush border. In contrast to the previously described NHE3-megalin complex, which principally resides in a dense membrane population (coated pits) in which NHE3 is inactive, the NHE3-DPPIV complex was predominantly in the microvillar fraction in which NHE3 is active. Serial precipitation experiments confirmed that anti-megalin and anti-DPPIV antibodies co-precipitate different pools of NHE3. Taken together, these studies revealed an unexpected association of the brush border Na+-H+ exchanger NHE3 with dipeptidyl peptidase IV in the proximal tubule. These findings raise the possibility that association with DPPIV may affect NHE3 surface expression and/or activity.	Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Aronson, PS (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, 333 Cedar St,LMP 2073,POB 208029, New Haven, CT 06520 USA.		Girardi, Adriana/C-4827-2012; Girardi, Adriana C. C./B-4334-2014	Girardi, Adriana/0000-0003-3715-6917; Girardi, Adriana C. C./0000-0003-3715-6917	NIDDK NIH HHS [DK-33793] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033793, R01DK033793] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; ALPERN RJ, 1993, J LAB CLIN MED, V122, P137; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; Bertog M, 1999, J PHYSIOL-LONDON, V521, P3, DOI 10.1111/j.1469-7793.1999.00003.x; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 2001, J BIOL CHEM, V276, P10161, DOI 10.1074/jbc.M008098200; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; BIEMESDERFER D, 1997, AM J PHYSIOL, V273, P289; Choi JY, 2000, J CLIN INVEST, V105, P1141, DOI 10.1172/JCI9260; Girardi Adriana C. C., 2000, Journal of the American Society of Nephrology, V11, p4A; HINO M, 1976, CLIN CHEM, V22, P1256; HONG WJ, 1989, EXP CELL RES, V182, P256, DOI 10.1016/0014-4827(89)90296-6; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Ohtsuki T, 2000, J DERMATOL SCI, V22, P152, DOI 10.1016/S0923-1811(99)00081-X; Paillard M, 1997, EXP NEPHROL, V5, P277; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RODMAN JS, 1986, J CELL BIOL, V102, P77, DOI 10.1083/jcb.102.1.77; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SZASZ G, 1969, CLIN CHEM, V15, P124; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; Wang T, 1999, AM J PHYSIOL-RENAL, V277, pF298, DOI 10.1152/ajprenal.1999.277.2.F298; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	42	97	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46671	46677		10.1074/jbc.M106897200	http://dx.doi.org/10.1074/jbc.M106897200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590171	hybrid			2022-12-27	WOS:000172573100155
J	Ruiz, FA; Marchesini, N; Seufferheld, M; Govindjee; Docampo, R				Ruiz, FA; Marchesini, N; Seufferheld, M; Govindjee; Docampo, R			The polyphosphate bodies of Chlamydomonas reinhardtii possess a proton-pumping pyrophosphatase and axe similar to acidocalcisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-PYROPHOSPHATASE; CONTRACTILE VACUOLE; INORGANIC POLYPHOSPHATE; PLASMA-MEMBRANE; ATPASE; PLANT; FRACTIONATION; REVERSIBILITY; LOCALIZATION; GRANULES	Acidocalcisomes are acidic calcium storage compartments described initially in trypanosomatid and apicomplexan parasites. In this work, we describe organelles with properties similar to acidocalcisomes in the green alga Chlamydomonas reinhardtii. Nigericin and NH4Cl released Ca-45(2+) from preloaded permeabilized cells, suggesting the incorporation of a significant amount of this cation into an acidic compartment. X-ray microanalysis of the electron-dense vacuoles or polyphosphate bodies of C. reinhardtii showed large amounts of phosphorus, magnesium, calcium, and zinc. Immunofluorescence microscopy, using antisera raised against a peptide sequence of the vacuolar type proton pyrophosphatase (H+-PPase) of Arabidopsis thaliana which is conserved in the C. reinhardtii enzyme, indicated localization in the plasma membrane, in intracellular vacuoles, and the contractile vacuole where it colocalized with the vacuolar proton ATPase (V-H+-ATPase). Purification of the electron-dense vacuoles using iodixanol density gradients indicated a preferential localization of the H+-PPase and the V-H+-ATPase activities in addition to high concentrations of PPi and short and long chain polyphosphate, but lack of markers for mitochondria and chloroplasts. In isolated electron-dense vacuoles, PPi-driven proton translocation was stimulated by potassium ions and inhibited by the PPi analog aminomethylenediphosphonate. Potassium fluoride, imidodiphosphate, N,N'-dicyclohexylcarbodiimide, and N-ethylmaleimide also inhibited PPi hydrolysis in the isolated organelles in a dose-dependent manner. These results indicate that the electron-dense vacuoles of C. reinhardtii are very similar to acidocalcisomes with regard to their chemical composition and the presence of proton pumps. Polyphosphate was also localized to the contractile vacuole by 4',6-diamidino-2-phenylindole staining, suggesting, with the immunochemical data, a link between these organelles and the acidocalcisomes.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Dept Plant Biol, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Govindjee, Govindjee/ABF-3362-2021; Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015	NIAID NIH HHS [AI-23259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN RA, 1980, CAN J MICROBIOL, V26, P912, DOI 10.1139/m80-158; Ault-Riche D, 1998, J BACTERIOL, V180, P1841; CLARK TB, 1959, J PROTOZOOL, V6, P227, DOI 10.1111/j.1550-7408.1959.tb04362.x; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Facanha AR, 1998, PLANT PHYSIOL, V116, P1487, DOI 10.1104/pp.116.4.1487; FOK AK, 1993, J CELL SCI, V106, P1103; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; HARRIS EH, 1988, CHLAMYDOMONAS SOURCE, P25; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; Hirata T, 2000, J BIOL CHEM, V275, P386, DOI 10.1074/jbc.275.1.386; KLEIN U, 1983, PLANT PHYSIOL, V72, P481, DOI 10.1104/pp.72.2.481; Komine Y, 1996, J PHOTOCH PHOTOBIO B, V36, P301, DOI 10.1016/S1011-1344(96)07386-1; Komine Y, 2000, PLANTA, V210, P897, DOI 10.1007/s004250050695; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KREUZBERG K, 1987, PHYSIOL PLANTARUM, V69, P481, DOI 10.1111/j.1399-3054.1987.tb09229.x; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LINDER JC, 1979, J CELL BIOL, V83, P371, DOI 10.1083/jcb.83.2.371; LONG AR, 1995, J PLANT PHYSIOL, V146, P629, DOI 10.1016/S0176-1617(11)81925-5; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Meyer A., 1904, BOT Z, V62, P113; Moniakis J, 1999, J CELL SCI, V112, P405; NIYOGI KK, 1977, PLANT CELL, V4, P1369; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; PEREZCATINEIRA JR, 2001, NEW TRENDS INORGANIC, P129; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; Robinson DG, 1996, PLANTA, V198, P95, DOI 10.1007/BF00197591; Robinson DG, 1998, BOT ACTA, V111, P108, DOI 10.1111/j.1438-8677.1998.tb00685.x; Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; Siderius M, 1996, J PHYCOL, V32, P402, DOI 10.1111/j.0022-3646.1996.00402.x; WIAME JM, 1947, BIOCHIM BIOPHYS ACTA, V1, P234, DOI 10.1016/0006-3002(47)90137-6; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	40	145	151	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46196	46203		10.1074/jbc.M105268200	http://dx.doi.org/10.1074/jbc.M105268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579086	hybrid			2022-12-27	WOS:000172573100096
J	Chen, CP; Hsu, CH; Su, NY; Lin, YC; Chiou, SH; Wu, SH				Chen, CP; Hsu, CH; Su, NY; Lin, YC; Chiou, SH; Wu, SH			Solution structure of a Kunitz-type chymotrypsin inhibitor isolated from the elapid snake Bungarus fasciatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; TICK ANTICOAGULANT PEPTIDE; BETA-PROTEIN PRECURSOR; NMR SOLUTION STRUCTURE; FACTOR-XA INHIBITOR; CRYSTAL-STRUCTURE; DENDROTOXIN-K; DOMAIN; VENOM	Bungarus fasciatus fraction IX (BF9), a chymotrypsin inhibitor, consists of 65 amino acid residues with three disulfide bridges. It was isolated from the snake venom of B. fasciatus by ion-exchange chromatography and belongs to the bovine pancreatic trypsin inhibitor (BPTI)-like superfamily. It showed a dissociation constant of 5.8 x 10(-8) mr with a-chymotrypsin as measured by a BIAcore binding assay system. The isothermal titration calorimetry revealed a 1:1 binding stoichiometry between this inhibitor and chymotrypsin and apparently no binding with trypsin. We further used CD and NMR to determine the solution structure of this venom-derived chymotrypsin inhibitor. The three-dimensional NMR solution structures of BF9 were determined on the basis of 582 restraints by simulated annealing and energy minimization calculations. The final set of 10 NMR structures was well defined, with average root mean square deviations of 0.47 Angstrom for the backbone atoms in the secondary structure regions and 0.86 Angstrom for residues The side chains of Phe(23), Tyr(24), Tyr(25), Phe(35), and Phe(47) exhibited many long-range nuclear Overhauser effects and were the principal components of the hydrophobic core in BF9. To gain insight into the structure-function relationships among proteins in the BPTI-like superfamily, we compared the three-dimensional structure of BF9 with three BPTI-like proteins that possess distinct biological functions. These proteins possessed similar secondary structure elements, but the loop regions and beta -turn were different from one another. Based on residues at the functional site of each protein, we suggest that the flexibility, rigidity, and variations of the amino acid residues in both the loop and beta -turn regions are related to their biological functions.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, CP (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.		HSU, CHUN-HUA/W-4554-2019; Chen, Chinpan/O-4202-2018	HSU, CHUN-HUA/0000-0002-0008-7383; 				ANTUCH W, 1994, FEBS LETT, V352, P251, DOI 10.1016/0014-5793(94)00941-4; ANTUCH W, 1993, EUR J BIOCHEM, V212, P675, DOI 10.1111/j.1432-1033.1993.tb17705.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; BERNDT KD, 1993, J MOL BIOL, V234, P735, DOI 10.1006/jmbi.1993.1623; BRUNGER AT, 1998, XPLOR VERSION 98; DUFTON MJ, 1985, EUR J BIOCHEM, V153, P647, DOI 10.1111/j.1432-1033.1985.tb09349.x; DUNWIDDIE CT, 1992, BIOCHEMISTRY-US, V31, P12126, DOI 10.1021/bi00163a022; FORAY MF, 1993, EUR J BIOCHEM, V211, P813, DOI 10.1111/j.1432-1033.1993.tb17613.x; Gilquin B, 1999, PROTEINS, V34, P520, DOI 10.1002/(SICI)1097-0134(19990301)34:4<520::AID-PROT11>3.0.CO;2-N; HARVEY AL, 1991, DENDROTOXINS SNAKE T, P131; HEALD SL, 1991, BIOCHEMISTRY-US, V30, P10467, DOI 10.1021/bi00107a015; HYBERTS SG, 1987, EUR J BIOCHEM, V164, P625, DOI 10.1111/j.1432-1033.1987.tb11173.x; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIMWILBY MSL, 1995, PROTEIN SCI, V4, P178; LIU CS, 1983, INT J PEPT PROT RES, V21, P209; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RITONJA A, 1983, BIOCHIM BIOPHYS ACTA, V746, P138, DOI 10.1016/0167-4838(83)90067-5; SASAKI T, 1984, J BIOCHEM-TOKYO, V95, P1009, DOI 10.1093/oxfordjournals.jbchem.a134688; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; Sorensen MD, 1997, BIOCHEMISTRY-US, V36, P10439, DOI 10.1021/bi9705570; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; vandeLocht A, 1996, EMBO J, V15, P6011, DOI 10.1002/j.1460-2075.1996.tb00989.x; WAGNER G, 1982, J MOL BIOL, V160, P343, DOI 10.1016/0022-2836(82)90180-2; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Zweckstetter M, 1996, STRUCTURE, V4, P195, DOI 10.1016/S0969-2126(96)00022-6	38	55	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45079	45087		10.1074/jbc.M106182200	http://dx.doi.org/10.1074/jbc.M106182200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11562364	Green Published, hybrid			2022-12-27	WOS:000172406700098
J	Fukushima, T; Takata, M; Morrison, C; Araki, R; Fujimori, A; Abe, M; Tatsumi, K; Jasin, M; Dhar, PK; Sonoda, E; Chiba, T; Takeda, S				Fukushima, T; Takata, M; Morrison, C; Araki, R; Fujimori, A; Abe, M; Tatsumi, K; Jasin, M; Dhar, PK; Sonoda, E; Chiba, T; Takeda, S			Genetic analysis of the DNA-dependent protein kinase reveals an inhibitory role of Ku in late S-G(2) phase DNA double-strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CELL ANTIGEN RECEPTOR; V(D)J RECOMBINATION; LIGASE-IV; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; CATALYTIC SUBUNIT; VERTEBRATE CELLS; MAMMALIAN-CELLS; IN-VIVO	Two major complementary double-strand break (DSB) repair pathways exist in vertebrates, homologous recombination (HR), which involves Rad54, and non-homologous end joining, which requires the DNA-dependent protein kinase (DNA-PK). DNA-PK comprises a catalytic subunit (DNA-PKcs) and a DNA-binding Ku70 and Ku80 heterodimer. To define the activities of individual DNA-PK components in DSB repair, we targeted the DNA-PKcs gene in chicken DT40 cells. DNA-PKcs deficiency caused a DSB repair defect that was, unexpectedly, suppressed by KU70 disruption. We have shown previously that genetic ablation of Ku70 confers RAD54-dependent radioresistance on S-G(2) phase cells, when sister chromatids are available for HR repair. To test whether direct interference by Ku70 with HR might explain the Ku70(-/-)/DNA-PKcs(-/-/-) radioresistance, we monitored HR activities directly in Ku- and DNA-PKcs-deficient cells. The frequency of intrachromosomal HR induced by the I-SceI restriction enzyme was increased in the absence of Ku but not of DNA-PKcs. Significantly, abrogation of HR activity by targeting RAD54 in Ku 70(-/-) or DNA-PKcs(-/-/-) cells caused extreme radiosensitivity, suggesting that the relative radioresistance seen with loss of Ku70 was because of HR-dependent repair pathways. Our findings suggest that Ku can interfere with HR-mediated DSB repair, perhaps competing with HR for DSB recognition.	Kyoto Univ, Fac Med, CREST Res Project, Sakyo Ku, Kyoto 6068501, Japan; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Natl Inst Radiol Sci, Inage Ku, Chiba 2638555, Japan; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Kyoto Univ, Grad Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Sakyo Ku, Kyoto 6068507, Japan	Japan Science & Technology Agency (JST); Kyoto University; University of Edinburgh; National Institutes for Quantum Science & Technology; Memorial Sloan Kettering Cancer Center; Cornell University; Kyoto University	Takeda, S (corresponding author), Kyoto Univ, Fac Med, CREST Res Project, Sakyo Ku, Konoe Yoshida, Kyoto 6068501, Japan.		Morrison, Ciaran/B-6568-2008; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Abe, Masumi/0000-0003-1550-2006; Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991				Adachi N, 2001, P NATL ACAD SCI USA, V98, P12109, DOI 10.1073/pnas.201271098; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fujimori A, 2000, IMMUNOGENETICS, V51, P965, DOI 10.1007/s002510000227; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	37	134	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44413	44418		10.1074/jbc.M106295200	http://dx.doi.org/10.1074/jbc.M106295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577093	Green Submitted, hybrid			2022-12-27	WOS:000172406700010
J	Yamasaki, S; Nishida, K; Hibi, M; Sakuma, M; Shiina, R; Takeuchi, A; Ohnishi, H; Hirano, T; Saito, T				Yamasaki, S; Nishida, K; Hibi, M; Sakuma, M; Shiina, R; Takeuchi, A; Ohnishi, H; Hirano, T; Saito, T			Docking protein Gab2 is phosphorylated by ZAP-70 and negatively regulates T cell receptor signaling by recruitment of inhibitory molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEINS; ACTIVATION; CYTOKINE; KINASE; SHP-2; TRANSDUCTION	To maintain various T cell responses and immune equilibrium, activation signals triggered by T cell antigen receptor (TCR) must be regulated by inhibitory signals. Gab2, an adaptor protein of the insulin receptor substrate-1 family, has been shown to be involved in the downstream signaling from cytokine receptors. We investigated the functional role of Gab2 in TCR-mediated signal transduction. Gab2 was phosphorylated by ZAP-70 and co-precipitated with phosphoproteins, such as ZAP-70, LAT, and CD3 zeta, upon TCR stimulation. Overexpression of Gab2 in Jurkat cells or antigen-specific T cell hybridomas resulted in the inhibition of NF-AT activation, interleukin-2 production, and tyrosine phosphorylation. The structure-function relationship of Gab2 was analyzed by mutants of Gab2. The Gab2 mutants lacking SHP-2-binding sites mostly abrogated the inhibitory activity of Gab2, but its inhibitory function was restored by fusing to active SHP-2 as a chimeric protein. A mutant with defective phosphatidylinositol 3-kinase binding capacity also impaired the inhibitory activity, and the pleckstrin homology domain-deletion mutant revealed a crucial function of the pleckstrin homology domain for localization to the plasma membrane. These results suggest that Gab2 is a substrate of ZAP-70 and functions as a switch molecule toward inhibition of TCR signal transduction by mediating the recruitment of inhibitory molecules to the TCR signaling complex.	Chiba Univ, Grad Sch Med, Chiba 2608670, Japan; Osaka Univ, Grad Sch Med, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan	Chiba University; Osaka University	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Chiba 2608670, Japan.		Hibi, Masahiko/I-6215-2014; Hirano, Toshio/C-8194-2009	Hibi, Masahiko/0000-0002-9142-4444; Takeuchi, Arata/0000-0003-0412-533X				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; CANTRELL D, 1994, CURR OPIN IMMUNOL, V6, P380, DOI 10.1016/0952-7915(94)90116-3; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HANSBURG D, 1983, J IMMUNOL, V131, P319; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 2001, J BIOL CHEM, V276, P12257, DOI 10.1074/jbc.M010590200; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kitamura T, 1998, INT J HEMATOL, V67, P351; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NAKAMURA K, 1994, BBA-MOL CELL RES, V1224, P495, DOI 10.1016/0167-4889(94)90287-9; Nakaseko C, 1999, J EXP MED, V190, P765, DOI 10.1084/jem.190.6.765; NAKAYAMA T, 1988, EUR J IMMUNOL, V18, P761, DOI 10.1002/eji.1830180516; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Newman DK, 2001, BLOOD, V97, P2351, DOI 10.1182/blood.V97.8.2351; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Olcese L, 1996, J IMMUNOL, V156, P4531; Pratt JC, 2000, J IMMUNOL, V165, P4158, DOI 10.4049/jimmunol.165.8.4158; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Saito T, 1998, CURR OPIN IMMUNOL, V10, P313, DOI 10.1016/S0952-7915(98)80170-2; Samelson LE, 1995, ANN NY ACAD SCI, V766, P157, DOI 10.1111/j.1749-6632.1995.tb26659.x; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Stofega MR, 2000, J BIOL CHEM, V275, P28222; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	55	70	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45175	45183		10.1074/jbc.M105384200	http://dx.doi.org/10.1074/jbc.M105384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572860	hybrid			2022-12-27	WOS:000172406700110
J	Zhou, MS; Nekhai, S; Bharucha, DC; Kumar, A; Ge, H; Price, DH; Egly, JM; Brady, JN				Zhou, MS; Nekhai, S; Bharucha, DC; Kumar, A; Ge, H; Price, DH; Egly, JM; Brady, JN			TFIIH inhibits CDK9 phosphorylation during human immunodeficiency virus type 1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; TAT-ASSOCIATED KINASE; HUMAN CYCLIN T1; PROTEINS SPECIFICALLY ASSOCIATE; ELONGATION-FACTOR-B; FACTOR P-TEFB; HIV-1 TAT; ACTIVATING KINASE; SACCHAROMYCES-CEREVISIAE	Tat stimulates human immunodeficiency virus, type 1 (HIV-1), transcription elongation by recruitment of the human transcription elongation factor P-TEFb, consisting of CDK9 and cyclin T1, to the TAR RNA structure. It has been demonstrated further that CDK9 phosphorylation is required for high affinity binding of Tat/P-TEFb to the TAR RNA structure and that the state of P-TEFb phosphorylation may regulate Tat transactivation. We now demonstrate that CDK9 phosphorylation is uniquely regulated in the HIV-1 preinitiation and elongation complexes. The presence of TFIIH in the HIV-1 preinitiation complex inhibits CDK9 phosphorylation. As TFIIH is released from the elongation complex between +14 and +36, CDK9 phosphorylation is observed. In contrast to the activity in the "soluble" complex, phosphorylation of CDK9 is increased by the presence of Tat in the transcription complexes. Consistent with these observations, we have demonstrated that purified TFIIH directly inhibits CDK9 autophosphorylation. By using recombinant TFIIH subcomplexes, our results suggest that the XPB subunit of TFIIH is responsible for this inhibition of CDK9 phosphorylation. Interestingly, our results further suggest that the phosphorylated form of CDK9 is the active kinase for RNA polymerase II carboxyl-terminal domain phosphorylation.	NCI, Virus Tumor Biol Sect, Basic Res Lab, Div Basic Sci,NIH, Bethesda, MD 20892 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; NICHHD, Mol Embryol Lab, Bethesda, MD 20892 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU De Strasbour, France	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Iowa; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Basic Res Lab, Div Basic Sci,NIH, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov	, nekhai/AFO-2652-2022; Price, David H/F-6173-2010; , nekhai/AAW-3105-2021	Price, David/0000-0002-5597-385X				Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Bieniasz PD, 1999, J VIROL, V73, P5777, DOI 10.1128/JVI.73.7.5777-5786.1999; Bieniasz PD, 1999, MOL CELL BIOL, V19, P4592, DOI 10.1128/mcb.19.7.4592; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Boris-Lawrie Kathleen A., 1992, Gene Expression, V2, P215; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Chen D, 1999, MOL CELL BIOL, V19, P2863; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; GARRIGA J, 1996, BIOCHEM J, V320, P4; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGAN DO, 1998, CANC J SCI AM S1, V4, P77; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Parada CA, 1999, EMBO J, V18, P3688, DOI 10.1093/emboj/18.13.3688; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; POON RYC, 1994, J CELL SCI, V107, P2789; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Taube R, 2000, J VIROL, V74, P892, DOI 10.1128/JVI.74.2.892-898.2000; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Yankulov K, 1998, CURR BIOL, V8, pR447, DOI 10.1016/S0960-9822(98)70289-1; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zhau MS, 2000, VIROLOGY, V268, P452, DOI 10.1006/viro.1999.0177; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	105	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44633	44640		10.1074/jbc.M107466200	http://dx.doi.org/10.1074/jbc.M107466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572868	hybrid			2022-12-27	WOS:000172406700041
J	Willment, JA; Gordon, S; Brown, GD				Willment, JA; Gordon, S; Brown, GD			Characterization of the human beta-glucan receptor and its alternatively spliced isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR; LECTIN SITE; COMPLEMENT; BINDING; ACTIVATION; CLONING; CELLS; GENE; PHAGOCYTOSIS; LEUKOCYTES	beta -1,3-D-Glucans are biological response modifiers with potent effects on the immune system. A number of receptors are thought to play a role in mediating these responses, including murine Dectin-1, which we recently identified as a beta -glucan receptor. In this study we describe the characterization of the human homologue of this receptor and show that it is structurally and functionally similar to the mouse receptor. The human beta -glucan receptor is a type II transmembrane receptor with a single extracellular carbohydrate recognition domain and an immunoreceptor tyrosine activation motif in its cytoplasmic tail. The human beta -glucan receptor is widely expressed and functions as a pattern recognition receptor, recognizing a variety of beta -1,3- and/or beta -1,6-linked glucans as well as intact yeast. In contrast to the murine receptor, the human receptor mRNA is alternatively spliced, resulting in two major (A and B) and six minor isoforms. The two major isoforms differ by the presence of a stalk region separating the carbohydrate recognition domain from the transmembrane region and are the only isoforms that are functional for beta -glucan binding. The human receptor also binds T-lymphocytes at. a site distinct from the beta -glucan binding site, indicating that this receptor can recognize both endogenous and exogenous ligands.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Brown, GD (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	gbrown@molbiol.ox.ac.uk	brown, gordon/B-4249-2012	brown, gordon/0000-0002-0287-5383; Willment, Janet/0000-0002-7040-0857				Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; Battle J, 1998, BIOCHEM BIOPH RES CO, V249, P499, DOI 10.1006/bbrc.1998.9175; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; COOK JA, 1982, INFECT IMMUN, V37, P1261, DOI 10.1128/IAI.37.3.1261-1269.1982; CZOP JK, 1986, PATHOL IMMUNOPATH R, V5, P286, DOI 10.1159/000157022; CZOP JK, 1978, J IMMUNOL, V120, P1132; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; Furukawa H, 1998, IMMUNOGENETICS, V48, P87, DOI 10.1007/s002510050407; Gough PJ, 1998, J LIPID RES, V39, P531; Hernanz-Falcon P, 2001, IMMUNOGENETICS, V53, P288, DOI 10.1007/s002510100326; Itoh W, 1997, MEDIAT INFLAMM, V6, P267, DOI 10.1080/09629359791596; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lian RH, 1998, J IMMUNOL, V161, P2301; Llera AS, 2001, J BIOL CHEM, V276, P7312, DOI 10.1074/jbc.M008573200; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Muller A, 1996, J IMMUNOL, V156, P3418; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2; ROSS GD, 1985, J IMMUNOL, V134, P3307; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Thornton BP, 1996, J IMMUNOL, V156, P1235; Tone M, 2001, P NATL ACAD SCI USA, V98, P1751, DOI 10.1073/pnas.98.4.1751; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WILLIAMS DL, 1978, J RETICULOENDOTH SOC, V23, P479; WILLIAMS DL, 1991, CARBOHYD RES, V219, P203, DOI 10.1016/0008-6215(91)89052-H; Williams DL, 1996, CLIN IMMUNOTHER, V5, P392, DOI 10.1007/BF03259335; Yokota K, 2001, GENE, V272, P51, DOI 10.1016/S0378-1119(01)00528-5; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	36	241	258	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43818	43823		10.1074/jbc.M107715200	http://dx.doi.org/10.1074/jbc.M107715200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11567029	hybrid			2022-12-27	WOS:000172297700045
J	Yoon, KS; Bobst, C; Hemann, CF; Hille, R; Tabita, FR				Yoon, KS; Bobst, C; Hemann, CF; Hille, R; Tabita, FR			Spectroscopic and functional properties of novel 2[4Fe-4S] cluster-containing ferredoxins from the green sulfur bacterium Chlorobium tepidum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGENOBACTER-THERMOPHILUS TK-6; PYROCOCCUS-FURIOSUS FERREDOXIN; 2 4FE-4S CLUSTERS; HYPERTHERMOPHILIC ARCHAEON; METHANOBACTERIUM-THERMOAUTOTROPHICUM; AZOTOBACTER-VINELANDII; RHODOBACTER-CAPSULATUS; REDUCTION POTENTIALS; THERMOTOGA-MARITIMA; CHROMATIUM-VINOSUM	Two distinct ferredoxins, Fd I and Fd II, were isolated and purified to homogeneity from photoautotrophically grown Chlorobium tepidum, a moderately thermophilic green sulfur bacterium that assimilates carbon dioxide by the reductive tricarboxylic acid cycle. Both ferredoxins serve a crucial role as electron donors for reductive carboxylation, catalyzed by a key enzyme of this pathway, pyruvate synthase/pyruvate ferredoxin oxidoreductase. The reduction potentials of Fd I and Fd II were determined by cyclic voltammetry to be -514 and -584 mV, respectively, which are more electronegative than any previously studied Fds in which two [4Fe-4S] clusters display a single transition. Further spectroscopic studies indicated that the CD spectrum of oxidized Fd I closely resembled that of Fd Il; however, both spectra appeared to be unique relative to ferredoxins studied previously. Double integration of the EPR signal of the two Fds yielded approximately similar to2.0 spins per molecule, compatible with the idea that C. tepidum Fd I and Fd II accept 2 electrons upon reduction. These results suggest that the C. tepidum Fd I and Fd Il polypeptides each contain two bound [4Fe-4S] clusters. C. tepidum Fd I and Fd II are novel 2[4Fe-4S] Fds, which were shown previously to function as biological electron donors or acceptors for C. tepidum pyruvate synthase/pyruvate ferredoxin oxidoreductase (Yoon, K.-S., Hille, R., Hemann, C. F., and Tabita, F. R. (1999) J. Biol. Chem. 274, 29772-29778). Kinetic measurements indicated that Fd I had similar to2.3-fold higher affinity than Fd IL The results of amino acid sequence alignments, molecular modeling, oxidation-reduction potentials, and spectral properties strongly indicate that the C. tepidum Fds are chimeras of both clostridial-type and chromatium-type Fds, suggesting that the two Fds are likely intermediates in the evolutional development of 2[4Fe-4S] clusters compared with the well described clostridial and chromatium types.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Plant Mol Biol Biotechnol Program, Columbus, OH 43210 USA; Ohio State Univ, Prot Res Grp, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.			Hemann, Craig/0000-0002-7380-4072	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058481] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58481] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; Boll M, 2000, BIOCHEMISTRY-US, V39, P4929, DOI 10.1021/bi9927890; Brereton PS, 1998, BIOCHEMISTRY-US, V37, P7351, DOI 10.1021/bi972864b; Brereton PS, 1999, BIOCHEMISTRY-US, V38, P10594, DOI 10.1021/bi990671d; BUCHANAN BB, 1969, BIOCHIM BIOPHYS ACTA, V189, P46, DOI 10.1016/0005-2728(69)90223-0; Camba R, 2000, BIOCHEMISTRY-US, V39, P10587, DOI 10.1021/bi000832+; CARTER KR, 1980, J BIOL CHEM, V255, P4213; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; CHEN JS, 1979, ANAL BIOCHEM, V93, P216, DOI 10.1016/S0003-2697(79)80140-2; CHEN JS, 1977, ANAL BIOCHEM, V79, P157, DOI 10.1016/0003-2697(77)90390-6; CHEN K, 1997, J BIOL CHEM, V274, P36479; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DARIMONT B, 1994, EMBO J, V13, P1772, DOI 10.1002/j.1460-2075.1994.tb06445.x; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; EVANS MCW, 1966, P NATL ACAD SCI USA, V55, P928, DOI 10.1073/pnas.55.4.928; EVANS MCW, 1965, P NATL ACAD SCI USA, V53, P1420, DOI 10.1073/pnas.53.6.1420; Florin L, 2001, J BIOL CHEM, V276, P6125, DOI 10.1074/jbc.M008470200; Furdui C, 2000, J BIOL CHEM, V275, P28494, DOI 10.1074/jbc.M003291200; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HUGHES NJ, 1995, J BACTERIOL, V177, P3953, DOI 10.1128/jb.177.14.3953-3959.1995; Ishii M, 1996, BIOSCI BIOTECH BIOCH, V60, P1513, DOI 10.1271/bbb.60.1513; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; JOUANNEAU Y, 1993, J BIOL CHEM, V268, P10636; Jung YS, 1999, J BIOL CHEM, V274, P2978, DOI 10.1074/jbc.274.5.2978; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Menon AL, 1998, BIOCHEMISTRY-US, V37, P12838, DOI 10.1021/bi980979p; Menon S, 1997, BIOCHEMISTRY-US, V36, P8484, DOI 10.1021/bi970403k; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; Morelli X, 2000, BIOCHEMISTRY-US, V39, P2530, DOI 10.1021/bi992306s; MORENO SNJ, 1984, J BIOL CHEM, V259, P8252; MOULIS JM, 1984, BIOCHEMISTRY-US, V23, P6605, DOI 10.1021/bi00321a050; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; Moulis JM, 1996, FEBS LETT, V380, P287, DOI 10.1016/0014-5793(96)00062-2; Nakajima Y, 1998, J BIOCHEM-TOKYO, V123, P521; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PIEULLE L, 1995, BBA-PROTEIN STRUCT M, V1250, P49, DOI 10.1016/0167-4838(95)00029-T; Saeki K, 1996, J BIOL CHEM, V271, P31399, DOI 10.1074/jbc.271.49.31399; Schut GJ, 2001, METHOD ENZYMOL, V331, P144; Seo D, 2001, BBA-BIOENERGETICS, V1503, P377, DOI 10.1016/S0005-2728(00)00245-0; SIREVAG R, 1977, ARCH MICROBIOL, V112, P35, DOI 10.1007/BF00446651; SMITH ET, 1990, J BIOL CHEM, V265, P14371; Smith ET, 2001, J BIOL INORG CHEM, V6, P227, DOI 10.1007/s007750000179; SMITH ET, 1994, BIOCHEMISTRY-US, V33, P1008, DOI 10.1021/bi00170a020; STEIGERWALD VJ, 1992, P NATL ACAD SCI USA, V89, P6929, DOI 10.1073/pnas.89.15.6929; Sticht H, 1998, PROG BIOPHYS MOL BIO, V70, P95, DOI 10.1016/S0079-6107(98)00027-3; TANAKA M, 1974, BIOCHEMISTRY-US, V13, P2953, DOI 10.1021/bi00711a026; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAHL RC, 1987, J BIOL CHEM, V262, P10489; Wahlund TM, 1997, J BACTERIOL, V179, P4859, DOI 10.1128/jb.179.15.4859-4867.1997; WAHLUND TM, 1991, ARCH MICROBIOL, V156, P81, DOI 10.1007/BF00290978; Yoon KS, 1999, J BIOL CHEM, V274, P29772, DOI 10.1074/jbc.274.42.29772; Yoon KS, 1997, BIOSCI BIOTECH BIOCH, V61, P510, DOI 10.1271/bbb.61.510; Yoon KS, 1997, ARCH MICROBIOL, V167, P275, DOI 10.1007/s002030050443; Yoon KS, 1996, J BACTERIOL, V178, P3365, DOI 10.1128/jb.178.11.3365-3368.1996; Yoon KS, 1996, FEMS MICROBIOL LETT, V139, P139, DOI 10.1111/j.1574-6968.1996.tb08193.x; ZEIKUS JG, 1977, J BACTERIOL, V132, P604, DOI 10.1128/JB.132.2.604-613.1977; Zhou ZH, 1997, BIOCHEMISTRY-US, V36, P10892, DOI 10.1021/bi9708141	63	29	30	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44027	44036		10.1074/jbc.M107852200	http://dx.doi.org/10.1074/jbc.M107852200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11568186	hybrid			2022-12-27	WOS:000172297700071
J	Zhang, M; Chen, WG; Smith, SM; Napoli, JL				Zhang, M; Chen, WG; Smith, SM; Napoli, JL			Molecular characterization of a mouse short chain dehydrogenase/reductase active with all-trans-retinol in intact cells, mRDH1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; GENE-EXPRESSION; BINDING-PROTEIN; ACID RECEPTORS; ALDEHYDE DEHYDROGENASE; CDNA CLONING; SUBSTRATE; IDENTIFICATION; RAT; RECOGNITION	Metabolic activation of retinol (vitamin A) via sequential actions of retinol and retinal dehydrogenases pro. duces the active metabolite all-trans-retinoic acid. This work reports cDNA cloning, enzymatic characterization, function in a reconstituted path of all-trans-retinoic acid biosynthesis in cell culture, and mRNA expression patterns in adult tissues and embryos of a mouse retinol dehydrogenase, RDH1. RDH1 represents a new member of the short chain dehydrogenase/reductase superfamily that differs from other mouse RDH in relative activity with all-trans and cis-retinols. RDH1 has a multifunctional catalytic nature, as do other short chain dehydrogenase/reductases. In addition to retinol dehydrogenase activity, RDH1 has strong 3 alpha -hydroxy and weak 17 beta -hydroxy steroid dehydrogenase activities. RDH1 has widespread and intense mRNA expression in tissues of embryonic and adult mice. The mouse embryo expresses RDH1 as early as 7.0 days post-coitus, and expression is especially intense within the neural tube, gut, and neural crest at embryo day 10.5. Cells cotransfected with RDH1 and any one of three retinal dehydrogenase isozymes synthesize all-trans-retinoic acid from retinol, demonstrating that RDH1 contributes to a path of all-trans-retinoic acid biosynthesis in intact cells. These characteristics are consistent with RDH1 functioning in a path of all-trans-retinoic acid biosynthesis starting early during embryogenesis.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of California System; University of California Berkeley; University of Wisconsin System; University of Wisconsin Madison	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009090] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47839] Funding Source: Medline; NIEHS NIH HHS [ES09090] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; Bailey TL, 1997, J STEROID BIOCHEM, V62, P29, DOI 10.1016/S0960-0760(97)00013-7; BAKER ME, 1994, STEROIDS, V59, P248, DOI 10.1016/0039-128X(94)90109-0; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Bok D, 1999, NEURON, V23, P412, DOI 10.1016/S0896-6273(00)80791-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HSU LC, 1994, GENOMICS, V24, P333, DOI 10.1006/geno.1994.1624; Huang XF, 2000, J BIOL CHEM, V275, P29452, DOI 10.1074/jbc.M000562200; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; Maden M, 2000, P NUTR SOC, V59, P65, DOI 10.1017/S0029665100000082; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Napoli JL, 2001, MOL CELL ENDOCRINOL, V171, P103, DOI 10.1016/S0303-7207(00)00392-0; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Schoonjans K, 1996, J LIPID RES, V37, P907; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; VONESCH JL, 1994, DEV DYNAM, V199, P199, DOI 10.1002/aja.1001990305; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; WILKINSON DG, 1998, IN SITU HYBRIDIZATIO; Zhai Y, 1997, J CELL PHYSIOL, V173, P36, DOI 10.1002/(SICI)1097-4652(199710)173:1<36::AID-JCP5>3.0.CO;2-K; ZHAO D, 1996, EUR J BIOCHEM, V240, P5	40	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44083	44090		10.1074/jbc.M105748200	http://dx.doi.org/10.1074/jbc.M105748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562362	hybrid			2022-12-27	WOS:000172297700078
J	Kotsonis, P; Frohlich, LG; Raman, CS; Li, HY; Berg, M; Gerwig, R; Groehn, V; Kang, YH; Al-Masoudi, N; Taghavi-Moghadam, S; Mohr, D; Munch, U; Schnabel, J; Martasek, P; Masters, BSS; Strobel, H; Poulos, T; Matter, H; Pfleiderer, W; Schmidt, HHHW				Kotsonis, P; Frohlich, LG; Raman, CS; Li, HY; Berg, M; Gerwig, R; Groehn, V; Kang, YH; Al-Masoudi, N; Taghavi-Moghadam, S; Mohr, D; Munch, U; Schnabel, J; Martasek, P; Masters, BSS; Strobel, H; Poulos, T; Matter, H; Pfleiderer, W; Schmidt, HHHW			Structural basis for pterin antagonism in nitric-oxide synthase - Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC PHYSICOCHEMICAL PARAMETERS; DIRECTED QUANTITATIVE STRUCTURE; MICE LACKING; L-ARGININE; HOMOLOGOUS PROTEINS; L-THIOCITRULLINE; TETRAHYDROBIOPTERIN; INHIBITOR; NO; POTENT	Pathological nitric oxide (NO) generation in sepsis, inflammation, and stroke may be therapeutically controlled by inhibiting NO synthases (NOS). Here we targeted the (6R)-5,6,7,8-tetrahydro-L-biopterin (H(4)Bip)binding site of NOS, which, upon cofactor binding, maximally increases enzyme activity and NO production from substrate L-arginine. The first generation of H(4)Bip-based NOS inhibitors employed a 4-amino pharmacophore of H(4)Bip analogous to antifolates such as methotrexate. We developed a novel series of 4-oxo-pteridine derivatives that were screened for inhibition against neuronal NOS (NOS-I) and a structure-activity relationship was determined. To understand the structural basis for pterin antagonism, selected derivatives were docked into the NOS pterin binding cavity. Using a reduced 4-oxo-pteridine scaffold, derivatives with certain modifications such as electron-rich aromatic phenyl or benzoyl groups at the 5- and 6-positions, were discovered to markedly inhibit NOS-I, possibly due to hydrophobic and electrostatic interactions with Phe(462) and Ser(104), respectively, within the pterin binding pocket. One of the most effective 4-oxo compounds and, for comparisons an active 4-amino derivative, were then co-crystallized with the endothelial NOS (NOS-III) oxygenase domain and this structure solved to confirm the hypothetical binding modes. Collectively, these findings suggest (i) that, unlike the antifolate principle, the 4-amino substituent is not essential for developing pterin-based NOS inhibitors and (ii), provide a steric and electrostatic basis for their rational design.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Texas, Sch Med, Struct Biol Ctr MSB 6 128, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Program Macromol Struct, Irvine, CA 92697 USA; Univ Konstanz, Fac Chem, D-78434 Constance, Germany; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Aventis Pharma, Res Chem Frankfurt, D-65926 Frankfurt, Germany	University of Wurzburg; University of Texas System; University of California System; University of California Irvine; University of Konstanz; University of Texas System; University of Texas Health San Antonio; Sanofi-Aventis	Kotsonis, P (corresponding author), Novartis Inst Med Sci, 5 Gower Pl, London WC1E 6BS, England.	peter.kotsonis@pharma.novartis.com; Harald.Schmidt@pharma.med.uni-giessen.de	Martásek, Pavel/G-6622-2017; Schmidt, Harald HHW/B-1549-2008	Martásek, Pavel/0000-0001-6165-4444; Schmidt, Harald HHW/0000-0003-0419-5549; Raman, C. S./0000-0002-1036-3193; Prof.Dr. Al-Masoudi, Najim/0000-0001-6811-191X				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAUGH CM, 1964, J ORG CHEM, V29, P3610, DOI 10.1021/jo01035a042; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; BOYLE PH, 1980, CHEM BER-RECL, V113, P1514, DOI 10.1002/cber.19801130431; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brickmann J., 1987, TAGUNGSBER VORTRAGST, P93; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FREY C, 1994, J BIOL CHEM, V269, P26083; Frohlich LG, 1999, J MED CHEM, V42, P4108, DOI 10.1021/jm981129a; FURCHGOTT R F, 1988, P401; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GHOSE AK, 1986, J COMPUT CHEM, V7, P565, DOI 10.1002/jcc.540070419; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Griffith O. W., 1996, METHODS NITRIC OXIDE, P187; HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359; HEIDEN W, 1993, J COMPUT CHEM, V14, P246, DOI 10.1002/jcc.540140212; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; Huang H, 1999, J MED CHEM, V42, P3147, DOI 10.1021/jm990111c; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KATO K, 1996, Patent No. 737671; KATSURA Y, 1997, Patent No. 9702254; KEIL M, 1988, J MOL MODEL, V4, P335; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Komarov AM, 2000, FREE RADICAL BIO MED, V28, P739, DOI 10.1016/S0891-5849(00)00156-8; Kotsonis P, 1999, BIOCHEM J, V340, P745, DOI 10.1042/0264-6021:3400745; KWON NS, 1989, J BIOL CHEM, V264, P20496; MACDONALD JE, 1996, Patent No. 0624588; MACDONALD JE, 1996, Patent No. 9601817; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; NARAYANAN K, 1995, J BIOL CHEM, V270, P11103, DOI 10.1074/jbc.270.19.11103; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SRINIVASAN N, 1993, PROTEIN ENG, V6, P501, DOI 10.1093/protein/6.5.501; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P385, DOI 10.1093/protein/1.5.385; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; *SYBYL, 1999, MOL MOD PACK VERS 6; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Traub H, 1999, PTERIDINES, V10, P79; VISWANADHAN VN, 1989, J CHEM INF COMP SCI, V29, P163, DOI 10.1021/ci00063a006; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Werner ER, 2000, HANDB EXP PHARMACOL, V143, P137	72	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49133	49141		10.1074/jbc.M011469200	http://dx.doi.org/10.1074/jbc.M011469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11590164	hybrid			2022-12-27	WOS:000173922100068
J	Bhowmick, NA; Zent, R; Ghiassi, M; McDonnell, M; Moses, HL				Bhowmick, NA; Zent, R; Ghiassi, M; McDonnell, M; Moses, HL			Integrin beta(1) signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II RECEPTOR; CELLS; PROTEIN; BINDING; TRANSDIFFERENTIATION; TRANSCRIPTION; TRANSDUCTION; FIBRONECTIN; REQUIREMENT; MEDIATOR	Transforming growth factor-beta (TGF-beta) can induce epithelial to mesenchymal transdifferentiation (EMT) in mammary epithelial cells. TGF-beta -meditated EMT involves the stimulation of a number of signaling path. ways by the sequential binding of the type II and type I serine/threonine kinase receptors, respectively. Integrins comprise a family of heterodimeric extracellular matrix receptors that mediate cell adhesion and intracellular signaling, hence making them crucial for EMT progression. In light of substantial evidence indicating TGF-beta regulation of various beta (1), integrins and their extracellular matrix ligands, we examined the cross-talk between the TGF-P and integrin signal transduction pathways. Using an inducible system for the expression of a cytoplasmically truncated dominant negative TGF-beta type II receptor, we blocked TGF-beta -mediated growth inhibition, transcriptional activation, and EMT progression. Dominant negative TGF-beta type II receptor expression inhibited TGF-P signaling to the SMAD and AKT pathways, but did not block TGF-beta -mediated p38MAPK activation. Interestingly, blocking integrin beta (1) function inhibited TGF-p-mediated p383LAPK activation and EMT progression. Limiting p38MAPK activity through the expression of a dominant negative-p38MAPK also blocked TGF-p-mediated EMT. In summary, TGF-beta -mediated p38MAPK activation is dependent on functional integrin beta (1), and p38MAPK activity is required but is not sufficient to induce EMT.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	NATIONAL CANCER INSTITUTE [R35CA042572, R01CA085492, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85492, CA 68485, CA 42572] Funding Source: Medline; NIDDK NIH HHS [DK 20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Brown LA, 1999, ONCOGENE, V18, P7985, DOI 10.1038/sj.onc.1203197; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; KUMAR NM, 1995, EXP CELL RES, V221, P385, DOI 10.1006/excr.1995.1389; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MOSES HL, 1981, CANCER RES, V41, P2842; Piek E, 1999, J CELL SCI, V112, P4557; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; Tafazoli F, 2000, INFECT IMMUN, V68, P5335, DOI 10.1128/IAI.68.9.5335-5343.2000; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	36	316	331	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46707	46713		10.1074/jbc.M106176200	http://dx.doi.org/10.1074/jbc.M106176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590169	hybrid			2022-12-27	WOS:000172768500006
J	Chellaiah, MA; Biswas, RS; Yuen, D; Alvarez, UM; Hruska, KA				Chellaiah, MA; Biswas, RS; Yuen, D; Alvarez, UM; Hruska, KA			Phosphatidylinositol 3,4,5-trisphosphate directs association of Src homology 2-containing signaling proteins with gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FOCAL ADHESION KINASE; PHOSPHATASE PTP-PEST; BONE-RESORPTION; SH3 DOMAINS; CELL-MIGRATION; C-SRC; OSTEOCLAST CYTOSKELETON; CYTOPLASMIC DOMAIN; INTEGRIN FUNCTIONS; ACTIN-FILAMENTS	Podosomes are adhesion structures in osteoclasts and are structurally related to focal adhesions mediating cell motility during bone resorption. Here we show that gelsolin coprecipitates some of the focal adhesion-associated proteins such as c-Src, phosphoinositide 3-kinase (PI3K), p130(Cas), focal adhesion kinase, integrin alpha (v)beta (3), vinculin, talin, and paxillin. These proteins were inducibly tyrosine-phosphorylated in response to integrin activation by osteopontin. Previous studies have defined unique biochemical properties of gelsolin related to phosphatidylinositol 3,4,5-trisphosphate in osteoclast podosomes, and here we demonstrate phosphatidylinositol 3,4,5-trisphosphate/gelsolin function in mediating organization of the podosome signaling complex. Overlay and GST pull-down assays demonstrated strong phosphatidylinositol 3,4,5-trisphosphate-PI3K interactions based on the Src homology 2 domains of PI3K. Furthermore, lipid extraction of lysates from activated osteoclasts eliminated interaction between gelsolin, c-Src, PI3K, and focal adhesion kinase despite equal amounts of gelsolin in both the lipid-extracted and unextracted experiment. The cytoplasmic protein tyrosine phosphatase (PTP)-proline-glutamic acid-serine-threonine amino acid sequences (PEST) was also found to be associated with gelsolin in osteoclast podosomes and with stimulation of alpha (v)beta (3)-regulated phosphorylation of PTP-PEST. We conclude that gelsolin plays a key role in recruitment of signaling proteins to the plasma membrane through phospholipid-protein interactions and by regulation of their phosphorylation status through its association with PTP-PEST. Because both gelsolin deficiency and PI3K inhibition impair bone resorption, we conclude that phosphatidylinositol 3,4,5-trisphosphate-based protein interactions are critical for osteoclast function.	Univ Maryland, Dept Oral & Craniofacial Biol Sci, Baltimore, MD 21201 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	University System of Maryland; University of Maryland Baltimore; Washington University (WUSTL)	Chellaiah, MA (corresponding author), Univ Maryland, Dept Oral & Craniofacial Biol Sci, 666 W Baltimore St, Baltimore, MD 21201 USA.	mac001@dental.umaryland.edu			NIAMS NIH HHS [AR 46292, AR 41677] Funding Source: Medline; NIDDK NIH HHS [DK 09976] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR046292, R01AR041677, R01AR046292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Baron Roland, 1993, P445; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; De Deyne PG, 1998, J CELL SCI, V111, P2729; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gopalakrishna P, 2000, J CELL BIOCHEM, V77, P517, DOI 10.1002/(SICI)1097-4644(20000615)77:4<517::AID-JCB1>3.3.CO;2-Y; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Gupta A, 1999, J BONE MINER RES, V14, pS182; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hawiger J, 1997, CURR OPIN IMMUNOL, V9, P189, DOI 10.1016/S0952-7915(97)80134-3; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Isenberg G, 1998, INT REV CYTOL, V178, P73; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756-3282(90)90082-A; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Levy JB, 1997, J BONE MINER RES, V12, P28; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Lu PJ, 1997, J BIOL CHEM, V272, P466; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MEENAKSHI T, 1993, J CELL BIOCHEM, V53, P145, DOI 10.1002/jcb.240530207; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Pande G, 2000, CURR OPIN CELL BIOL, V12, P569, DOI 10.1016/S0955-0674(00)00133-2; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schneider GB, 1998, CELL ADHES COMMUN, V5, P207, DOI 10.3109/15419069809040292; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; TURKSEN K, 1988, J BONE MINER RES, V3, P389; Turner CE, 2000, J CELL SCI, V113, P4139; TURNER CE, 1994, J CELL SCI, V107, P1583; Ueda H, 2000, J CELL BIOL, V149, P423, DOI 10.1083/jcb.149.2.423; WARSHAFSKY B, 1985, BONE, V6, P179, DOI 10.1016/8756-3282(85)90051-1; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xiong WC, 1998, J CELL SCI, V111, P1981; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YU FX, 1992, J BIOL CHEM, V267, P14616; ZALLONE AZ, 1983, J ANAT, V137, P57; ZAMBONINZALLONE A, 1988, J BONE MINER RES, V3, P517; ZHANG D, 1995, J CELL SCI, V108, P2285; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	116	88	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47434	47444		10.1074/jbc.M107494200	http://dx.doi.org/10.1074/jbc.M107494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577104	hybrid			2022-12-27	WOS:000172768500099
J	Simberg, D; Danino, D; Talmon, Y; Minsky, A; Ferrari, ME; Wheeler, CJ; Barenholz, Y				Simberg, D; Danino, D; Talmon, Y; Minsky, A; Ferrari, ME; Wheeler, CJ; Barenholz, Y			Phase behavior, DNA ordering, and size instability of cationic lipoplexes - Relevance to optimal transfection activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERTED HEXAGONAL PHASE; CIRCULAR-DICHROISM; GENE-TRANSFER; STRUCTURAL-PROPERTIES; LIPOSOME COMPLEXES; PLASMID DNA; IN-VITRO; CHOLESTEROL; TRANSITIONS; DELIVERY	Mechanisms of cationic lipid-based nucleic acid delivery are receiving increasing attention, but despite this the factors that determine high or low activity of lipoplexes are poorly understood. This study is focused on the fine structure of cationic lipid-DNA complexes (lipoplexes) and its relevance to transfection efficiency. Monocationic (N-(1-(2,3-dioleoyloxy)propyl),N,N,N-trimethylammonium chloride, N-(1-(2,3-dimyristyloxypropyl)-N,N-dimethyl-(2-hydroxyethyl)ammonium bromide) and polycationic (2,3-dioleyloxy-N-[2(sperminecarboxamido) ethyl]-N,N-dimethyl-1-propanammonium trifluoroacetate) lipid-based assemblies, with or without neutral lipid (1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine, cholesterol) were used to prepare lipoplexes of different L+/DNA(-) charge ratios. Circular dichroism, cryogenic-transmission electron microscopy, and static light scattering were used for lipoplex characterization, whereas expression of human growth hormone or green fluorescent protein was used to quantify transfection efficiency. All monocationic lipids in the presence of inverted hexagonal phase-promoting helper lipids (1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine, cholesterol) induced appearance of Psi (-) DNA, a chiral tertiary DNA structure. The formation of Psi (-) DNA was also dependent on cationic lipid-DNA charge ratio. On the other hand, monocationic lipids either alone or with 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine as helper lipid, or polycationic 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]N,N-dimethyl-1-propanammonium trifluoroacetate-based assemblies, neither of which promotes a lipid-DNA hexagonal phase, did not induce the formation of Psi (-) DNA. Parallel transfection studies reveal that the size and phase instability of the lipoplexes, and not the formation of Psi (-) DNA structure, correlate with optimal transfection.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Liposome Res, IL-91120 Jerusalem, Israel; Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel; Weizmann Inst Sci, Dept Organ Chem & Struct Biol, IL-76100 Rehovot, Israel; Vical Inc, San Diego, CA 92121 USA	Hebrew University of Jerusalem; Technion Israel Institute of Technology; Weizmann Institute of Science	Barenholz, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Liposome Res, POB 12272, IL-91120 Jerusalem, Israel.	yb@cc.huji.ac.il	Talmon, Yeshayahu/N-1076-2019; Danino, Dganit/D-6832-2016	Talmon, Yeshayahu/0000-0002-9854-3972; Danino, Dganit/0000-0002-9782-4940				Birchall JC, 1999, INT J PHARM, V183, P195, DOI 10.1016/S0378-5173(99)00117-9; COORSSEN JR, 1990, BIOCHEM CELL BIOL, V68, P65, DOI 10.1139/o90-008; Daniels GA, 2001, CURR OPIN MOL THER, V3, P70; Dunlap DD, 1997, NUCLEIC ACIDS RES, V25, P3095, DOI 10.1093/nar/25.15.3095; Even-Chen S, 2000, BBA-BIOMEMBRANES, V1509, P176, DOI 10.1016/S0005-2736(00)00292-3; FELGNER PL, 1996, HDB NONMEDICAL APPL, V4, P43; Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GOSULE LC, 1976, NATURE, V259, P333, DOI 10.1038/259333a0; HAYNES M, 1970, BIOCHEMISTRY-US, V9, P4410, DOI 10.1021/bi00824a600; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Hofland HEJ, 1997, PHARMACEUT RES, V14, P742, DOI 10.1023/A:1012146305040; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683; Lin AJ, 2000, J DRUG TARGET, V8, P13, DOI 10.3109/10611860009009206; LIVOLANT F, 1988, BIOCHEMISTRY-US, V27, P3056, DOI 10.1021/bi00408a058; Madry H, 2001, J MOL MED-JMM, V79, P184, DOI 10.1007/s001090000186; MAESTRE MF, 1980, BIOCHEMISTRY-US, V19, P5214, DOI 10.1021/bi00564a010; May S, 2000, BIOPHYS J, V78, P1681, DOI 10.1016/S0006-3495(00)76720-8; Meidan VM, 2000, BBA-BIOMEMBRANES, V1464, P251, DOI 10.1016/S0005-2736(00)00151-6; Monk KWC, 1997, BIOPHYS J, V73, P2534, DOI 10.1016/S0006-3495(97)78282-1; Pector V, 2000, J BIOL CHEM, V275, P29533, DOI 10.1074/jbc.M909996199; Pitard B, 1997, P NATL ACAD SCI USA, V94, P14412, DOI 10.1073/pnas.94.26.14412; Sakurai F, 2001, GENE THER, V8, P677, DOI 10.1038/sj.gt.3301460; SIEGEL DP, 1994, BIOPHYS J, V66, P402, DOI 10.1016/S0006-3495(94)80790-8; Simberg D, 2000, J LIPOSOME RES, V10, P1, DOI 10.3109/08982100009031091; Strekas TC, 1999, ARCH BIOCHEM BIOPHYS, V364, P129, DOI 10.1006/abbi.1999.1108; Talmon Y, 1999, SURF SCI SERIES, V83, P147; TILCOCK CPS, 1982, BIOCHEMISTRY-US, V21, P4596, DOI 10.1021/bi00262a013; TINOCO I, 1980, ANNU REV BIOPHYS BIO, V9, P107, DOI 10.1146/annurev.bb.09.060180.000543; Wagner K, 2000, LANGMUIR, V16, P303, DOI 10.1021/la991268a; Zuidam NJ, 1999, FEBS LETT, V457, P419, DOI 10.1016/S0014-5793(99)01053-4; Zuidam NJ, 1999, BBA-BIOMEMBRANES, V1419, P207, DOI 10.1016/S0005-2736(99)00069-3; Zuidam NJ, 1998, BBA-BIOMEMBRANES, V1368, P115, DOI 10.1016/S0005-2736(97)00187-9; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	37	167	168	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47453	47459		10.1074/jbc.M105588200	http://dx.doi.org/10.1074/jbc.M105588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11564736	hybrid			2022-12-27	WOS:000172768500101
J	Woldman, I; Varinou, L; Ramsauer, K; Rapp, B; Decker, T				Woldman, I; Varinou, L; Ramsauer, K; Rapp, B; Decker, T			The Stat1 binding motif of the interferon-gamma receptor is sufficient to mediate Stat5 activation and its repression by SOCS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; PHASE RESPONSE FACTOR/STAT3; JANUS TYROSINE KINASE; IFN-GAMMA; DIFFERENTIAL ACTIVATION; ANTIAPOPTOTIC ACTIVITY; TARGETED DISRUPTION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTORS; IMMUNE INTERFERON	Signal transduction via the interferon-gamma (IFN-gamma) receptor requires the tyrosine phosphorylation of signal transducers and activators of transcription (Stats). Whereas tyrosine phosphorylation of Stat1 occurs in all cells, activation of Stat5 by IFN-gamma is cell type-restricted. Here we investigated the mechanism of Stat5 activation by the IFN-gamma receptor. In transfection assays both Stat5 isoforms, Stat5a and Stat5b, were phosphorylated on tyrosine in response to IFN-gamma. Stat5 activation required the presence of tyrosine 420 (Tyr-420) in the murine IFNGR1 receptor chain, which also serves as the Stat1 binding site. Moreover, a peptide including Tyr-440, the Stat1 binding site of the human IFNGR1 chain, conferred the ability upon a synthetic receptor to activate Stat5. Suppressor of cytokine signaling 3 (SOCS3) inhibited the activation of Stat5 by the IFN-gamma receptor, and the Tyr-440-containing peptide stretch was sufficient for repression. SOCS3 expression had little effect on the activity of Jak kinases not associated with cytokine receptors. In IFN-gamma -treated, Stat1-deficient fibroblasts Stat5 was inefficient in inducing transcription of a Stat-dependent reporter gene, suggesting it does not per se make a major contribution to the expression of IFN-gamma -responsive genes.	Inst Microbiol & Genet, Vienna Bioctr, A-1030 Vienna, Austria	Vienna Biocenter (VBC)	Decker, T (corresponding author), Inst Microbiol & Genet, Vienna Bioctr, Dr Bohr Gasse 9, A-1030 Vienna, Austria.							Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Barahmand-Pour F, 1998, J BIOL CHEM, V273, P12567, DOI 10.1074/jbc.273.20.12567; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Kieslinger M, 2000, GENE DEV, V14, P232; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; NACY CA, 1991, CURR OPIN IMMUNOL, V3, P330, DOI 10.1016/0952-7915(91)90033-W; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stoiber D, 1999, J IMMUNOL, V163, P2640; Stoiber D, 2001, J IMMUNOL, V166, P466, DOI 10.4049/jimmunol.166.1.466; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Woldman I, 1997, J IMMUNOL, V159, P877; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	57	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45722	45728		10.1074/jbc.M105320200	http://dx.doi.org/10.1074/jbc.M105320200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577084	hybrid			2022-12-27	WOS:000172573100031
J	Zhang, T; Wolfe, MW; Roberson, MS				Zhang, T; Wolfe, MW; Roberson, MS			An early growth response protein (Egr) 1 cis-element is required for gonadotropin-releasing hormone-induced mitogen-activated protein kinase phosphatase 2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; ALPHA-T3-1 CELL-LINE; SIGNAL-REGULATED KINASE; NGFI-A EGR-1; TYROSINE-PHOSPHATASE; MAP KINASE; BETA-GENE; CATALYTIC ACTIVATION; TRANSCRIPTION FACTOR; SUBUNIT GENE	In pituitary gonadotropes, gonadotropin-releasing hormone (GnRH) activates all three major mitogen-activated protein kinase (MAPK) cascades. The MAPKs play key roles in transcriptional activation of GnRH-responsive genes. MAPK phosphatases (MKPs) are dual specificity protein phosphatases involved in feedback regulation of MAPK activity. Previous studies indicate that GnRH activates MKP-2 expression in gonadotropes, dependent upon activation of multiple MAPKs and discrete Ca2+ signals. To further understand the transcriptional mechanism(s) of MKP-2 induction by GnRH, we studied the activity of a 198-nucleotide MKP-2 proximal promoter region that supports GnRH responsiveness in reporter gene assays. Functional analysis of the MKP-2 promoter confirmed a requirement for the protein kinase C-extracellular signal-regulated kinase (ERK) pathway and VGCC-derived Ca2+ signals in transcriptional activation of the MKP-2 gene. However, the inhibitory effect of thapsigargin on MKP-2 protein expression previously identified was not mediated at the level of promoter activation, suggesting a distinct mechanism for the action of thapsigargin-sensitive Ca2+ signals. MGRE (MKP-2 GnRH response element) within the MKP-2 promoter mediated promoter activation through the protein kinase C-ERK pathway. The zinc finger transcription factor Egr-1 was identified in the MGRE-binding complex. Egr-1/MGRE binding was induced by GnRH in an ERK-dependent manner. Transcriptional activity of Egr-1 protein was enhanced by GnRH treatment. In addition, overexpression of the Egr-interacting protein, NAB1, resulted in increased GnRH-stimulated MKP-2 gene transcription. Consistent with the putative role of Egr-1 in MKP-2 promoter regulation, Egr-1 protein expression closely correlated with the expression of MKP-2 protein in alpha T3-1 cells. Together, these data suggest that Egr-1 may be a key factor in mediating GnRH-dependent transcriptional activation of the MKP-2 gene.	Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA	Cornell University; University of Kansas; University of Kansas Medical Center	Roberson, MS (corresponding author), Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034722] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034722] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34722] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Bokemeyer D, 1997, J AM SOC NEPHROL, V8, P40; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Call GB, 1999, BIOL REPROD, V61, P715, DOI 10.1095/biolreprod61.3.715; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; CESNJAJ M, 1994, ENDOCRINOLOGY, V135, P692, DOI 10.1210/en.135.2.692; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Dowd S, 1998, J CELL SCI, V111, P3389; Fukada T, 2001, J BIOL CHEM, V276, P25512, DOI 10.1074/jbc.M101354200; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Halvorson LM, 1999, MOL ENDOCRINOL, V13, P106, DOI 10.1210/me.13.1.106; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Harris D, 1997, J BIOL CHEM, V272, P13534, DOI 10.1074/jbc.272.21.13534; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Johnson MS, 1996, MOL CELL BIOCHEM, V165, P65; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; King AG, 1995, ONCOGENE, V11, P2553; Kratzmeier M, 1996, MOL CELL ENDOCRINOL, V118, P103, DOI 10.1016/0303-7207(96)03788-4; KWAK SP, 1994, J BIOL CHEM, V269, P3596; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MITCHELL R, 1994, J ENDOCRINOL, V140, pR15, DOI 10.1677/joe.0.140R015; Muda M, 1996, J BIOL CHEM, V271, P4319; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Roberson MS, 2000, MOL CELL BIOL, V20, P3331, DOI 10.1128/MCB.20.10.3331-3344.2000; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Stanislaus D, 1998, ENDOCRINOLOGY, V139, P2710, DOI 10.1210/en.139.6.2710; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; WERLEN G, 1993, J BIOL CHEM, V268, P16596; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752; Zhang T, 2001, MOL CELL ENDOCRINOL, V172, P79, DOI 10.1016/S0303-7207(00)00378-6; Zhang T, 2001, GENE, V273, P71, DOI 10.1016/S0378-1119(01)00574-1; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526	76	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45604	45613		10.1074/jbc.M107075200	http://dx.doi.org/10.1074/jbc.M107075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591707	hybrid			2022-12-27	WOS:000172573100017
J	Arakaki, AK; Orellano, EG; Calcaterra, NB; Ottado, J; Ceccarelli, EA				Arakaki, AK; Orellano, EG; Calcaterra, NB; Ottado, J; Ceccarelli, EA			Involvement of the flavin si-face function of ferredoxin-NADP(+) reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANABAENA PCC 7119; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; OXIDIZED FLAVODOXIN; ELECTRON-TRANSFER; 3-DIMENSIONAL STRUCTURE; WILD-TYPE; ANGSTROM RESOLUTION; REFINED STRUCTURES	In ferredoxin-NADP(+) reductase (FNR), FAD is bound outside of an anti-parallel beta -barrel with the Isoalloxazine lying in a two-tyrosine pocket. To elucidate the function of the flavin si-face tyrosine (Tyr-89 in pea FNR) on the enzyme structure and catalysis, we performed ab initio molecular orbital calculations and site-directed mutagenesis. Our results indicate that the position of Tyr-89 in pea FNR is mainly governed by the energetic minimum of the pairwise interaction between the phenol ring and the flavin. Moreover, most of FNR-like proteins displayed geometries for the si-face tyrosine phenol and the flavin, which correspond to the more negative free energy theoretical value. FNR mutants were obtained replacing Tyr-89 by Phe, Trp, Ser, or Gly. Structural and functional features of purified FNR mutants indicate that aromaticity on residue 89 is essential for FAD binding and proper folding of the protein. Moreover, hydrogen bonding through the Tyr-89 hydroxyl group may be responsible of the correct positioning of FAD and the substrate NADP(+).	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn,Div Mol Biol, Rosario, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario	Ceccarelli, EA (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn,Div Mol Biol, Suipacha 531,S2002LRK, Rosario, Argentina.	cecca@arnet.com.ar	Arakaki, Adrian K/C-6564-2008; Ceccarelli, Eduardo A./V-2600-2019; Ceccarelli, Eduardo A./M-8699-2014; Calcaterra, Nora/AAP-7469-2021	Ceccarelli, Eduardo A./0000-0001-5776-3306; Ceccarelli, Eduardo A./0000-0001-5776-3306; 				Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; ALIVERTI A, 1991, EUR J BIOCHEM, V198, P21, DOI 10.1111/j.1432-1033.1991.tb15981.x; ALIVERTI A, 1991, J BIOL CHEM, V266, P17760; Aliverti A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P653; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; BURKHART BM, 1995, ACTA CRYSTALLOGR D, V51, P318, DOI 10.1107/S0907444994011716; CARRILLO N, 1987, LIGHT REACTIONS, P527; CECCARELLI EA, 1991, J BIOL CHEM, V266, P14283; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Cunane LM, 2000, J MOL BIOL, V295, P357, DOI 10.1006/jmbi.1999.3290; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Dorowski A, 2001, J BIOL CHEM, V276, P9253, DOI 10.1074/jbc.M004576200; Drennan CL, 1999, J MOL BIOL, V294, P711, DOI 10.1006/jmbi.1999.3151; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Feller D., 1990, REV COMPUTATIONAL CH, V1, P1; FUKUYAMA K, 1992, J MOL BIOL, V225, P775, DOI 10.1016/0022-2836(92)90400-E; GADDA G, 1990, J BIOL CHEM, V265, P11955; HANUKOGLU I, 1987, EUR J BIOCHEM, V169, P449, DOI 10.1111/j.1432-1033.1987.tb13632.x; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Hoover DM, 1999, J MOL BIOL, V294, P725, DOI 10.1006/jmbi.1999.3152; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; Itoh T, 2000, BIOCONJUGATE CHEM, V11, P8, DOI 10.1021/bc990045t; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; JUNGERMA.K, 1974, FEBS LETT, V43, P203, DOI 10.1016/0014-5793(74)81000-8; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Krapp AR, 1997, EUR J BIOCHEM, V249, P556, DOI 10.1111/j.1432-1033.1997.00556.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lombard M, 2000, J BIOL CHEM, V275, P115, DOI 10.1074/jbc.275.1.115; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; Martinez-Julvez M, 1999, J BIOL INORG CHEM, V4, P568, DOI 10.1007/s007750050379; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P17680, DOI 10.1021/bi981718i; Mattevi A, 1997, PROTEINS, V27, P601, DOI 10.1002/(SICI)1097-0134(199704)27:4<601::AID-PROT12>3.0.CO;2-O; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; MOORE SA, 1992, J MOL BIOL, V224, P523, DOI 10.1016/0022-2836(92)91015-H; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; Piubelli L, 2000, J BIOL CHEM, V275, P10472, DOI 10.1074/jbc.275.14.10472; SANCHO J, 1988, ARCH BIOCHEM BIOPHYS, V260, P200, DOI 10.1016/0003-9861(88)90441-9; SERRA EC, 1993, PROTEIN EXPRES PURIF, V4, P539, DOI 10.1006/prep.1993.1071; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRIDHAR P, 1998, PROTEIN SCI, V0007; STOCKMAN BJ, 1994, BIOCHEMISTRY-US, V33, P15298, DOI 10.1021/bi00255a011; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WATT W, 1991, J MOL BIOL, V218, P195, DOI 10.1016/0022-2836(91)90884-9; ZANETTI G, 1976, BIOCHIM BIOPHYS ACTA, V445, P14, DOI 10.1016/0005-2744(76)90157-1; Zhao Q, 1999, PROTEIN SCI, V8, P298; Zheng YJ, 1996, J AM CHEM SOC, V118, P9402, DOI 10.1021/ja9608151; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029	72	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44419	44426		10.1074/jbc.M107568200	http://dx.doi.org/10.1074/jbc.M107568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577105	hybrid			2022-12-27	WOS:000172406700011
J	Korn, T; Kuhlkamp, T; Track, C; Schatz, I; Baumgarten, K; Gorboulev, V; Koepsell, H				Korn, T; Kuhlkamp, T; Track, C; Schatz, I; Baumgarten, K; Gorboulev, V; Koepsell, H			The plasma membrane-associated protein RS1 decreases transcription of the transporter SGLT1 in confluent LLC-PK1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/GLUCOSE COTRANSPORTER SGLT1; D-GLUCOSE COTRANSPORTER; DEPENDENT HEXOSE-TRANSPORT; CYCLIC-AMP ELEVATION; GENE-EXPRESSION; MESSENGER-RNA; 3'-UNTRANSLATED REGION; MODIFIER RS1; KINASE-C; CLONING	Previously we cloned RS1, a 67-kDa polypeptide that is associated with the intracellular side of the plasma membrane. Upon co-expression in Xenopus laevis oocytes, human RS1 decreased the concentration of the Na+-D-glucose co-transporter hSGLT1 in the plasma membrane (Valentin, M., Kuhlkamp, T., Wagner, K., Krohne, G., Arndt, P., Baumgarten, K., Weber, W.-M., Segal, A., Veyhl, M., and Koepsell, H. (2000) Biochim. Biophys. Acta 1468, 367-380). Here, the porcine renal epithelial cell line LLC-PK1 was used to investigate whether porcine RS1 (pRS1) plays a role in transcriptional up-regulation of SGLT1 after confluence and in down-regulation of SGLT1 by high extracellular D-glucose concentrations. Western blots indicated a dramatic decrease of endogenous pRS1 protein at the plasma membrane after confluence but no significant effect of D-glucose. In confluent LLC-PK1 cells overexpressing pRS1, SGLT1 mRNA, protein, and methyl-alpha -D-glucopyranoside uptakes were drastically decreased; however, the reduction of methyl-alpha -D-glucopyranoside uptake after cultivation with 25 mM D-glucose remained. In confluent pRS1 antisense cells, the expression of SGLT1 mRNA and protein was strongly increased, whereas the reduction of SGLT1 expression during cultivation with high D-glucose was not influenced. Nuclear run-on assays showed that the transcription of SGLT1 was 10-fold increased in the pRS1 antisense cells. The data suggest that RSI participates in transcriptional up-regulation of SGLT1 after confluence but not in down-regulation by D-glucose.	Univ Wurzburg, Inst Anat, D-97070 Wurzburg, Germany	University of Wurzburg	Koepsell, H (corresponding author), Univ Wurzburg, Inst Anat, Koellikerstr 6, D-97070 Wurzburg, Germany.		Korn, Thomas/AAE-6960-2019	Korn, Thomas/0000-0002-3633-0955				AMSLER K, 1991, AM J PHYSIOL, V260, pC1290, DOI 10.1152/ajpcell.1991.260.6.C1290; AMSLER K, 1982, AM J PHYSIOL, V242, pC94, DOI 10.1152/ajpcell.1982.242.1.C94; AYO SH, 1991, AM J PHYSIOL, V261, pF571, DOI 10.1152/ajprenal.1991.261.4.F571; BELL GI, 1993, J BIOL CHEM, V268, P19161; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cheeseman CI, 1997, AM J PHYSIOL-REG I, V273, pR1965, DOI 10.1152/ajpregu.1997.273.6.R1965; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; FARRELL CR, 1992, MOL BRAIN RES, V15, P221, DOI 10.1016/0169-328X(92)90112-O; FERRARIS RP, 1992, AM J PHYSIOL, V262, pG1069, DOI 10.1152/ajpgi.1992.262.6.G1069; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; HAASE W, 1990, EUR J CELL BIOL, V52, P297; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HEILIG CW, 1995, J CLIN INVEST, V96, P1802, DOI 10.1172/JCI118226; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; Ishikawa Y, 1997, BBA-MOL CELL RES, V1357, P306, DOI 10.1016/S0167-4889(97)00043-8; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KIMMICH GA, 1994, AM J PHYSIOL-CELL PH, V267, pC1119; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambotte S, 1996, DNA CELL BIOL, V15, P769, DOI 10.1089/dna.1996.15.769; LASHERAS C, 1988, AM J PHYSIOL, V255, pC745, DOI 10.1152/ajpcell.1988.255.6.C745; Lee WY, 2000, J BIOL CHEM, V275, P33998, DOI 10.1074/jbc.M005040200; MORAN A, 1983, J BIOL CHEM, V258, P5087; MORAN A, 1982, AM J PHYSIOL, V243, pC293, DOI 10.1152/ajpcell.1982.243.5.C293; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; Oku A, 1999, DIABETES, V48, P1794, DOI 10.2337/diabetes.48.9.1794; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; Reinhardt J, 1999, BBA-BIOMEMBRANES, V1417, P131, DOI 10.1016/S0005-2736(98)00250-8; Rhoads DB, 1998, J BIOL CHEM, V273, P9510, DOI 10.1074/jbc.273.16.9510; Sambrook J., 2002, MOL CLONING LAB MANU; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIODA T, 1994, P NATL ACAD SCI USA, V91, P11919, DOI 10.1073/pnas.91.25.11919; SHIRAZIBEECHEY SP, 1991, J PHYSIOL-LONDON, V437, P699, DOI 10.1113/jphysiol.1991.sp018620; Tanaka T, 1998, BIOCHEM J, V331, P225, DOI 10.1042/bj3310225; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valentin M, 2000, BBA-BIOMEMBRANES, V1468, P367, DOI 10.1016/S0005-2736(00)00277-7; VEYHL M, 1993, J BIOL CHEM, V268, P25041; YET SF, 1994, J CELL PHYSIOL, V158, P506, DOI 10.1002/jcp.1041580315	50	26	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45330	45340		10.1074/jbc.M105975200	http://dx.doi.org/10.1074/jbc.M105975200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11562363	hybrid			2022-12-27	WOS:000172406700128
J	Skabkin, MA; Evdokimova, V; Thomas, AAM; Ovchinnikov, LP				Skabkin, MA; Evdokimova, V; Thomas, AAM; Ovchinnikov, LP			The major messenger ribonucleoprotein particle protein p50 (YB-1) promotes nucleic acid strand annealing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-BOX PROTEINS; RNA-BINDING-PROTEINS; TYPE-1 NUCLEOCAPSID PROTEIN; COMPLEMENTARY-DNA STRANDS; MURINE LEUKEMIA-VIRUS; COLD-SHOCK DOMAIN; ESCHERICHIA-COLI; CYTOPLASMIC MRNP; CORE PROTEIN; TRANSCRIPTION FACTOR	p50, a member of the Y-box binding transcription factor family, is tightly associated with eukaryotic mRNAs and is responsible for general translational regulation. Here we show that p50, in addition to its previously described ability to melt mRNA secondary structure, is capable of promoting rapid annealing of complementary nucleic acid strands. p50 accelerates annealing of RNA and DNA duplexes up to 1500-fold within a wide range of salt concentrations and temperatures. Phosphorylation of p50 selectively inhibits DNA annealing. Moreover, p50 catalyzes strand exchange between double-stranded and single-stranded RNAs yielding a product bearing a more extended double-stranded structure. Strikingly, p50 displays both RNA-melting and -annealing activities in a dose-dependent manner; a relatively low amount of p50 promotes formation of RNA duplexes, whereas an excess of p50 causes unwinding of double-stranded forms. Our results suggest that the alteration of nucleic acid conformation is a basic mechanism of the p50-dependent regulation of gene expression.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands	Russian Academy of Sciences; Utrecht University	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	ovchinn@vega.protres.ru	Ovchinnikov, Lev/L-2397-2015					BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BLOBEL G, 1972, BIOCHEM BIOPH RES CO, V47, P88, DOI 10.1016/S0006-291X(72)80014-7; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; Chansky HA, 2001, CANCER RES, V61, P3586; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Graumann P, 1996, BIOESSAYS, V18, P309, DOI 10.1002/bies.950180409; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HERRICK G, 1976, J BIOL CHEM, V251, P2133; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Hitti E, 1998, NUCLEIC ACIDS RES, V26, P4382, DOI 10.1093/nar/26.19.4382; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Jiang WN, 1997, J BIOL CHEM, V272, P196; KARPEL RL, 1980, BIOCHEMISTRY-US, V19, P4674, DOI 10.1021/bi00561a021; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LEE CG, 1993, J BIOL CHEM, V268, P13472; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Manival X, 2001, NUCLEIC ACIDS RES, V29, P2223, DOI 10.1093/nar/29.11.2223; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1990, MOL BIOL REP, V14, P65, DOI 10.1007/BF00360418; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; SABATH DE, 1990, J BIOL CHEM, V265, P12671; SAMARINA OP, 1968, J MOL BIOL, V33, P251, DOI 10.1016/0022-2836(68)90292-1; Shibao K, 1999, INT J CANCER, V83, P732; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Ustinov VA, 1996, BIOCHEMISTRY-MOSCOW+, V61, P414; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VANVENROOIJ WJ, 1977, NATURE, V270, P189, DOI 10.1038/270189a0; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8	64	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44841	44847		10.1074/jbc.M107581200	http://dx.doi.org/10.1074/jbc.M107581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11585833	hybrid			2022-12-27	WOS:000172406700069
J	Weiss, JL; Burgoyne, RD				Weiss, JL; Burgoyne, RD			Voltage-independent inhibition of P/Q-type Ca2+ channels in adrenal chromaffin cells via a neuronal Ca2+ sensor-1-dependent pathway involves Src family tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNELS; G-PROTEIN; BINDING-PROTEINS; SENSOR 1; MODULATION; CURRENTS; STIMULATION; ACTIVATION; EXOCYTOSIS; FREQUENIN	In common with many neurons, adrenal chromaffin cells possess distinct voltage-dependent and voltage-independent pathways for Ca2+ channel regulation. In this study, the voltage-independent pathway was revealed by addition of naloxone and suramin to remove tonic blockade of Ca2+ currents via opioid and purinergic receptors due to autocrine feedback inhibition. This pathway requires the Ca2+-binding protein neuronal calcium sensor-1 (NCS-1). The voltage-dependent pathway was pertussis toxin-sensitive, whereas the voltage-independent pathway was largely pertussis toxin-insensitive. Characterization of the voltage-independent inhibition of Ca2+ currents revealed that it did not involve protein kinase C-dependent signaling pathways but did require the activity of a Src family tyrosine kinase. Two structurally distinct Src kinase inhibitors, 4-amino-5-(4-methylphenyl)7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP1) and a Src inhibitory peptide, increased the Ca2+ currents, and no further increase in Ca2+ currents was elicited by addition of naloxone and suramin. In addition, the Src-like kinase appeared to act in the same pathway as NCS-1. In contrast, addition of PP1 did not prevent a voltage-dependent facilitation elicited by a strong pre-pulse depolarization indicating that this pathway was independent of Src kinase activity. PPI no longer increased Ca2+ currents after addition of the P/Q-type channel blocker omega -agatoxin TK. The alpha (1A) subunit of P/Q-type Ca2+ channels was immunoprecipitated from chromaffin cell extracts and found to be phosphorylated in a PP1-sensitive manner by endogenous kinases in the immunoprecipitate. A high molecular mass (around 220 kDa) form of the alpha (1A) subunit was detected by anti-phosphotyrosine, suggesting a possible target for Src family kinase action. These data demonstrate a voltage-independent mechanism for autocrine inhibition of P/Q-type Ca2+ channel currents in chromaffin cells that requires Src family kinase activity and suggests that this may be a widely distributed pathway for Ca2+ channel regulation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert/C-6706-2008; Weiss, Jamie/HHS-2536-2022; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387; Weiss, Jamie L/0000-0001-6784-5831				ALBILLOS A, 1993, FEBS LETT, V336, P259, DOI 10.1016/0014-5793(93)80815-C; Albillos A, 1996, J PHYSIOL-LONDON, V494, P687, DOI 10.1113/jphysiol.1996.sp021524; Allen CM, 1996, J NEUROSCI RES, V44, P421, DOI 10.1002/(SICI)1097-4547(19960601)44:5<421::AID-JNR2>3.0.CO;2-H; BEECH DJ, 1991, P NATL ACAD SCI USA, V88, P652, DOI 10.1073/pnas.88.2.652; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; Burgoyne RD, 2001, BIOCHEM J, V353, P1; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Carabelli V, 1998, NEURON, V20, P1255, DOI 10.1016/S0896-6273(00)80505-X; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CENA V, 1991, J MEMBRANE BIOL, V122, P23, DOI 10.1007/BF01872736; Currie KPM, 2000, J NEUROPHYSIOL, V83, P1435, DOI 10.1152/jn.2000.83.3.1435; Currie KPM, 1997, J NEUROSCI, V17, P4570; Currie KPM, 1996, NEURON, V16, P1027, DOI 10.1016/S0896-6273(00)80126-9; Delmas P, 1998, EUR J NEUROSCI, V10, P1654, DOI 10.1046/j.1460-9568.1998.00170.x; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; DIVERSEPIERLUISSI M, 1991, P NATL ACAD SCI USA, V88, P1261, DOI 10.1073/pnas.88.4.1261; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; DOUPNIK CA, 1994, J MEMBRANE BIOL, V140, P47; Dunlap KL, 1998, SEMIN NEUROSCI, V9, P198, DOI 10.1006/smns.1997.0119; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Evans GJO, 1999, EUR J NEUROSCI, V11, P279, DOI 10.1046/j.1460-9568.1999.00427.x; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Kammermeier PJ, 2000, J NEUROSCI, V20, P5623, DOI 10.1523/JNEUROSCI.20-15-05623.2000; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; Perroy J, 2000, J NEUROSCI, V20, P7896; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Powell AD, 2000, J NEUROSCI, V20, P606, DOI 10.1523/JNEUROSCI.20-02-00606.2000; RANE SG, 1986, P NATL ACAD SCI USA, V83, P184, DOI 10.1073/pnas.83.1.184; SAKURAI T, 1995, J BIOL CHEM, V270, P21234, DOI 10.1074/jbc.270.36.21234; SATO K, 1990, BIOCHEM BIOPH RES CO, V171, P1152, DOI 10.1016/0006-291X(90)90805-W; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Shapiro MS, 1999, P NATL ACAD SCI USA, V96, P10899, DOI 10.1073/pnas.96.19.10899; TERAMOTO T, 1993, BIOCHEM BIOPH RES CO, V196, P134, DOI 10.1006/bbrc.1993.2225; TWITCHELL WA, 1993, NEURON, V10, P701, DOI 10.1016/0896-6273(93)90171-M; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Wijetunge S, 2000, BRIT J PHARMACOL, V129, P1347, DOI 10.1038/sj.bjp.0703186; Winkler H, 1998, CELL MOL NEUROBIOL, V18, P193, DOI 10.1023/A:1022516919932; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	55	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44804	44811		10.1074/jbc.M103262200	http://dx.doi.org/10.1074/jbc.M103262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11583988	hybrid			2022-12-27	WOS:000172406700064
J	Ge, YB; Matherly, LH; Taub, JW				Ge, YB; Matherly, LH; Taub, JW			Transcriptional regulation of cell-specific expression of the human cystathionine beta-synthase gene by differential binding of Sp1/Sp3 to the-1b promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; DEPENDENT PROTEIN-KINASE; DOWN-SYNDROME CHILDREN; IN-VITRO SENSITIVITY; ZINC-FINGER GENE; FACTORS NF-Y; CYTOSINE-ARABINOSIDE; MESSENGER-RNA; SP FAMILY; PHOSPHORYLATION	Cystathionine beta -synthase (CBS) catalyzes the condensation of serine and homocysteine to form cystathionine, an intermediate step in the synthesis of cysteine. We previously characterized the CBS -1b minimal promoter (-3792 to -3667) and found that Sp1/Sp3, nuclear factor Y, and USF-1 were involved in the regulation of basal promoter activity (Ge, Y., Konrad, M. A., Matherly, L. H., Taub, J. W. (2001) Biochem. J. 357, 97-105). In this study, the critical cis-elements and transcription factors in the CBS -1b upstream region (-4046 to -3792) were examined in HT1080 and HepG2 cells, which differ 10-fold in levels of CBS transcripts transcribed from the CBS -1b promoter. In DNase I footprint and gel shift analyses and transient transfections of mutant CBS -1b promoter constructs into HT1080 and HepG2 cells, transcriptionally important roles for Sp1/Sp3 binding to three GC boxes and one GT box and for binding of myeloid zinc finger 1-like proteins to two myeloid zinc finger I elements were indicated. In gel shift assays, very low levels of Sp1/Sp3 DNA-protein complexes were detected in HT1080 cells compared with HepG2 cells despite comparable levels of nuclear factor Y and USF-1 binding and similar levels of Spl and Sp3 proteins on Western blots. Mixing of HT1080 and HepG2 nuclear extracts resulted in no difference in total Sp factor binding in gel shift assays, thus excluding a role for an unknown activator or inhibitor in the disparate Sp1/Sp3 binding between the lines. Increased Sp1/Sp3 binding in gel shift assays was observed upon treatment of HT1080 nuclear extracts with protein kinase A, and decreased Sp1/Sp3 binding resulted from treatment of HepG2 nuclear extracts with calf alkaline phosphatase, suggesting a role for changes in Sp1/Sp3 phosphorylation in transcription factor binding and transactivation of the CBS -1b promoter. Characterization of CBS promoter structure and function should clarify the molecular bases for variations in CBS gene expression in genetic diseases and the relationship between CBS and Down syndrome.	Childrens Hosp Michigan, Div Pediat Hematol Oncol, Detroit, MI 48201 USA; Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA	Children's Hospital of Michigan; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Taub, JW (corresponding author), Childrens Hosp Michigan, Div Pediat Hematol Oncol, 3901 Beaubien Blvd, Detroit, MI 48201 USA.			Ge, Yubin/0000-0002-8748-716X	NATIONAL CANCER INSTITUTE [R01CA092308] Funding Source: NIH RePORTER; NCI NIH HHS [CA92308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1999, MOL CELL BIOL, V19, P1961; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bao LM, 1998, ARCH BIOCHEM BIOPHYS, V350, P95, DOI 10.1006/abbi.1997.0486; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BUKOVSKA G, 1994, PROTEIN EXPRES PURIF, V5, P442, DOI 10.1006/prep.1994.1063; CHADEFAUX B, 1988, LANCET, V2, P741; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Fodinger M, 1999, MINER ELECTROL METAB, V25, P269, DOI 10.1159/000057459; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kraus JP, 1998, GENOMICS, V52, P312, DOI 10.1006/geno.1998.5437; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Murakami Y, 1997, BBA-GENE STRUCT EXPR, V1352, P311, DOI 10.1016/S0167-4781(97)00032-8; PAN JL, 1993, J BIOL CHEM, V268, P22600; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SKOVBY F, 1984, AM J HUM GENET, V36, P452; Sugiura N, 2000, BIOCHEM J, V347, P155, DOI 10.1042/0264-6021:3470155; Taub JW, 1997, LEUKEMIA, V11, P1594, DOI 10.1038/sj.leu.2400747; Taub JW, 2000, CANCER RES, V60, P6421; Taub JW, 1999, BLOOD, V94, P1393; Taub JW, 1996, BLOOD, V87, P3395, DOI 10.1182/blood.V87.8.3395.bloodjournal8783395; Taub JW, 1999, BLOOD, V94, p382A; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; ZHAO ZD, 2000, J BIOL CHEM, V275, P18602	43	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43570	43579		10.1074/jbc.M104930200	http://dx.doi.org/10.1074/jbc.M104930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562358	hybrid			2022-12-27	WOS:000172297700014
J	Khadilkar, A; Iannuzzi, P; Orlowski, J				Khadilkar, A; Iannuzzi, P; Orlowski, J			Identification of sites in the second exomembrane loop and ninth transmembrane helix of the mammalian Na+/H+ exchanger important for drug recognition and cation translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; H+ EXCHANGE; FUNCTIONAL-PROPERTIES; AMILORIDE; INHIBITOR; ISOFORM; ANTIPORT; NHE-1; TRANSFORMATION; MUTAGENESIS	Mammalian Na+/H+ exchanger (NHE) isoforms are differentially sensitive to inhibition by several distinct classes of pharmacological agents, including amiloride- and benzoyl guanidinium-based derivatives. The determinants of drug sensitivity, however, are only partially understood. Earlier studies of the drug-sensitive NHE1 isoform have shown that residues within the fourth membrane-spanning helix (M4) (Phe(165), Phe(166), Leu(167), and Gly(178)) and a 66-amino acid segment encompassing M9 contribute significantly to drug recognition. In this report, we have identified two residues within M9, one highly conserved (Glu(350)) and the other non-conserved (Gly(356)), that are major determinants of drug sensitivity. In addition, residues in the second exomembrane loop between M3 and M4 (Gly(152), Phe(157), and Pro(158)) were also found to modestly influence drug sensitivity. A double substitution of crucial sites within M4 and M9 of NHE1 with the corresponding residues present in the drug-resistant NHE3 isoform (i.e. L167F/G356A) greatly reduced drug sensitivity in a cooperative manner to levels nearing that of wild type NHE3. The above mutations did not appreciably affect Na-o(+) affinity but did markedly decrease the catalytic turnover of the transporter. These data suggest that specific sites encompassing M4 and M9 are critical determinants of both drug recognition and cation translocation.	McGill Univ, Dept Physiol, Montreal, PQ H3Q 1Y6, Canada	McGill University	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3Q 1Y6, Canada.	orlowski@med.mcgill.ca		Orlowski, John/0000-0001-7371-175X				Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Bookstein C, 1996, AM J PHYSIOL-CELL PH, V271, pC1629, DOI 10.1152/ajpcell.1996.271.5.C1629; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Chambrey R, 1997, AM J PHYSIOL-CELL PH, V272, pC90, DOI 10.1152/ajpcell.1997.272.1.C90; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; FRELIN C, 1986, EUR J BIOCHEM, V154, P241, DOI 10.1111/j.1432-1033.1986.tb09388.x; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; Gumina RJ, 1998, J PHARMACOL EXP THER, V286, P175; HARPER IS, 1993, BASIC RES CARDIOL, V88, P430, DOI 10.1007/BF00795410; Humphreys RA, 1999, AM J PHYSIOL-HEART C, V276, pH749, DOI 10.1152/ajpheart.1999.276.2.H749; IVES HE, 1983, J BIOL CHEM, V258, P9710; Jandeleit-Dahm K, 2000, CIRC RES, V87, P1133, DOI 10.1161/01.RES.87.12.1133; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PARIS S, 1983, J BIOL CHEM, V258, P3503; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Rupprecht HJ, 2000, CIRCULATION, V101, P2902, DOI 10.1161/01.CIR.101.25.2902; SCHOLZ W, 1995, CARDIOVASC RES, V29, P260, DOI 10.1016/S0008-6363(96)88579-8; SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x; Schwark JR, 1998, PFLUG ARCH EUR J PHY, V436, P797, DOI 10.1007/s004240050704; Shrode LD, 1998, AM J PHYSIOL-CELL PH, V275, pC431, DOI 10.1152/ajpcell.1998.275.2.C431; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; Szabo EZ, 2000, J BIOL CHEM, V275, P6302, DOI 10.1074/jbc.275.9.6302; Touret N, 2001, BIOCHEMISTRY-US, V40, P5095, DOI 10.1021/bi0025464; Vallon V, 2000, AM J PHYSIOL-RENAL, V278, pF375, DOI 10.1152/ajprenal.2000.278.3.F375; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; WARNOCK DG, 1988, J BIOL CHEM, V263, P7216; YU FH, 1993, J BIOL CHEM, V268, P25536; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHU WH, 1995, BBA-MOL CELL RES, V1269, P122, DOI 10.1016/0167-4889(95)00102-X	47	45	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43792	43800		10.1074/jbc.M106659200	http://dx.doi.org/10.1074/jbc.M106659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564737	hybrid			2022-12-27	WOS:000172297700042
J	Treins, C; Giorgetti-Peraldi, S; Murdaca, J; Van Obberghen, E				Treins, C; Giorgetti-Peraldi, S; Murdaca, J; Van Obberghen, E			Regulation of vascular endothelial growth factor expression by advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; HYPOXIA-INDUCIBLE FACTOR-1; DIABETIC-RETINOPATHY; GLIOMA-CELLS; FACTOR GENE; TRANSCRIPTIONAL ACTIVATION; OXIDANT STRESS; FACTOR-I; PROTEIN; RECEPTOR	Advanced glycation end products (AGEs) are generated during long term diabetes and are correlated with the development of diabetic complications, such as retinopathy. Diabetic retinopathy is characterized by an increased retinal neovascularization due to the action of the angiogenic factor, vascular endothelial growth factor (VEGF). In this report, we show that injection of insulin and glycated albumin (Alb-AGE) to mice increases VEGF mRNA expression in eyes. Insulin and Alb-AGE stimulate VEGF mRNA and protein expression in retinal epithelial cells (ARPE-19). Alb-AGE-induced VEGF expression is not modulated by the use of antioxidants, N-acetyl-L-cysteine or pyrrolidinedithiocarbamate, or by an inhibitor of phosphatidylinositol 3-kinase (PI3K), wortmannin. However, using an inhibitor of ERK activation, U0126, we show that Alb-AGE stimulates VEGF expression through an ERK-dependent pathway. Accordingly, we found that Alb-AGE activated mitogen-activate protein kinase, ERK1/2, JNK1/2, but not p38, and that Alb-AGE did not activate PI3K and PKB. Moreover, Alb-AGE activated the transcription factor, hypoxia inducible factor-1 (HIF-1) DNA binding activity. This activation is mediated by an increase in accumulation of the HIF-1 alpha protein through an ERK-dependent pathway. Thus, stimulation of VEGF expression by Alb-AGE, through the activation of HIF-1, could play an important role in the development of diabetic retinopathy.	Fac Med, INSERM, U145, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Giorgetti-Peraldi, S (corresponding author), Fac Med, INSERM, U145, Ave Valombrose,IFR 50, F-06107 Nice 2, France.			Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Fonseca V, 1996, SOUTH MED J, V89, P839, DOI 10.1097/00007611-199609000-00001; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; McKinlay J, 2000, LANCET, V356, P757, DOI 10.1016/S0140-6736(00)02641-6; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	45	169	188	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43836	43841		10.1074/jbc.M106534200	http://dx.doi.org/10.1074/jbc.M106534200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571295	hybrid			2022-12-27	WOS:000172297700048
J	Yu, CJ; Kim, SH; Ikeuchi, T; Xu, HX; Gasparini, L; Wang, R; Sisodia, SS				Yu, CJ; Kim, SH; Ikeuchi, T; Xu, HX; Gasparini, L; Wang, R; Sisodia, SS			Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma - Evidence for distinct mechanisms involved in gamma-secretase processing or the APP and Notch1 transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; INTRACELLULAR DOMAIN; CLEAVAGE; ENDOPROTEOLYSIS; MEMBRANE; RELEASE; CELLS; COMPARTMENTS; PROTEOLYSIS; DEFICIENCY	A variety of investigations have led to the conclusion that presenilins (PS) play a critical role in intramembranous, gamma -secretase proteolysis of selected type I membrane proteins, including Notch1 and amyloid precursor protein (APP). We now show that the generation of the S3/Notch intracellular domain and APP-carboxyl-terminal fragment gamma (CTF gamma) derivatives are dependent on PS expression and inhibited by a highly selective and potent gamma -secretase inhibitor. Unexpectedly, the APP-CTF-gamma derivative is generated by processing between Leu-645 and Val-646 (of APP(695)), several amino acids carboxyl-terminal to the scissile bonds for production of amyloid beta protein peptides. Although the relationship of APP-CTF gamma to the production of amyloid beta protein peptides is not known, we conclude that in contrast to the highly selective PS-dependent processing of Notch, the PS-dependent gamma -secretase processing of APP is largely nonselective and occurs at multiple sites within the APP transmembrane domain.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Rockefeller Univ, Dept Mol & Cellular Neurosci, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry, New York, NY 10021 USA	University of Chicago; Rockefeller University; Rockefeller University	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.		Xu, Huaxi/AAV-7177-2021; Wang, Rong/A-8721-2009; Gasparini, Laura/G-7711-2011; Yu, Chunjiang/E-9419-2012	Gasparini, Laura/0000-0003-3894-9898; 	NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG014248, P01 AG14248] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lamb BT, 1999, NAT NEUROSCI, V2, P695, DOI 10.1038/11154; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; McLendon C, 2000, FASEB J, V14, P2383; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Selkoe DJ, 2000, P NATL ACAD SCI USA, V97, P5690, DOI 10.1073/pnas.97.11.5690; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	38	190	196	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43756	43760		10.1074/jbc.C100410200	http://dx.doi.org/10.1074/jbc.C100410200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11583985	hybrid			2022-12-27	WOS:000172297700037
J	Ushio-Fukai, M; Hilenski, L; Santanam, N; Becker, PL; Ma, YX; Griendling, KK; Alexander, RW				Ushio-Fukai, M; Hilenski, L; Santanam, N; Becker, PL; Ma, YX; Griendling, KK; Alexander, RW			Cholesterol detection inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells - Role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; REGULATED KINASE; TYROSINE KINASE; PLASMA-MEMBRANE; MEDIATED TRANSPORT; TYPE-1 RECEPTOR; CAVEOLAE; PHOSPHORYLATION; TRANSDUCTION; LOCALIZATION	Angiotensin II (Ang II) induces transactivation of the epidermal growth factor (EGF) receptor (EGF-R), which serves as a scaffold for various signaling molecules in vascular smooth muscle cells (VSMCs). Cholesterol and sphingomyelin-enriched lipid rafts are plasma membrane microdomains that concentrate various signaling molecules. Caveolae are specialized lipid rafts that are organized by the cholesterol-binding protein, caveolin, and have been shown to be associated with EGF-Rs. Angiotensin II stimulation promotes a rapid movement of AT, receptors to caveolae; however, their functional role in angiotensin II signaling has not been elucidated. Here we show that cholesterol depletion by beta -cyclodextrin disrupts caveolae structure and concomitantly inhibits tyrosine phosphorylation of the EGF-R and subsequent activation of protein kinase B (PKB)/Akt induced by angiotensin II. Similar inhibitory effects were obtained with other cholesterol-binding agents, filipin and nystatin. In contrast, EGF-R autophosphorylation and activation of Akt/PKB in response to EGF are not affected by cholesterol depletion. The early Ang II-induced upstream signaling events responsible for transactivation of the EGF-R, such as the intracellular Ca2+ increase and c-Src, activation, also remain intact. The EGF-R initially binds caveolin, but these two proteins rapidly dissociate following angiotensin Il stimulation during the time when EGF-R transactivation is observed. The activated EGF-R is localized in focal adhesions together with tyrosine-phosphorylated caveolin. These findings suggest that 1) a scaffolding role of caveolin is essential for EGF-R transactivation by angiotensin II and 2) cholesterol-rich microdomains as well as focal adhesions are important signal-organizing compartments required for the spatial and temporal organization of angiotensin II signaling in VSMCs.	Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Obstet & Gynecol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Ushio-Fukai, M (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 1639 Pierce Dr,Rm 319, Atlanta, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL38206, HL58000, HL60728] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038206, R37HL038206, R01HL038206, R01HL060728, P01HL058000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gingras D, 1998, BIOCHEM BIOPH RES CO, V247, P888, DOI 10.1006/bbrc.1998.8885; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; Guo XQ, 1997, J BIOL CHEM, V272, P16984, DOI 10.1074/jbc.272.27.16984; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hansen GH, 2001, J BIOL CHEM, V276, P32338, DOI 10.1074/jbc.M102667200; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Kwiterovich PO, 1998, ARTERIOSCL THROM VAS, V18, P57, DOI 10.1161/01.ATV.18.1.57; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; Ushio-Fukai M, 1999, MOL PHARMACOL, V55, P142, DOI 10.1124/mol.55.1.142; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022	33	168	170	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48269	48275		10.1074/jbc.M105901200	http://dx.doi.org/10.1074/jbc.M105901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585822	hybrid			2022-12-27	WOS:000172927000072
J	Hullinger, TG; Panek, RL; Xu, XY; Karathanasis, SK				Hullinger, TG; Panek, RL; Xu, XY; Karathanasis, SK			p21-activated kinase-1 (PAK1) inhibition of the human scavenger receptor class B, type I promoter in macrophages is independent of PAK1 kinase activity, but requires the GTPase-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ACTIVATED PROTEIN-KINASE; NUCLEOTIDE EXCHANGE FACTORS; SR-BI; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; HUMAN MONOCYTES; HUMAN HOMOLOG; EXPRESSION; CDC42	Scavenger receptor class B, type I (SR-BI), is a high density lipoprotein receptor that mediates the flux of cholesterol between high density lipoprotein and cells. Recent evidence suggests that SR-Bl plays a role in atherosclerosis and that inflammatory mediators downregulate SR-BI in the macrophage. The purpose of this study was to evaluate the ability of lipopolysaccharide (LPS) to down-regulate the activity of the human SR-BI promoter in the macrophage and to delineate the mechanisms involved. Experiments with cultured cells and in vivo derived macrophages showed that LPS has a powerful suppressive effect on SR-BI expression both in vitro and in vivo. Transient transfection studies demonstrated that LPS represses SR-Bl promoter activity in the macrophage cell line RAW 264.7. Cotransfection with either a constitutively active p21-activated protein kinase-1 (PAK1) construct (T423E) or a kinase-deficient PAR1 construct (K299R) resulted in repression of the SR-BI promoter, similar to LPS. These results demonstrate that PAK1-mediated down-regulation of the SR-BI promoter is independent of PAKI kinase activity and suggest that PAKI mediates the LPS-induced decrease in promoter activity. Cotransfection with constitutively active Cdc42 or Rac expression constructs also resulted in down-regulation of the promoter; whereas the dominant-negative Cdc42 and Rac constructs elevated basal promoter activity and blunted the LPS response. Cotransfection of PAK1 constructs containing mutations in both the kinase domain and the Cdc42/Rac-binding domain attenuated the PAR1-mediated downregulation of the promoter, suggesting that Rac and Cdc42 are required for PAK1-mediated decreases in SR-Bl promoter activity. 5'-Deletion analysis and gel shift data suggest that LPS inhibits binding of a novel transcription factor to a myeloid zing finger protein-1-like element (-476 to -456) in the human SR-BI promoter. These results demonstrate that the PAK1 pathway down-regulates the SR-BI promoter and suggest that activation of this pathway may play an important role in cholesterol trafficking in the vessel wall.	Pfizer Global Res & Dev, Dept Cardiovasc Pharmacol, Ann Arbor, MI 48105 USA	Pfizer	Hullinger, TG (corresponding author), Pfizer Global Res & Dev, Cardiovasc Therapeut Dept, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.							Abraham LA, 1998, J BONE MINER RES, V13, P818, DOI 10.1359/jbmr.1998.13.5.818; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Azim AC, 2000, BLOOD, V95, P959, DOI 10.1182/blood.V95.3.959.003k22_959_964; Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buechler C, 1999, BIOCHEM BIOPH RES CO, V262, P251, DOI 10.1006/bbrc.1999.1193; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Haeffner A, 1997, J IMMUNOL, V158, P1310; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hirano K, 1999, CIRC RES, V85, P108; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P2522, DOI 10.1210/jc.82.8.2522; Lopez D, 1999, ENDOCRINOLOGY, V140, P5669, DOI 10.1210/en.140.12.5669; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mizutani T, 2000, J BIOL CHEM, V275, P22512, DOI 10.1074/jbc.M001631200; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782; Zhu W, 2000, J IMMUNOL, V164, P6349, DOI 10.4049/jimmunol.164.12.6349	49	13	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46807	46814		10.1074/jbc.M103176200	http://dx.doi.org/10.1074/jbc.M103176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585816	hybrid			2022-12-27	WOS:000172768500019
J	Kawasaki-Nishi, S; Bowers, K; Nishi, T; Forgac, M; Stevens, TH				Kawasaki-Nishi, S; Bowers, K; Nishi, T; Forgac, M; Stevens, TH			The amino-terminal domain of the vacuolar proton-translocating ATPase a subunit controls targeting and in vivo dissociation, and the carboxyl-terminal domain affects coupling of proton transport and ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST V-ATPASE; H+-ATPASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; SORTING RECEPTOR; PREVACUOLAR COMPARTMENT; LUMINAL ACIDIFICATION; CARBOXYPEPTIDASE-Y; STRUCTURAL-CHANGES; CDNA SEQUENCE	The 100-kDa "a" subunit of the vacuolar proton-translocating ATPase (V-ATPase) is encoded by two genes in yeast, VPII1 and STV1. The Vph1p-containing complex localizes to the vacuole, whereas the Stv1p-containing complex resides in some other intracellular compartment, suggesting that the a subunit contains information necessary for the correct targeting of the V-ATPase. We show that Stv1p localizes to a late Golgi compartment at steady state and cycles continuously via a prevacuolar endosome back to the Golgi. V-ATPase complexes containing Vph1p and Stv1p also differ in their assembly properties, coupling of proton transport to ATP hydrolysis, and dissociation in response to glucose depletion. To identify the regions of the a subunit that specify these different properties, chimeras were constructed containing the cytosolic amino-terminal domain of one isoform and the integral membrane, carboxyl-terminal domain from the other isoform. Like the Stv1p-containing complex, the V-ATPase complex containing the chimera with the amino-terminal domain of Stv1p localized to the Golgi and the complex did not dissociate in response to glucose depletion. Like the Vph1p-containing complex, the V-ATPase complex containing the chimera with the amino-terminal domain of Vph1p localized to the vacuole and the complex exhibited normal dissociation upon glucose withdrawal. Interestingly, the V-ATPase complex containing the chimera with the carboxyl-terminal domain of Vph1p exhibited a higher coupling of proton transport to ATP hydrolysis than the chimera containing the carboxyl-terminal domain of Stv1p. Our results suggest that whereas targeting and in vivo dissociation are controlled by sequences located in the amino-terminal domains of the subunit a isoforms, coupling efficiency is controlled by the carboxyl-terminal region.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	Tufts University; University of Oregon	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu	Bowers, Katherine/U-2013-2019	Bowers, Katherine/0000-0001-5085-5208; Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006, R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [GM 38006, GM 34478, R01 GM034478, R37 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; Brown D, 2000, J EXP BIOL, V203, P137; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Bryant NJ, 1998, J CELL BIOL, V142, P651, DOI 10.1083/jcb.142.3.651; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; Gerrard SR, 2000, TRAFFIC, V1, P45, DOI 10.1034/j.1600-0854.2000.010108.x; Graham LA, 2000, J EXP BIOL, V203, P61; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MORANO KA, 1994, J CELL SCI, V107, P2813; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rossanese OW, 2001, J CELL BIOL, V153, P47, DOI 10.1083/jcb.153.1.47; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wieczorek H, 2000, J EXP BIOL, V203, P127; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	68	192	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47411	47420		10.1074/jbc.M108310200	http://dx.doi.org/10.1074/jbc.M108310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592965	hybrid			2022-12-27	WOS:000172768500097
J	Lam, M; Oleinick, NL; Nieminen, AL				Lam, M; Oleinick, NL; Nieminen, AL			Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells - Reactive oxygen species and mitochondrial inner membrane permeabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; TRANSITION PORE; CYCLOSPORINE-A; LETHAL INJURY; RELEASE; LOCALIZATION; HEPATOCYTES; DEATH; ACTIVATION; INHIBITION	Photodynamic therapy (PDT), a novel and promising cancer treatment that employs a combination of a photosensitizing chemical and visible light, induces apoptosis in human epidermoid carcinoma A431 cells. However, the precise mechanism of PDT-induced apoptosis is not well characterized. To dissect the pathways of PDT-induced apoptosis, we investigated the involvement of mitochondrial damage by examining a second generation photosensitizer, the silicon phthalocyanine 4 (Pc 4). By using laser-scanning confocal microscopy, we found that Pc 4 localized to cytosolic membranes primarily, but not exclusively, in mitochondria. Formation of mitochondrial reactive oxygen species (ROS) was detected within minutes when cells were exposed to Pc 4 and 670-675 nm light. This was followed by mitochondrial inner membrane permeabilization, depolarization and swelling, cytochrome c release, and apoptotic death. Desferrioxamine prevented mitochondrial ROS production and the events thereafter. Cyclosporin A plus trifluoperazine, blockers of the mitochondrial permeability transition, inhibited mitochondrial inner membrane permeabilization and depolarization without affecting mitochondrial ROS generation. These data indicate that the mitochondrial ROS are critical in initiating mitochondrial inner membrane permeabilization, which leads to mitochondrial swelling, cytochrome c release to the cytosol, and apoptotic death during PDT with Pc 4.	Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Nieminen, AL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Anat, W520,10900 Euclid Ave, Cleveland, OH 44106 USA.	axn25@po.cwru.edu			NCI NIH HHS [T32 CA 59366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; BERG K, 1994, INT J CANCER, V59, P814, DOI 10.1002/ijc.2910590618; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Chen JY, 2000, PHOTOCHEM PHOTOBIOL, V72, P541, DOI 10.1562/0031-8655(2000)072<0541:TBCAIL>2.0.CO;2; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chiu SM, 2001, CANCER LETT, V165, P51, DOI 10.1016/S0304-3835(01)00422-0; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; DOUGHERTY TJ, 1992, EUR J CANCER, V28A, P1734, DOI 10.1016/0959-8049(92)90080-L; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581; HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; Lemasters JJ, 1999, BIOCHEM SOC SYMP, V66, P205, DOI 10.1042/bss0660205; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; POHFITZPATRICK MB, 1986, PHOTODERMATOLOGY, V3, P148; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICCHELLI F, 1995, EUR J BIOCHEM, V233, P165, DOI 10.1111/j.1432-1033.1995.165_1.x; Ricchelli F, 1999, BIOCHEMISTRY-US, V38, P9295, DOI 10.1021/bi9900828; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Taguchi H, 1996, INVEST OPHTH VIS SCI, V37, P1444; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	58	258	281	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47379	47386		10.1074/jbc.M107678200	http://dx.doi.org/10.1074/jbc.M107678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579101	hybrid			2022-12-27	WOS:000172768500093
J	Pudota, BN; Hommema, EL; Hallgren, KW; McNally, BA; Lee, S; Berkner, KL				Pudota, BN; Hommema, EL; Hallgren, KW; McNally, BA; Lee, S; Berkner, KL			Identification of sequences within the gamma-carboxylase that represent a novel contact site with vitamin K-dependent proteins and that are required for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMATIC MUTATIONAL ANALYSIS; BLOOD-COAGULATION FACTORS; PROPEPTIDE BINDING-SITE; GLUTAMYL CARBOXYLASE; FACTOR-IX; CARBOXYGLUTAMIC-ACID; MAMMALIAN-CELLS; PARTIAL-PURIFICATION; COMBINED DEFICIENCY; RECOGNITION SITE	The vitamin K-dependent (VKD) carboxylase converts clusters of Glu residues to gamma -carboxylated Glu residues (Glas) in VKD proteins, which is required for their activity. VKD precursors are targeted to the carboxylase by their carboxylase recognition site, which in most cases is a propeptide. We have identified a second tethering site for carboxylase and VKD proteins that is required for carboxylase activity, called the vitamin K-dependent protein site of interaction (VKS). Several VKD proteins specifically bound an immobilized peptide comprising amino acids 343-355 of the human carboxylase (CVYKRSRGKSGQK) but not a scrambled peptide containing the same residues in a different order. Association with the 343-355 peptide was independent of propeptide binding, because the VKD proteins lacked the propeptide and because the 343-355 peptide did not disrupt association of a propeptide factor IX-carboxylase complex, Analysis with peptides that overlapped amino acids 343-355 indicated that the 343-345 CVY residues were necessary but not sufficient for prothrombin binding. Ionic interactions were also suggested because peptide-VKD protein binding could be disrupted by changes in ionic strength or pH. Mutagenesis Of Cys(343) to Ser and Tyr(345) to Phe resulted in 7-11-fold decreases in vitamin K epoxidation and peptide (EEL) substrate and carboxylase carboxylation, and kinetic analysis showed 5-6-fold increases in K-m values for the Glusubstrate. These results suggest that Cys(343) and Tyr(345) are near the catalytic center and affect the active site conformation required for correct positioning of the Glu substrate. The 343-355 VKS peptide had a higher affinity for carboxylated prothrombin (K-d = 5 mum) than uncarboxylated prothrombin (K-d = 60 mum), and the basic VKS region may also facilitate exiting of the Gla product from the catalytic center by ionic attraction. Tethering of VKD proteins to the carboxylase via the propeptide-binding site and the VKS region has important implications for the mechanism of VKD protein carboxylation, and a model is proposed for how the carboxylase VKS region may be required for efficient and processive VKD protein carboxylation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Berkner, KL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.			Berkner, Kathleen/0000-0001-8054-8081	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055666] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 55666] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; BANFIELD DK, 1994, J MOL EVOL, V38, P177, DOI 10.1007/BF00166164; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; Begley GS, 2000, J BIOL CHEM, V275, P36245, DOI 10.1074/jbc.M003944200; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; Berkner KL, 2000, J NUTR, V130, P1877, DOI 10.1093/jn/130.8.1877; Berkner KL, 1997, METHOD ENZYMOL, V282, P313; BERKNER KL, 1993, METHOD ENZYMOL, V222, P450; Berkner KL, 1998, P NATL ACAD SCI USA, V95, P466, DOI 10.1073/pnas.95.2.466; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; Chu K, 1996, J CLIN INVEST, V98, P1619, DOI 10.1172/JCI118956; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DEMETZ M, 1981, FEBS LETT, V123, P215, DOI 10.1016/0014-5793(81)80290-6; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HARBECK MC, 1989, THROMB RES, V56, P317, DOI 10.1016/0049-3848(89)90173-4; Houben RJTJ, 1999, BIOCHEM J, V341, P265, DOI 10.1042/0264-6021:3410265; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; Lingenfelter SE, 1996, BIOCHEMISTRY-US, V35, P8234, DOI 10.1021/bi9523318; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; PRICE PA, 1984, ANAL BIOCHEM, V136, P119, DOI 10.1016/0003-2697(84)90313-0; Pudota BN, 2000, P NATL ACAD SCI USA, V97, P13033, DOI 10.1073/pnas.97.24.13033; Romero EE, 1998, BIOCHEM BIOPH RES CO, V248, P783, DOI 10.1006/bbrc.1998.8987; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V251, P22, DOI 10.1006/bbrc.1998.9410; Spronk HMH, 2000, BLOOD, V96, P3650; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; Stenina O, 2001, BIOCHEMISTRY-US, V40, P10301, DOI 10.1021/bi0107039; Sugiura I, 1996, J BIOL CHEM, V271, P17837, DOI 10.1074/jbc.271.30.17837; SWANSON JC, 1982, BIOCHEMISTRY-US, V21, P6011, DOI 10.1021/bi00266a044; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; WERTMAN KF, 1992, GENETICS, V132, P337; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009	51	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46878	46886		10.1074/jbc.M108696200	http://dx.doi.org/10.1074/jbc.M108696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591726	hybrid			2022-12-27	WOS:000172768500029
J	Chen, YB; Yoo, B; Lee, JB; Weng, GZ; Iyengar, R				Chen, YB; Yoo, B; Lee, JB; Weng, GZ; Iyengar, R			The signal transfer regions of G alpha(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; CRYSTAL-STRUCTURE; IDENTIFICATION; RESIDUES; ALPHA(S); DOMAINS	The crystal structure of soluble functional fragments of adenylyl cyclase complexed with G alpha (s) and forskolin, shows three regions of G alpha (s) in direct contact with adenylyl cyclase. The functions of these three regions are not known. We tested synthetic peptides encoding these regions of G alpha (s) on the activities of full-length adenylyl cyclases 2 and 6. A peptide encoding the Switch II region (amino acids 222-247) stimulated both adenylyl cyclases 2- to 3-fold. Forskolin synergized the stimulation. Addition of peptides in the presence of activated Ga. partially inhibited G alpha (s) stimulation. Corresponding Switch II region peptides from G alpha (q) and G alpha (i) did not stimulate adenylyl cyclase. A peptide encoding the Switch I region (amino acids 199-216) also stimulated AC2 and AC6. The stimulatory effects of the two peptides at saturating concentrations were non-additive. A peptide encoding the third contact region (amino acids 268-286) located in the alpha3-beta5 region, inhibits basal, forskolin, and G alpha (s)-stimulated enzymatic activities. Since this region in G alpha (s) interacts with both the central cytoplasmic loop and C-terminal tail of adenylyl cyclases this peptide may be involved in blocking interactions between these two domains. These functional data in conjunction with the available structural information suggest that G alpha (s) activation of adenylyl cyclase is a complex event where the alpha3-beta5 loop of G alpha (s) may bring together the central cytoplasmic loop and C-terminal tail of adenylyl cyclase thus allowing the Switch I and Switch II regions to function as signal transfer regions to activate adenylyl cyclase.	Mt Sinai Med Ctr, Sch Med, Dept Pharmacol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Iyengar, R (corresponding author), Mt Sinai Med Ctr, Sch Med, Dept Pharmacol, 1 Gustave Levy,Box 1215, New York, NY 10029 USA.	ravi.iyengar@mssm.edu			NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Buck E, 2001, J BIOL CHEM, V276, P36014, DOI 10.1074/jbc.M103228200; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; Harry A, 1997, J BIOL CHEM, V272, P19017, DOI 10.1074/jbc.272.30.19017; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968	17	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45751	45754		10.1074/jbc.M107191200	http://dx.doi.org/10.1074/jbc.M107191200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579096	hybrid			2022-12-27	WOS:000172573100035
J	Muyderman, H; Angehagen, M; Sandberg, M; Bjorklund, U; Olsson, T; Hansson, E; Nilsson, M				Muyderman, H; Angehagen, M; Sandberg, M; Bjorklund, U; Olsson, T; Hansson, E; Nilsson, M			alpha(1)-Adrenergic modulation of metabotropic glutamate receptor-induced calcium oscillations and glutamate release in astrocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CA-2+ RESPONSES; IN-SITU RESPOND; CULTURED ASTROCYTES; GLIAL-CELLS; NEUROTRANSMITTER RECEPTORS; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; CORTICAL ASTROCYTES; ASTROGLIAL CELLS; ARACHIDONIC-ACID	Astrocytic responses to activation of metabotropic glutamate receptors group I (mGluRs I) and alpha (1)-adrenoreceptors in cultured cells have been assessed using spectral analyzes and calcium imaging. Concentration-dependent changes were observed after stimulation with the mGluR I agonist (S)-3,5-dihydroxyphenylglycine (DHPG). These responses changed from a regular low frequency signal with sharp peaks at 1 muM to a pronounced stage of irregularity at 10 muM. After stimulation with 100 muM the signal was again homogenous in shape and regularity but occurred at a higher frequency. In contrast, the spectral properties after stimulation with the alpha (1)-adrenoreceptor agonist phenylephrine, exhibited considerable variation for all investigated concentrations. DHPG-induced increases in [Ca2+](i) were also associated with astroglial glutamate release, whereas no release was observed after noradrenergic stimulation. Both DHPG-mediated calcium signaling and glutamate release were inhibited by preincubation with 10 or 100 muM phenylephrine. Collectively, the present investigation provides new information about the spatial-temporal characteristics of astroglial intracellular calcium responses and demonstrates distinct differences between noradrenergic and glutamatergic receptors regarding intracellular calcium signaling and coupling to glutamate release. The noradrenergic modulation of DHPG-induced responses indicates that intracellular astroglial processes can be regulated in a bi-directional feedback loop between closely connected astrocytes and neurons in the central nervous system.	Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden; Univ Gothenburg, Dept Med Biophys, SE-41345 Gothenburg, Sweden; Chalmers Univ Technol, Dept Signals & Syst, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg; University of Gothenburg; Chalmers University of Technology	Muyderman, H (corresponding author), Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden.		NILSSON, MICHAEL/ABE-7821-2020	NILSSON, MICHAEL/0000-0002-8826-1621				Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Araque A, 1999, CAN J PHYSIOL PHARM, V77, P699, DOI 10.1139/cjpp-77-9-699; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; Balazs R, 1998, J NEUROCHEM, V70, P2446; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Condorelli DF, 1999, ADV EXP MED BIOL, V468, P49; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DANI JW, 1995, CIBA F SYMP, V188, P195; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUFFY S, 1995, J NEUROSCI, V15, P5535; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HANSSON E, 1988, PROG NEUROBIOL, V30, P369, DOI 10.1016/0301-0082(88)90008-1; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; HERTZ L, 1984, PROG NEURO-PSYCHOPH, V8, P521, DOI 10.1016/0278-5846(84)90010-1; Hosli E, 2000, NEUROCHEM INT, V36, P301, DOI 10.1016/S0197-0186(99)00138-2; Innocenti B, 2000, J NEUROSCI, V20, P1800; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kulik A, 1999, J NEUROSCI, V19, P8401; LONGO EA, 1991, J BIOL CHEM, V266, P9314; Manolakis D, 1996, DIGITAL SIGNAL PROCE; MASON WT, 1988, J EXP BIOL, V139, P287; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; Muyderman H, 1998, BRAIN RES, V793, P127, DOI 10.1016/S0006-8993(98)00151-6; Muyderman H, 1997, NEUROSCI LETT, V238, P33, DOI 10.1016/S0304-3940(97)00838-0; Nakahara K, 1997, J NEUROCHEM, V69, P1467; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NILSSON M, 1991, LIFE SCI, V49, P1339, DOI 10.1016/0024-3205(91)90198-K; NILSSON M, 1991, DEV BRAIN RES, V63, P33, DOI 10.1016/0165-3806(91)90064-P; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PASTI L, 1995, J BIOL CHEM, V270, P15203, DOI 10.1074/jbc.270.25.15203; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Pasti L, 1997, J NEUROSCI, V17, P7817; PEARCE B, 1986, EUR J PHARMACOL, V121, P231, DOI 10.1016/0014-2999(86)90494-2; PEARCE B, 1985, J NEUROCHEM, V45, P1534, DOI 10.1111/j.1471-4159.1985.tb07224.x; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Porter JT, 1996, J NEUROSCI, V16, P5073; PORTER JT, 1995, GLIA, V13, P101, DOI 10.1002/glia.440130204; Ruan Y, 1998, J PHARMACOL EXP THER, V284, P576; Sanzgiri RP, 1999, J NEUROBIOL, V41, P221, DOI 10.1002/(SICI)1097-4695(19991105)41:2<221::AID-NEU5>3.3.CO;2-1; Schafer C, 1998, NATURE, V392, P239, DOI 10.1038/32567; Schools GP, 1999, J NEUROSCI RES, V58, P533, DOI 10.1002/(SICI)1097-4547(19991115)58:4<533::AID-JNR6>3.0.CO;2-G; Simpson PB, 1998, J NEUROSCI RES, V52, P672; Simpson PB, 1997, BIOCHEM J, V325, P239, DOI 10.1042/bj3250239; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; Soen Y, 1999, PHYS REV LETT, V82, P3556, DOI 10.1103/PhysRevLett.82.3556; STELLA N, 1994, J NEUROSCI, V14, P568; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Tass P, 1998, PHYS REV LETT, V81, P3291, DOI 10.1103/PhysRevLett.81.3291; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Thorlin T, 1998, J NEUROSCI RES, V54, P390, DOI 10.1002/(SICI)1097-4547(19981101)54:3<390::AID-JNR10>3.0.CO;2-#; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Wallin C, 1999, J NEUROCHEM, V73, P1566, DOI 10.1046/j.1471-4159.1999.0731566.x; Winder DG, 1996, J PHYSIOL-LONDON, V494, P743, DOI 10.1113/jphysiol.1996.sp021529; YAGODIN S, 1995, MOL CELL BIOCHEM, V149, P137, DOI 10.1007/BF01076572; Yuan LL, 1999, SCIENCE, V283, P1343, DOI 10.1126/science.283.5406.1343	61	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46504	46514		10.1074/jbc.M103849200	http://dx.doi.org/10.1074/jbc.M103849200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579082	hybrid			2022-12-27	WOS:000172573100136
J	Loven, MA; Likhite, VS; Choi, I; Nardulli, AM				Loven, MA; Likhite, VS; Choi, I; Nardulli, AM			Estrogen response elements alter coactivator recruitment through allosteric modulation of estrogen receptor beta conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; TRANSCRIPTIONAL COACTIVATOR; HORMONE RECEPTORS; BINDING DOMAINS; ER-BETA; DNA; ACTIVATION; SEQUENCE; REGION; MCF-7	Estrogen receptor beta (ER beta) activates transcription by binding to estrogen response elements (EREs) and coactivator proteins that act as bridging proteins between the receptor and the basal transcription machinery. Although the imperfect vitellogenin B1, pS2, and oxytocin (OT) EREs each differ from the consensus vitellogenin A2 ERE sequence by a single base pair, ER beta activates transcription of reporter plasmids containing A2, pS2, Bl, and OT EREs to different extents. To explain how these differences in transactivation might occur, we have examined the interaction of ER beta with these EREs and monitored recruitment of the coactivators amplified in breast cancer (AIB1) and transcription intermediary factor 2 (TIF2). Protease sensitivity, antibody interaction, and DNA pull-down assays demonstrated that ER beta undergoes ERE-dependent changes in conformation resulting in differential recruitment of AI beta1 and TIF2 to the DNA-bound receptor. Overexpression of TIF2 or AIB1 in transient transfection assays differentially enhanced ER beta -mediated transcription of reporter plasmids containing the A2, pS2, B1, and OT EREs. Our studies demonstrate that individual ERE sequences induce changes in conformation of the DNA-bound receptor and influence coactivator recruitment. DNA-induced modulation of receptor conformation may contribute to the ability of ER beta to differentially activate transcription of genes containing divergent ERE sequences.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Nardulli, AM (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NCI NIH HHS [CA18119] Funding Source: Medline; NICHD NIH HHS [5T32 HD07028] Funding Source: Medline; NIDDK NIH HHS [DK53884] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007028] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053884, R01DK053884] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Choi I, 2001, MOL CELL ENDOCRINOL, V181, P139, DOI 10.1016/S0303-7207(01)00492-0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; ECKERT RL, 1982, CANCER RES, V42, P139; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hanstein B, 1999, MOL ENDOCRINOL, V13, P129, DOI 10.1210/me.13.1.129; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; NUNEZ AM, 1987, ENDOCRINOLOGY, V121, P1759, DOI 10.1210/endo-121-5-1759; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; ONATE SA, 1995, SCIENCE, V270, P1354; Peters GA, 1999, MOL ENDOCRINOL, V13, P286, DOI 10.1210/me.13.2.286; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Takeshita A, 1998, J BIOL CHEM, V273, P21554, DOI 10.1074/jbc.273.34.21554; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VOEGEL JJ, 1996, EMBO J, V15, P101; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114	45	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45282	45288		10.1074/jbc.M106211200	http://dx.doi.org/10.1074/jbc.M106211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574541	hybrid			2022-12-27	WOS:000172406700123
J	Masters, SC; Fu, H				Masters, SC; Fu, H			14-3-3 proteins mediate an essential anti-apoptotic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOENZYME-S; PHOSPHOINOSITIDE 3-KINASE; SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS-AERUGINOSA; AMPHIPATHIC GROOVE; 14-3-3-PROTEINS; PHOSPHORYLATION; SURVIVAL; KINASE; DEATH	The 14-3-3 proteins are a family of highly conserved eukaryotic regulatory molecules that play important roles in many biological processes including cell cycle control and regulation of cell death. They are able to carry out these effects through binding and modulating the activity of a host of signaling proteins. The ability of 14-3-3 to inhibit Bad and other proapoptotic proteins argues that 14-3-3 can support cell survival. To examine this issue in a global sense, a specific inhibitor of 14-3-3/ligand interactions, difopein, was used. Difopein expression led to induction of apoptosis. Studies using various components of survival and death signaling pathways were consistent with a vital role for 14-3-3/ligand interactions in signal transduction from upstream pro-survival kinases to the core apoptotic machinery. Because these kinases often become activated during oncogenesis, the effect of difopein on cell death induced by antineoplastic drugs was examined. It was found that difopein enhances the ability of cisplatin to kill cells. These data support the model that 14-3-3, through binding to Bad and other ligands, is critical for cell survival signaling. Inhibition of 14-3-3 may represent a useful therapeutic target for treatment of cancer and other diseases involving inappropriate cell survival.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA	Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.				NIGMS NIH HHS [GM60033, GM53165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060033, R01GM053165, R29GM053165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARANTEMENDES GP, 1998, CELLS LAB MANUAL, V1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Henriksson ML, 2000, BIOCHEM J, V349, P697, DOI 10.1042/bj3490697; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MASTERS SC, 2001, IN PRESS MOL PHARM; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; YAFFE MB, 1997, CELL, V91, P9619; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	32	241	258	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45193	45200		10.1074/jbc.M105971200	http://dx.doi.org/10.1074/jbc.M105971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577088	hybrid			2022-12-27	WOS:000172406700112
J	Sarin, J; Aggarwal, S; Chaba, R; Varshney, GC; Chakraborti, PK				Sarin, J; Aggarwal, S; Chaba, R; Varshney, GC; Chakraborti, PK			B-subunit of phosphate-specific transporter from Mycobacterium tuberculosis is a thermostable ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-BINDING; MALTOSE TRANSPORT; ABC TRANSPORTER; MULTIDRUG-RESISTANCE; ENCODING PROTEINS; BACILLUS-SUBTILIS; TRAFFIC ATPASE	The B-subunit of phosphate-specific transporter (PstB) is an ABC protein. pstB was polymerase chain reaction-amplified from Mycobacterium tuberculosis and overexpressed in Escherichia coli. The overexpressed protein was found to be in inclusion bodies. The protein was solubilized using 1.5% N-lauroylsarcosine and was purified by gel permeation chromatography. The molecular mass of the protein was similar to 31 kDa. The eluted protein showed ATP-binding ability and exhibited ATPase activity. Among different nucleotide triphosphates, ATP was found to be the preferred substrate for M. tuberculosis PstB-ATPase. The study of the kinetics of ATP hydrolysis yielded K-m of similar to 72 muM and V-max of similar to0.12 mu mol/min/mg of protein. Divalent cation like manganese was inhibitory to the ATPase activity. Magnesium or calcium, on the other hand, had no influence on the functionality of the enzyme. The classical ATPase inhibitors like sodium azide, sodium vanadate, and N-ethylmaleimide were without any effect but an ATP analogue, 5'-p-fluorosulfonylbenzoyl adenosine, inhibited the ATPase function of the recombinant protein with a K-i of similar to0.40 mM. Furthermore, there was hardly any ATP hydrolyzing ability of the PstB as a result of mutation of the conserved aspartic acid residue to lysine in the Walker motif B, confirming the recombinant protein is an ATPase. Interestingly, analysis of the recombinant PstB revealed that it is a thermostable ATPase; thus, our results highlight for the first time the presence of such an enzyme in any mesophilic bacteria.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Chakraborti, PK (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.							ANOSTARIO M, 1990, ANAL BIOCHEM, V190, P60, DOI 10.1016/0003-2697(90)90133-T; Banerjee SK, 1998, FEBS LETT, V425, P151, DOI 10.1016/S0014-5793(98)00214-2; Banerjee SK, 2000, MOL GEN GENET, V262, P949, DOI 10.1007/PL00008663; Bhatt K, 2000, EUR J BIOCHEM, V267, P4028, DOI 10.1046/j.1432-1327.2000.01437.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braibant M, 1996, FEBS LETT, V394, P206, DOI 10.1016/0014-5793(96)00953-2; Braibant M, 2000, FEMS MICROBIOL REV, V24, P449, DOI 10.1111/j.1574-6976.2000.tb00550.x; Chakravarty S, 2000, FEBS LETT, V470, P65, DOI 10.1016/S0014-5793(00)01267-9; Chan FY, 1996, J BACTERIOL, V178, P3974, DOI 10.1128/jb.178.13.3974-3977.1996; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coligan JE, 1995, CURRENT PROTOCOLS PR; Cross SJ, 1996, BIOCHEM J, V316, P615, DOI 10.1042/bj3160615; DEAN DA, 1990, J BIOL CHEM, V265, P21005; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HANLEY P, 1999, P NATL ACAD SCI USA, V96, P3578; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 1999, FEBS LETT, V448, P131, DOI 10.1016/S0014-5793(99)00356-7; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Lefevre P, 1997, J BACTERIOL, V179, P2900, DOI 10.1128/jb.179.9.2900-2906.1997; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Morlang S, 1999, J MOL BIOL, V294, P795, DOI 10.1006/jmbi.1999.3282; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Novak R, 1999, J BACTERIOL, V181, P1126, DOI 10.1128/JB.181.4.1126-1133.1999; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Qi Y, 1997, J BACTERIOL, V179, P2534, DOI 10.1128/jb.179.8.2534-2539.1997; Quentin Y, 1999, J MOL BIOL, V287, P467, DOI 10.1006/jmbi.1999.2624; Rana S, 1999, J MOL BIOL, V286, P669, DOI 10.1006/jmbi.1998.2505; Sambrook J., 2002, MOL CLONING LAB MANU; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; STUDIER OFW, 1990, METHOD ENZYMOL, V185, P60; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WAKAGI T, 1985, BIOCHIM BIOPHYS ACTA, V817, P33, DOI 10.1016/0005-2736(85)90065-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; WANNER BL, 1996, E COLI SALMONELLA CE, V1, P1356; WEBB DC, 1992, J BIOL CHEM, V267, P24661; Welsh MJ, 1998, NATURE, V396, P623, DOI 10.1038/25234	50	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44590	44597		10.1074/jbc.M105401200	http://dx.doi.org/10.1074/jbc.M105401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567022	hybrid			2022-12-27	WOS:000172406700035
J	Yin, L; Laevsky, G; Giardina, C				Yin, L; Laevsky, G; Giardina, C			Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; QUIESCENT ULCERATIVE-COLITIS; COLONIC EPITHELIAL-CELLS; SODIUM-BUTYRATE; DIETARY FIBER; CANCER CELLS; WHEAT BRAN; PROTEOLYTIC PATHWAY; GENE-EXPRESSION; BETA-CATENIN	Butyrate is derived from the microbial metabolism of dietary fiber in the colon where it plays an important role in linking colonocyte turnover and differentiation to luminal content. In addition, butyrate appears to have both anti-inflammatory and cancer chemopreventive activities. Using confocal microscopy and cell fractionation studies, butyrate pretreatment of a human colon cell line (HT-29 cells) inhibited the tumor necrosis factor-alpha (TNF-alpha)-induced nuclear translocation of the proinflammatory transcription factor NF-kappaB. Butyrate inhibited NF-kappaB DNA binding within 30 min of TNF-alpha stimulation, consistent with an inhibition of nuclear translocation. I kappaB.NF-kappaB complexes extracted from butyrate-treated cells were relatively resistant to in vitro dissociation by deoxycholate, suggesting a change in cellular I kappaB composition. Butyrate treatment increased p100 expression, an I kappaB that was not degraded upon TNF-alpha treatment. Butyrate also reduced the extent of TNF-alpha -induced I kappaB-alpha degradation and enhanced the presence of ubiquitin-conjugated I kappaB-alpha. The suppression of I kappaB-alpha degradation corresponded with a reduction in cellular proteasome activity as determined by in vitro proteasome assays and the increased presence of ubiquitin-conjugated proteins. The butyrate suppression of I kappaB-alpha degradation and proteasome activity may derive from its ability to inhibit histone deacetylases since the specific deacetylase inhibitor trichostatin A had similar effects. These results suggest a potential mechanism for the anti-inflammatory activity of butyrate and demonstrate the interplay between short chain fatty acids and cellular proteasome activity.	Univ Connecticut, Dept Mol & Cellular Biol, Storrs, CT 06269 USA	University of Connecticut	Giardina, C (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 75 N Eagleville Rd,U-125, Storrs, CT 06269 USA.	Giardina@uconnvm.uconn.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; ANTALIS TM, 1995, INT J CANCER, V62, P619, DOI 10.1002/ijc.2910620521; Avivi-Green C, 2000, ONCOL RES, V12, P83, DOI 10.3727/096504001108747558; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Barshishat M, 2000, BRIT J CANCER, V82, P195; Benard O, 1997, MOL CELL BIOCHEM, V170, P109, DOI 10.1023/A:1006892929652; BINDER HJ, 1989, GASTROENTEROLOGY, V96, P989, DOI 10.1016/0016-5085(89)91614-4; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BOFFA LC, 1992, CANCER RES, V52, P5906; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakravortty D, 2000, J ENDOTOXIN RES, V6, P243, DOI 10.1179/096805100101532108; CHAPMAN MAS, 1995, BRIT J SURG, V82, P36, DOI 10.1002/bjs.1800820115; CHAPMAN MAS, 1994, GUT, V35, P1152, DOI 10.1136/gut.35.8.1152-a; CHAPMAN MAS, 1994, GUT, V35, P73, DOI 10.1136/gut.35.1.73; Ciechanover A, 2000, J CELL BIOCHEM, P40; Compher CW, 1999, JPEN-PARENTER ENTER, V23, P269, DOI 10.1177/0148607199023005269; Crinelli R, 1999, EUR J BIOCHEM, V263, P202, DOI 10.1046/j.1432-1327.1999.00485.x; Csordas A, 1996, EUR J CANCER PREV, V5, P221, DOI 10.1097/00008469-199608000-00002; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; EDMONDS CJ, 1982, PHILOS T ROY SOC B, V299, P575, DOI 10.1098/rstb.1982.0153; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Giardina C, 1998, BBA-MOL CELL RES, V1401, P277, DOI 10.1016/S0167-4889(97)00140-7; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOPE R, 1993, CELL MOL BIOL, V39, P589; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1996, P NUTR SOC, V55, P937, DOI 10.1079/PNS19960090; Hallahan DE, 2000, INT J RADIAT ONCOL, V47, P859, DOI 10.1016/S0360-3016(00)00517-4; Hassig CA, 1997, CHEM BIOL, V4, P783, DOI 10.1016/S1074-5521(97)90111-3; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hodin R, 2000, GASTROENTEROLOGY, V118, P798, DOI 10.1016/S0016-5085(00)70150-8; HOWARD MD, 1995, J NUTR, V125, P2604; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; JACOBS LR, 1987, PREV MED, V16, P566, DOI 10.1016/0091-7435(87)90073-9; JACOBS LR, 1986, CANCER RES, V46, P1727; JACOBS LR, 1983, AM J CLIN NUTR, V37, P945, DOI 10.1093/ajcn/37.6.945; JACOBS LR, 1984, AM J PHYSIOL, V246, pG378, DOI 10.1152/ajpgi.1984.246.4.G378; Jobin C, 1997, J IMMUNOL, V158, P226; Kanauchi O, 1999, J GASTROEN HEPATOL, V14, P880, DOI 10.1046/j.1440-1746.1999.01971.x; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Luciano L, 1996, CELL TISSUE RES, V286, P81, DOI 10.1007/s004410050677; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Maki CG, 1996, CANCER RES, V56, P2649; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PETIT JM, 1993, ANTICANCER RES, V13, P487; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHEPPACH W, 1992, GASTROENTEROLOGY, V103, P51, DOI 10.1016/0016-5085(92)91094-K; SCHEPPACH W, 1995, EUR J CANCER, V31A, P1077, DOI 10.1016/0959-8049(95)00165-F; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SOULEIMANI A, 1993, FEBS LETT, V326, P45, DOI 10.1016/0014-5793(93)81758-R; SOULEIMANI A, 1993, BIOCHEM BIOPH RES CO, V193, P330, DOI 10.1006/bbrc.1993.1628; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Takahashi T, 1999, CANCER LETT, V141, P139, DOI 10.1016/S0304-3835(99)00096-8; Thomas GL, 1996, IN VITRO CELL DEV-AN, V32, P505; Tomoda H, 2000, YAKUGAKU ZASSHI, V120, P935, DOI 10.1248/yakushi1947.120.10_935; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; UMESAKI Y, 1979, PFLUG ARCH EUR J PHY, V379, P43, DOI 10.1007/BF00622903; Velazquez OC, 1996, DIGEST DIS SCI, V41, P727, DOI 10.1007/BF02213129; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P169; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wachtershauser A, 2000, EUR J NUTR, V39, P164, DOI 10.1007/s003940070020; Whiteley LO, 2000, NUTR CANCER, V36, P131, DOI 10.1207/S15327914NC3602_1; Williams A, 1999, SURGERY, V126, P744, DOI 10.1067/msy.2099.99888; Wilson L, 1999, GASTROENTEROLOGY, V117, P106, DOI 10.1016/S0016-5085(99)70556-1; Wu GD, 1999, J LEUKOCYTE BIOL, V66, P1049, DOI 10.1002/jlb.66.6.1049	85	211	222	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44641	44646		10.1074/jbc.M105170200	http://dx.doi.org/10.1074/jbc.M105170200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572859	hybrid			2022-12-27	WOS:000172406700042
J	Makowski, AM; Dutnall, RN; Annunziato, AT				Makowski, AM; Dutnall, RN; Annunziato, AT			Effects of acetylation of histone H4 at lysines 8 and 16 on activity of the Hat1 histone acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; ASSEMBLY FACTOR-I; DNA-REPLICATION; CHROMATIN; YEAST; H3; PHOSPHORYLATION; PURIFICATION; ASSOCIATION; TETRAHYMENA	During nucleosome assembly in vivo, newly synthesized histone H4 is specifically diacetylated. on lysines 5 and 12 within the H4 NH2-terminal tail domain. The highly conserved "K5/K12" deposition pattern of acetylation is thought to be generated by the Hat1 histone acetyltransferase, which in vivo is found in the HAT-B complex. In the following report, the activity and substrate specificity of the human HAT-B complex and of recombinant yeast Hat1p have been examined, using synthetic H4 NH2-terminal peptides as substrates. As expected, the unacetylated H4 peptide was a good substrate for acetylation by yeast Hat1p and human RAT-B, while the K5/K12-diacetylated peptide was not significantly acetylated. Notably, an H4 peptide previously diacetylated on lysines 8 and 16 was a very poor substrate for acetylation by either yeast Hat1p or human RAT-B. Treating the K8/KI6-diacetylated peptide with histone deacetylase prior to the HAT-B reaction raised acetylation at K5/K12 to 70-80% of control levels. These results present strong support for the model of H4-Hat1p interaction proposed by Dutnall et al. (Dutnall, R. N., Tafrov, S. T., Sternglanz, R., and Ramakrishnan, V. (1998) Cell 94, 427-438) and provide evidence for the first time that site-specific acetylation of histones can regulate the acetylation of other substrate sites.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	Boston College; University of California System; University of California San Diego	Annunziato, AT (corresponding author), Boston Coll, Dept Biol, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035837] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35837] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; ANNUNZIATO AT, 1982, J BIOL CHEM, V257, P8507; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Dutnall RN, 1998, COLD SPRING HARB SYM, V63, P501, DOI 10.1101/sqb.1998.63.501; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; Imhof A, 1999, BIOCHEMISTRY-US, V38, P13085, DOI 10.1021/bi9912490; INOUE A, 1970, BIOCHIM BIOPHYS ACTA, V220, P307, DOI 10.1016/0005-2744(70)90015-X; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kolle D, 1998, FEBS LETT, V421, P109, DOI 10.1016/S0014-5793(97)01544-5; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lusser A, 1999, NUCLEIC ACIDS RES, V27, P4427, DOI 10.1093/nar/27.22.4427; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; VANHOLDE KE, 1988, CHROMATIN SPRINGER S; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 2000, GENE DEV, V14, P1430; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wolffe A. P., 1999, CHROMATIN STRUCTURE; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	40	37	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43499	43502		10.1074/jbc.C100549200	http://dx.doi.org/10.1074/jbc.C100549200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11585814	hybrid			2022-12-27	WOS:000172297700004
J	Ardon, O; Bussey, H; Philpott, C; Ward, DM; Davis-Kaplan, S; Verroneau, S; Jiang, B; Kaplan, J				Ardon, O; Bussey, H; Philpott, C; Ward, DM; Davis-Kaplan, S; Verroneau, S; Jiang, B; Kaplan, J			Identification of a Candida albicans ferrichrome transporter and its characterization by expression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBIAL IRON TRANSPORT; USTILAGO-MAYDIS; GENE; PERMEASE; ENCODES; YEAST; SIDEROPHORES	Saccharomyces cerevisiae can accumulate iron through the uptake of siderophore-iron. Siderophore-iron uptake can occur through the reduction of the complex and the subsequent uptake of iron by the high affinity iron transporter Fet3p/Ftr1p. Alternatively, specific siderophore transporters can take up the siderophore-iron complex. The pathogenic fungus Candida albicans can also take up siderophore-iron. Here we identify a C. albicans siderophore transporter, CaArn1p, and characterize its activity. CaARN1 is transcriptionally regulated in response to iron. Through expression studies in S. cerevisiae strains lacking endogenous siderophore transporters, we demonstrate that CaArn1p specifically mediates the uptake of ferrichrome-iron. Iron-ferrichrome and gallium-ferrichrome, but not desferri-ferrichrome, could competitively inhibit the uptake of iron from ferrichrome. Uptake of siderophore-iron resulting from expression of CaARN1 under the control of the MET25-promoter in S. cerevisiae was independent of the iron status of the cells and of Aft1p, the iron-sensing transcription factor. These studies demonstrate that the expression of CaArn1p is both necessary and sufficient for the non-reductive uptake of ferrichrome-iron and suggests that the transporter may be the only required component of the siderophore uptake system that is regulated by iron and Aft1p.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; McGill Univ, Dept Biol, Montreal, PQ M3A 25T, Canada; NIDDK, Liver Dis Sect, NIH, Bethesda, MD USA; Elitra, Montreal, PQ H2X 248, Canada	Utah System of Higher Education; University of Utah; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu		Ardon, Orly/0000-0001-8147-933X	NCI NIH HHS [5 P30 CA 42014] Funding Source: Medline; NIDDK NIH HHS [DK 30534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, Z01DK054507, R01DK030534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ardon O, 1998, J BACTERIOL, V180, P2021, DOI 10.1128/JB.180.8.2021-2026.1998; Ardon O, 1997, MICROBIOL-UK, V143, P3625, DOI 10.1099/00221287-143-11-3625; Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; De Luca NG, 2000, ADV MICROB PHYSIOL, V43, P39, DOI 10.1016/S0065-2911(00)43002-X; Diarra MS, 1996, ANTIMICROB AGENTS CH, V40, P2610, DOI 10.1128/AAC.40.11.2610; Eck R, 1999, MICROBIOL-UK, V145, P2415, DOI 10.1099/00221287-145-9-2415; EMERY T, 1971, BIOCHEMISTRY-US, V10, P1483, DOI 10.1021/bi00784a033; FONZI WA, 1993, GENETICS, V134, P717; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Howard DH, 1999, CLIN MICROBIOL REV, V12, P394, DOI 10.1128/CMR.12.3.394; ISMAIL A, 1986, MYCOPATHOLOGIA, V96, P109, DOI 10.1007/BF00436669; ISMAIL A, 1985, BIOCHEM BIOPH RES CO, V130, P885, DOI 10.1016/0006-291X(85)90499-1; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; MINNICK AA, 1991, ANAL BIOCHEM, V194, P223, DOI 10.1016/0003-2697(91)90171-O; Moore DD, 1995, GLOB MOB SURV; Morrissey JA, 1996, MICROBIOL-UK, V142, P485, DOI 10.1099/13500872-142-3-485; Neilands J.B., 1987, IRON TRANSPORT MICRO, P3; NEILANDS JB, 1981, ANNU REV BIOCHEM, V50, P715, DOI 10.1146/annurev.bi.50.070181.003435; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Nudelman R, 1998, J MED CHEM, V41, P1671, DOI 10.1021/jm970581b; Ramanan N, 2000, SCIENCE, V288, P1062, DOI 10.1126/science.288.5468.1062; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10691, DOI 10.1073/pnas.200318797; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	34	47	49	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43049	43055		10.1074/jbc.M108701200	http://dx.doi.org/10.1074/jbc.M108701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562378	hybrid			2022-12-27	WOS:000172169300056
J	Mason, JM; Xu, HP; Rao, SK; Leask, A; Barcia, M; Shan, JD; Stephenson, R; Tabibzadeh, S				Mason, JM; Xu, HP; Rao, SK; Leask, A; Barcia, M; Shan, JD; Stephenson, R; Tabibzadeh, S			Lefty contributes to the remodeling of extracellular matrix by inhibition of connective tissue growth factor and collagen mRNA expression and increased proteolytic activity in a fibrosarcoma model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; BETA TGF-BETA; HUMAN-FIBROBLASTS; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION; STROMAL FIBROBLASTS; MOLECULAR-CLONING; PROGELATINASE-A; LUNG FIBROSIS; MESSENGER-RNA	Homeostasis of the extracellular matrix (ECM) of tissues is regulated by controlling deposition and degradation of ECM proteins. The breakdown of ECM is essential in blastocyst implantation and embryonic development, tissue morphogenesis, menstrual shedding, bone formation, tissue resorption after delivery, and tumor growth and invasion. TGF-beta family members are one of the classes of proteins that actively participate in the homeostasis of ECM. Here, we report on the effect of lefty, a novel member of the TGF-beta family, on the homeostasis of extracellular matrix in a fibrosarcoma model. Fibroblastic cells forced to express lefty by retroviral transduction lost their ability to deposit collagen in vivo. This event was associated with down-regulation of the steady-state level of connective tissue growth factor that induces collagen type I mRNA. In addition, lefty transduction significantly decreased collagen type I mRNA expression and simultaneously increased collagenolytic, gelatinolytic, elastolytic, and caseinolytic activities in vivo by the transduced fibroblasts. These findings provide a new insight on the actions of lefty and suggest that this cytokine plays an active role in remodeling of the extracellular matrix in vivo.	N Shore Long Isl Jewish Res Inst, Dept Pathol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Res Inst, Gene Therapy Vector Lab, Res Dept, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Res Inst, Dept Mol Oncol, Manhasset, NY 11030 USA; NYU, Sch Med, Manhasset, NY 11030 USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA; FibroGen Inc, San Francisco, CA 94080 USA	Northwell Health; Northwell Health; Northwell Health; New York University; Northwell Health; Yeshiva University; FibroGen	Tabibzadeh, S (corresponding author), Frontiers Biosci, POB 160, Searingtown, NY 11507 USA.	tabibzadeh@bioscience.org	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015					Akagi Y, 1996, KIDNEY INT, V50, P148, DOI 10.1038/ki.1996.297; Asakura S, 1999, HUM PATHOL, V30, P195, DOI 10.1016/S0046-8177(99)90275-7; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Berndt A, 1995, HISTOCHEM J, V27, P1014; Bettinger DA, 1996, PLAST RECONSTR SURG, V98, P827, DOI 10.1097/00006534-199610000-00012; Bieth JG, 1986, REGULATION MATRIX AC, P217; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Cadene M, 1997, J BIOL CHEM, V272, P9950, DOI 10.1074/jbc.272.15.9950; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Clark RAF, 1997, J CELL PHYSIOL, V170, P69; Coker RK, 1997, AM J PATHOL, V150, P981; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Edwards DR, 1996, EXP GERONTOL, V31, P207, DOI 10.1016/0531-5565(95)02010-1; El-Gamel A, 1998, EUR J CARDIO-THORAC, V13, P424, DOI 10.1016/S1010-7940(98)00048-7; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; FRANZEN L, 1994, IN VITRO CELL DEV-AN, V30A, P460; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; GILFILLAN RF, 1968, CANCER RES, V28, P137; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hao JM, 1999, J MOL CELL CARDIOL, V31, P667, DOI 10.1006/jmcc.1998.0902; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Islam M, 2001, KIDNEY INT, V59, P498, DOI 10.1046/j.1523-1755.2001.059002498.x; KAHARI VM, 1991, LAB INVEST, V64, P807; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Khanna AK, 1999, TRANSPLANTATION, V67, P882, DOI 10.1097/00007890-199903270-00016; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kothapalli R, 1997, J CLIN INVEST, V99, P2342, DOI 10.1172/JCI119415; Kubo M, 1998, BRIT J DERMATOL, V139, P192; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Lohr M, 2001, CANCER RES, V61, P550; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; Martinet Y, 1996, ARCH TOX S, V18, P127; Mason JM, 1998, GENE THER, V5, P1098, DOI 10.1038/sj.gt.3300703; MASON JM, 2001, CLIN ORTHOPAEDICS, V379, pS171; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mathrubutham M, 2001, FRONT BIOSCI-LANDMRK, V6, pA13, DOI 10.2741/Mathrub; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEUMANN U, 1994, J BIOL CHEM, V269, P21561; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; OVERALL CM, 1989, CONNECT TISSUE RES, V20, P289, DOI 10.3109/03008208909023899; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Polo M., 1997, Journal of Burn Care and Rehabilitation, V18, P477, DOI 10.1097/00004630-199711000-00002; Querfeld C, 2000, BRIT J DERMATOL, V142, P1228, DOI 10.1046/j.1365-2133.2000.03579.x; Randall K, 1996, INT J RADIAT BIOL, V70, P351, DOI 10.1080/095530096145085; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SLAVIN J, 1994, GROWTH FACTORS, V11, P205, DOI 10.3109/08977199409046918; TABIBZADEH S, 1995, HUM REPROD, V10, P1579, DOI 10.1093/HUMREP/10.6.1579; TABIBZADEH S, 1997, FRONT BIOSCI, V2, P18; TABIBZADEH SS, 1985, J HISTOCHEM CYTOCHEM, V33, P884, DOI 10.1177/33.9.2410482; THOMPSON RW, 1995, J CLIN INVEST, V96, P318, DOI 10.1172/JCI118037; Ulloa L, 2001, J BIOL CHEM, V276, P21397, DOI 10.1074/jbc.M010783200; Ulloa L, 2001, J BIOL CHEM, V276, P21387, DOI 10.1074/jbc.M006933200; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Velasco G, 2000, CANCER RES, V60, P877; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	86	29	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					407	415		10.1074/jbc.M108103200	http://dx.doi.org/10.1074/jbc.M108103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11572876	hybrid			2022-12-27	WOS:000173087900055
J	Lin, MT; Lee, RC; Yang, PC; Ho, FM; Kuo, ML				Lin, MT; Lee, RC; Yang, PC; Ho, FM; Kuo, ML			Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells - Involvement of phosphatidylinositol 3-kinase/Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; INDUCED APOPTOSIS; CANCER CELLS; EXPRESSION; MCL-1; GENE; CARCINOMA; BCL-2; TUMORIGENESIS; ACTIVATORS	Cyclooxygenase 2 (COX-2) has been reported to be commonly expressed in advanced stages of human lung adenocarcinoma. In this study, the COX-2 constitutive expression vector was transfected into a human lung adenocarcinoma cell line CL1.0 and several clones were obtained which stably expressed COX-2. These COX-2-overexpressed clones demonstrated remarkable resistance to apoptosis induced by Ultraviolet B (UVB) irradiation, vinblastine B (VBL) cell lymphoma-2 (Bcl-2), or other anti-cancer drugs. To understand how COX-2 prevents apoptosis, the investigators examined the expression level of Bcl-2 family members. Mcl-1, but not other Bcl-2 members, was significantly up-regulated by COX-2 transfection or prostaglandin E, (PGE(2)) treatment. Treatment of COX-2-overexpressed cells (cox-2/cl.4) with two specific COX-2 inhibitors, NS-398 and celecoxib, caused an effective reduction of the increased level of Mcl-1. These data suggest that the expression level of Mcl-1 is tightly regulated by COX-2. Moreover, transfection of cox-2/cl.4 cells with antisense Mcl-1 enhanced apoptosis induced by UVB irradiation, revealing that Mcl-1 plays a crucial role in cell survival activity mediated by COX-2. Furthermore, COX-2 transfection or PGE(2), treatment evidently activated the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Inhibition of the PI3K pathway by LY294002 or wortmannin effectively attenuated the increased level of Mcl-1 induced by COX-2 or PGE(2). Blocking the PI3K activity with a dominant-negative vector, DN-p85, also greatly diminished the level of Mcl-1 and enhanced UVB-elicited cell death in cells transfected by COX-2. In a similar way, LY294002 inhibited cell survival and Mcl-1 level in PGE(2)-treated CL1.0 cells. These findings suggest that COX-2 promotes cell survival by up-regulating the level of Mcl-1 by activating the PI3K/Akt-dependent pathway.	Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Tao Yuan Gen Hosp, Tao Yuan 330, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Kuo, ML (corresponding author), Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, 1 Sec 1 Jen Ai Rd, Taipei 100, Taiwan.		Yang, Pan-Chyr/B-8808-2009; Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; LIN, MING-TSAN/0000-0001-7313-7057; YANG, PAN-CHYR/0000-0001-6330-6048				Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hida T, 1998, CANCER RES, V58, P3761; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KELLEY RJ, 1998, AM J PHYSIOL, V274, pL990; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; Noel A, 1997, INVAS METAST, V17, P221; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rioux N, 1998, CANCER RES, V58, P5354; Ristimaki A, 1997, CANCER RES, V57, P1276; SANO H, 1995, CANCER RES, V55, P3785; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wolff H, 1998, CANCER RES, V58, P4997; Zimmermann KC, 1999, CANCER RES, V59, P198	34	160	175	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48997	49002		10.1074/jbc.M107829200	http://dx.doi.org/10.1074/jbc.M107829200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11585835	hybrid			2022-12-27	WOS:000173922100051
J	Le Roy, F; Bisbal, C; Silhol, M; Martinand, C; Lebleu, B; Salehzada, T				Le Roy, F; Bisbal, C; Silhol, M; Martinand, C; Lebleu, B; Salehzada, T			The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; APOPTOSIS; ACTIVATION; CLONING; IMPORT; LOCALIZATION; EXPRESSION; MEMBRANE; CLEAVAGE; SIGNAL	Interferon alpha (IFN alpha) belongs to a cytokine family that exhibits antiviral properties, immuno-modulating effects, and antiproliferative activity on normal and neoplasic cells in vitro and in vivo. IFN alpha exerts antitumor action by inducing direct cytotoxicity against tumor cells. This toxicity is at least partly due to induction of apoptosis. Although the molecular basis of the inhibition of cell growth by IFN alpha is only partially understood, there is a direct correlation between the sensitivity of cells to the antiproliferative action of IFN alpha and the down-regulation of their mitochondrial mRNAs. Here, we studied the role of the 2-5A/RNase L system and its inhibitor RLI in this regulation of the mitochondrial mRNAs by IFNa. We found that a fraction of cellular RNase L and RLI is localized in the mitochondria. Thus, we down-regulated RNase L activity in human H9 cells by stably transfecting (i) RNase L antisense cDNA or (ii) RLI sense cDNA constructions. In contrast to control cells, no post-transcriptional down-regulation of mitochondrial mRNAs and no cell growth inhibition were observed after IFN alpha treatment in these transfectants. These results demonstrate that IFNa exerts its antiproliferative effect on H9 cells at least in part via the degradation of mitochondrial mRNAs by RNase L.	Inst Genet Mol, EP2030 CNRS, F-34293 Montpellier, France	Universite de Montpellier	Bisbal, C (corresponding author), Inst Human Genet, UPR CNRS 1142, 141 Rue Cardonille, F-34396 Montpellier, France.	Catherine.Bisbal@igh.cnrs.fr	Le Roy, florence/J-7455-2013; Bisbal, Catherine/I-6984-2016	Bisbal, Catherine/0000-0003-1086-020X				BAYARD B, 1984, EUR J BIOCHEM, V142, P291, DOI 10.1111/j.1432-1033.1984.tb08284.x; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; BONNIEU A, 1989, ONCOGENE, V4, P881; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Enriquez J A, 1996, Methods Enzymol, V264, P50, DOI 10.1016/S0076-6879(96)64008-7; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JARVIS JA, 1995, J BIOL CHEM, V270, P1323, DOI 10.1074/jbc.270.3.1323; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KELLY JM, 1986, EMBO J, V5, P1601, DOI 10.1002/j.1460-2075.1986.tb04402.x; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Lewis JA, 1996, J BIOL CHEM, V271, P13184, DOI 10.1074/jbc.271.22.13184; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOU J, 1994, J INTERFERON RES, V14, P33, DOI 10.1089/jir.1994.14.33; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Pelicano L, 1998, B CANCER, V85, P313; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; REID GA, 1982, J BIOL CHEM, V257, P3056; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; Rusch L, 2000, J INTERF CYTOK RES, V20, P1091, DOI 10.1089/107999000750053762; Sambrook J., 1989, MOL CLONING LAB MANU, P3; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VON HG, 1989, EUR J BIOCHEM, V180, P535; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Waterhouse NJ, 1999, J CLIN IMMUNOL, V19, P378, DOI 10.1023/A:1020550716138; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; Yanase N, 2000, J INTERF CYTOK RES, V20, P1121, DOI 10.1089/107999000750053799; Zhou AM, 1998, J INTERF CYTOK RES, V18, P953, DOI 10.1089/jir.1998.18.953; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	67	64	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48473	48482		10.1074/jbc.M107482200	http://dx.doi.org/10.1074/jbc.M107482200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585831	hybrid, Green Published			2022-12-27	WOS:000172927000100
J	Chang, WJ; Alvarez-Gonzalez, R				Chang, WJ; Alvarez-Gonzalez, R			The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTION FACTOR; DEPENDENT TRANSCRIPTION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; LIFE-SPAN; IN-VITRO; ACTIVATION; PROTEIN; CELLS	Recent studies suggest that the synthesis of protein-bound ADP-ribose polymers catalyzed by poly(ADP-ribose) polymerase-1 (PARP-1) regulates eucaryotic gene expression, including the NF-kappaB-dependent pathway. Here, we report the molecular mechanism by which PARP-1 activates the sequence-specific binding of NF-kappaB to its oligodeoxynucleotide. We co-incubated pure recombinant human PARP-1 and the p50 subunit of NF-kappaB (NF-kappaB-p50) in the presence or absence of beta NAD(+) in vitro. Electrophoretic mobility shift assays showed that, when PARP-1 was present, NF-kappaB-p50 DNA binding was dependent on the presence of beta NAD(+). DNA binding by NF-kappaB-p50 was not efficient in the absence of beta NAD(+). In fact, the binding was not efficient in the presence of 3-aminobenzamide (3-AB) either. Thus, we conclude that NF-kappaB-p50 DNA binding is protein-poly(ADP-ribosylation dependent. Co-immunoprecipitation and immunoblot analysis revealed that PARP-1 physically interacts with NF-kappaB-p50 with high specificity in the absence of beta NAD(+). Because NF-kappaB-p50 was not an efficient covalent target for poly(ADP-ribosylation, our results are consistent with the conclusion that the auto-poly(ADP-ribosyl)ation reaction catalyzed by PARP-1 facilitates the binding of NF-kappaB-p50 to its DNA by inhibiting the specific protein-protein interactions between NF-kappaB-p50 and PARP-1. We also report the activation of NF-kappaB(-)DNA binding by the automodification reaction of PARP-1 in cultured HeLa cells following exposure to H2O2. In these experiments, preincubation of HeLa cells with 3-AB, prior to oxidative damage, strongly inhibited NF-kappaB activation in vivo as well.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Alvarez-Gonzalez, R (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.		Gonzalez, Rafael Alvarez/I-4560-2019	Alvarez-Gonzalez, Rafael/0000-0003-1038-7512	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Beneke S, 2000, EXP GERONTOL, V35, P989, DOI 10.1016/S0531-5565(00)00134-0; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kumari SR, 1998, CANCER RES, V58, P5075; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P3481, DOI 10.1073/pnas.90.8.3481; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WesierskaGadek J, 1996, J CELL BIOCHEM, V62, P90, DOI 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879	48	120	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47664	47670		10.1074/jbc.M104666200	http://dx.doi.org/10.1074/jbc.M104666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577079	hybrid			2022-12-27	WOS:000172768500128
J	Iko, Y; Sambongi, Y; Tanabe, M; Iwamoto-Kihara, A; Saito, K; Ueda, I; Wada, Y; Futai, M				Iko, Y; Sambongi, Y; Tanabe, M; Iwamoto-Kihara, A; Saito, K; Ueda, I; Wada, Y; Futai, M			ATP synthase F-1 sector rotation - Defective torque generation in the beta subunit Ser-174 to Phe mutant and its suppression by second mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL REGION; GLYCINE-RICH SEQUENCE; ESCHERICHIA-COLI; H+-ATPASE; GAMMA-SUBUNIT; CATALYTIC SITE; F-TYPE; F1-ATPASE; F-1-ATPASE; OLIGOMER	Subunit gamma of the ATP synthase F-1 sector is located at the center of the alpha (3)beta (3), hexamer and rotates unidirectionally during ATP hydrolysis, generating the rotational torque of similar to 45 pN.nm. A mutant F-1 with the beta Ser-174 to Phe substitution (beta S174F) in the beta subunit generated lower torque (similar to 17 pN.nm), indicating that beta S174F is mechanically defective, the first such mutant reported. The defective rotation of beta S174F was suppressed by a second-site mutation, beta Gly-149 to Ala, beta Ile-163 to Ala, or beta Ile-166 to Ala in the same subunit, but not by beta Leu-238 to Ala. These results suggest that the region between beta Gly-149 and beta Ser-174 plays an important role in the coupling between ATP hydrolysis and mechanical work.	Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, CREST,Japan Sci & Technol Corp, Ibaraki, Osaka 5670047, Japan; Univ Tokyo, Dept Life Sci, Grad Sch Arts & Sci, Tokyo 1538902, Japan; Kanazawa Univ, Dept Phys, Kanazawa, Ishikawa 9201192, Japan	Japan Science & Technology Agency (JST); Osaka University; University of Tokyo; Kanazawa University	Futai, M (corresponding author), Osaka Univ, Div Biol Sci, Inst Sci & Ind Res, CREST,Japan Sci & Technol Corp, Ibaraki, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; IDA K, 1991, J BIOL CHEM, V266, P5424; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; NOUMI T, 1984, J BIOL CHEM, V259, P71; OMOTE H, 1992, J BIOL CHEM, V267, P20571; OMOTE H, 1994, J BIOL CHEM, V269, P10265; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sambongi Y, 2000, J BIOENERG BIOMEMBR, V32, P441, DOI 10.1023/A:1005656706248; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHIN K, 1992, J BIOL CHEM, V267, P20835; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	25	25	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47508	47511		10.1074/jbc.M108803200	http://dx.doi.org/10.1074/jbc.M108803200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590180	hybrid			2022-12-27	WOS:000172768500108
J	Ishiguro, K; Kadomatsu, K; Kojima, T; Muramatsu, H; Iwase, M; Yoshikai, Y; Yanada, M; Yamamoto, K; Matsushita, T; Nishimura, M; Kusugami, K; Saito, H; Muramatsu, T				Ishiguro, K; Kadomatsu, K; Kojima, T; Muramatsu, H; Iwase, M; Yoshikai, Y; Yanada, M; Yamamoto, K; Matsushita, T; Nishimura, M; Kusugami, K; Saito, H; Muramatsu, T			Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GROWTH-FACTOR; ENDOTOXIC-SHOCK; EXPRESSION; PATHOGENESIS; ENDOTHELIUM; ACTIVATION; CYTOKINES; RESPONSES; IMPAIRS	Syndecan-4 is a transmembrane heparan sulfate proteoglycan belonging to the syndecan family. Following intraperitoneal injection of lipopolysaccharide (LPS), syndecan-4-deficient mice exhibited high mortality compared with wild-type controls. Severe endotoxin shock was observed in the deficient mice: systolic blood pressure and left ventricular fractional shortening were lower in the deficient mice than in the wild-type controls 9 h after LPS injection. Although histological examinations revealed no apparent differences between two groups, the plasma level of interleukin (IL)-1 beta was higher in the deficient mice than in the wild-type controls 9 h after LPS injection. Consistent with the regulatory roles of syndecan-4, its expression in monocytes and endothelial cells of microvasculature increased in the wild-type mice after LPS administration. Although IL-1 beta was produced to the same extent by macrophages from syndecan-4-deficient and wild-type mice after LPS stimulation, inhibition of its production by transforming growth factor-beta1 was impaired in the syndecan-4-deficient macropbages. These results indicate that syndecan-4 could be involved in prevention of endotoxin shock, at least partly through the inhibitory action of transforming growth factor-beta1 on IL-1 beta production.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med,Res Inst Dis Mechanism & Control, Lab Host Def & Germfree Life, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Inst Lab Anim Res, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Nagoya Natl Hosp, Naka Ku, Nagoya, Aichi 4600001, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University; Nagoya University	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tmurama@med.nagoya-u.ac.jp	Yanada, Masamitsu/B-5146-2012; Kojima, Tetsuhito/I-6271-2014; Yanada, Masamitsu/AAX-1343-2021; Matsushita, Tadadshi/I-7349-2014; Kadomatsu, Kenji/G-8083-2012	Kojima, Tetsuhito/0000-0002-1905-1065; Yanada, Masamitsu/0000-0003-1602-9775; Ishiguro, Kazuhiro/0000-0003-1776-2805				Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Dinarello CA, 1997, CHEST, V112, p321S, DOI 10.1378/chest.112.6_Supplement.321S; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; GALANOS C, 1993, IMMUNOBIOLOGY, V187, P346, DOI 10.1016/S0171-2985(11)80349-9; Imai K, 2000, INFECT IMMUN, V68, P2418, DOI 10.1128/IAI.68.5.2418-2423.2000; Ishiguro K, 2000, DEV DYNAM, V219, P539, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1081>3.0.CO;2-K; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Ishiguro K, 1999, HISTOCHEM CELL BIOL, V112, P25, DOI 10.1007/s004180050388; Ishiguro K, 2001, LAB INVEST, V81, P509, DOI 10.1038/labinvest.3780259; Kaisho T, 2000, CRIT REV IMMUNOL, V20, P393; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; Krishnaswamy G, 1999, J INTERF CYTOK RES, V19, P91, DOI 10.1089/107999099314234; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; Marsh CB, 1996, CLIN CHEST MED, V17, P183, DOI 10.1016/S0272-5231(05)70308-7; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MIOSSEC P, 1986, J IMMUNOL, V136, P2486; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Tanaka Y, 1998, P ASSOC AM PHYSICIAN, V110, P118; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Yamamoto K, 1996, J CLIN INVEST, V97, P2440, DOI 10.1172/JCI118691; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	35	105	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47483	47488		10.1074/jbc.M106268200	http://dx.doi.org/10.1074/jbc.M106268200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585825	hybrid			2022-12-27	WOS:000172768500105
J	Lundqvist, ML; Middleton, DL; Hazard, S; Warr, GW				Lundqvist, ML; Middleton, DL; Hazard, S; Warr, GW			The immunoglobulin heavy chain locus of the duck - Genomic organization and expression of D, J, and C region genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE THIOESTERASE; CONSTANT-REGION; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; ANAS-PLATYRHYNCHOS; GERMINAL-CENTERS; DNA-SEQUENCES; CLASS SWITCH; B-CELLS; IGA	The region of the duck IgH locus extending from upstream of the proximal diversity (D) segment to downstream of the constant gene cluster has been cloned and mapped. A sequence contig of 48,796 base pairs established that the organization of the genes is D-J(H)-mu-alpha-upsilon. No evidence for a functional homologue (or remnant) of a delta gene was found. The a gene is in inverted transcriptional orientation; class switch to IgA expression thus requires inversion of the similar to 27-kilobase pair region that includes both mu and alpha genes. The secreted forms of duck alpha and mu are each encoded by 4 constant region exons, and the hydrophobic C-terminal regions of the membrane receptor forms of a and tx are encoded by one and two transmembrane exons, respectively. Putative switch (S) regions were identified for duck mu and upsilon by comparison with chicken S mu and S upsilon sequences and for duck alpha by comparison with mouse S alpha. The duck IgH locus is rich in complex variable number tandem repeats, which occupy similar to 60% of the sequenced region, and occur at a much higher frequency in the IgH locus than in other sequenced regions of the duck genome.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Biomol Comp Resource, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Warr, GW (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045111] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 45111] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arakawa H, 1996, EMBO J, V15, P2540, DOI 10.1002/j.1460-2075.1996.tb00611.x; Arakawa H, 1998, J IMMUNOL, V160, P4232; BARKER WC, 1972, ATLAS PROTEIN SEQUEN, V5, P31; Bengten E, 2000, CURR TOP MICROBIOL, V248, P189; BRUGGEMANN M, 1987, MOL GENETICS IMMUNOG, P51; Brusco A, 1999, J IMMUNOL, V163, P4392; Campbell K S, 1994, Semin Immunol, V6, P393, DOI 10.1006/smim.1994.1049; Coyle JH, 2000, J IMMUNOL, V164, P3659, DOI 10.4049/jimmunol.164.7.3659; DAHAN A, 1983, NUCLEIC ACIDS RES, V11, P5381, DOI 10.1093/nar/11.16.5381; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; Du Pasquier L, 2000, CURR TOP MICROBIOL, V248, P159; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HIGGINS DA, 1993, AVIAN PATHOL, V22, P211, DOI 10.1080/03079459308418916; JACK HM, 1988, P NATL ACAD SCI USA, V85, P1581, DOI 10.1073/pnas.85.5.1581; Kitao H, 2000, INT IMMUNOL, V12, P959, DOI 10.1093/intimm/12.7.959; LESLIE GA, 1976, INT ARCH ALLER A IMM, V51, P175, DOI 10.1159/000231590; LI X, 1995, BBA-GENE STRUCT EXPR, V1261, P25, DOI 10.1016/0167-4781(94)00211-K; Longmire JL, 1999, J HERED, V90, P574, DOI 10.1093/jhered/90.5.574; Magor KE, 1999, IMMUNOGENETICS, V49, P692, DOI 10.1007/s002510050666; Magor KE, 1998, EUR J IMMUNOL, V28, P1063, DOI 10.1002/(SICI)1521-4141(199803)28:03&lt;1063::AID-IMMU1063&gt;3.0.CO;2-O; MAGOR KE, 1994, J IMMUNOL, V153, P5549; MAGOR KE, 1992, J IMMUNOL, V149, P2627; MANSIKKA A, 1992, J IMMUNOL, V149, P855; MCCORMACK WT, 1991, ANNU REV IMMUNOL, V9, P219; NG PLK, 1986, IMMUNOLOGY, V58, P323; PARVARI R, 1988, EMBO J, V7, P739, DOI 10.1002/j.1460-2075.1988.tb02870.x; Primmer CR, 1997, GENOME RES, V7, P471, DOI 10.1101/gr.7.5.471; REYNAUD CA, 1994, ADV IMMUNOL, V57, P353, DOI 10.1016/S0065-2776(08)60676-8; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROSE TM, 1994, DNA CELL BIOL, V13, P669, DOI 10.1089/dna.1994.13.669; Ross DA, 1998, IMMUNOL REV, V166, P143, DOI 10.1111/j.1600-065X.1998.tb01259.x; SASAKI GC, 1988, DNA-J MOLEC CELL BIO, V7, P449, DOI 10.1089/dna.1.1988.7.449; SEIPELT RL, 1995, MOL IMMUNOL, V32, P277, DOI 10.1016/0161-5890(94)00141-M; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; TUCKER PW, 1981, P NATL ACAD SCI-BIOL, V78, P7684, DOI 10.1073/pnas.78.12.7684; van Tuinen M, 2000, MOL BIOL EVOL, V17, P451, DOI 10.1093/oxfordjournals.molbev.a026324; Vergnaud G, 2000, GENOME RES, V10, P899, DOI 10.1101/gr.10.7.899; WACHTEL SS, 1993, COMP BIOCHEM PHYS B, V104, P207, DOI 10.1016/0305-0491(93)90360-H; WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167-5699(95)80008-5; WHITE MB, 1985, SCIENCE, V228, P733, DOI 10.1126/science.3922054; Wilson M, 1997, P NATL ACAD SCI USA, V94, P4593, DOI 10.1073/pnas.94.9.4593; YU LM, 1990, J IMMUNOL, V145, P3932; Zhao Y, 2000, IMMUNOLOGY, V101, P348, DOI 10.1046/j.1365-2567.2000.00106.x	46	70	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46729	46736		10.1074/jbc.M106221200	http://dx.doi.org/10.1074/jbc.M106221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592961	hybrid			2022-12-27	WOS:000172768500009
J	Androutsellis-Theotokis, A; Ghassemi, F; Rudnick, G				Androutsellis-Theotokis, A; Ghassemi, F; Rudnick, G			A conformationally sensitive residue on the cytoplasmic surface of serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; TRANSMEMBRANE DOMAIN; PLATELET 5-HYDROXYTRYPTAMINE; SCANNING MUTAGENESIS; EXPRESSION CLONING; GABA TRANSPORTER; COCAINE BINDING; BETA-ALANINE	Serotonin transporter (SERT) contains a single reactive external cysteine residue at position 109 (Chen, J. G., Liu-Chen, S., and Rudnick, G. (1997) Biochemistry 36, 1479-1486) and seven predicted cytoplasmic cysteines. A mutant of rat SERT (X8C) in which those eight cysteine residues were replaced by other amino acids retained similar to 32% of wild type transport activity and similar to 56% of wild type binding activity. In contrast to wild-type SERT or the C109A mutant, X8C was resistant to inhibition of high affinity cocaine analog binding by the cysteine reagent 2-(aminoethyl)methanethiosulfonate hydrobromide (MTSEA) in membrane preparations from transfected cells. Each predicted cytoplasmic cysteine residue was reintroduced, one at a time, into the X8C template. Reintroduction of Cys-357, located in the third intracellular loop, restored MTSEA sensitivity similar to that of C109A. Replacement of only Cys-109 and Cys-357 was sufficient to prevent MTSEA sensitivity. Thus, Cys-357 was the sole cytoplasmic determinant of MTSEA sensitivity in SERT. Both serotonin and cocaine protected SERT from inactivation by MTSEA at Cys-357. This protection was apparently mediated through a conformational change following ligand binding. Although both ligands bind in the absence of Na+ and at 4 degreesC, their ability to protect Cys-357 required Na+ and was prevented at 4 degreesC. The accessibility of Cys-357 to MTSEA inactivation was increased by monovalent cations. The K+ ion, which is believed to serve as a countertransport substrate for SERT, was the most effective ion for increasing Cys-357 reactivity.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,POB 3333, New Haven, CT 06510 USA.			Androutsellis-Theotokis, Andreas/0000-0002-1985-4589				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BOYER WF, 1992, INT CLIN PSYCHOPHARM, V6, P5, DOI 10.1097/00004850-199206005-00001; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; MAYSER W, 1991, FEBS LETT, V295, P203, DOI 10.1016/0014-5793(91)81418-8; Nelson N, 1998, J NEUROCHEM, V71, P1785; NELSON PJ, 1979, J BIOL CHEM, V254, P84; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; SMITH KE, 1992, MOL PHARMACOL, V42, P563; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1994, J EXP BIOL, V196, P229; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; WALL SC, 1993, MOL PHARMACOL, V43, P264; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	41	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45933	45938		10.1074/jbc.M107462200	http://dx.doi.org/10.1074/jbc.M107462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11592963	hybrid			2022-12-27	WOS:000172573100061
J	Blanchard-Fillion, B; Souza, JM; Friel, T; Jiang, GCT; Vrana, K; Sharov, V; Barron, L; Schoneich, C; Quijano, C; Alvarez, B; Radi, R; Przedborski, S; Fernando, GS; Horwitz, J; Ischiropoulos, H				Blanchard-Fillion, B; Souza, JM; Friel, T; Jiang, GCT; Vrana, K; Sharov, V; Barron, L; Schoneich, C; Quijano, C; Alvarez, B; Radi, R; Przedborski, S; Fernando, GS; Horwitz, J; Ischiropoulos, H			Nitration and inactivation of tyrosine hydroxylase by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; TRYPTOPHAN-HYDROXYLASE; OXIDATIVE STRESS; PROTEIN; IDENTIFICATION; MICE; INHIBITION; METHIONINE; SUBSTRATE	Tyrosine hydroxylase (TH) is modified by nitration after exposure of mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydrophenylpyridine. The temporal association of tyrosine nitration with inactivation of TH activity in vitro suggests that this covalent post-translational modification is responsible for the in vivo loss of TH function (Ara, J., Przedborski, S., Naini, A. B., Jackson-Lewis, V., Trifiletti, R. R., Horwitz, J., and Ischiropoulos, H. (1998) Proc. Natl. Acad Sci. U. S. A. 95, 7659 -7663). Recent data showed that cysteine oxidation rather than tyrosine nitration is responsible for TH inactivation after peroxynitrite exposure in vitro (Kuhn, D. M., Aretha, C. W., and Geddes, T. J. (1999) J. Neurosci. 19, 10289-10294). However, re-examination of the reaction of peroxynitrite with purified TH failed to produce cysteine oxidation but resulted in a concentration-dependent increase in tyrosine nitration and inactivation. Cysteine oxidation is only observed after partial unfolding of the protein. Tyrosine residue 423 and to lesser extent tyrosine residues 428 and 432 are modified by nitration. Mutation of Tyr(423) to Phe resulted in decreased nitration as compared with wild type protein without loss of activity. Stopped-flow experiments reveal a second order rate constant of (3.8 +/- 0.9) X 10(3) M-1 s(-1) at pH 7.4 and 25 degreesC for the reaction of peroxynitrite with TH. Collectively, the data indicate that peroxynitrite reacts with the metal center of the protein and results primarily in the nitration of tyrosine residue 423, which is responsible for the inactivation of TH.	Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27106 USA; Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Republica, Fac Ciencas, Lab Enzimol, Montevideo 11800, Uruguay; Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Columbia Univ, Dept Neurol, Movement Disorder Div, New York, NY 10032 USA; Columbia Univ, Dept Pathol, Movement Disorder Div, New York, NY 10032 USA; MCP Hahnemann Sch Med, Dept Physiol & Pharmacol, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Wake Forest University; University of Kansas; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Columbia University; Columbia University; Drexel University	Ischiropoulos, H (corresponding author), Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ischirop@mial.med.upenn.edu		Alvarez, Beatriz/0000-0001-6911-3132; Vrana, Kent/0000-0003-4902-7733	NIA NIH HHS [AG13966] Funding Source: Medline; NINDS NIH HHS [NS38370, NS38586, NS37345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038370, R29NS037345, R01NS038586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013966] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; Ellis HR, 2000, BIOCHEMISTRY-US, V39, P4174, DOI 10.1021/bi9928546; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Fahn S., 2000, MERRITTS NEUROLOGY, P679; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; Kaufman S, 1995, Adv Enzymol Relat Areas Mol Biol, V70, P103; Kuhn DM, 1999, J NEUROSCI, V19, P10289; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; Minetti M, 2000, BIOCHEMISTRY-US, V39, P6689, DOI 10.1021/bi9927991; NAGATSU T, 1990, NEUROCHEM RES, V15, P425, DOI 10.1007/BF00969928; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Perl DP, 1998, ANN NEUROL, V44, pS19, DOI 10.1002/ana.410440705; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Quijano C, 2001, J BIOL CHEM, V276, P11631, DOI 10.1074/jbc.M009429200; Quinsey NS, 1996, J NEUROCHEM, V66, P908; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; RIBEIRO P, 1991, J BIOL CHEM, V266, P16207; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; VRANA KE, 1994, LIFE SCI, V55, P1045, DOI 10.1016/0024-3205(94)00639-3; WALKER SJ, 1994, BBA-PROTEIN STRUCT M, V1206, P113, DOI 10.1016/0167-4838(94)90079-5; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Yohrling GJ, 1999, J MOL NEUROSCI, V12, P23, DOI 10.1385/JMN:12:1:23; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	47	131	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46017	46023		10.1074/jbc.M105564200	http://dx.doi.org/10.1074/jbc.M105564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590168	hybrid			2022-12-27	WOS:000172573100072
J	Chen, C; Wang, Q; Fang, XD; Xu, Q; Chi, CW; Gu, JX				Chen, C; Wang, Q; Fang, XD; Xu, Q; Chi, CW; Gu, JX			Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-VIII; HAMSTER OVARY CELLS; RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; GLUCOSE-REGULATED PROTEINS; VON-WILLEBRAND-FACTOR; PORCINE FACTOR-VIII; FACTOR-V; MAMMALIAN-CELLS; REFSUM-DISEASE; LIVER-TRANSPLANTATION	The coagulation factor VIII (FVIII) is the coagulation factor deficient in the X-chromosome-linked bleeding disorder hemophilia A. Previous transfection studies demonstrated that factor VIII was 10-100-fold less efficiently expressed than the homologous coagulation factor, factor V. To investigate the regulatory mechanisms of FVIII synthesis and secretion, we used the yeast two-hybrid system as an approach to search for proteins that associated with FVIII. The A2 domain (337-740 amino acids) of factor VIII (FVIII-A2) was used as a bait and phytanoyl-CoA alpha -hydroxylase (PAHX) was identified as a binding protein of FVIII-A2. PAHX had potential to interact with the residues 373-508 within the A2 domain, but not with A1 and A3 (the homologous domains of A2). The interaction between the A2 domain and PAHX was independent of the type 2 peroxisomal targeting signal (PTS2) of PAHX. Overexpression of PABX in FVIII-produced cells decreased the expression of FVIII by about 70%. The elevated expression of von Willebrand factor had no effect on the suppression of FVIII secretion by PAHX. Expression of the green fluorescent PAHX fusion protein in SMMC-7721 cells affected the intracellular trafficking of FVIII-A2. These results suggested that the interaction between PABX and FVIII-A2 was in part responsible for the low-level expression of factor VIII.	Fudan Univ, Ctr Gene Res, Med Ctr, Shanghai 200032, Peoples R China; Acad Sinica, Shanghai Inst Biochem, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Gu, JX (corresponding author), Fudan Univ, Ctr Gene Res, Med Ctr, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn						BONTEMPO FA, 1987, BLOOD, V69, P1721; Chambraud B, 1999, P NATL ACAD SCI USA, V96, P2104, DOI 10.1073/pnas.96.5.2104; Chen C, 1999, THROMB RES, V95, P105, DOI 10.1016/S0049-3848(99)00031-6; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; Fallaux FJ, 1996, MOL CELL BIOL, V16, P4264; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GROTH CG, 1974, SURGERY, V75, P725; HOEFLER G, 1988, J PEDIATR-US, V112, P726, DOI 10.1016/S0022-3476(88)80689-9; Iwano M, 1996, BIOCHEM BIOPH RES CO, V229, P355, DOI 10.1006/bbrc.1996.1805; Jansen GA, 1997, J INHERIT METAB DIS, V20, P444, DOI 10.1023/A:1005379406639; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Jansen GA, 1997, NEW ENGL J MED, V337, P133, DOI 10.1056/NEJM199707103370215; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Kaufman RJ, 1997, BLOOD COAGUL FIBRIN, V8, pS3; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KELLY DA, 1984, BRIT J HAEMATOL, V56, P535, DOI 10.1111/j.1365-2141.1984.tb02178.x; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; LAROCCA D, 1990, CANCER RES, V50, P5925; LEWIS JH, 1985, NEW ENGL J MED, V312, P1189; LIU LX, 1994, TRANSPLANT INT, V7, P201, DOI 10.1111/j.1432-2277.1994.tb01291.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MANN KG, 1993, METHOD ENZYMOL, V222, P1; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Saenko EL, 1999, J BIOL CHEM, V274, P37685, DOI 10.1074/jbc.274.53.37685; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Swaroop M, 1997, J BIOL CHEM, V272, P24121, DOI 10.1074/jbc.272.39.24121; Takayama M, 1999, EXP NEPHROL, V7, P295; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VELTKAMP JJ, 1968, THROMB DIATH HAEMOST, V19, P279, DOI 10.1055/s-0038-1651206; Waterham HR, 1997, BIOESSAYS, V19, P57, DOI 10.1002/bies.950190110; WEBSTER WP, 1971, AM J PHYSIOL, V220, P1147, DOI 10.1152/ajplegacy.1971.220.5.1147; WILSON DB, 1984, J CLIN INVEST, V73, P654, DOI 10.1172/JCI111256; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; ZELECHOWSKA MG, 1985, NATURE, V317, P729, DOI 10.1038/317729a0	50	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46340	46346		10.1074/jbc.M106124200	http://dx.doi.org/10.1074/jbc.M106124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574539	hybrid			2022-12-27	WOS:000172573100116
J	Dow, R; Hendley, J; Pirkmaier, A; Musgrove, EA; Germain, D				Dow, R; Hendley, J; Pirkmaier, A; Musgrove, EA; Germain, D			Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT PROTEOLYSIS; BREAST-CARCINOMA CELLS; CYCLIN D1; EXPRESSION; P27(KIP1); COMPLEX; DIFFERENTIATION; SUPPRESSION; PHOSPHORYLATION; CHEMOPREVENTION	The mechanism by which all-trans retinoic acid (ATRA) leads to a Gi arrest of the cell cycle remains unclear. We show here that the decrease in D-type cyclin levels observed following ATRA treatment correlates with an increase in the rate of cyclin D1 ubiquitylation in both T-47D and MCF-7 breast cancer cell lines. However, MCF-7 cells are more resistant to ATRA than T-47D cells indicating that cyclin DI degradation is not sufficient for ATRA-mediated arrest. We found a striking difference between these cells in that while ATRA induces an elevation in the cdk inhibitor p27 in T-47D cells, this is not observed in the ATRA-resistant MCF-7 cells. Furthermore, we demonstrate that ATRA promotes the ubiquitylation of Skp2, an F-box protein that targets p27 for degradation. Moreover, overexpression of Skp2 in T-47D cells prevents accumulation of p27 and promotes resistance to ATRA In addition, overexpression of cyclin DI in T-47D cells also promotes ATRA resistance. We found that the mechanism of ATRA-induced ubiquitylation of cyclin D1 and Skp2 is independent of CUL-1 expression and that ATRA can rescue cyclin DI degradation in the uterine cell line SK-UT-1, where D-type cyclins are stabilized due to a specific defect in proteolysis. These data suggest that ATRA induces a novel pathway of ubiquitylation and that the degradation of the F-box protein Skp2 is the mechanism underlying p27 accumulation and cyclin E-cdk2 inactivation following ATRA treatment.	Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Peter Maccallum Cancer Center; University of Melbourne; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Germain, D (corresponding author), Peter MacCallum Canc Inst, St Andrews Pl, Melbourne, Vic 3002, Australia.	d.germain@pmei.unimelb.edu.au						Ahn MJ, 1995, ONCOGENE, V11, P2357; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; COBLEIGH MA, 1994, LEUKEMIA, V8, pS59; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ganiatsas S, 2001, ONCOGENE, V20, P3641, DOI 10.1038/sj.onc.1204501; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Welcker M, 1996, ONCOGENE, V13, P419; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zajac-Kaye M, 2000, BIOCHEM J, V345, P535, DOI 10.1042/0264-6021:3450535; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	39	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45945	45951		10.1074/jbc.M103593200	http://dx.doi.org/10.1074/jbc.M103593200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11595732	hybrid			2022-12-27	WOS:000172573100063
J	Emrick, MA; Hoofnagle, AN; Miller, AS; Ten Eyck, LF; Ahn, NG				Emrick, MA; Hoofnagle, AN; Miller, AS; Ten Eyck, LF; Ahn, NG			Constitutive activation of extracellular signal-regulated kinase 2 by synergistic point mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OF-FUNCTION MUTATION; PROTEIN-KINASE; PHOSPHORYLATION SITES; CATALYTIC ACTIVATION; MAP KINASES; ERK2; AUTOPHOSPHORYLATION; TRANSFORMATION; IDENTIFICATION; TYROSINE	Constitutively active mutant forms of signaling enzymes provide insight into mechanisms of activation as well as useful molecular tools for probing downstream targets. In this study, point mutations in ERK2 at conserved residues L73P and S151D were identified that individually led to 8-12-fold increased specific activity and in combination reached 50-fold, indicating synergistic interactions between these residues. Examination by mass spectrometry, phosphatase sensitivity, and Western blotting revealed that the mutations enhanced ERK2 activity by facilitating intramolecular autophosphorylation predominantly at Tyr-185 and to a lesser extent at Thr-183 and that phosphorylation at both sites is required for activation. A set of short molecular dynamics simulations were carried out using different random seeds to sample locally accessible configurations. Simulations of the active mutant showed potential hydrogen bonding interactions between the phosphoryl acceptor and catalytic nucleophile, which could account for enhanced intramolecular autophosphorylation. In intact cells, the ERK2 mutants were functionally active in phosphorylating Elk-1 and RSK1 and activating the e-fos promoter. This activity was only partially reduced upon treatment of cells with the MKK1/2 inhibitor, U0126, indicating that in vivo the mechanism of ERK2 activation occurs substantially through autophosphorylation and partially through phosphorylation by MKK1/2.	Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA; Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of California System; University of California San Diego	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Campus Box 215, Boulder, CO 80309 USA.				NIGMS NIH HHS [T32 GM008759, GM48521, T32 GM142607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048521, T32GM008759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; BRUNET A, 1994, ONCOGENE, V9, P3379; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CASE D, 1997, AMBER 5 0; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hall JP, 1996, MOL CELL BIOL, V16, P6715; Ikeda H, 1997, P NATL ACAD SCI USA, V94, P6375, DOI 10.1073/pnas.94.12.6375; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Resing KA, 1997, METHOD ENZYMOL, V283, P29; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5778; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	34	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46469	46479		10.1074/jbc.M107708200	http://dx.doi.org/10.1074/jbc.M107708200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591711	hybrid			2022-12-27	WOS:000172573100132
J	Jho, SH; Radoja, N; Im, MJ; Tomic-Canic, M				Jho, SH; Radoja, N; Im, MJ; Tomic-Canic, M			Negative response elements in keratin genes mediate transcriptional repression and the cross-talk among nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID; BINDING-SPECIFICITY; DNA; IDENTIFICATION; EXPRESSION; POSITION; HETERODIMERIZATION; DIFFERENTIATION; TRANSFECTION	Very little is known about the mechanisms responsible for the findings that binding of nuclear receptors (NR) to some promoter elements leads to transcriptional activation, whereas binding to others leads to repression. Case in point is the group of epidermal keratin genes and their DNA sequences responsible for repression by NR. Keratin response elements (KREs) interact with receptors for retinoic acid, thyroid hormone, and glucocorticoids. KREs, by their structure and sequence, direct the binding of retinoic acid and thyroid hormone as homodimers and glucocorticoids as monomers. Such specific DNA-receptor interactions are crucial for the repression signal of transcription. In this paper we have analyzed the interactions between the KREs and NR that lead to such repression. We have found that KREs are promoter-independent. They not only provide a docking platform for the receptors, but also play a key role in directing the receptors to bind into particular configurations and coordinating the interactions among different receptors. Both an intact KRE and an intact receptor DNA-binding domain are necessary for the regulation to occur, which emphasizes the importance of interaction between the DNA and NR. for proper signaling. Furthermore, KREs allow simultaneous binding of multiple receptors, thus providing fine-tuning of transcriptional regulation. The DNA/DNA-binding domain interactions in keratin promoters exemplify tissue and gene specificity of hormone action.	NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY 10016 USA; Inst Vinca, YU-11000 Belgrade, Yugoslavia	New York University; University of Belgrade	Tomic-Canic, M (corresponding author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, 550 1St Ave, New York, NY 10016 USA.	tomicm01@med.nyu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045974] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLUMENBERG M, 1997, FORMATION STRUCTURE; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1994, J BIOL CHEM, V269, P4175; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; FISHER C, 1995, CRIT REV ORAL BIOL M, V6, P284, DOI 10.1177/10454411950060040201; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Hagerty T, 2001, J NEUROCHEM, V76, P825, DOI 10.1046/j.1471-4159.2001.00072.x; Hanley K, 1997, J CLIN INVEST, V100, P705, DOI 10.1172/JCI119583; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; Komuves LG, 1998, J INVEST DERMATOL, V111, P429, DOI 10.1046/j.1523-1747.1998.00296.x; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2000, J STEROID BIOCHEM, V74, P351, DOI 10.1016/S0960-0760(00)00112-6; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; PONEC M, 1981, J INVEST DERMATOL, V76, P211, DOI 10.1111/1523-1747.ep12525761; PUNNONEN R, 1980, J ENDOCRINOL INVEST, V3, P217, DOI 10.1007/BF03348266; QI JS, 1995, MOL CELL BIOL, V15, P1817; Radoja N, 1997, J INVEST DERMATOL, V109, P566, DOI 10.1111/1523-1747.ep12337483; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Randolph RK, 1997, J LIPID RES, V38, P1374; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; Reginato MJ, 1996, J BIOL CHEM, V271, P28199, DOI 10.1074/jbc.271.45.28199; Reichardt HM, 2000, Z RHEUMATOL, V59, P1; Rivier M, 1998, J INVEST DERMATOL, V111, P1116, DOI 10.1046/j.1523-1747.1998.00439.x; SLOAN KB, 1996, CUTANEOUS MED SURG, V1, P160; Slominski A, 2000, BBA-GEN SUBJECTS, V1474, P1, DOI 10.1016/S0304-4165(99)00215-9; Taylor AH, 1996, BIOCHEMISTRY-US, V35, P8281, DOI 10.1021/bi960269o; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; TOMIC M, 1990, NUCLEIC ACIDS RES, V18, P1656, DOI 10.1093/nar/18.6.1656; Tomic-Canic M, 1996, Methods Mol Biol, V57, P249; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; TOMICCANIC M, 1992, J INVEST DERMATOL, V99, P842, DOI 10.1111/1523-1747.ep12614806; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; WU Y, 2001, J BIOL CHEM, V276, P3939; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	42	24	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45914	45920		10.1074/jbc.M103144200	http://dx.doi.org/10.1074/jbc.M103144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591699	Green Published, hybrid			2022-12-27	WOS:000172573100058
J	San, AK; Tribble, GD; Grainge, I; Frohlich, RF; Knudsen, BR; Jayaram, M				San, AK; Tribble, GD; Grainge, I; Frohlich, RF; Knudsen, BR; Jayaram, M			Biochemical and kinetic analysis of the RNase active sites of the integrase/tyrosine family site-specific DNA recombinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-MU-M CIRCLE PLASMID; FLP RECOMBINASE; RIBONUCLEASE-ACTIVITIES; CRYSTAL-STRUCTURE; INT FAMILY; TOPOISOMERASE; CLEAVAGE; MODEL; AMPLIFICATION; SIMILARITIES	In this study, we have used multiple strategies to characterize the mechanisms of the type I and type II RNA cleavage activities harbored by the Flp (pronounced here as "flip") site-specific DNA recombinase (Flp-RNase I and II, respectively). Reactions using half-sites prebound by step-arrest mutants of Flp agree with a "shared active site" being responsible for the type I reaction (as is the case with normal DNA recombination). In a "pre-cleaved" type I substrate containing a 3'-phosphotyrosyl bond, the Flp-RNase I activity can be elicited by either wild type Flp or by Flp(Y343F). Kinetic analyses of the type I reaction are consistent with the above observations and support the notion that the DNA recombinase and type I RNase active sites are identical. The type II RNase activity is expressed by Flp(Y343F) in a half-site substrate and is unaffected by the catalytic constitution of a Flp monomer present on a partner half-site. Reaction conditions that proscribe the assembly of a DNA bound Flp dimer have no effect on Flp-RNase II. These biochemical results, together with kinetic data, are consistent with the reaction being performed from a "non-shared active site" contained within a single Flp monomer. The Flp-related recombinase Cre, which utilizes a non-shared recombination active site, exhibits the type I RNA cleavage reaction. So far, we have failed to detect the type II RNase activity in Cre. Despite their differences in active site assembly, Cre functionally mimics Flp in being able to provide two functional active sites from a trimer of Cre bound to a three-armed (Y-shaped) substrate.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark	University of Texas System; University of Texas Austin; Aarhus University	Jayaram, M (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.	Jayaram@icmb.utexas.edu	Grainge, Ian RF/A-9031-2010; Tribble, Gena/A-8755-2011	Grainge, Ian RF/0000-0001-8268-583X; Tribble, Gena/0000-0002-6468-2851; Knudsen, Birgitta Ruth/0000-0002-3484-3802	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019687] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM019687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROACH JR, 1991, MOL CELLULAR BIOL YE, V1, P297; Burgin AB, 1997, CELL, V91, P873, DOI 10.1016/S0092-8674(00)80478-X; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; FUTCHER B, 1988, GENETICS, V118, P411; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; Grainge I, 2000, J MOL BIOL, V298, P749, DOI 10.1006/jmbi.2000.3679; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; JAYARAM M, 2000, IN PRESS MOBILE DN 2; Knudsen BR, 1997, J MOL BIOL, V266, P93, DOI 10.1006/jmbi.1996.0767; Knudsen BR, 1998, J BIOL CHEM, V273, P22028, DOI 10.1074/jbc.273.34.22028; LEE J, 1993, J BIOL CHEM, V268, P17564; Lee J, 1996, J MOL BIOL, V257, P532, DOI 10.1006/jmbi.1996.0183; Lee J, 2000, J MOL BIOL, V296, P403, DOI 10.1006/jmbi.1999.3472; Lee J, 1997, GENE DEV, V11, P3061, DOI 10.1101/gad.11.22.3061; Lee J, 1997, GENE DEV, V11, P2438, DOI 10.1101/gad.11.18.2438; Lee J, 1999, EMBO J, V18, P784, DOI 10.1093/emboj/18.3.784; LUETKE KH, 1995, J MOL BIOL, V251, P493, DOI 10.1006/jmbi.1995.0451; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PAN GH, 1992, J BIOL CHEM, V267, P12397; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; Tribble G, 2000, J BIOL CHEM, V275, P22255, DOI 10.1074/jbc.M908261199; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2; Voziyanov Y, 1996, J MOL BIOL, V256, P720, DOI 10.1006/jmbi.1996.0120; Voziyanov Y, 1999, NUCLEIC ACIDS RES, V27, P930, DOI 10.1093/nar/27.4.930; Woods KC, 2001, J MOL BIOL, V313, P49, DOI 10.1006/jmbi.2001.5012; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6; Xu CJ, 1998, J BIOL CHEM, V273, P30591, DOI 10.1074/jbc.273.46.30591	37	5	6	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46612	46623		10.1074/jbc.M106492200	http://dx.doi.org/10.1074/jbc.M106492200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585826	hybrid			2022-12-27	WOS:000172573100148
J	Yarmola, EG; Parikh, S; Bubb, MR				Yarmola, EG; Parikh, S; Bubb, MR			Formation and implications of a ternary complex of profilin, thymosin beta(4), and actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE ACTIN; F-ACTIN; FILAMENT DYNAMICS; POLYMORPHONUCLEAR LEUKOCYTES; PROTEIN-STRUCTURE; MONOMERIC ACTIN; PLANT PROFILIN; BARBED-END; BINDING; BETA-4	Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that profilin, thymosin beta (4), and actin form a ternary complex. In contrast, steady-state assays measuring F-actin concentration are insensitive to the formation of such a complex. Experiments using a peptide that corresponds to the N terminus of thymosin beta (4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta (4), and explain why thymosin beta (4) and profilin can bind simultaneously to actin. Surprisingly, despite much lower affinity, the N-terminal thymosin beta (4) peptide has a very slow dissociation rate constant relative to the intact protein, consistent with a catalytic effect of the C terminus on conformational change occurring at the N terminus of thymosin beta (4). Intracellular concentrations of thymosin beta (4) and profilin may greatly exceed the equilibrium dissociation constant of the ternary complex, inconsistent with models showing sequential formation of complexes of profilin-actin or thymosin beta (4)-actin during dynamic remodeling of the actin cytoskeleton. The formation of a ternary complex results in a very large amplification mechanism by which profilin and thymosin beta (4) can sequester much more actin than is possible for either protein acting alone, providing an explanation for significant sequestration even if molecular crowding results in a very low critical concentration of actin in vivo.	Univ Florida, Dept Med, Gainesville, FL 32610 USA; Vet Affairs Med Ctr, Malcom Randall Dept, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bubb, MR (corresponding author), Univ Florida, Dept Med, Box 100277, Gainesville, FL 32610 USA.							Ballweber E, 1998, FEBS LETT, V425, P251, DOI 10.1016/S0014-5793(98)00240-3; Bonnet D, 1996, EXP HEMATOL, V24, P776; BUBB MR, 1991, J BIOL CHEM, V266, P3820; CARLIER MF, 1991, J BIOL CHEM, V266, P1; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; CZISCH M, 1993, EUR J BIOCHEM, V218, P335, DOI 10.1111/j.1432-1033.1993.tb18382.x; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; Feinberg J, 1996, BIOCHEM BIOPH RES CO, V222, P127, DOI 10.1006/bbrc.1996.0709; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; Huff T, 1997, FEBS LETT, V414, P39, DOI 10.1016/S0014-5793(97)00946-0; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kang F, 1999, J BIOL CHEM, V274, P36963, DOI 10.1074/jbc.274.52.36963; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Selden LA, 1999, BIOCHEMISTRY-US, V38, P2769, DOI 10.1021/bi981543c; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STROMQVIST M, 1984, J MUSCLE RES CELL M, V5, P443, DOI 10.1007/BF00818262; Tarachandani A, 1996, CELL MOTIL CYTOSKEL, V34, P313, DOI 10.1002/(SICI)1097-0169(1996)34:4<313::AID-CM6>3.0.CO;2-8; TELLAM RL, 1983, BIOCHEM J, V213, P651, DOI 10.1042/bj2130651; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; Young JD, 1999, NAT MED, V5, P1424; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	45	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45555	45563		10.1074/jbc.M105723200	http://dx.doi.org/10.1074/jbc.M105723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579089	hybrid			2022-12-27	WOS:000172573100011
J	Ashton, AC; Volynski, KE; Lelianova, VG; Orlova, EV; Van Renterghem, C; Canepari, M; Seagar, M; Ushkaryov, YA				Ashton, AC; Volynski, KE; Lelianova, VG; Orlova, EV; Van Renterghem, C; Canepari, M; Seagar, M; Ushkaryov, YA			alpha-latrotoxin, acting via two Ca2+-dependent pathways, triggers exocytosis of two pools of synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED NERVE-TERMINALS; RAT HIPPOCAMPAL-NEURONS; WIDOW SPIDER VENOM; CEREBRAL CORTICAL SYNAPTOSOMES; FROG NEUROMUSCULAR-JUNCTION; GAMMA-AMINOBUTYRIC-ACID; READILY RELEASABLE POOL; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; DIVALENT-CATIONS	alpha -Latrotoxin stimulates three types of [H-3]gamma -aminobutyric acid and [C-14]glutamate release from synaptosomes. The Ca2+-independent component (i) is insensitive to SNAP-25 cleavage or depletion of vesicle contents by bafilomycin A1 and represents transmitter efflux mediated by alpha -latrotoxin pores. Two other components of release are Ca2+-dependent and vesicular but rely on distinct mechanisms. The fast receptor-mediated pathway (ii) involves intracellular Ca2+ stores and acts upon sucrose-sensitive readily releasable vesicles; this mechanism is insensitive to inhibition of phosphatidylinositol 4-kinase (PI 4-kinase). The delayed pore-dependent exocytotic component (iii) is stimulated by Ca2+ entering through alpha -latrotoxin pores; it requires PI 4-kinase and occurs mainly from depot vesicles. Lanthanum perturbs alpha -latrotoxin pores and blocks the two pore-mediated components (i, iii) but not the receptor-mediated release (ii). alpha -Latrotoxin mutant (LTXN4C) cannot form pores and stimulates only the Ca2+-dependent receptor-mediated amino acid exocytosis (ii) (detectable biochemically and electrophysiologically). These findings explain experimental data obtained by different laboratories and implicate the toxin receptors in the regulation of the readily releasable pool of synaptic vesicles. Our results also suggest that, similar to noradrenergic vesicles, amino acid-containing vesicles at some point in their cycle require PI 4-kinase.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Fac Med Secteur Nord Marseille, INSERM, U464, Lab Neurobiol Canaux Ion, F-13916 Marseille 20, France; Natl Inst Med Res, Div Neurophysiol, London NW7 1AA, England	Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; MRC National Institute for Medical Research	Ushkaryov, YA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Exhibit Rd, London SW7 2AY, England.		Orlova, Elena/CAF-8290-2022; Ushkaryov, Yuri/AAQ-2985-2020; Canepari, Marco/AAJ-6709-2021; Canepari, Marco/H-6772-2012	Ushkaryov, Yuri/0000-0002-5712-8297; Canepari, Marco/0000-0001-9759-2388; Canepari, Marco/0000-0001-9759-2388; Volynski, Kirill/0000-0001-8208-1905; Orlova, Elena/0000-0003-3371-415X				Ashton AC, 2000, J NEUROCHEM, V74, P1979, DOI 10.1046/j.1471-4159.2000.0741979.x; Ashton AC, 2000, BIOCHIMIE, V82, P453, DOI 10.1016/S0300-9084(00)00199-1; Ashton AC, 1997, J NEUROCHEM, V68, P649; Auger C, 1997, NEURON, V19, P139, DOI 10.1016/S0896-6273(00)80354-2; Bittner MA, 2000, J BIOL CHEM, V275, P25351, DOI 10.1074/jbc.M004884200; Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DERI Z, 1993, J NEUROCHEM, V60, P1065, DOI 10.1111/j.1471-4159.1993.tb03255.x; FESCE R, 1986, J GEN PHYSIOL, V88, P59, DOI 10.1085/jgp.88.1.59; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Irving AJ, 1998, J PHYSIOL-LONDON, V511, P747, DOI 10.1111/j.1469-7793.1998.747bg.x; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; Khvotchev M, 2000, EMBO J, V19, P3250, DOI 10.1093/emboj/19.13.3250; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Liu J, 1998, J NEUROSCI, V18, P6113; Lonart G, 2000, J BIOL CHEM, V275, P27703; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MISLER S, 1987, AM J PHYSIOL, V253, pC469, DOI 10.1152/ajpcell.1987.253.3.C469; NICHOLLS DG, 1989, J NEUROCHEM, V52, P331, DOI 10.1111/j.1471-4159.1989.tb09126.x; OKAMOTO M, 1971, SCIENCE, V172, P733, DOI 10.1126/science.172.3984.733; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Rahman MA, 1999, PHILOS T ROY SOC B, V354, P379, DOI 10.1098/rstb.1999.0390; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; Savic N, 1998, EUR J NEUROSCI, V10, P3379, DOI 10.1046/j.1460-9568.1998.00342.x; SCHEER HW, 1989, J NEUROCHEM, V52, P1590, DOI 10.1111/j.1471-4159.1989.tb09213.x; SIHRA TS, 1987, J NEUROCHEM, V49, P261, DOI 10.1111/j.1471-4159.1987.tb03424.x; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; Stevens CF, 1999, NEURON, V24, P1017, DOI 10.1016/S0896-6273(00)81047-8; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; VERHAGE M, 1992, J NEUROCHEM, V58, P1313, DOI 10.1111/j.1471-4159.1992.tb11344.x; VERHAGE M, 1991, NEUROSCIENCE, V43, P59, DOI 10.1016/0306-4522(91)90417-M; Volynski KE, 1999, FEBS LETT, V442, P25, DOI 10.1016/S0014-5793(98)01624-X; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; WATANABE O, 1983, NEUROSCIENCE, V10, P1011, DOI 10.1016/0306-4522(83)90239-7; Wiedemann C, 1998, J NEUROSCI, V18, P5594; WILKINSON RJ, 1989, NEUROCHEM INT, V15, P191, DOI 10.1016/0197-0186(89)90100-9; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	47	60	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44695	44703		10.1074/jbc.M108088200	http://dx.doi.org/10.1074/jbc.M108088200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572875	hybrid			2022-12-27	WOS:000172406700049
J	Chen, Q; Nussbaum-Shochat, A; Amster-Choder, O				Chen, Q; Nussbaum-Shochat, A; Amster-Choder, O			A novel sugar-stimulated covalent switch in a sugar sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; BETA-GLUCOSIDE PERMEASE; OXYR TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; BGL SYSTEM; ANTITERMINATOR PROTEIN; PHOSPHORYLATION; DOMAIN; DIMERIZATION; REQUIREMENTS	The bgl sensory system is composed of a membrane-bound sugar sensor, BglF, and a transcriptional regulator, BglG. The sensor BglF has several enzymatic activities: in its nonstimulated state, it acts as BglG phosphorylase; in the presence of beta -glucoside in the growth medium, it acts as BglG dephosphorylase and as the beta -glucoside phosphotransferase. The same active site on BglF, Cys-24, is responsible for the phosphorylation of both the stimulating sugar and the BglG protein. BglF is composed of three domains, two hydrophilic and one hydrophobic. Our previous results suggested that catalysis of the sugar-stimulated functions depends on specific interactions between the B domain, which contains the active site cysteine, and the integral membrane C domain. We report here that the stimulating sugar triggers the formation of a disulfide bond between the active site cysteine and another cysteine in the membrane-embedded domain of BglF. Inability of a mutant BglF protein to form the disulfide bridge between the B and C domains correlates with its inability to catalyze the sugar-stimulated functions. The ability of the cysteine residue in BglF to bind covalently either to a phosphoryl group or to another cysteine residue, depending on the protein stimulation state, suggests a novel way to control signaling by alternative bond formation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Amster-Choder, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.							AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Chen Q, 1998, BIOCHEMISTRY-US, V37, P17040, DOI 10.1021/bi980067n; Chen Q, 1999, J BACTERIOL, V181, P462, DOI 10.1128/JB.181.2.462-468.1999; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Chen Q, 2000, J BACTERIOL, V182, P2033, DOI 10.1128/JB.182.7.2033-2036.2000; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; Paget MSB, 1998, EMBO J, V17, P5776, DOI 10.1093/emboj/17.19.5776; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; ROBILLARD GT, 1986, BIOCHEMISTRY-US, V25, P1346, DOI 10.1021/bi00354a024; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; van Montfort BA, 2001, J BIOL CHEM, V276, P12756, DOI 10.1074/jbc.M010728200; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	25	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44751	44756		10.1074/jbc.M108729200	http://dx.doi.org/10.1074/jbc.M108729200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579106	hybrid			2022-12-27	WOS:000172406700056
J	Ronald, KM; Mirshahi, T; Woodward, JJ				Ronald, KM; Mirshahi, T; Woodward, JJ			Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTORS; HIPPOCAMPAL-NEURONS; SUBSTITUTED CYSTEINES; WITHDRAWAL SEIZURES; TYROSINE KINASE; HEK-293 CELLS; CALCIUM FLUX; C0 DOMAIN; SENSITIVITY; CHANNEL	N-Methyl-D-aspartate (NMDA) receptors (NRs) are ionotropic receptors activated by glutamate and the coagonist glycine. Ethanol inhibits NMDA receptor function, although its site of action is undefined. We hypothesized that ethanol acts at specific amino acids contained within the transmembrane (TM) domains of the receptor. In this study, NR1 and NR2A subunits were altered by mutagenesis and tested for sensitivity to ethanol. Three NR1 mutants (W636A, F817A, and L819A) and one NR2A mutant (F637A) failed to generate functional receptors. Pre-TM1 (1546A, L551A, F554A, and F558A), TM1 (W563A), and TM2 (W611A) NR1 mutations did not affect ethanol sensitivity of heteromeric receptors. In contrast, altering a TM3 phenylalanine to alanine (F639A) reduced the ethanol inhibition of NMDA receptors expressed in oocytes and human embryonic kidney 293 cells. Mutation of the nearby methionine (M641) to alanine did not affect ethanol sensitivity, whereas changing Phe(639) to tryptophan slightly enhanced ethanol inhibition. NR1(F639A) did not alter the agonist potency of glutamate but did produce a leftward shift in the glycine concentration response for receptors containing NR2A and NR2B subunits. NR1(F639A) also reduced the potency of the competitive glycine antagonist 5,7-dichlorokynurenic acid and increased the efficacy of the glycine partial agonist 3-amino-1-hydroxy-2-pyrrolidinone ((+)-HA-966). These results suggest that ethanol may interact with amino acids contained in the TM3 domain of NMDA subunits that are involved in transducing agonist binding to channel opening.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Mt Sinai Sch Med, Dept Mol Biophys, New York, NY 10029 USA	Virginia Commonwealth University; Icahn School of Medicine at Mount Sinai	Woodward, JJ (corresponding author), Med Univ S Carolina, Dept Physiol & Neurosci, MUSC IOP 4N,POB 250861, Charleston, SC 29425 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000238, R37AA009986, R01AA009986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007027] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01-AA009986, R01 AA009986, K02-AA00238, R37 AA009986] Funding Source: Medline; NIDA NIH HHS [T32-DA07027] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Anders DL, 1999, J NEUROCHEM, V72, P1389, DOI 10.1046/j.1471-4159.1999.721389.x; Anders DL, 1999, ALCOHOL CLIN EXP RES, V23, P357, DOI 10.1111/j.1530-0277.1999.tb04122.x; Anders DL, 2000, J BIOL CHEM, V275, P15019, DOI 10.1074/jbc.275.20.15019; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Beck C, 1999, NEURON, V22, P559, DOI 10.1016/S0896-6273(00)80710-2; Blevins T, 1995, NEUROSCI LETT, V200, P214, DOI 10.1016/0304-3940(95)12086-J; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; CHU B, 1995, J NEUROCHEM, V65, P140; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DILDY JE, 1989, BRAIN RES, V499, P383, DOI 10.1016/0006-8993(89)90789-0; Feldmeyer D, 1996, J NEUROCYTOL, V25, P857, DOI 10.1007/BF02284847; GONZALES RA, 1990, J PHARMACOL EXP THER, V253, P1138; GOTHERT M, 1989, N-S ARCH PHARMACOL, V340, P516; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; IORIO KR, 1993, EUR J PHARM-ENVIRON, V248, P209, DOI 10.1016/0926-6917(93)90045-R; Kohda K, 2000, NAT NEUROSCI, V3, P315, DOI 10.1038/73877; Koltchine VV, 1999, MOL PHARMACOL, V56, P1087, DOI 10.1124/mol.56.5.1087; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; Krystal JH, 1998, ARCH GEN PSYCHIAT, V55, P354, DOI 10.1001/archpsyc.55.4.354; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MASOOD K, 1994, MOL PHARMACOL, V45, P324; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Mirshahi T, 1998, J NEUROCHEM, V71, P1095; MORRISETT RA, 1990, EUR J PHARMACOL, V176, P103, DOI 10.1016/0014-2999(90)90138-V; Peoples RW, 2000, NEUROPHARMACOLOGY, V39, P1681, DOI 10.1016/S0028-3908(00)00067-8; Peoples RW, 1997, BRIT J PHARMACOL, V122, P1035, DOI 10.1038/sj.bjp.0701483; RONALD KM, 2000, ALCOHOL CLIN EXP RES, V24, P9; SIMSON PE, 1991, J PHARMACOL EXP THER, V257, P225; WOODWARD JJ, 1994, J NEUROCHEM, V62, P987; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	35	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44729	44735		10.1074/jbc.M102800200	http://dx.doi.org/10.1074/jbc.M102800200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572853	hybrid			2022-12-27	WOS:000172406700053
J	Hall, C; Brown, M; Jacobs, T; Ferrari, G; Cann, N; Teo, M; Monfries, C; Lim, L				Hall, C; Brown, M; Jacobs, T; Ferrari, G; Cann, N; Teo, M; Monfries, C; Lim, L			Collapsin response mediator protein switches RhoA and Rac1 morphology in N1E-115 neuroblastoma cells and is regulated by Rho kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-CONE COLLAPSE; ACTIN STRESS FIBERS; LYSOPHOSPHATIDIC ACID; FOCAL COMPLEXES; NERVOUS-SYSTEM; ACTIVATING RHO; AXON OUTGROWTH; SEMAPHORIN 3A; SMALL GTPASES; PC12 CELLS	The formation and directional guidance of neurites involves dynamic regulation of Rho family GTPases. Rac and Cdc42 promote neurite outgrowth, whereas Rho activation causes neurite retraction. Here we describe a role for collapsin response mediator protein (Crmp-2), a neuronal protein implicated in axonal outgrowth and a component of the semaphorin 3A pathway, in switching GTPase signaling when expressed in combination with either dominant active Rac or Rho. In neuroblastoma N1E-115 cells, co-expression of Crmp-2 with dominant active RhoA V14 induced Rac morphology, cell spreading and ruffling (and the formation of neurites). Conversely, co-expression of Crmp-2 with dominant active Rac1 V12 inhibited Rac morphology, and in cells already expressing Rac1 V12, Crmp-2 caused localized peripheral collapse, involving pivotal Rho (and Cdc42) activation. Rho kinase was a regulator of Crmp-2; Crmp-2 phosphorylation was required for Crmp-2/Rac1 V12 inhibition, but not Crmp2/RhoA V14 induction, of Rac morphology. Thus Crmp-2, regulated by Rho kinase, promotes outgrowth and collapse in response to active Rho and Rac, respectively, reversing their usual morphological effects and providing a mechanism for dynamic modulation of growth cone guidance.	UCL, Inst Neurol, Dept Neurochem, London WC1N 1PJ, England; Inst Mol & Cell Biol, Glaxo IMCB Grp, Singapore 117609, Singapore	University of London; University College London; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline	Hall, C (corresponding author), UCL, Inst Neurol, Dept Neurochem, 1 Wakefield St, London WC1N 1PJ, England.	C.Hall@ion.ucl.ac.uk	Hall, Christine/C-8390-2009					Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hall C, 2001, J NEUROSCI, V21, P5191, DOI 10.1523/JNEUROSCI.21-14-05191.2001; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Jin Z, 1997, J NEUROSCI, V17, P6256; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuhn TB, 1999, J NEUROSCI, V19, P1965; LI W, 1992, GENETICS, V132, P675; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohm B, 2000, FEBS LETT, V486, P68, DOI 10.1016/S0014-5793(00)02240-7; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tigyi G, 1996, J NEUROCHEM, V66, P549; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wong WT, 2000, CURR OPIN NEUROBIOL, V10, P118, DOI 10.1016/S0959-4388(99)00059-8; Yuan G, 1999, J BIOL CHEM, V274, P8175, DOI 10.1074/jbc.274.12.8175	38	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43482	43486		10.1074/jbc.C100455200	http://dx.doi.org/10.1074/jbc.C100455200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11583986	hybrid			2022-12-27	WOS:000172169300109
J	Dutoya, S; Gibert, S; Lemercier, G; Santarelli, X; Baltz, D; Baltz, T; Bakalara, N				Dutoya, S; Gibert, S; Lemercier, G; Santarelli, X; Baltz, D; Baltz, T; Bakalara, N			A novel C-terminal kinesin is essential for maintaining functional acidocalcisomes in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE MOTOR; AFRICAN TRYPANOSOMES; ACIDIC COMPARTMENT; MEMBRANE-TRANSPORT; CYTOPLASMIC PH; POINT MUTATION; CA2+ STORAGE; PROTEIN; PURIFICATION; BINDING	Kinesins are cytoskeletal motor proteins that play roles in a variety of fundamental cellular processes including cell division and the anterograde transport of vesicles and organelles. We purified, cloned, and functionally characterized in Trypanosoma brucei a new member of the C-terminal kinesin family, TbKIFC1. Kinetic constants of the recombinant motor domain of TbKIFC1 were estimated at 0.56 muM for the microtubule dissociation constant (K-d) with a k(cat) of 0.2 s(-1). Immunolocalization analysis showed an association of TbKIFC1 with punctate structures. Because they were rapidly transported to the negative pole of the microtubule after NH4Cl treatment, these structures were considered to be associated with acidic vesicles. To determine the role of the kinesin in vivo, we produced an inducible kinesin-deficient strain by double-stranded RNA interference methodology. Mutant cells were loaded with the fluorescent reagent fura2/acetoxymethylester to measure intracellular free calcium ([Ca2+](i)). The resting [Ca2+](i) was unchanged in mutant cells; how. ever, alkalinization of acidic vesicles induced by NH4Cl or nigericin was not followed by release of Ca2+. These data and the relative importance of the ionomycin-releasable and the ionomycin-plus-NH4Cl-releasable Ca2+ pools suggest a lower Ca2+ content in acidocalcisomes and dysfunctional Ca2+ release.	Univ Bordeaux 2, Lab Immunol & Parasitol Mol, Ecole Super Technol & Biomol, F-33076 Bordeaux, France; Univ Victor Segalen, CNRS, UMR 5016, Mol Parasitol Lab, F-33076 Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bakalara, N (corresponding author), Univ Bordeaux 2, Lab Immunol & Parasitol Mol, Ecole Super Technol & Biomol, BP 12,146 Rue Leo Saignat, F-33076 Bordeaux, France.			SANTARELLI, Xavier/0000-0003-1530-4632				Bakalara N, 2000, J BIOL CHEM, V275, P8863, DOI 10.1074/jbc.275.12.8863; Bakalara N, 1995, EUR J BIOCHEM, V234, P871, DOI 10.1111/j.1432-1033.1995.871_a.x; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P458, DOI 10.1093/nar/17.1.458; CHANDRA R, 1993, J CELL SCI, V104, P899; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FAZEKAS S, 1980, J IMMUNOL METHODS, V35, P1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FraserLhostis C, 1997, BIOL CHEM, V378, P1039, DOI 10.1515/bchm.1997.378.9.1039; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; GOODSON HV, 1994, J CELL SCI, V107, P1875; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; HOLDER AA, 1981, MOL BIOCHEM PARASIT, V2, P135, DOI 10.1016/0166-6851(81)90095-5; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Hurd DD, 1996, GENETICS, V142, P195; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Lingnau A, 1999, J CELL SCI, V112, P3061; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MACRAE TH, 1990, BIOCHEM J, V265, P87, DOI 10.1042/bj2650087; Marszalek JR, 2000, BBA-MOL CELL RES, V1496, P142, DOI 10.1016/S0167-4889(00)00015-X; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MITSUI H, 1994, PLANT MOL BIOL, V25, P865, DOI 10.1007/BF00028881; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PAMER EG, 1989, MOL BIOCHEM PARASIT, V33, P27, DOI 10.1016/0166-6851(89)90038-8; Parsons M, 2000, PARASITOL TODAY, V16, P56, DOI 10.1016/S0169-4758(99)01590-2; Piperno G, 1997, P NATL ACAD SCI USA, V94, P4457, DOI 10.1073/pnas.94.9.4457; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROSS CA, 1987, ACTA TROP, V44, P293; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; Scott DA, 1998, BIOCHEM J, V331, P583, DOI 10.1042/bj3310583; SEYFANG A, 1993, EUR J BIOCHEM, V214, P593, DOI 10.1111/j.1432-1033.1993.tb17958.x; Sheetz MP, 1999, EUR J BIOCHEM, V262, P19, DOI 10.1046/j.1432-1327.1999.00340.x; Sloboda Roger D., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P5447, DOI 10.1093/emboj/18.20.5447; Song HB, 1998, NATURE, V396, P587, DOI 10.1038/25153; STIEGER J, 1984, J BIOL CHEM, V259, P4596; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vannier-Santos MA, 1999, MICROBIOL-UK, V145, P3213, DOI 10.1099/00221287-145-11-3213; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Xiong ZH, 1997, J BIOL CHEM, V272, P31022, DOI 10.1074/jbc.272.49.31022	64	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49117	49124		10.1074/jbc.M105962200	http://dx.doi.org/10.1074/jbc.M105962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11581257	hybrid			2022-12-27	WOS:000173922100066
J	Bash, RC; Yodh, J; Lyubchenko, Y; Woodbury, N; Lohr, D				Bash, RC; Yodh, J; Lyubchenko, Y; Woodbury, N; Lohr, D			Population analysis of subsaturated 172-12 nucleosomal arrays by atomic force microscopy detects nonrandom behavior that is favored by histone acetylation and short repeat length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST CHROMATIN STRUCTURE; HIGHER-ORDER STRUCTURE; RNA-POLYMERASE-III; MICROCOCCAL NUCLEASE; ACTIVE CHROMATIN; GENE-EXPRESSION; DNA-SEQUENCES; TRANSCRIPTION; ORGANIZATION; DISRUPTION	Concatameric 5 S rDNA templates reconstituted in vitro into nueleosomal arrays provide very popular chromatin models for many kinds of studies. Here, atomic force microscopy is used to determine the population distributions for one such nucleosomal array, the 172-12, reconstituted to various subsaturated levels with nonacetylated or hyperacetylated HeLa histones. This array is a model for short linker length genomes and transcriptionally active and newly replicated chromatins. The analysis shows that as input histone levels increase, template occupation increases progressively as discrete population distributions. The distributions are random at (n(av) < 4) and high (n(av) > 8) loadings but display specific nonrandom features, such as a deficit of molecules with one nucleosome more or less than the peak species in the distribution and enhanced distribution breadths, in the mid-range (n(av) = 4-8). Thus, the mid-range of occupation on polynucleosomal arrays may be a special range for chromatin structure and/or assembly. The mid-range nonrandom. features are enhanced in distributions from short repeat (172-12) arrays, particularly for unacetylated chromatin, and in distributions from hyperacetylated chromatin, particularly for long repeat (208-12) arrays. Thus, short repeat length and acetylation can affect basic chromatin properties, like population tendencies, in very similar ways and therefore may cause similar changes in chromatin structure. Some possible effects are suggested. The data also indicate that it is thermodynamically more difficult for hyperacetylated nucleosomes to assemble onto the 172-12 templates, a result having implications for in vivo chromatin assembly.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Midwestern Univ, Arizona Coll Osteopath Med, Div Basic Sci, Glendale, AZ 85308 USA; Arizona State Univ, Dept Microbiol, Tempe, AZ 85287 USA; Arizona State Univ, Dept Biol, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Midwestern University; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Lohr, D (corresponding author), Arizona State Univ, Dept Chem & Biochem, POB 871604, Tempe, AZ 85287 USA.	dlohr@asu.edu			NCI NIH HHS [CA85990] Funding Source: Medline; NIGMS NIH HHS [GM54991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM054991, R44GM054991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MJ, 1993, BIOCHEMISTRY-US, V32, P8390, DOI 10.1021/bi00084a002; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; BERKOWITZ EM, 1981, BIOCHEMISTRY-US, V20, P7284, DOI 10.1021/bi00528a036; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BURGOYNE LA, 1981, BIOCHEM BIOPH RES CO, V99, P893, DOI 10.1016/0006-291X(81)91247-X; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; COMPTON JL, 1976, P NATL ACAD SCI USA, V73, P4382, DOI 10.1073/pnas.73.12.4382; DAVIE JR, 1981, J BIOL CHEM, V256, P2574; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; FRITZSCHE W, 1997, SCANNING, P1942; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; LOHR D, 1986, J BIOL CHEM, V261, P9904; Lohr D, 1997, J BIOL CHEM, V272, P26795, DOI 10.1074/jbc.272.43.26795; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LOHR D, 1977, P NATL ACAD SCI USA, V74, P79, DOI 10.1073/pnas.74.1.79; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; LYUBCHENKO YL, 1992, J BIOMOL STRUCT DYN, V10, P589, DOI 10.1080/07391102.1992.10508670; Lyubchenko YL, 1996, SCANNING MICROSCOPY SUPPLEMENT 10, 1996, P97; LYUBCHENKO YL, 1995, SCANNING MICROSCOPY, V9, P705; LYUHCHENKO YL, 2001, METHOD MOL BIOL, V147, P569; MARTIN LD, 1995, BIOCHEMISTRY-US, V34, P4610, DOI 10.1021/bi00014a014; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Sato MH, 1999, FEBS LETT, V452, P267, DOI 10.1016/S0014-5793(99)00644-4; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; Staynov DZ, 2000, NUCLEIC ACIDS RES, V28, P3092, DOI 10.1093/nar/28.16.3092; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Holde K.E., 1988, CHROMATIN; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Widlund HR, 2000, BIOCHEMISTRY-US, V39, P3835, DOI 10.1021/bi991957l; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yodh JG, 1999, BIOCHEMISTRY-US, V38, P15756, DOI 10.1021/bi991034q	57	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48362	48370		10.1074/jbc.M104916200	http://dx.doi.org/10.1074/jbc.M104916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11583994	hybrid			2022-12-27	WOS:000172927000085
J	Lu, ZH; Solioz, M				Lu, ZH; Solioz, M			Copper-induced proteolysis of the CopZ copper chaperone of Enterococcus hirae.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; ESCHERICHIA-COLI; ATX1 GENE; HOMEOSTASIS; TRANSPORT; PROTEIN; DEGRADATION; RESISTANCE; ENDOCYTOSIS; EXPRESSION	The cop operon is a key element of copper homeostasis in Enterococcus hirae. It encodes two copper ATPases, CopA and CopB, the Copy repressor, and the CopZ metallochaperone. It was previously shown that the transcription of the operon is induced by copper. The concomitant increase in the levels of Cop proteins, particularly the CopB copper export ATPase, allows uncompromised growth of E. hirae in up to 5 mm ambient copper. We here show by Western blotting that the steady-state level of CopZ was increased only up to 0.5 mm copper. At higher copper concentrations, the level of CopZ was decreased and became undetectable at 5 mm media copper. When CopZ was overexpressed from a plasmid, the cells exhibited increased sensitivity to copper and oxidative stress, suggesting that high CopZ expression could become toxic to cells. In wild-type cells, the level of mRNA transcripts from the cop operon remained high in up to 5 mm copper, suggesting that CopZ was proteolyzed. Cell extracts were found to contain a copper-activated proteolytic activity that degraded CopZ in vitro. In this assay, Cu-CopZ was more susceptible to degradation than apo-CopZ. The growth of E. hirae in copper increased the copper-inducible proteolytic activity in extracts. Zymographic studies showed the presence of a copper-dependent protease in crude cell lysates. Thus, copper-stimulated proteolysis plays an important role in the regulation of copper homeostasis in E. hirae.	Univ Bern, Dept Clin Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Solioz, M (corresponding author), Univ Bern, Dept Clin Pharmacol, Murtenstr 35, CH-3010 Bern, Switzerland.		Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721; Lu, Zen H./0000-0002-9408-0579				Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; Cobine P, 1999, FEBS LETT, V445, P27, DOI 10.1016/S0014-5793(99)00091-5; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Horn N, 1999, J TRACE ELEM EXP MED, V12, P297; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Kelner GS, 2000, J BIOL CHEM, V275, P580, DOI 10.1074/jbc.275.1.580; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Multhaup G, 2001, BIOCHEM BIOPH RES CO, V288, P172, DOI 10.1006/bbrc.2001.5757; Naeve GS, 1999, NEUROSCIENCE, V93, P1179, DOI 10.1016/S0306-4522(99)00175-X; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; ODERMATT A, 1995, J BIOL CHEM, V270, P4349, DOI 10.1074/jbc.270.9.4349; ODERMATT A, 1992, ANN NY ACAD SCI, V671, P484, DOI 10.1111/j.1749-6632.1992.tb43836.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; SILVER S, 1993, MOL MICROBIOL, V10, P7, DOI 10.1111/j.1365-2958.1993.tb00898.x; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Strausak D, 1997, J BIOL CHEM, V272, P8932; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Willett WS, 1996, BIOCHEMISTRY-US, V35, P5992, DOI 10.1021/bi9530191; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Wunderli-Ye H, 1999, BIOCHEM BIOPH RES CO, V259, P443, DOI 10.1006/bbrc.1999.0807; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	43	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47822	47827		10.1074/jbc.M106218200	http://dx.doi.org/10.1074/jbc.M106218200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585824	hybrid			2022-12-27	WOS:000172927000014
J	Szafer, E; Rotman, M; Cassel, D				Szafer, E; Rotman, M; Cassel, D			Regulation of GTP hydrolysis on ADP-ribosylation factor-1 at the Golgi membrane.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PUTATIVE CARGO RECEPTORS; ACTIVATING PROTEIN; ARF-GAP; ENDOPLASMIC-RETICULUM; BINDING PROTEIN; COATED VESICLES; PHOSPHOLIPASE-D; SACCHAROMYCES-CEREVISIAE; COATOMER BINDING	The interaction of the coatomer coat complex with the Golgi membrane is initiated by the active, GTP-bound state of the small GTPase ADP-ribosylation factor I (ARF1), whereas GTP hydrolysis triggers coatomer dissociation. The hydrolysis of GTP on ARF1 depends on the action of members of a family of ARF1-directed GTPase-activating proteins (GAPs). Previous studies in well defined systems indicated that the activity of a mammalian Golgi membrane-localized ARF GAP (GAP1) might be subjected to regulation by membrane lipids as well as by the coatomer complex. Coatomer was found to strongly stimulate GAP-dependent GTP hydrolysis on a membrane-independent mutant of ARF1, whereas we reported that GTP hydrolysis on wild type, myristoylated ARF1 loaded with GTP in the presence of phospholipid vesicles was coatomer-independent. To investigate the regulation of ARF1 GAPs under more physiological conditions, we studied GTP hydrolysis on Golgi membrane-associated ARF1. The activities at the Golgi of recombinant GAP1 as well as coatomer-depleted fractions from rat brain cytosol resembled those observed in the presence of liposomes; however, unlike in liposomes, GAP activities on Golgi membranes were approximately doubled upon addition of coatomer. By contrast, endogenous GAP activity in Golgi membrane preparations was unaffected by coatomer. Cytosolic GAP activity was partially reduced following immunodepletion of GAP1, indicating that GAP1 plays a significant although not exclusive role in the regulation of GTP hydrolysis at the Golgi. Unlike the activities of the mammalian proteins, the Saccharomyces cerevisiae Glo3 ARF GAP displayed activity at the Golgi that was highly dependent on coatomer. We conclude that ARF GAPs in themselves can efficiently stimulate GTP hydrolysis on ARF1 at the Golgi, and that coatomer may play an auxiliary role in this reaction, which would lead to an increased cycling rate of ARF1 in COPI-coated regions of the Golgi membrane.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Cassel, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.							Andreev J, 1999, MOL CELL BIOL, V19, P2338; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Dogic D, 1999, EUR J CELL BIOL, V78, P305, DOI 10.1016/S0171-9335(99)80064-8; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Goldberg J, 2000, CELL, V100, P671, DOI 10.1016/S0092-8674(00)80703-5; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; Huber I, 2001, METHOD ENZYMOL, V329, P307; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Liu XQ, 2001, FEBS LETT, V490, P79, DOI 10.1016/S0014-5793(01)02134-2; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Nickel W, 1998, SEMIN CELL DEV BIOL, V9, P493, DOI 10.1006/scdb.1998.0256; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Poon PP, 2001, METHOD ENZYMOL, V329, P317; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; TABAS I, 1979, J BIOL CHEM, V254, P1655; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Uchida H, 2001, J EXP MED, V193, P955, DOI 10.1084/jem.193.8.955; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; WEISS O, 1989, J BIOL CHEM, V264, P21066; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198	65	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47834	47839		10.1074/jbc.M106000200	http://dx.doi.org/10.1074/jbc.M106000200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11592960	hybrid			2022-12-27	WOS:000172927000016
J	Jiang, DM; Sullivan, PG; Sensi, SL; Steward, O; Weiss, JH				Jiang, DM; Sullivan, PG; Sensi, SL; Steward, O; Weiss, JH			Zn2+ induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; GLUTAMATE NEUROTOXICITY; ZINC; DEATH; BRAIN; INHIBITION; NECROSIS; ACCUMULATION; SUPEROXIDE; CULTURES	Rapid entry of Ca2+ or Zn2+ kills neurons. Mitochondria are major sites of Ca2+-dependent toxicity. This study examines Zn2+-initiated mitochondrial cell death signaling. 10 nm Zn2+ induced acute swelling of isolated mitochondria, which was much greater than that induced by higher Ca2+ levels. Zn2+ entry into mitochondria was dependent upon the Ca2+ uniporter, and the consequent swelling resulted from opening of the mitochondrial permeability transition pore. Confocal imaging of intact neurons revealed entry of Zn2+ (with Ca2+) to cause pronounced mitochondrial swelling, which was far greater than that induced by Ca2+ entry alone. Further experiments compared the abilities of Zn2+ and Ca2+ to induce mitochondrial release of cytochrome c (Cyt-c) or apoptosis-inducing factor. In isolated mitochondria, 10 nm Zn2+ exposures induced Cyt-c release. Induction of Zn2+ entry into cortical neurons resulted in distinct increases in cytosolic Cyt-c immunolabeling and in cytosolic and nuclear apoptosis-inducing factor labeling within 60 min. In comparison, higher absolute [Ca2+](i) rises were less effective in inducing release of these factors. Addition of the mitochondrial permeability transition pore inhibitors cyclosporin A and bongkrekic acid decreased Zn2+-dependent release of the factors and attenuated neuronal cell death as assessed by trypan blue staining 5-6 h after the exposures.	Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA; Univ G DAnnunzio, Dept Neurol, I-66013 Chieti, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; G d'Annunzio University of Chieti-Pescara	Weiss, JH (corresponding author), Univ Calif Irvine, Dept Neurol, 2101 Gillespie Neurosci Facil, Irvine, CA 92697 USA.	jweiss@uci.edu	Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019; weiss, john/B-4283-2008	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; weiss, john/0000-0001-9323-7813; Steward, Oswald/0000-0001-7069-8756	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032280, R01NS030884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000096] Funding Source: NIH RePORTER; NIA NIH HHS [2T32 AG 00096, AG 00836, AG 00919] Funding Source: Medline; NINDS NIH HHS [NS 32280, NS 30884] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brand IA, 1996, J BIOL CHEM, V271, P1941, DOI 10.1074/jbc.271.4.1941; BRIERLEY GP, 1967, BIOCHEMISTRY-US, V6, P3892, DOI 10.1021/bi00864a035; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buckman JF, 2001, J NEUROSCI METH, V104, P165, DOI 10.1016/S0165-0270(00)00340-X; Canzoniero LMT, 1999, J NEUROSCI, V19; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Hyrc K, 1997, J NEUROSCI, V17, P6669; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Lobner D, 2000, CELL MOL BIOL, V46, P797; Manev H, 1997, EXP NEUROL, V146, P171, DOI 10.1006/exnr.1997.6510; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicotera P, 1999, J CEREBR BLOOD F MET, V19, P583, DOI 10.1097/00004647-199906000-00001; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; SARIS NEL, 1994, FEBS LETT, V356, P195, DOI 10.1016/0014-5793(94)01256-3; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SKULACHE.VP, 1967, BIOCHEM BIOPH RES CO, V26, P1, DOI 10.1016/0006-291X(67)90242-2; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Wudarczyk J, 1999, ARCH BIOCHEM BIOPHYS, V363, P1, DOI 10.1006/abbi.1998.1058; Yin HZ, 1998, BRAIN RES, V781, P45, DOI 10.1016/S0006-8993(97)01208-0	34	224	232	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47524	47529		10.1074/jbc.M108834200	http://dx.doi.org/10.1074/jbc.M108834200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595748	hybrid			2022-12-27	WOS:000172768500111
J	Tam, A; Schmidt, WK; Michaelis, S				Tam, A; Schmidt, WK; Michaelis, S			The multispanning membrane protein Ste24p catalyzes CAAX proteolysis and NH2-terminal processing of the yeast a-factor precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FARNESYLTRANSFERASE; METHYLTRANSFERASE; RAS; PREDICTION; IDENTIFICATION; MECHANISMS; INHIBITORS; MATURATION	Saccharomyces cerevisiae Ste24p is a multispanning membrane protein implicated in the CAAX proteolysis step that occurs during biogenesis of the prenylated a-factor mating pheromone. Whether Ste24p acts directly as a CAAX protease or indirectly to activate a downstream protease has not yet been established. In this study, we demonstrate that purified, detergent-solubilized Ste24p directly mediates CAAX proteolysis in a zinc-dependent manner. We also show that Ste24p mediates a separate proteolytic step, the first NH2-terminal cleavage in a-factor maturation. These results establish that Ste24p functions both as a bona fide COOH-terminal CAAX protease and as an a-factor NH2-terminal protease. Importantly, this study is the first to directly demonstrate that a eukaryotic multispanning membrane protein can possess intrinsic proteolytic activity.	Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	Johns Hopkins University	Michaelis, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA.	michaelis@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041223] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Ambroziak P., 2001, ENZYMES, P155; ANSORGE S, 1984, BIOMED BIOCHIM ACTA, V43, P39; ASHBY MN, 1995, METHOD ENZYMOL, V250, P235; AULD DS, 1995, METHOD ENZYMOL, V248, P228; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P1; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dekker N, 2001, BIOCHEMISTRY-US, V40, P1694, DOI 10.1021/bi0014195; Desrosiers RR, 1999, BIOCHEM BIOPH RES CO, V261, P790, DOI 10.1006/bbrc.1999.0936; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HRYCYNA CA, 1995, METHOD ENZYMOL, V250, P251; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Juretic D, 1998, COMPUT CHEM, V22, P279, DOI 10.1016/S0097-8485(97)00070-3; Kumagai H, 1999, BBA-GEN SUBJECTS, V1426, P468, DOI 10.1016/S0304-4165(98)00170-6; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Omer CA, 1997, TRENDS PHARMACOL SCI, V18, P437, DOI 10.1016/S0165-6147(97)90677-5; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; REISS Y, 1992, J BIOL CHEM, V267, P6403; RINE J, 1990, New Biologist, V2, P219; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; SIKORSKI RS, 1989, GENETICS, V122, P19; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	49	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46798	46806		10.1074/jbc.M106150200	http://dx.doi.org/10.1074/jbc.M106150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581258	hybrid			2022-12-27	WOS:000172768500018
J	Zhang, XY; Bi, EF; Novick, P; Du, LL; Kozminski, KG; Lipschutz, JH; Guo, W				Zhang, XY; Bi, EF; Novick, P; Du, LL; Kozminski, KG; Lipschutz, JH; Guo, W			Cdc42 interacts with the exocyst and regulates polarized secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL POLARITY; BUDDING YEAST; SEC6/8 COMPLEX; GTPASE; ACTIN; EXOCYTOSIS; DELIVERY; VESICLES; ESTABLISHMENT	Polarized delivery and incorporation of proteins and lipids to specific domains of the plasma membrane is fundamental to a wide range of biological processes such as neuronal synaptogenesis and epithelial cell polarization. The exocyst complex is specifically localized to sites of active exocytosis and plays essential roles in secretory vesicle targeting and docking at the plasma membrane. Sec3p, a component of the exocyst, is thought to be a spatial landmark for polarized exocytosis. In a search for proteins that regulate the localization of the exocyst in the budding yeast Saccharomyces cerevisiae, we found that certain cdc42 mutants affect the polarized localization of the exocyst proteins. In addition, we found that these mutant cells have a randomized protein secretion pattern on the cell surface. Biochemical experiments indicated that Sec3p directly interacts with Cdc42 in its GTP-bound form. Genetic studies demonstrated synthetically lethal interactions between cdc42 and several exocyst mutants. These results have revealed a role for Cdc42 in exocytosis. We propose that Cdc42 coordinates the vesicle docking machinery and the actin cytoskeleton for polarized secretion.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Yale University; University of California System; University of California Berkeley	Guo, W (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	guowei@sas.upenn.edu		Du, Li-Lin/0000-0002-1028-7397	NIGMS NIH HHS [GM 59216, GM 35370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059216, R37GM035370, R01GM035370] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bi EF, 1996, MOL CELL BIOL, V16, P5264; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; CHANG LW, 1995, BIOMED ENG-APP BAS C, V7, P1; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Finger FP, 2000, GENETICS, V156, P943; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Gladfelter AS, 2001, MOL BIOL CELL, V12, P1239, DOI 10.1091/mbc.12.5.1239; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Karpova TS, 2000, MOL BIOL CELL, V11, P1727, DOI 10.1091/mbc.11.5.1727; Kozminski KG, 2000, MOL BIOL CELL, V11, P339, DOI 10.1091/mbc.11.1.339; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Richman TJ, 2000, MOL CELL BIOL, V20, P8548, DOI 10.1128/MCB.20.22.8548-8559.2000; Richman TJ, 1999, J BIOL CHEM, V274, P16861, DOI 10.1074/jbc.274.24.16861; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	38	273	279	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46745	46750		10.1074/jbc.M107464200	http://dx.doi.org/10.1074/jbc.M107464200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595741	hybrid			2022-12-27	WOS:000172768500011
J	Imai, S; Tezuka, H; Furuhashi, Y; Muto, R; Fujita, K				Imai, S; Tezuka, H; Furuhashi, Y; Muto, R; Fujita, K			A factor of inducing IgE from a filarial parasite is an agonist of human CD40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; B-CELL PROLIFERATION; HELMINTH INFECTION; DENDRITIC CELLS; ABA-1 ALLERGEN; T-CELLS; LIGAND; EXPRESSION; CYTOKINES; RESPONSES	Immune responses to parasitic helminth are usually characterized by quite mysterious phenomena: dominance of Th2-like immunity and antigen-nonspecific IgE secretion. We previously purified a factor from Dirofilaria immitis that induces antigen-nonspecific IgE in rats and named it DiAg. In the presence of IL-4, DiAg induces mouse B cells to secrete IgE, which is antigen-nonspecific polyclonal antibody. We investigated the biochemical characteristics of DiAg as a factor of inducing IgE in this study. Recombinant DiAg (rDiAg) with interleukin (IL)-4 induced IgE synthesis in highly purified human normal B cells in vitro cell culture systems. The addition of recombinant human soluble CD40 IgG fusion protein (rsCD40-Ig) inhibited induction of IgE synthesis by rDiAg with IL-4. Monocyte cells were stimulated with rDiAg and recombinant human soluble CD40L (rsCD40L); IL-12 and TNF-alpha were induced. The addition of rsCD40-Ig to THP-1 cells activated with rDiAg and rsCD40L inhibited the production of IL-12. rDiAg bound to the monocyte cell membrane fraction and recombinant human soluble CD40; this binding of rDiAg was competitively inhibited by addition of rsCD40L. Moreover, in CD40-deficient mice, IgE production and MLN-B cell proliferation by rDiAg were completely absent. Based on these results, we concluded that DiAg is an agonist of CD40.	Tokyo Med & Dent Univ, Sect Environm Parasitol, Dept Int Hlth Dev, Div Publ Hlth,Grad Sch,Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Imai, S (corresponding author), Tokyo Med & Dent Univ, Sect Environm Parasitol, Dept Int Hlth Dev, Div Publ Hlth,Grad Sch,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							AJUH PM, 1995, EXP PARASITOL, V81, P145, DOI 10.1006/expr.1995.1103; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; BRITTON C, 1995, MOL BIOCHEM PARASIT, V72, P77, DOI 10.1016/0166-6851(95)00088-I; Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805; CLARK EA, 1990, TISSUE ANTIGENS, V36, P33, DOI 10.1111/j.1399-0039.1990.tb01795.x; DUNLAP NE, 1989, LEUCOCYTE TYPING, V4, P487; Else KJ, 1998, INT J PARASITOL, V28, P1145, DOI 10.1016/S0020-7519(98)00087-3; FANSLOW WC, 1992, J IMMUNOL, V149, P655; Furuhashi Y, 2001, INT ARCH ALLERGY IMM, V125, P144, DOI 10.1159/000053808; GALY AHM, 1992, J IMMUNOL, V149, P775; HORII Y, 1986, J PARASITOL, V72, P315, DOI 10.2307/3281611; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; INDZHIIA LV, 1992, J CLIN IMMUNOL, V12, P225, DOI 10.1007/BF00918093; ISHIZAKA T, 1976, J ALLERGY CLIN IMMUN, V58, P523, DOI 10.1016/0091-6749(76)90196-2; Jabara HH, 1996, INT IMMUNOL, V8, P1503, DOI 10.1093/intimm/8.10.1503; JARRETT EEE, 1982, PROG ALLERGY, V31, P178; Kato T, 1997, CELL IMMUNOL, V181, P59, DOI 10.1006/cimm.1997.1196; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; LEE TDG, 1993, INT ARCH ALLERGY IMM, V102, P185, DOI 10.1159/000236570; LEE TDG, 1995, J ALLERGY CLIN IMMUN, V95, P1247; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MALISZEWSKI CR, 1993, EUR J IMMUNOL, V23, P1044, DOI 10.1002/eji.1830230510; MAZZEI GJ, 1995, J BIOL CHEM, V270, P7025, DOI 10.1074/jbc.270.13.7025; Ning ZQ, 1996, EUR J IMMUNOL, V26, P2356, DOI 10.1002/eji.1830261013; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OWHASHI M, 1993, MOL IMMUNOL, V30, P1315, DOI 10.1016/0161-5890(93)90048-G; PRITCHARD DI, 1993, PARASITE IMMUNOL, V15, P5, DOI 10.1111/j.1365-3024.1993.tb00566.x; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SPENCE HJ, 1993, MOL BIOCHEM PARASIT, V57, P339, DOI 10.1016/0166-6851(93)90210-O; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TWEEDIE S, 1993, EXP PARASITOL, V76, P156, DOI 10.1006/expr.1993.1018; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; WARE CF, 1991, J IMMUNOL, V147, P4229; Wynn TA, 1997, MEM I OSWALDO CRUZ, V92, P105, DOI 10.1590/S0074-02761997000800014; Xia Y, 2000, PARASITOLOGY, V120, P211, DOI 10.1017/S0031182099005363; YAMAOKA KA, 1994, IMMUNOLOGY, V81, P507; Yoshimoto T, 1997, EUR J IMMUNOL, V27, P3461, DOI 10.1002/eji.1830271247	40	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46118	46124		10.1074/jbc.M104581200	http://dx.doi.org/10.1074/jbc.M104581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591702	hybrid			2022-12-27	WOS:000172573100086
J	Iwamoto, T; Fukumoto, S; Kanaoka, K; Sakai, E; Shibata, M; Fukumoto, E; Inokuchi, J; Takamiya, K; Furukawa, K; Furukawa, K; Kato, Y; Mizuno, A				Iwamoto, T; Fukumoto, S; Kanaoka, K; Sakai, E; Shibata, M; Fukumoto, E; Inokuchi, J; Takamiya, K; Furukawa, K; Furukawa, K; Kato, Y; Mizuno, A			Lactosylceramide is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappa B ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; NEURITE OUTGROWTH; BONE-RESORPTION; CELL-ADHESION; GLUCOSYLCERAMIDE SYNTHASE; SIGNAL-TRANSDUCTION; GLYCOSPHINGOLIPID SYNTHESIS; COMPLEX GANGLIOSIDES	Glycosphingolipids and their metabolites play important roles in a variety of biological processes. Several signal molecules are localized in a glycolipid-enriched microdomain on the cell surface, and their signals are regulated by the glycolipid composition. However, the function of glycolipids in osteoclastogenesis has not been clearly understood. We found that D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanoI (D-PDMP), a glucosylceramide synthase inhibitor, completely inhibits the osteoclast formation induced by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappaB ligand (RANKL) in a dose-dependent manner. Expression of RANK, the receptor of RANKL, induced by macrophage colony-stimulating factor, was reduced markedly in D-PDMP-treated cells. D-PDMP also inhibited the phosphorylation. of the inhibitor of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2 induced by RANKL. In several experiments with the addition of glycolipids to D-PDMP-treated purified bone marrow cells, lactosylceramide (LacCer) strongly affected the differentiation into tartrate-resistant acid phosphatase mononucleated cells, but not positive multinucleated cells. GM3 and GM1 also recovered, but less effectively compared with LacCer. Moreover, exogenous LacCer recovered the reduced expression of RANK and the phosphorylation of inhibitor of NF-kappaB and extracellular signal-regulated kinase 1/2 after stimulation by RANKL at the same level of cells without D-PDMP treatment. Our data suggest that glycosphingolipids, especially LacCer, are necessary for the initiation step of RANKL-induced osteoclastogenesis.	Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Oral & Maxillofacial Surg 1, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Prevent Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Sch Dent, Dept Pharmacol, Nagasaki 8528588, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Sapporo, Hokkaido 0600812, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Hokkaido University; Nagoya University	Fukumoto, S (corresponding author), Nagasaki Univ, Sch Dent, Dept Pediat Dent, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	satoshi@dh.nagasaki-u.ac.jp	Inokuchi, Jin-ichi/AAW-9964-2020; Iwamoto, Tsutomu/AAA-6597-2019; Iwamoto, Tsutomu/AAI-8952-2021	Inokuchi, Jin-ichi/0000-0002-0703-5746; Iwamoto, Tsutomu/0000-0001-8472-605X; Fukumoto, Satoshi/0000-0002-5046-6891; sakai, eiko/0000-0002-6776-6540; Takamiya, Kogo/0000-0001-7240-6307				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; CHAMBERS TJ, 1984, J CELL SCI, V66, P383; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CLOVER J, 1992, J CELL SCI, V103, P267; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; FURUKAWA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P70, DOI 10.1016/0003-9861(90)90414-T; Harada H, 1998, ENDOCRINOLOGY, V139, P3967, DOI 10.1210/en.139.9.3967; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; Hynds DL, 1997, J NEUROSCI RES, V47, P617, DOI 10.1002/(SICI)1097-4547(19970315)47:6<617::AID-JNR7>3.0.CO;2-G; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; KATO H, 1993, J BIOL CHEM, V268, P2655; KOIKE T, 1993, IMMUNOL LETT, V35, P207, DOI 10.1016/0165-2478(93)90184-4; KRUPPA G, 1992, J IMMUNOL, V148, P3152; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Probstmeier R, 1999, EUR J NEUROSCI, V11, P2474, DOI 10.1046/j.1460-9568.1999.00670.x; Probstmeier R, 1999, GLYCOBIOLOGY, V9, P101, DOI 10.1093/glycob/9.2.101; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Sakai H, 2000, BIOCHEM BIOPH RES CO, V270, P550, DOI 10.1006/bbrc.2000.2485; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHINAR DM, 1993, J BONE MINER RES, V8, P403; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; Takeda H, 1998, FEBS LETT, V422, P255, DOI 10.1016/S0014-5793(98)00005-2; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tsurukai T, 1998, J CELL PHYSIOL, V177, P26, DOI 10.1002/(SICI)1097-4652(199810)177:1<26::AID-JCP3>3.0.CO;2-G; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; Usuki S, 1996, J NEUROCHEM, V67, P1821; VANDERPLUIJM G, 1994, J BONE MINER RES, V9, P1021; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744	64	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46031	46038		10.1074/jbc.M104464200	http://dx.doi.org/10.1074/jbc.M104464200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11592959	hybrid			2022-12-27	WOS:000172573100074
J	Satou, A; Taira, T; Iguchi-Ariga, SMM; Ariga, H				Satou, A; Taira, T; Iguchi-Ariga, SMM; Ariga, H			A novel transrepression pathway of c-Myc. Recruitment of a transcriptional corepressor complex to c-Myc by MM-1, a c-Myc-binding protein.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; ESSENTIAL COFACTOR; REPRESSOR DOMAIN; SWI/SNF COMPLEX; CELL-GROWTH; TIF1 BETA; HETEROCHROMATIN; INTERACTS; KAP-1; MAD	The protooncogene product c-Myc plays a role in transcription regulation both for activation and repression. While transactivation pathways of c-Myc either from the N-proximal or the C-proximal region that is linked to the chromatin remodeling complex have been identified, a transrepression pathway had been identified only from the C-proximal region via Max and Mad that recruit the histone deacetylase (HDAC) complex. We have reported that a novel c-Myc-binding protein, MM-1, repressed the E-box-dependent transcription activity of c-Myc (Mori, K., Maeda, Y., Kitaura, H., Taira, T., Iguchi-Ariga, S. M. M., and Ariga, H. (1998) J. Biol. Chem. 273, 29794-29800). To clarify the molecular mechanisms of MM-1 toward c-Myc, cDNAs encoding MM-l-binding proteins were screened by the two-hybrid method with MM-1 as a bait using a human HeLa cDNA library, and a cDNA encoding TIF1 beta /KAP1, a transcriptional corepressor, was obtained. MM-1 was found to bind to the central portion of TIF1 beta in vitro and in vivo, and these proteins were found to be colocalized in the nucleus. MM-1 and TIF1 beta complex in human HeLa cells was found to also contain c-Myc, mSin3, and HDAC1. Introduction of the C-terminal half of TIF1 beta as a dominant negative form abrogated the inhibitory activity of MM-1 toward c-Myc and greatly stimulated the transcription activity of c-Myc. Moreover, the inhibitory activity of MM-1 toward c-Myc was canceled by trichostatin A, an inhibitor of HDAC1. These results indicate that MM-1 is a connecting factor that forms a novel transcription repression pathway of c-Myc.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 060, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Sanae/H-9647-2013; Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guo QM, 2000, CANCER RES, V60, P5922; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; NEGISHI Y, 1994, ONCOGENE, V9, P1133; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Prendergast GC, 1999, ONCOGENE, V18, P2914, DOI 10.1038/sj.onc.1202784; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SINGH PB, 1994, J CELL SCI, V107, P2653; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Takayama M, 2000, GENES CELLS, V5, P481, DOI 10.1046/j.1365-2443.2000.00338.x; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X	38	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46562	46567		10.1074/jbc.M104937200	http://dx.doi.org/10.1074/jbc.M104937200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585818	hybrid			2022-12-27	WOS:000172573100142
J	Rani, MRS; Asthagiri, AR; Singh, A; Sizemore, N; Sathe, SS; Li, XX; DiDonato, JD; Stark, GR; Ransohoff, RM				Rani, MRS; Asthagiri, AR; Singh, A; Sizemore, N; Sathe, SS; Li, XX; DiDonato, JD; Stark, GR; Ransohoff, RM			A role for NF-kappa B in the induction of beta-R1 by interferon-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; DNA-BINDING; MEDIATED PHOSPHORYLATION; DEPENDENT TRANSCRIPTION; P65 SUBUNIT; IFN-GAMMA; ACTIVATION; GENE; PROTEIN; INTERLEUKIN-1	Previous experiments have suggested that induction of the beta3-R1 gene by interferon (IFN)-beta required transcription factor ISGF-3 (IFN-stimulated gene factor-3) and an additional component. We now provide evidence that nuclear factor-kappaB (NF-kappaB) can serve as this component. Site-directed mutagenesis of an NF-kappaB binding site in the beta -R1 promoter or over-expression of an I kappaB alpha super-repressor abrogated IFN-beta -mediated induction of a beta -R1 promoter-reporter. IFN-beta treatment did not augment abundance of NF-kappaB but did lead to phosphorylation of the p65 NF-kappaB subunit. It is proposed that IFN-beta -mediated enhancement of the transactivation competence of NF-kappaB components is required for inducible transcription of the beta -R1 promoter. These results provide a novel insight into the role of NF-kappaB in the transcriptional response to IFN-beta.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, NC30, Cleveland, OH 44195 USA.	ransohr@ccf.org			NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [2PO1 CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GRESSER I, 1990, J INVEST DERMATOL, V95, pS66, DOI 10.1111/1523-1747.ep12874776; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Li XX, 1999, MOL CELL BIOL, V19, P4643; Majumder S, 1998, J IMMUNOL, V161, P4736; Moitreyee CK, 1998, MOL CELL BIOCHEM, V178, P103, DOI 10.1023/A:1006816806138; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; Rani MRS, 1999, J BIOL CHEM, V274, P1891, DOI 10.1074/jbc.274.4.1891; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WIEST JS, 1994, ONCOGENE, V9, P2449; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	27	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44365	44368		10.1074/jbc.C100417200	http://dx.doi.org/10.1074/jbc.C100417200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11591697	hybrid			2022-12-27	WOS:000172406700002
J	Siman, R; Flood, DG; Thinakaran, G; Neumar, RW				Siman, R; Flood, DG; Thinakaran, G; Neumar, RW			Endoplasmic reticulum stress-induced cysteine protease activation in cortical neurons - Effect of an Alzheimer's disease-linked presenilin-1 knock-in mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CELL-DEATH; HIPPOCAMPAL-NEURONS; TRANSLATIONAL CONTROL; AMYLOID-BETA; CALPAIN-I; LAMIN-A; APOPTOSIS; EXPRESSION; BRAIN	Endoplasmic reticulum (ER) stress elicits protective responses of chaperone induction and translational suppression and, when unimpeded, leads to caspase-mediated apoptosis. Alzheimer's disease-linked mutations in presenilin-1 (PS-1) reportedly impair ER stress-mediated protective responses and enhance vulnerability to degeneration. We used cleavage site-specific antibodies to characterize the cysteine protease activation responses of primary mouse cortical neurons to ER stress and evaluate the influence of a PS-1 knock-in mutation on these and other stress responses. Two different ER stressors lead to processing of the ER-resident protease procaspase-12, activation of calpain, caspase-3, and caspase-6, and degradation of ER and non-ER protein substrates. Immunocytochemical localization of activated caspase-3 and a cleaved substrate of caspase-6 confirms that caspase activation extends into the cytosol and nucleus. ER stress-induced proteolysis is unchanged in cortical neurons derived from the PS-1 P264L knock-in mouse. Furthermore, the PS-1 genotype does not influence stress-induced increases in chaperones Grp78/BiP and Grp94 or apoptotic neurodegeneration. A similar lack of effect of the PS-1 P264L mutation on the activation of caspases and induction of chaperones is observed in fibroblasts. Finally, the PS-1 knock-in mutation does not alter activation of the protein kinase PKR-like ER kinase (PERK), a trigger for stress-induced translational suppression. These data demonstrate that ER stress in cortical neurons leads to activation of several cysteine proteases within diverse neuronal compartments and indicate that Alzheimer's disease-linked PS-1 mutations do not invariably alter the proteolytic, chaperone induction, translational suppression, and apoptotic responses to ER stress.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Cephalon Inc, W Chester, PA 19380 USA; Univ Chicago, Sch Med, Chicago, IL 60637 USA	University of Pennsylvania; Teva Pharmaceutical Industries; Cephalon Inc.; University of Chicago	Siman, R (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	siman@pharm.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017138] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG17138] Funding Source: Medline; NINDS NIH HHS [R01-NS29481] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chang JY, 1996, EXP NEUROL, V137, P201, DOI 10.1006/exnr.1996.0019; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Fraser PE, 2000, BBA-MOL BASIS DIS, V1502, P1, DOI 10.1016/S0925-4439(00)00028-4; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Lord JM, 2000, SEMIN CELL DEV BIOL, V11, P159; Masters CL, 1998, BRIT MED J, V316, P446, DOI 10.1136/bmj.316.7129.446; Mattson MP, 1998, J NEUROCHEM, V70, P1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Siman R, 1999, NEUROSCIENCE, V92, P1425, DOI 10.1016/S0306-4522(99)00034-2; SIMAN R, 1983, J NEUROCHEM, V41, P950, DOI 10.1111/j.1471-4159.1983.tb09039.x; Siman R, 2000, J NEUROSCI, V20, P8717; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	60	85	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44736	44743		10.1074/jbc.M104092200	http://dx.doi.org/10.1074/jbc.M104092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574534	hybrid			2022-12-27	WOS:000172406700054
J	Empadinhas, N; Marugg, JD; Borges, N; Santos, H; da Costa, MS				Empadinhas, N; Marugg, JD; Borges, N; Santos, H; da Costa, MS			Pathway for the synthesis of mannosylglycerate in the hyperthermophilic archaeon Pyrococcus horikoshii - Biochemical and genetic characterization of key enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL-PHOSPHATE; COMPATIBLE SOLUTES; RHODOTHERMUS-MARINUS; ACCUMULATION; SALINITY; ACID; GLYCOSYLTRANSFERASES; CLASSIFICATION; BIOSYNTHESIS; TEMPERATURE	The biosynthetic pathway for the synthesis of the compatible solute alpha -mannosylglycerate in the hyperthermophilic archaeon Pyrococcus horikoshii is proposed based on the activities of purified recombinant mannosyl-3-phosphoglycerate (MPG) synthase and mannosyl-3-phosphoglycerate phosphatase. The former activity was purified from cell extracts, and the N-terminal sequence was used to identify the encoding gene in the completely sequenced P. horikoshii genome. This gene, designated PH0927, and a gene immediately downstream (PH0926) were cloned and overexpressed in Escherichia coli. The recombinant product of gene PH0927 catalyzed the synthesis of alpha -mannosyl-beta -phosphoglycerate (MPG) from GDP-mannose and D-3-phosphoglycerate retaining the configuration about the anomeric carbon, whereas the recombinant gene product of PH0926 catalyzed the dephosphorylation of mannosyl-3-phosphoglycerate to yield the compatible solute a-mannosylglycerate. The MPG synthase and the MPG phosphatase were specific for these substrates. Two genes immediately downstream from mpgs and mpgp were identified as a putative bifunctional phosphomannose isomeraselmannose-1-phosphateguanylyltransferase (PH0925) and as a putative phosphomannose mutase (PH0923). Genes PH0927, PH0926, PH0925, and PH0923 were contained in an operon-like structure, leading to the hypothesis that these genes were under the control of an unknown osmosensing mechanism that would lead to a-mannosylglycerate synthesis. Recombinant MPG synthase had a molecular mass of 45,208 Da, a temperature for optimal activity between 90 and 100 degreesC, and a pH optimum between 6.4 and 7.4; the recombinant MPG phosphatase had a molecular mass of 27,958 Da and optimum activity between 95 and 100 degreesC and between pH 5.2 and 6.4. This is the first report of the characterization of MPG synthase and MPG phosphatase and the elucidation of a pathway for the synthesis of mannosylglycerate in an archaeon.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland; Univ Coimbra, Dept Bioquim, P-3000 Coimbra, Portugal	Universidade Nova de Lisboa; Nestle SA; Universidade de Coimbra	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apartado 127, P-2780156 Oeiras, Portugal.	santos@itqb.unl.pt	Santos, Helena/B-9141-2011; Borges, Nuno/Q-3515-2019; Empadinhas, Nuno/G-3118-2011; Borges, Nuno/A-1427-2011	Santos, Helena/0000-0002-8050-9485; Borges, Nuno/0000-0002-3277-8517; Empadinhas, Nuno/0000-0001-8938-7560; Borges, Nuno/0000-0002-3277-8517; da Costa, Milton/0000-0003-4027-4412; Marugg, John/0000-0003-2657-6692				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Bauer MW, 1998, CURR OPIN BIOTECH, V9, P141, DOI 10.1016/S0958-1669(98)80106-7; BORGES N, 2001, IN PRESS EXTREMOPHIL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; da Costa M. S., 1998, V61, P117; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Galinski E A, 1995, Adv Microb Physiol, V37, P272, DOI 10.1016/S0065-2911(08)60148-4; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; Gonzalez JM, 1998, EXTREMOPHILES, V2, P123, DOI 10.1007/s007920050051; Hagemann M, 1997, J BACTERIOL, V179, P1727, DOI 10.1128/jb.179.5.1727-1733.1997; HAGEMANN M, 1994, MICROBIOL-SGM, V140, P1427, DOI 10.1099/00221287-140-6-1427; Hansen T, 2001, J BACTERIOL, V183, P3428, DOI 10.1128/JB.183.11.3428-3435.2001; Henrissat B, 2001, METHOD ENZYMOL, V330, P183; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; JACIN H, 1965, J CHROMATOGR, V18, P170, DOI 10.1016/S0021-9673(01)80341-1; Jensen SO, 1998, BBA-PROTEIN STRUCT M, V1382, P5, DOI 10.1016/S0167-4838(97)00122-2; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; KOPLIN R, 1992, J BACTERIOL, V174, P191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamosa P, 1998, APPL ENVIRON MICROB, V64, P3591; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Martin D D, 2001, Biochim Biophys Acta, V1524, P1; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; Martins LO, 1996, J BACTERIOL, V178, P5644, DOI 10.1128/jb.178.19.5644-5651.1996; Martins LO, 1997, APPL ENVIRON MICROB, V63, P896, DOI 10.1128/AEM.63.3.896-902.1997; Martins LO, 1999, J BIOL CHEM, V274, P35407, DOI 10.1074/jbc.274.50.35407; NUNES OC, 1995, APPL ENVIRON MICROB, V61, P2351, DOI 10.1128/AEM.61.6.2351-2357.1995; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Ramos A, 1997, APPL ENVIRON MICROB, V63, P4020, DOI 10.1128/AEM.63.10.4020-4025.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santos H, 2001, METHOD ENZYMOL, V334, P302; Scandurra R, 1998, BIOCHIMIE, V80, P933, DOI 10.1016/S0300-9084(00)88890-2; Silva Z, 1999, EXTREMOPHILES, V3, P163, DOI 10.1007/s007920050112; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YOKOYAMA K, 1987, EUR J BIOCHEM, V165, P47, DOI 10.1111/j.1432-1033.1987.tb11192.x	45	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43580	43588		10.1074/jbc.M108054200	http://dx.doi.org/10.1074/jbc.M108054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562374	hybrid			2022-12-27	WOS:000172297700015
J	Mansell, A; Khelef, N; Cossart, P; O'Neill, LAJ				Mansell, A; Khelef, N; Cossart, P; O'Neill, LAJ			Internalin B activates nuclear factor-kappa B via Ras, phosphoinositide 3-kinase, and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOVEMENT; LISTERIA-MONOCYTOGENES; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN-CELLS; GROWTH-FACTOR; TYROSINE KINASE; INVASION PROTEIN; T-LYMPHOCYTES; INIB PROTEIN; RECEPTOR	Internalin B (InIB), a 630-amino acid protein loosely attached to the surface of Listeria monocytogenes, participates in the entry of the bacterium into mammalian cells. This process requires the activation of phosphoinositide (Pl) 3-kinase by InIB. Previously, we demonstrated that InIB activates the transcription factor Nuclear Factor-kappaB in murine J774 macrophage-like cells, an event that also requires PI 3-kinase. Here we have further investigated this phenomenon. InIB activated the small G-protein Ras in J774 cells. Inhibition of Ras with the farnesyltransferase inhibitor manumycin A inhibited NF-kappaB activation and the recruitment of the p85 subunit of PI 3-kinase, implying that Ras is required for PI 3-kinase activation. InIB also activated the PI 3-kinase downstream effector, Akt, as assessed by increased phosphorylation of Akt on serine 473. Transfection of Hep2 cells with dominant negative Ras N17 or dominant negative Akt inhibited the induction of a reporter gene linked to the interleukin-8 promoter by InIB. Furthermore, the Ras inhibitor manumycin A, the PI 3-kinase inhibitor LY294002, and an Akt inhibitor all blocked the induction of interleukin-8 by InIB. Our study is the first report of a bacterial product activating a pathway involving Ras, PI 3-kinase, and Akt, which leads to NF-kappaB activation. This process could be involved in host defense or the inhibition of apoptosis during infection.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Biotechnol, Dublin 2, Ireland; Inst Pasteur, Unite Interact Bacteries Cellules, Paris 15, France	Trinity College Dublin; Trinity College Dublin; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.		Mansell, Ashley/B-9553-2008	Mansell, Ashley/0000-0002-6540-1281; KHELEF, Nadia/0000-0003-0391-2403; O'Neill, Luke/0000-0002-4333-2748				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Braun L, 1999, MOL MICROBIOL, V34, P10, DOI 10.1046/j.1365-2958.1999.01560.x; Braun L, 1998, MOL MICROBIOL, V27, P1077, DOI 10.1046/j.1365-2958.1998.00750.x; Braun L, 1997, MOL MICROBIOL, V25, P285, DOI 10.1046/j.1365-2958.1997.4621825.x; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chakraborty T, 1999, IMMUNOBIOLOGY, V201, P155, DOI 10.1016/S0171-2985(99)80055-2; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Cossart P, 2001, TRENDS MICROBIOL, V9, P105, DOI 10.1016/S0966-842X(00)01943-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Dramsi S, 1996, CURR TOP MICROBIOL, V209, P61; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Hu YH, 2001, BIOORG MED CHEM LETT, V11, P173, DOI 10.1016/S0960-894X(00)00640-5; Ireton K, 1997, ANNU REV GENET, V31, P113, DOI 10.1146/annurev.genet.31.1.113; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; LACASSE EC, 1998, MOL CELL BIOL, V19, P3247; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mansell A, 2000, CELL MICROBIOL, V2, P127, DOI 10.1046/j.1462-5822.2000.00038.x; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125	44	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43597	43603		10.1074/jbc.M105202200	http://dx.doi.org/10.1074/jbc.M105202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571285	hybrid, Green Published			2022-12-27	WOS:000172297700017
J	Park, SH; Waxman, DJ				Park, SH; Waxman, DJ			Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3 beta - Impact on the regulation of growth hormone pulse-stimulated, male-specific liver cytochrome P-450 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SIGNAL TRANSDUCER; SEXUAL DIMORPHISM; TYROSINE PHOSPHORYLATION; ACID 6-BETA-HYDROXYLASE; GENDER DIFFERENCES; BINDING-PROTEIN; TRANSCRIPTION; ACTIVATION; RECEPTOR	STAT5b is repeatedly activated in rodent liver by the male pattern of intermittent plasma growth hormone (GH) stimulation and is required to maintain the GH pulse-regulated, male-specific pattern of liver gene expression. We presently investigate the interactions between STAT5b and hepatocyte-enriched nuclear factors (HNFs) that contribute to regulation of GH pulse-inducible, male-specific liver cytochrome P-450 (CYP) genes. STAT5 binding sites were identified in the 5'-flank of the adult male-expressed genes CYP2A2 (nucleotides -2255 to -2247), CYP4A2 (nucleotides -1872 to -1864), and CYP2C11 (nucleotides -1150 to -1142). STAT5-DNA complexes were formed by each CYP sequence with nuclear extract from GH pulse-activated male, but not female, rat liver. The CYP2C11 STAT5 site, which is flanked by HNF3 consensus sequences, conferred STAT5b-inducible reporter gene activity in GH-treated HepG2 cells. trans-Activation of the intact CYP2C11 promoter (1.8-kilobase 5'-flank) was strongly induced by the liver nuclear factors HNF1 alpha and HNF3 beta but, unexpectedly, was inhibited by GH-activated STAT5b. This STAT5b inhibitory effect could be reversed by HNF1 alpha and reflects a functional antagonism between STAT5b and HNF3 beta, as evidenced by the inhibition of HNF3 beta DNA binding and transcriptional activity by STAT5b. HNF3 beta, in turn, inhibited STAT5b by a novel mechanism that leads to suppression of GH-inducible STAT5b tyrosine phosphorylation, DNA binding activity, and transcriptional activity. The potential for GH-activated STAT5b to stimulate male-specific liver CYP expression can thus be modulated by HNF3 beta, highlighting the complex interrelationship between STAT5b and liver transcription factors controlling expression of GH-regulated CYP genes.	Boston Univ, Dept Biol, Div Cell & Mol Biol, Boston, MA 02215 USA	Boston University	Waxman, DJ (corresponding author), Boston Univ, Dept Biol, Div Cell & Mol Biol, 5 Cummington St, Boston, MA 02215 USA.	djw@bu.edu		Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK033765, DK33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Buggs C, 1998, MOL ENDOCRINOL, V12, P1294, DOI 10.1210/me.12.9.1294; Choi HK, 1999, ENDOCRINOLOGY, V140, P5126, DOI 10.1210/en.140.11.5126; Choi HK, 2000, ENDOCRINOLOGY, V141, P3245, DOI 10.1210/en.141.9.3245; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; Delesque-Touchard N, 2000, J BIOL CHEM, V275, P34173, DOI 10.1074/jbc.M004027200; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Ganguly TC, 1997, J CLIN INVEST, V99, P2906, DOI 10.1172/JCI119485; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Gonzalez FJ, 1996, FASEB J, V10, P1112, DOI 10.1096/fasebj.10.10.8751713; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Iber H, 2000, ARCH BIOCHEM BIOPHYS, V377, P187, DOI 10.1006/abbi.2000.1772; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; John S, 1999, MOL CELL BIOL, V19, P1910; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; MODE A, 1993, J REPROD FERTIL, P77; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Rastegar M, 2000, MOL CELL ENDOCRINOL, V164, P1, DOI 10.1016/S0303-7207(00)00263-X; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sasaki Y, 1999, J BIOL CHEM, V274, P37117, DOI 10.1074/jbc.274.52.37117; SHAPIRO BH, 1995, INT J BIOCHEM CELL B, V27, P9, DOI 10.1016/1357-2725(94)00056-5; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; Sueyoshi T, 1999, MOL PHARMACOL, V56, P473, DOI 10.1124/mol.56.3.473; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; Tannenbaum GS, 2001, ENDOCRINOLOGY, V142, P4599, DOI 10.1210/en.142.11.4599; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Veldhuis JD, 1996, EUR J ENDOCRINOL, V134, P287, DOI 10.1530/eje.0.1340287; Waxman David J., 1995, P391; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Waxman DJ, 2000, PRINCIPLES OF MOLECULAR REGULATION, P55; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zaphiropoulos P G, 1988, Acta Med Scand Suppl, V723, P161; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672	49	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43031	43039		10.1074/jbc.M107597200	http://dx.doi.org/10.1074/jbc.M107597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562369	hybrid			2022-12-27	WOS:000172169300054
J	Shigaki, T; Cheng, NH; Pittman, JK; Hirschi, K				Shigaki, T; Cheng, NH; Pittman, JK; Hirschi, K			Structural determinants of Ca2+ transport in the Arabidopsis H+/Ca2+ antiporter CAX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; NA+/H+ ANTIPORTER; NHAA; YEAST; SENSITIVITY; SELECTIVITY; EXPRESSION; MANGANESE; RETICULUM	Ca2+ levels in plants, fungi, and bacteria are controlled in part by H+/Ca2+ exchangers; however, the relationship between primary sequence and biological activity of these transporters has not been reported. The Arabidopsis H+/cation exchangers, CAX1 and CAX2, were identified by their ability to suppress yeast mutants defective in vacuolar Ca2+ transport. CAX1 has a much higher capacity for Ca2+ transport than CAX2. An Arabidopsis thaliana homolog of CAX1, CAX3, is 77% identical (93% similar) and, when expressed in yeast, localized to the vacuole but did not suppress yeast mutants defective in vacuolar Ca2+ transport. Chimeric constructs and site-directed mutagenesis showed that CAX3 could suppress yeast vacuolar Ca2+ transport mutants if a nine-amino acid region of CAX1 was inserted into CAX3 (CAX3-9). Biochemical analysis in yeast showed CAX3-9 had 36% of the H+/Ca2+ exchange activity as compared with CAX1; however, CAX3-9 and CAX1 appear to differ in their transport of other ions. Exchanging the nine-amino acid region of CAX1 into CAX2 doubled yeast vacuolar Ca2+ transport but did not appear to alter the transport of other ions. This nine-amino acid region is highly variable among the plant CAX-like transporters. These findings suggest that this region is involved in CAX-mediated Ca2+ specificity.	Baylor Coll Med, Plant Physiol Grp, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Texas A&M University System; Texas A&M University College Station	Hirschi, K (corresponding author), Baylor Coll Med, Plant Physiol Grp, USDA ARS, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.		hirschi, kendal/GNP-0351-2022	Pittman, Jon/0000-0001-7197-1494	NIGMS NIH HHS [1R01 GM57427] Funding Source: Medline; PHS HHS [5 P30] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057427] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE S, 1986, Memoirs of the College of Agriculture Ehime University, V31, P187; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Del Pozo L, 1999, YEAST, V15, P371, DOI 10.1002/(SICI)1097-0061(19990330)15:5<371::AID-YEA380>3.3.CO;2-G; DIBROV PA, 1993, FEBS LETT, V336, P530, DOI 10.1016/0014-5793(93)80870-Z; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hirschi K, 2001, TRENDS PLANT SCI, V6, P100, DOI 10.1016/S1360-1385(00)01863-X; Hirschi KD, 2000, PLANT PHYSIOL, V124, P125, DOI 10.1104/pp.124.1.125; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; IVEY DM, 1993, J BIOL CHEM, V268, P11296; Liang F, 1998, PLANT PHYSIOL, V118, P817, DOI 10.1104/pp.118.3.817; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; PITTMAN JK, 2001, IN PRESS PLANT PHYSL; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Shigaki T, 2000, GENE, V257, P291, DOI 10.1016/S0378-1119(00)00390-5; SHIGAKI T, 2001, ANAL BIOCH; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueoka-Nakanishi H, 1999, EUR J BIOCHEM, V262, P417, DOI 10.1046/j.1432-1327.1999.00377.x; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; Wiebe CA, 2001, BIOCHEM J, V357, P1, DOI 10.1042/0264-6021:3570001; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534	30	58	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43152	43159		10.1074/jbc.M106637200	http://dx.doi.org/10.1074/jbc.M106637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562366	hybrid			2022-12-27	WOS:000172169300068
J	Hicke, BJ; Marion, C; Chang, YF; Gould, T; Lynott, CK; Parma, D; Schmidt, PG; Warren, S				Hicke, BJ; Marion, C; Chang, YF; Gould, T; Lynott, CK; Parma, D; Schmidt, PG; Warren, S			Tenascin-C aptamers are generated using tumor cells and purified protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMON RESONANCE BIOSENSORS; ENDOTHELIAL GROWTH-FACTOR; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; HUMAN BREAST; PHASE-I; OLIGONUCLEOTIDE INHIBITORS; VASCULAR-PERMEABILITY; PROSTATIC HYPERPLASIA; MONOCLONAL-ANTIBODIES	Tenascin-C (TN-C) is an extracellular matrix protein that is overexpressed during tissue remodeling processes, including tumor growth. To identify an aptamer for testing as a tumor-selective ligand, SELEX (systematic evolution of ligands by exponential enrichment) procedures were performed using both TN-C and TN-C-expressing U251 glioblastoma cells. The different selection techniques yielded TN-C aptamers that are related in sequence. In addition, a crossover procedure that switched from tumor cell to purified protein selections was effective in isolating two high-affinity TN-C aptamers. When targeting tumor cells in vitro, the observed propensity of naive oligonucleotide pools to evolve TN-C aptamers may be due to the abundance of this protein. In vivo, TN-C abundance may also be well suited for aptamer accumulation in the tumor milieu. A size-minimized and nuclease-stabilized aptamer, TTA1, binds to the fibrinogen-like domain of TN-C with an equilibrium dissociation constant (K-d) of 5 x 10(-9) M. At 13 kDa, this aptamer is intermediate in size between peptides and single chain antibody fragments, both of which are superior to antibodies for tumor targeting because of their smaller size. TTA1 defines a new class of ligands that are intended for targeted delivery of radioisotopes or chemical agents to diseased tissues.	SomaLog, Boulder, CO 80301 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Novus Biol, Littleton, CO 80160 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; PR Pharmaceut Inc, Ft Collins, CO 80524 USA; IOMED Inc, Salt Lake City, UT 84120 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder	Hicke, BJ (corresponding author), SomaLog, Boulder, CO 80301 USA.							AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Bigner DD, 1998, J CLIN ONCOL, V16, P2202, DOI 10.1200/JCO.1998.16.6.2202; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; Charlton J, 1999, RNA, V5, P1326, DOI 10.1017/S1355838299991021; Drolet DW, 1999, COMB CHEM HIGH T SCR, V2, P271; Dueck M, 1999, INT J CANCER, V82, P477, DOI 10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; Famulok M, 1999, CURR TOP MICROBIOL, V243, P123; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; HAUPTMANN S, 1995, LAB INVEST, V73, P172; Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324; Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006; HOWEEDY AA, 1990, LAB INVEST, V63, P798; IBRAHIM SN, 1993, HUM PATHOL, V24, P982, DOI 10.1016/0046-8177(93)90112-T; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; Ishihara A, 1995, CLIN CANCER RES, V1, P1035; Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714; Jahkola T, 1998, EUR J CANCER, V34, P1687, DOI 10.1016/S0959-8049(98)00215-9; Jenison RD, 1998, ANTISENSE NUCLEIC A, V8, P265, DOI 10.1089/oli.1.1998.8.265; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kostianovsky M, 1997, ULTRASTRUCT PATHOL, V21, P537, DOI 10.3109/01913129709016370; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LIGHTNER VA, 1990, ANN NY ACAD SCI, V580, P260, DOI 10.1111/j.1749-6632.1990.tb17935.x; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0; Riedl S, 1998, DIS COLON RECTUM, V41, P86, DOI 10.1007/BF02236901; Ringquist S, 1998, CYTOMETRY, V33, P394, DOI 10.1002/(SICI)1097-0320(19981201)33:4<394::AID-CYTO2>3.0.CO;2-0; Riva P, 1999, CLIN CANCER RES, V5, p3275S; Riva P, 1999, ACTA ONCOL, V38, P351; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; SAKAI T, 1993, BRIT J CANCER, V67, P1058, DOI 10.1038/bjc.1993.194; SCHALKWIJK J, 1991, AM J PATHOL, V139, P1143; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SOINI Y, 1993, AM J CLIN PATHOL, V100, P145, DOI 10.1093/ajcp/100.2.145; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; Tokes AM, 1999, PATHOL RES PRACT, V195, P821; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Vacca A, 1996, LEUKEMIA LYMPHOMA, V22, P473, DOI 10.3109/10428199609054786; Vant-Hull B, 1998, J MOL BIOL, V278, P579, DOI 10.1006/jmbi.1998.1727; VENTIMIGLIA JB, 1992, J NEUROIMMUNOL, V36, P41, DOI 10.1016/0165-5728(92)90029-K; Wallner K, 1999, CIRCULATION, V99, P1284, DOI 10.1161/01.CIR.99.10.1284; Watson SR, 2000, ANTISENSE NUCLEIC A, V10, P63, DOI 10.1089/oli.1.2000.10.63; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Xue Y, 1998, BRIT J UROL, V81, P844; YARUS M, 1970, ANAL BIOCHEM, V35, P450, DOI 10.1016/0003-2697(70)90207-1; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; Zagzag D, 1996, CANCER RES, V56, P182; ZAGZAG D, 1995, CANCER RES, V55, P907; Zuker M., 1999, V70, P11	56	255	296	5	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48644	48654		10.1074/jbc.M104651200	http://dx.doi.org/10.1074/jbc.M104651200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11590140	hybrid			2022-12-27	WOS:000173922100007
J	Takahashi, Y; Kahyo, T; Toh-e, A; Yasuda, H; Kikuchi, Y				Takahashi, Y; Kahyo, T; Toh-e, A; Yasuda, H; Kikuchi, Y			Yeast Ull1/Siz1 is a novel SUM01/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SMT3P; UBIQUITIN; SUMO-1; NUCLEOLUS; HOMOLOG; RINGS; GENE; E2	SUMO1/Smt3, a ubiquitin-like protein modifier, is known to conjugate to other proteins and modulate their functions in various important processes. Similar to the ubiquitin conjugation system, SUMO/Smt3 is transferred to substrate lysine residues through the thioester cascade of El (activating enzyme) and E2 (conjugating enzyme). In our previous report (Takahashi, Y., Toh-e, A., and Kikuchi, Y. (2001) Gene 275, 223-231), we showed that Siz1/Ull1 (YDR409w) of budding yeast, a member of the human PLAS family containing a RING-like domain, is a strong candidate for SUMO1/Smt3 ligase because the SUMO1/Smt3 modification of septin components was abolished in the ull1 mutant and Ull1 associated with E2 (Ubc9) and the substrates (septin components) in immunoprecipitation experiments. Here we have developed an in vitro Smt3 conjugation system for a septin component (Cdc3) using purified recombinant proteins. In this system, Ull1 is additionally required as well as El (Sua1(.)Uba2 complex), E2 (Ubc9), and ATP. A cysteine residue of the RING-like domain was essential for the conjugation both in vivo and in vitro. Furthermore, a region containing the RING-like domain directly interacted with Ubc9 and Cdc3. Thus, this SUMO/Smt3 ligase functions as an adaptor between E2 and the target proteins.	Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Kikuchi, Y (corresponding author), Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James P, 1996, GENETICS, V144, P1425; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kaiser C., 1994, METHODS YEAST GENETI; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	24	156	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48973	48977		10.1074/jbc.M109295200	http://dx.doi.org/10.1074/jbc.M109295200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11577116	hybrid			2022-12-27	WOS:000173922100048
J	Ermilov, AN; Olshevskaya, EV; Dizhoor, AM				Ermilov, AN; Olshevskaya, EV; Dizhoor, AM			Instead of binding calcium, one of the EF-hand structures in guanylyl cyclase activating protein-2 is required for targeting photoreceptor guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEINS; MAMMALIAN RETINAS; EXPRESSION; GCAP-2; LIGHT; RODS; PHOTOTRANSDUCTION; LOCALIZATION; DIMERIZATION; NEUROCALCIN	Guanylyl cyclase activator proteins (GCAPs) are calcium-binding proteins closely related to recoverin, neurocalcin, and many other neuronal Ca2+-sensor proteins of the EF-hand superfamily. GCAP-1 and GCAP-2 interact with the intracellular portion of photoreceptor membrane guanylyl cyclase and stimulate its activity by promoting tight dimerization of the cyclase subunits. At low free Ca2+ concentrations, the activator form of GCAP-2 associates into a dimer, which dissociates when GCAP-2 binds Ca2+ and becomes inhibitor of the cyclase. GCAP-2 is known to have three active EF-hands and one additional EF-hand-like structure, EF-1, that deviates form the EF-hand consensus sequence. We have found that various point mutations within the EF-1 domain can specifically affect the ability of GCAP-2 to interact with the target cyclase but do not hamper the ability of GCAP-2 to undergo reversible Ca2+-sensitive dimerization. Point mutations within the EF-1 region can interfere with both the activation of the cyclase by the Ca2+. free form of GCAP-2 and the inhibition of retGC basal activity by the Ca2+-loaded GCAP-2. Our results strongly indicate that evolutionary conserved and GCAP-specific amino acid residues within the EF-1 can create a contact surface for binding GCAP-2 to the cyclase. Apparently, in the course of evolution GCAP-2 exchanged the ability of its first EF-hand motif to bind Ca2+ for the ability to interact with the target enzyme.	Wayne State Univ, Sch Med, Dept Ophthalmol, Kresge Eye Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol Anat & Cell Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Dizhoor, AM (corresponding author), Wayne State Univ, Ophthalmol Kresge Eye Inst, K-456,4717 St Antoine Blvd, Detroit, MI 48201 USA.			Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY11522] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Celio MR, 1996, GUIDEBOOK CALCIUM BI, P15; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Hurley JB, 2000, METHOD ENZYMOL, V315, P708; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; Krylov DM, 2001, J BIOL CHEM, V276, P30648, DOI 10.1074/jbc.M104121200; LADANT D, 1995, J BIOL CHEM, V270, P3179; Lange C, 1999, FEBS LETT, V460, P27, DOI 10.1016/S0014-5793(99)01312-5; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; NEF P, 1996, GUIDEBOOK CALCIUM BI, P15; Olshevskaya EV, 1999, J BIOL CHEM, V274, P25583, DOI 10.1074/jbc.274.36.25583; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sampath AP, 1999, J GEN PHYSIOL, V113, P267, DOI 10.1085/jgp.113.2.267; Sokal I, 1999, BIOCHEMISTRY-US, V38, P1387, DOI 10.1021/bi982512k; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; Yu H, 1999, J BIOL CHEM, V274, P15547, DOI 10.1074/jbc.274.22.15547	45	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48143	48148		10.1074/jbc.M107539200	http://dx.doi.org/10.1074/jbc.M107539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11584009	hybrid			2022-12-27	WOS:000172927000055
J	Buslepp, J; Zhao, R; Donnini, D; Loftus, D; Saad, M; Appella, E; Collins, EJ				Buslepp, J; Zhao, R; Donnini, D; Loftus, D; Saad, M; Appella, E; Collins, EJ			T cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MAXIMUM-LIKELIHOOD; ANTAGONIST LIGANDS; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; TCR; MOLECULES; REFINEMENT; ACTIVATION; ANTIGEN	Recognition of virally infected cells by CD8(+) T cells requires differentiation between self and nonself peptide-class I major histocompatibility complexes (pMHC). Recognition of foreign pMHC by host T cells is a major factor in the rejection of transplanted organs from the same species (allotransplant) or different species (xenotransplant). AHIII12.2 is a murine T cell clone that recognizes the xenogeneic (human) class I NMC HLA-A2.1 molecule (A2) and the syngeneic murine class I MHC H-2 D-b molecule (D-b). Recognition of both A2 and D-b are peptide-dependent, and the sequences of the peptides recognized have been determined. Alterations in the antigenic peptides bound to A2 cause large changes in AHIII12.2 T cell responsiveness. Crystal structures of three representative peptides (agonist, null, and antagonist) bound to A2 partially explain the changes in AHIII12.2 responsiveness. Using class I pMHC octamers, a strong correlation is seen between T cell activity and the affinity of pMHC complexes for the T cell receptor. However, contrary to previous studies, we see similar half-lives for the pMHC multimers bound to the AHIII12.2 cell surface.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Collins, EJ (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, CB 7290,804 ME Jones Bldg, Chapel Hill, NC 27599 USA.			SAAD, Mohamed/0000-0003-0458-5942				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; Batalia MA, 1997, BIOPOLYMERS, V43, P281, DOI 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R; Batalia MA, 2000, BIOCHEMISTRY-US, V39, P9030, DOI 10.1021/bi000442n; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1997, DOI 10.1002/eji.1830210905; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; Hennecke J, 2000, EMBO J, V19, P5611, DOI 10.1093/emboj/19.21.5611; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647; Loftus DJ, 1998, CANCER RES, V58, P2433; Loftus DJ, 1997, J IMMUNOL, V158, P3651; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Sharma AK, 2001, J BIOL CHEM, V276, P21443, DOI 10.1074/jbc.M010791200; SILVERMAN T, 1988, J IMMUNOL, V140, P4378; Sykulev Y, 1998, IMMUNITY, V9, P475, DOI 10.1016/S1074-7613(00)80631-7; Zhao R, 1999, J EXP MED, V189, P359, DOI 10.1084/jem.189.2.359	47	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47320	47328		10.1074/jbc.M109231200	http://dx.doi.org/10.1074/jbc.M109231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584024	hybrid			2022-12-27	WOS:000172768500087
J	Hernandez, H; Robinson, CV				Hernandez, H; Robinson, CV			Dynamic protein complexes: Insights from mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SOLVENT ACCESSIBILITY; HYDROGEN-EXCHANGE; CRYSTAL-STRUCTURE; FIBRIL FORMATION; CHAPERONIN; BINDING; OXIDATION; STATES; BETA-2-MICROGLOBULIN; INTERMEDIATE		Oxford Ctr Mol Sci, Oxford OX1 3QT, England	University of Oxford	Robinson, CV (corresponding author), Oxford Ctr Mol Sci, S Parks Rd, Oxford OX1 3QT, England.	carolr@bioch.ox.ac.uk		robinson, carol/0000-0001-7829-5505				Bellotti V, 1998, EUR J BIOCHEM, V258, P61, DOI 10.1046/j.1432-1327.1998.2580061.x; Benjamin DR, 1998, P NATL ACAD SCI USA, V95, P7391, DOI 10.1073/pnas.95.13.7391; Broo K, 2001, P NATL ACAD SCI USA, V98, P2274, DOI 10.1073/pnas.051598298; Chen JW, 2000, BIOCHEMISTRY-US, V39, P4250, DOI 10.1021/bi992619n; Coyle JE, 1999, NAT STRUCT BIOL, V6, P683; Craig TA, 1999, NAT BIOTECHNOL, V17, P1214, DOI 10.1038/70767; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Finke JM, 2000, BIOCHEMISTRY-US, V39, P15633, DOI 10.1021/bi001307d; Fuerstenau SD, 2001, ANGEW CHEM INT EDIT, V40, P542, DOI 10.1002/1521-3773(20010202)40:3<541::AID-ANIE541>3.0.CO;2-K; Gehrig PM, 2000, PROTEIN SCI, V9, P395; He F, 2000, J AM SOC MASS SPECTR, V11, P120, DOI 10.1016/S1044-0305(99)00132-4; Hoofnagle AN, 2001, P NATL ACAD SCI USA, V98, P956, DOI 10.1073/pnas.98.3.956; Hughes CA, 2001, J MOL BIOL, V307, P967, DOI 10.1006/jmbi.2001.4523; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Johnson KA, 2001, ANAL CHEM, V73, P803, DOI 10.1021/ac001004p; Johnson KA, 2000, ANAL CHEM, V72, P1410, DOI 10.1021/ac991183e; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Larson JL, 2000, PROTEIN SCI, V9, P427; Lei QP, 1998, ANAL CHEM, V70, P1838, DOI 10.1021/ac971181z; Leroux MR, 1999, EMBO J, V18, P6730, DOI 10.1093/emboj/18.23.6730; Loo JA, 2001, INT J MASS SPECTROM, V204, P113, DOI 10.1016/S1387-3806(00)00334-1; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Nettleton EJ, 2000, BIOPHYS J, V79, P1053, DOI 10.1016/S0006-3495(00)76359-4; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Rappsilber J, 2000, ANAL CHEM, V72, P267, DOI 10.1021/ac991081o; Robinson CV, 1996, J AM CHEM SOC, V118, P8646, DOI 10.1021/ja960211x; Rostom AA, 2000, P NATL ACAD SCI USA, V97, P5185, DOI 10.1073/pnas.97.10.5185; Rostom AA, 1998, PROTEINS, P3; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Siuzdak G, 1996, CHEM BIOL, V3, P45, DOI 10.1016/S1074-5521(96)90083-6; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Tito MA, 2000, J AM CHEM SOC, V122, P3550, DOI 10.1021/ja993740k; Tito P, 2000, J MOL BIOL, V303, P267, DOI 10.1006/jmbi.2000.4142; Van Berkel WJH, 2000, PROTEIN SCI, V9, P435; Veenstra TD, 1998, NAT BIOTECHNOL, V16, P262, DOI 10.1038/nbt0398-262; Vis H, 1998, J AM CHEM SOC, V120, P6427, DOI 10.1021/ja9811187; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WETZEL R, 1992, STABILITY PROTEIN B, V3, P43; Whittal RM, 2000, BIOCHEMISTRY-US, V39, P8406, DOI 10.1021/bi000282f; Whittal RM, 2000, PROTEIN SCI, V9, P332; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+	48	63	66	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46685	46688		10.1074/jbc.R100024200	http://dx.doi.org/10.1074/jbc.R100024200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585844	hybrid			2022-12-27	WOS:000172768500001
J	Jiang, JL; Zhou, Q; Yu, MK; Ho, LS; Chen, ZN; Chan, HC				Jiang, JL; Zhou, Q; Yu, MK; Ho, LS; Chen, ZN; Chan, HC			The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 MATRIX-METALLOPROTEINASE; INHIBITOR CARBOXYAMIDO-TRIAZOLE; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL-TRANSDUCTION; MEDIATED MOTILITY; MOUSE BASIGIN; GELATINASE-A; CA2+ ENTRY	The present study examined the effect of hepatoma. associated antigen HAb18G (homologous to CD147) expression on the NO/cGMP-regulated Ca2+ mobilization and metastatic process of human hepatoma cells. HAb18G/CD147 cDNA was transfected into human 7721 hepatoma cells to obtain a cell line stably expressing HAb18G/CD147, T7721, as demonstrated by Northern blot and immunocytochemical studies. 8-Bromo-cGMP (cGMP) inhibited the thapsigargin-induced Ca2+ entry in a concentration-dependent manner in 7721 cells. The cGMP-induced inhibition was abolished by an inhibitor of protein kinase G, KT5823 (1 mum). However, expression of HAb18G/CD147 in T7721 cells decreased the inhibitory response to cGMP. A similar concentration-dependent inhibitory effect on the Ca2+ entry was observed in 7721 cells in response to a NO donor, (+/-)-S-nitroso-N-acetylpenicillamine (SNAP). The inhibitory effect of SNAP on the thapsigargin-induced Ca2+ entry was significantly reduced in HAb18G/CD147-expressing T7721 cells, indicating a role for HAb18G/CD147 in NO/cGMP-regulated Ca2+ entry. Experiments investigating metastatic potentials demonstrated that HAb18G/CD147-expressing T7721 cells attached to the Matrigel-coated culture plates and invaded through Matrigel-coated permeable filters at the rate significantly greater than that observed in 7721 cells. Both the attachment and invasion rates could be suppressed by SNAP, and the inhibitory effect of SNA-P could be reversed by NO inhibitor, NI-nitro-L-arginine methyl ester. The sensitivity of the attachment and invasion rates to cGMP was significantly reduced in T7721 cells as compared with 7721 cells when cells were pretreated with thapsigargin. The difference in the sensitivity between the two cells could be abolished by a Ca2+ channel blocker, Ni2+ (3 mm). These results suggest that HAb18G/CD147 enhances metastatic potentials in human hepatoma cells by disrupting the regulation of store-operated Ca2+ entry by NO/cGMP.	Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; Fourth Mil Med Univ, Cell Engn Res Ctr, Xian 710032, Peoples R China	Chinese University of Hong Kong; Air Force Military Medical University	Chan, HC (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China.		Chan, Hsiao Chang/E-1507-2016					Alessandro R, 1996, IN VIVO, V10, P153; Arii S, 1996, HEPATOLOGY, V24, P316; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Bauer KS, 2000, J PHARMACOL EXP THER, V292, P31; BISCHOF G, 1995, CELL CALCIUM, V17, P250, DOI 10.1016/0143-4160(95)90071-3; BISWAS C, 1982, BIOCHEM BIOPH RES CO, V109, P1026, DOI 10.1016/0006-291X(82)92042-3; BISWAS C, 1995, CANCER RES, V55, P434; Chen ZN, 1999, J CELL MOL IMMUNOL, V15, P34; CHEN ZN, 1989, REPORTS MONOCLONAL A, V27, P33; CHEN ZN, 1992, CHINESE J ONCOL, V14, P9; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLE K, 1994, CANCER METAST REV, V13, P31, DOI 10.1007/BF00690417; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Farias EF, 1998, INT J CANCER, V78, P727, DOI 10.1002/(SICI)1097-0215(19981209)78:6<727::AID-IJC10>3.0.CO;2-A; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; George SJ, 1997, ARTERIOSCL THROM VAS, V17, P2500, DOI 10.1161/01.ATV.17.11.2500; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; HAUANG AJ, 1993, J CELL BIOL, V120, P1371; JI Y, 1991, CHIN MED J, V71, P369; Jiang JL, 2001, CELL BIOL INT, V25, P993, DOI 10.1006/cbir.2001.0751; Jurasz P, 2001, CANCER RES, V61, P376; KANEKURA T, 1991, CELL STRUCT FUNCT, V16, P23, DOI 10.1247/csf.16.23; KASINRERK W, 1992, J IMMUNOL, V149, P847; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOHN EC, 1994, CANCER RES, V54, P935; Kwan HY, 2000, J BIOL CHEM, V275, P6758, DOI 10.1074/jbc.275.10.6758; Lala PK, 1998, CANCER METAST REV, V17, P1, DOI 10.1023/A:1005963400984; LESTER BR, 1989, CANCER RES, V49, P5940; LESTER BR, 1991, INT J CANCER, V48, P113; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; LIU Y, 1991, CHIN MED J, V71, P362; Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x; MAMACHI T, 1986, BIOOCH BIOPHYS ACTA, V889, P136; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; MIYAUCHI T, 1991, J BIOCHEM-TOKYO, V110, P770, DOI 10.1093/oxfordjournals.jbchem.a123657; MONCADA S, 1991, PHARMACOL REV, V43, P109; Ogata R, 1999, HUM PATHOL, V30, P443, DOI 10.1016/S0046-8177(99)90121-1; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; Sameshima T, 2000, INT J CANCER, V88, P21, DOI 10.1002/1097-0215(20001001)88:1<21::AID-IJC4>3.0.CO;2-S; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; SEULBERGER H, 1992, NEUROSCI LETT, V140, P93, DOI 10.1016/0304-3940(92)90690-9; STOCKINGER H, 1997, LEUKOCYTE TYPING, V6, P760; Sun JJ, 2000, J CANCER RES CLIN, V126, P595, DOI 10.1007/PL00008470; Sun JX, 2001, CANCER RES, V61, P2276; Theret N, 2001, HEPATOLOGY, V34, P82, DOI 10.1053/jhep.2001.25758; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; WINEGAR BD, 1991, J GEN PHYSIOL, V97, P351, DOI 10.1085/jgp.97.2.351; Wu YG, 1997, CLIN CANCER RES, V3, P1915; XU X, 1994, J BIOL CHEM, V269, P12645; Yao X, 2000, FASEB J, V14, P932, DOI 10.1096/fasebj.14.7.932; Zabrenetzky V., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P33; Zeng L, 1996, J BIOL CHEM, V271, P27744, DOI 10.1074/jbc.271.44.27744; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	58	111	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46870	46877		10.1074/jbc.M108291200	http://dx.doi.org/10.1074/jbc.M108291200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591720	hybrid			2022-12-27	WOS:000172768500028
J	Ahuja, A; Purcarea, C; Guy, HI; Evans, DR				Ahuja, A; Purcarea, C; Guy, HI; Evans, DR			A novel carbamoyl-phosphate synthetase from Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; SITE-DIRECTED MUTAGENESIS; ARCHAEON PYROCOCCUS-FURIOSUS; COOH-TERMINAL DOMAIN; ATP-BINDING-SITES; ESCHERICHIA-COLI; AMIDOTRANSFERASE DOMAIN; LARGE SUBUNIT; ASPARTATE TRANSCARBAMOYLASE; REVERSIBLE DISSOCIATION	Aquifex aeolicus, an extreme hyperthermophile, has neither a full-length carbamoyl-phosphate synthetase (CPSase) resembling the enzyme found in all mesophilic organisms nor a carbamate kinase-like CPSase such as those present in several hyperthermophilic archaea. However, the genome has open reading frames encoding putative proteins that are homologous to the major CPSase domains. The glutaminase, CPS.A and CPS.B homologs from A. aeolicus were cloned, overexpressed in Escherichia coli, and purified to homogeneity. The isolated proteins could catalyze several partial reactions but not the overall synthesis of carbamoyl phosphate. However, a stable 124-kDa complex could be reconstituted from stoichiometric amounts of CPS.A and CPS.B proteins that synthesized carbamoyl phosphate from ATP, bicarbonate, and ammonia. The inclusion of the glutaminase subunit resulted in the formation of a 171-kDa complex that could utilize glutamine as the nitrogen-donating substrate, although the catalytic efficiency was significantly compromised. Molecular modeling, using E. coli CPSase as a template, showed that the enzyme has a similar structural organization and interdomain interfaces and that. all of the residues known to be essential for function are conserved and properly positioned. A steady state kinetic study at 78 degreesC indicated that although the substrate affinity was similar for bicarbonate, ammonia, and glutamine, the K-m for ATP was appreciably higher than that of any known CPSase. The A. aeolicus complex, with a split gene encoding the major synthetase domains and relatively inefficient coupling of amidotransferase and synthetase functions, may be more closely related to the ancestral precursor of contemporary mesophilic CPSases.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu		Purcarea, Cristina/0000-0001-5784-8545	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM/CA60371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; Bueso J, 1999, BIOCHEMISTRY-US, V38, P3910, DOI 10.1021/bi982871f; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cervera J, 1996, BIOCHEMISTRY-US, V35, P7247, DOI 10.1021/bi952549u; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Durbecq V, 1997, P NATL ACAD SCI USA, V94, P12803, DOI 10.1073/pnas.94.24.12803; GUY HI, 1995, J BIOL CHEM, V270, P2190, DOI 10.1074/jbc.270.5.2190; Guy HI, 1998, J BIOL CHEM, V273, P14172, DOI 10.1074/jbc.273.23.14172; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hewagama A, 1998, BBA-PROTEIN STRUCT M, V1388, P489, DOI 10.1016/S0167-4838(98)00212-X; HOOGENRAAD NJ, 1971, BIOCHEM BIOPH RES CO, V44, P981, DOI 10.1016/0006-291X(71)90808-4; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; Marina A, 1999, PROTEIN SCI, V8, P934; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; Mora P, 1999, FEBS LETT, V446, P133, DOI 10.1016/S0014-5793(99)00197-0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; Purcarea C, 1999, J BIOL CHEM, V274, P6122, DOI 10.1074/jbc.274.10.6122; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; Serre V, 1999, J BIOL CHEM, V274, P23794, DOI 10.1074/jbc.274.34.23794; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; Thoden JB, 1999, J BIOL CHEM, V274, P22502, DOI 10.1074/jbc.274.32.22502; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; ZALKIN H, 1985, METHOD ENZYMOL, V113, P263	52	14	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45694	45703		10.1074/jbc.M106382200	http://dx.doi.org/10.1074/jbc.M106382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574542	hybrid			2022-12-27	WOS:000172573100028
J	Guo, YL; Guettouche, T; Fenna, M; Boellmann, F; Pratt, WB; Toft, DO; Smith, DF; Voellmy, R				Guo, YL; Guettouche, T; Fenna, M; Boellmann, F; Pratt, WB; Toft, DO; Smith, DF; Voellmy, R			Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MOLECULAR CHAPERONES; FACTOR HSF1; FACTOR-I; PHOSPHORYLATION; HSP90; RECEPTOR; GELDANAMYCIN; SALICYLATE; OXIDATION	In the absence of stress, human heat shock factor I (hHSF1) is in its unactivated form. hHSF1 polypeptide is in a dynamic heterocomplex with Hsp90 and is incapable of specifically binding DNA. When cells are stressed, heterocomplex assembly is disrupted. Unbound hHSF1 homotrimerizes, acquires DNA binding activity, and concentrates in the nucleus, but remains transcriptionally inactive. A subsequent reaction converts this inactive, trimeric form into the active, hyperphosphorylated transcription factor. Subsequent to the stressful event, hHSF1 is deactivated and eventually returned to its unactivated form. Evidence is presented herein that trimeric hHSF1 has the propensity to dynamically associate with an Hsp90-immunophilin-p23 complex through its regulatory domain. Formation of this heterocomplex results in repression of the transcriptional activity of trimeric hHSF1. Stress-denatured proteins effectively compete with trimeric hHSF1 for Hsp90-immunophilin-p23 complex, counteracting assembly of the heterocomplex and repression of hHSF1 transcriptional activity. This repression mechanism may be required for a proportional transcriptional response to stress. Formation of the heterocomplex may also represent the first step toward returning the hHSF1 to its unactivated form.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Biol, Scottsdale, AZ 85259 USA	University of Miami; University of Michigan System; University of Michigan; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix	Voellmy, R (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, 1011 NW 15th St, Miami, FL 33136 USA.	rvoellmy@molbio.med.miami.edu			NIGMS NIH HHS [GM31125] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRUCE JL, 1993, CANCER RES, V53, P12; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; FOWDEN L, 1967, ADV ENZYMOL RAMB, V29, P89; FOWDEN L, 1963, BIOCHIM BIOPHYS ACTA, V71, P459, DOI 10.1016/0006-3002(63)91104-1; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Freeman ML, 1999, FREE RADICAL BIO MED, V26, P737, DOI 10.1016/S0891-5849(98)00258-5; GREEN M, 1995, MOL CELL BIOL, V15, P3354; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LEPOCK JR, 1988, J CELL PHYSIOL, V137, P14, DOI 10.1002/jcp.1041370103; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; MIVECHI NF, 1995, CANCER RES, V55, P5512; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Ohnishi K, 1999, MOL CELL BIOCHEM, V197, P129, DOI 10.1023/A:1006937513154; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; Voellmy R, 1996, EXS, V77, P121; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; Xiao NQ, 1997, MOL ENDOCRINOL, V11, P1365, DOI 10.1210/me.11.9.1365; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL STRESS CHAPERON, V3, P130, DOI 10.1379/1466-1268(1998)003<0130:CBGOAT>2.3.CO;2; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	47	161	176	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45791	45799		10.1074/jbc.M105931200	http://dx.doi.org/10.1074/jbc.M105931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583998	hybrid			2022-12-27	WOS:000172573100040
J	Mikita, T; Porter, G; Lawn, RM; Shiffman, D				Mikita, T; Porter, G; Lawn, RM; Shiffman, D			Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED RECEPTOR-GAMMA; RETINOID-X-RECEPTOR; GENE-EXPRESSION; PPAR-GAMMA; INTERLEUKIN-12 PRODUCTION; CHOLESTEROL EFFLUX; LIVER DEGENERATION; NUCLEAR RECEPTOR; MESSENGER-RNA	av6Macrophage-derived foam cells in atherosclerotic lesions are generally thought to play a major role in the pathology of the disease. Because macrophages play a central role in the inflammatory response, and the atherosclerotic lesion has features associated with chronic inflammatory settings, we investigated foam cell inflammatory potential. THP-IL-derived macrophages were treated with oxidized low density lipoprotein (OxLDL) for 3 days to lipid load the macrophages and establish a foam cell-like phenotype. The cells were then activated by treatment with lipopolysaccharide (LPS), and RNA was harvested at 0, 1, and 6 h after LPS addition. RNA from treated and control cells was hybridized to microarrays containing similar to 16,000 human cDNAs. Genes that exhibited a 4-fold or greater increase or decrease at either 1 or 6 h after LPS treatment were counted as LPS-responsive genes. Employing these criteria, 127 LPS-responsive genes were identified. Prior treatment of THP-1 macrophages with OxLDL affected the expression of 57 of these 127 genes. Among these 57 genes was a group of chemokine, cytokine, and signal transduction genes with pronounced expression changes. OxLDL pretreatment resulted in a significant perturbation of LPS-induced NF kappaB activation. Furthermore, some of the OxLDL effects appear to be mediated by the nuclear receptors retinoid X receptor and peroxisomal proliferator-activated receptor gamma because pretreatment of THP-1 macrophages with ligands for these receptors, followed by LPS treatment, recapitulates the OxLDL plus LPS results for several of the most significantly modulated genes.	CV Therapeut, Palo Alto, CA 94304 USA; Incyte Genom, Palo Alto, CA 94304 USA	Incyte	Mikita, T (corresponding author), CV Therapeut, 3172 Porter Dr, Palo Alto, CA 94304 USA.	tomm@cvt.com						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; Costet P, 2000, J BIOL CHEM, V275, P28240; de Boer OJ, 2000, J PATHOL, V190, P237, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;237::AID-PATH541&gt;3.0.CO;2-N; Denecke B, 1999, J BIOL CHEM, V274, P26860, DOI 10.1074/jbc.274.38.26860; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Eligini S, 1999, ARTERIOSCL THROM VAS, V19, P1719, DOI 10.1161/01.ATV.19.7.1719; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Gimbrone MA, 1999, AM J PATHOL, V155, P1, DOI 10.1016/S0002-9440(10)65090-0; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; Hansson GK, 1997, CURR OPIN LIPIDOL, V8, P301, DOI 10.1097/00041433-199710000-00009; Heermeier K, 2001, J AM SOC NEPHROL, V12, P456, DOI 10.1681/ASN.V123456; Horkko S, 2000, FREE RADICAL BIO MED, V28, P1771, DOI 10.1016/S0891-5849(00)00333-6; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kim CH, 1998, J IMMUNOL, V161, P2580; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee H, 2000, CIRC RES, V87, P516; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIBBY P, 2000, AM J CARDIOL S, V86, P3, DOI DOI 10.1016/S0002-9149(00)01339-4; Liu Y, 1997, ARTERIOSCL THROM VAS, V17, P317, DOI 10.1161/01.ATV.17.2.317; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rudolph D, 2000, GENE DEV, V14, P854; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shanley TP, 2000, CYTOKINE, V12, P1054, DOI 10.1006/cyto.1999.0655; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; Simpson AECM, 1997, INFLAMM RES, V46, P65, DOI 10.1007/s000110050078; Stenvinkel P, 2001, BLOOD PURIFICAT, V19, P53, DOI 10.1159/000014479; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sullivan GW, 2000, J LEUKOCYTE BIOL, V67, P591, DOI 10.1002/jlb.67.5.591; Suzuki T, 2000, BLOOD, V96, P2584; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TEMESGEN Z, 2001, EXPERT OPIN PHARMACO, V2, P765; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YUE H, 2001, NUCLEIC ACIDS RES, V15, P29	65	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45729	45739		10.1074/jbc.M106114200	http://dx.doi.org/10.1074/jbc.M106114200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577090	hybrid			2022-12-27	WOS:000172573100032
J	Spodsberg, N; Alfalah, M; Naim, HY				Spodsberg, N; Alfalah, M; Naim, HY			Characteristics and structural requirements of apical sorting of the rat growth hormone through the O-glycosylated stalk region of intestinal sucrase-isomaltase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS NEURAMINIDASE; CANINE KIDNEY-CELLS; POLARIZED EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE DOMAIN; MDCK CELLS; MEMBRANE GLYCOPROTEIN; SECRETORY PATHWAY; SURFACE TRANSPORT; GLYCANS MEDIATE	The apical sorting of the small intestinal membrane glycoprotein sucrase-isomaltase (SI) depends on the presence of O-linked glycans and the transmembrane domain. Here, we investigate the role of O-glycans carried by the Ser/Thr-rich stalk region of SI as an apical sorting signal and evaluate the spatial requirements for an efficient recognition of this signal. Several hybrid proteins are generated comprising the unsorted and unglycosylated protein, the rat growth hormone (rGH), fused to either the transmembrane domain of SI (GHSI(TM)), or the transmembrane and the stalk domains (GH-SISR/TM). Both constructs are randomly distributed over the apical and basolateral membranes of MDCK cells indicating that neither the transmembrane domain nor the O-glycans are sufficient per se for an apical delivery. Only when a polyglycine spacer is inserted between the stalk region of Sl and the luminal part of rGH in the GH-SIGly/SR/TM fusion protein does efficient apical sorting of an O-glycosylated protein as well as a time-dependent association with detergent-insoluble lipid microdomains occur. Obviously, the polyglycine spacer facilitates the accessibility of the O-glycans in GH-SIGly/SR/TM to a putative sorting receptor, whereas these glycans are inadequately recognized in GH-SISR/TM. We conclude that the O-glycans in the stalk region of SI act as an apical sorting signal within a sorting machinery that comprises at least a carbohydrate-binding protein and fulfills specific spatial requirements provided, for example by a polyglycine spacer in the context of rGH or the P-domain within the Sl enzyme complex.	Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Hannover Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Al Falah, Dr. Marwan/C-6281-2011					Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Barman S, 2000, J VIROL, V74, P6538, DOI 10.1128/JVI.74.14.6538-6545.2000; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Fiedler K, 1996, J CELL SCI, V109, P271; Fullekrug J, 1999, J CELL SCI, V112, P2813; GARCIA M, 1993, J CELL SCI, V104, P1281; GORMAN CM, 1984, PHILOS T ROY SOC B, V307, P343, DOI 10.1098/rstb.1984.0137; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Huang XF, 1997, J BIOL CHEM, V272, P27598, DOI 10.1074/jbc.272.44.27598; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JACOB R, 1994, J BIOL CHEM, V269, P2712; JONES LV, 1985, MOL CELL BIOL, V5, P2181, DOI 10.1128/MCB.5.9.2181; Keller P, 1997, J CELL SCI, V110, P3001; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J BIOL CHEM, V263, P7242; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; NAIM HY, 1991, J BIOL CHEM, V266, P12313; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SINHA YN, 1972, ENDOCRINOLOGY, V91, P784, DOI 10.1210/endo-91-3-784; THIBAULT V, 1993, ENDOCRINOLOGY, V132, P468, DOI 10.1210/en.132.1.468; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	44	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46597	46604		10.1074/jbc.M108187200	http://dx.doi.org/10.1074/jbc.M108187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577111	hybrid			2022-12-27	WOS:000172573100146
J	Yuan, X; Lu, ML; Li, T; Balk, SP				Yuan, X; Lu, ML; Li, T; Balk, SP			SRY interacts with and negatively regulates androgen receptor transcriptional activity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL HYPOPLASIA CONGENITA; PROSTATE-SPECIFIC ANTIGEN; LIGAND-BINDING DOMAIN; ESTROGEN RESPONSE ELEMENT; INHIBITING SUBSTANCE GENE; TESTIS-DETERMINING FACTOR; AUTOSOMAL SEX REVERSAL; AMINO-TERMINAL DOMAIN; Y-CHROMOSOME GENES; NUCLEAR-RECEPTOR	This study investigated interactions between SRY, the Y chromosome encoded male sex determining factor, and the androgen receptor (AR). Coexpression of AR and SRY caused marked repression of AR transcriptional activity on a series of androgen-responsive reporter genes. Mammalian one- and two-hybrid experiments demonstrated an AR-SRY interaction mediated by the AR DNA binding domain. Precipitations with glutathione S-transferase fusion proteins indicated that AR-SRY interactions were direct and mediated by the AR DNA binding domain and the SRY high mobility group box DNA binding domain. Transient expression of SRY in LNCaP prostate cancer cells repressed expression of an androgen-dependent prostate-specific antigen (PSA) reporter gene and stable SRY expression repressed the endogenous PSA gene. SRY protein expression was increased by proteosome inhibitors and by the androgen-liganded AR in transient and stable transfectants. AR transcriptional activity was also repressed by DAX1, and the effects of SRY and DAX1 on the AR were additive. These findings indicate that interactions between the AR, SRY, and DAX1 contribute to normal male development and function and suggest a general role for protein-protein interactions between high mobility group box proteins and steroid hormone receptors in regulating tissue-specific gene expression.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Dept Med, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Urol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Yuan, X (corresponding author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Dept Med, Canc Biol Program, 330 Brookline Ave, Boston, MA 02215 USA.	xyuan@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA065647] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA65647] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bowles J, 1999, NAT GENET, V22, P405, DOI 10.1038/11981; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Gottlieb B, 1999, AM J MED GENET, V89, P210, DOI 10.1002/(SICI)1096-8628(19991229)89:4<210::AID-AJMG5>3.0.CO;2-P; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO WW, 1995, BIOCHEM MOL MED, V56, P8, DOI 10.1006/bmme.1995.1049; Habiby RL, 1996, J CLIN INVEST, V98, P1055, DOI 10.1172/JCI118866; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Harley VR, 1996, FEBS LETT, V391, P24, DOI 10.1016/0014-5793(96)00694-1; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Lau YFC, 2000, MOL CARCINOGEN, V27, P308, DOI 10.1002/(SICI)1098-2744(200004)27:4<308::AID-MC9>3.0.CO;2-R; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; McElreavey K, 1999, AM J MED GENET, V89, P176, DOI 10.1002/(SICI)1096-8628(19991229)89:4<176::AID-AJMG2>3.0.CO;2-B; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; ONATE SA, 1995, SCIENCE, V270, P1354; Perinchery G, 2000, J UROLOGY, V163, P1339, DOI 10.1016/S0022-5347(05)67774-9; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Romine LE, 1998, MOL ENDOCRINOL, V12, P664, DOI 10.1210/me.12.5.664; Salas-Cortes L, 1999, INT J DEV BIOL, V43, P135; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRICOLI JV, 1993, GENE CHROMOSOME CANC, V8, P28, DOI 10.1002/gcc.2870080106; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Weiss MA, 2001, MOL ENDOCRINOL, V15, P353, DOI 10.1210/me.15.3.353; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	78	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46647	46654		10.1074/jbc.M108404200	http://dx.doi.org/10.1074/jbc.M108404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585838	hybrid			2022-12-27	WOS:000172573100152
J	Chakraborty, S; Senyuk, V; Sitailo, S; Chi, YQ; Nucifora, G				Chakraborty, S; Senyuk, V; Sitailo, S; Chi, YQ; Nucifora, G			Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASES; TRANSCRIPTIONAL CONTROL; CO-REPRESSOR; EV11 GENE; EXPRESSION; ENCODES; RAR; DNA	EVIL is a very complex protein with two domains of zinc fingers and is inappropriately expressed in many types of human myeloid leukemias. Using reporter gene assays, several investigators showed that EVI1 is a transcription repressor, and recently it was shown that EVI1 interacts with the co-repressor carboxyl-terminal binding protein 1 (CtBP1). Earlier, we showed that the inappropriate expression of EVI1 in murine hematopoietic precursor cells leads to their abnormal differentiation and to increased proliferation. Using biochemical assays, we have identified two groups of transcription co-regulators that associate with EVIL presumably to regulate gene expression. One group of co-regulators includes the CtBP1 and histone deacetylase. The second group includes the two co-activators cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF), both of which have histone acetyltransferase (HAT) activity. All of these proteins require separate regions of EVI1 for efficient interaction, and they divergently affect the ability of EVI1 to regulate gene transcription in reporter gene assays. Confocal microscopy analysis shows that in the majority of the cells, EVI1 is nuclear and diffused, whereas in about 10%, of the cells EVI1 localizes in nuclear speckles. However, in the presence of the added exogenous co-repressors histone deacetylase or CtBP1, all of the nuclei have a diffuse EVI1 staining, and the proteins do not appear to reside together in obvious nuclear structures. In contrast, when CBP or P/CAF are added, defined speckled bodies appear in the nucleus. Analysis of the staining pattern indicates that EVI1 and CBP or EVIL and P/CAF are contained within these structures. These nuclear structures are not observed when CBP is substituted with a point mutant HAT-inactive CBP with which EVI1 also physically interacts. Finally, we show that the interaction of EVI1 with either CBP or P/CAF leads to acetylation of EVI1. These results suggest that the assembly of EVIL in nuclear speckles requires the intact HAT activity of the co-activators.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,M-C 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu			NCI NIH HHS [CA72675, CA67189] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072675, R29CA067189, R01CA067189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; FICHELSON S, 1992, LEUKEMIA, V6, P93; FontenayRoupie M, 1997, HEMATOL CELL THER, V39, P5, DOI 10.1007/s00282-997-0005-8; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P167, DOI 10.1016/0165-4608(89)90182-9; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; RUSSELL M, 1993, LEUKEMIA, V7, P1654; Sitailo S, 1999, LEUKEMIA, V13, P1639, DOI 10.1038/sj.leu.2401585; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; SUZUKAWA K, 1994, BLOOD, V84, P2681; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang JX, 1999, CANCER RES, V59, P2766; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535	39	75	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44936	44943		10.1074/jbc.M106733200	http://dx.doi.org/10.1074/jbc.M106733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11568182	hybrid			2022-12-27	WOS:000172406700081
J	Dimaano, C; Ball, JR; Prunuske, AJ; Ullman, KS				Dimaano, C; Ball, JR; Prunuske, AJ; Ullman, KS			RNA association defines a functionally conserved domain in the nuclear pore protein Nup153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; NUCLEOPORIN NUP153; COMPLEX PROTEIN; BINDING-PROTEIN; EXPORT; IMPORT; RAN; CYTOPLASM; NUP98; RIBONUCLEOPROTEIN	Traffic between the nucleus and cytoplasm takes place through a macromolecular structure termed the nuclear pore complex. To understand how the vital process of nucleocytoplasmic transport occurs, the contribution of individual pore proteins must be elucidated. One such protein, the nucleoporin Nup153, is localized to the nuclear basket of the pore complex and has been shown to be a central component of the nuclear transport machinery. Perturbation of Nup153 function was demonstrated previously to block the export of several classes of RNA cargo. Moreover, these studies also showed that Nup153 can stably associate with RNA in vitro. In this study, we have mapped a domain within Nup153, encompassing amino acids 250-400 in human Nup153, that is responsible for RNA association. After cloning this region of Xenopus Nup153, we performed a cross-species analysis. Despite variation in sequence conservation between Drosophila, Xenopus, and human, this domain of Nup153 displayed robust RNA binding activity in each case, indicating that this property is a hallmark feature of Nup153 and pointing toward a subset of amino acid residues that are key to conferring this ability. We have further determined that a recombinant fragment of Nup153 can bind directly to RNA and that this fragment can interact with endogenous RNA targets. Our findings identify a functionally conserved domain in Nup153 and suggest a role for RNA binding in Nup153 function at the nuclear pore.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Ullman, KS (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	katharine.ullman@hci.utah.edu			NIGMS NIH HHS [GM61275, R01 GM061275] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061275] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; Bastos R, 1997, J CELL BIOL, V137, P989, DOI 10.1083/jcb.137.5.989; Bellini M, 1998, MOL BIOL CELL, V9, P2987, DOI 10.1091/mbc.9.10.2987; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; CARMICHAEL GG, 1975, J BIOL CHEM, V250, P6160; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Enarson P, 1998, CHROMOSOMA, V107, P228, DOI 10.1007/s004120050301; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grandi P, 1997, MOL BIOL CELL, V8, P2017, DOI 10.1091/mbc.8.10.2017; GROTE M, 1995, J CELL SCI, V108, P2963; Guan TL, 2000, MOL CELL BIOL, V20, P5619, DOI 10.1128/MCB.20.15.5619-5630.2000; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Kiseleva E, 1996, J MOL BIOL, V260, P304, DOI 10.1006/jmbi.1996.0401; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Macara LG, 1999, CURR BIOL, V9, pR436, DOI 10.1016/S0960-9822(99)80275-9; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	48	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45349	45357		10.1074/jbc.M102592200	http://dx.doi.org/10.1074/jbc.M102592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567018	hybrid			2022-12-27	WOS:000172406700130
J	Hawkins, SM; Kohwi-Shigematsu, T; Skalnik, DG				Hawkins, SM; Kohwi-Shigematsu, T; Skalnik, DG			The matrix attachment region-binding protein SATB1 interacts with multiple elements within the gp91(phox) promoter and is down-regulated during myeloid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; CHROMOSOMAL LOOP ANCHORAGE; CUT HOMEODOMAIN PROTEINS; LEUKEMIA CELL-LINE; NUCLEAR-MATRIX; DNA-BINDING; GP91-PHOX PROMOTER; GENE-EXPRESSION; T-CELLS	The gp91(phox) gene encodes a component of the respiratory burst NADPH oxidase complex and is highly expressed in mature myeloid cells. The transcriptional repressor CCAAT displacement protein binds to at least five sites within the proximal gp91(phox) promoter and represses expression prior to terminal phagocyte differentiation. The DNA binding activity of CCAAT displacement protein decreases during terminal phagocyte differentiation, thus permitting the binding of transcriptional activators and induction of gp91(phox) expression. We report here that the matrix attachment region-binding protein SATB1 interacts with at least seven sites within the -1542 to +12-base pair gp91(phox) promoter. Four additional binding sites for CCAAT displacement protein were also identified. Furthermore, the most proximal SATB1-binding site within the gp91(phox) promoter binds specifically to the nuclear matrix fraction in vitro. SATB1 expression is downregulated during terminal myeloid cell differentiation, coincident with induction of gp91(phox) expression. Transient transfection assays demonstrate that a SATB1-binding site derived from the gp91(phox) promoter represses promoter activity in cells expressing SATB1. These findings underscore the importance of transcriptional repression in the regulation of gp91(phox) expression and reveal a candidate myeloid cell target gene for SATB1, a factor previously found to be essential for T cell development.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Canc Res Bldg,1044 W Walnut St,Rm 472, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu	Hawkins, Shannon/AAX-5216-2020; Hawkins, Shannon M/B-7095-2015	Hawkins, Shannon/0000-0002-0727-3971; Hawkins, Shannon M/0000-0002-0727-3971	NCI NIH HHS [R01 CA39681, R01 CA58947] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058947, R01CA039681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad K, 2001, CELL, V104, P839, DOI 10.1016/S0092-8674(01)00281-1; Alvarez JD, 2000, GENE DEV, V14, P521; AMREIN PC, 1980, BLOOD, V56, P442; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BIDWELL JP, 1994, CANCER RES, V54, P28; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Case SS, 1999, DNA CELL BIOL, V18, P805, DOI 10.1089/104454999314809; Catt D, 1999, BLOOD, V94, P3151, DOI 10.1182/blood.V94.9.3151.421k38_3151_3160; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chen HY, 1996, BIOCHEM J, V320, P257, DOI 10.1042/bj3200257; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COCKERILL PN, 1986, FEBS LETT, V204, P5, DOI 10.1016/0014-5793(86)81377-1; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DWORETZKY SI, 1990, P NATL ACAD SCI USA, V87, P4605, DOI 10.1073/pnas.87.12.4605; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 1996, J IMMUNOL, V157, P2418; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Fiering S, 2000, BIOESSAYS, V22, P381, DOI 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-E; Getzenberg RH, 1996, CANCER RES, V56, P1690; GEY GO, 1952, CANCER RES, V12, P264; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gotzmann J, 2000, CELL DEATH DIFFER, V7, P425, DOI 10.1038/sj.cdd.4400668; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Lien LL, 1997, MOL CELL BIOL, V17, P2279, DOI 10.1128/MCB.17.4.2279; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1999, MOL CELL BIOL, V19, P4918; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Martelli AM, 1997, HISTOCHEM CELL BIOL, V108, P1, DOI 10.1007/s004180050140; Martelli AM, 1999, J CELL BIOCHEM, V72, P35, DOI 10.1002/(SICI)1097-4644(19990101)72:1<35::AID-JCB5>3.0.CO;2-S; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; NEWBURGER PE, 1984, J BIOL CHEM, V259, P3771; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 1989, MOL CLONING, P1666; Samuel SK, 1997, CANCER RES, V57, P147; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; STUURMAN N, 1989, EXP CELL RES, V180, P460, DOI 10.1016/0014-4827(89)90072-4; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; TUCKER KA, 1987, BLOOD, V70, P372; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Voo KS, 1999, BLOOD, V93, P3512, DOI 10.1182/blood.V93.10.3512.410k19_3512_3520; WEISS A, 1984, J IMMUNOL, V133, P123; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; Yang D, 2000, J BIOL CHEM, V275, P9425, DOI 10.1074/jbc.275.13.9425	70	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44472	44480		10.1074/jbc.M104193200	http://dx.doi.org/10.1074/jbc.M104193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577075	hybrid			2022-12-27	WOS:000172406700018
J	Saha, S; Nicholson, A; Kapler, GM				Saha, S; Nicholson, A; Kapler, GM			Cloning and biochemical analysis of the Tetrahymena origin binding protein TIF1 - Competitive DNA binding in vitro and in vivo to critical rDNA replication determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; RIBOSOMAL-RNA GENE; BETA-GLOBIN LOCUS; IN-VIVO; SACCHAROMYCES-CEREVISIAE; SPECIFICALLY RECOGNIZES; PROMOTER REGION; FISSION YEAST; ARS ELEMENTS; THERMOPHILA	Cis-acting type I elements regulate the initiation of DNA replication, replication fork movement, and transcription of the Tetrahymena thermophila rDNA minichromosome and are required for cell cycle-controlled replication and developmentally programmed gene amplification. Previous studies identified three in vitro single-stranded type I element binding activities that were proposed to play distinct roles in replication control. Here we describe the cloning of one of these genes, TIF1, and we provide evidence for its association with type I elements in vivo. Furthermore, we show that TIF1 interacts (in vitro and an vivo) with pause site elements (PSE), which co-localize with replication initiation and fork arrest sites, and are shown to be essential. The in vivo accessibility of PSE and type I elements to potassium permanganate suggests that origin regions are frequently unwound in native chromatin. TIF1 contains sequence similarity to the Solanum tuberosum single strand-specific transcription factor, p24, and a related Arabidopsis protein. Antisense inhibition studies suggest that TIF1 competes with other proteins for PSE and type I element binding. TIF1 displays a marked strand bias in vivo, discriminating between origin- and promoter-proximal type I elements. We propose that this bias selectively modulates the binding of a different subset of proteins to the respective regulatory elements.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Kapler, GM (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053572, R29GM053572] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53572] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; Baber JL, 1999, J MOL BIOL, V289, P949, DOI 10.1006/jmbi.1999.2818; Bayarsaihan D, 1996, BIOCHEM J, V314, P293, DOI 10.1042/bj3140293; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; Desveaux D, 2000, PLANT CELL, V12, P1477, DOI 10.1105/tpc.12.8.1477; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DU CY, 1995, NUCLEIC ACIDS RES, V23, P1766, DOI 10.1093/nar/23.10.1766; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; ENGBERG J, 1990, NUCLEIC ACIDS RES, V18, P6915, DOI 10.1093/nar/18.23.6915; GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196; Gallagher RC, 1998, MOL CELL BIOL, V18, P3021, DOI 10.1128/MCB.18.5.3021; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; HOU Z, 1995, BIOCHEMISTRY-US, V34, P4583, DOI 10.1021/bi00014a011; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KAPLER GM, 1994, GENE DEV, V8, P84, DOI 10.1101/gad.8.1.84; KAPLER GM, 1994, GENETICS, V137, P455; KAPLER GM, 1996, DNA REPLICATION EUKA, P915; Kim Soo-Mi, 2001, BMC Molecular Biology, V2, P1, DOI 10.1186/1471-2199-2-1; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LARSON DD, 1986, CELL, V47, P229, DOI 10.1016/0092-8674(86)90445-9; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Lu L, 2001, GENE DEV, V15, P134, DOI 10.1101/gad.822101; MacAlpine DM, 1997, MOL CELL BIOL, V17, P4517, DOI 10.1128/MCB.17.8.4517; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Menon RK, 1997, MOL ENDOCRINOL, V11, P1291, DOI 10.1210/me.11.9.1291; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIYAHARA K, 1993, GENE, V127, P209; Mohammad M, 2000, NUCLEIC ACIDS RES, V28, P843, DOI 10.1093/nar/28.3.843; Muralidharan V, 1997, J CELL BIOCHEM, V66, P524, DOI 10.1002/(SICI)1097-4644(19970915)66:4<524::AID-JCB11>3.0.CO;2-B; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; ORIAS E, 1992, DEV GENET, V13, P87, DOI 10.1002/dvg.1020130114; ORIAS E, 1975, METHOD CELL BIOL, V13, P247; PALEN TE, 1984, CELL, V36, P933, DOI 10.1016/0092-8674(84)90043-6; PAN WJ, 1995, MOL CELL BIOL, V15, P3372; Reischmann KP, 1999, NUCLEIC ACIDS RES, V27, P3079, DOI 10.1093/nar/27.15.3079; Saha S, 2000, J MOL BIOL, V295, P423, DOI 10.1006/jmbi.1999.3365; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; Sweeney R, 1996, P NATL ACAD SCI USA, V93, P8518, DOI 10.1073/pnas.93.16.8518; Tomonaga T, 1998, MOL CELL, V1, P759, DOI 10.1016/S1097-2765(00)80075-1; UMTHUN AR, 1994, NUCLEIC ACIDS RES, V22, P4432, DOI 10.1093/nar/22.21.4432; YAEGER PC, 1989, MOL CELL BIOL, V9, P452, DOI 10.1128/MCB.9.2.452; YAO MC, 1989, MOL CELL BIOL, V9, P1092, DOI 10.1128/MCB.9.3.1092; YU GL, 1989, P NATL ACAD SCI USA, V86, P8487, DOI 10.1073/pnas.86.21.8487; Yue M, 1998, NUCLEIC ACIDS RES, V26, P4635, DOI 10.1093/nar/26.20.4635; Zhang Z, 1997, MOL CELL BIOL, V17, P6147, DOI 10.1128/MCB.17.10.6147; ZHU JG, 1994, CHROMOSOMA, V103, P414, DOI 10.1007/s004120050050	58	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45417	45426		10.1074/jbc.M106162200	http://dx.doi.org/10.1074/jbc.M106162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577092	hybrid			2022-12-27	WOS:000172406700139
J	Molero, JC; Whitehead, JP; Meerloo, T; James, DE				Molero, JC; Whitehead, JP; Meerloo, T; James, DE			Nocodazole inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes via a microtubule-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; GLUT4; LOCALIZATION; TRANSLOCATION; TRAFFICKING; BIOGENESIS; MEMBRANE; VESICLES; TERMINUS	Insulin stimulates glucose transport in adipocytes and muscle cells by triggering redistribution of the GLUT4 glucose transporter from an intracellular perinuclear location to the cell surface. Recent reports have shown that the microtubule-depolymerizing agent nocodazole inhibits insulin-stimulated glucose transport, implicating an important role for microtubules in this process. In the present study we show that 2 mum nocodazole completely depolymerized microtubules in 3T3-L1 adipocytes, as determined morphologically and biochemically, resulting in dispersal of the perinuclear GLUT4 compartment and the Golgi apparatus. However, 2 mum nocodazole did not significantly effect either the kinetics or magnitude of insulin-stimulated glucose transport. Consistent with previous studies, higher concentrations of nocodazole (10-33 mum) significantly inhibited basal and insulin-stimulated glucose uptake in adi. pocytes. This effect was not likely the result of microtubule depolymerization because in the presence of taxol, which blocked nocodazole-induced depolymerization of microtubules as well as the dispersal of the perinuclear GLUT4 compartment, the inhibitory effect of 10-33 muM nocodazole on insulin-stimulated glucose uptake prevailed. Despite the decrease in insulin-stimulated glucose transport with 33 muM nocodazole we did not observe inhibition of insulin-stimulated GLUT4 translocation to the cell surface under these conditions. Consistent with a direct effect of nocodazole on glucose transporter function we observed a rapid inhibitory effect of nocodazole on glucose transport activity when added to either 3T3-L1 adipocytes or to Chinese hamster ovary cells at 4 degreesC. These studies reveal a new and unexpected effect of nocodazole in mammalian cells which appears to occur independently of its microtubule-depolymerizing effects.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland	Molero, JC (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.		Whitehead, Jonathan/F-5022-2014	James, David/0000-0001-5946-5257; Whitehead, Jonathan/0000-0003-3978-3148				Arcangeletti C, 1997, J STRUCT BIOL, V119, P35, DOI 10.1006/jsbi.1997.3871; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; JIN MJ, 1993, J BIOL CHEM, V268, P18390; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Martin S, 2000, J CELL SCI, V113, P3427; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1991, AM J PHYSIOL, V260, P570; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162	28	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43829	43835		10.1074/jbc.M105452200	http://dx.doi.org/10.1074/jbc.M105452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571289	Green Submitted, hybrid			2022-12-27	WOS:000172297700047
J	Bunemann, M; Bucheler, MM; Philipp, M; Lohse, MJ; Hein, L				Bunemann, M; Bucheler, MM; Philipp, M; Lohse, MJ; Hein, L			Activation and deactivation kinetics of alpha(2A)- and alpha(2C)-adrenergic receptor-activated G protein-activated inwardly rectifying K+ channel currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2A)-ADRENERGIC RECEPTOR; ALPHA-2-ADRENERGIC RECEPTORS; HUMAN ALPHA(2)-ADRENOCEPTORS; CALCIUM-CHANNELS; MODULATION; G(I); INHIBITION; POTASSIUM; DESENSITIZATION; IDENTIFICATION	Although G protein-coupled receptor-mediated signaling is one of the best studied biological events, little is known about the kinetics of these processes in intact cells. Experiments with neurons from alpha (2A)-adrenergic receptor knockout mice suggested that the alpha (2A)-receptor subtype inhibits neurotransmitter release with higher speed and at higher action potential frequencies than the a,c-adrenergic receptor. Here we investigated whether these functional differences between presynaptic alpha (2)-adrenergic receptor subtypes are the result of distinct signal transduction kinetics of these two receptors and their coupling to G proteins. alpha (2A)- and alpha (2C)-receptors were stably expressed in HEK293 cells at moderate (similar to2 pmol/mg) or high (17-24 pmol/mg) levels. Activation of G protein-activated inwardly rectifying K+ (GIRK) channels was similar in extent and kinetics for alpha (2A)- and alpha (2C)-receptors at both expression levels. However, the two receptors differed significantly in their deactivation kinetics after removal of the agonist norepinephrine. alpha (2C)-Receptor-activated GIRK currents returned much more slowly to base line than did alpha (2A)-stimulated currents. This observation correlated with a higher affinity of norepinephrine at the murine alpha (2C)- than at the alpha (2A)-receptor subtype and may explain why alpha (2C)-adrenergic receptors are especially suited to control sympathetic neurotransmission at low action potential frequencies in contrast to the alpha (2A)-receptor subtype.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany	University of Wurzburg	Hein, L (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.	hein@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Philipp, Melanie/B-5198-2016	Lohse, Martin J/0000-0002-0599-3510; Philipp, Melanie/0000-0003-2714-965X				Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CERESA BP, 1994, J BIOL CHEM, V269, P29557; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; Docherty JR, 1998, EUR J PHARMACOL, V361, P1, DOI 10.1016/S0014-2999(98)00682-7; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; EASON MG, 1992, J BIOL CHEM, V267, P25473; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; Hein L, 2001, REV PHYSIOL BIOCH P, V142, P161, DOI 10.1007/BFb0117493; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hurt CM, 2000, J BIOL CHEM, V275, P35424, DOI 10.1074/jbc.M006241200; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; LANGER SZ, 1974, BIOCHEM PHARMACOL, V23, P1793, DOI 10.1016/0006-2952(74)90187-7; MacDonald E, 1997, TRENDS PHARMACOL SCI, V18, P211; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; Olli-Lahdesmaki T, 1999, J NEUROSCI, V19, P9281; Pihlavisto M, 1998, BBA-MOL CELL RES, V1448, P135, DOI 10.1016/S0167-4889(98)00118-9; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Shekter LR, 1997, MOL PHARMACOL, V52, P282, DOI 10.1124/mol.52.2.282; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; STARKE K, 1975, NATURE, V254, P440, DOI 10.1038/254440a0; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; Trendelenburg AU, 2001, N-S ARCH PHARMACOL, V364, P117, DOI 10.1007/s002100100423; VON ZM, 1993, J BIOL CHEM, V268, P763	33	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47512	47517		10.1074/jbc.M108652200	http://dx.doi.org/10.1074/jbc.M108652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591725	hybrid			2022-12-27	WOS:000172768500109
J	Chen, NY; Ma, WY; She, QB; Wu, E; Liu, GM; Bode, AM; Dong, ZG				Chen, NY; Ma, WY; She, QB; Wu, E; Liu, GM; Bode, AM; Dong, ZG			Transactivation of the epidermal growth factor receptor is involved in 12-O-tetradecanoylphorbol-13-acetate-induced signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACID RESPONSE ELEMENT; TUMOR PROMOTION; METALLOPROTEINASE CLEAVAGE; INDUCED TRANSFORMATION; RETINOIC ACID; AP-1 ACTIVITY; EGF RECEPTOR; FACTOR-ALPHA; SKIN TUMORS	The mechanism of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced tumor promotion is still not well understood even though it is thought to be related to the protein kinase C/mitogen-activated protein kinase/AP-1 pathway. Recently, TPA was also found to induce epidermal growth factor receptor (EGFR) activity. Here, we investigated whether the EGFR is a necessary component for TPA-induced signal transduction associated with tumor promotion. We demonstrated that potent inhibitors of the EGFR, PD153035 and AG1478, blocked TPA-induced phosphorylation of extracellular signal-regulated kinases (ERKs), AP-1 activity, and cell transformation. Egfr gene deficiency blocked TPA-induced ERK activity and AP-1 binding activity. The blocking of the ectodomain of the EGFR by a monoclonal antibody depressed TPA-induced ERK activity and AP-1 DNA binding activity. The use of a neutralizing antibody for heparin-binding EGF, one of the ligands of EGFR, blocked TPA-induced phosphorylation of ERKs. BB-94, a potent inhibitor of matrix metalloproteinases, which are activators of ectodomain shedding of EGFR ligands, also blocked TPA-induced ERK activity, AP-1 DNA binding, and cell transformation but had no effect on EGF-induced signal transduction. Anti-EGFR, anti-heparin-binding EGF, and BB-94 each blocked TPA-induced EGFR phosphorylation, but only anti-EGFR could block EGF-induced EGFR phosphorylation. Based on these results, we conclude that the EGFR is required for mediating TPA-induced signal transduction. EGFR transactivation induced by TPA is a mechanism by which the EGFR mediates TPA-induced tumor promotion-relate signal transduction.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	University of Minnesota System; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Wu, Erxi/0000-0002-1680-3639; She, Qing-Bai/0000-0002-7207-0599	NATIONAL CANCER INSTITUTE [R37CA081064, R01CA081064, R29CA074916, R01CA077646] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74916, CA 81064, CA 77646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Angel J M, 1999, Prog Exp Tumor Res, V35, P143; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; DIGIOVANNI J, 1995, SKIN CANC MECH HUMAN, P181; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 1997, CANCER RES, V57, P4414; DONG ZG, 1994, CARCINOGENESIS, V15, P1001, DOI 10.1093/carcin/15.5.1001; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HOSHI M, 1988, J BIOL CHEM, V263, P5396; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; Li JJ, 1996, CANCER RES, V56, P483; LOO D, 1994, CELL BIOL LAB HDB, P45; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; WU EX, 1999, NATO SCI SERIES, P263; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	43	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46722	46728		10.1074/jbc.M107156200	http://dx.doi.org/10.1074/jbc.M107156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592962	hybrid			2022-12-27	WOS:000172768500008
J	Leu, FP; O'Donnell, M				Leu, FP; O'Donnell, M			Interplay of clamp loader subunits in opening the beta sliding clamp of Escherichia coli DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; ACCESSORY PROTEINS; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; LAGGING-STRAND; GAMMA-SUBUNIT; COMPLEX; BINDING; MACHINE; PCNA	The Escherichia coli beta dimer is a ring-shaped protein that encircles DNA and acts as a sliding clamp to tether the replicase, DNA polymerase III holoenzyme, to DNA. The gamma complex (gamma delta delta'chi psi) clamp loader couples ATP to the opening and closing of beta in assembly of the ring onto DNA. These proteins are functionally and structurally conserved in all cells. The eukaryotic equivalents are the replication factor C (RFQ clamp loader and the proliferating cell nuclear antigen (PCNA) clamp. The delta subunit of the E. coli gamma complex clamp loader is known to bind beta and open it by parting one of the dimer interfaces. This study demonstrates that other subunits of gamma complex also bind beta, although weaker than delta. The gamma subunit like delta, affects the opening of beta, but with a lower efficiency than delta. The delta' subunit regulates both gamma and ring opening activities in a fashion that is modulated by ATP interaction with gamma. The implications of these actions for the workings of the E. coli clamp loading machinery and for eukaryotic RFC and PCNA are discussed.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Dept Pharmacol, Ithaca, NY 14853 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BONNER CA, 1992, J BIOL CHEM, V267, P11431; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; MAKI S, 1988, J BIOL CHEM, V263, P6555; McAlear MA, 1996, GENETICS, V142, P65; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; ROWEN L, 1978, J BIOL CHEM, V253, P758; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	56	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47185	47194		10.1074/jbc.M106780200	http://dx.doi.org/10.1074/jbc.M106780200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11572866	hybrid			2022-12-27	WOS:000172768500070
J	Zvereva, MI; Ivanov, PV; Teraoka, Y; Topilina, NI; Dontsova, OA; Bogdanov, AA; Kalkum, M; Nierhaus, KH; Shpanchenko, OV				Zvereva, MI; Ivanov, PV; Teraoka, Y; Topilina, NI; Dontsova, OA; Bogdanov, AA; Kalkum, M; Nierhaus, KH; Shpanchenko, OV			Complex of transfer-messenger RNA and elongation factor Tu - Unexpected modes of interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; DIRECTED CROSS-LINKING; 10SA RNA; ANGSTROM RESOLUTION; TERNARY COMPLEX; LOOP-IV; 23S RNA; EF-TU; TMRNA; PROTEINS	Transfer-messenger RNA (tmRNA) is a stable RNA in bacteria of 360 +/- 40 nucleotides that can be charged with alanine and can function as both tRNA and mRNA. Ribosomes that are stalled either in a coding region of mRNA or at the 3 ' end of an mRNA fragment lacking a stop codon are rescued by replacing their mRNA for tmRNA. Here we demonstrate that the interaction of tmRNA with the elongation factor Tu shows unexpected features. Deacylated tmRNA can form a complex with either EF-Tu-GDP or EF-Tu-GTP, the association constants are about one order of magnitude smaller than that of an Ala-tRNA(.)EF-Tu(.)GTP complex. tmRNA as well as Ala-tmRNA can be efficiently cross-linked with EF-Tu(.)GDP using a zero-length cross-link. The efficiency of cross-linking in the case of deacylated tmRNA does not depend on an intact CCA-3 ' end and is about the same, regardless whether protein mixtures such as the post-ribosomal supernatant (S100 enzymes) or purified EF-Tu are present. Two cross-linking sites with EF-Tu(.)GDP have been identified that are located outside the tRNA part of tmRNA, indicating an unusual interaction of tmRNA with EF-Tu-GDP.	Max Planck Inst Mol Genet, AG Ribosomen, D-14195 Berlin, Germany; Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia	Max Planck Society; Lomonosov Moscow State University	Nierhaus, KH (corresponding author), Max Planck Inst Mol Genet, AG Ribosomen, Ihnestr 73, D-14195 Berlin, Germany.	Nierhaus@molgen.mpg.de	Shpanchenko, Olga/C-7813-2015; Zvereva, Maria Imilievna/J-9724-2013; Dontsova, Olga/T-6072-2019; Bogdanov, Alexey A/L-1407-2013; Ivanov, Pavel/AAZ-9197-2021; Ivanov, Pavel/F-3339-2016	Zvereva, Maria Imilievna/0000-0002-7432-1574; Ivanov, Pavel/0000-0002-7986-7760; Ivanov, Pavel/0000-0002-7986-7760; Kalkum, Markus/0000-0002-9506-671X				Alexeeva EV, 1996, NUCLEIC ACIDS RES, V24, P2228, DOI 10.1093/nar/24.12.2228; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BOMMER U, 1996, SUBCELLULAR FRACTION, P271; BOON K, 1992, EUR J BIOCHEM, V210, P177, DOI 10.1111/j.1432-1033.1992.tb17406.x; Dokudovskaya S, 1996, RNA, V2, P146; DONTSOVA O, 1994, P NATL ACAD SCI USA, V91, P4125, DOI 10.1073/pnas.91.10.4125; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DRAPER DE, 1988, METHOD ENZYMOL, V164, P203; Felden B, 1996, BIOCHIMIE, V78, P979, DOI 10.1016/S0300-9084(97)86720-X; Felden B, 1997, RNA, V3, P89; Felden B, 1999, BBA-GENE STRUCT EXPR, V1446, P145, DOI 10.1016/S0167-4781(99)00085-8; Felden B, 1998, EMBO J, V17, P3188, DOI 10.1093/emboj/17.11.3188; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Karzai AW, 2001, P NATL ACAD SCI USA, V98, P3040, DOI 10.1073/pnas.051628298; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller D L, 1974, Methods Enzymol, V30, P219; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; Petrushenko ZM, 1997, FEBS LETT, V407, P13, DOI 10.1016/S0014-5793(97)00242-1; RINKEAPPEL J, 1991, EMBO J, V10, P2195, DOI 10.1002/j.1460-2075.1991.tb07755.x; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4693; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; SERGIEV P, 2001, IN PRESS MOL BIOL MO, V35; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; Stelzl U, 2000, P NATL ACAD SCI USA, V97, P4597, DOI 10.1073/pnas.090009297; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1998, NUCLEIC ACIDS RES, V26, P163, DOI 10.1093/nar/26.1.163; Williams KP, 1996, RNA, V2, P1306; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; YOKOSAWA H, 1973, J BIOL CHEM, V248, P375; Zwieb C, 1999, NUCLEIC ACIDS RES, V27, P2063, DOI 10.1093/nar/27.10.2063	45	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47702	47708		10.1074/jbc.M106786200	http://dx.doi.org/10.1074/jbc.M106786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595738	hybrid			2022-12-27	WOS:000172768500134
J	Artemenko, IP; Zhao, D; Hales, DB; Hales, KH; Jefcoate, CR				Artemenko, IP; Zhao, D; Hales, DB; Hales, KH; Jefcoate, CR			Mitochondrial processing of newly synthesized steroidogenic acute regulatory protein (StAR), but not total StAR, mediates cholesterol transfer to cytochrome P450 side chain cleavage enzyme in adrenal cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; DIAZEPAM-BINDING INHIBITOR; BENZODIAZEPINE-RECEPTOR; TARGETED DISRUPTION; HORMONE STIMULATION; RAPID ACCUMULATION; ACTH REGULATION; GENE; BIOSYNTHESIS; MECHANISM	The metabolism of cholesterol by cytochrome P450 side chain cleavage enzyme is hormonally regulated in steroidogenic tissues via intramitochondrial cholesterol transport. The mediating steroidogenic acute regulatory protein (StAR) is synthesized as a 37-kDa (p37) precursor that is phosphorylated by protein kinase A and cleaved within the mitochondria to generate 30-kDa forms (p30, pp30). The effectiveness of modified recombinant StAR forms in COS-1 cells without mitochondrial import has led to a prevailing view that cholesterol transport is mediated by p37 StAR via activity on the outer mitochondrial membrane. The present study of the activation of cholesterol metabolism by bromo-cAMP in adrenal cells in relation to S-35-StAR turnover indicates that targeting of pp30 to the inner membrane provides the dominant cholesterol transport mechanism. We show that 1) only newly synthesized StAR is functional, 2) phosphorylation and processing of p37 to pp30 occurs rapidly and stoichiometrically, 3) both steps are necessary for optimum transport, and 4) newly synthesized pp30 exhibits very high activity (400 molecules of cholesterol/StAR/min). Segregation of cAMP activation and synthesis of StAR from cholesterol metabolism showed that very low levels of newly synthesized StAR (1 fmol/min/10(6) cells) sustained activated cholesterol metabolism (0.4 pmol/min/10(6) cells, t(1/2) = 70 min) long after complete removal of p37 (t(1/2) = 5 min). This activity was highly sensitive to inhibition of processing by CCCP only until sufficient pp30 was formed. Maximum activation preceded bromo-cAMP-induced StAR expression, indicating other limiting steps in cholesterol metabolism.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Jefcoate, CR (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	jefcoate@facstaff.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009090, R01ES009827] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18585] Funding Source: Medline; NIEHS NIH HHS [ES09827, ES09090] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAM GE, 1973, J CLIN ENDOCR METAB, V37, P40, DOI 10.1210/jcem-37-1-40; ALBERTA JA, 1989, J BIOL CHEM, V264, P20467; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; BRAKE PB, 1995, ENDOCRINOLOGY, V136, P5034, DOI 10.1210/en.136.11.5034; BROWNIE AC, 1973, ANN NY ACAD SCI, V212, P344, DOI 10.1111/j.1749-6632.1973.tb47606.x; BRUNNER M, 1995, METHOD ENZYMOL, V248, P717; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CHURCHILL PF, 1979, J BIOL CHEM, V254, P443; Clark BJ, 1996, TRENDS ENDOCRIN MET, V7, P227, DOI 10.1016/S1043-2760(96)00114-2; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CRIVELLO JF, 1978, BIOCHIM BIOPHYS ACTA, V542, P315, DOI 10.1016/0304-4165(78)90027-2; DIBARTOLOMEIS MJ, 1984, J BIOL CHEM, V259, P159; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Finkielstein C, 1998, EUR J BIOCHEM, V256, P60, DOI 10.1046/j.1432-1327.1998.2560060.x; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Garren L D, 1971, Recent Prog Horm Res, V27, P433; HALL PF, 1984, CAN J BIOCHEM CELL B, V62, P653, DOI 10.1139/o84-087; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; ISAYA G, 1995, METHOD ENZYMOL, V248, P556; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; King SR, 2000, MOL CELL ENDOCRINOL, V166, P147, DOI 10.1016/S0303-7207(00)00280-X; King SR, 1999, J STEROID BIOCHEM, V69, P143, DOI 10.1016/S0960-0760(98)00152-6; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; KNUDSEN J, 1990, BIOCHEM J, V265, P927, DOI 10.1042/bj2650927; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Maloberti P, 2000, ENDOCR RES, V26, P653, DOI 10.3109/07435800009048585; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAPADOPOULOS V, 1991, J BIOL CHEM, V266, P3682; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; PON LA, 1986, J BIOL CHEM, V261, P3309; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; SIMPSON ER, 1972, EUR J BIOCHEM, V28, P442, DOI 10.1111/j.1432-1033.1972.tb01931.x; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Watari H, 2000, EXP CELL RES, V255, P56, DOI 10.1006/excr.1999.4774	57	168	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46583	46596		10.1074/jbc.M107815200	http://dx.doi.org/10.1074/jbc.M107815200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579102	hybrid			2022-12-27	WOS:000172573100145
J	Kim, RH; Flanders, KC; Reffey, SB; Anderson, LA; Duckett, CS; Perkins, ND; Roberts, AB				Kim, RH; Flanders, KC; Reffey, SB; Anderson, LA; Duckett, CS; Perkins, ND; Roberts, AB			SNIP1 inhibits NF-kappa B signaling by competing for its binding to the C/H1 domain of CBP/p300 transcriptional Co-activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MOLECULAR-CLONING; COACTIVATOR P300; GENE-EXPRESSION; MICE LACKING; GROWTH; PROTEIN; CBP; AP-1; TRANSACTIVATION	SNIP1 is a 396-amino acid nuclear protein shown to be an inhibitor of the TGF-beta signal transduction. pathway and to be important in suppressing transcriptional activation dependent on the co-activators CBP and p300. In this report we show that SNIP1 potently inhibits the activity of NF-kappaB, which binds the C/H1 domain of CBP/p300, but does not interfere with the activity of transcription factors such as p53, which bind to other domains of p300, or factors such as VP16, which are independent of these co-activators. Inhibition of NF-kappaB activity is a function of the N-terminal domain of SNIP1 and involves competition of SNIP1 and the NF-kappaB subunit, RelA/p65, for binding to p300, similar to the mechanism of inhibition of Smad signaling by SNIP1. Immunohistochemical staining shows that expression of SNIP1 is strictly regulated in development and that it colocalizes, in certain tissues, with nuclear staining for RelA/p65 and for p300, suggesting that they may regulate NF-kappaB activity in vivo in a spatially and temporally controlled manner. These data led us to suggest that SNIP1 may be an inhibitor of multiple transcriptional pathways that require the C/H1 domain of CBP/p300.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NCI, Metab Branch, Bethesda, MD 20892 USA; Univ Dundee, Dept Biochem, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Dundee	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bldg 41,Rm C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.			Duckett, Colin/0000-0001-9413-2263				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goodman RH, 2000, GENE DEV, V14, P1553; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kim RH, 2000, GENE DEV, V14, P1605; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, P418; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	54	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46297	46304		10.1074/jbc.M103819200	http://dx.doi.org/10.1074/jbc.M103819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567019	hybrid			2022-12-27	WOS:000172573100110
J	Miyao, T; Barnett, JD; Woychik, NA				Miyao, T; Barnett, JD; Woychik, NA			Deletion of the RNA polymerase subunit RPB4 acts as a global, not stress-specific, shut-off switch for RNA polymerase II transcription at high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PROTEIN; MEDIATOR; GROWTH; MUTANT	We used whole genome expression analysis to investigate the changes in the mRNA profile in cells lacking the Saccharomyces cerevisiae RNA polymerase II subunit RPB4 (Delta RPB4). Our results indicated that an essentially complete shutdown of transcription occurs upon temperature shift of this conditionally lethal mutant; 98% of mRNA transcript levels decrease at least 2-fold, 96% at least 4-fold. This data was supported by in vivo experiments that revealed a rapid and greater than 5-fold decline in steady state poly(A) RNA levels after the temperature shift. Expression of several individual genes, measured by Northern analysis, was also consistent with the whole genome expression profile. Finally we demonstrated that the loss of RNA polymerase II activity causes secondary effects on RNA polymerase I, but not RNA polymerase III, transcription. The transcription phenotype of the Delta RPB4 mutant closely mirrors that of the temperature-sensitive rpb1-1 mutant frequently implemented as a tool to inactivate the RNA polymerase II in vivo. Therefore, the Delta RPB4 mutant can be used to easily design strains that enable the study of distinct post-transcriptional cellular processes in the absence of RNA polymerase II transcription.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Massachusetts Institute of Technology (MIT); Whitehead Institute	Woychik, NA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	nancy.woychik@umdnj.edu			NIGMS NIH HHS [GM 55736] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Bourbonnais Y, 2001, MOL GEN GENET, V264, P763, DOI 10.1007/s004380000365; BURKE D, 2000, METHODS YEAST GENETI, P117; CHODER M, 1993, J BACTERIOL, V175, P6358, DOI 10.1128/JB.175.19.6358-6363.1993; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Li BJ, 1999, MOL CELL BIOL, V19, P5393; Maillet I, 1999, J BIOL CHEM, V274, P22586, DOI 10.1074/jbc.274.32.22586; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; Pillai B, 2001, J BIOL CHEM, V276, P30641, DOI 10.1074/jbc.M010952200; Rosenheck S, 1998, J BACTERIOL, V180, P6187; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; Tan Q, 2000, MOL CELL BIOL, V20, P8124, DOI 10.1128/MCB.20.21.8124-8133.2000; Tan Q, 2000, GENE DEV, V14, P339; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; WARNER JR, 1978, NATURE, V275, P338, DOI 10.1038/275338a0; Woychik NA, 1998, COLD SPRING HARB SYM, V63, P311, DOI 10.1101/sqb.1998.63.311; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	29	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46408	46413		10.1074/jbc.M107012200	http://dx.doi.org/10.1074/jbc.M107012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577101	hybrid			2022-12-27	WOS:000172573100124
J	Stannard, AK; Riddell, DR; Sacre, SM; Tagalakis, AD; Langer, C; von Eckardstein, A; Cullen, P; Athanasopoulos, T; Dickson, G; Owen, JS				Stannard, AK; Riddell, DR; Sacre, SM; Tagalakis, AD; Langer, C; von Eckardstein, A; Cullen, P; Athanasopoulos, T; Dickson, G; Owen, JS			Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD-PLATELETS; NITRIC-OXIDE; LIPOPROTEIN METABOLISM; GENE-EXPRESSION; DEFICIENT MICE; VLDL RECEPTOR; ATHEROSCLEROSIS; MACROPHAGES; CHOLESTEROL; AGGREGATION	Sub-endothelial infiltration of monocytes occurs early in atherogenesis and is facilitated by cell adhesion molecules that are up-regulated on activated endothelium. Apolipoprotein E (apoE) helps protect against atherosclerosis, in part, because apoE particles secreted by macrophages have local beneficial effects at lesion sites. Here, we hypothesize that such protection includes antiinflammatory actions and investigate whether cell-derived apoE can inhibit tumor necrosis factor-a-mediated up-regulation of vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HuVECs). Two models were used to mimic endothelial exposure to macrophage-derived apoE. In the first, HUVECs were transiently transfected to secrete apoE; VCAM-1 induction inversely correlated with secretion of apoE into the media (r = -0.76, p < 0.001). In the second, incubation of HUVECs with media from recombinant Chinese hamster ovary (CHO) cells expressing apoE (CHO(apoE)) also reduced VCAM-1 in a dose-dependent manner (r = -0.70, p < 0.001). Characterization of CHO(apoE) cell-derived apoE revealed several similarities to apoE particles secreted by human blood monocyte-derived macrophages. The suppression of endothelial activation by apoE most likely occurs via stimulation of endothelial nitric oxide synthase; apoE increased levels of intracellular nitric oxide and its surrogate marker, cyclic guanosine monophosphate, while the nitric oxide synthase inhibitor, ethyl-isothiourea, blocked its effect. We propose that apoE secreted locally at lesion sites by macrophages may be anti-inflammatory by stimulating endothelium to release NO and suppress VCAM-1 expression.	UCL, Dept Med, Royal Free & Univ Coll, Sch Med, London NW3 2PF, England; Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; University College London; UCL Medical School; University of Munster; University of Munster; University of London; Royal Holloway University London	Owen, JS (corresponding author), UCL, Dept Med, Royal Free & Univ Coll, Sch Med, Rowland Hill St, London NW3 2PF, England.	j.owen@rfc.ucl.ac.uk	Owen, James/C-5908-2009; Tagalakis, Aristides/E-8883-2011; Athanasopoulos, Takis/C-5739-2009; Owen, James S./AAP-8628-2020; Sacre, Sandra/AAE-2297-2020	Athanasopoulos, Takis/0000-0003-2620-4952; Sacre, Sandra/0000-0003-1665-1142				Chia MC, 1998, CRIT REV CL LAB SCI, V35, P573, DOI 10.1080/10408369891234282; Cioffi L, 1999, GENE THER, V6, P1153, DOI 10.1038/sj.gt.3300890; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; DE CR, 1995, J CLIN INVEST, V96, P60; DESAI K, 1989, J LIPID RES, V30, P831; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Korschineck I, 2001, J BIOL CHEM, V276, P13192, DOI 10.1074/jbc.M011795200; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LINCOLN J, 1997, NITRIC OXIDE HLTH DI; Linton MF, 1999, CURR OPIN LIPIDOL, V10, P97, DOI 10.1097/00041433-199904000-00003; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; Nilsson L, 1999, J LIPID RES, V40, P913; Paka L, 1999, J BIOL CHEM, V274, P4816, DOI 10.1074/jbc.274.8.4816; Pitas RE, 1998, BIOCHEM SOC T, V26, P257, DOI 10.1042/bst0260257; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Riddell DR, 1999, VITAM HORM, V57, P25; Riddell DR, 2001, J LIPID RES, V42, P998; Riddell DR, 1997, J BIOL CHEM, V272, P89; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saxena Uday, 1994, Current Opinion in Lipidology, V5, P316, DOI 10.1097/00041433-199410000-00002; SOUTHAN GJ, 1995, BRIT J PHARMACOL, V114, P510, DOI 10.1111/j.1476-5381.1995.tb13256.x; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; Stannard AK, 1998, ATHEROSCLEROSIS, V139, P57, DOI 10.1016/S0021-9150(98)00052-5; Tagalakis AD, 2001, J BIOL CHEM, V276, P13226, DOI 10.1074/jbc.C000883200; Takahashi S, 1996, FEBS LETT, V386, P197, DOI 10.1016/0014-5793(96)00439-5; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Truskey GA, 1999, ARTERIOSCL THROM VAS, V19, P393, DOI 10.1161/01.ATV.19.2.393; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wolle J, 1996, ARTERIOSCL THROM VAS, V16, P1501, DOI 10.1161/01.ATV.16.12.1501	42	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46011	46016		10.1074/jbc.M104812200	http://dx.doi.org/10.1074/jbc.M104812200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590165	hybrid			2022-12-27	WOS:000172573100071
J	Zhang, Z; Yu, Y; Musser, JM; Palzkill, T				Zhang, Z; Yu, Y; Musser, JM; Palzkill, T			Amino acid sequence determinants of extended spectrum cephalosporin hydrolysis by the class CP99 beta-lactamase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEINS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; KLEBSIELLA-PNEUMONIAE; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-AERUGINOSA; AMPC CEPHALOSPORINASE; MOLECULAR EVOLUTION; AEROMONAS-SOBRIA	Class C beta -lactamases are commonly encoded on the chromosome of Gram-negative bacterial species. Mutations leading to increased expression of these enzymes are a common cause of resistance to many cephalosporins including extended spectrum cephalosporins. Recent reports of plasmid- and integrin-encoded class C beta -lactamases are a cause for concern because these enzymes are likely to spread horizontally to susceptible strains. Because of their increasing clinical significance, it is critical to identify the determinants of catalysis and substrate specificity of these enzymes. For this purpose, the codons of a set of 21 amino acid residues that encompass the active site region of the P99 beta -lactamase were individually randomized to create libraries containing all possible amino acid substitutions. The amino acid sequence requirements for the hydrolysis of ceftazidime, an extended spectrum cephalosporin commonly used to treat serious infections, were determined by selecting resistant mutants from each of the 21 libraries. DNA sequencing identified the residue positions that are critical for ceftazidime hydrolysis. In addition, it was found that certain amino acid substitutions in the omega -loop region of the P99 enzyme result in increased ceftazidime hydrolysis suggesting the loop is an important determinant of substrate specificity.	Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; NIAID, Rocky Mt Labs, Lab Human Bacterial Pathogenesis, NIH, Hamilton, MT 59840 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Palzkill, T (corresponding author), Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; Barnaud G, 1997, FEMS MICROBIOL LETT, V148, P15, DOI 10.1016/S0378-1097(97)00006-2; Bauernfeind A, 1996, ANTIMICROB AGENTS CH, V40, P1926, DOI 10.1128/AAC.40.8.1926; Bauernfeind A, 1999, ANTIMICROB AGENTS CH, V43, P1924, DOI 10.1128/AAC.43.8.1924; Bou G, 2000, ANTIMICROB AGENTS CH, V44, P428, DOI 10.1128/AAC.44.2.428-432.2000; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Bulychev A, 1999, ANTIMICROB AGENTS CH, V43, P1743, DOI 10.1128/AAC.43.7.1743; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1998, J BIOL CHEM, V273, P26603, DOI 10.1074/jbc.273.41.26603; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Caselli E, 2001, CHEM BIOL, V8, P17, DOI 10.1016/S1074-5521(00)00052-1; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Crichlow GV, 1999, BIOCHEMISTRY-US, V38, P10256, DOI 10.1021/bi9908787; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Dubus A, 1996, PROTEINS, V25, P473, DOI 10.1002/prot.7; DUBUS A, 1994, BIOCHEM J, V301, P485, DOI 10.1042/bj3010485; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; GALLENI M, 1988, BIOCHEM J, V250, P753, DOI 10.1042/bj2500753; Gazouli M, 1996, ANTIMICROB AGENTS CH, V40, P1736, DOI 10.1128/AAC.40.7.1736; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gonzalez Leiza M, 1994, Antimicrob Agents Chemother, V38, P2150; HORII T, 1993, ANTIMICROB AGENTS CH, V37, P984, DOI 10.1128/AAC.37.5.984; HUANG W, 2000, J BIOL CHEM, V275, P14984; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JAURIN B, 1981, P NATL ACAD SCI-BIOL, V78, P4897, DOI 10.1073/pnas.78.8.4897; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LOBKOVSKY E, 1993, P NATL ACAD SCI USA, V90, P11257, DOI 10.1073/pnas.90.23.11257; Marchese A, 1998, ANTIMICROB AGENTS CH, V42, P464; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; MAZZELLA LJ, 1989, BIOCHEM J, V259, P255, DOI 10.1042/bj2590255; MONNAIE D, 1994, BIOCHEM J, V302, P1; MONNAIE D, 1994, BIOCHEMISTRY-US, V33, P5193, DOI 10.1021/bi00183a024; NOMURA K, 1990, FEMS MICROBIOL LETT, V70, P295, DOI 10.1016/S0378-1097(05)80011-4; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; NUKAGA M, 1993, FEBS LETT, V332, P93, DOI 10.1016/0014-5793(93)80491-C; Nukaga M, 1998, BIOCHEMISTRY-US, V37, P10461, DOI 10.1021/bi980184i; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PAPANICOLAOU GA, 1990, ANTIMICROB AGENTS CH, V34, P2200, DOI 10.1128/AAC.34.11.2200; Patera A, 2000, J AM CHEM SOC, V122, P10504, DOI 10.1021/ja001676x; Petrosino J, 1998, TRENDS MICROBIOL, V6, P323, DOI 10.1016/S0966-842X(98)01317-1; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Preston KE, 2000, ANTIMICROB AGENTS CH, V44, P3158, DOI 10.1128/AAC.44.11.3158-3162.2000; RASMUSSEN BA, 1994, ANTIMICROB AGENTS CH, V38, P2078, DOI 10.1128/AAC.38.9.2078; SEOANE A, 1992, ANTIMICROB AGENTS CH, V36, P1049, DOI 10.1128/AAC.36.5.1049; Tenover FC, 1996, JAMA-J AM MED ASSOC, V275, P300, DOI 10.1001/jama.275.4.300; Trepanier S, 1999, ANTIMICROB AGENTS CH, V43, P543, DOI 10.1128/AAC.43.3.543; TZOUVELEKIS LS, 1994, ANTIMICROB AGENTS CH, V38, P2207, DOI 10.1128/AAC.38.9.2207; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Usher KC, 1998, BIOCHEMISTRY-US, V37, P16082, DOI 10.1021/bi981210f; WALSH TR, 1995, J ANTIMICROB CHEMOTH, V36, P41, DOI 10.1093/jac/36.1.41; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	59	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46568	46574		10.1074/jbc.M102757200	http://dx.doi.org/10.1074/jbc.M102757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591698	hybrid			2022-12-27	WOS:000172573100143
J	Chai, YH; Wu, LZ; Griffin, JD; Paulson, HL				Chai, YH; Wu, LZ; Griffin, JD; Paulson, HL			The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACHADO-JOSEPH-DISEASE; CREB-BINDING-PROTEIN; SCA1 TRANSGENIC MICE; HUNTINGTONS-DISEASE; EXPANDED POLYGLUTAMINE; MOUSE MODEL; GENE-PRODUCT; IN-VITRO; NEURODEGENERATIVE DISEASES; INTRANUCLEAR INCLUSIONS	Intracellular inclusions are a unifying feature of polyglutamine (polyQ) neurodegenerative diseases, yet each polyQ disease displays a unique pattern of neuronal degeneration. This implies that the protein context of expanded polyQ plays an important role in establishing selective neurotoxicity. Here, in studies of the spinocerebellar ataxia type 3 disease protein ataxia-3, we demonstrate that the protein sequence surrounding polyQ specifies the constituents of nuclear inclusions (NI) formed by the disease protein. The nuclear proteins cAMP response element-binding protein-binding protein (CBP) and Mastermind-like-1 strongly colocalize only to NI formed by full-length ataxia-3, whereas the splicing factor SC35 colocalizes only to NI formed by a polyQ-containing, carboxyl-terminal fragment of ataxia-3. These differences in NI formation reflect specific protein interactions normally undertaken by ataxia-3, as both normal and mutant full-length ataxia-3 co-immunoprecipitate with CBP and sediment on density gradients as macromolecular complexes. Moreover, normal ataxia-3 represses cAMP response element-binding protein-mediated transcription, indicating a functional consequence of ataxia-3 interactions with CBP. Finally, we show that mutant ataxia-3 forms insoluble intranuclear complexes, or MIL croaggregates, before NI can be detected, implying a precursor-product relationship. These results suggest that protein context-dependent recruitment of nuclear proteins to intranuclear microaggregates, and subsequently to NI, may contribute to selective neurotoxicity in polyQ diseases.	Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Iowa; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Paulson, HL (corresponding author), Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu			NINDS NIH HHS [NS38712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038712] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 1999, J NEUROSCI, V19, P10338; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Goodman RH, 2000, GENE DEV, V14, P1553; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Holbert S, 2001, P NATL ACAD SCI USA, V98, P1811, DOI 10.1073/pnas.041566798; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nayler O, 2000, J CELL BIOL, V150, P949, DOI 10.1083/jcb.150.5.949; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perez MK, 1999, HUM MOL GENET, V8, P2377, DOI 10.1093/hmg/8.13.2377; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SANDOU F, 1998, CELL, V95, P55; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tait D, 1998, HUM MOL GENET, V7, P991, DOI 10.1093/hmg/7.6.991; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yasuda S, 1999, GENES CELLS, V4, P743, DOI 10.1046/j.1365-2443.1999.00294.x; Zhu QZ, 2001, CANCER RES, V61, P64; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	55	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44889	44897		10.1074/jbc.M106575200	http://dx.doi.org/10.1074/jbc.M106575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572863	hybrid			2022-12-27	WOS:000172406700075
J	Sohda, M; Misumi, Y; Yamamoto, A; Yano, A; Nakamura, N; Ikehara, Y				Sohda, M; Misumi, Y; Yamamoto, A; Yano, A; Nakamura, N; Ikehara, Y			Identification and characterization of a novel Golgi protein, GCP60, that interacts with the integral membrane protein giantin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; COILED-COIL PROTEINS; BREFELDIN-A; MOLECULAR CHARACTERIZATION; BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; GUANINE-NUCLEOTIDE; SECRETORY PROTEINS; MATRIX PROTEIN; DOMAIN	We demonstrated previously that the integral membrane protein giantin has the Golgi localization signal at the COOH-terminal cytoplasmic domain (Misumi, Y., Sohda, M., Tashiro, A., Sato, H., and Ikehara, Y. (2001) J Biol. Chem. 276, 6867-6873). In the present study, using this domain as bait in the yeast two-hybrid screening system, we identified a novel protein interacting with giantin. The 3.6-kilobase mRNA encoding a 528-amino acid protein of 60 kDa designated GCP60 was ubiquitously expressed and was especially abundant in the testis and ovary. Immunofluorescence and immunoelectron microscopy confirmed that GCP60 was co-localized with giantin in the Golgi complex. GCP60 was found to be a peripheral protein associated with the Golgi membrane, where a COOH-terminal domain of GCP60 interacts with the COOH-terminal cytoplasmic domain of giantin. Overexpression of the COON-terminal domain of GCP60 caused disassembly of the Golgi structure and blocked protein transport from the endoplasmic reticulum to the Golgi. Taken together, these results suggest that GCP60 is involved in the maintenance of the Golgi structure by interacting with giantin, affecting protein transport between the endoplasmic reticulum and the Golgi.	Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140180, Japan; Fukuoka Univ, Adv Mat Inst, Jonan Ku, Fukuoka 8140180, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan; Kanazawa Univ, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan	Fukuoka University; Fukuoka University; Kansai Medical University; Kanazawa University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140180, Japan.		Nakamura, Nobuhiro/F-7811-2011	Nakamura, Nobuhiro/0000-0002-8836-6714				Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Kragelund BB, 1999, BIOCHEMISTRY-US, V38, P2386, DOI 10.1021/bi982427c; LEE SC, 1993, J BIOL CHEM, V268, P12164; Lesa GM, 2000, J BIOL CHEM, V275, P2831, DOI 10.1074/jbc.275.4.2831; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Miller J.H., 1992, SHORT COURSE BACTERI, P74; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Misumi Y, 2001, J BIOL CHEM, V276, P6867, DOI 10.1074/jbc.M010121200; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Sohda M, 1998, J BIOL CHEM, V273, P5385, DOI 10.1074/jbc.273.9.5385; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Toki C, 1997, CELL STRUCT FUNCT, V22, P565, DOI 10.1247/csf.22.565; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; WEUDLER F, 2001, TRAFFIC, V2, P606; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	58	101	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45298	45306		10.1074/jbc.M108961200	http://dx.doi.org/10.1074/jbc.M108961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11590181	hybrid			2022-12-27	WOS:000172406700125
J	Spielhaupter, C; Schatzl, HM				Spielhaupter, C; Schatzl, HM			PrPC directly interacts with proteins involved in signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PRION PROTEIN; GROWTH-FACTOR RECEPTORS; SYNAPSIN-I; SCRAPIE ISOFORM; SYNTHETIC PEPTIDES; SYNAPTIC FUNCTION; SH3 DOMAIN; BINDING; MICE; CELLS	The cellular prion protein (PrPc) is a conserved glycoprotein predominantly expressed in neuronal cells. Its purpose in living cells is still enigmatic. To elucidate on its cellular function, we performed a yeast two-hybrid screen for interactors. We used murine PrPc (amino acids 23-231) as bait to search a mouse brain cDNA expression library. Several interaction partners were identified. Three of them with a high homology to known sequences were further characterized. These candidates were the neuronal phosphoprotein synapsin Ib, the adaptor protein Grb2, and the still uncharacterized prion interactor Pint1. The in vivo interaction of the three proteins with PrPc was confirmed by co-immunoprecipitation assays with recombinant and authentic proteins in mammalian cells. The binding regions were mapped using truncated PrP constructs. As both synapsin Ib and Grb2 are implicated in neuronal signaling processes, our findings further strengthen the putative role of the prion protein in signal transduction.	Univ Munich, Gene Ctr Munich, Dept Virol, Max von Pettenkofer Inst, D-81377 Munich, Germany	University of Munich	Schatzl, HM (corresponding author), Univ Munich, Gene Ctr Munich, Dept Virol, Max von Pettenkofer Inst, Feodor Lynen Str 25, D-81377 Munich, Germany.	schaetzl@lmb.uni-muenchen.de	Schatzl, Hermann/G-4958-2011	Schatzl, Hermann/0000-0003-4972-8740				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CLINTON J, 1993, NEUROREPORT, V4, P65, DOI 10.1097/00001756-199301000-00017; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; Gohel C, 1999, J NEUROSCI RES, V55, P261, DOI 10.1002/(SICI)1097-4547(19990115)55:2<261::AID-JNR14>3.0.CO;2-I; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HARPER JW, 1993, CELL, V75, P805; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Matsumoto K, 1999, J BIOL CHEM, V274, P2053, DOI 10.1074/jbc.274.4.2053; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Meyer RK, 2000, J BIOL CHEM, V275, P38081, DOI 10.1074/jbc.M007114200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; Negro A, 2000, BIOCHEM BIOPH RES CO, V271, P337, DOI 10.1006/bbrc.2000.2628; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130	57	180	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44604	44612		10.1074/jbc.M103289200	http://dx.doi.org/10.1074/jbc.M103289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571277	hybrid			2022-12-27	WOS:000172406700037
J	Sun, P; Loh, HH				Sun, P; Loh, HH			Transcriptional regulation of mouse delta-opioid receptor gene - Role of Ets-1 in the transcriptional activation of mouse delta-opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROENKEPHALIN MESSENGER-RNA; DNA-BINDING MOTIF; FACTOR USF; AUTO-INHIBITION; NG108-15 CELLS; CORE PROMOTER; MURINE ETS-1; ADULT-RAT; T-CELLS; EXPRESSION	Previously, we identified a minimum core promoter of the mouse delta -opioid receptor (DOR) gene. The DOR promoter contains an E-box that binds upstream stimulatory factor and is crucial for the DOR promoter activity in NS20Y cells, a mouse neuronal cell line that constitutively expresses DOR. In the present study, we further analyzed the DOR promoter in NS20Y cells and have demonstrated that transcription factor Ets-1 binds to an Ets-1-binding site overlapping the E-box and trans-activates the DOR promoter by synergizing with upstream stimulatory factor in specific DNA binding. In addition, the Ets-1 DNA-binding domain is sufficient to play the functional role of Ets-1 in trans-activating the DOR promoter. Furthermore, through in vivo cross-linking assays and Northern blot analyses, we have demonstrated that Ets-1 binds to the DOR promoter in the neonatal mouse brain and that overexpressed Ets-1 can significantly enhance the expression of DOR mRNA in primary neonatal mouse neuronal cells. Collectively, our data suggest that Ets-1 functions as a trans-activator of the DOR promoter in the neonatal mouse brain and thus may contribute to the development of the mouse brain DOR system.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Sun, P (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NIDA NIH HHS [DA-01583, DA-11806, DA-00546, KO5-DA-70554] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, K05DA070554, R37DA001583, R01DA001583] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABOOD ME, 1995, J PHARMACOL EXP THER, V274, P1566; Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Beczkowska IW, 1996, BRAIN RES BULL, V39, P193, DOI 10.1016/0361-9230(95)02104-3; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRANN A W JR, 1977, Clinics in Perinatology, V4, P149; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHARNESS ME, 1993, MOL PHARMACOL, V44, P1119; Cowley DO, 2000, GENE DEV, V14, P366; Dang W, 1998, MOL CELL BIOL, V18, P1477, DOI 10.1128/MCB.18.3.1477; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; El-Khodor BF, 2000, BEHAV BRAIN RES, V107, P171, DOI 10.1016/S0166-4328(99)00119-9; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Gylys KH, 1997, NEUROREPORT, V8, P2369, DOI 10.1097/00001756-199707070-00053; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOSEN MD, 1996, MOL CELL BIOL, V16, P2065; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIMBERLY P, 1994, J PHARMACOL EXP THER, V268, P683; KIMBERLY P, 1994, J PHARMACOL EXP THER, V268, P74; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1689; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Liu HC, 1999, J BIOL CHEM, V274, P23617, DOI 10.1074/jbc.274.33.23617; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mayfield KP, 1996, NEUROSCIENCE, V72, P785, DOI 10.1016/0306-4522(95)00585-4; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SACCHI N, 1991, ONCOGENE, V6, P2149; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SMIRNOV D, 1993, MOL PHARMACOL, V60, P331; Thorlin T, 1999, GLIA, V25, P370, DOI 10.1002/(SICI)1098-1136(19990215)25:4<370::AID-GLIA6>3.0.CO;2-J; Tian G, 1999, MOL CELL BIOL, V19, P2946; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1990, ONCOGENESIS; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; YAVIN Z, 1977, EXP BRAIN RES, V29, P137; ZAGON IS, 1983, SCIENCE, V221, P1179, DOI 10.1126/science.6612331; ZAGON IS, 1994, MOL BRAIN RES, V21, P85, DOI 10.1016/0169-328X(94)90381-6; ZAGON IS, 1995, MOL BRAIN RES, V33, P111, DOI 10.1016/0169-328X(95)00119-D; Zawia NH, 1998, DEV BRAIN RES, V107, P291, DOI 10.1016/S0165-3806(98)00023-6; Zhu YX, 1998, J NEUROSCI, V18, P2538	59	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45462	45469		10.1074/jbc.M104793200	http://dx.doi.org/10.1074/jbc.M104793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11583993	hybrid			2022-12-27	WOS:000172406700144
J	van der Vliet, HN; Sammels, MG; Leegwater, ACJ; Levels, JHM; Reitsma, PH; Boers, W; Chamuleau, RAFM				van der Vliet, HN; Sammels, MG; Leegwater, ACJ; Levels, JHM; Reitsma, PH; Boers, W; Chamuleau, RAFM			Apolipoprotein A-V - A novel apolipoprotein associated with an early phase of liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED H-35 CELLS; FACTOR-KAPPA-B; MESSENGER-RNA; PROTEIN SECRETION; GENE-EXPRESSION; DEFICIENT MICE; 3T3 CELLS; IV GENE; C-III; RAT	Liver regeneration in response to various forms of liver injury is a complex process, which ultimately results in restoration of the original liver mass and function. Because the underlying mechanisms that initiate this response are still incompletely defined, this study was aimed to identify novel factors. Liver genes that were up-regulated 6 h after 70% hepatectomy (PHx) in the rat were selected by cDNA subtractive hybridization. Besides known genes associated with cell proliferation, several novel genes were isolated. The novel gene that was most up-regulated was further studied. Its mRNA showed a liver-specific expression and encoded a protein comprising 367 amino acids. The mouse and human cDNA analogues were also isolated and appeared to be highly homologous. The human gene analogue was located at an apolipoprotein gene cluster on chromosome 11q23. The protein encoded by this gene had appreciable homology with apolipoproteins A-I and A-IV. Maximal expression of the gene in the rat liver and its gene product in rat plasma was observed 6 h after PHx. The protein was present in plasma fractions containing high density lipoprotein particles. Therefore, we have identified a novel apolipoprotein, designated apolipoprotein A-V, that is associated with an early phase of liver regeneration.	Univ Amsterdam, Acad Med Ctr, Dept Expt Hepatol, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Chamuleau, RAFM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Room C2-331,POB 22660, NL-1100 DD Amsterdam, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BOGUSKI MS, 1984, P NATL ACAD SCI-BIOL, V81, P5021, DOI 10.1073/pnas.81.16.5021; CAPUTI M, 1995, NUCLEIC ACIDS RES, V23, P238, DOI 10.1093/nar/23.2.238; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DALLINGATHIE GM, 1985, J LIPID RES, V26, P970; Davies C, 1998, J MOL BIOL, V279, P873, DOI 10.1006/jmbi.1998.1780; DRAGANI TA, 1987, CANCER RES, V47, P795; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto Nelson, 1994, P1059; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; GOYETTE M, 1983, SCIENCE, V219, P510, DOI 10.1126/science.6297003; GROEN AK, 1995, GASTROENTEROLOGY, V109, P1997, DOI 10.1016/0016-5085(95)90768-8; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HELPS NR, 1995, GENE, V162, P245, DOI 10.1016/0378-1119(95)00356-B; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Jensen LE, 1998, BIOCHEM J, V334, P489, DOI 10.1042/bj3340489; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Kurumiya Y, 2000, J HEPATOL, V32, P636, DOI 10.1016/S0168-8278(00)80226-3; Lambotte L, 1997, AM J PHYSIOL-GASTR L, V273, pG905, DOI 10.1152/ajpgi.1997.273.4.G905; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Levels JHM, 2001, INFECT IMMUN, V69, P2821, DOI 10.1128/IAI.69.5.2821-2828.2001; LU XP, 1992, J BIOL CHEM, V267, P2841; Metzger S, 1996, EUR J CLIN INVEST, V26, P71, DOI 10.1046/j.1365-2362.1996.00100.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; RABES H, 1970, VIRCHOWS ARCH B, V6, P302; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Sakaguchi M, 1997, CURR OPIN BIOTECH, V8, P595, DOI 10.1016/S0958-1669(97)80035-3; Sambrook J., 2002, MOL CLONING LAB MANU; Scriver C. R., 2000, METABOLIC MOL BASES; Starkel P, 1999, HEPATOLOGY, V29, P1463, DOI 10.1002/hep.510290503; TANAHASHI T, 1995, J BIOCHEM-TOKYO, V118, P355, DOI 10.1093/oxfordjournals.jbchem.a124914; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON NL, 1986, CANCER RES, V46, P3111; VanKempen MJA, 1996, CARDIOVASC RES, V32, P886; Voshol PJ, 1998, GASTROENTEROLOGY, V114, P1024, DOI 10.1016/S0016-5085(98)70323-3; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679; WOLLENBERG GK, 1991, INT J CANCER, V47, P311, DOI 10.1002/ijc.2910470223; Wu CG, 1997, CARCINOGENESIS, V18, P47, DOI 10.1093/carcin/18.1.47; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	49	237	251	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44512	44520		10.1074/jbc.M106888200	http://dx.doi.org/10.1074/jbc.M106888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577099	hybrid			2022-12-27	WOS:000172406700024
J	Koh, SD; Monaghan, K; Sergeant, GP; Ro, S; Walker, RL; Sanders, KM; Horowitz, B				Koh, SD; Monaghan, K; Sergeant, GP; Ro, S; Walker, RL; Sanders, KM; Horowitz, B			TREK-1 regulation by nitric oxide and cGMP-dependent protein kinase - An essential role in smooth muscle inhibitory neurotransmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE PROXIMAL COLON; RECTIFIER K+ CHANNEL; POTASSIUM CHANNELS; GUANYLATE-CYCLASE; MEMBRANE STRETCH; FATTY-ACIDS; CELLS; ACTIVATION; ARTERY; EXPRESSION	Potassium channels activated by membrane stretch may contribute to maintenance of relaxation of smooth muscle cells in visceral hollow organs. Previous work has identified K+ channels in murine colon that are activated by stretch and further regulated by NO-dependent mechanisms. We have screened murine gastrointestinal, vascular, bladder, and uterine smooth muscles for the expression of TREK and TRAAK mRNA. Although TREK-1 was expressed in many of these smooth muscles, TREK-2 was expressed only in murine antrum and pulmonary artery. TRAAK was not expressed in any smooth muscle cells tested. Whole cell currents from TREK-1 expressed in mammalian COS cells were activated by stretch, and single channel re cordings showed that the stretch-dependent conductance was due to 90 pS channels. Sodium nitroprusside (10(-6) or 10(-5) M) and 8-Br-cGMP (10(-4) or 10(-3) M) increased TREK-1 currents in perforated whole cell and single channel recordings. Mutation of the PKG consensus sequence at serine 351 blocked the stimulatory effects of sodium nitroprusside and 8-Br-cGMP on open probability without affecting the inhibitory effects of 8-Br-cAMP. TREK-1 encodes a component of the stretch-activated K+ conductance in smooth muscles and may contribute to nitrergic inhibition of gastrointestinal muscles.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Horowitz, B (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA.			Ro, Seungil/0000-0003-0861-8334; Sergeant, Gerard/0000-0001-9443-5491	NHLBI NIH HHS [HL 49254] Funding Source: Medline; NIDDK NIH HHS [DK 41315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049254, R01HL049254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; DALZIEL HH, 1991, AM J PHYSIOL, V260, pG789, DOI 10.1152/ajpgi.1991.260.5.G789; DOPICO AM, 1994, AM J HYPERTENS, V7, P82, DOI 10.1093/ajh/7.1.82; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Edwards G, 1996, BRIT J PHARMACOL, V119, P691, DOI 10.1111/j.1476-5381.1996.tb15728.x; Epperson A, 1999, AM J PHYSIOL-GASTR L, V277, pG127, DOI 10.1152/ajpgi.1999.277.1.G127; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Franck H, 1997, BRIT J PHARMACOL, V122, P1223, DOI 10.1038/sj.bjp.0701487; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; HART PJ, 1993, P NATL ACAD SCI USA, V90, P9659, DOI 10.1073/pnas.90.20.9659; Horowitz B, 1999, ANNU REV PHYSIOL, V61, P19, DOI 10.1146/annurev.physiol.61.1.19; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; Koh SD, 1996, PFLUG ARCH EUR J PHY, V432, P401, DOI 10.1007/s004240050151; Koh SD, 2001, J PHYSIOL-LONDON, V533, P155, DOI 10.1111/j.1469-7793.2001.0155b.x; Koh SD, 1995, J PHYSIOL-LONDON, V489, P735, DOI 10.1113/jphysiol.1995.sp021087; KRISHNAN BR, 1991, NUCLEIC ACIDS RES, V19, P1153, DOI 10.1093/nar/19.5.1153; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; ORDWAY RW, 1995, J PHYSIOL-LONDON, V484, P331, DOI 10.1113/jphysiol.1995.sp020668; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Rajan S, 2001, J BIOL CHEM, V276, P7302, DOI 10.1074/jbc.M008985200; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Sausbier M, 2000, CIRC RES, V87, P825, DOI 10.1161/01.RES.87.9.825; Shuttleworth CWR, 1999, BRIT J PHARMACOL, V127, P1495, DOI 10.1038/sj.bjp.0702674; Vogalis F, 1997, J PHYSIOL-LONDON, V502, P497, DOI 10.1111/j.1469-7793.1997.497bj.x; Zygmunt PM, 1997, BRIT J PHARMACOL, V121, P141, DOI 10.1038/sj.bjp.0701108	34	115	120	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44338	44346		10.1074/jbc.M108125200	http://dx.doi.org/10.1074/jbc.M108125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11560940	hybrid			2022-12-27	WOS:000172297700107
J	Zhang, WH; Srihari, R; Day, RN; Schaufele, F				Zhang, WH; Srihari, R; Day, RN; Schaufele, F			CCAAT/enhancer-binding protein alpha alters histone H3 acetylation at large subnuclear domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; CENTROMERIC HETEROCHROMATIN; CHROMATIN STRUCTURE; MAMMALIAN-CELLS; TRANSCRIPTION; ORGANIZATION; LOCALIZATION; ACTIVATION; GENES; SUFFICIENT	Transcriptional regulation is commonly associated with local levels of histone acetylation, which controls chromatin structure at specific genes or within contiguous chromosomal domains. Less well understood are the higher order determinants of histone acetylation. The transcription factor, CCAAT/enhancer-binding protein alpha (C/EBP alpha), concentrates at one higher order structure, the peri-centromeric chromatin, and regulates differentiation in many cell types, including pituitary cells. We used quantitative fluorescence microscopy to show that immunostained acetylated histone H3 is relatively absent from peri-centromeric domains visible as large structures in mouse pituitary progenitor GHFT1-5 cells. GHFT1-5 cells do not contain C/EBP alpha. We observed that expression of C/EBP alpha in GHFT1-5 cells leads to an increased level of acetylated historic H3, but not acetylated historic H4, at the peri-centromeric domains. Only transcriptionally active forms of C/EBP alpha altered histone acetylation at the peri-centromeric domain. The altered state of histone acetylation at large intranuclear domains may complement, counteract, or supercede the more gene-local activities of other transcription factors to coordinate C/EBP alpha -induced cellular differentiation.	Univ Calif San Francisco, Diabet Ctr, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Natl Sci Fdn Ctr Biol Timing, Charlottesville, VA 22908 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia	Schaufele, F (corresponding author), Univ Calif San Francisco, Diabet Ctr, Metab Res Unit, San Francisco, CA 94143 USA.				NIDDK NIH HHS [R01 DK054345-02, DK54345] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; EARNSHAW WC, 1991, COLD SH Q B, V56, P675; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; He D, 1996, J CELL SCI, V109, P2693; Hendzel MJ, 1998, MOL BIOL CELL, V9, P2491, DOI 10.1091/mbc.9.9.2491; Hendzel MJ, 2001, J STEROID BIOCHEM, V76, P9, DOI 10.1016/S0960-0760(00)00153-9; Jacob KK, 1999, ENDOCRINOLOGY, V140, P4542, DOI 10.1210/en.140.10.4542; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schubeler D, 2000, GENE DEV, V14, P940; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	32	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40373	40376		10.1074/jbc.C100505200	http://dx.doi.org/10.1074/jbc.C100505200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11568179	hybrid			2022-12-27	WOS:000171925600002
J	Harbers, M; Nomura, T; Ohno, S; Ishii, S				Harbers, M; Nomura, T; Ohno, S; Ishii, S			Intracellular localization of the Ret finger protein depends on a functional nuclear export signal and protein kinase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; PML-RAR-ALPHA; LEPTOMYCIN B; TRANSFORMING GENE; MAP-KINASE; TRANSPORT; RECEPTOR; INTERACTS; BINDING; IMPORT	The Ret finger protein (RFP) was identified initially as an oncogene product and belongs to a family of proteins that contain a tripartite motif consisting of a RING finger, a B box, and a coiled-coil domain. RFP represses transcription by interacting with Enhancer of Polycomb and is localized to the cytoplasm or nucleus depending on the cell type. Here, we have identified the nuclear export signal (NES) located in the coiled-coil region of RFP. Mutation of this NES or treatment with leptomycin B abrogated the nuclear export of RFP in NIH3T3 cells. In addition, fusion of this NES to other nuclear proteins, such as yeast transcription factor Gal4, resulted in their release into the cytoplasm of NIH3T3 cells. Although the NES function of RFP in HepG2 cells is masked by another domain in RFP or by another protein, 12-O-tetradecanoylphorbol-13-acetate treatment or overexpression of constitutively active protein kinase C alpha (PKC alpha) abrogated masking, leading to the cytoplasmic localization of RFP. Furthermore, treatment of NIH3T3 cells with PKC inhibitors blocked the function of NES, resulting in nuclear localization of RFP. Thus, the nuclear export of RFP is regulated positively by PKC activation. However, RFP was not a direct substrate of PKC, and additional signaling pathways may be involved in the regulation of nuclear export of RFP.	RIKEN Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, CREST Project, Tsukuba, Ibaraki 3050074, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan	RIKEN; Japan Science & Technology Agency (JST); Yokohama City University	Ishii, S (corresponding author), RIKEN Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ohno, Shigeo/B-1768-2010; Ishii, Shunsuke/A-5271-2016	Ohno, Shigeo/0000-0002-1294-5269; Ishii, Shunsuke/0000-0002-6530-2478; Harbers, Matthias/0000-0002-5613-7220				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BORNER C, 1992, J BIOL CHEM, V267, P12900; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; Cao TY, 1996, DEV GENET, V19, P309, DOI 10.1002/(SICI)1520-6408(1996)19:4<309::AID-DVG4>3.3.CO;2-1; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Douarin BL, 1996, EMBO J, V15, P6701; DOUARIN BL, 1995, EMBO J, V14, P2020; DOUARIN BL, 1995, NUCLEIC ACIDS RES, V23, P876; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FANDREY J, 1994, EUR J BIOCHEM, V226, P335, DOI 10.1111/j.1432-1033.1994.tb20057.x; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; HALLER H, 1994, HYPERTENSION, V23, P848, DOI 10.1161/01.HYP.23.6.848; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hasegawa N, 1996, BIOCHEM BIOPH RES CO, V225, P627, DOI 10.1006/bbrc.1996.1221; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schmalz D, 1998, J CELL SCI, V111, P1823; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; STUNNENBERG HG, 1998, BIOCHIM BIOPHYS ACTA, V1423, pF15; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; THE H, 1991, CELL, V66, P675; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zini N, 1997, EUR J CELL BIOL, V72, P142	64	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48596	48607		10.1074/jbc.M108077200	http://dx.doi.org/10.1074/jbc.M108077200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11591718	hybrid			2022-12-27	WOS:000172927000115
J	Gregson, HC; Schmiesing, JA; Kim, JS; Kobayashi, T; Zhou, S; Yokomori, K				Gregson, HC; Schmiesing, JA; Kim, JS; Kobayashi, T; Zhou, S; Yokomori, K			A potential role for human cohesin in mitotic spindle aster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; NUCLEAR MATRIX; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; YEAST COHESIN; SMC PROTEINS; CELL-CYCLE; COMPLEX; NUMA; IDENTIFICATION	The cohesin multiprotein complex containing SMC1, SMC3, Scc3 (SA), and Scc1 (1Rad2l) is required for sister chromatid cohesion in eukaryotes. Although metazoan cohesin associates with chromosomes and was shown to function in the establishment of sister chromatid cohesion during interphase, the majority of cohesin was found to be off chromosomes and reside in the cytoplasm in metaphase. Despite its dissociation from chromosomes, however, microinjection of an antibody against human SMC1 led to disorganization of the metaphase plate and cell cycle arrest, indicating that human cohesin still plays an important role in metaphase. To address the mitotic function of human cohesin, the subcellular localization of cohesin components was reexamined in human cells. Interestingly, we found that cohesin localizes to the spindle poles during mitosis and interacts with NuMA, a spindle pole-associated factor required for mitotic spindle organization. The interaction with NuMA persists during interphase. Similar to NuMA, a significant amount of cohesin was found to associate with the nuclear matrix. Furthermore, in the absence of cohesin, mitotic spindle asters failed to form in vitro. Our results raise the intriguing possibility that in addition to its well demonstrated function in sister chromatid cohesion, cohesin may be involved in spindle assembly during mitosis.	Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Irvine; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Yokomori, K (corresponding author), Univ Calif Irvine, Coll Med, Dept Biol Chem, 240D Mod Sci 1, Irvine, CA 92697 USA.			Kobayashi, Toshiki/0000-0001-6158-9670	NIGMS NIH HHS [GM 59150] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059150] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; COMPTON DA, 1995, J CELL SCI, V108, P621; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Hsu HL, 1996, J CELL SCI, V109, P277; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Shimizu K, 1998, J BIOL CHEM, V273, P6591, DOI 10.1074/jbc.273.12.6591; SUMARA I, 2000, J CELL BIOL; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zheng L, 1999, MOL CELL BIOL, V19, P5417	38	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47575	47582		10.1074/jbc.M103364200	http://dx.doi.org/10.1074/jbc.M103364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590136	hybrid			2022-12-27	WOS:000172768500117
J	Appa, RS; Shin, CG; Lee, P; Chow, SA				Appa, RS; Shin, CG; Lee, P; Chow, SA			Role of the nonspecific DNA-binding region and alpha helices within the core domain of retroviral integrase in selecting target DNA sites for integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AVIAN-SARCOMA VIRUS; PHOTO-CROSS-LINKING; N-TERMINAL DOMAIN; HIV-1 INTEGRASE; TYPE-1 INTEGRASE; VIRAL-DNA; IN-VITRO; ESCHERICHIA-COLI; RESTRICTION ENDONUCLEASES	Retroviral integrase plays an import-ant role in choosing host chromosomal sites for integration of the cDNA copy of the viral genome. The domain responsible for target site selection has been previously mapped to the central core of the protein (amino acid residues 49-238). Chimeric integrases between human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus (FIV) were prepared to examine the involvement of a nonspecific DNA-binding region (residues 213-266) and certain a helices within the core domain in target site selection. Determination of the distribution and frequency of integration events of the chimeric integrases narrowed the target site-specifying motif to within residues 49-187 and showed that alpha3 and alpha4 helices (residues 123-166) were not involved in target site selection. Furthermore, the chimera with the alpha2 helix (residues 118-121) of FIV identity displayed characteristic integration events from both HIV-1 and FIV integrases. The results indicate that the alpha2 helix plays a role in target site preference as either part of a larger or multiple target site-specifying motif.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, AIDS Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chow, SA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Inst Mol Biol, 23-133 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R01CA068859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA68859] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; Bor YC, 1996, VIROLOGY, V222, P283, DOI 10.1006/viro.1996.0422; Brannvall M, 1999, J MOL BIOL, V292, P53, DOI 10.1006/jmbi.1999.3048; Brown P.O., 1997, INTEGRATION RETROVIR, P161; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; Dorner LF, 1999, J MOL BIOL, V285, P1515, DOI 10.1006/jmbi.1998.2408; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Gerton JL, 1999, J BIOL CHEM, V274, P33480, DOI 10.1074/jbc.274.47.33480; Gerton JL, 1997, J BIOL CHEM, V272, P25809, DOI 10.1074/jbc.272.41.25809; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Goulaouic H, 1996, J VIROL, V70, P37, DOI 10.1128/JVI.70.1.37-46.1996; Harper AL, 2001, J VIROL, V75, P7756, DOI 10.1128/JVI.75.16.7756-7762.2001; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; Holmes-Son M L, 2001, Adv Genet, V43, P33, DOI 10.1016/S0065-2660(01)43003-3; HUGHES SH, 1978, CELL, V15, P1397, DOI 10.1016/0092-8674(78)90064-8; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katzman M, 1996, J VIROL, V70, P2598, DOI 10.1128/JVI.70.4.2598-2604.1996; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; Katzman M, 1998, J VIROL, V72, P1744, DOI 10.1128/JVI.72.3.1744-1753.1998; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KRUGER DH, 1995, GENE, V157, P165, DOI 10.1016/0378-1119(95)00699-7; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Lukacs CM, 2000, NAT STRUCT BIOL, V7, P134; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, P NATL ACAD SCI USA, V89, P9237, DOI 10.1073/pnas.89.19.9237; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Rhodes D, 1996, PHILOS T ROY SOC B, V351, P501, DOI 10.1098/rstb.1996.0048; Shibagaki Y, 1997, J BIOL CHEM, V272, P8361, DOI 10.1074/jbc.272.13.8361; Shibagaki Y, 1997, VIROLOGY, V230, P1, DOI 10.1006/viro.1997.8466; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; Skinner LM, 1998, J ACQ IMMUN DEF SYND, V19, P99, DOI 10.1097/00042560-199810010-00001; Su LHJ, 2001, J MOL BIOL, V306, P655, DOI 10.1006/jmbi.2000.4323; van den Ent FMI, 1999, J VIROL, V73, P3176, DOI 10.1128/JVI.73.4.3176-3183.1999; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P2433; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659; Zhou HB, 2001, J VIROL, V75, P1359, DOI 10.1128/JVI.75.3.1359-1370.2001	75	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45848	45855		10.1074/jbc.M107365200	http://dx.doi.org/10.1074/jbc.M107365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585830	hybrid			2022-12-27	WOS:000172573100048
J	Grosshans, H; Lecointe, F; Grosjean, H; Hurt, E; Simos, G				Grosshans, H; Lecointe, F; Grosjean, H; Hurt, E; Simos, G			Pus1p-dependent tRNA pseudouridinylation becomes essential when tRNA biogenesis is compromised in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEAR EXPORT; SYNTHASE PUS1P; SUBSTRATE-SPECIFICITY; NUCLEOPORIN MUTANTS; RIBOSOMAL-RNA; AMINOACYLATION; CLONING; GENES	Yeast Pus1p catalyzes the formation of pseudouridine (psi) at specific sites of several tRNAs, but its function is not essential for cell viability. We show here that Pus1p becomes essential when another tRNA: pseudouridine synthase, Pus4p, or the essential minor tRNA for glutamine are mutated. Strikingly, this mutant tRNA, which carries a mismatch in the T psiC arm, displays a nuclear export defect. Furthermore, nuclear export of at least one wild-type tRNA species becomes defective in the absence of Pus1p. Our data, thus, show that the modifications formed by Pus1p are essential when other aspects of tRNA biogenesis or function are compromised and suggest that impairment of nuclear tRNA export in the absence of Pus1p might contribute to this phenotype.	Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; CNRS, Lab Enzymol & Biochim Struct, UPR, F-91198 Gif Sur Yvette, France	Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Simos, G (corresponding author), Univ Thessaly, Biochem Lab, Sch Med, 22 Papakiriazi Str, Larisa 41222, Greece.		Ed Hurt, Dr./AAE-8874-2019; Simos, George/AAH-2596-2021; Grosshans, Helge/W-8931-2019	Ed Hurt, Dr./0000-0002-4535-8255; Grosshans, Helge/0000-0002-8169-6905; Lecointe, Francois/0000-0002-9596-2514; Simos, George/0000-0001-5453-3185				Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Arluison V, 1999, J MOL BIOL, V289, P491, DOI 10.1006/jmbi.1999.2789; Azad AK, 2001, MOL BIOL CELL, V12, P1381, DOI 10.1091/mbc.12.5.1381; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; BERGES T, 1994, EMBO J, V13, P3136, DOI 10.1002/j.1460-2075.1994.tb06612.x; Bjork Glenn R., 1995, P165; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; Charette M, 2000, IUBMB LIFE, V49, P341; Chen JG, 1999, RNA, V5, P409, DOI 10.1017/S1355838299981591; Chen JG, 2000, BIOCHEM J, V352, P465, DOI 10.1042/0264-6021:3520465; Davis DR., 1998, MODIFICATION EDITING, P85; EDELMAN I, 1991, EMBO J, V10, P1481, DOI 10.1002/j.1460-2075.1991.tb07668.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; Grosjean H, 1997, BIOCHIMIE, V79, P293, DOI 10.1016/S0300-9084(97)83517-1; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; Grosshans H, 2000, GENE DEV, V14, P830; Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588; Hani J, 1998, NUCLEIC ACIDS RES, V26, P689, DOI 10.1093/nar/26.3.689; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hellmuth K, 2000, NUCLEIC ACIDS RES, V28, P4604, DOI 10.1093/nar/28.23.4604; HURT DJ, 1987, MOL CELL BIOL, V7, P1208, DOI 10.1128/MCB.7.3.1208; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; Jiang HQ, 1997, NUCLEIC ACIDS RES, V25, P2694, DOI 10.1093/nar/25.14.2694; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; LIN JP, 1986, GENE, V49, P383, DOI 10.1016/0378-1119(86)90375-6; Lipowsky G, 1999, RNA, V5, P539, DOI 10.1017/S1355838299982134; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Meroueh M, 2000, NUCLEIC ACIDS RES, V28, P2075, DOI 10.1093/nar/28.10.2075; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Murray LE, 1998, P NATL ACAD SCI USA, V95, P8619, DOI 10.1073/pnas.95.15.8619; Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Sambrook J., 2002, MOL CLONING LAB MANU; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Sharma K, 1996, MOL CELL BIOL, V16, P294; SIKORSKI RS, 1989, GENETICS, V122, P19; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WEISS WA, 1987, P NATL ACAD SCI USA, V84, P8031, DOI 10.1073/pnas.84.22.8031; Winkler ME, 1998, MODIFICATION EDITING, P441; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	50	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46333	46339		10.1074/jbc.M107141200	http://dx.doi.org/10.1074/jbc.M107141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571299	Green Published, hybrid			2022-12-27	WOS:000172573100115
J	Kamitani, T; Kito, K; Fukuda-Kamitani, T; Yeh, ETH				Kamitani, T; Kito, K; Fukuda-Kamitani, T; Yeh, ETH			Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CUL-1; UBIQUITIN; IDENTIFICATION; PROTEINS; SUBUNIT; DOMAIN	NEDD8 is a ubiquitin-like protein that controls vital biological events through its conjugation to cullin family members. Recently, we identified a negative regulator of the NEDD8 conjugation system, NUB1, which interacts with NEDD8 and down-regulates NEDD8 expression post-transcriptionally (Kito, K., Yeh, E. T. H., and Kamitani, T. (2001) J. Biol. Chem. 276, 20603-20609). Here, we show that NUB1 possesses a ubiquitin-like domain at the N-terminal region and binds to S5a of the 19 S proteasome activator (PA700). A GST pull-down assay revealed that the overexpression of NUB1 leads to a greater precipitation of NEDD8 conjugates with GST-S5a, suggesting that NUB1 might have an adaptor function between S5a and NEDD8. Furthermore, proteasome inhibitors completely block NUB1-mediated down-regulation of NEDD8 expression. These results suggest that NUB1 recruits NEDD8 and its conjugates to the proteasome for degradation, providing a direct functional link between the NEDD8 conjugation system and the proteasomal degradation pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Kamitani, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, 1515 Holcombe Blvd,Box 449, Houston, TX 77030 USA.	tkamitani@mdanderson.org	Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056298] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56298] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Wada H, 2000, J BIOL CHEM, V275, P17008, DOI 10.1074/jbc.275.22.17008; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	25	111	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46655	46660		10.1074/jbc.M108636200	http://dx.doi.org/10.1074/jbc.M108636200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585840	hybrid			2022-12-27	WOS:000172573100153
J	Kischkel, FC; Lawrence, DA; Tinel, A; LeBlanc, H; Virmani, A; Schow, P; Gazdar, A; Blenis, J; Arnott, D; Ashkenazi, A				Kischkel, FC; Lawrence, DA; Tinel, A; LeBlanc, H; Virmani, A; Schow, P; Gazdar, A; Blenis, J; Arnott, D; Ashkenazi, A			Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; TNF RECEPTOR; CELL-DEATH; MEDIATED APOPTOSIS; SIGNALING COMPLEX; DECOY RECEPTORS; DOMAIN; FAS; FADD; PROTEIN	Caspase-8 is believed to play an obligatory role in apoptosis initiation by death receptors, but the role of its structural relative, caspase-10, remains controversial. Although earlier evidence implicated caspase-10 in apoptosis signaling by CD95L and Apo2L/TRAIL, recent studies indicated that these death receptor ligands recruit caspase-8 but not caspase-10 to their death-inducing signaling complex (DISC) even in presence of abundant caspase-10. We characterized a series of caspase-10-specific antibodies and found that certain commercially available antibodies cross-react with HSP60, shedding new light on previous results. The majority of 55 lung and breast carcinoma cell lines expressed mRNA for both caspase-8 and -10; however, immunoblot analysis revealed that caspase-10 protein expression was more frequently absent than that of caspase-8, suggesting a possible selective pressure against caspase-10 production in cancer cells. In nontransfected cells expressing both caspases, CD95L and Apo2L/TRAIL recruited endogenous caspase-10 as well as caspase-8 to their DISC, where both enzymes were proteolytically processed with similar kinetics. Caspase-10 recruitment required the adaptor FADD/ Mort1, and caspase-10 cleavage in vitro required DISC assembly, consistent with the processing of an apoptosis initiator. Cells expressing only one of the caspases underwent ligand-induced apoptosis, indicating that each caspase can initiate apoptosis independently of the other. Thus, apoptosis signaling by death receptors involves not only caspase-8 but also caspase-10, and both caspases may have equally important roles in apoptosis initiation.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Cell Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Univ Texas, SW Med Sch, Dallas, TX 75390 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gelmini S, 1997, CLIN CHEM, V43, P752; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Gronbaek K, 2000, BLOOD, V95, P2184; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; ITOH N, 1993, J BIOL CHEM, V268, P10932; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 1998, CYTOGENET CELL GENET, V82, P95, DOI 10.1159/000015073; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Phelps RM, 1996, J CELL BIOCHEM, P32; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733	43	394	412	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46639	46646		10.1074/jbc.M105102200	http://dx.doi.org/10.1074/jbc.M105102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583996	hybrid			2022-12-27	WOS:000172573100151
J	Lau, PP; Villanueva, H; Kobayashi, K; Nakamuta, M; Chang, BHJ; Chan, L				Lau, PP; Villanueva, H; Kobayashi, K; Nakamuta, M; Chang, BHJ; Chan, L			A DnaJ protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; MESSENGER-RNA; J-DOMAIN; MOLECULAR CHAPERONES; SECONDARY STRUCTURE; 40-KDA PROTEIN; NMR STRUCTURE; RICH REGION; CLONING	Mammalian homologues of DnaJ proteins, also known as Hsp40 proteins, are co-chaperonins that complement Hsp70 chaperone function. Using the yeast two-hybrid system, we cloned an apolipoprotein (apo) B mRNA editing complementation protein, called apobec-1-binding protein-2 (ABBP-2), and found that it is a Class II DnaJ homologue. ABBP-2 binds to apobec-1, the mammalian apoB mRNA editase, via its J domain and neighboring G/F domain. It is a ubiquitously expressed protein, and, by transfection analysis of GFP-ABBP-2, we found that the protein is located in both the nucleus and cytosol of transfected cells, with predominance in the nucleus. Down-regulation of ABBP-2 expression in cultured cells inhibits endogenous apobec-1-mediated apoB mRNA editing. Like other Hsp40 proteins, ABBP-2 binds to Hsp70 and has ATPase-stimulating activity. Apobec-1-mediated apoB mRNA editing activity of in vitro tissue extracts requires the presence of Hsp70/ABBP-2. Although exogenously added ATP is not required for editing activity, removal of the endogenous ATP present in these extracts, which disrupts ABBP-2-Hsp70 interaction, completely inhibits editing. ABBP-2 differs from previously described auxiliary proteins (ABBP-1, ACF, and GRY-RBP) in that it does not contain any RNA recognition motifs. Not only is ABBP-2 required for efficient apoB mRNA editing, this newly discovered apobec-1-binding protein may help determine the subcellular distribution and trafficking of apobec-1 via its interaction with the chaperonin Hsp70.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.	lchan@bcm.tmc.edu	Villanueva, Helena/AAB-7911-2019; Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X	NHLBI NIH HHS [HL-56668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056668] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Chan L, 2000, RECENT PROG HORM RES, V55, P93; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CRAIG E, 1990, ANTON LEEUW INT J G, V58, P137, DOI 10.1007/BF00548924; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; HARPER JW, 1993, CELL, V75, P805; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; Hirano H, 1997, J LIPID RES, V38, P847; Huang K, 1999, PROTEIN SCI, V8, P203; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Mallouk Y, 1999, INT J MOL MED, V4, P463; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; OHTSUKA K, 1990, BIOCHEM BIOPH RES CO, V166, P642, DOI 10.1016/0006-291X(90)90857-J; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Teng BB, 1999, J LIPID RES, V40, P623; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Yan W, 1999, MOL CELL BIOL, V19, P7751; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	47	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46445	46452		10.1074/jbc.M109215200	http://dx.doi.org/10.1074/jbc.M109215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584023	hybrid			2022-12-27	WOS:000172573100129
J	Litterst, CM; Pfitzner, E				Litterst, CM; Pfitzner, E			Transcriptional activation by STAT6 requires the direct interaction with NCoA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; GERMLINE EPSILON-PROMOTER; CREB-BINDING PROTEIN; NF-KAPPA-B; DNA-BINDING; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; TYROSINE PHOSPHORYLATION; SYNERGISTIC ACTIVATION; INTERFERON ACTIVATION	Signal transducer and activator of transcription 6 (STAT6) is a transcription factor that is activated by interleukin-4 (IL-4)-induced tyrosine phosphorylation and mediates most of the IL-4-induced gene expression. Transcriptional activation by STAT6 requires the interaction with coactivators like p300 and the CREB-binding protein (CBP). In this study we have investigated the function of the CBP-associated members of the p160/ steroid receptor coactivator family in the transcriptional activation by STAT6. We found that only one of them, NCoA-1, acts as a coactivator for STAT6 and interacts directly with the transactivation domain of STAT6. The N-terminal part of NCoA-1 interacts with the far C-terminal part of the STAT6 transactivation domain but does not interact with the other members of the STAT family. This domain of NCoA-1 has a strong inhibitory effect on STAT6-mediated transactivation when overexpressed in cells, illustrating the importance of NCoA-1 for STAT6-mediated transactivation. In addition, we showed that both coactivators CBP and NCoA-1 bind independently to specific regions within the STAT6 transactivation domain. Our results suggest that multiple contacts between NCoA-1, CBP, and STAT6 are required for transcriptional activation. These findings provide new mechanistic insights into how STAT6 can recruit coactivators required for IL-4-dependent transactivation.	Inst Biomed Res, D-60596 Frankfurt, Germany		Pfitzner, E (corresponding author), Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.		Pfitzner, Edith/AAU-7927-2021	Pfitzner, Edith/0000-0002-3484-9649				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Goenka S, 1999, J IMMUNOL, V163, P4663; Goodman RH, 2000, GENE DEV, V14, P1553; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; LISCHKE A, 1995, EUR J BIOCHEM, V234, P100, DOI 10.1111/j.1432-1033.1995.100_c.x; Lu BF, 1997, J IMMUNOL, V159, P1255; LUNDGREN M, 1994, J IMMUNOL, V153, P2983; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Richards ML, 1997, J IMMUNOL, V158, P263; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Stutz AM, 1999, J IMMUNOL, V163, P4383; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WARREN WD, 1995, J IMMUNOL, V155, P5637; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	64	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45713	45721		10.1074/jbc.M108132200	http://dx.doi.org/10.1074/jbc.M108132200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574547	hybrid			2022-12-27	WOS:000172573100030
J	Liu, CJ; Dib-Hajj, SD; Black, JA; Greenwood, J; Lian, Z; Waxman, SG				Liu, CJ; Dib-Hajj, SD; Black, JA; Greenwood, J; Lian, Z; Waxman, SG			Direct interaction with contactin targets voltage-gated sodium channel Na(v)1.9/NaN to the cell membrane.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; PROMOTES NEURITE OUTGROWTH; RECOGNITION MOLECULE F11; FIBRONECTIN TYPE-III; TENASCIN-R; SENSORY NEURONS; PROTEIN CASPR; FUNCTIONAL EXPRESSION; TRANSCRIPTION FACTOR; PARANODAL JUNCTIONS	The mechanisms that target various sodium channels within different regions of the neuronal membrane, which they endow with different physiological properties, are not yet understood. To examine this issue we studied the voltage-gated sodium channel Na(v)1.9/NaN, which is preferentially expressed in small sensory neurons of dorsal root ganglia and trigeminal ganglia and the nonmyelinated axons that arise from them. Our results show that the cell adhesion molecule contactin binds directly to Na(v)1.9/NaN and recruits tenascin to the protein complex in vitro. Na(v)1.9/NaN and contactin coimmunoprecipitate from dorsal root ganglia and transfected Chinese hamster ovary cell line, and co-localize in the C-type neuron soma and along nonmyelinated C-fibers and at nerve endings in the skin. Co-transfection of Chinese hamster ovary cells with Na(v)1.9/NaN and contactin enhances the surface expression of the sodium channel over that of Na,1.9/NaN alone. Thus contactin binds directly to Na(v)1.9/NaN and participates in the surface localization of this channel along nonmyelinated axons.	Yale Univ, Sch Med, Dept Neurol, Neurosci Res Ctr,, New Haven, CT 06510 USA; Yale Univ, Sch Med, Paralyzed Vet Amer,Eastern Paralysed Vet Assoc, Neurosci Res Ctr, New Haven, CT 06510 USA; Transmol Inc, Birmingham, AL 35243 USA; Vet Affairs Connecticut Healthcare Syst, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06536 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Waxman, SG (corresponding author), Yale Univ, Sch Med, Dept Neurol, Neurosci Res Ctr,, 333 Cedar St,LCI 707, New Haven, CT 06510 USA.		Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177; liu, chuanju/0000-0002-7181-8032				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Amaya F, 2000, MOL CELL NEUROSCI, V15, P331, DOI 10.1006/mcne.1999.0828; Berglund EO, 1999, NEURON, V24, P739, DOI 10.1016/S0896-6273(00)81126-5; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Black JA, 1996, MOL BRAIN RES, V43, P117, DOI 10.1016/S0169-328X(96)00163-5; BLACK JA, 1988, PROC R SOC SER B-BIO, V233, P45, DOI 10.1098/rspb.1988.0011; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; BRUMMENDORF T, 1993, NEURON, V10, P711; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; CUNNINGHAM TP, 1993, GENE, V124, P93, DOI 10.1016/0378-1119(93)90766-V; Dib-Hajj SD, 1999, FEBS LETT, V462, P117, DOI 10.1016/S0014-5793(99)01519-7; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; DURBEC P, 1992, J CELL BIOL, V117, P877, DOI 10.1083/jcb.117.4.877; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; Fjell J, 1999, MOL BRAIN RES, V67, P267, DOI 10.1016/S0169-328X(99)00070-4; Fjell J, 2000, NEUROREPORT, V11, P199, DOI 10.1097/00001756-200001170-00039; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Herzog RI, 2001, J NEUROPHYSIOL, V86, P1351, DOI 10.1152/jn.2001.86.3.1351; HONMOU O, 1994, J NEUROPHYSIOL, V71, P1627, DOI 10.1152/jn.1994.71.5.1627; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PELLEGRINO RG, 1984, BRAIN RES, V305, P357, DOI 10.1016/0006-8993(84)90442-6; Perrin FE, 2001, NEURON, V30, P707, DOI 10.1016/S0896-6273(01)00315-4; Pesheva P, 2000, PROG NEUROBIOL, V61, P465, DOI 10.1016/S0301-0082(99)00061-1; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; Qu YS, 1999, J BIOL CHEM, V274, P32647, DOI 10.1074/jbc.274.46.32647; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; RITCHIE JM, 1977, P NATL ACAD SCI USA, V74, P211, DOI 10.1073/pnas.74.1.211; RIZZO MA, 1994, J NEUROPHYSIOL, V72, P2796, DOI 10.1152/jn.1994.72.6.2796; ROY ML, 1992, J NEUROSCI, V12, P2104; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; Sleeper AA, 2000, J NEUROSCI, V20, P7279; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; UNDROVINAS AI, 1995, AM J PHYSIOL-HEART C, V269, pH203, DOI 10.1152/ajpheart.1995.269.1.H203; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Volkmer H, 1998, J CELL BIOL, V142, P1083, DOI 10.1083/jcb.142.4.1083; Wang H, 2000, J BIOL CHEM, V275, P27377; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	70	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46553	46561		10.1074/jbc.M108699200	http://dx.doi.org/10.1074/jbc.M108699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581273	hybrid			2022-12-27	WOS:000172573100141
J	Perroy, J; Gutierrez, GJ; Coulon, V; Bockaert, J; Pin, JP; Fagni, L				Perroy, J; Gutierrez, GJ; Coulon, V; Bockaert, J; Pin, JP; Fagni, L			The C terminus of the metabotropic glutamate receptor subtypes 2 and 7 specifies the receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; CALCIUM-CHANNELS; GAMMA-SUBUNITS; CA2+ CHANNELS; MODULATION; PHOSPHORYLATION; ACTIVATION; EXPRESSION; NEURONS; INHIBITION	There is accumulating evidence that the specificity of the transduction cascades activated by G protein-coupled receptors cannot solely depend on the nature of the coupled G protein. To identify additional structural determinants, we studied two metabotropic glutamate (mGlu) receptors, the mGlu2 and mGlu7 receptors, that are both coupled to G. proteins but are known to affect different effectors in neurons. Thus, the mGlu2 receptor selectively blocks N- and L-type Ca2+ channels via a protein kinase C-independent pathway, whereas the mGlu7 receptor selectively blocks P/Q-type Ca2+ channels via a protein kinase C-dependent pathway, and both effects are pertussis toxin-sensitive. We examined the role of the C-terminal domain of these receptors in this coupling. Chimeras were constructed by exchanging the C terminus of these receptors and transfected into neurons. Different chimeric receptors bearing the C terminus of mGlu7 receptor blocked selectively P/Q-type Ca2+ channels, whereas chimeras bearing the C terminus of mGlu2 receptor selectively blocked N- and L-type Ca2+ channels. These results show that the C terminus of mGlu2 and mGlu7 receptors is a key structural determinant that allows these receptors to select a specific signaling pathway in neurons.	CNRS, UPR 9032, CCIPE, F-34000 Montpellier, France; EMBL, D-69117 Heidelberg, Germany; CNRS, UMR 5535, Inst Genet Mol Montpellier, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Fagni, L (corresponding author), CNRS, UPR 9032, CCIPE, 141 Rue Cardonille, F-34000 Montpellier, France.	fagni@bacchus.montp.inserm.fr	Coulon, Vincent/B-2437-2009; Pin, Jean-Philippe/Y-6668-2019; Gutierrez, Gustavo/AAO-9957-2021; Gutierrez, Gustavo/B-6771-2013; Coulon, Vincent/AFF-7934-2022	Coulon, Vincent/0000-0002-3168-8755; Pin, Jean-Philippe/0000-0002-1423-345X; Gutierrez, Gustavo/0000-0001-8652-972X; Gutierrez, Gustavo/0000-0003-4133-5002; Coulon, Vincent/0000-0002-3168-8755; perroy, julie/0000-0001-6199-0448				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; BOSS V, 1992, J NEUROCHEM, V59, P2340; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; CHAVIS P, 1994, J NEUROSCI, V14, P7067; CHAVIS P, 1995, NEUROPHARMACOLOGY, V34, P929, DOI 10.1016/0028-3908(95)00082-H; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Corti C, 1998, EUR J NEUROSCI, V10, P3629, DOI 10.1046/j.1460-9568.1998.00371.x; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; Dev KK, 2001, TRENDS PHARMACOL SCI, V22, P355, DOI 10.1016/S0165-6147(00)01684-9; Dev KK, 2000, J NEUROSCI, V20, P7252; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Ferraguti F, 1999, EUR J NEUROSCI, V11, P2073, DOI 10.1046/j.1460-9568.1999.00626.x; Flor PJ, 1997, NEUROPHARMACOLOGY, V36, P153, DOI 10.1016/S0028-3908(96)00176-1; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Garcia DE, 1998, J NEUROSCI, V18, P9163; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; Jeong SW, 1999, J NEUROSCI, V19, P4755; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Perroy J, 2000, J NEUROSCI, V20, P7896; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; PREZEAU L, 1994, MOL PHARMACOL, V45, P570; SAHARA Y, 1993, J NEUROSCI, V13, P3041; Shapiro MS, 1999, P NATL ACAD SCI USA, V96, P10899, DOI 10.1073/pnas.96.19.10899; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229	46	23	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45800	45805		10.1074/jbc.M106876200	http://dx.doi.org/10.1074/jbc.M106876200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584003	Green Published, hybrid			2022-12-27	WOS:000172573100041
J	Fujimoto, M; Poe, JC; Hasegawa, M; Tedder, TF				Fujimoto, M; Poe, JC; Hasegawa, M; Tedder, TF			CD19 amplification of B lymphocyte Ca2+ responses - A role for Lyn sequestration in extinguishing negative regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION MOLECULE; CYTOPLASMIC DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED ACTIVATION; CD22-DEFICIENT MICE; PHOSPHATASE 1C; CD22; COMPLEX	B lymphocyte antigen receptor (BCR) signals are regulated by CD19, with BCR-induced intracellular calcium ([Ca2+](i)) responses enhanced by CD19 co-ligation. In this study, CD19 engagement using a dimeric anti-CD19 antibody induced [Ca2+](i) mobilization and significantly enhanced BCR-induced [Ca2+](i) responses without a requirement for CD19/BCR co-ligation. Although simultaneous CD19 and BCR engagement significantly enhanced CD19/Lyn complex formation and [Ca2+](i) responses, downstream tyrosine phosphorylation of CD22 and multiple other cellular proteins was inhibited, as teas SHP1 recruitment to phosphorylated CD22. CD19 overexpression also enhanced BCR-induced [Ca2+](i) responses, but down-regulated tyrosine phosphorylation of CD22 and multiple other cellular proteins following BCR ligation. Because CD19 and Lyn expression are genetically titrated in B cells, CD19 engagement may augment BCR-induced [Ca2+](i) responses by sequestering the available pool of functional Lyn away from downstream negative regulatory proteins such as CD22. Consistent with this, simultaneous CD19 engagement did not further enhance the BCR-induced [Ca2+](i) responses of Lyn- or CD22-deficient B cells. Thus, CD19 recruitment of Lyn may preferentially activate selective signaling pathways downstream of the CD19/Lyn complex to the exclusion of other downstream regulatory and effector pathways. Other receptors may also utilize a similar strategy to regulate kinase availability and downstream intermolecular signaling.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Tedder, TF (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Box 3010, Durham, NC 27710 USA.			Poe, Jonathan/0000-0002-7789-1564; Fujimoto, Manabu/0000-0002-3062-4872	NATIONAL CANCER INSTITUTE [R55CA054464, R01CA054464, R01CA081776] Funding Source: NIH RePORTER; NCI NIH HHS [CA54464, CA81776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT TB, 1990, EUR J IMMUNOL, V20, P1053, DOI 10.1002/eji.1830200516; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; Buhl AM, 1999, J IMMUNOL, V162, P4438; Buhl AM, 1997, IMMUNOL REV, V160, P127, DOI 10.1111/j.1600-065X.1997.tb01033.x; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cherukuri A, 2001, IMMUNITY, V14, P169; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; de Fougerolles AR, 2001, EUR J IMMUNOL, V31, P2189, DOI 10.1002/1521-4141(200107)31:7<2189::AID-IMMU2189>3.0.CO;2-V; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Fujimoto M, 1998, SEMIN IMMUNOL, V10, P267, DOI 10.1006/smim.1998.9999; Hasegawa M, 2001, J IMMUNOL, V167, P3190, DOI 10.4049/jimmunol.167.6.3190; Hasegawa M, 2001, J IMMUNOL, V167, P2469, DOI 10.4049/jimmunol.167.5.2469; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Li XL, 1998, J IMMUNOL, V161, P5901; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; Poe JC, 2000, J BIOL CHEM, V275, P17420, DOI 10.1074/jbc.M001892200; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; RIGLEY KP, 1991, EUR J IMMUNOL, V21, P535, DOI 10.1002/eji.1830210302; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; Sato S, 2000, J IMMUNOL, V165, P6635, DOI 10.4049/jimmunol.165.11.6635; SATO S, 1995, P NATL ACAD SCI USA, V92, P11558, DOI 10.1073/pnas.92.25.11558; Sato S, 1997, J IMMUNOL, V159, P3278; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1997, J IMMUNOL, V158, P4662; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sato T, 1996, SUPRAMOL CHEM, V7, P157, DOI 10.1080/10610279608035192; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Somani AK, 2001, J BIOL CHEM, V276, P1938, DOI 10.1074/jbc.M006820200; Tedder TF, 1998, SEMIN IMMUNOL, V10, P259, DOI 10.1006/smim.1998.0118; TEDDER TF, 1989, J IMMUNOL, V143, P712; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; WENG WK, 1994, J BIOL CHEM, V269, P32514; ZHOU LJ, 1991, J IMMUNOL, V147, P1424; ZHOU LJ, 1994, MOL CELL BIOL, V14, P3884, DOI 10.1128/MCB.14.6.3884; Zipfel PA, 2000, J IMMUNOL, V165, P6872, DOI 10.4049/jimmunol.165.12.6872	66	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44820	44827		10.1074/jbc.M107559200	http://dx.doi.org/10.1074/jbc.M107559200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584010	hybrid			2022-12-27	WOS:000172406700066
J	Perez-Ferreiro, CM; Luque, CM; Correas, I				Perez-Ferreiro, CM; Luque, CM; Correas, I			4.1R proteins associate with interphase microtubules in human T cells - A 4.1R constitutive region is involved in tubulin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MEMBRANE SKELETAL PROTEIN-4.1; SPECTRIN-ACTIN BINDING; ERYTHROCYTE PROTEIN-4.1; STRUCTURAL PROTEIN-4.1; NONERYTHROID ISOFORM; MULTIPLE ISOFORMS; LEUCINE-ZIPPER; DOMAIN; INTERACTS	Red blood cell protein 4.1 (4.1R) is an 80-kDa protein that stabilizes the spectrin-actin network and anchors it to the plasma membrane. To contribute to the characterization of functional roles and partners of specific nonerythroid 4.1R isoforms, we analyzed 4.1R in human T cells and found that endogenous 4.1R was distributed to the microtubule network. Transfection experiments of T cell 4.1R cDNAs in conjunction with confocal microscopy analysis revealed the colocalization of exogenous 4.1R isoforms with the tubulin skeleton. Biochemical analyses using Taxol(R) (paclitaxel)-polymerized microtubules from stably transfected T cells confirmed the association of the exogenous 4.1R proteins with microtubules. Consistent with this, endogenous 4.1R immunoreactive proteins were also detected in the microtubule-containing fraction. In vitro binding assays using glutathione S-transferase-4.1R fusion proteins showed that a constitutive domain of the 4.1R molecule, one that is therefore present in all 4.1R isoforms, is responsible for the association with tubulin. A 22-amino acid sequence comprised in this domain and containing heptad repeats of leucine residues was essential for tubulin binding. Furthermore, ectopic expression of 4.1R in COS-7 cells provoked microtubule disorganization. Our results suggest an involvement of 4.1R in interphase microtubule architecture and support the hypothesis that some 4.1R functional activities are cell type-regulated.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Correas, I (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain.		Luque, Carlos M./Q-6043-2019; Luque, Carlos/H-6810-2015; Correas, Isabel/O-4061-2018	Luque, Carlos M./0000-0002-2993-4152; Luque, Carlos/0000-0002-2993-4152; Correas, Isabel/0000-0002-2286-186X				ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Charrasse S, 1998, J CELL SCI, V111, P1371; COHEN CM, 1982, NATURE, V299, P648, DOI 10.1038/299648a0; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; CORREAS I, 1988, BIOCHEM J, V255, P217; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DELAUNAY J, 1995, CRIT REV ONCOL HEMAT, V19, P79, DOI 10.1016/1040-8428(94)00139-K; DOMINGUEZ JE, 1994, J CELL SCI, V107, P601; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gascard P, 1998, BLOOD, V92, P4404, DOI 10.1182/blood.V92.11.4404.423k50_4404_4414; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; Han BG, 2000, NAT STRUCT BIOL, V7, P871; HORNE WC, 1993, BLOOD, V82, P2558; Hou CL, 2000, BLOOD, V96, P747; HUANG JP, 1993, J BIOL CHEM, V268, P3758; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Kontrogianni-Konstantopoulos A, 2000, MOL BIOL CELL, V11, P3805, DOI 10.1091/mbc.11.11.3805; Kontrogianni-Konstantopoulos A, 2001, J BIOL CHEM, V276, P20679, DOI 10.1074/jbc.M010581200; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1997, J CELL SCI, V110, P239; Lallena MJ, 1998, J CELL SCI, V111, P1963; LEE JK, 1988, CELL, V55, P807, DOI 10.1016/0092-8674(88)90136-5; Luque CM, 1998, J BIOL CHEM, V273, P11643, DOI 10.1074/jbc.273.19.11643; Luque CM, 1999, P NATL ACAD SCI USA, V96, P14925, DOI 10.1073/pnas.96.26.14925; Luque CM, 2000, J CELL SCI, V113, P2485; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PASTERNACK GR, 1989, P NATL ACAD SCI USA, V86, P9712, DOI 10.1073/pnas.86.24.9712; Pu WT, 1999, MOL CELL BIOL, V19, P4113; Ratner S, 1997, J IMMUNOL, V159, P1063; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Schischmanoff PO, 1997, J BIOL CHEM, V272, P10254, DOI 10.1074/jbc.272.15.10254; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673	52	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44785	44791		10.1074/jbc.M107369200	http://dx.doi.org/10.1074/jbc.M107369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579097	hybrid			2022-12-27	WOS:000172406700061
J	Samejima, K; Tone, S; Earnshaw, WC				Samejima, K; Tone, S; Earnshaw, WC			CAD/DFF40 nuclease is dispensable for high molecular weight DNA cleavage and stage I chromatin condensation in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENTATION FACTOR; TOPOISOMERASE-II; ENDONUCLEASE-G; ACTIVATION; INHIBITOR; CELLS; CAD; DEGRADATION; EXTRACTS; EXCISION	DNA degradation during apoptotic execution generally occurs at two levels: early as high molecular weight (HMW) fragments and later on as oligonucleosomal fragments. Two nucleases, CAD/CPAN/DFF40 and endonuclease G, can digest nuclear chromatin to produce the oligonucleosomal fragments, and it has been suggested that CAD might be responsible for HMW DNA cleavage. To more clearly define the role of CAD in nuclear disassembly, we have generated CAD(-/-) sublines of chicken DT40 cells in which the entire CAD open reading frame has been deleted. These cells grow normally and undergo apoptosis with kinetics essentially identical to wild type cells. However, they fail to undergo detectable oligonucleosomal fragmentation, proving that CAD is essential for this stage of DNA cleavage, at least in DT40 cells. Other aspects of nuclear disassembly, including HMW DNA cleavage and early stage apoptotic chromatin condensation against the nuclear periphery proceed normally in the absence of CAD. However, the final stages of chromatin condensation and nuclear fragmentation do not occur. Our results demonstrate that CAD is required for complete disassembly of the nucleus during apoptosis and reveal the existence of one or more as yet unidentified second factors responsible for HMW DNA cleavage and the early stages of apoptotic chromatin condensation.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Inst Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Kawasaki Med Sch, Dept Biochem, Okayama 7010192, Japan	University of Edinburgh; Kawasaki Medical School	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Inst Cell Biol, Swann Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	bill.earnshaw@ed.ac.uk	Earnshaw, William/AAY-7438-2020; Tone, Shigenobu/L-2694-2019	Earnshaw, William/0000-0002-7191-0621	Wellcome Trust [073915] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEERE HM, 1995, MOL PHARMACOL, V47, P986; Boulares AH, 2001, J BIOL CHEM, V276, P38185; COHEN JJ, 1984, J IMMUNOL, V132, P38; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kawane K, 1999, CELL DEATH DIFFER, V6, P745, DOI 10.1038/sj.cdd.4400547; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; TANABE K, 1991, CANCER RES, V51, P4903; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122	37	88	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45427	45432		10.1074/jbc.M108844200	http://dx.doi.org/10.1074/jbc.M108844200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577114	hybrid			2022-12-27	WOS:000172406700140
J	Rose, SD; Swift, GH; Peyton, MJ; Hammer, RE; MacDonald, RJ				Rose, SD; Swift, GH; Peyton, MJ; Hammer, RE; MacDonald, RJ			The role of PTF1-P48 in pancreatic acinar gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PTF1; CELL-SPECIFIC TRANSCRIPTION; DNA-BINDING SUBUNIT; ELASTASE-I GENE; HOMEODOMAIN PROTEIN; EXOCRINE; INSULIN; BETA; ENHANCER; ELEMENT	The 100-base pair ELA1 transcriptional enhancer drives high level transcription to pancreatic acinar cells of transgenic mice and in transfected pancreatic acinar cells in culture. The A element within the enhancer is the sole positively acting element for acinar specificity. We show that the acinar cell-specific bHLH protein PTF1-P48 and the common bHLH cofactor HEB are part of the PTF1 complex that binds the A element and mediates its activity. Acinar-like activity of the enhancer can be reconstituted in HeLa cells by the introduction of P48, HEB, and the PDX1-containing trimeric homeodomain complex that binds the second pancreatic element of the enhancer. The 5' region of the mouse Ptf1-p48 gene from -12.5 to +0.2 kilobase pairs contains the regulatory information to direct expression in transgenic mice to the pancreas and other organs of the gat that express the endogenous Ptf1-p48 gene. The 5'-flanking sequence contains two activating regions, one of which is specific for acinar cells, and a repressing domain active in non-pancreatic cells. Comparison of the 5'-gene flanking regions of the mouse, rat, and human genes identified conserved sequence blocks containing binding sites for known gut transcription factors within the acinar cell-specific control region.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MacDonald, RJ (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	raymond.macdonald@utsouthwestern.edu	MacDonald, Ray/AAA-1290-2022; Peyton, Michael/A-8728-2008	Hammer, Robert E./0000-0001-5487-7551	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061220, R01DK055266] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61220, DK055266] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; CECI JD, 1991, ONCOGENE, V6, P323; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DAVIS BP, 1992, J BIOL CHEM, V267, P26070; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GOLDSTEIN S, 1989, NUCLEIC ACIDS RES, V17, P3959, DOI 10.1093/nar/17.10.3959; GUZ Y, 1995, DEVELOPMENT, V121, P11; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jonsson J, 1995, INT J DEV BIOL, V39, P789; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Knofler M, 1996, J BIOL CHEM, V271, P21993; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LIN HH, 1993, J BIOL CHEM, V268, P10214; Liu Y, 2001, J BIOL CHEM, V276, P17985, DOI 10.1074/jbc.M100678200; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; Rose SD, 1997, HUM MOL GENET, V6, P897, DOI 10.1093/hmg/6.6.897; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; SOUTHARDSMITH M, 1994, GENOMICS, V22, P404, DOI 10.1006/geno.1994.1402; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; SWIFT GH, 1984, CELL, V38, P639, DOI 10.1016/0092-8674(84)90258-7; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Viswanath RL, 2000, J BIOL CHEM, V275, P40273, DOI 10.1074/jbc.M007021200; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	53	86	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44018	44026		10.1074/jbc.M106264200	http://dx.doi.org/10.1074/jbc.M106264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562365	hybrid			2022-12-27	WOS:000172297700070
J	Ducoux, M; Urbach, S; Baldacci, G; Hubscher, U; Koundrioukoff, S; Christensen, J; Hughes, P				Ducoux, M; Urbach, S; Baldacci, G; Hubscher, U; Koundrioukoff, S; Christensen, J; Hughes, P			Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; IN-VITRO; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL INTERACTION; CATALYTIC SUBUNIT; P21; INHIBITOR	The subunit that mediates binding of proliferating cell nuclear antigen (PCNA) to human DNA polymerase delta has not been clearly defined. We show that the third subunit of human DNA polymerase delta, p66, interacts with PCNA through a canonical PCNA-binding sequence located in its C terminus. Conversely, p66 interacts with the domain-interconnecting loop of PCNA, a region previously shown to be important for DNA polymerase delta activity and for binding of the cell cycle inhibitor P21(CiP1). In accordance with this, a peptide containing the PCNA-binding domain of p21(CiP1) inhibited p66 binding to PCNA and the activity of native three-subunit DNA polymerase delta. Furthermore, pull-down assays showed that DNA polymerase delta requires p66 for interaction with PCNA. More importantly, only reconstituted three-subunit DNA polymerase delta displayed PCNA-dependent DNA replication that could be inhibited by the PCNA-binding domain of p21(CiP1). Direct participation of p66 in PCNA-dependent DNA replication in vivo is demonstrated by co-localization of p66 with PCNA and DNA polymerase 8 within DNA replication foci. Finally, in vitro phosphorylation of p66 by cyclin-dependent kinases suggests that p66 activity may be subject to cell cycle-dependent regulation. These results suggest that p66 is the chief mediator of PCNA-dependent DNA synthesis by DNA polymerase delta.	Ctr Univ Orsay, CNRS, UMR 2027, Inst Curie, F-91405 Orsay, France; Univ Zurich Irchel, Dept Vet Biochem, CH-8057 Zurich, Switzerland; Univ Copenhagen, Dept Immunol & Microbiol, DK-2200 Copenhagen, Denmark	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Zurich; University of Copenhagen	Hughes, P (corresponding author), Ctr Univ Orsay, CNRS, UMR 2027, Inst Curie, Batiment 110, F-91405 Orsay, France.	hughes@curie.u-psud.fr		Ducoux-Petit, Manuelle/0000-0002-5346-2044				Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1993, CELL, V75, P805; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Huang ME, 2000, CURR GENET, V38, P178, DOI 10.1007/s002940000149; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; HUGHES DA, 1992, MOL GEN GENET, V231, P401, DOI 10.1007/BF00292709; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MacNeill SA, 2001, TRENDS BIOCHEM SCI, V26, P16, DOI 10.1016/S0968-0004(00)01709-6; Marians KJ, 1998, J BIOL CHEM, V273, P2452, DOI 10.1074/jbc.273.4.2452; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Perderiset M, 1998, BIOCHEM J, V335, P581, DOI 10.1042/bj3350581; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Roos G, 1996, EXP CELL RES, V226, P208, DOI 10.1006/excr.1996.0220; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Suzuki S, 2000, Nagoya J Med Sci, V63, P99; Tratner I, 1997, BIOCHEM BIOPH RES CO, V231, P321, DOI 10.1006/bbrc.1997.6082; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	53	84	88	15	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49258	49266		10.1074/jbc.M106990200	http://dx.doi.org/10.1074/jbc.M106990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595739	hybrid, Green Accepted			2022-12-27	WOS:000173922100084
J	Anant, S; Henderson, JO; Mukhopadhyay, D; Navaratnam, N; Kennedy, S; Min, J; Davidson, NO				Anant, S; Henderson, JO; Mukhopadhyay, D; Navaratnam, N; Kennedy, S; Min, J; Davidson, NO			Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing - CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSKAR MESSENGER-RNA; TRANSLATIONAL REPRESSOR BRUNO; MOLECULAR-CLONING; CYTIDINE DEAMINASE; CATALYTIC SUBUNIT; EVOLUTIONARY ORIGINS; MYOTONIC-DYSTROPHY; GENE-EXPRESSION; ENZYME-COMPLEX; SITE	Mammalian apolipoprotein B (apoB) mRNA editing is mediated by a multicomponent holoenzyme containing apobec-1 and ACF. We have now identified CUGBP2, a 54-kDa RNA-binding protein, as a component of this holoenzyme. CUGBP2 and ACF co-fractionate in bovine liver S-100 extracts, and addition of recombinant apobec-1 leads to assembly of a holoenzyme. Immunodepletion of CUGBP2 co-precipitates ACF, and these proteins co-localize the nucleus of transfected cells, suggesting that CUGBP2 and ACF are bound in vivo. CUGBP2 binds apoB RNA, specifically an AU-rich sequence located immediately upstream of the edited cytidine. ApoB RNA from McA cells, bound to CUGBP2, was more extensively edited than the unbound fraction. However, addition of recombinant CUGBP2 to a reconstituted system demonstrated a dose-dependent inhibition of C to U RNA editing, which was rescued with either apobec-1 or ACF. Antisense CUGBP2 knockout increased endogenous apoB RNA editing, whereas antisense knockout of either apobec-1 or ACF expression eliminated apoB RNA editing, establishing the absolute requirement of these components of the core enzyme. These data suggest that CUGBP2 plays a role in apoB mRNA editing by forming a regulatory complex with the three components of the minimal editing enzyme, apobec-1, ACF, and apoB RNA.	Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol & Mol Biol, St Louis, MO 63110 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, Med Res Council Mol Med Grp, London W12 0NN, England	Washington University (WUSTL); Washington University (WUSTL); Imperial College London	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Campus Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.		Anant, Shrikant/AAF-8020-2020		NHLBI NIH HHS [HL 38180] Funding Source: Medline; NIDDK NIH HHS [DK 52574, DK 56260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056260, P30DK052574] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Anant S, 1998, BIOL CHEM, V379, P1075, DOI 10.1515/bchm.1998.379.8-9.1075; ANANT S, 1997, NUCL ACIDS S SER, V36, P115; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Chen L, 1996, J THEOR BIOL, V183, P391, DOI 10.1006/jtbi.1996.0230; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Choi DK, 1999, GENE, V237, P135, DOI 10.1016/S0378-1119(99)00312-1; Choi DK, 1998, GENE, V223, P21, DOI 10.1016/S0378-1119(98)00364-3; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; FUNAHASHI T, 1995, J LIPID RES, V36, P414; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Lie YS, 1999, DEVELOPMENT, V126, P4989; Lie YS, 1999, DEVELOPMENT, V126, P1129; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; Morrison JR, 1996, P NATL ACAD SCI USA, V93, P7154, DOI 10.1073/pnas.93.14.7154; Nakamuta M, 1996, J BIOL CHEM, V271, P25981, DOI 10.1074/jbc.271.42.25981; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	57	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47338	47351		10.1074/jbc.M104911200	http://dx.doi.org/10.1074/jbc.M104911200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577082	hybrid			2022-12-27	WOS:000172768500089
J	Bag, J				Bag, J			Feedback inhibition of poly(A)-binding protein mRNA translation - A possible mechanism of translation arrest by stalled 40 S ribosomal subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYADENYLATE-BINDING-PROTEIN; MESSENGER-RNA; XENOPUS-LAEVIS; IN-VITRO; DEPENDENT TRANSLATION; EXPRESSION; INITIATION; YEAST; IDENTIFICATION; SEQUENCE	An adenine-rich cis element at the 5'-untranslated region (UTR) of Pabp1 mRNA is able to inhibit translation of its own mRNA. Similar inhibition of translation of a reporter beta -galactosidase mRNA is observed when the adenine-rich auto regulatory sequence (ARS) is placed within the 5'-UTR of this mRNA. For this translational control the distance of the ARS from the 5' cap is not important. However, it determines the number of 40 S ribosomal subunits bound to the translationally arrested mRNA. Inhibition of mRNA translation by this regulatory sequence occurs at the step of joining of the 60 S ribosomal subunit to the pre-initiation complex. Translational arrest of the ARS containing mRNA in a rabbit reticulocyte lysate cell-free system in the presence of exogenous Pabp1 protects the 5'-flanking region of the ARS from nuclease digestion. This protection depends on the binding of the 40 S ribosomal subunit to the mRNA. The size and the sequence of the nucleotide-protected fragment depends on the location of the ARS within the 5'-UTR. When the ARS is located at a distance of about 78 nucleotides from the 5' cap, a 40-nucleotide-long region adjacent to the ARS is protected. On the other hand, when the ARS is moved further away from the 5' cap to a distance of similar to 267 nucleotides, a 100-nucleotide- long region adjacent to the ARS is protected from nuclease digestion. Nuclease protection is attributed to the presence of one or more stalled 40 S ribosomal subunits near the Pabp1-bound ARS.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Bag, J (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	jbag@uoguelph.ca						ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ADAMOU J, 1992, EUR J BIOCHEM, V209, P803, DOI 10.1111/j.1432-1033.1992.tb17351.x; Amrani N, 1997, MOL CELL BIOL, V17, P3694, DOI 10.1128/MCB.17.7.3694; Bag J, 1996, EUR J BIOCHEM, V237, P143, DOI 10.1111/j.1432-1033.1996.0143n.x; BAG J, 1991, TRANSLATION EUKARYOT, P71; BELOSTOTSKY DA, 1993, P NATL ACAD SCI USA, V90, P6686, DOI 10.1073/pnas.90.14.6686; BERGER LC, 1992, EUR J BIOCHEM, V204, P733, DOI 10.1111/j.1432-1033.1992.tb16688.x; BERGER LC, 1992, BIOCHEM CELL BIOL, V70, P770, DOI 10.1139/o92-117; Biberman Y, 1999, FEBS LETT, V456, P357, DOI 10.1016/S0014-5793(99)00983-7; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Cao JH, 1996, MOL CELL BIOL, V16, P603; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CARDINATI B, 1993, NUCLEIC ACIDS RES, V21, P2300; Cherkasova V, 2000, J MOL BIOL, V300, P433, DOI 10.1006/jmbi.2000.3880; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; Deo RC, 2001, P NATL ACAD SCI USA, V98, P4414, DOI 10.1073/pnas.071552198; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ERNSTEIN P, 1989, MOL CELL BIOL, V9, P659; Fraser CS, 1999, J BIOL CHEM, V274, P196, DOI 10.1074/jbc.274.1.196; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; GREENBERG JR, 1981, P NATL ACAD SCI-BIOL, V78, P2923, DOI 10.1073/pnas.78.5.2923; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; KASPAR RL, 1992, J BIOL CHEM, V267, P508; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; Kolupaeva VG, 2000, J VIROL, V74, P6242, DOI 10.1128/JVI.74.14.6242-6250.2000; Korner CG, 1997, J BIOL CHEM, V272, P10448; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MAUNDRELL K, 1983, J BIOL CHEM, V258, P1387; MERCER WE, 1989, EXP CELL RES, V181, P531, DOI 10.1016/0014-4827(89)90109-2; Mohr E, 2001, P NATL ACAD SCI USA, V98, P7072, DOI 10.1073/pnas.111146598; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; Pellizzoni L, 1998, J MOL BIOL, V281, P593, DOI 10.1006/jmbi.1998.1961; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SEVERSON WE, 1995, EUR J BIOCHEM, V229, P426, DOI 10.1111/j.1432-1033.1995.tb20483.x; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; ULRICH SJ, 1986, EXP CELL RES, V178, P273; VAZQUEZ D, 1979, INHIBITIONS PROTEIN, P10; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	64	31	31	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47352	47360		10.1074/jbc.M107676200	http://dx.doi.org/10.1074/jbc.M107676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590158	hybrid			2022-12-27	WOS:000172768500090
J	Klezovitch, O; Edelstein, C; Scanu, AM				Klezovitch, O; Edelstein, C; Scanu, AM			Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a) Evidence for a critical involvement of elements in its C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-1; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; LP(A) LIPOPROTEIN; RISK FACTOR; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; ATHEROSCLEROSIS; PROTEIN; FRAGMENTS	In the vessel wall, macrophages are among the cells that upon activation contribute to the atherosclerotic process. Low density lipoproteins (LDL) can mediate this activation but only after enzymatic or oxidative modification. Lipoprotein(a) (Lp(a)) is an LDL variant that has been shown to have an atherogenic potential by no clearly established mechanisms. In the present study we examined whether native Lp(a) can activate macrophages and, if so, identify the structural elements involved in this action. For this purpose, we utilized human THP-1 macrophages, prepared by treating THP-1 monocytes with phorbol ester, and we exposed them to Lp(a) and its two derivatives, apo(a)-free LDL (Lp(a-)) and free apo(a). We also studied apo(a) fragments, F1 (N terminus) and F2 (C terminus) and subfragments thereof, obtained by leukocyte elastase digestion. By Northern blot analyses, Lp(a), but not Lp(a-), caused up to a 12-fold increase in interleukin 8 (IL-8) mRNA as compared with untreated cells. Free apo(a) also induced the production of IL-8 mRNA; however, the effect was 3-4-fold higher than that of Lp (a). The increase in mRNA was associated with the accumulation of IL-8 protein in the culture medium. F1 had only a minimal effect, whereas F2 was 1.5-2-fold more potent than apo(a), an activity mostly contained in the Kringle V-protease region. A monoclonal antibody specific for Kringle V inhibited the apo(a)-mediated effect on IL-8. We conclude that Lp(a) via elements contained in the C-terminal domain of apo(a) causes in THP-1 macrophages an increased production of IL-8, a chemokine with pro-inflammatory properties, an event that may be relevant to the process of atherosclerosis.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Scanu, AM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC5041, Chicago, IL 60637 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, R01HL063115] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63115, HL 18577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BANDELLO F, 1994, THROMB HAEMOSTASIS, V72, P39; Berge KE, 1997, CLIN GENET, V52, P314; Boisvert WA, 2000, IMMUNOL RES, V21, P129, DOI 10.1385/IR:21:2-3:129; BOLGER C, 1995, NEUROSURGERY, V37, P241, DOI 10.1227/00006123-199508000-00008; BUDDE T, 1994, ARTERIOSCLER THROMB, V14, P1730, DOI 10.1161/01.ATV.14.11.1730; COLDITZ IG, 1990, J LEUKOCYTE BIOL, V48, P129, DOI 10.1002/jlb.48.2.129; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1995, BIOCHEMISTRY-US, V34, P16483, DOI 10.1021/bi00050a032; Edelstein C, 1997, J BIOL CHEM, V272, P11079; Edelstein C, 1999, J BIOL CHEM, V274, P10019, DOI 10.1074/jbc.274.15.10019; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; Fortunato JE, 2000, J VASC SURG, V32, P555, DOI 10.1067/mva.2000.107757; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Grenett HE, 1998, ARTERIOSCL THROM VAS, V18, P1803, DOI 10.1161/01.ATV.18.11.1803; GROVES P, 1993, BRIT HEART J, V69, P26; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; Klezovitch O, 1998, J BIOL CHEM, V273, P23856, DOI 10.1074/jbc.273.37.23856; KOCH AE, 1992, SCIENCE, V268, P447; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEVIN EG, 1994, ARTERIOSCLER THROMB, V14, P438, DOI 10.1161/01.ATV.14.3.438; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; NAGAYAMA M, 1994, STROKE, V25, P74, DOI 10.1161/01.STR.25.1.74; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VALENTINE RJ, 1994, ARCH INTERN MED, V154, P801, DOI 10.1001/archinte.154.7.801; VIA DP, 1989, J LIPID RES, V30, P1515; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; WILSON L, 1993, FEBS LETT, V325, P295, DOI 10.1016/0014-5793(93)81092-E; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1; YUE TL, 1993, EUR J PHARMACOL, V240, P81	45	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46864	46869		10.1074/jbc.M107943200	http://dx.doi.org/10.1074/jbc.M107943200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591715	hybrid			2022-12-27	WOS:000172768500027
J	Morrison, CJ; Butler, GS; Bigg, HF; Roberts, CR; Soloway, PD; Overall, CM				Morrison, CJ; Butler, GS; Bigg, HF; Roberts, CR; Soloway, PD; Overall, CM			Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-3 MATRIX METALLOPROTEINASES; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; TISSUE INHIBITOR; PROGELATINASE-A; 72-KDA GELATINASE; CATALYTIC DOMAIN; EFFICIENT ACTIVATION; BRAIN-TUMORS; CDNA LIBRARY	The role of membrane-type (AIT) 2-matrix metalloproteinase (MMP) in the cellular activation of MMP-2 and the tissue inhibitor of matrix metalloproteinase (TIMP) requirements for this process have not been clearly established. To address these issues a TIMP-2-free cell line derived from a Timp2-/- mouse was transfected for stable cell surface expression of hMT2-MMP. Untransfected cells did not activate endogenous or exogenous TIMP-2-free MMP-2 unless both TIMP-2 and concanavalin A (ConA) were added. Transfected cells expressing hMT2-MMP efficiently activated both endogenous and exogenous MMP-2 (within 4 h) via the 68-kDa intermediate in the absence of TIMP-2 and ConA. In contrast, activation of MMP-2 by Timp2-/- cells expressing recombinant hMT1-MMP occurred more slowly (12 h) and required the addition of 0.3-27 nM TIMP-2. Addition of TIMP-2 or TIMP-4 did not enhance MMP-2 activation by MT2-MMP at any concentration tested; furthermore, activation was inhibited by both TIMPs at concentrations >9 ml, consistent with the similar association rate constants (k(on)) calculated for the binding of TIMP-4 and TIMP-2 to MT2-MMP (3.56 x 10(5) M-1 s(-1) and 6.52 x 10(5) M-1 s(-1), respectively). MT2-MMP-mediated activation involved cell surface association of the MMP-2 in a hemopexin carboxyl-terminal domain (C domain)-dependent manner: Exogenous MMP-2 hemopexin C domain blocked activation, and cells expressing hMT2-MMP did not bind or activate a truncated form of MMP-2 lacking the hemopexin C domain. These studies demonstrate the existence of an alternative TIMP-2-independent pathway for MMP-2 activation involving MT2-MMP, which may be important in mediating MMP-2 activation in specific tissues or pathologies where MT2-MMP is expressed.	Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY USA	University of British Columbia; University of British Columbia; Roswell Park Cancer Institute	Overall, CM (corresponding author), Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.		Butler, Georgina/GQP-7553-2022; Soloway, Paul/T-8243-2019	Butler, Georgina/0000-0003-1172-1578; Soloway, Paul/0000-0003-1967-0437				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kinoshita T, 1996, CANCER RES, V56, P2535; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Llano E, 1999, CANCER RES, V59, P2570; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Mitas M, 2001, INT J CANCER, V93, P162, DOI 10.1002/ijc.1312; Mitsiades N, 2001, CANCER RES, V61, P577; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morrison CJ, 1997, BIOTECHNOL BIOENG, V53, P594, DOI 10.1002/(SICI)1097-0290(19970320)53:6<594::AID-BIT7>3.3.CO;2-M; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; OVERALL CM, 1987, J DENT RES, V66, P1271, DOI 10.1177/00220345870660071201; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	60	152	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47402	47410		10.1074/jbc.M108643200	http://dx.doi.org/10.1074/jbc.M108643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584019	hybrid			2022-12-27	WOS:000172768500096
J	Wurmbach, E; Yuen, T; Ebersole, BJ; Sealfon, SC				Wurmbach, E; Yuen, T; Ebersole, BJ; Sealfon, SC			Gonadotropin-releasing hormone receptor-coupled gene network organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; BETA-GENE; GNRH RECEPTOR; FOS PROTEIN; EXPRESSION; ACTIVATION; PROMOTER; TRANSCRIPTION; MICROARRAYS; DIVERGENT	An early gene cDNA microarray was developed to study genes that are regulated immediately following gonadotropin-releasing hormone (GnRH) receptor activation. 956 selected candidate genes were printed in triplicate, a t statistic-based regulation algorithm was used for data analysis, and the response to GnRH in a time course from 1 to 6 h was determined. Measurements were highly reproducible within arrays, between arrays, and between experiments. Accuracy and algorithm reliability were established by real-time polymerase chain reaction assays of 60 genes. Gene changes ranging from 1.3- to 31 -fold on the microarray were confirmed by real-time polymerase chain reaction. Many of the genes were found to be highly regulated. The regulated genes identified were all elevated at 1 h of treatment and returned nearly or completely to baseline levels of expression by 3 h of treatment. This broad, robust and transient transcriptional response to constant GnRH exposure includes modulators of signal transduction (e.g. Rgs2 and I kappaB), cytoskeletal proteins (e.g. gamma -actin), and transcription factors (e.g. c-Fos, Egr1, and LRG21). The interplay of the activators, repressors, and feedback inhibitors identified embodies a combinatorial code to direct the activity of specific downstream secondary genes.	Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Sealfon, SC (corresponding author), Mt Sinai Sch Med, Dept Neurol, Box 1137, New York, NY 10029 USA.	Stuart.Sealfon@mssm.edu		SEALFON, Stuart/0000-0001-5791-1217	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 46943] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas MM, 2000, NEUROENDOCRINOLOGY, V71, P292, DOI 10.1159/000054549; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Box G.E.P., 1978, STAT EXPT INTRO DESI, P165; Cheng KW, 2000, ENDOCRINOLOGY, V141, P3611, DOI 10.1210/en.141.10.3611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALKIN AC, 1989, ENDOCRINOLOGY, V125, P917, DOI 10.1210/endo-125-2-917; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Klein C, 2000, ANN NEUROL, V47, P369, DOI 10.1002/1531-8249(200003)47:3<369::AID-ANA14>3.3.CO;2-0; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; Taylor E, 2001, BIOTECHNIQUES, V31, P62, DOI 10.2144/01311st01; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Venables W., 2013, MODERN APPL STAT S, V53, P86; Weck J, 2000, MOL ENDOCRINOL, V14, P472, DOI 10.1210/me.14.4.472; WEISS J, 1990, MOL ENDOCRINOL, V4, P557, DOI 10.1210/mend-4-4-557; Yokoi T, 2000, J BIOL CHEM, V275, P21639, DOI 10.1074/jbc.M910252199; Yuen T, 2002, METHOD ENZYMOL, V345, P556	33	151	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47195	47201		10.1074/jbc.M108716200	http://dx.doi.org/10.1074/jbc.M108716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581274	hybrid			2022-12-27	WOS:000172768500071
J	Bauer, Z; Gomez-Gomez, L; Boller, T; Felix, G				Bauer, Z; Gomez-Gomez, L; Boller, T; Felix, G			Sensitivity of different ecotypes and mutants of Arabidopsis thaliana toward the bacterial elicitor flagellin correlates with the presence of receptor-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PLANT-DISEASE RESISTANCE; PLASMA-MEMBRANES; SYRINGOLIDE ELICITORS; CLADOSPORIUM-FULVUM; TOBACCO CELLS; TOMATO CELLS; PROTEIN; KINASE; GENE	Flagellin, the main building block of the bacterial flagellum, acts as potent elicitor of defense responses in different plant species. Genetic analysis in Arabidopsis thaliana identified two distinct loci, termed FLS1 and FLS2, that are essential for perception of flagellin-derived elicitors. FLS2 was found to encode a leucine-rich repeat transmembrane receptor-like kinase with similarities to Toll-like receptors involved in the innate immune system of mammals and insects. Here we used a radiolabeled derivative of flg22, a synthetic peptide representing the elicitor-active domain of flagellin, to probe the interaction of flagellin with its receptor in A. thaliana The high affinity binding site detected in in- tact cells and membrane preparations exhibited specificity for flagellin-derived peptides with biological activity as agonists or antagonists of the elicitor responses. Specific binding activity was measurable in all ecotypes of A. thaliana that show sensitivity to flagellin but was barely detectable in the flagellin-insensitive ecotype Ws-O affected in FLS1. A strongly impaired binding of flagellin was observed also in several independent flagellin-insensitive mutants isolated from the flagellin-sensitive ecotype La-er. In particular, no binding was found in plants carrying a mutation in the LRR domain of FLS2. These data indicate that the formation of functional receptor-binding sites depends on genes encoded by both loci, FLS1 and FLS2. The tight correlation between the presence of the binding site and elicitor response provides strong evidence that this binding site acts as the physiological receptor of flagellin.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Felix, G (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	Felix@fmi.ch	Gomez-Gomez, Lourdes/AAF-2371-2020; Bruening, Stefan/B-8505-2011; Boller, Thomas/G-3500-2012	Gomez-Gomez, Lourdes/0000-0003-2586-4457; Boller, Thomas/0000-0001-6768-7503				Alfano JR, 1996, PLANT CELL, V8, P1683, DOI 10.1105/tpc.8.10.1683; Atkinson MM, 1996, PLANT PHYSIOL, V112, P297, DOI 10.1104/pp.112.1.297; BAUREITHEL K, 1994, J BIOL CHEM, V269, P17931; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Bonas U, 1997, PLANT J, V12, P1, DOI 10.1046/j.1365-313X.1997.12010001.x; Bourque S, 1999, J BIOL CHEM, V274, P34699, DOI 10.1074/jbc.274.49.34699; CHEONG JJ, 1993, PLANT PHYSIOL, V103, P1173, DOI 10.1104/pp.103.4.1173; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gomez-Gomez L, 2001, PLANT CELL, V13, P1155, DOI 10.1105/tpc.13.5.1155; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; He ZH, 2000, SCIENCE, V288, P2360, DOI 10.1126/science.288.5475.2360; Heath MC, 2000, CURR OPIN PLANT BIOL, V3, P315, DOI 10.1016/S1369-5266(00)00087-X; Ji C, 1998, P NATL ACAD SCI USA, V95, P3306, DOI 10.1073/pnas.95.6.3306; Ji C, 1997, PLANT CELL, V9, P1425, DOI 10.1105/tpc.9.8.1425; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KEEN NT, 1992, PLANT MOL BIOL, V19, P109, DOI 10.1007/BF00015609; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KoomanGersmann M, 1996, PLANT CELL, V8, P929, DOI 10.1105/tpc.8.5.929; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Meindl T, 2000, PLANT CELL, V12, P1783, DOI 10.1105/tpc.12.9.1783; Mithofer A, 2000, BIOL CHEM, V381, P705, DOI 10.1515/BC.2000.091; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Shibuya N, 1996, PLANT CELL PHYSIOL, V37, P894, DOI 10.1093/oxfordjournals.pcp.a029030; Song WY, 1997, PLANT CELL, V9, P1279, DOI 10.1105/tpc.9.8.1279; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; Umemoto N, 1997, P NATL ACAD SCI USA, V94, P1029, DOI 10.1073/pnas.94.3.1029	35	140	147	4	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45669	45676		10.1074/jbc.M102390200	http://dx.doi.org/10.1074/jbc.M102390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11564731	hybrid			2022-12-27	WOS:000172573100025
J	Bilej, M; De Baetselier, P; Van Dijck, E; Stijlemans, B; Colige, A; Beschin, A				Bilej, M; De Baetselier, P; Van Dijck, E; Stijlemans, B; Colige, A; Beschin, A			Distinct carbohydrate recognition domains of an invertebrate defense molecule recognize Gram-negative and Gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPHENOLOXIDASE-ACTIVATING SYSTEM; EISENIA-FOETIDA; BOMBYX-MORI; BINDING PROTEIN; CELOMIC FLUID; LUMBRICUS-TERRESTRIS; GLUCAN-BINDING; CDNA CLONING; PEPTIDOGLYCAN; SILKWORM	Coelomic fluid of Eisenia foetida earthworms (Oligochaeta, Annelida) contains a 42-kDa defense molecule named CCF for coelomic cytolytic factor. By binding microbial antigens, namely the O-antigen of lipopolysaccharide (LPS), beta -1,3-glucans, or N,N'-diacetylchitobiose present, respectively, on Gram-negative bacteria or yeast cell walls, CCF triggers the prophenoloxidase activating pathway. We report that CCF recognizes lysozyme-predigested Gram-positive bacteria or the peptidoglycan constituent muramyl dipeptide as well as muramic acid. To identify the pattern recognition domains of CCF, deletion mutants were tested for their ability to reconstitute the prophenoloxidase cascade in E. foetida coelomic fluid depleted of endogenous CCF in the presence of LPS, beta -1,3-glucans, N,N'-diacetylchitobiose, and muramic acid. In addition, affinity chromatography of CCF peptides was performed on immobilized beta -1,3-glucans or N,N'-diacetylchitobiose. We found that the broad specificity of CCF for pathogen-associated molecular patterns results from the presence of two distinct pattern recognition domains. One domain, which shows homology with the polysaccharide and glucanase motifs of beta -1,3-glucanases and invertebrate defense molecules located in the central part of the CCF polypeptide chain, interacts with LPS and beta -1,3-glucans. The C-terminal tryptophan-rich domain mediates interactions of CCF with N,N'-diacetylchitobiose and muramic acid. These data provide evidence for the presence of spatially distinct carbohydrate recognition domains within this invertebrate defense molecule.	Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, B-1640 Rhode St Genese, Belgium; Acad Sci Czech Republ, Inst Microbiol, Dept Immunol, Prague 4, Czech Republic; Univ Liege, Lab Connect Tissue Biol, B-4000 Liege, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Liege	Beschin, A (corresponding author), Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, 65 Paardenstr,St Genesius Rode, B-1640 Rhode St Genese, Belgium.	abeschin@vub.ac.be	Beschin, Alain/L-2154-2014; Bilej, Martin/I-4564-2014; De Baetselier, Patrick/D-3866-2014; Stijlemans, Benoit/AAD-9122-2021	Beschin, Alain/0000-0001-8478-6941; Stijlemans, Benoit/0000-0003-0082-9751				Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Beschin A, 1999, NATURE, V400, P627, DOI 10.1038/23164; Bianchet MA, 2000, PROTEINS, V40, P378, DOI 10.1002/1097-0134(20000815)40:3<378::AID-PROT40>3.0.CO;2-7; BILEJ M, 1995, IMMUNOL LETT, V45, P123, DOI 10.1016/0165-2478(94)00248-P; Bilej M, 1998, IMMUNOL LETT, V60, P23, DOI 10.1016/S0165-2478(97)00127-2; Bilej M, 2000, FOLIA MICROBIOL, V45, P283, DOI 10.1007/BF02817549; COTUK A, 1984, COMP BIOCHEM PHYS A, V78, P469, DOI 10.1016/0300-9629(84)90580-2; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Iketani M, 1999, INSECT BIOCHEM MOLEC, V29, P19, DOI 10.1016/S0965-1748(98)00099-X; Ito Y, 1999, EUR J BIOCHEM, V259, P456, DOI 10.1046/j.1432-1327.1999.00064.x; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Johansson M.W., 1996, Progress in Molecular and Subcellular Biology, V15, P46; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim YS, 2000, J BIOL CHEM, V275, P2071, DOI 10.1074/jbc.275.3.2071; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEIPNER C, 1993, COMP BIOCHEM PHYS B, V105, P637, DOI 10.1016/0305-0491(93)90099-Q; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; SEKI N, 1994, J BIOL CHEM, V269, P1370; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Smith V.J., 1996, Advances in Comparative and Environmental Physiology, V23, P75; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; TUCKOVA L, 1986, DEV COMP IMMUNOL, V10, P181, DOI 10.1016/0145-305X(86)90002-9; Valembois P., 1986, P74; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; YAMAMOTO M, 1993, BIOSCI BIOTECH BIOCH, V57, P1518, DOI 10.1271/bbb.57.1518; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	37	63	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45840	45847		10.1074/jbc.M107220200	http://dx.doi.org/10.1074/jbc.M107220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585829	hybrid			2022-12-27	WOS:000172573100047
J	Leung, D; Schroder, K; White, H; Fang, NX; Stoermer, MJ; Abbenante, G; Martin, JL; Young, PR; Fairlie, DP				Leung, D; Schroder, K; White, H; Fang, NX; Stoermer, MJ; Abbenante, G; Martin, JL; Young, PR; Fairlie, DP			Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; SERINE-PROTEASE; DRUG-DESIGN; IN-VITRO; NONSTRUCTURAL PROTEINS; STRUCTURAL PROTEINS; DELETION ANALYSIS; CRYSTAL-STRUCTURE; AMINO-ACIDS; FLAVIVIRUS	Recombinant forms of the dengue 2 virus NS3 protease linked to a 40-residue co-factor, corresponding to part of NS2B, have been expressed in Escherichia coli and shown to be active against para-nitroanilide substrates comprising the P6-P1 residues of four substrate cleavage sequences. The enzyme is inactive alone or after the addition of a putative 13-residue co-factor peptide but is active when fused to the 40-residue co-factor, by either a cleavable or a noncleavable glycine linker. The NS4B/NS5 cleavage site was processed most readily, with optimal processing conditions being pH 9, I = 10 mm, 1 mm CHAPS, 20% glycerol. A longer 10-residue peptide corresponding to the NS2B/NS3 cleavage site (P6-P4') was a poorer substrate than the hexapeptide (P6-P1) para-nitroanilide substrate under these conditions, suggesting that the prime side substrate residues did not contribute significantly to protease binding. We also report the first inhibitors of a co-factor-complexed, catalytically active flavivirus NS3 protease. Aprotinin was the only standard serine protease inhibitor to be active, whereas a number of peptide substrate analogues were found to be competitive inhibitors at micromolar concentrations.	Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Fairlie, DP (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.		Young, Paul R/A-6176-2010; Stoermer, Martin J/E-2317-2012; Schroder, Kate/C-6132-2008; Fairlie, David P/F-8865-2014; Martin, Jennifer L./A-6039-2010	Young, Paul R/0000-0002-2040-5190; Stoermer, Martin J/0000-0003-3445-2104; Schroder, Kate/0000-0001-9261-3805; Fairlie, David P/0000-0002-7856-8566; Martin, Jennifer L./0000-0002-9225-8863				ABBENANTE G, 2001, IN PRESS LETT PEPT S; Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; BAZAN JF, 1990, SEMIN VIROL, V1, P311; Bennett JM, 2001, BIOORG MED CHEM LETT, V11, P355, DOI 10.1016/S0960-894X(00)00654-5; Brinkworth RI, 1999, J GEN VIROL, V80, P1167, DOI 10.1099/0022-1317-80-5-1167; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; Droll DA, 2000, VIROLOGY, V275, P335, DOI 10.1006/viro.2000.0488; EDWARDS PD, 1994, MED RES REV, V14, P127, DOI 10.1002/med.2610140202; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; Han W, 2000, BIOORG MED CHEM LETT, V10, P711, DOI 10.1016/S0960-894X(00)00074-3; Jacobs MG, 1998, CURR OPIN INFECT DIS, V11, P319, DOI 10.1097/00001432-199806000-00009; Kempf DJ, 1996, CURR PHARM DESIGN, V2, P225; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; LEUNG D, 2001, THESIS U QUEENSLAND; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PREUGSCHAT F, 1991, J VIROL, V65, P4749, DOI 10.1128/JVI.65.9.4749-4758.1991; Ripka AS, 1998, CURR OPIN CHEM BIOL, V2, P441, DOI 10.1016/S1367-5931(98)80119-1; RIPKA WC, 1998, Patent No. 5731413; Seife C, 1997, SCIENCE, V277, P1602, DOI 10.1126/science.277.5332.1602; Semple JE, 1997, BIOORG MED CHEM LETT, V7, P2421, DOI 10.1016/S0960-894X(97)00446-0; SPEIGHT G, 1988, J GEN VIROL, V69, P23, DOI 10.1099/0022-1317-69-1-23; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; Steinkuhler C, 1996, J BIOL CHEM, V271, P6367, DOI 10.1074/jbc.271.11.6367; Steinkuhler C, 1996, J VIROL, V70, P6694; Tamura SY, 1996, TETRAHEDRON LETT, V37, P4109, DOI 10.1016/0040-4039(96)00777-0; WEBB TR, 1996, Patent No. 5514777; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4; Yusof R, 2000, J BIOL CHEM, V275, P9963, DOI 10.1074/jbc.275.14.9963	39	246	259	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45762	45771		10.1074/jbc.M107360200	http://dx.doi.org/10.1074/jbc.M107360200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581268	hybrid, Green Published			2022-12-27	WOS:000172573100037
J	Pan, L; Black, TA; Shi, Q; Jones, CA; Petrovic, N; Loudon, J; Kane, C; Sigmund, CD; Gross, KW				Pan, L; Black, TA; Shi, Q; Jones, CA; Petrovic, N; Loudon, J; Kane, C; Sigmund, CD; Gross, KW			Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM STIMULATORY FACTOR-1; CELL SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR USF; G(S) PROTEIN MUTATIONS; MOLECULAR-BIOLOGY; PROXIMAL PROMOTER; PITUITARY-TUMORS; TRANSGENIC MICE; MURINE REN-1; MUSCLE CELLS	Mouse As4.1 cells, obtained after transgene-targeted oncogenesis to induce neoplasia in renal renin expressing cells, express high levels of renin mRNA from their endogenous Ren-1(c) gene. We have previously identified a 242-base pair enhancer (coordinates -2866 to -2625 relative to the CAP site) upstream of the mouse Ren-1(c) gene. This enhancer, in combination with the proximal promoter (-117 to +6), activates transcription nearly 2 orders of magnitude in an orientation independent fashion. To further delimit sequences necessary for transcriptional activation, renin promoter-luciferase reporter gene constructs containing selected regions of the Ren-1(c) enhancer were analyzed after transfection into As4.1 cells. These results demonstrate that several regions are required for full enhancer activity. Sequences from -2699 to -2672, which are critical for the enhancer activity, contain a cyclic AMP responsive element (CRE) and an E-box. Electrophoretic mobility shift assays demonstrated that transcription factors CREB/CREM and USF1/USF2 in As4.1 cell nuclear extracts bind to oligonucleotides containing the Ren-1(c) CRE and E-box, respectively. These two elements are capable of synergistically activating transcription from the Ren-1(c) promoter. Moreover, mutation of either the CRE or E-box results in almost complete loss of enhancer activity, suggesting the critical roles these two elements play in regulating mouse Ren-1(c) gene expression. Although the Ren-1(c) gene contains a CRE, its expression is not induced by cAMP in As4.1 cells. This appears to reflect constitutive activation of protein kinase A in As4.1 cells since treatment with the protein kinase A inhibitor, H-89, caused a significant reduction in Ren-1(c) gene expression and this reduction is mediated through the CRE at -2699 to -2688.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Roswell Park Cancer Institute; University of Iowa; University of Iowa	Gross, KW (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Sts, Buffalo, NY 14263 USA.	gross@acsu.buffalo.edu	Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006, R01HL048058, R01HL061446, R01HL048459, R37HL048058] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056] Funding Source: Medline; NHLBI NIH HHS [HL61446, HL48459, HL55006, HL48058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL KJ, 1990, GENETICS, V124, P937; ABEL KJ, 1988, NUCLEIC ACIDS RES, V16, P2111, DOI 10.1093/nar/16.5.2111; Affolter M, 2001, SCIENCE, V292, P1080, DOI 10.1126/science.1060856; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Breen GAM, 2000, BBA-GENE STRUCT EXPR, V1517, P119, DOI 10.1016/S0167-4781(00)00269-4; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; Faglia G, 1996, METABOLISM, V45, P117, DOI 10.1016/S0026-0495(96)90103-1; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; Guss KA, 2001, SCIENCE, V292, P1164, DOI 10.1126/science.1058312; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Harris PE, 1996, METABOLISM, V45, P120, DOI 10.1016/S0026-0495(96)90104-3; HARTROFT PM, 1963, CIRC RES, V12, P525, DOI 10.1161/01.RES.12.5.525; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; HORIUCHI M, 1991, J BIOL CHEM, V266, P16247; Jensen BL, 1998, PFLUG ARCH EUR J PHY, V436, P673, DOI 10.1007/s004240050688; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Kim JC, 1998, J BIOL CHEM, V273, P26130, DOI 10.1074/jbc.273.40.26130; KINGSLEYKALLESE.M, 1996, J BIOL CHEM, V274, P34020; KURTZ A, 1989, REV PHYSIOL BIOCH P, V113, P1; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Malyankar UM, 1999, EXP CELL RES, V250, P535, DOI 10.1006/excr.1999.4537; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Marty T, 2001, DEVELOPMENT, V128, P2833; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Petrovic N, 1997, HYPERTENSION, V30, P230, DOI 10.1161/01.HYP.30.2.230; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; Shi Q, 2001, J BIOL CHEM, V276, P3597, DOI 10.1074/jbc.M008361200; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; Takahashi Y, 1997, J BIOL CHEM, V272, P30025, DOI 10.1074/jbc.272.48.30025; TAMURA K, 1994, J CLIN INVEST, V94, P1959, DOI 10.1172/JCI117547; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558; Ying LH, 1997, J BIOL CHEM, V272, P2412	55	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45530	45538		10.1074/jbc.M103010200	http://dx.doi.org/10.1074/jbc.M103010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11564732	hybrid			2022-12-27	WOS:000172573100008
J	Todisco, A; Pausawasdi, N; Ramamoorthy, S; Del Valle, J; Van Dyke, RW; Askari, FK				Todisco, A; Pausawasdi, N; Ramamoorthy, S; Del Valle, J; Van Dyke, RW; Askari, FK			Functional role of protein kinase B/Akt in gastric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FORKHEAD TRANSCRIPTION FACTOR; SUBUNIT GENE-EXPRESSION; PARIETAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; ACTIVATION; AKT; ALPHA; PHOSPHORYLATION	Epidermal growth factor (EGF) stimulates gastric acid secretion and H+/K+-ATPase a-subunit gene expression. Because EGF activates the serine-threonine protein kinase Akt, we explored the role of Akt in gastric acid secretion. Akt phosphorylation and activation were measured by kinase assays and by Western blots with an anti-phospho-Akt antibody, using lysates of purified (> 95%) canine gastric parietal cells in primary culture. EGF induced Akt phosphorylation and activation, whereas carbachol had no effect. LY294002, an inhibitor of phosphoinositide 3-kinase, completely blocked EGF induction of Akt phosphorylation, whereas the MEK1 inhibitor PD98059 and the protein kinase C inhibitor GF109203X had no effect. We examined the role of Akt in H+/K+-ATPase gene expression by Northern blotting using a canine H+/K+-ATPase a-subunit cDNA probe. The parietal cells were transduced with a multiplicity of infection of 100 of the adenoviral vector Ad.Myr-Akt, which overexpresses a constitutively active Akt gene, or with the control vector Ad.CMV-beta -gal, which expresses beta -galactosidase. Ad.Myr-Akt induced H+/K+-ATPase alpha -subunit gene expression 3-fold, whereas it failed to stimulate the gene cyclooxygenase-2, which was potently induced by carbachol in the same parietal cells. Ad.Myr-Akt induced aminopyrine uptake 4-fold, and it potentiated the stimulatory action of carbachol 3-fold. In contrast, Ad.Myr-Akt failed to induce changes in either parietal cell actin content, measured by Western blots with an anti-actin antibody or in the organization of the actin cellular cytoskeleton, visualized by fluorescein phalloidin staining and confocal microscopy. Transduction of the parietal cells with a multiplicity of infection of 100 of the adenoviral vector Ad.dom. neg.Akt, which overexpresses an inhibitor of Akt, blocked the stimulatory effect of EGF on both aminopyrine uptake and H+/K+-ATPase production, measured by Western blots with an anti-H+/K+-ATPase alpha -subunit antibody. Thus, EGF induces a cascade of events in the parietal cells that results in the activation of Akt. The functional role of AAt appears to be stimulation of gastric acid secretion through induction of H+/K+-ATPase expression.	Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Todisco, A (corresponding author), 6520 MSRB 1, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, K08DK002336] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-05813, K08DK02336, P30DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agnew BJ, 1999, J CELL SCI, V112, P2639; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Askari FK, 1996, GENE THER, V3, P381; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAMPBELL VW, 1989, J BIOL CHEM, V264, P11381; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEW CS, 1994, AM J PHYSIOL-GASTR L, V267, pG818, DOI 10.1152/ajpgi.1994.267.5.G818; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DELVALLE J, 1992, AM J PHYSIOL, V262, pG420, DOI 10.1152/ajpgi.1992.262.3.G420; DELVALLE J, 1994, TXB GASTROENTEROLOGY, P278; DEMBINSKI AB, 1985, ENDOCRINOLOGY, V116, P90, DOI 10.1210/endo-116-1-90; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Dufner A, 1999, MOL CELL BIOL, V19, P4525; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gooz M, 2000, AM J PHYSIOL-GASTR L, V278, pG981, DOI 10.1152/ajpgi.2000.278.6.G981; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; KAISE M, 1995, J BIOL CHEM, V270, P18637, DOI 10.1074/jbc.270.31.18637; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LJUNGSTROM M, 1991, AM J PHYSIOL, V260, pC67, DOI 10.1152/ajpcell.1991.260.1.C67; Muraoka A, 1996, AM J PHYSIOL-GASTR L, V271, pG1104, DOI 10.1152/ajpgi.1996.271.6.G1104; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nagahara A, 1998, AM J PHYSIOL-GASTR L, V275, pG740, DOI 10.1152/ajpgi.1998.275.4.G740; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Podolsky Daniel K., 1994, P129; Smolka AJ, 1999, BIOCHEM J, V340, P601, DOI 10.1042/0264-6021:3400601; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SOROKA CJ, 1993, EUR J CELL BIOL, V60, P76; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Takeuchi Y, 1999, AM J PHYSIOL-GASTR L, V276, pG1484, DOI 10.1152/ajpgi.1999.276.6.G1484; Takeuchi Y, 1997, AM J PHYSIOL-GASTR L, V273, pG1263, DOI 10.1152/ajpgi.1997.273.6.G1263; Van Dyke RW, 2000, HEPATOLOGY, V32, P1357, DOI 10.1053/jhep.2000.19790; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Wang LD, 1996, GASTROENTEROLOGY, V110, P469, DOI 10.1053/gast.1996.v110.pm8566594; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46436	46444		10.1074/jbc.M009645200	http://dx.doi.org/10.1074/jbc.M009645200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11564730	hybrid			2022-12-27	WOS:000172573100128
J	Pucar, D; Dzeja, PP; Bast, P; Juranic, N; Macura, S; Terzic, A				Pucar, D; Dzeja, PP; Bast, P; Juranic, N; Macura, S; Terzic, A			Cellular energetics in the preconditioned state - Protective role for phosphotransfer reactions captured by O-18-assisted P-31 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-CATALYZED PHOSPHOTRANSFER; ACTIVATED PROTEIN-KINASE; SENSITIVE K+ CHANNELS; CREATINE-KINASE; ADENYLATE KINASE; PHOSPHORYL TRANSFER; SKELETAL-MUSCLE; ENERGY-METABOLISM; HEART-FAILURE; ATP SYNTHESIS	Cell survival is critically dependent on the preservation of cellular bioenergetics. However, the metabolic mechanisms that confer resistance to injury are poorly understood. Phosphotransfer reactions integrate ATP-consuming with ATP-producing processes and could thereby contribute to the generation of a protective phenotype. Here, we used ischemic preconditioning to induce a stress-tolerant state and O-18-assisted P-31 nuclear magnetic resonance spectroscopy to capture intracellular phosphotransfer dynamics. Preconditioning of isolated perfused hearts triggered a redistribution in phosphotransfer flux with significant increase in creatine kinase and glycolytic rates. High energy phosphoryl fluxes through creatine kinase, adenylate kinase, and glycolysis in preconditioned hearts correlated tightly with post-ischemic functional recovery. This was associated with enhanced metabolite exchange between subcellular compartments, manifested by augmented transfer of inorganic phosphate from cellular ATPases to mitochondrial ATP synthase. Preconditioning-induced energetic remodeling protected cellular ATP synthesis and ATP consumption, improving contractile performance following ischemia-reperfusion insult. Thus, the plasticity of phosphotransfer networks contributes to the effective functioning of the cellular energetic system, providing a mechanism for increased tolerance toward injury.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Div Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Guggenheim 7, Rochester, MN 55905 USA.	terzic.andre@mayo.edu			NHLBI NIH HHS [HL-64822] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barany M., 1984, PHOSPHORUS 31 NMR PR, P511; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79; De Sousa E, 1999, CIRC RES, V85, P68; Dzeja P P, 2000, Curr Cardiol Rep, V2, P212, DOI 10.1007/s11886-000-0071-9; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Garnier A, 1996, J MOL CELL CARDIOL, V28, P1671, DOI 10.1006/jmcc.1996.0157; Gibbs CL, 1998, ADV EXP MED BIOL, V453, P527; Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V; Gross GJ, 2000, BASIC RES CARDIOL, V95, P280, DOI 10.1007/s003950050004; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hassinen IE, 1998, MOL CELL BIOCHEM, V184, P393, DOI 10.1023/A:1006818708565; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Hochachka PW, 1999, P NATL ACAD SCI USA, V96, P12233, DOI 10.1073/pnas.96.22.12233; JANIER MF, 1994, AM J PHYSIOL-HEART C, V267, pH1353, DOI 10.1152/ajpheart.1994.267.4.H1353; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Jennings R B, 1995, Monogr Pathol, V37, P47; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; KINGSLEYHICKMAN PB, 1987, BIOCHEMISTRY-US, V26, P7501, DOI 10.1021/bi00397a045; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; SAKO EY, 1988, J BIOL CHEM, V263, P10600; Saks VA, 1996, MOL CELL BIOCHEM, V161, P195, DOI 10.1007/BF00240050; Saupe KW, 1998, CIRC RES, V82, P898; Saupe KW, 2000, J BIOL CHEM, V275, P19742, DOI 10.1074/jbc.M001932200; Shen WQ, 1999, CIRCULATION, V100, P2113, DOI 10.1161/01.CIR.100.20.2113; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; TAEGTMEYER H, 1994, CURR PROB CARDIOLOGY, V19, P61, DOI 10.1016/0146-2806(94)90008-6; Takeo S, 1999, CARDIOVASC RES, V43, P32, DOI 10.1016/S0008-6363(99)00079-6; Terzic A, 1999, CLIN PHARMACOL THER, V66, P105, DOI 10.1053/cp.1999.v66.99991; Terzic A, 2000, J MOL CELL CARDIOL, V32, P1911, DOI 10.1006/jmcc.2000.1256; Tian R, 1997, J CLIN INVEST, V99, P745, DOI 10.1172/JCI119220; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Weiss RG, 1996, CIRC RES, V79, P435, DOI 10.1161/01.RES.79.3.435; WEVERS RA, 1995, CLIN CHEM, V41, P744; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	56	86	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44812	44819		10.1074/jbc.M104425200	http://dx.doi.org/10.1074/jbc.M104425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11583991	hybrid			2022-12-27	WOS:000172406700065
J	Dong, K; Xu, J; Vanoye, CG; Welch, R; MacGregor, GG; Giebisch, G; Hebert, SC				Dong, K; Xu, J; Vanoye, CG; Welch, R; MacGregor, GG; Giebisch, G; Hebert, SC			An amino acid triplet in the NH2 terminus of rat ROMK1 determines interaction with SUR2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; SULFONYLUREA RECEPTOR; REGULATOR; STOICHIOMETRY; GLIBENCLAMIDE; SENSITIVITY; EXPRESSION; CLONING; PROTEIN; KIR6.2	ATP-regulated (K-ATP) channels are formed by an inward rectifier pore-forming subunit (Kir) and a sulfonylurea (glibenclamide)-binding protein, a member of the ATP binding cassette family (sulfonylurea receptor (SUR) or cystic fibrosis transmembrane conductance regulator). The latter is required to confer glibenclamide sensitivity to KATP channels. In the mammalian kidney ROMK1-3 are components of K-ATP channels that mediate K+ secretion into urine. ROMK1 and ROMK3 splice variants share the core polypeptide of ROMK2 but also have distinct NH2-terminal extensions of 19 and 26 amino acids, respectively. The SUR2B is also expressed in rat kidney tubules and may combine with Kir.1 to form renal K-ATP channels. Our previous studies showed that co-expression of ROMK2, but not ROMK1 or ROMK3, with rat SUR2B in oocytes generated glibenclamide-sensitive K+ currents. These data suggest that the NH2-terminal extensions in both ROMK1 and ROMK3 block ROMK-SUR2B interaction. Seven amino acids in the NH2-terminal extensions of ROMK1 and ROMK3 are identical (amino acids 13-19 in ROMK1 and 20-26 in ROMK3) and may determine ROMK-SUR2B interaction. We constructed a series of hemagglutinin-tagged ROM]KI NH2-terminal deletion and substitution mutants and examined glibenclamide-sensitive K+ currents in oocytes when co-expressed with SUR2B. These studies identified an amino acid triplet "IRA" within the conserved segment in the NH2 terminus of ROMK1 and ROMK3 that blocks the ability of SUR2B to confer glibenclamide sensitivity to the expressed K+ currents. The position of this triplet in the ROMK1 NH2-terminal extension is also important for the ROMK-SUR2B interactions. In vitro co-translation and immunoprecipitation studies with hemagglutinin-tagged ROMK mutants and SUR2B indicted that direct interaction between these two proteins is required for glibenclamide sensitivity of induced K+ currents in oocytes. These results suggest that the IRA triplet in the NH2-terminal extensions of both ROMK1 and ROMK3 plays a key role in subunit assembly of the renal secretary K-ATP channel.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Vanderbilt Univ, Med Ctr, Div Med Genet, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Nephrol, Nashville, TN 37232 USA	Yale University; Vanderbilt University; Vanderbilt University	Hebert, SC (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	steven.hebert@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054998, R01DK037605, R01DK054999] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54999, DK54998, DK37605] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Beesley AH, 1999, PFLUG ARCH EUR J PHY, V438, P1, DOI 10.1007/s004240050872; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Bryan J, 1999, BBA-BIOMEMBRANES, V1461, P285, DOI 10.1016/S0005-2736(99)00164-9; Cahill P, 2000, J BIOL CHEM, V275, P16697, DOI 10.1074/jbc.M910205199; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; KOZAK M, 1991, J BIOL CHEM, V266, P19867; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Misler S, 1992, Curr Opin Nephrol Hypertens, V1, P21, DOI 10.1097/00041552-199210000-00005; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Reimann F, 1999, J PHYSIOL-LONDON, V518, P325, DOI 10.1111/j.1469-7793.1999.0325p.x; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Tanemoto M, 2000, AM J PHYSIOL-RENAL, V278, pF659, DOI 10.1152/ajprenal.2000.278.4.F659; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44347	44353		10.1074/jbc.M108072200	http://dx.doi.org/10.1074/jbc.M108072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11567030	hybrid			2022-12-27	WOS:000172297700108
J	Belden, WJ; Barlowe, C				Belden, WJ; Barlowe, C			Distinct roles for the cytoplasmic tail sequences of Emp24p and Erv25p in transport between the endoplasmic reticulum and Golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPII-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; FAMILY MEMBERS; YEAST; MEMBRANE; COATOMER; LOCALIZATION; COMPONENT	Heteromeric complexes of p24 proteins cycle between early compartments of the secretory pathway and are required for efficient protein sorting. Here we investigated the role of cytoplasmically exposed tail sequences on two p24 proteins, Emp24p and Erv25p, in directing their movement and subcellular location in yeast. Studies on a series of deletion and chimeric Emp24p-Erv25p proteins indicated that the tail sequences impart distinct functional properties that were partially redundant but not entirely interchangeable. Export of an Emp24p-Erv25p complex from the endoplasmic reticulum (ER) did not depend on two other associated p24 proteins, Erp1 and Erp2p. To examine interactions between the Emp24p and Erv25p tail sequences with the COPI and COPII coat proteins, binding experiments with immobilized tail peptides and coat proteins were performed. The Emp24p and Erv25p tail sequences bound the Sec13p/Sec31p subunit of the COPII coat (K-d similar to 100 mum), and binding depended on a pair of aromatic residues found in both tail sequences. COPI subunits also bound to these Emp24p and Erv25p peptides; however, the Erv25p tail sequence, which contains a dilysine motif, bound COPI more efficiently. These results suggest that both the Emp24p and Erv25p cytoplasmic sequences contain a di-aromatic motif that binds subunits of the COPII coat and promotes export from the ER. The Erv25p tail sequence binds COPI and is responsible for returning this complex to the ER.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	Barlowe@Dartmouth.edu						ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Belden WJ, 2001, MOL BIOL CELL, V12, P957, DOI 10.1091/mbc.12.4.957; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Ciufo LF, 2000, J BIOL CHEM, V275, P8382, DOI 10.1074/jbc.275.12.8382; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DUDEN R, 1994, J BIOL CHEM, V269, P24486; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Rojo M, 2000, J CELL SCI, V113, P1043; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WADA I, 1991, J BIOL CHEM, V266, P19599; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	37	60	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43040	43048		10.1074/jbc.M108113200	http://dx.doi.org/10.1074/jbc.M108113200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560939	hybrid			2022-12-27	WOS:000172169300055
J	Bechard, D; Gentina, T; Delehedde, M; Scherpereel, A; Lyon, M; Aumercier, M; Vazeux, R; Richet, C; Degand, P; Jude, B; Janin, A; Fernig, DG; Tonnel, AB; Lassalle, P				Bechard, D; Gentina, T; Delehedde, M; Scherpereel, A; Lyon, M; Aumercier, M; Vazeux, R; Richet, C; Degand, P; Jude, B; Janin, A; Fernig, DG; Tonnel, AB; Lassalle, P			Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-SCATTER FACTOR; CELL-SPECIFIC MOLECULE-1; HEPARAN-SULFATE; C-MET; DERMATAN SULFATE; TYROSINE KINASE; HIGH-AFFINITY; FIBROBLAST-GROWTH; FACTOR ISOFORMS; IN-VITRO	Proteoglycans that modulate the activities of growth factors, chemokines, and coagulation factors regulate in turn the vascular endothelium with respect to processes such as inflammation, hemostasis, and angiogenesis. Endothelial cell-specific molecule-1 is mainly expressed by endothelial cells and regulated by pro-inflammatory cytokines (Lassalle, P., Molet, S., Janin, A., Heyden, J. V., Tavernier, J., Fiers, W., Devos, R., and Tonnel, A. B. (1996) J. Biol. Chem. 271, 20458-20464). We demonstrate that this molecule is secreted as a soluble dermatan sulfate (DS) proteoglycan. This proteoglycan represents the major form either secreted by cell lines or circulating in the human bloodstream. Because this proteoglycan is specifically secreted by endothelial cells, we propose to nam it endocan. The glycosaminoglycan component of endocan consists of a single DS chain covalently attached to serine 137. Endocan dose-dependently increased the hepatocyte growth factor/scatter factor (HGF/SF)-mediated proliferation of human embryonic kidney cells, whereas the nonglycanated form of endocan did not. Moreover, DS chains purified from endocan mimicked the endocan-mediated increase of cell proliferation in the presence of HGF/SF. Overall, our results demonstrate that endocan is a novel soluble dermatan sulfate proteoglycan produced by endothelial cells. Endocan regulates HGF/SF-mediated mitogenic activity and may support the function of HGF/SF not only in embryogenesis and tissue repair after injury but also in tumor progression.	Inst Pasteur, INSERM, U416, F-59019 Lille, France; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Manchester, Christie Hosp NHS Trust, Canc Res Campaign, Dept Med Oncol, Manchester M20 4BX, Lancs, England; CNRS, UMR 8526, Inst Biol Lille, F-75700 Paris, France; CHRU, Hop Cardiol, Lab Hematol A, F-59019 Lille, France; ICOS Corp, Bothell, WA 98021 USA; INSERM, U377, F-59019 Lille, France; Hop St Louis, Serv Anat Pathol, F-75475 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Liverpool; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; CHU Lille; Icos Corporation; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Lassalle, P (corresponding author), Inst Pasteur, INSERM, U416, 1 Rue Pr A Calmette,BP 245, F-59019 Lille, France.	philippe.lassalle@pasteur-lille.fr	Lassalle, Philippe/L-6705-2018; Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Lyon, Malcolm/0000-0001-9575-6879; Aumercier, Marc/0000-0002-0370-3452; lassalle, philippe/0000-0001-6434-0344; DELEHEDDE, Maryse/0000-0003-2724-143X				Bechard D, 2000, J VASC RES, V37, P417, DOI 10.1159/000025758; Bechard D, 2001, J IMMUNOL, V167, P3099, DOI 10.4049/jimmunol.167.6.3099; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Borghesi LA, 1999, BLOOD, V93, P140, DOI 10.1182/blood.V93.1.140.401k40_140_148; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; Deakin JA, 1999, J CELL SCI, V112, P1999; Delorme MA, 1996, THROMB HAEMOSTASIS, V75, P747; Fernig D G, 2001, Methods Mol Biol, V171, P505; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Hammerman MR, 1998, CURR OPIN NEPHROL HY, V7, P419, DOI 10.1097/00041552-199807000-00012; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Lassalle P, 1996, J BIOL CHEM, V271, P20458, DOI 10.1074/jbc.271.34.20458; LASSALLE P, 1992, EUR J IMMUNOL, V22, P425, DOI 10.1002/eji.1830220221; Leygue E, 2000, J PATHOL, V192, P313; Leygue E, 1998, CANCER RES, V58, P1348; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; Matsumoto K, 1996, CANCER CHEMOTH PHARM, V38, pS42, DOI 10.1007/s002800051037; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; Okada M, 1999, BIOCHEM BIOPH RES CO, V255, P80, DOI 10.1006/bbrc.1999.0150; Otsuka T, 1998, CANCER RES, V58, P5157; Penc SF, 1998, J LEUKOCYTE BIOL, V64, P351, DOI 10.1002/jlb.64.3.351; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Sakata H, 1997, J BIOL CHEM, V272, P9457; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; Sergeant N, 2000, J BIOL CHEM, V275, P17094, DOI 10.1074/jbc.M000237200; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; TAKEBAYASHI T, 1995, J CELL BIOL, V129, P1411, DOI 10.1083/jcb.129.5.1411; Takigawa N, 1997, LUNG CANCER-J IASLC, V17, P211, DOI 10.1016/S0169-5002(97)00651-X; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	66	178	186	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48341	48349		10.1074/jbc.M108395200	http://dx.doi.org/10.1074/jbc.M108395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11590178	hybrid			2022-12-27	WOS:000172927000082
J	Brzeska, H; Young, R; Tan, C; Szczepanowska, J; Korn, ED				Brzeska, H; Young, R; Tan, C; Szczepanowska, J; Korn, ED			Calmodulin-binding and autoinhibitory domains of Acanthamoeba myosin I heavy chain kinase, a p21-activated kinase (PAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CATALYTIC DOMAIN; SUBSTRATE-SPECIFICITY; RAC GTPASES; ACTIVATION; CDC42; PHOSPHORYLATION; IDENTIFICATION; SEQUENCE; FAMILY	The sequence homology between Acanthamoeba myosin I heavy chain kinase (MIHCK) and other p21-activated kinases (PAKs) is relatively low, including only the catalytic domain and a short PAK N-terminal motif (PAN), and even these regions are not highly homologous. In this paper, we report the expression in insect cells of full-length, fully regulated Acanthamoeba MIHCK and further characterize the regulation of this PAK by Rac, calmodulin, and autoinhibition. We map the autoinhibitory region of MIHCK to its PAN region and show that the PAN region inhibits autophosphorylation and kinase activity of unphosphorylated full-length MIHCK and its expressed catalytic domain but has very little effect on either when they are phosphorylated. These properties are similar to those reported for mammalian PAK1. Unlike PAK1, MIHCK is activated by Rac only in the presence of phospholipid. However, peptides containing the PAN region of MIHCK bind Rac in the absence of lipid, and Rac binding reverses the inhibition of the MIHCK catalytic domain by PAN peptides. Our data suggest that a region N-terminal to PAN is required for optimal binding of Rac. Also unlike mammalian PAK, phospholipid stimulation of Acanthamoeba MIHCK and Dictyostelium MIHCK) (which is also a PAK) is inhibited by Ca2+-calmodulin. In contrast to Dictyostelium MIHCK, however, Ca2+-calmodulin also inhibits Rac-induced activity of Acanthamoeba MIHCK. The basic region N-terminal to PAN is essential for calmodulin binding.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Korn, ED (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 50,Rm 2517,9000 Rockville Pike, Bethesda, MD 20892 USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295; Szczepanowska, Joanna/0000-0002-0434-1262	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000506, Z01HL000506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; Brzeska H, 1996, J BIOL CHEM, V271, P27049, DOI 10.1074/jbc.271.43.27049; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Gizachew D, 2000, BIOCHEMISTRY-US, V39, P3963, DOI 10.1021/bi992646d; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee SF, 1998, J BIOL CHEM, V273, P27911, DOI 10.1074/jbc.273.43.27911; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Stevens WK, 1999, BIOCHEMISTRY-US, V38, P5968, DOI 10.1021/bi990426u; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	41	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47468	47473		10.1074/jbc.M108957200	http://dx.doi.org/10.1074/jbc.M108957200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579107	hybrid			2022-12-27	WOS:000172768500103
J	Inokuchi, A; Hinoshita, E; Iwamoto, Y; Kohno, K; Kuwano, M; Uchiumi, T				Inokuchi, A; Hinoshita, E; Iwamoto, Y; Kohno, K; Kuwano, M; Uchiumi, T			Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes - A transcriptional control of a plausible bile acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; EXPORT PUMP; HUMAN ILEAL; CMOAT GENE; CELL LINE; CHOLESTEROL; MUTATIONS; MRP3; IDENTIFICATION; LIGANDS	The enterohepatic circulation is essential for the maintenance of bile acids and cholesterol homeostasis. The ileal bile acid transporter on the apical membrane of enterocytes mediates the intestinal uptake of bile salts, but little is known about the bile salt secretion from the basolateral membrane of enterocytes into blood. In the basolateral membrane of enterocytes, an ATP-binding cassette transporter, multidrug resistance protein 3 (MRP3), is expressed, which has the ability to transport bile salts. We hypothesized that MRP3 might play a role in the enterohepatic circulation of bile salts by transporting them from enterocytes into circulating blood through the up-regulation of MRP3 expression, so we investigated the transcriptional control of MRP3 in response to bile salts. MRP3 mRNA levels were increased about 3-fold in human colon cells by chenodeoxycholic acid (CDCA), in a dose- and time-dependent manner. In the promoter assay, the promoter activity of MRP3 was increased about 3-fold over the basal promoter activity when treated with CDCA, and the putative bile salt-responsive elements exist in the region -229/-138 including two alpha -1 fetoprotein transcription factor (FTF)-like elements. Constructs with a specific mutation in the consensus sequence of FTF elements showed no increase in basal transcriptional activity following CDCA treatment. In electrophoretic mobility shift assay with nuclear extracts, specific binding of FTF to FTF-like elements was observed when treated with CDCA. The expression of FTF mRNA levels were also markedly enhanced in response to CDCA, and overexpression of FTF specifically activated the MRP3 promoter activity about 4-fold over the basal promoter activity. FTF thus might play a key role not only in the bile salt synthetic pathway in hepatocytes but also in the bile salt excretion pathway in enterocytes through the regulation of MRP3 expression. MRP3 may contribute as a plausible bile salt-exporting transporter to the enterohepatic circulation of bile salts.	Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthoped Surg, Higashi Ku, Fukuoka 8128582, Japan; Univ Occupat & Environm Hlth, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	Kyushu University; Kyushu University; University of Occupational & Environmental Health - Japan	Uchiumi, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	uchiumi@biochem1.med.kyushu-u.ac.jp						Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chen WL, 2001, J LIPID RES, V42, P1402; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hirohashi T, 2000, J PHARMACOL EXP THER, V292, P265; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; Keppler D, 1998, METHOD ENZYMOL, V292, P607; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1997, CANCER RES, V57, P3537; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; Lee J, 2000, SEMIN LIVER DIS, V20, P373, DOI 10.1055/s-2000-9390; Lee JM, 2000, GASTROENTEROLOGY, V118, P163, DOI 10.1016/S0016-5085(00)70425-2; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MEUNIER V, 1995, CELL BIOL TOXICOL, V11, P187, DOI 10.1007/BF00756522; Nies AT, 1998, HEPATOLOGY, V28, P1332, DOI 10.1002/hep.510280523; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; OELKERS P, 1995, BBA-LIPID LIPID MET, V1257, P199, DOI 10.1016/0005-2760(95)00098-W; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Ortiz DF, 1999, AM J PHYSIOL-GASTR L, V276, pG1493, DOI 10.1152/ajpgi.1999.276.6.G1493; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stravitz RT, 1997, GASTROENTEROLOGY, V113, P1599, DOI 10.1053/gast.1997.v113.pm9352862; Tanaka T, 1999, HEPATOLOGY, V30, P1507, DOI 10.1002/hep.510300617; Taniguchi K, 1996, CANCER RES, V56, P4124; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Tsujii H, 1999, GASTROENTEROLOGY, V117, P653, DOI 10.1016/S0016-5085(99)70459-2; Uchiumi T, 1998, BIOCHEM BIOPH RES CO, V252, P103, DOI 10.1006/bbrc.1998.9546; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; Walters JRF, 2000, GUT, V46, P308, DOI 10.1136/gut.46.3.308; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228	48	96	101	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46822	46829		10.1074/jbc.M104612200	http://dx.doi.org/10.1074/jbc.M104612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590139	hybrid			2022-12-27	WOS:000172768500021
J	Rousse, S; Lallemand, F; Montarras, D; Pinset, C; Mazars, A; Prunier, C; Atfi, A; Dubois, C				Rousse, S; Lallemand, F; Montarras, D; Pinset, C; Mazars, A; Prunier, C; Atfi, A; Dubois, C			Transforming growth factor-beta inhibition of insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells involves a c-Jun N-terminal kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOGENIC DIFFERENTIATION; MYOBLAST DIFFERENTIATION; SIGNAL-TRANSDUCTION; EXPRESSION; ACTIVATION; INDUCTION; PROLIFERATION; TRANSCRIPTION; TGF-BETA-2; SECRETION	Transforming growth factor-beta (TGF-beta) and insulin-like growth factors (IGFs) play critical roles in the control of myogenesis. Insulin-like growth factor-binding protein-5 (IGFBP-5), by regulating the bioavailability of IGFs, is involved in controlling IGF-dependent differentiation. We investigated the effects of TGF-13 on the IGFBP-5 production induced by IGFs in mouse myoblasts. TGF-beta leads to a decrease in IGFBP-5 synthesis at both transcript and protein levels, and blocked muscle differentiation. The Smad proteins and the e-Jun N-terminal kinase (JNK) have been shown to be involved in TGF-beta signaling pathways. We provide evidence that the JNK pathway, rather than Smad proteins, is involved in the response of muscle cells to TGF-beta. This factor failed to stimulate the GAL4-Smad 2/3 transcriptional activities of the constructs used to transfect myoblasts. Moreover, stable expression of the antagonistic Smad7 did not abolish the inhibitory effect of TGF-beta on IGFBP-5 production whereas expression of a dominant-negative version of MKK4, an upstream activator of JNK, did. We also showed, using a specific inhibitor, that the p38 mitogen-activated protein kinase (p38 MAPK) was not involved in the inhibition of IGFBP-5 production. Thus, TGF-beta -mediated IGFBP-5 inhibition is independent of Smads and requires activation of the JNK signaling pathway.	Hop St Antoine, INSERM U482, F-75571 Paris 12, France; INSERM U515, F-75571 Paris 12, France; Inst Pasteur, Lab Dev Cellulaire, URA CNRS 1947, F-75724 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Dubois, C (corresponding author), Hop St Antoine, INSERM U482, F-75571 Paris 12, France.	dubois@st-antoine.inserm.fr	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BOSCHE WJ, 1995, J CELL PHYSIOL, V164, P324, DOI 10.1002/jcp.1041640213; CARONI P, 1994, J NEUROSCI, V14, P3378; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; EWTON DZ, 1995, J ENDOCRINOL, V144, P539, DOI 10.1677/joe.0.1440539; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; Frey RS, 1997, CANCER RES, V57, P628; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HEINO J, 1990, J BIOL CHEM, V265, P10181; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; LAFYATIS R, 1991, MOL CELL BIOL, V11, P3795, DOI 10.1128/MCB.11.7.3795; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; LANDSTROM M, 2000, CELL, V87, P565; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; MCCUSKER RH, 1989, J BIOL CHEM, V264, P7795; MCCUSKER RH, 1994, ENDOCRINOLOGY, V134, P2095, DOI 10.1210/en.134.5.2095; McLennan IS, 1997, DEV DYNAM, V208, P278, DOI 10.1002/(SICI)1097-0177(199702)208:2<278::AID-AJA14>3.0.CO;2-#; Montarras D, 1996, J CELL SCI, V109, P551; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; Rousse S, 1998, ENDOCRINOLOGY, V139, P1487, DOI 10.1210/en.139.4.1487; SCHOFIELD JN, 1990, EXP CELL RES, V191, P144, DOI 10.1016/0014-4827(90)90048-F; SCHULLER AGP, 1994, MOL CELL ENDOCRINOL, V104, P57, DOI 10.1016/0303-7207(94)90051-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	51	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46961	46967		10.1074/jbc.M104440200	http://dx.doi.org/10.1074/jbc.M104440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598109	hybrid			2022-12-27	WOS:000172768500040
J	Sengupta, S; Wehbe, C; Majors, AK; Ketterer, ME; DiBello, PM; Jacobsen, DW				Sengupta, S; Wehbe, C; Majors, AK; Ketterer, ME; DiBello, PM; Jacobsen, DW			Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; REDOX STATUS; CATALYZED OXIDATION; PROTEIN-BINDING; IN-VIVO; PLASMA; COPPER; HYPERHOMOCYSTEINEMIA; ATHEROSCLEROSIS; AMINOTHIOLS	Disulfide forms of homocysteine account for > 98% of total homocysteine in plasma from healthy individuals. We recently reported that homocysteine reacts with albumin-Cys(34)-S-S-cysteine to form homocysteine-cysteine mixed disulfide and albumin-Cys(34) thiolate anion. The latter then reacts with homocystine or homocysteine-cysteine mixed disulfide to form albumin-bound homocysteine (Sengupta, S., Chen, H., Togawa, T., DiBello, P. M., Majors, A. K, Budy, B., Ketterer, M. E., and Jacobsen, D. W. (2001) J. Biol. Chem. 276, 30111-30117). We now extend these studies to show that human albumin, but not ceruloplasmin, mediates the conversion of homocysteine to its low molecular weight disulfide forms (homocystine and homocysteine-cysteine mixed disulfide) by thiol/disulfide exchange reactions. Only a small fraction of homocystine is formed by an oxidative process in which copper bound to albumin, but not ceruloplasmin, mediates the reaction. When copper is removed from albumin by chelation, the overall conversion of homocysteine to its disulfide forms is reduced by only 20%. Ceruloplasmin was an ineffective catalyst of homocysteine oxidation, and immunoprecipitation of ceruloplasmin from human plasma did not inhibit the capacity of plasma to mediate the conversion of homocysteine to its disulfide forms. In contrast, ceruloplasmin was a highly efficient catalyst for the oxidation of cysteine and cysteinylglycine to cystine and bis(-S-cysteinylglycine), respectively. However, when thiols (cysteine and homocysteine) that are disulfide-bonded to albumin-Cys(34) are removed by treatment with dithiothreitol to form albumin-Cys(34)-SH (mercaptalbumin), the conversion of homocysteine to its disulfide forms is completely blocked. In conclusion, albumin mediates the formation of disulfide forms of homocysteine by thiol/disulfide exchange, whereas ceruloplasmin converts cysteine to cystine by copper-dependent autooxidation.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; No Arizona Univ, Dept Chem, Flagstaff, AZ 86011 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Northern Arizona University	Jacobsen, DW (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	jacobsd@ccf.org						BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; Bescond A, 1999, BIOCHEM BIOPH RES CO, V263, P498, DOI 10.1006/bbrc.1999.1391; CAVALLINI D, 1969, ARCH BIOCHEM BIOPHYS, V130, P354, DOI 10.1016/0003-9861(69)90044-7; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; DUDMAN NPB, 1983, CLIN CHIM ACTA, V127, P105, DOI 10.1016/0009-8981(83)90080-3; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FELDMAN SL, 1985, J INORG BIOCHEM, V17, P51; FRIEDMAN M, 1965, J AM CHEM SOC, V87, P3672, DOI 10.1021/ja01094a025; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; HOUK RS, 1994, ACCOUNTS CHEM RES, V27, P333, DOI 10.1021/ar00047a003; JACOBSEN DW, 1984, BIOCHEMISTRY-US, V23, P2017, DOI 10.1021/bi00304a021; Jacobsen DW, 2000, ARTERIOSCL THROM VAS, V20, P1182, DOI 10.1161/01.ATV.20.5.1182; JACOBSEN DW, 1993, J INORG BIOCHEM, V50, P47, DOI 10.1016/0162-0134(93)80013-Y; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JOCELYN PC, 1972, BIOCH SH GROUP, P54; JOYCE DA, 1991, J PHARM SCI, V80, P1370; Kachur AV, 1999, FREE RADICAL RES, V31, P23, DOI 10.1080/10715769900300571; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; MANSOOR MA, 1993, CLIN CHEM, V39, P980; MANSOOR MA, 1993, METABOLISM, V42, P1481, DOI 10.1016/0026-0495(93)90202-Y; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; McCaddon A, 1998, INT J GERIATR PSYCH, V13, P235, DOI 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; Miller JW, 2000, NUTRITION, V16, P675, DOI 10.1016/S0899-9007(00)00307-5; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Muniz P, 2001, FREE RADICAL BIO MED, V30, P354, DOI 10.1016/S0891-5849(00)00480-9; Nygard O, 1999, J INTERN MED, V246, P425, DOI 10.1046/j.1365-2796.1999.00512.x; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; Poddar R, 2001, CIRCULATION, V103, P2717; REFSUM H, 1985, CLIN CHEM, V31, P624; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; Sengupta S, 2001, J BIOL CHEM, V276, P30111, DOI 10.1074/jbc.M104324200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGAMI M, 1984, INT J PEPT PROT RES, V24, P96; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; SUZUKI KT, 1989, ARCH BIOCHEM BIOPHYS, V273, P572, DOI 10.1016/0003-9861(89)90517-1; TIETZ NW, 1983, CLIN GUIDE LAB TESTS, P168; TRAVIS J, 1976, BIOCHEM J, V157, P301, DOI 10.1042/bj1570301; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Welch GN, 1997, ANN NY ACAD SCI, V811, P48, DOI 10.1111/j.1749-6632.1997.tb51988.x; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YOSHIDA Y, 1992, ACTA NEUROL SCAND, V86, P490, DOI 10.1111/j.1600-0404.1992.tb05130.x; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582	55	111	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46896	46904		10.1074/jbc.M108451200	http://dx.doi.org/10.1074/jbc.M108451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592966	hybrid			2022-12-27	WOS:000172768500031
J	Aman, MJ; Tosello-Trampont, AC; Ravichandran, K				Aman, MJ; Tosello-Trampont, AC; Ravichandran, K			Fc gamma RIIB1/SHIP-mediated inhibitory signaling in B cells involves lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATASE SHIP; FC-GAMMA-RIIB; ANTIGEN RECEPTOR; 5'-PHOSPHATASE SHIP; 5-PHOSPHATASE SHIP; DEFICIENT MICE; MEMBRANE RAFTS; LINKER PROTEIN; ACTIVATION; TRANSDUCTION	One type of membrane microdomain, enriched in glycosphingolipids and cholesterol and referred to as lipid rafts, has been implicated in the generation of activating signals triggered by a variety of stimuli. Several laboratories, including ours, have recently demonstrated that the B cell receptor (BCR) inducibly localizes to the rafts upon activation and that functional lipid rafts are important for BCR-mediated "positive" signaling. In the later phases of the immune response, coligation of the BCR and the inhibitory receptor Fc gamma RIIB1 leads to potent inhibition of BCR-induced positive signaling through the recruitment of the inositol phosphatase SHIP to Fc gamma RIIB1. One potential model is that the Fc gamma RIIB1 itself might be excluded from the rafts basally and that destabilization of raft-dependent BCR signaling might be part of the mechanism for the Fc gamma RIIB1-mediated negative regulation. We tested this hypothesis and observed that preventing BCR raft localization is not the mechanism for this inhibition. Surprisingly, a fraction of Fc gamma RIIB1 is constitutively localized in the rafts and increases further after BCR + Felt coligation. SHIP is actively recruited to lipid rafts under negative stimulation conditions, and the majority of Fc gamma RIIB1-SHIP complexes localize to lipid rafts compared with non-raft regions of the plasma membrane. This suggested that this negative feedback loop is also initiated in the lipid rafts. Despite its basal localization to the rafts, Fc gamma RIIB1 did not become phosphorylated after BCR alone cross-linking and did not colocalize with the BCR that moves to rafts upon BCR engagement alone (positive signaling conditions), perhaps suggesting the existence of different subsets of rafts. Taken together, these data suggest that lipid rafts play a role in both the positive signaling via the BCR as well as the inhibitory signaling through Fc gamma RIIB1/SHIP.	Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Ravichandran, K (corresponding author), Univ Virginia, Carter Immunol Ctr, HSC, Bldg MR4,Rm 4012F, Charlottesville, VA 22908 USA.				NIAID NIH HHS [R01 AI43425] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; Aman MJ, 2000, MOL CELL BIOL, V20, P3576, DOI 10.1128/MCB.20.10.3576-3589.2000; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brauweiler A, 2000, J EXP MED, V191, P1545, DOI 10.1084/jem.191.9.1545; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cherukuri A, 2001, IMMUNITY, V14, P169; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Field KA, 1999, J BIOL CHEM, V274, P1753, DOI 10.1074/jbc.274.3.1753; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gold MR, 1999, J IMMUNOL, V163, P1894; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Hashimoto A, 1999, J BIOL CHEM, V274, P11203, DOI 10.1074/jbc.274.16.11203; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; LEVIS GM, 1976, BIOCHEM J, V156, P103, DOI 10.1042/bj1560103; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Lou ZK, 2000, J EXP MED, V191, P347, DOI 10.1084/jem.191.2.347; March ME, 2000, J BIOL CHEM, V275, P29960, DOI 10.1074/jbc.M003714200; Okada H, 1998, J IMMUNOL, V161, P5129; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tridandapani S, 1997, J IMMUNOL, V158, P1125; Vely F, 1997, J IMMUNOL, V159, P2075; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Weintraub BC, 1998, CURR BIOL, V8, pR575, DOI 10.1016/S0960-9822(07)00365-X; Wollscheid B, 1999, CURR TOP MICROBIOL, V246, P283; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	59	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46371	46378		10.1074/jbc.M104069200	http://dx.doi.org/10.1074/jbc.M104069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571279	hybrid			2022-12-27	WOS:000172573100119
J	Curat, CA; Eck, M; Dervillez, X; Vogel, WF				Curat, CA; Eck, M; Dervillez, X; Vogel, WF			Mapping of epitopes in discoidin domain receptor 1 critical for collagen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED JUVENILE RETINOSCHISIS; COAGULATION-FACTOR-V; TYROSINE KINASE; BRAIN-TUMORS; I-DOMAIN; EXPRESSION; PROTEIN; IDENTIFICATION; C2-DOMAIN; INTEGRIN	The binding and activation of the discoidin domain receptor I by collagen has led to the conclusion that proteins from the extracellular matrix can directly induce receptor tyrosine kinase-mediated signaling cascades. A region in the extracellular domain of DDR1 homologous to the Dictyostelium discoideum protein discoidin-I is also present in the secreted human protein RS1. Mutations in RS1 cause retinoschisis, a genetic disorder characterized by ablation of the retina. By introducing point mutations into the discoidin domain of DDR1 at positions homologous to the retinoschisis mutations, ligand binding epitopes in the discoidin domain of DDR1 were mapped. Surprisingly, some residues only affected receptor phosphorylation, whereas others influenced both collagen-binding and receptor activation. Furthermore, two truncated DDR1 variants, lacking either the discoidin domain or the stalk region between the discoidin and transmembrane domain, were generated. We showed that (i) the discoidin domain was necessary and sufficient for collagen binding, (ii) only the region between discoidin and transmembrane domain was glycosylated, and (iii) the entire extracellular domain was essential for transmembrane signaling. Using these results, we were able to predict key sites in the collagen-binding epitope of DDR1 and to suggest a potential mechanism of signaling.	Goethe Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Lab Extracellular Matrix Signaling & Tumor Invas, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Dept Infect Dis, D-60596 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Vogel, WF (corresponding author), Goethe Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Lab Extracellular Matrix Signaling & Tumor Invas, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	Wolfgangfvogel@hotmail.com	Dervillez, Xavier/AAB-4798-2020					ALEXANDER S, 1992, DIFFERENTIATION, V51, P149, DOI 10.1111/j.1432-0436.1992.tb00691.x; ALVES F, 1995, ONCOGENE, V10, P609; Alves F, 2001, FASEB J, V15, P1321, DOI 10.1096/fj.00-0626fje; BARKER KT, 1995, ONCOGENE, V10, P569; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; Chin GS, 2000, PLAST RECONSTR SURG, V106, P1532, DOI 10.1097/00006534-200012000-00014; den Dunnen JT, 1998, HUM MOL GENET, V7, P1185; Dervillez X, 1997, IMMUNOPHARMACOLOGY, V38, P129, DOI 10.1016/S0162-3109(97)00066-0; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Foehr ED, 2000, FASEB J, V14, P973, DOI 10.1096/fasebj.14.7.973; George NDL, 1996, ARCH OPHTHALMOL-CHIC, V114, P274, DOI 10.1001/archopht.1996.01100130270007; Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873; Hiriyanna KT, 1999, HUM MUTAT, V14, P423, DOI 10.1002/(SICI)1098-1004(199911)14:5<423::AID-HUMU8>3.0.CO;2-D; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Jansson M, 2001, J CELL SCI, V114, P2043; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Layne MD, 2001, MOL CELL BIOL, V21, P5256, DOI 10.1128/MCB.21.15.5256-5261.2001; Leitinger B, 2000, NAT STRUCT BIOL, V7, P614, DOI 10.1038/77895; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Mohan RR, 2001, EXP EYE RES, V72, P87, DOI 10.1006/exer.2000.0932; Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Nicolaes GAF, 2000, BLOOD COAGUL FIBRIN, V11, P89, DOI 10.1097/00001721-200011010-00010; PEREZ JL, 1994, ONCOGENE, V9, P211; Perez JL, 1996, ONCOGENE, V12, P1469; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Reid SNM, 1999, GENE, V227, P257, DOI 10.1016/S0378-1119(98)00578-2; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Sakamoto O, 2001, EUR RESPIR J, V17, P969, DOI 10.1183/09031936.01.17509690; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; ZERLIN M, 1993, ONCOGENE, V8, P2731	50	59	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45952	45958		10.1074/jbc.M104360200	http://dx.doi.org/10.1074/jbc.M104360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11598108	hybrid			2022-12-27	WOS:000172573100064
J	Gurezka, R; Langosch, D				Gurezka, R; Langosch, D			In vitro selection of membrane-spanning leucine zipper protein-protein interaction motifs using POSSYCCAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; ESCHERICHIA-COLI; ERYTHROPOIETIN RECEPTOR; GXXXG MOTIF; ASSOCIATION; DIMERIZATION; TRANSCRIPTION; GLYCOPHORIN; ACTIVATION; RESIDUES	A membrane-spanning heptad repeat motif mediates interaction between transmembrane segments. This motif was randomized with three different sets of mostly hydrophobic residues in the context of POSSYCCAT, a modified ToxR transcription activator system. The resulting combinatorial libraries were subjected to different levels of selective pressure to obtain groups of transmembrane segments that are distinguished by their ability to self-interact in bacterial membranes. Upon relating self-interaction to amino acid composition, the following conclusions were made. First, randomization with only Leu, Ile, Val, Met, and Phe resulted in unexpected robust self-interaction with little sequence specificity. Second, with more complex amino acid mixtures that represent natural transmembrane segments more closely, self-interaction critically depended on amino acid composition of the interface. Whereas the contents of Ile and Leu residues increased with the ability to self-interact, the contents of Pro and Arg residues decreased. Third, heptad repeat motifs composed of Leu, Ile, Val, Met, and Phe were similar to 40-fold over-represented in transmembrane segments of single-span membrane proteins as compared with motifs composed of the more complex amino acid mixtures. This suggests that heptad motifs composed of the smaller subset of amino acids were enriched in the course of natural single-span membrane protein evolution.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Langosch, D (corresponding author), Tech Univ Munich, Lehrstuhl Chem Biopolymere, Weihenstephaner Berg 3, D-85354 Freising Weihenstephan, Germany.							Arkin IT, 1998, BBA-PROTEIN STRUCT M, V1429, P113, DOI 10.1016/S0167-4838(98)00225-8; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Bowie JU, 2000, NAT STRUCT BIOL, V7, P91, DOI 10.1038/72454; Brosig B, 1998, PROTEIN SCI, V7, P1052; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dieckmann GR, 1997, CURR OPIN STRUC BIOL, V7, P486, DOI 10.1016/S0959-440X(97)80111-X; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Huber O, 1999, J CELL SCI, V112, P4415; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; KOLMAR H, 1994, BIOL CHEM H-S, V375, P61; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MCGINNES L, 1993, VIROLOGY, V196, P101, DOI 10.1006/viro.1993.1458; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; Niland P, 1996, J MOL BIOL, V264, P667, DOI 10.1006/jmbi.1996.0668; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	35	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45580	45587		10.1074/jbc.M105362200	http://dx.doi.org/10.1074/jbc.M105362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585820	hybrid			2022-12-27	WOS:000172573100014
J	Lindemann, RK; Ballsehmieter, P; Nordheim, A; Dittmer, J				Lindemann, RK; Ballsehmieter, P; Nordheim, A; Dittmer, J			Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS TRANSCRIPTION FACTORS; GENE-EXPRESSION; DNA-BINDING; PTHRP GENE; C-JUN; ACTIVATION; PROMOTER; RECEPTOR; RAS; SP1	The majority of breast cancers metastasizing to bone secrete parathyroid hormone-related protein (PTHrP). PTHrP induces local osteolysis that leads to activation of bone matrix-borne transforming growth factor beta (TGF beta). In turn, TGF beta stimulates PTHrP expression and, thereby, accelerates bone destruction. We studied the mechanism by which TGF beta activates PTHrP in invasive MDA-MB-231 breast cancer cells. We demonstrate that TGF beta1 up-regulates specifically the level of PTHrP P3 promoter-derived RNA in an actinomycin D-sensitive fashion. Transient transfection studies revealed that TGF beta1 and its effector Smad3 are able to activate the P3 promoter. This effect depended upon an AGAC box and a previously described Ets binding site. Addition of Etsl greatly enhanced the Smad3/TGF beta -mediated activation. Ets2 had also some effect, whereas other Ets proteins, Elf-1, Ese-1, and Erf-1, failed to cooperate with Smad3. In comparison, Ets1 did not increase Smad3/TGF beta -induced stimulation of the TGF beta -responsive plasminogen activator inhibitor 1 (PAI-1) promoter. Smad3 and Smad4 were able to specifically interact with the PTHrP P3-AGAC box and to bind to the P3 promoter together with Etsl. Inhibition of endogenous Etsl expression by calphostin C abrogated TGF beta -induced up-regulation of the P3 transcript, whereas it did not affect the TGF beta effect on PAI expression. In TGF beta receptor II- and Ets1-deficient, noninvasive MCF-7 breast cancer cells, TGF beta1 neither influenced endogenous PTHrP expression nor stimulated the PTHrP P3 promoter. These data suggest that TGF beta activates PTHrP expression by specifically up-regulating transcription from the PTHrP P3 promoter through a novel Smad3/Ets1 synergism.	Univ Tubingen, Inst Zellbiol, Abt Mol Biol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Dittmer, J (corresponding author), Univ Tubingen, Inst Zellbiol, Abt Mol Biol, Morgenstelle 15, D-72076 Tubingen, Germany.	juergen.dittmer@uni-tuebingen.de	Dittmer, Juergen/G-1160-2011					Aklilu F, 1997, CANCER RES, V57, P4517; Benitez-Verguizas J, 1999, LIFE SCI, V65, P1807, DOI 10.1016/S0024-3205(99)00437-3; BIRCH MA, 1995, BRIT J CANCER, V72, P90, DOI 10.1038/bjc.1995.282; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bouizar Z, 1999, J BONE MINER RES, V14, P406, DOI 10.1359/jbmr.1999.14.3.406; Carron JA, 1997, BRIT J CANCER, V76, P1095, DOI 10.1038/bjc.1997.513; CASEY ML, 1993, J CLIN ENDOCR METAB, V77, P188, DOI 10.1210/jc.77.1.188; Chen ZQ, 1997, CANCER RES, V57, P2013; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Cowley DO, 2000, GENE DEV, V14, P366; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Farina AR, 1998, INT J CANCER, V75, P721; Foley J, 1999, MOL CELL ENDOCRINOL, V156, P13, DOI 10.1016/S0303-7207(99)00151-3; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; Grill V, 1998, EUR J CANCER, V34, P222, DOI 10.1016/S0959-8049(97)10130-7; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Guise TA, 1997, CANCER-AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.3.CO;2-D; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karperien M, 1997, MOL ENDOCRINOL, V11, P1435, DOI 10.1210/me.11.10.1435; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; LI X, 1994, J BIOL CHEM, V269, P6263; LIAPIS H, 1993, AM J PATHOL, V143, P1169; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Naito S, 1998, AM J PHYSIOL-CELL PH, V274, pC472, DOI 10.1152/ajpcell.1998.274.2.C472; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SOUTHBY J, 1995, BRIT J CANCER, V72, P702, DOI 10.1038/bjc.1995.397; Strewler GJ, 2000, ENDOCRIN METAB CLIN, V29, P629, DOI 10.1016/S0889-8529(05)70154-7; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Tian G, 1999, MOL CELL BIOL, V19, P2946; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Werkmeister JR, 1998, ENDOCRINE, V8, P291, DOI 10.1385/ENDO:8:3:291; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431; WYSOLMERSKI JJ, 1994, ANNU REV MED, V45, P189, DOI 10.1146/annurev.med.45.1.189; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	72	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46661	46670		10.1074/jbc.M105816200	http://dx.doi.org/10.1074/jbc.M105816200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590145	hybrid			2022-12-27	WOS:000172573100154
J	Wain, R; Pertinhez, TA; Tomlinson, EJ; Hong, L; Dobson, CM; Ferguson, SJ; Smith, LJ				Wain, R; Pertinhez, TA; Tomlinson, EJ; Hong, L; Dobson, CM; Ferguson, SJ; Smith, LJ			The cytochrome c fold can be attained from a compact apo state by occupancy of a nascent heme binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE INTERMEDIATE; X-RAY-SCATTERING; APOCYTOCHROME-C; STRUCTURAL-ANALYSIS; DENATURED STATE; NMR; PROTEINS; BIOGENESIS; STABILITY; C(552)	NMR techniques and 8-anilino-1-napthalenesulphonate (ANS) binding studies have been used to characterize the apo state of a variant of cytochrome C-552 from Hydrogenobacter thermophilus. In this variant the two cysteines that form covalent thioether linkages to the heme group have been replaced by alanine residues (C11A/C14A). CD studies show that the apo state contains similar to 14% helical secondary structure, and measurements of hydrodynamic radii using pulse field gradient NAM methods show that it is compact (R-h, 16.6 Angstrom). The apo state binds 1 mol of ANS/mol of protein, and a linear reduction in fluorescence enhancement is observed on adding aliquots of hemin to a solution of apo C11A/C14A cytochrome c(552) with ANS bound. These results suggest that the bound ANS is located in the heme binding pocket, which would therefore be at least partially formed in the apo state. Consistent with these characteristics, the formation of the holo state of the variant cytochrome c(552) from the apo state on the addition of heme has been demonstrated using NMR techniques. The properties of the apo state of C11A/C14A cytochrome c(552) reported here contrast strongly with those of mitochondrial cytochrome c whose apo state resembles a random coil under similar conditions.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Cent Chem Lab, Oxford OX1 3QU, England; Natl Synchrotron Light Lab, Ctr Mol & Struct Biol, BR-13084971 Campinas, Brazil	University of Oxford; University of Oxford; Laboratorio Nacional de Luz Sincrotron (LNLS)	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ferguson@bioch.ox.ac.uk; lorna.smith@chem.ox.ac.uk						BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; DAMASCHUN G, 1991, BIOCHIM BIOPHYS ACTA, V1078, P289, DOI 10.1016/0167-4838(91)90571-G; DEJONGH HHJ, 1992, BIOCHEMISTRY-US, V31, P1636, DOI 10.1021/bi00121a008; Dobson CM., 1992, CURR OPIN STRUC BIOL, V2, P6; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; EDEN D, 1982, P NATL ACAD SCI-BIOL, V79, P815, DOI 10.1073/pnas.79.3.815; Englander SW, 1998, ACCOUNTS CHEM RES, V31, P737, DOI 10.1021/ar970085h; FENG YQ, 1994, NAT STRUCT BIOL, V1, P30, DOI 10.1038/nsb0194-30; FENG YQ, 1991, BIOCHEMISTRY-US, V30, P7711, DOI 10.1021/bi00245a007; FENG YQ, 1990, BIOCHEMISTRY-US, V29, P3505, DOI 10.1021/bi00466a012; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Gillespie JR, 1997, J MOL BIOL, V268, P170, DOI 10.1006/jmbi.1997.0953; GOTO Y, 1994, METHOD ENZYMOL, V232, P3; HAMADA D, 1993, BIOCHEMISTRY-US, V32, P10351, DOI 10.1021/bi00090a010; Hasegawa J, 2000, J BIOL CHEM, V275, P37824, DOI 10.1074/jbc.M005861200; Hasegawa J, 1999, J BIOL CHEM, V274, P37533, DOI 10.1074/jbc.274.53.37533; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; Kortemme T, 2000, J MOL BIOL, V297, P1217, DOI 10.1006/jmbi.2000.3618; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; MOORE CD, 1991, BIOCHEMISTRY-US, V30, P8357, DOI 10.1021/bi00098a012; MOORE CD, 1993, BIOCHEMISTRY-US, V32, P199, DOI 10.1021/bi00052a026; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pan H, 1997, PROTEIN SCI, V6, P1985, DOI 10.1002/pro.5560060919; Pettigrew G.W., 1990, CYTOCHROMES C EVOLUT; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rankin SE, 1999, PROTEIN SCI, V8, P381; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SAMBONGI Y, 1994, FEBS LETT, V344, P207, DOI 10.1016/0014-5793(94)00399-8; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; Schwalbe H, 1997, BIOCHEMISTRY-US, V36, P8977, DOI 10.1021/bi970049q; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Shastry MCR, 1998, ACCOUNTS CHEM RES, V31, P717; Shortle DR, 1996, CURR OPIN STRUC BIOL, V6, P24, DOI 10.1016/S0959-440X(96)80091-1; Sinha A, 2000, BIOCHEM J, V345, P711, DOI 10.1042/0264-6021:3450711; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; TREWHELLA J, 1988, BIOCHEMISTRY-US, V27, P1121, DOI 10.1021/bi00404a007; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Yeh SR, 1998, ACCOUNTS CHEM RES, V31, P727, DOI 10.1021/ar970084p	43	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45813	45817		10.1074/jbc.M107572200	http://dx.doi.org/10.1074/jbc.M107572200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584011	hybrid			2022-12-27	WOS:000172573100043
J	Westendorf, JJ				Westendorf, JJ			The formin/diaphanous-related protein, FHOS, interacts with Rac1 and activates transcription from the serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB DEFORMITY GENE; GTP-BINDING PROTEIN; RHO-FAMILY; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; TERNARY COMPLEX; HUMAN HOMOLOG; DROSOPHILA; GTPASES; FORMINS	FHOS is a member of the formin homology (FH) family of proteins and is expressed at high levels in splenic cells. FH proteins link cellular signaling pathways to the actin cytoskeleton and serum response factor-dependent transcription. In these studies, the role of FHOS in Rho family GTPase signaling pathways was analyzed. FHOS interacted with the polybasic domain in the Rac1 C terminus in a guanine nucleotide-independent manner but did not interact with RhoA, Cdc42Hs, Rac2, or Rac3. Intramolecular autoinhibitory interactions between the C terminus of FHOS and an N-terminal region partially overlapping the Rac1 interaction domain were also identified. FHOS truncation mutants lacking the N- or C-terminal autoregulatory domains stimulated transcription of a c-fos serum response element (SRE)-driven reporter. Overexpression of wild-type and mutant (N17 and V12) Rac1 proteins repressed SRE induction by the N-terminal FHOS deletion mutant but not by the C-terminal FHOS deletion mutant. Immunofluorescence studies indicated that the localization of the mutant FHOS proteins might contribute to their differential responses to Rac1. Wild-type FHOS and the N-terminal deletion mutant localized to the perinuclear region and membrane edges. In contrast, the C-terminal FHOS mutants were diffusely localized. These data suggest that FHOS induces transcription from SREs by multiple pathways and that Rac1 may influence the course of some FHOS-induced signaling events.	Univ Minnesota, Dept Orthopaed Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Univ Minnesota Canc Ctr, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Westendorf, JJ (corresponding author), Univ Minnesota, Dept Orthopaed Surg, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.				NATIONAL CANCER INSTITUTE [F32CA077167] Funding Source: NIH RePORTER; NCI NIH HHS [F32-CA77167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 2000, J BIOL CHEM, V16, P16; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P209; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Norris PS, 1998, J VIROL METHODS, V75, P161, DOI 10.1016/S0166-0934(98)00108-6; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Treisman R, 1990, Semin Cancer Biol, V1, P47; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uetz P, 1996, J BIOL CHEM, V271, P33525, DOI 10.1074/jbc.271.52.33525; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000; Zhang BL, 2001, J BIOL CHEM, V276, P8958, DOI 10.1074/jbc.M008720200	47	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46453	46459		10.1074/jbc.M105162200	http://dx.doi.org/10.1074/jbc.M105162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590143	hybrid			2022-12-27	WOS:000172573100130
J	Chaya, D; Hayamizu, T; Bustin, M; Zaret, KS				Chaya, D; Hayamizu, T; Bustin, M; Zaret, KS			Transcription factor FoxA (HNF3) on a nucleosome at an enhancer complex in liver chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MMTV PROMOTER; GENE-EXPRESSION; CORE PARTICLE; DNASE-I; BINDING; SITE; DIFFERENTIATION; RESOLUTION; INVITRO; VIVO	Nucleosome-like particles and acetylated histones occur near active promoters and enhancers, and certain transcription factors can recognize their target sites on the surface of a nucleosome in vitro; yet it has been unclear whether transcription factors can occupy target sites on nucleosomes in native chromatin. We developed a method for sequential chromatin immunoprecipitation of distinct nuclear proteins that are simultaneously cross-linked to nucleosome-sized genomic DNA segments. We find that core histone H2A co-occupies, along with the FoxA (hepatocyte nuclear factor-3) transcription factor, DNA for the albumin transcriptional enhancer in native liver chromatin, where the enhancer is active. Because histone H2A on nuclear DNA is only known to exist in nucleosomes, we conclude that transcription factors can form a stable complex on nucleosomes at an active enhancer element in. vivo.	Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA; Ctr Canc Res, Lab Metab, Prot Sect, Bethesda, MD 20892 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zaret, KS (corresponding author), Fox Chase Canc Ctr, Program Cell & Dev Biol, 7701 Burholme Ave,Rm W410, Philadelphia, PA 19111 USA.	zaret@fccc.edu	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047903] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [R01 GM47903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; AUSUBEL FM, 1999, CURRENT PROTOCOLS MO, V1; Bossard P, 1998, DEVELOPMENT, V125, P4909; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLDBLATT D, 1975, BIOCHEMISTRY-US, V14, P1689, DOI 10.1021/bi00679a022; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Harlow E., 1988, ANTIBODIES LAB MANUA; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; Kruger G, 1999, GENE, V236, P63, DOI 10.1016/S0378-1119(99)00271-1; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; Stevens K, 2000, J BIOL CHEM, V275, P30471, DOI 10.1074/jbc.M004891200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VANHOLDE KE, 1989, CHROMATIN, V1; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	36	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44385	44389		10.1074/jbc.M108214200	http://dx.doi.org/10.1074/jbc.M108214200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571307	hybrid			2022-12-27	WOS:000172406700006
J	Greenberg, AS; Shen, WJ; Muliro, K; Patel, S; Souza, SC; Roth, RA; Kraemer, FB				Greenberg, AS; Shen, WJ; Muliro, K; Patel, S; Souza, SC; Roth, RA; Kraemer, FB			Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LIPID STORAGE DROPLETS; SEQUENCE SIMILARITY; 3T3-L1 ADIPOCYTES; COUPLED RECEPTORS; BROWN ADIPOCYTES; RAT ADIPOCYTES; PERILIPIN-A; IN-VITRO; PHOSPHORYLATION	Hormonally stimulated lipolysis occurs by activation of cyclic AMP-dependent protein kinase (PKA) which phosphorylates hormone-sensitive lipase (HSL) and increases adipocyte lipolysis. Evidence suggests that catecholamines not only can activate PKA, but also the mitogen-activated protein kinase pathway and extracellular signal-regulated kinase (ERK). We now demonstrate that two different inhibitors of MEK, the upstream activator of ERK, block catecholamine- and beta (3)-stimulated lipolysis by similar to 30%. Furthermore, treatment of adipocytes with dioctanoylglycerol, which activates ERK, increases lipolysis, although MEK inhibitors decrease dioctanoylglycerol-stimulated activation of lipolysis. Using a tamoxifen regulatable Raf system expressed in 3T3-L1 preadipocytes, exposure to tamoxifen causes a 14-fold activation of ERK within 15-30 min and results in similar to2-fold increase in HSL activity. In addition, when differentiated 3T3-L1 cells expressing the regulatable Raf were exposed to tamoxifen, a 2-fold increase in lipolysis is observed. HSL is a substrate of activated ERK and site-directed mutagenesis of putative ERK consensus phosphorylation sites in HSL identified Ser(600) as the site phosphorylated by active ERK. When S600A HSL was expressed in 3T3-L1 cells expressing the regulatable Raf, tamoxifen treatment fails to increase its activity. Thus, activation of the ERK pathway appears to be able to regulate adipocyte lipolysis by phosphorylating HSL on Ser(600) and increasing the activity of HSL.	Stanford Univ, Dept Med, Div Endocrinol, Stanford, CA 94305 USA; Tufts Univ New England Med Ctr, Dept Med, Boston, MA 02111 USA; Tufts Univ, USDA, Jean Meyer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Kraemer, FB (corresponding author), Stanford Univ, Dept Med, Div Endocrinol, S-005, Stanford, CA 94305 USA.		Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Shen, Wen-Jun/0000-0001-5150-1698	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050647, R01DK049705, R01DK046942] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50647, DK 49705, DK 46942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Choo DW, 1998, APPL ENVIRON MICROB, V64, P486; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GARTON AJ, 1988, FEBS LETT, V229, P68, DOI 10.1016/0014-5793(88)80799-3; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GORDON RS, 1956, J CLIN INVEST, V35, P206, DOI 10.1172/JCI103265; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KRAEMER FB, 1993, J LIPID RES, V34, P663; Lindquist JM, 2000, J BIOL CHEM, V275, P22670, DOI 10.1074/jbc.M909093199; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Manco G, 1998, BIOCHEM J, V332, P203, DOI 10.1042/bj3320203; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mizuno K, 1999, EUR J PHARMACOL, V385, P63, DOI 10.1016/S0014-2999(99)00733-5; Morimoto C, 2001, J LIPID RES, V42, P120; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1999, J BIOL CHEM, V274, P15382, DOI 10.1074/jbc.274.22.15382; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; PROBST MR, 1994, J BIOL CHEM, V269, P21650; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 1998, BIOCHEMISTRY-US, V37, P8973, DOI 10.1021/bi980545u; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; SZTALRYD C, 1994, AM J PHYSIOL, V266, pE179, DOI 10.1152/ajpendo.1994.266.2.E179; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wei YY, 1999, NAT STRUCT BIOL, V6, P340	57	271	285	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45456	45461		10.1074/jbc.M104436200	http://dx.doi.org/10.1074/jbc.M104436200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581251	hybrid			2022-12-27	WOS:000172406700143
J	Lowry, WE; Huang, JY; Lei, M; Rawlings, D; Huang, XY				Lowry, WE; Huang, JY; Lei, M; Rawlings, D; Huang, XY			Role of the PHTH module in protein substrate recognition by Bruton's agammaglobulinemia tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SRC-FAMILY; CRYSTAL-STRUCTURE; HOMOLOGY DOMAIN; SH3 DOMAIN; BTK; PHOSPHORYLATION; ACTIVATION; HCK; ASSOCIATION	Defects in Bruton's tyrosine kinase (Btk) are responsible for X chromosome-linked agammaglobulinemia in patients. Mutations in each of the structural domains of Btk have been detected in patients, yet a mechanistic explanation for most of these mutant phenotypes is lacking. To understand the possible role of the unique pleckstrin homology and Tee homology (PHTH) module of Btk, we have compared the enzymatic properties of full-length Btk and a Btk mutant lacking the PHTH module (Btk Delta PHTH). Here we show that Btk and Btk Delta PHTH have similar basal catalytic activity but very different abilities to recognize protein substrates. Furthermore, the catalytic domain of Btk is inactive, in contrast to the catalytic domain of the prototypical Src tyrosine kinase that retains full catalytic ability. These data suggest that the PHTH module plays an important role in protein substrate recognition, that. Btk and Src likely have different interdomain organizations and regulations, and that alterations in substrate recognition might play a role in X chromosome-linked agammaglobulinemia.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA	Cornell University; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, 1300 York Ave,Rm C512, New York, NY 10021 USA.							Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Baba K, 1999, MOL CELL BIOL, V19, P4405; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACHIDE M, 1995, ONCOGENE, V11, P619; Mao C, 2001, J BIOL CHEM, V276, P41435, DOI 10.1074/jbc.M104828200; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2	32	12	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45276	45281		10.1074/jbc.M104449200	http://dx.doi.org/10.1074/jbc.M104449200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577078	hybrid			2022-12-27	WOS:000172406700122
J	Matsuura, T; Sakai, H; Unno, M; Ida, K; Sato, M; Sakiyama, F; Norioka, S				Matsuura, T; Sakai, H; Unno, M; Ida, K; Sato, M; Sakiyama, F; Norioka, S			Crystal structure at 1.5-angstrom resolution of Pyrus pyrifolia pistil ribonuclease responsible for gametophytic self-incompatibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-RNASE; POSITIVE SELECTION; RHIZOPUS-NIVEUS; JAPANESE PEAR; NUCLEOTIDE SUBSTITUTION; HISTIDINE-RESIDUES; ENZYMATIC-ACTIVITY; POLLEN; PROTEIN; RH	The crystal structure of the Pyrus pyrifolia pistil ribonuclease (S-3-RNase) responsible for gametophytic self-incompatibility was determined at 1.5-Angstrom resolution. It consists of eight helices and seven beta -strands, and its folding topology is typical of RNase T-2 family enzymes. Based on a structural comparison of S-3-RNase with RNase Rh, a fungal RNase T-2 family enzyme, the active site residues of S-3-RNase assigned were His(33) and His(88) as catalysts and Glu(84) and Lys(87) as stabilizers of an intermediate in the transition state. Moreover, amino acid residues that constitute substrate binding sites of the two RNases could be superimposed geometrically. A hypervariable (HV) region that has an S-allele-specific sequence comprises a long loop and short alpha -helix. This region is far from the active site cleft, exposed on the molecule's surface, and positively charged. Four positively selected (PS) regions, in which the number of nonsynonymous substitutions exceeds that of synonymous ones, are located on either side of the active site cleft, and accessible to solvent. These structural features suggest that the HV or PS regions may interact with a pollen S-gene product(s) to recognize self and non-self pollen.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Int Buddhist Univ, Osaka 5388501, Japan	Osaka University; Yokohama City University	Norioka, S (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Osaka 5650871, Japan.	norioka@protein.osaka-u.ac.jp	Matsuura, Takanori/J-1413-2012	Matsuura, Takanori/0000-0003-2001-9537				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRANDEN C, 1999, INTRO PROTEIN STRUCT, P16; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dodds PN, 1996, CELL, V85, P141, DOI 10.1016/S0092-8674(00)81090-9; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; HUANG S, 1994, PLANT CELL, V6, P1021, DOI 10.1105/tpc.6.7.1021; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; Ishimizu T, 1996, J BIOCHEM-TOKYO, V120, P326, DOI 10.1093/oxfordjournals.jbchem.a021417; Ishimizu T, 1998, FEBS LETT, V440, P337, DOI 10.1016/S0014-5793(98)01470-7; Ishimizu T, 1998, PLANT MOL BIOL, V37, P931, DOI 10.1023/A:1006078500664; Ishimizu T, 1999, EUR J BIOCHEM, V263, P624, DOI 10.1046/j.1432-1327.1999.00499.x; Ishimizu T, 1996, EUR J BIOCHEM, V242, P627, DOI 10.1111/j.1432-1033.1996.0627r.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kao TH, 1996, P NATL ACAD SCI USA, V93, P12059, DOI 10.1073/pnas.93.22.12059; KARUNANANDAA B, 1994, PLANT CELL, V6, P1933, DOI 10.1105/tpc.6.12.1933; KAWATA Y, 1990, EUR J BIOCHEM, V187, P255, DOI 10.1111/j.1432-1033.1990.tb15303.x; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIHARA H, 1992, FEBS LETT, V306, P189, DOI 10.1016/0014-5793(92)80997-U; Kurihara H, 1996, J MOL BIOL, V255, P310, DOI 10.1006/jmbi.1996.0025; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE HS, 1994, NATURE, V367, P560, DOI 10.1038/367560a0; LEE YH, 1995, MOL BIOL EVOL, V12, P231; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; Luu DT, 2000, NATURE, V407, P649, DOI 10.1038/35036623; Matsuura T, 2001, ACTA CRYSTALLOGR D, V57, P172, DOI 10.1107/S090744490001756X; Matton DP, 1997, PLANT CELL, V9, P1757, DOI 10.1105/tpc.9.10.1757; Matton DP, 1999, PLANT CELL, V11, P2087, DOI 10.1105/tpc.11.11.2087; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; McCubbin AG, 1997, PLANT CELL, V9, P85, DOI 10.2307/3870373; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURFETT J, 1994, NATURE, V367, P563, DOI 10.1038/367563a0; Nakagawa A, 1999, BBA-PROTEIN STRUCT M, V1433, P253, DOI 10.1016/S0167-4838(99)00126-0; Nettancourt, 2001, INCOMPATIBILITY INCO; NEWBIGIN E, 1993, PLANT CELL, V5, P1315, DOI 10.1105/tpc.5.10.1315; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norioka N, 1996, J BIOCHEM-TOKYO, V120, P335, DOI 10.1093/oxfordjournals.jbchem.a021418; OHGI K, 1991, J BIOCHEM-TOKYO, V109, P776, DOI 10.1093/oxfordjournals.jbchem.a123456; Ohgi K, 1996, BIOL PHARM BULL, V19, P1080; OHGI K, 1992, J BIOCHEM-TOKYO, V112, P132, DOI 10.1093/oxfordjournals.jbchem.a123852; OHGI K, 1993, J BIOCHEM-TOKYO, V113, P219, DOI 10.1093/oxfordjournals.jbchem.a124029; OHGI K, 1995, J BIOCHEM-TOKYO, V117, P27, DOI 10.1093/oxfordjournals.jbchem.a124716; Ohgi K, 1997, BIOSCI BIOTECH BIOCH, V61, P432, DOI 10.1271/bbb.61.432; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oxley D, 1996, EUR J BIOCHEM, V242, P75, DOI 10.1111/j.1432-1033.1996.0075r.x; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; RICHARDS FM, 1971, ENZYMES, V4, P647; Richman AD, 1997, AM J BOT, V84, P912, DOI 10.2307/2446281; SANDA A, 1980, J BIOCHEM-TOKYO, V87, P1079; SANDA A, 1985, J BIOCHEM, V98, P125, DOI 10.1093/oxfordjournals.jbchem.a135250; SANDA A, 1985, CHEM PHARM BULL, V33, P4515; SWANSON WJ, 1995, P NATL ACAD SCI USA, V92, P4957, DOI 10.1073/pnas.92.11.4957; Tanaka N, 2000, J MOL BIOL, V298, P859, DOI 10.1006/jmbi.2000.3707; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	57	50	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45261	45269		10.1074/jbc.M107617200	http://dx.doi.org/10.1074/jbc.M107617200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577107	hybrid			2022-12-27	WOS:000172406700120
J	Samuel, T; Weber, HO; Rauch, P; Verdoodt, B; Eppel, JT; McShea, A; Hermeking, H; Funk, JO				Samuel, T; Weber, HO; Rauch, P; Verdoodt, B; Eppel, JT; McShea, A; Hermeking, H; Funk, JO			The G(2)/M regulator 14-3-3 sigma prevents apoptosis through sequestration of Bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; PROTEIN FAMILY; CELL-CYCLE; IN-VIVO; P53; CHECKPOINT; INHIBITORS; EXPRESSION; CASPASES; KINASES	In response to DNA damage and genotoxic stress, the p53 tumor suppressor triggers either cell cycle arrest or apoptosis. The G(2) arrest after damage is, in part, mediated by the p53 target, 14-3-3 sigma (sigma). Colorectal tumor cells lacking a are exquisitely sensitive to DNA damage. Here we analyzed the mechanism of this sensitivity in sigma (-/-) as compared with sigma (+/+) human colorectal tumor cells. Exposure to adriamycin resulted in rapid apoptosis only in sigma (-/-) cells. This was further characterized by caspase-3 activation, p21(CIP1) cleavage, and CDK2 activation. Moreover, Bax was rapidly translocated out of the cytoplasm, and cytochrome c was released in sigma (-/-) cells. Transient adenovirus-mediated reconstitution of or in the sigma (-/-) cells led to effective rescue of this phenotype and protected cells against apoptosis. The association of sigma, Bax, and CDK1 in protein complexes may be the basis for this antiapoptotic mechanism. In conclusion, a not only enforces the p53-dependent G(2) arrest but also delays the apoptotic signal transduction.	Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, D-91052 Erlangen, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Erlangen Nuremberg; Fred Hutchinson Cancer Center; Max Planck Society	Funk, JO (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol, Lab Mol Tumor Biol, Hartmannstr 14, D-91052 Erlangen, Germany.							Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Funk JO, 1998, TRENDS BIOCHEM SCI, V23, P337; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Herzinger T, 1995, ONCOGENE, V11, P2051; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krajewski S, 1996, CANCER RES, V56, P2849; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	39	139	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45201	45206		10.1074/jbc.M106427200	http://dx.doi.org/10.1074/jbc.M106427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574543	hybrid			2022-12-27	WOS:000172406700113
J	Young, ME; Laws, FA; Goodwin, GW; Taegtmeyer, H				Young, ME; Laws, FA; Goodwin, GW; Taegtmeyer, H			Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CARDIAC-HYPERTROPHY; GENE-EXPRESSION; HYPOLIPIDEMIC DRUGS; PRESSURE-OVERLOAD; MECHANICAL-STRESS; FATTY-ACIDS; MYOCYTES; METABOLISM; INCREASE	In pressure overload-induced hypertrophy, the heart increases its reliance on glucose as a fuel while decreasing fatty acid oxidation. A key regulator of this substrate switching in the hypertrophied heart is peroxisome proliferator-activated receptor alpha (PPAR alpha). We tested the hypothesis that down-regulation of PPAR alpha is an essential component of cardiac hypertrophy at the levels of increased mass, gene expression, and metabolism by pharmacologically reactivating PPA alpha. Pressure overload (induced by constriction of the ascending aorta for 7 days in rats) resulted in cardiac hypertrophy, increased expression of fetal genes (atrial natriuretic factor and skeletal alpha -actin), decreased expression of PPAR alpha and PPAR alpha -regulated genes (medium chain acyl-CoA dehydrogenase and pyruvate dehydrogenase kinase 4), and caused substrate switching (measured ex vivo in the isolated working heart preparation). Treatment of rats with the specific PPAR alpha agonist WY-14,643 (8 days) did not affect the trophic response or atrial natriuretic factor induction to pressure overload. However, PPAR alpha activation blocked skeletal alpha -actin induction, reversed the down-regulation of measured PPAR alpha -regulated genes in the hypertrophied heart, and prevented substrate switching. This PPAR alpha reactivation concomitantly resulted in severe depression of cardiac power and efficiency in the hypertrophied heart (measured ex vivo). Thus, PPAR alpha down-regulation is essential for the maintenance of contractile function of the hypertrophied heart.	Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA	University of Texas System	Taegtmeyer, H (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Cardiol, 6431 Fannin,MSB 1-246, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061483, R01HL043133, F32HL067609] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43133, F32HL-67609, HL-61483] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLARD MF, 1994, AM J PHYSIOL, V267, pH742, DOI 10.1152/ajpheart.1994.267.2.H742; ANDERSON PG, 1990, CIRC RES, V67, P948, DOI 10.1161/01.RES.67.4.948; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Barger PM, 2000, TRENDS CARDIOVAS MED, V10, P238, DOI 10.1016/S1050-1738(00)00077-3; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Doenst T, 2001, METABOLISM, V50, P1083, DOI 10.1053/meta.2001.25605; FACTOR SM, 1981, AM J PATHOL, V102, P219; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goodwin GW, 1998, J BIOL CHEM, V273, P29530, DOI 10.1074/jbc.273.45.29530; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; KAGAYA Y, 1990, CIRCULATION, V81, P1353, DOI 10.1161/01.CIR.81.4.1353; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Katz Arnold M., 1998, Cardiology Clinics, V16, P633, DOI 10.1016/S0733-8651(05)70040-0; KLEINMAN LH, 1978, AM J PHYSIOL, V234, pH515, DOI 10.1152/ajpheart.1978.234.5.H515; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LAZAROW PB, 1977, SCIENCE, V197, P580, DOI 10.1126/science.195342; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Meguro T, 1999, CIRC RES, V84, P735, DOI 10.1161/01.RES.84.6.735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; PAULSON DJ, 1992, LIFE SCI, V51, P1557, DOI 10.1016/0024-3205(92)90618-Y; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Takeishi Y, 2000, CIRC RES, V86, P1218, DOI 10.1161/01.RES.86.12.1218; van der Lee KAJM, 2000, J LIPID RES, V41, P41; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Young ME, 2001, AM J PHYSIOL-ENDOC M, V280, pE471, DOI 10.1152/ajpendo.2001.280.3.E471; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	35	195	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44390	44395		10.1074/jbc.M103826200	http://dx.doi.org/10.1074/jbc.M103826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574533	hybrid			2022-12-27	WOS:000172406700007
J	Fu, YX; Sies, H; Lei, XG				Fu, YX; Sies, H; Lei, XG			Opposite roles of selenium-dependent glutathione peroxidase-1 in superoxide generator diquat- and peroxynitrite-induced apoptosis and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MICE; ACTIVATION; PARAQUAT; CYTOTOXICITY; OXIDATION; KNOCKOUT; OXYGEN; CELLS; P21(WAF1/CIP1)	Oxidative injuries including apoptosis can be induced by reactive oxygen species (ROS) and reactive nitrogen species (RNS) in aerobic metabolism. We determined impacts of a selenium-dependent glutathione peroxidase-1 (GPX1) on apoptosis induced by diquat (DQ), a ROS (superoxide) generator, and peroxynitrite (PN), a potent RNS. Hepatocytes were isolated from GPX1 knockout (GPX1-/-) or wild-type (WT) mice, and treated with 0.5 mm DQ or 0.1-0.8 mm PN for up to 12 h. Loss of cell viability, high levels of apoptotic cells, and severe DNA fragmentation were produced by DQ in only GPX1-/- cells and by PN in only WT cells. These two groups of cells shared similar cytochrome c release, caspase-3 activation, and p21(WAF1/CIP1) cleavage. Higher levels of protein nitration were induced by PN in WT than GPX1-/- cells. Much less and/or slower cellular GSH depletion was caused by DQ or PN in GPX1-/- than in WT cells, and corresponding GSSG accumulation occurred only in the latter. In conclusion, it is most striking that, although GPX1 protects against apoptosis induced by superoxide-generator DQ, the enzyme actually promotes apoptosis induced by PN in murine hepatocytes. Indeed, GSH is a physiological substrate for GPX1 in coping with ROS in these cells.	Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA; Univ Dusseldorf, Inst Physiol Chem 1, D-40001 Dusseldorf, Germany	Cornell University; Heinrich Heine University Dusseldorf	Lei, XG (corresponding author), Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA.	xl20@cornell.edu	Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Sies, Helmut/0000-0002-1000-3198; fu, yang-xin/0000-0001-8441-6617	NIDDK NIH HHS [R01 DK053018, DK53018] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON AE, 1985, CRC HDB METHOD OXYGE, P317; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brito C, 1999, J IMMUNOL, V162, P3356; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070; Cheng WH, 1999, FASEB J, V13, P1467, DOI 10.1096/fasebj.13.11.1467; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; EVANS MD, 1997, ADV MOL CEL, V20, P25; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; Flohe L, 2000, IUBMB LIFE, V49, P411; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Fu YX, 1999, FREE RADICAL BIO MED, V27, P605, DOI 10.1016/S0891-5849(99)00104-5; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; HOEKSTRA WG, 1975, FED PROC, V34, P2083; Jiang D, 2000, EXP NEUROL, V164, P257, DOI 10.1006/exnr.2000.7431; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LIU RH, 1992, CANCER RES, V52, P4139; Lu YP, 1997, CANCER RES, V57, P1468; MAIORINO M, 1993, FEBS LETT, V330, P174, DOI 10.1016/0014-5793(93)80267-X; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Midorikawa K, 2001, FEBS LETT, V495, P187, DOI 10.1016/S0014-5793(01)02383-3; Mirochnitchenko O, 1999, J BIOL CHEM, V274, P10349, DOI 10.1074/jbc.274.15.10349; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; SIES H, 1972, FEBS LETT, V27, P171, DOI 10.1016/0014-5793(72)80434-4; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369	59	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43004	43009		10.1074/jbc.M106946200	http://dx.doi.org/10.1074/jbc.M106946200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562367	hybrid			2022-12-27	WOS:000172169300050
J	Kuwasako, K; Kitamura, K; Ito, K; Uemura, T; Yanagita, Y; Kato, J; Sakata, T; Eto, T				Kuwasako, K; Kitamura, K; Ito, K; Uemura, T; Yanagita, Y; Kato, J; Sakata, T; Eto, T			The seven amino acids of human RAMP2 (86-92) and RAMP3 (59-65) are critical for agonist binding to human adrenomedullin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; ACTIVITY-MODIFYING PROTEINS; CALCITONIN; CELLS	When co-expressed with a receptor activity-modifying protein (RAMP) accessory protein, calcitonin receptor-like receptor (CRLR) can function as a calcitonin gene-related peptide receptor (CRLR-RAMP1) or an adrenomedullin (AM) receptor (CRLR-RAMP2/3). Here we report on the structural domain(s) involved in selective AM binding that were examined using various RAMP chimeras and deletion mutants. Co-expression of chimeric RAMPS and CRLR in HEK293 cells revealed that residues 77-101, situated in the extracellular N-terminal domain of human RAMP2 (hRAMP2), were crucial for selective AM-evoked cAMP production. More detailed analysis showed that deletion of hRAMP2 residues 86-92 significantly attenuated high-affinity I-125-AM binding and AM-evoked cAMP production despite full cell surface expression of the receptor heterodimer and that deletion of hRAMP3 residues 59-65 had a similar effect. There is little sequence identity between hRAMP3 residues 59-65 and hRAMP2 residues 86-92; moreover, substituting alanine for Trp(86) (Ala(87)), Met(88), Ile(89), Ser(90), Arg(91), or Pro(92) of hRAMP2 had no effect on AM-evoked cAMP production. It thus seems unlikely that any one amino acid residue is responsible for determining selective AM binding or that AM binds directly to these peptide segments. Instead these findings suggest that the respective seven-amino acid sequences confer selectivity either by directly contributing to the structure of ligand binding pocket or by allosteric modulation of the conformation of CRLR.	Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Osaka 5660022, Japan	University of Miyazaki; Shionogi & Company Limited	Kuwasako, K (corresponding author), Miyazaki Med Coll, Dept Internal Med 1, 5200 Kihara, Miyazaki 8891692, Japan.		Kuwasako, Kenji/H-8065-2016					Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; GUON XM, 1992, J BIOL CHEM, V267, P21995; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Husmann K, 2000, MOL CELL ENDOCRINOL, V162, P35, DOI 10.1016/S0303-7207(00)00212-4; Kitamura K, 1997, CURR OPIN NEPHROL HY, V6, P80, DOI 10.1097/00041552-199701000-00015; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Muff R, 1998, FEBS LETT, V441, P366, DOI 10.1016/S0014-5793(98)01587-7; Samson WK, 1998, FRONT NEUROENDOCRIN, V19, P100, DOI 10.1006/frne.1998.0164; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	20	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49459	49465		10.1074/jbc.M108369200	http://dx.doi.org/10.1074/jbc.M108369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591721	hybrid			2022-12-27	WOS:000173922100108
J	Lonigro, R; Donnini, D; Zappia, E; Damante, G; Bianchi, ME; Guazzi, S				Lonigro, R; Donnini, D; Zappia, E; Damante, G; Bianchi, ME; Guazzi, S			Nestin is a neuroepithelial target gene of thyroid transcription factor-1, a homeoprotein required for forebrain organogenesis.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; FACTOR-I TTF-1; ENHANCER-BINDING PROTEIN; CNS STEM-CELL; B GENE; EXPRESSION; PROMOTER; HOMEODOMAIN; SEQUENCE; LUNG	Thyroid transcription factor-1 (TTF-1, also known as NKX2.1 and T/EBP), a transcription factor belonging to the NKX-2 family of homeodomain-containing genes, plays an essential role in the organogenesis of the thyroid gland, lung, and ventral forebrain. Nestin is an intermediate filament protein strongly expressed in multipotential neuroepithelial stem cells and rapidly down-regulated during postnatal life. Here we show that stable fibroblastic clones expressing TTF-1 acquire a phenotype reminiscent of neuroepithelial cells in culture and up-regulate the endogenous nestin gene. TTF-1 transactivates in HeLa and NIH3T3 cells a reporter gene driven by a central nervous system-specific enhancer element from the second intron of the rat nestin gene, where it recognizes a DNA-binding site (NestBS) whose sequence resembles a nuclear hormone/cAMP-responsive element very different from canonical TTF-1 binding sites. Nuclear extracts from the head of mouse embryos form a retarded complex with NestBS of the same mobility of the extracts obtained from TTF1-expressing clones, which is either abolished or supershifted in the presence of two different antibodies recognizing the TTF-1 protein. Thus, the neuroepithelial marker nestin is a direct central nervous system-specific target gene of TTF-1, leading to the hypothesis that it might be the effector through which TTF-1 plays its role in the organogenesis of the forebrain.	San Raffaele Sci Inst, Dept Biol & Biotechnol, DNA Prot Interact Unit, I-20132 Milan, Italy; Univ Udine, Dept Biol Sci & Technol, I-33100 Udine, Italy; Univ Udine, Dept Expt & Clin Pathol & Med, I-33100 Udine, Italy; Univ Genoa, Dept Expt Med, Human Anat Sect, I-16132 Genoa, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Udine; University of Udine; University of Genoa	Guazzi, S (corresponding author), San Raffaele Sci Inst, Dept Biol & Biotechnol, DNA Prot Interact Unit, Via Olgettina 58, I-20132 Milan, Italy.		Bianchi, Marco Emilio/K-3417-2018; Damante, Giuseppe/AAC-5200-2022	Bianchi, Marco Emilio/0000-0002-5329-6445; Damante, Giuseppe/0000-0003-2312-4009	Telethon [E.0601] Funding Source: Medline	Telethon(Fondazione Telethon)		BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; FABBRO D, 1995, BIOCHEM BIOPH RES CO, V213, P781, DOI 10.1006/bbrc.1995.2198; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FROIMAN K, 1997, DIFFERENTIATION, V61, P243; Guazzi S, 1998, J BIOL CHEM, V273, P11092, DOI 10.1074/jbc.273.18.11092; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Hackett BP, 1996, ANNU REV PHYSIOL, V58, P51, DOI 10.1146/annurev.physiol.58.1.51; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Josephson R, 1998, DEVELOPMENT, V125, P3087; KACHINSKY AM, 1994, DEV BIOL, V165, P216, DOI 10.1006/dbio.1994.1248; KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843, DOI 10.1177/43.8.7542682; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LAZZARO D, 2001, DEVELOPMENT, V17, P107; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lothian C, 1999, EXP CELL RES, V248, P509, DOI 10.1006/excr.1999.4417; Marin O, 2000, J NEUROSCI, V20, P6063; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Oguchi H, 1998, ENDOCRINOLOGY, V139, P1999, DOI 10.1210/en.139.4.1999; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; Ramirez MI, 1997, J BIOL CHEM, V272, P26285, DOI 10.1074/jbc.272.42.26285; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; Sussel L, 1999, DEVELOPMENT, V126, P3359; Suzuki K, 1998, MOL CELL BIOL, V18, P7410, DOI 10.1128/MCB.18.12.7410; Suzuki K, 1998, ENDOCRINOLOGY, V139, P3014, DOI 10.1210/en.139.6.3014; Terling C, 1995, INT J DEV BIOL, V39, P947; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249; Zhang LQ, 1997, BBA-GENE STRUCT EXPR, V1350, P359, DOI 10.1016/S0167-4781(96)00180-7	41	22	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47807	47813		10.1074/jbc.M107692200	http://dx.doi.org/10.1074/jbc.M107692200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11584016	hybrid			2022-12-27	WOS:000172927000012
J	Trevillyan, JM; Chiou, XG; Chen, YW; Ballaron, SJ; Sheets, MP; Smith, ML; Wiedeman, PE; Warrior, U; Wilkins, J; Gubbins, EJ; Gagne, GD; Fagerland, J; Carter, GW; Luly, JR; Mollison, KW; Djuric, SW				Trevillyan, JM; Chiou, XG; Chen, YW; Ballaron, SJ; Sheets, MP; Smith, ML; Wiedeman, PE; Warrior, U; Wilkins, J; Gubbins, EJ; Gagne, GD; Fagerland, J; Carter, GW; Luly, JR; Mollison, KW; Djuric, SW			Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; CALCINEURIN; INDUCTION; SIGNAL; IMMUNOSUPPRESSANT; DEPHOSPHORYLATION; KINASES; PATHWAY; BINDING; FK-506	NFAT (nuclear factor of activated T cell) proteins are expressed in most immune system cells and regulate the transcription of cytokine genes critical for the immune response. The activity of NFAT proteins is tightly regulated by the Ca2+/calmodulin-dependent protein phosphatase 2B/calcineurin (CaN). Dephosphorylation of NFAT by CaN is required for NFAT nuclear localization. Current immunosuppressive drugs such as cyclosporin A and FK506 block CaN activity thus inhibiting nuclear translocation of NFAT and consequent cytokine gene transcription. The inhibition of CaN in cells outside of the immune system may contribute to the toxicities associated with cyclosporin A therapy. In a search for safer immunosuppressive drugs, we identified a series of 3,5-bistrifluoromethyl pyrazole (BTP) derivatives that block Th1 and Th2 cytokine gene transcription. The BTP compounds block the activation-dependent nuclear localization of NFAT as determined by electrophoretic mobility shift assays. Confocal microscopy of cells expressing fluorescent-tagged NFAT confirmed that the BTP compounds block calcium-induced movement of NFAT from the cytosol. to the nucleus. Inhibition of NFAT was selective because the BTP compounds did not affect the activation of NF-kappaB and AP-1 transcription factors. Treatment of intact T cells with the BTP compounds prior to calcium ionophore-induced activation of CaN caused NFAT to remain in a highly phosphorylated state. However, the BTP compounds did not directly inhibit the dephosphorylation of NFAT by CaN in vitro, nor did the drugs block the dephosphorylation of other CaN substrates including the type II regulatory subunit of protein kinase A and the transcription factor Elk-1. The data suggest that the BTP compounds cause NFAT to be maintained in the cytosol in a phosphorylated state and block the nuclear import of NFAT and, hence, NFAT-dependent cytokine gene transcription by a mechanism other than direct inhibition of CaN phosphatase activity. The novel inhibitors described herein will be useful in better defining the cellular regulation of NFAT activation and may lead to identification of new therapeutic targets for the treatment of autoimmune disease and transplant rejection.	Abbott Labs, Global Pharmaceut Prod Div, Abbott Pk, IL 60064 USA	Abbott Laboratories	Trevillyan, JM (corresponding author), D-47R,AP10-103,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	james.m.trevillyan@abbott.com						Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; Djuric SW, 2000, J MED CHEM, V43, P2975, DOI 10.1021/jm990615a; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FERRARI JR, 1997, J PREVENTION INTERVE, V15, P83; FLANAGAN WM, 1992, J BIOL CHEM, V267, P399; FUNG JJ, 1991, TRANSPLANT P, V23, P3105; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JUNE CH, 1989, J IMMUNOL, V143, P153; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu WF, 2001, FEBS LETT, V496, P105, DOI 10.1016/S0014-5793(01)02411-5; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; Matsuda S, 2000, EMBO REP, V1, P428, DOI 10.1093/embo-reports/kvd090; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORRIS RE, 1995, TRANSPLANTATION LIVE, P760; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; THOMSON AW, 1993, SPRINGER SEMIN IMMUN, V14, P323, DOI 10.1007/BF00192307; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TSUCHIDA T, 1988, J IMMUNOL, V140, P3446; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	39	84	97	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48118	48126		10.1074/jbc.M107919200	http://dx.doi.org/10.1074/jbc.M107919200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11592964	hybrid			2022-12-27	WOS:000172927000052
J	Godsey, MH; Baranova, NN; Neyfakh, AA; Brennan, RG				Godsey, MH; Baranova, NN; Neyfakh, AA; Brennan, RG			Crystal structure of MtaN, a global multidrug transporter gene activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINGED HELIX PROTEIN; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; COILED-COILS; TRANSCRIPTIONAL ACTIVATION; ANOMALOUS DIFFRACTION; SEQUENCE ALIGNMENTS; MUTANTS IMPLICATE; MERR HOMOLOG; DNA	MtaN (Multidrug Transporter Activation, N terminus) is a constitutive, transcriptionally active 109-residue truncation mutant, which contains only the N-terminal DNA-binding and dimerization domains of MerR family member Mta. The 2.75 Angstrom resolution crystal structure of apo-MtaN reveals a winged helix-turn-helix protein with a protruding 8-turn helix (alpha5) that is involved in dimerization by the formation of an antiparallel coiled-coil. The hydrophobic core and helices al through alpha4 are structurally homologous to MerR family member BmrR bound to DNA, whereas one wing (Wing 1) is shifted. Differences between the orientation of alpha5 with respect to the core and the revolution of the antiparallel coiled-coil lead to significantly altered conformations of MtaN and BmrR dimers. These shifts result in a conformation of MtaN that appears to be incompatible with the transcription activation mechanism of BmrR and suggest that additional DNA-induced structural changes are necessary.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	Oregon Health & Science University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Brennan, RG (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	brennanr@ohsu.edu		Godsey, Michael/0000-0003-1006-7084; Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048593] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 48593] Funding Source: Medline; NIGMS NIH HHS [GM 08617-05] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED M, 1995, J BACTERIOL, V177, P3904, DOI 10.1128/jb.177.14.3904-3910.1995; AHMED M, 1994, J BIOL CHEM, V269, P28506; Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; Baranova NN, 1999, MOL MICROBIOL, V31, P1549, DOI 10.1046/j.1365-2958.1999.01301.x; Barbosa TM, 2000, J BACTERIOL, V182, P3467, DOI 10.1128/JB.182.12.3467-3474.2000; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caguiat JJ, 1999, J BACTERIOL, V181, P3462, DOI 10.1128/JB.181.11.3462-3471.1999; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Godsey MH, 2000, ACTA CRYSTALLOGR D, V56, P1456, DOI 10.1107/S0907444900010295; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Grkovic S, 2001, SEMIN CELL DEV BIOL, V12, P225, DOI 10.1006/scdb.2000.0248; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELMANN JD, 1995, NUCLEIC ACIDS RES, V23, P2351, DOI 10.1093/nar/23.13.2351; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; Jin CW, 1999, J MOL BIOL, V289, P683, DOI 10.1006/jmbi.1999.2819; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 PLUS ESF, V26; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; NISHIKAWA K, 1976, MACROMOLECULES, V9, P395, DOI 10.1021/ma60051a004; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; Outten CE, 1999, J BIOL CHEM, V274, P37517, DOI 10.1074/jbc.274.53.37517; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2340, DOI 10.1021/bi00431a053; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Veen HW, 1999, BBA-BIOMEMBRANES, V1461, P201, DOI 10.1016/S0005-2736(99)00172-8; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zeng QD, 1998, BIOCHEMISTRY-US, V37, P15885, DOI 10.1021/bi9817562; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250	49	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47178	47184		10.1074/jbc.M105819200	http://dx.doi.org/10.1074/jbc.M105819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581256	hybrid			2022-12-27	WOS:000172768500069
J	Shohat, G; Spivak-Kroizman, T; Cohen, O; Bialik, S; Shani, G; Berrisi, H; Eisenstein, M; Kimchi, A				Shohat, G; Spivak-Kroizman, T; Cohen, O; Bialik, S; Shani, G; Berrisi, H; Eisenstein, M; Kimchi, A			The pro-apoptotic function of death-associated protein kinase is controlled by a unique inhibitory autophosphorylation-based mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; CELL LUNG-CANCER; DAP-KINASE; PROMOTER HYPERMETHYLATION; INTRASTERIC REGULATION; STRUCTURAL BASIS; SMOOTH-MUSCLE; CPG ISLAND; CALMODULIN; PHOSPHORYLATION	Death-associated protein kinase is a calcium/calmodulin serine/threonine kinase, which positively mediates programmed cell death in a variety of systems. Here we addressed its mode of regulation and identified a mechanism that restrains its apoptotic function in growing cells and enables its activation during cell death. It involves autophosphorylation of Ser(308) within the calmodulin (CaM)-regulatory domain, which occurs at basal state, in the absence of Ca2+/CaM, and is inversely correlated with substrate phosphorylation. This type of phosphorylation takes place in growing cells and is strongly reduced upon their exposure to the apoptotic stimulus of C-6-ceramide. The substitution of Ser(308) to alanine, which mimics the ceramide-induced dephosphorylation at this site, increases Ca2+/CaM-independent substrate phosphorylation as well as binding and overall sensitivity of the kinase to CaM. At the cellular level, it strongly enhances the death-promoting activity of the kinase. Conversely, mutation to aspartic acid reduces the binding of the protein to CaM and abrogates almost completely the death-promoting function of the protein. These results are consistent with a molecular model in which phosphorylation on Ser(308) stabilizes a locked conformation of the CaM-regulatory domain within the catalytic cleft and simultaneously also interferes with CaM binding. We propose that this unique mechanism of auto-inhibition evolved to impose a locking device, which keeps death-associated protein kinase silent in healthy cells and ensures its activation only in response to apoptotic signals.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Chem Serv, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.							Abe M, 1996, CELL STRUCT FUNCT, V21, P183, DOI 10.1247/csf.21.183; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 1999, CANCER RES, V59, P67; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; LOU LL, 1989, J NEUROSCI, V9, P2020; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; Nakatsuka S, 2000, LAB INVEST, V80, P1651, DOI 10.1038/labinvest.3780175; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Shani G, 2001, EMBO J, V20, P1099, DOI 10.1093/emboj/20.5.1099; SITKOFF D, 1994, BIOPHYS CHEM, V51, P397, DOI 10.1016/0301-4622(94)00062-X; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031	37	125	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47460	47467		10.1074/jbc.M105133200	http://dx.doi.org/10.1074/jbc.M105133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579085	hybrid			2022-12-27	WOS:000172768500102
J	Estepa, AM; Rocha, AI; Mas, V; Perez, L; Encinar, JA; Nunez, E; Fernandez, A; Ros, JMG; Gavilanes, F; Coll, JM				Estepa, AM; Rocha, AI; Mas, V; Perez, L; Encinar, JA; Nunez, E; Fernandez, A; Ros, JMG; Gavilanes, F; Coll, JM			A protein G fragment from the Salmonid viral hemorrhagic septicemia rhabdovirus induces cell-to-cell fusion and membrane phosphatidylserine translocation at low pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS GLYCOPROTEIN-G; VESICULAR STOMATITIS; FISH RHABDOVIRUS; CONFORMATIONAL-CHANGES; SYNTHETIC PEPTIDES; RABIES; MUTATIONS; BINDING; DOMAIN; VHSV	The fusion-related properties of segments p9, p3, p4, and p9 + p2 surrounding the p2 phospholipid-binding domain of the protein G (pG) of the salmonid rhabdovirus of viral hemorrhagic septicemia (VHS) (Nunez, E., Fernandez, A. M., Estepa, A., Gonzalez-Ros, J. M., Gavilanes, F., and Coll, J. M. (1998) Virology 243,322-330; Estepa, A., and Coll, J. M. (1996) Virology 216, 60-70), have been studied at neutral and fusion (low) pH values by using its derived peptides. Cell-to-cell fusion, translocation of phosphatidylserine, and inhibition of fusion of pG-transfected cells defined the p9 + p2 (fragment 11, sequence 56-110) as a fragment with higher specific activity for anionic phospholipid aggregation than the previously reported p2. While fragment 11, p2, and p3 showed interactions with anionic phospholipids, p9 and p4 showed no interactions with any phospholipids. When added to a cell monolayer model at low pH, fragment 11 induced pH-dependent cell-to-cell fusion and translocated phosphatidylserine from the inner to the outer leaflet of the membrane. At low pH and in the presence of anionic phospholipids, fragment 11 showed more than 80% beta -sheet conformation (IR and CD spectroscopies). Finally, anti-fragment 11 antibodies inhibited low pH-dependent pG-transfected cell-to-cell fusion. All of the data support the conclusion that fragment 11 is a primary determinant of some of the viral cell fusion events in VHSV.	Inst Nacl Invest Agrarias & Alimentar, Subdirecc Gen Invest & Tecnol, Dept Biotecnol, Madrid 28040, Spain; Univ Miguel Hernandez, Ctr Biol Mol & Celular, Elche 03202, Spain; Univ Complutense Madrid, Dept Bioquim, Madrid 28028, Spain	Universidad Miguel Hernandez de Elche; Complutense University of Madrid	Coll, JM (corresponding author), Inst Nacl Invest Agrarias & Alimentar, Subdirecc Gen Invest & Tecnol, Dept Biotecnol, Crt Coruna Km 7, Madrid 28040, Spain.	coll@inia.es	Encinar, José Antonio/AAE-9141-2020; Coll, julio/M-6071-2019; Encinar, José A/F-2946-2013; Coll, Julio M/G-4533-2010; Carvajal, Asia Fernandez/G-8877-2015; Mas, Vicente/M-4776-2015; Gavilanes, Francisco/K-9903-2014	Encinar, José Antonio/0000-0002-7219-3863; Coll, julio/0000-0001-8496-3493; Encinar, José A/0000-0002-7219-3863; Coll, Julio M/0000-0001-8496-3493; Mas, Vicente/0000-0002-0887-0743; Gavilanes, Francisco/0000-0003-1047-2362; Gonzalez Ros, Jose Manuel/0000-0002-4804-6855; Perez Garcia-Estan, Luis/0000-0003-4078-8763; Fernandez-Carvajal, Asia/0000-0003-2741-1427				BASURCO B, 1991, ARCH VIROL, V119, P153, DOI 10.1007/BF01310666; BEARZOTTI M, 1995, VET RES, V26, P413; Bearzotti M, 1999, J VIROL, V73, P7703, DOI 10.1128/JVI.73.9.7703-7709.1999; Budker V, 1996, NAT BIOTECHNOL, V14, P760, DOI 10.1038/nbt0696-760; Carneiro FA, 2001, J BIOL CHEM, V276, P62, DOI 10.1074/jbc.M008753200; COLL JM, 1987, J IMMUNOL METHODS, V104, P219, DOI 10.1016/0022-1759(87)90507-2; COLL JM, 1995, ARCH VIROL, V140, P827, DOI 10.1007/BF01314961; Coll JM, 1997, ARCH VIROL, V142, P2089, DOI 10.1007/s007050050227; COLL JM, 1995, VIRUS GENES, V10, P107, DOI 10.1007/BF01702591; COLL JM, 1999, RRD VIROLOGY 1, V1, P75; Delos SE, 2000, J VIROL, V74, P1686, DOI 10.1128/JVI.74.4.1686-1693.2000; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; Einer-Jensen K, 1998, J VIROL, V72, P10189, DOI 10.1128/JVI.72.12.10189-10196.1998; Estepa A, 1996, VIROLOGY, V216, P60, DOI 10.1006/viro.1996.0034; Estepa A, 1997, DIS AQUAT ORGAN, V28, P185, DOI 10.3354/dao028185; Estepa A, 1996, J VIROL METHODS, V61, P37, DOI 10.1016/0166-0934(96)02067-8; Estepa A, 1999, VIRUS RES, V63, P27, DOI 10.1016/S0168-1702(99)00055-6; Fernandez-Alonso M, 1999, J FISH DIS, V22, P237, DOI 10.1046/j.1365-2761.1999.00161.x; FLAMAND A, 1993, VIROLOGY, V194, P302, DOI 10.1006/viro.1993.1261; Fredericksen BL, 1996, VIROLOGY, V217, P49, DOI 10.1006/viro.1996.0092; Gaudin Y, 1999, J GEN VIROL, V80, P1221, DOI 10.1099/0022-1317-80-5-1221; Gaudin Y, 1999, MOL MEMBR BIOL, V16, P21, DOI 10.1080/096876899294724; GAUDIN Y, 1993, J VIROL, V67, P1365, DOI 10.1128/JVI.67.3.1365-1372.1993; le Berre M, 1977, Bulletin Off int Epizoot, V87, P391; LECOCQXHONNEUX F, 1994, J GEN VIROL, V75, P1579, DOI 10.1099/0022-1317-75-7-1579; LENARD J, 1993, VIRAL FUSION MECHANI, P425; Lopez A, 2001, BIOTECHNOL LETT, V23, P481, DOI 10.1023/A:1010393723002; Lorenzo G, 1996, J VIROL METHODS, V58, P1, DOI 10.1016/0166-0934(95)01972-3; Nunez E, 1998, VIROLOGY, V243, P322, DOI 10.1006/viro.1998.9076; Odell D, 1997, J VIROL, V71, P7996, DOI 10.1128/JVI.71.10.7996-8000.1997; Perez L, 1998, J VIROL METHODS, V76, P1, DOI 10.1016/S0166-0934(98)00028-7; SANZ FA, 1992, AM J VET RES, V53, P897; SCHULZ GE, 1984, PRINCIPLES PROTEIN S, P2; Shokralla S, 1998, VIROLOGY, V242, P39, DOI 10.1006/viro.1997.8986; THIRY M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P345, DOI 10.1016/0167-4781(91)90200-6; Walker PJ, 1999, J GEN VIROL, V80, P1211, DOI 10.1099/0022-1317-80-5-1211; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994	37	30	32	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46268	46275		10.1074/jbc.M108682200	http://dx.doi.org/10.1074/jbc.M108682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590161	hybrid, Green Published			2022-12-27	WOS:000172573100106
J	Kelly, A; Lynch, A; Vereker, E; Nolan, Y; Queeman, P; Whittaker, E; O'Neill, LAJ; Lynch, MA				Kelly, A; Lynch, A; Vereker, E; Nolan, Y; Queeman, P; Whittaker, E; O'Neill, LAJ; Lynch, MA			The anti-inflammatory cytokine, interleukin (IL)-10, blocks the inhibitory effect of IL-1 beta on long term potentiation - A role for JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED ACTIVATION; CENTRAL-NERVOUS-SYSTEM; SUPEROXIDE-DISMUTASE; ARACHIDONIC-ACID; GLUTAMATE RELEASE; DENTATE GYRUS; IL-10; RAT	Several effects of the proinflammatory cytokine, interleukin-1 beta (IL-1 beta), have been described in the central nervous system, and one area of the brain where marked changes have been reported is the hippocampus. Among these changes are an IL-1 beta -induced inhibition of long term potentiation (LTP) in perforant path-granule cell synapses and an attenuation of glutamate release in synaptosomes prepared from the hippocampus. Evidence suggests that, at least in circulating cells, the anti-inflammatory cytokine, IL-10, antagonizes certain effects of IL-1. We investigated the effect of IL-10 on IL-1 beta -induced inhibition of LTP and glutamate release. The evidence presented indicates that IL-1 beta stimulates the stress-activated protein kinase, c-Jun-activated protein kinase (JNK), and IL-1 receptor-associated kinase, which may explain its inhibitory effect on release and LTP, and that IL-10 reversed the IL-10-induced stimulation of JNK activity and inhibition of release and LTP. We observed that IL-10 abrogated the stimulatory effect of IL-1 beta on superoxide dismutase activity and reactive oxygen species production, whereas the H2O2-induced inhibition of LTP was also blocked by IL-10. We present evidence that suggests that the action of IL-10 may be mediated by its ability to induce shedding of the IL-1 type I receptor.	Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	Lynch, MA (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland.	lynchma@tcd.ie		O'Neill, Luke/0000-0002-4333-2748; Lynch, Marina/0000-0002-4631-0499; Whittaker, Elizabeth/0000-0002-7944-8793; Nolan, Yvonne/0000-0003-2426-234X; Kelly, Aine/0000-0002-9255-0848				AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; Bluthe RM, 1999, PSYCHONEUROENDOCRINO, V24, P301, DOI 10.1016/S0306-4530(98)00077-8; BORG LAH, 1992, ENDOCRINOLOGY, V130, P2851, DOI 10.1210/en.130.5.2851; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chou YK, 1998, CELL IMMUNOL, V188, P125, DOI 10.1006/cimm.1998.1342; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; Dandona P, 1999, CLIN PHARMACOL THER, V66, P58, DOI 10.1016/S0009-9236(99)70054-8; Delgado M, 2000, J NEUROIMMUNOL, V110, P97, DOI 10.1016/S0165-5728(00)00359-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUREZ P, 1993, J EXP MED, V177, P551, DOI 10.1084/jem.177.2.551; Ericsson A., 1993, Society for Neuroscience Abstracts, V19, P95; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Gunnett CA, 2000, AM J PHYSIOL-HEART C, V279, pH1555, DOI 10.1152/ajpheart.2000.279.4.H1555; Hu SX, 1999, J LEUKOCYTE BIOL, V65, P815, DOI 10.1002/jlb.65.6.815; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; Leon LR, 1998, ANN NY ACAD SCI, V856, P69, DOI 10.1111/j.1749-6632.1998.tb08314.x; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; Maroney AC, 1998, J NEUROSCI, V18, P104; McGahon B, 1996, NEUROSCIENCE, V72, P847, DOI 10.1016/0306-4522(95)00579-X; McGahon B, 1999, NEUROSCIENCE, V90, P1167, DOI 10.1016/S0306-4522(98)00528-4; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; Murray CA, 1998, J NEUROSCI, V18, P2974; Niiro H, 1998, BIOCHEM BIOPH RES CO, V250, P200, DOI 10.1006/bbrc.1998.9287; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OPP MR, 1995, J NEUROIMMUNOL, V60, P165, DOI 10.1016/0165-5728(95)00066-B; ORDRONNEAU P, 1991, J IMMUNOL METHODS, V142, P169, DOI 10.1016/0022-1759(91)90103-M; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; PARNET P, 1994, MOL BRAIN RES, V27, P63, DOI 10.1016/0169-328X(94)90185-6; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; PLATASALAMAN CR, 1994, EUR J PHARM-MOLEC PH, V266, P1, DOI 10.1016/0922-4106(94)90202-X; Pousset F, 1999, GLIA, V26, P12, DOI 10.1002/(SICI)1098-1136(199903)26:1<12::AID-GLIA2>3.0.CO;2-S; Qin SF, 1999, BIOCHEM BIOPH RES CO, V262, P231, DOI 10.1006/bbrc.1999.1079; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; RADY PL, 1995, CELL MOL NEUROBIOL, V15, P289, DOI 10.1007/BF02073335; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Sato K, 1999, J IMMUNOL, V162, P3865; SHOHAM S, 1987, AM J PHYSIOL, V253, pR142, DOI 10.1152/ajpregu.1987.253.1.R142; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; VANDERPOLL T, 1994, J EXP MED, V180, P1985, DOI 10.1084/jem.180.5.1985; Vannier E, 1999, EUR CYTOKINE NETW, V10, P37; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200	54	112	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45564	45572		10.1074/jbc.M108757200	http://dx.doi.org/10.1074/jbc.M108757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581275	hybrid			2022-12-27	WOS:000172573100012
J	Misenheimer, TM; Hahr, AJ; Harms, AC; Annis, DS; Mosher, DF				Misenheimer, TM; Hahr, AJ; Harms, AC; Annis, DS; Mosher, DF			Disulfide connectivity of recombinant C-terminal region of human thrombospondin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; BINDING COMPETITIVE INHIBITOR; HUMAN-PLATELET THROMBOSPONDIN; GENE FAMILY; MONOCLONAL-ANTIBODIES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; TYPE-3 REPEATS; PSEUDOACHONDROPLASIA	The thrombospondin (TSP) family of extracellular glycoproteins consists of five members in vertebrates, TSP1 to -4 and TSP5/cartilage oligomeric matrix protein, and a single member in Drosophila. TSPs are modular multimeric proteins. The C-terminal end of a monomer consists of 3-6 EGF-like modules; seven tandem 23-, 36-, or 38-residne aspartate-rich, Ca2+-binding repeats; and an similar to 230-residue C-terminal sequence. The Ca2+-binding repeats and C-terminal sequence are spaced almost exactly the same in different TSPs and share many blocks of identical residues. We studied the C-terminal portion of human TSP2 from the third EGF-like module through the end of the protein (E3CaG2). E3CaG2, CaG2 lacking the EGF module, and Ca2 composed of only the Ca2+. binding repeats were expressed using recombinant baculoviruses and purified from conditioned media of insect cells. As previously described for intact TSP1, E3CaG2 bound Ca2+ in a cooperative manner as assessed by equilibrium dialysis, and its circular dichroism spectrum was sensitive to the presence of Ca2+. Mass spectrometry of the recombinant proteins digested with endoproteinase Asp-N revealed that disulfide pairing of the IS cysteines in the Ca2+-binding repeats and C-terminal sequence is sequential, i.e. a 1-2, 3-4, 5-6, etc., pattern.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Misenheimer, TM (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.			Harms, Amy/0000-0002-2931-4295	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V188, P190; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adolph KW, 2001, GENE, V269, P177, DOI 10.1016/S0378-1119(01)00441-3; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; CHEN H, 1994, J BIOL CHEM, V269, P32226; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; OLDBERG A, 1992, J BIOL CHEM, V267, P346; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Tooney PA, 1998, MATRIX BIOL, V17, P131, DOI 10.1016/S0945-053X(98)90026-9; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; VOS HL, 1992, J BIOL CHEM, V267, P12192	49	23	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45882	45887		10.1074/jbc.M104218200	http://dx.doi.org/10.1074/jbc.M104218200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590138	hybrid			2022-12-27	WOS:000172573100053
J	Zhang, H; Gallo, KA				Zhang, H; Gallo, KA			Autoinhibition of mixed lineage kinase 3 through its Src homology 3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; PROTEIN-KINASE; LEUCINE-ZIPPER; SH3 DOMAINS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING MOTIF; JNK PATHWAY; HUMAN BRAIN; ACTIVATION	Mixed lineage kinase 3 (MLK3) is a serine/threonine protein kinase that functions as a mitogen-activated protein kinase kinase kinase to activate the c-Jun NH2-terminal kinase pathway. MLK3 has also been implicated as an I kappaB kinase kinase in the activation of NF-kappaB. Amino-terminal to its catalytic domain, MLK3 contains a Src homology 3 (SH3) domain. SH3 domains harbor three highly conserved aromatic amino acids that are important for ligand binding. In this study, we mutated one of these corresponding residues within MLK3 to deliberately disrupt the function of its SH3 domain. This SH3-defective mutant of MLK3 exhibited increased catalytic activity compared with wild type MLK3 suggesting that the SH3 domain negatively regulates MLK3 activity. We report herein that the SH3 domain of MLK3 interacts with full-length MLK3, and we have mapped the site of interaction to a region between the zipper and the Cdc42/Rac interactive binding motif. Interestingly, the SH3-binding region contains not a proline-rich sequence but, rather, a single proline residue. Mutation of this sole proline abrogates SH3 binding and increases MLK3 catalytic activity. Taken together, these data demonstrate that MLK3 is autoinhibited through its SH3 domain. The critical proline residue in the SH3 binding site of MLK3 is conserved in the closely related family members, MLK1 and MLK2, suggesting a common autoinhibitory mechanism among these kinases. Our study has revealed the first example of SH3 domain-mediated autoinhibition of a serine/threonine kinase and provides insight into the regulation of the mixed lineage family of protein kinases.	Michigan State Univ, Dept Physiol, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Gallo, KA (corresponding author), Michigan State Univ, Dept Physiol, Cell & Mol Biol Program, 108 Giltner Hall, E Lansing, MI 48824 USA.				NATIONAL CANCER INSTITUTE [R29CA076306] Funding Source: NIH RePORTER; NCI NIH HHS [CA76306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hubbard SR, 1999, NAT STRUCT BIOL, V6, P711, DOI 10.1038/11468; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KATOH M, 1995, ONCOGENE, V10, P1447; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45598	45603		10.1074/jbc.M107176200	http://dx.doi.org/10.1074/jbc.M107176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590155	hybrid			2022-12-27	WOS:000172573100016
J	Guzman-Verri, C; Chaves-Olarte, E; von Eichel-Streiber, C; Lopez-Goni, I; Thelestam, M; Arvidson, S; Gorvel, JP; Moreno, E				Guzman-Verri, C; Chaves-Olarte, E; von Eichel-Streiber, C; Lopez-Goni, I; Thelestam, M; Arvidson, S; Gorvel, JP; Moreno, E			GTPases of the Rho subfamily are required for Brucella abortus internalization in nonprofessional phagocytes - Direct activation of Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN EPITHELIAL-CELLS; KINASE INHIBITORS BLOCK; HUMAN-ENDOTHELIAL-CELLS; TISSUE-CULTURE CELLS; LISTERIA-MONOCYTOGENES; SALMONELLA-TYPHIMURIUM; BACTERIAL INVASION; SHIGELLA-FLEXNERI; PHOSPHATIDYLINOSITOL 3-KINASE; CLOSTRIDIUM-DIFFICILE	Members of the genus Brucella are intracellular a-Proteobacteria responsible for brucellosis, a chronic disease of humans and animals. Little is known about Brucella virulence mechanisms, but the abilities of these bacteria to invade and to survive within cells are decisive factors for causing disease. Transmission electron and fluorescence microscopy of infected nonprofessional phagocytic HeLa cells revealed minor membrane changes accompanied by discrete recruitment of F-actin at the site of Brucella abortus entry. Cell uptake of B. abortus was negatively affected to various degrees by actin, actin-myosin, and microtubule chemical inhibitors. Modulators of MAPKs and protein-tyrosine kinases hampered Brucella cell internalization. Inactivation of Rho small GTPases using clostridial toxins TcdB-10463, TcdB-1470, TcsL-1522, and TcdA significantly reduced the uptake of B. abortus by HeLa cells. In contrast, cytotoxic necrotizing factor from Escherichia coli, known to activate Rho, Rac, and Cdc42 small GTPases, increased the internalization of both virulent and non-virulent B. abortus. Expression of dominant-positive Rho, Rac, and Cdc42 forms in HeLa cells promoted the uptake of B. abortus, whereas expression of dominant-negative forms of these GTPases in HeLa cells hampered Brucella uptake. Cdc42 was activated upon cell contact by virulent B. abortus, but not by a noninvasive isogenic strain, as proven by affinity precipitation of active Rho, Rac, and Cdc42. The polyphasic approach used to discern the molecular events leading to Brucella internalization provides new alternatives for exploring the complexity of the signals required by intracellular pathogens for cell invasion.	Univ Nacl, Escuela Med Vet, Programa Invest Enfermedades Trop, Heredia 3000, Costa Rica; Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Univ Costa Rica, Fac Microbiol, Ctr Invest Enfermedades Trop, San Jose 1000, Costa Rica; Univ Mainz, Inst Med Mikrobiol & Hyg, Verfugungsgebaude Forsch & Entwicklung, D-55101 Mainz, Germany; Univ Navarra, Dept Microbiol, E-31080 Pamplona, Spain; CNRS, INSERM, Ctr Immunol Marseille Luminy, Marseille, France	Universidad Nacional Costa Rica; Karolinska Institutet; Universidad Costa Rica; Johannes Gutenberg University of Mainz; University of Navarra; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Moreno, E (corresponding author), Univ Nacl, Escuela Med Vet, Programa Invest Enfermedades Trop, POB 304, Heredia 3000, Costa Rica.		López-Goñi, Ignacio/K-2572-2017; Guzman-Verri, Caterina/AAP-3074-2020; Gorvel, Jean-Pierre/O-1332-2018	López-Goñi, Ignacio/0000-0002-3873-8743; Guzman-Verri, Caterina/0000-0003-1036-920X; Gorvel, Jean-Pierre/0000-0002-2829-9804; Moreno, Edgardo/0000-0001-8771-3959				ACKERMANN MR, 1988, VET PATHOL, V25, P28, DOI 10.1177/030098588802500104; ADAM T, 1995, J CELL BIOL, V129, P367, DOI 10.1083/jcb.129.2.367; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON TD, 1986, AM J PATHOL, V124, P226; ANDERSON TD, 1986, VET PATHOL, V23, P227, DOI 10.1177/030098588602300302; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BERMUDEZ LE, 1994, INFECT IMMUN, V62, P2021, DOI 10.1128/IAI.62.5.2021-2026.1994; CAMPBELL GA, 1994, VET IMMUNOL IMMUNOP, V41, P295, DOI 10.1016/0165-2427(94)90103-1; Celli J, 2000, CELL MICROBIOL, V2, P1, DOI 10.1046/j.1462-5822.2000.00033.x; Chaves-Olarte E, 1999, J BIOL CHEM, V274, P11046, DOI 10.1074/jbc.274.16.11046; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; Comerci DJ, 1998, INFECT IMMUN, V66, P3862, DOI 10.1128/IAI.66.8.3862-3866.1998; Comerci DJ, 2001, CELL MICROBIOL, V3, P159, DOI 10.1046/j.1462-5822.2001.00102.x; Corbel MJ, 1997, J MED MICROBIOL, V46, P101, DOI 10.1099/00222615-46-2-101; Corbel MJ, 1984, BERGEYS MANUAL SYSTE, P377; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Coxon PY, 1998, INFECT IMMUN, V66, P2905, DOI 10.1128/IAI.66.6.2905-2913.1998; DETEJADA GM, 1995, INFECT IMMUN, V63, P3054; DETILLEUX PG, 1991, AM J VET RES, V52, P1658; DETILLEUX PG, 1990, INFECT IMMUN, V58, P2320, DOI 10.1128/IAI.58.7.2320-2328.1990; DETILLEUX PG, 1990, VET PATHOL, V27, P317, DOI 10.1177/030098589002700503; Drevets DA, 1998, INFECT IMMUN, V66, P232, DOI 10.1128/IAI.66.1.232-238.1998; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; FRANCIS CL, 1991, J INFECT DIS, V164, P693, DOI 10.1093/infdis/164.4.693; Freer E, 1996, J BACTERIOL, V178, P5867, DOI 10.1128/jb.178.20.5867-5876.1996; Freer E, 1999, INFECT IMMUN, V67, P6181, DOI 10.1128/IAI.67.11.6181-6186.1999; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; HARMON BG, 1988, AM J VET RES, V49, P1092; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; HERRMANN C, 1992, BIOCHEMISTRY-US, V31, P12227, DOI 10.1021/bi00163a036; Hu L, 1999, INFECT IMMUN, V67, P4171, DOI 10.1128/IAI.67.8.4171-4182.1999; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; JANDA JM, 1991, INFECT IMMUN, V59, P154, DOI 10.1128/IAI.59.1.154-161.1991; Jerse AE, 1997, TRENDS MICROBIOL, V5, P217, DOI 10.1016/S0966-842X(97)01056-1; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kazmierczak BI, 2001, CELL MICROBIOL, V3, P85, DOI 10.1046/j.1462-5822.2001.00091.x; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kespichayawattana W, 2000, INFECT IMMUN, V68, P5377, DOI 10.1128/IAI.68.9.5377-5384.2000; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Krendel M, 1998, CELL MOTIL CYTOSKEL, V40, P368, DOI 10.1002/(SICI)1097-0169(1998)40:4<368::AID-CM5>3.3.CO;2-R; Kugler S, 1997, FEMS MICROBIOL LETT, V157, P131; Kuhn M, 1998, FEMS MICROBIOL LETT, V160, P87, DOI 10.1016/S0378-1097(98)00017-2; Kusumawati A, 2000, MICROB PATHOGENESIS, V28, P343, DOI 10.1006/mpat.2000.0354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMONT RJ, 1995, INFECT IMMUN, V63, P3878, DOI 10.1128/IAI.63.10.3878-3885.1995; Linder S, 2001, INFECT IMMUN, V69, P1739, DOI 10.1128/IAI.69.3.1739-1746.2001; Meier C, 1996, INFECT IMMUN, V64, P2391, DOI 10.1128/IAI.64.7.2391-2399.1996; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Meyer DH, 1999, INFECT IMMUN, V67, P6518; MILIOTIS MD, 1995, INFECT IMMUN, V63, P4959, DOI 10.1128/IAI.63.12.4959-4963.1995; MOUNIER J, 1992, INFECT IMMUN, V60, P237, DOI 10.1128/IAI.60.1.237-248.1992; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Nhieu GTV, 2000, CELL MICROBIOL, V2, P187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OELSCHLAEGER TA, 1993, P NATL ACAD SCI USA, V90, P6884, DOI 10.1073/pnas.90.14.6884; Oelschlaeger TA, 1997, INFECT IMMUN, V65, P2950, DOI 10.1128/IAI.65.7.2950-2958.1997; Pizarro-Cerda J, 1999, ADV CELL MOL BIOL ME, V6, P201, DOI 10.1016/S1874-5172(99)80013-3; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P5711; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387; Pizarro-Cerda J, 2000, MICROBES INFECT, V2, P829, DOI 10.1016/S1286-4579(00)90368-X; PIZON V, 1994, J CELL SCI, V107, P1661; PLOTKOWSKI MC, 1994, INFECT IMMUN, V62, P5456, DOI 10.1128/IAI.62.12.5456-5463.1994; Porte F, 1999, INFECT IMMUN, V67, P4041, DOI 10.1128/IAI.67.8.4041-4047.1999; Procyk KJ, 1999, INFECT IMMUN, V67, P1011, DOI 10.1128/IAI.67.3.1011-1017.1999; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RICHARDSON WP, 1988, INFECT IMMUN, V56, P2512, DOI 10.1128/IAI.56.9.2512-2514.1988; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROBINSON DG, 1987, METHODS PREPARATION, P69; Rochlin MW, 1999, MOL BIOL CELL, V10, P2309, DOI 10.1091/mbc.10.7.2309; ROJAS N, 1994, CLIN DIAGN LAB IMMUN, V1, P206, DOI 10.1128/CDLI.1.2.206-213.1994; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; ROSENSHINE I, 1994, METHOD ENZYMOL, V236, P467; SALYERS AA, 1994, BACTERIAL PATHOGENES; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SANGARI F, 1991, MICROB PATHOGENESIS, V11, P443, DOI 10.1016/0882-4010(91)90040-H; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; Sola-Landa A, 1998, MOL MICROBIOL, V29, P125, DOI 10.1046/j.1365-2958.1998.00913.x; STEVENS MG, 1994, INFECT IMMUN, V62, P3206, DOI 10.1128/IAI.62.8.3206-3212.1994; STGEME JW, 1990, INFECT IMMUN, V58, P4036, DOI 10.1128/IAI.58.12.4036-4044.1990; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tang P, 1998, INFECT IMMUN, V66, P1106, DOI 10.1128/IAI.66.3.1106-1112.1998; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; Thelestam M, 2000, CURR TOP MICROBIOL, V250, P85; Ugalde RA, 1999, MICROBES INFECT, V1, P1211, DOI 10.1016/S1286-4579(99)00240-3; VASSELON T, 1991, INFECT IMMUN, V59, P1723, DOI 10.1128/IAI.59.5.1723-1732.1991; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; Velge P, 1997, J MED MICROBIOL, V46, P681, DOI 10.1099/00222615-46-8-681; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WALKER RL, 1999, VET MICROBIOL, P196; WALKER TS, 1984, INFECT IMMUN, V44, P205, DOI 10.1128/IAI.44.2.205-210.1984; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wells CL, 1998, INFECT IMMUN, V66, P2410, DOI 10.1128/IAI.66.6.2410-2419.1998; Wells CL, 1999, J NUTR, V129, P634, DOI 10.1093/jn/129.3.634; Wilson SL, 1998, J INFECT DIS, V178, P1658, DOI 10.1086/314490; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283	114	86	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44435	44443		10.1074/jbc.M105606200	http://dx.doi.org/10.1074/jbc.M105606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579087	hybrid			2022-12-27	WOS:000172406700013
J	Homma, KJ; Tanaka, Y; Matsushita, T; Yokoyama, K; Matsui, H; Natori, S				Homma, KJ; Tanaka, Y; Matsushita, T; Yokoyama, K; Matsui, H; Natori, S			Adenosine deaminase activity of insect-derived growth factor is essential for its growth factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAT EYE SYNDROME; EMBRYONIC-CELL LINE; PEREGRINA FLESH FLY; SARCOPHAGA-PEREGRINA; CRITICAL REGION; CULTURE-MEDIUM; CDNA CLONING; PURIFICATION; NIH-SAPE-4; RECEPTORS	Insect-derived growth factor (IDGF) was originally isolated from conditioned medium of NIH-Sape-4 cells derived from flesh fly embryos. Here we demonstrated that IDGF has adenosine deaminase activity. The substrate specificity of IDGF was similar to that of the mammalian cytoplasmic adenosine deaminase. The adenosine deaminase activity of IDGF was shown to be indispensable for its growth factor activity toward NIH-Sape-4 cells. We found that there are specific binding sites for IDGF on the surface of NIH-Sape-4 cells and that it binds to these sites with a K-d, value of 2.4 X 10(-10) m. We propose that the cell surface binding sites for IDGF are specific receptors modified with an adenosine moiety. When IDGF binds to these receptors, it may deaminate the adenosine moiety, and this process may be prerequisite for the signal transduction via this receptor.	RIKEN, Inst Phys & Chem Res, Natori Special Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Natori, S (corresponding author), RIKEN, Inst Phys & Chem Res, Natori Special Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Dong RP, 1997, J IMMUNOL, V159, P6070; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hershfield M., 1995, METABOLIC MOL BASIS; HOMMA K, 1994, J BIOL CHEM, V269, P15258; Homma K, 1996, J BIOL CHEM, V271, P13770, DOI 10.1074/jbc.271.23.13770; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KODAMA K, 1979, AGR BIOL CHEM TOKYO, V43, P2375, DOI 10.1080/00021369.1979.10863817; KOMANO H, 1987, BIOCHEM J, V248, P217, DOI 10.1042/bj2480217; KRAUT EH, 1986, BLOOD, V68, P1119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li S, 2000, GENE, V252, P83, DOI 10.1016/S0378-1119(00)00226-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsushita T, 2000, J BIOL CHEM, V275, P36934, DOI 10.1074/jbc.M003455200; MCDERMID HE, 1986, SCIENCE, V232, P646, DOI 10.1126/science.3961499; McDermid HE, 1996, GENOME RES, V6, P1149, DOI 10.1101/gr.6.12.1149; MEARS AJ, 1995, AM J HUM GENET, V57, P667; MITSUHAS.J, 1964, CONTRIB BOYCE THOMPS, V22, P435; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; OHTAKI T, 1966, JPN J MED SCI BIOL, V19, P97, DOI 10.7883/yoken1952.19.97; PAGE B, 1993, INT J ONCOL, V3, P473; Raffery L.A., 1999, DEV BIOL, V210, P251; Riazi MA, 2000, GENOMICS, V64, P277, DOI 10.1006/geno.1999.6099; RUETER SM, 1998, MODIFICATION EDITING, V1, P1725; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINZEL A, 1981, HUM GENET, V57, P148; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Sideraki V, 1996, BIOCHEMISTRY-US, V35, P15019, DOI 10.1021/bi961427e; Sideraki V, 1996, BIOCHEMISTRY-US, V35, P7862, DOI 10.1021/bi952920d; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; VALLEJO AN, 1994, PCR METH APPL, V4, P123; Westermark B, 1989, CURR OPIN CELL BIOL, V1, P279, DOI 10.1016/0955-0674(89)90101-4; WIGINTON DA, 1981, BIOCHEM J, V195, P389, DOI 10.1042/bj1950389; YAMAGUCHI K, 1986, LEUKEMIA RES, V10, P989, DOI 10.1016/0145-2126(86)90251-1	45	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43761	43766		10.1074/jbc.M105088200	http://dx.doi.org/10.1074/jbc.M105088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562360				2022-12-27	WOS:000172297700038
J	McQuibban, GA; Butler, GS; Gong, JH; Bendall, L; Power, C; Clark-Lewis, I; Overall, CM				McQuibban, GA; Butler, GS; Gong, JH; Bendall, L; Power, C; Clark-Lewis, I; Overall, CM			Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A; CD34(+) CELLS; GROWTH-FACTOR; LYMPHOCYTE CHEMOATTRACTANT; EXTRACELLULAR-MATRIX; BINDING-PROPERTIES; HEPARIN-BINDING; LEUKEMIA CELLS; ACTIVATION; MARROW	Chemokines provide directional cues for leukocyte migration and activation that are essential for normal leukocytic trafficking and for host responses during processes such as inflammation, infection, and cancer. Recently we reported that matrix metalloproteinases (MMPs) modulate the activity of the CC chemokine monocyte chemoattractant protein-3 by selective proteolysis to release the N-terminal tetrapeptide. Here we report the N-terminal processing, also at position 4-5, of the CXC chemokines stromal cell-derived factor (SDF)-1 alpha and beta by MMP-2 (gelatinase A). Robustness of the MMP family for chemokine cleavage was revealed from identical cleavage site specificity of MMPs 1, 3, 9, 13, and 14 (MT1-MMP) toward SDF-1; selectivity was indicated by absence of cleavage by AMP's 7 and 8. Efficient cleavage of SDF-1 alpha by MMP-2 is the result of a strong interaction with the NMP hemopexin C domain at an exosite that overlaps the monocyte chemoattractant protein-3 binding site. The association of SDF-1 alpha with different glycosaminoglycans did not inhibit cleavage. MMP cleavage of SDF-1 alpha resulted in loss of binding to its cognate receptor CXCR-4. This was reflected in a loss of chemoattractant activity for CD34(+) hematopoietic progenitor stem cells and pre-B cells, and unlike full-length SDF-1 alpha, the MMP-cleaved chemokine was unable to block CXCR-4-dependent human immunodeficiency virus-1 infection of CD4(+) cells. These data suggest that MMPs may be important regulatory proteases in attenuating SDF-1 function and point to a deep convergence of two important networks, chemokines and MMPs, to regulate leukocytic activity in vivo.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ Sydney, Westmead Inst Canc Res, Sydney, NSW 2145, Australia; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of Sydney; University of Calgary	Overall, CM (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022; Power, Christopher/C-7181-2013	Butler, Georgina/0000-0003-1172-1578; Power, Christopher/0000-0002-5131-9711				Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bendall LJ, 1997, BRIT J HAEMATOL, V98, P828, DOI 10.1046/j.1365-2141.1997.2993116.x; BENDALL LJ, 1993, BLOOD, V82, P3125; Bigg HF, 2001, CANCER RES, V61, P3610; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Deryugina EI, 1997, J CELL SCI, V110, P2473; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Janowska-Wieczorek A, 1999, BLOOD, V93, P3379, DOI 10.1182/blood.V93.10.3379.410k09_3379_3390; Johnston JB, 2000, J VIROL, V74, P7211, DOI 10.1128/JVI.74.16.7211-7220.2000; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Overall CM, 2000, METH MOL B, V151, P79, DOI 10.1385/1-59259-046-2:079; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Power C, 1998, J VIROL, V72, P9045, DOI 10.1128/JVI.72.11.9045-9053.1998; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Shen HM, 2001, J IMMUNOL, V166, P5027, DOI 10.4049/jimmunol.166.8.5027; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; SODEK J, 1988, BIOL MECHANISMS TOOT, P303; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; Vecchi A, 1999, J LEUKOCYTE BIOL, V66, P489, DOI 10.1002/jlb.66.3.489; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WILLEMS J, 1989, IMMUNOLOGY, V67, P540; Xia MH, 1996, J IMMUNOL, V156, P160	52	507	532	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43503	43508		10.1074/jbc.M107736200	http://dx.doi.org/10.1074/jbc.M107736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571304	hybrid			2022-12-27	WOS:000172297700005
J	Fukunaga, K; Ishii, S; Asano, K; Yokomizo, T; Shiomi, T; Shimizu, T; Yamaguchi, K				Fukunaga, K; Ishii, S; Asano, K; Yokomizo, T; Shiomi, T; Shimizu, T; Yamaguchi, K			Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR ACETYLHYDROLASE DEFICIENCY; MISSENSE MUTATION; RISK FACTOR; CELLS; MICE; HYPERREACTIVITY; PHOSPHOLIPASE; EXPRESSION; CHEMOTAXIS; ENDOTOXIN	Various proinflammatory and vasoactive actions of platelet-activating factor (PAF) are mediated through a specific G-protein-coupled PAF receptor (PAFR). We identified a novel DNA variant in the human PAFR gene, which substitutes an aspartic acid for an alanine residue at position 224 (A224D) in the putative third cytoplasmic loop. This mutation was observed in a Japanese population at an allele frequency of 7.8%. To delineate the functional consequences of this structural alteration, Chinese hamster ovary cells were stably transfected with constructs encoding either wild-type or A224D mutated PAFR. No significant difference was observed in the expression level of the receptor or the affinity to PAF or to an antagonist, WEB2086, between the cells transfected with wild-type and mutant PAFR. Chinese hamster ovary cells expressing A224D mutant PAFR displayed partial but significant reduction of PAF-induced intracellular signals such as calcium mobilization, inositol phosphate production, inhibition of adenylyl cyclase, and chemotaxis. These findings suggest that this variant receptor produced by a naturally occurring mutation exhibits impaired coupling to G-proteins and may be a basis for interindividual variation in PAF-related physiological responses, disease predisposition or phenotypes, and drug responsiveness.	Keio Univ, Sch Med, Dept Med, Cardiopulm Div,Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1608582, Japan	Keio University; University of Tokyo; Japan Science & Technology Agency (JST)	Asano, K (corresponding author), Keio Univ, Sch Med, Dept Med, Cardiopulm Div,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Yokomizo, Takehiko/P-5673-2016; Fukunaga, Koichi/R-5338-2019	Yokomizo, Takehiko/0000-0002-5219-1553; 				ALI H, 1994, J BIOL CHEM, V269, P24557; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Brzustowicz LM, 1997, HYPERTENSION, V29, P158, DOI 10.1161/01.HYP.29.1.158; Carlson SA, 1998, MOL PHARMACOL, V53, P451, DOI 10.1124/mol.53.3.451; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; Hiramoto M, 1997, STROKE, V28, P2417, DOI 10.1161/01.STR.28.12.2417; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Longphre M, 1996, AM J RESP CELL MOL, V14, P461, DOI 10.1165/ajrcmb.14.5.8624251; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; RODRIGUEZROISIN R, 1994, J CLIN INVEST, V93, P188, DOI 10.1172/JCI116944; Satoh N, 1999, AM J RESP CRIT CARE, V159, P974, DOI 10.1164/ajrccm.159.3.9807093; Shi LC, 1996, J NEUROCHEM, V67, P1478; Small KM, 2000, J BIOL CHEM, V275, P23059, DOI 10.1074/jbc.M000796200; Small KM, 2001, J BIOL CHEM, V276, P4917, DOI 10.1074/jbc.M008118200; Small KM, 2000, J BIOL CHEM, V275, P38518, DOI 10.1074/jbc.M004550200; Stafforini DM, 1999, J CLIN INVEST, V103, P989, DOI 10.1172/JCI5574; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STRADER CD, 1987, J BIOL CHEM, V262, P16439; Tanaka R, 1999, AM J KIDNEY DIS, V34, P289, DOI 10.1016/S0272-6386(99)70357-4; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Yamada Y, 1998, METABOLISM, V47, P177, DOI 10.1016/S0026-0495(98)90216-5; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	34	38	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43025	43030		10.1074/jbc.M108288200	http://dx.doi.org/10.1074/jbc.M108288200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11560941	hybrid			2022-12-27	WOS:000172169300053
J	Andersen, PS; Menne, C; Mariuzza, RA; Geisler, C; Karjalainen, K				Andersen, PS; Menne, C; Mariuzza, RA; Geisler, C; Karjalainen, K			A response calculus for immobilized T cell receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; ANTIGEN RECOGNITION; PEPTIDE COMPLEXES; CRYSTAL-STRUCTURE; LOW-AFFINITY; BETA-CHAIN; TCR; ACTIVATION; ADHESION; MOLECULES	To address the molecular mechanism of T cell receptor (TCR) signaling, we have formulated a model for T cell activation, termed the 2D-affinity model, in which the density of TCR on the T cell surface, the density of ligand on the presenting surface, and their corresponding two-dimensional affinity determine the level of T cell activation. When fitted to T cell responses against purified ligands immobilized on plastic surfaces, the 2D-affinity model adequately simulated changes in cellular activation as a result of varying ligand affinity and ligand density. These observations further demonstrated the importance of receptor cross-linking density in determining TCR signaling. Moreover, it was found that the functional two-dimensional affinity of TCR ligands was affected by the chemical composition of the ligand-presenting surface. This makes it possible that cell. bound TCR ligands, despite their low affinity in solution, are of optimal two-dimensional affinity thereby allowing effective TCR binding under physiological conditions, i.e. at low ligand densities in cellular interfaces.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark; Univ Maryland, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Basel Inst Immunol, CH-4005 Basel, Switzerland	University of Copenhagen	Andersen, PS (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Bldg 24-2,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.	psa@symphogen.com	Geisler, Carsten/A-7056-2012; Karjalainen, Klaus/A-2206-2011	Geisler, Carsten/0000-0002-8472-0771; Bonefeld, Charlotte Menne/0000-0002-0523-6229				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Andersen PS, 1999, IMMUNITY, V10, P473, DOI 10.1016/S1074-7613(00)80047-3; Andersen PS, 2001, J BIOL CHEM, V276, P33452, DOI 10.1074/jbc.M103750200; Bachmann MF, 1998, EUR J IMMUNOL, V28, P2571, DOI 10.1002/(SICI)1521-4141(199808)28:08<2571::AID-IMMU2571>3.0.CO;2-T; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Bot A, 1996, J IMMUNOL, V157, P3436; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Gett AV, 2000, NAT IMMUNOL, V1, P239, DOI 10.1038/79782; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Pecorari F, 1999, J MOL BIOL, V285, P1831, DOI 10.1006/jmbi.1998.2422; Pierres A, 1996, P NATL ACAD SCI USA, V93, P15114, DOI 10.1073/pnas.93.26.15114; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Redpath S, 1999, J IMMUNOL, V163, P6; Riper JW, 1998, BIOPHYS J, V74, P492, DOI 10.1016/S0006-3495(98)77807-5; Schodin BA, 1996, IMMUNITY, V5, P137, DOI 10.1016/S1074-7613(00)80490-2; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Sykulev Y, 1995, P NATL ACAD SCI USA, V92, P11990, DOI 10.1073/pnas.92.26.11990; Sykulev Y, 1998, IMMUNITY, V9, P475, DOI 10.1016/S1074-7613(00)80631-7; Tissot AC, 2000, J MOL BIOL, V302, P873, DOI 10.1006/jmbi.2000.4501; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; van der Merwe PA, 2000, NAT IMMUNOL, V1, P194, DOI 10.1038/79729; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; WALLNY HJ, 1995, EUR J IMMUNOL, V25, P1262, DOI 10.1002/eji.1830250520; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Williams TE, 2001, J BIOL CHEM, V276, P13283, DOI 10.1074/jbc.M010427200	51	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49125	49132		10.1074/jbc.M109396200	http://dx.doi.org/10.1074/jbc.M109396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11592972	hybrid			2022-12-27	WOS:000173922100067
J	Ridsdale, R; Tseu, I; Wang, JX; Post, M				Ridsdale, R; Tseu, I; Wang, JX; Post, M			CTP : phosphocholine cytidylyltransferase alpha is a cytosolic protein in pulmonary epithelial cells and tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT LUNG; NUCLEAR-LOCALIZATION; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; MEMBRANE INTERACTIONS; II CELLS; SURFACTANT; IDENTIFICATION; PHOSPHATIDYLGLYCEROL; DIACYLGLYCEROL	CTP:phosphocholine cytidylyltransferase (CCT) is a rate-determining enzyme in de novo synthesis of phosphatidylcholine (PC). The lung requires a steady synthesis of PC for lung surfactant of which disaturated PC is the essential active agent. Surfactant synthesis occurs in alveolar type II cells. Studies with non-pulmonary cells have suggested that COT is both a nuclear and cytoplasmic protein. The unusual requirements of the lung for PC synthesis and, therefore, COT activity suggest a unique mechanism of regulation and possibly localization of COT. The localization of CCTalpha in lung epithelial cells and, of greater consequence, lung tissues are yet unknown. Three isoforms of COT have been identified. Herein we investigated the localization of the ubiquitously expressed CCTalpha isoform. To ascertain CCTalpha localization in lungs and lung-related epithelial cells, we employed a number of localization methods. Immunogold electron microscopy using polyclonal antibodies raised to either the carboxyl terminus, catalytic domain, or amino terminus of CCTalpha localized CCTalpha mostly to the exterior plasma membrane or regions of the endoplasmic reticulum (ER) in both A549 and MLE-15 epithelial lung cell lines and primary cultures of fetal rat lung epithelial cells. In contrast to other studies, little or no nuclear labeling was observed. Indirect immunofluorescence of these cells with anti-CCTalpha antibodies resulted in a similar distribution. Indirect visualization of both hemagglutinin- and FLAG-tagged CCTalpha as well as direct visualization of enhanced green fluorescence protein-CCTalpha fusion protein corroborated a cytoplasmic localization of CCTalpha in pulmonary cells. Moreover, analysis of lung tissue from fetal and adult mouse by either immunogold electron microscopy or indirect immunofluorescence yielded a strong cytoplasmic CCTalpha signal with virtually no nuclear localization in epithelial cells lining the airways. The cytoplasmic localization of CCTalpha in type II cells was further substantiated with transgenic mice overexpressing FLAG-tagged CCTalpha using the lung-specific human surfactant protein C (SP-C) promoter. We conclude that CCTa does not localize to the nucleus in pulmonary tissues, and, therefore, nuclear localization of CCTalpha is not a universal event.	Univ Toronto, Hosp Sick Children, Res Inst,Canadian Inst,Hlth Res Grp, Inst Med Sci,Programme Lung Biol Res, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Post, M (corresponding author), Univ Toronto, Hosp Sick Children, Res Inst,Canadian Inst,Hlth Res Grp, Inst Med Sci,Programme Lung Biol Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; DeLong CJ, 2000, J BIOL CHEM, V275, P32325, DOI 10.1074/jbc.M004644200; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; HALLMAN M, 1985, PEDIATR RES, V19, P286, DOI 10.1203/00006450-198503000-00006; HOGAN M, 1994, AM J PHYSIOL, V267, pL25, DOI 10.1152/ajplung.1994.267.1.L25; Houweling M, 1996, EUR J CELL BIOL, V69, P55; JASSAL D, 1991, IN VITRO CELL DEV B, V27, P625; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; POST M, 1988, BIOCHIM BIOPHYS ACTA, V947, P249, DOI 10.1016/0304-4157(88)90011-1; SCHLAME M, 1986, BIOCHEM J, V240, P247, DOI 10.1042/bj2400247; SCHLAME M, 1988, BIOCHEM J, V253, P209, DOI 10.1042/bj2530209; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615; Yang JL, 1997, BIOCHEM J, V325, P29, DOI 10.1042/bj3250029; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; ZIMMERMANN LJ, 1994, BBA-LIPID LIPID MET, V1211, P44, DOI 10.1016/0005-2760(94)90137-6; ZIMMERMANN LJ, 1993, AM J PHYSIOL, V264, pF575	36	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49148	49155		10.1074/jbc.M103566200	http://dx.doi.org/10.1074/jbc.M103566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11583989	hybrid			2022-12-27	WOS:000173922100070
J	Gerrish, K; Cissell, AA; Stein, R				Gerrish, K; Cissell, AA; Stein, R			The role of hepatic nuclear factor 1 alpha and PDX-1 in transcriptional regulation of the pdx-1 gene.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC TRANSCRIPTION; HUMAN INSULIN GENE; HOMEODOMAIN PROTEIN; FACTOR-I; DIABETES-MELLITUS; HOMEOBOX FACTOR; BETA-CELLS; PANCREAS DEVELOPMENT; FACTOR 3-BETA; ISLET CELLS	The PDX-1 homeodomain transcription factor regulates pancreatic development and adult islet beta cell function. Expression of the pdx-1 gene is almost exclusively localized to beta cells within the adult endocrine pancreas. Islet beta cell-selective transcription is controlled by evolutionarily conserved subdomain sequences (termed Areas I (-2839 to -2520 base pairs (bp)), II (-2252 to -2023 bp), and III (-1939 to -1664 bp)) found within the 5'-flanking region of the pdx-1 gene. Areas I and II are independently capable of directing beta cell-selective reporter gene activity in transfection assays, with Area I-mediated stimulation dependent upon binding of hepatic nuclear factor 3 beta (HN-F3 beta), a key regulator of islet beta cell function. To identify other transactivators of Area I, highly conserved sequence segments within this subdomain were mutagenized, and their effect on activation was determined. Several of the sensitive sites were found by transcription factor data base analysis to potentially bind endodermally expressed transcription factors, including HNF1 alpha (-2758 to -2746 bp, Segment 2), HNF4 (-2742 to -2730 bp, Segment 4; -2683 to -2671 bp, Segment 7-8), and HNF6 (-2727 to -2715 bp, Segment 5). HNF1 alpha, but not HNF4 and HNF6, binds specifically to Area I sequences in vitro. HNF1 alpha was also shown to specifically activate Area I-driven transcription through Segment 2. In addition, PDX-1 itself was found to stimulate Area I activation. The chromatin immunoprecipitation assay performed with PDX-1 antisera also demonstrated that this factor bound to Area I within the endogenous pdx-1 gene in beta cells. Our results indicate that regulatory factors binding to Area I conserved sequences contribute to the selective transcription pattern of the pdx-1 gene and that control is mediated by endodermal regulators like HNF1 alpha, HNF3 beta, and PDX-1.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37215 USA	Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37215 USA.	roland.stein@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050203, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK50203, P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Crane-Robinson C, 1998, TRENDS GENET, V14, P477, DOI 10.1016/S0168-9525(98)01621-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DiMattia GE, 1997, DEV BIOL, V182, P180, DOI 10.1006/dbio.1996.8472; Drewes T, 1996, MOL CELL BIOL, V16, P925; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; GUZ Y, 1995, DEVELOPMENT, V121, P11; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jiang GQ, 1997, J BIOL CHEM, V272, P1218, DOI 10.1074/jbc.272.2.1218; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jorgensen MC, 1999, FEBS LETT, V461, P287, DOI 10.1016/S0014-5793(99)01436-2; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Oka T, 1997, HEART VESSELS, P10; Okita K, 1999, BIOCHEM BIOPH RES CO, V263, P566, DOI 10.1006/bbrc.1999.1412; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Packer AI, 1998, DEVELOPMENT, V125, P1991; Pankratova EV, 1998, FEBS LETT, V426, P81, DOI 10.1016/S0014-5793(98)00316-0; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Poitout V, 1996, ANNU REV MED, V47, P69; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; St-Onge L, 1999, CURR OPIN GENET DEV, V9, P295, DOI 10.1016/S0959-437X(99)80044-6; STEIN R, 2001, HDB PHYSL 7, V2, P25; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Tronche F, 1997, J MOL BIOL, V266, P231, DOI 10.1006/jmbi.1996.0760; TRONCHE F, 1994, LIVER GENE EXPRESSIO, P207; Velho G, 1998, EUR J ENDOCRINOL, V138, P233, DOI 10.1530/eje.0.1380233; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xu FH, 1999, J BIOL CHEM, V274, P34310, DOI 10.1074/jbc.274.48.34310; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	78	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47775	47784		10.1074/jbc.M109244200	http://dx.doi.org/10.1074/jbc.M109244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11590182	hybrid			2022-12-27	WOS:000172927000008
J	Kalivendi, SV; Kotamraju, S; Zhao, H; Joseph, J; Kalyanaraman, B				Kalivendi, SV; Kotamraju, S; Zhao, H; Joseph, J; Kalyanaraman, B			Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase - Effect of antiapoptotic antioxidants and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL FORMATION; OXIDATIVE STRESS MEASUREMENTS; REACTIVE OXYGEN; HORSERADISH-PEROXIDASE; INDUCED CARDIOMYOPATHY; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; APAF-1 APOPTOSOME; HYDROGEN-PEROXIDE; ADRIAMYCIN	The clinical efficacy of the antitumor antibiotic drug doxorubicin (DOX) is severely limited by its dose-limiting cardiotoxicity in cancer patients. DOX-induced generation of reactive oxygen species was proposed to be a major mechanism of its cardiotoxicity. Previously, we showed that DOX undergoes a reductive activation at the reductase domain of endothelial nitric-oxide synthase (eNOS) forming the semiquinone and superoxide (Vasquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, K. A., Jr., and Kalyanaraman, B. (1997) Biochemistry 36, 11293-11297). In this report, we provide evidence for DOX-induced increase in eNOS transcription and protein expression in bovine aortic endothelial cells (BAEC). We propose that DOX-induced hydrogen peroxide formation is responsible for the increased transcription of eNOS. BAEC treated with antisense eNOS oligonucleotide inhibits DOX-induced endothelial apoptosis. Treatment with antioxidants restored the levels of antiapoptotic proteins (Hsp70 and Bcl-2) in DOX-treated BAEC. DOX-induced intracellular oxidative stress, as measured by oxidation of dichlorodihydrofluorescein diacetate to dichlorofluorescein and hydroethidium to ethidium, was inhibited by antisense eNOS oligonucleotide and antioxidant treatment. Furthermore, antiapoptotic antioxidants (e.g. FeTBAP, ebselen, and alpha -phenyl-tert-butyl nitrone) inhibited DOX-induced eNOS transcription. We conclude that DOX-induced apoptosis is linked to the redox activation of DOX by eNOS.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77822] Funding Source: Medline; NCRR NIH HHS [RR 01008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aoyama M, 1998, BIOCHEM J, V336, P727, DOI 10.1042/bj3360727; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BALLA GH, 1991, ARTERIOSCLER THROMB, V111, P1700; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Garner AP, 1999, CANCER RES, V59, P1929; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Gorodeski GI, 2000, AM J PHYSIOL-CELL PH, V279, pC1495, DOI 10.1152/ajpcell.2000.279.5.C1495; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANDA K, 1976, GANN, V67, P523; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Hensley K, 1998, J NEUROCHEM, V71, P2549; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Ito H, 1999, LIFE SCI, V64, P755, DOI 10.1016/S0024-3205(98)00617-1; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Katusic ZS, 2001, AM J PHYSIOL-HEART C, V281, pH981, DOI 10.1152/ajpheart.2001.281.3.H981; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; KUSUOKA H, 1991, J CARDIOVASC PHARM, V18, P437, DOI 10.1097/00005344-199109000-00017; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Mortensen K, 1999, J BIOL CHEM, V274, P37679, DOI 10.1074/jbc.274.53.37679; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS C, 1986, FASEB J, V45, P2792; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; Nakamura T, 2000, CIRCULATION, V102, P572; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Sen CK, 2000, ANTIOXIDANT REDOX RE; Shi Y, 2000, FREE RADICAL BIO MED, V29, P695, DOI 10.1016/S0891-5849(00)00364-6; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SVINGEN BA, 1981, ARCH BIOCHEM BIOPHYS, V209, P119, DOI 10.1016/0003-9861(81)90263-0; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; UBEZIO P, 1994, FREE RADICAL BIO MED, V16, P509, DOI 10.1016/0891-5849(94)90129-5; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Volk T, 1997, MOL CELL BIOCHEM, V171, P11, DOI 10.1023/A:1006886215193; Xiao ZS, 1997, J CELL PHYSIOL, V171, P205, DOI 10.1002/(SICI)1097-4652(199705)171:2<205::AID-JCP11>3.3.CO;2-3; Zhao HT, 2001, FREE RADICAL BIO MED, V31, P599, DOI 10.1016/S0891-5849(01)00619-0	57	167	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47266	47276		10.1074/jbc.M106829200	http://dx.doi.org/10.1074/jbc.M106829200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579094	hybrid			2022-12-27	WOS:000172768500080
J	Galea, MA; Eleftheriou, A; Henderson, BR				Galea, MA; Eleftheriou, A; Henderson, BR			ARM domain-dependent nuclear import of adenomatous polyposis coli protein is stimulated by the B56 alpha subunit of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-LINE MUTATIONS; BETA-CATENIN; APC GENE; TUMOR-SUPPRESSOR; EXPORT SIGNALS; WILD-TYPE; CANCER; PHOSPHORYLATION; LOCALIZATION; CYTOPLASM	Inactivating mutations in the adenomatous polyposis coli (APC) gene correlate with progression of colon cancer and familial adenomatous polyposis. The APC tumor suppressor contributes to chromosome segregation and turnover of the oncogenic transcriptional activator beta -catenin, and these activities are impaired by truncating cancer mutations. APC was recently identified as a shuttling protein whose subcellular distribution is regulated by two nuclear localization signals (NLSs) and multiple nuclear export signals (NESs). Here, we show that mutant disease-linked truncated forms of APC, most of which lack the two central NLSs and certain NES sequences, retain nuclear-cytoplasmic shuttling activity. Nuclear export of truncated APC is mediated by a dominant N-terminal NES. Nuclear import of NLS-deficient APC mutants is facilitated by the N-terminal ARM domain. Furthermore, co-expression of the ARM-binding protein, B56 alpha, increased the nuclear localization of mutant and wild-type APC. The minimal B56 alpha -responsive sequence mapped to APC amino acids 302-625. B56 alpha is a regulatory subunit of protein phosphatase 2A, however, its ability to shift APC to the nucleus was independent of phosphatase activity. We conclude that APC nuclear import is regulated by the ARM domain through its interaction with B56 alpha and postulate that APC/B56 alpha complexes target the dephosphorylation of specific proteins within the nucleus.	Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.		Galea, Melanie A/I-2236-2014					Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAGASE H, 1992, CANCER RES, V52, P4055; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2000, EMBO REP, V1, P519; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Polakis P, 2000, GENE DEV, V14, P1837; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, CANCER RES, V53, P2728; SU LK, 1995, CANCER RES, V55, P2972; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	37	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45833	45839		10.1074/jbc.M107149200	http://dx.doi.org/10.1074/jbc.M107149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585828	hybrid			2022-12-27	WOS:000172573100046
J	Lukong, KE; Seyrantepe, V; Landry, K; Trudel, S; Ahmad, A; Gahl, WA; Lefrancois, S; Morales, CR; Pshezhetsky, AV				Lukong, KE; Seyrantepe, V; Landry, K; Trudel, S; Ahmad, A; Gahl, WA; Lefrancois, S; Morales, CR; Pshezhetsky, AV			Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-ASSOCIATED MOLECULE-4; FACTOR-II RECEPTOR; BETA-GALACTOSIDASE; RAPID INTERNALIZATION; CATHEPSIN-A; T-CELLS; TRANSFERRIN RECEPTOR; ACID-PHOSPHATASE; NEURAMINIDASE; MEMBRANE	Sialidase (neuraminidase), encoded by the neu-1 gene in the major histocompatibility complex locus catalyzes the intralysosomal degradation of sialylated glycoconjugates. Inherited deficiency of sialidase results in sialidosis or galactosialidosis, both severe metabolic disorders associated with lysosomal storage of oligosaccharides and glycopeptides. Sialidase also plays an important role in cellular signaling and is specifically required for the production of cytokine interleukin-4 by activated T lymphocytes. In these cells, neu-1-encoded sialidase activity is increased on the cell surface, suggesting that a specific mechanism regulates sorting of this enzyme to the plasma membrane. We investigated that mechanism by first showing that sialidase contains the internalization signal found in lysosomal membrane proteins targeted to endosomes via clathrin-coated pits. The signal consists of a C-terminal tetrapeptide (412)YGTL(415), with Tyr(412) and Leu(415) essential for endocytosis of the enzyme. We further demonstrated that redistribution of sialidase from lysosomes to the cell surface of activated lymphocytes is accompanied by increased reactivity of the enzyme with anti-phosphotyrosine antibodies. We speculate that phosphorylation of Tyr(412) results in inhibition of sialidase internalization in activated lymphocytes.	Hop St Justine, Serv Genet Med, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3T 1C5, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; NICHHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	Universite de Montreal; Universite de Montreal; McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Pshezhetsky, AV (corresponding author), Hop St Justine, Serv Genet Med, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	alex@justine.umontreal.ca	Morales, Carlos R./H-1055-2011	A, Pshezhetsky/0000-0002-6612-1062				Ahmad A, 2000, J VIROL, V74, P7196, DOI 10.1128/JVI.74.16.7196-7203.2000; AKASAKI K, 1994, J BIOCHEM, V116, P670; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Carrillo MB, 1997, GLYCOBIOLOGY, V7, P975; Chen XP, 1997, J IMMUNOL, V158, P3070; Chen XP, 2000, CYTOKINE, V12, P972, DOI 10.1006/cyto.1999.0596; Chikuma S, 2000, J CELL BIOCHEM, V78, P241, DOI 10.1002/(SICI)1097-4644(20000801)78:2<241::AID-JCB7>3.3.CO;2-B; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Gingras R, 1999, J BIOL CHEM, V274, P11742, DOI 10.1074/jbc.274.17.11742; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; Hinek A, 1996, BIOL CHEM, V377, P471; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Iida T, 2000, J IMMUNOL, V165, P5062, DOI 10.4049/jimmunol.165.9.5062; JADOT M, 1992, J BIOL CHEM, V267, P11069; Jarousse N, 2000, TRAFFIC, V1, P378, DOI 10.1034/j.1600-0854.2000.010502.x; KALISH DI, 1978, BIOCHIM BIOPHYS ACTA, V506, P97, DOI 10.1016/0005-2736(78)90437-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LANDOLFI NF, 1985, IMMUNOGENETICS, V22, P159, DOI 10.1007/BF00563513; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LEUNG HT, 1995, J BIOL CHEM, V270, P25107, DOI 10.1074/jbc.270.42.25107; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Lukong KE, 2000, HUM MOL GENET, V9, P1075, DOI 10.1093/hmg/9.7.1075; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Miyatake S, 1998, BIOCHEM BIOPH RES CO, V249, P444, DOI 10.1006/bbrc.1998.9191; NARAPARAJU VR, 1994, IMMUNOL LETT, V43, P143, DOI 10.1016/0165-2478(94)90214-3; OKADA S, 1968, SCIENCE, V160, P1002, DOI 10.1126/science.160.3831.1002; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; Ostrov DA, 2000, SCIENCE, V290, P816, DOI 10.1126/science.290.5492.816; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; PETERS C, 1994, FEBS LETT, V346, P108, DOI 10.1016/0014-5793(94)00499-4; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SEYMOUR CA, 1977, CLIN SCI MOL MED, V52, P229, DOI 10.1042/cs0520229; Thomas G., 2001, DISORDERS GLYCOPROTE, P3507; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VERHEIJEN FW, 1983, BIOCHEM BIOPH RES CO, V117, P470, DOI 10.1016/0006-291X(83)91224-X; Vinogradova MV, 1998, BIOCHEM J, V330, P641; WATTIAUX R, 1983, IODINATED DENSITY GR; YAMAMOTO N, 1993, J IMMUNOL, V151, P2794; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	84	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46172	46181		10.1074/jbc.M104547200	http://dx.doi.org/10.1074/jbc.M104547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571282	hybrid			2022-12-27	WOS:000172573100093
J	Mimura, Y; Sondermann, P; Ghirlando, R; Lund, J; Young, SP; Goodall, M; Jefferis, R				Mimura, Y; Sondermann, P; Ghirlando, R; Lund, J; Young, SP; Goodall, M; Jefferis, R			Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IGG-FC; CRYSTAL-STRUCTURE; CARBOHYDRATE STRUCTURE; PROTEIN INTERACTIONS; EFFECTOR FUNCTIONS; INTERACTION SITES; RECEPTOR IIB; ANTIBODY; GLYCOSYLATION; CELLS	Engagement of Fc gamma receptors (Fc gamma Rs) with the Fe region of IgG elicits immune responses by leukocytes. The recent crystal structure of Fc gamma RIII in complex with IgG-Fc has provided details of molecular interactions between these components (Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) Nature 406, 267-273). One of the most intriguing issues is that glycosylation of IgG-Fc is essential for the recognition by Fc gamma Rs although the carbohydrate moieties are on the periphery of the Fc gamma RIII-Fc interface. To better understand the role of Fe glycosylation in Fc gammaR binding we prepared homogeneous glycoforms of IgG-Fc (Cri) and investigated the interactions with a soluble form of Fc gamma RIIb (sFc gamma RIIb). A 1:1 complex stoichiometry was observed in solution at 30 degreesC (K-d, 0.94 muM; DeltaG, - 8.4 kcal mol(-1); DeltaH, -6.5 kcal mol(-1); T DeltaS, 1.9 kcal mol(-1); DeltaC(p), -160 cal mol(-1) K-1). Removal of terminal galactose residues did not alter the thermodynamic parameters significantly. Outer-arm GlcNAc residues contributed significantly to thermal stability of the C(H)2 domains but only slightly to sFc gamma RIIb binding. Truncation of 1,3- and 1,6-arm mannose residues generates a linear trisaccharide core structure and resulted in a significantly decreased affinity, a less exothermic DeltaH, and a more negative DeltaC(p) for sFc gamma RIIb binding, which may result from a conformational change coupled to complex formation. Deglycosylation of the C(H)2 domains abrogated sFc gamma RIIb binding and resulted in the lowest thermal stability accompanied with noncooperative unfolding. These results suggest that truncation of the oligosaccharides of IgG-Fc causes disorder and a closed disposition of the two C(H)2 domains, impairing sFc gamma RIIb binding.	Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Birmingham; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mimura, Y (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	mimuray@bioch.ox.ac.uk	Ghirlando, Rodolfo/A-8880-2009; Young, Stephen P/A-7380-2008	Young, Stephen P/0000-0002-6355-3361				ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; BOLT S, 1993, EUR J IMMUNOL, V23, P403, DOI 10.1002/eji.1830230216; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Davies J, 2001, BIOTECHNOL BIOENG, V74, P288, DOI 10.1002/bit.1119.abs; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dong X, 1999, J IMMUNOL, V163, P5427; ENGELHARDT W, 1990, EUR J IMMUNOL, V20, P1367, DOI 10.1002/eji.1830200624; FANGER MW, 1989, CHEM IMMUNOL, V47, P214; FLEISCHMAN JB, 1963, BIOCHEM J, V88, P220, DOI 10.1042/bj0880220; Ghirlando R, 1999, IMMUNOL LETT, V68, P47, DOI 10.1016/S0165-2478(99)00029-2; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; JEFFERIS R, 1990, BIOCHEM J, V268, P529, DOI 10.1042/bj2680529; Kato K, 2000, J MOL BIOL, V295, P213, DOI 10.1006/jmbi.1999.3351; LUND J, 1995, FASEB J, V9, P115, DOI 10.1096/fasebj.9.1.7821750; Lund J, 2000, EUR J BIOCHEM, V267, P7246, DOI 10.1046/j.1432-1327.2000.01839.x; LUND J, 1991, J IMMUNOL, V147, P2657; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; MAENAKA K, 2001, J BIOL CHEM     0905; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; Marino M, 2000, NAT BIOTECHNOL, V18, P735, DOI 10.1038/77296; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Metzger, 1990, FC RECEPTORS ACTION, P12; Mimura Y, 2000, MOL IMMUNOL, V37, P697, DOI 10.1016/S0161-5890(00)00105-X; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sondermann P, 1999, BIOL CHEM, V380, P717, DOI 10.1515/BC.1999.090; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TAO MH, 1989, J IMMUNOL, V143, P2595; Tishchenko VM, 1998, BIOCALORIMETRY, P267; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Wright A, 1998, J IMMUNOL, V160, P3393; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	50	196	320	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45539	45547		10.1074/jbc.M107478200	http://dx.doi.org/10.1074/jbc.M107478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567028	hybrid			2022-12-27	WOS:000172573100009
J	Pfeffer, LM; Yang, CH; Murti, A; McCormack, SA; Viar, MJ; Ray, RM; Johnson, LR				Pfeffer, LM; Yang, CH; Murti, A; McCormack, SA; Viar, MJ; Ray, RM; Johnson, LR			Polyamine depletion induces rapid NF-kappa B activation in IEC-6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; P65 SUBUNIT; INTERFERON; APOPTOSIS; TRANSCRIPTION; INFLAMMATION; INHIBITION; STAT3; MICE; LINE	The proliferation of the rat intestinal mucosal IEC-6 cell line requires polyamines, whose synthesis is catalyzed by the enzyme ornithine decarboxylase (ODC). ODC inhibition leads to polyamine depletion, as well as inhibition of both cell proliferation and apoptosis by regulating gene expression. The NF-kappaB transcription factor regulates genes involved in apoptotic, immune, and inflammatory responses. In the present study we tested the hypothesis that NF-KB is activated following ODC inhibition. We found that the inhibition of ODC by a-difluoromethylornithine (DFMO) resulted in a similar to 50% decrease in intracellular putrescine levels within Ih. NF-KB is activated by DFMO through the degradation of the inhibitory protein I kappaB alpha that sequesters NF-kappaB in the cytoplasm. The DFMO-induced NF-KB complexes contain the p65 and p50 members of the Rel protein family. DFMO-induced NF-kappaB activation was accompanied by the translocation of p65 from the cytoplasm into the nucleus. DFMO selectively inhibited a gene reporter construct dependent on the kappaB site present in the HLA-B7 gene. In contrast, DFMO had no effect on a gene reporter construct dependent on the kappaB site present in the interleukin-8 gene. Thus, we report that ODC inhibition activates the NF-KB transcription factor, which may mediate the altered physiological state of intestinal cells that occurs following polyamine depletion.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pfeffer, LM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 899 Madison Ave, Memphis, TN 38163 USA.			Pfeffer, Lawrence/0000-0003-2809-1234	NCI NIH HHS [CA73753] Funding Source: Medline; NIDDK NIH HHS [DK-16505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016505, R01DK016505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CELANO P, 1989, J BIOL CHEM, V264, P8922; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; MCCORMACK SA, 1993, AM J PHYSIOL, V264, pG367, DOI 10.1152/ajpgi.1993.264.2.G367; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; PEGG AE, 1982, AM J PHYSIOL, V243, P212; POULIN R, 1995, BIOCHEM J, V311, P723, DOI 10.1042/bj3110723; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ray RM, 2000, AM J PHYSIOL-CELL PH, V278, pC480, DOI 10.1152/ajpcell.2000.278.3.C480; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Schmid RM, 2000, GASTROENTEROLOGY, V118, P1208, DOI 10.1016/S0016-5085(00)70374-X; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Shah N, 2001, ONCOGENE, V20, P1715, DOI 10.1038/sj.onc.1204247; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOBIAS KE, 1995, CELL GROWTH DIFFER, V6, P1279; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG JY, 1993, AM J PHYSIOL, V265, pG331, DOI 10.1152/ajpgi.1993.265.2.G331; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057	28	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45909	45913		10.1074/jbc.M108097200	http://dx.doi.org/10.1074/jbc.M108097200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590175	hybrid			2022-12-27	WOS:000172573100057
J	Vielhaber, EL; Duricka, D; Ullman, KS; Virshup, DM				Vielhaber, EL; Duricka, D; Ullman, KS; Virshup, DM			Nuclear export of mammalian PERIOD proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; CIRCADIAN CLOCK; MOUSE SCN; MPER1; ENTRY; MECHANISMS; EXPRESSION	The timing of mammalian circadian rhythm is determined by interlocking negative and positive transcriptional feedback loops that govern the cyclic expression of both clock regulators and output genes. In mammals, nuclear localization of the circadian regulators PER1-3 is controlled by multiple mechanisms, including multimerization with PER and CRY proteins. In addition, nuclear entry of mammalian PER1 (mPER1) can be regulated by a phosphorylation-dependent masking of its nuclear localization signal. Here we present evidence suggesting that nuclear localization of PER proteins is a dynamic process determined by both nuclear import and previously unrecognized nuclear export pathways. Examination of the subcellular localization of a series of truncated mPER1 proteins demonstrated that cytoplasmic localization is mediated by an I IL-amino acid region with homology to leucine-rich nuclear export signals (NESs). Similar sequences were identified in mPER2 and mPER3 as well as in several insect PER proteins. The putative NESs from mPER1 and mPER2 were able to direct cytoplasmic accumulation when fused to a heterologous protein. Mutations in conserved NES residues and the nuclear export inhibitor leptomycin B each blocked the function of the NES. Full-length mPER1 was also exported from microinjected Xenopus laevis oocyte nuclei in an NES-dependent manner. The presence of a functional NES in mPER1 and mPER2 as well as related sequences in a variety of other PER proteins suggests that nuclear export may be a conserved and important feature of circadian regulators.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Div Hematol Oncol, Dept Pediat, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.	david.virshup@hci.utah.edu	Virshup, David M/C-1449-2009; Duricka, Deborah/AAA-2671-2022	Virshup, David M/0000-0001-6976-850X; Duricka, Deborah/0000-0002-5057-6361; Ullman, Katharine/0000-0003-3693-2830	NCI NIH HHS [R01 CA71074, P30 CA042014, 3P30 CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM060387-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Yagita K, 2000, GENE DEV, V14, P1353; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	29	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45921	45927		10.1074/jbc.M107726200	http://dx.doi.org/10.1074/jbc.M107726200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591712	Green Accepted, hybrid			2022-12-27	WOS:000172573100059
J	Barger, PM; Browning, AC; Garner, AN; Kelly, DP				Barger, PM; Browning, AC; Garner, AN; Kelly, DP			p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha - A potential role in the cardiac metabolic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ENZYME GENE-EXPRESSION; ACID OXIDATION ENZYME; RETINOID-X RECEPTOR; TRANSCRIPTIONAL ACTIVITY; LIPID-METABOLISM; PPAR-ALPHA; VENTRICULAR MYOCYTES; HYPERTROPHIC GROWTH; HORMONE-RECEPTOR	The expression of enzymes involved in fatty acid beta -oxidation (FAO), the principal source of energy production in the adult mammalian heart, is controlled at the transcriptional level via the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR alpha). Evidence has emerged that PPAR alpha activity is activated as a component of an energy metabolic stress response. The p38 mitogen-activated protein kinase (MAPK) pathway is activated by cellular stressors in the heart, including ischemia, hypoxia, and hypertrophic growth stimuli. We show here that PPAR alpha is phosphorylated in response to stress stimuli in rat neonatal cardiac myocytes; in vitro kinase assays demonstrated that p38 MAPK phosphorylates serine residues located within the NH2-terminal A/B domain of the protein. Transient transfection studies in cardiac myocytes and in CV-1 cells utilizing homologous and heterologous PPAR alpha target element reporters and mammalian one-hybrid transcription assays revealed that p38 MAPK phosphorylation of PPAR alpha significantly enhanced ligand-dependent transactivation. Cotransfection studies performed with several known coactivators of PPAR alpha demonstrated that p38 MAPK markedly increased coactivation specifically by PGC-1, a transcriptional coactivator implicated in myocyte energy metabolic gene regulation and mitochondrial biogenesis. These results identify PPAR alpha as a downstream effector of p38 kinase-dependent stress-activated signaling in the heart, linking extracellular stressors to alterations in energy metabolic gene expression.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.		Kelly, Daniel/ABG-2056-2021		NHLBI NIH HHS [P50 HL61006, K08 HL03808, R01 HL58493] Funding Source: Medline; NIDDK NIH HHS [P30 DK56341, P01 DK52574] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL061006, K08HL003808, R01HL058493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, P30DK056341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Auricchio F, 1996, ANN NY ACAD SCI, V784, P149, DOI 10.1111/j.1749-6632.1996.tb16234.x; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Barger PM, 1997, J BIOL CHEM, V272, P2722, DOI 10.1074/jbc.272.5.2722; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Barger PM, 2000, TRENDS CARDIOVAS MED, V10, P238, DOI 10.1016/S1050-1738(00)00077-3; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Cresci S, 1996, AM J PHYSIOL-CELL PH, V270, pC1413, DOI 10.1152/ajpcell.1996.270.5.C1413; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Djouadi F, 1999, PROSTAG LEUKOTR ESS, V60, P339, DOI 10.1016/S0952-3278(99)80009-X; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Horowitz JF, 2000, AM J PHYSIOL-ENDOC M, V279, pE348, DOI 10.1152/ajpendo.2000.279.2.E348; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; KELLY DP, 1989, J BIOL CHEM, V264, P18921; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; NAGAO M, 1993, J BIOL CHEM, V268, P24114; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	47	207	233	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44495	44501		10.1074/jbc.M105945200	http://dx.doi.org/10.1074/jbc.M105945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577087	hybrid			2022-12-27	WOS:000172406700021
J	Feng, ZP; Arnot, MI; Doering, CJ; Zamponi, GW				Feng, ZP; Arnot, MI; Doering, CJ; Zamponi, GW			Calcium channel beta subunits differentially regulate the inhibition of N-type channels by individual G beta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN INHIBITION; VOLTAGE-DEPENDENT MODULATION; KINASE-C; CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; SYMPATHETIC NEURONS; CROSS-TALK; DETERMINANTS; GAMMA; INACTIVATION	The direct inhibition of N- and P/Q-type calcium channels by G protein beta gamma subunits is considered a key mechanism for regulating presynaptic calcium levels. We have recently reported that a number of features associated with this G protein inhibition are dependent on the G protein beta subunit isoform (Arnot, M. I., Stotz, S. C., Jarvis, S. E., Zamponi, G. W. (2000) J. Physiol. (Loud.) 527, 203-212; Cooper, C. B., Arnot, M. I., Feng, Z.-P., Jarvis, S. E., Hamid, J., Zamponi, G. W. (2000) J. Biol. Chem. 275, 40777-40781). Here, we have examined the abilities of different types of ancillary calcium channel beta subunits to modulate the inhibition of alpha (1B) N-type calcium channels by the five known different G beta subunit subtypes. Our data reveal that the degree of inhibition by a particular G beta subunit is strongly dependent on the specific calcium channel beta subunit, with N-type channels containing the beta (4) subunit being less susceptible to G beta gamma -induced inhibition. The calcium channel beta (2a) subunit uniquely slows the kinetics of recovery from G protein inhibition, in addition to mediating a dramatic enhancement of the G protein-induced kinetic slowing. For G beta (3)-mediated inhibition, the latter effect is reduced following site-directed mutagenesis of two palmitoylation sites in the beta (2a) N-terminal region, suggesting that the unique membrane tethering of this subunit serves to modulate G protein inhibition of N-type calcium channels. Taken together, our data suggest that the nature of the calcium channel beta subunit present is an important determinant of G protein inhibition of N-type channels, thereby providing a possible mechanism by which the cellular/subcellular expression pattern of the four calcium channel beta subunits may regulate the G protein sensitivity of N-type channels expressed at different loci throughout the brain and possibly within a neuron.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada	University of Calgary; University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Zamponi@ucalgary.ca		Zamponi, Gerald W./0000-0002-0644-9066				Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bertram R, 1999, J COMPUT NEUROSCI, V7, P197, DOI 10.1023/A:1008976129832; BOLAND LM, 1993, J NEUROSCI, V13, P516; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; Canti C, 2000, J PHYSIOL-LONDON, V527, P419, DOI 10.1111/j.1469-7793.2000.t01-1-00419.x; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Cooper CB, 2000, J BIOL CHEM, V275, P40777, DOI 10.1074/jbc.C000673200; Currie KPM, 1997, J NEUROSCI, V17, P4570; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Garcia DE, 1998, J NEUROSCI, V18, P9163; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2000, J BIOL CHEM, V275, P6388, DOI 10.1074/jbc.275.9.6388; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; Lu Q, 2001, J NEUROSCI, V21, P2949, DOI 10.1523/JNEUROSCI.21-09-02949.2001; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; Mirotznik RR, 2000, J NEUROSCI, V20, P7614; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Restituito S, 2000, J NEUROSCI, V20, P9046; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Stotz SC, 2001, J BIOL CHEM, V276, P33001, DOI 10.1074/jbc.M104387200; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V413, P319, DOI 10.1007/BF00583548; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; Wittemann S, 2000, J BIOL CHEM, V275, P37807, DOI 10.1074/jbc.M004653200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zamponi GW, 2001, CELL BIOCHEM BIOPHYS, V34, P79, DOI 10.1385/CBB:34:1:79; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; Zhou JY, 2000, J NEUROSCI, V20, P7143	45	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45051	45058		10.1074/jbc.M107784200	http://dx.doi.org/10.1074/jbc.M107784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11560937	hybrid			2022-12-27	WOS:000172406700095
J	Mollard, C; Moali, C; Papamicael, C; Damblon, C; Vessilier, S; Amicosante, G; Schofield, CJ; Galleni, M; Frere, JM; Roberts, GCK				Mollard, C; Moali, C; Papamicael, C; Damblon, C; Vessilier, S; Amicosante, G; Schofield, CJ; Galleni, M; Frere, JM; Roberts, GCK			Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases - Kinetic and spectroscopic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITOR; THIOL ESTER DERIVATIVES; N-TERMINAL DOMAIN; BACTEROIDES-FRAGILIS; BACILLUS-CEREUS; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; BIOCHEMICAL-CHARACTERIZATION; RESOLUTION STRUCTURE; ANGSTROM RESOLUTION	Resistance to beta -lactam antibiotics mediated by metallo-beta -lactamases is an increasingly worrying clinical problem. Candidate inhibitors include mercaptocarboxylic acids, and we report studies of a simple such compound, thiomandelic acid. A series of 35 analogues were synthesized and examined as metallo-beta -lactamase inhibitors. The K-i values (Bacillus cereus enzyme) are 0.09 muM for R-thiomandelic acid and 1.28 muM for the S-isomer. Structure-activity relationships show that the thiol is essential for activity and the carboxylate increases potency; the affinity is greatest when these groups are close together. Thioesters of thiomandelic acid are substrates for the enzyme, liberating thiomandelic acid, suggesting a starting point for the design of "pro-drugs." Importantly, thiomandelic acid is a broad spectrum inhibitor of metallo-beta -lactamases, with a submicromolar K-i value for all nine enzymes tested, except the Aeromonas hydrophila enzyme; such a wide spectrum of activity is unprecedented. The binding of thiomandelic acid to the B. cereus enzyme was studied by NMR; the results are consistent with the idea that the inhibitor thiol binds to both zinc ions, while its carboxylate binds to Arg(91). Amide chemical shift perturbations for residues 30-40 (the beta (3)-beta (4) loop) suggest that this small inhibitor induces a movement of this loop of the kind seen for other larger inhibitors.	Univ Leicester, Dept Biochem, Biol NMR Ctr, Leicester LE1 9HN, Leics, England; Univ Liege, Inst Chim B6, Ctr Ingn Prot, B-4000 Liege, Belgium; Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy	University of Leicester; University of Liege; University of Oxford; University of Oxford; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila	Roberts, GCK (corresponding author), Univ Leicester, Dept Biochem, Biol NMR Ctr, POB 138,Univ Rd, Leicester LE1 9HN, Leics, England.	gcr@le.ac.uk	Vessillier, Sandrine/E-2502-2013	Vessillier, Sandrine/0000-0002-9697-1834; papamicael, cyril/0000-0001-6884-6844; Schofield, Christopher/0000-0002-0290-6565; Roberts, Gordon/0000-0001-6200-1373; amicosante, gianfranco/0000-0002-6813-2101; MOALI, Catherine/0000-0003-2479-4290				BALDWIN GS, 1980, J INORG BIOCHEM, V13, P189, DOI 10.1016/S0162-0134(00)80068-9; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P1878, DOI 10.1128/AAC.44.7.1878-1886.2000; BONNER WA, 1968, J ORG CHEM, V33, P1831, DOI 10.1021/jo01269a027; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; Chu YW, 2001, ANTIMICROB AGENTS CH, V45, P710, DOI 10.1128/AAC.45.3.710-714.2001; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; Damblon C, 1999, J AM CHEM SOC, V121, P11575, DOI 10.1021/ja992896h; ELOY F, 1962, CHEM REV, V62, P155, DOI 10.1021/cr60216a003; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; Franceschini N, 2000, ANTIMICROB AGENTS CH, V44, P3003, DOI 10.1128/AAC.44.11.3003-3007.2000; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Goto M, 1997, BIOL PHARM BULL, V20, P1136, DOI 10.1248/bpb.20.1136; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Greenlee ML, 1999, BIOORG MED CHEM LETT, V9, P2549, DOI 10.1016/S0960-894X(99)00425-4; Hammond GG, 1999, FEMS MICROBIOL LETT, V179, P289, DOI 10.1111/j.1574-6968.1999.tb08740.x; Huntley JJA, 2000, BIOCHEMISTRY-US, V39, P13356, DOI 10.1021/bi001210r; Iranpoor N, 1999, SYNTHESIS-STUTTGART, P49; Iyobe S, 2000, ANTIMICROB AGENTS CH, V44, P2023, DOI 10.1128/AAC.44.8.2023-2027.2000; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUWABARA S, 1967, BIOCHEM J, V103, pC27, DOI 10.1042/bj1030027C; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P902, DOI 10.1128/AAC.43.4.902; Lian LY, 2000, STRUCT FOLD DES, V8, P47, DOI 10.1016/S0969-2126(00)00080-0; Matagne A, 1999, NAT PROD REP, V16, P1, DOI 10.1039/a705983c; Mercuri PS, 2001, ANTIMICROB AGENTS CH, V45, P1254, DOI 10.1128/AAC.45.4.1254-1262.2001; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Page MI, 1998, CHEM COMMUN, P1609, DOI 10.1039/a803578d; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; PAYNE DJ, 1993, J MED MICROBIOL, V39, P93, DOI 10.1099/00222615-39-2-93; Payne DJ, 1997, FEMS MICROBIOL LETT, V157, P171, DOI 10.1016/S0378-1097(97)00472-2; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Riccio ML, 2000, ANTIMICROB AGENTS CH, V44, P1229, DOI 10.1128/AAC.44.5.1229-1235.2000; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; STRIJTVEEN B, 1986, J ORG CHEM, V51, P3664, DOI 10.1021/jo00369a020; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; WALSH TR, 1994, BBA-GENE STRUCT EXPR, V1218, P199, DOI 10.1016/0167-4781(94)90011-6; Walter MW, 1999, BIOORG CHEM, V27, P35, DOI 10.1006/bioo.1998.1111; Walter MW, 1996, BIOORG MED CHEM LETT, V6, P2455, DOI 10.1016/0960-894X(96)00453-2; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Yano H, 2001, ANTIMICROB AGENTS CH, V45, P1343, DOI 10.1128/AAC.45.5.1343-1348.2001	57	97	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45015	45023		10.1074/jbc.M107054200	http://dx.doi.org/10.1074/jbc.M107054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564740	hybrid, Green Published			2022-12-27	WOS:000172406700091
J	Moon, YA; Shah, NA; Mohapatra, S; Warrington, JA; Horton, JD				Moon, YA; Shah, NA; Mohapatra, S; Warrington, JA; Horton, JD			Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID ELONGATION; SACCHAROMYCES-CEREVISIAE; SYNTHASE PROMOTER; TRANSGENIC MICE; ADIPOSE-TISSUE; CULTURED-CELLS; GENE FAMILY; FAE1 GENE; BIOSYNTHESIS; CHOLESTEROL	Fatty acids are synthesized de novo from acetyl-CoA and malonyl-CoA through a series of reactions mediated by acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). In rodents, the principal fatty acid produced by FAS is palmitic acid (16:0). Sterol regulatory element-binding proteins (SREBPs) enhance the transcription of many genes responsible for fatty acid synthesis. In transgenic mice that overexpress SREBPs in liver, the rate of fatty acid synthesis is markedly increased, owing to the activation of these biosynthetic genes, which include ATP citrate lyase, ACC, FAS, and stearoyl-CoA desaturase. The fatty acids that accumulate in livers of SREBP transgenic mice are 18 carbons rather than 16 carbons in length, suggesting that the enzymes required for the elongation of palmitic to stearic acid may be induced. Here, we report the cDNA cloning of a murine long chain fatty acyl elongase (LCE) that was identified initially by oligonucleotide array analysis of mRNA from SREBP transgenic mouse livers. LCE mRNA is highly expressed in liver and adipose tissue. The cDNA encodes a protein of 267 amino acids that shares sequence identity with previously identified very long chain fatty acid elongases. Cells that overexpress LCE show enhanced addition of 2-carbon units to C12-C16 fatty acids. We provide evidence that LCE catalyzes the rate-limiting condensing step in this reaction. The current studies suggest that mouse LCE expression is increased by SREBPs and that the enzyme is a component of the elusive mammalian elongation system that converts palmitic to stearic acid.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Affymetrix Inc, Santa Clara, CA 95051 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Affymetrix	Horton, JD (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; APRAHAMIAN SA, 1982, COMP BIOCH PHYSL B, V71, P557; Barret P, 1998, THEOR APPL GENET, V96, P177, DOI 10.1007/s001220050725; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lassner MW, 1996, PLANT CELL, V8, P281, DOI 10.1105/tpc.8.2.281; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; NAGI MN, 1989, BIOCHEM BIOPH RES CO, V165, P1428, DOI 10.1016/0006-291X(89)92763-0; NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Todd J, 1999, PLANT J, V17, P119, DOI 10.1046/j.1365-313X.1999.00352.x; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817	34	263	297	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45358	45366		10.1074/jbc.M108413200	http://dx.doi.org/10.1074/jbc.M108413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567032	hybrid			2022-12-27	WOS:000172406700131
J	Sundaram, M; Yao, SYM; Ingram, JC; Berry, ZA; Abidi, F; Cass, CE; Baldwin, SA; Young, JD				Sundaram, M; Yao, SYM; Ingram, JC; Berry, ZA; Abidi, F; Cass, CE; Baldwin, SA; Young, JD			Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PROTEINS; MEMBRANE; EI; IDENTIFICATION; PREDICTION; CLEAVAGE; SEGMENTS; BINDING; RENT1	The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. We have produced recombinant hENT1 in Xenopus oocytes and used native and engineered N-glycosylation sites in combination with immunological approaches to experimentally define the membrane architecture of this prototypic nucleoside transporter. hENT1 (456 amino acid residues) is shown to contain 11 transmembrane helical segments with an amino terminus that is intracellular and a carboxyl terminus that is extracellular. Transmembrane helices are linked by short hydrophilic regions, except for a large glycosylated extracellular loop between transmembrane helices 1 and 2 and a large central cytoplasmic loop between transmembrane helices 6 and 7. Sequence analyses suggest that this membrane topology is common to all mammalian, insect, nematode, protozoan, yeast, and plant members of the ENT protein family.	Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada; Cross Canc Inst, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	james.young@ualberta.ca	Cass, Carol E/F-5861-2010					Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DAVIES A, 1990, BIOCHEM J, V266, P799; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PLAGEMANN PGW, 1987, BIOCHIM BIOPHYS ACTA, V899, P295, DOI 10.1016/0005-2736(87)90411-1; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; SIVAPRASADARAO A, 1994, BIOCHEM J, V300, P437, DOI 10.1042/bj3000437; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Yao SYM, 2000, PRACT APPROACH SER, P47; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Young JD, 2001, CURR TOP MEMBR, V50, P329	32	113	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45270	45275		10.1074/jbc.M107169200	http://dx.doi.org/10.1074/jbc.M107169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584005	hybrid			2022-12-27	WOS:000172406700121
J	Burgers, PMJ; Koonin, EV; Bruford, E; Blanco, L; Burtis, KC; Christman, MF; Copeland, WC; Friedberg, EC; Hanaoka, F; Hinkle, DC; Lawrence, CW; Nakanishi, M; Ohmori, H; Prakash, L; Prakash, S; Reynaud, CA; Sugino, A; Todo, T; Wang, ZG; Weill, JC; Woodgate, R				Burgers, PMJ; Koonin, EV; Bruford, E; Blanco, L; Burtis, KC; Christman, MF; Copeland, WC; Friedberg, EC; Hanaoka, F; Hinkle, DC; Lawrence, CW; Nakanishi, M; Ohmori, H; Prakash, L; Prakash, S; Reynaud, CA; Sugino, A; Todo, T; Wang, ZG; Weill, JC; Woodgate, R			Eukaryotic DNA polymerases: Proposal for a revised nomenclature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BASE EXCISION-REPAIR; HUMAN DINB1 GENE; TRANSLESION REPLICATION; DROSOPHILA-MELANOGASTER; LYASE ACTIVITY; DAMAGE CONTROL; LESION BYPASS; IN-VITRO; MUTAGENESIS; IOTA		Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; UCL, Galton Lab, HUGO Nomenclature Comm, London NW1 2HE, England; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Osaka Univ, Inst Mol & Cellular Biol, Osaka 5650871, Japan; Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Nagoya City Univ, Dept Biochem, Sch Med, Nagoya, Aichi 4678601, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Fac Med Necker Enfants Malad, F-75730 Paris 15, France; Osaka Univ, Microbial Dis Res Inst, Osaka 5650871, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 6068501, Japan; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; NICHHD, Sect DNA Replicat Repair & Mutagenesis, Bethesda, MD 20892 USA	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of London; University College London; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of California System; University of California Davis; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Osaka University; University of Rochester; University of Rochester; Nagoya City University; Kyoto University; University of Texas System; University of Texas Medical Branch Galveston; UDICE-French Research Universities; Universite Paris Cite; Osaka University; Kyoto University; University of Kentucky; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Bruford, Elspeth/AAU-4961-2020; Burgers, Peter M/AAW-6621-2021; Blanco, Luis/I-1848-2015; Copeland, William/C-4242-2019; Prakash, Satya/C-6420-2013	Bruford, Elspeth/0000-0002-8380-5247; Copeland, William/0000-0002-0359-0953; Prakash, Louise/0000-0001-9143-6261; Burtis, Kenneth/0000-0002-9644-3265; Prakash, Satya/0000-0001-7228-1444; Woodgate, Roger/0000-0001-5581-4616	NIGMS NIH HHS [GM58534, R01 GM032431] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065077, Z01ES061058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058534, R01GM032431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burtis KC, 1997, CURR BIOL, V7, pR743, DOI 10.1016/S0960-9822(06)00391-5; Cann IKO, 1999, GENETICS, V152, P1249; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gerlach VL, 2000, COLD SPRING HARB SYM, V65, P41, DOI 10.1101/sqb.2000.65.41; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; Harris PV, 1996, MOL CELL BIOL, V16, P5764; HARRIS PV, 1999, THESIS U CALIFORNIA; Hindges R, 1997, BIOL CHEM, V378, P345; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lawrence CW, 1996, CANCER SURV, V28, P21; Lawrence CW, 2001, PHILOS T R SOC B, V356, P41, DOI 10.1098/rstb.2000.0001; LEEM SH, 1994, NUCLEIC ACIDS RES, V22, P3011, DOI 10.1093/nar/22.15.3011; Leipe DD, 1999, NUCLEIC ACIDS RES, V27, P3389, DOI 10.1093/nar/27.17.3389; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McDonald JP, 2001, PHILOS T R SOC B, V356, P53, DOI 10.1098/rstb.2000.0748; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Oshige M, 1999, MUTAT RES-DNA REPAIR, V433, P183, DOI 10.1016/S0921-8777(99)00005-1; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reynaud CA, 2001, PHILOS T ROY SOC B, V356, P91, DOI 10.1098/rstb.2000.0753; Ruiz JF, 2001, PHILOS T R SOC B, V356, P99, DOI 10.1098/rstb.2000.0754; Sekelsky JJ, 1998, GENETICS, V148, P1587; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wang SW, 2000, MOL CELL BIOL, V20, P3234, DOI 10.1128/MCB.20.9.3234-3244.2000; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; WEISSBACH A, 1975, SCIENCE, V190, P401, DOI 10.1126/science.1179222; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	63	264	298	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43487	43490		10.1074/jbc.R100056200	http://dx.doi.org/10.1074/jbc.R100056200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11579108	hybrid			2022-12-27	WOS:000172297700001
J	Thuahnai, ST; Lund-Katz, S; Williams, DL; Phillips, MC				Thuahnai, ST; Lund-Katz, S; Williams, DL; Phillips, MC			Scavenger receptor class B, type I-mediated uptake of various lipids into cells - Influence of the nature of the donor particle interaction with the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTERYL ESTER UPTAKE; APOLIPOPROTEIN-A-I; SR-BI; SELECTIVE UPTAKE; UNILAMELLAR VESICLES; BINDING; HDL; ATHEROSCLEROSIS; METABOLISM	Scavenger receptor (SR)-BI is the first molecularly defined receptor for high density lipoprotein (HDL) and it can mediate the selective uptake of cholesteryl ester into cells. To elucidate the molecular mechanisms by which SR-BI facilitates lipid uptake, we examined the connection between lipid donor particle binding and lipid uptake using kidney COS-7 cells transiently transfected with SR-BI. We systematically compared the uptake of [H-3]cholesteryl oleoyl ether (CE) and [C-14]sphingomyelin (SM) from apolipoprotein (apo) A-I-containing reconstituted HDL (rHDL) particles and apo-free lipid donor particles. Although both types of lipid donor could bind to SR-BI, only apo-containing lipid donors exhibited preferential delivery of CE over SM (i.e. nonstoichiometric lipid uptake). In contrast, apo-free lipid donor particles (phospholipid unilamellar vesicles, lipid emulsion particles) gave rise to stoichiometric lipid uptake due to interaction with SR-BI. This apparent whole particle uptake was not due to endocytosis, but rather fusion of the lipid components of the lipid donor with the cell plasma membrane; this process is perhaps mediated by a fusogenic motif in the extracellular domain of SR-BI. The interaction of apoA-I with SR-BI not only prevents fusion of the lipid donor with the plasma membrane but also allows the optimal selective lipid uptake. A comparison of rHDL particles containing apoA-I and apoE-3 showed that while both particles bound equally well to SR-BI, the apoA-I particle gave similar to2-fold greater CE selective uptake. Catabolism of all major HDL lipids can occur via SR-BI with the relative selective uptake rate constants for CE, free cholesterol, triglycerides (triolein), and phosphatidylcholine being 1, 1.6, 0.7, and 0.2, respectively. It follows that a putative nonpolar channel created by SR-BI between the bound HDL particle and the cell plasma membrane is better able to accommodate the uptake of neutral lipids (e.g. cholesterol) relative to polar phospholipids.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,GI Nutr Div, Philadelphia, PA 19104 USA; SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Abramson Res Ctr,GI Nutr Div, Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083, P01HL022633, T32HL007443, R01HL058012] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443, HL56083, HL22633, HL58012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; DIJKSTRA J, 1984, EXP CELL RES, V150, P161, DOI 10.1016/0014-4827(84)90711-0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAUSER H, 1973, J BIOL CHEM, V248, P8585; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, CURR OPIN LIPIDOL, V10, P491, DOI 10.1097/00041433-199912000-00003; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Reaven E, 1996, J BIOL CHEM, V271, P16208, DOI 10.1074/jbc.271.27.16208; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1987, J LIPID RES, V28, P1313; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P2132, DOI 10.1161/01.ATV.17.10.2132; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Saito H, 1996, J BIOL CHEM, V271, P15515, DOI 10.1074/jbc.271.26.15515; SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200	44	102	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43801	43808		10.1074/jbc.M106695200	http://dx.doi.org/10.1074/jbc.M106695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564739	hybrid			2022-12-27	WOS:000172297700043
J	Negrerie, M; Bouzhir, L; Martin, JL; Liebl, U				Negrerie, M; Bouzhir, L; Martin, JL; Liebl, U			Control of nitric oxide dynamics by guanylate cyclase in its activated state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; GEMINATE RECOMBINATION; PROXIMAL LIGAND; HEME-PROTEINS; MUTANT; IRON; HEMOGLOBIN; BINDING; NO; IDENTIFICATION	Soluble guanylate cyclase (sGC) is the target of nitric oxide (NO) released by nitric-oxide synthase in endothelial cells, inducing an increase of cGMP synthesis in response. This heterodimeric protein possesses a regulatory subunit carrying a heme where NO binding occurs, while the second subunit harbors the catalytic site. The binding of NO and the subsequent breaking of the bond between the proximal histidine and the heme-Fe2+ are assumed to induce conformational changes, which are the origin of the catalytic activation. At the molecular level, the activation and deactivation mechanisms are unknown, as is the dynamics of NO once in the heme pocket. Using ultrafast time-resolved absorption spectroscopy, we measured the kinetics of NO rebinding to sGC after photodissociation. The main spectral transient in the Soret band does not match the equilibrium difference spectrum of NO-liganded minus unliganded sGC, and the geminate rebinding was found to be monoexponential and ultrafast (tau = 7.5 ps), with a relative amplitude close to unity (0.97). These characteristics, so far not observed in other hemoproteins, indicate that NO encounters a high energy barrier for escaping from the heme pocket once the His-Fe2+ bond has been cleaved; this bond does not reform before NO recombination. The deactivation of isolated sGC cannot occur by only simple diffusion of NO from the heme; therefore, several allosteric states may be inferred, including a desensitized one, to induce NO release. Thus, besides the structural change leading to activation, a consequence of the decoupling of the proximal histidine may also be to induce a change of the heme pocket distal geometry, which raises the energy barrier for NO escape, optimizing the efficiency of NO trapping. The non-single exponential character of the NO picosecond rebinding coexists only with the presence of the protein structure surrounding the heme, and the single exponential rate observed in sGC is very likely to be due to a closed conformation of the heme pocket. Our results emphasize the physiological importance of NO geminate recombination in hemoproteins like nitric-oxide synthase and sGC and show that the protein structure controls NO dynamics in a manner adapted to their function. This control of ligand dynamics provides a regulation at molecular level in the function of these enzymes.	Ecole Polytech, Lab Opt & Biosci, INSERM, U451, F-91128 Palaiseau, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris	Negrerie, M (corresponding author), Ecole Polytech, Lab Opt & Biosci, INSERM, U451, F-91128 Palaiseau, France.	negrerie@enstay.ensta.fr	Negrerie, Michel/L-2283-2018	Negrerie, Michel/0000-0001-9918-031X; LIEBL, Ursula/0000-0003-0869-4388				BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; Brunori M, 1999, BIOPHYS J, V76, P1259, DOI 10.1016/S0006-3495(99)77289-9; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Das TK, 1999, INORG CHEM, V38, P1952, DOI 10.1021/ic990049+; Decatur SM, 1996, BIOCHEMISTRY-US, V35, P4939, DOI 10.1021/bi951661p; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DEPILLIS GD, 1994, J AM CHEM SOC, V116, P6981, DOI 10.1021/ja00094a081; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Friebe A, 1997, BIOCHEMISTRY-US, V36, P1194, DOI 10.1021/bi962047w; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; JONES CM, 1992, BIOCHEMISTRY-US, V31, P6692, DOI 10.1021/bi00144a008; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; Kholodenko Y, 1999, BIOCHEMISTRY-US, V38, P5918, DOI 10.1021/bi983022v; KIM TD, 1994, J BIOL CHEM, V269, P15540; LeclercLHostis E, 1996, BBA-PROTEIN STRUCT M, V1293, P140, DOI 10.1016/0167-4838(95)00237-5; Margulis A, 2000, BIOCHEMISTRY-US, V39, P1034, DOI 10.1021/bi992040p; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; MULSCH A, 1991, METHOD ENZYMOL, V195, P377; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PRESS WH, 1988, NUMERICAL RECIPES, P59; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rohlfs RJ, 1998, J BIOL CHEM, V273, P12128, DOI 10.1074/jbc.273.20.12128; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Tomita T, 1997, BIOCHEMISTRY-US, V36, P10155, DOI 10.1021/bi9710131; Vos MH, 2000, J CHIN CHEM SOC-TAIP, V47, P765; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhao YD, 1998, BIOCHEMISTRY-US, V37, P12458, DOI 10.1021/bi9811563	39	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46815	46821		10.1074/jbc.M102224200	http://dx.doi.org/10.1074/jbc.M102224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590135	hybrid			2022-12-27	WOS:000172768500020
J	Shimada, N; Suzuki, T; Watanabe, K				Shimada, N; Suzuki, T; Watanabe, K			Dual mode recognition of two isoacceptor tRNAs by mammalian mitochondrial seryl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; HIGHER-ORDER STRUCTURE; ESCHERICHIA-COLI; TRANSFER RNA(SER); AMINOACYLATION SPECIFICITY; TERTIARY STRUCTURE; CRYSTAL-STRUCTURE; CODON CUG; IN-VITRO; IDENTITY	Animal mitochondrial translation systems contain two serine tRNAs, corresponding to the codons AGY (Y = U and C) and UCN (N = U, C, A, and G), each possessing an unusual secondary structure; tRNA(GCU)(Ser) (for AGY) lacks the entire D arm, whereas tRNA(UGA)(Ser) (for UCN) has an unusual cloverleaf configuration. We previously demonstrated that a single bovine mitochondrial seryl-tRNA synthetase (mt SerRS) recognizes these topologically distinct isoacceptors having no common sequence or structure. Recombinant mt SerRS clearly footprinted at the T PsiC loop of each isoacceptor, and kinetic studies revealed that mt SerRS specifically recognized the T PsiC loop sequence in each isoacceptor. However, in the case of tRNA(UGA)(Ser), T PsiC loop-D loop interaction was further required for recognition, suggesting that mt SerRS recognizes the two substrates by distinct mechanisms. mt SerRS could slightly but significantly misacylate mitochondrial tRNA(Gln), which has the same T PsiC loop sequence as tRNA(UGA)(Ser), implying that the fidelity of mitochondrial translation is maintained by kinetic discrimination of tRNAs in the network of aminoacyl-tRNA synthetases.	Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778583, Japan	University of Tokyo; University of Tokyo	Watanabe, K (corresponding author), Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	kw@kwl.t.u-tokyo.ac.jp	Suzuki, Tsutomu/J-1776-2015	Suzuki, Tsutomu/0000-0002-9731-1731				ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; ASAHARA H, 1994, J MOL BIOL, V236, P738, DOI 10.1006/jmbi.1994.1186; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Chang KY, 1999, P NATL ACAD SCI USA, V96, P11764, DOI 10.1073/pnas.96.21.11764; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEBRUIJN MHL, 1983, EMBO J, V2, P1309, DOI 10.1002/j.1460-2075.1983.tb01586.x; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; Hayashi I, 1997, NUCLEIC ACIDS RES, V25, P3503, DOI 10.1093/nar/25.17.3503; Hayashi I, 1998, J MOL BIOL, V284, P57, DOI 10.1006/jmbi.1998.2151; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; Himeno H, 1997, J MOL BIOL, V268, P704, DOI 10.1006/jmbi.1997.0991; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; KAWAGUCHI Y, 1989, NATURE, V341, P164, DOI 10.1038/341164a0; KUMAZAWA Y, 1991, J BIOCHEM, V109, P421, DOI 10.1093/oxfordjournals.jbchem.a123397; Lenhard B, 1999, NUCLEIC ACIDS RES, V27, P721, DOI 10.1093/nar/27.3.721; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NISHIOKA N, 1994, NUCL ACIDS S SER, V31, P187; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; Oakley MG, 1997, BIOCHEMISTRY-US, V36, P2544, DOI 10.1021/bi962391t; OHAMA T, 1993, NUCLEIC ACIDS RES, V21, P4039, DOI 10.1093/nar/21.17.4039; PAPE LK, 1985, J BIOL CHEM, V260, P5362; PARKER J, 1989, MICROBIOL REV, V53, P273, DOI 10.1128/MMBR.53.3.273-298.1989; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; Ramos A, 1997, NUCLEIC ACIDS RES, V25, P2083, DOI 10.1093/nar/25.11.2083; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SHIMIZU M, 1992, J MOL EVOL, V35, P436; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STEINBERG S, 1994, J MOL BIOL, V236, P982, DOI 10.1016/0022-2836(94)90004-3; Suzuki T, 1997, EMBO J, V16, P1122, DOI 10.1093/emboj/16.5.1122; TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421; UEDA T, 1992, NUCLEIC ACIDS RES, V20, P2217, DOI 10.1093/nar/20.9.2217; VLASSOV VV, 1981, FEBS LETT, V123, P277, DOI 10.1016/0014-5793(81)80307-9; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WATANABE Y, 1994, NUCLEIC ACIDS RES, V22, P5378, DOI 10.1093/nar/22.24.5378; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; YOKOGAWA T, 1991, NUCLEIC ACIDS RES, V19, P6101, DOI 10.1093/nar/19.22.6101; Yokogawa T, 2000, J BIOL CHEM, V275, P19913, DOI 10.1074/jbc.M908473199	48	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46770	46778		10.1074/jbc.M105150200	http://dx.doi.org/10.1074/jbc.M105150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577083	hybrid			2022-12-27	WOS:000172768500015
J	Xing, YN; Lin, W; Jiang, M; Myers, RV; Cao, DH; Bernard, MP; Moyle, WR				Xing, YN; Lin, W; Jiang, M; Myers, RV; Cao, DH; Bernard, MP; Moyle, WR			Alternatively folded choriogonadotropin analogs - Implications for hormone folding and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LEUCINE-RICH REPEATS; ALPHA-SUBUNIT; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; DISULFIDE BONDS; LH ACTIVITY	Most heterodimeric proteins are stabilized by intersubunit contacts or disulfide bonds. In contrast, human chorionic gonadotropin (hCG) and other glycoprotein hormones are secured by a strand of their beta -subunits that is wrapped around alpha -subunit loop 2 "like a seatbelt." During studies of hCG synthesis in COS-7 cells, we found that, when the seatbelt was prevented from forming the disulfide that normally "latches" it to the beta -subunit, its carboxyl-terminal end can "scan" the surface of the heterodimer and become latched by a disulfide to cysteines substituted for residues in the a-subunit. Analogs in which the seatbelt was latched to residues 35, 37,41-43, and 56 of alpha -subunit loop 2 had similar lutropin activities to those of hCG; that in which it was latched to residue 92 at the carboxyl terminus had 10-20% the activity of hCG. Attachment of the seatbelt to a-subunit residues 45-51, 86, 88, 90, and 91 reduced lutropin activity substantially. These findings show that the heterodimer can form before the beta -subunit has folded completely and support the notions that the carboxyl-terminal end of the seatbelt, portions of alpha -subunit loop 2, and the end of the alpha -subunit carboxyl terminus do not participate in lutropin receptor interactions. They suggest also that several different architectures could have been sampled without disrupting hormone activity as the glycoprotein hormones diverged from other cysteine knot proteins.	Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Obstet & Gynecol, 675 Hoes Lane, Piscataway, NJ 08854 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014907, R01HD014907, R01HD038547] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 14907, HD 38547] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAHL OP, 1969, J BIOL CHEM, V244, P567; BenMenahem D, 1997, J BIOL CHEM, V272, P6827, DOI 10.1074/jbc.272.11.6827; Bernard MP, 1998, BIOCHEM J, V335, P611, DOI 10.1042/bj3350611; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; Campbell RK, 1997, NAT BIOTECHNOL, V15, P439, DOI 10.1038/nbt0597-439; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; Galet C, 2000, J ENDOCRINOL, V167, P117, DOI 10.1677/joe.0.1670117; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Han Y, 1996, MOL CELL ENDOCRINOL, V124, P151, DOI 10.1016/S0303-7207(96)03936-6; Heikoop JC, 1997, EUR J BIOCHEM, V245, P656, DOI 10.1111/j.1432-1033.1997.00656.x; Jackson AM, 1999, MOL ENDOCRINOL, V13, P2175, DOI 10.1210/me.13.12.2175; JI I, 1993, J BIOL CHEM, V268, P20851; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LI CH, 1964, NATURE, V202, P291; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; Lin W, 1999, MOL CELL ENDOCRINOL, V152, P91, DOI 10.1016/S0303-7207(99)00056-8; Marichatou H, 2000, EUR J ENDOCRINOL, V142, P402, DOI 10.1530/eje.0.1420402; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; Moyle WR, 1998, CHEM BIOL, V5, P241, DOI 10.1016/S1074-5521(98)90617-2; Myers RV, 2000, BBA-GEN SUBJECTS, V1475, P390, DOI 10.1016/S0304-4165(00)00097-0; PANTEL J, 1993, BIOCHEM BIOPH RES CO, V195, P588, DOI 10.1006/bbrc.1993.2086; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Wang YH, 2000, MOL CELL ENDOCRINOL, V170, P67, DOI 10.1016/S0303-7207(00)00331-2; WOODRUFF TK, 1995, ANNU REV PHYSIOL, V57, P219; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	41	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46953	46960		10.1074/jbc.M108374200	http://dx.doi.org/10.1074/jbc.M108374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591722	hybrid			2022-12-27	WOS:000172768500039
J	Blanc, V; Henderson, JO; Kennedy, S; Davidson, NO				Blanc, V; Henderson, JO; Kennedy, S; Davidson, NO			Mutagenesis of apobec-1 complementation factor reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1, and complementation of C to U RNA-editing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; APOLIPOPROTEIN-B; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SECONDARY STRUCTURE; CYTIDINE DEAMINASE; SEQUENCE; SITE; ENZYME; DETERMINANTS	C to U editing of apolipoprotein B (apoB) RNA requires a multicomponent holoenzyme complex in which minimal constituents include apobec-1 and apobec-1 complementation factor (ACF). We have examined the predicted functional domains in ACF in binding apoB RNA, interaction with apobec-1, and complementation of RNA editing. We demonstrate that apoB RNA binding and apobec-1-interacting domains are defined by two partially overlapping regions containing the NH2-terminal RNA recognition motifs of ACF. Both apoB RNA binding and apobec-1 interaction are required for editing complementation activity. ACF is a nuclear protein that upon cotransfection with apobec-1 results in nuclear colocalization and redistribution of apobec-1 from the cytoplasm. ACF constructs with deletions or mutations in the putative nuclear localization signal (NLS) still localize in the nucleus of transfected cells but do not colocalize with apobec-1, the latter remaining predominantly cytoplasmic. These observations suggest that the putative NLS motif in ACF is not responsible for its nucleo-cytoplasmic trafficking. By contrast, protein-protein interaction is important for the nuclear import of apobec-1. Taken together, these data suggest that functional complementation of C to U RNA editing by apobec-1 involves the NH2-terminal 380 residues of ACF.	Washington Univ, Sch Med, Div Gastroenterol, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Davidson, NO (corresponding author), Washington Univ, Sch Med, Div Gastroenterol, Dept Internal Med, Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, R01DK056260] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38180] Funding Source: Medline; NIDDK NIH HHS [DK-56260, DK52574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; HENDERSON JO, 2001, IN PRESS BIOCH BIOPH; Hersberger M, 1999, J BIOL CHEM, V274, P34590, DOI 10.1074/jbc.274.49.34590; Hersberger M, 1998, J BIOL CHEM, V273, P9435, DOI 10.1074/jbc.273.16.9435; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Maas S, 2000, BIOESSAYS, V22, P790, DOI 10.1002/1521-1878(200009)22:9<790::AID-BIES4>3.0.CO;2-0; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, RNA, V2, P274; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Wan LL, 2001, J BIOL CHEM, V276, P7681, DOI 10.1074/jbc.M010207200; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; Yang Y, 2001, EXP CELL RES, V267, P153, DOI 10.1006/excr.2001.5255; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199	44	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46386	46393		10.1074/jbc.M107654200	http://dx.doi.org/10.1074/jbc.M107654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571303	hybrid			2022-12-27	WOS:000172573100121
J	Grisendi, S; Chambraud, B; Gout, I; Comoglio, PM; Crepaldi, T				Grisendi, S; Chambraud, B; Gout, I; Comoglio, PM; Crepaldi, T			Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR-RECEPTOR; MET RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL CONTROL; BIOLOGICAL RESPONSES; C-MET; PROTEIN; HGF; PHOSPHORYLATION	We have used the yeast two-hybrid system to identify proteins that interact with the intracellular portion of the hepatocyte growth factor (HGF) receptor (Met). We isolated a human cDNA encoding a novel protein of 68 kDa, which we termed FAP68. This protein is homologous to a previously described FK506-binding protein-associated protein, FAP48, which derives from an alternative spliced form of the same cDNA, lacking an 85-nucleotide exon and leading to an early stop codon. Here we show that epithelial cells, in which the HGF receptor is naturally expressed, contain FAP68 and not FAP48 proteins. FAP68 binding to Met requires the last 30 amino acids of the C-terminal tail, which are unique to the HGF receptor. Indeed, FAP68 does not interact with related tyrosine kinases of the Met and insulin receptor families. FAP68 interacts specifically with the inactive form of HGF receptor, such as a kinase-defective receptor or a dephosphorylated wild type receptor. In vivo, endogenous FAP68 can be coimmunoprecipitated with the HGF receptor in the absence of stimuli and not upon HGF stimulation. Thus, FAP68 represents a novel type of effector that interacts with the inactive HGF receptor and is released upon receptor phosphorylation. Free FAP68 exerts a specific stimulatory activity toward the downstream target p70 S6 protein kinase (p70S6K). Significantly, nonphosphorylated HGF receptor prevents FAP68 from stimulating p70S6K. These data suggest a role for FAP68 in coupling HGF receptor signaling to the p70S6K pathway.	Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; INSERM, U488, F-94276 Le Kremlin Bicetre, Paris, France; Ludwig Inst Canc Res, London W1P 8BY, England	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Institut National de la Sante et de la Recherche Medicale (Inserm); Ludwig Institute for Cancer Research	Crepaldi, T (corresponding author), Univ Turin, Dept Anat Pharmacol & Forens Med, Corso M DAzeglio 52, I-10126 Turin, Italy.		Comoglio, Paolo/G-6323-2011; crepaldi, tiziana/AAY-7207-2020	crepaldi, tiziana/0000-0003-3410-947X; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Chambraud B, 1996, J BIOL CHEM, V271, P32923, DOI 10.1074/jbc.271.51.32923; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOLEMIS EA, 1995, CURRENT PROTOCOLS MO; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kimura M, 1997, J PHARMACOL EXP THER, V282, P1146; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; ONeill TJ, 1997, J BIOL CHEM, V272, P10035; PELICCI G, 1995, ONCOGENE, V10, P1631; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621	39	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46632	46638		10.1074/jbc.M104323200	http://dx.doi.org/10.1074/jbc.M104323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571281	hybrid			2022-12-27	WOS:000172573100150
J	Nakanishi, M; Yatome, C; Ishida, N; Kitade, Y				Nakanishi, M; Yatome, C; Ishida, N; Kitade, Y			Putative ACP phosphodiesterase gene (acpD) encodes an azoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; NAD(P)H-QUINONE REDUCTASE; PROTEIN; PNEUMONIAE; CLONING; MAP	An FMN-dependent NADH-azoreductase of Escherichia coli was purified and analyzed for identification of the gene responsible for azo reduction by microorganisms. The N-terminal sequence of the azoreductase conformed to that of the acpD gene product, acyl carrier protein phosphodiesterase. Overexpression of the acpD gene provided the E. coli with a large amount of the 23-kDa protein and more than 800 times higher azoreductase activity. The purified gene product exhibited activity corresponding to that of the native azoreductase. The reaction followed a ping-pong mechanism requiring 2 mol of NADH to reduce I mol of methyl red (4 ' -dimethylaminoazobenzene-2-carboxylic acid) into 2-aminobenzoic acid and N,N ' -dimethyl-p-phenylenediamine. On the other hand, the gene product could not convert holo-acyl carrier protein into the apo form under either in vitro or in vivo conditions. These data indicate that the acpD gene product is not acyl carrier protein phosphodiesterase but an azoreductase.	Gifu Univ, Fac Engn, Dept Biomol Sci, Lab Mol Biochem, Gifu 5011193, Japan	Gifu University	Kitade, Y (corresponding author), Gifu Univ, Fac Engn, Dept Biomol Sci, Lab Mol Biochem, 1-1 Yanagido, Gifu 5011193, Japan.	kitade@biomol.gifu-u.ac.jp						BAYNEY RM, 1987, J BIOL CHEM, V262, P572; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CRONAN JE, 1980, J BACTERIOL, V141, P1291, DOI 10.1128/JB.141.3.1291-1297.1980; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Ghosh Dilip K., 1993, Indian Journal of Experimental Biology, V31, P951; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Holme I., 1984, ECOLOGICAL ASPECTS C, P111; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; MORRIS SA, 1993, BIOCHEM J, V294, P521, DOI 10.1042/bj2940521; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Suzuki Y, 2001, J BIOL CHEM, V276, P9059, DOI 10.1074/jbc.M008083200; Takami H, 1999, EXTREMOPHILES, V3, P21, DOI 10.1007/s007920050095; THERISOD H, 1986, P NATL ACAD SCI USA, V83, P7236, DOI 10.1073/pnas.83.19.7236; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317; Wong PK, 1996, WATER RES, V30, P1736, DOI 10.1016/0043-1354(96)00067-X; ZIMMERMANN T, 1984, ARCH MICROBIOL, V138, P37, DOI 10.1007/BF00425404; ZIMMERMANN T, 1982, EUR J BIOCHEM, V129, P197, DOI 10.1111/j.1432-1033.1982.tb07040.x	27	131	145	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46394	46399		10.1074/jbc.M104483200	http://dx.doi.org/10.1074/jbc.M104483200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583992	hybrid			2022-12-27	WOS:000172573100122
J	Nogueira, V; Rigoulet, M; Piquet, MA; Devin, A; Fontaine, E; Leverve, XM				Nogueira, V; Rigoulet, M; Piquet, MA; Devin, A; Fontaine, E; Leverve, XM			Mitochondrial respiratory chain adjustment to cellular energy demand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; RAT-LIVER MITOCHONDRIA; FATTY-ACID DEFICIENCY; OXIDATIVE-PHOSPHORYLATION; THYROID-HORMONE; THERMODYNAMIC CONTROL; H+/E STOICHIOMETRY; BOVINE HEART; HYPERTHYROIDISM; HEPATOCYTES	Because adaptation to physiological changes in cellular energy demand is a crucial imperative for life, mitochondrial oxidative phosphorylation is tightly controlled by ATP consumption. Nevertheless, the mechanisms permitting such large variations in ATP synthesis capacity, as well as the consequence on the overall efficiency of oxidative phosphorylation, are not known. By investigating several physiological models in vivo in rats (hyper- and hypothyroidism, polyunsaturated fatty acid deficiency, and chronic ethanol intoxication) we found that the increase in hepatocyte respiration (from 9.8 to 22.7 nmol of O-2/min/mg dry cells) was tightly correlated with total mitochondrial cytochrome content, expressed both per mg dry cells or per mg mitochondrial protein. Moreover, this increase in total cytochrome content was accompanied by an increase in the respective proportion of cytochrome oxidase; while total cytochrome content increased 2-fold (from 0.341 +/- 0.021 to 0.821 +/- 0.024 nmol/mg protein), cytochrome oxidase increased 10-fold (from 0.020 +/- 0.002 to 0.224 +/- 0.006 nmol/mg protein). This modification was associated with a decrease in the overall efficiency of the respiratory chain. Since cytochrome oxidase is well recognized for slippage between redox reactions and proton pumping, we suggest that this dramatic increase in cytochrome oxidase is responsible for the decrease in the overall efficiency of respiratory chain and, in turn, of ATP synthesis yield, linked to the adaptive increase in oxidative phosphorylation capacity.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France; Univ Bordeaux 2, Inst Biochim & Genet Cellulaire, CNRS, F-33077 Bordeaux, France; CHU Cote Nacre, Serv Hepatogastroenterol & Nutr, F-14033 Caen, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; CHU de Caen NORMANDIE; Universite de Caen Normandie	Leverve, XM (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, BP 53X, F-38041 Grenoble, France.		Fontaine, Eric/ABA-8853-2020	Fontaine, Eric/0000-0002-5204-9477				AKERBOOM TPM, 1979, TECH METAB RES B, V105, P1; AZZONE GF, 1985, J INORG BIOCHEM, V23, P349, DOI 10.1016/0162-0134(85)85045-5; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Bobyleva V, 1998, FEBS LETT, V430, P409, DOI 10.1016/S0014-5793(98)00700-5; BRAND MD, 1992, EUR J BIOCHEM, V206, P775, DOI 10.1111/j.1432-1033.1992.tb16984.x; CAPITANIO N, 1991, FEBS LETT, V288, P179, DOI 10.1016/0014-5793(91)81029-8; CHEN YDI, 1977, ARCH BIOCHEM BIOPHYS, V181, P470, DOI 10.1016/0003-9861(77)90253-3; DEAVER OE, 1986, J NUTR, V116, P1148, DOI 10.1093/jn/116.7.1148; DIVAKARAN P, 1978, EXPERIENTIA, V34, P1540, DOI 10.1007/BF02034659; DIVAKARAN P, 1977, J NUTR, V107, P1621, DOI 10.1093/jn/107.9.1621; ESPIE P, 1995, BBA-BIOENERGETICS, V1230, P139, DOI 10.1016/0005-2728(95)00045-K; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; Fontaine EM, 1996, BBA-BIOENERGETICS, V1276, P181, DOI 10.1016/0005-2728(96)00075-8; Frank V, 1996, FEBS LETT, V382, P121, DOI 10.1016/0014-5793(96)00096-8; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1098, P61; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HOCH FL, 1988, PROG LIPID RES, V27, P199, DOI 10.1016/0163-7827(88)90013-6; HOLNESS M, 1984, FEBS LETT, V177, P231, DOI 10.1016/0014-5793(84)81289-2; HORRUM MA, 1991, MOL CELL BIOCHEM, V103, P9; HULBERT AJ, 1976, BIOCHIM BIOPHYS ACTA, V455, P597, DOI 10.1016/0005-2736(76)90328-X; Huttemann M, 2000, EUR J BIOCHEM, V267, P2098, DOI 10.1046/j.1432-1327.2000.01216.x; KLINGENBERG M, 1959, BIOCHEM Z, V331, P486; LUVISETTO S, 1991, J BIOL CHEM, V266, P1034; LUVISETTO S, 1991, FEBS LETT, V291, P17, DOI 10.1016/0014-5793(91)81093-N; LUVISETTO S, 1992, J BIOL CHEM, V267, P15348; MADDAIAH VT, 1981, ARCH BIOCHEM BIOPHYS, V210, P666, DOI 10.1016/0003-9861(81)90234-4; MURPHY MP, 1992, BIOCHEM PHARMACOL, V43, P2663, DOI 10.1016/0006-2952(92)90158-F; Nogueira V, 2001, J BIOENERG BIOMEMBR, V33, P53, DOI 10.1023/A:1005624707780; OHNISHI T, 1966, J BIOL CHEM, V241, P797; OUHABI R, 1989, FEBS LETT, V254, P199, DOI 10.1016/0014-5793(89)81038-5; PAPA S, 1991, FEBS LETT, V288, P183, DOI 10.1016/0014-5793(91)81030-C; PAPA S, 1987, EUR J BIOCHEM, V164, P507, DOI 10.1111/j.1432-1033.1987.tb11156.x; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Piquet MA, 1996, BIOCHEM J, V317, P667, DOI 10.1042/bj3170667; Piquet MA, 2000, FEBS LETT, V468, P239, DOI 10.1016/S0014-5793(00)01225-4; RAFAEL J, 1984, J NUTR, V114, P255, DOI 10.1093/jn/114.2.255; Rigoulet M, 1998, MOL CELL BIOCHEM, V184, P35, DOI 10.1023/A:1006858104988; Rigoulet M, 1998, BBA-BIOENERGETICS, V1365, P117, DOI 10.1016/S0005-2728(98)00051-6; ROHDICH F, 1993, BIOCHEMISTRY-US, V32, P8499, DOI 10.1021/bi00084a015; SARTI P, 1985, P NATL ACAD SCI USA, V82, P4876, DOI 10.1073/pnas.82.15.4876; SCHMEHL I, 1995, FEBS LETT, V375, P206, DOI 10.1016/0014-5793(95)01211-V; SHEARS SB, 1979, BIOCHEM J, V178, P505, DOI 10.1042/bj1780505; SOBOLL S, 1992, BIOCHEM J, V281, P171, DOI 10.1042/bj2810171; SOBOLL S, 1993, BIOCHIM BIOPHYS ACTA, V1144, P1, DOI 10.1016/0005-2728(93)90024-A; SONE N, 1984, BIOCHEMISTRY-US, V23, P6550, DOI 10.1021/bi00321a042; STEVERDING D, 1990, BIOCHEMISTRY-US, V29, P2945, DOI 10.1021/bi00464a009; STONER CD, 1987, J BIOL CHEM, V262, P10445; SUMMER JB, 1944, SCIENCE, V100, P413; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; VERHOEVEN AJ, 1985, BIOCHEM J, V226, P183, DOI 10.1042/bj2260183; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514	54	51	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46104	46110		10.1074/jbc.M107425200	http://dx.doi.org/10.1074/jbc.M107425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579099	hybrid			2022-12-27	WOS:000172573100084
J	Reddy, MS; Guhan, N; Muniyappa, K				Reddy, MS; Guhan, N; Muniyappa, K			Characterization of single-stranded DNA-binding proteins from mycobacteria - The carboxyl-terminal domain of SSB is essential for stable association with its cognate RecA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; TUBERCULOSIS-RECA; SSDNA COMPLEXES; ATPASE ACTIVITY; REPLICATION; MULTIPLE; RECOMBINATION; PURIFICATION; SEQUENCE	Single-stranded DNA-binding proteins (SSB) play an important role in most aspects of DNA metabolism including DNA replication, repair, and recombination. We report here the identification and characterization of SSB proteins of Mycobacterium smegmatis and Mycobacterium tuberculosis. Sequence comparison of M. smegmatis SSB revealed that it is homologous to M. tuberculosis SSB, except for a small spacer connecting the larger amino-terminal domain with the extreme carboxyl-terminal tail. The purified SSB proteins of mycobacteria bound single-stranded DNA with high affinity, and the association and dissociation constants were similar to that of the prototype SSB. The proteolytic signatures of free and bound forms of SSB proteins disclosed that DNA binding was associated with structural changes at the carboxyl-terminal domain. Significantly, SSB proteins from mycobacteria displayed high affinity for cognate RecA, whereas Escherichia coli SSB did not under comparable experimental conditions. Accordingly, SSB and RecA were coimmunoprecipitated from cell lysates, further supporting an interaction between these proteins in vivo. The carboxyl-terminal domain of M. smegmatis SSB, which is not essential for interaction with ssDNA, is the site of binding of its cognate RecA. These studies provide the first evidence for stable association of eubacterial SSB proteins with their cognate RecA, suggesting that these two proteins might function together during DNA repair and/or recombination.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Muniyappa, K (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	kmbc@biochem.iisc.ernet.in						ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALMA NCM, 1983, J MOL BIOL, V163, P47, DOI 10.1016/0022-2836(83)90029-3; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; BUJALOWSKI W, 1989, J MOL BIOL, V207, P269, DOI 10.1016/0022-2836(89)90455-5; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1991, J MOL BIOL, V217, P63, DOI 10.1016/0022-2836(91)90611-9; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COX MM, 1981, J BIOL CHEM, V256, P4676; Datta S, 2000, NUCLEIC ACIDS RES, V28, P4964, DOI 10.1093/nar/28.24.4964; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Gascon I, 2000, J MOL BIOL, V296, P989, DOI 10.1006/jmbi.2000.3521; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; Kumar RA, 1996, BIOCHEMISTRY-US, V35, P1793, DOI 10.1021/bi9517751; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LI L, 1995, MOL CELL BIOL, V15, P5396; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Mazin AV, 1998, EMBO J, V17, P1161, DOI 10.1093/emboj/17.4.1161; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; Muniyappa K, 2000, MICROBIOL-UK, V146, P2093, DOI 10.1099/00221287-146-9-2093; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Papavinasasundaram KG, 1998, MOL MICROBIOL, V30, P525, DOI 10.1046/j.1365-2958.1998.01083.x; Purnapatre K, 1999, EUR J BIOCHEM, V264, P591, DOI 10.1046/j.1432-1327.1999.00684.x; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Reddy MS, 2000, BIOCHEMISTRY-US, V39, P14250, DOI 10.1021/bi001187+; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandigursky M, 1996, RADIAT RES, V145, P619, DOI 10.2307/3579281; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEPPENHEIM R, 1987, EUR J CLIN MICROBIOL, V6, P49, DOI 10.1007/BF02097190; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; Vaze MB, 1999, BIOCHEMISTRY-US, V38, P3175, DOI 10.1021/bi9819125; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	59	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45959	45968		10.1074/jbc.M103523200	http://dx.doi.org/10.1074/jbc.M103523200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577073	hybrid			2022-12-27	WOS:000172573100065
J	Terao, M; Kurosaki, M; Marini, M; Vanoni, MA; Saltini, G; Bonetto, V; Bastone, A; Federico, C; Saccone, S; Fanelli, R; Salmona, M; Garattini, E				Terao, M; Kurosaki, M; Marini, M; Vanoni, MA; Saltini, G; Bonetto, V; Bastone, A; Federico, C; Saccone, S; Fanelli, R; Salmona, M; Garattini, E			Purification of the aldehyde oxidase homolog 1 (AOH1) protein and cloning of the AOH1 and aldehyde oxidase homolog 2 (AOH2) genes - Identification of a novel molybdo-flavoprotein gene cluster on mouse chromosome 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER XANTHINE DEHYDROGENASE; MOLECULAR-CLONING; CDNA CLONING; BINDING SITE; OXIDOREDUCTASE; SEQUENCE; EXPRESSION; HYDROXYLASES; CANDIDATE; MUTANTS	We report the cloning of the AOH1 and AOH2 genes, which encode two novel mammalian molybdo-flavoproteins. We have purified the AOH1 protein to homogeneity in its catalytically active form from mouse liver. Twenty tryptic peptides, identified or directly sequenced by mass spectrometry, confirm the primary structure of the polypeptide deduced from the AOH1 gene. The enzyme contains one molecule of FAD, one atom of molybdenum, and four atoms of iron per subunit and shows spectroscopic features similar to those of the prototypic molybdo-flavoprotein xanthine oxidoreductase. The AOH1 and AOH2 genes are 98 and 60 kilobases long, respectively, and consist of 35 coding exons. The AOH1 gene has the potential to transcribe an extra leader non-coding exon, which is located downstream of exon 26, and is transcribed in the opposite orientation relative to all the other exons. AOH1 and AOH2 map to chromosome I in close proximity to each other and to the aldehyde oxidase gene, forming a molybdo-flavoenzyme gene cluster. Conservation in the position of exon/intron junctions among the mouse AOH1, AOH2, aldehyde oxidase, and xanthine oxidoreductase loci indicates that these genes are derived from the duplication of an ancestral precursor.	Mario Negri Inst Pharmacol Res, Mol Biol Lab, Ctr Catullo & Daniela Borgomainerio, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Environm Toxicol, I-20157 Milan, Italy; Univ Insubria, Dipartimento Sci Chim Fis & Matemat, I-22100 Como, Italy; Univ Catania, Dipartimento Biol Anim, I-95124 Catania, Italy; Univ Bologna, Dipartimento Protez Valorizzaz Agroalimentare, I-42100 Reggio Emilia, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Insubria; University of Catania; University of Bologna	Garattini, E (corresponding author), Mario Negri Inst Pharmacol Res, Mol Biol Lab, Ctr Catullo & Daniela Borgomainerio, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@marionegri.it	Bonetto, Valentina/I-4694-2018; salmona, mario/AAA-7116-2020; Vanoni, Maria/AAP-2089-2021; Garattini, Enrico/AAI-1998-2019; salmona, mario/ABI-4066-2020; KUROSAKI, Mami/ABG-2224-2020; Bonetto, Valentina/ABB-6383-2020; Terao, Mineko/AAA-6415-2020; Saccone, Salvatore/H-1548-2012; terao, mineko/AAU-8089-2020; Federico, Concetta/M-5553-2015	Bonetto, Valentina/0000-0003-0456-2054; salmona, mario/0000-0002-9098-9873; Vanoni, Maria/0000-0001-7213-732X; KUROSAKI, Mami/0000-0001-8231-713X; Bonetto, Valentina/0000-0003-0456-2054; Terao, Mineko/0000-0002-9976-9869; Saccone, Salvatore/0000-0001-7568-5823; Federico, Concetta/0000-0002-0160-9040; Garattini, Enrico/0000-0001-8983-886X	Telethon [D.088] Funding Source: Medline	Telethon(Fondazione Telethon)		Aliverti A, 1999, METH MOL B, V131, P9; BEEDHAM C, 1990, BIOCHEM PHARMACOL, V39, P1213, DOI 10.1016/0006-2952(90)90265-M; BERGER R, 1995, SOMAT CELL MOLEC GEN, V21, P121, DOI 10.1007/BF02255787; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CATES LA, 1980, J MED CHEM, V23, P300, DOI 10.1021/jm00177a018; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Demontis S, 1999, BBA-GENE STRUCT EXPR, V1489, P207, DOI 10.1016/S0167-4781(99)00174-8; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; FABRE G, 1986, BIOCHEM PHARMACOL, V35, P1325, DOI 10.1016/0006-2952(86)90277-7; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HILLE R, 1992, CHEM BIOCH FLAVOENZY, V3, P21; HILLIKER AJ, 1992, P NATL ACAD SCI USA, V89, P4343, DOI 10.1073/pnas.89.10.4343; HOLMES RS, 1978, COMP BIOCHEM PHYS B, V61, P339, DOI 10.1016/0305-0491(78)90134-7; Huang DY, 1999, ARCH BIOCHEM BIOPHYS, V364, P264, DOI 10.1006/abbi.1999.1129; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; KUROSAKI M, 1995, BIOCHEM J, V306, P225, DOI 10.1042/bj3060225; Labrador M, 2001, NATURE, V409, P1000, DOI 10.1038/35059000; LI CZ, 1995, J BIOL CHEM, V270, P31037; NISHINO T, 1989, J BIOL CHEM, V264, P5468; Ori N, 1997, J BIOL CHEM, V272, P1019, DOI 10.1074/jbc.272.2.1019; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rebelo J, 2000, J MOL BIOL, V297, P135, DOI 10.1006/jmbi.2000.3552; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Saccone S, 1997, CHROMOSOME RES, V5, P293, DOI 10.1023/B:CHRO.0000038759.09018.a7; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Segel I.H., 1975, ENZYME KINETICS; Sekimoto H, 1997, J BIOL CHEM, V272, P15280, DOI 10.1074/jbc.272.24.15280; Shambrook J, 1989, MOL CLONING LAB MANU; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stover NA, 2001, P NATL ACAD SCI USA, V98, P5693, DOI 10.1073/pnas.101049998; Terao M, 1997, BIOCHEM SOC T, V25, P791, DOI 10.1042/bst0250791; Terao M, 2000, J BIOL CHEM, V275, P30690, DOI 10.1074/jbc.M005355200; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TRIPLETT EW, 1982, ARCH BIOCHEM BIOPHYS, V219, P39, DOI 10.1016/0003-9861(82)90131-X; Vandenberghe AE, 2001, GENE DEV, V15, P294, DOI 10.1101/gad.865401; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Wright RM, 1999, J BIOL CHEM, V274, P3878, DOI 10.1074/jbc.274.6.3878; Wright RM, 1997, REDOX REP, V3, P135, DOI 10.1080/13510002.1997.11747101; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; Yasukochi Y, 1998, GENET RES, V71, P11, DOI 10.1017/S0016672397003078; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	48	41	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46347	46363		10.1074/jbc.M105744200	http://dx.doi.org/10.1074/jbc.M105744200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11562361	hybrid			2022-12-27	WOS:000172573100117
J	Chen, HP; Wu, SH; Lin, YL; Chen, CM; Tsay, SS				Chen, HP; Wu, SH; Lin, YL; Chen, CM; Tsay, SS			Cloning, sequencing, heterologous expression, purification, and characterization of adenosylcobalamin-dependent D-ornithine aminomutase from Clostridium sticklandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; X-RAY STRUCTURE; GLUTAMATE MUTASE; RECOMBINANT ENZYME; ESCHERICHIA-COLI; B-12; COCHLEARIUM; BINDING	D-Ornithine aminomutase from Clostridium sticklandii catalyzes the reversible rearrangement of D-ornithine to (2R,4S)-2,4-diaminopentanoic acid. The two genes encoding D-ornithine aminomutase have been cloned, sequenced, and expressed in Escherichia coli. The oraS gene, which encodes a protein of 121 amino acid residues with M-r 12,800, is situated upstream of the oraE gene, which encodes a protein of 753 amino acid residues with M-r 82,900. The holoenzyme appears to comprise a alpha (2)beta (2)-heterotetramer. OraS shows no significant homology to other proteins in the Swiss-Prot data base. The deduced amino acid sequence of OraE includes a conserved base-off/histidine-on cobalamin-binding motif, DXHXXG. OraE was expressed in E. coli as inclusion bodies. Refolding experiments on OraE indicate that the interactions between OraS and OraE and the binding of either pyridoxal phosphate or adenosylcobalamin play important roles in refolding process. The K-m values for D-ornithine, 5'-deoxyadenosylcobalamin (AdoCbl), and pyridoxal 5'-phosphate (PLP) are 44.5 +/- 2.8, 0.43 +/- 0.04, and 1.5 +/- 0.1 muM, respectively; the k(cat) is 6.3 +/- 0.1 s(-1). The reaction was absolutely dependent upon OraE, OraS, AdoCbl, PLP, and D-ornithine being present in the assay; no other cofactors were required. A red-shift in UV-visible absorption spectrum is observed when free adenosylcobinamide is bound by recombinant D-ornithine aminomutase and no significant change in spectrum when free adenosylcobinamide is bound by mutant OraE-H618G, demonstrating that the enzyme binds adenosylcobalamin in base-off/histidine-on mode.	China Med Coll, Dept Biochem, Taichung 404, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Dept Bot, Taipei 106, Taiwan	China Medical University Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, HP (corresponding author), China Med Coll, Dept Biochem, 91 Hseuh Shih Rd, Taichung 404, Taiwan.		Chen, Hao-Ping/Q-3283-2019	Chen, Hao-Ping/0000-0002-6491-2178				ANDREESEN JR, 1989, CLOSTRIDIA, pCH2; BAKER JJ, 1984, B12, V2, P203; BARKER HA, 1981, ANNU REV BIOCHEM, V50, P23, DOI 10.1146/annurev.bi.50.070181.000323; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang CH, 2000, J BIOL CHEM, V275, P106, DOI 10.1074/jbc.275.1.106; Chen HP, 2000, J BACTERIOL, V182, P2052, DOI 10.1128/JB.182.7.2052-2054.2000; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Frey P A, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P1; HAN O, 1990, J AM CHEM SOC, V112, P8982, DOI 10.1021/ja00180a054; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLOWAY DE, 1994, J BIOL CHEM, V269, P20425; LEUTBECHER U, 1992, EUR J BIOCHEM, V205, P759, DOI 10.1111/j.1432-1033.1992.tb16840.x; LJUNGDAHL LG, 1989, CLOSTRIDIA, pCH5; Ludwig M. L., 1999, Chemistry and biochemistry of B12., P595; MANICA F, 1996, STRUCTURE, V4, P339; MARSH EN, 1993, BIOCHEM J, V290, P551, DOI 10.1042/bj2900551; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; Marston F. A. O., 1987, DNA CLONING, P59; MORLEY C G D, 1972, Biochemistry, V11, P600, DOI 10.1021/bi00754a019; PADMAKUMAR R, 1995, J AM CHEM SOC, V117, P7033, DOI 10.1021/ja00131a039; Ratnatilleke A, 1999, J BIOL CHEM, V274, P31679, DOI 10.1074/jbc.274.44.31679; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; Smith DM, 1999, J AM CHEM SOC, V121, P9388, DOI 10.1021/ja991649a; SOMACK R, 1973, BIOCHEMISTRY-US, V12, P2597, DOI 10.1021/bi00738a008; TAOKA S, 1994, J BIOL CHEM, V269, P31630; TSUDA Y, 1970, J BIOL CHEM, V245, P5914; Wetmore SD, 2000, J AM CHEM SOC, V122, P10208, DOI 10.1021/ja001651y	29	46	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44744	44750		10.1074/jbc.M108365200	http://dx.doi.org/10.1074/jbc.M108365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577113	Green Published, hybrid			2022-12-27	WOS:000172406700055
J	Cong, M; Perry, SJ; Hu, LYA; Hanson, PI; Claing, A; Lefkowitz, RJ				Cong, M; Perry, SJ; Hu, LYA; Hanson, PI; Claing, A; Lefkowitz, RJ			Binding of the beta 2 adrenergic receptor to N-ethylmaleimide-sensitive factor regulates receptor recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA(1)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; SYNAPTIC TRANSMISSION; MEDIATED ENDOCYTOSIS; CLATHRIN ADAPTER; SILENT SYNAPSES; AMPA RECEPTORS	Following agonist stimulation, most G protein-coupled receptors become desensitized and are internalized, either to be degraded or recycled back to the cell surface. What determines the fate of a specific receptor type after it is internalized is poorly understood. Here we show that the rapidly recycling beta2 adrenergic receptor (beta 2AR) binds via a determinant including the last three amino acids in its carboxyl-terminal tail to the membrane fusion regulatory protein, N-ethylmaleimide-sensitive factor (NSF). This is documented by in vitro overlay assays and by cellular coimmunoprecipitations. Receptors bearing mutations in any of the last three residues fail to interact with NSF. After stimulation with the agonist isoproterenol, a green fluorescent protein fusion of NSF colocalizes with the wild type beta 2AR but not with a tail-mutated beta 2AR. The beta 2AR-NSF interaction is required for efficient internalization of the receptors and for their recycling to the cell surface. Mutations in the beta 2AR tail that ablate NSF binding reduce the efficiency of receptor internalization upon agonist stimulation. Upon subsequent treatment of cells with the antagonist propranolol, wild type receptors return to the cell surface, while tail-mutated receptors remain sequestered. Thus, the direct binding of the beta 2AR to NSF demonstrates how, after internalization, the fate of a receptor is reliant on a specific interaction with a component of the cellular membrane-trafficking machinery.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Washington University (WUSTL)	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Hanson, Phyllis/E-9420-2012; Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERTEL C, 1983, J CELL BIOL, V97, P1538, DOI 10.1083/jcb.97.5.1538; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Moore RH, 1999, J CELL SCI, V112, P329; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Neuwald AF, 1999, STRUCTURE, V7, pR19, DOI 10.1016/S0969-2126(99)80015-X; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	52	115	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45145	45152		10.1074/jbc.M106087200	http://dx.doi.org/10.1074/jbc.M106087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577089	hybrid			2022-12-27	WOS:000172406700106
J	Huang, KC; Gao, HL; Yamasaki, EF; Grabowski, DR; Liu, SJ; Shen, LL; Chan, KK; Ganapathi, R; Snapka, RM				Huang, KC; Gao, HL; Yamasaki, EF; Grabowski, DR; Liu, SJ; Shen, LL; Chan, KK; Ganapathi, R; Snapka, RM			Topoisomerase II poisoning by ICRF-193	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; SUMO-1 CONJUGATION; CELL-CYCLE; INHIBITION; BISDIOXOPIPERAZINES; PROTEIN; YEAST; LINE; DEXRAZOXANE; DERIVATIVES	Antineoplastic bis(dioxopiperazine)s, such as meso-2,3-bis(2,6-dioxopiperazin-4-yl)butane (ICRF-193), are widely believed to be only catalytic inhibitors of topoisomerase II. However, topoisomerase inhibitors have little or no antineoplastic activity unless they are topoisomerase poisons, a special subclass of topoisomerase-targeting drugs that stabilize topoisomerase-DNA strand passing intermediates and thus cause the topoisomerase to become a cytotoxic DNA-damaging agent. Here we report that ICRF-193 is a very significant topoisomerase II poison. Detection of topoisomerase II Poisoning by ICRF-193 required the use of a chaotropic protein denaturant in the topoisomerase poisoning assays. ICRF-193 caused dose-dependent cross-linking of human topoisomerase II beta to DNA and stimulated topoisomerase II beta -mediated DNA cleavage at specific sites on P-32-end-labeled DNA. Human topoisomerase Ha-mediated DNA cleavage was stimulated to a lesser extent by ICRF-193. In vivo experiments with MCF-7 cells also showed the requirement of a chaotropic protein denaturant in the assays and selectivity for the beta -isozyme of human topoisomerase II. Studies with two topoisomerase II beta -negative cell model systems confirmed significant topoisomerase II poisoning by ICRF-193 in the wild type cells and were consistent with beta -isozyme selectivity. Common use of only the detergent, SDS, in assays may have led to failure to detect topoisomerase II poisoning by ICRF-193 in earlier studies.	Ohio State Univ, Coll Med, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA; Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; Abbott Labs, Abbott Pk, IL 60064 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; University System of Ohio; Ohio State University; Abbott Laboratories	Snapka, RM (corresponding author), Ohio State Univ, Coll Med, Dept Radiol, 103 Wiseman Hall,400 W 12th Ave, Columbus, OH 43210 USA.				NCI NIH HHS [R01 CA80961, CA16058, CA74939, N01-CM-57201, U01CA63185] Funding Source: Medline; NIDDK NIH HHS [DK56917] Funding Source: Medline; DIVISION OF CANCER TREATMENT [N01CM057201] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA080961, R01CA074939, P30CA016058, U01CA063185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF CANCER TREATMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CREIGHTON AM, 1970, INT J CANCER, V5, P47, DOI 10.1002/ijc.2910050107; CREIGHTON AM, 1969, NATURE, V222, P384, DOI 10.1038/222384a0; CREIGHTON AM, 1970, PROGR ANTIMICROB ANT, V1, P167; FELIX CA, 1995, CANCER RES, V55, P4287; Gao HL, 1999, P NATL ACAD SCI USA, V96, P12168, DOI 10.1073/pnas.96.21.12168; Gao HL, 2000, CANCER RES, V60, P5937; HASINOFF BB, 1995, BIOCHEM PHARMACOL, V50, P953, DOI 10.1016/0006-2952(95)00218-O; Hasinoff BB, 1997, BIOCHEM PHARMACOL, V53, P1843, DOI 10.1016/S0006-2952(97)00013-0; HEMPEL A, 1982, J AM CHEM SOC, V104, P3453, DOI 10.1021/ja00376a034; HERMAN EH, 1982, ADV PHARMACOL CHEMOT, V19, P249, DOI 10.1016/S1054-3589(08)60025-3; Herzog CE, 1998, CANCER RES, V58, P5298; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; PERMANA PA, 1994, BIOCHEM BIOPH RES CO, V201, P1510, DOI 10.1006/bbrc.1994.1875; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sambrook J., 2002, MOL CLONING LAB MANU; Sehested M, 1996, BIOCHEM PHARMACOL, V51, P879, DOI 10.1016/0006-2952(95)02241-4; SHIN CG, 1990, TERATOGEN CARCIN MUT, V10, P41, DOI 10.1002/tcm.1770100106; Snapka RM, 2001, BIOCHEM BIOPH RES CO, V280, P1155, DOI 10.1006/bbrc.2001.4249; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; Snapka RM, 1996, BIOCHEM PHARMACOL, V52, P543, DOI 10.1016/0006-2952(96)00305-X; SNAPKA RM, 1996, SV40 REPLICON MODEL, P65; Strumberg D, 1999, J BIOL CHEM, V274, P28246, DOI 10.1074/jbc.274.40.28246; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; Tabata M, 2001, J BIOL CHEM, V276, P8029, DOI 10.1074/jbc.M009831200; TANABE K, 1991, CANCER RES, V51, P4903; van Hille B, 1999, BRIT J CANCER, V81, P800, DOI 10.1038/sj.bjc.6690767; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; Witiak D T, 1990, Prog Drug Res, V35, P249; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	37	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44488	44494		10.1074/jbc.M104383200	http://dx.doi.org/10.1074/jbc.M104383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577077	hybrid			2022-12-27	WOS:000172406700020
J	Tsou, CL; Haskell, CA; Charo, IF				Tsou, CL; Haskell, CA; Charo, IF			Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CX(3)CR1; TNF RECEPTOR; CHEMOKINE; METALLOPROTEINASE; IDENTIFICATION; LYMPHOCYTES; INHIBITOR; ADHESION; CELLS	Fractalkine (FK, CX3CL1) is a novel multidomain protein expressed on the surface of endothelial cells. As a full-length transmembrane protein, FK binds cells expressing CX3CR1, its cognate receptor, with high affinity. Proteolytic cleavage of FK releases a soluble form that is a potent chemoattractant for monocytes, T cells, and natural killer cells. Activation of protein kinase C dramatically increases the rate of this cleavage. Regulation of FK cleavage is critical for maintaining the balance between the immobilized and soluble forms, but the protease responsible has not been identified. Here we report that tumor necrosis factor-alpha -converting enzyme (TACE) is primarily responsible for the inducible cleavage of FK. After transfection into host cells, the proteolytic cleavage of FK was blocked by TACE-specific inhibitors and was not detected in cells genetically altered to remove TALE activity. In contrast, the constitutive cleavage of FK was not mediated by TALE and proceeded normally in TALE-null fibroblasts. We conclude that TALE is primarily responsible for the inducible cleavage of FK. These studies identify a potentially important link between local generation of potent cytokines and control of the balance between the cell adhesion and chemotactic properties of FK.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Charo, IF (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773, R01HL063894] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63894, HL 52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Lucas AD, 2001, AM J PATHOL, V158, P855, DOI 10.1016/S0002-9440(10)64034-5; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Robinson LA, 2000, J IMMUNOL, V165, P6067, DOI 10.4049/jimmunol.165.11.6067; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511	26	183	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44622	44626		10.1074/jbc.M107327200	http://dx.doi.org/10.1074/jbc.M107327200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571300	hybrid			2022-12-27	WOS:000172406700039
J	Brosius, U; Dehmel, T; Gartner, J				Brosius, U; Dehmel, T; Gartner, J			Two different targeting signals direct human peroxisomal membrane protein 22 to peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; PICHIA-PASTORIS; SACCHAROMYCES-CEREVISIAE; ZELLWEGER-SYNDROME; CANDIDA-BOIDINII; PEX19P INTERACTS; BIOGENESIS; GENE; IMPORT; PEX3P	The 22-kDa peroxisomal membrane protein (PMP22) is a major component of peroxisomal membranes in mammals. Although its precise role in peroxisome function is poorly understood, it seems to be involved in pore forming activity and may contribute to the unspecific permeability of the organelle membrane. PMP22 is synthesized on free cytosolic ribosomes and then directed to the peroxisome membrane by specific targeting information. Previous studies in rats revealed that PMP22 contains one distinct peroxisomal membrane targeting signal in the amino-terminal cytoplasmic tail. We cloned and characterized the targeting signal of human PMP22 and compared it with the already described characteristics of the corresponding rat protein. Amino acid sequence alignment of rat and human protein revealed 77% identity including a high conservation of several protein motifs. We expressed various deletion constructs of PMP22 in fusion with the green fluorescent protein in COS-7 cells and determined their intracellular localization. In contrast to previous studies on rat PMP22 and most other peroxisomal membrane proteins, we showed that human as well as rat PMP22 contains two distinct and nonoverlapping peroxisomal membrane targeting signals, one in the amino-terminal and the other in the carboxyl-terminal protein region. They consist of two transmembrane domains and adjacent protein loops with almost identical basic clusters. Both of these peroxisomal targeting regions interact with PEX19, a factor required for peroxisome membrane synthesis. In addition, we observed that fusing the green fluorescent protein immediately adjacent to the targeting region completely abolishes targeting function and mislocalizes PMP22 to the cytosol.	Univ Dusseldorf, Zentrum Kinderheilkunde, Dept Pediat, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Gartner, J (corresponding author), Univ Dusseldorf, Zentrum Kinderheilkunde, Dept Pediat, Moorenstr 5, D-40225 Dusseldorf, Germany.							ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Gotte K, 1998, MOL CELL BIOL, V18, P616; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ., 2001, METABOLIC MOL BASES, P3181; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; KALDI K, 1993, FEBS LETT, V315, P217, DOI 10.1016/0014-5793(93)81167-X; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MORENO M, 1994, YEAST, V10, P1447, DOI 10.1002/yea.320101108; Pause B, 2000, FEBS LETT, V471, P23, DOI 10.1016/S0014-5793(00)01332-6; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tugal HB, 1999, PLANT PHYSIOL, V120, P309, DOI 10.1104/pp.120.1.309; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x	44	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					774	784		10.1074/jbc.M108155200	http://dx.doi.org/10.1074/jbc.M108155200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11590176	hybrid			2022-12-27	WOS:000173087900100
J	Chen, GP; Paka, L; Kako, Y; Singhal, P; Duan, WL; Pillarisetti, S				Chen, GP; Paka, L; Kako, Y; Singhal, P; Duan, WL; Pillarisetti, S			A protective role for kidney apolipoprotein E - Regulation of mesangial cell proliferation and matrix expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE-CELLS; DIABETIC-NEPHROPATHY; DENSITY-LIPOPROTEIN; TRANSGENIC MICE; ATHEROSCLEROSIS; EXPRESSION; PERLECAN; DISEASE; ALLELE	Mesangial expansion is a key feature in the pathogenesis of numerous renal diseases involving the glomerulus. Studies indicate that mutations in apolipoprotein E (apoE) might independently contribute to kidney dysfunction. Although the role of apoE as an atheroprotective molecule is well established, its role in kidney is unclear. In this study, we sought to explore whether apoE has a protective function in kidney. Northern blotting and reverse transcriptase-polymerase chain reaction showed apoE expression in kidney, and mesangial cell is a major source of apoE in kidney. In the kidneys of 14-16-month-old apoE-null mice, hematoxylin-eosin (HE) staining revealed increased mesangial cell proliferation and matrix formation compared with wild type mice or apoB-overexpressing mice, which have elevated plasma cholesterol and triglycerides. These data suggest that lack of apoE, rather than hyperlipidemia, contributes to increased mesangial expansion. We isolated mesangial cells from mouse kidney and determined the effect of apoE on cell growth. ApoE (E3, 10 mug/ml) completely inhibited serum, platelet-derived growth factor (10 ng/ml), as well as low density lipoprotein-induced mesangial cell proliferation. Among the three isoforms, E3 was found to be most effective in inhibiting mesangial cell proliferation. ApoE did not show any cytotoxic effect, and moreover, inhibited mesangial cell apoptosis induced by oxidized low density lipoprotein. These data suggest that apoE regulates growth as well as survival of mesangial cells. We previously showed that apoE induces matrix heparan sulfate proteoglycan (HSPG) in vascular cells, which has an antiproliferative effect. Similarly, apoE induced the mesangial matrix HSPG. Perlecan is the major HSPG of mesangial matrix and subendothelial space, and consistent with this, blockade of perlecan reversed the antiproliferative effect of apoE. Immunohistochemistry revealed reduced staining of perlecan in kidney from apoE-null mice. Because the loss of anionic HSPG in the basement membrane and mesangial matrix is associated with disruption of filtration barrier, these data suggest a novel role for kidney apoE in preserving the filtration barrier. In summary, apoE has a protective function in kidney as an autocrine regulator of mesangial expansion and kidney function.	Reddy US Therapeut, Norcross, GA 30071 USA; N Shore Long Isl Jewish Hlth Syst, Dept Radiat Oncol, Manhasset, NY 11030 USA; N Shore Long Isl Jewish Hlth Syst, Dept Med, Manhasset, NY 11030 USA; Columbia Univ, Dept Med, Div Prevent Med, New York, NY 10032 USA	Northwell Health; Northwell Health; Columbia University	Pillarisetti, S (corresponding author), Reddy US Therapeut, 3065 Northwoods Circle, Norcross, GA 30071 USA.	Ram@reddyus.com		Singhal, Pravin/0000-0002-6898-358X				Araki S, 2000, DIABETES, V49, P2190, DOI 10.2337/diabetes.49.12.2190; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; CASTELLOT JJ, 1985, AM J PATHOL, V120, P427; Chowdhury TA, 1998, DIABETES, V47, P278, DOI 10.2337/diab.47.2.278; COUSER WG, 1994, AM J KIDNEY DIS, V23, P193, DOI 10.1016/S0272-6386(12)80971-1; Eitner F, 1997, KIDNEY INT, V51, P69, DOI 10.1038/ki.1997.9; Eto M, 1995, CLIN GENET, V48, P288; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Groffen AJA, 1999, NEPHROL DIAL TRANSPL, V14, P2119, DOI 10.1093/ndt/14.9.2119; GROND J, 1990, CONTRIB NEPHROL, V81, P229; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Jensen T, 1997, DIABETES, V46, pS98, DOI 10.2337/diab.46.2.S98; Kako Y, 1999, J LIPID RES, V40, P2185; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAKINO H, 1992, NEPHRON, V61, P415, DOI 10.1159/000186959; Makino H, 2000, KIDNEY INT, V58, pS67, DOI 10.1046/j.1523-1755.2000.07711.x; Mamputu JC, 2000, ARTERIOSCL THROM VAS, V20, P2212, DOI 10.1161/01.ATV.20.10.2212; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Obunike JC, 2000, ARTERIOSCL THROM VAS, V20, P111, DOI 10.1161/01.ATV.20.1.111; Onuma T, 1996, J AM SOC NEPHROL, V7, P1075; Paka L, 1999, J BIOL CHEM, V274, P4816, DOI 10.1074/jbc.274.8.4816; Paka L, 1999, J BIOL CHEM, V274, P36403, DOI 10.1074/jbc.274.51.36403; Pillarisetti S, 2000, TRENDS CARDIOVAS MED, V10, P60, DOI 10.1016/S1050-1738(00)00048-7; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAIJ L, 1984, KIDNEY INT, V26, P137, DOI 10.1038/ki.1984.147; Rossert J, 2000, DIABETES METAB, V26, P16; Saleh H, 2000, KIDNEY INT, V58, P1876, DOI 10.1046/j.1523-1755.2000.00359.x; Schocklmann HO, 1999, KIDNEY INT, V56, P1199, DOI 10.1046/j.1523-1755.1999.00710.x; Sharma K, 2000, CYTOKINE GROWTH F R, V11, P115, DOI 10.1016/S1359-6101(99)00035-0; Sharma P, 1996, KIDNEY INT, V50, P1604, DOI 10.1038/ki.1996.476; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Stevenson FT, 2001, KIDNEY INT, V59, P2062, DOI 10.1046/j.1523-1755.2001.0590062062.x; Stockand JD, 1997, AM J KIDNEY DIS, V29, P971, DOI 10.1016/S0272-6386(97)90476-5; TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060; van der Woude FJ, 1999, HAEMOSTASIS, V29, P61; VANDENBORN J, 1995, DIABETOLOGIA, V38, P1169, DOI 10.1007/BF00422365; WALLIS SC, 1983, EMBO J, V2, P2369, DOI 10.1002/j.1460-2075.1983.tb01748.x; Werle E, 1998, DIABETES CARE, V21, P994, DOI 10.2337/diacare.21.6.994; WOLF G, 1992, AM J PATHOL, V140, P95; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	44	66	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49142	49147		10.1074/jbc.M104879200	http://dx.doi.org/10.1074/jbc.M104879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11579084	hybrid			2022-12-27	WOS:000173922100069
J	Thoma, NH; Niculae, A; Goody, RS; Alexandrov, K				Thoma, NH; Niculae, A; Goody, RS; Alexandrov, K			Double prenylation by RabGGTase can proceed without dissociation of the mono-prenylated intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE TYPE-II; RAB ESCORT PROTEIN; TERNARY COMPLEX; BINDING; TRANSFERASE; MECHANISM; PEPTIDE; ENZYME; TOOLS; REP-1	Rab geranylgeranyltransferase (RabGGTase) catalyzes the prenylation of Rab proteins. Despite possessing a single active site, RabGGTase is able to add geranylgeranyl moieties onto each of the two C-terminal cysteine residues of Rab. We have studied the kinetics of Rab double prenylation employing a combination of a novel high pressure liquid chromatography (HPLC)-based in vitro prenylation assay and fluorescence spectroscopy. Transfer of the first geranylgeranyl group proceeds with a k(1) = 0.16 s(-1), while the conversion from singly to double prenylated Rab is 4-fold slower (k(2) = 0.039 s(-1)). We found that following the first transfer reaction, the conjugated lipid is removed from the active site of RabGGTase but mono-prenylated Rab.REP complex remains bound to RabGGTase with a K-d < 1nM. In contrast to the doubly prenylated Rab7.REP dissociation of the mono-prenylated species from RabGGTase was only weakly stimulated by phosphoisoprenoid. Based on the obtained rate constants we calculated that at least 72% of mono-prenylated Rab molecules proceed to double prenylation without dissociating from RabGGTase. The obtained data provides an explanation of how RabGGTase discriminates between mono-prenylated intermediate and double prenylated reaction product. It also indicates that the phosphoisoprenoid acts both as a substrate and as a sensor governing the kinetics of protein-protein interactions in the double prenylation reaction.	Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany	Max Planck Society	Alexandrov, K (corresponding author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hahn Str 11, D-44227 Dortmund, Germany.	kirill.alexandrov@mpi-dortmund.mpg.de	Alexandrov, Kirill/A-5830-2013; Goody, Roger S/J-8845-2014	Alexandrov, Kirill/0000-0002-0957-6511; Goody, Roger S/0000-0002-0772-0444				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; Alexandrov K, 1999, EUR J BIOCHEM, V265, P160, DOI 10.1046/j.1432-1327.1999.00699.x; Alexandrov K, 1998, FEBS LETT, V425, P460, DOI 10.1016/S0014-5793(98)00290-7; Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; Cane DE, 1999, CHEM BIOL, V6, pR319, DOI 10.1016/S1074-5521(00)80001-0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Desnoyers L, 1998, P NATL ACAD SCI USA, V95, P12266, DOI 10.1073/pnas.95.21.12266; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Iakovenko A, 2000, FEBS LETT, V468, P155, DOI 10.1016/S0014-5793(00)01143-1; Kalinin A, 2001, PROTEIN EXPRES PURIF, V22, P84, DOI 10.1006/prep.2001.1423; Owen DJ, 1999, ANGEW CHEM INT EDIT, V38, P509, DOI 10.1002/(SICI)1521-3773(19990215)38:4<509::AID-ANIE509>3.0.CO;2-3; PETER M, 1992, J CELL SCI, V102, P857; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Shen F, 1996, J BIOL CHEM, V271, P3692; Stenmark H, 2001, GENOME BIOL, V2; Thoma NH, 2000, BIOCHEMISTRY-US, V39, P12043, DOI 10.1021/bi000835m; Thoma NH, 2001, BIOCHEMISTRY-US, V40, P268, DOI 10.1021/bi002034p; Wilson AL, 1998, BIOCHEM J, V333, P497, DOI 10.1042/bj3330497; Witter DJ, 1996, BIOCHEMISTRY-US, V35, P10454, DOI 10.1021/bi960500y; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7	23	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48631	48636		10.1074/jbc.M106470200	http://dx.doi.org/10.1074/jbc.M106470200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591706	hybrid			2022-12-27	WOS:000173922100005
J	Fukuda, M; Hiraoka, N; Akama, TO; Fukuda, MN				Fukuda, M; Hiraoka, N; Akama, TO; Fukuda, MN			Carbohydrate-modifying sulfotransferases: Structure, function and pathophysiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MACULAR CORNEAL-DYSTROPHY; N-DEACETYLASE/N-SULFOTRANSFERASE; MOLECULAR-CLONING; HEPARAN-SULFATE; KERATAN SULFATE; CDNA CLONING; HNK-1 SULFOTRANSFERASE; EXPRESSION CLONING; FIBROBLAST-GROWTH; CELL-SURFACE		Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham.org			NCI NIH HHS [CA33000, CA71932, CA48737, CA33895] Funding Source: Medline; NICHD NIH HHS [HD34108] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034108] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA071932, R01CA033000, R01CA033895, R01CA048737, R37CA033000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Bhakta S, 2000, J BIOL CHEM, V275, P40226, DOI 10.1074/jbc.M006414200; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; El-Fasakhany FM, 2001, J BIOL CHEM, V276, P26988, DOI 10.1074/jbc.M100348200; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GREEN ED, 1986, J BIOL CHEM, V261, P6309; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 2001, GLYCOBIOLOGY, V11, P495, DOI 10.1093/glycob/11.6.495; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Humphries DE, 1998, BIOCHEM J, V332, P303, DOI 10.1042/bj3320303; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; KLINTWORTH GK, 1986, OPHTHALMIC PAED GEN, V7, P139, DOI 10.3109/13816818609004130; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Lee JK, 2000, GLYCOBIOLOGY, V10, P1109; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Seki N, 1997, DNA Res, V4, P345, DOI 10.1093/dnares/4.5.345; Seko A, 2001, J BIOL CHEM, V276, P25697, DOI 10.1074/jbc.M101558200; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SICILIANO RA, 1994, J BIOL CHEM, V269, P910; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Suzuki A, 2001, J BIOL CHEM, V276, P24388, DOI 10.1074/jbc.M103135200; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Vance JM, 1996, AM J HUM GENET, V58, P757; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	62	89	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47747	47750		10.1074/jbc.R100049200	http://dx.doi.org/10.1074/jbc.R100049200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585845	hybrid			2022-12-27	WOS:000172927000001
J	Degraeve, F; Bolla, M; Blaie, S; Creminon, C; Quere, I; Boquet, P; Levy-Toledano, S; Bertoglio, J; Habib, A				Degraeve, F; Bolla, M; Blaie, S; Creminon, C; Quere, I; Boquet, P; Levy-Toledano, S; Bertoglio, J; Habib, A			Modulation of COX-2 expression by statins in human aortic smooth muscle cells - Involvement of geranylgeranylated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; COENZYME-A REDUCTASE; ENDOTHELIAL-CELLS; CYCLOOXYGENASE-2 EXPRESSION; NECROTIZING FACTOR-1; CEREBRAL-ISCHEMIA; ONCOGENIC RAS; RHO GTPASES; K-RAS; INHIBITION	Cyclooxygenase (COX)-2 and COX-1 play an important role in prostacyclin production in vessels and participate in maintaining vascular homeostasis. Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which is crucial in cholesterol biosynthesis. Recently, cholesterol-independent effects of statins have been described. In this study, we evaluated the effect of two inhibitors of HMG CoA reductase, mevastatin and lovastatin, on the production of prostacyclin and the expression of COX in human aortic smooth muscle cells. Treatment of cells with 25 muM mevastatin or lovastatin resulted in the induction of COX-2 and increase in prostacyclin production. Mevalonate, the direct metabolite of HMG CoA reductase, and geranylgeranyl-pyrophosphate reversed this effect. GGTI-286, a selective inhibitor of geranylgeranyltransferases, increased COX-2 expression and prostacyclin formation, thus indicating the involvement of geranylgeranylated proteins in the down-regulation of COX-2. Furthermore, Clostridium difficile toxin B, an inhibitor of the Rho GTP-binding protein family, the Rho selective inhibitor C3 transferase, and Y-27632, a selective inhibitor of the Rho-associated kinases, targets of Rho A, increased COX-2 expression whereas the activator of the Rho GTPase, the cytotoxic necrotizing factor 1, blocked interlukin-1 alpha -dependent COX-2 induction. These results demonstrate that statins up-regulate COX-2 expression and subsequent prostacyclin formation in human aortic smooth muscle cells in part through inhibition of Rho.	CEA, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; St Eloi Hosp, Dept Internal Med B, F-34295 Montpellier, France; INSERM, U452, F-06107 Nice, France; INSERM, U461, F-92296 Chatenay Malabry, France; Hop Lariboisiere, INSERM, U348, Inst Federat Circulat Paris 6 7, F-75010 Paris, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Habib, A (corresponding author), INSERM, U348, 8 Rue Guy Patin, F-75475 Paris 10, France.	aida.habib@inserm.lrb.ap-hop-paris.fr	Habib, Aida/H-8647-2019; Quere, Isabelle/AAB-8519-2020	Habib, Aida/0000-0001-6027-0043; Quere, Isabelle/0000-0002-1492-9764				Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Bellosta S, 1998, ATHEROSCLEROSIS, V137, pS101, DOI 10.1016/S0021-9150(97)00319-5; Bernard C, 1999, CIRC RES, V85, P1124; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bishop-Bailey D, 1999, INT J MOL MED, V3, P41; Bishop-Bailey D, 1998, BIOCHEM BIOPH RES CO, V249, P44, DOI 10.1006/bbrc.1998.8966; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Chen H, 2000, HYPERTENSION, V36, P923, DOI 10.1161/01.HYP.36.6.923; Colli S, 1997, ARTERIOSCL THROM VAS, V17, P265, DOI 10.1161/01.ATV.17.2.265; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; FALKE P, 1989, PHARMACOL TOXICOL, V64, P173, DOI 10.1111/j.1600-0773.1989.tb00624.x; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; FitzGerald GA, 1998, LANCET, V351, P1206, DOI 10.1016/S0140-6736(05)79155-8; Fujita M, 2000, J GASTROEN HEPATOL, V15, P1277, DOI 10.1046/j.1440-1746.2000.02399.x; GERSON RJ, 1989, AM J MED, V87, pS28, DOI 10.1016/S0002-9343(89)80596-0; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Habib A, 1997, J IMMUNOL, V158, P3845; HABIB A, 1993, J BIOL CHEM, V268, P23448; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; JONES DA, 1993, J BIOL CHEM, V268, P9049; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Knapp AC, 2000, ATHEROSCLEROSIS, V152, P217, DOI 10.1016/S0021-9150(99)00462-1; Koh KK, 2000, CARDIOVASC RES, V47, P648, DOI 10.1016/S0008-6363(00)00146-2; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laufs U, 2000, CIRC RES, V87, P526, DOI 10.1161/01.RES.87.7.526; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 2000, TRENDS CARDIOVAS MED, V10, P143, DOI 10.1016/S1050-1738(00)00044-X; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Muniyappa R, 2000, AM J PHYSIOL-HEART C, V278, pH1762, DOI 10.1152/ajpheart.2000.278.6.H1762; NOTARBARTOLO A, 1995, ARTERIOSCL THROM VAS, V15, P247, DOI 10.1161/01.ATV.15.2.247; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; Park HJ, 1999, P NATL ACAD SCI USA, V96, P11525, DOI 10.1073/pnas.96.20.11525; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; Pratico D, 2000, BLOOD, V96, P3823, DOI 10.1182/blood.V96.12.3823.h8003823_3823_3826; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Shibata R, 2001, CIRCULATION, V103, P284; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; ZHANG SZ, 1990, CELL BIOL TOXICOL, V6, P219	73	90	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46849	46855		10.1074/jbc.M104197200	http://dx.doi.org/10.1074/jbc.M104197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591701	hybrid			2022-12-27	WOS:000172768500025
J	Dimitroff, CJ; Lee, JY; Schor, KS; Sandmaier, BM; Sackstein, R				Dimitroff, CJ; Lee, JY; Schor, KS; Sandmaier, BM; Sackstein, R			Differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTANEOUS LYMPHOCYTE ANTIGEN; P-SELECTIN; GLYCOPROTEIN LIGAND-1; PROGENITOR CELLS; EXPRESSION CLONING; PLATELET RECOVERY; CD34(+) CELLS; ADHESION; EXPANSION; STEM	Expression of L-selectin on human hematopoietic cells (HC) is associated with a higher proliferative activity and a more rapid engraftment after hematopoietic stem cell transplantation. Two L-selectin ligands are expressed on human HCs, P-selectin glycoprotein ligand-1 (PSGL-1) and a specialized glycoform of CD44 (hematopoietic cell E- and L-selectin ligand, HCELL). Although the structural biochemistry of HCELL and PSGL-1 is well characterized, the relative capacity of these molecules to mediate L-selectin-dependent adhesion has not been explored. In this study, we examined under shear stress conditions L-selectin-dependent leukocyte adhesive interactions mediated by HCELL and PSGL-1, both as naturally expressed on human HC membranes and as purified molecules. By utilizing both Stamper-Woodruff and parallel-plate flow chamber assays, we found that HCELL displayed a 5-fold greater capacity to support L-selectin-dependent leukocyte adherence across a broad range of shear stresses compared with that of PSGL-1. Moreover, L-selectin-mediated leukocyte binding to immunopurified HCELL was consistently > 5-fold higher than leukocyte binding to equivalent amounts of PSGL-1. Taken together, these data indicate that HCELL is a more avid L-selectin ligand than PSGL-1 and may be the preferential mediator of L-selectin-dependent adhesive interactions among human HCs in the bone marrow.	Harvard Univ, Brigham & Womens Hosp, Dept Dermatol, Skin Dis Res Ctr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Med, Skin Dis Res Ctr, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Clin Res, Seattle, WA 98109 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Sackstein, R (corresponding author), Harvard Univ, Inst Med, Skin Dis Res Ctr, Dept Dermatol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	rsackstein@rics.bwh.harvard.edu		Lee, Jack/0000-0002-4543-4000	NATIONAL CANCER INSTITUTE [R01CA084156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444, R01HL060528] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 84156] Funding Source: Medline; NHLBI NIH HHS [R01 HL 60528, HL 36444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; DERCKSEN MW, 1995, BLOOD, V85, P3313, DOI 10.1182/blood.V85.11.3313.bloodjournal85113313; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; GOELZ S, 1994, J BIOL CHEM, V269, P1033; Greenberg AW, 2000, BLOOD, V95, P478, DOI 10.1182/blood.V95.2.478; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; Koenig JM, 1999, PEDIATR RES, V45, P867, DOI 10.1203/00006450-199906000-00015; KOLLER MR, 1993, BIO-TECHNOL, V11, P358, DOI 10.1038/nbt0393-358; KOLLER MR, 1993, BLOOD, V82, P378; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1987, BLOOD, V70, P1284; LEON WM, 1993, BLOOD, V82, P109; Levesque JP, 1999, IMMUNITY, V11, P369, DOI 10.1016/S1074-7613(00)80112-0; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; OXLEY SM, 1994, BLOOD, V84, P3299; PALSSON BO, 1993, BIO-TECHNOL, V11, P368, DOI 10.1038/nbt0393-368; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ramos CL, 1998, BLOOD, V91, P1067, DOI 10.1182/blood.V91.3.1067.1067_1067_1075; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Sackstein R, 2000, BLOOD, V96, P2765, DOI 10.1182/blood.V96.8.2765.h8002765_2765_2774; Sackstein R, 1997, BLOOD, V89, P2773, DOI 10.1182/blood.V89.8.2773; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Tu L, 1999, J EXP MED, V189, P241, DOI 10.1084/jem.189.2.241; Tu LL, 1999, J IMMUNOL, V163, P5070; Tu LL, 1996, J IMMUNOL, V157, P3995; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; VANZANT G, 1994, BLOOD CELLS, V20, P482; Watanabe T, 1998, EXP HEMATOL, V26, P10; ZANDSTRA PW, 1994, BIO-TECHNOL, V12, P909, DOI 10.1038/nbt0994-909; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	38	41	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47623	47631		10.1074/jbc.M105997200	http://dx.doi.org/10.1074/jbc.M105997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591704	hybrid			2022-12-27	WOS:000172768500123
J	Jakobsen, SN; Hardie, DG; Morrice, N; Tornqvist, HE				Jakobsen, SN; Hardie, DG; Morrice, N; Tornqvist, HE			5 '-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4carboxamide riboside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; ACETYL-COA CARBOXYLASE; SKELETAL-MUSCLE; GLUCOSE-UPTAKE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; RAT MUSCLE; CONTRACTION; TRANSPORT; EXERCISE	Exercise is known to increase insulin sensitivity and is an effective form of treatment for the hyperglycemia observed in type 2 diabetes. Activation of 5'-AMP-activated protein kinase (AMPK) by 5-aminoimidazole-4-carboxamide riboside (AICAR), exercise, or electrically stimulated contraction leads to increased glucose transport in skeletal muscle. Here we report the first evidence of a direct interaction between AMPK and the most upstream component of the insulin-signaling cascade, insulin receptor substrate-1 (IRS-1). We find that AMPK rapidly phosphorylates IRS-1 on Ser-789 in cell-free assays as well as in mouse C2C12 myotubes incubated with AICAR. In the C2C12 myotubes activation of AMPK by AICAR matched the phosphorylation of IRS-1 on Ser-789. This phosphorylation correlates with a 65% increase in insulin-stimulated IRS-1-associated phosphatidylinositol 3-kinase activity in C2C12 myotubes preincubated with AICAR. The binding of phosphatidylinositol 3-kinase to IRS-1 was not affected by AICAR. These results demonstrate the existence of an interaction between AMPK and early insulin signaling that could be of importance to our understanding of the potentiating effects of exercise on insulin signaling.	Novo Nordisk AS, Diabet Biol, DK-2880 Bagsvaerd, Denmark; Univ Dundee, Wellcome Trust Bioctr, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, MRC,Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	Novo Nordisk; University of Dundee; University of Dundee	Jakobsen, SN (corresponding author), Novo Nordisk AS, Diabet Biol, Novo Alle, DK-2880 Bagsvaerd, Denmark.	snyj@novonordisk.com	Hardie, David/Z-1979-2019	jakobsen, soren nyboe/0000-0002-2227-8615; Hardie, Grahame/0000-0002-8373-7379				Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; PLOUG T, 1984, AM J PHYSIOL, V247, pE726, DOI 10.1152/ajpendo.1984.247.6.E726; PLOUG T, 1987, AM J PHYSIOL, V253, pE12, DOI 10.1152/ajpendo.1987.253.1.E12; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; VRANIC M, 1976, J CLIN INVEST, V57, P245, DOI 10.1172/JCI108275; Whitehead JP, 2000, BIOCHEM J, V349, P775, DOI 10.1042/bj3490775; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wojtaszewski JFP, 1996, J APPL PHYSIOL, V81, P1501, DOI 10.1152/jappl.1996.81.4.1501; Wojtaszewski JFP, 1997, DIABETES, V46, P1775, DOI 10.2337/diabetes.46.11.1775; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	39	201	216	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46912	46916		10.1074/jbc.C100483200	http://dx.doi.org/10.1074/jbc.C100483200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598104	hybrid			2022-12-27	WOS:000172768500033
J	Schumann, D; Chen, CJ; Kaplan, B; Shively, JE				Schumann, D; Chen, CJ; Kaplan, B; Shively, JE			Carcinoembryonic antigen cell adhesion molecule 1 directly associates with cytoskeleton proteins actin and tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY GLYCOPROTEIN CD66A; PHOSPHOTYROSINE-CONTAINING PROTEIN; C-CAM CELL-CAM-105; GENE FAMILY MEMBER; EPITHELIAL-CELLS; CYTOPLASMIC DOMAIN; ECTO-ATPASE; IMMUNOGLOBULIN SUPERFAMILY; TYROSINE PHOSPHORYLATION; COLORECTAL CARCINOMAS	CEA cell adhesion molecule 1 (CEACAM1), a type I transmembrane and homotypic cell adhesion protein belonging to the carcinoembryonic antigen (CEA) gene family and expressed on epithelial cells, is alternatively spliced to produce four major isoforms with three or four Ig-like ectodomains and either long (CEACAM1-L) or short (CEACAM1-S) cytoplasmic domains. When murine MC38 (methylcholanthrene-induced adenocarcinoma 38) cells were transfected with human CEACAM1-L and stimulated with sodium pervanadate, actin was found to co-localize with CEACAM1-L at cell-cell boundaries but not in untreated cells. When CEACAM1-L was immunoprecipitated from pervanadate-treated MC38/CEACAM1-L cells and the associated proteins were analyzed by two-dimensional get analysis and mass spectrometry, actin and tropomyosin, among other proteins, were identified. Whereas a glutathione S-transferase (GST) fusion protein containing the L-isoform. (GST-Cyto-L) bound poorly to F-actin in a cosedimentation assay, the S-isoform fusion protein (GST-Cyto-S) co-sedimented with F-actin, especially when incubated with G-actin during polymerization (K-D = 7.0 muM). Both GST-Cyto-S and GST-Cyto-L fusion proteins bind G-actin and tropomyosin by surface plasmon resonance studies with binding constants of 0.7 x 10(-8) and 1.0 x 10(-7) M for GST-Cyto-L to G-actin and tropomyosin, respectively, and 3.1 x 10(-8) and 1.3 x 10(-7) M for GST-Cyto-S to G-actin and tropomyosin, respectively. Calmodulin or EDTA inhibited binding of the GST-Cyto-L fusion protein to G-actin, whereas calmodulin and G-actin, but not EDTA, stimulated binding to tropomyosin. A biotinylated 14-amino acid peptide derived from the juxtamembrane portion of the cytoplasmic domain of CEACAM1-L associated with both G-actin and tropomyosin with KD values of 1.3 x 10(-5) and 1.8 x 10(-5) M, respectively. These studies demonstrate the direct interaction of CEACAM1 isoforms with G-actin and tropomyosin and the direct interaction of CEACAM1-S with F-actin.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA.				NATIONAL CANCER INSTITUTE [R01CA084202] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BLIKSTAD I, 1992, FEBS LETT, V302, P26, DOI 10.1016/0014-5793(92)80276-M; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; BRUMMER J, 1995, ONCOGENE, V11, P1649; Chen CJ, 1996, J BIOL CHEM, V271, P28181, DOI 10.1074/jbc.271.45.28181; Da Silva-Azevedo L, 1999, BIOCHEM BIOPH RES CO, V256, P404, DOI 10.1006/bbrc.1999.0351; Davis MT, 1998, J AM SOC MASS SPECTR, V9, P194, DOI 10.1016/S1044-0305(97)00282-1; DVESKSLER GS, 1993, J VIROL, V67, P1; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; Griffiths Gillian M., 1997, P1251; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; Hnath EJ, 1996, BIOPHYS J, V71, P1920, DOI 10.1016/S0006-3495(96)79391-8; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIS JF, 1982, P NATL ACAD SCI-BIOL, V79, P6507, DOI 10.1073/pnas.79.21.6507; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SKUBITZ KM, 1992, J IMMUNOL, V148, P852; SKUBITZ KM, 1993, FEBS LETT, V318, P200, DOI 10.1016/0014-5793(93)80021-L; Steinmetz MO, 1997, J STRUCT BIOL, V119, P295, DOI 10.1006/jsbi.1997.3873; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Temm-Grove CJ, 1998, CELL MOTIL CYTOSKEL, V40, P393, DOI 10.1002/(SICI)1097-0169(1998)40:4<393::AID-CM7>3.0.CO;2-C; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Turbide C, 1997, CANCER RES, V57, P2781; TURBIDE C, 1991, J BIOL CHEM, V266, P309; TYNAN K, 1992, NUCLEIC ACIDS RES, V20, P1629, DOI 10.1093/nar/20.7.1629; WAGENER C, 1983, J IMMUNOL, V130, P2302; Wang FL, 1996, CANCER RES, V56, P3634; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	61	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47421	47433		10.1074/jbc.M109110200	http://dx.doi.org/10.1074/jbc.M109110200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595750	hybrid			2022-12-27	WOS:000172768500098
J	Qureshi, MH; Yeung, JC; Wu, SC; Wong, SL				Qureshi, MH; Yeung, JC; Wu, SC; Wong, SL			Development and characterization of a series of soluble tetrameric and monomeric streptavidin muteins with differential biotin binding affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR INTERACTIONS; SUBUNIT ASSOCIATION; BACILLUS-SUBTILIS; AVIDIN; COMPLEX; TRYPTOPHAN; SYSTEM; EQUILIBRIUM; CONTACTS; PROTEINS	The strong biotin-streptavidin interaction limits the application of streptavidin as a reversible affinity matrix for purification of biotinylated biomolecules. To address this concern, a series of single, double, and triple streptavidin muteins with different affinities to biotin were designed. The strategy involves mutating one to three strategically positioned residues (Ser-45, Thr-90, and Asp-128) that interact with biotin and other framework structure-maintaining residues of streptavidin. The muteins were produced in soluble forms via secretion from Bacillus subtilis. The impact of individual residues on the overall structure of streptavidin is reflected by the formation of monomeric streptavidin to different extents. Of the three targeted residues, Asp-128 has the most dramatic effect (Asp-128 > Thr-90 > Ser-45). Conversion of all three targeted residues to alanine results in a soluble biotin binding mutein that exists 100% in the monomeric state. Both wild-type and mutated (monomeric and tetrameric) streptavidin proteins were purified, and their kinetic parameters (on- and off-rates) were determined using a BIAcore biosensor with biotin-conjugated bovine serum albumin immobilized to the sensor chip. This series of muteins shows a wide spectrum of affinity toward biotin (K-d from 10(-6) to 10(-11) M). Some of them have the potential to serve as reversible biotin binding agents.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada	University of Calgary	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.			Yeung, Jonathan/0000-0001-5759-3028				Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; Chu V, 1998, PROTEIN SCI, V7, P848; Ewalt KL, 2001, ANAL BIOCHEM, V289, P162, DOI 10.1006/abio.2000.4927; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; Freitag S, 1999, BIOMOL ENG, V16, P13, DOI 10.1016/S1050-3862(99)00048-0; Freitag S, 1999, P NATL ACAD SCI USA, V96, P8384, DOI 10.1073/pnas.96.15.8384; Freitag S, 1997, PROTEIN SCI, V6, P1157, DOI 10.1002/pro.5560060604; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENRIKSON KP, 1979, ANAL BIOCHEM, V94, P366, DOI 10.1016/0003-2697(79)90374-9; HOFMANN K, 1980, P NATL ACAD SCI-BIOL, V77, P4666, DOI 10.1073/pnas.77.8.4666; Hyre DE, 2000, PROTEIN SCI, V9, P878, DOI 10.1110/ps.9.5.878; Klumb LA, 1998, BIOCHEMISTRY-US, V37, P7657, DOI 10.1021/bi9803123; KOHANSKI RA, 1990, METHOD ENZYMOL, V184, P194; Kurihara A, 1999, BIOCONJUGATE CHEM, V10, P502, DOI 10.1021/bc980123x; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; Maraveyas A, 1998, INT J CANCER, V78, P610, DOI 10.1002/(SICI)1097-0215(19981123)78:5<610::AID-IJC14>3.3.CO;2-K; MUZYKANTOV VR, 1994, J NUCL MED, V35, P1358; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; Rosebrough SF, 1996, J PHARMACOL EXP THER, V276, P770; Sano T, 1997, P NATL ACAD SCI USA, V94, P6153, DOI 10.1073/pnas.94.12.6153; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Schechter B, 1999, J DRUG TARGET, V6, P337, DOI 10.3109/10611869908996841; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; Wong J, 1999, BIOMOL ENG, V16, P45, DOI 10.1016/S1050-3862(99)00035-2; Wu SC, 1998, J BACTERIOL, V180, P2830, DOI 10.1128/JB.180.11.2830-2835.1998; WU SC, 2000, 11 INT C ANT ENG SAN; WU XC, 1990, J BIOL CHEM, V265, P6845; YAO ZS, 1995, J NUCL MED, V36, P837; Zhang ML, 1998, NUCL MED BIOL, V25, P101, DOI 10.1016/S0969-8051(97)00157-1	40	76	86	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46422	46428		10.1074/jbc.M107398200	http://dx.doi.org/10.1074/jbc.M107398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584006	hybrid			2022-12-27	WOS:000172573100126
J	Sokolova, A; Malfois, M; Caldentey, J; Svergun, DI; Koch, MHJ; Bamford, DH; Tuma, R				Sokolova, A; Malfois, M; Caldentey, J; Svergun, DI; Koch, MHJ; Bamford, DH; Tuma, R			Solution structure of bacteriophage PRD1 vertex complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING PROTEIN; ADENOVIRUS FIBER; BIOLOGICAL MACROMOLECULES; SOLUTION SCATTERING; HYDRODYNAMIC PROPERTIES; COAT PROTEIN; LINEAR DNA; RAY; MEMBRANE; PROGRAM	Bacteriophage PRD1 is a prototype of viruses with an internal membrane. The icosahedral capsid and major coat protein share structural similarity with the corresponding structures of adenovirus. The present study further explores similarities between these viruses, considering the 5-fold vertex assemblies. The vertex structure of bacteriophage PRD1 consists of proteins P2, P5, and P31. The vertex complex mediates host cell binding and controls double-stranded DNA delivery. Quaternary structures and interactions of purified spike proteins were studied by synchrotron radiation x-ray solution scattering. Low resolution models of the vertex proteins P5, P2, and P31 were reconstructed ab initio from the scattering data. Protein P5 is a long trimer that resembles the adenovirus spike protein pIV. The receptor-binding protein P2 is a 15.5-nm long, thin monomer and does not have an adenovirus counterpart. P31 forms a pentameric base with a maximum diameter of 8.5 nm, which is thinner than the adenovirus penton pIII P5 further polymerize into a nonameric form ((p5(3))(3)). In the presence of P31, P5 associates into a P5(6):P31 complex. The constructed models of these assemblies provided support for a model of vertex assembly onto the virion. Although similar in overall architecture, clear differences between PRD1 and adenovirus spike assemblies have been revealed.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, Viikki Bioctr, FIN-00014 Helsinki, Finland; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany	University of Helsinki; University of Helsinki; Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Tuma, R (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56 Viikinkaari 5, FIN-00014 Helsinki, Finland.	roman.tuma@helsinki.fi	Tuma, Roman/AAL-4436-2020; Malfois, Marc/L-2974-2014	Tuma, Roman/0000-0003-0047-0013; Malfois, Marc/0000-0001-5231-1896; Svergun, Dmitri/0000-0003-0830-5696; Sokolova, Anna/0000-0002-2772-7395				BAMFORD D, 1983, J VIROL, V47, P311, DOI 10.1128/JVI.47.2.311-316.1983; BAMFORD DH, 1990, NATURE, V344, P497, DOI 10.1038/344497b0; BAMFORD DH, 1995, ADV VIRUS RES, V45, P281, DOI 10.1016/S0065-3527(08)60064-0; BAMFORD DH, 1984, J VIROL, V50, P309, DOI 10.1128/JVI.50.2.309-315.1984; Bamford JKH, 2000, J VIROL, V74, P7781, DOI 10.1128/JVI.74.17.7781-7786.2000; BAMFORD JKH, 1991, VIROLOGY, V183, P658, DOI 10.1016/0042-6822(91)90995-N; BAMFORD JKH, 1990, VIROLOGY, V177, P445, DOI 10.1016/0042-6822(90)90508-O; Belnap DM, 2000, TRENDS MICROBIOL, V8, P91, DOI 10.1016/S0966-842X(00)01704-2; Benson SD, 1999, CELL, V98, P825, DOI 10.1016/S0092-8674(00)81516-0; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Butcher SJ, 1995, EMBO J, V14, P6078, DOI 10.1002/j.1460-2075.1995.tb00298.x; Caldentey J, 2000, BIOCHEMISTRY-US, V39, P10566, DOI 10.1021/bi000711+; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P68; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Grahn AM, 1999, J BACTERIOL, V181, P6689, DOI 10.1128/JB.181.21.6689-6696.1999; Hendrix RW, 1999, CURR BIOL, V9, pR914, DOI 10.1016/S0960-9822(00)80103-7; HONG JS, 1991, VIROLOGY, V185, P758; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LYRA C, 1991, MOL GEN GENET, V228, P65, DOI 10.1007/BF00282449; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; OLSEN RH, 1974, J VIROL, V14, P689, DOI 10.1128/JVI.14.3.689-699.1974; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; Rydman PS, 1999, J MOL BIOL, V291, P575, DOI 10.1006/jmbi.1999.2978; San Martin C, 2001, STRUCTURE, V9, P917, DOI 10.1016/S0969-2126(01)00642-6; SAVILAHTI H, 1986, GENE, V49, P199, DOI 10.1016/0378-1119(86)90280-5; Schoehn G, 1996, EMBO J, V15, P6841, DOI 10.1002/j.1460-2075.1996.tb01075.x; Smith MCM, 1998, SCIENCE, V279, P1834; STEWART PL, 1993, J MOL BIOL, V230, P349, DOI 10.1006/jmbi.1993.1148; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; Xu L, 2000, J STRUCT BIOL, V131, P159, DOI 10.1006/jsbi.2000.4275	46	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46187	46195		10.1074/jbc.M106848200	http://dx.doi.org/10.1074/jbc.M106848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577098	hybrid			2022-12-27	WOS:000172573100095
J	Thibeault, D; Maurice, R; Pilote, L; Lamarre, D; Pause, A				Thibeault, D; Maurice, R; Pilote, L; Lamarre, D; Pause, A			In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE ACTIVITIES; NS2-3 PROTEASE; NON-A; NS3; NS4A; POLYPROTEIN; INHIBITION; PRODUCTS; REGION	The cleavage of the hepatitis C virus polyprotein between the nonstructural proteins NS2 and NS3 is mediated by the NS2/3 protease, whereas the NS3 protease is responsible for the cleavage of the downstream proteins. Purification and in vitro characterization of the NS2/3 protease has been hampered by its hydrophobic nature. NS2/3 protease activity could only be detected in cells or in in vitro translation assays with the addition of microsomal membranes or detergent. To facilitate purification of this poorly characterized protease, we truncated the N-terminal hydrophobic domain, resulting in an active enzyme with improved biophysical properties. We define a minimal catalytic region of NS2/3 protease retaining autocleavage activity that spans residues 904-1206 and includes the C-terminal half of NS2 and the N-terminal NS3 protease domain. The NS2/3 (904-1206) variant was purified from Escherichia coli inclusion bodies and refolded by gel filtration chromatography. The purified inactive form of NS2/3 (904-1206) was activated by the addition of glycerol and detergent to induce autocleavage at the predicted site between Leu(1026) and Ala(1027). NS2/3 (904-1206) activity was dependent on zinc ions and could be inhibited by NS4A peptides, peptides that span the cleavage site, or an N-terminal peptidic cleavage product. This NS2/3 variant will facilitate the development of an assay suitable for identifying inhibitors of HCV replication.	Boehringer Ingelheim Canada Ltd, Dept Sci Biol, Res & Dev, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim	Thibeault, D (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Sci Biol, Res & Dev, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	dthibeault@lav.boehringer-ingelheim.com						BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; BODANSKY M, 1993, PEPTIDE CHEM; Buchanan SK, 1999, CURR OPIN STRUC BIOL, V9, P455, DOI 10.1016/S0959-440X(99)80064-5; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Darke PL, 1999, J BIOL CHEM, V274, P34511, DOI 10.1074/jbc.274.49.34511; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Dymock BW, 2000, ANTIVIR CHEM CHEMOTH, V11, P79, DOI 10.1177/095632020001100201; Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIROWATARI Y, 1993, ARCH VIROL, V133, P349, DOI 10.1007/BF01313774; Hong Z, 2000, ACTA GASTRO-ENT BELG, V63, P210; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; KOMODA Y, 1994, GENE, V145, P221; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lin TY, 1996, PROTEIN SCI, V5, P372; Liu QY, 1999, BIOCHEM BIOPH RES CO, V254, P572, DOI 10.1006/bbrc.1998.9986; Liu X, 1998, J VIROL, V72, P4463, DOI 10.1128/JVI.72.5.4463-4466.1998; Liu X, 2000, J VIROL, V74, P5949, DOI 10.1128/JVI.74.13.5949-5956.2000; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; REED KE, 1995, J VIROL, V69, P4127, DOI 10.1128/JVI.69.7.4127-4136.1995; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SANTOLINI E, 1995, J VIROL, V69, P7461, DOI 10.1128/JVI.69.12.7461-7471.1995; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Steinkuhler C, 1996, J VIROL, V70, P6694; Tijms MA, 2001, P NATL ACAD SCI USA, V98, P1889, DOI 10.1073/pnas.041390398; Walker MA, 1999, DRUG DISCOV TODAY, V4, P518, DOI 10.1016/S1359-6446(99)01414-2; Yan YW, 1998, PROTEIN SCI, V7, P837; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	36	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46678	46684		10.1074/jbc.M108266200	http://dx.doi.org/10.1074/jbc.M108266200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591719	hybrid			2022-12-27	WOS:000172573100156
J	Tuo, J; Muftuoglu, M; Chen, C; Jaruga, P; Selzer, RR; Brosh, RM; Rodriguez, H; Dizdaroglu, M; Bohr, VA				Tuo, J; Muftuoglu, M; Chen, C; Jaruga, P; Selzer, RR; Brosh, RM; Rodriguez, H; Dizdaroglu, M; Bohr, VA			The Cockayne Syndrome group B gene product is involved in general genome base excision repair of 8-hydroxyguanine in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; SITE-DIRECTED MUTAGENESIS; AQUEOUS-SOLUTION; SYNDROME CELLS; ACTIVE GENES; XERODERMA-PIGMENTOSUM; PREFERENTIAL REPAIR; PUTATIVE HELICASES; DEFECTIVE REPAIR	Cockayne Syndrome (CS) is a human genetic disorder with two complementation groups, CS-A and CS-B. The CSB gene product is involved in transcription-coupled repair of DNA damage but may participate in other pathways of DNA metabolism. The present study investigated the role of different conserved helicase motifs of CSB in base excision repair. Stably transformed human cell lines with site-directed CSB mutations in different motifs within its putative helicase domain were established. We find that CSB null and helicase motif V and VI mutants had greater sensitivity than wild type cells to gamma -radiation. Whole cell extracts from CSB null and motif V/VI mutants had lower activity of 8-hydroxyguanie incision in DNA than wild type cells. Also, 8-hydroxyguanine accumulated more in CSB null and motif VI mutant cells than in wild type cells after exposure to gamma -radiation. We conclude that a deficiency in general genome base excision repair of selective modified DNA base(s) might contribute to CS pathogenesis. Furthermore, whereas the disruption of helicase motifs V or VI results in a CSB phenotype, mutations in other helicase motifs do not cause this effect. The biological functions of CSB in different DNA repair pathways may be mediated by distinct functional motifs of the protein.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIST, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Jaruga, Pawel/M-4378-2015; Muftuoglu, Meltem/AAG-5004-2019; Bohr, Vilhelm/AAP-5931-2020	Muftuoglu, Meltem/0000-0001-5372-4780; Jaruga, Pawel/0000-0001-9192-6084	NATIONAL INSTITUTE ON AGING [Z01AG000737, ZIAAG000727, Z01AG000727, Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; Balajee AS, 2000, ONCOGENE, V19, P477, DOI 10.1038/sj.onc.1203372; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Citterio E, 2000, CELL, V101, P447, DOI 10.1016/S0092-8674(00)80854-5; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; COOPER PK, 1994, ANN NY ACAD SCI, V726, P330, DOI 10.1111/j.1749-6632.1994.tb52842.x; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; DIZDAROGLU M, 1985, BIOCHEMISTRY-US, V24, P4476, DOI 10.1021/bi00337a032; Douki T, 1997, CARCINOGENESIS, V18, P2385, DOI 10.1093/carcin/18.12.2385; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; Mallery DL, 1998, AM J HUM GENET, V62, P77, DOI 10.1086/301686; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; May A, 2000, BIOCHEM BIOPH RES CO, V269, P433, DOI 10.1006/bbrc.2000.2264; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Ohshima H, 1996, J RADIAT RES, V37, P199, DOI 10.1269/jrr.37.199; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Piekoszewski W, 2000, POL J PHARMACOL, V52, P389; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; Sunesen M, 2000, NUCLEIC ACIDS RES, V28, P3151, DOI 10.1093/nar/28.16.3151; Tabocchini MA, 2000, MUTAT RES-DNA REPAIR, V461, P71, DOI 10.1016/S0921-8777(00)00041-0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	55	126	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45772	45779		10.1074/jbc.M107888200	http://dx.doi.org/10.1074/jbc.M107888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581270	hybrid			2022-12-27	WOS:000172573100038
J	Vila, R; Ponte, I; Collado, M; Arrondo, JLR; Jimenez, MA; Rico, M; Suau, P				Vila, R; Ponte, I; Collado, M; Arrondo, JLR; Jimenez, MA; Rico, M; Suau, P			DNA-induced alpha-helical structure in the NH2-terminal domain of histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSCRIPTION IN-VIVO; C-TERMINAL DOMAIN; SECONDARY STRUCTURE; INFRARED-SPECTROSCOPY; GENE-EXPRESSION; LINKER HISTONES; GLOBULAR DOMAIN; PROTEINS; CHROMATIN	It is important to establish the structural properties of linker histones to understand the role they play in chromatin higher order structure and gene regulation. Here, we use CD, NAM, and IR spectroscopy to study the conformation of the amino-terminal domain of histone H1 degrees, free in solution and bound to the DNA. The NH2-terminal domain has little structure in aqueous solution, but it acquires a substantial amount of a-helical structure in the presence of trifluoroethanol (TFE). As in other H1 subtypes, the basic residues of the NH2-terminal domain of histone H1 degrees are clustered in its COOH-terminal half. According to the NMR results, the helical region comprises the basic cluster (Lys(11)-Lys(20)) and extends until Asp(23). The fractional helicity of this region in 90% TFE is about 50%. His(24) together with Pro(25) constitute the joint between the NH2-terminal helix and helix I of the globular domain. Infrared spectroscopy shows that interaction with the DNA induces an amount of a-helical structure equivalent to that observed in TFE. As coulombic interactions are involved in complex formation, it is highly likely in the complexes with DNA that the minimal region with a-helical structure is that containing the basic cluster. In chromatin, the high positive charge density of the inducible NH2-terminal helical element may contribute to the binding stability of the globular domain.	Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; CSIC, Inst Estructura Mat, E-28006 Madrid, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); University of Basque Country	Suau, P (corresponding author), Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain.	pere.suau@uab.es	Suau, Pedro/D-2695-2009; Ponte, Inma/AGN-5337-2022; Jimenez, M. Angeles/C-7193-2008; Vila, Roger/A-1817-2012; Ponte, Inma/E-6848-2015	Suau, Pedro/0000-0001-6673-8209; Jimenez, M. Angeles/0000-0001-6835-5850; Vila, Roger/0000-0002-2447-4388; Ponte, Inma/0000-0002-9448-6915				ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOHM L, 1985, FEBS LETT, V193, P1, DOI 10.1016/0014-5793(85)80067-3; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; Howe L, 1998, BIOCHEMISTRY-US, V37, P7077, DOI 10.1021/bi980410o; JIMENEZ MA, 1993, EUR J BIOCHEM, V211, P569, DOI 10.1111/j.1432-1033.1993.tb17584.x; JOHNSON NP, 1994, P NATL ACAD SCI USA, V91, P4840, DOI 10.1073/pnas.91.11.4840; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MIRZABEKOV AD, 1990, J MOL BIOL, V211, P479, DOI 10.1016/0022-2836(90)90366-T; Padmanabhan S, 1997, BIOCHEMISTRY-US, V36, P5193, DOI 10.1021/bi962927a; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REISDORF WC, 1996, BIOCHEMISTRY-US, V35, P1386; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SUZUKI M, 1993, PROTEIN ENG, V6, P565, DOI 10.1093/protein/6.6.565; TORII H, 1992, J CHEM PHYS, V96, P3379, DOI 10.1063/1.461939; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Vila R, 2000, PROTEIN SCI, V9, P627; Vila R, 2001, J BIOL CHEM, V276, P30898, DOI 10.1074/jbc.M104189200; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; ZLATANOVA J, 1992, J CELL SCI, V103, P889	38	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46429	46435		10.1074/jbc.M106952200	http://dx.doi.org/10.1074/jbc.M106952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584004	hybrid			2022-12-27	WOS:000172573100127
J	Inoue, T; Geyer, RK; Howard, D; Yu, ZK; Maki, CG				Inoue, T; Geyer, RK; Howard, D; Yu, ZK; Maki, CG			MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; RING-FINGER DOMAIN; DNA-DAMAGE; PROTEIN; PHOSPHORYLATION; PATHWAY; ASSOCIATION; INHIBITION; TERMINUS	MDM2 can bind the N terminus of p53 and promote its ubiquitination and export from the nucleus to the cytoplasm, where p53 can then be degraded by cytoplasmic proteasomes. Several studies have reported that an intact MDM2 binding domain is necessary for p53 to be targeted for ubiquitination, nuclear export, and degradation by MDM2. In the current study, we examined whether the MDM2 binding domain of p53 could be provided in trans through oligomerization between two p53 molecules. p53 proteins mutated in their MDM2 binding domains were unable to bind MDM2 directly and were resistant to MDM2-mediated ubiquitination, nuclear export, and degradation when expressed with MDM2 alone. However, these same p53 mutants formed a complex with MDM2 and were efficiently ubiquitinated, exported from the nucleus, and degraded when co-expressed with MDM2 and wild-type p53. Moreover, this effect required MDM2 binding by wild-type p53 as well as oligomerization between wild-type p53 and the MDM2 binding-deficient p53 mutants. Taken together, these results support a model whereby MDM2 binding-deficient forms of p53 can bind MDM2 indirectly through oligomerization with wild-type p53 and are subsequently targeted for ubiquitination, nuclear export, and degradation. These findings may have important implications regarding the DNA damage response of p53.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Maki, CG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,4th Floor, Boston, MA 02115 USA.				NCI NIH HHS [1R01 CA80918-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Prives C, 1999, J PATHOL, V187, P112; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	28	47	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45255	45260		10.1074/jbc.M107477200	http://dx.doi.org/10.1074/jbc.M107477200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572869	hybrid			2022-12-27	WOS:000172406700119
J	Lim, SR; Hertel, KJ				Lim, SR; Hertel, KJ			Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3 ' splice site pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; ANTISENSE OLIGONUCLEOTIDES; SINGLE NUCLEOTIDE; DETERMINING GENE; FACTOR U2AF(35); SMN; ENHANCER; PROTEIN; IDENTIFICATION; BINDING	Spinal muscular atrophy is caused by the loss of functional survival motor neuron (SMN1) alleles. A translationally silent nucleotide transition in the duplicated copy of the gene (SMN2) leads to exon 7 skipping and expression of a nonfunctional gene product. It has been suggested that differential SMN2 splicing is caused by the disruption of an exonic splicing enhancer. Here we show that the single nucleotide difference reduces the intrinsic strength of the 3' splice site of exon 7 2-fold, whereas the strength of the 5' splice site of the exon 7 is not affected. Thus, a decrease in splice site strength is magnified in the context of competing exons. These data suggest that lower levels of exon 7 definition not only reduce intron 6 removal but, more importantly, increase the efficiency of the competing exon 7 skipping pathway. Antisense oligonucleotides were tested to modulate exon 7 inclusion, which contains the authentic translation stop codon. Oligonucleotides directed toward the 3' splice site of exon 8 were shown to alter SMN2 splicing in favor of exon 7 inclusion. These results suggest that antisense oligonucleotides could be used as a therapeutic strategy to counteract the progression of SMA.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine	Hertel, KJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.			Hertel, Klemens/0000-0002-7560-9529	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062287] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062287] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; Friedman KJ, 1999, J BIOL CHEM, V274, P36193, DOI 10.1074/jbc.274.51.36193; FU XD, 1995, RNA, V1, P663; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Rio Donald C., 1992, Gene Expression, V2, P1; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; WANG Z, 1995, RNA, V1, P21; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	35	131	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45476	45483		10.1074/jbc.M107632200	http://dx.doi.org/10.1074/jbc.M107632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584013	hybrid, Green Published			2022-12-27	WOS:000172406700146
J	Rashevsky-Finkel, A; Silkov, A; Dikstein, R				Rashevsky-Finkel, A; Silkov, A; Dikstein, R			A composite nuclear export signal in the TBP-associated factor TAF(II)105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION IN-VIVO; NF-KAPPA-B; CELL-CYCLE PROGRESSION; HISTONE-LIKE TAFS; ACTIVATION; COMPLEX; YEAST; PROMOTER; BINDING; SAGA	TAF(II)105 is a sub-stoichiometric subunit of TFIID important for activation of anti-apoptotic genes and B cell specific genes by the transcription factors NF-kappaB and OCA-B. This subunit is highly enriched in B and T lymphocytes, and its expression is regulated at a posttranscriptional level. In the present study we investigated the subcellular localization of TAF(II)105. In normal B cells, a significant portion of native TAF(II)105 protein is found in the cytoplasm. Treatment of these cells with B cell-specific stimuli decreased the level of cytoplasmic TAF(II)105. In adherent cultured cells, TAFII105 is predominantly nuclear; however, a small fraction of the cells showed either cytoplasmic or homogenous distribution of TAF(II)105. Analysis of different TAF(II)105 mutants and green fluorescence protein fusion proteins identified a region composed of two adjacent sequences displaying nuclear export activity, suggesting that nuclear export of TAF(II)105 is mediated by a composite nuclear export signal. TAF(II)105 nuclear export signal is leptomycin B-resistant indicating that it belongs to a CRM1-independent nuclear export pathway. These results reveal a novel mode of regulation of a specialized component of the general transcription apparatus that may affect the transcription of its target genes.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Allen TD, 2000, J CELL SCI, V113, P1651; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; FUKUDA M, 1997, NATURE, V390, P303; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193; Hay RT, 1999, PHILOS T R SOC B, V354, P1601, DOI 10.1098/rstb.1999.0504; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; Matza D, 2001, J BIOL CHEM, V276, P27203, DOI 10.1074/jbc.M104684200; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wolstein O, 2000, J BIOL CHEM, V275, P16459, DOI 10.1074/jbc.275.22.16459; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180	39	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44963	44969		10.1074/jbc.M106112200	http://dx.doi.org/10.1074/jbc.M106112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567023	hybrid			2022-12-27	WOS:000172406700084
J	Teckman, JH; Burrows, J; Hidvegi, T; Schmidt, B; Hale, PD; Perlmutter, DH				Teckman, JH; Burrows, J; Hidvegi, T; Schmidt, B; Hale, PD; Perlmutter, DH			The proteasome participates in degradation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; INTRACELLULAR DEGRADATION; MEMBRANE-PROTEIN; LIVER-DISEASE; DEFICIENCY; ER; SECRETION; DISTINCT; REQUIRES; PATHWAY	Because retention of mutant alpha (1)-antitrypsin (alpha (1)-AT) Z in the endoplasmic reticulum (ER) is associated with liver disease in alpha (1)-AT-deficient individuals, the mechanism by which this aggregated glycoprotein is degraded has received considerable attention. In previous studies using stable transfected human fibroblast cell lines and a cell-free microsomal translocation system, we found evidence for involvement of the proteasome in degradation of alpha (1)-ATZ (Qu, D., Teckman, J. H., Omura, S., and Perlmutter, D. H. (1996) J. Biol. Chem. 271,22791-22795). In more recent studies, Cabral et al. (Cabral, C. M., Choudhury, P., Liu, Y., and Sifers, R. N. (2000) J. Biol. Chem. 275, 25015-25022) found that degradation of alpha (1)-ATZ in a stable transfected marine hepatoma cell line was inhibited by tyrosine phosphatase inhibitors, but not by the proteasomal inhibitor lactacystin and concluded that the proteasome was only involved in ER degradation of alpha (1)-ATZ in nonhepatocytic cell types or in cell types with levels of alpha (1)-AT expression that are substantial lower than that which occurs in hepatocytes. To examine this important issue in further detail, in this study we established rat and murine hepatoma cell lines with constitutive and inducible expression of alpha (1)-ATZ. In each of these cell lines degradation of alpha (1)-ATZ was inhibited by lactacystin, MG132, epoxomicin, and clasto-lactacystin beta -lactone. Using the inducible expression system to regulate the relative level of alpha (1)-ATZ expression, we found that lactacystin had a similar inhibitory effect on degradation of alpha (1)-ATZ at high and low levels of al-AT expression. Although there is substantial evidence that other mechanisms contribute to ER degradation of alpha (1)-ATZ, the data reported here indicate that the proteasome plays an important role in many cell types including hepatocytes.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Physiol, Pittsburgh, PA 15213 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL)	Perlmutter, DH (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Hidvegi, Tunda/A-8041-2008	Schmidt, Bela Z/0000-0003-1085-9372; Teckman, Jeffrey/0000-0002-4870-2621				Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; COX DW, 1995, METABOLIC MOL BASES, P4125; Dul JL, 2001, J CELL BIOL, V152, P705, DOI 10.1083/jcb.152.4.705; DYCAICO JM, 1988, SCIENCE, V242, P1404; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; GELLER SA, 1994, HEPATOLOGY, V19, P389; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Novoradovskaya N, 1998, J CLIN INVEST, V101, P2693, DOI 10.1172/JCI549; PERLMUTTER DH, 1999, SCHIFFS DIS LIVER, P1131; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rollini P, 1999, P NATL ACAD SCI USA, V96, P10308, DOI 10.1073/pnas.96.18.10308; SVEGER T, 1995, HEPATOLOGY, V22, P514, DOI 10.1002/hep.1840220221; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V278, pG39, DOI 10.1152/ajpgi.2000.278.1.G39; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014	23	104	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44865	44872		10.1074/jbc.M103703200	http://dx.doi.org/10.1074/jbc.M103703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577074	hybrid			2022-12-27	WOS:000172406700072
J	Yammani, RR; Seetharam, S; Seetharam, B				Yammani, RR; Seetharam, S; Seetharam, B			Identification and characterization of two distinct ligand binding regions of cubilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC FACTOR-COBALAMIN; FACTOR VITAMIN-B-12 RECEPTOR; BRUSH-BORDER EXPRESSION; HEREDITARY MEGALOBLASTIC-ANEMIA-1; RAT; MEMBRANE; PROTEINS; ENDOCYTOSIS; KIDNEY; CELLS	Using polymerase chain reaction-amplified fragments of cubilin, an endocytic receptor of molecular mass 460 kDa, we have identified two distinct ligand binding regions. Region 1 of molecular mass 71 kDa, which included the 113-residue N terminus along with the eight epidermal growth factor (EGF)-like repeats and CUB domains 1 and 2, and region 2 of molecular mass 37 kDa consisting of CUB domains 6-8 bound both intrinsic factor-cobalamin (vitamin B-12; Cbl) (IF-Cbl) and albumin. Within these two regions, the binding of both ligands was confined to a 110-115-residue stretch that encompassed either the 113-residue N terminus or CUB domain 7 and 8. Ca2+ dependence of ligand binding or the ability of cubilin antiserum to inhibit ligand binding to the 113-residue N terminus was 60-65%. However, a combination of CUB domains 7 and 8 or 6-8 was needed to demonstrate significant Ca2+ dependence or inhibition of ligand binding by cubilin antiserum. Antiserum to EGF inhibited albumin but not IF-Cbl binding to the N-terminal cubilin fragment that included the eight EGF-like repeats. While the presence of excess albumin had no effect on binding to IF-Cbl, IF-Cbl in excess was able to inhibit albumin binding to both regions of cubilin. Reductive alkylation of the 113-residue N terminus or CUB 6-8, CUB 7, or CUB 8 domain resulted in the abolishment of ligand binding. These results indicate that (a) cubilin contains two distinct regions that bind both IF-Cbl and albumin and that (b) binding of both IF-Cbl and albumin to each of these regions can be distinguished and is regulated by the nonassisted formation of local disulfide bonds.	Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Rm 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.							Aminoff M, 1999, NAT GENET, V21, P309, DOI 10.1038/6831; BATUMAN V, 1990, AM J PHYSIOL, V258, pF1259, DOI 10.1152/ajprenal.1990.258.5.F1259; Batuman V, 1998, AM J PHYSIOL-RENAL, V275, pF246, DOI 10.1152/ajprenal.1998.275.2.F246; Birn H, 2000, J CLIN INVEST, V105, P1353, DOI 10.1172/JCI8862; Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562; COLLAN Y, 1979, NEPHRON, V23, P297, DOI 10.1159/000181654; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; HILLE A, 1989, J BIOL CHEM, V264, P13460; KADERBHAI MA, 1985, EUR J BIOCHEM, V15, P167; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kristiansen M, 2000, BLOOD, V96, P405; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lindblom A, 1999, J BIOL CHEM, V274, P6374, DOI 10.1074/jbc.274.10.6374; MAHER PA, 1986, P NATL ACAD SCI USA, V83, P9001, DOI 10.1073/pnas.83.23.9001; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; MOHAMED SD, 1966, Q J MED, V139, P433; RAMANUJAM KS, 1991, J BIOL CHEM, V266, P13135; RAMANUJAM KS, 1994, ARCH BIOCHEM BIOPHYS, V315, P8, DOI 10.1006/abbi.1994.1464; RAMANUJAM KS, 1993, BIOCHIM BIOPHYS ACTA, V1146, P243, DOI 10.1016/0005-2736(93)90362-4; RAMANUJAM KS, 1993, COMP BIOCHEM PHYS A, V104, P771, DOI 10.1016/0300-9629(93)90153-U; SEETHARAM B, 1981, J BIOL CHEM, V256, P9813; SEETHARAM B, 1982, J BIOL CHEM, V257, P183; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SEETHARAM B, 1983, BIOCHEM BIOPH RES CO, V115, P238, DOI 10.1016/0006-291X(83)90995-6; Seetharam B, 1999, ANNU REV NUTR, V19, P173, DOI 10.1146/annurev.nutr.19.1.173; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM S, 1992, J BIOL CHEM, V267, P7421; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; TIRUPPATHI C, 1986, ANAL BIOCHEM, V153, P330, DOI 10.1016/0003-2697(86)90100-4; Yammani RR, 2001, AM J PHYSIOL-ENDOC M, V281, pE900, DOI 10.1152/ajpendo.2001.281.5.E900	32	41	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44777	44784		10.1074/jbc.M106419200	http://dx.doi.org/10.1074/jbc.M106419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581259	hybrid			2022-12-27	WOS:000172406700060
J	Arocas, V; Bock, SC; Raja, S; Olson, ST; Bjork, I				Arocas, V; Bock, SC; Raja, S; Olson, ST; Bjork, I			Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; BETA-SHEET-A; CONFORMATIONAL CHANGE; RECOMBINANT ANTITHROMBIN; PROTEINASE REACTIONS; FACTOR-XA; ACTIVATION; SITE; GLYCOSYLATION; CARBOHYDRATE	Lys(114) of the plasma coagulation proteinase inhibitor, antithrombin, has been implicated in binding of the glycosaminoglycan activator, heparin, by previous mutagenesis studies and by the crystal structure of antithrombin in complex with the active pentasaccharide unit of heparin. In the present work, substitution of Lys(114) by Ala or Met was shown to decrease the affinity of antithrombin for heparin and the pentasaccharide by similar to 10(5)-fold at I 0.15, corresponding to a reduction in binding energy of similar to 50%,. The decrease in affinity was due to the loss of two to three ionic interactions, consistent with Lys(114) and at least one other basic residue of the inhibitor binding cooperatively to heparin, as well as to substantial nonionic interactions. The mutation minimally affected the initial, weak binding of the two-step mechanism of pentasaccharide binding to antithrombin but appreciably (> 40-fold) decreased the forward rate constant of the conformational change in the second step and greatly (> 1000-fold) increased the reverse rate constant of this step. Lys(114) is thus of greater importance for the affinity of heparin binding than any of the other antithrombin residues investigated so far, viz. Arg(47), Lys(125), and Arg(129). It contributes more than Arg(47) and Arg(129) to increasing the rate of induction of the activating conformational change, a role presumably exerted by interactions with the nonreducing end trisaccharide unit of the heparin pentasaccharide. However, its major effect, also larger than that of these two residues, is in maintaining antithrombin in the activated state by interactions that most likely involve the reducing end disaccharide unit.	Swedish Univ Agr Sci, Dept Vet Med Chem, Uppsala Biomed Ctr, SE-75123 Uppsala, Sweden; Univ Utah, Hlth Sci Ctr, Pulm Div, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Pulm Div, Dept Bioengn, Salt Lake City, UT 84132 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	Swedish University of Agricultural Sciences; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bjork, I (corresponding author), Swedish Univ Agr Sci, Dept Vet Med Chem, Uppsala Biomed Ctr, Box 575, SE-75123 Uppsala, Sweden.	Ingemar.Bjork@vmk.slu.se	Arocas, Veronique/M-7075-2017	Arocas, Veronique/0000-0002-2872-8058	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039888, R37HL039888, R01HL039888, R01HL030712] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39888, HL30712] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 1999, BIOCHEMISTRY-US, V38, P10196, DOI 10.1021/bi990686b; BJORK I, 1992, BIOCHEM J, V286, P793; BJROK I, 1997, CHEM BIOL SERPINS, P17; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P15; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; Kridel SJ, 1997, J BIOL CHEM, V272, P7656, DOI 10.1074/jbc.272.12.7656; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LIU CS, 1987, J BIOL CHEM, V262, P17356; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson ST, 1997, ARCH BIOCHEM BIOPHYS, V341, P212, DOI 10.1006/abbi.1997.9973; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188	40	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43809	43817		10.1074/jbc.M105294200	http://dx.doi.org/10.1074/jbc.M105294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11567021	hybrid			2022-12-27	WOS:000172297700044
J	Riefler, GM; Firestein, BL				Riefler, GM; Firestein, BL			Binding of neuronal nitric-oxide synthase (nNOS) to carboxyl-terminal-binding protein (CtBP) changes the localization of CtBP from the nucleus to the cytosol - A novel function for targeting by the PDZ domain of nNOS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; PSD-95; POTENTIATION; COREPRESSOR; EXPRESSION; MESSENGER; SEQUENCES; TISSUES; KINASE; MUTANT	Recent work suggests a role for PDZ domains in the targeting of binding partners to specific sites in the cell. To identify whether the PDZ domain of neuronal nitric-oxide synthase (nNOS) can play such a role, we performed affinity chromatography of brain extract with the nNOS PDZ domain. We identified the carboxyl-terminal-binding protein (CtBP), a phosphoprotein first identified as a binding partner to adenovirus EIA, as a nNOS binding partner. CtBP interacts with the PDZ domain of nNOS, and this interaction can be competed with peptide that binds to the PDZ peptide-binding site. In addition, binding of CtBP to nNOS is dependent on its carboxyl-terminal sequence -DXL, residues conserved between species that. fit the canonical sequence for nNOS PDZ binding. Immunoprecipitation studies show that CtBP and nNOS associate in the brain. When CtBP is expressed in Madin-Darby canine kidney cells, its distribution is primarily nuclear; however, when CtBP is co-expressed with nNOS, its localization becomes more cytosolic. This change in CtBP localization does not occur when its carboxyl-terminal nNOS PDZ binding motif is mutated or when CtBP is co-expressed with postsynaptic density 95, another PDZ domain-containing protein. Taken together, our data suggest a new function for nNOS as a regulator of CtBP nuclear localization.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Firestein, BL (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.			Firestein, Bonnie/0000-0002-1679-3565				Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Firestein BL, 1998, J NEUROCHEM, V71, P1846; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gonzalez-Mariscal L, 1999, EXP CELL RES, V248, P97, DOI 10.1006/excr.1999.4392; Hawkins RD, 1996, NEURON, V16, P465, DOI 10.1016/S0896-6273(00)80064-1; HECKER M, 1994, J NEUROCHEM, V62, P1524; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Park CS, 2000, NITRIC OXIDE-BIOL CH, V4, P459, DOI 10.1006/niox.2000.0300; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587	35	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48262	48268		10.1074/jbc.M106503200	http://dx.doi.org/10.1074/jbc.M106503200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11590170	hybrid			2022-12-27	WOS:000172927000071
J	Adachi, Y; Lakka, SS; Chandrasekar, N; Yanamandra, N; Gondi, CS; Mohanam, S; Dinh, DH; Olivero, WC; Gujrati, M; Tamiya, T; Ohmoto, T; Kouraklis, G; Aggarwal, B; Rao, JS				Adachi, Y; Lakka, SS; Chandrasekar, N; Yanamandra, N; Gondi, CS; Mohanam, S; Dinh, DH; Olivero, WC; Gujrati, M; Tamiya, T; Ohmoto, T; Kouraklis, G; Aggarwal, B; Rao, JS			RETRACTED: Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes (Retracted article. See vol. 295, pg. 13134, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							MALIGNANT GLIOMA; VITRONECTIN; APOPTOSIS; PROTEIN; P21(WAF1/CIP1); INVASIVENESS; LOCALIZATION; SUPPRESSION; INHIBITION; INVASION	Interaction between the extracellular matrix and integrin receptors on cell surfaces leads not only to cell adhesion but also to intracellular signaling events that affect cell migration, proliferation, and survival. The vitronectin receptor alpha (v)beta (3) integrin is of key importance in glioma cell biology. The expression of urokinase-type plasminogen activator receptor (uPAR) was recently shown to co-regulate with the expression of alpha (v)beta (3), integrin. Moreover, restoration of the p16 protein in glioma cells inhibits the alpha (v)beta (3) integrin-mediated spreading of those cells on vitronectin. Thus we hypothesized that adenovirus-mediated down-regulation of uPAR and overexpression of p16 might down-regulate the expression of alpha (v)beta (3) integrin and the integrin-mediated signaling in glioma cells, thereby defeating the malignant phe. notype. In this study, we used replication-deficient adenovirus vectors that contain either a uPAR antisense expression cassette (Ad-uPAR) or wild-type p16 cDNA (Ad-p16) and a bicistronic adenovirus construct in which both the uPAR antisense and p16 sense expression cassettes (Ad-uPAR/p16) are inserted in the El-deleted region of the vector. Infecting the malignant glioma cell line SNB19 with Ad-uPAR, Ad-p16, or Ad-uPAR/p16 in the presence of vitronectin resulted in decreased alpha (v)beta (3) integrin expression and integrin-mediated biological effects, including adhesion, migration, proliferation, and survival Our results support the therapeutic potential of simultaneously targeting uPAR and p16 in the treatment of gliomas.	Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Div Canc Biol, Dept Neuropathol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Div Canc Biol, Dept Neurosurg, Peoria, IL 61656 USA; MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan; Univ Athens, Sch Med, Dept Propedeut Surg, Athens 11526, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; Okayama University; Athens Medical School; National & Kapodistrian University of Athens	Rao, JS (corresponding author), Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA.	jrao@uic.edu	Aggarwal, Bharat B/G-3388-2013	Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [CA 76350, CA 75557] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350, R01CA075557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carron CP, 1998, CANCER RES, V58, P1930; Chatterjee S, 2000, J NEURO-ONCOL, V46, P135, DOI 10.1023/A:1006444300504; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; CHOUCAIR AK, 1986, J NEUROSURG, V65, P654, DOI 10.3171/jns.1986.65.5.0654; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GLADSON CL, 1995, AM J PATHOL, V146, P1150; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kin Y, 2000, INT J ONCOL, V17, P61; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohan PM, 1999, CANCER RES, V59, P3369; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Uhm Joon H., 1999, Frontiers in Bioscience, V4, pD188, DOI 10.2741/Uhm; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; YAMAMOTO M, 1994, CANCER RES, V54, P3656	35	44	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47171	47177		10.1074/jbc.M104334200	http://dx.doi.org/10.1074/jbc.M104334200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11572856				2022-12-27	WOS:000172768500068
J	Purdue, PE; Lazarow, PB				Purdue, PE; Lazarow, PB			Pex18p is constitutively degraded during peroxisome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; UBIQUITIN-CONJUGATING ENZYME; MATRIX PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PICHIA-PASTORIS; TARGETING SIGNAL; PTS2 RECEPTOR; 3-KETOACYL-COA THIOLASE; GENE ENCODES; FUNCTIONAL COMPLEMENTATION	Pex18p and Pex21p are structurally related yeast peroxins (proteins required for peroxisome biogenesis) that are partially redundant in function. One or the other is essential for the import into peroxisomes of proteins with type 2 peroxisomal targeting sequences (PTS2). These sequences bind to the soluble PTS2 receptor, Pex7p, which in turn binds to Pex18p (or Pex21p or possibly both). Here we show that Pex18p is constitutively degraded with a half-time of less than 10 min in wild-type Saccharomyces cerevisiae. This degradation probably occurs in proteasomes, because it requires the related ubiquitin-conjugating enzymes Ubc4p and Ubc5p and occurs normally in a mutant lacking the Pep4p vacuolar protease. The turnover of Pex18p stops, and Pex18p accumulates to a much higher than normal abundance in pex mutants in which the import of all peroxisomal matrix proteins is blocked. This includes mutants that lack peroxins involved in receptor docking at the membrane (Delta pex13 or Delta pex14), a mutant that lacks the peroxisomal member of the E2 family of ubiquitin-conjugating enzymes (Delta pex4), and others (Delta pex1). This stabilization in a variety of pex mutants indicates that Pex18p turnover is associated with its normal function. A Pex18p-Pex7p complex is detected by immunoprecipitation in wild type cells, and its abundance increases considerably in the Delta pex14 peroxisome biogenesis mutant. Cells that lack Pex7p fail to stabilize and accumulate Pex18p, indicating an important role for complex formation in the stabilization. Mono- and diubiquitinated forms of Pex18p are detected in wild-type cells, and there is no Pex18p turnover in a yeast doa4 mutant in which ubiquitin homeostasis is defective. These data represent, to the best of our knowledge, the first instance of an organelle biogenesis factor that is degraded constitutively and rapidly.	CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Purdue, PE (corresponding author), CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, 1190 5th Ave, New York, NY 10029 USA.				NIDDK NIH HHS [DK 19394] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019394, R37DK019394] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; CRANE DI, 1994, J BIOL CHEM, V269, P21835; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1999, PHILOS T ROY SOC B, V354, P1513, DOI 10.1098/rstb.1999.0495; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Koller A, 1999, J CELL BIOL, V146, P99, DOI 10.1083/jcb.146.1.99; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Purdue PE, 1998, J CELL BIOL, V143, P1859; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Terlecky SR, 2000, TRAFFIC, V1, P465, DOI 10.1034/j.1600-0854.2000.010604.x; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; THIERINGER R, 1991, MOL CELL BIOL, V11, P510, DOI 10.1128/MCB.11.1.510; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VOORNBROUWER T, 1993, BIOCHIM BIOPHYS ACTA, V1216, P325, DOI 10.1016/0167-4781(93)90166-B; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	52	66	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47684	47689		10.1074/jbc.M106823200	http://dx.doi.org/10.1074/jbc.M106823200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590152	hybrid			2022-12-27	WOS:000172768500131
J	Raczniak, G; Becker, HD; Min, B; Soll, D				Raczniak, G; Becker, HD; Min, B; Soll, D			A single amidotransferase forms asparaginyl-tRNA and glutaminyl-tRNA in Chlamydia trachomatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; THERMUS-THERMOPHILUS; PROTEIN-SYNTHESIS; GENOME SEQUENCE; AMINO-ACIDS; L-CELLS; PSITTACI; PURIFICATION; PHOSPHATE; PATHOGEN	Aminoacyl-tRNA is generally formed by aminoacyl-tRNA synthetases, a family of 20 enzymes essential for accurate protein synthesis. However, most bacteria generate one of the two amide aminoacyl-tRNAs, Asn-tRNA or Gln-tRNA, by transamidation of mischarged AsptRNA(Asn) or Glu-tRNA(Gln) catalyzed by a heterotrimeric amidotransferase (encoded by the gatA, gatB, and gatC genes). The Chlamydia trachomatis genome sequence reveals genes for 18 synthetases, whereas those for asparaginyl-tRNA synthetase and glutaminyl-tRNA synthetase are absent. Yet the genome harbors three gat genes in an operon-like arrangement (gatCAB). We reasoned that Chlamydia uses the gatCAB-encoded amidotransferase to generate both Asn-tRNA and Gln-tRNA. C. trachomatis aspartyl-tRNA synthetase and glutamyl-tRNA synthetase were shown to be non-discriminating synthetases that form the misacylated tRNA(Asn) and tRNA(Gln) species. A preparation of pure heterotrimeric recombinant C. trachomatis amidotransferase converted Asp-tRNA(Asn) and Glu-tRNA(Gln) into Asn-tRNA and Gln-tRNA, respectively. The enzyme used glutamine, asparagine, or ammonia as amide donors in the presence of either ATP or GTP. These results suggest that C. trachomatis employs the dual specificity gatCAB-encoded amidotransferase and 18 aminoacyl-tRNA synthetases to create the complete set of 20 aminoacyl-tRNAs.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.			Becker, Hubert/0000-0002-4102-7520				Becker HD, 2000, BIOCHEMISTRY-US, V39, P3216, DOI 10.1021/bi992573y; Becker HD, 2000, FEBS LETT, V476, P140, DOI 10.1016/S0014-5793(00)01697-5; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Curi R, 1999, BRAZ J MED BIOL RES, V32, P15, DOI 10.1590/S0100-879X1999000100002; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; FRIIS RR, 1972, J BACTERIOL, V110, P706, DOI 10.1128/JB.110.2.706-721.1972; Gagnon Y, 1996, J BIOL CHEM, V271, P14856, DOI 10.1074/jbc.271.25.14856; HATCH TP, 1975, INFECT IMMUN, V12, P211, DOI 10.1128/IAI.12.1.211-220.1975; HATCH TP, 1975, J BACTERIOL, V122, P393, DOI 10.1128/JB.122.2.393-400.1975; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAHN D, 1990, J BIOL CHEM, V265, P8059; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; PELASCHIER J, 2000, THESIS YALE U; Putz J, 1997, NUCLEIC ACIDS RES, V25, P1862, DOI 10.1093/nar/25.9.1862; Raczniak G, 2001, TOXICOLOGY, V160, P181, DOI 10.1016/S0300-483X(00)00454-6; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; Salazar JC, 2001, FEBS LETT, V500, P129, DOI 10.1016/S0014-5793(01)02600-X; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; Scidmore MA, 1996, INFECT IMMUN, V64, P5366, DOI 10.1128/IAI.64.12.5366-5372.1996; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; STANZEL M, 1994, EUR J BIOCHEM, V219, P435, DOI 10.1111/j.1432-1033.1994.tb19956.x; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	35	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45862	45867		10.1074/jbc.M109494200	http://dx.doi.org/10.1074/jbc.M109494200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585842	hybrid			2022-12-27	WOS:000172573100050
J	Santiago, J; Guzman, GR; Rojas, LV; Marti, R; Asmar-Rovira, GA; Santana, LF; McNamee, M; Lasalde-Dominicci, JA				Santiago, J; Guzman, GR; Rojas, LV; Marti, R; Asmar-Rovira, GA; Santana, LF; McNamee, M; Lasalde-Dominicci, JA			Probing the effects of membrane cholesterol in the Torpedo californica acetylcholine receptor and the novel lipid-exposed mutation alpha C418W in Xenopus oocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M4 TRANSMEMBRANE DOMAIN; ION-CHANNEL FUNCTION; SECONDARY STRUCTURE; TRYPTOPHAN SUBSTITUTIONS; BINDING-SITES; CYCLODEXTRINS; SPECTROSCOPY; INTERFACE; SUBUNIT; OXIDASE	The effects of cholesterol on the ion-channel function of the Torpedo acetylcholine receptor (nAChR) and the novel lipid-exposed gain in function alpha C418W mutation have been investigated in Xenopus laevis oocytes. We found conditions to increase the cholesterol/phospholipid (C/P) molar ratio on the plasma membrane of Xenopus oocytes from 0.5 to 0.87, without significant physical damage or change in morphology to the oocytes. In addition, we developed conditions to deplete endogenous cholesterol from oocytes using a methyl-beta -cyclodextrin incubation procedure without causing membrane instability of the cells. Methyl-beta -cyclodextrin was also used to examine the reversibility of the inhibitory effect of cholesterol on AChR function. Depletion of 43% of endogenous cholesterol from oocytes (C/P = 0.3) did not show any significant change in macroscopic response of the wild type, whereas in the alpha C418W mutant the same cholesterol depletion caused a dramatic gain-in-function response of this lipid-exposed mutation in addition to the increased response caused by the mutation itself. Increasing the C/P ratio to 0.87 caused an inhibition of the macroscopic response of the Torpedo wild type of about 52%, whereas the alpha C418W mutation showed an 81% inhibition compared with the responses of control oocytes. The wild type receptor did not recover from this inhibition when the excess cholesterol was depleted to near normal C/P ratios; however, the alpha C418W mutant displayed 63% of the original current, which indicates that the inhibition of this lipid-exposed mutant was significantly reversed. The ability of the alpha C418W mutation to recover from the inhibition caused by cholesterol enrichment suggests that the interaction of cholesterol with this lipid-exposed mutation is significantly different from that of the wild type. The present data demonstrate that a single lipid-exposed position in the AChR could alter the modulatory effect of cholesterol on AChR function.	Univ Puerto Rico, Dept Biol, San Juan, PR 00931 USA; Univ Puerto Rico, Inst Neurobiol, San Juan, PR 00901 USA; Univ Cent Caribe, Dept Physiol, Sch Med, Bayamon, PR 00960 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of California System; University of California Davis	Lasalde-Dominicci, JA (corresponding author), Univ Puerto Rico, Dept Biol, POB 23360, San Juan, PR 00931 USA.	joseal@coqui.net	Santana, Luis/AAF-9298-2019	Santana, Luis/0000-0002-4297-8029	NCRR NIH HHS [G12RR03035, RR 13705-01] Funding Source: Medline; NIGMS NIH HHS [GM56371-04, GM08102-27] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003035, S10RR013705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056371] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antollini SS, 1998, BIOCHEMISTRY-US, V37, P16653, DOI 10.1021/bi9808215; Arias HR, 1998, BBA-REV BIOMEMBRANES, V1376, P173, DOI 10.1016/S0304-4157(98)00004-5; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Barrantes FJ, 1997, SER CENT ES, P199; BARRY MA, 1993, MICROSC RES TECHNIQ, V26, P231, DOI 10.1002/jemt.1070260306; BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Christian AE, 1997, J LIPID RES, V38, P2264; Corbin J, 1998, BBA-BIOMEMBRANES, V1414, P65, DOI 10.1016/S0005-2736(98)00153-9; DIPAOLA M, 1989, J BIOL CHEM, V264, P15457; FERNANDEZBALLESTER G, 1994, BIOCHEM SOC T, V22, P776, DOI 10.1042/bst0220776; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; JOHNSON SM, 1979, ANAL BIOCHEM, V95, P344, DOI 10.1016/0003-2697(79)90737-1; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Lasalde JA, 1996, BIOCHEMISTRY-US, V35, P14139, DOI 10.1021/bi961583l; LASALDE JA, 1992, JERUS SYM Q, V25, P199; LASALDE JA, 1995, BIOCHIM BIOPHYS ACTA, V1235, P427; LECHLEITER J, 1986, BIOCHIM BIOPHYS ACTA, V856, P640, DOI 10.1016/0005-2736(86)90159-8; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NARAYANASWAMI V, 1993, BIOCHEMISTRY-US, V32, P12420, DOI 10.1021/bi00097a021; OCHOA ELM, 1983, BIOCHIM BIOPHYS ACTA, V727, P151, DOI 10.1016/0005-2736(83)90379-6; OHLSSON RI, 1981, EUR J BIOCHEM, V115, P367, DOI 10.1111/j.1432-1033.1981.tb05247.x; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; OrtizMiranda SI, 1997, J MEMBRANE BIOL, V158, P17, DOI 10.1007/s002329900240; PRADIER L, 1992, STRUCTURE BIOL MEMBR, P1047; Raines DE, 1998, BIOCHEMISTRY-US, V37, P956, DOI 10.1021/bi971689w; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; RICHMOND W, 1973, CLIN CHEM, V19, P1350; SUNSHINE C, 1994, BIOCHIM BIOPHYS ACTA, V1108, P240; Tamamizu S, 2000, BIOCHEMISTRY-US, V39, P4666, DOI 10.1021/bi992835w; Tamamizu S, 1999, J MEMBRANE BIOL, V170, P157, DOI 10.1007/s002329900545; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Zanello LP, 1996, BIOPHYS J, V70, P2155, DOI 10.1016/S0006-3495(96)79781-3	41	61	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46523	46532		10.1074/jbc.M104563200	http://dx.doi.org/10.1074/jbc.M104563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567020	hybrid			2022-12-27	WOS:000172573100138
J	Shepard, LW; Yang, M; Xie, P; Browning, DD; Voyno-Yasenetskaya, T; Kozasa, T; Ye, RD				Shepard, LW; Yang, M; Xie, P; Browning, DD; Voyno-Yasenetskaya, T; Kozasa, T; Ye, RD			Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve G alpha(13) and RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; GENE-EXPRESSION; P115 RHOGEF; GRO-ALPHA; TRANSCRIPTION; CHEMOKINES; KINASE; GTPASES; HUMAN-HERPESVIRUS-8; IDENTIFICATION	The Kaposi's sarcoma herpesvirus (KSHV) open reading frame 74 encodes a G protein-coupled receptor (GPCR) for chemokines. Exogenous expression of this constitutively active GPCR leads to cell transformation and vascular overgrowth characteristic of Kaposi's sarcoma. We show here that expression of KSHV-GPCR in transfected cells results in constitutive transactivation of nuclear factor kappaB (NF-kappaB) and secretion of interleukin-8, and this response involves activation of Gals and RhoA. The induced expression of a NF-kappaB luciferase reporter was partially reduced by pertussis toxin and the G beta gamma scavenger transducin, and enhanced by co-expression of Gals and to a lesser extent, G alpha (q). These results indicate coupling of KSHV-GPCR to multiple G proteins for NF-kappaB activation. Expression of KSHV-GPCR led to stress fiber formation in NIH 3T3 cells. To examine the involvement of the G alpha (13)-RhoA pathway in KSHV-GPCR-mediated NF-kappaB activation, HeLa cells were transfected with KSHV-GPCR alone and in combination with the regulator of G protein signaling (RGS) from p115RhoGEF or a dominant negative RhoA(T19N). Both constructs, as well as the C3 exoenzyme from Clostritium botulinum, partially reduced NF-kappaB activation by KSHV-GPCR, and by a constitutively active G alpha (13)(Q226L). KSHV-GPCR-induced NF-kappaB activation is accompanied by increased secretion of IL-8, a function mimicked by the activated G alpha (13) but not by an activated G alpha (q)(Q209L). These results suggest coupling of KSHV-GPCR to the G alpha (13)-RhoA pathway in addition to other G proteins.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA.	yer@uic.edu	Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016; voyno-yasenetskaya, tatyana/A-3171-2008	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620	NIAID NIH HHS [AI40176] Funding Source: Medline; NIGMS NIH HHS [GM56159, GM61454] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040176, R56AI040176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159, R01GM061454] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Browning DD, 2000, AM J PHYSIOL-LUNG C, V279, pL1129, DOI 10.1152/ajplung.2000.279.6.L1129; Burger M, 1999, J IMMUNOL, V163, P2017; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Devalaraja MN, 1999, CANCER RES, V59, P1372; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hermouet S, 2000, LEUKEMIA LYMPHOMA, V38, P39, DOI 10.3109/10428190009060317; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; Maruyama I, 1997, ANN NY ACAD SCI, V811, P429, DOI 10.1111/j.1749-6632.1997.tb52024.x; Montaner S, 2001, CANCER RES, V61, P2641; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MORII N, 1995, METHOD ENZYMOL, V256, P196; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murdoch C, 2000, BLOOD, V95, P3032; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1137, DOI 10.1006/bbrc.1994.2784; Norgauer J, 1996, J IMMUNOL, V156, P1132; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; SCHINDLER R, 1990, BLOOD, V76, P1631; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Sodhi A, 2000, CANCER RES, V60, P4873; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; VAN AD, 1996, SCIENCE, V274, P787; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Ye RD, 1996, GENE EXPRESSION, V5, P205; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	63	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45979	45987		10.1074/jbc.M104783200	http://dx.doi.org/10.1074/jbc.M104783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590141	hybrid			2022-12-27	WOS:000172573100067
J	Wilstermann, AM; Osheroff, N				Wilstermann, AM; Osheroff, N			Base excision repair intermediates as topoisomerase II poisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; APURINIC APYRIMIDINIC SITES; ANTICANCER DRUGS; MAMMALIAN-CELLS; TARGETED DRUGS; ABASIC SITES; CHROMOSOMAL-ABERRATIONS; DEOXYRIBONUCLEIC-ACID; SPONTANEOUS MUTATION; ESCHERICHIA-COLI	Abasic sites are the most commonly formed DNA lesions in the cell and are produced by numerous endogenous and environmental insults. In addition, they are generated by the initial step of base excision repair (BER). When located within a topoisomerase II DNA cleavage site, "intact" abasic sites act as topoisomerase II poisons and dramatically stimulate enzyme-mediated DNA scission. However, most abasic sites in cells are not intact. They exist as processed BER intermediates that contain DNA strand breaks proximal to the damaged residue. When strand breaks are located within a topoisomerase II DNA cleavage site, they create suicide substrates that are not religated readily by the enzyme and can generate permanent double-stranded DNA breaks. Consequently, the effects of processed abasic sites on DNA cleavage by human topoisomerase II alpha were examined. Unlike substrates with intact abasic sites, model BER intermediates containing 5'- or 3'-nicked abasic sites or deoxyribosephosphate flaps were suicide substrates. Furthermore, abasic sites flanked by 5'- or 3'-nicks were potent topoisomerase II poisons, enhancing DNA scission similar to 10-fold compared with corresponding nicked oligonucleotides that lacked abasic sites. These findings suggest that topoisomerase II is able to convert processed BER intermediates to permanent double-stranded DNA breaks.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Robinson Res Bldg, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09385] Funding Source: Medline; NIGMS NIH HHS [GM53960] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen A H, 1994, Adv Pharmacol, V29A, P83; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; Bakshi RP, 2001, CRIT REV BIOCHEM MOL, V36, P1, DOI 10.1080/20014091074165; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; CORBETT AH, 1992, J BIOL CHEM, V267, P683; DARPA P, 1990, CANCER RES, V50, P6919; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FEIEDBERG EC, DNA REAPIR MUTAGENES, V135, P95; FELIX CA, 1995, CANCER RES, V55, P4287; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; Garvish JF, 1999, J BIOL CHEM, V274, P9786, DOI 10.1074/jbc.274.14.9786; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Holden Joseph A., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P1, DOI 10.2174/1568011013354859; HOLM C, 1989, CANCER RES, V49, P6365; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kohn KW, 1996, BIOESSAYS, V18, P505, DOI 10.1002/bies.950180613; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LIU LF, 1983, J BIOL CHEM, V258, P5365; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McCullough AK, 1998, J BIOL CHEM, V273, P13136, DOI 10.1074/jbc.273.21.13136; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Osheroff N, 1998, BBA-GENE STRUCT EXPR, V1400, P1, DOI 10.1016/S0167-4781(98)00123-7; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Sabourin M, 2000, NUCLEIC ACIDS RES, V28, P1947, DOI 10.1093/nar/28.9.1947; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANDER M, 1983, J BIOL CHEM, V258, P8421; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wilstermann AM, 2001, J BIOL CHEM, V276, P17727, DOI 10.1074/jbc.M100197200; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	70	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46290	46296		10.1074/jbc.M105733200	http://dx.doi.org/10.1074/jbc.M105733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591703	hybrid			2022-12-27	WOS:000172573100109
J	Kurland, JF; Kodym, R; Story, MD; Spurgers, KB; McDonnell, TJ; Meyn, RE				Kurland, JF; Kodym, R; Story, MD; Spurgers, KB; McDonnell, TJ; Meyn, RE			NF-kappa B1 (p50) homodimers contribute to transcription of the bcl-2 oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CANDIDATE ONCOPROTEIN BCL-3; RADIATION-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CONSTITUTIVE ACTIVATION; PERSISTENT ACTIVATION; EXPRESSION; CELLS; INDUCTION; B/REL	The bcl-2 proto-oncogene is frequently expressed in human cancer. Although bcl-2 was first cloned as the t(14;18) translocation breakpoint from human follicular B-cell lymphoma, it has become apparent that many cell types express bcl-2 because of transcriptional regulation. As such, several transcription factors have been demonstrated to activate expression of bcl-2, including NF-kappaB. We investigated the role of NF-K beta1 (p50) homodimers in the expression of Bcl-2 in two murine B-cell lymphoma cell lines: LY-as, an apoptosis-proficient line with low Bcl-2 protein expression and no nuclear NF-kappaB activity, and LY-ar, a nonapoptotic line with constitutive p50 homodimer activity and 30 times more Bcl-2 protein expression than LY-as. We found that nuclear p50 homodimer activity correlated with Bcl-2 expression in these cell types and identified several sites within the bcl-2 5'-flanking region that p50 was capable of binding. In vitro transcription revealed that recombinant p50 enhanced the production of run-off transcripts from the bcl-2 P1 promoter. Additional in vitro transcription experiments suggested the sites by which p50 afforded this effect. We conclude that the p50 homodimer is capable of transcriptional activation of the bcl-2 gene and suggest that its nuclear activity contributes to the expression of bcl-2 in LY-ar cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	rmeyn@mdanderson.org	Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NATIONAL CANCER INSTITUTE [R01CA069003] Funding Source: NIH RePORTER; NCI NIH HHS [CA69003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Claudio E, 1996, EXP CELL RES, V224, P63, DOI 10.1006/excr.1996.0111; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYER RB, 1995, BIOTECHNIQUES, V19, P192; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; Kistler B, 1998, J IMMUNOL, V160, P2308; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mori N, 1999, BLOOD, V93, P2360; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Papakonstantinou G, 2001, BRIT J HAEMATOL, V113, P383, DOI 10.1046/j.1365-2141.2001.02727.x; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; STORY MD, 1994, INT J RADIAT BIOL, V66, P659; Strasser A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	57	106	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45380	45386		10.1074/jbc.M108294200	http://dx.doi.org/10.1074/jbc.M108294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567031	hybrid			2022-12-27	WOS:000172406700134
J	Russwurm, M; Wittau, N; Koesling, D				Russwurm, M; Wittau, N; Koesling, D			Guanylyl cyclase/PSD-95 interaction - Targeting of the nitric oxide-sensitive alpha(2)beta(1) guanylyl cyclase to synaptic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; ACTIVITY REQUIRES; ENZYME SUBUNITS; PSD-95 FAMILY; PDZ DOMAINS; SYNTHASE; EXPRESSION; ACTIVATION; CLONING	The signaling molecule nitric oxide (NO) exerts most of its effects by the stimulation of the NO-sensitive guanylyl cyclase. Two isoforms of the NO receptor molecule exist: the ubiquitously occurring alpha (1)beta (1) and the alpha (2)beta (1) with a more limited distribution. As the isoforms are functionally indistinguishable, the physiological relevance of these isoforms remained unclear. The neuronal NO synthase has been reported to be associated with PSD-95. Here, we demonstrate the interaction of the so far unnoticed alpha (2)beta (1) isoform with PSD-95 in rat brain as shown by coprecipitation. The interaction is mediated by the alpha (2) C-terminal peptide and the third PDZ domain of PSD-95. As a consequence of the PSD-95 interaction, the so far considered "soluble" alpha (2)beta (1) isoform is recruited to the membrane fraction of synaptosomes, whereas the alpha (1)beta (1) isoform is found in the cytosol. Our results establish the alpha (1)beta (1) as the cytosolic and the alpha (2)beta (1) as the membrane-associated NO-sensitive guanylyl cyclase and suggest the alpha (2)beta (1) isoform as the sensor for the NO formed by the PSD-95-associated neuronal NO synthase.	Ruhr Univ Bochum, Med Fak MA N1, D-44780 Bochum, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Ruhr University Bochum; Free University of Berlin	Koesling, D (corresponding author), Ruhr Univ Bochum, Med Fak MA N1, D-44780 Bochum, Germany.							Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Budworth J, 1999, BIOCHEM BIOPH RES CO, V263, P696, DOI 10.1006/bbrc.1999.1444; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gibb BJ, 2001, EUR J NEUROSCI, V13, P539, DOI 10.1046/j.1460-9568.2001.01421.x; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Hoffmuller U, 1999, ANGEW CHEM INT EDIT, V38, P2000, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<2000::AID-ANIE2000>3.0.CO;2-V; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; KIEDROWSKI L, 1992, J NEUROCHEM, V58, P335, DOI 10.1111/j.1471-4159.1992.tb09315.x; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MAYER B, 1992, J NEUROCHEM, V59, P2024; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m	37	164	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44647	44652		10.1074/jbc.M105587200	http://dx.doi.org/10.1074/jbc.M105587200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572861	hybrid			2022-12-27	WOS:000172406700043
J	Senn, ME; Rubio, F; Banuelos, MA; Rodriguez-Navarro, A				Senn, ME; Rubio, F; Banuelos, MA; Rodriguez-Navarro, A			Comparative functional features of plant potassium HvHAK1 and HvHAK2 transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY K+ TRANSPORTER; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SALT TOLERANCE; ARABIDOPSIS; HKT1; EXPRESSION; CLONING; CELLS; CDNAS	Plant K+ transporters of the HAK family belong to four rather divergent phylogenetic clusters, although most of the transporters belong to clusters I or II. A simple phylogenetic analysis of fungal and plant HAK transporters suggests that an original HAK gene duplicated even before fungi and plants diverged, generating transporters that at present fulfill different functions in the plant. The HvHAK1 transporter belongs to cluster I and mediates high-affinity K+ uptake in barley roots, but no function is known for the cluster II transporter, HvHAK2, which is not functional in yeast. The function of HvHAK2 was investigated by constructing HvHAK1-HAK2 chimeric transporters, which were not functional even when they included only short fragments of HvHAK2. Then, amino acids characteristic of cluster II in the N terminus and in the first transmembrane domain were introduced into HvHAK1. All of these changes increased the Rb+ K-m, introducing minimal changes in the Na+ K-m, which suggested that HvHAK2 is a low-affinity, Na+-sensitive K+ transporter. Using a K+-defective Escherichia coli mutant, we functionally expressed HvHAK2 and found that the predicted characteristics were correct, as well as discovering that the bacterial expression of HvHAK2 is functional at pH 5.5 but not at 7.5. We discuss whether HvHAK2 may be a tonoplast transporter effective for vacuolar K+ depletion in K+ starved plants.	Univ Politecn Madrid, Escuela Tecn Super Ingenieros Agron, Dept Biotecnol, E-28040 Madrid, Spain	Universidad Politecnica de Madrid	Rodriguez-Navarro, A (corresponding author), Univ Politecn Madrid, Escuela Tecn Super Ingenieros Agron, Dept Biotecnol, E-28040 Madrid, Spain.	arodrignavar@bit.etsia.upm.es	Rubio, Francisco/ABF-8662-2020; Rubio, Francisco/K-2854-2014; Rodriguez-Navarro, Alonso/AAB-4574-2019	Rubio, Francisco/0000-0001-7640-9548; Rubio, Francisco/0000-0001-7640-9548; Rodriguez-Navarro, Alonso/0000-0003-0462-223X; BANUELOS BERNABE, MARIA ANTONIA/0000-0002-0924-754X				Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CAO YW, 1995, J BIOL CHEM, V270, P17697, DOI 10.1074/jbc.270.30.17697; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; Diatloff E, 1998, FEBS LETT, V432, P31, DOI 10.1016/S0014-5793(98)00833-3; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; EPSTEIN E, 1963, P NATL ACAD SCI USA, V49, P684, DOI 10.1073/pnas.49.5.684; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; Fu HH, 1998, PLANT CELL, V10, P63, DOI 10.1105/tpc.10.1.63; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMA H, 1993, J BIOL CHEM, V268, P10060; Haro R, 1999, MOL MICROBIOL, V31, P511, DOI 10.1046/j.1365-2958.1999.01192.x; KABACK HR, 1992, INT REV CYTOL, V137A, P97; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Kim EJ, 1998, PLANT CELL, V10, P51, DOI 10.1105/tpc.10.1.51; Liu WH, 2000, J BIOL CHEM, V275, P27924; Muller ML, 1996, J BIOL CHEM, V271, P1916; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; Quintero FJ, 1997, FEBS LETT, V415, P206, DOI 10.1016/S0014-5793(97)01125-3; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; Rigas S, 2001, PLANT CELL, V13, P139, DOI 10.1105/tpc.13.1.139; Rodriguez-Navarro A, 2000, BBA-REV BIOMEMBRANES, V1469, P1, DOI 10.1016/S0304-4157(99)00013-1; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; Rubio F, 1999, J BIOL CHEM, V274, P6839, DOI 10.1074/jbc.274.11.6839; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Rubio F, 2000, PHYSIOL PLANTARUM, V109, P34, DOI 10.1034/j.1399-3054.2000.100106.x; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Santa-Maria GE, 1997, PLANT CELL, V9, P2281, DOI 10.1105/tpc.9.12.2281; Schachtman DP, 2000, BBA-BIOMEMBRANES, V1465, P127, DOI 10.1016/S0005-2736(00)00134-6; Serrano R, 2001, CURR OPIN CELL BIOL, V13, P399, DOI 10.1016/S0955-0674(00)00227-1; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249; Walker DJ, 1996, P NATL ACAD SCI USA, V93, P10510, DOI 10.1073/pnas.93.19.10510	37	80	89	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44563	44569		10.1074/jbc.M108129200	http://dx.doi.org/10.1074/jbc.M108129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11562376	hybrid			2022-12-27	WOS:000172406700031
J	Toonkool, P; Jensen, SA; Maxwell, AL; Weiss, AS				Toonkool, P; Jensen, SA; Maxwell, AL; Weiss, AS			Hydrophobic domains of human tropoelastin interact in a context-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; CIRCULAR-DICHROISM; FIBER FORMATION; ELASTIN; COACERVATION; SEQUENCE; CHAINS	Tropoelastin is the soluble precursor of elastin, the major component of the extracellular elastic fiber. Tropoelastin undergoes self-association via an inverse temperature transition termed coacervation, which is a crucial step in elastogenesis. Coacervation of tropoelastin takes place through multiple intermolecular interactions of its hydrophobic domains. Previous work has implicated those hydrophobic domains located near the center of the polypeptide as playing a dominant role in coacervation. Short constructs of domains 18, 20, 24, and a mutated form of domain 26 were largely disordered at 20 degreesC but displayed increased order on heating that was consistent with the formation of beta -structures. However, their conformational transitions were not sensitive to physiological temperature in contrast to the observed behavior of the native domain 26. A polypeptide consisting of domains 17-27 of tropoelastin coacervated at temperatures above 60 degreesC, whereas individually expressed hydrophobic regions were not capable of coacervation. We conclude that coacervation depends on the hydrophobicity of the molecule and, by inference, the number of hydrophobic domains. Tropoelastin mutants were constructed to contain a Pro --> Ala mutation in domain 26, separate deletions of domains 18 and 26, and a displacement of domain 26. These constructs displayed unequal capacities for coacervation, even when they contained the same number of hydrophobic regions and comparable levels of secondary structure. Thus, the capability for coacervation is determined by contributions from individual hydrophobic domains for which function should be considered in the context of their positions in the intact tropoelastin molecule.	Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia	University of Sydney	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia.		Weiss, Anthony S/F-8103-2010; Weiss, Anthony S/GYV-0157-2022; Jensen, Sacha A./AAB-4034-2019	Weiss, Anthony S/0000-0002-8106-4836; Jensen, Sacha A./0000-0002-0560-9531; Kongsaeree, Prachumporn/0000-0003-0273-2638				BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BRESSAN GM, 1983, J ULTRA MOL STRUCT R, V82, P335, DOI 10.1016/S0022-5320(83)80021-5; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; COX BA, 1974, J BIOL CHEM, V249, P997; COX BA, 1973, BIOCHIM BIOPHYS ACTA, V317, P209, DOI 10.1016/0005-2795(73)90215-8; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; DEBELLE L, 1995, J MOL STRUCT, V348, P321, DOI 10.1016/0022-2860(95)08653-D; GOWDA DC, 1995, INT J PEPT PROT RES, V46, P453; Jensen SA, 2000, J BIOL CHEM, V275, P28449, DOI 10.1074/jbc.M004265200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; RAPAKA RS, 1978, INT J PEPT PROT RES, V11, P109; RAPAKA RS, 1978, INT J PEPT PROT RES, V11, P97; STARCHER BC, 1973, BIOCHIM BIOPHYS ACTA, V310, P481, DOI 10.1016/0005-2795(73)90132-3; TAMBURRO AM, 1992, J BIOMOL STRUCT DYN, V10, P441, DOI 10.1080/07391102.1992.10508661; TAMBURRO AM, 1977, BIOCHIM BIOPHYS ACTA, V492, P370, DOI 10.1016/0005-2795(77)90088-5; Toonkool P, 2001, J BIOL CHEM, V276, P28042, DOI 10.1074/jbc.M103391200; Urry D W, 1977, Adv Exp Med Biol, V79, P685; URRY D W, 1976, Critical Reviews in Biochemistry, V4, P1, DOI 10.3109/10409237609102557; Urry D W, 1974, Adv Exp Med Biol, V43, P211; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; URRY DW, 1982, METHOD ENZYMOL, V82, P673; Urry DW, 1995, CIBA F SYMP, V192, P4; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; WU J, 1992, ANAL BIOCHEM, V200, P359, DOI 10.1016/0003-2697(92)90479-Q; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719; Wu WJ, 1999, EUR J BIOCHEM, V266, P308, DOI 10.1046/j.1432-1327.1999.00891.x	29	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44575	44580		10.1074/jbc.M107920200	http://dx.doi.org/10.1074/jbc.M107920200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564742	hybrid			2022-12-27	WOS:000172406700033
J	Urbina, HD; Silberg, JJ; Hoff, KG; Vickery, LE				Urbina, HD; Silberg, JJ; Hoff, KG; Vickery, LE			Transfer of sulfur from IscS to IscU during Fe/S cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE SYSTEM; IN-VITRO BIOSYNTHESIS; NIFS-LIKE PROTEIN; COLI TRANSFER-RNA; ESCHERICHIA-COLI; EXTINCTION COEFFICIENTS; AZOTOBACTER-VINELANDII; CYSTEINE DESULFURASE; 2FE-2S CLUSTERS; S CLUSTER	The cysteine desulfurase enzymes NifS and IscS provide sulfur for the biosynthesis of Fe/S proteins. NifU and IscU have been proposed to serve as template or scaffold proteins in the initial Fe/S cluster assembly events, but the mechanism of sulfur transfer from NifS or IscS to NifU or IscU has not been elucidated. We have employed [S-35]cysteine radiotracer studies to monitor sulfur transfer between IscS and IscU from Escherichia coli and have used direct binding measurements to investigate interactions between the proteins. IscS catalyzed transfer of S-35 from [S-35]cysteine to IscU in the absence of additional thiol reagents, suggesting that transfer can occur directly and without involvement of an intermediate carrier. Surface plasmon resonance studies and isothermal titration calorimetry measurements further revealed that IscU binds to Ises with high affinity (K-d similar to2 muM) in support of a direct transfer mechanism. Transfer was inhibited by treatment of IscU with iodoacetamide, and 35S was released by reducing reagents, suggesting that transfer of persulfide sulfur occurs to cysteinyl groups of IscU. A deletion mutant of IscS lacking C-terminal residues 376-413 (IscS Delta 376-413) displayed cysteine desulfurase activity similar to the full-length protein but exhibited lower binding affinity for IscU, decreased ability to transfer S-35 to IscU, and reduced activity in assays of Fe/S cluster assembly on IscU. The findings with IscS Delta 376-413 provide additional support for a mechanism of sulfur transfer involving a direct interaction between IscS and IscU and suggest that the C-terminal region of IscS may be important for binding IscU.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Silberg, Jonathan J/A-3817-2010		NIGMS NIH HHS [GM54264, GM07311] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Bui BTS, 2000, EUR J BIOCHEM, V267, P2688; Flint DH, 1996, J BIOL CHEM, V271, P16068; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; RIORDAN JF, 1967, METHOD ENZYMOL, V11, P545; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; STONE KL, 1989, TECHNIQUES PROTEIN C, P379; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	31	224	229	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44521	44526		10.1074/jbc.M106907200	http://dx.doi.org/10.1074/jbc.M106907200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577100	hybrid, Green Accepted			2022-12-27	WOS:000172406700025
J	Yamamoto, N; Yamamoto, S; Inagaki, F; Kawaichi, M; Fukamizu, A; Kishi, N; Matsuno, K; Nakamura, K; Weinmaster, G; Okano, H; Nakafuku, M				Yamamoto, N; Yamamoto, S; Inagaki, F; Kawaichi, M; Fukamizu, A; Kishi, N; Matsuno, K; Nakamura, K; Weinmaster, G; Okano, H; Nakafuku, M			Role of Deltex-1 as a transcriptional regulator downstream of the notch receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLIT COMPLEX GENES; LOOP-HELIX FACTORS; SIGNALING PATHWAY; CELL DIFFERENTIATION; ANKYRIN REPEATS; NERVOUS-SYSTEM; MADS-BOX; RBP-J; P300; PROTEIN	Intercellular signaling through the cell-surface receptor Notch plays important roles in a variety of developmental processes as well as in pathogenesis of some human cancers and genetic disorders. However, the mechanisms by which Notch signals are transduced into cells still remain elusive. Here we investigated the signaling mechanisms for Notch in the cell fate control of neural progenitor cells. We show that Deltex-1 (DTX1), a mammalian homolog of Drosophila Deltex, mediates a Notch signal to block differentiation of neural progenitor cells. We found that a significant fraction of DTX1 proteins were localized in the nucleus and physically interacted with the transcriptional coactivator p300. Through its binding to p300, DTX1 inhibited transcriptional activation by the neural-specific helix-loop-helix-type transcription factor MASH1, and this mechanism is likely responsible for the differentiation inhibition of neural progenitor cells. Our results further suggest that DTX1 regulates transcription independently of the previously characterized Notch signaling pathway involving RBP-J and HES1/HES5. Thus, DTX1 serves as an important signaling component downstream of Notch that regulates transcription in the nucleus.	Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1130033, Japan; Nara Adv Inst Sci & Technol, Div Anim Gene Funct, Nara 6300101, Japan; Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Keio Univ, Sch Med, Dept Physiol, Tokyo 1608582, Japan; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo 1050011, Japan; Tokyo Univ Sci, Dept Biol Sci & Technol, Chiba 2788510, Japan	University of Tokyo; University of Tokyo; Nara Institute of Science & Technology; University of Tsukuba; Keio University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Japan Science & Technology Agency (JST); Tokyo University of Science	Nakafuku, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Neurobiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	nakafuku@m.u-tokyo.ac.jp	fukamizu, akiyoshi/J-5350-2012; Nakafuku, Masato/J-3068-2013; Okano, Hideyuki/I-7584-2019; Kishi, Noriyuki/L-1379-2013	fukamizu, akiyoshi/0000-0002-8786-6020; Nakafuku, Masato/0000-0001-7783-9005				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gho M, 1996, DEVELOPMENT, V122, P1673; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; James P, 1996, GENETICS, V144, P1425; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kato H, 1997, DEVELOPMENT, V124, P4133; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Ligoxygakis P, 1998, DEVELOPMENT, V125, P2893; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Torii MA, 1999, DEVELOPMENT, V126, P443; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Wang SW, 1997, DEVELOPMENT, V124, P4435; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	56	152	163	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45031	45040		10.1074/jbc.M105245200	http://dx.doi.org/10.1074/jbc.M105245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564735	hybrid			2022-12-27	WOS:000172406700093
J	Kinkl, N; Sahel, J; Hicks, D				Kinkl, N; Sahel, J; Hicks, D			Alternate FGF2-ERK1/2 signaling pathways in retinal photoreceptor and glial cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; BASIC FIBROBLAST; FACTOR RECEPTORS; GANGLIOSIDE COMPOSITION; MAP KINASES; TGF-BETA; ERK; EXPRESSION; NEURONS	Basic fibroblast growth factor (FGF2) stimulates photoreceptor survival in vivo and in vitro, but the molecular signaling mechanism(s) involved are unknown. Immunohistochemical and immunoblotting analyses of pure photoreceptors, inner retinal neurons, and Muller glial cells (MGC) in vitro revealed differential expression of the high affinity FGF receptors (FGFR1-4), as well as many cytoplasmic signaling intermediates known to mediate the extracellular signal-regulated kinase (ERK1/2) pathway. FGF2-induced tyrosine phosphorylation in vitro exhibited distinct profiles for each culture type, and FGF2-induced ERK1/2 activation was observed for all three preparations. Whereas U0126, a specific inhibitor of ERK kinase (MEK), completely abolished FGF2-induced ERK1/2 tyrosine phosphorylation and survival in cultured photoreceptors, persistent ERK1/2 phosphorylation was observed in cultured inner retinal cells and MGC. Furthermore U0126 treatment entirely blocked nerve growth factor-induced ERK1/2 activation in MGC, as well as FGF2-induced ERK1/2 activation in cerebral glial cells. Taken together, these data indicate that FGF2-induced ERK1/2 activation is entirely mediated by MEK within photoreceptors, which is responsible for FGF2-stimulated photoreceptor survival. In contrast, inner retina/glia possess alternative, cell type, and growth factor-specific MEK-independent ERK1/2 activation pathways. Hence signaling and biological effects elicited by FGF2 within retina are mediated by cell type-specific pathways.	Univ Strasbourg, Ctr Hosp Reg, INSERM,Clin Med A, Lab Physiopathol Cellulaire & Mol Retine,EMI 9918, F-67091 Strasbourg, France	Centre Hospitalier Annecy Genevois; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hicks, D (corresponding author), Univ Strasbourg, Ctr Hosp Reg, INSERM,Clin Med A, Lab Physiopathol Cellulaire & Mol Retine,EMI 9918, BP 426,1 Pl Hop, F-67091 Strasbourg, France.	hicks@neurochem.u-strasbg.fr	Sahel, Jose-Alain/F-3172-2017	Sahel, Jose-Alain/0000-0002-4831-1153				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; Baron W, 2000, MOL CELL NEUROSCI, V15, P314, DOI 10.1006/mcne.1999.0827; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bhat NR, 1996, J NEUROCHEM, V66, P1986; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Campochiaro PA, 1996, J NEUROSCI, V16, P1679; Cha YK, 2000, J NEUROCHEM, V75, P298, DOI 10.1046/j.1471-4159.2000.0750298.x; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Delehedde M, 2000, J BIOL CHEM, V275, P33905, DOI 10.1074/jbc.M005949200; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Desire L, 2000, J NEUROCHEM, V75, P151, DOI 10.1046/j.1471-4159.2000.0750151.x; Dimitropoulou A, 2000, BRAIN RES, V858, P205, DOI 10.1016/S0006-8993(00)01946-6; Dreyfus H, 1996, INVEST OPHTH VIS SCI, V37, P574; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ECKENSTEIN FP, 1994, PROG BRAIN RES, V103, P55; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; Fontaine V, 1998, J NEUROSCI, V18, P9662; Fontaine V, 1998, GLYCOBIOLOGY, V8, P183, DOI 10.1093/glycob/8.2.183; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Gu X, 1996, INVEST OPHTH VIS SCI, V37, P2326; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1; HICKS D, 1990, EXP EYE RES, V51, P119, DOI 10.1016/0014-4835(90)90063-Z; HICKS D, 1992, J NEUROSCI, V12, P2022; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLINT P, 1999, FRONT BIOSCI, V4, P165; Lau D, 2000, INVEST OPHTH VIS SCI, V41, P3622; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Learish RD, 2000, DEV BRAIN RES, V122, P97; Lesort M, 1997, MOL BRAIN RES, V45, P127, DOI 10.1016/S0169-328X(96)00284-7; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Meuillet E, 1996, GLIA, V17, P206, DOI 10.1002/(SICI)1098-1136(199607)17:3<206::AID-GLIA3>3.0.CO;2-Z; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; Pizon V, 2000, ONCOGENE, V19, P6074, DOI 10.1038/sj.onc.1203984; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Ryan PJ, 1998, BIOCHEM BIOPH RES CO, V244, P763, DOI 10.1006/bbrc.1998.8326; Saeki Y, 2000, INT J MOL MED, V6, P155; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; Saneto RP., 1987, NEUROCHEMISTRY PRACT, P27; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SHAOUL E, 1995, ONCOGENE, V10, P1553; SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; TOURNIER C, 1994, GLIA, V10, P81, DOI 10.1002/glia.440100202; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEISE B, 1993, J NEUROSCI RES, V34, P442, DOI 10.1002/jnr.490340409; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yardin C, 1998, NEUROREPORT, V9, P2077, DOI 10.1097/00001756-199806220-00030; Yue JB, 1999, J CELL PHYSIOL, V178, P387	67	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43871	43878		10.1074/jbc.M105256200	http://dx.doi.org/10.1074/jbc.M105256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571286	hybrid			2022-12-27	WOS:000172297700052
J	Kraus, J; Borner, C; Giannini, E; Hickfang, K; Braun, H; Mayer, P; Hoehe, MR; Ambrosch, A; Konig, W; Holt, V				Kraus, J; Borner, C; Giannini, E; Hickfang, K; Braun, H; Mayer, P; Hoehe, MR; Ambrosch, A; Konig, W; Holt, V			Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTE-ENRICHED CULTURES; BETA-ENDORPHIN; DENDRITIC CELLS; T-CELLS; KAPPA-B; INTERLEUKIN-1-BETA-MEDIATED REGULATION; DIFFERENTIAL EXPRESSION; FUNCTIONAL-ANALYSIS; RESPONSE ELEMENT; NERVOUS-SYSTEM	Morphine and the endogenous opioid peptide P-endorphin exert neuromodulatory as well as immunomodulatory effects, which are transduced by mu -opioid receptors. In this report we show that stimulation with interleukin-4 induces Ik-opioid receptor transcripts in human primary blood cells (T cells and polymorphonuclear leukocytes), immune cell lines (Raji, U-937, and HMEC-1), and dendritic cells. In nonstimulated immune cells this gene is silent. In addition, mu receptor transcription is up-regulated by interleukin-4 in cultures of primary rat neurons. Transient transfection experiments in Raji and SH SY5Y neuronal cells with human and rat reporter gene constructs linked the interleukin-4 effect directly to cis-active mu receptor promoter elements located at nucleotide -997 on the human gene and nucleotide -727 on the rat gene. The interleukin-4 response elements function orientation independently. They bind STAT6 transcription factors as shown by electrophoretic mobility shift assays. In the human gene, a single nucleotide polymorphism within the interleukin-4 response element reduces the trans-activating potential of this element by 50%, which may affect the phenotype of persons carrying this variation. These findings provide a molecular basis for understanding bidirectional interactions between the opioid system and the immune system.	Univ Magdeburg, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Med Microbiol, D-39120 Magdeburg, Germany; Univ Rome, Dept Med Pharmacol, I-00185 Rome, Italy; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Otto von Guericke University; Otto von Guericke University; Sapienza University Rome; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kraus, J (corresponding author), Univ Magdeburg, Dept Pharmacol & Toxicol, 44 Leipziger Str, D-39120 Magdeburg, Germany.	juergen.kraus@medizin.uni-magdeburg.de	Ambrosch, Andreas/GRO-1438-2022					Aharoni R, 2000, P NATL ACAD SCI USA, V97, P11472, DOI 10.1073/pnas.97.21.11472; Bank U, 1999, J INTERF CYTOK RES, V19, P1277, DOI 10.1089/107999099312957; Bencsics A, 1997, J NEUROIMMUNOL, V73, P1, DOI 10.1016/S0165-5728(96)00163-4; Bianchi M, 1999, EUR J NEUROSCI, V11, P1501, DOI 10.1046/j.1460-9568.1999.00563.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De-Fraja C, 1998, J NEUROSCI RES, V54, P320, DOI 10.1002/(SICI)1097-4547(19981101)54:3<320::AID-JNR3>3.0.CO;2-R; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; GAVERIAUX C, 1995, FEBS LETT, V369, P272, DOI 10.1016/0014-5793(95)00766-3; Gaveriaux-Ruff C, 1998, P NATL ACAD SCI USA, V95, P6326, DOI 10.1073/pnas.95.11.6326; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; HEIJNEN CJ, 1991, IMMUNOL REV, V119, P41, DOI 10.1111/j.1600-065X.1991.tb00577.x; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Im HJ, 1999, BRAIN RES, V829, P174, DOI 10.1016/S0006-8993(99)01364-5; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KRAUS J, 1995, BIOCHEM BIOPH RES CO, V215, P591, DOI 10.1006/bbrc.1995.2505; LEFKOWITZ SS, 1975, LIFE SCI, V17, P1763, DOI 10.1016/0024-3205(75)90458-0; Li HL, 2001, J NEUROIMMUNOL, V116, P5, DOI 10.1016/S0165-5728(01)00264-8; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; Liu HY, 2000, CYTOKINE, V12, P1656, DOI 10.1006/cyto.2000.0773; Lovett-Racke AE, 2000, BRAIN RES, V870, P27, DOI 10.1016/S0006-8993(00)02398-2; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; McCarthy L, 2001, J NEUROIMMUNOL, V114, P173, DOI 10.1016/S0165-5728(01)00248-X; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Neumann M, 2000, BLOOD, V95, P277; Ohmori Y, 2000, J BIOL CHEM, V275, P38095, DOI 10.1074/jbc.M006227200; Peterson PK, 1998, J NEUROIMMUNOL, V83, P63, DOI 10.1016/S0165-5728(97)00222-1; Reisine Terry, 1994, Current Opinion in Neurobiology, V4, P406, DOI 10.1016/0959-4388(94)90103-1; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; ROUVEIX B, 1992, THERAPIE, V47, P503; Roy S, 1999, J NEUROIMMUNOL, V95, P107, DOI 10.1016/S0165-5728(98)00265-3; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; Ruzicka BB, 1996, J NEUROCHEM, V66, P425; Ruzicka BB, 1997, NEUROSCIENCE, V79, P517, DOI 10.1016/S0306-4522(96)00669-0; Sacerdote P, 1998, CLIN EXP IMMUNOL, V113, P465; Sacerdote P, 2000, BLOOD, V95, P2031, DOI 10.1182/blood.V95.6.2031; Sacerdote P, 1996, REGUL PEPTIDES, V63, P79; Sambrook J., 2001, MOL CLONING LAB MANU; SCHOUSBOE A, 1985, DEV NEUROSCI-BASEL, V7, P252, DOI 10.1159/000112294; SEDQI M, 1995, BIOCHEM BIOPH RES CO, V209, P563, DOI 10.1006/bbrc.1995.1538; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; Takeda K, 1997, J MOL MED-JMM, V75, P317, DOI 10.1007/s001090050117; VANDENBERGH P, 1993, CELL IMMUNOL, V149, P180, DOI 10.1006/cimm.1993.1146; VANDENBERGH P, 1994, LYMPHOKINE CYTOK RES, V13, P63; Vidal EL, 1998, IMMUNOPHARMACOLOGY, V38, P261, DOI 10.1016/S0162-3109(97)00085-4; WEBER RJ, 1989, SCIENCE, V245, P188, DOI 10.1126/science.2749256; Wendel B, 1998, J MOL MED-JMM, V76, P525, DOI 10.1007/s001090050246; Wick MJ, 1996, J NEUROIMMUNOL, V64, P29, DOI 10.1016/0165-5728(95)00144-1; Woltje M, 1998, FEBS LETT, V440, P107, DOI 10.1016/S0014-5793(98)01441-0; Woltje M, 2000, J NEUROCHEM, V74, P1355, DOI 10.1046/j.1471-4159.2000.0741355.x; ZADINA JE, 1993, J PHARMACOL EXP THER, V265, P254; Zimprich A, 2000, J NEUROCHEM, V74, P472, DOI 10.1046/j.1471-4159.2000.740472.x	60	138	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43901	43908		10.1074/jbc.M107543200	http://dx.doi.org/10.1074/jbc.M107543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11572871	hybrid			2022-12-27	WOS:000172297700056
J	Chairoungdua, A; Kanai, Y; Matsuo, H; Inatomi, J; Kim, DK; Endou, H				Chairoungdua, A; Kanai, Y; Matsuo, H; Inatomi, J; Kim, DK; Endou, H			Identification and characterization of a novel member of the heterodimeric amino acid transporter family presumed to be associated with an unknown heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; MONOCLONAL-ANTIBODY 4F2; RED-BLOOD-CELLS; FUNCTIONAL-CHARACTERIZATION; SUBSTRATE SELECTIVITY; EXPRESSION CLONING; MOLECULAR-BIOLOGY; MEMBRANE-PROTEIN; SYSTEM ASC; GLYCOPROTEIN	We identified a novel amino acid transporter designated Asc-2 (for ase-type amino acid transporter 2). Asc-2 exhibited relatively low but significant sequence similarity to the members of the heterodimeric amino acid transporters. The cysteine residue responsible for the disulfide bond formation between transporters (light chains) and heavy chain subunits in the heterodimeric amino acid transporters is conserved for Asc-2. Asc-2 is, however, not colocalized with the already known heavy chains such as 4F2 heavy chain (4F2hc) or related to b(o,+) amino acid transporter (rBAT) in mouse kidney. Because Ase-2 solely expressed or coexpressed with 4F2hc or rBAT did not induce functional activity, we generated fusion proteins in which Asc-2 is connected with 4F2hc or rBAT. The fusion proteins were sorted to the plasma membrane and expressed the function corresponding to the Na'-independent small neutral amino acid transport system asc. Distinct from the already identified system asc transporter Ase-1 which is associated with 4F2hc, Ase-2-mediated transport is less stereoselective and did not accept some of the high affinity substrates of Asc-1 such as alpha-aminoisobutyric acid and beta-alanine. Ase-2 message was detected in kidney, placenta, spleen, lung, and skeletal muscle. In kidney, Asc-2 protein was present in the epithelial cells lining collecting ducts. In the Western blot analysis on mouse erythrocytes and kidney, Ase-2 was detected as multiple bands in the nonreducing condition, whereas the bands shifted to a single band at lower molecular weight, suggesting the association of Asc-2 with other protein(s) via a disulfide bond. The finding of Ase-2 would lead to the establishment of a new subgroup of heterodimeric amino acid transporter family which includes transporters associated not with 4F2hc or rBAT but with other unknown heavy chains.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Natl Def Med Coll, Dept Physiol 1, Tokorozawa, Saitama 3598513, Japan; Japan Sci & Technol Corp, PRESTO, Mitaka, Tokyo 1818611, Japan	Kyorin University; National Defense Medical College - Japan; Japan Science & Technology Agency (JST)	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.			Matsuo, Hirotaka/0000-0003-4302-8719				ALBI JL, 1994, J MEMBRANE BIOL, V140, P189; ALTMAN A, 1984, P NATL ACAD SCI-BIOL, V81, P2176, DOI 10.1073/pnas.81.7.2176; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; BURG MB, 1995, AM J PHYSIOL, V268, P983; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; FINCHAM DA, 1990, J EXP BIOL, V154, P355; FINCHAM DA, 1985, BIOCHEM J, V227, P13, DOI 10.1042/bj2270013; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GALLARDO MA, 1993, J MEMBRANE BIOL, V134, P251; HARA H, 1976, AM J HEMATOL, V1, P453, DOI 10.1002/ajh.2830010410; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HEMLER ME, 1982, J IMMUNOL, V129, P623; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JANS AWH, 1988, BIOCHIM BIOPHYS ACTA, V971, P157, DOI 10.1016/0167-4889(88)90187-5; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2000, J BIOL CHEM, V275, P20787, DOI 10.1074/jbc.M000634200; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1994, J BIOL CHEM, V269, P20599; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kim JY, 2001, BBA-BIOMEMBRANES, V1512, P335, DOI 10.1016/S0005-2736(01)00338-8; KUHLMANN MK, 1991, J BIOL CHEM, V266, P15042; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAW RO, 1991, COMP BIOCHEM PHYS A, V99, P263, DOI 10.1016/0300-9629(91)90001-S; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Matsuo H, 2000, NEUROREPORT, V11, P3507, DOI 10.1097/00001756-200011090-00021; Mizoguchi K, 2001, KIDNEY INT, V59, P1821, DOI 10.1046/j.1523-1755.2001.0590051821.x; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Nakauchi J, 2000, NEUROSCI LETT, V287, P231, DOI 10.1016/S0304-3940(00)01169-1; NORMAN PSR, 1987, J MEMBRANE BIOL, V96, P153, DOI 10.1007/BF01869241; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1997, BIOCHEM J, V328, P657, DOI 10.1042/bj3280657; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VADGAMA JV, 1985, J BIOL CHEM, V260, P2912; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	58	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49390	49399		10.1074/jbc.M107517200	http://dx.doi.org/10.1074/jbc.M107517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591708	hybrid			2022-12-27	WOS:000173922100100
J	Thuerauf, DJ; Hoover, H; Meller, J; Hernandez, J; Su, L; Andrews, C; Dillmann, WH; McDonough, PM; Glembotski, CC				Thuerauf, DJ; Hoover, H; Meller, J; Hernandez, J; Su, L; Andrews, C; Dillmann, WH; McDonough, PM; Glembotski, CC			Sarco/endoplasmic reticulum calcium ATPase-2 expression is regulated by ATF6 during the endoplasmic reticulum stress response - Intracellular signaling of calcium stress in a cardiac myocyte model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TRANSCRIPTIONAL INDUCTION; TRANSMEMBRANE PROTEIN; GENE-EXPRESSION; CELL-GROWTH; NF-Y; ELEMENT; GLUCOSE; CA2+; ER	The recently described transcription factor, ATF6, mediates the expression of proteins that compensate for potentially stressful changes in the endoplasmic reticulum (ER), such as reduced ER calcium. In cardiac myo. cytes the maintenance of optimal calcium levels in the sarcoplasmic reticulum (SR), a specialized form of the ER, is required for proper contractility. The present study investigated the hypothesis that ATF6 serves as a regulator of the expression of sarco/endoplasmic reticulum calcium ATPase-2 (SERCA2), a protein that transports calcium into the SR from the cytoplasm. Depletion of SR calcium in cultured cardiac myocytes fostered the translocation of ATF6 from the ER to the nucleus, activated the promoter for rat SERCA2, and led to increased levels of SERCA2 protein. SERCA2 promoter induction by calcium depletion was partially blocked by dominant-negative ATF6, whereas constitutively activated ATF6 led to SERCA2 promoter activation. Mutation analyses identified a promoter-proximal ER stress-response element in the rat SERCA2 gene that was required for maximal induction by ATF6 and calcium depletion. Although this element was shown to be responsible for all of the effects of ATF6 on SERCA2 promoter activation, it was responsible for only a portion of the effects of calcium depletion. Thus, SERCA2 induction in response to calcium depletion appears to be a potentially physiologically important compensatory response to this stress that involves intracellular signaling pathways that are both dependent and independent of ATF6.	San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Inst Heart, San Diego, CA 92182 USA.	cglembotski@sciences.sdsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL056861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56861, HL-46345] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; CHEEK TR, 1993, J EXP BIOL, V184, P183; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Ho PD, 2001, CIRC RES, V88, P63, DOI 10.1161/01.RES.88.1.63; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kimura H, 1998, CELL SIGNAL, V10, P349, DOI 10.1016/S0898-6568(97)00134-4; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; Misquitta CM, 1999, CELL CALCIUM, V25, P277, DOI 10.1054/ceca.1999.0032; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Periasamy M, 2001, CIRC RES, V88, P373; Pieske B, 1999, CIRC RES, V85, P38; PROTSKO CR, 1995, J BIOL CHEM, V270, P6211; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Samuel CE, 1997, INT J HEMATOL, V65, P227; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tse FT, 1999, BIOESSAYS, V21, P861, DOI 10.1002/(SICI)1521-1878(199910)21:10<861::AID-BIES8>3.0.CO;2-9; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Heugten HAA, 1998, CARDIOVASC RES, V37, P503, DOI 10.1016/S0008-6363(97)00254-X; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	46	79	81	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48309	48317		10.1074/jbc.M107146200	http://dx.doi.org/10.1074/jbc.M107146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11595740	hybrid			2022-12-27	WOS:000172927000077
J	Brooks, DR; Denise, H; Westrop, GD; Coombs, GH; Mottram, JC				Brooks, DR; Denise, H; Westrop, GD; Coombs, GH; Mottram, JC			The stage-regulated expression of Leishmania mexicana CPB cysteine proteases is mediated by an intercistronic sequence element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRYPANOSOMA-BRUCEI; 3'-UNTRANSLATED REGION; CHAGASI PROMASTIGOTES; GENOMIC ORGANIZATION; GENE FAMILY; SURFACE GLYCOPROTEIN; INFECTIOUS FORM; PROTEINASE; GP63	The tandemly arranged CPB genes of Leishmania mexicana are polycistronically transcribed and encode cysteine proteases that are differentially stage-specific; CPB1 and CPB2 are expressed predominantly in meta-cyclics, whereas CPB3-CPB18 are expressed mainly in amastigotes. The mechanisms responsible for this differential expression have been studied via gene analysis and re-integration of individual CPB genes, and variants thereof, into a CPB-deficient parasite mutant. Comparison of the nucleotide sequences of the repeat units of CPB1 and CPB2 with CPB2.8 (typical of CPB3-CPB18) revealed two major regions of divergence as follows: one of 258 base pairs (bp) corresponding to the C-terminal extension of CPB2.8; another, designated InS, of 120 bp, with insertions totaling 57 bp, localized to the intercistronic region downstream of CPB1 and CPB2. Cell lines expressing CPB2.8 or CPB2 with the W-untranslated region and intercistronic sequence of CPB2.8 showed upregulation in amastigotes. Conversely, metacyclic-specific expression occurred with CPB2 or CPB2.8 with the W-untranslated region and intercistronic sequence of CPB2. Moreover, the InS down-regulated expression in amastigotes of a reporter gene integrated into the CPB locus. It is proposed that the InS mediates metacyclic-specific stage-regulated expression of CPB by affecting the maturation of polycistronic pre-mRNA, This is the first well defined cis-regulatory element implicated in post-transcriptional stage-specific gene expression in Leishmania.	Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	Mottram, JC (corresponding author), Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.			Denise, Hubert/0000-0001-9862-5890; Westrop, Gareth/0000-0002-8011-6219; Mottram, Jeremy/0000-0001-5574-3766				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Bai CY, 1998, NUCLEIC ACIDS RES, V26, P1597, DOI 10.1093/nar/26.7.1597; Bates EJ, 2000, NUCLEIC ACIDS RES, V28, P1211, DOI 10.1093/nar/28.5.1211; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Brittingham A, 2001, MOL BIOCHEM PARASIT, V112, P51, DOI 10.1016/S0166-6851(00)00346-7; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; D'Orso I, 2001, J BIOL CHEM, V276, P34801, DOI 10.1074/jbc.M102120200; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Drozdz M, 1999, RNA, V5, P1632, DOI 10.1017/S1355838299990623; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; FONG D, 1981, P NATL ACAD SCI-BIOL, V78, P7624, DOI 10.1073/pnas.78.12.7624; Frame MJ, 2000, PARASITOLOGY, V121, P367, DOI 10.1017/S0031182099006435; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Hotz HR, 1995, MOL BIOCHEM PARASIT, V75, P1, DOI 10.1016/0166-6851(95)02503-0; Huang T, 2001, MOL CELL BIOL, V21, P1111, DOI 10.1128/MCB.21.4.1111-1120.2001; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; Kelly BL, 2001, MOL BIOCHEM PARASIT, V116, P101, DOI 10.1016/S0166-6851(01)00307-3; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; Liu YM, 2001, RNA, V7, P176, DOI 10.1017/S1355838201002333; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; McCoy JJ, 1998, MOL BIOCHEM PARASIT, V95, P251, DOI 10.1016/S0166-6851(98)00112-1; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X; Molyneux D. H., 1997, Trypanosomiasis and leishmaniasis: biology and control., P39; Mottram JC, 1998, CURR OPIN MICROBIOL, V1, P455, DOI 10.1016/S1369-5274(98)80065-9; Mottram JC, 1997, J BIOL CHEM, V272, P14285, DOI 10.1074/jbc.272.22.14285; MOTTRAM JC, 1992, MOL MICROBIOL, V6, P1925, DOI 10.1111/j.1365-2958.1992.tb01365.x; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Myler PJ, 2000, BIOCHEM SOC T, V28, P527, DOI 10.1042/bst0280527; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1995, J BIOL CHEM, V270, P8884, DOI 10.1074/jbc.270.15.8884; ROBERTSON CD, 1992, FEMS MICROBIOL LETT, V94, P127, DOI 10.1111/j.1574-6968.1992.tb05301.x; ROBERTSON CD, 1994, MICROBIOL-SGM, V140, P417, DOI 10.1099/13500872-140-2-417; Sanderson SJ, 2000, BIOCHEM J, V347, P383, DOI 10.1042/0264-6021:3470383; SOUZA AE, 1992, FEBS LETT, V311, P124, DOI 10.1016/0014-5793(92)81382-V; SPITHILL TW, 1987, MOL BIOCHEM PARASIT, V24, P23, DOI 10.1016/0166-6851(87)90112-5; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wincker P, 1996, NUCLEIC ACIDS RES, V24, P1688, DOI 10.1093/nar/24.9.1688; Wu Y, 2000, MOL BIOCHEM PARASIT, V110, P345, DOI 10.1016/S0166-6851(00)00290-5	56	53	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47061	47069		10.1074/jbc.M108498200	http://dx.doi.org/10.1074/jbc.M108498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592967	hybrid			2022-12-27	WOS:000172768500053
J	Chiti, F; De Lorenzi, E; Grossi, S; Mangione, P; Giorgetti, S; Caccialanza, G; Dobson, CM; Merlini, G; Ramponi, G; Bellotti, V				Chiti, F; De Lorenzi, E; Grossi, S; Mangione, P; Giorgetti, S; Caccialanza, G; Dobson, CM; Merlini, G; Ramponi, G; Bellotti, V			A partially structured species of beta(2)-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY-ZONE-ELECTROPHORESIS; QUANTITATIVE-ANALYSIS; AMYLOID FIBRILS; IN-VITRO; BETA-2-MICROGLOBULIN; CONFORMATIONS; PROTEINS	The folding Of beta (2)-microglobulin (beta (2)-M), the protein forming amyloid deposits in dialysis-related amyloidosis, involves formation of a partially folded conformation named I-2, which slowly converts into the native fold, N. Here we show that the partially folded species I-2 can be separated from N by capillary electrophoresis. Data obtained with this technique and analysis of kinetic data obtained with intrinsic fluorescence indicate that the I-2 conformation is populated to similar to 14 +/- 8% at equilibrium under conditions of pH and temperature close to physiological. In the presence of fibrils extracted from patients, the I-2 conformer has a 5-fold higher propensity to aggregate than N, as indicated by the thioflavine T test and light scattering measurements. A mechanism of aggregation of beta (2)-M in vivo involving the association of the preformed fibrils with the fraction of I-2, existing at equilibrium is proposed from these results. The possibility of isolating and quantifying a partially folded conformer of beta (2)-M involved in the amyloidogenesis process provides new opportunities to monitor hemodialytic procedures aimed at the reduction of such species from the pool of circulating beta (2)-m but also to design new pharmaceutical approaches that consider such species as a putative molecular target.	Univ Pavia, Dipartimento Biochim, I-27100 Pavia, Italy; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Pavia, Dipartimento Chim Farmaceut, I-27100 Pavia, Italy; Policlin San Matteo, Biotechnol Labs, IRCCS, I-27100 Pavia, Italy; Univ Pavia, Ctr Interdipartimentale Biol Appl, I-27100 Pavia, Italy; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Pavia; University of Florence; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia; University of Pavia; University of Cambridge	Bellotti, V (corresponding author), Univ Pavia, Dipartimento Biochim, Via Taramelli 3B, I-27100 Pavia, Italy.		De Lorenzi, Ersilia/ABC-5635-2021; Bellotti, Vittorio/A-6201-2014; Merlini, Giampaolo/A-3817-2008; Giorgetti, Sofia/AAD-4341-2019	De Lorenzi, Ersilia/0000-0002-5450-7208; Bellotti, Vittorio/0000-0001-8678-662X; Merlini, Giampaolo/0000-0001-7680-3254; Giorgetti, Sofia/0000-0001-9438-6511; Mangione, Palma/0000-0003-0260-1400	Telethon [453/BI, GP0186Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ACKERMANS MT, 1991, J CHROMATOGR, V549, P345, DOI 10.1016/S0021-9673(00)91445-6; ARUGA E, 1993, LAB INVEST, V69, P223; Bellotti V, 1999, CELL MOL LIFE SCI, V55, P977, DOI 10.1007/s000180050348; Bellotti V, 1998, EUR J BIOCHEM, V258, P61, DOI 10.1046/j.1432-1327.1998.2580061.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; CONNORS LH, 1985, BIOCHEM BIOPH RES CO, V131, P1063, DOI 10.1016/0006-291X(85)90198-6; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Drueke TB, 2000, NEPHROL DIAL TRANSPL, V15, P17, DOI 10.1093/oxfordjournals.ndt.a027958; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; FLOEGE J, 1996, NEPHRON, V723, P9; Heegaard NHH, 2001, J BIOL CHEM, V276, P32657, DOI 10.1074/jbc.M104452200; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; HILSER VJ, 1995, ANAL BIOCHEM, V224, P465, DOI 10.1006/abio.1995.1075; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Nangaku M, 1999, AM J MED SCI, V317, P410, DOI 10.1097/00000441-199906000-00010; SWENSON RP, 1982, J BIOL CHEM, V257, P8817; Verzola B, 2000, ANAL BIOCHEM, V282, P239, DOI 10.1006/abio.2000.4620; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; ZAOUI PM, 1990, KIDNEY INT, V38, P962, DOI 10.1038/ki.1990.298	23	126	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46714	46721		10.1074/jbc.M107040200	http://dx.doi.org/10.1074/jbc.M107040200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590172	hybrid			2022-12-27	WOS:000172768500007
J	Nakama, T; Nureki, O; Yokoyama, S				Nakama, T; Nureki, O; Yokoyama, S			Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ANGSTROM CRYSTAL-STRUCTURE; PSEUDOMONIC ACID; ESCHERICHIA-COLI; ANTIBACTERIAL ACTIVITY; STAPHYLOCOCCUS-AUREUS; RESISTANCE; COMPLEX; ENZYME; SITE	An analogue of isoleucyl-adenylate (Ile-AMS) potently inhibits the isoleucyl-tRNA synthetases (IleRSs) from the three primary kingdoms, whereas the antibiotic mupirocin inhibits only the eubacterial and archaeal IleRSs, but not the eukaryotic enzymes, and therefore is clinically used against methicillin-resistant Staphylococcus aureus. We determined the crystal structures of the IleRS from the thermophilic eubacterium, Thermus thermophilus, in complexes with Ile-AMS and mupirocin at 3.0- and 2.5-Angstrom resolutions, respectively. A structural comparison of the IleRS-Ile-AMS complex with the adenylate complexes of other aminoacyl-tRNA synthetases revealed the common recognition mode of aminoacyladenylate by the class I aminoacyl-tRNA synthetases. The Ile-AMS and mupirocin, which have significantly different chemical structures, are recognized by many of the same amino acid residues of the IleRS, suggesting that the antibiotic inhibits the enzymatic activity by blocking the binding site of the high energy intermediate, Ile-AMP. In contrast, the two amino acid residues that concomitantly recognize Ile-AMS and mupirocin are different between the eubacterial/archaeal IleRSs and the eukaryotic IleRSs. Mutagenic analyses revealed that the replacement of the two residues significantly changed the sensitivity to mupirocin.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN Genome Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN Harima Inst, SPring 8, Mikazuki, Hyogo 6795148, Japan	University of Tokyo; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Nureki, O (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; Brown P, 1997, J MED CHEM, V40, P2563, DOI 10.1021/jm960738k; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAIN EB, 1977, J CHEM SOC PERK T, V3, P294; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; DYKE KGH, 1991, FEMS MICROBIOL LETT, V77, P195, DOI 10.1111/j.1574-6968.1991.tb04346.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; GILBART J, 1993, ANTIMICROB AGENTS CH, V37, P32, DOI 10.1128/AAC.37.1.32; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; Ilyin VA, 2000, PROTEIN SCI, V9, P218; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAHMAN M, 1987, LANCET, V2, P387; RAHMAN M, 1990, J MED MICROBIOL, V33, P97, DOI 10.1099/00222615-33-2-97; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; Sassanfar M, 1996, BIOCHEMISTRY-US, V35, P9995, DOI 10.1021/bi9603027; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; SUTHERLAND R, 1985, ANTIMICROB AGENTS CH, V27, P495, DOI 10.1128/AAC.27.4.495; YANAGISAWA T, 1994, J BIOL CHEM, V269, P24304	29	140	145	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47387	47393		10.1074/jbc.M109089200	http://dx.doi.org/10.1074/jbc.M109089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584022	hybrid			2022-12-27	WOS:000172768500094
J	Zamora, R; Alarcon, L; Vodovotz, Y; Betten, B; Kim, PKM; Gibson, KF; Billiar, TR				Zamora, R; Alarcon, L; Vodovotz, Y; Betten, B; Kim, PKM; Gibson, KF; Billiar, TR			Nitric oxide suppresses the expression of Bcl-2 binding protein BNIP3 in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; BCL-2-BINDING PROTEIN; FUNCTIONAL-ANALYSIS; INHIBITS APOPTOSIS; ORGAN DYSFUNCTION; GUANYLATE-CYCLASE; GENE-EXPRESSION; HUMAN HOMOLOG; BH3 DOMAIN; SYNTHASE	Nitric oxide (NO) is not only an important signaling molecule, but it also regulates the expression of a number of genes in the liver. We have previously shown that apoptosis in hepatocytes exposed to tumor necrosis factor-a and actinomycin D is prevented by NO derived from the inducible nitric-oxide synthase (iNOS), by mechanisms that are both dependent on and independent of modulation of cyclic guanosine monophosphate (cGMP) subsequent to activation of soluble guanylyl cyclase (sGC). We hypothesize that one mechanism by which NO exerts these effects is by regulating the expression of genes involved in apoptosis. We used differential display-polymerase chain reaction to isolate NO-regulated genes in hepatocytes from iNOS knockout mice (to eliminate endogenous inducible NO production). Using this analysis, we identified a NO-suppressed gene fragment homologous with the pro-apoptotic Bcl-2 binding protein BNIP3. Northern analysis confirmed the NO-dependent suppression of BNIP3 in cultured cells. Similarly, the NO donor S-nitroso-N-acetyl-DL-penicillamine (1-1000 mum) down-regulated the expression of BNIP3 in both iNOS knockout and wild-type hepatocytes. This effect of NO was reversed by the sGC inhibitor 1H-(1,2,4)-oxadiazole[4,3-alpha ]quinoxalon-1-one (ODQ), suggesting the involvement of the sGC/cGMP pathway in the modulation of BNIP3 by NO. We propose that suppression of BNIP3 expression is one sGC/cGMP-dependent mechanism by which NO might affect the process of hepatocyte apoptosis.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zamora, R (corresponding author), Rangos Res Ctr, CHP, Dept Pediat Surg, 3705 5th Ave,Rm 8125, Pittsburgh, PA 15213 USA.	zamorar@pitt.edu	Zamora, Renato/ABE-6898-2020	Zamora, Renato/0000-0002-2223-3361	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SG, 1999, BIOCHEM BIOPH RES CO, V260, P216, DOI 10.1006/bbrc.1999.0856; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Hakoda S, 1999, SURG TODAY, V29, P1059, DOI 10.1007/s005950050645; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Jarrar D, 1999, INT J MOL MED, V4, P575; Johnson ML, 1998, WORLD J SURG, V22, P187, DOI 10.1007/s002689900368; Juan TSC, 1996, ONCOGENE, V13, P749; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li JR, 2000, SEMIN PERINATOL, V24, P46, DOI 10.1016/S0146-0005(00)80055-5; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Nakata M, 1999, CELL STRUCT FUNCT, V24, P451, DOI 10.1247/csf.24.451; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; Ou JH, 1997, NITRIC OXIDE-BIOL CH, V1, P404, DOI 10.1006/niox.1997.0136; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Remick DG, 1996, J LEUKOCYTE BIOL, V59, P471, DOI 10.1002/jlb.59.4.471; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; STAMLER JS, 1996, NITRIX OXIDE RES, P521; Szabo C, 1999, SHOCK, V12, P1, DOI 10.1097/00024382-199907000-00001; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Taylor BS, 1998, BIOCHEMISTRY-MOSCOW+, V63, P766; Tirmenstein MA, 2000, TOXICOL SCI, V53, P56, DOI 10.1093/toxsci/53.1.56; Tzeng E, 1996, MOL MED, V2, P211, DOI 10.1007/BF03401618; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wang HR, 1998, J BIOCHEM-TOKYO, V124, P892, DOI 10.1093/oxfordjournals.jbchem.a022204; Wink David A., 1999, P245; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; YODOVOTZ Y, 2001, NITRIC OXIDE INFLAMM, P41; Zamora R, 2001, ARCH BIOCHEM BIOPHYS, V390, P287, DOI 10.1006/abbi.2001.2391; Zamora Ruben, 2000, Nitric Oxide, V4, P183	51	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46887	46895		10.1074/jbc.M101865200	http://dx.doi.org/10.1074/jbc.M101865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592958	hybrid			2022-12-27	WOS:000172768500030
J	Boeuf, H; Merienne, K; Jacquot, S; Duval, D; Zeniou, M; Hauss, C; Reinhardt, B; Huss-Garcia, Y; Dierich, A; Frank, DA; Hanauer, A; Kedinger, C				Boeuf, H; Merienne, K; Jacquot, S; Duval, D; Zeniou, M; Hauss, C; Reinhardt, B; Huss-Garcia, Y; Dierich, A; Frank, DA; Hanauer, A; Kedinger, C			The ribosomal S6 kinases, cAMP-responsive element-binding, and STAT3 proteins are regulated by different leukemia inhibitory factor signaling pathways in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INDUCED TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; CREB PHOSPHORYLATION; SELF-RENEWAL; MAPK PATHWAY; DNA-BINDING; RECEPTOR; GENE; LIF	Mouse embryonic stem (ES) cells remain "pluripotent" in vitro in the continuous presence of leukemia inhibitory factor (LIF). In the absence of LIF, ES cells are irreversibly committed to differentiate into various lineages. In this study we have set up an in vitro assay based on the anti-apoptotic activity of LIF to distinguish pluripotent from "differentiation-committed" ES cells. We have examined the phosphorylation profiles of known (STAT3 and ERKs) and identified new (ribosomal S6 kinases (RSKs) and cAMP-responsive element-binding protein (CREB)) LIF-regulated targets in ES and in ES-derived neuronal cells. We have demonstrated that although STAT3, a crucial player in the maintenance of ES cell pluripotency, is induced by LIF in all cell types tested, the LIF-dependent activation of RSKs is restricted to ES cells. We have shown that LIF-induced phosphorylation of RSKs in ES cells is dependent on ERKs, whereas STAT3 phosphorylation is not mediated by any known MAPK activities. Our results also demonstrate that the LIF-dependent phosphorylation of CREB is partially under the control of the RSK2 kinase.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; Univ Zurich, Div Neuroanat & Behav, Inst Anat, Zurich, Switzerland; Ecole Super Biotechnol Strasbourg, FRE 2370, F-67400 Strasbourg, France; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Zurich; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Harvard University; Dana-Farber Cancer Institute	Kedinger, C (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163, F-67404 Illkirch Graffenstaden, France.	ln@igbmc.u-strasbg.fr	DUVAL, David/B-8586-2011	Merienne, Karine/0000-0003-2549-2315; Duval, David/0000-0001-6933-3354				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; ALOISI F, 1994, J IMMUNOL, V152, P5022; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bradley A, 1998, INT J DEV BIOL, V42, P943; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cheng JG, 1997, MOL CELL NEUROSCI, V9, P372, DOI 10.1006/mcne.1997.0635; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gadient RA, 1998, BRAIN RES, V798, P140, DOI 10.1016/S0006-8993(98)00236-4; Gollob JA, 1999, J IMMUNOL, V162, P4472; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hoey T, 1999, Adv Immunol, V71, P145; HOGAN BL, 1994, LAB MANUAL, P255; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jacquot S, 1999, AM J MED GENET, V85, P214, DOI 10.1002/(SICI)1096-8628(19990730)85:3<214::AID-AJMG5>3.0.CO;2-1; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lake JA, 2000, J CELL SCI, V113, P555; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pera MF, 2001, CURR OPIN GENET DEV, V11, P595, DOI 10.1016/S0959-437X(00)00238-0; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shellard J, 1996, EUR CYTOKINE NETW, V7, P699; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Taupin J L, 1998, Int Rev Immunol, V16, P397, DOI 10.3109/08830189809043003; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Walton M, 1999, J NEUROCHEM, V73, P1836; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Westmoreland JJ, 2001, BIOCHEM BIOPH RES CO, V284, P674, DOI 10.1006/bbrc.2001.5031; Woetmann A, 1999, P NATL ACAD SCI USA, V96, P10620, DOI 10.1073/pnas.96.19.10620; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	85	47	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46204	46211		10.1074/jbc.M106718200	http://dx.doi.org/10.1074/jbc.M106718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581263	hybrid			2022-12-27	WOS:000172573100097
J	Liu, XH; Collier, RJ; Youle, RJ				Liu, XH; Collier, RJ; Youle, RJ			Inhibition of axotomy-induced neuronal apoptosis by extracellular delivery of a Bcl-XL fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL GANGLION-CELLS; NERVE GROWTH-FACTOR; TOXIN-MEDIATED DELIVERY; TRANSGENIC MICE; ANTHRAX TOXIN; LETHAL FACTOR; PROTECTIVE ANTIGEN; IN-VITRO; DEATH; EXPRESSION	Bcl-2 and Bcl-XL prevent neuronal apoptosis during development, neurodegenerative disease, and trauma. To test a new anti-apoptosis strategy for neuroprotection, we engineered nontoxic components of anthrax toxin into a Bcl-XL delivery system. Delivery of Bcl-XL by this system prevented apoptosis of cultured rat cerebellar granule cells and macrophages, and the prevention depended on both the Bcl-XL and the anthrax toxin receptor binding/translocation moieties. Furthermore, neuronal death in vivo in a retinal ganglion cell model of axotomy-induced apoptosis was inhibited by administration of this fusion protein. Thus, Bcl-XL protein can he delivered into cells from the medium or interstitial space, offering a new way to block apoptosis upstream of many caspases and the mitochondria dysfunction phase of apoptosis.	NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Harvard University; Harvard Medical School	Youle, RJ (corresponding author), NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bldg 10,Rm 5D-37,MSC 1414,10 Ctr Dr, Bethesda, MD 20892 USA.	youle@helix.nih.gov		Collier, R John/0000-0002-2427-4239	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002674, ZIANS002859, ZIANS002674, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; ARORA N, 1994, J BIOL CHEM, V269, P26165; Ballard JD, 1998, INFECT IMMUN, V66, P615, DOI 10.1128/IAI.66.2.615-619.1998; Ballard JD, 1996, P NATL ACAD SCI USA, V93, P12531, DOI 10.1073/pnas.93.22.12531; Ballard JD, 1998, INFECT IMMUN, V66, P4696, DOI 10.1128/IAI.66.10.4696-4699.1998; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonfanti L, 1996, J NEUROSCI, V16, P4186; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BRAGG TS, 1989, GENE, V81, P45, DOI 10.1016/0378-1119(89)90335-1; Cenni MC, 1996, EUR J NEUROSCI, V8, P1735, DOI 10.1111/j.1460-9568.1996.tb01317.x; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doling AM, 1999, INFECT IMMUN, V67, P3290, DOI 10.1128/IAI.67.7.3290-3296.1999; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FANG W, 1994, J IMMUNOL, V153, P4388; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goletz TJ, 1997, P NATL ACAD SCI USA, V94, P12059, DOI 10.1073/pnas.94.22.12059; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HARVEY AR, 1994, EUR J NEUROSCI, V6, P550, DOI 10.1111/j.1460-9568.1994.tb00299.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Kasarskis EJ, 1999, NEUROLOGY, V52, P1427; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Lawrence MS, 1996, J NEUROSCI, V16, P486; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu XH, 1999, P NATL ACAD SCI USA, V96, P9563, DOI 10.1073/pnas.96.17.9563; Lonser RR, 1998, J NEUROSURG, V89, P616, DOI 10.3171/jns.1998.89.4.0616; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McArthur, 2000, NEUROLOGY, V55, P162; McArthur JC, 2000, NEUROLOGY, V54, P1080, DOI 10.1212/WNL.54.5.1080; MERRY DE, 1994, DEVELOPMENT, V120, P301; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Mufson EJ, 1999, PROG NEUROBIOL, V57, P451, DOI 10.1016/S0301-0082(98)00059-8; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nir I, 2000, J NEUROSCI, V20, P2150; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Porciatti V, 1996, P NATL ACAD SCI USA, V93, P14955, DOI 10.1073/pnas.93.25.14955; RABACCHI SA, 1994, J NEUROSCI, V14, P5292; Rosenblum WI, 1999, STROKE, V30, P1154, DOI 10.1161/01.STR.30.5.1154; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SMALE G, 1995, EXP NEUROL, V55, P481; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	72	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46326	46332		10.1074/jbc.M108930200	http://dx.doi.org/10.1074/jbc.M108930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574549	hybrid			2022-12-27	WOS:000172573100114
J	Southall, MD; Isenberg, JS; Nakshatri, H; Yi, QF; Pei, Y; Spandau, DF; Travers, JB				Southall, MD; Isenberg, JS; Nakshatri, H; Yi, QF; Pei, Y; Spandau, DF; Travers, JB			The platelet-activating factor receptor protects epidermal cells from tumor necrosis factor (TNF) alpha and TNF-related apoptosis-inducing ligand-induced apoptosis through an NF-kappa B-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; HUMAN KERATINOCYTES; TRANSFORMED KERATINOCYTES; DEATH; SUPPRESSION; INHIBITOR; IAP; IDENTIFICATION; BIOSYNTHESIS; EXPRESSION	A number of chemical mediators can induce human keratinocytes and epidermal-derived carcinomas to undergo apoptosis, or programmed cell death. Recent evidence suggests pro-inflammatory cytokines, such as interleukin-1 beta or transforming growth factor alpha, protects carcinomas from numerous pro-apoptotic stimuli. Platelet-activating factor (1-alkyl-2-acetyl-3-glycerophosphocholine; PAF) is a lipid mediator with pro-inflammatory effects on numerous cell types. Although PAF can be metabolized to other bioactive lipids, the majority of PAF effects occur through activation of a G protein-coupled receptor. Using a model system created by retroviral transduction of the PAF receptor (PAF-R) into the PAF-R-negative human epidermal cell line KB and the PAF-R-expressing keratinocyte cell line HaCaT, we now demonstrate that activation of the epidermal PAF-R results in protection from apoptosis induced by tumor necrosis factor (TNF) alpha or TNF-related apoptosis-inducing ligand. The PAF-mediated protection was inhibited by PAF-R antagonists, and protection did not occur in PAF-R-negative KB cells. Additionally, we show protection from TNF alpha- or TRAIL-induced apoptosis by PAF-R activation is dependent on the transcription factor nuclear factor (NF)-kappaB, because PAF-R activation-induced NF-kappaB and epidermal cells transduced with a super-repressor form of inhibitor kappaB were not protected by the PAF-R. These studies provide a mechanism whereby the epidermal PAF-R, and possibly other G protein-coupled receptors, can exert anti-apoptotic effects through an NF-kappaB-dependent process.	Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Travers, JB (corresponding author), Indiana Univ, Sch Med, Riley Hosp Children, HB Wells Ctr Pediat Res, 702 Barnhill Dr,Rm 2659, Indianapolis, IN 46202 USA.			Travers, Jeffrey/0000-0001-7232-1039; Nakshatri, Harikrishna/0000-0001-8876-0052	NHLBI NIH HHS [R01HL62996] Funding Source: Medline; NIAMS NIH HHS [K08AR1993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; AZZOUZI BE, 1993, BIOCHEM BIOPH RES CO, V190, P320; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bours V, 2000, TOXICOLOGY, V153, P27, DOI 10.1016/S0300-483X(00)00302-4; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; DENIZOT Y, 1995, CANCER LETT, V88, P185, DOI 10.1016/0304-3835(94)03631-R; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DOSSANTOS OFP, 1991, KIDNEY INT, V40, P742, DOI 10.1038/ki.1991.269; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Dy LC, 1999, J BIOL CHEM, V274, P26917, DOI 10.1074/jbc.274.38.26917; EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Foo SY, 1999, TRENDS GENET, V15, P229; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Grignani F, 1998, CANCER RES, V58, P14; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Leverkus M, 2000, CANCER RES, V60, P553; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Mustapha S, 2000, AM J PHYSIOL-HEART C, V279, pH939, DOI 10.1152/ajpheart.2000.279.3.H939; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Pei Y, 1998, J IMMUNOL, V161, P1954; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Pulliam L, 1998, J NEUROSCI RES, V54, P530, DOI 10.1002/(SICI)1097-4547(19981115)54:4<530::AID-JNR10>3.0.CO;2-1; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reinartz J, 1996, EXP CELL RES, V228, P334, DOI 10.1006/excr.1996.0333; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Toledano BJ, 1999, CELL IMMUNOL, V191, P60, DOI 10.1006/cimm.1998.1410; Travers JB, 1999, J INVEST DERMATOL, V112, P279, DOI 10.1046/j.1523-1747.1999.00521.x; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Williams DA, 2000, BLOOD, V96, P1646; WOODCOCK A, 1976, BRIT J DERMATOL, V95, P459, DOI 10.1111/j.1365-2133.1976.tb00854.x	54	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45548	45554		10.1074/jbc.M105978200	http://dx.doi.org/10.1074/jbc.M105978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571293	hybrid, Green Published			2022-12-27	WOS:000172573100010
J	Yoo, SH; Oh, YS; Kang, MK; Huh, YH; So, SH; Park, HS; Park, HY				Yoo, SH; Oh, YS; Kang, MK; Huh, YH; So, SH; Park, HS; Park, HY			Localization of three types of the inositol 1,4,5-trisphosphate receptor/Ca2+ channel in the secretory granules and coupling with the Ca2+ storage proteins chromogranins A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSE-MEDIATED RELEASE; MEMBRANE-BINDING REGION; CYTOSOLIC CA2+; TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; CONFORMATIONAL CHANGE; ADRENAL-MEDULLA; CELLS; PH; EXPRESSION	Although the role of secretory granules as the inositol 1,4,5-trisphosphate (IP3)-sensitive intracellular Ca2+ store and the presence of the IP3 receptor (IP3R)/Ca2+ channel on the secretory granule membrane have been established, the identity of the IP3R types present in the secretory granules is not known. We have therefore investigated the presence of different types of IP3R in the secretory granules of bovine adrenal medullary chromaffin cells using immunogold electron microscopy and found the existence of all three types of IP3R in the secretory granules. To determine whether these IP(3)Rs interact with CGA and CGB, each IP3R isoform was cotransfected with CGA or CGB into NIH3T3 or COS-7 cells, and the expressed IP3R isoform. and CGA or CGB were co-immunoprecipitated. From these studies it was shown that all three types of IP3R form complexes with CGA and CGB in the cells. To further confirm whether the IP3R isoforms and CGA and CGB form a complex in the secretory granules the potential interaction between all three isoforms of IP3R and CGA and CGB was tested by co-immunoprecipitation experiements of the mixture of secretory granule lysates and the granule membrane proteins. The three isoforms of IP3R were shown to form complexes with CGA and CGB, indicating the complex formation between the three isoforms of IP3R and CGA and CGB in the secretory granules. Moreover, the pH-dependent Ca2+ binding property of CGB was also studied using purified recombinant CGB, and it was shown that CGB bound 93 mol of Ca2+/mol with a dissociation constant (K-d) of 1.5 mm at pH 5.5 but virtually no Ca2+ at pH 7.5. The high capacity, low affinity Ca2+-binding property of CGB at pH 5.5 is comparable with that of CGA and is in line with its role as a Ca2+ storage protein in the secretory granules.	Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Secretory Granule Res, Yu Sung Gu, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Yoo, SH (corresponding author), Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Secretory Granule Res, Yu Sung Gu, Taejon 305701, South Korea.							Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; Chen YA, 2001, J BIOL CHEM, V276, P26680, DOI 10.1074/jbc.M103522200; DeSmedt H, 1997, BIOCHEM J, V322, P575; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GILL BM, 1991, REGUL PEPTIDES, V33, P223, DOI 10.1016/0167-0115(91)90216-4; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; HAGN C, 1986, LAB INVEST, V55, P405; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Kern Horst F., 1993, P9; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Mak DOD, 1999, J BIOL CHEM, V274, P22231, DOI 10.1074/jbc.274.32.22231; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MATTER N, 1993, J BIOL CHEM, V268, P732; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Mundorf ML, 1999, J NEUROCHEM, V73, P2397, DOI 10.1046/j.1471-4159.1999.0732397.x; Mundorf ML, 2000, J BIOL CHEM, V275, P9136, DOI 10.1074/jbc.275.13.9136; Murphy SM, 1998, J HISTOCHEM CYTOCHEM, V46, P1261, DOI 10.1177/002215549804601106; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; NORDMANN JJ, 1984, J NEUROCHEM, V42, P434, DOI 10.1111/j.1471-4159.1984.tb02696.x; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; Quesada I, 2001, BIOPHYS J, V80, P2133, DOI 10.1016/S0006-3495(01)76186-3; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMON JP, 1989, BIOCHEM J, V262, P1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Thrower EC, 2001, BIOPHYS J, V80, p455A; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199	57	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45806	45812		10.1074/jbc.M107532200	http://dx.doi.org/10.1074/jbc.M107532200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584008	hybrid			2022-12-27	WOS:000172573100042
J	Bello, RI; Gomez-Diaz, C; Navarro, F; Alcain, FJ; Villalba, JM				Bello, RI; Gomez-Diaz, C; Navarro, F; Alcain, FJ; Villalba, JM			Expression of NAD(P)H : Quinone oxidoreductase 1 in HeLa cells - Role of hydrogen peroxide and growth phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANTIOXIDANT-RESPONSE-ELEMENT; DT-DIAPHORASE; RAT HEPATOCYTES; PROLIFERATING CELLS; AEROBIC GLYCOLYSIS; OXIDATIVE STRESS; MITOMYCIN-C; VITAMIN-E; REDUCTASE	The aim of this work was to study the role of H2O2 in the regulation of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.99.2) with relation to cell density of HeLa cells cultures and the function played by NQO1 in these cells. Levels of NQO1 activity were much higher (40-fold) in confluent HeLa cells than in sparse cells, the former cells being much more resistant to H2O2. Addition of sublethal concentrations of H2O2 (up to 24 muM) produced a significant increase of NQO1 (up to 16-fold at 12 muM) in sparse cells but had no effect in confluent cells. When cells reached confluency in the presence of pyruvate, a H2O2 scavenger, NQO1 activity was decreased compared with cultures grown to confluency without pyruvate. Inhibition of quinone reductases by dicumarol substantially decreased viability of confluent cells in serum-free medium. This is the first demonstration that regulation of NQO1 expression by H2O2 is dependent on the cell density in HeLa cells and that endogenous generation of H2O2 participates in the increase of NQO1 activity as cell density is higher. This enzyme is required to promote survival of confluent cells.	Univ Cordoba, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Cordoba 14071, Spain	Universidad de Cordoba	Villalba, JM (corresponding author), Univ Cordoba, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Edificio C-6,3A Planta, Cordoba 14014, Spain.	bc1vimoj@uco.es	Navarro Roldán, Francisco/H-8611-2015; Alcain, Francisco J./N-7503-2016	Navarro Roldán, Francisco/0000-0002-6384-5575; Alcain, Francisco J./0000-0002-6833-7940; Villalba Montoro, Jose Manuel/0000-0001-8554-3802				Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; Brand K, 1997, J BIOENERG BIOMEMBR, V29, P355, DOI 10.1023/A:1022498714522; Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507; BROWN JM, 1989, INFLAMMATION, V13, P583, DOI 10.1007/BF00916764; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; BURDON RH, 1993, FREE RADICAL RES COM, V18, P369, DOI 10.3109/10715769309147503; Burdon RH, 1996, FEBS LETT, V383, P150, DOI 10.1016/0014-5793(96)00230-X; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Del Bello B, 1999, FASEB J, V13, P69; DELBELLO B, 1976, FASEB J, V32, P465; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; ERNSTER L, 1958, FED PROC, V17, P216; ERNSTER L, 1958, ACTA CHEM SCAND, V12, P595, DOI 10.3891/acta.chem.scand.12-0595; Faig M, 2000, P NATL ACAD SCI USA, V97, P3177, DOI 10.1073/pnas.050585797; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200; Garrido C, 1997, CANCER RES, V57, P2661; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Joseph P, 2000, BRIT J CANCER, V82, P1305; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kreuzer T, 1998, FREE RADICAL BIO MED, V25, P42, DOI 10.1016/S0891-5849(98)00029-X; Landi L, 1997, FREE RADICAL BIO MED, V22, P329, DOI 10.1016/S0891-5849(96)00294-8; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; LIND C, 1990, METHOD ENZYMOL, V186, P287; Long DJ, 2000, CANCER RES, V60, P5913; Marin A, 1997, BRIT J CANCER, V76, P923, DOI 10.1038/bjc.1997.485; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Navarro F, 1999, BIOFACTORS, V9, P163, DOI 10.1002/biof.5520090211; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Petitpas I, 2001, J BIOL CHEM, V276, P22804, DOI 10.1074/jbc.M100575200; Phillips RM, 1997, BRIT J CANCER, V75, P196, DOI 10.1038/bjc.1997.33; PHILLIPS RM, 1994, CANCER RES, V54, P3766; Phillips RM, 2000, CANCER RES, V60, P6384; PREUSCH PC, 1991, FREE RADICAL BIO MED, V11, P77, DOI 10.1016/0891-5849(91)90191-5; RAHMAN MH, 1992, J PHARMACOBIO-DYNAM, V15, P7, DOI 10.1248/bpb1978.15.7; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHLAGER JJ, 1993, CANCER RES, V53, P1338; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; Sieger D, 2000, FREE RADICAL BIO MED, V29, P246, DOI 10.1016/S0891-5849(00)00310-5; Siemankowski LM, 2000, CANCER RES, V60, P3638; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Suzuki K, 1997, J BIOCHEM, V121, P496; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Takahashi T, 1999, BIOL PHARM BULL, V22, P1226; Uchida N, 2000, J BACTERIOL, V182, P6933, DOI 10.1128/JB.182.24.6933-6939.2000; WOSILAIT WD, 1981, DRUG METAB DISPOS, V9, P80; Wu KB, 1997, ARCH BIOCHEM BIOPHYS, V347, P221, DOI 10.1006/abbi.1997.0344; YOSHPEPURER Y, 1976, APPL ENVIRON MICROB, V32, P465, DOI 10.1128/AEM.32.4.465-469.1976	59	45	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44379	44384		10.1074/jbc.M107168200	http://dx.doi.org/10.1074/jbc.M107168200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567026	hybrid			2022-12-27	WOS:000172406700005
J	Bieberich, E; MacKinnon, S; Silva, J; Yu, RK				Bieberich, E; MacKinnon, S; Silva, J; Yu, RK			Regulation of apoptosis during neuronal differentiation by ceramide and b-series complex gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; NEUROBLASTOMA-CELLS; SIGNAL-TRANSDUCTION; STEM-CELLS; PKC-ZETA; PROTEIN; EXPRESSION; GROWTH; DEATH; INSULIN-LIKE-GROWTH-FACTOR-1	Lipid analysis of gestational day E14.5 mouse brain revealed elevation of ceramide to a tissue concentration that induced apoptosis when added to the medium of neuroprogenitor cells grown in cell culture. Elevation of ceramide was coincident with the first appearance of b-series complex gangliosides (BCGs). Expression of BCGs by stable transfection of murine neuroblastoma (F-11) cells with sialyltransferase-II (ST2) resulted in a 70% reduction of ceramide-induced apoptosis. This was most likely due to an 80% reduced expression of prostate apoptosis response-4 (PAR-4). PAR-4 expression and apoptosis were restored by preincubation of ST2-transfected cells with N-butyl deoxinojirimycin (NB-DNJ) or PD98059, two inhibitors of ganglioside biosynthesis or p42/44 mitogen-activated protein (MAPK) kinase, respectively. In sections of day E14.5 mouse brain, the intermediate zone showed intensive staining for complex gangliosides, but only low staining for apoptosis (TUNEL) and PAR-4. Apoptosis and PAR-4 expression, however, were elevated in the ventricular zone which only weakly stained for complex gangliosides. Whole cell patch clamping revealed a 2-fold increased calcium influx in ST2-transfected cells, the blocking of which with nifedipine restored apoptosis to the level of untransfected cells. In serum-free culture, supplementation of the medium with IGF-1 was required to maintain MAPK phosphorylation and the anti-apoptotic effect of BCG expression. BCG-enhanced calcium influx and the presence of insulin-like growth factor-1 may thus activate a cell survival mechanism that selectively protects developing neurons against ceramide-induced apoptosis by up-regulation of MAPK and reduction of PAR-4 expression.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Bieberich, E (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St CB-2803, Augusta, GA 30912 USA.			Silva, PhD, MPA, EdS, EdD, MB(ASCP)CM, Jeane/0000-0003-3368-3963	NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH061934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853] Funding Source: NIH RePORTER; NIMH NIH HHS [MH61934-04] Funding Source: Medline; NINDS NIH HHS [NS11853] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bieberich E, 2000, J NEUROCHEM, V74, P2359, DOI 10.1046/j.1471-4159.2000.0742359.x; Bieberich E, 2000, J BIOL CHEM, V275, P177, DOI 10.1074/jbc.275.1.177; Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Blair LAC, 1999, J NEUROSCI, V19, P1940; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Conway AM, 2000, CELL SIGNAL, V12, P737, DOI 10.1016/S0898-6568(00)00119-4; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FRANCEL PC, 1987, J NEUROCHEM, V48, P1624, DOI 10.1111/j.1471-4159.1987.tb05711.x; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Furuse H, 1998, EXP BRAIN RES, V123, P307, DOI 10.1007/s002210050573; Garcia-de Lacoba M, 1999, ENDOCRINOLOGY, V140, P233, DOI 10.1210/en.140.1.233; GERSHONI JM, 1983, ANAL BIOCHEM, V13, P1; Goswami R, 2000, J NEUROSCI RES, V60, P141, DOI 10.1002/(SICI)1097-4547(20000415)60:2<141::AID-JNR2>3.0.CO;2-5; Goswami R, 1999, J NEUROSCI RES, V57, P884, DOI 10.1002/(SICI)1097-4547(19990915)57:6<884::AID-JNR14>3.3.CO;2-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hancock CR, 2000, BIOCHEM BIOPH RES CO, V271, P418, DOI 10.1006/bbrc.2000.2631; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; Liour SS, 2000, J NEUROSCI RES, V62, P363, DOI 10.1002/1097-4547(20001101)62:3<363::AID-JNR6>3.0.CO;2-E; Liu B, 1999, MATER CHEM PHYS, V57, P219, DOI 10.1016/S0254-0584(98)00219-3; MACALA LJ, 1983, J LIPID RES, V24, P1243; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20-22-08435.2000; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; RAHMANN H, 1995, BEHAV BRAIN RES, V66, P105, DOI 10.1016/0166-4328(94)00131-X; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Schwarz A, 1997, J NEUROSCI, V17, P2929; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Tanaka Y, 1997, NEUROREPORT, V8, P2203, DOI 10.1097/00001756-199707070-00023; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Wu GS, 2001, P NATL ACAD SCI USA, V98, P307, DOI 10.1073/pnas.011523698; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; YU RK, 1994, PROG BRAIN RES, V101, P31; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	45	66	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44396	44404		10.1074/jbc.M107239200	http://dx.doi.org/10.1074/jbc.M107239200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574545	hybrid			2022-12-27	WOS:000172406700008
J	Cho, EG; Kim, MG; Kim, C; Kim, SR; Seong, IS; Chung, CH; Schwartz, RH; Park, D				Cho, EG; Kim, MG; Kim, C; Kim, SR; Seong, IS; Chung, CH; Schwartz, RH; Park, D			N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; HAGEMAN-FACTOR; DEPENDENT AUTOACTIVATION; PLASMINOGEN-ACTIVATOR; BLOOD-COAGULATION; 1ST COMPONENT; FACTOR-VII; IDENTIFICATION; MATRIPTASE	Epithin was originally identified as a mouse type II membrane serine protease. Its human orthologue membrane type-serine protease 1 (MT-SP1)/matriptase has been reported to be localized on the plasma membrane. In addition, soluble forms of matriptase were isolated from human breast milk and breast cancer cell-conditioned medium. In this paper, we report a processing mechanism that appears to be required for the release of epithin. CHO-K1 or COS7 cells transfected with single full-length epithin cDNA generated two different-sized proteins in cell lysates, 110 and 92 kDa. The 92-kDa epithin was found to be an N-terminally truncated form of the 110-kDa epithin, and it was the only form detected in the culture medium. The 92-kDa epithin was also found on the cell surface, where it was anchored by the N-terminal fragment. The results of in vivo cell labeling experiments indicate that the 110-kDa epithin is rapidly processed to the 92-kDa epithin. Using site-directed mutagenesis experiments, we identified Gly(149) of the GSVIA sequence in epithin as required for the processing and release of the protein. These results suggest that N-terminal processing of epithin at Gly149 is a necessary prerequisite step for release of the protein.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; NIAID, Cellular & Mol Immunol Lab, NIH, Bethesda, MD 20892 USA; Chungbuk Natl Univ, Coll Med, Cheongju 361763, South Korea	Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Chungbuk National University	Park, D (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000613] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander DS, 1998, J BIOL CHEM, V273, P7457, DOI 10.1074/jbc.273.13.7457; BENAUD C, 2001, EUR J BIOCHEM, V268, P1; BIANCHINO AC, 1988, J IMMUNOL, V141, P3930; DODDS AW, 1978, BIOCHEM J, V175, P383, DOI 10.1042/bj1750383; DUNN JT, 1982, J BIOL CHEM, V257, P1779; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; SHI YE, 1993, CANCER RES, V53, P1409; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; TANS G, 1983, J BIOL CHEM, V258, P8215; Vu TKH, 1997, J BIOL CHEM, V272, P31315, DOI 10.1074/jbc.272.50.31315; WIGGINS RC, 1979, J EXP MED, V150, P1122, DOI 10.1084/jem.150.5.1122; Yamada K, 2000, GENE, V252, P209, DOI 10.1016/S0378-1119(00)00225-0	22	72	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44581	44589		10.1074/jbc.M107059200	http://dx.doi.org/10.1074/jbc.M107059200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567025	hybrid			2022-12-27	WOS:000172406700034
J	Hiser, L; Hosler, JP				Hiser, L; Hosler, JP			Heme A is not essential for assembly of the subunits of cytochrome c oxidase of Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; ESCHERICHIA-COLI; GENE; CLONING; YEAST; COX10; PURIFICATION; RESOLUTION; DEFICIENCY; STABILITY	The aa(3)-type cytochrome c oxidase of Rhodohacter sphaeroides, a proteobacterium of the alpha subgroup, is structurally similar to the core subunits of the terminal oxidase in the mitochondrial electron transport chain. Subunit I, the product of the coil gene, normally binds two heme A molecules. A deletion of cox10, the gene for the farnesyltransferase required for heme A synthesis, did not prevent high level accumulation of subunit I in the cytoplasmic membrane. Thus, subunit I can be expressed and stably inserted into the cytoplasmic membrane in the absence of heme A. Aposubunit I was purified via affinity chromatography to a polyhistidine tag. Copurification of subunits II and III with aposubunit I indicated that assembly of the core oxidase complex occurred without the binding of heme A. In addition to formation of the apooxidase containing all three large structural proteins, CoxI-II and CoxI-III heterodimers were isolated from cox10 deletion strains harboring expression plasmids with coxI and coxII or with coxI and coxIII, respectively. This demonstrated that subunit assembly of the apoenzyme was not an inherently ordered or sequential process. Thus, multiple paths must be considered for understanding the assembly of this integral membrane metalloprotein complex.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Hosler, JP (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA.	jhosler@biochem.umsmed.edu			NIGMS NIH HHS [GM56824] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056824] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bratton MR, 2000, BIOCHEMISTRY-US, V39, P12989, DOI 10.1021/bi0003083; CAO J, 1992, J BIOL CHEM, V267, P24273; CAO JL, 1991, GENE, V101, P133, DOI 10.1016/0378-1119(91)90235-4; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; FENG YQ, 1991, BIOCHEMISTRY-US, V30, P10150, DOI 10.1021/bi00106a011; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Ostermeier C, 1996, CURR OPIN STRUC BIOL, V6, P460, DOI 10.1016/S0959-440X(96)80110-2; PEIFFER WE, 1990, BIOCHEMISTRY-US, V29, P8696, DOI 10.1021/bi00489a027; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; Robinson BH, 2000, PEDIATR RES, V48, P581, DOI 10.1203/00006450-200011000-00004; SAIKI K, 1993, J BIOL CHEM, V268, P26041; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; Toledo-Cuevas M, 1998, BBA-BIOENERGETICS, V1365, P421, DOI 10.1016/S0005-2728(98)00095-4; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; WIELBURSKI A, 1983, BIOCHEM J, V212, P829, DOI 10.1042/bj2120829; Wong C, 2000, BIOTECHNIQUES, V28, P426, DOI 10.2144/00283bm07; WOODS JS, 1977, MOL PHARMACOL, V13, P50; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; Zhen Y, 1998, PROTEIN EXPRES PURIF, V13, P326, DOI 10.1006/prep.1998.0903	36	17	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45403	45407		10.1074/jbc.M107016200	http://dx.doi.org/10.1074/jbc.M107016200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574544	hybrid			2022-12-27	WOS:000172406700137
J	Malek, S; Chen, Y; Huxford, T; Ghosh, G				Malek, S; Chen, Y; Huxford, T; Ghosh, G			I kappa B beta but not I kappa B alpha, functions as a classical cytoplasmic inhibitor of NF-kappa B dimers by masking both NF-kappa B nuclear localization sequences in resting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; EXPORT SIGNAL; PEST DOMAIN; P50/P65 HETERODIMER; CRYSTAL-STRUCTURE; C-REL; PHOSPHORYLATION; PROTEINS; MECHANISM; P50	NF-kappaB dimers, inhibitor I kappaB proteins, and NF-kappaB .I kappaB complexes exhibit distinct patterns in partitioning between nuclear and cytoplasmic cellular compartments. I kappaB-dependent modulation of NF-kappaB subcellular localization represents one of the more poorly understood processes in the NF-kappaB signaling pathway. In this study, we have combined in vitro biochemical and cell-based methods to elucidate differences in NF-kappaB regulation exhibited by the inhibitors I kappaB beta and I kappaB alpha. We show that although both I kappaB alpha and I kappaB beta bind to NF-kappaB with similar global architecture and stability, significant differences exist that contribute to their unique functional roles. I kappaB beta derives its high affinity toward NF-kappaB dimers by binding to both NF-kappaB subunit nuclear localization signals. In contrast, I kappaB alpha contacts only one NF-kappaB NLS and employs its carboxyl-terminal proline, glutamic acid, serine, and threonine-rich region for high affinity NF-kappaB binding. We show that the presence of one free NLS in the NF-kappaB .I kappaB alpha complex renders it a dynamic nucleocytoplasmic complex, whereas NF-kappaB .I kappaB beta complexes are localized to the cytoplasm of resting cells.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0359,Urey Hall 5230,9500 Gilman Dr, La Jolla, CA 92093 USA.			Malek, Shiva/0000-0002-9526-7968; Huxford, Tom/0000-0002-1939-7373	NCI NIH HHS [CA-78749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Huxford T, 2000, J BIOL CHEM, V275, P32800, DOI 10.1074/jbc.M006037200; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	46	138	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45225	45235		10.1074/jbc.M105865200	http://dx.doi.org/10.1074/jbc.M105865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571291	hybrid			2022-12-27	WOS:000172406700116
J	Miller, SA; Binder, EM; Blackman, MJ; Carruthers, VB; Kim, K				Miller, SA; Binder, EM; Blackman, MJ; Carruthers, VB; Kim, K			A conserved subtilisin-like protein TgSUB1 in microneme organelles of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN-1; MOLECULAR CHARACTERIZATION; HOST-CELLS; INVASION; PARASITE; HOMOLOG; SURFACE; REDISTRIBUTION; ERYTHROCYTE; SUBTILASES	Proteolytic processing plays a significant role in the process of invasion by the obligate intracellular parasite Toxoplasma gondii. We have cloned a gene, TgSUB1, encoding for a subtilisin-type serine protease found in T. gondii tachyzoites. TgSUB1 protein is homologous to other Apicomplexan and bacterial subtilisins and is processed within the secretory pathway of the parasite. Initial cleavage occurs in the endoplasmic reticulum, after which the protein is transported to micronemes, vesicles that secrete early during host cell invasion. Upon stimulation of microneme secretion, TgSUB1 is cleaved into smaller products that are secreted from the parasite. This secondary processing is inhibited by brefeldin A and serine protease inhibitors. TgSUB1 is a candidate processing enzyme for several microneme proteins cleaved within the secretory pathway or during invasion.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; MRC National Institute for Medical Research; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kim, K (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Infect Dis, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kkim@aecom.yu.edu		Carruthers, Vern/0000-0001-6859-8895; Kim, Kami/0000-0003-3384-152X	NIAID NIH HHS [T32-AI07506] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; PHS HHS [R01-A146985, 513504] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANYAL HS, 1981, J PARASITOL, V67, P623, DOI 10.2307/3280435; Barale JC, 1999, P NATL ACAD SCI USA, V96, P6445, DOI 10.1073/pnas.96.11.6445; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; Boothroyd JC, 1997, PHILOS T ROY SOC B, V352, P1347, DOI 10.1098/rstb.1997.0119; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; BRETON CB, 1992, P NATL ACAD SCI USA, V89, P9647, DOI 10.1073/pnas.89.20.9647; Brown PJ, 2000, MOL BIOCHEM PARASIT, V107, P91, DOI 10.1016/S0166-6851(00)00179-1; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Conseil V, 1999, ANTIMICROB AGENTS CH, V43, P1358, DOI 10.1128/AAC.43.6.1358; DEJKRIENGKRAIKHUL PN, 1983, Z PARASITENKD, V69, P313, DOI 10.1007/BF00927873; Dobrowolski JM, 1997, MOL MICROBIOL, V26, P163, DOI 10.1046/j.1365-2958.1997.5671913.x; Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; Garcia-Reguet N, 2000, CELL MICROBIOL, V2, P353, DOI 10.1046/j.1462-5822.2000.00064.x; Hackett F, 1999, MOL BIOCHEM PARASIT, V103, P183, DOI 10.1016/S0166-6851(99)00122-X; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; Kocken CHM, 2000, MOL BIOCHEM PARASIT, V109, P147, DOI 10.1016/S0166-6851(00)00250-4; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Louie K, 1999, MOL BIOCHEM PARASIT, V103, P211, DOI 10.1016/S0166-6851(99)00127-9; MAYER R, 1991, J MED CHEM, V34, P3029, DOI 10.1021/jm00114a011; OLAYA P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P217, DOI 10.1016/0925-4439(91)90008-W; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; Pacheco-Soares C, 1998, CELL STRUCT FUNCT, V23, P159, DOI 10.1247/csf.23.159; Qin CL, 1998, MOL BIOCHEM PARASIT, V93, P273, DOI 10.1016/S0166-6851(98)00042-5; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; Sajid M, 2000, J BIOL CHEM, V275, P631, DOI 10.1074/jbc.275.1.631; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; SussToby E, 1996, P NATL ACAD SCI USA, V93, P8413, DOI 10.1073/pnas.93.16.8413; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	41	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45341	45348		10.1074/jbc.M106665200	http://dx.doi.org/10.1074/jbc.M106665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564738	hybrid			2022-12-27	WOS:000172406700129
J	Polesskaya, A; Harel-Bellan, A				Polesskaya, A; Harel-Bellan, A			Acetylation of MyoD by p300 requires more than its histone acetyltransferase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COACTIVATORS P300; PCAF; TRANSCRIPTION; DISTINCT; BINDING; PROTEIN; ROLES; CBP	MyoD, an essential transcription factor involved in muscle cell terminal differentiation, is regulated by acetylation, as are a number of other transcription factors, but the histone acetyltransferase enzyme responsible for this acetylation is a matter of controversy. In particular, contradictory findings have been reported concerning the ability of CBP/p300 to acetylate MyoD in vitro. Here we provide an explanation for this discrepancy: although full-length p300 does indeed acetylate MyoD, a fragment of p300 corresponding to its histone acetyltransferase domain does not. In addition to clearly demonstrating that p300 acetylates MyoD in vitro, these results underscore the necessity of using full-length histone acetyltransferase enzymes to draw valid conclusions from acetylation experiments.	Inst Andre Lwoff, CNRS, Unite Propre Rech 9079, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Harel-Bellan, A (corresponding author), Inst Andre Lwoff, CNRS, Unite Propre Rech 9079, 7 Rue Guy Moquet, F-94800 Villejuif, France.		Harel-Bellan, Annick/M-9795-2015	Harel-Bellan, Annick/0000-0002-2339-153X				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Buckingham M, 1996, BIOCHEM SOC T, V24, P506, DOI 10.1042/bst0240506; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	17	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44502	44503		10.1074/jbc.M106501200	http://dx.doi.org/10.1074/jbc.M106501200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577095	hybrid			2022-12-27	WOS:000172406700022
J	Zhou, XM; Li, JX; Kucik, DF				Zhou, XM; Li, JX; Kucik, DF			The microtubule cytoskeleton participates in control of beta(2) integrin avidity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; BINDING PROTEIN-RHO; C-KINASE SUBSTRATE; CELL-ADHESION; ACTIN CYTOSKELETON; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; CONFORMATIONAL CHANGE; CYTOPLASMIC TAIL	Leukocyte avidity is regulated by cytoskeletal constraints, which keep beta (2) integrins in an inactive mode. Releasing these constraints results in increased lateral mobility and clustering of integrins, effectively activating adhesion. At least part of the constraint on beta (2) integrins is due to actin; whether other cytoskeletal components are involved has not previously been investigated. Microtubules are a candidate for control of integrin rearrangement, because they modulate focal adhesions, which are sites of interaction between integrins and the cytoskeleton. Here we report that both depolymerization of microtubules by colchicine or nocodazole and stabilization of microtubules by taxol increased the lateral mobility of beta (2) integrins, activating adhesion. Increased integrin mobility was accompanied by an increase in tyrosine phosphorylation of paxillin, a biochemical event associated with activation of beta (2) integrins. Further, C3 exoenzyme, an inhibitor of Rho, blocked induction of integrin mobility by nocodazole, but not by taxol, suggesting that there are multiple microtubule-dependent pathways to integrin rearrangement, only some of which require Rho activity. Taken together, our data suggest that a dynamic microtubule system is required to regulate integrin-cytoskeleton interactions. Furthermore, these data demonstrate that microtubules participate in control of integrin rearrangement, one of the earliest steps in activation of integrin-mediated adhesion.	Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Birmingham Med Ctr, Vet Affairs Med Res Serv, Birmingham, AL 35294 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Alabama System; University of Alabama Birmingham	Li, JX (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina, Chicago, IL 60612 USA.	jxli@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG HC, 1993, RANDOM WALKS BIOL, P1; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHEUNG HT, 1980, CELL BIOL INT REP, V4, P1125, DOI 10.1016/0309-1651(80)90050-8; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEBRABANDER M, 1977, CELL BIOL INT REP, V1, P453, DOI 10.1016/0309-1651(77)90080-7; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IVANOVA OY, 1976, EXP CELL RES, V101, P207, DOI 10.1016/0014-4827(76)90431-6; Kadi A, 1998, BIOCHEM BIOPH RES CO, V246, P690, DOI 10.1006/bbrc.1998.8536; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Kucik DF, 1999, BIOPHYS J, V76, P314, DOI 10.1016/S0006-3495(99)77198-5; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SLICHENMYER WJ, 1990, J CLIN PHARMACOL, V30, P770, DOI 10.1002/j.1552-4604.1990.tb01873.x; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VASILIEV JM, 1970, J EMBRYOL EXP MORPH, V24, P625; VASILIEV JM, 1987, J CELL SCI, P1; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wright S D, 1986, Methods Enzymol, V132, P204; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Yue LL, 1999, J CELL PHYSIOL, V181, P355, DOI 10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B; Yue LL, 2000, CELL ADHES COMMUN, V7, P359, DOI 10.3109/15419060009109018; Yue LL, 2000, J BIOL CHEM, V275, P23948, DOI 10.1074/jbc.M001845200; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	59	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44762	44769		10.1074/jbc.M104029200	http://dx.doi.org/10.1074/jbc.M104029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579083	hybrid			2022-12-27	WOS:000172406700058
J	Chang, JY				Chang, JY			The folding pathway of alpha-lactalbumin elucidated by the technique of disulfide scrambling - Isolation of on-pathway and off-pathway intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; TICK ANTICOAGULANT PEPTIDE; SECONDARY STRUCTURE; BOND FORMATION; PROTEINS; COOPERATIVITY; DETERMINANTS; CYANYLATION; LEVINTHAL; STABILITY	The technique of disulfide scrambling permits reversible conversion of the native and denatured (scrambled) proteins via shuffling and reshuffling of disulfide bonds. Under strong denaturing conditions (e.g. 6 m guanidinium chloride) and in the presence of a thiol initiator, a-lactalbumin (alphaLA) denatures by shuffling its four native disulfide bonds and converts to an assembly of 45 species of scrambled isomers. Among them, two predominant isomers, designated as X-alphaLA-a and X-alphaLA-d, account for about 50% of the total denatured structure of alphaLA. X-alphaLA-a and X-alphaLA-d, which adopt the disulfide patterns of (1-2,3-4,5-6,7-8) and (1-2,3-6,4-5,7-8), respectively, represent the most unfolded structures among the 104 possible scrambled isomers (Chang, J.-Y., and Li, L. (2001) J. Biol. Chem. 276, 9705-9712). In this study, X-alphaLA-a and X-alphaLA-d were purified and allowed to refold through disulfide scrambling to form the native alphaLA. Folding intermediates were trapped kinetically by acid quenching and analyzed quantitatively by reversed phase high pressure liquid chromatography. The results revealed two major on-pathway productive intermediates, two major off-pathway kinetic traps, and at least 30 additional minor transient intermediates. Of the two major on-pathway intermediates, one takes on a native-like a-helical domain, and the other comprises a structured beta-sheet, calcium binding domain. The two major kinetic traps are apparently stabilized by locally formed non-native-like structures. Overall, the folding mechanism of alphaLA is essentially congruent with the model of "folding funnel" furnished with a rather intricate energy landscape.	Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA; Univ Texas, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas System	Chang, JY (corresponding author), Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA.	Rowen.Chang@uth.tmc.edu						Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; Baldwin RL, 2001, NAT STRUCT BIOL, V8, P92, DOI 10.1038/84189; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; Chang JY, 2000, J PROTEIN CHEM, V19, P299, DOI 10.1023/A:1007099430211; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHANG JY, 1995, J BIOL CHEM, V270, P25661; Chang JY, 2001, J BIOL CHEM, V276, P9705, DOI 10.1074/jbc.M010700200; Chang JY, 2000, FEBS LETT, V487, P298, DOI 10.1016/S0014-5793(00)02341-3; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; Creighton TE, 1997, TRENDS BIOCHEM SCI, V22, P6, DOI 10.1016/S0968-0004(96)20030-1; Dill KA, 1999, PROTEIN SCI, V8, P1166, DOI 10.1110/ps.8.6.1166; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; Forge V, 1999, J MOL BIOL, V288, P673, DOI 10.1006/jmbi.1999.2687; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Grantcharova V, 2001, CURR OPIN STRUC BIOL, V11, P70, DOI 10.1016/S0959-440X(00)00176-7; Honig B, 1999, J MOL BIOL, V293, P283, DOI 10.1006/jmbi.1999.3006; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Kim P S, 1986, Methods Enzymol, V131, P136; Kim S, 1998, PROTEIN SCI, V7, P1930, DOI 10.1002/pro.5560070908; KLEFHABER T, 1995, NATURE, V375, P513; KUWAJIMA K, 1993, FEBS LETT, V334, P265, DOI 10.1016/0014-5793(93)80691-M; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; Labhardt A M, 1986, Methods Enzymol, V131, P126; Luo YZ, 1999, P NATL ACAD SCI USA, V96, P11283, DOI 10.1073/pnas.96.20.11283; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Mirny L, 2001, ANNU REV BIOPH BIOM, V30, P361, DOI 10.1146/annurev.biophys.30.1.361; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; PARDON E, 1995, J BIOL CHEM, V270, P10514, DOI 10.1074/jbc.270.18.10514; Peng ZY, 2000, ADV PROTEIN CHEM, V53, P1; PENG ZY, 1995, BIOCHEMISTRY-US, V34, P3248, DOI 10.1021/bi00010a014; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; Plaxco KW, 2000, BIOCHEMISTRY-US, V39, P11177, DOI 10.1021/bi000200n; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Radford SE, 2000, TRENDS BIOCHEM SCI, V25, P611, DOI 10.1016/S0968-0004(00)01707-2; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; Redfield C, 1999, NAT STRUCT BIOL, V6, P948, DOI 10.1038/13318; Sadana A, 2001, BIOTECHNOL APPL BIOC, V33, P7, DOI 10.1042/BA20000044; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; Schultz CP, 2000, NAT STRUCT BIOL, V7, P7, DOI 10.1038/71197; SUGAI S, 1994, ADV BIOPHYS, V30, P37, DOI 10.1016/0065-227X(94)90010-8; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Troullier A, 2000, NAT STRUCT BIOL, V7, P78, DOI 10.1038/71286; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WOLYNES PG, 1995, SCIENCE, V267, P1619, DOI 10.1126/science.7886447; Woycechowsky KJ, 2000, CURR OPIN CHEM BIOL, V4, P533, DOI 10.1016/S1367-5931(00)00128-9; Wu J, 1998, PROTEIN SCI, V7, P1017; Wu LC, 1996, BIOCHEMISTRY-US, V35, P859, DOI 10.1021/bi951408p; Wu LC, 1998, J MOL BIOL, V280, P175, DOI 10.1006/jmbi.1998.1825; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; Yang Y, 1999, J BIOL CHEM, V274, P37598, DOI 10.1074/jbc.274.53.37598	70	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					120	126		10.1074/jbc.M108057200	http://dx.doi.org/10.1074/jbc.M108057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11560938	hybrid			2022-12-27	WOS:000173087900017
J	Mayanil, CSK; George, D; Freilich, L; Miljan, EJ; Mania-Farnell, B; McLone, DG; Bremer, EG				Mayanil, CSK; George, D; Freilich, L; Miljan, EJ; Mania-Farnell, B; McLone, DG; Bremer, EG			Microarray analysis detects novel Pax3 downstream target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAX3-FKHR FUSION PROTEIN; CELL-ADHESION; WAARDENBURG SYNDROME; SULFATE PROTEOGLYCANS; TRANSCRIPTION FACTOR; GENOMIC STRUCTURE; POLYSIALIC ACID; PAIRED DOMAIN; EXPRESSION; BINDING	Pax3 is a transcription factor that is required for the development of embryonic neural tube, neural crest, and somatic derivatives. Our previous study (Mayanil, C. S. K., George, D., Mania-Farnell, B., Bremer, C. L., McLone, D. G., and Bremer, E. G. (2000) J. BioL Chem. 275, 23259-23266) reveals that overexpression of Pax3 in a human medulloblastoma cell line, DAOY, resulted in an up-regulation in alpha-2,8-polysialyltransferase (STX) gene expression and an increase in polysialic acid on neural cell adhesion molecule. This finding suggests that STX might be a previously undescribed downstream target of Pax3. Because Pax3 is important in diverse cellular functions during development, we are interested in the identification of additional downstream targets of Pax3. We utilized oligonucleotide arrays and RNA isolated from stable Pax3 transfectants to identify potential target genes. A total of 270 genes were altered in the Pax3 transfectants as compared with the vector control and parental cell line. An independent analysis by cDNA expression array and real-time quantitative polymerase chain reaction of several genes confirmed the changes observed by the oligonucleotide microarray data. Of the genes that displayed significant changes in expression, several contain paired and homeodomain binding motifs of Pax3 in their promoter regions. Using promoter-luciferase reporter transfeetion assays and electromobility shift assays, we showed at least one previously undescribed downstream target, STX, to be a biological downstream target of Pax3. Thus we report several previously undescribed candidate genes to be potential downstream targets of Pax3.	Northwestern Univ, Sch Med, Dept Neurol Surg, Pediat Brain Tumor Res Program, Chicago, IL 60614 USA; Childrens Mem Inst Educ & Res, Chicago, IL 60614 USA; Purdue Univ Calumet, Dept Biol, Hammond, IN 46321 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Purdue University System; Purdue University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bremer, EG (corresponding author), Childrens Mem Med Ctr, Brain Tumor Res Program, 2300 Childrens Plaza,M-C 226, Chicago, IL 60614 USA.	egbremer@northwestern.edu			NINDS NIH HHS [NS34333] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1995, NATURE, V377, P3; AFINK GB, 1995, ONCOGENE, V10, P1667; BALDWIN CT, 1995, AM J MED GENET, V58, P115, DOI 10.1002/ajmg.1320580205; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Boonyaratanakornkit V, 1999, J BIOL CHEM, V274, P26431, DOI 10.1074/jbc.274.37.26431; Cai J, 1998, DIABETES, V47, P1803, DOI 10.2337/diabetes.47.11.1803; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Daston G, 1996, DEVELOPMENT, V122, P1017; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; Edelman GM, 1998, BRAIN RES REV, V26, P337, DOI 10.1016/S0165-0173(97)00034-9; Epstein JA, 2000, DEVELOPMENT, V127, P1869; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Galibert MD, 1999, J BIOL CHEM, V274, P26894, DOI 10.1074/jbc.274.38.26894; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; Ginsberg JP, 1998, CANCER RES, V58, P3542; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; GOULDING M, 1994, CIBA F SYMP, V181, P103; Goulding M, 2000, CURR BIOL, V10, pR565, DOI 10.1016/S0960-9822(00)00615-1; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khan J, 1998, CANCER RES, V58, P5009; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; MIURA M, 1989, GENE, V75, P31; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; NASO MF, 1994, J BIOL CHEM, V269, P32999; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Patrone G, 1997, FEBS LETT, V419, P76, DOI 10.1016/S0014-5793(97)01435-X; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; Stumpo DJ, 1998, GENOMICS, V49, P253, DOI 10.1006/geno.1998.5247; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TASSABEHJI M, 1994, HUM MOL GENET, V3, P1069, DOI 10.1093/hmg/3.7.1069; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	53	98	98	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49299	49309		10.1074/jbc.M107933200	http://dx.doi.org/10.1074/jbc.M107933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11590174	hybrid			2022-12-27	WOS:000173922100089
J	Coxon, FP; Helfrich, MH; Larijani, B; Muzylak, M; Dunford, JE; Marshall, D; McKinnon, AD; Nesbitt, SA; Horton, MA; Seabra, MC; Ebetino, FH; Rogers, MJ				Coxon, FP; Helfrich, MH; Larijani, B; Muzylak, M; Dunford, JE; Marshall, D; McKinnon, AD; Nesbitt, SA; Horton, MA; Seabra, MC; Ebetino, FH; Rogers, MJ			Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN-CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE; BONE-RESORPTION; PROTEIN PRENYLATION; IN-VITRO; MEVALONATE PATHWAY; SQUALENE SYNTHASE; MECHANISM; GTPASES; GROWTH	Nitrogen-containing bisphosphonate drugs inhibit bone resorption by inhibiting FPP synthase and thereby preventing the synthesis of isoprenoid lipids required for protein prenylation in bone-resorbing osteoclasts. NE10790 is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent. Although NE10790 was a poor inhibitor of FPP synthase, it did inhibit prenylation in J774 macrophages and osteoclasts, but only of proteins of molecular mass similar to 22-26 kDa, the prenylation of which was not affected by peptidomimetic inhibitors of either farnesyl transferase (FTI-277) or geranylgeranyl transferase I (GGTI-298). These 22-26-kDa proteins were shown to be geranylgeranylated by labelling J774 cells with [(3)H]geranylgeraniol. Furthermore, NE10790 inhibited incorporation of [(14)C]mevalonic acid into Rab6, but not into H-Ras or Rap1, proteins that are modified by FTase and GGTase I, respectively. These data demonstrate that NE10790 selectively prevents Rab prenylation in intact cells. In accord, NE10790 inhibited the activity of recombinant Rab GGTase in vitro, but did not affect the activity of recombinant FTase or GGTase I. NE10790 therefore appears to be the first specific inhibitor of Rab GGTase to be identified. In contrast to risedronate, NE10790 inhibited bone resorption in vitro without markedly affecting osteoclast number or the F-actin "ring" structure in polarized osteoclasts. However, NE10790 did alter osteoclast morphology, causing the formation of large intracellular vacuoles and protrusion of the basolateral membrane into large, "domed" structures that lacked microvilli. The anti-resorptive activity of NE10790 is thus likely due to disruption of Rab-dependent intracellular membrane trafficking in osteoclasts.	Univ Aberdeen, Sch Med, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Imperial Coll Sch Med, Div Biomed Sci, Cell & Mol Biol Sect, London SW7 2AZ, England; UCL, Bone & Mineral Ctr, London WC1E 6JJ, England; Procter & Gamble Pharmaceut, Cincinnati, OH 45040 USA	University of Aberdeen; Imperial College London; University of London; University College London; Procter & Gamble	Coxon, FP (corresponding author), Univ Aberdeen, Sch Med, Dept Med & Therapeut, Polwarth Bldg, Aberdeen AB25 2ZD, Scotland.	f.p.coxon@abdn.ac.uk	Seabra, Miguel/AAC-3099-2019; Larijani, Banafshe/H-3909-2015; Seabra, Miguel C/M-3280-2013	Larijani, Banafshe/0000-0003-4735-1169; Seabra, Miguel C/0000-0002-6404-4892; Dunford, James/0000-0002-9932-4042; Rogers, Michael/0000-0002-1818-9249				Abu-Amer Y, 1999, J BONE MINER RES, V14, P1855, DOI 10.1359/jbmr.1999.14.11.1855; AMIN D, 1992, J LIPID RES, V33, P1657; Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; Bialek-Wyrzykowska U, 2000, MOL MICROBIOL, V35, P1295, DOI 10.1046/j.1365-2958.2000.01782.x; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; Coxon FP, 1998, MOL PHARMACOL, V54, P631; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Hardcastle IR, 1999, BIOCHEM PHARMACOL, V57, P801, DOI 10.1016/S0006-2952(98)00349-9; Holstein SA, 1998, BIOORGAN MED CHEM, V6, P687, DOI 10.1016/S0968-0896(98)00034-0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Ory S, 2000, J CELL SCI, V113, P1177; Palokangas H, 1997, J CELL SCI, V110, P1767; Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171-9335(99)80058-2; Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006-2952(97)00151-2; Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193; Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C; Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756-3282(99)00116-7; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seabra MC, 1996, OPHTHALMIC GENET, V17, P43, DOI 10.3109/13816819609057869; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Seabra MC, 1998, METH MOL B, V84, P251; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756-3282(98)00120-3; VANTHOF RJ, 1995, INT J EXP PATHOL, V76, P205	37	140	142	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48213	48222		10.1074/jbc.M106473200	http://dx.doi.org/10.1074/jbc.M106473200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11581260	hybrid			2022-12-27	WOS:000172927000064
J	Rotem, D; Sal-man, N; Schuldiner, S				Rotem, D; Sal-man, N; Schuldiner, S			In vitro monomer swapping in EmrE, a multidrug transporter from Escherichia coli, reveals that the oligomer is the functional unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ ANTIPORTER; MEMBRANE; BINDING; H+; GLUTAMATE; PROTEIN	EmrE is a small multidrug transporter, 110 amino acids long that extrudes various drugs in exchange with protons, thereby rendering Escherichia coli cells resistant to these compounds. Negative dominance studies and radiolabeled substrate-binding studies suggested that EmrE functions as an oligomer. Projection structure of two-dimensional crystals of the protein revealed an asymmetric dimer. To identify the functional unit of EmrE, a novel approach was developed. In this method, quantitative monomer swapping is induced in detergent-solubilized EmrE by exposure to 80 degreesC, a treatment that does not impair transport activity. Oligomer formation is highly specific as judged by several criteria, among them the fact that S-35-EmrE can be "pulled out" from a mixture prepared from generally labeled cells. Using this technique, we show that inactive mutant subunits are functionally complemented when mixed with wild type subunits. The hetero-oligomers thus formed display a decreased affinity to substrates. In addition, sulfhydryl reagents inhibit the above hetero-oligomer even though Cys residues are present only in the inactive monomer. It is concluded that, in EmrE, the oligomer is the functional unit.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012; Rotem, Dvir/G-1396-2013	Schuldiner, Shimon/0000-0002-4874-6237; Rotem, Dvir/0000-0002-1840-6530; Sal-Man, Neta/0000-0002-1109-479X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; Friesen RHE, 2000, J BIOL CHEM, V275, P33527, DOI 10.1074/jbc.M004066200; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Jack DL, 2000, J BACTERIOL, V182, P2311, DOI 10.1128/JB.182.8.2311-2313.2000; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Lee A, 2000, J BACTERIOL, V182, P3142, DOI 10.1128/JB.182.11.3142-3150.2000; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	26	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48243	48249		10.1074/jbc.M108229200	http://dx.doi.org/10.1074/jbc.M108229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11572877	hybrid			2022-12-27	WOS:000172927000068
J	Yang, JM; Fan, GH; Wadzinski, BE; Sakurai, H; Richmond, A				Yang, JM; Fan, GH; Wadzinski, BE; Sakurai, H; Richmond, A			Protein phosphatase 2A interacts with and directly dephosphorylates Re1A.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; CATALYTIC SUBUNIT; CELL-GROWTH; ACTIVATION; ALPHA; PHOSPHORYLATION; SIGNAL; UBIQUITINATION	Nuclear factor-kappaB (NF-kappaB)/Rel transcription factors are key regulators of a variety of genes involved in inflammatory responses, growth, differentiation, apoptosis, and development. There are increasing lines of evidence that NF-kappaB/Rel activity is controlled to a great extent by its phosphorylation state. In this study, we demonstrated that RelA physically associated with protein phosphatase 2A (PP2A) subunit A (PR65). Both the N- and C-terminal regions of RelA were responsible for the PP2A binding. RelA co-immunoprecipitated with PP2A in melanocytes in the absence of stimulation, indicating that RelA forms a signaling complex with PP2A in the cells. RelA was dephosphorylated by a purified PP2A core enzyme, a heterodimer formed by the catalytic subunit of PP2A (PP2Ac) and PR65, in a concentration-dependent manner. Okadaic acid, an inhibitor of PP2A at lower concentration, increased the basal phosphorylation of RelA in melanocytes and blocked the dephosphorylation of RelA after interleukin-1 stimulation. Interestingly, PP2A immunoprecipitated from melanocytes was able to dephosphorylate RelA, whereas PP2A immunoprecipitated from melanoma cell lines exhibited decreased capacity to dephosphorylate RelA in vitro. Moreover, in melanoma cells in which I kappaB kinase activity was inhibited by sulindac to a similar level as in melanocytes, the phosphorylation state of RelA and the relative NF-KB activity were still higher than those in normal melanocytes. These data suggest that the constitutive activation of RelA in melanoma cells (Yang, J., and Richmond, A. (2001) Cancer Res. 61, 4901-4909) could be due, at least in part, to the deficiency of PP2A, which exhibits decreased dephosphorylation of NF-kappaB/RelA.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Dept Vet Affairs, Nashville, TN 37212 USA; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan	Vanderbilt University; Vanderbilt University; Mitsubishi Tanabe Pharma Corporation	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, T2212 MCN,1161 21st Ave S, Nashville, TN 37232 USA.		Sakurai, Hiroaki/AAE-4294-2019; Richmond, Ann/A-3048-2014	Sakurai, Hiroaki/0000-0003-0657-9570; RICHMOND, ANN/0000-0002-9580-900X	NATIONAL CANCER INSTITUTE [R01CA056704, R01CA034590, P30CA068485, R23CA034590] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA068485, CA68485, R01 CA056704-09, R01 CA056704-08, CA56740, R01 CA056704-07, CA34590, R01 CA034590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIANNINI E, 1995, J IMMUNOL, V154, P4055; Gilmore TD, 1996, ONCOGENE, V13, P1367; HARPER JW, 1993, CELL, V75, P805; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Krueger KM, 1997, J BIOL CHEM, V272, P5; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; THEVENIN C, 1990, New Biologist, V2, P793; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Weil R, 1997, J BIOL CHEM, V272, P9942; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wuyts A, 2000, BIOCHEMISTRY-US, V39, P14549, DOI 10.1021/bi0011227; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yang JM, 2001, CANCER RES, V61, P4901; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	51	102	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47828	47833		10.1074/jbc.M106103200	http://dx.doi.org/10.1074/jbc.M106103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11591705	Green Accepted, hybrid			2022-12-27	WOS:000172927000015
J	Chen, CC; Mo, FE; Lau, LF				Chen, CC; Mo, FE; Lau, LF			The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR; FACTOR-BETA; INTEGRIN ALPHA(V)BETA(3); MATRICELLULAR PROTEINS; COLLAGEN LATTICES; ENDOTHELIAL-CELLS; MESENCHYMAL CELLS	Cyr61 is a heparin-binding, extracellular matrix-associated protein of the CCN family, which also includes connective tissue growth factor, Nov, WISP-1, WISP-2, and WISP-3. Cyr61 is capable of multiple functions, including induction of angiogenesis in vivo. Purified Cyr61 mediates cell adhesion and induces adhesive signaling, stimulates cell migration, enhances cell proliferation, and promotes cell survival in both fibroblasts and endothelial cells. In this study, we have used cDNA array hybridization to identify genes regulated by Cyr61 in primary human skin fibroblasts. The Cyr61-regulated genes fall into several groups known to participate in processes important for cutaneous wound healing, including: 1) angiogenesis and lymphogenesis (VEGF-A and VEGF-C); 2) inflammation (interleukin-1 beta); 3) extracellular matrix remodeling (MMP1, MMP3, TIMP1, uPA, and PAI-1); and 4) cell-matrix interactions (Col1 alpha1, Col1 alpha2, and integrins alpha (3) and alpha (5)). Cyr61-mediated gene expression requires heparin binding activity of Cyr61, cellular de novo transcription, and protein synthesis and is largely dependent on the activation of p42/p44 MAPKs. Cyr61 regulates gene expression not only in serum-free medium but also in fibroblasts cultured on various matrix proteins or in the presence of 10% serum. These effects of Cyr61 can be sustained for at least 5 days, consistent with the time course of wound healing in vivo. Interestingly, Cyr61 can interact with transforming growth factor-beta1 to regulate expression of specific genes in an antagonistic, additive, or synergistic manner. Furthermore, we show that the Cyr61 gene is highly induced in dermal fibroblasts of granulation tissue during cutaneous wound repair. Together, these results show that Cyr61 is inducibly expressed in granulation tissues after wounding and that Cyr61 activates a genetic program for wound repair in skin fibroblasts. We propose a model in which Cyr61 integrates its activities on endothelial cells, fibroblasts, and macrophages to regulate the processes of angiogenesis, inflammation, and matrix remodeling in the context of cutaneous wound healing.	Univ Illinois, Dept Mol Genet, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Dept Mol Genet, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.			Mo, Fan-E/0000-0002-0087-7043; Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA 46565, CA 80080] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chaudhary LR, 2000, J CELL BIOCHEM, V76, P354, DOI 10.1002/(SICI)1097-4644(20000301)76:3<354::AID-JCB2>3.0.CO;2-U; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMBRY RM, 1986, AM J PATHOL, V125, P81; HOGAN B, 1994, MANIPULATING MOUSE E, P373; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JONES PL, 1995, J CELL SCI, V108, P519; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; LANE TF, 1992, J BIOL CHEM, V267, P16736; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MO FE, 2001, THESIS U ILLINOIS CH; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Reunanen N, 2000, J BIOL CHEM, V275, P34634, DOI 10.1074/jbc.C000175200; Rezzonico R, 2000, BLOOD, V95, P3868; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; SEGARINI PR, 2001, J BIOL CHEM     0822; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353	60	226	239	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47329	47337		10.1074/jbc.M107666200	http://dx.doi.org/10.1074/jbc.M107666200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584015	hybrid			2022-12-27	WOS:000172768500088
J	de Figueiredo, P; Doody, A; Polizotto, RS; Drecktrah, D; Wood, S; Banta, M; Strang, MS; Brown, WJ				de Figueiredo, P; Doody, A; Polizotto, RS; Drecktrah, D; Wood, S; Banta, M; Strang, MS; Brown, WJ			Inhibition of transferrin recycling and endosome tubulation by phospholipase A(2) antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MANNOSE 6-PHOSPHATE RECEPTORS; POLARIZED MDCK CELLS; CANINE KIDNEY-CELLS; TRANS-GOLGI NETWORK; BREFELDIN-A; MEMBRANE TUBULATION; PLASMA-MEMBRANE; HELA-CELLS; CARCINOMA A431-CELLS	We report here that a broad spectrum of phospholipase A(2) (PLA(2)) antagonists produce a concentration-dependent, differential block in the endocytic recycling pathway of transferrin (Tf) and Tf receptors (TfRs) but have no acute affect on Tf uptake from the cell surface. At low concentrations of antagonists (similar to1 muM), Tf and TfR accumulated in centrally located recycling endosomes, whereas at higher concentrations (similar to 10 muM), Tf-TfR accumulated in peripheral sorting endosomes. Several independent lines of evidence suggest that this inhibition of recycling may result from the inhibition of tubule formation. First, BFA-stimulated endosome tubule formation was similarly inhibited by PLA(2) antagonists. Second, endocytosed tracers were found in larger spherical endosomes in the presence of PLA(2) antagonists. And third, endosome tubule formation in a cell-free, cytosol-dependent reconstitution system was equally sensitive PLA(2) antagonists. These results are consistent with the conclusion that endosome membrane tubules are formed by the action of a cytoplasmic PLA(2) and that PLA(2)-dependent tubules are involved in intracellular recycling of Tf and TfR. When taken together with previous studies on the Golgi complex, these results also indicate that an intracellular PLA(2) activity provides a novel molecular mechanism for inducing tubule formation from multiple organelles.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Brown, WJ (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.		Brown, William/GXN-2777-2022		NIGMS NIH HHS [GM 60373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060373] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; APODACA G, 1994, J BIOL CHEM, V269, P19005; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BANTA M, 1995, BIOCHEMISTRY-US, V34, P13359, DOI 10.1021/bi00041a012; BRETSCHER MS, 1985, EUR J CELL BIOL, V37, P78; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DAMKE H, 1991, J BIOL CHEM, V266, P24829; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; de Figueiredo P, 2000, TRAFFIC, V1, P504, DOI 10.1034/j.1600-0854.2000.010608.x; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 1999, MOL BIOL CELL, V10, P1763, DOI 10.1091/mbc.10.6.1763; DEFIGUEIREDO P, 1995, MOL BIOL CELL, V6, P871, DOI 10.1091/mbc.6.7.871; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Gaynor EC, 1998, MOL BIOL CELL, V9, P653, DOI 10.1091/mbc.9.3.653; GELB MH, 1994, FASEB J, V8, P916, DOI 10.1096/fasebj.8.12.8088457; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Handley D. A., 1989, COLLOIDAL GOLD PRINC, V1, P13; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KILLISCH I, 1992, J CELL SCI, V103, P211; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MCGRAW TE, 1999, CURRENT PROTOCOLS CE, V1; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Polizotto RS, 1999, J CELL BIOCHEM, V74, P670, DOI 10.1002/(SICI)1097-4644(19990915)74:4<670::AID-JCB16>3.3.CO;2-R; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; ROME LH, 1985, TRENDS BIOCHEM SCI, V10, P151, DOI 10.1016/0968-0004(85)90153-7; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON JA, 1992, J CELL SCI, V103, P201; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; TOOZE J, 1992, J CELL BIOL, V118, P813, DOI 10.1083/jcb.118.4.813; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WAN JS, 1992, J BIOL CHEM, V267, P13446; WHITNEY JA, 1995, CELL, V83, P703; WILLINGHAM MC, 1984, P NATL ACAD SCI-BIOL, V81, P175, DOI 10.1073/pnas.81.1.175; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	79	59	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47361	47370		10.1074/jbc.M108508200	http://dx.doi.org/10.1074/jbc.M108508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585839	hybrid			2022-12-27	WOS:000172768500091
J	Sarcina, M; Tobin, MJ; Mullineaux, CW				Sarcina, M; Tobin, MJ; Mullineaux, CW			Diffusion of phycobilisomes on the thylakoid membranes of the cyanobacterium Synechococcus 7942 - Effects of phycobilisome size, temperature, and membrane lipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT LACKING PHOTOSYSTEM; EXCITATION-ENERGY TRANSFER; MOLECULAR CHARACTERIZATION; PORPHYRIDIUM-CRUENTUM; POLYPEPTIDE; LOCALIZATION; MOBILITY	A variant of fluorescence recovery after photobleaching allows us to observe the diffusion of photosynthetic complexes in cyanobacterial thylakoid membranes in vivo. The unicellular cyanobacterium Synechococcus sp. PCC7942 is a wonderful model organism for fluorescence recovery after photobleaching, because it has a favorable membrane geometry and is well characterized and transformable. In Synechococcus 7942 (as in other cyanobacteria) we find that photosystem II is immobile, but phycobilisomes diffuse rapidly on the membrane surface. The diffusion coefficient is 3 X 10(-10) cm(2) s(-1) at 30 degreesC. This shows that the association of phycobilisomes with reaction centers is dynamic; there are no stable phycobilisome-reaction center complexes in vivo. Ive report the effects of mutations that change the phycobilisome size and membrane lipid composition. 1) In a mutant with no phycobilisome rods, the phycobilisomes remain mobile with a slightly faster diffusion coefficient. This confirms that the diffusion we observe is of intact phycobilisomes rather than detached rod elements. The faster diffusion coefficient in the mutant indicates that the rate of diffusion is partly determined by the phycobilisome size. 2) The temperature dependence of the phycobilisome diffusion coefficient indicates that the phycobilisomes have no integral membrane domain. It is likely that association with the membrane is mediated by multiple weak interactions with lipid head groups. 3) Changing the lipid composition of the thylakoid membrane has a dramatic effect on phycobilisome mobility. The results cannot be explained in terms of changes in the fluidity of the membrane; they suggest that lipids play a role in controlling phycobilisome-reaction center interaction.	UCL, Dept Biol, London WC1E 6BT, England; SERC, Daresbury Lab, Cent Lab Res Councils, Warrington WA4 4AD, Cheshire, England	University of London; University College London; STFC Daresbury Laboratory	Mullineaux, CW (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	c.mullineaux@ucl.ac.uk	Tobin, Mark J/B-8208-2015	Tobin, Mark J/0000-0003-1862-0649				Ajlani G, 1998, EUR J BIOCHEM, V257, P154, DOI 10.1046/j.1432-1327.1998.2570154.x; Ashby MK, 1999, PHOTOSYNTH RES, V61, P169, DOI 10.1023/A:1006217201666; Bald D, 1996, PHOTOSYNTH RES, V49, P103, DOI 10.1007/BF00117661; BHALERAO RP, 1995, PHOTOSYNTH RES, V45, P61, DOI 10.1007/BF00032236; BITTERSMANN E, 1991, BIOCHIM BIOPHYS ACTA, V1098, P105; CAPUANO V, 1991, J BIOL CHEM, V266, P7239; CASTENHOLZ RW, 1988, METHOD ENZYMOL, V167, P68; CLEMENTMETRAL JD, 1985, ARCH BIOCHEM BIOPHYS, V238, P10, DOI 10.1016/0003-9861(85)90135-3; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; GLAZER AN, 1984, BIOCHIM BIOPHYS ACTA, V768, P29, DOI 10.1016/0304-4173(84)90006-5; GLAZER AN, 1988, METHOD ENZYMOL, V167, P304; Gombos Z, 1997, PLANT PHYSIOL, V115, P551, DOI 10.1104/pp.115.2.551; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; HOUMARD J, 1990, P NATL ACAD SCI USA, V87, P2152, DOI 10.1073/pnas.87.6.2152; KATOH T, 1988, METHOD ENZYMOL, V167, P313; MacColl R, 1998, J STRUCT BIOL, V124, P311, DOI 10.1006/jsbi.1998.4062; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; MULLINEAUX CW, 1992, BIOCHIM BIOPHYS ACTA, V1100, P285, DOI 10.1016/0167-4838(92)90483-T; MULLINEAUX CW, 1994, BBA-BIOENERGETICS, V1184, P71, DOI 10.1016/0005-2728(94)90155-4; Mullineaux CW, 1997, NATURE, V390, P421, DOI 10.1038/37157; Mullineaux CW, 1999, AUST J PLANT PHYSIOL, V26, P671, DOI 10.1071/PP99027; MURATA N, 1989, J BIOENERG BIOMEMBR, V21, P61, DOI 10.1007/BF00762212; MUSTARDY L, 1992, P NATL ACAD SCI USA, V89, P10021, DOI 10.1073/pnas.89.21.10021; O'Toole PJ, 1999, BBA-BIOMEMBRANES, V1419, P64, DOI 10.1016/S0005-2736(99)00048-6; REDLINGER T, 1982, P NATL ACAD SCI-BIOL, V79, P5542, DOI 10.1073/pnas.79.18.5542; Sarcina M, 2000, FEMS MICROBIOL LETT, V191, P25, DOI 10.1016/S0378-1097(00)00365-7; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHEN GZ, 1995, PHOTOSYNTH RES, V44, P41, DOI 10.1007/BF00018295; SHERMAN DM, 1994, PLANT PHYSIOL, V106, P251, DOI 10.1104/pp.106.1.251; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; Sippola K, 1998, EUR J BIOCHEM, V251, P641, DOI 10.1046/j.1432-1327.1998.2510641.x; van Thor JJ, 1998, BOT ACTA, V111, P430, DOI 10.1111/j.1438-8677.1998.tb00731.x; VERMAAS WFJ, 1994, BBA-BIOENERGETICS, V1187, P181, DOI 10.1016/0005-2728(94)90107-4; Yu JJ, 1999, IUBMB LIFE, V48, P625, DOI 10.1080/152165499306513; Zhang CC, 1998, FEMS MICROBIOL LETT, V161, P285, DOI 10.1016/S0378-1097(98)00084-6; ZHANG F, 1993, BIOESSAYS, V15, P579, DOI 10.1002/bies.950150903	36	99	104	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46830	46834		10.1074/jbc.M107111200	http://dx.doi.org/10.1074/jbc.M107111200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590154	hybrid			2022-12-27	WOS:000172768500022
J	Shen, K; Keng, YF; Wu, L; Guo, XL; Lawrence, DS; Zhang, ZY				Shen, K; Keng, YF; Wu, L; Guo, XL; Lawrence, DS; Zhang, ZY			Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LOW-MOLECULAR-WEIGHT; SUBSTRATE-TRAPPING MUTANTS; SOLID-PHASE SYNTHESIS; INSULIN SENSITIVITY; O-PHOSPHOTYROSINE; KINASE INHIBITORS; STRUCTURAL BASIS; IN-VIVO; 1B	Protein-tyrosine phosphatases (PTPases) form a large family of enzymes that serve as key regulatory components in signal transduction pathways. Defective or inappropriate regulation of PTPase activity leads to aberrant tyrosine phosphorylation, which contributes to the development of many human diseases including cancers and diabetes. For example, recent gene knockout studies in mice identify PTP1B as a promising target for anti-diabetes/obesity drug discovery. Thus, there is intense interest in obtaining specific and potent PTPase inhibitors for biological studies and pharmacological development. However, given the highly conserved nature of the PTPase active site, it is unclear whether selectivity in PTPase inhibition can be achieved. We describe a combinatorial approach that is designed to target both the active site and a unique peripheral site in PTP1B. Compounds that can simultaneously associate with both sites are expected to exhibit enhanced affinity and specificity. We also describe a novel affinity-based high-throughput assay procedure that can be used for PTPase inhibitor screening. The combinatorial library/high-throughput screen protocols furnished a small molecule PTP1B inhibitor that is both potent (K-i = 2.4 nm) and selective (little or no activity against a panel of phosphatases including Yersinia PTPase, SHP1, SHP2, LAR, HePTP, PTP alpha, CD45, VHR, MKP3, Cdc25A, Stp1, and PP2C). These results demonstrate that it is possible to acquire potent, yet highly selective inhibitors for individual members of the large PTPase family of enzymes.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Bleasdale JE, 2001, BIOCHEMISTRY-US, V40, P5642, DOI 10.1021/bi002865v; BROWNSHIMER S, 1992, CANCER RES, V52, P478; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; BURKE TR, 1993, J ORG CHEM, V58, P1336, DOI 10.1021/jo00058a009; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Cohen P, 1999, CURR OPIN CHEM BIOL, V3, P459, DOI 10.1016/S1367-5931(99)80067-2; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GANEM B, 1974, TETRAHEDRON LETT, P917; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LAUNIKONIS A, 1986, AUST J CHEM, V39, P1053, DOI 10.1071/CH9861053; Lawrence DS, 1998, PHARMACOL THERAPEUT, V77, P81, DOI 10.1016/S0163-7258(97)00052-1; Lee TR, 1999, J MED CHEM, V42, P784, DOI 10.1021/jm980663f; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Montserat J, 1996, J BIOL CHEM, V271, P7868, DOI 10.1074/jbc.271.13.7868; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; SMYTH MS, 1994, TETRAHEDRON LETT, V35, P551, DOI 10.1016/S0040-4039(00)75835-7; Solas D, 1996, J ORG CHEM, V61, P1537, DOI 10.1021/jo9517508; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Vetter SW, 2000, J BIOL CHEM, V275, P2265, DOI 10.1074/jbc.275.4.2265; WIENER JR, 1994, AM J OBSTET GYNECOL, V170, P1177, DOI 10.1016/S0002-9378(94)70118-0; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; WILLIAMS RM, 1991, J AM CHEM SOC, V113, P9276, DOI 10.1021/ja00024a038; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; Wrobel J, 1999, J MED CHEM, V42, P3199, DOI 10.1021/jm990260v; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Yokomatsu T, 1997, TETRAHEDRON, V53, P815, DOI 10.1016/S0040-4020(96)01063-0; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; Zhang ZY, 1997, CURR TOP CELL REGUL, V35, P21, DOI 10.1016/S0070-2137(97)80002-7; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200	52	191	208	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47311	47319		10.1074/jbc.M106568200	http://dx.doi.org/10.1074/jbc.M106568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584002	hybrid			2022-12-27	WOS:000172768500086
J	Bussell, R; Eliezer, D				Bussell, R; Eliezer, D			Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; A-BETA COMPONENT; LEWY BODIES; IN-VITRO; NEURODEGENERATIVE DISORDERS; PROTEIN CONFORMATION; SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; BACKBONE DYNAMICS	alpha -Synuclein (alphaS) is a pre-synaptic protein that has been implicated as a possible causative agent in the pathogenesis of Parkinson's disease (PD). Two autosomal dominant missense mutations in the aS gene are associated with early onset PD. Because aS is found in an aggregated fibrillar form in the Lewy body deposits characteristic of Parkinson's patients, aggregation of the protein is believed to be related to its involvement in the disease process. The wild type (WT) and early onset mutants A30P and A53T display diverse in vitro aggregation kinetics even though the gross physicochemical and morphological properties of the mutants are highly similar. We used high resolution solution NMR spectroscopy to compare the structural and dynamic properties of the A53T and A30P mutants with those of WT aS in the free state. We found that the A30P mutation disrupts a region of residual helical structure that exists in the WT protein, whereas the A53T mutation results in a slight enhancement of a small region around the site of mutation with a preference for extended conformations. Based on these results and on the anticipated effects of these mutations on elements of secondary structure, we proposed a model of how these two PD-linked mutations influence aS fibril formation that is consistent with the documented differences in the fibrillization kinetics of the two mutants.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Program Struct Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol Biophys & Mol Med, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Eliezer, D (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	dae2005@med.cornell.edu	Eliezer, David/GRS-5702-2022		NATIONAL INSTITUTE ON AGING [R01AG019391, R37AG019391] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG019391, AG19391, R01 AG019391, R01 AG019391-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arima K, 2000, ACTA NEUROPATHOL, V100, P115, DOI 10.1007/s004010050002; Baba M, 1998, AM J PATHOL, V152, P879; Cavanagh John, 1996, P243; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2000, BIOCHEMISTRY-US, V39, P2894, DOI 10.1021/bi992545f; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, CLIN CHEM LAB MED, V39, P308, DOI 10.1515/CCLM.2001.047; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kruger R, 2000, J NEURAL TRANSM, V107, P31, DOI 10.1007/s007020050002; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	55	214	218	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45996	46003		10.1074/jbc.M106777200	http://dx.doi.org/10.1074/jbc.M106777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590151	hybrid			2022-12-27	WOS:000172573100069
J	Fu, MG; Zhang, JF; Zhu, XJ; Myles, DE; Willson, TM; Liu, XD; Chen, YQE				Fu, MG; Zhang, JF; Zhu, XJ; Myles, DE; Willson, TM; Liu, XD; Chen, YQE			Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; POTENTIAL MEDIATOR; ATHEROSCLEROSIS; MACROPHAGES; HYPERPLASIA; PATHWAY; LIGANDS; GENE	Activation of peroxisome proliferator-activated receptor gamma (PPAR gamma) after balloon injury significantly inhibits VSMC proliferation and neointima formation. However, the precise mechanisms of this inhibition have not been determined. We hypothesized that activation of PPAR gamma in vascular injury could attenuate VSMC growth and matrix production during vascular lesion formation. Since connective tissue growth factor (CTGF) is a key factor regulating extracellular matrix production, abrogation of transforming growth factor beta (TGF-beta) -induced CTGF production by PPAR gamma activation may be one of the mechanisms through which PPAR gamma agonists inhibit neointima formation after vascular injury. In this study, we demonstrate that the PPAR gamma natural ligand (15-deoxyprostaglandin J(2)) and a synthetic ligand (GW7845) significantly inhibit TGF-beta -induced CTGF production in a dose-dependent manner in HASMCs. In addition, suppression of CTGF mRNA expression is relieved by pretreatment with an antagonist of PPAR gamma (GW9662), suggesting that the inhibition of CTGF expression is mediated by PPAR gamma. To elucidate further the molecular mechanism by which PPAR gamma inhibits CTGF expression, an similar to2-kilobase pair CTGF promoter was cloned. We found that PPAR gamma activation inhibits TGF-beta -induced CTGF promoter activity in a dose-dependent manner, and suppression of CTGF promoter activity by PPAR gamma activation is completely rescued by overexpression of Smad3, but not by Smad4. Furthermore, PPAR gamma physically interacts with Smad3 but not Smad4 in vitro in glutathione S-transferase pull-down experiments. Taken together, the data suggest that PPAR gamma inhibits TGF-beta -induced CTGF expression in HASMCs by directly interfering with the Smad3 signaling pathway.	Morehouse Sch Med, Inst Cardiovasc Res, Atlanta, GA 30310 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Morehouse School of Medicine; GlaxoSmithKline; University of Colorado System; University of Colorado Boulder	Chen, YQE (corresponding author), Morehouse Sch Med, Inst Cardiovasc Res, 720 Westview Dr SW, Atlanta, GA 30310 USA.		feinstein, doug/M-9414-2019	LIU, XUEDONG/0000-0001-7209-4964; Myles, David/0000-0002-3839-0644	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 UH1 HL03676-02] Funding Source: Medline; NIGMS NIH HHS [S06GM08248] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KOLPAKOV V, 1995, CIRC RES, V76, P305, DOI 10.1161/01.RES.76.2.305; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200	30	151	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45888	45894		10.1074/jbc.M105490200	http://dx.doi.org/10.1074/jbc.M105490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590167	hybrid			2022-12-27	WOS:000172573100054
J	Goldshmit, Y; Erlich, S; Pinkas-Kramarski, R				Goldshmit, Y; Erlich, S; Pinkas-Kramarski, R			Neuregulin rescues PC12-ErbB4 cells from cell death induced by H2O2 - regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; HYDROGEN-PEROXIDE; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; OXIDATIVE STRESS; H2O2-INDUCED APOPTOSIS	Neuregulins (NRGs), a large family of transmembrane polypeptide growth factors, mediate various cellular responses depending on the cell type and receptor expression. We previously showed that NRG mediates survival of PC12-ErbB4 cells from apoptosis induced by serum deprivation or tumor necrosis factor-a treatment. In the present study we show that NRG induces a significant protective effect from H2O2-induced death. This effect of NRG is mediated by the phosphatidylinositol 3-kinase (PI3K)-signaling pathway since NRG failed to rescue cells from H2O2 insult in the presence of the PI3K inhibitor, LY294002. Furthermore, the downstream effector of PI3K, protein kinase B/AKT, is activated by NRG in the presence of H2O2, and protein kinase B/AKT activation is inhibited by LY294002. In addition, our results demonstrate that reactive oxygen species (ROS) elevation induced by H2O2 is inhibited by NRG. LY294002, which blocks NRG-mediated rescue, increases ROS levels. Moreover, both H2O2-induced ROS elevation and cell death are reduced by expression of activated PI3K. These results suggest that PI3K-dependent pathways may regulate toxic levels of ROS generated by oxidative stress.	Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	lironit@post.tau.ac.il		Pinkas-Kramarski, Ronit/0000-0002-1000-369X				Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Calderon FH, 1999, J NEUROSCI RES, V56, P620; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN MGM, 1977, P NATL ACAD SCI USA, V74, P5559, DOI 10.1073/pnas.74.12.5559; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; de la Monte SM, 2000, CELL MOL LIFE SCI, V57, P1471, DOI 10.1007/PL00000630; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eilam R, 1998, P NATL ACAD SCI USA, V95, P1888, DOI 10.1073/pnas.95.4.1888; ENOKIDO Y, 1990, BRAIN RES, V536, P23, DOI 10.1016/0006-8993(90)90004-U; Erlich S, 2001, NEUROSCIENCE, V107, P353, DOI 10.1016/S0306-4522(01)00350-5; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haviv R, 1999, J NEUROSCI RES, V55, P269; Hong F, 2001, LIFE SCI, V68, P1095, DOI 10.1016/S0024-3205(00)01012-2; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; Kamata H, 1996, NEUROSCI LETT, V212, P179, DOI 10.1016/0304-3940(96)12806-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Knight JA, 1997, ANN CLIN LAB SCI, V27, P93; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Marchionni MA, 1999, ADV EXP MED BIOL, V468, P283; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PEREZPOLO JR, 1990, MOL NEUROBIOL, V4, P57, DOI 10.1007/BF02935585; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; RATAN RR, 1994, J NEUROCHEM, V62, P376; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yamakawa H, 2000, NEUROL RES, V22, P556; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YING Z, 1993, J CEREBR BLOOD F MET, V13, P378, DOI 10.1038/jcbfm.1993.51	62	114	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46379	46385		10.1074/jbc.M105637200	http://dx.doi.org/10.1074/jbc.M105637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590144	hybrid			2022-12-27	WOS:000172573100120
J	Mackem, S; Baumann, CT; Hager, GL				Mackem, S; Baumann, CT; Hager, GL			A glucocorticoid/retinoic acid receptor chimera that displays cytoplasmic/nuclear translocation in response to retinoic acid - A real time sensing assay for nuclear receptor ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTORS; BINDING DOMAIN; LIVING CELLS; CRYSTAL-STRUCTURE; LOCALIZATION; HSP90; VISUALIZATION; FORM	Members of the nuclear receptor superfamily play key roles in a host of physiologic and pathologic processes from embryogenesis to cancer. Some members, including the retinoic acid receptor (RAR), are activated by ligand binding but are unaffected in their subcellular distribution, which is predominantly nuclear. In contrast, several members of the steroid receptor family, including the glucocorticoid receptor, are cytoplasmic and only translocate to the nucleus after ligand binding. We have constructed chimeras between RAR and glucocorticoid receptor that selectively respond to RAR agonists but display cytoplasmic localization in the absence of ligand. These chimeric receptors manifest both nuclear translocation and gene activation functions in response to physiological concentrations of PLAR ligands. The ability to achieve regulated subcellular trafficking with a heterologous ligand binding domain has implications both for current models of receptor translocation and for structural-functional conservation of ligand binding domains broadly across the receptor superfamily. When coupled to the green fluorescent protein, chimeric receptors offer a powerful new tool to 1) study mechanisms of steroid receptor translocation, 2) detect dynamic and graded distributions of ligands in complex microenvironments such as embryos, and 3) screen for novel ligands of "orphan" receptors in vivo.	NCI, Lab Receptor Biol & Gene Express, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hager, GL (corresponding author), NCI, Lab Receptor Biol & Gene Express, Canc Res Ctr, NIH, Bldg 41,Rm B602, Bethesda, MD 20892 USA.	hagerg@exchange.nci.nih.gov						Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hager GL, 1999, METHOD ENZYMOL, V302, P73, DOI 10.1016/S0076-6879(99)02011-X; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Maden M, 1998, DEVELOPMENT, V125, P4133; MCGRATH ME, 1994, J MOL BIOL, V237, P236, DOI 10.1006/jmbi.1994.1224; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1989, CANCER RES, V49, pS2222; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; WAGNER M, 1992, DEVELOPMENT, V116, P55; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	34	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45501	45504		10.1074/jbc.C100269200	http://dx.doi.org/10.1074/jbc.C100269200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585812	hybrid			2022-12-27	WOS:000172573100002
J	Mamedov, TG; Suzuki, K; Miura, K; Kucho, K; Fukuzawa, H				Mamedov, TG; Suzuki, K; Miura, K; Kucho, K; Fukuzawa, H			Characteristics and sequence of phosphoglycolate phosphatase from a eukaryotic green alga Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORESPIRATORY MUTANT; CHLOROPLAST; DEFICIENT; PROTEINS; PURIFICATION; ACTIVATION; ENZYMES; BINDING; SPINACH; CATION	Phosphoglycolate phosphatase (PGPase), a key enzyme of photorespiration in photosynthetic organisms, was purified from Chlamydomonas reinhardtii. The enzyme was an similar to 65-kDa homodimer with a pI value of 5.1 composed of similar to 32-kDa subunits not connected by any S-S bridges. It was also highly specific for phosphoglycolate with a K-m value of 140 mum and an optimal pH between 8 and 9. The activity was strongly inhibited by CaCl2, and it recovered competitively following the addition of MgCl2 or EGTA. A mobility shift was observed in SDS-polyacrylamide gel electrophoresis by the addition of CaCl2. indicating that the enzyme binds to Ca2+. The N-terminal region of amino acid sequence deduced from cDNA sequence that was not contained in the purified PGPase had similar characteristics to those of typical stroma-targeting transit peptides in C. reinhardtii. The following region of the deduced sequence containing 302 amino acid residues was similar to p-nitrophenylphosphatase-like proteins, although the purified PGPase did not hydrolyze p-nitrophenylphosphate. Genomic DNA fragments from wild type containing the sequence homologous to the cDNA for PGPase complemented the PGPase-deficient mutant pgp1. Possible regulatory mechanisms during adaptation to limiting CO2 were discussed based on the characteristics of the purified PGPase and the deduced amino acid sequence.	Tohoku Natl Agr Res Ctr, Plant Physiol Lab, Morioka, Iwate 0200198, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Plant Mol Biol Lab,Sakyo Ku, Kyoto 6068502, Japan	National Agriculture & Food Research Organization - Japan; Kyoto University	Suzuki, K (corresponding author), Tohoku Natl Agr Res Ctr, Plant Physiol Lab, Morioka, Iwate 0200198, Japan.		Fukuzawa, Hideya/I-5906-2018; Suzuki, Kensaku/A-5944-2012; Mammedov, Tarlan/J-3853-2013; Miura, Kenji/C-2803-2011; Miura, Kenji/AAB-4716-2020	Fukuzawa, Hideya/0000-0003-0963-5662; Suzuki, Kensaku/0000-0002-6006-9785; Miura, Kenji/0000-0003-1262-2176; Miura, Kenji/0000-0003-1262-2176				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDERSON LE, 1971, BIOCHIM BIOPHYS ACTA, V235, P237, DOI 10.1016/0005-2744(71)90051-9; Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; BALDY P, 1989, PHOTOSYNTH RES, V22, P147, DOI 10.1007/BF00035445; BELANGER FC, 1987, PHOTOSYNTH RES, V14, P3, DOI 10.1007/BF00019588; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLES SA, 1980, BIOCHEM J, V188, P775, DOI 10.1042/bj1880775; CHRISTELLER JT, 1978, J BIOL CHEM, V253, P1780; CHRISTELLER JT, 1978, J BIOL CHEM, V253, P1786; CHRISTELLER JT, 1978, J BIOL CHEM, V253, P1791; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; Fukuzawa H, 2001, P NATL ACAD SCI USA, V98, P5347, DOI 10.1073/pnas.081593498; HALL NP, 1987, PHOTOSYNTH RES, V11, P89, DOI 10.1007/BF00117676; HARDY P, 1986, PLANTA, V168, P245, DOI 10.1007/BF00402970; HERTIG C, 1980, BIOCHEM BIOPH RES CO, V97, P325, DOI 10.1016/S0006-291X(80)80171-9; HUSIC HD, 1984, ARCH BIOCHEM BIOPHYS, V229, P64, DOI 10.1016/0003-9861(84)90130-9; HUSIC HD, 1985, PLANT PHYSIOL, V79, P394, DOI 10.1104/pp.79.2.394; Ito M, 1997, COMPUT APPL BIOSCI, V13, P415; KERR M W, 1974, Biochemical Society Transactions, V2, P338; Krimm I, 1999, EUR J BIOCHEM, V265, P171, DOI 10.1046/j.1432-1327.1999.00701.x; Kucho K, 1999, PLANT PHYSIOL, V121, P1329, DOI 10.1104/pp.121.4.1329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAREK LF, 1991, PLANT PHYSIOL, V97, P420, DOI 10.1104/pp.97.1.420; MULLEY JC, 1990, CYTOGENET CELL GENET, V53, P175, DOI 10.1159/000132923; NORMAN EG, 1991, PLANT PHYSIOL, V95, P693, DOI 10.1104/pp.95.3.693; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RANDALL D D, 1976, Australian Journal of Plant Physiology, V3, P105; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROSE ZB, 1986, J BIOL CHEM, V261, P996; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; SEAL SN, 1987, J BIOL CHEM, V262, P13496; SOMERVILLE CR, 1979, NATURE, V280, P833, DOI 10.1038/280833a0; Suzuki K, 1999, PLANT CELL PHYSIOL, V40, P792, DOI 10.1093/oxfordjournals.pcp.a029607; SUZUKI K, 1990, PLANT PHYSIOL, V93, P231, DOI 10.1104/pp.93.1.231; SUZUKI K, 1995, PLANT CELL PHYSIOL, V36, P95; VERINVERGEAU C, 1979, PHYTOCHEMISTRY, V18, P1279, DOI 10.1016/0031-9422(79)83007-1; WINTERMANS JF, 1965, BIOCHIM BIOPHYS ACTA, V109, P448, DOI 10.1016/0926-6585(65)90170-6; WOLFENDEN R, 1970, BIOCHEMISTRY-US, V9, P3404, DOI 10.1021/bi00819a018; WOLOSIUK RA, 1982, FEBS LETT, V140, P31, DOI 10.1016/0014-5793(82)80514-0; ZECHER R, 1982, INT J BIOCHEM, V14, P775, DOI 10.1016/0020-711X(82)90097-0	40	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45573	45579		10.1074/jbc.M103882200	http://dx.doi.org/10.1074/jbc.M103882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581250	Green Published, hybrid			2022-12-27	WOS:000172573100013
J	Strachan, GD; Rallapalli, R; Pucci, B; Lafond, TP; Hall, DJ				Strachan, GD; Rallapalli, R; Pucci, B; Lafond, TP; Hall, DJ			A transcriptionally inactive E2F-1 targets the MDM family of proteins for proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE-PRODUCT; CELL-GROWTH CONTROL; RETINOBLASTOMA PROTEIN; P53-BINDING PROTEIN; P53; APOPTOSIS; ONCOPROTEIN; PATHWAY; DOMAIN; P73	E2F-1-activated transcription promotes cell cycle progression and apoptosis. These functions are regulated by several factors including the E2F-1-binding protein MDM2 and the retinoblastoma protein pRb. Using a yeast two-hybrid screen we have identified the MDM2-related protein, MDMX as an E2F-1-binding protein. In these studies we find that coexpression of MDMX with E2F-1 results in degradation of the MDMX protein. Although this proteolytic degradation can be blocked by the protease inhibitors bafilomycin A(1), N-acetyl-Leu-Leu-Norleu-AL, and N-acetyl-Leu-Leu-Met-AL, MDMX degradation is not inhibited by lactacystin, suggesting that degradation occurs by a proteasome-independent mechanism. Using an E2F-1 deletion mutant (E2F-1(180-437)) we show that E2F-1-targeted degradation of MDMX does not require the E2F-1 DNA binding domain and therefore is independent of E2F-1-driven transcription. We also find that this transcriptionally inactive E2F-1 mutant is capable of degrading the MDMX-related protein MDM2 and the MDMX isoform MDMX-S. Mapping of the E2F-1 C terminus reveals that neither a previously characterized C-terminal MDM2 binding domain nor the pRb binding domain on E2F-1 is required for MDMX and MDM2 degradation.	Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Hall, DJ (corresponding author), NIAMS, Cartilage Biol & Orthoped Branch, NIH, Bldg 13,Rm 3W17,13 S Dr,MSC 5755, Bethesda, MD 20892 USA.				NCI NIH HHS [CA67032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Craighead MW, 1999, J NEUROSCI RES, V57, P236, DOI 10.1002/(SICI)1097-4547(19990715)57:2<236::AID-JNR9>3.3.CO;2-4; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Flores C, 2000, REV MED CHILE, V128, P539; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; INOUE S, 1991, J BIOL CHEM, V266, P13311; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JORDAN KL, 1994, ONCOGENE, V9, P1177; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Loughlin C, 2000, ASSEMBLY AUTOM, V20, P6; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PYRE JJ, 1992, BIOCHEMISTRY-US, V31, P4102; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yang HL, 1999, CLIN CANCER RES, V5, P2242; Zhu JH, 1998, CANCER RES, V58, P5061	46	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45677	45685		10.1074/jbc.M103765200	http://dx.doi.org/10.1074/jbc.M103765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11568180	hybrid			2022-12-27	WOS:000172573100026
J	Fredenburgh, JC; Stafford, AR; Weitz, JI				Fredenburgh, JC; Stafford, AR; Weitz, JI			Conformational changes in thrombin when complexed by serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-BINDING EXOSITE; HEPARIN-COFACTOR-II; HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; THROMBOMODULIN COMPLEX; MOLECULAR MECHANISMS; PROTEIN-C; INACTIVATION; PROTHROMBIN; INHIBITION	Thrombin possesses two positively charged surface domains, termed exosites, that orient substrates and inhibitors for reaction with the enzyme. Because the exosites also allosterically modulate thrombin's activity, we set out to determine whether the structure or function of the exosites changes when thrombin forms complexes with antithrombin, heparin cofactor II, or alpha (1)-antitrypsin (M358R), serpins that utilize both, one, or neither of the exosites, respectively. Using a hirudin-derived peptide to probe the integrity of exosite 1, no binding was detected when thrombin was complexed with heparin cofactor II or alpha (1)-antitrypsin (M358R), and the peptide exhibited a 55-fold lower affinity for the thrombin-antithrombin complex than for thrombin. Bound peptide or HD-1, an exosite 1-binding DNA aptamer, was displaced from thrombin by each of the three serpins. Thrombin binding to fibrin also was abrogated when the enzyme was complexed with serpins. These data reveal that, regardless of the initial mode of interaction, the function of exosite 1 is lost when thrombin is complexed by serpins. In contrast, the integrity of exosite 2 is largely retained when thrombin is complexed by serpins, because interaction with heparin or an exosite 2-directed DNA aptamer was only modestly altered. The disorganization of exosite 1 that occurs when thrombin is complexed by serpins is consistent with results of protease sensitivity studies and crystallographic analysis of a homologous enzyme-serpin complex.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; ARITOMI M, 1993, THROMB HAEMOSTASIS, V70, P418; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; Baerga-Ortiz A, 2000, J MOL BIOL, V296, P651, DOI 10.1006/jmbi.1999.3447; BINNIE CG, 1993, BLOOD, V81, P3186; BISCHOFF R, 1991, BIOCHEMISTRY-US, V30, P3464, DOI 10.1021/bi00228a017; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK SC, 2000, HEMOSTASIS THROMBOSI, P321; BODE W, 1992, PROTEIN SCI, V1, P426; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; Colman RWCA, 2001, HEMOSTASIS THROMBOSI, P3; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; Duffy EJ, 1997, BIOCHEM J, V321, P361, DOI 10.1042/bj3210361; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; ESMON CT, 2000, HEMATOLOGY BASIC PRI, P1714; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Hogg PJ, 1997, THROMB HAEMOSTASIS, V77, P424; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; LIU LW, 1991, J BIOL CHEM, V266, P23632; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; Nesheim ME, 1999, FIBRINOLYSIS PROTEOL, V13, P72, DOI 10.1016/S0268-9499(99)90082-6; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Wells MJ, 1999, THROMB HAEMOSTASIS, V81, P325, DOI 10.1055/s-0037-1614472; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; WU QY, 1994, J BIOL CHEM, V269, P3725	45	23	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44828	44834		10.1074/jbc.M108710200	http://dx.doi.org/10.1074/jbc.M108710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584020	hybrid			2022-12-27	WOS:000172406700067
J	Ingles-Esteve, J; Espinosa, L; Milner, LA; Caelles, C; Bigas, A				Ingles-Esteve, J; Espinosa, L; Milner, LA; Caelles, C; Bigas, A			Phosphorylation of Ser2078 modulates the Notch2 function in 32D cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; HEMATOPOIETIC PROGENITORS; INHIBITS DIFFERENTIATION; NUCLEAR TRANSLOCATION; EXPRESSION; CLEAVAGE; FATE; RECEPTOR; FRINGE; LIGAND	Notch signaling is involved in the regulation of many cell fate determination events in both embryonic development and adult tissue homeostasis. We previously demonstrated that Notch1 and Notch2 molecules inhibit myeloid differentiation in a cytokine-specific manner and that the Notch cytokine response domain is necessary for this functional specificity. We have now investigated the putative role of phosphorylation in the activity of Notch in response to cytokine signals. Our results show that the granulocyte colony-stimulating factor (G-CSF) stimulation of 32D cells expressing the intracellular Notch2 protein induces phosphorylation at specific sites of this molecule, rendering the molecule inactive and permitting differentiation of these cells. In contrast, when cells are stimulated with granulocyte macrophage colony-stimulating factor (GM-CSF), intracellular notch2 is not phosphorylated at these residues and differentiation is inhibited. We also show that deletion of the Ser/Thr-rich region between amino acids 2067 and 2099 abrogates G-CSF-induced phosphorylation and results in a molecule that inhibits differentiation in response to either G-CSF or GM-CSF. Our results further indicate that Ser(2078) is a critical residue for phosphorylation and modulation of Notch2 activity in the context of G-CSF-induced differentiation of 32D cells.	Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Barcelona, Fac Farm, Dept Bioquim, E-08028 Barcelona, Spain	Fred Hutchinson Cancer Center; University of Barcelona	Bigas, A (corresponding author), Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain.	abigas@iro.es	Bigas, Anna/A-7457-2014	Bigas, Anna/0000-0003-4801-6899				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Baonza A, 2000, P NATL ACAD SCI USA, V97, P2609, DOI 10.1073/pnas.040576497; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Egan SE, 1998, CURR TOP MICROBIOL, V228, P273; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Han W, 2000, BLOOD, V95, P1616, DOI 10.1182/blood.V95.5.1616.005k31_1616_1625; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Ikeya T, 1999, DEVELOPMENT, V126, P4455; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jehn BM, 1999, J IMMUNOL, V162, P635; JOHNSTON LA, 1998, NATURE, P62; Jones P, 1998, BLOOD, V92, P1505, DOI 10.1182/blood.V92.5.1505.417k42_1505_1511; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; MILNER LA, 1994, BLOOD, V83, P2057; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; MITSIADIS TA, 1995, J CELL BIOL, V130, P407, DOI 10.1083/jcb.130.2.407; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Ohishi K, 2000, BLOOD, V95, P2847, DOI 10.1182/blood.V95.9.2847.009k19_2847_2854; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 2000, J EXP MED, V191, P1085, DOI 10.1084/jem.191.7.1085; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Singh N, 2000, EXP HEMATOL, V28, P527, DOI 10.1016/S0301-472X(00)00146-6; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Sotillos S, 1997, DEVELOPMENT, V124, P4769; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tan-Pertel HT, 2000, J IMMUNOL, V165, P4428, DOI 10.4049/jimmunol.165.8.4428; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	70	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44873	44880		10.1074/jbc.M104703200	http://dx.doi.org/10.1074/jbc.M104703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577080	hybrid			2022-12-27	WOS:000172406700073
J	Lee, BC; Croonquist, PA; Hoff, WD				Lee, BC; Croonquist, PA; Hoff, WD			Mimic of photocycle by a protein folding reaction in photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; P-COUMARIC ACID; ECTOTHIORHODOSPIRA-HALOPHILA; TRANSITION-STATE; PROTON-TRANSFER; ACTIVE-SITE; CHROMOPHORE; INTERMEDIATE; KINETICS; THERMODYNAMICS	The blue light receptor photoactive yellow protein (PYP) displays rhodopsin-like photochemistry based on the trans to cis photoisomerization of its p-coumaric acid chromophore. Here, we report that protein refolding from the acid-denatured state of PYP mimics the last photocycle transition in PYP. This implies a direct link between transient protein unfolding and photosensory signal transduction. We utilize this link to study general issues in protein folding. Chromophore trans to cis photoisomerization in the acid-denatured state strongly decelerates refolding, and converts the pH dependence of the barrier for refolding from linear to nonlinear. We propose transition state movement to explain this phenomenon. The cis chromophore significantly stabilizes the acid-denatured state, but acidification of PYP results in the accumulation of the acid-denatured state containing a trams chromophore. This provides a clear example of kinetic control in a protein unfolding reaction. These results demonstrate the power of PYP as a light-triggered model system to study protein folding.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Hoff, WD (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063805] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM63805-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brudler R, 2000, BIOCHEMISTRY-US, V39, P13478, DOI 10.1021/bi0009946; Craven CJ, 2000, BIOCHEMISTRY-US, V39, P14392, DOI 10.1021/bi001628p; Demchuk E, 2000, BIOCHEMISTRY-US, V39, P1100, DOI 10.1021/bi991513p; Devanathan S, 1999, BIOCHEMISTRY-US, V38, P13766, DOI 10.1021/bi991634p; Devanathan S, 1998, BIOCHEMISTRY-US, V37, P11563, DOI 10.1021/bi9803776; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hoff WD, 1997, BBA-BIOENERGETICS, V1322, P151, DOI 10.1016/S0005-2728(97)00082-0; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; Lee BC, 2001, P NATL ACAD SCI USA, V98, P9062, DOI 10.1073/pnas.111153598; Lee BC, 2001, J BIOL CHEM, V276, P20821, DOI 10.1074/jbc.C100106200; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Ohishi S, 2001, BIOCHEMISTRY-US, V40, P2854, DOI 10.1021/bi001846i; Oliveberg M, 1996, BIOCHEMISTRY-US, V35, P2726, DOI 10.1021/bi9509661; Otzen DE, 1999, BIOCHEMISTRY-US, V38, P6499, DOI 10.1021/bi982819j; Parker MJ, 1999, J MOL BIOL, V293, P1195, DOI 10.1006/jmbi.1999.3204; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Richter HT, 1996, BIOCHEMISTRY-US, V35, P15461, DOI 10.1021/bi9612430; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Tan YJ, 1996, J MOL BIOL, V264, P377, DOI 10.1006/jmbi.1996.0647; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a	41	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44481	44487		10.1074/jbc.M104362200	http://dx.doi.org/10.1074/jbc.M104362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577076	hybrid			2022-12-27	WOS:000172406700019
J	Levesque, L; Guzik, B; Guan, TL; Coyle, J; Black, BE; Rekosh, D; Hammarskjold, ML; Paschal, BM				Levesque, L; Guzik, B; Guan, TL; Coyle, J; Black, BE; Rekosh, D; Hammarskjold, ML; Paschal, BM			RNA export mediated by Tap involves NXT1-dependent interactions with the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE TRANSPORT ELEMENT; MESSENGER-RNA; MONOCLONAL-ANTIBODIES; BINDING-PROTEIN; REV PROTEIN; P62 COMPLEX; IDENTIFICATION; MEX67P; CTE; GLYCOPROTEINS	Nuclear export of ribonucleoprotein complexes requires cis-acting signals and recognition by receptors that mediate translocation through the nuclear pore complex. Translocation is likely to involve a series of physical interactions between the ribonucleoprotein complex and nucleoporins within the nuclear pore complex. Here, we have characterized the function of NXT1 in the context of the Tap-dependent RNA export pathway. Tap has been implicated in the nuclear export of RNA transcripts derived from Mason-Pfizer monkey virus that contain the constitutive transport element. We demonstrate that NXT1 stimulates binding of a Tap-RNA complex to nucleoporins in vitro, and we provide mutational analysis that shows these interactions are necessary for nuclear export of an intron-containing viral mRNA in vivo. Tap contains separate domains for binding to nucleoporins and NXT1, both of which are critical for its export function. RNA export is mediated by a heterodimer of Tap and NXT1, and the function of NXT1 on this pathway is to regulate the affinity of the Tap-RNA complex for nucleoporins within the nuclear pore complex. We propose that NXT1-dependent binding of the Tap-RNA complex to the nucleoporin p62, which we have reconstituted in vitro using recombinant proteins, represents a single step of the translocation reaction.	Univ Virginia, Dept Biochem & Mol Genet, Ctr Cell Signaling, Hlth Sci Syst, Charlottesville, VA 22908 USA; Univ Virginia, Myles H Thaler Ctr AIDS & Human Retrovirus Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Virginia; University of Virginia; University of Virginia; Scripps Research Institute	Paschal, BM (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Ctr Cell Signaling, Hlth Sci Syst, Box 800577, Charlottesville, VA 22908 USA.		Guzik, Brian/ABB-7468-2021		NIAID NIH HHS [AI47008, AI34721] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034721, R01AI047008] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bear J, 1999, MOL CELL BIOL, V19, P6306; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Black BE, 1999, MOL CELL BIOL, V19, P8616; Black BE, 2001, J CELL BIOL, V152, P141, DOI 10.1083/jcb.152.1.141; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; Ernst RK, 1997, RNA, V3, P210; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; KADOWAKI T, 1994, MOL BIOL CELL, V5, P1253, DOI 10.1091/mbc.5.11.1253; Kang YB, 2000, J VIROL, V74, P5863, DOI 10.1128/JVI.74.13.5863-5871.2000; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Srinivasakumar N, 1997, J VIROL, V71, P5841, DOI 10.1128/JVI.71.8.5841-5848.1997; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374	43	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44953	44962		10.1074/jbc.M106558200	http://dx.doi.org/10.1074/jbc.M106558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579093	hybrid			2022-12-27	WOS:000172406700083
J	Parizek, P; Roeckl, C; Weber, J; Flechsig, E; Aguzzi, A; Raeber, AJ				Parizek, P; Roeckl, C; Weber, J; Flechsig, E; Aguzzi, A; Raeber, AJ			Similar turnover and shedding of the cellular prion protein in primary lymphoid and neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICULAR DENDRITIC CELLS; PRP KNOCKOUT MICE; ASPARAGINE-LINKED GLYCOSYLATION; SOLUBLE FORM; HAMSTER SCRAPIE; CULTURED-CELLS; HUMAN BLOOD; EXPRESSION; REPLICATION; SUSCEPTIBILITY	The cellular prion protein (PrPc) is essential for pathogenesis and transmission of prion diseases. Although prion replication in the brain is accompanied by neurodegeneration, prions multiply efficiently in the lymphoreticular system without any detectable pathology. We have used pulse-chase metabolic radiolabeling experiments to investigate the turnover and processing of PrPc in primary cell cultures derived from lymphoid and nervous tissues. Similar kinetics of PrPc degradation were observed in these tissues. This indicates that the differences between these two organs with respect to their capacity to replicate prions is not due to differences in the turnover of PrPc. Substantial amounts of a soluble form of PrP that lacks the glycolipid anchor appeared in the medium of splenocytes and cerebellar granule cells. Soluble PrP was detected in murine and human serum, suggesting that it might be of physiological relevance.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; St Marys Hosp, Imperial Coll Med, Neurogenet Unit, London W2 1PG, England	University of Zurich; University Zurich Hospital; Imperial College London	Raeber, AJ (corresponding author), Cytos Proteome Therapeut GmbH, Fritz Arnold Str 23, D-78467 Constance, Germany.	raeber@cytos.com	Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY B, 1993, BRIT MED BULL, V49, P860, DOI 10.1093/oxfordjournals.bmb.a072651; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Holada K, 2000, BRIT J HAEMATOL, V110, P472, DOI 10.1046/j.1365-2141.2000.02158.x; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Kaeser PS, 2001, J VIROL, V75, P7097, DOI 10.1128/JVI.75.15.7097-7106.2001; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kubosaki A, 2001, BIOCHEM BIOPH RES CO, V282, P103, DOI 10.1006/bbrc.2001.4538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letho MT, 1998, BIOCHEM J, V332, P101, DOI 10.1042/bj3320101; Mabbott NA, 2000, NAT MED, V6, P719, DOI 10.1038/77401; MacGregor I, 1999, VOX SANG, V77, P88; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; MIZUKAMI IF, 1995, BLOOD, V86, P203; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Montrasio F, 2001, P NATL ACAD SCI USA, V98, P4034, DOI 10.1073/pnas.051609398; Perini F, 1996, BIOCHEM BIOPH RES CO, V223, P572, DOI 10.1006/bbrc.1996.0936; RACE RE, 1995, NEURON, V15, P1183, DOI 10.1016/0896-6273(95)90105-1; Raeber AJ, 1999, P NATL ACAD SCI USA, V96, P3987, DOI 10.1073/pnas.96.7.3987; Raeber AJ, 2000, IMMUNOL TODAY, V21, P66, DOI 10.1016/S0167-5699(99)01562-5; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Schneider SD, 1997, GENE THER, V4, P524, DOI 10.1038/sj.gt.3300432; SCHNIZLEIN CT, 1985, J IMMUNOL, V134, P1360; Smith GM, 1997, J CLIN IMMUNOL, V17, P502, DOI 10.1023/A:1027327912204; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAGLIAVINI F, 1992, BIOCHEM BIOPH RES CO, V184, P1398, DOI 10.1016/S0006-291X(05)80038-5; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262	45	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44627	44632		10.1074/jbc.M107458200	http://dx.doi.org/10.1074/jbc.M107458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571302	hybrid, Green Accepted			2022-12-27	WOS:000172406700040
J	Pawliczak, R; Cowan, MJ; Huang, XL; Nanavaty, UB; Alsaaty, S; Logun, C; Shelhamer, JH				Pawliczak, R; Cowan, MJ; Huang, XL; Nanavaty, UB; Alsaaty, S; Logun, C; Shelhamer, JH			p11 expression in human bronchial epithelial cells is increased by nitric oxide in a cGMP-dependent pathway involving protein kinase G activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-II TETRAMER; BIOCHEMICAL-CHARACTERIZATION; PHOSPHOLIPASE A(2); C-JUN; TRANSCRIPTION; BINDING; PHOSPHORYLATION; STIMULATION; SUBSTRATE; RELEASE	The effect of nitric oxide on p11 expression was studied in an immortalized human bronchial epithelial cell line (BEAS-2B cells). Three nitric oxide donors were used: spermine NONOate (SP), (+/-)-S-nitroso-N-acetylpenicillamine (SNAP), and S-nitrosoglutathione (SNOG). All three nitric oxide donors had similar effects resulting in dose-dependent and time-dependent accumulation of pll protein and an increase of steady-state p11 mRNA. Studies using a reporter gene containing the region from -1499 to +89 of the pll promoter demonstrated an increase in transcriptional activity after stimulation with NO donors for 4 h. These effects were abolished at the promoter and protein level using protein kinase G inhibitors (KT5823 and R-p-8-pCPT-cGMPS). Incubation of transfected cells with a cell permeable cGMP analogue (8-Br-cGMP) resulted in a dose-related increase of promoter activity. An electrophoretic mobility shift assay of nuclear proteins extracted from BEAS-2B cells identified an AP-1 site located at -82 to -77 of the p11 promoter region as an NO- and cGMP- dependent response element. These data were confirmed using a c-jun dominant negative mutant vector and a e-jun expression plasmid. Therefore, we conclude that nitric oxide-induced p11 expression in human bronchial epithelial cells is mediated at least in part through increased binding of activator protein one to the p11 promoter.	NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA; Med Univ Lodz, Dept Allergy & Clin Immunol, PL-92211 Lodz, Poland	National Institutes of Health (NIH) - USA; Medical University Lodz	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bldg 10,Rm 7D43,9000 Rockville Pike, Bethesda, MD 20892 USA.		Pawliczak, Rafa/S-2021-2019; Pawliczak, Rafal Tomasz/S-9649-2016	Pawliczak, Rafa/0000-0001-6784-453X; 	CLINICAL CENTER [Z01CL001160] Funding Source: NIH RePORTER	CLINICAL CENTER		Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BROWN PH, 1993, ONCOGENE, V8, P877; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; delaTorre A, 1998, SURGERY, V124, P137, DOI 10.1016/S0039-6060(98)70113-8; ERIKSON E, 1984, MOL CELL BIOL, V4, P77, DOI 10.1128/MCB.4.1.77; Filep JG, 1998, J IMMUNOL, V161, P5656; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GERKE V, 1990, BIOCHEM SOC T, V18, P1106, DOI 10.1042/bst0181106; GERKE V, 1991, P11 MEMBER S100 PROT, P139; Gertzberg N, 2000, AM J RESP CELL MOL, V22, P105, DOI 10.1165/ajrcmb.22.1.3801; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; LANDER HM, 1993, J IMMUNOL, V151, P7182; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Matsumoto T, 1997, PATHOL INT, V47, P339, DOI 10.1111/j.1440-1827.1997.tb04506.x; MOORE KG, 1992, PROTEIN EXPRES PURIF, V3, P1, DOI 10.1016/1046-5928(92)90049-3; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; von Knethen A, 2000, BIOCHEMISTRY-US, V39, P1532, DOI 10.1021/bi990820s; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	30	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44613	44621		10.1074/jbc.M104993200	http://dx.doi.org/10.1074/jbc.M104993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571284	hybrid			2022-12-27	WOS:000172406700038
J	Stadtman, ER				Stadtman, ER			The story of glutamine synthetase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							INTERCONVERTIBLE ENZYME CASCADES; ESCHERICHIA-COLI; METABOLIC-REGULATION; PROTEIN OXIDATION; ADENYLYLATION; SYSTEMS; URIDYLYLTRANSFERASE; DEADENYLYLATION; PURIFICATION; SUPERIORITY		NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Stadtman, ER (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000211] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER SP, 1975, J BIOL CHEM, V250, P6264; ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; ANDERSON WB, 1970, P NATL ACAD SCI USA, V67, P1417, DOI 10.1073/pnas.67.3.1417; ANDERSON WB, 1970, BIOCHEM BIOPH RES CO, V41, P704, DOI 10.1016/0006-291X(70)90070-7; ANDERSON WB, 1971, ARCH BIOCHEM BIOPHYS, V143, P428, DOI 10.1016/0003-9861(71)90229-3; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BROWN MS, 1971, P NATL ACAD SCI USA, V68, P2949, DOI 10.1073/pnas.68.12.2949; Carr PD, 1996, ACTA CRYSTALLOGR D, V52, P93, DOI 10.1107/S0907444995007293; CHOCK PB, 1977, P NATL ACAD SCI USA, V74, P2766, DOI 10.1073/pnas.74.7.2766; DENTON MD, 1969, BIOCHEMISTRY-US, V8, P1714, DOI 10.1021/bi00832a055; EBNER E, 1970, EUR J BIOCHEM, V14, P535, DOI 10.1111/j.1432-1033.1970.tb00320.x; EGGERER H, 1960, J AM CHEM SOC, V82, P2643, DOI 10.1021/ja01495a064; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GARCIA E, 1983, J BIOL CHEM, V258, P2246; HENNIG SB, 1970, P NATL ACAD SCI USA, V67, P1761, DOI 10.1073/pnas.67.4.1761; HOHMAN RJ, 1978, BIOCHEM BIOPH RES CO, V82, P865, DOI 10.1016/0006-291X(78)90863-X; HOHMAN RJ, 1982, ARCH BIOCHEM BIOPHYS, V218, P548, DOI 10.1016/0003-9861(82)90379-4; HOHMAN RJ, 1980, P NATL ACAD SCI-BIOL, V77, P7410, DOI 10.1073/pnas.77.12.7410; HOLZER H, 1969, ADV ENZYMOL RAMB, V32, P297; HOLZER H, 1969, A BENS S 1 ROL NUCL, P94; HOLZER H, 1969, FEBS S, V19, P171; KINGDON HS, 1967, P NATL ACAD SCI USA, V58, P1703, DOI 10.1073/pnas.58.4.1703; KINGDON HS, 1967, J BACTERIOL, V94, P949, DOI 10.1128/JB.94.4.949-957.1967; LIAW SH, 1993, P NATL ACAD SCI USA, V90, P4996, DOI 10.1073/pnas.90.11.4996; MANGUM JH, 1973, ARCH BIOCHEM BIOPHYS, V158, P514, DOI 10.1016/0003-9861(73)90543-2; MURA U, 1981, J BIOL CHEM, V256, P3022; MURA U, 1981, J BIOL CHEM, V256, P3014; RHEE SG, 1985, CURR TOP CELL REGUL, V27, P221; RHEE SG, 1983, ISOZYMES-CURR T BIOL, V8, P141; SHACTER E, 1984, J BIOL CHEM, V259, P2252; SHACTER E, 1984, J BIOL CHEM, V259, P2260; SHAPIRO BM, 1968, BIOCHEM BIOPH RES CO, V30, P32, DOI 10.1016/0006-291X(68)90708-0; SHAPIRO BM, 1967, J BIOL CHEM, V242, P5069; SHAPIRO BM, 1970, ANNU REV MICROBIOL, V24, P501, DOI 10.1146/annurev.mi.24.100170.002441; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; SHAPIRO BM, 1967, P NATL ACAD SCI USA, V58, P642, DOI 10.1073/pnas.58.2.642; SHAPIRO BM, 1969, BIOCHEMISTRY-US, V8, P659, DOI 10.1021/bi00830a030; SON HS, 1987, J BIOL CHEM, V262, P8690; STADTMAN ER, 1977, P NATL ACAD SCI USA, V74, P2761, DOI 10.1073/pnas.74.7.2761; STADTMAN ER, 1961, J BIOL CHEM, V236, P2033; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; STADTMAN ER, 1963, BACTERIOL REV, V27, P170, DOI 10.1128/MMBR.27.2.170-181.1963; STADTMAN ER, 1961, ANN NY ACAD SCI, V94, P952, DOI 10.1111/j.1749-6632.1961.tb35587.x; STADTMAN ER, 1975, METABOLIC INTERCONVE, P142; STADTMAN ER, 1961, P S DRUGS AFF LIP ME, P68; STADTMAN ER, 1969, A BENS S 1 ROL NUCL, P142; STADTMAN ER, 1959, BIOCHEM BIOPH RES CO, V2, P1; SUH SW, 1983, J BIOL CHEM, V258, P294; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; WOOLFOLK CA, 1966, ARCH BIOCHEM BIOPHYS, V116, P177, DOI 10.1016/0003-9861(66)90026-9; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V122, P174, DOI 10.1016/0003-9861(67)90137-3; WOOLFOLK CA, 1964, BIOCHEM BIOPH RES CO, V17, P313, DOI 10.1016/0006-291X(64)90003-8; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V118, P736, DOI 10.1016/0003-9861(67)90412-2; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	54	106	109	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44357	44364		10.1074/jbc.R100055200	http://dx.doi.org/10.1074/jbc.R100055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11585846	hybrid			2022-12-27	WOS:000172406700001
J	Kim, SH; Leem, JY; Lah, JJ; Slunt, HH; Levey, AI; Thinakaran, G; Sisodia, SS				Kim, SH; Leem, JY; Lah, JJ; Slunt, HH; Levey, AI; Thinakaran, G; Sisodia, SS			Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; SUBCELLULAR-LOCALIZATION; ENDOGENOUS PRESENILIN-1; IN-VIVO; TRANSMEMBRANE ASPARTATES; INTRACELLULAR DOMAIN; TRANSFECTED CELLS	PS1 deficiency and expression of PS1 with substitutions of two conserved transmembrane aspartate residues ("PS1 aspartate variants") leads to the reduction of A beta peptide secretion and the accumulation of amyloid precursor protein (APP) C-terminal fragments. To define the nature of the "dominant negative" effect of the PS1 aspartate variants, we stably expressed PS1 harboring aspartate to alanine substitutions at codons 257 (D257A) or 385 (D385A), singly or in combination (D257A/ D385A), in mouse neuroblastoma, N2a cells. Expression of the PS1 aspartate variants resulted in marked accumulation of intracellular and cell surface APP C-terminal fragments. While expression of the D385A PS1 variant reduced the levels of secreted AP peptides, we now show that neither the PS1 D257A nor D257A/D385A variants impair A beta production. Surprisingly, the stability of both immature and mature forms of APP is dramatically elevated in cells expressing PS1 aspartate variants, commensurate with an increase in the cell surface levels of APP. These findings lead us to conclude that the stability and trafficking of APP can be profoundly modulated by coexpression of PS1 with mutations at aspartate 257 and aspartate 385.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Johns Hopkins Univ, Neuropathol Lab, Baltimore, MD 21205 USA	University of Chicago; Emory University; Johns Hopkins University	Sisodia, SS (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Abbott 510,947 E 58th St, Chicago, IL 60637 USA.	ssisodia@drugs.bsd.uchicago.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X	NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER; NIA NIH HHS [AG14248] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ANNAERT WG, 2000, NEUROBIOL AGING, V21, pS133; Arduengo PM, 1998, J CELL SCI, V111, P3645; ARMOGIDA M, 2001, IN PRESS NAT CELL BI; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KIMBERLY WT, 2001, IN PRESS J BIOL CHEM; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lah JJ, 1997, J NEUROSCI, V17, P1971; LaPointe CF, 2000, J BIOL CHEM, V275, P1502, DOI 10.1074/jbc.275.2.1502; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Morihara T, 2000, MOL BRAIN RES, V85, P85, DOI 10.1016/S0169-328X(00)00229-1; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VANNOSTRAND WE, 1989, NATURE, V341, P546; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILTFANG J, 2001, IN PRESS J BIOL CHEM; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YU C, 2001, IN PRESS J BIOL CHEM; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	72	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43343	43350		10.1074/jbc.M108245200	http://dx.doi.org/10.1074/jbc.M108245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11564743	hybrid			2022-12-27	WOS:000172169300093
J	Minic, Z; Pastra-Landis, S; Gaill, F; Herve, G				Minic, Z; Pastra-Landis, S; Gaill, F; Herve, G			Catabolism of pyrimidine Nucleotides in the deep-sea tube worm Riftia pachyptila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-NUCLEOTIDASE INHIBITOR; DIHYDROPYRIMIDINE DEHYDROGENASE; CHEMOAUTOTROPHIC SYMBIONTS; PARTIAL-PURIFICATION; KINETIC-PROPERTIES; ESCHERICHIA-COLI; INORGANIC CARBON; RAT-LIVER; NITROGEN; JONES	The present study describes the distribution and properties of enzymes of the catabolic pathway of pyrimidine nucleotides in Riftia pachyptila, a tubeworm living around deep-sea hydrothermal vents and known to be involved in a highly specialized symbiotic association with a bacterium. The catabolic enzymes, 5'-nucleotidase, uridine phosphorylase, and uracil reductase, are present in all tissues of the worm, whereas none of these enzymatic activities were found in the symbiotic bacteria. The 5'-nucleotidase activity was particularly high in the trophosome, the symbiont-harboring tissue. These results suggest that the production of nucleosides in the trophosome may represent an alternative source of carbon and nitrogen for R. pachyptila, because these nucleosides can be delivered to other parts of the worm. This process would complement the source of carbon and nitrogen from organic metabolites provided by the bacterial assimilatory pathways. The localization of the enzymes participating in catabolism, 5'-nucleotidase and uridine phosphorylase, and of the enzymes involved in the biosynthesis of pyrimidine nucleotides, aspartate transcarbamylase and dihydroorotase, shows a non-homogeneous distribution of these enzymes in the trophosome. The catabolic enzymes 5'-nucleotidase and uridine phosphorylase activities increase from the center of the trophosome to its periphery. In contrast, the anabolic enzymes aspartate transcarbamylase and dihydroorotase activities decrease from the center toward the periphery of the trophosome. We propose a general scheme of anatomical and physiological organization of the metabolic pathways of the pyrimidine nucleotides in R. pachyptila and its bacterial endosymbiont.	Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France; Wheaton Coll, Dept Chem, Norton, MA 02766 USA; Univ Paris 06, CNRS, UMR 7622, Biol Marine Lab, F-75252 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	Herve, G (corresponding author), Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, 96 Blvd Raspail, F-75006 Paris, France.	gherve@ccr.jussieu.fr	Minic, Zoran/AAH-2091-2021					BERLIN RD, 1975, INT REV CYTOL, V42, P287, DOI 10.1016/S0074-7696(08)60983-3; BEUTLER E, 1982, BIOCHEM MED METAB B, V27, P334, DOI 10.1016/0006-2944(82)90038-2; BOREL JP, 1997, BIOCHIMIE DYNAMIQUE, P773; BOSCH C, 1984, CR ACAD SCI III-VIE, V299, P371; BOSMANN HB, 1971, BIOCHIM BIOPHYS ACTA, V227, P402, DOI 10.1016/0005-2744(71)90071-4; Bright M, 2000, MAR BIOL, V136, P621, DOI 10.1007/s002270050722; BURGER RM, 1975, BIOCHEMISTRY-US, V14, P2362, DOI 10.1021/bi00682a014; CAMICI M, 1985, BIOCHIM BIOPHYS ACTA, V840, P6, DOI 10.1016/0304-4165(85)90155-2; CAMPBELL TA, 1991, MOL BIOCHEM PARASIT, V47, P109, DOI 10.1016/0166-6851(91)90153-W; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; CHILDRESS JJ, 1993, NATURE, V362, P147, DOI 10.1038/362147a0; De Cian MC, 2000, J EXP BIOL, V203, P2907; DISTEL DL, 1987, MAR BIOL, V96, P97; ELKOUNI MH, 1982, P NATL ACAD SCI-BIOL, V79, P1037; ELLIMS PH, 1978, CLIN CHIM ACTA, V88, P99, DOI 10.1016/0009-8981(78)90155-9; FELBECK H, 1981, SCIENCE, V213, P336, DOI 10.1126/science.213.4505.336; FRITZSON P, 1969, BIOCHIM BIOPHYS ACTA, V178, P534, DOI 10.1016/0005-2744(69)90222-8; GAILL F, 1993, FASEB J, V7, P558, DOI 10.1096/fasebj.7.6.8472894; Gardiner S.L., 1993, MICROSCOPIC ANATOMY, V12, P371; Girguis PR, 2000, APPL ENVIRON MICROB, V66, P2783, DOI 10.1128/AEM.66.7.2783-2790.2000; GRONDAL EJM, 1987, BIOCHEM J, V245, P805, DOI 10.1042/bj2450805; HENTSCHEL U, 1993, NATURE, V366, P338, DOI 10.1038/366338a0; HERVE G, 1991, COLLOQ INSE, V203, P195; JENSEN MH, 1980, CLIN CHIM ACTA, V104, P221, DOI 10.1016/0009-8981(80)90199-0; Johnson S, 2000, FEMS MICROBIOL LETT, V192, P59, DOI 10.1016/S0378-1097(00)00409-2; Jones M.L., 1981, Proceedings of the Biological Society of Washington, V93, P1295; JONES ML, 1981, SCIENCE, V213, P333, DOI 10.1126/science.213.4505.333; Lee RW, 1999, J EXP BIOL, V202, P289; Lee RW, 1996, BIOL BULL, V190, P373, DOI 10.2307/1543030; LEGER D, 1988, BIOCHEMISTRY-US, V27, P4293, DOI 10.1021/bi00412a015; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADRIDMARINA V, 1986, J BIOL CHEM, V261, P444; MALLOL J, 1983, J NEUROCHEM, V40, P1205, DOI 10.1111/j.1471-4159.1983.tb13558.x; MASOOD R, 1987, ANN INST PASTEUR MIC, V138, P501, DOI 10.1016/0769-2609(87)90036-6; MILSTEIN OA, 1976, J BACTERIOL, V127, P1; Minic Z, 2001, J BIOL CHEM, V276, P23777, DOI 10.1074/jbc.M102249200; NAITO Y, 1976, BIOCHIM BIOPHYS ACTA, V438, P159, DOI 10.1016/0005-2744(76)90232-1; Nelson D.C., 1995, DEEP SEA HYDROTHERMA, P125; NEU HC, 1967, J BIOL CHEM, V242, P3905; NIEDZWICKI JG, 1983, BIOCHEM PHARMACOL, V32, P399, DOI 10.1016/0006-2952(83)90517-8; Niedzwiecka J, 1996, BIOCHEM BIOPH RES CO, V221, P471, DOI 10.1006/bbrc.1996.0619; NIEMANN MA, 1981, BIOCHIM BIOPHYS ACTA, V652, P347, DOI 10.1016/0005-2787(81)90124-6; PAGLIA DE, 1975, J BIOL CHEM, V250, P7973; PAPAS PW, 1983, MOL BIOCHEM PARASIT, V8, P1; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; POLYA GM, 1975, BIOCHIM BIOPHYS ACTA, V384, P443, DOI 10.1016/0005-2744(75)90045-5; POWELL MA, 1986, BIOL BULL, V171, P274, DOI 10.2307/1541923; RAJPUT A, 1992, INDIAN J BIOCHEM BIO, V29, P204; Schmitt U, 1996, ARCH BIOCHEM BIOPHYS, V332, P175, DOI 10.1006/abbi.1996.0330; Scocca J J, 1978, Methods Enzymol, V51, P432; SCOTT KM, 1994, PHYSIOL ZOOL, V67, P617, DOI 10.1086/physzool.67.3.30163761; Simon V, 2000, MAR BIOL, V136, P115, DOI 10.1007/s002270050014; SONADA T, 1978, BIOCHIM BIOPHYS ACTA, V521, P55; TORRANCE J, 1977, J LAB CLIN MED, V90, P563; TORRANCE JD, 1977, P NATL ACAD SCI USA, V74, P3701, DOI 10.1073/pnas.74.9.3701; UCHINO K, 1985, J ANTIBIOT, V38, P157, DOI 10.7164/antibiotics.38.157; West TP, 1997, ARCH MICROBIOL, V168, P237, DOI 10.1007/s002030050493; Zal F, 1996, J BIOL CHEM, V271, P8869, DOI 10.1074/jbc.271.15.8869; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	60	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					127	134		10.1074/jbc.M108035200	http://dx.doi.org/10.1074/jbc.M108035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11591717	hybrid			2022-12-27	WOS:000173087900018
J	Dafforn, TR; Della, M; Miller, AD				Dafforn, TR; Della, M; Miller, AD			The molecular interactions of heat shock protein 47 (Hsp47) and their implications for collagen biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEWLY SYNTHESIZED PROCOLLAGEN; ENDOPLASMIC-RETICULUM; DISULFIDE-ISOMERASE; ANGSTROM STRUCTURE; CHAPERONE HSP47; REACTIVE LOOP; BINDING; ALPHA(1)-ANTITRYPSIN; PH	Heat shock protein 47 (Hsp47) is a procollagen/collagen-specific molecular chaperone protein derived from the serpin family of proteins and essential for the early stages of collagen biosynthesis. In this paper, the results of an extensive biophysical analysis of mature recombinant mouse Hsp47 show the existence of both a structurally mesostable monomer with a 5-strand A-sheet and/or a hyperstable trimer; both states have biological activity. It is also demonstrated that Hsp47 is able to bind to a monomeric and partially folded conformation collagen mimic peptide (PPG)(10). Upon peptide binding Hsp47 has the capacity to induce the peptide backbone to fold into a polyproline type II conformation. Induction of this conformation results in (PPG)(10) peptides associating into higher order assemblies with increased stability compared with the monomeric peptide alone. These assemblies are similar to those observed by others (Go, N., and Suezaki, Y. (1973) Biopolyiners 12,1927-1930; Engel, J., Chen, H. T., Prockop, D. J., and Klump, H. (1977) Biopolymers 16, 601-622) when the peptide is dissolved at high concentration and are proposed to be long chains of peptides in a collagen-like configuration. Examination of the biophysical characteristics of both monomeric and trimeric Hsp47-(PPG)(10) complexes is also used to determine that the peptide-binding site does not reside in strand 4 position of sheet A, as observed for other serpins (Skinner, R., Chang, W. S. W., Jin, L., Pei, YL, Huntington, J. A., Abrahams, J. P., Carrell, R. W., and Lomas, D. A. (1998) J. Mol. BioL 283,9-14), leaving earlier proposals of a binding site near helix A viable.	Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, London SW7 2AZ, England; Univ Cambridge, Dept Haematol, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Imperial College London; University of Cambridge	Miller, AD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, Flowers Bldg,Armstrong Rd, London SW7 2AZ, England.		Miller, Andrew/G-8291-2019; Dafforn, Tim/A-9072-2015	Miller, Andrew/0000-0003-0661-249X; Dafforn, Tim/0000-0003-2257-6679				Becerril C, 1999, AM J RESP CELL MOL, V20, P1020, DOI 10.1165/ajrcmb.20.5.3288; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davids JW, 1995, BIOORG CHEM, V23, P427, DOI 10.1006/bioo.1995.1029; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ElThaher TSH, 1996, PROTEIN PEPTIDE LETT, V3, P1; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Engel J, 2000, MATRIX BIOL, V19, P235, DOI 10.1016/S0945-053X(00)00071-8; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; GO N, 1973, BIOPOLYMERS, V12, P1927, DOI 10.1002/bip.1973.360120818; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAGATA K, 1988, BIOCHEM BIOPH RES CO, V153, P428, DOI 10.1016/S0006-291X(88)81242-7; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Rocnik E, 2000, CIRCULATION, V101, P1229, DOI 10.1161/01.CIR.101.11.1229; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Sivasothy P, 1999, AM J RESP CRIT CARE, V159, pA481; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; Sunamoto M, 1998, INT J EXP PATHOL, V79, P133, DOI 10.1046/j.1365-2613.1998.00061.x; Sunamoto M, 1998, LAB INVEST, V78, P967; Takeda K, 2000, CORONARY ARTERY DIS, V11, P57, DOI 10.1097/00019501-200002000-00011; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomson CA, 2000, BIOCHEM J, V349, P877, DOI 10.1042/bj3490877; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Williams RS, 2000, CIRCULATION, V101, P1227, DOI 10.1161/01.CIR.101.11.1227; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637	54	91	96	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49310	49319		10.1074/jbc.M108896200	http://dx.doi.org/10.1074/jbc.M108896200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11592970	hybrid			2022-12-27	WOS:000173922100090
J	D'Aurelio, M; Pallotti, F; Barrientos, A; Gajewski, CD; Kwong, JQ; Bruno, C; Beal, MF; Manfredi, G				D'Aurelio, M; Pallotti, F; Barrientos, A; Gajewski, CD; Kwong, JQ; Bruno, C; Beal, MF; Manfredi, G			In vivo regulation of oxidative phosphorylation in cells harboring a stop-codon mutation in mitochondrial DNA-encoded cytochrome c oxidase subunit I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN; MTDNA MUTATION; COX DEFICIENCY; GENE; ENCEPHALOMYOPATHY; PROTEIN; PATIENT; ELECTROPHORESIS; MICRODELETION; COMPLEXES	The mechanisms that regulate oxidative phosphorylation in mammalian cells are largely unknown. To address this issue, cybrids were generated by fusing osteosarcoma cells devoid of mitochondrial DNA (mtDNA) with platelets from a patient with a stop-codon mutation in cytochrome c oxidase subunit I (COX I). The molecular and biochemical characteristics of cybrids harboring varying levels of mutated mitochondrial DNA were studied. We found a direct correlation between the levels of mutated COX I DNA and mutated COX I mRNA, whereas the levels of COX I total mRNA were unchanged. COX I polypeptide synthesis and steady-state levels were inversely proportional to mutation levels. Cytochrome c oxidase subunit Il was reduced proportionally to COX I, indicating impairment in complex assembly. COX enzymatic activity was inversely proportional to the levels of mutated mtDNA. However, both cell respiration and ATP synthesis were preserved in cells with lower proportions of mutated genomes, with a threshold at similar to 40%, and decreased linearly with increasing mutated mtDNA. These results indicate that COX levels in mutated cells were not regulated at the transcriptional, translational, and post-translational levels. Because of a small excess of COX capacity, the levels of expression of COX subunits exerted a relatively tight control on oxidative phosphorylation.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Genoa, Ist Giannina Gaslini, Dept Pediat, I-16147 Genoa, Italy	Cornell University; Columbia University; Columbia University; University of Genoa; IRCCS Istituto Giannina Gaslini	Manfredi, G (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St,A-505, New York, NY 10021 USA.		Kwong, Jennifer/L-4348-2019; Bruno, Claudio/A-3148-2015	Bruno, Claudio/0000-0002-3426-2901; Pallotti, Francesco/0000-0001-9946-8516				Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197; Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361; Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Glerum DM, 1997, FEBS LETT, V412, P410, DOI 10.1016/S0014-5793(97)00799-0; GROSS NJ, 1969, J BIOL CHEM, V244, P1552; Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; Hoffbuhr KC, 2000, J BIOL CHEM, V275, P13994, DOI 10.1074/jbc.275.18.13994; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900; Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; King M P, 1996, Methods Enzymol, V264, P339, DOI 10.1016/S0076-6879(96)64032-4; Kunz WS, 2000, J BIOL CHEM, V275, P27741; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lehtinen SK, 2000, GENETICS, V154, P363; Manfredi G, 2001, METHOD CELL BIOL, V65, P133, DOI 10.1016/S0091-679X(01)65008-8; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Papadopoulou LC, 1999, NAT GENET, V23, P333; POLOSA PL, 1991, J BIOL CHEM, V266, P10011; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Valnot I, 2000, AM J HUM GENET, V67, P1104; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	40	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46925	46932		10.1074/jbc.M106429200	http://dx.doi.org/10.1074/jbc.M106429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595737	hybrid			2022-12-27	WOS:000172768500035
J	Hui, YQ; Yang, GC; Galczenski, H; Figueroa, DJ; Austin, CP; Copeland, NG; Gilbert, DJ; Jenkins, NA; Funk, CD				Hui, YQ; Yang, GC; Galczenski, H; Figueroa, DJ; Austin, CP; Copeland, NG; Gilbert, DJ; Jenkins, NA; Funk, CD			The murine cysteinyl leukotriene 2 (CysLT(2)) receptor - cDNA and genomic cloning, alternative splicing, and in vitro characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HUMAN LUNG; RELEASE; AGONIST; TISSUE	Two classes of cysteinyl leukotriene receptor, CysLT(1) and CysLT(2), have been identified and pharmacologically characterized in human tissues. Although the CysLT(1) receptor mediates the proinflammatory effects of leukotrienes in human asthma, the physiological roles of CysLT(2) receptor are not defined, and a suitable mouse model would be useful in delineating function. We report here the molecular cloning and characterization of the mouse CysLT2 receptor (mCysLT(2)R) from heart tissue. mCysLT(2)R cDNA encodes a protein of 309 amino acids, truncated at both ends compared with the human ortholog (hCysLT(2)R). The gene resides on the central region of mouse chromosome 14 and is composed of 6 exons with the entire coding region located in the last exon. Two W-untranslated region splice variants were identified with the short form lacking exon 3 as the predominant transcript. Although the overall expression of mCysLT2R is very low, the highest expression was detected in spleen, thymus, and adrenal gland by ribonuclease protection assay, and discrete sites of expression in heart were observed by in situ hybridization. Intracellular calcium mobilization in response to cysteinyl leukotriene administration was detected in human embryonic kidney 293T cells transfected with recombinant mCysLT2R with a rank order of potency leukotriene C-4 (LTC4) = LTD4 > > LTE4. [H-3]LTD4 binding to membranes expressing mCysLT2R could be effectively competed by LTC, and LTD, and only partially inhibited by LTE4 and BAYu9773. The identification of mCysLT2R will be useful for establishing CysLT(2)R-deficient mice and determining novel leukotriene functions.	Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA; Merck & Co Inc, Dept Pharmacol, W Point, PA 19486 USA; NCI, Mouse Canc Genet Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	University of Pennsylvania; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Rm 814 BRBII-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Back M, 2000, EUR J PHARMACOL, V401, P381, DOI 10.1016/S0014-2999(00)00452-0; Bisgaard H, 2001, PEDIATRICS, V107, P381, DOI 10.1542/peds.107.2.381; BUSSE WW, 1991, AM REV RESPIR DIS, V143, pS103, DOI 10.1164/ajrccm/143.5_Pt_2.S103; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Dahlen SE, 1999, CLIN REV ALLERG IMMU, V17, P179, DOI 10.1007/BF02737603; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; LETTS LG, 1983, ADV PROSTAG THROMB L, V11, P391; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; ORTIZ JL, 1995, BRIT J PHARMACOL, V115, P1382, DOI 10.1111/j.1476-5381.1995.tb16627.x; SAADI M, 1990, LIFE SCI, V46, P1857, DOI 10.1016/0024-3205(90)90238-M; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SAUSSY DL, 1989, J BIOL CHEM, V264, P19845; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Walch L, 2000, AM J RESP CRIT CARE, V161, pS107, DOI 10.1164/ajrccm.161.supplement_1.ltta-21	26	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47489	47495		10.1074/jbc.M107556200	http://dx.doi.org/10.1074/jbc.M107556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591709	hybrid			2022-12-27	WOS:000172768500106
J	Iakhiaev, A; Pendurthi, UR; Rao, LVM				Iakhiaev, A; Pendurthi, UR; Rao, LVM			Active site blockade of factor VIIa alters its intracellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; ESCHERICHIA-COLI; GROWTH-FACTOR; BINDING; ACTIVATION; EXPRESSION; MECHANISM; CELLS; COAGULATION; FIBROBLASTS	Factor VIIa binding to tissue factor on cell surfaces not only triggers the coagulation cascade but also induces various intracellular responses that may contribute to many pathophysiological processes. Active site-inhibited factor VIIa, similar to factor VIIa, binds to tissue factor on cell surfaces and subsequently gets internalized and degraded. At present, it is unknown whether factor VIIa and active site-inhibited factor VIIa undergo a similar intracellular processing. The data presented herein show that although a fraction of both the internalized factor VIIa and active site-inhibited factor VIIa recycle back to the cell surface, the amount of active site-inhibited factor VIIa recycled back to the cell surface was substantially higher than that of factor VIIa. Furthermore, internalized factor VIIa and not active site-inhibited factor VIIa associates with nuclear fractions. Factor VIIa associated with the nuclear fraction was intact and functionally active. In contrast to factor VIIa, tissue factor is not found in the nuclear fraction. Additional studies show that the internalized factor VIIa specifically associates with cytoskeletal proteins, actin, and tubulin. In summary, the present data reveal that despite the common pathway of tissue factor-mediated processing, considerable differences exist in the trafficking of factor VIIa and active site-inhibited factor VIIa in fibroblasts.	Univ Texas Hlth Ctr, Biomed Res Div, Tyler, TX 75708 USA		Rao, LVM (corresponding author), Univ Texas Hlth Ctr, Biomed Res Div, 11937 US HWY 271, Tyler, TX 75708 USA.	Vijay.Rao@uthct.edu						BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Brossart P, 1997, BLOOD, V90, P1594, DOI 10.1182/blood.V90.4.1594.1594_1594_1599; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Citores L, 1999, MOL BIOL CELL, V10, P3835, DOI 10.1091/mbc.10.11.3835; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Hansen CB, 2001, BLOOD, V97, P1712, DOI 10.1182/blood.V97.6.1712; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; Hong SS, 1999, VIROLOGY, V262, P163, DOI 10.1006/viro.1999.9864; Iakhiaev A, 1999, J BIOL CHEM, V274, P36995, DOI 10.1074/jbc.274.52.36995; LE DT, 1992, J BIOL CHEM, V267, P15447; Mahdi F, 2000, THROMB RES, V99, P267, DOI 10.1016/S0049-3848(00)00245-0; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Pendurthi UR, 2002, VITAM HORM, V64, P323, DOI 10.1016/S0083-6729(02)64009-9; Prydz H, 1999, THROMB HAEMOSTASIS, V82, P183; RAO LVM, 1988, THROMB RES, V51, P373, DOI 10.1016/0049-3848(88)90373-8; Rao LVM, 2001, TRENDS CARDIOVAS MED, V11, P14, DOI 10.1016/S1050-1738(01)00077-9; Rao LVM, 2000, BLOOD COAGUL FIBRIN, V11, pS135, DOI 10.1097/00001721-200004001-00026; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; REFOLO LM, 1991, J NEUROSCI, V11, P3888; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Ruf W, 1999, THROMB HAEMOSTASIS, V82, P175; Ruf W, 1996, Curr Opin Hematol, V3, P379; Sai Y, 1998, J BIOCHEM-TOKYO, V123, P630; Semeraro N, 1997, THROMB HAEMOSTASIS, V78, P759; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; Taylor FB, 1996, HAEMOSTASIS, V26, P83; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45895	45901		10.1074/jbc.M107603200	http://dx.doi.org/10.1074/jbc.M107603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590156	hybrid			2022-12-27	WOS:000172573100055
J	Nomura, M; Kaji, A; He, ZW; Ma, WY; Miyamoto, K; Yang, CS; Dong, ZG				Nomura, M; Kaji, A; He, ZW; Ma, WY; Miyamoto, K; Yang, CS; Dong, ZG			Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P70 S6 KINASE; INDUCED AP-1 ACTIVATION; GREEN TEA; GROWTH-FACTOR; CANCER-CELLS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; MAMMALIAN TARGET; P53 MUTATIONS	In this study, we investigated the effect of tea polyphenols, (-)-epigallocatechin-3-gallate or theaflavins, on UVB-induced phosphatidylinositol 3-kinase (PIM activation in mouse epidermal JB6 Cl 41 cells. Pretreatment of cells with these polyphenols inhibited UVB-induced PI3K activation. Furthermore, UVB-induced activation of Akt and ribosomal p70 S6 kinase (p70 S6-K), PI3K downstream effectors, were also attenuated by the polyphenols. In addition to LY294002, a PI3K inhibitor, pretreatment with a specific mitogen-activated protein/ extracellular signal-regulated protein kinases (Erks) kinase I inhibitor, U0126, or a specific p38 kinase inhibitor, SB202190, blocked UVB-induced activation of both Akt and p70 S6-K. Pretreatment with LY294002 restrained UVB-induced phosphorylation of Erks, suggesting that in UVB signaling, the Erk pathway is mediated by PI3K. Moreover, pretreatment with rapamycin, an inhibitor of p70 S6-K, inhibited UVB-induced activation of p70 S6-K, but UVB-induced activation of Akt did not change. Interestingly, UVB-induced p70 S6-K activation was directly blocked by the addition of (-)-epigallocatechin-3-gallate or theaflavins, whereas these polyphenols showed only a weak inhibition on UVB-induced Akt activation. Because PI3K is an important factor in carcinogenesis, the inhibitory effect of these polyphenols on activation of PI3K and its downstream effects may further explain the anti-tumor promotion action of these tea constituents.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Kanazawa Univ, Dept Hosp Pharm, Sch Med, Kanazawa, Ishikawa 9200934, Japan; Rutgers State Univ, Canc Res Lab, Piscataway, NJ 08854 USA	University of Minnesota System; Kanazawa University; Rutgers State University New Brunswick	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu			NCI NIH HHS [CA81064, CA74916, CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA081064, R29CA074916, P01CA027502, R01CA081064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Baxter NJ, 1997, BIOCHEMISTRY-US, V36, P5566, DOI 10.1021/bi9700328; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Bostrom J, 1998, CANCER RES, V58, P29; Brenneisen P, 2000, J BIOL CHEM, V275, P4336, DOI 10.1074/jbc.275.6.4336; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COFFER PJ, 1995, ONCOGENE, V11, P561; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Davies MA, 1999, CANCER RES, V59, P2551; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dong ZG, 1997, CANCER RES, V57, P4414; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fu YC, 2000, BIOMED ENVIRON SCI, V13, P170; Fukazawa H, 2000, CANCER RES, V60, P2104; Gensler HL, 1996, NUTR CANCER, V26, P325, DOI 10.1080/01635589609514488; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; HUANG MT, 1992, CARCINOGENESIS, V13, P947, DOI 10.1093/carcin/13.6.947; Kabuyama Y, 1998, FEBS LETT, V441, P297, DOI 10.1016/S0014-5793(98)01565-8; Katiyar S K, 1996, World Rev Nutr Diet, V79, P154; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Koh HK, 1995, ENVIRON HEALTH PERSP, V103, P255, DOI 10.2307/3432321; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moore SM, 1998, CANCER RES, V58, P5239; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Mukhtar H, 1999, P SOC EXP BIOL MED, V220, P234, DOI 10.1046/j.1525-1373.1999.d01-40.x; MURRAY NJ, 1994, EUR J BIOCHEM, V219, P923, DOI 10.1111/j.1432-1033.1994.tb18574.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Nomura M, 2000, MOL CARCINOGEN, V28, P148, DOI 10.1002/1098-2744(200007)28:3<148::AID-MC3>3.0.CO;2-Q; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Record IR, 1998, NUTR CANCER, V32, P71, DOI 10.1080/01635589809514721; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; RONAI ZA, 1988, ONCOGENE, V2, P201; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Siebert KJ, 1999, J AGR FOOD CHEM, V47, P353, DOI 10.1021/jf980703o; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; Trevisanato SI, 2000, NUTR REV, V58, P1, DOI 10.1111/j.1753-4887.2000.tb01818.x; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; WANG ZY, 1992, CANCER RES, V52, P1162; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wiseman SA, 1997, CRIT REV FOOD SCI, V37, P705, DOI 10.1080/10408399709527798; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	99	81	86	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46624	46631		10.1074/jbc.M107897200	http://dx.doi.org/10.1074/jbc.M107897200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591714	hybrid			2022-12-27	WOS:000172573100149
J	Baig, AH; Swords, FM; Noon, LA; King, PJ; Hunyady, L; Clark, AJL				Baig, AH; Swords, FM; Noon, LA; King, PJ; Hunyady, L; Clark, AJL			Desensitization of the Y1 cell adrenocorticotropin receptor - Evidence for a restricted heterologous mechanism implying a role for receptor-effector complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BETA(2)-ADRENERGIC RECEPTOR; MESSENGER-RNA; ACTH RECEPTORS; MOUSE; CORTICOTROPIN; PHOSPHORYLATION; SEQUESTRATION; EXPRESSION; CLONING	Receptor desensitization provides a potential mechanism for the regulation of adrenocortical adrenocorticotropin (ACTH) responsiveness. Using the mouse adrenocortical Y1 cell line we demonstrate that ACTH effectively desensitizes the cAMP response of its own receptor, the melanocortin 2 receptor (MC2R), in these cells with a maximal effect between 30 and 60 min. Neither forskolin nor isoproterenol (in Y1 cells stably transfected with the beta (2)-adrenergic receptor) desensitize this ACTH response. ACTH desensitizes its receptor at concentrations at which only a fraction of receptors are occupied, implying that this mechanism acts on agonist-unoccupied receptors. Y1 cells express G protein-coupled receptor kinase (GRK) 2 and 5, but stable expression of a dominant negative GRK2 (K220W) only marginally reduces the desensitization by ACTH. The protein kinase A (PKA) inhibitor, H89, extinguishes almost the entire desensitization response over the initial 30-min period at all concentrations of ACTH. A mutant MC2R in which the single consensus PKA phosphorylation site has been mutated (S208A) when expressed in MC2R-negative Y6 cells is also unable to desensitize. These data imply a heterologous, PKA-dependent, mode of desensitization, which is restricted to agonist-occupied and -unoccupied MC2R, possibly as a consequence of receptor/effector complexes that functionally compartmentalize this receptor.	Univ London, Queen Marys Sch Med, Dept Endocrinol, London EC1A 7BE, England; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary	University of London; Queen Mary University London; Semmelweis University	Clark, AJL (corresponding author), Univ London, Queen Marys Sch Med, Dept Endocrinol, W Smithfield, London EC1A 7BE, England.	aj.clark@mds.qmw.ac.uk	Noon, Luke A/H-4141-2014	Noon, Luke A/0000-0002-0502-4322; Baig, Asma/0000-0002-3764-1456				ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; Cammas FM, 1997, MOL ENDOCRINOL, V11, P867, DOI 10.1210/me.11.7.867; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Clark AJL, 1996, BAILLIERE CLIN ENDOC, V10, P29, DOI 10.1016/S0950-351X(96)80282-5; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Elias LLK, 1999, J CLIN ENDOCR METAB, V84, P2766, DOI 10.1210/jc.84.8.2766; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYNES RC, 1958, J BIOL CHEM, V233, P1220; LEBRETHON MC, 1994, J CLIN INVEST, V93, P1828, DOI 10.1172/JCI117168; LEFKOWITZ RJ, 1970, P NATL ACAD SCI USA, V65, P745, DOI 10.1073/pnas.65.3.745; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Liakos P, 1998, ENDOCR RES, V24, P427, DOI 10.3109/07435809809032628; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MORERA AM, 1978, BIOCHEM BIOPH RES CO, V83, P1553, DOI 10.1016/0006-291X(78)91398-0; Mountjoy KG, 2000, RECEPTORS, P209; MOUNTJOY KG, 1994, MOL CELL ENDOCRINOL, V99, pR17, DOI 10.1016/0303-7207(94)90160-0; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PENHOAT A, 1989, P NATL ACAD SCI USA, V86, P4978, DOI 10.1073/pnas.86.13.4978; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Tepe NM, 2000, J RECEPT SIGNAL TR R, V20, P75, DOI 10.3109/10799890009150038; TSUGA H, 1994, J BIOL CHEM, V269, P32522; WATT VM, 1982, J BIOL CHEM, V257, P1684; Xia Y, 1996, CELL TISSUE RES, V286, P63, DOI 10.1007/s004410050675; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274	36	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44792	44797		10.1074/jbc.M108572200	http://dx.doi.org/10.1074/jbc.M108572200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579104	hybrid			2022-12-27	WOS:000172406700062
J	Beher, D; Wrigley, JDJ; Nadin, A; Evin, G; Masters, CL; Harrison, T; Castro, JL; Shearman, MS				Beher, D; Wrigley, JDJ; Nadin, A; Evin, G; Masters, CL; Harrison, T; Castro, JL; Shearman, MS			Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma-secretase inhibitor - Implications for presenilin biology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; BETA-SECRETASE; TRANSMEMBRANE ASPARTATES; SIGNAL-TRANSDUCTION; MISSENSE MUTATIONS; CLEAVAGE; GENE; CHROMOSOME-1; COMPLEX	Intramembranous cleavage of the beta -amyloid precursor protein by gamma -secretase is the final processing event generating amyloid-beta peptides, which are thought to be causative agents for Alzheimer's disease. Missense mutations in the presenilin genes co-segregate with early-onset Alzheimer's disease, and, recently, a close biochemical linkage between presenilins and the identity of gamma -secretase has been established. Here we describe for the first time that certain potent gamma -secretase inhibitors are able to interfere with the endoproteolytic processing of presenilin 1 (PS1). In addition, we identified a novel gamma -secretase inhibitor, {1S-benzyl-4R-[1-(5-cyclohexyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3(R,S)-ylcarbamoyl)-S-ethylcarbamoyl]-2R-hydroxy-5-phenyl-pentyl}-carbamic acid tertbutyl ester (CBAP), which not only physically interacts with PS1, but upon chronic treatment produces a "pharmacological knock-down" of PS1 fragments. This indicates that the observed accumulation of full-length PS1 is caused by a direct inhibition of its endoproteolysis. The subsequent use of CBAP as a biological tool to increase full-length PS1 levels in the absence of exogenous PS1 expression has provided evidence that wild-type PS1 endoproteolysis is not required either for PS1/gamma -secretase complex assembly or trafficking. Furthermore, in cell-based systems CBAP does not completely recapitulate PS1 loss-of-function phenotypes. Even though the beta -amyloid precursor protein cleavage and the S3 cleavage of the Notch receptor are inhibited by CBAP, an impairment of Trk receptor maturation was not observed.	Merck Sharp & Dohme Ltd, Res Labs, Dept Biochem & Mol Biol, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Merck Sharp & Dohme Ltd, Res Labs, Dept Med Chem, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England; Mental Hlth Inst Victoria, Neuropathol Lab, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia	Merck & Company; GlaxoSmithKline; Merck & Company; University of Melbourne	Beher, D (corresponding author), Merck Sharp & Dohme Ltd, Res Labs, Dept Biochem & Mol Biol, Neurosci Res Ctr, Terlings Pk, Harlow CM20 2QR, Essex, England.	dirk_beher@merck.com	Evin, Genevieve M/E-5891-2013	Beher, Dirk/0000-0001-8005-5359				Beher D, 1999, J NEUROCHEM, V72, P1564, DOI 10.1046/j.1471-4159.1999.721564.x; Bilsland JG, 1998, J NEUROSCI METH, V84, P121, DOI 10.1016/S0165-0270(98)00106-X; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHAMBERS MS, 1993, BIOORG MED CHEM LETT, V3, P1919, DOI 10.1016/S0960-894X(01)80987-2; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Clarke EE, 2000, J NEUROSCI METH, V102, P61, DOI 10.1016/S0165-0270(00)00280-6; Culvenor JG, 2000, EXP CELL RES, V255, P192, DOI 10.1006/excr.1999.4791; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESOLMS SJ, 1991, J MED CHEM, V34, P2852, DOI 10.1021/jm00113a025; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATRITZKY AR, 1990, J ORG CHEM, V55, P2206, DOI 10.1021/jo00294a042; Khorkova OE, 1998, J NEUROSCI METH, V82, P159, DOI 10.1016/S0165-0270(98)00053-3; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Nadin A, 2001, TETRAHEDRON, V57, P1861, DOI 10.1016/S0040-4020(00)01167-4; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRILL RG, 1995, J ORG CHEM, V60, P730, DOI 10.1021/jo00108a044; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YANG HJ, 1994, BIO-TECHNOL, V12, P193, DOI 10.1038/nbt0294-193; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	54	81	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45394	45402		10.1074/jbc.M103075200	http://dx.doi.org/10.1074/jbc.M103075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574530	hybrid			2022-12-27	WOS:000172406700136
J	Gomez-Angelats, M; Cidlowski, JA				Gomez-Angelats, M; Cidlowski, JA			Protein kinase C regulates FADD recruitment and death-inducing signaling complex formation in Fas/CD95-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; CD95-MEDIATED APOPTOSIS; CELL SHRINKAGE; CD95 FAS/APO-1; PHORBOL ESTER; ACTIVATION; RESISTANCE; EXPRESSION; RECEPTOR; INHIBITION	Activation of protein kinase C (PKC) triggers cellular signals that inhibit Fas/CD95-induced cell death in Jurkat T-cells by poorly defined mechanisms. Previously, we have shown that one effect of PKC on Fas/CD95-dependent cell death occurs through inhibition of cell shrinkage and K+ efflux (Gomez-Angelats, M., Bortner, C. D., and Cidlowski, J. A. (2000) J. Biol. Chem. 275, 19609-19619). Here we report that PKC alters Fas/CD95 signaling from the plasma membrane to the activation of caspases by exerting a profound action on survival/cell death decisions. Specific activation of PKC with 12-O-tetradecanoylphorbol-13-acetate or bryostatin-1 induced translocation of PKC from the cytosol to the membrane and effectively inhibited cell shrinkage and cell death triggered by anti-Fas antibody in Jurkat cells. In contrast, inhibition of classical PKC isotypes with Go6976 exacerbated the effect of Fas activation on both apoptotic volume decrease and cell death. PKC activation/inhibition did not affect anti-Fas antibody binding to the cell surface, intracellular levels of FADD ((F) under bar as-(a) under bar ssociated protein with (d) under bar eath (d) under bar omain), or c-FLIP (cellular (FL) under bar ICE-like (i) under bar nhibitory (p) under bar rotein) expression. However, processing/activation of both caspase-8 and caspase-3 and BID cleavage were markedly blocked upon PKC activation and, conversely, were augmented during PKC inhibition, suggesting a role for PKC upstream of caspase-8 processing and activation. Analysis of death-inducing signaling complex (DISC) formation was carried out to examine the influence of PKC on recruitment of both FADD and procaspase-8 to the Fas receptor. PKC activation blocked FADD recruitment and caspase-8 activation and thus DISC formation in both type I and II cells. In contrast, inhibition of classical PKCs promoted the opposite effect on the Fas pathway by rapidly increasing FADD recruitment, caspase-8 activation, and DISC formation. Together, these data show that PKC finely modulates Fas/CD95 signaling by altering the efficiency of DISC formation.	NIEHS, Lab Signal Transduct, Mol Endocrinol Grp, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, Mol Endocrinol Grp, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	cidlowski@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Fenton RG, 1998, CANCER RES, V58, P3391; Foote LC, 1996, J IMMUNOL, V157, P2749; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irisarri M, 2000, LEUKEMIA, V14, P2149, DOI 10.1038/sj.leu.2401954; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JARVIS WD, 1994, BIOCHEM PHARMACOL, V47, P839; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Karas M, 2001, HUM IMMUNOL, V62, P32, DOI 10.1016/S0198-8859(00)00223-8; KEENAN C, 1995, EUR J IMMUNOL, V25, P13, DOI 10.1002/eji.1830250104; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; KVANTA A, 1991, FEBS LETT, V283, P321, DOI 10.1016/0014-5793(91)80618-D; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MODIANO JF, 1991, J BIOL CHEM, V266, P10552; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Mueller CM, 2000, J IMMUNOL, V165, P1854, DOI 10.4049/jimmunol.165.4.1854; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; Scaffidi C, 2000, METHOD ENZYMOL, V322, P363; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Suzuki A, 2001, NAT MED, V7, P88, DOI 10.1038/83401; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wei MC, 2000, GENE DEV, V14, P2060; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	58	85	87	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44944	44952		10.1074/jbc.M104919200	http://dx.doi.org/10.1074/jbc.M104919200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581255	hybrid			2022-12-27	WOS:000172406700082
J	Kowcun, A; Honson, N; Plettner, E				Kowcun, A; Honson, N; Plettner, E			Olfaction in the gypsy moth, Lymantria dispar - Effect of pH, ionic strength, and reductants on pheromone transport by pheromone-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBYX-MORI; ANTHERAEA-POLYPHEMUS; SENSORY DENDRITES; SILKWORM MOTH; PORE TUBULES; NUN MOTH; SILKMOTH; MEMBRANE; DISCRIMINATION; ENANTIOMERS	The pheromone-binding proteins (PBPs) are 16-kDa abundant proteins in specialized olfactory hairs in insects. The mechanism by which the PBPs remove the pheromone from the inner surface of sensory hairs and deliver it to the sensory cell remains unclear. Existing qualitative models postulate that pheromone is released near the dendrite by a decrease in pH or by a reduced form of the PBP. This study focuses on the two PBPs from the gypsy moth and the enantiomers of the pheromone cis-2-methyl-7,8-epoxyoctadecane. The pH dependence of pheromone binding has revealed three ionizations that are important. The type of ligand influences two of these ionizations. We propose that the (-)-enantiomer of the pheromone interacts with one of the ionizable residues on the protein while the (+)-enantiomer does not. Simultaneous variation of pH and KCl concentration in the physiological range or reduction of disulfide bridges does not change the affinity of PBP for pheromone. We propose a revised model of pheromone transport from the inner surface of the sensory hair to the sensory neuron.	Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Plettner, E (corresponding author), Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada.							BARBER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P253, DOI 10.1016/0304-4173(80)90003-8; Campanacci V, 1999, EUR J BIOCHEM, V264, P707, DOI 10.1046/j.1432-1327.1999.00666.x; CARDE RT, 1977, ENVIRON ENTOMOL, V6, P768, DOI 10.1093/ee/6.6.768; CUNNINGHAM LW, 1959, J BIOL CHEM, V234, P1447; Damberger F, 2000, PROTEIN SCI, V9, P1038, DOI 10.1110/ps.9.5.1038; Danty E, 1999, J NEUROSCI, V19, P7468, DOI 10.1523/JNEUROSCI.19-17-07468.1999; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; Grant GG, 1996, NATURWISSENSCHAFTEN, V83, P328, DOI 10.1007/BF01152217; Gries G, 1996, NATURWISSENSCHAFTEN, V83, P382, DOI 10.1007/BF01142006; HANSEN K, 1984, PHYSIOL ENTOMOL, V9, P9, DOI 10.1111/j.1365-3032.1984.tb00676.x; Hildebrand J.G., 1980, RECEPTORS NEUROTRANS, P261; KAISSLIN.KE, 1970, NATURWISSENSCHAFTEN, V57, P23, DOI 10.1007/BF00593550; Kaissling K.-E., 1971, Handbook of sensory physiology, Vol. IV, P351; Kaissling K-E, 1987, RH WRIGHT LECT INSEC; Kaissling KE, 2001, CHEM SENSES, V26, P125, DOI 10.1093/chemse/26.2.125; KAISSLING KE, 1977, CHEM CONTROL INSECT, P45; KANAUJIA S, 1985, J INSECT PHYSIOL, V31, P71, DOI 10.1016/0022-1910(85)90044-7; KEIL TA, 1982, TISSUE CELL, V14, P451, DOI 10.1016/0040-8166(82)90039-8; KEIL TA, 1984, TISSUE CELL, V16, P131, DOI 10.1016/0040-8166(84)90025-9; KEIL TA, 1984, TISSUE CELL, V16, P705, DOI 10.1016/0040-8166(84)90004-1; KRAMER JJD, 1987, PHEROMONE BIOCH, P433; Krieger J, 1999, SCIENCE, V286, P720, DOI 10.1126/science.286.5440.720; KRIEGER J, 1993, INSECT BIOCHEM MOLEC, V23, P449, DOI 10.1016/0965-1748(93)90052-T; Leal WS, 2000, BIOCHEM BIOPH RES CO, V268, P521, DOI 10.1006/bbrc.2000.2158; Leal WS, 1999, FEBS LETT, V464, P85, DOI 10.1016/S0014-5793(99)01683-X; MAIDA R, 1993, INSECT BIOCHEM MOLEC, V23, P243, DOI 10.1016/0965-1748(93)90005-D; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; Merritt TJS, 1998, J MOL EVOL, V46, P272, DOI 10.1007/PL00006303; MILLER JR, 1977, J INSECT PHYSIOL, V23, P1447, DOI 10.1016/0022-1910(77)90171-8; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; Plettner E, 2000, BIOCHEMISTRY-US, V39, P8953, DOI 10.1021/bi000461x; Prestwich G.D., 1987, P473; Rogers ME, 1997, J BIOL CHEM, V272, P14792, DOI 10.1074/jbc.272.23.14792; Sandler BH, 2000, CHEM BIOL, V7, P143, DOI 10.1016/S1074-5521(00)00078-8; Scaloni A, 1999, BIOCHEM BIOPH RES CO, V266, P386, DOI 10.1006/bbrc.1999.1791; SCHNEIDER D, 1968, NATURWISSENSCHAFTEN, V55, P395, DOI 10.1007/BF00593307; SCHNEIDER D, 1977, J COMP PHYSIOL, V113, P1, DOI 10.1007/BF00610450; Skoog D.A., 1988, FUNDAMENTALS ANAL CH, V5th, P124; VANDENBERG MJ, 1991, J INSECT PHYSIOL, V37, P79, DOI 10.1016/0022-1910(91)90022-R; Vogt R.G., 1987, P385; VOGT RG, 1989, J NEUROSCI, V9, P3332; Vogt RG, 1999, CHEM SENSES, V24, P481, DOI 10.1093/chemse/24.5.481; VOGT RG, 1990, NATO ASI SERIES H, V39, P33; Wojtasek H, 1999, J BIOL CHEM, V274, P30950, DOI 10.1074/jbc.274.43.30950; ZIEGELBERGER G, 1995, EUR J BIOCHEM, V232, P706, DOI 10.1111/j.1432-1033.1995.tb20864.x	46	39	42	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44770	44776		10.1074/jbc.M104688200	http://dx.doi.org/10.1074/jbc.M104688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581252	hybrid			2022-12-27	WOS:000172406700059
J	Degousee, N; Stefanski, E; Lindsay, TF; Ford, DA; Shahani, R; Andrews, CA; Thuerauf, DJ; Glembotski, CC; Nevalainen, TJ; Tischfield, J; Rubin, BB				Degousee, N; Stefanski, E; Lindsay, TF; Ford, DA; Shahani, R; Andrews, CA; Thuerauf, DJ; Glembotski, CC; Nevalainen, TJ; Tischfield, J; Rubin, BB			p38 MAPK regulates group IIa phospholipase A(2) expression in interleukin-1 beta-stimulated rat neonatal cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ARACHIDONIC-ACID; CARDIAC MYOCYTES; GENE-EXPRESSION; PROSTAGLANDIN PRODUCTION; INFLAMMATORY CYTOKINES; P388D(1) MACROPHAGES; SELECTIVE ACTIVATION	Group IIa phospholipase A(2) (GII(a) PLA(2)) is released by some cells in response to interleukin-1 beta. The purpose of this study was to determine whether interieukin-1 beta would stimulate the Synthesis and release of GIIa PLA2 from cardiomyocytes, and to define the role of p38 MAPK and cytosolic PLA(2) in the regulation of this process. Whereas GIIa PLA(2) mRNA was not identified in untreated cells, exposure to interleukin-1 beta resulted in the sustained expression of GIIa PLA(2) mRNA. Interleukin-1 beta also stimulated a progressive increase in cellular and extracellular GIIa PLA(2) protein levels and increased extracellular PLA(2) activity 70-fold. In addition, interleukin-1 beta stimulated the p38 MAPK-dependent activation of the downstream MAPK-activated protein kinase, MAPKAP-K2. Treatment with the p38 MAPK inhibitor, SB202190, decreased interleukin-1 beta stimulated,, mRNA expression, GIIa MAPKAP-K2 activity, GIIa PLA, PLA(2) protein synthesis, and the release of extracellular PLA(2) activity. Infection with an adenovirus encoding a constitutively active form of MKK6, MKK6(Glu), which selectively phosphorylates p38 MAPK, induced cellular GIIa PLA protein synthesis and the release of GIIa PLA(2) and increased extracellular PLA(2) activity 3-fold. In contrast, infection with an adenovirus encoding a phosphorylation-resistant MKK6, MKKK6(A), did not result in GIIa PLA(2) protein synthesis or release by unstimulated cardiomyocytes. In addition, infection with an adenovirus encoding MKK6(A) abrogated GIIa PLA(2) protein synthesis and release by interleukin-1 beta -stimulated cells. These results provide direct evidence that p38 MAPK activation was necessary for interleukin-1 beta -induced synthesis and release of GIIa PLA(2) by cardiomyocytes.	Toronto Gen Hosp, Div Vasc Surg, Max Bell Res Ctr 1 917, Toronto, ON M5G 2C4, Canada; St Louis Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; San Diego State Univ, Heart Inst, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Saint Louis University; California State University System; San Diego State University; California State University System; San Diego State University; University of Turku; Rutgers State University New Brunswick	Rubin, BB (corresponding author), Toronto Gen Hosp, Div Vasc Surg, Max Bell Res Ctr 1 917, 200 Elizabeth St,EC5-302A, Toronto, ON M5G 2C4, Canada.	barry.rubin@uhn.on.ca	; Ford, David/D-1819-2018	Tischfield, Jay/0000-0003-3217-8287; Ford, David/0000-0002-0029-1560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL042665, R01HL042665, R01HL063975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42665, HL-25037, HL-63975] Funding Source: Medline; NIDDK NIH HHS [DK38185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ALAM T, 1992, J BIOL CHEM, V267, P5021; Andreani M, 2000, BBA-MOL CELL BIOL L, V1488, P149, DOI 10.1016/S1388-1981(00)00117-7; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BORGEAT P, 1990, CLIN BIOCHEM, V23, P459, DOI 10.1016/0009-9120(90)90272-V; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; CHOCK SP, 1994, BIOCHEM J, V300, P619, DOI 10.1042/bj3000619; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Couturier C, 2000, ARTERIOSCL THROM VAS, V20, P2559, DOI 10.1161/01.ATV.20.12.2559; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; HUWILER A, 1994, FEBS LETT, V350, P135, DOI 10.1016/0014-5793(94)00754-3; Isenovic E, 2000, HYPERTENSION, V35, P249, DOI 10.1161/01.HYP.35.1.249; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KONIECZKOWSKI M, 1993, J CLIN INVEST, V92, P2524, DOI 10.1172/JCI116861; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LaPointe MC, 1996, HYPERTENSION, V27, P709, DOI 10.1161/01.HYP.27.3.709; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Massaad C, 2000, J BIOL CHEM, V275, P22686, DOI 10.1074/jbc.M001250200; MCDONALD PP, 1992, BRIT J PHARMACOL, V107, P226, DOI 10.1111/j.1476-5381.1992.tb14491.x; McHowat J, 1997, AM J PHYSIOL-CELL PH, V272, pC450, DOI 10.1152/ajpcell.1997.272.2.C450; McHowat J, 1998, AM J PHYSIOL-CELL PH, V274, pC1727, DOI 10.1152/ajpcell.1998.274.6.C1727; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Nyman KM, 2000, J HISTOCHEM CYTOCHEM, V48, P1469, DOI 10.1177/002215540004801104; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Shioi T, 1997, CIRC RES, V81, P664; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Testa M, 1996, J AM COLL CARDIOL, V28, P964, DOI 10.1016/S0735-1097(96)00268-9; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; van der Helm HA, 2001, BBA-MOL CELL BIOL L, V1530, P86, DOI 10.1016/S1388-1981(00)00171-2; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wen YS, 2001, CIRC RES, V88, P70, DOI 10.1161/01.RES.88.1.70; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	73	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43842	43849		10.1074/jbc.M101516200	http://dx.doi.org/10.1074/jbc.M101516200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571275	hybrid			2022-12-27	WOS:000172297700049
J	Song, HK; Mulrooney, SB; Huber, R; Hausinger, RP				Song, HK; Mulrooney, SB; Huber, R; Hausinger, RP			Crystal structure of Klebsiella aerogenes UreE, a nickel-binding metallochaperone for urease activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; IN-VIVO; APOPROTEIN COMPLEXES; ACCESSORY PROTEIN; METAL-BINDING; PURIFICATION; IDENTIFICATION; CRYSTALLOGRAPHY; MOLSCRIPT; PROGRAM	UreE is proposed to be a metallochaperone that delivers nickel ions to urease during activation of this bacterial virulence factor. Wild-type Klebsiella aerogenes UreE binds approximately six nickel ions per homodimer, whereas H144*UreE (a functional C-terminal truncated variant) was previously reported to bind two. We determined the structure of H144*UreE by multi-wavelength anomalous diffraction and refined it to 1.5 Angstrom resolution. The present structure reveals an Hsp40-like peptide-binding domain, an wAtx1-like metal-binding domain, and a flexible C terminus. Three metal-binding sites per dimer, defined by structural analysis of Cu-H144*UreE, are on the opposite face of the Atx1-like domain than observed in the copper metallochaperone. One metal bridges the two subunits via the pair of His-96 residues, whereas the other two sites involve metal coordination by His-110 and His-112 within each subunit. In contrast to the copper metallochaperone mechanism involving thiol ligand exchanges between structurally similar chaperones and target proteins, we propose that the Hsp40-like module interacts with urease apoprotein and/or other urease accessory proteins, while the Atx1-like domain delivers histidyl-bound nickel to the urease active site.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Max Planck Inst Biochem, Abt Strukt Forsch, D-82152 Planegg Martinsried, Germany; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Max Planck Society; Michigan State University	Song, HK (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	hksong@red.dfci.harvard.edu; hausinge@msu.edu	Song, Hyun Kyu/D-6763-2016	Song, Hyun Kyu/0000-0001-5684-4059; Hausinger, Robert/0000-0002-3643-2054	NIDDK NIH HHS [R01 DK045686, DK45686] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Brayman TG, 1996, J BACTERIOL, V178, P5410, DOI 10.1128/jb.178.18.5410-5416.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Colpas GJ, 1998, J BIOL INORG CHEM, V3, P150, DOI 10.1007/s007750050216; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Colpas GJ, 2000, J BIOL CHEM, V275, P10731, DOI 10.1074/jbc.275.15.10731; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ha NC, 2001, NAT STRUCT BIOL, V8, P505, DOI 10.1038/88563; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hausinger R.P., 2001, HDB METALLOPROTEINS, P867; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Jabri E, 1996, BIOCHEMISTRY-US, V35, P10616, DOI 10.1021/bi960424z; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minor W, 2000, STRUCTURE, V8, pR105, DOI 10.1016/S0969-2126(00)00139-8; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Moncrief MBC, 1996, J BACTERIOL, V178, P5417, DOI 10.1128/jb.178.18.5417-5421.1996; Moncrief MBC, 1997, J BACTERIOL, V179, P4081, DOI 10.1128/jb.179.13.4081-4086.1997; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PARK IS, 1995, J BACTERIOL, V177, P1947, DOI 10.1128/jb.177.8.1947-1951.1995; Pearson MA, 1997, BIOCHEMISTRY-US, V36, P8164, DOI 10.1021/bi970514j; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Watt RK, 1998, J BIOL CHEM, V273, P10019, DOI 10.1074/jbc.273.16.10019; Watt RK, 1999, CELL MOL LIFE SCI, V56, P604, DOI 10.1007/s000180050456; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; 1994, ACTA CRYSTALLOG D, V50, P760	47	76	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49359	49364		10.1074/jbc.M108619200	http://dx.doi.org/10.1074/jbc.M108619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11591723	hybrid			2022-12-27	WOS:000173922100096
J	Yue, JC; Liu, J; Shen, X				Yue, JC; Liu, J; Shen, X			Inhibition of phosphatidylinositol 4-kinase results in a significant reduced respiratory burst in formyl-methionyl-leucyl-phenylalanine-stimulated human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PURIFICATION; SENSITIVITY; ENDOCYTOSIS; ACTIVATION; CHEMOKINES; LOCATION; CLONING; PI3K	The effects of phenylarsine oxide and a monoclonal antibody directed against type II phosphatidylinositol 4-kinase (PI4K) on the N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated respiratory burst and the PI4K activity in neutrophils were investigated. Fluorescence microscopic imaging showed that the antibody labeled with LANBD amide (N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethyl-enediamine) could enter into the cytosol possibly by endocytosis. It was found that the antibody inhibited the fMLP-stimulated respiratory burst but had little effect on the phorbol myristate acetate-activated respiratory burst in neutrophils, whereas phenylarsine oxide inhibited both. It was found that even at higher concentration, the antibody could not completely inhibit the cell response. Using cells preincubated with human immunoglobulin G of the same concentration as the control, the maximal inhibition of the fMLP-stimulated respiratory burst by the antibody against type II PI4K was found to be about 70%, whereas the PI4K activity was inhibited by only about 40%. The discrepancy in depressing the cell response and the enzyme activity may be the result of depletion of the phosphatidylinositol 4,5-bisphosphate or phosphatidylinositol 3,4,5-trisphosphate pools during the incubation of cells with the antibody. Both the 40% inhibition of PI4K activity and 70% depression of the respiratory burst by the type II P4K antibody may imply that at least 40% of the phosphatidylinositol 4,5-biphosphate was synthesized promptly by all forms of PI4K and phosphatidylinositol-4-phosphate 5-kinase in the fMLP-activated cells. The results suggest that PI4K plays a central role in either phospholipase C or PI3K signaling and that PI3K, PI4K, and phosphatidylinositol 4-phosphate 5-kinase must be considered as an integrated family for the phosphatidylinositol 3,4,5-trisphosphate initiated signaling.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomol, Beijing 100101, Peoples R China; Chinese Acad Sci, Dept Cell Biophys, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences	Shen, X (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomol, 15 Datun Rd, Beijing 100101, Peoples R China.	shenxun@sun5.ibp.ac.cn						Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berg K, 1999, CANCER RES, V59, P1180; Condliffe AM, 1998, FEBS LETT, V439, P147, DOI 10.1016/S0014-5793(98)01358-1; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Kiliaan AJ, 1996, CELL TISSUE RES, V285, P51, DOI 10.1007/s004410050619; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MATTANA J, 1995, AM J PATHOL, V147, P529; Megias L, 2000, INT J DEV BIOL, V44, P209; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nishioka H, 1998, FEBS LETT, V441, P63, DOI 10.1016/S0014-5793(98)01526-9; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; Reynolds AJ, 1999, J NEUROCHEM, V73, P87, DOI 10.1046/j.1471-4159.1999.0730087.x; SCHOLZ G, 1991, EUR J BIOCHEM, V201, P249, DOI 10.1111/j.1432-1033.1991.tb16281.x; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Sorensen SD, 1998, MOL PHARMACOL, V53, P827; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Yue JC, 1999, PROG BIOCHEM BIOPHYS, V26, P473; Yue JC, 2000, CHIN J BIOCH MOL BIO, V16, P234	30	11	11	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49093	49099		10.1074/jbc.M101328200	http://dx.doi.org/10.1074/jbc.M101328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11592957	hybrid			2022-12-27	WOS:000173922100063
J	Boix, E; Swaminathan, GJ; Zhang, YN; Natesh, R; Brew, K; Acharya, KR				Boix, E; Swaminathan, GJ; Zhang, YN; Natesh, R; Brew, K; Acharya, KR			Structure of UDP complex of UDP-galactose :beta-galactoside-alpha-1,3-galactosyltransferase at 1.53-angstrom resolution reveals a conformational change in the catalytically important C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE REFINEMENT; EXPRESSION CLONING; CRYSTAL-STRUCTURES; GALACTOSYLTRANSFERASE; GLYCOSYLTRANSFERASES; MECHANISM; BIOSYNTHESIS; PARAMETERS; MOLSCRIPT; EVOLUTION	UDP-galactose:beta -galactosyl alpha -1,3-galactosyltransferase (alpha 3GT) catalyzes the transfer of galactose from UDP-alpha -D-galactose into an alpha -1,3 linkage with beta -galactosyl groups in glycoconjugates. The enzyme is expressed in many mammalian species but is absent from humans, apes, and old world monkeys as a result of the mutational inactivation of the gene; in humans, a large fraction of natural antibodies are directed against its product, the alpha -galactose epitope. a3GT is a member of a family of metal-dependent retaining glycosyltransferases including the histo-blood group A and B synthases. A crystal structure of the catalytic domain of a3GT was recently reported (Gastinel, L. N., Bignon, C., Misra, A. K., Hindsgaul, O., Shaper, J. H., and Joziasse, D. H. (2001) EMBO J. 20,638-649). However, because of the limited resolution (2.3 Angstrom) and high mobility of the atoms (as indicated by high B-factors) this structure,(form I) does not provide a clear depiction of the catalytic site of the enzyme. Here we report a new, highly ordered structure for the catalytic domain of a3GT at 1.53-Angstrom resolution (form II). This provides a more accurate picture of the details of the catalytic site that includes a bound UDP molecule and a Mn2+ cofactor. Significantly, in the new structure, the C-terminal segment (residues 358-368) adopts a very different, highly structured conformation and appears to form part of the active site. The properties of an Arg-365 to Lys mutant indicate that this region is important for catalysis, possibly reflecting its role in a donor substrate-induced conformational change.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33341 USA	University of Bath; State University System of Florida; Florida Atlantic University	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.		NATESH, Ramanathan/C-4488-2008; Brew, Keith/A-6746-2009; Boix, Ester/B-9038-2012; Brew, Keith/W-1643-2019	NATESH, Ramanathan/0000-0002-1145-5962; Brew, Keith/0000-0003-1306-1032; Boix, Ester/0000-0003-1790-2142; Acharya, K. Ravi/0000-0002-3009-4058; Swaminathan, Jawahar/0000-0002-0215-4084	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058773] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58773] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Breton C, 1998, J BIOCHEM, V123, P1000; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gijsen HJM, 1996, CHEM REV, V96, P443, DOI 10.1021/cr950031q; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nixon B, 2001, CELLS TISSUES ORGANS, V168, P46, DOI 10.1159/000016805; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; POWELL JT, 1976, J BIOL CHEM, V251, P3645; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shetterly S, 2001, GLYCOBIOLOGY, V11, P645, DOI 10.1093/glycob/11.8.645; Shi XD, 2001, DEVELOPMENT, V128, P645; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Watt GM, 1997, CURR OPIN STRUC BIOL, V7, P652, DOI 10.1016/S0959-440X(97)80074-7; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Zhang YN, 2001, J BIOL CHEM, V276, P11567, DOI 10.1074/jbc.M006530200; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	42	79	80	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48608	48614		10.1074/jbc.M108828200	http://dx.doi.org/10.1074/jbc.M108828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11592969	hybrid			2022-12-27	WOS:000172927000116
J	Lim, HM; Kaneshige, M; Zhao, L; Zhang, XY; Hanover, JA; Cheng, SY				Lim, HM; Kaneshige, M; Zhao, L; Zhang, XY; Hanover, JA; Cheng, SY			An isoform of branched-chain aminotransferase is a novel co-repressor for thyroid hormone nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE-3; MYC REGULATION; GENE; PROTEIN; TARGET; IDENTIFICATION; COREPRESSOR; INTERACTS; CLONING	The functions of thyroid hormone receptors (TRs) are regulated by a host of co-regulatory proteins. Tissue-specific expression of these co-regulators leads to distinct expression patterns and regulation of thyroid hormone (T3) target genes in tissues. Previously we have found that human colon carcinoma RKO cells exhibit strong U-independent transcriptional activity. We therefore searched for co-regulatory proteins in RKO cells using a yeast two-hybrid system with the intact TR beta1 as bait. One of the three positive clones, designated as P3, was identified to be an isoform of human mitochondria branched-chain amino-transferase (BCATm). P3 was a spliced variant of BCATm with an internal 12-amino acid deletion near the carboxyl-terminal region and was abundantly expressed in RKO cells. The expressed protein localized both to the mitochondria and the nucleus of transfected CV1 cells. P3 physically interacted with TR beta1 in a T3-independent manner that led to the inhibition in binding of TRIM to thyroid hormone-responsive element. P3 not only enhanced the repressor activity of the unliganded TR but also repressed the ligand-dependent activation of TIL This repression was reversed by treatment of cells with trichostatin A, suggesting that in addition to the inhibition of DNA binding, the repression activity of P3 on TR may also be mediated by histone deacetylase activity. Thus, unlike the currently known corepressors, P3 is a novel ligand-independent co-repressor for TR.	NCI, Gene Regulat Sect, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cheng, SY (corresponding author), NCI, Gene Regulat Sect, Mol Biol Lab, NIH, Bldg 37,Rm 2D-24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Ben-Yosef T, 1998, MAMM GENOME, V9, P595, DOI 10.1007/s003359900825; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BHAT MK, 1995, BIOCHEMISTRY-US, V34, P10591, DOI 10.1021/bi00033a034; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Bledsoe RK, 1997, BBA-PROTEIN STRUCT M, V1339, P9, DOI 10.1016/S0167-4838(97)00044-7; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; Faure M, 1999, EUR J BIOCHEM, V259, P104, DOI 10.1046/j.1432-1327.1999.00009.x; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1993, J BIOL CHEM, V268, P3084; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; ING NH, 1992, J BIOL CHEM, V267, P17617; Kao HY, 2000, GENE DEV, V14, P55; LEVINE M, 1989, CELL, V59, P404; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Tong GX, 1996, MOL CELL BIOL, V16, P1909; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu XG, 2000, MOL CELL BIOL, V20, P2604, DOI 10.1128/MCB.20.7.2604-2618.2000	39	2	2	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48196	48205		10.1074/jbc.M104320200	http://dx.doi.org/10.1074/jbc.M104320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11574535	hybrid			2022-12-27	WOS:000172927000062
J	Driggers, PH; Segars, JH; Rubino, DM				Driggers, PH; Segars, JH; Rubino, DM			The proto-oneoprotein Brx activates estrogen receptor beta by a p38 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; BREAST-CANCER; GROWTH-FACTOR; DBL FAMILY; C-JUN; STRESS; CELLS; PHOSPHORYLATION; DIFFERENTIATION; TRANSFORMATION	The estrogen receptors (ERs) are ligand-inducible transcription factors that play key roles in the control of growth and differentiation in reproductive tissues. We showed that the novel Dbl family proto-oncoprotein Brx enhances ligand-dependent activity of ER alpha via a Cdc42-dependent pathway. Brx also significantly enhances ligand-dependent activity of ER beta. This enhancement is not affected by inhibition of p44/42 mitogen-activated protein kinase (MAPK) activation by PD98059. However, addition of the p38 MAPK inhibitor SB202190 abrogates the enhancement of ER beta activity by Brx, showing that p38 MAPK activity is required for the enhancement of ER beta function by Brx. In COS-7 cells, transfection of Brx leads to activation of endogenous p38 MAPK activity. Co-expression of the beta2 isoform of human p38 MAPK and a constitutively active form of the p38 MAPK kinase MKK6 (MKK6-EE) synergistically augments ligand-dependent activity of ER beta. Our findings suggest that p38 MAPKs may be important regulators of ER beta activity.	Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA; US Mil Canc Inst, Bethesda, MD 20814 USA; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Driggers, PH (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				Intramural NIH HHS [Z99 HD999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Miller BT, 2000, AM J OBSTET GYNECOL, V182, P286, DOI 10.1016/S0002-9378(00)70213-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Puri PL, 2000, GENE DEV, V14, P574; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VAN AL, 1997, GENE DEV, V11, P2295	38	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46792	46797		10.1074/jbc.M106927200	http://dx.doi.org/10.1074/jbc.M106927200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11579095	hybrid, Green Accepted			2022-12-27	WOS:000172768500017
J	Ko, TP; Chen, YK; Robinson, H; Tsai, PC; Gao, YG; Chen, APC; Wang, AHJ; Liang, PH				Ko, TP; Chen, YK; Robinson, H; Tsai, PC; Gao, YG; Chen, APC; Wang, AHJ; Liang, PH			Mechanism of product chain length determination and the role of a flexible loop in Escherichia coli undecaprenyl-pyrophosphate synthase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; SITE-DIRECTED MUTAGENESIS; BACILLUS-STEAROTHERMOPHILUS; CONSERVED ASPARTATE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; IDENTIFICATION; RESIDUES; PRENYLTRANSFERASE; PURIFICATION	The Escherichia coli undecaprayl-pyrophosphate synthase (UPPs) structure has been solved using the single wavelength anomalous diffraction method. The putative substrate-binding site is located near the end of the betaA-strand with Asp-26 playing a critical catalytic role. In both subunits, an elongated hydrophobic tunnel is found, surrounded by four beta -strands (betaA-betaB-betaD-betaC) and two helices (alpha2 and alpha3) and lined at the bottom with large residues Ile-62, Leu-137, Val-105, and His-103. The product distributions formed by the use of the I62A, V105A, and H103A mutants are similar to those observed for wild-type UPPs. Catalysis by the L137A UPPs, on the other hand, results in predominantly the formation of the C-70 polymer rather than the C-55 polymer. Ala-69 and Ala-143 are located near the top of the tunnel. In contrast to the A143V reaction, the C-30 intermediate is formed to a greater extent and is longer lived in the process catalyzed by the A69L mutant. These findings suggest that the small side chain of Ala-69 is required for rapid elongation to the C-55 product, whereas the large hydrophobic side chain of Leu-137 is required to limit the elongation to the C-55 product. The roles of residues located on a flexible loop were investigated. The S71A, N74A, or R77A mutants displayed 25-200-fold decrease in k(cat) values. W75A showed an 8-fold increase of the FPP K-m value, and 22-33-fold increases in the IPP K-m values were observed for E81A and S71A. The loop may function to bridge the interaction of IPP with FPP, needed to initiate the condensation reaction and serve as a hinge to control the substrate binding and product release.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Wang, AHJ (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	ahjwang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041612] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41612] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUKHTIYAROV YE, 1993, J BIOCHEM-TOKYO, V113, P721, DOI 10.1093/oxfordjournals.jbchem.a124110; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; Fujikura K, 2000, J BIOCHEM, V128, P917, DOI 10.1093/oxfordjournals.jbchem.a022842; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JOLY A, 1993, J BIOL CHEM, V268, P26983; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kharel Y, 2001, J BIOL CHEM, V276, P28459, DOI 10.1074/jbc.M102057200; KOYAMA T, 1995, BIOCHEM BIOPH RES CO, V212, P681, DOI 10.1006/bbrc.1995.2022; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; OGURA K, 1997, DYNAMIC ASPECTS NATU, P1; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma S, 1998, J BIOL CHEM, V273, P26705, DOI 10.1074/jbc.273.41.26705; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P10936, DOI 10.1021/bi000992l; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P13856, DOI 10.1021/bi001226h; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Quellhorst GJ, 1998, BIOCHEM BIOPH RES CO, V244, P546, DOI 10.1006/bbrc.1998.8098; RIP JW, 1985, PROG LIPID RES, V24, P269, DOI 10.1016/0163-7827(85)90008-6; ROBYT J, 1998, ESSENTIALS CARBOHYDR, P305; Schulbach MC, 2000, J BIOL CHEM, V275, P22876, DOI 10.1074/jbc.M003194200; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072	40	78	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47474	47482		10.1074/jbc.M106747200	http://dx.doi.org/10.1074/jbc.M106747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581264	hybrid			2022-12-27	WOS:000172768500104
J	Frueauf, JB; Ballicora, MA; Preiss, J				Frueauf, JB; Ballicora, MA; Preiss, J			Aspartate residue 142 is important for catalysis by ADP-glucose pyrophosphorylase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DIPHOSPHATE GLUCOSE; SITE-DIRECTED MUTAGENESIS; ALLOSTERIC ACTIVATOR SITE; BACTERIAL GLYCOGEN; COVALENT MODIFICATION; NUCLEOTIDE-SEQUENCE; SUBUNIT STRUCTURE; BINDING SITES; POTATO-TUBER; GLGC GENE	Structural prediction of several bacterial and plant ADP-glucose pyrophosphorylases, as well as of other sugar-nucleotide pyrophosphorylases, was used for comparison with the three-dimensional structures of two crystallized pyrophosphorylases (Brown, K., Pompeo, F., Dixon, S., Mengin-Lecreulx, D., Cambillau, C., and Bourne, Y. (1999) EMBO J. 18,4096-4107; Blankenfeldt, W., Asuncion, M., Lam, J. S., and Naismith, J. H. (2000) EMBO J. 19, 6652-6663). This comparison led to the discovery of highly conserved residues throughout the superfamily of pyrophosphorylases despite the low overall homology. One of those residues, Asp(142) in the ADP-glucose pyrophosphorylase from Escherichia coli, was predicted to be near the substrate site. To elucidate the function that Asp(142) might play in the E. coli ADP-glucose pyrophosphorylase, aspartate was replaced by alanine, asparagine, or glutamate using site-directed mutagenesis. Kinetic analysis in the direction of synthesis or pyrophosphorolysis of the purified mutants showed a decrease in specific activity of up to 4 orders of magnitude. Comparison of other kinetic parameters, i.e. the apparent affinities for substrates and allosteric effectors, showed no significant changes, excluding this residue from the specific role of ligand binding. Only the D142E mutant exhibited altered K-m values but none as pronounced as the decrease in specific activity. These results show that residue Asp(142) is important in the catalysis of the ADP-glucose pyrophosphorylase from E. coli.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Preiss, J (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	preiss@msu.edu		Ballicora, Miguel/0000-0002-5324-0724				BALL K, 1994, J BIOL CHEM, V269, P24706; Ballicora MA, 1998, PLANT PHYSIOL, V118, P265, DOI 10.1104/pp.118.1.265; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; CHARNG YY, 1994, J BIOL CHEM, V269, P24107; ESPADA J, 1962, J BIOL CHEM, V237, P3577; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; GARDIOL A, 1990, ARCH BIOCHEM BIOPHYS, V280, P175, DOI 10.1016/0003-9861(90)90533-5; GENTNER N, 1967, BIOCHEM BIOPH RES CO, V27, P417, DOI 10.1016/S0006-291X(67)80116-5; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; GHOSH P, 1992, ARCH BIOCHEM BIOPHYS, V296, P122, DOI 10.1016/0003-9861(92)90553-9; HAUGEN TH, 1976, J BIOL CHEM, V251, P7880; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; HILL MA, 1991, J BIOL CHEM, V266, P12455; KRISHNAN HB, 1986, PLANT PHYSIOL, V81, P642, DOI 10.1104/pp.81.2.642; KUMAR A, 1988, J BIOL CHEM, V263, P14634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YM, 1986, ARCH BIOCHEM BIOPHYS, V244, P585, DOI 10.1016/0003-9861(86)90627-2; LEE YM, 1986, J BIOL CHEM, V261, P1058; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MELO A, 1965, J BIOL CHEM, V240, P398; MEYER CR, 1992, J BACTERIOL, V174, P4509, DOI 10.1128/JB.174.13.4509-4512.1992; MORELL M, 1988, J BIOL CHEM, V263, P633; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; NEUFELD E. F., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P602, DOI 10.1016/0003-9861(57)90524-6; OKITA TW, 1981, J BIOL CHEM, V256, P6944; OZAKI H, 1972, METHOD ENZYMOL, V28, P406; PARSONS TF, 1978, J BIOL CHEM, V253, P7638; PARSONS TF, 1978, J BIOL CHEM, V253, P6197; PAULE MR, 1971, J BIOL CHEM, V246, P4602; PREISS J, 1966, BIOCHEMISTRY-US, V5, P1833, DOI 10.1021/bi00870a008; PREISS J, 1984, ANNU REV MICROBIOL, V38, P419, DOI 10.1146/annurev.mi.38.100184.002223; Preiss J, 1998, COMPREHENSIVE NATURA, P441; Preiss J, 1973, ENZYMES, V8, P73; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SANWAL GG, 1967, ARCH BIOCHEM BIOPHYS, V119, P454, DOI 10.1016/0003-9861(67)90477-8; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHEN L, 1964, BIOCHEM BIOPH RES CO, V17, P424, DOI 10.1016/0006-291X(64)90023-3; Sivak M.N., 1998, ADV FOOD NUTR RES, V41, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; SOWOKINOS JR, 1982, PLANT PHYSIOL, V69, P1459, DOI 10.1104/pp.69.6.1459; TSUBOI KK, 1969, J BIOL CHEM, V244, P1008; Wu MX, 1998, ARCH BIOCHEM BIOPHYS, V358, P182, DOI 10.1006/abbi.1998.0846	48	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46319	46325		10.1074/jbc.M107408200	http://dx.doi.org/10.1074/jbc.M107408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11567027	hybrid			2022-12-27	WOS:000172573100113
J	Marsin, S; McGovern, S; Ehrlich, SD; Bruand, C; Polard, P				Marsin, S; McGovern, S; Ehrlich, SD; Bruand, C; Polard, P			Early steps of Bacillus subtilis primosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN PRIA; ESCHERICHIA-COLI; DNA-REPLICATION; NUCLEOTIDE-SEQUENCE; RECOMBINATION; INITIATION; BINDING; GENE; SITE	Primosomes are nucleoprotein assemblies designed for the activation of DNA replication forks. Their primary role is to recruit the replicative helicase onto single-stranded DNA. The "replication restart" primosome, defined in Escherichia coli, is involved in the reactivation of arrested replication forks. Binding of the PriA protein to forked DNA triggers its assembly. PriA is conserved in bacteria, but its primosomal partners are not. In Bacillus subtilis, genetic analysis has revealed three primosomal proteins, DnaB, DnaD, and DnaI, that have no obvious homologues in E. coli. Interestingly, they are involved in primosome function both at arrested replication forks and at the chromosomal origin. Our biochemical analysis of the DnaB, and DnaD proteins unravels their role in primosome assembly. They are both multimeric and bind individually to DNA. Furthermore, DnaD stimulates DnaB binding activities. DnaD alone and the DnaD/DnaB pair interact specifically with PriA of B. subtilis on several DNA substrates. This suggests that the nucleoprotein assembly is sequential in the PriA, DnaD, DnaB order. The preferred DNA substrate mimics an arrested DNA replication fork with unreplicated lagging strand, structurally identical to a product of recombinational repair of a stalled replication fork.	INRA, Lab Genet Microbienne, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Polard, P (corresponding author), INRA, Lab Genet Microbienne, Domaine de Vilvert, F-78352 Jouy En Josas, France.	polard@biotec.jouy.inra.fr	Bruand, Claude/AAF-7695-2020; Ehrlich, S./Y-2423-2019	Ehrlich, S./0000-0002-7563-4046; Bruand, Claude/0000-0002-2367-0782; MARSIN, Stephanie/0000-0002-7074-7818				BRUAND C, 1995, MICROBIOL-UK, V141, P1199, DOI 10.1099/13500872-141-5-1199; BRUAND C, 1995, EMBO J, V14, P2642, DOI 10.1002/j.1460-2075.1995.tb07262.x; Bruand C, 2001, MOL MICROBIOL, V42, P245, DOI 10.1046/j.1365-2958.2001.02631.x; BRUAND C, 1995, MICROBIOL-UK, V141, P321, DOI 10.1099/13500872-141-2-321; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; Imai Y, 2000, MOL MICROBIOL, V36, P1037, DOI 10.1046/j.1365-2958.2000.01928.x; Ishigo-oka D, 2001, J BACTERIOL, V183, P2148, DOI 10.1128/JB.183.6.2148-2150.2001; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; KOONIN EV, 1992, NUCLEIC ACIDS RES, V20, P1997, DOI 10.1093/nar/20.8.1997; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; MARIANS KJ, 1996, ESCHERICHIA COLI SAL, P749; MASAI H, 1996, FRONT BIOSCI, V1, P48; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Moriya S, 1999, PLASMID, V41, P17, DOI 10.1006/plas.1998.1381; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; OGASAWARA N, 1986, NUCLEIC ACIDS RES, V14, P9989, DOI 10.1093/nar/14.24.9989; Polard P, 1996, J MOL BIOL, V264, P68, DOI 10.1006/jmbi.1996.0624; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 2000, GENETICS, V155, P487; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUEOKA N, 1993, PROG NUCL ACIDS RES, V59, P35; WAHLE E, 1989, J BIOL CHEM, V264, P2469; Yoshiakwa H., 1993, P507; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337	41	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45818	45825		10.1074/jbc.M101996200	http://dx.doi.org/10.1074/jbc.M101996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585815	Green Published, hybrid			2022-12-27	WOS:000172573100044
J	Weiss, S; Rossi, R; Pellegrino, MA; Bottinelli, R; Geeves, MA				Weiss, S; Rossi, R; Pellegrino, MA; Bottinelli, R; Geeves, MA			Differing ADP release rates from myosin heavy chain isoforms define the shortening velocity of skeletal muscle fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALI LIGHT-CHAIN; ACTOMYOSIN ATPASE; CONTRACTION; ACTIN; MECHANISM; PROTEINS; SLOW; QUANTITIES; PHOTOLYSIS; DIVERSITY	To understand mammalian skeletal myosin isoform diversity, pure myosin isoforms of the four major skeletal muscle myosin types (myosin heavy chains I, IIA, IIX, and IIB) were extracted from single rat muscle fibers. The extracted myosin (1-2 mug/15-mm length) was sufficient to define the actomyosin dissociation reaction in flash photolysis using caged-ATP (Weiss, S., Chizhov, I., and Geeves, M. A. (2000) J. Muscle Res. Cell Motil. 21, 423-432). The ADP inhibition of the dissociation reaction was also studied to give the ADP affinity for actomyosin (K-AD). The apparent second order rate constant of actomyosin dissociation gets faster (K(1)k(+2) = 0.17 -0.26 mum(-1).s(-1)), whereas the affinity for ADP is weakened (250-930 mum) in the isoform order I, IIA, IIX, IIB. Both sets of values correlate well with the measured maximum shortening velocity (V-0) of the parent fibers. If the value of KAD is controlled largely by the rate constant of ADP release (k(-AD)), then the estimated value of k(-AD) is sufficiently low to limit V.. In contrasts [ATP]K(1)k(+2) at a physiological concentration of 5 mm ATP would be 2.5-6 times faster than k(-AD).	Univ Kent, Res Sch Biosci, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Pavia, Inst Human Physiol, I-27100 Pavia, Italy	University of Kent; University of Pavia	Geeves, MA (corresponding author), Univ Kent, Res Sch Biosci, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	mag@ukc.ac.uk	Bottinelli, Roberto/AAC-1904-2020; Geeves, Michael/F-7583-2011; Pellegrino, Maria Antonietta/AAC-4680-2022	Bottinelli, Roberto/0000-0002-4960-7490; Geeves, Michael/0000-0002-9364-8898; Pellegrino, Maria Antonietta/0000-0002-1653-1266				BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V481, P663, DOI 10.1113/jphysiol.1994.sp020472; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; Canepari M, 2000, J MUSCLE RES CELL M, V21, P375, DOI 10.1023/A:1005640004495; Canepari M, 1999, EXP PHYSIOL, V84, P803, DOI 10.1111/j.1469-445X.1999.00350.x; Chizhov I, 1996, BIOPHYS J, V71, P2329, DOI 10.1016/S0006-3495(96)79475-4; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABUCHI K, 1980, MUSCLE NERVE, V3, P233, DOI 10.1002/mus.880030308; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; PATE E, 1992, AM J PHYSIOL, V262, pC1039; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; RANATUNGA KW, 1984, J PHYSIOL-LONDON, V351, P517, DOI 10.1113/jphysiol.1984.sp015260; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STARON RS, 1987, PFLUG ARCH EUR J PHY, V409, P67, DOI 10.1007/BF00584751; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; Weiss S, 2000, J MUSCLE RES CELL M, V21, P423, DOI 10.1023/A:1005690106951; WEST JJ, 1967, J BIOL CHEM, V242, P1140; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020	33	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45902	45908		10.1074/jbc.M107434200	http://dx.doi.org/10.1074/jbc.M107434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590173	hybrid			2022-12-27	WOS:000172573100056
J	Caruso, M; Maitan, MA; Bifulco, G; Miele, C; Vigliotta, G; Oriente, F; Formisano, P; Beguinot, F				Caruso, M; Maitan, MA; Bifulco, G; Miele, C; Vigliotta, G; Oriente, F; Formisano, P; Beguinot, F			Activation and mitochondrial translocation of protein kinase C delta are necessary for insulin stimulation of pyruvate dehydrogenase complex activity in muscle and liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ADIPOSE-TISSUE; PHOSPHATE PHOSPHATASE; MAMMALIAN PYRUVATE; OUTER-MEMBRANE; RAT-LIVER; RECEPTOR; PHOSPHORYLATION; ALPHA; DEPHOSPHORYLATION	In L6 skeletal muscle cells and immortalized hepatocytes, insulin induced a 2-fold increase in the activity of the pyruvate dehydrogenase (PDH) complex. This effect was almost completely blocked by the protein kinase C (PKC) delta inhibitor Rottlerin and by PKC delta antisense oligonucleotides. At variance, overexpression of wild-type PKC delta or of an active PKC delta mutant induced PDH complex activity in both L6 and liver cells. Insulin stimulation of the activity of the PDH complex was accompanied by a 2.5-fold increase in PDH phosphatases 1 and 2 (PDP1/2) activity with no change in the activity of PDH kinase. PKC delta antisense blocked insulin activation of PDP1/2, the same as with PDH. In insulin-exposed cells, PDP1/2 activation was paralleled by activation and mitochondrial translocation of PKC8 delta, as revealed by cell subfractionation and confocal microscopy studies. The mitochondrial translocation of PKC delta, like its activation, was prevented by Rottlerin. In extracts from insulin-stimulated cells, PKC delta co-precipitated with PDP1/2. PKC delta also bound to PDP1/2 in overlay blots, suggesting that direct PKC delta -PDP interaction may occur in vivo as well. In intact cells, insulin exposure determined PDP1/2 phosphorylation, which was specifically prevented by PKC delta antisense. PKC delta also phosphorylated PDP in vitro, followed by PDP1/2 activation. Thus, in muscle and liver cells, insulin causes activation and mitochondrial translocation of PKC delta, accompanied by PDP phosphorylation and activation. These events are necessary for insulin activation of the PDH complex in these cells.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	beguino@unina.it	vigliotta, giovanni/AAW-6401-2020; Vigliotta, Giovanni/GPF-7237-2022; Formisano, Pietro/J-4237-2018; Bifulco, Giuseppe/A-5413-2011; ORIENTE, Francesco/J-6652-2018	vigliotta, giovanni/0000-0001-5132-0037; Bifulco, Giuseppe/0000-0002-1788-5170; ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		ASSIMACOPOULOSJEANNET F, 1983, FEBS LETT, V159, P83, DOI 10.1016/0014-5793(83)80421-9; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; BENELLI C, 1994, METABOLISM, V43, P1030, DOI 10.1016/0026-0495(94)90185-6; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Braiman L, 1999, MOL ENDOCRINOL, V13, P2002, DOI 10.1210/me.13.12.2002; BUFFINGTON CK, 1984, DIABETES, V33, P681, DOI 10.2337/diabetes.33.7.681; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; Caruso M, 2000, DIABETES, V49, P1194, DOI 10.2337/diabetes.49.7.1194; Caruso R, 1999, J BIOL CHEM, V274, P28637, DOI 10.1074/jbc.274.40.28637; Chalfant CE, 2000, ENDOCRINOLOGY, V141, P2773, DOI 10.1210/en.141.8.2773; CLOT JP, 1988, METABOLISM, V37, P1101, DOI 10.1016/0026-0495(88)90075-3; CLOT JP, 1992, J CLIN ENDOCR METAB, V74, P1258, DOI 10.1210/jc.74.6.1258; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DAVIS PF, 1977, BIOCHEM BIOPH RES CO, V75, P541, DOI 10.1016/0006-291X(77)91506-6; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENTON RM, 1989, ANN NY ACAD SCI, V573, P285, DOI 10.1111/j.1749-6632.1989.tb15005.x; DENTON RM, 1975, MOL CELL BIOCHEM, V9, P27, DOI 10.1007/BF01731731; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Formisano P, 2001, J ENDOCRINOL INVEST, V24, P460, DOI 10.1007/BF03351048; GATEAU O, 1978, EUR J BIOCHEM, V88, P613, DOI 10.1111/j.1432-1033.1978.tb12488.x; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; LILLEY K, 1992, ARCH BIOCHEM BIOPHYS, V296, P170, DOI 10.1016/0003-9861(92)90559-F; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; MACAULAY SL, 1985, ARCH BIOCHEM BIOPHYS, V237, P142, DOI 10.1016/0003-9861(85)90263-2; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; MANDARINO LJ, 1987, J CLIN INVEST, V80, P655, DOI 10.1172/JCI113118; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; MUKHERJEE C, 1975, BIOCHEM J, V148, P229, DOI 10.1042/bj1480229; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SEALS JR, 1980, P NATL ACAD SCI-BIOL, V77, P77, DOI 10.1073/pnas.77.1.77; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; STEPP LR, 1983, J BIOL CHEM, V258, P9454; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WIELAND OH, 1972, EUR J BIOCHEM, V26, P426, DOI 10.1111/j.1432-1033.1972.tb01783.x; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072	46	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45088	45097		10.1074/jbc.M105451200	http://dx.doi.org/10.1074/jbc.M105451200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577086	hybrid			2022-12-27	WOS:000172406700099
J	Philip, S; Bulbule, A; Kundu, GC				Philip, S; Bulbule, A; Kundu, GC			Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; INTEGRIN; BINDING; INVASION; INVASIVENESS; TUMORIGENICITY; OVEREXPRESSION; TRANSCRIPTION	Matrix metalloproteinases (MMPs) degrade the extracellular matrix (ECM) and play critical roles in tissue repair, tumor invasion, and metastasis. MMPs are regulated by different cytokines, ECM proteins, and other factors. However, the molecular mechanisms by which osteopontin (OPN), an ECM protein, regulates ECM invasion and tumor growth and modulates MMP activation in B16F10 cells are not well defined. We have purified OPN from human milk and shown that OPN induces pro-MMP-2 production and activation in these cells. Moreover, our data revealed that OPN-induced membrane type 1 (MT1) MMP expression correlates with translocation of p65 (nuclear factor-kappaB (NF-kappaB)) into the nucleus. However, when the super-repressor form of I kappaB alpha (inhibitor of NF-kappaB) was transfected into cells followed by treatment with OPN, no induction of MT1-MMP expression was observed, indicating that OPN activates pro-MMP-2 via an NF-kappaB-mediated pathway. OPN also enhanced cell migration and ECM invasion by interacting with alpha (v)beta (3) integrin, but these effects were reduced drastically when the MMP-2-specific antisense S-oligonucleotide was used to suppress MMP-2 expression. Interestingly, when the OPN-treated cells were injected into nude mice, the mice developed larger tumors, and the MMP-2 levels in the tumors were significantly higher than in controls. The proliferation data indicate that OPN increases the growth rate in these cells. Both tumor size and MMP-2 expression were reduced dramatically when anti-MMP-2 antibody or antisense S-oligonucleotide-transfected cells were injected into the nude mice. To our knowledge, this is the first report that MMP-2 plays a direct role in OPN-induced cell migration, invasion, and tumor growth and that demonstrates that OPN-stimulated MMP-2 activation occurs through NF-kappaB-mediated induction of MT1-MMP.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	gopalkundu@hotmail.com	Kundu, Gopal C./ABA-9897-2020					Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHEN Y, 1992, J BIOL CHEM, V267, P24871; COTTAM DW, 1993, INT J ONCOL, V2, P861; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARDNER HAR, 1994, ONCOGENE, V9, P2321; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIOTTA LA, 1992, CELL, V71, P411; Maquoi E, 2000, EXP CELL RES, V261, P348, DOI 10.1006/excr.2000.5063; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; RITTER NM, 1992, J BONE MINER RES, V7, P877; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; SINGH K, 1990, J BIOL CHEM, V265, P18696; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; Sun Y, 1996, ANTICANCER RES, V16, P1; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.3.CO;2-K; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; Zhang ZJ, 1999, P NATL ACAD SCI USA, V96, P3963, DOI 10.1073/pnas.96.7.3963	40	215	241	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44926	44935		10.1074/jbc.M103334200	http://dx.doi.org/10.1074/jbc.M103334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564733	hybrid			2022-12-27	WOS:000172406700080
J	Turkson, J; Ryan, D; Kim, JS; Zhang, Y; Chen, Z; Haura, E; Laudano, A; Sebti, S; Hamilton, AD; Jove, R				Turkson, J; Ryan, D; Kim, JS; Zhang, Y; Chen, Z; Haura, E; Laudano, A; Sebti, S; Hamilton, AD; Jove, R			Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; JAK-STAT PATHWAY; CONSTITUTIVE ACTIVATION; TRANSCRIPTIONAL ACTIVATION; MYELOID DIFFERENTIATION; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; MYCOSIS-FUNGOIDES	Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic signaling proteins that participates in normal cellular responses to cytokines and growth factors. Frequently, however, constitutive activation of certain STAT family members, particularly Stat3, has accompanied a wide variety of human malignancies. To identify small molecule inhibitors of Stat3, we investigated the ability of the Stat3 SH2 domain-binding peptide, PY*LKTK (where Y* represents phosphotyrosine), to disrupt Stat3 activity in vitro. The presence of PY*LKTK, but not PYLKTK or PFLKTK, in nuclear extracts results in significant reduction in the levels of DNA binding activities of Stat3, to a lesser extent of Stat1, and with no effect on that of Stat5. Analyses of alanine scanning mutagenesis and deletion derivatives of PY*LKTK reveal that the Leu residue at the Y+1 position and a substituent at the Y-1 position (but not necessarily Pro) are essential for the disruption of active Stat3, thereby mapping the minimum active sequence to the tripeptide, XY*L. Studies involving bead-coupled PY*LKTK peptide demonstrate that this phosphopeptide directly complexes with Stat3 monomers in vitro, suggesting that PY*LKTK disrupts Stat3:Stat3 dieters. As evidence for the functional importance of peptide-directed inhibition of Stat3, PY*LKTK-mts (rots, membrane translocating sequence) selectively inhibits constitutive and ligand-induced Stat3 activation in vivo. Furthermore, PY*LKTK-mts suppresses transformation by the Src oncoprotein, which has been shown previously to require constitutive Stat3 activation. Altogether, we have identified a minimal peptide that inhibits Stat3 signaling and provides the conceptual basis for use of this peptide as a lead for novel peptidomimetic drug design.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University; University System Of New Hampshire; University of New Hampshire	Turkson, J (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 4019,12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA055652, P01CA078038] Funding Source: NIH RePORTER; NCI NIH HHS [CA78038, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Ben-Bassat H, 2000, CURR PHARM DESIGN, V6, P933, DOI 10.2174/1381612003400182; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chakraborty A, 2000, BLOOD CELL MOL DIS, V26, P320, DOI 10.1006/bcmd.2000.0309; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Inoue M, 1997, J BIOL CHEM, V272, P9550; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Mikita T, 1998, J BIOL CHEM, V273, P17634, DOI 10.1074/jbc.273.28.17634; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 1999, CANCER RES, V59, P5059; Planas AM, 1997, J NEUROCHEM, V68, P1345; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephens JM, 1996, J BIOL CHEM, V271, P10441, DOI 10.1074/jbc.271.18.10441; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZVELEBIL MJJM, 1995, PROTEIN ENG, V8, P527, DOI 10.1093/protein/8.6.527	65	364	408	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45443	45455		10.1074/jbc.M107527200	http://dx.doi.org/10.1074/jbc.M107527200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579100	hybrid			2022-12-27	WOS:000172406700142
J	Wang, J; Dreyfuss, G				Wang, J; Dreyfuss, G			Characterization of functional domains of the SMN protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; SURVIVAL MOTOR-NEURON; DISEASE GENE-PRODUCT; MOLECULAR ANALYSIS; BINDING-PROTEIN; SNRNP PROTEINS; MOUSE MODEL; COMPLEX; DELETIONS; POMBE	The Survival of Motor Neurons (SMN) is the disease gene of spinal muscular atrophy. We have previously established a genetic system based on the chicken pre-B cell line DT40, in which expression of SMN protein is regulated by tetracycline, to study the function of SMN in vivo. Depletion of SMN protein is lethal to these cells. Here we tested the functionality of mutant SMN proteins by determining their capacity to rescue the cells after depletion of wild-type SMN. Surprisingly, all of the spinal muscular atrophy-associated missense mutations tested were able to support cell viability and proliferation. Deletion of the amino acids encoded by exon 7 of the SMN gene resulted in a partial loss of function. A mutant SMN protein lacking both the tyrosine/glycine repeat (in exon 6) and exon 7 failed to sustain viability, indicating that the C terminus of the protein is critical for SMN activity. Interestingly, the Tudor domain of SMN, encoded by exon 3, does not appear to be essential for SMN function since a mutant deleted of this domain restored cell viability. Unexpectedly, a chicken SMN mutant (Delta N39) lacking the N-terminal 39 amino acids that encompass the Gemin2-binding domain also rescued the lethal phenotype. Moreover, the level of Gemin2 in Delta N39-rescued cells was significantly reduced, indicating that Gemin2 is not required for Delta N39 to perform the essential function of SMN in DT40 cells. These findings suggest that SMN may perform a novel function in DT40 cells.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774	NINDS NIH HHS [R0I-NS40575-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040575] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; CHANG JG, 1995, AM J HUM GENET, V57, P1503; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Cifuentes-Diaz C, 2001, J CELL BIOL, V152, P1107, DOI 10.1083/jcb.152.5.1107; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Frugier T, 2000, HUM MOL GENET, V9, P849, DOI 10.1093/hmg/9.5.849; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P165; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 1998, HUM MOL GENET, V7, P1269, DOI 10.1093/hmg/7.8.1269; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; Paushkin S, 2000, J BIOL CHEM, V275, P23841, DOI 10.1074/jbc.M001441200; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; Talbot K, 1998, HUM MOL GENET, V7, P2149, DOI 10.1093/hmg/7.13.2149; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; Wang J, 2001, J BIOL CHEM, V276, P9599, DOI 10.1074/jbc.M009162200; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869	43	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45387	45393		10.1074/jbc.M105059200	http://dx.doi.org/10.1074/jbc.M105059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572858	hybrid			2022-12-27	WOS:000172406700135
J	Zhao, DZ; Keates, AC; Kuhnt-Moore, S; Moyer, MP; Kelly, CP; Pothoulakis, C				Zhao, DZ; Keates, AC; Kuhnt-Moore, S; Moyer, MP; Kelly, CP; Pothoulakis, C			Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INFLAMMATORY-BOWEL-DISEASE; MAP KINASE; CELL-LINE; CALCIUM MOBILIZATION; DEPENDENT ACTIVATION; RECEPTOR STIMULATION; HELICOBACTER-PYLORI; COUPLED RECEPTORS	Neurotensin (NT), a neuropeptide released in the gastrointestinal tract in response to several stimuli, is involved in the pathophysiology of colonic inflammation. However, the molecular mechanism(s) mediating this proinflammatory response remains unclear. We found that NCM460, non-transformed human colonocytes, express a functional high affinity NT receptor that mediates NT-induced Erk activation. By using NCM460 cells stably transfected with NTR1, we show that NTR1 activation leads to interleukin (IL)-8 secretion that is mediated via both NF-kappaB- and Erk-dependent pathways. In addition, NT-stimulated NF-kappaB activation is dependent on intracellular calcium release. NT-stimulated Erk activity requires Ras activation because overexpression of the dominant negative Ras mutant Ras-17N almost completely inhibits the Erk activation. Furthermore, NT directly stimulates Ras-GTP formation as shown by a Ras-GTP pull-down assay. By using reporter gene constructs containing targeted substitutions in the IL-8 promoter, we show that the NF-kappaB, AP-1, and to a lesser degree the C/EBP sites in the IL-8 promoter region are required for IL-8 gene expression induced by NT. In summary, our results demonstrate that NT stimulates calcium-dependent NF-kappaB and Ras-dependent Erk pathways that mediate the release of IL-8 from non-transformed human colonocytes. We speculate that these NT-related proinflammatory pathways are important in the pathophysiology of colonic inflammation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA; INCELL Corp, San Antonio, TX 78249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pothoulakis, C (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.				NIDDK NIH HHS [DK 33506, DK54920] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054920, P01DK033506] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAR S, 1986, FEBS LETT, V201, P31, DOI 10.1016/0014-5793(86)80565-8; Ardite E, 1998, BRIT J PHARMACOL, V124, P431, DOI 10.1038/sj.bjp.0701887; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Bliss CM, 1998, INFECT IMMUN, V66, P5357, DOI 10.1128/IAI.66.11.5357-5363.1998; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; Castagliuolo I, 1996, P NATL ACAD SCI USA, V93, P12611, DOI 10.1073/pnas.93.22.12611; Castagliuolo I, 1999, J CLIN INVEST, V103, P843, DOI 10.1172/JCI4217; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; CASTAGLIUOLO I, 1999, GASTROENTEROLOGY, V116, P799; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ehlers RA, 1998, SURGERY, V124, P239, DOI 10.1067/msy.1998.90370; Ehlers RA, 2000, BIOCHEM BIOPH RES CO, V269, P704, DOI 10.1006/bbrc.2000.2335; Ellis RD, 1998, INFLAMM RES, V47, P440, DOI 10.1007/s000110050358; EVERS BM, 1992, GASTROENTEROLOGY, V103, P86, DOI 10.1016/0016-5085(92)91099-P; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOLDMAN R, 1983, FEBS LETT, V159, P63, DOI 10.1016/0014-5793(83)80417-7; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Keates S, 1999, J IMMUNOL, V163, P5552; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEMAIRE I, 1988, J IMMUNOL, V140, P2983; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Lieb K, 1997, J IMMUNOL, V159, P4952; Linevsky JK, 1997, AM J PHYSIOL-GASTR L, V273, pG1333, DOI 10.1152/ajpgi.1997.273.6.G1333; Lucchesi PA, 1996, CIRC RES, V78, P962, DOI 10.1161/01.RES.78.6.962; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maoret JJ, 1999, INT J CANCER, V80, P448, DOI 10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MILLER LA, 1995, BRIT J PHARMACOL, V114, P1466, DOI 10.1111/j.1476-5381.1995.tb13371.x; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Papadakis KA, 2000, ANNU REV MED, V51, P289, DOI 10.1146/annurev.med.51.1.289; PoinotChazel G, 1996, BIOCHEM J, V320, P145, DOI 10.1042/bj3200145; POLAK JM, 1977, NATURE, V270, P183, DOI 10.1038/270183a0; Pothoulakis C, 1998, ANN NY ACAD SCI, V840, P635, DOI 10.1111/j.1749-6632.1998.tb09602.x; Riegler M, 2000, GASTROENTEROLOGY, V119, P348, DOI 10.1053/gast.2000.9310; SCHAEFFER P, 1995, J BIOL CHEM, V270, P3409, DOI 10.1074/jbc.270.7.3409; Schmid RM, 1998, GUT, V43, P587; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Suzuki M, 2000, FEBS LETT, V465, P23, DOI 10.1016/S0014-5793(99)01717-2; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOR K, 1986, GASTROENTEROLOGY, V90, P27, DOI 10.1016/0016-5085(86)90070-3; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WALSH JH, 1987, PHYSL GASTROINTESTIN, P181; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WOOD JG, 1988, AM J PHYSIOL, V255, pG813, DOI 10.1152/ajpgi.1988.255.6.G813; WOOD JG, 1988, PANCREAS, V3, P332, DOI 10.1097/00006676-198805000-00015; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yoshinaga K, 1992, Surg Oncol, V1, P127, DOI 10.1016/0960-7404(92)90025-G	60	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44464	44471		10.1074/jbc.M104942200	http://dx.doi.org/10.1074/jbc.M104942200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574537	hybrid			2022-12-27	WOS:000172406700017
J	Caputi, M; Zahler, AM				Caputi, M; Zahler, AM			Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H '/F/2H9 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IN-VITRO; SPLICING SILENCER; GENE-EXPRESSION; A/B PROTEINS; C PROTEIN; A1; ELEMENTS; EXON; TRACT	Members of the heterogeneous nuclear ribonucleoprotein (hnRNP) H protein family, H, H', F, and 2H9, are involved in pre-mRNA processing. We analyzed the assembly of these proteins from splicing extracts onto four RNA regulatory elements as follows: a high affinity hnRNP Al-binding site (WA1), a sequence involved in Rev-dependent export (p17gag INS), an exonic splicing silencer from the beta -tropomyosin gene, and an intronic splicing regulator (downstream control sequence (DCS) from the c-src gene. The entire family binds the WA1, instability (INS), and beta -tropomyosin substrates, and the core-binding site for each is a run of three G residues followed by an A. Transfer of small regions containing this sequence to a substrate lacking hnRNP H binding activity is sufficient to promote binding of all family members. The c-src DCS has been shown to assemble hnRNP H, not hnRNP F, from HeLa cell extracts, and we show that hnRNP 2H9 does not bind this element. The DCS contains five G residues followed by a C. Mutation of the C to an A changes the specificity of the DCS from a substrate that binds only hnRNP H/H' to a binding site for all hnRNP H family members. We conclude that the sequence GGGA is recognized by all hnRNP H family proteins.	Univ Calif Santa Cruz, Dept Mol & Cellular & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Ctr Mol Biol RNA, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Zahler, AM (corresponding author), Univ Calif Santa Cruz, Dept Mol & Cellular & Dev Biol, Santa Cruz, CA 95064 USA.	zahler@biology.ucsc.edu		Zahler, Alan/0000-0003-0027-1647	NIGMS NIH HHS [1R01GM61646] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061646] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashiya M, 1997, RNA, V3, P996; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; CHAN RC, 1995, MOL CELL BIOL, V15, P6377; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 1999, MOL CELL BIOL, V19, P69; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENGELBRECHT J, 1992, J MOL BIOL, V227, P108, DOI 10.1016/0022-2836(92)90685-D; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; FORNE T, 1995, J BIOL CHEM, V270, P16476, DOI 10.1074/jbc.270.27.16476; Gamberi C, 1997, MOL CELL BIOL, V17, P2587, DOI 10.1128/MCB.17.5.2587; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; Holzmann K, 1997, EUR J BIOCHEM, V244, P479, DOI 10.1111/j.1432-1033.1997.00479.x; HONORE B, 1995, J BIOL CHEM, V270, P28780; Honore B, 2000, BBA-GENE STRUCT EXPR, V1492, P108, DOI 10.1016/S0167-4781(00)00092-0; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LANGLAND JO, 1995, PROTEIN EXPRES PURIF, V6, P25, DOI 10.1006/prep.1995.1004; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; Mahe D, 2000, BBA-GENE STRUCT EXPR, V1492, P414, DOI 10.1016/S0167-4781(00)00144-5; Mahe D, 1997, J BIOL CHEM, V272, P1827, DOI 10.1074/jbc.272.3.1827; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; Najera I, 1999, J MOL BIOL, V285, P1951, DOI 10.1006/jmbi.1998.2473; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; NUSSINOV R, 1988, J THEOR BIOL, V133, P73, DOI 10.1016/S0022-5193(88)80025-0; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Shahied-Milam L, 1998, J BIOL CHEM, V273, P21359, DOI 10.1074/jbc.273.33.21359; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Yoshida T, 1999, FEBS LETT, V457, P251, DOI 10.1016/S0014-5793(99)01048-0	58	155	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43850	43859		10.1074/jbc.M102861200	http://dx.doi.org/10.1074/jbc.M102861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571276	hybrid			2022-12-27	WOS:000172297700050
J	Khan, MM; Nomura, T; Kim, H; Kaul, SC; Wadhwa, R; Zhong, S; Pandolfi, PP; Ishi, S				Khan, MM; Nomura, T; Kim, H; Kaul, SC; Wadhwa, R; Zhong, S; Pandolfi, PP; Ishi, S			PML-RAR alpha alleviates the transcriptional repression mediated by tumor suppressor Rb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE COMPLEX; RETINOBLASTOMA PROTEIN; GENE-PRODUCT; N-COR; RECEPTOR; TRANSLOCATION; COMPONENT; SMRT; LOCALIZATION	A fusion between the promyelocytic leukemia (PML) protein and the retinoic acid receptor-alpha (RAR alpha) results in the transforming protein of acute promyelocytic leukemia, PMM-RAR alpha. PML has growth-suppressive properties and is localized within distinct nuclear structures referred to as nuclear bodies. PML participates in numerous cellular functions, including transcriptional activation, apoptosis, and transcriptional repression, whereas PMM-RAR alpha blocks these functions. However, the role played by PMM-RAR alpha in leukemogenesis remains unclear. Here we report that PML is required for transcriptional repression mediated by the tumor suppressor Rb. Rb interacts with the histone decaetylase (HDAC) complex containing co-repressors and represses the transcription of the E2F target genes. Overexpression of PAM enhanced Rb-mediated repression. The degree of Rb-mediated repression was weakened by injecting antiPML antibodies and was lower in PML-deficient mouse embryonic fibroblasts. PAM-RAR alpha inhibited Rb-mediated repression, and two co-repressor-interacting sites on the PML-RAR alpha molecule were required for this activity. Furthermore, PMM-RAR alpha blocked the interaction between Rb and HDAC. Thus, aberrant binding of PML-RAR alpha to co-repressor-HDAC complexes may inhibit their association with Rb, resulting in the abrogation of Rb activity. Thus, the disruption of Rb-mediated repression may be a contributory factor in leukemogenesis.	RIKEN, Mol Genet Lab, Tsukuba Inst, Tsukuba, Ibaraki 3050074, Japan; CREST, Project JST, Tsukuba, Ibaraki 3050074, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Tsukuba, Ibaraki 3058566, Japan; Chugai Res Inst Mol Med, Ibaraki, Osaka 3004101, Japan; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Human Genet,Sloan Kettering Div, Program Mol Biol,Grad Sch Med Sci, New York, NY 10021 USA	RIKEN; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Cornell University; Memorial Sloan Kettering Cancer Center	Ishi, S (corresponding author), RIKEN, Mol Genet Lab, Tsukuba Inst, Tsukuba, Ibaraki 3050074, Japan.		Kaul, Sunil C/L-8671-2018	Kaul, Sunil C/0000-0002-0046-3916				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cao TY, 1998, J CELL SCI, V111, P1319; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang EY, 2000, GENE DEV, V14, P45; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kao HY, 2000, GENE DEV, V14, P55; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEVINS JR, 1992, SCIENCE, V258, P424; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PAGGI MG, 1995, CANCER RES, V55, P4552; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	32	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43491	43494		10.1074/jbc.C100532200	http://dx.doi.org/10.1074/jbc.C100532200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11583987	hybrid			2022-12-27	WOS:000172297700002
J	O'Connell, S; Wang, LJ; Robert, S; Jones, CA; Saint, R; Jones, RS				O'Connell, S; Wang, LJ; Robert, S; Jones, CA; Saint, R; Jones, RS			Polycomblike PHD fingers mediate conserved interaction with enhancer of zeste protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITHORAX GROUP GENES; DROSOPHILA-MELANOGASTER; SEQUENCE SIMILARITY; BMI-1 PROTOONCOGENE; PATTERN-FORMATION; BINDING-PROTEIN; SEX COMBS; COMPLEXES; EXPRESSION; CONTAINS	The products of Polycomb group (PcG) genes are required for the epigenetic repression of a number of important developmental regulatory genes, including homeotic genes. Enhancer of zeste (E(Z)) is a Drosophila PcG protein that previously has been shown to bind directly to another PcG protein, Extra Sex Combs (ESC), and is present along with ESC in a 600-kDa complex in Drosophila embryos. Using yeast two-hybrid and in vitro binding assays, we show that E(Z) binds directly to another PcG protein, Polycomblike (PCL). PCL-E(Z) interaction is shown to be mediated by the plant homeodomain (PHD) fingers domain of PCL, providing evidence that this motif can act as an independent protein interaction domain. An association was also observed between PHF1 and EZH2, human homologs of PCL and E(Z), respectively, demonstrating the evolutionary conservation of this interaction. EM was found to not interact with the PHD domains of three Drosophila trithorax group (trxG) proteins, which function to maintain the transcriptional activity of homeotic genes, providing evidence for the specificity of the interaction of E(Z) with the PCL PHD domain. Coimmunoprecipitation and gel filtration experiments demonstrate in vivo association of PCL with EM and ESC in Drosophila embryos. We discuss the implications of PCL association with ESC.E(Z) complexes and the possibility that PCL may either be a subunit of a subset of ESC.E(Z) complexes or a subunit of a separate complex that interacts with ESC.E(Z) complexes.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	Southern Methodist University; University of Adelaide; University of Adelaide	Saint, R (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	robert.saint@adelaide.edu.au; rjones@mail.smu.edu	Saint, Robert/A-4190-2008	Saint, Robert/0000-0002-7989-6043				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Adamson AL, 1996, GENETICS, V144, P621; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BREEN TR, 1986, DEV BIOL, V118, P442, DOI 10.1016/0012-1606(86)90015-1; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CAMPBELL RB, 1995, MOL GEN GENET, V246, P291, DOI 10.1007/BF00288601; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Chen HM, 1996, GENOMICS, V38, P30, DOI 10.1006/geno.1996.0588; CHENG NSN, 1994, GENETICS, V138, P1151; Coulson M, 1998, GENOMICS, V48, P381, DOI 10.1006/geno.1997.5201; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Gildea JJ, 2000, GENETICS, V156, P645; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; JONES RS, 1990, GENETICS, V126, P185; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; LAWRENCE PA, 1983, CELL, V35, P27, DOI 10.1016/0092-8674(83)90204-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LONIE A, 1994, DEVELOPMENT, V120, P2629; Mueller Juerg, 1995, Development (Cambridge), V121, P2847; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PHILLIPS MD, 1990, GENETICS, V125, P91; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SHEARN A, 1989, GENETICS, V121, P517; SHEARN A, 1978, GENETICS, V89, P341; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1992, DEVELOPMENT, V114, P493; SOTO MC, 1995, GENETICS, V140, P231; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; Tie F, 1998, DEVELOPMENT, V125, P3483; Tie F, 2001, DEVELOPMENT, V128, P275; Tripoulas N, 1996, GENETICS, V143, P913; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	53	86	93	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43065	43073		10.1074/jbc.M104294200	http://dx.doi.org/10.1074/jbc.M104294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11571280	hybrid			2022-12-27	WOS:000172169300058
J	Burma, S; Chen, BP; Murphy, M; Kurimasa, A; Chen, DJ				Burma, S; Chen, BP; Murphy, M; Kurimasa, A; Chen, DJ			ATM phosphorylates histone H2AX in response to DNA double-strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; EXPRESSION; LYMPHOMA; DAMAGE; REPAIR; CELLS	A very early step in the response of mammalian cells to DNA double-strand breaks is the phosphorylation of histone H2AX at serine 139 at the sites of DNA damage. Although the phosphatidylinositol 3-kinases, DNA-PK (DNA-dependent protein kinase), ATM (ataxia telangiectasia mutated), and ATR (ATM and Rad3-related), have all been implicated in H2AX phosphorylation, the specific kinase involved has not yet been identified. To definitively identify the specific kinase(s) that phosphorylates H2AX in vivo, we have utilized DNA-PKcs -/- and Atm-/- cell lines and mouse embryonic fibroblasts. We find that H2AX phosphorylation and nuclear focus formation are normal in DNA-PKes-/- cells and severely compromised in Atm-/- cells. We also find that ATM can phosphorylate H2AX in vitro and that ectopic expression of ATM in Atm-/- fibroblasts restores H2AX phosphorylation in vivo. The minimal H2AX phosphorylation in Atm-/- fibroblasts can be abolished by low concentrations of wortmannin suggesting that DNA-PK, rather than ATR, is responsible for low levels of H2AX phosphorylation in the absence of ATM. Our results clearly establish ATM as the major kinase involved in the phosphorylation of H2AX and suggest that ATM is one of the earliest kinases to be activated in the cellular response to double-strand breaks.	Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Chen, DJ (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA050519, R37CA050519] Funding Source: NIH RePORTER; NCI NIH HHS [CA50519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sarkaria JN, 1998, CANCER RES, V58, P4375; SKOG S, 1992, ANTI-CANCER DRUG, V3, P379, DOI 10.1097/00001813-199208000-00011; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 2000, METH MOL B, V99, P99	28	1411	1457	3	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42462	42467		10.1074/jbc.C100466200	http://dx.doi.org/10.1074/jbc.C100466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11571274	Green Submitted, hybrid			2022-12-27	WOS:000172450400118
J	Brooun, A; Richman, DD; Kornbluth, RS				Brooun, A; Richman, DD; Kornbluth, RS			HIV-1 preintegration complexes preferentially integrate into longer target DNA molecules in solution as detected by a sensitive, polymerase chain reaction-based integration assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL NUCLEIC-ACIDS; RETROVIRAL DNA; CDNA INTEGRATION; STRAND-TRANSFER; PROTEIN; AUTOINTEGRATION; ORGANIZATION; EXPRESSION; INHIBITORS	After entering a cell and undergoing reverse transcription, the retroviral genome is contained in a preintegration complex (PIC) that mediates its integration into host cell DNA. PICs have been shown to prefer torsionally strained DNA, but the effect of target DNA length has not been previously examined. In this report, concatemerization of a repeating 105-base pair unit was used to vary target DNA length independently from basic DNA sequence, while maintaining both PICs and target DNAs in solution. Integration junctions were quantified by real-time fluorescence-monitored polymerase chain reaction amplification using primers in the viral long terminal repeat and the target DNA. Unreacted target DNA severely inhibited the post-reaction polymerase chain reaction detection step, requiring its removal using lambda exonuclease digestion. Integration into a 32-unit concatemer of target DNA was markedly more efficient than integration into a monomeric unit, indicating that longer target DNA was preferred. This substrate was used to construct a simple, robust, and adaptable assay that can serve as a method for studying the host cell factors that enhance PIC integration, and as a drug discovery platform for integration inhibitors active against PICs.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Kornbluth, RS (corresponding author), Univ Calif San Diego, Dept Med, 0679,9500 Gilman Dr, La Jolla, CA 92093 USA.	rkornbluth@ucsd.edu		Kornbluth, Richard/0000-0002-0218-2026	NHLBI NIH HHS [HL 57911] Funding Source: Medline; NIAID NIH HHS [AI 25316, AI 36214, AI 07384] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025316, P30AI036214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; Bor YC, 1996, VIROLOGY, V222, P283, DOI 10.1006/viro.1996.0422; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; FARNET CM, 1991, J VIROL, V65, P6942, DOI 10.1128/JVI.65.12.6942-6952.1991; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Hansen MST, 1999, NAT BIOTECHNOL, V17, P578, DOI 10.1038/9886; Hansen MST, 1998, GENET ENG P, V20, P41; HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Kainz P, 2000, BBA-GENE STRUCT EXPR, V1494, P23, DOI 10.1016/S0167-4781(00)00200-1; Kainz P, 2000, BIOTECHNIQUES, V28, P278, DOI 10.2144/00282st04; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MILLER MD, 1995, CURR BIOL, V5, P1047, DOI 10.1016/S0960-9822(95)00209-0; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; PRINCE JT, 1995, BIOCHEMISTRY-US, V34, P10879, DOI 10.1021/bi00034a022; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Shibagaki Y, 1997, J BIOL CHEM, V272, P8361, DOI 10.1074/jbc.272.13.8361; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; Wei SQ, 1997, EMBO J, V16, P7511, DOI 10.1093/emboj/16.24.7511; Winkler S, 2000, BIOCHEMISTRY-US, V39, P12739, DOI 10.1021/bi001335w; Winkler S, 1999, INT J BIOL MACROMOL, V24, P265, DOI 10.1016/S0141-8130(98)00088-9; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995	37	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46946	46952		10.1074/jbc.M108000200	http://dx.doi.org/10.1074/jbc.M108000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595745	hybrid			2022-12-27	WOS:000172768500038
J	Fuku, A; Inoue, N; Matsumoto, M; Nomura, M; Yamada, K; Matsuda, Y; Toyoshima, K; Seya, T				Fuku, A; Inoue, N; Matsumoto, M; Nomura, M; Yamada, K; Matsuda, Y; Toyoshima, K; Seya, T			Molecular cloning and functional characterization of chicken toll-like receptors - A single chicken toll covers multiple molecular patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-SYSTEM; B-CELLS; DROSOPHILA TOLL; CUTTING EDGE; GENE; LIPOPOLYSACCHARIDE; PROTEIN; RECOGNITION; ACTIVATION; LIPOPEPTIDE	Toll-like receptors (TLR) in the innate immune system have not been identified in non-mammalian vertebrates. Two types of TLR were cloned from a chicken bursa cDNA library using degenerate primers based on the consensus sequences of mouse and Drosophila Toll and designated as chicken TLR (chTLR) type 1 and type 2. Of the nine human TLRs reported to date, these chTLRs showed the highest homology to human TLR2. The extracellular regions of type 1 and type 2 contained a distinct similar to 200-amino acid stretch and were 45.3 and 46.3% homologous to that of human TLR2. The intracellular Toll/interleukin-1R homology domain of type I and type 2 was perfectly identical to each other and highly homologous (80.7%) to that of human TLR2. Both types were widely detected by reverse transcriptase-polymerase chain reaction and immunoblotting in various chicken organs, especially those rich in connective tissue. Both genes were mapped to chromosome 4q1.1, suggesting that they arose by gene duplication. By reporter gene assay, type 2 and to a lesser extent type 1, selectively signaled the presence of mycoplasma macrophage-activating lipopeptide-2/M161Ag in the human embryonic kidney 293 cell system. Cotransfection of type 2 and human CD14 or MD-2 into human embryonic kidney 293 cells allowed the response to Escherichia coli lipopolysaccharide (LPS), whereas type I did not signal LPS or any other microbial components tested. These results indicated that chTLR type 2 covers two major microbe patterns, lipoproteins and LPS, which are regulated by TLR2 and TLR4 in mammals. In oviparous animals, the duplicated TLRs in the pattern-recognition system may function for host-pathogen discrimination in a manner that is distinct from that in mammals.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan; Nara Inst Sci & Technol, Dept Mol Immunol, Nara 6310101, Japan; Osaka Univ, Dept Pharmaceut Sci, Div Environm Pharmacol, Suita, Osaka 5650022, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Div Biosci, Lab Cytogenet,Kita Ku, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Fac Sci, Chromosome Res Unit, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Nara Institute of Science & Technology; Osaka University; Hokkaido University; Hokkaido University	Seya, T (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan.		Seya, Tsukasa/A-4336-2012; Inoue, Naokazu/A-9911-2009	Inoue, Naokazu/0000-0002-6187-8293				Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Boyd Y, 2001, IMMUNOGENETICS, V52, P294, DOI 10.1007/s002510000268; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COOPER EL, 1992, SCAND J IMMUNOL, V35, P247, DOI 10.1111/j.1365-3083.1992.tb02857.x; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Goitsuka R, 1997, J IMMUNOL, V159, P3126; GOUBIN G, 1983, NATURE, V302, P114, DOI 10.1038/302114a0; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu JX, 1997, GENOME RES, V7, P693, DOI 10.1101/gr.7.7.693; Inoue N, 2001, J IMMUNOL, V166, P424, DOI 10.4049/jimmunol.166.1.424; INOUE N, 2001, SCAND J IMMUNOL, V54, P80; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Kaiser P, 2000, MICROBIOL-UK, V146, P3217, DOI 10.1099/00221287-146-12-3217; Kaufman J, 1999, NATURE, V401, P923, DOI 10.1038/44856; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MCMICHAEL A, 1999, IMMUNOBIOLOGY IMMUNE, P363; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Miura Y, 1998, BLOOD, V92, P2815, DOI 10.1182/blood.V92.8.2815.420k09_2815_2822; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Nishiguchi M, 2001, J IMMUNOL, V166, P2610, DOI 10.4049/jimmunol.166.4.2610; Nishimura H, 2001, IMMUNOLOGY, V103, P519, DOI 10.1046/j.1365-2567.2001.01263.x; Ogata H, 2000, J EXP MED, V192, P23, DOI 10.1084/jem.192.1.23; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rescigno M, 1999, IMMUNOL TODAY, V20, P200, DOI 10.1016/S0167-5699(98)01427-3; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Suzuki T, 1999, CYTOGENET CELL GENET, V87, P32, DOI 10.1159/000015388; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1	44	146	157	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47143	47149		10.1074/jbc.M103902200	http://dx.doi.org/10.1074/jbc.M103902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590137	hybrid			2022-12-27	WOS:000172768500064
J	Gao, Y; Xing, J; Streuli, M; Leto, TL; Zheng, Y				Gao, Y; Xing, J; Streuli, M; Leto, TL; Zheng, Y			Trp(56) of Rac1 specifies interaction with a subset of guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; RHO-GTPASES; ONCOGENIC DBL; GTP ANALOG; FAMILY; TRIO; PROTEIN; ACTIVATION; KINASE	Signaling specificity of Rho GTPase pathways is achieved in part by selective interaction between members of the Dbl family guanine nucleotide exchange factors (GEFs) and their Rho GTPase substrates. For example, Trio, GEF-H1, and Tiam1 are a subset of GEFs that specifically activate Rac1 but not the closely related Cdc42. The Rac1 specificity of these GEFs appears to be governed by Rac1-GEF binding interaction. To understand the detailed mechanism underlying the GEF specificity issue, we have analyzed a panel of chimeras made between Rac1 and Cdc42 and examined a series of point mutants of Racl made at the switch I, switch II, and beta (2)/beta (3) regions for their ability to interact with and to be activated by the GEFs. The results reveal that Rac1 residues of both the switch I and switch II regions are involved in GEF docking and GEF-mediated nucleotide disruption, because mutation of Asp(38), Asn(39), Gln(61), Tyr(64), or Arg(66)/Leu(67) into Ala results in the loss of GEF binding, whereas mutation at Tyr(32), Asp(65), or Leu(70)/ Ser(71) leads to the loss of GEF catalysis while retaining the binding capability. The region between amino acids 53-72 of Rac1 is required for specific recognition and activation by the GEFs, and Trp(56) in beta (3), appears to be the critical determinant. Introduction of Trp(56) to Cdc42 renders it fully responsive to the Rac-specific GEF in vitro and in cells. Further, a polypeptide derived from the beta (3) region of Rac1 including the Trp,56 residue serves as a specific inhibitor for Rac1 interaction with the GEFs. Taken together, these results indicate that Trp-56 is the necessary and sufficient determinant of Rac1 for discrimination by the subset of Rac1-specific GEFs and suggest that a compound mimicking Trp 56 action could be explored as an interfering reagent specifically targeting Rac1 activation.	Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Zheng, Y (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA.	yzheng@utmem.edu	Zheng, Yi/J-7235-2015; Xing, Jinchuan/A-2489-2012	Zheng, Yi/0000-0001-7089-6074; 	NIGMS NIH HHS [GM 53943, GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943, R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Awasaki T, 2000, NEURON, V26, P119, DOI 10.1016/S0896-6273(00)81143-5; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; De molina AR, 2001, INT J ONCOL, V19, P5; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; HART MJ, 1994, J BIOL CHEM, V269, P16992; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOVILLA N, 2001, IN PRESS ONCOGENE; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; VAN AL, 1997, GENE DEV, V11, P2295; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	41	83	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47530	47541		10.1074/jbc.M108865200	http://dx.doi.org/10.1074/jbc.M108865200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595749	hybrid			2022-12-27	WOS:000172768500112
J	Secher, T; Lenz, C; Cazzamali, G; Sorensen, G; Williamson, M; Hansen, GN; Svane, P; Grimmelikhuijzen, CJP				Secher, T; Lenz, C; Cazzamali, G; Sorensen, G; Williamson, M; Hansen, GN; Svane, P; Grimmelikhuijzen, CJP			Molecular cloning of a functional allatostatin gut/brain receptor and an allatostatin preprohormone from the silkworm Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPTERAN LEU-CALLATOSTATIN; PROTEIN-COUPLED RECEPTOR; DROSOPHILA-MELANOGASTER; GENOMIC ORGANIZATION; DEVELOPMENTAL REGULATION; DIPLOPTERA-PUNCTATA; FRONTAL GANGLION; GALANIN RECEPTOR; IDENTIFICATION; COCKROACH	The cockroach-type or A-type allatostatins are inhibitory insect neuropeptides with the C-terminal sequence Tyr/Phe-X-Phe-Gly-Leu-NH2. Here, we have cloned an A-type allatostatin receptor from the silkworm Bombyx mori (BAR). BAR is 361 amino acid residues long, has seven transmembrane domains, shows 60% amino acid residue identity with the first Drosophila allatostatin receptor (DAR-1), and 48%, identity with the second Drosophila allatostatin receptor (DAR-2). The BAR gene has two introns and three exons. These two introns coincide with and have the same intron phasing as two introns in the DAR-1 and DAR-2 genes, showing that the three receptors are not only structurally but also evolutionarily related. Furthermore, we have cloned a Boinbyx allatostatin preprohormone that contains eight different A. type allatostatins. Chinese hamster ovary cells permanently transfeeted with BAR DNA react on the addition of 4 x 10(-9)M Bombyx A-type allatostatins with a second messenger cascade (measured as bioluminescence), showing that BAR is a functional A-type allatostatin receptor. Southern blots suggest that Bombyx has at least one other BAR-related gene in addition to the BAR gene described in this paper. Northern blots and quantitative reverse transcriptase-polymerase chain reaction of different larval tissues show that BAR mRNA is mainly expressed in the gut and to a much lesser extent in the brain. To our knowledge, this is the first report on the molecular cloning and functional expression of an insect gut/brain peptide hormone receptor.	Univ Copenhagen, Inst Zool, Dept Cell Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen	Grimmelikhuijzen, CJP (corresponding author), Univ Copenhagen, Inst Zool, Dept Cell Biol, Univ Pk 15, DK-2100 Copenhagen, Denmark.			Grimmelikhuijzen, Cornelis Johannes Pieter/0000-0001-6486-2046				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Audsley N, 2000, J COMP NEUROL, V424, P37, DOI 10.1002/1096-9861(20000814)424:1&lt;37::AID-CNE3&gt;3.0.CO;2-9; Auerswald L, 2001, BIOCHEM BIOPH RES CO, V282, P904, DOI 10.1006/bbrc.2001.4659; Bendena WG, 1999, ANN NY ACAD SCI, V897, P311, DOI 10.1111/j.1749-6632.1999.tb07902.x; Bendena WG, 1997, ANN NY ACAD SCI, V814, P53, DOI 10.1111/j.1749-6632.1997.tb46144.x; Birgul N, 1999, EMBO J, V18, P5892, DOI 10.1093/emboj/18.21.5892; Bowser PRF, 2000, GEN COMP ENDOCR, V119, P1, DOI 10.1006/gcen.2000.7483; Davey M, 1999, INSECT BIOCHEM MOLEC, V29, P1119, DOI 10.1016/S0965-1748(99)00092-2; Davis NT, 1997, J COMP NEUROL, V385, P265, DOI 10.1002/(SICI)1096-9861(19970825)385:2<265::AID-CNE6>3.0.CO;2-#; Duve H, 1997, PEPTIDES, V18, P1301, DOI 10.1016/S0196-9781(97)00188-5; Duve H, 1997, CELL TISSUE RES, V289, P73, DOI 10.1007/s004410050853; Duve H, 1999, J COMP NEUROL, V413, P405, DOI 10.1002/(SICI)1096-9861(19991025)413:3&lt;405::AID-CNE4&gt;3.0.CO;2-R; Duve H, 2000, CELL TISSUE RES, V300, P153, DOI 10.1007/s004410050056; East P, 1996, REGUL PEPTIDES, V67, P1, DOI 10.1016/S0167-0115(96)00109-7; Eriksen KK, 2000, GENOME RES, V10, P924, DOI 10.1101/gr.10.7.924; Hauser F, 1998, BIOCHEM BIOPH RES CO, V249, P822, DOI 10.1006/bbrc.1998.9230; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P1126, DOI 10.1006/bbrc.2000.3062; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P571, DOI 10.1006/bbrc.2000.2964; Lenz C, 2000, BIOCHEM BIOPH RES CO, V269, P91, DOI 10.1006/bbrc.2000.2251; Lorenz MW, 2000, INSECT BIOCHEM MOLEC, V30, P711, DOI 10.1016/S0965-1748(00)00042-4; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Parker EM, 1995, MOL BRAIN RES, V34, P179, DOI 10.1016/0169-328X(95)00159-P; Pratt GE, 1997, J INSECT PHYSIOL, V43, P627, DOI 10.1016/S0022-1910(97)00022-X; PRATT GE, 1991, P NATL ACAD SCI USA, V88, P2412, DOI 10.1073/pnas.88.6.2412; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Tazima Y, 1978, SILKWORM IMPORTANT L; Veelaert D, 1996, MOL CELL ENDOCRINOL, V122, P183, DOI 10.1016/0303-7207(96)03889-0; Wang S, 1997, MOL PHARMACOL, V52, P337, DOI 10.1124/mol.52.3.337; WEAVER RJ, 2000, RECENT ADV ARTHROPOD, P3; Williamson M, 2001, BIOCHEM BIOPH RES CO, V282, P124, DOI 10.1006/bbrc.2001.4565; Williamson M, 2001, BIOCHEM BIOPH RES CO, V281, P544, DOI 10.1006/bbrc.2001.4402	34	64	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47052	47060		10.1074/jbc.M106675200	http://dx.doi.org/10.1074/jbc.M106675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590150	hybrid			2022-12-27	WOS:000172768500052
J	Snyder, JT; Rossman, KL; Baumeister, MA; Pruitt, WM; Siderovski, DP; Der, CJ; Lemmon, MA; Sondek, J				Snyder, JT; Rossman, KL; Baumeister, MA; Pruitt, WM; Siderovski, DP; Der, CJ; Lemmon, MA; Sondek, J			Quantitative analysis of the effect of phosphoinositide interactions on the function of Dbl family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PLECKSTRIN-HOMOLOGY-DOMAIN; HIGH-AFFINITY BINDING; CRYSTAL-STRUCTURE; RHO-FAMILY; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SIGNAL-TRANSDUCTION; MEMBRANE-BINDING; KINETIC-ANALYSIS; STRUCTURAL BASIS	Normally, Rho GTPases are activated by the removal of bound GDP and the concomitant loading of GTP catalyzed by members of the Db1 family of guanine nucleotide exchange factors (GEFs). This family of GEFs invariantly contain a Db1 homology (DH) domain adjacent to a pleckstrin homology (PH) domain, and while the DH domain usually is sufficient to catalyze nucleotide exchange, possible roles for the conserved PH domain remain ambiguous. Here we demonstrate that the conserved PH domains of three distinct Db1 family proteins, intersectin, Dbs, and Tiam1, selectively bind lipid vesicles only when phosphoinositides are present. While the PH domains of intersectin and Dbs promiscuously bind several multiphosphorylated phosphoinositides, Tiam1 selectively interacts with phosphatidylinositol 3-phosphate (K-D similar to5-10 muM). In addition, and in contrast to recent reports, catalysis of nucleotide exchange on nonprenylated Rac1 provided by various extended portions of Tiam1 is not influenced by (a) soluble phosphoinositide head groups, (b) dibutyl versions of phosphoinositides, or (c) lipid vesicles containing phosphoinositides. Likewise, GEF activity afforded by DH/PH fragments of intersectin and Dbs are also not altered by phosphoinositide interactions. These results strongly suggest that unless all relevant components are localized to a lipid membrane surface, Db1 family GEFs generally are not intrinsically modulated by binding phosphoinositides.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Penn, Sch Med, Johnson Fdn, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; University of Pennsylvania	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.	sondek@med.unc.edu	Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Lemmon, Mark/0000-0002-3379-5319; Sondek, John/0000-0002-1127-8310; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA92240] Funding Source: Medline; NIGMS NIH HHS [R01-GM56846, GM62299, R01 GM056846, GM57391] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299, R01GM057391, R01GM056846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER W, 1994, BIOCHEMISTRY-US, V33, P11875, DOI 10.1021/bi00205a025; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 1999, BRIT J CANCER, V80, P25; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Jin LH, 1999, BIOCHEMISTRY-US, V38, P15659, DOI 10.1021/bi9916729; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	53	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45868	45875		10.1074/jbc.M106731200	http://dx.doi.org/10.1074/jbc.M106731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577097	Green Published, hybrid			2022-12-27	WOS:000172573100051
J	Price, RD; Weiner, DM; Chang, MSS; Sanders-Bush, E				Price, RD; Weiner, DM; Chang, MSS; Sanders-Bush, E			RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G(13) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND INTRACELLULAR LOOP; MUSCARINIC ACETYLCHOLINE-RECEPTOR; INVERSE AGONIST ACTIVITY; HIGH-THROUGHPUT ASSAYS; STRESS FIBER FORMATION; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; CHIMERIC RECEPTORS; COUPLED RECEPTORS; CYTOPLASMIC LOOP	The recent completion of the human genome predicted the presence of only 30,000 genes, stressing the importance of mechanisms that increase molecular diversity at the post-transcriptional level. One such posttranscriptional event is RNA editing, which generates multiple protein isoforms from a single gene, often with profound functional consequences. The human serotonin 5-HT2C receptor undergoes RNA editing that creates multiple receptor isoforms. One consequence of RNA editing of cell surface receptors may be to alter the pattern of activation of heterotrimeric G-proteins and thereby shift preferred intracellular signaling pathways. We examined the ability of the nonedited 5-HT2C receptor isoform (INI) and two extensively edited isoforms, VSV and VGV, to interact with various G-protein a subunits. Two functional assays were utilized: the cell-based functional assay, Receptor Selection/Amplification Technology, in which the pharmacological consequences of co-expression of 5HT(2C) receptor isoforms with G-protein a subunits in fibroblasts were studied, and 5HT(2C) receptor-mediated rearrangements of the actin cytoskeleton in stable cell lines. These studies revealed that the nonedited 5-HT2C receptor functionally couples to G(q) and G(13). In contrast, coupling to G(13) was not detected for the extensively edited 5-HT2C receptors. Thus, RNA editing represents a novel mechanism for regulating the pattern of activation of heterotrimeric G-proteins, molecular switches that control an enormous variety of biological processes.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; ACADIA Pharmaceut, La Jolla, CA 92121 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92121 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92121 USA	Vanderbilt University; University of California System; University of California San Diego; University of California System; University of California San Diego	Sanders-Bush, E (corresponding author), Vanderbilt Univ, Dept Pharmacol, 459 Preston Res Bldg, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034007, R01MH034007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07623] Funding Source: Medline; NIMH NIH HHS [MH34007] Funding Source: Medline; NINDS NIH HHS [NS35891] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; Burstein ES, 1997, J NEUROCHEM, V68, P525; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Egan C, 2000, SYNAPSE, V35, P144, DOI 10.1002/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.3.CO;2-B; Fitzgerald LW, 1999, NEUROPSYCHOPHARMACOL, V21, pS82, DOI 10.1038/sj.npp.1395328; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Grotewiel MS, 1999, N-S ARCH PHARMACOL, V359, P21, DOI 10.1007/PL00005318; HAMM HE, 1994, METHOD ENZYMOL, V237, P423; Herrick-Davis K, 2000, J PHARMACOL EXP THER, V295, P226; Herrick-Davis K, 1999, J NEUROCHEM, V73, P1711, DOI 10.1046/j.1471-4159.1999.731711.x; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MESSIER TL, 1995, PHARMACOL TOXICOL, V76, P308, DOI 10.1111/j.1600-0773.1995.tb00152.x; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; Niswender CM, 1998, ANN NY ACAD SCI, V861, P38, DOI 10.1111/j.1749-6632.1998.tb10171.x; Niswender CM, 2001, NEUROPSYCHOPHARMACOL, V24, P478, DOI 10.1016/S0893-133X(00)00223-2; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Price RD, 2000, MOL PHARMACOL, V58, P859, DOI 10.1124/mol.58.4.859; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sanders-Bush Elaine, 1995, P431; Sodhi MS, 2001, MOL PSYCHIATR, V6, P373, DOI 10.1038/sj.mp.4000920; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; Wang YC, 1997, EXP BRAIN RES, V114, P321, DOI 10.1007/PL00005640; Weiner DM, 2001, J PHARMACOL EXP THER, V299, P268; Wurch T, 2000, J NEUROCHEM, V75, P1180, DOI 10.1046/j.1471-4159.2000.0751180.x; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	45	85	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44663	44668		10.1074/jbc.M106745200	http://dx.doi.org/10.1074/jbc.M106745200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572865	hybrid			2022-12-27	WOS:000172406700045
J	You, YH; Lee, DH; Yoon, JH; Nakajima, S; Yasui, A; Pfeifer, GP				You, YH; Lee, DH; Yoon, JH; Nakajima, S; Yasui, A; Pfeifer, GP			Cyclobutane pyrimidine dimers are responsible for the vast majority of mutations induced by UVB irradiation in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; DNA-POLYMERASE-ETA; ESCHERICHIA-COLI; SKIN-CANCER; CIS-SYN; IN-VIVO; ULTRAVIOLET-LIGHT; 6-4 PHOTOPRODUCT; SOS CONDITIONS; INDUCED CC	The most prevalent DNA lesions induced by UVB are the cyclobutane pyrimidine dimers (CPDs) and the pyrimidine (6-4) pyrimidone photoproducts ((6-4)PPs). It has been a long standing controversy as to which of these photoproduct is responsible for mutations in mammalian cells. Here we have introduced photoproduct-specific DNA photolyases into a mouse cell line carrying the transgenic mutation reporter genes lacI and cII. Exposure of the photolyase-expressing cell lines to photoreactivating light resulted in almost complete repair of either CPDs or (6-4)PPs within less than 3 h. The mutations produced by the remaining, nonrepaired photoproducts were scored. The mutant frequency in the cII gene after photoreactivation by CPD photolyase was reduced from 127 x 10(-5) to 34 x 10(-5) (background, 8-10 x 10(-5)). Photoreactivation with (6-4) photolyase did not lower the mutant frequency appreciably. In the lacI gene the mutant frequency after photoreactivation repair of CPDs was reduced from 148 x 10(-5) to 28 x 10(-5) (background, 6-10 x 10(-5)). Mutation spectra obtained with and without photoreactivation by CPD photolyase indicated that the remaining mutations were derived from background mutations, unrepaired CPDs, and other DNA photopoducts including perhaps a small contribution from (6-4)PPs. We conclude that CPDs are responsible for at least 80% of the UVB-induced mutations in this mammalian cell model.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi 98077, Japan	City of Hope; Beckman Research Institute of City of Hope; Tohoku University	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asahina H, 1999, MUTAT RES-DNA REPAIR, V435, P255, DOI 10.1016/S0921-8777(99)00051-8; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Chigancas V, 2000, CANCER RES, V60, P2458; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DOUKI T, 1994, BIOCHEMISTRY-US, V33, P11942, DOI 10.1021/bi00205a033; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; Drouin Regen, 1996, P37; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; FIX D, 1981, MOL GEN GENET, V182, P7, DOI 10.1007/BF00422759; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; GIBBS PEM, 1993, NUCLEIC ACIDS RES, V21, P4059, DOI 10.1093/nar/21.17.4059; Heddle JA, 1999, MUTAGENESIS, V14, P257, DOI 10.1093/mutage/14.3.257; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; JIANG N, 1993, BIOCHEMISTRY-US, V32, P472, DOI 10.1021/bi00053a011; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Kamiya H, 1998, NUCLEIC ACIDS RES, V26, P2611, DOI 10.1093/nar/26.11.2611; KIM ST, 1993, PHOTOCHEM PHOTOBIOL, V57, P895, DOI 10.1111/j.1751-1097.1993.tb09232.x; KOCHEVAR IE, 1990, BIOORGANIC PHOTOCHEM, V1, P274; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; Lehmann AR, 2000, GENE, V253, P1, DOI 10.1016/S0378-1119(00)00250-X; LEMAIRE DGE, 1993, BIOCHEMISTRY-US, V32, P2525, DOI 10.1021/bi00061a009; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Marionnet C, 1998, CANCER RES, V58, P102; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Monroe JJ, 1998, MUTAT RES-FUND MOL M, V421, P121, DOI 10.1016/S0027-5107(98)00171-7; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nouspikel T, 2000, MOL CELL BIOL, V20, P1562, DOI 10.1128/MCB.20.5.1562-1570.2000; Otoshi E, 2000, CANCER RES, V60, P1729; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; PROTICSABLJIC M, 1986, MOL CELL BIOL, V6, P3349, DOI 10.1128/MCB.6.10.3349; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SETLOW RB, 1965, P NATL ACAD SCI USA, V53, P1111, DOI 10.1073/pnas.53.5.1111; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; Spatz A, 2001, CANCER RES, V61, P2480; Stuart GR, 2000, MUTAT RES-FUND MOL M, V452, P101, DOI 10.1016/S0027-5107(00)00058-0; Tanaka M, 2001, MUTAGENESIS, V16, P1, DOI 10.1093/mutage/16.1.1; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Tommasi S, 2000, NUCLEIC ACIDS RES, V28, P3991, DOI 10.1093/nar/28.20.3991; Tommasi S, 1997, CANCER RES, V57, P4727; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; Wallin H, 2000, MUTAT RES-FUND MOL M, V447, P317, DOI 10.1016/S0027-5107(99)00214-6; YAJIMA H, 1995, EMBO J, V14, P2393, DOI 10.1002/j.1460-2075.1995.tb07234.x; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Yasui A, 1998, BIOESSAYS, V20, P291, DOI 10.1002/(SICI)1521-1878(199804)20:4<291::AID-BIES5>3.0.CO;2-T; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001; Zhao XD, 1996, NUCLEIC ACIDS RES, V24, P1561, DOI 10.1093/nar/24.8.1561; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	70	207	218	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44688	44694		10.1074/jbc.M107696200	http://dx.doi.org/10.1074/jbc.M107696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572873	hybrid			2022-12-27	WOS:000172406700048
J	Baldwin, ME; Roufail, S; Halford, MM; Alitalo, K; Stacker, SA; Achen, MG				Baldwin, ME; Roufail, S; Halford, MM; Alitalo, K; Stacker, SA; Achen, MG			Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; VEGF-C; EXPRESSION PATTERN; CHIRONOMUS-TENTANS; TYROSINE KINASES; BALBIANI RING-3; TUMOR-CELLS; IN-VIVO; GENE; RECEPTOR	The secreted glycoprotein vascular endothelial growth factor-D (VEGF-D) is angiogenic, lymphangiogenic, and promotes metastatic spread of tumor cells via lymphatic vessels. VEGF-D consists of a receptor-binding domain (VEGF homology domain) and N- and G terminal propeptides. Proteolytic processing produces numerous forms of human VEGF-D, including fully processed derivatives (containing only the VEGF homology domain), partially processed, and unprocessed derivatives. Proteolysis is essential to generate human VEGF-D that binds the angiogenic receptor VEGF receptor-2 (VEGFR-2) and the lymphangiogenic receptor VEGFR-3 with high affinity. Here, we report that alternative use of an RNA splice donor site in exon 6 of the mouse VEGF-D gene produces two different protein isoforms, VEGF-D-358 and VEGF-D-326, with distinct C termini. The two isoforms were both expressed in all adult mouse tissues and embryonic stages of development analyzed. Both isoforms are proteolytically processed in a similar fashion to human VEGF-D to generate a range of secreted derivatives and bind and cross-link VEGFR-3 with similar potency. The isoforms are differently glycosylated when expressed in vitro. This study demonstrates that RNA splicing, protein glycosylation, and proteolysis are mechanisms for generating structural diversity of mouse VEGF-D.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Helsinki	Achen, MG (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Stacker, Steven/0000-0003-4096-9273; Achen, Marc/0000-0002-3791-803X				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM SS, 1990, GENE, V88, P133, DOI 10.1016/0378-1119(90)90024-L; Farnebo F, 1999, BIOCHEM BIOPH RES CO, V257, P891, DOI 10.1006/bbrc.1999.0562; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Jenkins NA, 1997, CHROMOSOME RES, V5, P502; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lymboussaki A, 2000, CURR TOP MICROBIOL, V251, P75; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Mattei MG, 1996, GENOMICS, V32, P168, DOI 10.1006/geno.1996.0098; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Paavonen K, 1996, CIRCULATION, V93, P1079, DOI 10.1161/01.CIR.93.6.1079; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; PAULSSON G, 1990, J MOL BIOL, V211, P331, DOI 10.1016/0022-2836(90)90355-P; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Rocchigiani M, 1998, GENOMICS, V47, P207, DOI 10.1006/geno.1997.5079; Saleh M, 1996, CANCER RES, V56, P393; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wei MH, 1996, HUM GENET, V97, P794; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	49	57	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44307	44314		10.1074/jbc.M106188200	http://dx.doi.org/10.1074/jbc.M106188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11574540	hybrid			2022-12-27	WOS:000172297700103
J	DeLuna, A; Avendano, A; Riego, L; Gonzalez, A				DeLuna, A; Avendano, A; Riego, L; Gonzalez, A			NADP-glutamate dehydrogenase isoenzymes of Saccharomyces cerevisiae - Purification, kinetic properties, and physiological roles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; GENES; ASSIMILATION; SYNTHASE; ENZYME; BIOSYNTHESIS; EXPRESSION	In the yeast Saccharomyces cerevisiae, two NADP(+)-dependent glutamate dehydrogenases (NADP-GDHs) encoded by GDH1 and GDH3 catalyze the synthesis of glutamate from ammonium and a-ketoglutarate. The GDH2-encoded NAD(+)-dependent glutamate dehydrogenase degrades glutamate producing ammonium and a-ketoglutarate. Until very recently, it was considered that only one biosynthetic NADP-GDH was present in S. cerevisiae. This fact hindered understanding the physiological role of each isoenzyme and the mechanisms involved in a-ketoglutarate channeling for glutamate biosynthesis. In this study, we purified and characterized the GDH1- and GDH3-encoded NADP-GDHs; they showed different allosteric properties and rates of a-ketoglutarate utilization. Analysis of the relative levels of these proteins revealed that the expression of GDH1 and GDH3 is differentially regulated and depends on the nature of the carbon source. Moreover, the physiological study of mutants lacking or overexpressing GDH1 or GDH3 suggested that these genes play nonredundant physiological roles. Our results indicate that the coordinated regulation of GDH1-, GDH3-, and GDH2-encoded enzymes results in glutamate biosynthesis and balanced utilization of a-ketoglutarate under fermentative and respiratory conditions. The possible relevance of the duplicated NADP-GDH pathway in the adaptation to facultative metabolism is discussed.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Genet Mol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Gonzalez, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Genet Mol, Apartado Postal 70-242, Mexico City 04510, DF, Mexico.		DeLuna, Alexander/H-9986-2016	DeLuna, Alexander/0000-0002-9236-2804; Riego-Ruiz, Lina/0000-0002-2883-8871				Avendano A, 1997, J BACTERIOL, V179, P5594, DOI 10.1128/jb.179.17.5594-5597.1997; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BENACHENHOULAHFA N, 1993, J MOL EVOL, V36, P335; Bonete MJ, 1996, BBA-GEN SUBJECTS, V1289, P14, DOI 10.1016/0304-4165(95)00134-4; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CAMARDELLA L, 1976, BIOCHIM BIOPHYS ACTA, V429, P324, DOI 10.1016/0005-2744(76)90280-1; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COGONI C, 1995, J BACTERIOL, V177, P792, DOI 10.1128/jb.177.3.792-798.1995; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P4455, DOI 10.1128/MCB.11.9.4455; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Dang VD, 1996, J BACTERIOL, V178, P1842, DOI 10.1128/jb.178.7.1842-1849.1996; Doherty D., 1970, METHODS ENZYMOLOGY A, V17, P850; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DUBOIS E, 1974, EUR J BIOCHEM, V48, P603, DOI 10.1111/j.1432-1033.1974.tb03803.x; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FUGE EK, 1994, J BACTERIOL, V176, P5802, DOI 10.1128/JB.176.18.5802-5813.1994; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GRENSON M, 1974, MOL GEN GENET, V128, P73, DOI 10.1007/BF00267295; GUTIERREZCIRLOS EB, 1994, J BIOL CHEM, V269, P9147; HOLZER H, 1957, BIOCHEM Z, V329, P361; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Janes BK, 2001, J BACTERIOL, V183, P2709, DOI 10.1128/JB.183.8.2709-2714.2001; KANG L, 1982, J BACTERIOL, V151, P29, DOI 10.1128/JB.151.1.29-35.1982; Kuruvilla FG, 2001, P NATL ACAD SCI USA, V98, P7283, DOI 10.1073/pnas.121186898; Kwast KE, 1998, J EXP BIOL, V201, P1177; LASCU I, 1977, BIOCHIM BIOPHYS ACTA, V482, P251, DOI 10.1016/0005-2744(77)90239-X; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MAZON MJ, 1979, J BACTERIOL, V139, P686; MILLER SM, 1990, J BACTERIOL, V172, P4927, DOI 10.1128/jb.172.9.4927-4935.1990; Minambres B, 2000, J BIOL CHEM, V275, P39529, DOI 10.1074/jbc.M005136200; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; Piskur J, 2001, TRENDS GENET, V17, P302, DOI 10.1016/S0168-9525(01)02308-3; Romero M, 2000, MICROBIOL-SGM, V146, P239, DOI 10.1099/00221287-146-1-239; ROON RJ, 1974, J BACTERIOL, V118, P89, DOI 10.1128/JB.118.1.89-95.1974; Sambrook J., 1989, MOL CLONING, pA1; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith E. L., 1975, ENZYMES, V11; TEMPEST DW, 1970, BIOCHEM J, V117, P405, DOI 10.1042/bj1170405; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Towbin H, 1992, Biotechnology, V24, P145; Valenzuela L, 1998, J BACTERIOL, V180, P3533, DOI 10.1128/JB.180.14.3533-3540.1998; VENARD R, 1975, EUR J BIOCHEM, V57, P371, DOI 10.1111/j.1432-1033.1975.tb02310.x; VERONESE FM, 1975, BIOCHIM BIOPHYS ACTA, V377, P217, DOI 10.1016/0005-2744(75)90304-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	50	119	129	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43775	43783		10.1074/jbc.M107986200	http://dx.doi.org/10.1074/jbc.M107986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562373	hybrid			2022-12-27	WOS:000172297700040
J	Ohtake, S; Ito, Y; Fukuta, M; Habuchi, O				Ohtake, S; Ito, Y; Fukuta, M; Habuchi, O			Human N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase cDNA is related to human B cell recombination activating gene-associated gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE-E; SEROSAL MAST-CELLS; MOUSE BONE-MARROW; SECRETORY GRANULES; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; EXPRESSION; PURIFICATION; PROTEINS; BINDING	N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase (Ga1NAc4S-6ST) transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate to position 6 of N-acetylgalactosamine 4-sulfate (Ga1NAc(4SO(4))) in chondroitin. sulfate and dermatan sulfate. We have previously purified the enzyme to apparent homogeneity from the squid cartilage. We report here cloning and characterization of human Ga1NAc4S-6ST. The strategy for identification of human Ga1NAc4S-6ST consisted of. 1) determination of the amino acid sequences of peptides derived from the purified squid Ga1NAc4S-6ST, 2) amplification of squid DNA by polymerase chain reaction, and 3) homology search using the amino acid sequence deduced from the squid DNA. The human Ga1NAc4S-6ST cDNA contains a single open reading frame that predicts a type H transmembrane protein composed of 561 amino acid residues. The recombinant protein expressed from the human Ga1NAc4S-6ST cDNA transferred sulfate from 3'-phosphoadenosine 5'-phosphosulfate to position 6 of the nonreducing terminal and internal Ga1NAc(4SO(4)) residues contained in chondroitin sulfate A and dermatan sulfate. When a trisaccharide and a pentasaccharide having sulfate groups at position 4 of N-acetylgalactosamine residues were used as acceptors, only nonreducing terminal Ga1NAc(4SO(4)) residues were sulfated. The nucleotide sequence of the human Ga1NAc4S-6ST cDNA was nearly identical to the sequence of human B cell recombination activating gene-associated gene.	Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan	Aichi University Education	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan.	ohabuchi@auecc.aichi-edu.ac.jp						ARUFFO A, 1998, CURRENT PROTOCOL S43, V3; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ELIAKIM R, 1986, P NATL ACAD SCI USA, V83, P461, DOI 10.1073/pnas.83.2.461; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HARADA T, 1967, J BIOL CHEM, V242, P2288; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; KATZ HR, 1986, J BIOL CHEM, V261, P3393; KAWAI Y, 1966, J BIOCHEM-TOKYO, V60, P317, DOI 10.1093/oxfordjournals.jbchem.a128438; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; KINSTON RE, 1996, CURRENT PROTOCOL S36, V1; KOBAYASHI S, 1985, BIOCHIM BIOPHYS ACTA, V841, P71, DOI 10.1016/0304-4165(85)90275-2; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; OHHASHI Y, 1984, BIOCHEM J, V217, P199, DOI 10.1042/bj2170199; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; Sakai T, 2000, THROMB RES, V100, P557, DOI 10.1016/S0049-3848(00)00365-0; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; Verkoczy LK, 1998, EUR J IMMUNOL, V28, P2839, DOI 10.1002/(SICI)1521-4141(199809)28:09<2839::AID-IMMU2839>3.0.CO;2-6; Verkoczy LK, 2000, J BIOL CHEM, V275, P20967, DOI 10.1074/jbc.M001866200; YAOITA E, 1990, J BIOL CHEM, V265, P522; Yuki M, 2000, ONCOL REP, V7, P1339	47	84	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43894	43900		10.1074/jbc.M104922200	http://dx.doi.org/10.1074/jbc.M104922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11572857	hybrid			2022-12-27	WOS:000172297700055
J	Okamoto, PM; Gamby, C; Wells, D; Fallon, J; Vallee, RB				Okamoto, PM; Gamby, C; Wells, D; Fallon, J; Vallee, RB			Dynamin isoform-specific interaction with the Shank/ProSAP scaffolding proteins of the postsynaptic density and actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; GTP-BINDING PROTEINS; SYNAPTIC TRANSMISSION; MAMMALIAN-CELLS; SH3 DOMAIN; DIFFERENTIAL EXPRESSION; MEDIATED ENDOCYTOSIS; GLUTAMATE RECEPTORS; DENDRITIC SPINES; NERVE-TERMINALS	Dynamin is a GTPase involved in endocytosis and other aspects of membrane trafficking. A critical function in the presynaptic compartment attributed to the brain-specific dynamin isoform, dynamin-1, is in synaptic vesicle recycling. We report that dynamin-2 specifically interacts with members of the Shank/ProSAP family of postsynaptic density scaffolding proteins and present evidence that dynamin-2 is specifically associated with the postsynaptic density. These data are consistent with a role for this otherwise broadly distributed form of dynamin in glutamate receptor down-regulation and other aspects of postsynaptic membrane turnover.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	University of Massachusetts System; University of Massachusetts Worcester; Brown University	Vallee, RB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 377 Plantat St, Worcester, MA 01605 USA.	Richard.Vallee@umassmed.edu			NCRR NIH HHS [P20 RR015578-020002, P20 RR015578] Funding Source: Medline; NIGMS NIH HHS [GM26701] Funding Source: Medline; NINDS NIH HHS [P01 NS039321-020002, P01 NS039321] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039321] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Estes PS, 1996, J NEUROSCI, V16, P5443; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Gold ES, 1999, J EXP MED, V190, P1849, DOI 10.1084/jem.190.12.1849; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GOSLIN GBA, 1991, RAT HIPPOCAMPAL NEUR, P339; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hunt CA, 1996, J NEUROSCI, V16, P1380; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; TUMA PL, 1993, J BIOL CHEM, V268, P17240; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463	70	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48458	48465		10.1074/jbc.M104927200	http://dx.doi.org/10.1074/jbc.M104927200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11583995	Green Accepted, hybrid			2022-12-27	WOS:000172927000098
J	Rundle, NT; Xu, L; Andersen, RJ; Roberge, M				Rundle, NT; Xu, L; Andersen, RJ; Roberge, M			G(2) DNA damage checkpoint inhibition and antimitotic activity of 13-hydroxy-15-oxozoapatlin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; PROTEIN-KINASE; RADIOSENSITIZING AGENT; CHROMOSOME ALIGNMENT; P34(CDC2) KINASE; TYROSINE KINASE; BHK CELLS; G2 ARREST; CAFFEINE; UCN-01	Checkpoints activated in response to DNA damage cause arrest in the G(1) and G(2) phases of the cell cycle. Inhibitors of the G(2) checkpoint may be used as tools to study this response and also to increase the effectiveness of DNA-damaging therapies against cancers lacking p53 function. Using a cell-based assay for G(2) check. point inhibitors, we have screened extracts from the NCI National Institutes of Health Natural Products Repository and have identified 13-hydroxy-15-oxozoapatlin (OZ) from the African tree Parinari curatellifolia. Flow cytometry with a mitosis-specific antibody showed that checkpoint inhibition by OZ was maximal at 10 muM, which released 20% of irradiated MCF-7 cells expressing defective p53 and 30% of irradiated HCT116p53(-/-) cells from G(2) arrest. OZ additively increased the response to the checkpoint inhibitors isogranulatimide and debromohymenialdisine, but it did not augment the effects of UCN-01 or caffeine. Unlike other checkpoint inhibitors, OZ did not inhibit ataxia-telangiectasia mutated (ATM), ATM and Rad3-related (ATR), Chk1, Chk2, Plk1, or Ser/Thr protein phosphatases in vitro. Treatment with OZ also caused G(2)-arrested and cycling cells to arrest in mitosis in a state resembling prometaphase. In these cells, the chromosomes were condensed and scattered over disordered mitotic spindles. The results demonstrate that OZ is both a G(2) checkpoint inhibitor and an antimitotic agent.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Oceanog Earth & Ocean Sci, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Roberge, M (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							Abe K, 1999, BRAIN RES, V837, P306, DOI 10.1016/S0006-8993(99)01658-3; Adams PD, 1998, CURR OPIN CELL BIOL, V10, P791, DOI 10.1016/S0955-0674(98)80123-3; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; BADEN DG, 1981, TOXICON, V19, P455, DOI 10.1016/0041-0101(81)90003-9; BRAYLAN RC, 1982, CYTOMETRY, V2, P337; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Busby EC, 2000, CANCER RES, V60, P2108; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; FAN SJ, 1995, CANCER RES, V55, P1649; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Garo E, 1997, HELV CHIM ACTA, V80, P538, DOI 10.1002/hlca.19970800218; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL L, 1994, COLD SPRING HARB SYM, V59, P259, DOI 10.1101/SQB.1994.059.01.030; Jiang XX, 2000, INT J ONCOL, V16, P971; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; KUPCHAN SM, 1975, J ORG CHEM, V40, P648, DOI 10.1021/jo00893a023; Lee IS, 1996, CHEM-BIOL INTERACT, V99, P193; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnor PM, 1997, CANCER SURV, V29, P151; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETTIT GR, 1982, CAN J CHEM, V60, P1374, DOI 10.1139/v82-202; POWELL SN, 1995, CANCER RES, V55, P1643; Roberge M, 1998, CANCER RES, V58, P5701; Robinson JP, 1993, HDB FLOW CYTOMETRY; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; ROWLEY R, 1984, RADIAT RES, V97, P178, DOI 10.2307/3576199; Russell KJ, 1996, INT J RADIAT ONCOL, V36, P1099, DOI 10.1016/S0360-3016(96)00432-4; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SUFFNESS M, 1982, J NAT PROD, V45, P1, DOI 10.1021/np50019a001; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455	51	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48231	48236		10.1074/jbc.M103990200	http://dx.doi.org/10.1074/jbc.M103990200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11572854	hybrid			2022-12-27	WOS:000172927000066
J	Hegde, SS; Javid-Majd, F; Blanchard, JS				Hegde, SS; Javid-Majd, F; Blanchard, JS			Overexpression and mechanistic analysis of chromosomally encoded aminoglycoside 2 '-N-acetyltransferase (AAC(2 ')-Ic) from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODIFYING ENZYMES; PROVIDENCIA-STUARTII; RESISTANCE; ANTIBIOTICS; GENES; GENTAMICIN	The chromosomally encoded aminoglycoside N-acetyltransferase, AAC(2')-Ic, of Mycobacterium tuberculosis has a yet unidentified physiological function. The aac(2')-Ic gene was cloned and expressed in Escherichia coli, and AAC(2')-Ic was purified. Recombinant AAC(2')-Ic was a soluble protein of 20,000 Da and acetylated all aminoglycosides substrates tested in vitro, including therapeutically important antibiotics. Acetyl-CoA was the preferred acyl donor. The enzyme, in addition to acetylating aminoglycosides containing 2'-amino substituents, also acetylated kanamycin A and amikacin that contain a 2'-hydroxyl substituent, although with lower activity, indicating the capacity of the enzyme to perform both N-acetyl and O-acetyl transfer. The enzyme exhibited "substrate activation" with many aminoglycoside substrates while exhibiting Michaelis-Menten kinetics with others. Kinetic studies supported a random kinetic mechanism for AAC(2')-Ic. Comparison of the kinetic parameters of different aminoglycosides suggested that their hexopyranosyl residues and, to a lesser extent, the central aminocyclitol residue carry the major determinants of substrate affinity.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Blanchard, JS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				PHS HHS [A133696] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ainsa JA, 1997, MOL MICROBIOL, V24, P431, DOI 10.1046/j.1365-2958.1997.3471717.x; Azucena E, 2001, DRUG RESIST UPDATE, V4, P106, DOI 10.1054/drup.2001.0197; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; Cleland W W, 1979, Methods Enzymol, V63, P103; COURVALIN P, 1980, J BACTERIOL, V143, P541, DOI 10.1128/JB.143.2.541-551.1980; Davies J, 1997, TRENDS MICROBIOL, V5, P234, DOI 10.1016/S0966-842X(97)01033-0; DAVIS BD, 1987, MICROBIOL REV, V51, P341, DOI 10.1128/MMBR.51.3.341-350.1987; Franklin K, 2001, ANTIMICROB AGENTS CH, V45, P2238, DOI 10.1128/AAC.45.8.2238-2244.2001; HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P249, DOI 10.1093/jac/8.4.249; Magnet S, 2001, BIOCHEMISTRY-US, V40, P3700, DOI 10.1021/bi002736e; MILLER GH, 1995, J CHEMOTHERAPY, V7, P31; Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P727, DOI 10.1128/AAC.43.4.727; Moore RA, 1999, ANTIMICROB AGENTS CH, V43, P465, DOI 10.1128/AAC.43.3.465; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; Payie KG, 1997, J BACTERIOL, V179, P4106, DOI 10.1128/jb.179.13.4106-4114.1997; RADHIKA K, 1984, J BIOL CHEM, V258, P12543; RADHIKA K, 1984, BIOCHEMISTRY-US, V23, P5118; RATHER PN, 1993, J BACTERIOL, V175, P6492, DOI 10.1128/jb.175.20.6492-6498.1993; Rather PN, 1998, DRUG RESIST UPDATE, V1, P285, DOI 10.1016/S1368-7646(98)80044-7; Rudant E, 1999, SYST APPL MICROBIOL, V22, P59, DOI 10.1016/S0723-2020(99)80028-9; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; TABER HW, 1987, MICROBIOL REV, V51, P439, DOI 10.1128/MMBR.51.4.439-457.1987; WILLIAMS JW, 1978, J BIOL CHEM, V253, P5908; WILLIAMS JW, 1978, J BIOL CHEM, V253, P5902; Wright GD, 1997, ANTIMICROB AGENTS CH, V41, P956, DOI 10.1128/AAC.41.5.956; Wright GD, 1999, CURR OPIN MICROBIOL, V2, P499, DOI 10.1016/S1369-5274(99)00007-7	26	71	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45876	45881		10.1074/jbc.M108810200	http://dx.doi.org/10.1074/jbc.M108810200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590162	hybrid			2022-12-27	WOS:000172573100052
J	Levavasseur, F; Miyadera, H; Sirois, J; Tremblay, ML; Kita, K; Shoubridge, E; Hekimi, S				Levavasseur, F; Miyadera, H; Sirois, J; Tremblay, ML; Kita, K; Shoubridge, E; Hekimi, S			Ubiquinone is necessary for mouse embryonic development but is not essential for mitochondrial respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; COENZYME-Q; CLK-1; PROTEIN; GENE	Ubiquinone (UQ) is a lipid found in most biological membranes and is a co-factor in many redox processes including the mitochondrial respiratory chain. UQ has been implicated in protection from oxidative stress and in the aging process. Consequently, it is used as a dietary supplement and to treat mitochondrial diseases. Mutants of the clk-1 gene of the nematode Caenorhabditis elegans are fertile and have an increased life span, although they do not produce UQ but instead accumulate a biosynthetic intermediate, demethoxyubiquinone (DMQ). DMQ appears capable to partially replace UQ for respiration in vivo and in vitro. We have produced a vertebrate model of cells and tissues devoid of UQ by generating a knockout mutation of the murine orthologue of clk-1 (mclk1). We find that mclk1-/- embryonic stem cells and embryos accumulate DMQ instead of UQ. As in the nematode mutant, the activity of the mitochondrial respiratory chain of -/- embryonic stem cells is only mildly affected (65% of wild-type oxygen consumption). However, mclk1-/- embryos arrest development at midgestation, although earlier developmental stages appear normal. These findings indicate that UQ is necessary for vertebrate embryonic development but suggest that mitochondrial respiration is not the function for which UQ is essential when DMQ is present.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Univ Tokyo, Dept Biomed Chem, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada	McGill University; University of Tokyo; McGill University; McGill University; McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.			Kita, Kiyoshi/0000-0002-0426-4308				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hekimi S, 2000, RES PRO CEL, V29, P81; Jiang N, 2001, J BIOL CHEM, V276, P29218, DOI 10.1074/jbc.M103686200; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Scott AE, 2001, TOXICOL APPL PHARM, V171, P149, DOI 10.1006/taap.2000.9115; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247	25	104	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46160	46164		10.1074/jbc.M108980200	http://dx.doi.org/10.1074/jbc.M108980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585841	hybrid			2022-12-27	WOS:000172573100091
J	Moore, LJ; Kiley, PJ				Moore, LJ; Kiley, PJ			Characterization of the dimerization domain in the FNR transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; ESCHERICHIA-COLI; GENE-EXPRESSION; 4FE-4S CLUSTER; COILED-COILS; PROTEIN; SULFUR; CONVERSION; REGULATOR; STABILITY	The global anaerobic regulator FNR from Escherichia coli is a dimeric Fe-S protein that is inactivated by O-2 through disruption of its [4Fe-4S] cluster and conversion to a monomeric form. As a first step in elucidating the molecular interactions that control FNR dimerization, we have performed alanine-scanning mutagenesis of a potential dimerization domain. Replacement of many hydrophobic residues (Met-143, Met-144, Leu-146, Met-147, Ile-151, Met-157, and Ile-158) and two charged residues (Arg-140 and Arg-145) with Ala decreased FNR activity in vivo. Size exclusion chromatography and Fe-S cluster analysis of three representative mutant proteins, FNR-M147A, FNR-I151A, and FNR-I158A, showed that the Ala substitutions produced specific defects in dimerization. Because hydrophobic side chains are known to stabilize subunit-subunit interactions between a-helices, we propose that Met-147, Ile-151, and Ile-158 lie on the same face of an a-helix that constitutes a dimerization interface. This alignment would also position Arg-140, Met-144, and Asp-154 on the same helical face. In support of the unusual positioning of a negatively charged residue at the dimer interface, we found that replacing Asp-154 with Ala repaired the defects caused by Ala substitutions of other residues located on the same helical face. These data also suggest that Asp-154 has an inhibitory effect on dimerization, which may be a key element in the control of FNR dimerization by O-2 availability.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Kiley, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave,574 Med Sci, Madison, WI 53706 USA.	pjkiley@facstaff.wisc.edu		Kiley, Patricia/0000-0002-8771-1782				Bates DM, 2000, J BIOL CHEM, V275, P6234, DOI 10.1074/jbc.275.9.6234; BATES DM, 1995, J BACTERIOL, V177, P3972, DOI 10.1128/jb.177.14.3972-3978.1995; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Guest John R., 1996, P317; HODGES RS, 1973, COLD SPRING HARB SYM, V37, P299, DOI 10.1101/SQB.1973.037.01.040; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOUNG JK, 1995, GENE DEV, V9, P2986, DOI 10.1101/gad.9.23.2986; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lamberg KE, 2000, MOL MICROBIOL, V38, P817, DOI 10.1046/j.1365-2958.2000.02172.x; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; Lee AI, 1999, J BACTERIOL, V181, P5309, DOI 10.1128/JB.181.17.5309-5316.1999; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PASCAL MC, 1986, FEMS MICROBIOL LETT, V36, P35; Patschkowski T, 2000, BACTERIAL STRESS RESPONSES, P61; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; SPIRO S, 1989, MOL MICROBIOL, V3, P601, DOI 10.1111/j.1365-2958.1989.tb00207.x; SPIRO S, 1987, J GEN MICROBIOL, V133, P3279; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; TROPSHA A, 1991, P NATL ACAD SCI USA, V88, P9488, DOI 10.1073/pnas.88.21.9488; VanSpanning RJM, 1997, MOL MICROBIOL, V23, P893, DOI 10.1046/j.1365-2958.1997.2801638.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZIEGLELHOFFER E, THESIS U WISCONSIN M	39	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45744	45750		10.1074/jbc.M106569200	http://dx.doi.org/10.1074/jbc.M106569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581261	hybrid			2022-12-27	WOS:000172573100034
J	Sass, E; Blachinsky, E; Karniely, S; Pines, O				Sass, E; Blachinsky, E; Karniely, S; Pines, O			Mitochondrial and cytosolic isoforms of yeast fumarase are derivatives of a single translation product and have identical amino termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-MALIC ACID; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; FUM1 GENE; PROTEIN; INITIATION; CLEAVAGE; PATHWAY; IMPORT; MOD5	We have previously proposed that a single translation product of the FUM1 gene encoding fumarase is distributed between the cytosol and mitochondria of Saccharomyces cerevisiae and that all fumarase translation products are targeted and processed in mitochondria before distribution. Alternative models for fumarase distribution have been proposed that require more than one translation product. In the current work (i) we show by using sequential Edman degradation and mass spectrometry that fumarase cytosolic and mitochondrial isoenzymes have an identical amino terminus that is formed by cleavage by the mitochondrial processing peptidase, (ii) we have generated fumarase mutants in which the second potential translation initiation codon (Met-24) has been substituted, yet the protein is processed efficiently and retains its ability to be distributed between the cytosol and mitochondria, and (iii) we show that although a signal peptide is required for fumarase targeting to mitochondria the specific fumarase signal peptide and the sequence immediately downstream to the cleavage site are not required for the dual distribution phenomenon. Our results are discussed in light of our model of fumarase targeting and distribution that suggests rapid folding into an import-incompetent state and retrograde movement of the processed protein back to the cytosol through the translocation pore.	Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Pines, O (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel.		Karniely, Sharon/AAN-7886-2021; pines, ophry/C-4086-2011	pines, ophry/0000-0001-7126-2575				Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; BLACHINSKY E, 2001, THESIS HEBREW U JERU; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; Haucke V, 1997, MOL CELL BIOL, V17, P4024, DOI 10.1128/MCB.17.7.4024; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; KANAREK L, 1964, J BIOL CHEM, V5, P465; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; Kurys G, 2000, J BIOL CHEM, V275, P30653, DOI 10.1074/jbc.M002373200; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; PELEG Y, 1990, APPL ENVIRON MICROB, V56, P2777, DOI 10.1128/AEM.56.9.2777-2783.1990; Pines O, 1996, APPL MICROBIOL BIOT, V46, P393, DOI 10.1007/s002530050835; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Rahali V, 1999, J PROTEIN CHEM, V18, P1, DOI 10.1023/A:1020635130077; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; SUZUKI T, 1992, EUR J BIOCHEM, V207, P767, DOI 10.1111/j.1432-1033.1992.tb17107.x; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; VESTLING MM, 1994, RAPID COMMUN MASS SP, V8, P786, DOI 10.1002/rcm.1290080925; Weitzman PDJ, 1969, METHOD ENZYMOL, V8, P22, DOI 10.1016/0076-6879(69)13009-8; Worthington CC, 1988, WORTHINGTON MANUAL; WU M, 1995, BIOCHEM BIOPH RES CO, V215, P578, DOI 10.1006/bbrc.1995.2504; WU M, 1987, J BIOL CHEM, V262, P12275	30	70	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46111	46117		10.1074/jbc.M106061200	http://dx.doi.org/10.1074/jbc.M106061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585823	hybrid			2022-12-27	WOS:000172573100085
J	Miles, RD; Iyer, PP; Ferry, JG				Miles, RD; Iyer, PP; Ferry, JG			Site-directed mutational analysis of active site residues in the acetate kinase from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN HEXOKINASE; MUTAGENESIS; BINDING; ATP; IDENTIFICATION; SUPERFAMILY; PROTEINS; HSC70; FOLD	Acetate kinase catalyzes the magnesium-dependent transfer of the gamma -phosphate of ATP to acetate. The recently determined crystal structure of the Methanosarcina thermophila enzyme identifies it as a member of the sugar kinase/Hsc70/actin superfamily based on the fold and the presence of five putative nucleotide and metal binding motifs that characterize the superfamily. Residues from four of these motifs in M. thermophila acetate kinase were selected for site-directed replacement and analysis of the variants. Replacement of Asp(148) and Asn(7) resulted in variants with catalytic efficiencies less than 1% of that of the wild-type enzyme, indicating that these residues are essential for activity. Glu(384) was also found to be essential for catalysis. A 30-fold increase in the magnesium concentration required for half-maximal activity of the E384A variant relative to that of the wild type implicated Glu(384) in magnesium binding. The kinetic analysis of variants and structural data is consistent with nonessential roles for active site residues Ser(10), Ser(12), and Lys(14) in catalysis. The results are discussed with respect to the acetate kinase catalytic mechanism and the relationship to other sugar kinase/Hsc70/actin superfamily members.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.							ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIJAL M, 1995, ARCH BIOCHEM BIOPHYS, V321, P413, DOI 10.1006/abbi.1995.1412; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buss KA, 2001, J BACTERIOL, V183, P680, DOI 10.1128/JB.183.2.680-686.2001; Buss KA, 1997, PROTEIN SCI, V6, P2659; Cane DE, 1996, BIOCHEMISTRY-US, V35, P12369, DOI 10.1021/bi961344y; CHEN X, 1995, J BIOL CHEM, V270, P11406, DOI 10.1074/jbc.270.19.11406; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FOX DK, 1986, J BIOL CHEM, V261, P3498; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; Hurley JH, 1996, ANNU REV BIOPH BIOM, V25, P137; Ingram-Smith C, 2000, J BIOL CHEM, V275, P33765, DOI 10.1074/jbc.M005303200; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; LIPMANN F, 1945, J BIOL CHEM, V159, P21; Lipmann F, 1944, J BIOL CHEM, V155, P55; Pettigrew DW, 1998, ARCH BIOCHEM BIOPHYS, V349, P236, DOI 10.1006/abbi.1997.0444; ROSE IA, 1954, J BIOL CHEM, V211, P737; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; Singh-Wissmann K, 2000, BIOCHEMISTRY-US, V39, P3671, DOI 10.1021/bi991998h; Singh-Wissmann K, 1998, J BACTERIOL, V180, P1129, DOI 10.1128/JB.180.5.1129-1134.1998; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; SPECTOR LB, 1980, P NATL ACAD SCI-BIOL, V77, P2626, DOI 10.1073/pnas.77.5.2626; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509; Zeng CB, 1998, J BIOL CHEM, V273, P700, DOI 10.1074/jbc.273.2.700	35	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45059	45064		10.1074/jbc.M108355200	http://dx.doi.org/10.1074/jbc.M108355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11562377	hybrid			2022-12-27	WOS:000172406700096
J	Seta, KA; Kim, R; Kim, HW; Millhorn, DE; Beitner-Johnson, D				Seta, KA; Kim, R; Kim, HW; Millhorn, DE; Beitner-Johnson, D			Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE-CELLS; CATALYTIC ACTIVATION; SELECTIVE ACTIVATION; ERYTHROPOIETIN GENE; SIGNALING PATHWAY; EXPRESSION; TRANSCRIPTION	Subtractive suppression hybridization was used to generate a cDNA library enriched in cDNA sequences corresponding to mRNA species that are specifically upregulated by hypoxia (6 h, 1% O-2) in the oxygen-responsive pheochromocytoma cell line. The dual specificity protein-tyrosine phosphatase (M) under bar AP (K) under bar (p) under bar hosphatase-(1) under bar (MKP-1) was highly represented in this library. Clones were arrayed on glass slides to create a hypoxia-specific cDNA microarray chip. Microarray, northern blot, and western blot analyses confirmed that MKP-1 mRNA and protein levels were up-regulated by hypoxia by similar to8-fold. The magnitude of the effect of hypoxia on MKP-1 was approximately equal to that induced by KCl depolarization and much larger than the effects of either epidermal growth factor or nerve growth factor on MKP-1 mRNA levels. In contrast to the calcium-dependent induction of MKP-1 by KCl depolarization, the effect of hypoxia on MKP-1 persisted under calcium-free conditions. Cobalt and deferoxamine also increased MKP-1 mRNA levels, suggesting that hypoxia-inducible factor proteins may play a role in the regulation of MKP-1 by hypoxia. Pretreatment of cells with SB203580, which inhibits p38 kinase activity, significantly reduced the hypoxia-induced increase in MKP-1 RNA levels. Thus, hypoxia robustly increases MKP-1 levels, at least in part through a p38 kinase-mediated mechanism.	Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Genome Res Inst, Cincinnati, OH 45267 USA	University of Cincinnati; University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, POB 67-0576, Cincinnati, OH 45267 USA.	david.millhorn@uc.edu			NHLBI NIH HHS [HL66312, HL59945, HL33831] Funding Source: Medline; NIDDK NIH HHS [DK58844] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL066312, R01HL059945, R01HL033831] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Burgun C, 2000, FEBS LETT, V484, P189, DOI 10.1016/S0014-5793(00)02153-0; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Jiang BH, 1997, CANCER RES, V57, P5328; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Martell KJ, 1998, MOL CELLS, V8, P2; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Millhorn DE, 2000, ADV EXP MED BIOL, V475, P131; Mishra RR, 1998, MOL BRAIN RES, V59, P74, DOI 10.1016/S0169-328X(98)00139-9; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PRABHAKAR NR, 1995, BRAIN RES, V697, P266, DOI 10.1016/0006-8993(95)00994-2; Rumora L, 2001, NEUROCHEM INT, V39, P25, DOI 10.1016/S0197-0186(01)00004-3; Sasaki H, 2001, J MOL CELL CARDIOL, V33, P283, DOI 10.1006/jmcc.2000.1299; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Sodhi A, 2000, CANCER RES, V60, P4873; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Wang GC, 2000, NUCLEIC ACIDS RES, V28, P2135, DOI 10.1093/nar/28.10.2135; WANG GL, 1993, BLOOD, V82, P3610; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Zawada WM, 2001, BRAIN RES, V891, P185; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	56	65	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44405	44412		10.1074/jbc.M103346200	http://dx.doi.org/10.1074/jbc.M103346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577072	hybrid			2022-12-27	WOS:000172406700009
J	Sonnenburg, ED; Gao, T; Newton, AC				Sonnenburg, ED; Gao, T; Newton, AC			The phosphoinositide-dependent kinase, PDK-1, phosphorylates conventional protein kinase C isozymes by a mechanism that is independent of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; DOWN-REGULATION; ACTIVATION; TRANSLOCATION; ALPHA; SITE; ZETA; PKC; AUTOPHOSPHORYLATION	Phosphorylation by the phosphoinositide-dependent kinase, PDK-1, is required for the activation of diverse members of the AGC family of protein kinases, including the protein kinase C (PKC) isozymes. Here we explore the subcellular location of the PDK-1-mediated phosphorylation of conventional PKCs, and we address whether this phosphorylation is regulated by phosphoinositide 3-kinase. Pulse-chase experiments reveal that newly synthesized endogenous PKC a is primarily phosphorylated in the membrane fraction of COS-7 cells, where it is processed to a species that is phosphorylated at the activation loop and at two carboxyl-terminal positions. This "mature" species is then released into the cytosol. Deletion of the plekstrin homology domain of PDK-1 results in a 4-fold increase in the rate of processing of PKC indicating an autoinhibitory role for this domain. Autoinhibition by the plekstrin homology domain is not relieved by binding 3'-phosphoinositides; PKC is phosphorylated at a similar rate in serum-treated cells and serum-starved cells treated with the phosphoinositide 3-kinase inhibitors, LY294002 and wortmannin. Under the same conditions, the PDK-1-catalyzed phosphorylation of another substrate, Akt/protein kinase B, is abolished by these inhibitors. Our data are consistent with a model in which PDK-1 phosphorylates newly synthesized PKC by a mechanism that is independent of 3'-phosphoinositides.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NIDDK NIH HHS [P01 DK54441] Funding Source: Medline; NIGMS NIH HHS [2T32 GM07752, GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R01GM043154, R37GM043154] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; England K, 2001, J BIOL CHEM, V276, P10437, DOI 10.1074/jbc.M009421200; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Gysin S, 1996, EUR J BIOCHEM, V240, P747, DOI 10.1111/j.1432-1033.1996.0747h.x; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li Y, 2001, J BIOL CHEM, V276, P20323, DOI 10.1074/jbc.M101309200; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Standaert ML, 2001, BIOCHEMISTRY-US, V40, P249, DOI 10.1021/bi0018234; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	40	99	102	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45289	45297		10.1074/jbc.M107416200	http://dx.doi.org/10.1074/jbc.M107416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579098	hybrid			2022-12-27	WOS:000172406700124
J	Nakamura, M; Barber, AJ; Antonetti, DA; LaNoue, KF; Robinson, KA; Buse, MG; Gardner, TW				Nakamura, M; Barber, AJ; Antonetti, DA; LaNoue, KF; Robinson, KA; Buse, MG; Gardner, TW			Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; MESANGIAL CELLS; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; DIABETIC-RETINOPATHY; KINASE-B; IN-VITRO; RESISTANCE; PROTEIN; PATHWAY	In addition to microvascular abnormalities, neuronal apoptosis occurs early in diabetic retinopathy, but the mechanism is unknown. Insulin may act as a neurotrophic factor in the retina via the phosphoinositide 3-kinase/Akt pathway. Excessive glucose flux through the hexosamine biosynthetic pathway (HBP) is implicated in the development of insulin resistance in peripheral tissues and diabetic complications such as nephropathy. We tested whether increased glucose flux through the HBP perturbs insulin action and induces apoptosis in retinal neuronal cells. Exposure of R28 cells, a model of retinal neurons, to 20 mm glucose for 24 h attenuated the ability of 10 mm insulin to rescue them from serum deprivation-induced apoptosis and to phosphorylate Akt compared with 5 mm glucose. Glucosamine not only impaired the neuroprotective effect of insulin but also induced apoptosis in R28 cells in a dose-dependent fashion. UDP-N-acetylhexosamines (UDP-HexNAc), end products of the HBP, were increased similar to2- and 15-fold after a 24-h incubation in 20 mm glucose and 1.5 nim glucosamine, respectively. Azaserine, a glutamine:fructose-6-phosphate amidotransferase inhibitor, reversed the effect of 20 rum glucose, but not that of 1.5 mm glucosamine, on attenuation of the ability of insulin to promote cell survival and phosphorylate Akt as well as accumulation of UDP-HexNAc. Glucosamine also impaired insulin receptor processing in a dose-dependent manner but did not decrease ATP content. By contrast, in L6 muscle cells, glucosamine impaired insulin receptor processing but did not induce apoptosis. These results suggest that the excessive glucose flux through the HBP may direct retinal neurons to undergo apoptosis in a bimodal fashion; i.e. via perturbation of the neuroprotective effect of insulin mediated by Akt and via induction of apoptosis possibly by altered glycosylation of proteins. The HBP may be involved in retinal neurodegeneration in diabetes.	Penn State Univ, Coll Med,Dept Ophthalmol, Ulerich Ophthalmol Res Ctr, Penn State Retina Res Grp, Hershey, PA 17033 USA; Penn State Univ, Coll Med,Dept Cellular & Mol Physiol, Ulerich Ophthalmol Res Ctr, Penn State Retina Res Grp, Hershey, PA 17033 USA; Med Univ S Carolina, Dept Med, Div Endocrinol Diab & Med Genet, Charleston, SC 29425 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Medical University of South Carolina	Gardner, TW (corresponding author), Penn State Univ, Coll Med,Dept Ophthalmol, Ulerich Ophthalmol Res Ctr, Penn State Retina Res Grp, 500 Univ Dr,H166, Hershey, PA 17033 USA.	tgardner@psu.edu		antonetti, david/0000-0003-1130-6577; Nakamura, Makoto/0000-0002-6464-4302; Barber, Alistair/0000-0003-4235-2293; Gardner, Thomas/0000-0002-5112-5810	NATIONAL EYE INSTITUTE [R01EY012021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK002001, R56DK002001] Funding Source: NIH RePORTER; NEI NIH HHS [EY12021] Funding Source: Medline; NIDDK NIH HHS [DK02001] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; BEKESI JG, 1969, J BIOL CHEM, V244, P3766; CHANG JY, 2000, NEUROTOXICOLOGY, V2, P601; Crook ED, 2000, ENDOCRINOLOGY, V141, P1962, DOI 10.1210/en.141.6.1962; DAVIDSON MB, 1994, BBA-GEN SUBJECTS, V1201, P113, DOI 10.1016/0304-4165(94)90159-7; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Gardner T W, 2000, Diabetes Technol Ther, V2, P601; Giardino I, 1998, DIABETES, V47, P1114, DOI 10.2337/diabetes.47.7.1114; GORDEN P, 1989, YALE J BIOL MED, V62, P521; HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hawkins M, 1999, J BIOL CHEM, V274, P31312, DOI 10.1074/jbc.274.44.31312; HEACOCK AM, 1982, BRAIN RES, V241, P307, DOI 10.1016/0006-8993(82)91068-X; Heart E, 2000, AM J PHYSIOL-ENDOC M, V278, pE103, DOI 10.1152/ajpendo.2000.278.1.E103; HEATH H, 1975, DIABETOLOGIA, V11, P57, DOI 10.1007/BF00422819; Heath H, 1967, Diabetologia, V3, P515, DOI 10.1007/BF01213570; HEDO JA, 1983, J BIOL CHEM, V258, P20; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; HUCK S, 1983, BRAIN RES BULL, V10, P667, DOI 10.1016/0361-9230(83)90036-9; James LR, 2000, AM J PHYSIOL-RENAL, V279, pF718, DOI 10.1152/ajprenal.2000.279.4.F718; Kang J, 2001, AM J PHYSIOL-ENDOC M, V280, pE428, DOI 10.1152/ajpendo.2001.280.3.E428; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Kumagai AK, 1999, DIABETES-METAB RES, V15, P261, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<261::AID-DMRR43>3.0.CO;2-Z; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; LEIST M, 1995, EUR J PHARM-ENVIRON, V292, P201, DOI 10.1016/0926-6917(95)90013-6; MAHER F, 1991, BIOCHIM BIOPHYS ACTA, V1089, P27, DOI 10.1016/0167-4781(91)90080-6; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MAZLEN RG, 1970, EXP EYE RES, V9, P1, DOI 10.1016/S0014-4835(70)80052-5; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Naeser P, 1997, UPSALA J MED SCI, V102, P35, DOI 10.3109/03009739709178930; Nawano M, 1999, BIOCHEM BIOPH RES CO, V266, P252, DOI 10.1006/bbrc.1999.1797; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P10; Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; RODRIGUES M, 1988, BRAIN RES, V443, P389, DOI 10.1016/0006-8993(88)91639-3; Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971; Seigel GM, 1996, IN VITRO CELL DEV-AN, V32, P66; SEIGEL GM, 2000, MOL VIS, V6, P21; Singh LP, 2001, J DIABETES COMPLICAT, V15, P88, DOI 10.1016/S1056-8727(00)00140-9; Singh LP, 2000, AM J PHYSIOL-RENAL, V279, pF646, DOI 10.1152/ajprenal.2000.279.4.F646; Song XM, 1999, DIABETES, V48, P664, DOI 10.2337/diabetes.48.3.664; Tang J, 2000, DIABETOLOGIA, V43, P1417, DOI 10.1007/s001250051548; TESORIERE G, 1975, BIOCHIM BIOPHYS ACTA, V385, P58, DOI 10.1016/0304-4165(75)90074-4; TESORIERE G, 1984, EXPERIENTIA, V40, P705, DOI 10.1007/BF01949733; TESORIERE G, 1971, EUR J BIOCHEM, V19, P289, DOI 10.1111/j.1432-1033.1971.tb01317.x; Tezel G, 1999, INVEST OPHTH VIS SCI, V40, P2660; TOLKOVSKY AM, 1987, J NEUROSCI, V7, P110; WALKER F, 1968, DIABETES, V17, P105, DOI 10.2337/diab.17.2.105; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	62	139	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43748	43755		10.1074/jbc.M108594200	http://dx.doi.org/10.1074/jbc.M108594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11560942	hybrid			2022-12-27	WOS:000172297700036
J	Ohtani, K; Suzuki, Y; Eda, S; Kawai, T; Kase, T; Keshi, H; Sakai, Y; Fukuoh, A; Sakamoto, T; Itabe, H; Suzutani, T; Gasawara, M; Yoshida, I; Wakamiya, N				Ohtani, K; Suzuki, Y; Eda, S; Kawai, T; Kase, T; Keshi, H; Sakai, Y; Fukuoh, A; Sakamoto, T; Itabe, H; Suzutani, T; Gasawara, M; Yoshida, I; Wakamiya, N			The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CARBOHYDRATE-RECOGNITION DOMAINS; PULMONARY SURFACTANT APOPROTEIN; MANNOSE-BINDING PROTEIN; BACTERICIDAL ACTIVITY; CLONING; MACROPHAGES; LIVER; VIRUS; IDENTIFICATION	Collectins are a family of C-type lectins that have collagen-like sequences and carbohydrate recognition domains (CRD). They are involved in host defense through their ability to bind to carbohydrate antigens of microorganisms. The scavenger receptors type A and MARCO are classical type scavenger receptors that have internal collagen-like domains. Here we describe a new scavenger receptor that is a membrane-type collectin from placenta (collectin placenta 1 (CL-P1)), which has a typical collectin collagen-like domain and a CRD. The cDNA has an insert of about 2.2 kilobases coding for a protein containing 742 amino acid residues. The deduced amino acid sequence shows that CL-P1 is a type II membrane protein, has a coiled-coil region, a collagen-like domain, and a CRD. It resembles type A scavenger receptors because the scavenger receptor cysteine-rich domain is replaced by a CRD. Northern analyses, reverse transcription-polymerase chain reaction, and immunohistochemistry show that CL-P1 is expressed in vascular endothelial cells but not in macrophages. By immunoblotting and flow cytometry CL-P1 appears to be a membrane glycoprotein of about 140 kDa in human umbilical vein or arterial endothelial cells, placental membrane extracts, and CL-P1 transfected Chinese hamster ovary cells. We found that CL-P1 can bind and phagocytose not only bacteria (Escherichia coli and Staphylococcus aureus) but also yeast (Saccharomyces cerevisiae). Furthermore, it reacts with oxidized low density lipoprotein (OxLDL) but not with acetylated LDL (AcLDL). These binding activities are inhibited by polyanionic ligands (polyinosinic acid, polyguanylic acid, dextran sulfate) and OxLDL but not by polycationic ligands (polyadenylic acid or polycytidylic acid), LDL, or AcLDL. These results indicate that CL-P1 might play important roles in host defenses that are different from those of soluble collectins in innate immunity.	Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan; Osaka Prefectural Inst Publ Hlth, Dept Pathol, Osaka 5370025, Japan; Osaka Prefectural Inst Publ Hlth, Dept Food Microbiol, Osaka 5370025, Japan; Osaka Prefectural Inst Publ Hlth, Dept Virol, Osaka 5370025, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 1990195, Japan	Asahikawa Medical College; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Osaka Prefectural Institute of Public Health; Teikyo University	Wakamiya, N (corresponding author), Asahikawa Med Coll, Dept Microbiol, Asahikawa, Hokkaido 0788510, Japan.		板部板部, 洋之/ABC-7746-2020; Suzuki, Yasuhiko/F-6890-2012					Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; HARTLEY CA, 1992, J VIROL, V66, P4358, DOI 10.1128/JVI.66.7.4358-4363.1992; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Itabe H, 1996, J BIOL CHEM, V271, P33208, DOI 10.1074/jbc.271.52.33208; Kawai T, 1997, GENE, V186, P161, DOI 10.1016/S0378-1119(96)00664-6; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; Laursen SB, 1998, IMMUNOLOGY, V93, P421, DOI 10.1046/j.1365-2567.1998.00446.x; Ling WH, 1997, J CLIN INVEST, V100, P244, DOI 10.1172/JCI119528; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SCHWEINLE JE, 1989, J CLIN INVEST, V84, P1821, DOI 10.1172/JCI114367; SHIMAMOTO A, 1997, SEIKAGAKU, V69, P574; STEPHAN ZF, 1993, J LIPID RES, V34, P325; Suzuki H, 1997, J Atheroscler Thromb, V4, P1; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; WAKAMIYA N, 1992, BIOCHEM BIOPH RES CO, V187, P1270, DOI 10.1016/0006-291X(92)90440-V; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; Yoshida H, 1998, BIOCHEM J, V334, P9, DOI 10.1042/bj3340009	34	161	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44222	44228		10.1074/jbc.M103942200	http://dx.doi.org/10.1074/jbc.M103942200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564734	hybrid, Green Submitted			2022-12-27	WOS:000172297700094
J	Okuda, H; Saitoh, K; Hirai, S; Iwai, K; Takaki, Y; Baba, M; Minato, N; Ohno, S; Shuin, T				Okuda, H; Saitoh, K; Hirai, S; Iwai, K; Takaki, Y; Baba, M; Minato, N; Ohno, S; Shuin, T			The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEOLYSIS; LIGASE COMPLEX; CELL-POLARITY; BETA-DOMAIN; PKC-LAMBDA; GENE; PRODUCT; CARCINOMA; BINDING; GROWTH	The von Hippel-Lindau tumor-suppressor protein (pVHL) forms a protein complex (VCB-Cul2) with elongin C, elongin B, Cul-2, and Rbx1, which functions as a ubiquitin-protein ligase (EU The a-subunits of the bypoxia-inducible factors have been identified as targets for the VCB-Cul2 ubiquitin ligase. However, a variety of cellular defects caused by the depletion of pVHL cannot be explained solely by the ubiquitin-mediated degradation of hypoxia-inducible factor-a. We show here that a member of the atypical protein kinase C (PKC) group, PKC lambda, is ubiquitinated by the pVHL-containing E3 enzyme. An active PKC lambda mutant is ubiquitinated more extensively than wild-type PKC lambda in HEK293 cells, and the ubiquitination is further enhanced by the overexpression of pVHL. The activation of wild-type PKC lambda by serum stimulation of cells enhances the ubiquitination of the protein, supporting the notion that active PKC lambda is preferentially ubiquitinated by VCB-Cul2 ubiquitin ligase. Furthermore, we show that PKC lambda can be ubiquitinated in vitro in a cell-free ubiquitination assay using purified recombinant components including VCB-Cul2. Given the known function of aPKC in the regulation of cell polarity and cell growth, PKC lambda may be a target of pVHL in its function as a tumor suppressor.	Yokohama City Univ, Sch Med, Dept Mol & Cellular Biol, Yokohama, Kanagawa 2360004, Japan; Kochi Med Sch, Dept Urol, Kochi 7838505, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto 6068501, Japan	Yokohama City University; Kochi University; Kyoto University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol & Cellular Biol, Yokohama, Kanagawa 2360004, Japan.		Ohno, Shigeo/B-1768-2010; IWAI, KAZUHIRO/GSN-7385-2022; Baba, Masaya/ABE-4893-2020; Baba, Masaya/L-7490-2013	Ohno, Shigeo/0000-0002-1294-5269; Baba, Masaya/0000-0002-5308-6683; Iwai, Kazuhiro/0000-0001-5620-5951				Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHEN F, 1995, CANCER RES, V55, P4804; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamada M, 2001, CANCER RES, V61, P4184; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x	39	143	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43611	43617		10.1074/jbc.M107880200	http://dx.doi.org/10.1074/jbc.M107880200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11574546	hybrid			2022-12-27	WOS:000172297700019
J	Sands, MS; Vogler, CA; Ohlemiller, KK; Roberts, MS; Grubb, JH; Levy, B; Sly, WS				Sands, MS; Vogler, CA; Ohlemiller, KK; Roberts, MS; Grubb, JH; Levy, B; Sly, WS			Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME REPLACEMENT THERAPY; BONE-MARROW TRANSPLANTATION; LYSOSOMAL STORAGE DISEASE; MANNOSE 6-PHOSPHATE; HEARING-LOSS; MOUSE; DEFICIENCY; EXPRESSION; CELLS; EMBRYOGENESIS	Enzyme replacement therapy (ERT) has been shown to be effective at reducing the accumulation of undegraded substrates in lysosomal storage diseases. Most ERT studies have been performed with recombinant proteins that are mixtures of phosphorylated and nonphosphorylated enzyme. Because different cell types use different receptors to take up phosphorylated or non-phosphorylated enzyme, it is difficult to determine which form of enzyme contributed to the clinical response. Here we compare the uptake, distribution, and efficacy of highly phosphorylated and non-phosphorylated P-glucuronidase (GUSB) in the MPS VII mouse. Highly phosphorylated murine GUSB was efficiently taken up by a wide range of tissues. In contrast, nonphosphorylated murine GUSB was taken up primarily by tissues of the reticuloendothelial (RE) system. Although the tissue distribution was different, the half-lives of both enzymes in any particular tissue were similar. Both preparations of enzyme were capable of preventing the accumulation of lysosomal storage in cell types they targeted. An important difference in clinical efficacy emerged in that phosphorylated GUSB was more efficient than non-phosphorylated enzyme at preventing the hearing loss associated with this disease. These data suggest that both forms of enzyme contribute to the clinical responses of ERT in MPS VII mice but that enzyme preparations containing phosphorylated GUSB are more broadly effective than non-phosphorylated enzyme.	Washington Univ, Sch Med, Cent Inst Deaf, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cent Inst Deaf, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cent Inst Deaf, Res Dept, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Saint Louis University; Saint Louis University	Sands, MS (corresponding author), Washington Univ, Sch Med, Cent Inst Deaf, Dept Internal Med, Box 8007,660 S Euclid Ave, St Louis, MO 63110 USA.			Sands, Mark/0000-0002-5559-0832	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034182] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD35671] Funding Source: Medline; NIGMS NIH HHS [R01 GM34182] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; AEED PA, 1994, BIOCHEMISTRY-US, V33, P8793, DOI 10.1021/bi00195a022; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1991, BLOOD, V78, P1183; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; Boose J A, 1990, Protein Expr Purif, V1, P111, DOI 10.1016/1046-5928(90)90003-H; CHANG PL, 1993, NEUROREPORT, V4, P507, DOI 10.1097/00001756-199305000-00011; COPPOLA G, 1994, GENE, V144, P197, DOI 10.1016/0378-1119(94)90378-6; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; Daly TM, 2000, PEDIATR RES, V47, P757, DOI 10.1203/00006450-200006000-00012; Dunder U, 2000, FASEB J, V14, P361, DOI 10.1096/fasebj.14.2.361; ENG DP, 2001, NEW ENGL J MED, V345, P9; GLASER JH, 1973, J LAB CLIN MED, V82, P969; GRUBB JH, 1993, FASEB J, V7, pA1255; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; MATZNER U, 1992, DEVELOPMENT, V114, P965; Miranda SRP, 2000, FASEB J, V14, P1988, DOI 10.1096/fj.00-0014com; NATOWICZ M, 1982, J BIOL CHEM, V257, P4412; NATOWICZ MR, 1979, P NATL ACAD SCI USA, V76, P4322, DOI 10.1073/pnas.76.9.4322; NEUFELD EF, 1970, SCIENCE, V169, P141, DOI 10.1126/science.169.3941.141; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P237, DOI 10.1159/000013847; Ohlemiller KK, 2000, EXP EYE RES, V71, P469, DOI 10.1006/exer.2000.0897; Sands MS, 1999, LAB ANIM SCI, V49, P328; SANDS MS, 1993, P NATL ACAD SCI USA, V90, P6567, DOI 10.1073/pnas.90.14.6567; SANDS MS, 1995, BLOOD, V86, P2033, DOI 10.1182/blood.V86.5.2033.bloodjournal8652033; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Sands MS, 1997, J CLIN INVEST, V99, P1596, DOI 10.1172/JCI119322; SENIOR PV, 1990, DEVELOPMENT, V109, P67; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; Takahashi K, 1998, CELL TISSUE RES, V292, P311, DOI 10.1007/s004410051062; Vogler C, 1999, PEDIATR RES, V45, P838, DOI 10.1203/00006450-199906000-00010; VOGLER C, 1990, AM J PATHOL, V136, P207; Vogler C, 1996, PEDIATR RES, V39, P1050, DOI 10.1203/00006450-199606000-00019; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028; WOLFE JH, 1996, GENE TRANSFER NEURON	40	59	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43160	43165		10.1074/jbc.M107778200	http://dx.doi.org/10.1074/jbc.M107778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562370	hybrid			2022-12-27	WOS:000172169300069
J	Werneburg, BG; Zoog, SJ; Dang, TTA; Kehry, MR; Crute, JJ				Werneburg, BG; Zoog, SJ; Dang, TTA; Kehry, MR; Crute, JJ			Molecular characterization of CD40 signaling intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; CROSS-LINKING CD40; CRYSTAL-STRUCTURE; FACTORS TRAFS; ANTENNAPEDIA HOMEODOMAIN; CYTOPLASMIC DOMAIN; ADAPTER PROTEINS; UP-REGULATION	Signal transduction through the CD40 receptor is initiated by binding of its trimeric ligand and propagated by interactions of tumor necrosis factor receptor-associated factor (TRAF) proteins with the multimerized CD40 cytoplasmic domain. Using defined multimeric constructs of the CD40 cytoplasmic domain expressed as either soluble or myristoylated proteins, we have addressed the extent of receptor multimerization needed to initiate signal transduction and identified components of CD40 signaling complexes. Signal transduction in human embryonic kidney 293 cells, measured by nuclear factor kappaB activation, was observed in cells expressing soluble trimeric CD40 cytoplasmic domain and to a lesser extent in cells expressing dimeric CD40 cytoplasmic domain. Nuclear factor kappaB activation was strongest in cells expressing myristoylated trimeric CD40 cytoplasmic domain. Signal transduction through trimeric CD40 cytoplasmic domains with various point mutations in the TRAF binding sites was similar to signal transduction through analogous full-length receptors. Transiently expressed soluble trimeric CD40 cytoplasmic domain was isolated as complexes that contained TRAF2, TRAF3, TRAF5, TRAF6, and the inhibitor of apoptosis protein (c-IAP1.). Association of c-IAP1 with the CD40 cytoplasmic domain complex was indirect and dependent on the presence of an intact TRAF1/2/3 binding site. These results suggest that extracellular ligation of CD40 can be bypassed and that soluble trimerized CD40 complexes can be isolated and used to identify components that link CD40 with signaling pathways.	Boehringer Ingelheim Pharmaceut Inc, Dept Biol, Ridgefield, CT 06877 USA	Boehringer Ingelheim	Crute, JJ (corresponding author), Aurora Biosci Corp, 11010 Torreyana Rd, San Diego, CA 92121 USA.							Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Clark LB, 1996, ADV IMMUNOL, V63, P43; Craxton A, 1998, J IMMUNOL, V161, P3225; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fang W, 1997, AM J PHYSIOL-CELL PH, V272, pC950, DOI 10.1152/ajpcell.1997.272.3.C950; Fenton M, 1998, J IMMUNOL METHODS, V212, P41, DOI 10.1016/S0022-1759(97)00208-1; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Hostager BS, 1996, J IMMUNOL, V157, P1047; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HU HM, 1994, J BIOL CHEM, V269, P30069; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; ICHIKI T, 1993, J IMMUNOL, V150, P5408; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; JACKSON S, 1982, J IMMUNOL METHODS, V48, P299, DOI 10.1016/0022-1759(82)90331-3; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Kehry M R, 1994, Semin Immunol, V6, P287, DOI 10.1006/smim.1994.1037; Kehry MR, 1996, J IMMUNOL, V156, P2345; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; McWhirter SM, 1999, COLD SPRING HARB SYM, V64, P551, DOI 10.1101/sqb.1999.64.551; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; PEREZ F, 1992, J CELL SCI, V102, P717; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schauer SL, 1996, J IMMUNOL, V157, P81; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	61	40	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43334	43342		10.1074/jbc.M104994200	http://dx.doi.org/10.1074/jbc.M104994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562359	hybrid			2022-12-27	WOS:000172169300092
J	Masters, J; Hinek, AA; Uddin, S; Platanias, LC; Zeng, W; McFadden, G; Fish, EN				Masters, J; Hinek, AA; Uddin, S; Platanias, LC; Zeng, W; McFadden, G; Fish, EN			Poxvirus infection rapidly activates tyrosine kinase signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR 5; VACCINIA VIRUS; DOWN-REGULATION; HIV-1 GP120; ENTRY; CD4; PHOSPHORYLATION; ASSOCIATION; PROTEINS; INSULIN	Viruses have evolved a number of strategies to gain entry and replicate in host target cells that, for human immunodeficiency virus (HIV) and the poxvirus, myxoma virus, involve appropriating chemokine receptors. In this report we demonstrate that activation of multiple intracellular tyrosine phosphorylation events rapidly ensues following virus adsorption to NIH 3T3.CD4.CCR5 cells and affects the ultimate level of myxoma virus replication. UV-inactivated myxoma virus induces the rapid phosphorylation of CCR5 on tyrosine residues, the association of CCR5 with Jaks and p56(lck), and their phosphorylation-activation within minutes of virus adsorption. Additionally, we provide evidence for myxoma virus-inducible signal transducers and activators of transcription (Stat) and insulin receptor substrate (IRS) activation. In contrast to CCR5 activation effected by HIV Env protein, these myxoma virus-inducible phosphorylation events are not sensitive to pertussis toxin treatment. Moreover, in cells that are non-permissive for myxoma virus infection, we provide evidence that myxoma virus fails to invoke this tyrosine phosphorylation cascade. Consistent with the observation that infection of CCR5-expressing cells is blocked by herbimycin A and the Jak 2 inhibitor, tyrophostin AG490, we infer that viral infectivity may be dependent on non-G-protein-coupled signal transduction pathways triggered by the infecting myxoma virus particle. This provides a novel post-binding mechanism by which viruses can co-opt a cellular receptor to permit productive virus infection.	Univ Toronto, Toronto Gen Res Inst, Hlth Network, Dept Cell & Mol Biol,Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Univ Illinois, Hematol Oncol Sect, Chicago, IL 60607 USA; Vet Affairs Hosp, Chicago, IL 60607 USA; Univ Western Ontario, John P Robarts Res Inst, London, ON 46G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON 46G 2V4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Western University (University of Western Ontario); Western University (University of Western Ontario)	Fish, EN (corresponding author), Univ Toronto, Toronto Gen Res Inst, Hlth Network, Dept Cell & Mol Biol,Div Cell & Mol Biol, Canadian Blood Serv Bldg,67 Coll St,Rm 424, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca		Uddin, Shahab/0000-0003-1886-6710	NCI NIH HHS [CA73381, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816, R29CA073381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alfano M, 1999, J EXP MED, V190, P597, DOI 10.1084/jem.190.5.597; BARRY M, 1995, J VIROL, V69, P5243, DOI 10.1128/JVI.69.9.5243-5251.1995; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Cicala C, 1999, J IMMUNOL, V163, P420; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Fenner F, 2000, FEMS MICROBIOL REV, V24, P123, DOI 10.1111/j.1574-6976.2000.tb00536.x; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Lalani AS, 2000, IMMUNOL TODAY, V21, P100, DOI 10.1016/S0167-5699(99)01556-X; Lalani AS, 1999, SCIENCE, V286, P1968, DOI 10.1126/science.286.5446.1968; Liu QH, 2000, P NATL ACAD SCI USA, V97, P4832, DOI 10.1073/pnas.090521697; Locker JK, 2000, MOL BIOL CELL, V11, P2497, DOI 10.1091/mbc.11.7.2497; Mashikian MV, 1999, J IMMUNOL, V163, P3123; MCFADDEN G, 1994, ENCY VIROLOGY, P1153; Nash P, 1999, IMMUNOL REV, V168, P103, DOI 10.1111/j.1600-065X.1999.tb01286.x; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Pease JE, 1998, SEMIN IMMUNOL, V10, P169, DOI 10.1006/smim.1998.0129; Ramsey-Ewing A, 1998, VIROLOGY, V242, P138, DOI 10.1006/viro.1997.8985; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Su SB, 1999, J IMMUNOL, V162, P7128; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Uddin S, 1998, BRIT J HAEMATOL, V101, P446, DOI 10.1046/j.1365-2141.1998.00731.x; Wang JM, 1999, J EXP MED, V190, P591, DOI 10.1084/jem.190.5.591; White MF, 1998, RECENT PROG HORM RES, V53, P119; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496	33	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48371	48375		10.1074/jbc.M108019200	http://dx.doi.org/10.1074/jbc.M108019200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11591716	hybrid			2022-12-27	WOS:000172927000086
J	Shin, JM; Goldshleger, R; Munson, KB; Sachs, G; Karlish, SJD				Shin, JM; Goldshleger, R; Munson, KB; Sachs, G; Karlish, SJD			Selective Fe2+-catalyzed oxidative cleavage of gastric H+,K+-ATPase - Implications for the energy transduction mechanism of P-type cation pumps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; CONFORMATIONAL TRANSITIONS; STRUCTURAL ASPECTS; CRYSTAL-STRUCTURE; + K+)-ATPASE; H,K ATPASE; H,K-ATPASE; NA,K-ATPASE	In the presence of ascorbate/H2O2, Fe2+ ions or the ATP-Fe2+ complex catalyze selective cleavage of the alpha subunit of gastric H+, K+-ATPase. The electrophoretic mobilities of the fragments and dependence of the cleavage patterns on E-1 and E-2 conformational states are essentially identical to those described previously for renal Na+, K+-ATPase. The cleavage pattern of H+, K+-ATPase by Fe2+ ions is consistent with the existence of two Fe2+ sites: site I within highly conserved sequences in the P and A domains, and site 2 at the cytoplasmic entrance to trans-membrane segments M3 and MI. The change in the pattern of cleavage catalyzed by Fe2+ or the ATP-Fe2+ complex induced by different ligands provides evidence for large conformational movements of the N, P, and A cytoplasmic domains of the enzyme. The results are consistent with the Ca2+-ATPase crystal structure (Protein Data Bank identification code 1EUL; Toyoshima, C., Nakasako, M., Nomura, H., and Ogawa, H. (2000) Nature 405, 647-655), an E1Ca2+ conformation, and a theoretical model of Ca2+-ATPase in an E2 conformation (Protein Data Bank identification code 1FQU). Thus, it can be presumed that the movements of N, P, and A cytoplasmic domains, associated with the E-1 <----> E-2 transitions, are similar in all P-type ATPases. Fe-2-catalyzed cleavage patterns also reveal sequences involved in phosphate, Mg2+, and ATP binding, which have not yet been shown in crystal structures, as well as changes which occur in E-1 <----> E2 transitions, and subconformations induced by H+, K+-ATPase-specific ligands such as SCH28080.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Calif Los Angeles, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90024 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	Weizmann Institute of Science; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	steven.karlish@weizmann.ac.il			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK053462, R01DK046917, R01DK017294, P30DK041301, R37DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK17294, DK46917, DK53462, DK41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRZEZINSKI P, 1988, BIOCHIM BIOPHYS ACTA, V942, P215, DOI 10.1016/0005-2736(88)90022-3; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; FUKUSHIMA Y, 1978, J BIOL CHEM, V253, P6853; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; Goldshleger R, 2001, J BIOENERG BIOMEMBR, V33, P387, DOI 10.1023/A:1010615422932; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HELMICHDEJONG ML, 1987, BIOCHIM BIOPHYS ACTA, V905, P358, DOI 10.1016/0005-2736(87)90464-0; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V858, P254, DOI 10.1016/0005-2736(86)90330-5; HELMICHDEJONG ML, 1985, BIOCHIM BIOPHYS ACTA, V821, P377, DOI 10.1016/0005-2736(85)90041-0; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; LORENTZON P, 1988, J BIOL CHEM, V263, P10705; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Melle-Milovanovic D, 1998, ACTA PHYSIOL SCAND, V163, P147; MENDLEIN J, 1990, J BIOL CHEM, V265, P5030; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Ogawa H, 1998, BIOPHYS J, V75, P41, DOI 10.1016/S0006-3495(98)77493-4; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; POST RL, 1972, J BIOL CHEM, V247, P6530; RABON E, 1985, J BIOL CHEM, V260, P200; RABON E, 1991, J BIOL CHEM, V266, P12395; RABON EC, 1993, J BIOL CHEM, V268, P8012; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; RABON EC, 1990, J BIOL CHEM, V265, P19594; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; RENDI R, 1964, BIOCHIM BIOPHYS ACTA, V89, P520, DOI 10.1016/0926-6569(64)90078-1; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; SACHS G, 1992, ANN NY ACAD SCI, V671, P204; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHIN JM, 1994, J BIOL CHEM, V269, P22533; Shin JM, 1997, ANN NY ACAD SCI, V834, P65, DOI 10.1111/j.1749-6632.1997.tb52226.x; SOUMARMON A, 1984, J BIOL CHEM, V259, P1861; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STEWART B, 1981, J BIOL CHEM, V256, P2682; Tal DM, 2001, BIOCHEMISTRY-US, V40, P12505, DOI 10.1021/bi011167n; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANDERHIJDEN HTWM, 1991, BIOCHIM BIOPHYS ACTA, V1061, P141, DOI 10.1016/0005-2736(91)90278-G; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	54	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48440	48450		10.1074/jbc.M106864200	http://dx.doi.org/10.1074/jbc.M106864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11585827	hybrid			2022-12-27	WOS:000172927000096
J	Barbieri, MA; Heath, CM; Peters, EM; Wells, A; Davis, JN; Stahl, PD				Barbieri, MA; Heath, CM; Peters, EM; Wells, A; Davis, JN; Stahl, PD			Phosphatidylinositol-4-phosphate 5-kinase-1 beta is essential for epidermal growth factor receptor-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-PHOSPHATE 5-KINASE; PHOSPHOINOSITIDE KINASES; MEMBRANE TRAFFICKING; PHOSPHOLIPASE-C; ALPHA; 4,5-BISPHOSPHATE; MOVEMENT; CLATHRIN; DOMAINS	Phosphatidylinositol-4,5-bisphosphate (PIP2) is known to play an important role in signal transduction and membrane trafficking. We show that one enzyme responsible for PIP2 production, phosphatidylinositol-4-phosphate 5-kinase type 1 beta (PIPK beta), is essential for epidermal growth factor receptor (EGFR)-mediated endocytosis. Expression of murine PIPK beta in NR6 cells expressing EGFR strikingly increased receptor internalization. Moreover, the kinase was shown to form an immunoprecipitable complex with EGFR. Expression of either a truncated kinase or a kinase dead mutant inhibited EGFR endocytosis and also blocked the membrane recruitment of PIPK beta and both clathrin light chain and dynamin. Our results delineate a novel mechanism by which PIPK beta regulates receptor-mediated endocytosis and receptor tyrosine kinase membrane traffic.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Washington University (WUSTL); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Campus Box 8228, St Louis, MO 63110 USA.		Stahl, Philip/D-6315-2012	Wells, Alan/0000-0002-1637-8150	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015, R01AI035884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35884, AI 20015] Funding Source: Medline; NIGMS NIH HHS [GM 42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; COCHET C, 1991, J BIOL CHEM, V266, P637; Cremona O, 2001, J CELL SCI, V114, P1041; Davis JN, 1997, MOL CELL BIOL, V17, P7398, DOI 10.1128/MCB.17.12.7398; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; LI GP, 1993, J BIOL CHEM, V268, P24475; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867	30	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47212	47216		10.1074/jbc.C100490200	http://dx.doi.org/10.1074/jbc.C100490200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581249	hybrid			2022-12-27	WOS:000172768500073
J	Hisamoto, K; Ohmichi, M; Kanda, Y; Adachi, K; Nishio, Y; Hayakawa, J; Mabuchi, S; Takahashi, K; Tasaka, K; Miyamoto, Y; Taniguchi, N; Murata, Y				Hisamoto, K; Ohmichi, M; Kanda, Y; Adachi, K; Nishio, Y; Hayakawa, J; Mabuchi, S; Takahashi, K; Tasaka, K; Miyamoto, Y; Taniguchi, N; Murata, Y			Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; BREAST-CANCER; GROWTH-FACTOR; ER-ALPHA; ACTIVATION; BETA; INHIBITOR; PROMOTER	Raloxifene is a tissue-selective estrogen receptor modulator. The effect of estrogen on cardiovascular disease is mainly dependent on direct actions on the vascular wall involving activation of endothelial nitric oxide synthase (eNOS) via Akt and extracellular signal-regulated protein kinase (ERK) cascades. Although raloxifene is also known to activate eNOS in the vascular endothelium, the molecular mechanism responsible for this effect remains to be elucidated. In studies of both human umbilical vein endothelial cells and simian virus 40-transformed rat lung vascular endothelial cells (TRLECs), the raloxifene analog LY117018 caused acute phosphorylation of eNOS that was unaffected by actinomycin D and was blocked by the pure estrogen receptor antagonist IC1182,780. Activation of Akt by raloxifene reached a plateau at 15-30 min and declined thereafter, a similar time frame to that of Akt activation by 17 beta -estradiol. On the other hand, both activation and phosphorylation of ERK by raloxifene showed a biphasic pattern (peaks at 5 min and 1 h), whereas ERK activation and phosphorylation by 17 beta -estradiol reached a plateau at 5 min and declined thereafter. A MEK inhibitor, PD98059, had no effect on the raloxifene-induced Akt activity, suggesting an absence of cross-talk between the ERK and Akt cascades. Either exogenous expression of a dominant-negative Akt or pretreatment of TRLECs with PD98059 decreased the raloxifene-induced eNOS phosphorylation. Moreover, raloxifene stimulated the activation of Akt, ERK, and eNOS in Chinese hamster ovary cells expressing estrogen receptor a but not Chinese hamster ovary cells expressing estrogen receptor beta. Our findings suggest that raloxifene-induced eNOS phosphorylation is mediated by estrogen receptor a via a nongenomic mechanism and is differentially mediated by Akt- and ERK-dependent cascades.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	masa@gyne.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Mabuchi, Seiji/AAX-1986-2020; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Coffer PJ, 1998, BIOCHEM J, V335, P1; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Cox DA, 1996, PHARMACOL REV, V48, P3; CUMMINGS S, 1998, P ASCO, V17, P3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duh JL, 1997, PHARMACEUT RES, V14, P186, DOI 10.1023/A:1012048626963; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; Figtree GA, 1999, CIRCULATION, V100, P1095, DOI 10.1161/01.CIR.100.10.1095; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hayakawa J, 2000, CANCER RES, V60, P5988; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Homma H, 2000, J BIOL CHEM, V275, P11404, DOI 10.1074/jbc.275.15.11404; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344-199800001-00042; JORDAN VC, 1998, P AN M AM SOC CLIN, V17, P466; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kimura A, 2000, J BIOL CHEM, V275, P3667, DOI 10.1074/jbc.275.5.3667; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P982, DOI 10.1016/0002-9378(95)90247-3; Mandlekar S, 2000, CANCER RES, V60, P5995; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Miller VM, 1999, CIRC RES, V85, P979; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; SCHWARTZ J, 1995, J CLIN PHARMACOL, V35, P314, DOI 10.1002/j.1552-4604.1995.tb04066.x; SEO HG, 1995, BIOCHEM BIOPH RES CO, V208, P10, DOI 10.1006/bbrc.1995.1298; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Simoncini T, 2000, J CLIN ENDOCR METAB, V85, P2966, DOI 10.1210/jc.85.8.2966; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Steinberg D, 1997, CIRCULATION, V95, P1062; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Yokoi T, 2000, J BIOL CHEM, V275, P21639, DOI 10.1074/jbc.M910252199; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zuckerman SH, 1996, ATHEROSCLEROSIS, V126, P65	72	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47642	47649		10.1074/jbc.M103853200	http://dx.doi.org/10.1074/jbc.M103853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595733	hybrid			2022-12-27	WOS:000172768500125
J	Kwon, KB; Yang, JY; Ryu, DG; Rho, HW; Kim, JS; Park, JW; Kim, HR; Park, BH				Kwon, KB; Yang, JY; Ryu, DG; Rho, HW; Kim, JS; Park, JW; Kim, HR; Park, BH			Vibrio vulnificus cytolysin induces superoxide anion-initiated apoptotic signaling pathway in human ECV304 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRONE SPIN TRAPS; EXTRACELLULAR CYTOLYSIN; ENDOTHELIAL-CELLS; DNA FRAGMENTATION; OXIDATIVE STRESS; PORE FORMATION; CYTOCHROME-C; ALPHA-TOXIN; MAST-CELLS; THYMOCYTES	Previous studies showed that exposure to Vibrio vulnificus cytolysin (VVC) caused characteristic morphologic changes and dysfunction of vascular structures in lung. VVC showed cytotoxicity for mammalian cells in culture and acted as a vascular permeability factor. In this study, the underlying mechanisms of VVC-induced cytotoxicity was investigated on ECV304 cell, a human vascular endothelial cell line. When cells were exposed to 0.4 hemolytic units (HU) of VVC, consecutive apoptotic events were observed; the elevation of superoxide anion (O(2)(-)over dot) the release of cytochrome c, the activation of caspase-3, the cleavage of poly(ADP-ribose) polymerase, and the DNA fragmentation. The pretreatment with 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO), O(2)(-)over dot scavenger, completely abolished O(2)(-)over dot 2 2 levels and downstream apoptotic events. Moreover, pretreatment with cyclosporin A (CsA), a mitochondrial permeability transition inhibitor, was capable of attenuating O(2)(-)over dot-mediated cytochrome c release and caspase-3 activation, and consequent apoptosis. Apoptosis, as demonstrated by oligonucleosomal DNA fragmentation and fluorescence microscopy, was induced 24 h after VVC treatment, which was also prevented by caspase-3 inhibitor, Ac-DEVD-CHO. Caspase-1 inhibitor, Ac-YVAD-CHO, did not protect ECV 304 cells from apoptosis. These results suggest a scenario where VVC-induced apoptosis is triggered by the generation of O(2)(-)over dot release of 2 cytochrome c from mitochondria, activation of caspase-3, degradation of poly(ADP-ribose) polymerase, and DNA fragmentation. The induction of apoptosis in endothelial cells by VVC may provide a pivotal mechanism for understanding the pathophysiology of septicemia.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561756, South Korea; Chonbuk Natl Univ, Sch Med, Inst Med Sci, Chonju 561756, South Korea; Won Kwang Univ, Sch Oriental Med, Dept Physiol, Iksan 570749, South Korea	Jeonbuk National University; Jeonbuk National University; Wonkwang University	Park, BH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561756, South Korea.	bhpark@moak.chonbuk.ac.kr						ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; BERNHEIMER AW, 1963, J GEN MICROBIOL, V30, P455, DOI 10.1099/00221287-30-3-455; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHEN YJ, 1994, MICROB PATHOGENESIS, V17, P203, DOI 10.1006/mpat.1994.1066; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Eguchi Y, 1997, CANCER RES, V57, P1835; ELSTEIN KH, 1994, EXP CELL RES, V211, P322, DOI 10.1006/excr.1994.1094; Galitovsky VE, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1374; GRAY LD, 1985, INFECT IMMUN, V48, P62, DOI 10.1128/IAI.48.1.62-72.1985; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAMEED A, 1989, J EXP MED, V169, P765, DOI 10.1084/jem.169.3.765; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; KIM HR, 1993, LIFE SCI, V53, P571, DOI 10.1016/0024-3205(93)90714-E; Kim Hyung-Rho, 1992, Korean Journal of Biochemistry, V24, P7; Kim JS, 1998, MICROBIOL IMMUNOL, V42, P837, DOI 10.1111/j.1348-0421.1998.tb02359.x; Kim JS, 1997, EXP MOL MED, V29, P117, DOI 10.1038/emm.1997.17; KIZAKI H, 1989, J IMMUNOL, V143, P1790; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KREGER A, 1981, INFECT IMMUN, V33, P583, DOI 10.1128/IAI.33.2.583-590.1981; KREGER AS, 1988, METHOD ENZYMOL, V165, P176; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MIYOSHI S, 1988, MICROBIOL IMMUNOL, V32, P1025, DOI 10.1111/j.1348-0421.1988.tb01467.x; MIYOSHI S, 1993, J TOXICOL-TOXIN REV, V12, P253, DOI 10.3109/15569549309014409; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OEZ S, 1990, BLUT, V60, P97, DOI 10.1007/BF01720515; OLIVER JD, 1986, DIAGN MICR INFEC DIS, V5, P99, DOI 10.1016/0732-8893(86)90112-4; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; Park JW, 1996, INFECT IMMUN, V64, P2873, DOI 10.1128/IAI.64.7.2873-2876.1996; PARK JW, 1994, BBA-BIOMEMBRANES, V1194, P166, DOI 10.1016/0005-2736(94)90216-X; PARK SD, 1991, J AM ACAD DERMATOL, V24, P397, DOI 10.1016/0190-9622(91)70059-B; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SHULACHEV VP, 1998, BIOCHIM BIOPHYS ACTA, V1363, P100; SIMPSON LM, 1987, INFECT IMMUN, V55, P269, DOI 10.1128/IAI.55.1.269-272.1987; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH GC, 1982, INFECT IMMUN, V35, P1155, DOI 10.1128/IAI.35.3.1155-1156.1982; SUN XM, 1992, ANAL BIOCHEM, V204, P351, DOI 10.1016/0003-2697(92)90251-2; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Torres-Roca JF, 2000, J IMMUNOL, V165, P4822, DOI 10.4049/jimmunol.165.9.4822; WALEV I, 1995, INFECT IMMUN, V63, P1188, DOI 10.1128/IAI.63.4.1188-1194.1995; Wilson MR, 1998, BIOCHEM CELL BIOL, V76, P573, DOI 10.1139/bcb-76-4-573; WRIGHT AC, 1991, INFECT IMMUN, V59, P192, DOI 10.1128/IAI.59.1.192-197.1991; WRIGHT AC, 1981, INFECT IMMUN, V34, P503, DOI 10.1128/IAI.34.2.503-507.1981; YAMANAKA H, 1990, J MED MICROBIOL, V32, P39, DOI 10.1099/00222615-32-1-39; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZITZER A, 1995, MED MICROBIOL IMMUN, V184, P37, DOI 10.1007/BF00216788	58	62	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47518	47523		10.1074/jbc.M108645200	http://dx.doi.org/10.1074/jbc.M108645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591724	hybrid			2022-12-27	WOS:000172768500110
J	Terada, M; Kuroda, T; Matsuyama, S; Tokuda, H				Terada, M; Kuroda, T; Matsuyama, S; Tokuda, H			Lipoprotein sorting signals evaluated as the Lo1A-dependent release of lipoproteins from the cytoplasmic membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; LOCALIZATION; PROTEIN; TRANSPORT; SEQUENCE; BACTERIA; SYSTEM	Escherichia coli lipoproteins are anchored to either the inner or outer membrane through fatty acyl chains covalently attached to an N-terminal cysteine. Aspartate at position 2 functions to retain lipoproteins in the inner membrane, although the retention is perturbed depending on the residue at position 3. We previously revealed that LolCDE and LolA play critical roles in this lipoprotein sorting. To clarify the sorting signals, the LolA-dependent release of lipoprotein derivatives having various residues at positions 2 and 3 was examined in spheroplasts. When the residue at position 3 was serine, only aspartate at position 2 caused the retention of lipoproteins in spheroplasts. We then examined the release of derivatives having aspartate at position 2 and various residues at position 3. Strong inner membrane retention occurred with a limited number of species of residues at position 3. These residues were present at position 3 of native lipoproteins having aspartate at position 2, whereas residues that inhibited the retention were not. It was also found that a strong inner membrane retention signal having residues other than Aspartate at position 2 could be formed through the combination of the residues at positions 2 and 3. These results indicate that the inner membrane localization of native lipoproteins is ensured by the use of a limited number of strong inner membrane retention signals.	Univ Tokyo, Inst Biol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Biol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KLEIN JR, 1991, MOL GEN GENET, V230, P230, DOI 10.1007/BF00290673; Kobayashi K, 2001, J BACTERIOL, V183, P2646, DOI 10.1128/JB.183.8.2646-2653.2001; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SEIFFER D, 1993, FEMS MICROBIOL LETT, V107, P175; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995	18	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47690	47694		10.1074/jbc.M109307200	http://dx.doi.org/10.1074/jbc.M109307200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592971	hybrid			2022-12-27	WOS:000172768500132
J	Vissers, MCM; Lee, WG; Hampton, MB				Vissers, MCM; Lee, WG; Hampton, MB			Regulation of apoptosis by vitamin C - Specific protection of the apoptotic machinery against exposure to chlorinated oxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOCHLOROUS ACID; ASCORBIC-ACID; HYDROGEN-PEROXIDE; CASPASE ACTIVATION; GROWTH ARREST; ANTIOXIDANT; CELLS; OXIDATION; MYELOPEROXIDASE; CHLORAMINES	We have investigated the ability of intracellular vitamin C to protect human umbilical vein endothelial cells from exposure to hypochlorous acid (HOCl) and a range of derived chloramines. Ascorbate provided minimal protection against the cytotoxicity induced by these oxidants, as measured by propidium iodide uptake. In contrast, there was a marked effect on apoptosis, monitored by caspase-3 activation and phosphatidylserine exposure. Extended incubation of the cells with glycine chloramine or histamine chloramine completely blocked apoptosis initiated in the cells by serum withdrawal. This effect was significantly abrogated by ascorbate. Inhibition of apoptosis required the oxidant to be present for an extended period after serum withdrawal and occurred prior to caspase-3 activation. General protection of thiols by ascorbate was not responsible for the protection of apoptosis, because intracellular oxidation by HOCl or chloramines was not prevented in supplemented cells. The results suggest a new role for vitamin C in the regulation of apoptosis. We propose that, by protection of an oxidant-sensitive step in the initiation phase, ascorbate allows apoptosis to proceed in endothelial cells under sustained oxidative stress.	Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, Christchurch 8001, New Zealand	University of Otago	Vissers, MCM (corresponding author), Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, POB 4345, Christchurch 8001, New Zealand.	margret.vissers@chmeds.ac.nz	Vissers, Margreet C M/T-4159-2017; Hampton, Mark B/A-8490-2008; Lee, Don/AAE-7069-2021	Hampton, Mark B/0000-0002-7349-3729; Lee, Don/0000-0002-2199-5364				BARNES MJ, 1975, ANN NY ACAD SCI, V258, P264, DOI 10.1111/j.1749-6632.1975.tb29287.x; Berger TM, 1997, J BIOL CHEM, V272, P15656, DOI 10.1074/jbc.272.25.15656; BIRDWELL CR, 1978, P NATL ACAD SCI USA, V75, P3273, DOI 10.1073/pnas.75.7.3273; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GAZDA M, 1994, INORG CHEM, V33, P118, DOI 10.1021/ic00079a022; GOLDSCHMIDT MC, 1991, AM J CLIN NUTR, V54, pS1214, DOI 10.1093/ajcn/54.6.1214s; Halliwell B., 1997, Vitamin C in health and disease., P59; HALLIWELL B, 1999, FREE RADICAL BIO MED, P200; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HU ML, 1993, J LAB CLIN MED, V121, P257; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kanno S, 2000, BIOL PHARM BULL, V23, P37; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; LEE W, 1982, CLIN CHEM, V28, P2165; LEIST M, 2001, FREE RADIC BIOL MED, V21, P297; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; McKenzie SJ, 1996, J CLIN INVEST, V98, P136, DOI 10.1172/JCI118757; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Prutz WA, 1996, ARCH BIOCHEM BIOPHYS, V332, P110, DOI 10.1006/abbi.1996.0322; Prutz WA, 1998, ARCH BIOCHEM BIOPHYS, V349, P183, DOI 10.1006/abbi.1997.0440; Prutz WA, 1999, ARCH BIOCHEM BIOPHYS, V371, P107, DOI 10.1006/abbi.1999.1377; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Pullar JM, 2001, J BIOL CHEM, V276, P22120, DOI 10.1074/jbc.M102088200; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; SAMUELS MP, 1987, ARCH DIS CHILD, V62, P1099, DOI 10.1136/adc.62.11.1099; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Smirnoff N, 2000, CURR OPIN PLANT BIOL, V3, P229, DOI 10.1016/S1369-5266(00)00069-8; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597, DOI 10.1152/ajpheart.1994.267.4.H1597; Thomas EL, 2000, REDOX REP, V5, P191, DOI 10.1179/135100000101535744; Tsao C. S., 1997, Vitamin C in health and disease., P25; TU B, 1995, TOXICOLOGY, V98, P125, DOI 10.1016/0300-483X(94)02977-3; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vile GF, 1998, ARCH BIOCHEM BIOPHYS, V359, P51, DOI 10.1006/abbi.1998.0881; Vile GF, 2000, ARCH BIOCHEM BIOPHYS, V377, P122, DOI 10.1006/abbi.2000.1706; VISSERS MCM, 1990, FREE RADICAL BIO MED, V8, P331, DOI 10.1016/0891-5849(90)90098-4; Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443; VISSERS MCM, 1995, BIOCHEM J, V307, P57, DOI 10.1042/bj3070057; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; WINTERBOURN CC, 1983, BIOCHIM BIOPHYS ACTA, V763, P175, DOI 10.1016/0167-4889(83)90041-1; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Witenberg B, 1999, RADIAT RES, V152, P468, DOI 10.2307/3580142	55	60	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46835	46840		10.1074/jbc.M107664200	http://dx.doi.org/10.1074/jbc.M107664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590157	hybrid			2022-12-27	WOS:000172768500023
J	Wilhelm, M; Uzun, O; Mules, EH; Gabriel, A; Wilhelm, FX				Wilhelm, M; Uzun, O; Mules, EH; Gabriel, A; Wilhelm, FX			Polypurine tract formation by Ty1 RNase H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DNA-SYNTHESIS; REVERSE-TRANSCRIPTASE; HUMAN-IMMUNODEFICIENCY; HYBRID DUPLEX; IMMEDIATELY UPSTREAM; CRYSTAL-STRUCTURE; 2ND ORIGIN; PRIMER; SEQUENCE; MECHANISM	To better understand the mechanism by which Ty1 RNase H creates the polypurine tract (PPT) primer, we have demonstrated the polymerase-dependent hydrolytic activity of Ty1 reverse transcriptase (RT) during minus-strand synthesis. Using RNase H and polymerase mutants of the recombinant Ty1 RT protein, we show that the two domains of Ty1 RT can act independently of one another. Our results indicate that RNA/DNA substrates containing a short RNA PPT, which serve as primers for plus-strand DNA synthesis, are relatively resistant to RNase H cleavage. RNA substrates with a correct 5 ' end but with 3 ' end extending beyond the plus-strand initiation site were cleaved specifically to generate the correct 3 ' end of the PPT. Using long RNA/DNA duplexes containing the PPT, we show that Ty1 RT is able to make specific internal cleavages that could generate the plus-strand primer with correct 5 ' and 3 ' ends. Long RNA/DNA duplexes with mutations in the PPT or in a U-rich region upstream of the PPT, which abolish plus-strand initiation in vivo, were not cleaved specifically at the 5 ' end of the PPT. Our work demonstrates that the in vitro enzyme can recapitulate key processes that control proper replication in vivo.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Rutgers State University New Brunswick	Wilhelm, FX (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, CABM 306,679 Hoes Ln, Piscataway, NJ 08854 USA.	wilhelm@ibmc.u-strasbg.fr			NIGMS NIH HHS [GM 60534] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060534] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Han GW, 1997, J MOL BIOL, V269, P811, DOI 10.1006/jmbi.1997.1085; HEYMAN T, 1995, J MOL BIOL, V253, P291, DOI 10.1006/jmbi.1995.0553; Ilyinskii PO, 1998, EMBO J, V17, P3766, DOI 10.1093/emboj/17.13.3766; KATI WM, 1992, J BIOL CHEM, V267, P25988; Noad RJ, 1998, J BIOL CHEM, V273, P32568, DOI 10.1074/jbc.273.49.32568; POCHART P, 1993, NUCLEIC ACIDS RES, V21, P3513, DOI 10.1093/nar/21.15.3513; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Robson ND, 2000, J VIROL, V74, P10293, DOI 10.1128/JVI.74.22.10293-10303.2000; Robson ND, 1999, J VIROL, V73, P948, DOI 10.1128/JVI.73.2.948-957.1999; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Stetor SR, 1999, BIOCHEMISTRY-US, V38, P3656, DOI 10.1021/bi982764l; Telesnitsky A., 1997, P121; Uzun O, 2001, J VIROL, V75, P6337, DOI 10.1128/JVI.75.14.6337-6347.2001; Wilhelm M, 1999, NUCLEIC ACIDS RES, V27, P4547, DOI 10.1093/nar/27.23.4547; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Xiong Y, 1998, STRUCTURE, V6, P1493, DOI 10.1016/S0969-2126(98)00148-8; Xiong Y, 2000, NUCLEIC ACIDS RES, V28, P2171, DOI 10.1093/nar/28.10.2171; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	29	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47695	47701		10.1074/jbc.M106067200	http://dx.doi.org/10.1074/jbc.M106067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595735	hybrid			2022-12-27	WOS:000172768500133
J	Kawai, H; Nie, LH; Wiederschain, D; Yuan, ZM				Kawai, H; Nie, LH; Wiederschain, D; Yuan, ZM			Dual role of p300 in the regulation of p53 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; DEGRADATION; MDM2; PHOSPHORYLATION; ACETYLATION; BINDING	While the function of p300 as a transcriptional coactivator of p53 is well documented, its role in the regulation of p53 stability remains ill-defined since opposite effects of p300 on p53 levels have been reported. We show here that p300 stabilizes both p53 and its negative regulator MDM2, thereby enhancing the p53/MDM2 negative regulatory loop. Binding of p300 is associated with the retention of p53 in the nucleus, which results in the accumulation of p53 in an acetylase-independent manner. Stabilization of MDM2, on the other hand, requires the acetylase activity of p300. Importantly, MDM2, once expressed, is able to reverse the stabilizing effect of p300 on p53. A temperature-permissive p53-expressing cell line enabled us to demonstrate the completely opposite roles of p300 in the regulation of p53 stability, depending on the expression of MDM2. Prior to p53 activation, when MDM2 levels are low, p300 acts as a positive regulator to increase p53 levels. Upon shifting to permissive temperature, however, when MDM2 expression is induced, p300 becomes a negative regulator of p53 by stabilizing MDM2 and thereby augmenting MDM2's ability to target p53 for degradation.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Program Biol Sci Publ Hlth, Grad Sch Arts & Sci, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 209,665 Huntington Ave, Boston, MA 02115 USA.			Kawai, Hidehiko/0000-0003-2213-7166				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	15	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45928	45932		10.1074/jbc.M107770200	http://dx.doi.org/10.1074/jbc.M107770200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11591713	hybrid			2022-12-27	WOS:000172573100060
J	Richter, G; Hayden-Ledbetter, M; Irgang, M; Ledbetter, JA; Westermann, J; Korner, I; Daemen, K; Clark, EA; Aicher, A; Pezzutto, A				Richter, G; Hayden-Ledbetter, M; Irgang, M; Ledbetter, JA; Westermann, J; Korner, I; Daemen, K; Clark, EA; Aicher, A; Pezzutto, A			Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC CELLS; MOLECULE ICOS; ACTIVATION; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; MACROPHAGES; INHIBITORS; CD4(+); CTLA-4	The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We used soluble ICOSIg and a newly developed murine anti-human ICOS ligand (ICOSL) monoclonal antibody to further characterize the ICOSL during ontogeny of antigen presenting cells. In a previous study, we found that ICOSL is expressed on monocytes, dendritic cells, and B cells. To define when ICOSL is first expressed on myeloid antigen presenting cells, we examined ICOSL expression on CD34(+) cells in bone marrow. We found that CD34(bright) cells regardless of their myeloid commitment were ICOSL-, whereas ICOSL was first expressed when CD34 expression diminished and the myeloid marker CD33 appeared. However, acute myeloid leukemia cells were ICOSL-negative, whereas among B-cell malignancies only some cases of the most mature tumors such as prolymphocytic leukemia and hairy cell leukemia were positive. Next, we investigated purified CD34(+) hematopoietic progenitor cells that did not constitutively express ICOSL but were induced to express ICOSL within 12 h after granulocyte/macrophage colony-stimulating factor/tumor necrosis factor alpha (TNF-alpha) stimulation. Interestingly, ICOSL was induced prior to CD80/CD86 induction on CD34(+) cells so that ICOSL was expressed in the absence of CD80/CD86. This suggests that ICOSL is an early differentiation marker along the monocytic/ dendritic maturation pathway. Induction of ICOSL was dependent on TNF-a and was regulated via NF-kappaB as revealed by use of inhibitors specific for I kappaB alpha phosphorylation such as BAY 11-7082 and BAY 11-7085. The antigen presenting capacity of TNF-alpha stimulated CD34(+) cells was strongly inhibited by ICOSIg fusion proteins or by NF-kappaB inhibition. Thus, TNF-alpha -induced ICOSL expression seemed to be functionally important for the costimulatory capacity of CD34(+) hematopoietic progenitor cells.	Humboldt Univ, Charite, Robert Rossle Klin, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Washington; University of Washington Seattle	Richter, G (corresponding author), Univ Halle Wittenberg, Med Ctr, Dept Pediat, Lab Transplantat Biol, Heinrich Damerow Str 1, D-06120 Halle An Der Saale, Germany.	guenther.richter@medizin.uni-halle.de	Aicher, Alexandra/GZK-8031-2022	Aicher, Alexandra/0000-0002-8920-9577; Pezzutto, Antonio/0000-0002-3246-4470; Clark, Edward A/0000-0001-8061-5475				Aicher A, 2000, J IMMUNOL, V164, P4689, DOI 10.4049/jimmunol.164.9.4689; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Ling V, 2000, J IMMUNOL, V164, P1653, DOI 10.4049/jimmunol.164.4.1653; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; Mapara MY, 1997, BLOOD, V89, P337, DOI 10.1182/blood.V89.1.337.337_337_344; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 1998, IMMUNOL REV, V165, P231; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Oosterwegel MA, 1999, CURR OPIN IMMUNOL, V11, P294, DOI 10.1016/S0952-7915(99)80047-8; Ozkaynak E, 2001, NAT IMMUNOL, V2, P591, DOI 10.1038/89731; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Rondelli D, 1996, BLOOD, V88, P2619, DOI 10.1182/blood.V88.7.2619.bloodjournal8872619; Ryncarz RE, 1998, BLOOD, V91, P3892, DOI 10.1182/blood.V91.10.3892.3892_3892_3900; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Slavik JM, 1999, IMMUNOL RES, V19, P1, DOI 10.1007/BF02786473; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Wallin JJ, 2001, J IMMUNOL, V167, P132, DOI 10.4049/jimmunol.167.1.132; Wang SD, 2000, BLOOD, V96, P2808; Yoshinaga SK, 2000, INT IMMUNOL, V12, P1439, DOI 10.1093/intimm/12.10.1439; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zheng Z, 1998, J EXP CLIN CANC RES, V17, P251	34	44	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45686	45693		10.1074/jbc.M108509200	http://dx.doi.org/10.1074/jbc.M108509200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571308	hybrid			2022-12-27	WOS:000172573100027
J	Dick, GM; Sanders, KM				Dick, GM; Sanders, KM			(Xeno)estrogen sensitivity of smooth muscle BK channels conferred by the regulatory beta 1 subunit - A study of beta 1 knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; CA2+-ACTIVATED K+ CHANNEL; DEPENDENT PROTEIN-KINASE; RAT CEREBRAL-ARTERIES; HIGH-CONDUCTANCE; CA CHANNELS; CALCIUM; TAMOXIFEN; CELLS; INHIBITION	Estrogen and xenoestrogens (i.e. agents that are not steroids but possess estrogenic activity) increase the open probability (P-o) of large conductance Ca2+-activated K+ (BK) channels in smooth muscle. The mechanism of action may involve the regulatory beta1 subunit. We used beta1 subunit knockout (beta1(-/-)) mice to test the hypothesis that the regulatory beta1 subunit is essential for the activation of BK channels by tamoxifen, 4-OH tamoxifen (a major biologically active metabolite), and 17 beta -estradiol in native myocytes. Patch clamp recordings demonstrate BK channels from beta1(-/-) mice were similar to wild type with the exception of markedly reduced Ca2+/voltage sensitivity and faster activation kinetics. In wild type myocytes, (xeno)estrogens increased NPo (P-o x the number of channels, N), shifted the voltage of half-activation (V-1/2) to more negative potentials, and decreased unitary conductance. These effects were non-genomic and direct, because they were rapid, reversible, and observed in cell-free patches. None of the (xeno)estrogens increased the NP. of BK channels from beta1(-/-) mice, but all three agents decreased single channel conductance. Thus, (xeno)estrogens increase BK NP. through a mechanism involving the beta1 subunit. The decrease in conductance did not require the beta1 subunit and probably reflects an interaction with the pore-forming a subunit. We demonstrate regulation of smooth muscle BK channels by physiological (steroid hormones) and pharmacological (chemotherapeutic) agents and reveal the critical role of the beta1 subunit in these responses in native myocytes.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Dick, GM (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Anderson Med Bldg 352, Reno, NV 89557 USA.	greg@physio.unr.edu	Dick, Gregory/G-3032-2010	Dick, Gregory/0000-0003-1444-6436	NIDDK NIH HHS [F32 DK09947, DK41315] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009947, P01DK041315] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen MC, 1998, EUR J PHARMACOL, V354, P261, DOI 10.1016/S0014-2999(98)00454-3; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BORGNA JL, 1981, J BIOL CHEM, V256, P859; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Dick GM, 1999, BRIT J PHARMACOL, V127, P1819, DOI 10.1038/sj.bjp.0702730; Dick GM, 2001, J BIOL CHEM, V276, P34594, DOI 10.1074/jbc.M104689200; Doughty JM, 1998, J PHYSIOL-LONDON, V507, P433, DOI 10.1111/j.1469-7793.1998.433bt.x; Fettiplace R, 1999, ANNU REV PHYSIOL, V61, P809, DOI 10.1146/annurev.physiol.61.1.809; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; Hardy SP, 1998, FEBS LETT, V434, P236, DOI 10.1016/S0014-5793(98)00974-0; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Koh SD, 1997, AM J PHYSIOL-CELL PH, V273, pC2010, DOI 10.1152/ajpcell.1997.273.6.C2010; Kostrzewska A, 1997, AM J OBSTET GYNECOL, V176, P381, DOI 10.1016/S0002-9378(97)70503-9; LATORRE R, 1982, P NATL ACAD SCI-BIOL, V79, P805, DOI 10.1073/pnas.79.3.805; LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842; MARSHALL K, 1987, BRIT J PHARMACOL, V92, P429, DOI 10.1111/j.1476-5381.1987.tb11339.x; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Nelson MT, 1997, J PHYSIOL-LONDON, V502, P259, DOI 10.1111/j.1469-7793.1997.259bk.x; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Silberberg SD, 1996, BIOPHYS J, V70, P2640, DOI 10.1016/S0006-3495(96)79833-8; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Welsh DG, 2000, J PHYSIOL-LONDON, V527, P139, DOI 10.1111/j.1469-7793.2000.t01-1-00139.x; White RE, 2000, CIRC RES, V86, P897, DOI 10.1161/01.RES.86.8.897	41	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44835	44840		10.1074/jbc.M106851200	http://dx.doi.org/10.1074/jbc.M106851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11590153	hybrid			2022-12-27	WOS:000172406700068
J	Heyduk, E; Baichoo, N; Heyduk, T				Heyduk, E; Baichoo, N; Heyduk, T			Interaction of the alpha-subunit of Escherichia coli RNA polymerase with DNA - Rigid body nature of the protein-DNA contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; FACTOR-INDEPENDENT ACTIVATION; FOOTPRINTING TECHNIQUE; RECEPTOR PROTEIN; RRNB P1; COMPLEX-FORMATION; PROMOTER; BINDING; ELEMENT; TRANSCRIPTION	The alpha -subunit of Escherichia coli RNA polymerase plays an important role in the activity of many promoters by providing a direct protein-DNA contact with a specific sequence (UP element) located upstream of the core promoter sequence. To obtain insight into the nature of thermodynamic forces involved in the formation of this protein-DNA contact, the binding of the alpha -subunit of E. coli RNA polymerase to a fluorochrome-labeled DNA fragment containing the rrnB P1 promoter UP element sequence was quantitatively studied using fluorescence polarization. The alpha dimer and DNA formed a 1:1 complex in solution. Complex formation at 25 degreesC was enthalpy-driven, the binding was accompanied by a net release of 1-2 ions, and no significant specific ion effects were observed. The van't Hoff plot of temperature dependence of binding was linear suggesting that the heat capacity change (Deltac(p)) was close to zero. Protein footprinting with hydroxyradicals showed that the protein did not change its conformation upon protein-DNA contact formation. No conformational changes in the DNA molecule were detected by CD spectroscopy upon protein-DNA complex formation. The thermodynamic characteristics of the binding together with the lack of significant conformational changes in the protein and in the DNA suggested that the alpha -subunit formed a rigid body-like contact with the DNA in which a tight complementary recognition interface between alpha -subunit and DNA was not formed.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@slu.edu			NIGMS NIH HHS [GM50514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM050514, R01GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baichoo N, 1999, J MOL BIOL, V290, P37, DOI 10.1006/jmbi.1999.2858; Baichoo N, 1999, PROTEIN SCI, V8, P518; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; ELLINGER T, 1994, J MOL BIOL, V239, P466, DOI 10.1006/jmbi.1994.1389; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; HALFMAN CJ, 1972, BIOCHEMISTRY-US, V11, P3493, DOI 10.1021/bi00768a025; Hard T, 1996, BIOPHYS CHEM, V62, P121, DOI 10.1016/S0301-4622(96)02197-7; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Heyduk T, 2001, MET IONS BIOL SYST, V38, P255; IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/bip.1973.360120109; IVANOV VI, 1995, J MOL BIOL, V245, P228, DOI 10.1006/jmbi.1994.0019; Jen-Jacobson L, 2000, STRUCTURE, V8, P1015, DOI 10.1016/S0969-2126(00)00501-3; Jen-Jacobson L, 2000, SUPRAMOL CHEM, V12, P143, DOI 10.1080/10610270008027446; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1996, EMBO J, V15, P4358, DOI 10.1002/j.1460-2075.1996.tb00809.x; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Riccelli PV, 1999, BIOCHEMISTRY-US, V38, P11197, DOI 10.1021/bi9904407; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Strainic MG, 1998, BIOCHEMISTRY-US, V37, P18074, DOI 10.1021/bi9813431; Tagami H, 1999, P NATL ACAD SCI USA, V96, P7202, DOI 10.1073/pnas.96.13.7202; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	39	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44598	44603		10.1074/jbc.M107760200	http://dx.doi.org/10.1074/jbc.M107760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571305	hybrid			2022-12-27	WOS:000172406700036
J	Lu, RQ; Pitha, PM				Lu, RQ; Pitha, PM			Monocyte differentiation to macrophage requires interferon regulatory factor 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; POSITIVE FEEDBACK; VIRUS-INFECTION; ALPHA GENES; CELLS; IRF-7; PROLIFERATION; ACTIVATION; EXPRESSION; INDUCTION	Interferon regulatory factors are a growing family of transcription factor that have been implicated in cellular events such as cell-growth regulation, antiviral defense, and development of the immune system. Interferon regulatory factor 7 (IRF-7) is expressed predominantly in lymphoid tissues and has been studied extensively in the context of viral infection and the induction of interferon and cytokine gene expression. In this paper, the involvement of IRF-7 in monocyte differentiation was examined in U937, HL60, and human primary macrophages. We report the induction of IRF-7 expression by 12-O-tetradecanoylphorbol-13-acetate in U937 and HL60 cells and demonstrate that this induction is essential for the monocyte differentiation to macrophages. We show that the monocyte differentiation is inhibited in cells expressing a dominant negative IRF-7 mutant, as evidenced by decreased expression of two macrophage-differentiation markers, CD11b and CD11c, and impaired phagocytic activity. In addition, we demonstrate that overexpression of IRF-7 is sufficient to trigger monocyte differentiation and to induce cell cycle arrest. The identification of IRF-7 as a key regulator in monocyte differentiation suggests a novel function of IRF-7 in innate immunity.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737, R21AI048081, R21AI019737] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19737-18, AI 48081] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Fantuzzi L, 2000, J LEUKOCYTE BIOL, V68, P391; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lohoff M, 2000, J EXP MED, V192, P325, DOI 10.1084/jem.192.3.325; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Manzella L, 1999, EUR J IMMUNOL, V29, P3009, DOI 10.1002/(SICI)1521-4141(199909)29:09<3009::AID-IMMU3009>3.0.CO;2-H; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001; Zhang LW, 2000, J VIROL, V74, P1061, DOI 10.1128/JVI.74.3.1061-1068.2000	31	69	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45491	45496		10.1074/jbc.C100421200	http://dx.doi.org/10.1074/jbc.C100421200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11585813	hybrid			2022-12-27	WOS:000172406700148
J	Wilson, GM; Sutphen, K; Bolikal, S; Chuang, KY; Brewer, G				Wilson, GM; Sutphen, K; Bolikal, S; Chuang, KY; Brewer, G			Thermodynamics and kinetics of Hsp70 association with A+U-rich mRNA-destabilizing sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; MOLECULAR CHAPERONE DNAK; HEAT-SHOCK RESPONSE; PROTEIN INTERACTIONS; BINDING ACTIVITY; MAMMALIAN-CELLS; ELEMENT; AUF1; DEGRADATION; RECOGNITION	Rapid mRNA degradation directed by A + U-rich elements (AREs) is mediated by the interaction of specific RNA-binding proteins to these sequences. The protein chaperone Hsp70 has been identified in a cellular complex containing the ARE-binding protein AUF1 and has also been detected in direct contact with A + U-rich RNA substrates, indicating that Hsp70 may be involved in the regulation of ARE-directed mRNA turnover. By using gel mobility shift and fluorescence anisotropy assays, we have determined that Hsp70 directly and specifically associates with U-rich RNA substrates in solution. With the ARE from tumor necrosis factor alpha (TNF alpha) mRNA, Hsp70 forms a dynamic complex consistent with a 1:1 association of protein:RNA but demonstrates cooperative binding behavior on polyuridylate substrates. Unlike AUF1, the RNA binding activity of Hsp70 is not regulated by ion-dependent folding of the TNF alpha ARE, suggesting that AUF1 and Hsp70 recognize distinct binding determinants on this RNA substrate. Binding of Hsp70 to the TNF alpha ARE is driven entirely by enthalpy at physiological temperatures, indicating that burial of hydrophobic surfaces is likely the principal mechanism stabilizing the Hsp70-RNA complex. Potential roles for the interaction of Hsp70 with ARE-containing mRNAs in the regulation of mRNA turnover and/or translational efficiency are discussed.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wilson, GM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA.	wilsongm@umdnj.edu; brewerga@umdnj.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; BEAUDETTE NV, 1980, CRC CR REV BIOCH MOL, V9, P145, DOI 10.3109/10409238009105433; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Brewer G, 1999, J BIOL CHEM, V274, P16174, DOI 10.1074/jbc.274.23.16174; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Carter DA, 1997, FEBS LETT, V416, P81, DOI 10.1016/S0014-5793(97)01174-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; Hall KB, 1995, METHOD ENZYMOL, V259, P261; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Horton LE, 2001, J BIOL CHEM, V276, P14426, DOI 10.1074/jbc.M100266200; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kasper P, 2000, PROTEINS, V40, P185, DOI 10.1002/(SICI)1097-0134(20000801)40:2<185::AID-PROT20>3.0.CO;2-X; Katsamba PS, 2001, J BIOL CHEM, V276, P21476, DOI 10.1074/jbc.M101624200; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; RAYMOND V, 1989, ONCOGENE RES, V5, P1; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Smykal P, 2000, EUR J BIOCHEM, V267, P2195, DOI 10.1046/j.1432-1327.2000.01223.x; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	66	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44450	44456		10.1074/jbc.M108521200	http://dx.doi.org/10.1074/jbc.M108521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581272	hybrid			2022-12-27	WOS:000172406700015
J	Wang, LQ; Wu, Q; Qiu, P; Mirza, A; McGuirk, M; Kirschmeier, P; Greene, JR; Wang, YL; Pickett, CB; Liu, SX				Wang, LQ; Wu, Q; Qiu, P; Mirza, A; McGuirk, M; Kirschmeier, P; Greene, JR; Wang, YL; Pickett, CB; Liu, SX			Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; EXPRESSION; PROMOTER; CELLS; TRANSACTIVATION; REPRESSION; APOPTOSIS; SEQUENCE; ELEMENT; BINDS	The completion of the human genome sequence (International Human Genome Sequence Consortium (2001) Nature 409, 860-921; Venter, J. C., et al (2001) Science 291, 1304-1351) allows for new ways to analyze global cellular regulatory mechanisms. Here we present a strategy to identify genes regulated by specific transcription factors in the human genome, and apply it to p53. We first collected promoters or introns of all genes available using two methods: GenBank (TM) annotation and a computationally derived transcript map. 4,852 genes analyzed in this way contained at least one p53 consensus binding sequence. Of 13 genes randomly selected for mRNA analysis, 11 were shown to respond to p53 expression. Five promoters were analyzed by chromatin immunoprecipitation, which revealed that all were bound by p53 in vivo. We then analyzed 33,615 unique human genes on cDNA microarrays, identifying 1,501 genes that respond to p53 expression. A parameter was derived that demonstrates that in silico prediction greatly enriches for genes that are activated and repressed by p53 and assists us to suggest other signaling pathways that may be connected to p53. The methods shown here illustrate a novel approach to analysis of global gene regulatory network through the integration of human genomic sequence information and genome-wide gene expression analysis.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Human Genom Res Dept, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Liu, SX (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA.	suxing.liu@spcorp.com						Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Daemen MARC, 2000, CIRCULATION, V102, P1420, DOI 10.1161/01.CIR.102.12.1420; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrer FA, 2000, J UROLOGY, V164, P1016, DOI 10.1016/S0022-5347(05)67240-0; FRANK SR, 2001, IN PRESS GENES DEV; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Hasegawa T, 1998, GROWTH HORM IGF RES, V8, P277, DOI 10.1016/S1096-6374(98)80122-6; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JUVEN T, 1993, ONCOGENE, V8, P3411; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SAMATAR A, 2001, ONCOGENOMICS DISSECT, P84; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wen SF, 2000, CANCER GENE THER, V7, P1469, DOI 10.1038/sj.cgt.7700257; YAGINUMA Y, 1992, CANCER RES, V52, P4196	36	132	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43604	43610		10.1074/jbc.M106570200	http://dx.doi.org/10.1074/jbc.M106570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571296	hybrid			2022-12-27	WOS:000172297700018
J	Mohammadi, K; Kometiani, P; Xie, ZJ; Askari, A				Mohammadi, K; Kometiani, P; Xie, ZJ; Askari, A			Role of protein kinase C in the signal pathways that link Na+/K+-ATPase to ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; TRANSDUCING FUNCTION; K+-ATPASE; DIFFERENTIAL REGULATION; ISOFORM EXPRESSION; INDUCED ACTIVATION; OUABAIN; INHIBITION; PHOSPHORYLATION; HYPERTROPHY	We have shown before that Na+/K+-ATPase acts as a signal transducer, through protein-protein interactions, in addition to being an ion pump. Interaction of ouabain with the enzyme of the intact cells causes activation of Src, transactivation of EGFR, and activation of the Ras/ERK1/2 cascade. To determine the role of protein kinase C (PKC) in this pathway, neonatal rat cardiac myocytes were exposed to ouabain and assayed for translocation/activation of PKC from cytosolic to particulate fractions. Ouabain caused rapid and sustained stimulation of this translocation, evidenced by the assay of Ca2+-dependent and Ca2+-independent PKC activities and by the immunoblot analysis of the alpha, delta, and epsilon isoforms of PKC. Dose-dependent stimulation of PKC translocation by ouabain (1-100 mum) was accompanied by no more than 50% inhibition of Na+/K+-ATPase and doubling of [Ca2+](i), changes that do not affect myocyte viability and are known to be associated with positive inotropic, but not toxic, effects of ouabain in rat cardiac ventricles. Ouabain-induced activation of ERK1/2 was blocked by PKC inhibitors calphostin C and chelerythrine. An inhibitor of phosphoinositide turnover in myocytes also antagonized ouabain-induced PKC translocation and ERK1/2 activation. These and previous findings indicate that ouabain-induced activation of PKC and Ras, each linked to Na+/K+-ATPase through Src/EGFR, are both required for the activation of ERK1/2. Ouabain-induced PKC translocation and ERK1/2 activation were dependent on the presence of Ca2+ in the medium, suggesting that the signal-transducing and ion-pumping functions of Na+/K+-ATPase cooperate in activation of these protein kinases and the resulting regulation of contractility and growth of the cardiac myocyte.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA		Askari, A (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	mheck@mco.edu			NHLBI NIH HHS [HL-63238, HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL063238] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1976, LIFE SCI, V18, P135, DOI 10.1016/0024-3205(76)90017-5; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CLERK A, 1994, J BIOL CHEM, V269, P32848; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; GOTOH H, 1993, BIOCHEM BIOPH RES CO, V194, P72, DOI 10.1006/bbrc.1993.1786; GRUPP G, 1984, P SOC EXP BIOL MED, V175, P39; GUSOVSKY F, 1986, P NATL ACAD SCI USA, V83, P3003, DOI 10.1073/pnas.83.9.3003; Haas M, 2000, J BIOL CHEM, V275, P27832; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HO AK, 1987, BIOCHEM BIOPH RES CO, V142, P819, DOI 10.1016/0006-291X(87)91487-2; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; Jiang TR, 1996, CIRC RES, V78, P553, DOI 10.1161/01.RES.78.4.553; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Kometiani P, 2001, AM J PHYSIOL-HEART C, V280, pH1415, DOI 10.1152/ajpheart.2001.280.3.H1415; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2000, J BIOL CHEM, V275, P27838; Lundmark JL, 1999, AM J PHYSIOL-HEART C, V277, pH999, DOI 10.1152/ajpheart.1999.277.3.H999; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; Mohammadi K, 1997, J MOL CELL CARDIOL, V29, P1687, DOI 10.1006/jmcc.1997.0411; Mohammadi K, 2000, BIOPHYS J, V78, p79A; Mohammadi K, 2001, FASEB J, V15, pA443; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; Naruse K, 2000, CIRC RES, V86, P1104; Nicolas JM, 1998, J MOL CELL CARDIOL, V30, P2591, DOI 10.1006/jmcc.1998.0816; OTANI H, 1989, MOL CELL BIOCHEM, V90, P111; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RouetBenzineb P, 1996, CIRC RES, V79, P153, DOI 10.1161/01.RES.79.2.153; Rybin V, 1996, CIRC RES, V79, P388, DOI 10.1161/01.RES.79.3.388; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwartz A, 1988, Prog Clin Biol Res, V268B, P321; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; STEMMER P, 1988, BIOCHIM BIOPHYS ACTA, V940, P188, DOI 10.1016/0005-2736(88)90194-0; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; THOMAS TP, 1987, METHOD ENZYMOL, V141, P399; Tian J, 2001, AM J PHYSIOL-HEART C, V281, pH1899, DOI 10.1152/ajpheart.2001.281.5.H1899; WARD CA, 1992, J MOL CELL CARDIOL, V24, P937, DOI 10.1016/0022-2828(92)91861-X; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323	52	115	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42050	42056		10.1074/jbc.M107892200	http://dx.doi.org/10.1074/jbc.M107892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11562372	hybrid			2022-12-27	WOS:000172450400069
J	Ma, YP; Li, DW; Chai, L; Luciani, AM; Ford, D; Morgan, J; Maizel, AL				Ma, YP; Li, DW; Chai, L; Luciani, AM; Ford, D; Morgan, J; Maizel, AL			Cloning and characterization of two promoters for the human HSAL2 gene and their transcriptional repression by the Wilms tumor suppressor gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOWNES-BROCKS-SYNDROME; ZINC-FINGER PROTEIN; HOMEOTIC GENE; DROSOPHILA EMBRYO; DNA METHYLATION; SPALT; EXPRESSION; HEDGEHOG; REGION; CANCER	HSAL2 is a member of a gene family that encodes a group of putative developmental transcription factors. The HSAL gene complex was originally identified on the basis of DNA sequence homology to a region-specific homeotic gene (SAL) in Drosophila. This study reveals a novel, functional 5' exon for HSAL2 and demonstrates that two distinct HSAL2 gene transcripts arise from two overlapping transcription units, resulting in proteins that differ by 25 amino acids. By utilizing functional luciferase reporter assays, two distinct promoters for HSAL2, P1 for the proximal promoter (upstream of exon 1) and P2 for the distal promoter (upstream of exon 1A), were identified. Evaluation of mRNA prevalence and tissue specificity, with particular focus on adult tissues, revealed that production of mRNA from P1 was selective and relatively rare. Production of mRNA from P2 was demonstrably higher and was expressed by a greater number of tissues. In contradistinction, HSAL2 expression directed by P2 was undetectable in some malignant populations as opposed to their normal human counterparts, suggesting a potential role as a tumor suppressor gene. Consensus-binding sites were identified for several transcriptional factors, with multiple sites for WT-1, and Hox-1.3 present within both the P1 and P2 regions. In transient transfection assays, transcription from both HSAL2 P1 and P2 was strikingly repressed by the WT-1 tumor suppressor protein. These findings suggest that an intracellular WT-1/HSAL2 pathway may play a role in development and hematopoiesis.	Boston Univ, Sch Med, Dept Pathol, Roger Williams Med Ctr, Providence, RI 02908 USA; Rhode Isl Hosp, Dept Pathol, Providence, RI 02903 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Boston University; Roger Williams Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital; Harvard University; Harvard Medical School	Maizel, AL (corresponding author), Boston Univ, Sch Med, Dept Pathol, Roger Williams Med Ctr, 825 Chalkstone Ave, Providence, RI 02908 USA.			Chai, Li/0000-0003-1937-4750	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049649] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-49649] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bandera CA, 1997, CANCER RES, V57, P513; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DRESSLER GR, 1995, SEMIN NEPHROL, V15, P263; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GLEAVE ME, 1993, CANCER RES, V53, P5300; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Hollemann T, 1996, MECH DEVELOP, V55, P19, DOI 10.1016/0925-4773(95)00485-8; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; Ingham PW, 1998, CURR OPIN GENET DEV, V8, P88, DOI 10.1016/S0959-437X(98)80067-1; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kohlhase J, 1999, GENOMICS, V62, P216, DOI 10.1006/geno.1999.6005; Kohlhase J, 1999, AM J HUM GENET, V64, P435, DOI 10.1086/302238; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Kohlhase J, 2000, MAMM GENOME, V11, P64, DOI 10.1007/s003350010012; Koster R, 1997, DEVELOPMENT, V124, P3147; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LI D, 2001, IN PRESS P NATL ACAD; Ma YP, 2001, PEDIATR NEPHROL, V16, P701, DOI 10.1007/s004670100624; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Ott T, 1996, MECH DEVELOP, V56, P117, DOI 10.1016/0925-4773(96)00516-3; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Schmutte C, 1998, BIOL CHEM, V379, P377; Stayner CK, 1998, J BIOL CHEM, V273, P25472, DOI 10.1074/jbc.273.39.25472; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135	37	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48223	48230		10.1074/jbc.M106468200	http://dx.doi.org/10.1074/jbc.M106468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11577094	hybrid			2022-12-27	WOS:000172927000065
J	Ferri-Fioni, ML; Schmitt, E; Soutourina, J; Plateau, P; Mechulam, Y; Blanquet, S				Ferri-Fioni, ML; Schmitt, E; Soutourina, J; Plateau, P; Mechulam, Y; Blanquet, S			Structure of crystalline D-Tyr-tRNA(Tyr) deacylase - A representative of a new class of tRNA-dependent hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN; REFINEMENT; RESOLUTION; METABOLISM; REJECTION; ISOLEUCYL; METHIONYL	Cell growth inhibition by several D-amino acids can be explained by an in vivo production Of D-aminoacyl-tRNA molecules. Escherichia coli and yeast cells express an enzyme, D-Tyr-tRNA(Tyr) deacylase, capable of recycling such D-aminoacyl-tRNA molecules into free tRNA and D-amino acid. Accordingly, upon inactivation of the genes of the above deacylases, the toxicity Of D-amino acids increases. Orthologs of the deacylase are found in many cells. In this study, the crystallographic structure of dimeric E. coli D-Tyr-tRNA(Tyr) deacylase at 1.55 Angstrom resolution is reported. The structure corresponds to a beta -barrel closed on one side by a beta -sheet lid. This barrel results from the assembly of the two subunits. Analysis of the structure in relation with sequence homologies in the orthologous family suggests the location of the active sites at the carboxy end of the beta -strands. The solved structure markedly differs from those of all other documented tRNA-dependent hydrolases.	Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris	Blanquet, S (corresponding author), Ecole Polytech, CNRS, UMR 7654, Biochim Lab, F-91128 Palaiseau, France.		Mechulam, Yves/F-3313-2019; SCHMITT, Emmanuelle/F-2605-2019; Soutourina, Julie/F-8305-2014; Emmanuelle, SCHMITT/ABF-8658-2020	Mechulam, Yves/0000-0003-3586-3554; SCHMITT, Emmanuelle/0000-0001-7532-338X; Soutourina, Julie/0000-0001-5218-2350; Emmanuelle, SCHMITT/0000-0001-7532-338X				Abrahams JP, 1998, CURR OPIN STRUC BIOL, V8, P601, DOI 10.1016/S0959-440X(98)80151-6; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CUZIN F, 1967, P NATL ACAD SCI USA, V58, P2079, DOI 10.1073/pnas.58.5.2079; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FOURMY D, 1993, J MOL BIOL, V231, P1068, DOI 10.1006/jmbi.1993.1352; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; MAYAUX JF, 1981, BIOCHEMISTRY-US, V20, P4647, DOI 10.1021/bi00519a020; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SOURGOUTCHOV A, 1974, EUR J BIOCHEM, V46, P431, DOI 10.1111/j.1432-1033.1974.tb03636.x; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	29	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47285	47290		10.1074/jbc.M106550200	http://dx.doi.org/10.1074/jbc.M106550200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11568181	hybrid			2022-12-27	WOS:000172768500082
J	Makino, T; Takaishi, M; Morohashi, M; Huh, NH				Makino, T; Takaishi, M; Morohashi, M; Huh, NH			Hornerin, a novel profilaggrin-like protein and differentiation-specific marker isolated from mouse skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; CALCIUM-BINDING PROTEIN; STRATUM-CORNEUM; INTERMEDIATE FILAMENTS; RHEUMATOID-ARTHRITIS; ICHTHYOSIS-VULGARIS; UROCANIC ACID; FILAGGRIN; LORICRIN; GENE	A novel mouse cDNA named hornerin was isolated by RNA differential display applied to developing mouse skin. Hornerin, which has 2,496 amino acids, comprises EF-hand domains at the N terminus followed by a spacer sequence and a large repetitive domain, indicating that hornerin is a novel member of the "fused gene"-type cornified envelope precursor protein family. The repetitive domain of hornerin was found to be rich in glycine, serine, and glutamine. Hornerin was expressed in the tongue, esophagus, forestomach, and skin among the adult mouse tissues examined, all of them cornifying stratified epithelium. In the embryonic mouse skin, hornerin mRNA was first detected on gestational day 15.5 in the epidermis coincidentally with the formation of a granular layer. In accordance with this, hornerin was detected in the granular and cornified layers of the mature epidermis. In the granular cells of the epidermis, the hornerin protein was detected in keratohyalin granules together with profilaggrin. Furthermore, Western blot analysis of the mouse skin showed that the hornerin protein was cleaved during the process of epidermal differentiation, indicating possible posttranslational proteolytic processing as is observed in profilaggrin. Differentiation of primary mouse epidermal keratinocytes with 0.12 mm Ca2+ resulted in the induction of hornerin. These results indicate that hornerin is structurally as well as functionally most similar to profilaggrin among the family members and possibly plays pleiotropic roles, including a role in cornification.	Okayama Univ, Grad Sch Med & Dent, Dept Cell Biol, Okayama 7008558, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Dermatol, Toyama 9300194, Japan	Okayama University; University of Toyama	Huh, NH (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Cell Biol, 2-5-1 Shikatachou, Okayama 7008558, Japan.	namu@md.okayama-u.ac.jp	HUH, Nam-ho/B-1613-2011					Dale B. A., 1994, KERATINOCYTE HDB, P323; DALE BA, 1977, BIOCHIM BIOPHYS ACTA, V491, P193, DOI 10.1016/0005-2795(77)90055-1; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531, DOI 10.1177/39.11.1717544; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOHL D, 1991, J BIOL CHEM, V266, P6626; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Ishida-Yamamoto A, 1998, HISTOL HISTOPATHOL, V13, P819, DOI 10.14670/HH-13.819; Ishisaki Z, 2001, GENOMICS, V74, P172, DOI 10.1006/geno.2001.6544; Korge BP, 1997, J INVEST DERMATOL, V109, P604, DOI 10.1111/1523-1747.ep12337534; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; KUBILUS J, 1985, J INVEST DERMATOL, V85, P513, DOI 10.1111/1523-1747.ep12277310; Kuechle MK, 2000, CELL DEATH DIFFER, V7, P566, DOI 10.1038/sj.cdd.4400687; LEE SC, 1993, J BIOL CHEM, V268, P12164; LONSDALEECCLES JD, 1984, BIOCHEMISTRY-US, V23, P1239, DOI 10.1021/bi00301a034; Maestrini E, 1996, NAT GENET, V13, P70, DOI 10.1038/ng0596-70; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; McGrath JA, 2001, ADV GENET, V43, P1, DOI 10.1016/S0065-2660(01)43002-1; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NIRUNSUKSIRI W, 1995, J BIOL CHEM, V270, P871, DOI 10.1074/jbc.270.2.871; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SCOTT IR, 1982, BIOCHIM BIOPHYS ACTA, V719, P110, DOI 10.1016/0304-4165(82)90314-2; SCOTT IR, 1981, BIOCHEM J, V194, P829, DOI 10.1042/bj1940829; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; SENGEL P, 1976, MORPHOGENESIS SKIN, P5; SIMON M, 1993, J CLIN INVEST, V92, P1387, DOI 10.1172/JCI116713; Slack SL, 1998, J RHEUMATOL, V25, P847; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; Takaishi M, 1999, BIOCHEM BIOPH RES CO, V264, P81, DOI 10.1006/bbrc.1999.1477; Takaishi M, 1998, J INVEST DERMATOL, V111, P128, DOI 10.1046/j.1523-1747.1998.00241.x	40	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47445	47452		10.1074/jbc.M107512200	http://dx.doi.org/10.1074/jbc.M107512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11572870	hybrid			2022-12-27	WOS:000172768500100
J	Sakamoto, JJ; Sasaki, M; Tsuchido, T				Sakamoto, JJ; Sasaki, M; Tsuchido, T			Purification and characterization of a Bacillus subtilis 168 nuclease, YokF, involved in chromosomal DNA degradation and cell death caused by thermal shock treatments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; SIGNAL PEPTIDASE; SECRETION; ENDONUCLEASE; EXPRESSION; SEQUENCE; GENES; LIPOPROTEIN; APOPTOSIS	We purified and characterized a 39-kDa Bacillus subtilis 168 nuclease that has been suggested in this laboratory to be involved in chromosomal DNA degradation induced by lethal heat and cold shock treatments in vivo. The nuclease activity was inhibited in vitro by aurintricalboxylic acid but not by Zn2+. By the mutant analysis, we identified the 39-kDa nuclease as a product of yokF gene. The yokF gene contained a putative lipoprotein signal peptide motif. After in vivo exposure to lethal heat and cold stresses, the chromosomal DNA fragmentation was reduced in the yokF mutant, which demonstrated about a 2-10-fold higher survival rate than the wild type. The yokF mutant was found to be more sensitive to mitomycin C than the wild type. The transformation efficiency of the yokF mutant was about 10 times higher than that of the wild type. It is suggested that when B. subtilis cells are exposed to a stressful thermal shock resulting in membrane perturbation, YokF nuclease consequently dislocates into the cytoplasm and then attacks DNA.	Kansai Univ, Dept Biotechnol, Fac Engn, Suita, Osaka 5648680, Japan; Kansai Univ, High Technol Res Ctr, Suita, Osaka 5648680, Japan	Kansai University; Kansai University	Tsuchido, T (corresponding author), Kansai Univ, Dept Biotechnol, Fac Engn, Yamate Cho, Suita, Osaka 5648680, Japan.			Mori, Miho/0000-0002-9651-9856				AHRENHOLTZ I, 1994, APPL ENVIRON MICROB, V60, P3746, DOI 10.1128/AEM.60.10.3746-3751.1994; Bendjennat M, 1997, J BACTERIOL, V179, P2210, DOI 10.1128/jb.179.7.2210-2220.1997; BRIDGES BA, 1969, J GEN MICROBIOL, V58, P115, DOI 10.1099/00221287-58-1-115; COUGHLIN SA, 1983, ANAL BIOCHEM, V133, P322, DOI 10.1016/0003-2697(83)90091-X; CRINE P, 1976, ANAL BIOCHEM, V75, P583, DOI 10.1016/0003-2697(76)90113-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ghim S Y, 1998, DNA Res, V5, P195, DOI 10.1093/dnares/5.3.195; GROEZ N, 1977, BIOCHEM BIOPH RES CO, V77, P1183; Handa N, 2000, J BACTERIOL, V182, P2218, DOI 10.1128/JB.182.8.2218-2229.2000; Hegarty CP, 1940, J BACTERIOL, V39, P475, DOI 10.1128/JB.39.5.475-484.1940; ISHIZAWA M, 1991, NUCLEIC ACIDS RES, V19, P5792, DOI 10.1093/nar/19.20.5792; Jarvill-Taylor KJ, 1999, J BACTERIOL, V181, P1853, DOI 10.1128/JB.181.6.1853-1860.1999; JEKEL M, 1995, GENE, V154, P55, DOI 10.1016/0378-1119(94)00835-G; KADOTA H, 1978, SPORES, V7, P27; KERR IM, 1965, BIOCHEM BIOPH RES CO, V20, P154, DOI 10.1016/0006-291X(65)90339-6; Kleanthous C, 1998, MOL MICROBIOL, V28, P227, DOI 10.1046/j.1365-2958.1998.00811.x; KOOISTRA J, 1991, J BACTERIOL, V173, P3644, DOI 10.1128/JB.173.12.3644-3655.1991; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lazarevic V, 1999, MICROBIOL-UK, V145, P1055, DOI 10.1099/13500872-145-5-1055; Le Loir Y, 1998, J BACTERIOL, V180, P1895, DOI 10.1128/JB.180.7.1895-1903.1998; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; LIN J-J, 1992, Proceedings of the National Science Council Republic of China Part B Life Sciences, V16, P1; MCGRATH RA, 1966, NATURE, V212, P534, DOI 10.1038/212534a0; MERCHANTE R, 1995, J BACTERIOL, V177, P6176, DOI 10.1128/jb.177.21.6176-6183.1995; MILLER JR, 1987, J BACTERIOL, V169, P3508, DOI 10.1128/jb.169.8.3508-3514.1987; Poquet I, 1998, J BACTERIOL, V180, P1904, DOI 10.1128/JB.180.7.1904-1912.1998; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SAMBROOKS J, 1992, MOL CLONING LAB MANU; SATO M, 1968, J GEN APPL MICROBIOL, V14, P417, DOI 10.2323/jgam.14.417; SATO M, 1970, J GEN APPL MICROBIOL, V16, P279, DOI 10.2323/jgam.16.4_279; SCHER B, 1976, J BACTERIOL, V126, P429, DOI 10.1128/JB.126.1.429-438.1976; SCHER B, 1973, BIOCHEM BIOPH RES CO, V553, P595; SHEMYAKIN MF, 1979, EUR J BIOCHEM, V98, P417, DOI 10.1111/j.1432-1033.1979.tb13201.x; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; SUTER W, 1982, MUTAT RES, V97, P1, DOI 10.1016/0165-1161(82)90015-2; SVARACHORN A, 1991, J FERMENT BIOENG, V71, P281, DOI 10.1016/0922-338X(91)90283-M; TAKANO M, 1982, J FERMENT TECHNOL, V82, P189; TAYLOR RG, 1993, NUCLEIC ACIDS RES, V21, P1677, DOI 10.1093/nar/21.7.1677; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191; Tsuchido T., 1996, BIOCONTROL SCI, V1, P19, DOI [10.4265/bio.1.19, DOI 10.4265/BIO.1.19]; VANSINDEREN D, 1995, MOL MICROBIOL, V15, P213; VOSMAN B, 1988, J BACTERIOL, V170, P3703, DOI 10.1128/jb.170.8.3703-3710.1988; WOODCOCK E, 1972, NATURE-NEW BIOL, V237, P76, DOI 10.1038/newbio237076a0; Yamanaka K, 1997, FEMS MICROBIOL LETT, V150, P269, DOI 10.1111/j.1574-6968.1997.tb10380.x	46	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47046	47051		10.1074/jbc.M106205200	http://dx.doi.org/10.1074/jbc.M106205200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11584000	hybrid			2022-12-27	WOS:000172768500051
J	Seekoe, T; Peall, S; McIntosh, DB				Seekoe, T; Peall, S; McIntosh, DB			Thapsigargin and dimethyl sulfoxide activate medium P-i <-> HOH oxygen exchange catalyzed by sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ TRANSPORT ATPASE; CALCIUM ADENOSINE-TRIPHOSPHATASE; S3 STALK SEGMENT; INORGANIC-PHOSPHATE; OCCLUDED STATE; TIGHT-BINDING; RAPID RELEASE; PHOSPHORYLATION; INHIBITION; CA-2+-ATPASE	Thapsigargin is a potent inhibitor of sarcoplasmic reticulum. Ca2+-ATPase. It binds the Ca2+-free E2 conformation in the picomolar range, supposedly resulting in a largely catalytically inactive species. We now find that thapsigargin has little effect on medium P-i <----> HOH oxygen exchange and that this activity is greatly stimulated (up to 30-fold) in the presence of 30% (v/v) Me2SO. Assuming a simple two-step mechanism, we have evaluated the effect of thapsigargin and Me,SO on the four rate constants governing the reaction of Pi with Ca2+-ATPase. The principal effect of thapsigargin alone is to stimulate EP hydrolysis (k(-2)), whereas that of Me2SO is to greatly retard P-i. dissociation (k(-1)), accounting for its well known effect on increasing the apparent affinity for Pi. These effects persist when the agents are used in combination and substantially account for the activated oxygen exchange (upsilon (exchange) = k(-2)[EP]). Kinetic simulations show that the over;YI rate constant for the formation of EP is very fast (similar to 300 s(-1)) when the exchange is maximal. Thapsigargin greatly stabilizes Ca (2+)-ATPase against denaturation in detergent in the absence of Ca2+, as revealed by glutaraldehyde cross-linking, suggesting that the membrane helices lock together. It seems that the reactions at the phosphorylation site, associated with the activated exchange reaction, are occurring without much movement of the transport site helices, and we suggest that they may be associated solely with an occluded H+ state.	Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa; Dept Hlth, Forens Chem Labs, ZA-7915 Cape Town, South Africa	University of Cape Town	McIntosh, DB (corresponding author), Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa.	davidmci@chempath.uct.ac.za						ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ARIKI M, 1980, BIOCHEMISTRY-US, V19, P2001, DOI 10.1021/bi00550a042; CARVALHOALVES PC, 1987, J BIOL CHEM, V262, P6610; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Cornelius F, 1998, BIOCHEMISTRY-US, V37, P16686, DOI 10.1021/bi981571v; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DANKO S, 2001, FEBS LETT, V2456, P1; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; DAVIDSON GA, 1996, BIOCHIM BIOPHYS ACTA, V1286, P187; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; DEMEIS L, 1988, J BIOL CHEM, V263, P157; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; FORBUSH B, 1988, J BIOL CHEM, V263, P7961; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORGE V, 1993, J BIOL CHEM, V268, P10961; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; GUILLAIN F, 1984, BIOCHEMISTRY-US, V23, P4754, DOI 10.1021/bi00315a034; Hackney D D, 1980, Methods Enzymol, V64, P60; HACKNEY DD, 1978, P NATL ACAD SCI USA, V75, P3133, DOI 10.1073/pnas.75.7.3133; HAO LN, 1994, J BIOL CHEM, V269, P14268; Hua SM, 1997, BIOCHEMISTRY-US, V36, P11865, DOI 10.1021/bi970105n; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, J BIOL CHEM, V265, P19524; LOOMIS CR, 1982, BIOCHEMISTRY-US, V21, P151, DOI 10.1021/bi00530a026; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; MARTIN DW, 1981, BIOCHEMISTRY-US, V20, P4597, DOI 10.1021/bi00519a013; MCINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MCINTOSH DB, 1985, BIOCHEMISTRY-US, V24, P1244, DOI 10.1021/bi00326a029; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MINTZ E, 1993, BIOCHIM BIOPHYS ACTA, V1162, P227, DOI 10.1016/0167-4838(93)90152-H; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; Moutin MJ, 1998, EUR J BIOCHEM, V251, P682, DOI 10.1046/j.1432-1327.1998.2510682.x; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; STEMPEL KE, 1986, METHOD ENZYMOL, V126, P618; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	64	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46737	46744		10.1074/jbc.M106320200	http://dx.doi.org/10.1074/jbc.M106320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595736	Green Published, hybrid			2022-12-27	WOS:000172768500010
J	Arrate, MP; Rodriguez, JM; Tran, TM; Brock, TA; Cunningham, SA				Arrate, MP; Rodriguez, JM; Tran, TM; Brock, TA; Cunningham, SA			Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; IMMUNOGLOBULIN SUPERFAMILY; SEGMENTAL DIFFERENTIATIONS; LEUKOCYTE RECRUITMENT; VASCULAR ENDOTHELIUM; MONOCLONAL-ANTIBODY; PLATELET ACTIVATION; F11 RECEPTOR; MEMBER; TRANSMIGRATION	We have identified a third member of the junctional adhesion molecule (JAM) family. At the protein level JAM3 displays 36 and 32% identity to JAM2 and JAM1, respectively. The coding region is distributed over 9 exons and maps to chromosome 11q25. The gene shows widespread tissue expression with higher levels apparent in the kidney, brain, and placenta. At the cellular level we show expression of JAM3 transcript within endothelial cells. Our major finding is that JAM3 and JAM2 are binding partners. Thus, JAM3 ectodomain binds firmly to JAM2-Fc. This heterotypic interaction is maintained when JAM3-Fc is used to capture Chinese hamster ovary cells expressing full-length JAM2. In static adhesion assays we show that JAM3 is unable to bind to leukocyte cell lines. This is consistent with the lack of JAM2 expression. However, using JAM2-Fc pulldown experiments in combination with polyclonal anti-JAM3 serum, we demonstrate that JAM3 is the previously uncharacterized 43-kDa counter-receptor that mediates JAM2 adhesion to T cells. Most significantly we demonstrate up-regulation of JAM3 protein on peripheral blood lymphocytes following activation. Finally we show the utility of JAM3 ectodomain as an inhibitor of JAM2 adhesion.	Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA		Cunningham, SA (corresponding author), Texas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA.							Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Ebnet K, 2000, J BIOL CHEM, V275, P27979; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gupta SK, 2000, IUBMB LIFE, V50, P51; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; KORNECKI E, 1990, J BIOL CHEM, V265, P10042; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; Lechner F, 2000, J INFECT DIS, V182, P978, DOI 10.1086/315765; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Liu Y, 2000, J CELL SCI, V113, P2363; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Mayhan WG, 2001, MICROCIRCULATION, V8, P89, DOI 10.1038/sj.mn.7300154; Michel C. C., 1995, Microcirculation (New York), V2, P125, DOI 10.3109/10739689509146761; Muller WA, 1999, J LEUKOCYTE BIOL, V66, P698, DOI 10.1002/jlb.66.5.698; NAIK UP, 1995, BIOCHEM J, V310, P155, DOI 10.1042/bj3100155; Ozaki H, 2000, BIOCHEM BIOPH RES CO, V276, P873, DOI 10.1006/bbrc.2000.3574; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SIMIONESCU M, 1975, J CELL BIOL, V67, P863, DOI 10.1083/jcb.67.3.863; SIMIONESCU M, 1976, J CELL BIOL, V68, P705, DOI 10.1083/jcb.68.3.705; Smith DK, 1997, J MOL BIOL, V274, P530, DOI 10.1006/jmbi.1997.1432; Sobocka MB, 2000, BLOOD, V95, P2600; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Wiedle G, 2001, CRIT REV CL LAB SCI, V38, P1, DOI 10.1080/20014091084164; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4; Woodside DG, 1996, J IMMUNOL, V157, P700	39	171	199	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45826	45832		10.1074/jbc.M105972200	http://dx.doi.org/10.1074/jbc.M105972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590146	hybrid			2022-12-27	WOS:000172573100045
J	Bork, JM; Cox, MM; Inman, RB				Bork, JM; Cox, MM; Inman, RB			RecA protein filaments disassemble in the 5 ' to 3 ' direction on single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DUPLEX DNA; BINDING-PROTEIN; NUCLEOPROTEIN FILAMENTS; COMPLEXES; EXCHANGE; RECOMBINATION; SSDNA; ATP; ENDS	RecA protein forms filaments on both single- and double-stranded DNA. Several studies confirm that filament extension occurs in the 5' to 3' direction on single-stranded DNA. These filaments also disassemble in an end-dependent fashion, and several indirect observations suggest that the disassembly occurs on the end opposite to that at which assembly occurs. By labeling the 5' end of single-stranded DNA with a segment of duplex DNA, we demonstrate unambiguously that RecA filaments disassemble uniquely in the 5' to 3' direction.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM052725, R01GM032335, R01GM014711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52725, GM32335, GM14711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Churchill JJ, 1999, GENE DEV, V13, P901, DOI 10.1101/gad.13.7.901; COX MM, 1982, J BIOL CHEM, V257, P8523; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DAVIS RW, 1980, MANUAL GENETIC ENG A; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DUTREIX M, 1991, J MOL BIOL, V219, P645, DOI 10.1016/0022-2836(91)90661-O; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; KONFORTI BB, 1991, J BIOL CHEM, V266, P10112; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; McIlwraith MJ, 2001, J MOL BIOL, V305, P23, DOI 10.1006/jmbi.2000.4268; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; PUGH BF, 1989, J MOL BIOL, V205, P487, DOI 10.1016/0022-2836(89)90219-2; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SHANER SL, 1987, J BIOL CHEM, V262, P9211; SHANER SL, 1987, J BIOL CHEM, V262, P9220; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L	40	50	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45740	45743		10.1074/jbc.M109247200	http://dx.doi.org/10.1074/jbc.M109247200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574550	hybrid			2022-12-27	WOS:000172573100033
J	Frolov, A; Srivastava, K; Daphna-Iken, D; Traub, LM; Schaffer, JE; Ory, DS				Frolov, A; Srivastava, K; Daphna-Iken, D; Traub, LM; Schaffer, JE; Ory, DS			Cholesterol overload promotes morphogenesis of a Niemann-Pick C (NPC)-like compartment independent of inhibition of NPC1 or HE1/NPC2 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; INTRACELLULAR TRAFFICKING; DISEASE; TRANSPORT; PROTEIN; COMPLEMENTATION; LYSOSOMES; ESTERIFICATION; HOMEOSTASIS	Cholesterol accumulation in an aberrant endosomal/lysosomal compartment is the hallmark of Niemann-Pick type C (NPC) disease. To gain insight into the etiology of the NPC compartment, we studied a novel Chinese hamster ovary cell mutant that was identified through a genetic screen and phenocopies the NPC1 mutation. We show that the M87 mutant harbors a mutation in a gene distinct from the NPC1 and HE1/NPC2 disease genes. M87 cells have increased total cellular cholesterol with accumulation in an aberrant compartment that contains LAMP-1, LAMP-2, and NPC1, but not Cl-MPR, similar to the cholesterol-rich compartment in NPC mutant cells. We demonstrate that low-density lipoprotein receptor activity is increased 3-fold in the M87 mutant, and likely contributes to accumulation of excess cholesterol. In contrast to NPC1-null cells, the M87 mutant exhibits normal rates of delivery of endosomal cholesterol to the endoplasmic reticulum and to the plasma membrane. The preserved late endosomal function in the M87 mutant is associated with the presence of NPC1-containing multivesicular late endosomes and supports a role for these multivesicular late endosomes in the sorting and distribution of cholesterol. Our findings implicate cholesterol overload in the formation of an NPC-like compartment that is independent of inhibition of NPC1 or HE1/NPC2 function.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Washington University (WUSTL); Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ory, DS (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.			Traub, Linton/0000-0002-1303-0298	NHLBI NIH HHS [T32HL07275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; Bright NA, 1997, J CELL SCI, V110, P2027; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAHL NK, 1994, J LIPID RES, V35, P1839; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; DENG YP, 1988, P NATL ACAD SCI USA, V85, P3860, DOI 10.1073/pnas.85.11.3860; Denzer K, 2000, J CELL SCI, V113, P3365; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Higaki K, 2001, J BIOCHEM-TOKYO, V129, P875, DOI 10.1093/oxfordjournals.jbchem.a002932; KINSKY SC, 1970, ANNU REV PHARMACOLOG, V10, P119, DOI 10.1146/annurev.pa.10.040170.001003; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Lusa S, 2001, J CELL SCI, V114, P1893; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Steinberg SJ, 1996, J INHERIT METAB DIS, V19, P769, DOI 10.1007/BF01799171; STEINBERG SJ, 1994, J MED GENET, V31, P317, DOI 10.1136/jmg.31.4.317; Vanier MT, 1996, AM J HUM GENET, V58, P118; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537	41	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46414	46421		10.1074/jbc.M108099200	http://dx.doi.org/10.1074/jbc.M108099200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571306	hybrid			2022-12-27	WOS:000172573100125
J	Gruendler, C; Lin, Y; Farley, J; Wang, TW				Gruendler, C; Lin, Y; Farley, J; Wang, TW			Proteasomal degradation of Smad1 induced by bone morphogenetic proteins.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA FAMILY; ORNITHINE DECARBOXYLASE; DEPENDENT DEGRADATION; SIGNALING PATHWAYS; I RECEPTORS; SUBUNIT; FKBP12; REGULATORS; ANTIZYME; CLONING	The bone morphogenetic proteins (BMPs) regulate early embryogenesis and morphogenesis of multiple organs, such as bone, kidney, limbs, and muscle. Smad1 is one of the key signal transducers of BMPs and is responsible for transducing receptor activation signals from the cytoplasm to the nucleus, where Smad1 serves as a transcriptional regulator of various BMP-responsive genes. Based upon the ability of Smad1 to bind multiple proteins involved in proteasome-mediated degradation pathway, we investigated whether Smad1 could be a substrate for proteasome. We found that Smad1 is targeted to proteasome for degradation in response to BMP type I receptor activation. The targeting of Smad1 to proteasome involves not only the receptor activation-induced Smad1 ubiquitination but also the targeting functions of the ornithine decarboxylase antizyme and the proteasome beta subunit HsN3. Our studies provide the first evidence for BMP-induced proteasomal targeting and degradation of Smad1 and also reveal new players and novel mechanisms involved in this important aspect of Smad1 regulation and function.	Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA	Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Harvard University; Massachusetts General Hospital	Wang, TW (corresponding author), Virginia Mason Res Ctr, 1201 9th Ave, Seattle, WA 98101 USA.							Ausubel FM, 1994, CURRENT PROTOCOLS MO; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cruz M, 1997, GENE, V190, P251, DOI 10.1016/S0378-1119(97)00003-6; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Guo X, 2001, J NEUROBIOL, V48, P120, DOI 10.1002/neu.1046; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOPP F, 1995, J MOL BIOL, V248, P264; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Li XQ, 1996, J BIOL CHEM, V271, P4441; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1999, MOL CELL BIOL, V19, P7216; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Stockwell BR, 1998, CHEM BIOL, V5, P385, DOI 10.1016/S1074-5521(98)90072-2; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Thomson S, 1996, BIOCHEM J, V315, P733, DOI 10.1042/bj3150733; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	44	78	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46533	46543		10.1074/jbc.M105500200	http://dx.doi.org/10.1074/jbc.M105500200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11571290	hybrid			2022-12-27	WOS:000172573100139
J	Kozin, SA; Bertho, G; Mazur, AK; Rabesona, H; Girault, JP; Haertle, T; Takahashi, M; Debey, P; Hoa, GHB				Kozin, SA; Bertho, G; Mazur, AK; Rabesona, H; Girault, JP; Haertle, T; Takahashi, M; Debey, P; Hoa, GHB			Sheep prion protein synthetic peptide spanning helix 1 and beta-strand 2 (residues 142-166) shows beta-hairpin structure in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETECTED CIRCULAR-DICHROISM; PUTATIVE ALPHA-HELICES; SECONDARY STRUCTURE; CONFORMATIONAL TRANSITIONS; MOLECULAR-DYNAMICS; AMINO-ACIDS; SCRAPIE; NMR; SPECTROSCOPY; PRP	According to the "protein only" hypothesis, a conformational conversion of the non-pathogenic "cellular" prion isoform. into a pathogenic "scrapie" isoform is the fundamental event in the onset of prion diseases. During this pathogenic conversion, helix H1 and two adjacent surface loops L2 and L3 of the normal prion protein are thought to undergo a conformational transition into an extended beta -like structure, which is prompted by interactions with the pre-existing beta -sheet. To get more insight into the interaction between the helix and one of the beta -strands in the partially unfolded prion protein, the solution structure of a synthetic linear peptide spanning helix HI and beta -strand S2 (residues 142-166 in human numbering) was studied by circular dichroism. and nuclear magnetic resonance spectroscopies. We found that, in contrast to many prion fragments studied earlier, this peptide (i) is highly soluble and does not aggregate up to a millimolar concentration range in aqueous medium and (ii) exhibits an intrinsic propensity to a beta -hairpin like conformation at neutral pH. This beta -propensity can be one of the internal driving forces of the molecular rearrangement responsible for the pathogenic conversion of the prion protein.	INSERM, U473, F-94276 Le Kremlin Bicetre, France; INSERM, Natl Museum Nat Hist, EA 2703, Inst Biol Physicochim, F-75005 Paris, France; Univ Paris 05, Chim & Biochim Pharmacol & Toxicol Lab, CNRS, UMR 8601, F-75270 Paris 06, France; CNRS, Lab Biochim Theor, Inst Biol Physicochim, F-75005 Paris, France; INRA, Lab Etud Interact Mol Alimentaires, F-44316 Nantes 3, France; Univ Nantes, FRE 2230, F-44322 Nantes 3, France; CNRS, F-44322 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; INRAE; Nantes Universite; Centre National de la Recherche Scientifique (CNRS)	Hoa, GHB (corresponding author), INSERM, U473, 84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	gaston@peptrans.org	Girault, Jean_Pierre JP/A-5403-2008; Haertlé, Thomas/K-1278-2013; HaertlÃ©, Thomas/K-1740-2017; Kozin, Sergey A/R-3637-2018	Haertlé, Thomas/0000-0002-7888-7698; Kozin, Sergey A/0000-0002-3018-7932; Haertle, Thomas/0000-0002-1696-2269; Mazur, Alexey/0000-0002-9371-0620; Bertho, Gildas/0000-0002-4929-763X				[Anonymous], 1996, CIRCULAR DICHROISM C; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BERTHO G, 2001, IN PRESS COMP REND A; BLANCO FJ, 1994, NAT STRUCT BIOL, V1, P584, DOI 10.1038/nsb0994-584; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Heller J, 1996, PROTEIN SCI, V5, P1655, DOI 10.1002/pro.5560050819; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; HURD RE, 1991, J MAGN RESON, V91, P648, DOI 10.1016/0022-2364(91)90395-A; Inouye H, 1997, J MOL BIOL, V268, P375, DOI 10.1006/jmbi.1997.0949; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOZIN SA, 2000, J PEPT SCI, V6, pS141; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liu AZ, 1999, BIOPOLYMERS, V51, P145, DOI 10.1002/(SICI)1097-0282(1999)51:2<145::AID-BIP4>3.0.CO;2-4; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; LOBENSTINE EW, 1981, J AM CHEM SOC, V103, P4936, DOI 10.1021/ja00406a044; Mazur AK, 1997, J COMPUT CHEM, V18, P1354, DOI 10.1002/(SICI)1096-987X(199708)18:11<1354::AID-JCC3>3.0.CO;2-K; Mazur AK, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P115; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; MUTO K, 1986, J AM CHEM SOC, V108, P6416, DOI 10.1021/ja00280a064; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pillot T, 1997, J MOL BIOL, V274, P381, DOI 10.1006/jmbi.1997.1382; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ragg E, 1999, EUR J BIOCHEM, V266, P1192, DOI 10.1046/j.1432-1327.1999.00985.x; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SERRANO L, 1995, J MOL BIOL, V254, P322, DOI 10.1006/jmbi.1995.0619; Sharman GJ, 1998, FOLD DES, V3, P313, DOI 10.1016/S1359-0278(98)00043-1; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	59	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46364	46370		10.1074/jbc.M108014200	http://dx.doi.org/10.1074/jbc.M108014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577109	hybrid			2022-12-27	WOS:000172573100118
J	Viard, T; Lamour, V; Duguet, M; de la Tour, CB				Viard, T; Lamour, V; Duguet, M; de la Tour, CB			Hyperthermophilic topoisomerase I from Thermotoga maritima. A very efficient enzyme that functions independently of zinc binding.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE TRANSCARBAMOYLASE; TRANSCRIPTION FACTOR IIE; ELONGATION-FACTOR TFIIS; ESCHERICHIA-COLI; DNA TOPOISOMERASE; REVERSE GYRASE; CLEAVAGE-SITE; DOMAIN; RIBBON; IDENTIFICATION	Topoisomerases, by controlling DNA supercoiling state, are key enzymes for adaptation to high temperatures in thermophilic organisms. We focus here on the topoisomerase I from the hyperthermophilic bacterium Thermotoga maritima (optimal growth temperature, 80 degreesC). To determine the properties of the enzyme compared with those of its mesophilic homologs, we overexpressed T. maritima topoisomerase I in Escherichia coli and purified it to near homogeneity. We show that T. maritima topoisomerase I exhibits a very high DNA relaxing activity. Mapping of the cleavage sites on a variety of single-stranded oligonucleotides indicates a strong preference for a cytosine at position -4 of the cleavage, a property shared by E. coli topoisomerase I and archaeal reverse gyrases. As expected, the mutation of the putative active site Tyr 288 to Phe led to a totally inactive protein. To investigate the role of the unique zinc motif (Cys-X-Cys-X-16-Cys-X-Cys) present in T. maritima topoisomerase I, experiments have been performed with the protein mutated on the tetracysteine motif. Strikingly, the results show that zinc binding is not required for DNA relaxation activity, contrary to the E. coli enzyme. Furthermore, neither thermostability nor cleavage specificity is altered in this mutant. This finding opens the question of the role of the zinc-binding motif in T. maritima topoisomerase I and suggests that this hyperthermophilic topoisomerase possesses a different mechanism from its mesophilic homolog.	Univ Paris 11, Lab Enzymol Acides Nucl,Ctr Orsay, Inst Genet & Microbiol, UMR 8621 CNRS, F-91405 Orsay, France; Inst Genet & Biol Mol & Cellulaire, Lab Biol & Genom Struct, UPR 9004 CNRS, F-67404 Illkirch Graffenstaden, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	de la Tour, CB (corresponding author), Univ Paris 11, Lab Enzymol Acides Nucl,Ctr Orsay, Inst Genet & Microbiol, UMR 8621 CNRS, Batiment 400, F-91405 Orsay, France.			Lamour, Valerie/0000-0001-7793-4029				Akimkina T, 1999, PLASMID, V42, P236, DOI 10.1006/plas.1999.1429; De la Tour CB, 1998, J BACTERIOL, V180, P274, DOI 10.1128/JB.180.2.274-281.1998; DEAN FB, 1985, J BIOL CHEM, V260, P4984; delaTour CB, 1995, BBA-GENE STRUCT EXPR, V1264, P279, DOI 10.1016/0167-4781(96)83596-2; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Grishin NV, 2000, J MOL BIOL, V299, P1165, DOI 10.1006/jmbi.2000.3841; Guipaud O, 1997, P NATL ACAD SCI USA, V94, P10606, DOI 10.1073/pnas.94.20.10606; HIASA H, 1994, J BIOL CHEM, V269, P2093; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Jaxel C, 1999, EUR J BIOCHEM, V260, P103, DOI 10.1046/j.1432-1327.1999.00128.x; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; Kaltoum H, 1997, SYST APPL MICROBIOL, V20, P505, DOI 10.1016/S0723-2020(97)80019-7; KIM RA, 1992, J BIOL CHEM, V267, P17178; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Li ZY, 2000, MOL MICROBIOL, V35, P888, DOI 10.1046/j.1365-2958.2000.01763.x; LopezGarcia P, 1997, MOL MICROBIOL, V23, P1267, DOI 10.1046/j.1365-2958.1997.3051668.x; MAXON ME, 1994, P NATL ACAD SCI USA, V91, P9529, DOI 10.1073/pnas.91.20.9529; MILLER KG, 1981, J BIOL CHEM, V256, P9334; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; TSE Y, 1980, CELL, V22, P269, DOI 10.1016/0092-8674(80)90174-9; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103; Zhang HL, 1996, J BIOL CHEM, V271, P9039, DOI 10.1074/jbc.271.15.9039; ZHANG HL, 1994, J BIOL CHEM, V269, P9052; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700; ZHU CX, 1995, J MOL BIOL, V250, P609, DOI 10.1006/jmbi.1995.0402; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46495	46503		10.1074/jbc.M107714200	http://dx.doi.org/10.1074/jbc.M107714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577108	hybrid			2022-12-27	WOS:000172573100135
J	Winklhofer, KF; Reintjes, A; Hoener, MC; Voellmy, R; Tatzelt, J				Winklhofer, KF; Reintjes, A; Hoener, MC; Voellmy, R; Tatzelt, J			Geldanamycin restores a defective heat shock response in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HSF1; K562 ERYTHROLEUKEMIC CELLS; STRESS-INDUCED APOPTOSIS; IN-VIVO; NEUROBLASTOMA-CELLS; DNA-BINDING; MOLECULAR CHAPERONES; PROTEIN EXPRESSION; ACTIVATION DOMAIN; TYROSINE KINASE	Induced expression of heat shock proteins (Hsps) plays a central role in promoting cellular survival after environmental and physiological stress. We have previously shown that scrapie-infected mouse neuroblastoma (ScN2a) cells fail to induce the expression of Hsp72 and Hsp28 after various stress conditions. Here we present evidence that this impaired stress response is due to an altered regulation of HSF1 activity. Upon stress in ScN2a cells, HSF1 was converted into hyperphosphorylated trimers but failed to acquire transactivation competence. A kinetic analysis of HSF1 activation revealed that in ScN2a cells trimer formation after stress was efficient, but disassembly of trimers proceeded much faster than in the uninfected cell line. Geldanamycin, a Hsp90-binding drug, significantly delayed disassembly of HSF1 trimers after a heat shock and restored stress-induced expression of Hsp72 in ScN2a cells. Heat-induced Hsp72 expression required geldanamycin to be present; following removal of the drug ScN2a cells again lost their ability to mount a stress response. Thus, our studies show that a defective stress response can be pharmacologically restored and suggest that the HSF1 deactivation pathway may play an important role in the regulation of Hsp expression.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	Max Planck Society; Max Planck Society; University of Miami	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de	Hoener, Marius C/I-6464-2012	Hoener, Marius C/0000-0001-6510-6250; Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECK SC, 1995, AM J PHYSIOL-REG I, V269, pR608, DOI 10.1152/ajpregu.1995.269.3.R608; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRUCE JL, 1993, CANCER RES, V53, P12; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHANG NT, 1993, J BIOL CHEM, V268, P1436; Chavany C, 1996, J BIOL CHEM, V271, P4974; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Drujan D, 1999, SHOCK, V12, P443, DOI 10.1097/00024382-199912000-00005; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GOLDENBERG CJ, 1988, J BIOL CHEM, V263, P19734; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HEYDARI AR, 1994, EXPERIENTIA, V50, P1092, DOI 10.1007/BF01923466; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Kim HR, 1999, IUBMB LIFE, V48, P425, DOI 10.1080/152165499306810; Kim HR, 1999, IUBMB LIFE, V48, P429, DOI 10.1080/713803536; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARINI AM, 1990, J NEUROCHEM, V54, P1509, DOI 10.1111/j.1471-4159.1990.tb01198.x; MATHUR SK, 1994, P NATL ACAD SCI USA, V91, P8695, DOI 10.1073/pnas.91.18.8695; McIlwrath AJ, 1996, CANCER CHEMOTH PHARM, V37, P423, DOI 10.1007/s002800050407; Morano KA, 1999, MOL CELL BIOL, V19, P402; Morimoto R I, 1996, EXS, V77, P139; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NISHIMURA RN, 1991, MOL BRAIN RES, V9, P39, DOI 10.1016/0169-328X(91)90128-K; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rosenhagen MC, 2001, BIOL CHEM, V382, P499, DOI 10.1515/BC.2001.063; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; VOELLMY R, 1985, P NATL ACAD SCI USA, V82, P4949, DOI 10.1073/pnas.82.15.4949; Voellmy R, 1996, EXS, V77, P121; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	72	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45160	45167		10.1074/jbc.M104873200	http://dx.doi.org/10.1074/jbc.M104873200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574536	hybrid			2022-12-27	WOS:000172406700108
J	Johansson, E; Majka, J; Burgers, PMJ				Johansson, E; Majka, J; Burgers, PMJ			Structure of DNA polymerase delta from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SMALL-SUBUNIT; REPLICATION FORK; YEAST; EPSILON; REPAIR; GENE; IDENTIFICATION; CHROMATOGRAPHY; STRANDS	DNA polymerase 8 (Pol 8) from Saccharomyces cerevisiae consists of three subunits, Pol3 (125 kDa), Pol31 (55 kDa), and Pol32 (40 kDa), present at a 1:1:1 stoichiometry in purified preparations. Previously, based on gel filtration studies of Pol delta, we suggested that the enzyme may be a dimer of catalytic cores, with dimerization mediated by the Pol32 subunit (Burgers, P. M., and Gerik, K J. (1998) J. Biol. Chem. 273, 19756-19762). We now report on extensive gel filtration, glycerol gradient sedimentation, and analytical equilibrium centrifugation studies of Pol delta and of several subassemblies of Pol S. The hydrodynamic parameters of these assemblies indicate that (i) Pol32 is a rod-shaped protein with a frictional ratio f/f(0) = 2.22; (ii) any complex containing Pol32 also has an extremely asymmetric shape; (iii) the results of these studies are independent of concentration (varied between 0.1-20 mum); (iv) all complexes are monomeric under the conditions studied (up to 20 muM). Moreover, a two-hybrid analysis of the Pol32 subunit did not detect a Pol32-Pol32 interaction in vivo. Therefore, we conclude that the assembly structure of Pol delta is that of a monomer.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid, St Louis, MO 63110 USA.		Burgers, Peter M/AAW-6621-2021	Johansson, Erik/0000-0002-8526-6224	NIGMS NIH HHS [GM58534, R01 GM032431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431, R01GM058534] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Giot L, 1997, GENETICS, V146, P1239; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; Hindges R, 1997, BIOL CHEM, V378, P345; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MacNeill SA, 2001, TRENDS BIOCHEM SCI, V26, P16, DOI 10.1016/S0968-0004(00)01709-6; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; PIGNEDE G, 1991, J MOL BIOL, V222, P209, DOI 10.1016/0022-2836(91)90207-M; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Shcherbakova PV, 1996, GENETICS, V142, P717; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 1975, HDB BIOCH MOL BIOL P, V2, P222; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	28	52	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43824	43828		10.1074/jbc.M108842200	http://dx.doi.org/10.1074/jbc.M108842200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11568188	hybrid			2022-12-27	WOS:000172297700046
J	Nguyen, BP; Ren, XD; Schwartz, MA; Carter, WG				Nguyen, BP; Ren, XD; Schwartz, MA; Carter, WG			Ligation of integrin alpha(3)beta(1) by laminin 5 at the wound edge activates Rho-dependent adhesion of leading keratinocytes on collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED EPITHELIAL-CELLS; PROTEIN-KINASE-C; ALPHA-3-BETA-1 INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; GENE-EXPRESSION; P120 CATENIN; LAMA3 GENE; HEMIDESMOSOMES	Wounding of the epidermis signals the transition of keratinocytes from quiescent anchorage on endogenous basement membrane laminin 5 to migration on exposed dermal collagen. In this study, we attempt to characterize activation signals that transform quiescent keratinocytes into migratory leading cells at the wound edge. Previously, we reported that adhesion and spreading on collagen via integrin alpha (2)beta (1) by cultured human foreskin keratinocytes (HFKs) requires RhoGTP, a regulator of actin stress fibers. In contrast, adhesion and spreading on laminin 5 requires integrins alpha (3)beta (1) and alpha (6)beta (4) and is dependent on phosphoinositide 3-hydroxykinase (Nguyen, B. P., Gil, S. G., and Carter, W. G. (2000) J. Biol. Chem. 275,31896-31907). Here, we report that quiescent HFKs do not adhere to collagen but adhere and spread on laminin 5. By using collagen adhesion as one criterion for conversion to a "leading wound cell," we found that activation of collagen adhesion requires elevation of RhoGTP. Adhesion of quiescent HFKs to laminin 5 via integrin alpha (3)beta (1), and alpha (6)beta (4) is sufficient to increase levels of RhoGTP required for adhesion and spreading on collagen. Consistently, adhesion of quiescent HFKs to laminin 5, but not collagen, also promotes expression of the precursor form of laminin 5, a characteristic of leading keratinocytes in the epidermal outgrowth. We suggest that wounding of quiescent epidermis initiates adhesion and spreading of keratinocytes at the wound edge on endogenous basement membrane laminin 5 via alpha (3)beta (1), and alpha (6)beta (4) in a Rho-independent mechanism. Spreading on endogenous laminin 5 via alpha (3)beta (1), is necessary but not sufficient to elevate expression of precursor laminin 5 and RhoGTP, allowing for subsequent collagen adhesion via alpha (2)beta (1), all characteristics of leading keratinocytes in the epidermal outgrowth.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Scripps Research Institute	Carter, WG (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.			schwartz, martin/0000-0002-2071-1243	NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR021557] Funding Source: NIH RePORTER; NCI NIH HHS [CA49259] Funding Source: Medline; NIAMS NIH HHS [AR21557] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; Brock J, 1996, J CELL BIOL, V135, P1097, DOI 10.1083/jcb.135.4.1097; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; Decline F, 2001, J CELL SCI, V114, P811; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; GIPSON IK, 1993, EXP CELL RES, V207, P86, DOI 10.1006/excr.1993.1166; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Kainulainen T, 1998, J HISTOCHEM CYTOCHEM, V46, P353, DOI 10.1177/002215549804600309; Kikkawa Y, 1996, IN VITRO CELL DEV-AN, V32, P46; KIM JP, 1992, J INVEST DERMATOL, V98, P764, DOI 10.1111/1523-1747.ep12499947; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McGowan K, 1998, Subcell Biochem, V31, P173; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; PAWAR S, 1995, J CELL PHYSIOL, V165, P556, DOI 10.1002/jcp.1041650314; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; STEPP MA, 1993, INVEST OPHTH VIS SCI, V34, P1829; Stepp MA, 1996, INVEST OPHTH VIS SCI, V37, P1593; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; TODA KI, 1987, J CELL BIOL, V105, P3097, DOI 10.1083/jcb.105.6.3097; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Wallis S, 2000, MOL BIOL CELL, V11, P1077, DOI 10.1091/mbc.11.3.1077; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WOODLEY DT, 1999, PROGR DERMATOLOGY, V33, P1; Xia MH, 1996, J CELL BIOCHEM, V61, P452, DOI 10.1002/(SICI)1097-4644(19960601)61:3<452::AID-JCB12>3.3.CO;2-9; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	44	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43860	43870		10.1074/jbc.M103404200	http://dx.doi.org/10.1074/jbc.M103404200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571278	hybrid			2022-12-27	WOS:000172297700051
J	Sheng, SH; McNulty, KA; Harvey, JM; Kleyman, TR				Sheng, SH; McNulty, KA; Harvey, JM; Kleyman, TR			Second transmembrane domains of ENaC subunits contribute to ion permeation and selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; RECTIFIER K+ CHANNEL; CORTICAL COLLECTING TUBULE; POTASSIUM CHANNELS; HYDROPHOBIC DOMAIN; NA+ CHANNEL; MOLECULAR-BASIS; ATP CHANNELS; PORE; VOLTAGE	Epithelial sodium channels (ENaC) are composed of three structurally related subunits (alpha, beta, and gamma). Each subunit has two transmembrane domains termed Ml and M2, and residues conferring cation selectivity have been shown to reside in a pore region immediately preceding the M2 domains of the three subunits. Negatively charged residues are interspersed within the M2 domains, and substitution of individual acidic residues within human alpha -ENaC with arginine essentially eliminated channel activity in oocytes, suggesting that these residues have a role in ion permeation. We examined the roles of M2 residues in contributing to the permeation pore by individually mutating residues within the M2 domain of mouse alpha ENaC to cysteine and systematically characterizing functional properties of mutant channels expressed in Xenopus oocytes by two-electrode voltage clamp. The introduction of cysteine residues at selected sites, including negatively charged residues (alpha Glu(595), alpha Glu(598), and alpha Asp(602)) led to a significant reduction of expressed amiloride-sensitive Na+ currents. Two mutations (alpha E595C and alpha D602C) resulted in K+-permeable channels whereas multiple mutations altered Li+/ Na+ current ratios. Channels containing alpha D602K or alpha D602A also conducted K+ whereas more conservative mutations (alpha D602E and alpha D602N) retained wild type selectivity. Cysteine substitution at the site equivalent to alpha Asp(602) within beta mENaC (beta D544C) did not alter either Li+/Na+ or K+/Na+ current ratios, although mutation of the equivalent site within gamma mENaC (gamma D562C) significantly increased the Li+/Na+ current ratio. Mutants containing introduced cysteine residues at alpha GlU(595), alpha Glu(598), alpha Asp(602), or alpha Thr(607). did not respond to externally applied sulfhydryl reagent with significant changes in macroscopic currents. Our results suggest that some residues within the M2 domain of alpha ENaC contribute to the channel's conduction pore and that, in addition to the pore region, selected sites within M2 (alpha Glu(595) and alpha Asp(602)) may have a role in conferring ion selectivity.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA 15261 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania	Kleyman, TR (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.		Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NIDDK NIH HHS [DK54354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrams CJ, 1996, J PHYSIOL-LONDON, V493, P643, DOI 10.1113/jphysiol.1996.sp021411; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Choe H, 2000, J GEN PHYSIOL, V115, P391, DOI 10.1085/jgp.115.4.391; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Feng ZP, 2001, J BIOL CHEM, V276, P5726, DOI 10.1074/jbc.C000791200; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; HILLOE B, 2001, ION CHANNELS EXCITAB; Immke D, 1998, RECEPTOR CHANNEL, V6, P179; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Keynes RD, 1999, P ROY SOC B-BIOL SCI, V266, P843, DOI 10.1098/rspb.1999.0714; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; Liu Y, 1998, PFLUG ARCH EUR J PHY, V435, P654, DOI 10.1007/s004240050566; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Loussouarn G, 2001, P NATL ACAD SCI USA, V98, P4227, DOI 10.1073/pnas.061452698; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; LU Z, 1995, BIOCHEMISTRY-US, V34, P13133, DOI 10.1021/bi00040a026; LU Z, 1994, J GEN PHYSIOL, V104, P477, DOI 10.1085/jgp.104.3.477; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Miller C, 2000, CURR OPIN CHEM BIOL, V4, P148, DOI 10.1016/S1367-5931(99)00068-X; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Ogielska EM, 1998, J GEN PHYSIOL, V112, P243, DOI 10.1085/jgp.112.2.243; Oliver D, 2000, EUR J BIOCHEM, V267, P5824, DOI 10.1046/j.1432-1327.2000.01669.x; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3	47	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					44091	44098		10.1074/jbc.M108522200	http://dx.doi.org/10.1074/jbc.M108522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11564745	hybrid			2022-12-27	WOS:000172297700079
J	Baumgrass, R; Weiwad, M; Erdmann, F; Liu, JO; Wunderlich, D; Grabley, S; Fischer, G				Baumgrass, R; Weiwad, M; Erdmann, F; Liu, JO; Wunderlich, D; Grabley, S; Fischer, G			Reversible inhibition of calcineurin by the polyphenolic aldehyde gossypol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOPHILIN LIGAND COMPLEXES; PROLYL CIS/TRANS ISOMERASES; CYCLOPHILIN-CYCLOSPORINE-A; TRANSCRIPTION FACTOR NFAT1; DEPENDENT PROTEIN-KINASE; BINUCLEAR METAL CENTER; PHOSPHATASE-ACTIVITY; AUTOINHIBITORY DOMAIN; ESCHERICHIA-COLI; CANCER CELLS	The reversible inhibition of calcineurin (CaN), which is the only Ca2+/calmodulin-dependent protein Ser/Thr phosphatase, is thought to be a key functional event for most cyclosporin A (CsA)- and tacrolimus (FK506)-mediated biological effects. In addition to CaN inhibition, however, CsA and FK506 have multiple biochemical effects because of their action in a gain-of-function model that requires prior binding to immunophilic proteins. We screened a small molecule library for direct inhibitors of CaN using CaN-mediated dephosphorylation of P-33-labeled 19-residue phosphopeptide substrate (RII phosphopeptide) as an assay and found the polyphenolic aldehyde gossypol to be a novel CaN inhibitor. Unlike CsA and FK506, gossypol does not require a matchmaker protein for reversible CaN inhibition with an IC50 value of 15 muM. Gossypolone, a gossypol analog, showed improved inhibition of both RII phosphopeptide and p-nitrophenyl phosphate dephosphorylation with an IC50 of 9 and 6 muM, respectively. In contrast, apogossypol hexaacetate was inactive. Gossypol acts noncompetitively, interfering with the binding site for the cyclophilin 18(.)CsA complex in CaN. In contrast to CsA and FK506, gossypol does not inactivate the peptidyl-prolyl-cis/trans-isomerase activity of immunophilins. Similar to CsA and FK506, T cell receptor signaling induced by phorbol 12-myristate 13-acetate/ionomycin is inhibited by gossypol in a dose-dependent manner, demonstrated by the inhibition of nuclear factor of activated T cell (NFAT) cl translocation from the cytosol into the nucleus and suppression of NFAT-luciferase reporter gene activity.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle Saale, Germany; Hans Knoll Inst Nat Prod Res, D-07745 Jena, Germany; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Max Planck Society; Hans Knoll Institute (HKI); Johns Hopkins University; Johns Hopkins University	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle Saale, Germany.			Baumgrass, Ria/0000-0002-3289-1608				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; BARTZ SR, 1995, P NATL ACAD SCI USA, V92, P5381, DOI 10.1073/pnas.92.12.5381; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; Bogumil R, 2000, EUR J BIOCHEM, V267, P1407, DOI 10.1046/j.1432-1327.2000.01133.x; BORN TL, 1995, J BIOL CHEM, V270, P25651, DOI 10.1074/jbc.270.43.25651; Brill GM, 1996, J ANTIBIOT, V49, P124, DOI 10.7164/antibiotics.49.124; CHAN CP, 1986, J BIOL CHEM, V261, P9890; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COYLE T, 1994, J NEURO-ONCOL, V19, P25, DOI 10.1007/BF01051046; DONELLADEANA A, 1991, BIOCHIM BIOPHYS ACTA, V1094, P130, DOI 10.1016/0167-4889(91)90034-U; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; Enz A, 1997, BIOORG MED CHEM LETT, V7, P2513, DOI 10.1016/S0960-894X(97)10005-1; Enz A, 1997, BIOCHEM PHARMACOL, V54, P321, DOI 10.1016/S0006-2952(97)00175-5; ENZ A, 1994, ANAL BIOCHEM, V216, P147, DOI 10.1006/abio.1994.1018; ETZKORN FA, 1994, BIOCHEMISTRY-US, V33, P2380, DOI 10.1021/bi00175a005; Fakata KL, 1998, BIOCHEM PHARMACOL, V55, P2017, DOI 10.1016/S0006-2952(98)00076-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FLACK MR, 1993, J CLIN ENDOCR METAB, V76, P1019, DOI 10.1210/jc.76.4.1019; FRICK J, 1988, CONTRACEPTION, V37, P153, DOI 10.1016/0010-7824(88)90125-4; GILBERT NE, 1995, LIFE SCI, V57, P61, DOI 10.1016/0024-3205(95)00243-Y; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Gomez MS, 1997, MOL BIOCHEM PARASIT, V90, P235, DOI 10.1016/S0166-6851(97)00140-0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Gualberto A, 1998, J BIOL CHEM, V273, P7088, DOI 10.1074/jbc.273.12.7088; Janowski B, 1997, BIOORGAN MED CHEM, V5, P179, DOI 10.1016/S0968-0896(96)00198-8; JINSART W, 1991, BIOL CHEM H-S, V372, P819, DOI 10.1515/bchm3.1991.372.2.819; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4850; KIM IC, 1984, CONTRACEPTION, V30, P253, DOI 10.1016/0010-7824(84)90088-X; KOCH C, 1999, DRUG DISCOVERY NATUR, P263; KREBS EG, 1958, J BIOL CHEM, V231, P73; Ligueros M, 1997, BRIT J CANCER, V76, P21, DOI 10.1038/bjc.1997.330; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P9430, DOI 10.1074/jbc.273.16.9430; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; Nakayama GR, 1998, J BIOMOL SCREEN, V3, P43, DOI 10.1177/108705719800300106; NELSON PA, 1993, J IMMUNOL, V150, P2139; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; Perrino BA, 1999, ARCH BIOCHEM BIOPHYS, V372, P159, DOI 10.1006/abbi.1999.1485; POSO H, 1980, LANCET, V1, P885; RICHTER A, 1995, BIOCHEM PHARMACOL, V49, P367, DOI 10.1016/0006-2952(94)00423-J; RUSSELL DH, 1987, J IMMUNOL, V138, P276; Sagoo JK, 1996, BIOCHEM J, V320, P879, DOI 10.1042/bj3200879; SCHREIBER SL, 1993, ACCOUNTS CHEM RES, V26, P412, DOI 10.1021/ar00032a004; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shidaifat F, 1997, ANTICANCER RES, V17, P1003; Sullivan E, 1997, J BIOMOL SCREEN, V2, P19, DOI 10.1177/108705719700200105; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; Tatlock JH, 1997, BIOORG MED CHEM LETT, V7, P1007, DOI 10.1016/S0960-894X(97)00141-8; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; Vander Jagt DL, 2000, CURR MED CHEM, V7, P479, DOI 10.2174/0929867003375119; WAELKENS E, 1984, BIOCHEM BIOPH RES CO, V120, P397, DOI 10.1016/0006-291X(84)91267-1; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P12400, DOI 10.1021/bi962972i; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040; ZARNT T, 1995, BIOCHEM J, V305, P159, DOI 10.1042/bj3050159; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	63	72	80	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47914	47921		10.1074/jbc.M103273200	http://dx.doi.org/10.1074/jbc.M103273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11598106	hybrid			2022-12-27	WOS:000172927000027
J	Schwenger, GTF; Fournier, G; Kok, CC; Mordvinov, VA; Yeoman, D; Sanderson, CJ				Schwenger, GTF; Fournier, G; Kok, CC; Mordvinov, VA; Yeoman, D; Sanderson, CJ			GATA-3 has dual regulatory functions in human interleukin-5 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; NUCLEAR FACTOR; IL-5 GENE; BINDING PROTEINS; CUTTING EDGE; TH1 CELLS; EXPRESSION; PROMOTER; ELEMENT; ENHANCER	Interleukin-5 (IL-5) is a T-cell cytokine involved in Type 2 diseases and is commonly described as being coordinately regulated with other Type 2 cytokines, such as IL-4 and IL-13. Considering the unique control of eosinophilia by IL-5, such coordinate regulation would be surprising. In fact, the biological specificity of eosinophilia and its control by IL-5 suggests a unique and independent control of IL-5 regulation. In this report we show the binding of GATA-3 to three sites in the human IL-5 promoter in the human T-cell line PER117. The previously identified -70 site and another site at position -152 are shown to positively regulate IL-5 transcription. More importantly, the site located at -400 acts as a powerful repressor of IL-5 transcription with mutagenesis of this site allowing a high level expression of IL-5 without the activation of other factors normally required for IL-5 expression. Whereas GATA-3 has been proposed to be involved in the regulation of the IL-4/IL5/IL-13 locus, we show here that it has another function in controlling IL-5 transcription that supports the observed unique biological function of this cytokine.	Curtin Univ Technol, Dept Mol Immunol, Perth, WA 6000, Australia; Western Australian Inst Med Res Level 5, Perth, WA 6000, Australia; Inst Francais Boissons Brasserie & Malterie, Biol Mol Lab, F-54500 Vandoeuvre Les Nancy, France; Free Univ Brussels, Fac Med, Expt Immunol Lab, B-1070 Brussels, Belgium	Curtin University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schwenger, GTF (corresponding author), Curtin Univ Technol, Dept Mol Immunol, Med Res Fdn Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; De Boer ML, 1999, INT J BIOCHEM CELL B, V31, P1221, DOI 10.1016/S1357-2725(99)00069-2; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; JUNG T, 1995, EUR J IMMUNOL, V25, P2413, DOI 10.1002/eji.1830250843; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KEES UR, 1994, J IMMUNOL METHODS, V168, P1, DOI 10.1016/0022-1759(94)90202-X; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Krug N, 1998, AM J RESP CRIT CARE, V158, P754, DOI 10.1164/ajrccm.158.3.9507038; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee HJ, 1998, J IMMUNOL, V160, P2343; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Miyatake S, 2000, IUBMB LIFE, V49, P473; Mordvinov VA, 1999, J ALLERGY CLIN IMMUN, V103, P1125, DOI 10.1016/S0091-6749(99)70188-0; Mordvinov VA, 1999, J IMMUNOL METHODS, V228, P163, DOI 10.1016/S0022-1759(99)00088-5; Mori A, 1997, INT ARCH ALLERGY IMM, V113, P272, DOI 10.1159/000237570; Nawijn MC, 2001, J IMMUNOL, V167, P724, DOI 10.4049/jimmunol.167.2.724; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Pomerantz O, 1998, NUCLEIC ACIDS RES, V26, P5684, DOI 10.1093/nar/26.24.5684; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Ranganath S, 1998, J IMMUNOL, V161, P3822; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Schwenger GTF, 1999, J ALLERGY CLIN IMMUN, V104, P820, DOI 10.1016/S0091-6749(99)70293-9; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Yamanaka R, 1998, INT J MOL MED, V1, P213; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	34	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48502	48509		10.1074/jbc.M107836200	http://dx.doi.org/10.1074/jbc.M107836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11579103	hybrid			2022-12-27	WOS:000172927000103
J	Hausrath, AC; Capaldi, RA; Matthews, BW				Hausrath, AC; Capaldi, RA; Matthews, BW			The conformation of the epsilon- and gamma-subunits within the Escherichia coli F-1 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; F1F0-TYPE ATPASE; SYNTHASE; RESOLUTION; F-1-ATPASE; F1-ATPASE; PACKAGE; COMPLEX	F-1 is the water-soluble portion of the ubiquitous F1F0 ATP synthase. Its structure includes three alpha- and three beta -subunits, arranged as a hexameric disc, plus a gamma -subunit that penetrates the center of the disc akin to an axle. Recently Hausrath et al. (Hausrath, A. C., Gruber, G., Matthews, B. W., and Capaldi, R. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13697-13702) obtained an electron density map of E. coli F-1 at 4.4-Angstrom resolution in which the coiled-coil a-helices of the gamma -subunit could be seen to extend 45 Angstrom from the base of the alpha (3)beta (3) hexamer. Subsequently the structure of a truncated form of the E. coli gamma -subunit in complex with epsilon has been described (Rodgers, A. J. W., and Wilce, M. C. J. (2000) Nat. Struct. Biol. 7, 1051-1054). In the present study the 4.4-Angstrom resolution electron density map of E. coli F-1 is re-evaluated in light of the newly available data on the gamma- and epsilon -subunits. It is shown that the map of the F-1 complex is consistent with the structure of the isolated subunits. When E. coli F-1 is compared with that from beef heart, the structures of the E. coli gamma- and epsilon -subunits are seen to be generally similar to their counterparts in the bovine enzyme but to undergo major shifts in position. In particular, the two long, coiled-coil alpha -helices that lie along the axis of F-1 both unwind and rotate. Also the c-subunit rotates around the axis by 81 degrees and undergoes a net translation of about 23 Angstrom. It is argued that these large-scale changes in conformation reflect distinct functional states that occur during the rotation of the gamma -subunit within the alpha (3)beta (3) hexamer.	Univ Oregon, Howard Hughes Med Inst, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Howard Hughes Med Inst, Dept Phys, Eugene, OR 97403 USA; Univ Oregon, Howard Hughes Med Inst, Dept Biol, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; Howard Hughes Medical Institute; University of Oregon; Howard Hughes Medical Institute; University of Oregon	Matthews, BW (corresponding author), Univ Oregon, Howard Hughes Med Inst, Inst Mol Biol, Eugene, OR 97403 USA.				NHLBI NIH HHS [HL 24526] Funding Source: Medline; NIGMS NIH HHS [GM 20066] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020066, R01GM020066] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; EVANS PR, 1991, CRYSTALLOGRAPHIC COM, V5, P136; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; READ RJ, 1991, CRYSTALLOGRAPHIC COM, V5, P158; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063	29	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47227	47232		10.1074/jbc.M107536200	http://dx.doi.org/10.1074/jbc.M107536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585832	hybrid			2022-12-27	WOS:000172768500075
J	Lin, YC; Shih, JW; Hsu, CL; Lin, JJ				Lin, YC; Shih, JW; Hsu, CL; Lin, JJ			Binding and partial denaturing of g-quartet DNA by Cdc13p of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUADRUPLEX TELOMERIC DNA; YEAST GENE-PRODUCT; CRYSTAL-STRUCTURE; RAT HEPATOCYTES; NUCLEIC-ACIDS; BETA-SUBUNIT; IN-VITRO; S-PHASE; PROTEIN; PARALLEL	The protein Cdc13p binds telomeres in vivo and is essential for the maintenance of the telomeres of Saccharomyces cerevisiae. In addition, Cdc13p is known to bind single-stranded TG(1-3) DNA in vitro. Here we have shown that Cdc13p also binds DNA quadruplex, G-quartet, formed by TG(1-3) DNA. Moreover, the binding of Cdc13p causes a partial denaturing of the G-quartet DNA. Formation of DNA quadruplexes may involve the intermolecular association of TG(1-3) DNA and inhibit the extension of telomeres by telomerase. Thus, our finding suggests that Cdc13p may disrupt telomere association and facilitate telomere replication.	Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lin, JJ (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	jjlin@ym.edu.tw	Lin, Jing-Jer/G-8068-2015; Shih, Jing-Wen/J-4555-2017	Shih, Jing-Wen/0000-0002-0417-9015; LIN, JING-JER/0000-0001-8250-7398				ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lin YC, 2001, J BIOL CHEM, V276, P24588, DOI 10.1074/jbc.M101642200; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Qi HY, 2000, GENE DEV, V14, P1777; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; VENCZEL EA, 1993, BIOCHEMISTRY-US, V32, P6220, DOI 10.1021/bi00075a015; WALSH K, 1992, J BIOL CHEM, V267, P13714; Wang MJ, 2000, NUCLEIC ACIDS RES, V28, P4733, DOI 10.1093/nar/28.23.4733; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	39	35	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47671	47674		10.1074/jbc.M104989200	http://dx.doi.org/10.1074/jbc.M104989200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585819	hybrid			2022-12-27	WOS:000172768500129
J	Minami, T; Aird, WC				Minami, T; Aird, WC			Thrombin stimulation of the vascular cell adhesion molecule-1 promoter in endothelial cells is mediated by tandem nuclear factor-kappa B and GATA motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; E-SELECTIN EXPRESSION; GENE-EXPRESSION; TRANSCRIPTION FACTORS; NEUTROPHIL ADHESION; IN-VITRO; ACTIVATION; RECEPTOR; VCAM-1; BINDING	The goal of this study was to delineate the transcriptional mechanisms underlying thrombin-mediated induction of vascular adhesion molecule-1 (VCAM-1). Treatment of human umbilical vein endothelial cells with thrombin resulted in a 3.3-fold increase in VCAM-1 promoter activity. The upstream promoter region of VCAM-1 contains a thrombin response element, two nuclear factor kappaB (NF-kappaB) motifs, and a tandem GATA motif. In transient transfection assays, mutation of the thrombin response element had no effect on thrombin induction. In contrast, mutation of either NF-kappaB site resulted in a complete loss of induction, whereas a mutation of the two GATA motifs resulted in a significant reduction in thrombin stimulation. In electrophoretic mobility shift assays, nuclear extracts from thrombin-treated endothelial cells displayed markedly increased binding to the tandem NF-kappaB and GATA motifs. The NF-kappaB complex was supershifted with anti-p65 antibodies, but not with antibodies to RelB, c-Rel, p50, or p52. The GATA complex was supershifted with antibodies to GATA-2, but not GATA-3 or GATA-6. A construct containing tandem copies of the VCAM-1 GATA motifs linked to a minimal thymidine kinase promoter was induced 2.4-fold by thrombin. Taken together, these results suggest that thrombin stimulation of VCAM-1 in endothelial cells is mediated by the coordinate action of NF-kappaB and GATA transcription factors.	Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Mol Med, RW-663, Boston, MA 02215 USA.				NHLBI NIH HHS [HL 63609-02, HL 59316-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL059316, P50HL063609, P01HL059316] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; AIRD WC, 1994, J BIOL CHEM, V269, P883; Aird WC, 2001, CRIT CARE MED, V29, pS28, DOI 10.1097/00003246-200107001-00013; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; COLOTTA F, 1994, AM J PATHOL, V144, P975; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P52; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Gross PL, 2000, SEMIN THROMB HEMOST, V26, P463, DOI 10.1055/s-2000-13202; Hayashi T, 1999, MOL CELL BIOL, V19, P8646; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Kaplanski G, 1998, BLOOD, V92, P1259, DOI 10.1182/blood.V92.4.1259.416k11_1259_1267; Kaplanski G, 1997, J IMMUNOL, V158, P5435; Lee YW, 2001, J LIPID RES, V42, P783; Li QJ, 2000, BLOOD, V96, P3696, DOI 10.1182/blood.V96.12.3696.h8003696_3696_3706; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425; MARRA F, 1995, HEPATOLOGY, V22, P780, DOI 10.1002/hep.1840220314; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; Rahman A, 1999, J IMMUNOL, V162, P5466; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Simoncini T, 2000, CIRC RES, V87, P19, DOI 10.1161/01.RES.87.1.19; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; Tarumoto T, 2000, BLOOD, V96, P1716, DOI 10.1182/blood.V96.5.1716.h8001716_1716_1722; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZIMMERMAN GA, 1985, CIRCULATION, V72, P718, DOI 10.1161/01.CIR.72.4.718; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	47	83	88	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47632	47641		10.1074/jbc.M108363200	http://dx.doi.org/10.1074/jbc.M108363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590177	hybrid			2022-12-27	WOS:000172768500124
J	Smith, ER; Capo-chichi, CD; He, JQ; Smedberg, JL; Yang, DH; Prowse, AH; Godwin, AK; Hamilton, TC; Xu, XX				Smith, ER; Capo-chichi, CD; He, JQ; Smedberg, JL; Yang, DH; Prowse, AH; Godwin, AK; Hamilton, TC; Xu, XX			Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN ADENOCARCINOMA CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR; TERATOCARCINOMA CELLS; ADAPTER PROTEIN; EXPRESSION; GENE; RECEPTOR; DOMAIN; MOUSE	F9 embryonic stem cell-like teratocarcinoma cells are widely used to study early embryonic development and cell differentiation. The cells can be induced by retinoic acid to undergo endodermal differentiation. The retinoic acid-induced differentiation accompanies cell growth suppression, and thus, F9 cells are also often used as a model for analysis of retinoic acid biological activity. We have recently shown that MAPK activation and c-Fos expression are uncoupled in F9 cells upon retinoic acid-induced endodermal differentiation. The expression of the candidate tumor suppressor Disabled-2 is induced and correlates with cell growth suppression in F9 cells. We were not able to establish stable Disabled-2 expression by cDNA transfection in F9 cells without induction of spontaneous cell differentiation. Transient transfection of Dab2 by adenoviral vector nevertheless suppresses Elk-1 phosphorylation, c-Fos expression, and cell growth. In PA-1, another teratocarcinoma cell line of human origin that has no or very low levels of Disabled-2, retinoic acid fails to induce Disabled-2, correlating with a lack of growth suppression, although PA-I is responsive to retinoic acid in morphological change. Transfection and expression of Disabled-2 in PA-1 cells mimic the effects of retinoic acid on growth suppression; the Disabled-2-expressing cells reach a much lower saturation density, and serum-stimulated c-Fos expression is greatly suppressed and disassociated from MAPK activation. Thus, Dab2 is one of the principal genes induced by retinoic acid involved in cell growth suppression, and expression of Dab2 alone is sufficient for uncoupling of MAPK activation and c-Fos expression. Resistance to retinoic acid regulation in PA-1 cells likely results from defects in retinoic acid up-regulation of Dab2 expression.	Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, Philadelphia, PA 19111 USA; Emory Univ, Sch Med, Atlanta, GA 30322 USA	Fox Chase Cancer Center; Emory University	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	X_XU@feee.edu			NATIONAL CANCER INSTITUTE [R01CA075389, R01CA079716] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 79716, R01 CA 75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BIELINSKA M, 1995, BIOCHEM J, V307, P183, DOI 10.1042/bj3070183; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Cho SY, 1999, MOL CELLS, V9, P179; CLARKSON B, 1991, CANCER CELL-MON REV, V3, P211; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DE LUCA LM, 1991, FASEB J, V5, P2924; EARLY E, 1995, J INVEST MED, V43, P337; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LERUPPERT K, 1992, INT J CANCER, V51, P646, DOI 10.1002/ijc.2910510423; Lin F, 2000, CANCER RES, V60, P3271; MENDRICK DL, 1990, EXP CELL RES, V188, P23, DOI 10.1016/0014-4827(90)90273-D; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Murakami A, 1999, J BIOL CHEM, V274, P17242, DOI 10.1074/jbc.274.24.17242; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Rice DS, 1999, GENE DEV, V13, P2758, DOI 10.1101/gad.13.21.2758; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng ZJ, 2000, GENOMICS, V70, P381, DOI 10.1006/geno.2000.6383; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHERMAN MI, 1978, DEV BIOL, V63, P27, DOI 10.1016/0012-1606(78)90110-0; Smith ER, 2001, J BIOL CHEM, V276, P32094, DOI 10.1074/jbc.M105009200; Soprano DR, 1996, ONCOGENE, V12, P577; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; TAYLOR DD, 1990, DIFFERENTIATION, V43, P123, DOI 10.1111/j.1432-0436.1990.tb00438.x; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1994, J BIOL CHEM, V269, P607; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	52	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47303	47310		10.1074/jbc.M106158200	http://dx.doi.org/10.1074/jbc.M106158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577091	hybrid			2022-12-27	WOS:000172768500085
J	Liu, QJ; Ling, TY; Shieh, HS; Johnson, FE; Huang, JS; Huang, SS				Liu, QJ; Ling, TY; Shieh, HS; Johnson, FE; Huang, JS; Huang, SS			Identification of the high affinity binding site in transforming growth factor-beta involved in complex formation with alpha(2)-macroglobulin - Implications regarding the molecular mechanisms of complex formation between alpha(2)-macroglobulin and growth factors, cytokines, and hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; MULTIFUNCTIONAL BINDING; ALPHA-MACROGLOBULIN; CRYSTAL-STRUCTURE; FACTOR-BB; FACTOR-BETA-1; PEPTIDE; GROWTH-FACTOR-BETA-2; INHIBITION	The biological activities of transforming growth factor-beta isoforms (TGF-beta (1,2)) are known to be modulated by alpha (2)-macroglobulin (alpha M-2). alpha M-2 forms complexes with numerous growth factors, cytokines, and hormones, including TGF-beta. Identification of the binding sites in TGF-beta isoforms responsible for high affinity interaction with a2M many unravel the molecular basis of the complex formation. Here we demonstrate that among nine synthetic pentacosapeptides with overlapping amino acid sequences spanning the entire TGF-beta (1), molecule, the peptide (residues 41-65) containing Trp-52 exhibited the most potent activity in inhibiting the formation of complexes between I-125-TGF-beta (1) and activated alpha M-2 (alpha M-2*) as determined by nondenaturing polyacrylamide gel electrophoresis and by plasma clearance in mice. TGF-beta (2) peptide containing the homologous sequence and Trp-52 was as active as the TGF-beta (1) peptide, whereas the corresponding TGF-beta (3) peptide lacking Trp-52, was inactive. The replacement of the Trp-52 with alanine abolished the inhibitory activities of these peptides. I-125-TGF-beta (3), which lacks Trp-52, bound to a2M* with an affinity lower than that of I-125-TGF-beta (1). Furthermore, unlabeled TGF-beta (3) and the mutant TGF-beta (1)W52A, in which Trp-52 was replaced with alanine, were less potent than unlabeled TGF-P, in blocking I-125-TGF-beta (1) binding to alpha M-2*.TGF-beta (1) and TGF-beta (2) peptides containing Trp-52 were also effective in inhibiting I-125-nerve growth factor binding to a2M*. These results suggest that Trp-52 is involved in high affinity binding of TGF-beta to alpha M-2*. They also imply that TGF-beta and other growth factors/cytokines/hormones may form complexes with a2M* via a common mechanism involving the interactions between topologically exposed Trp and/or other hydrophobic residues and a hydrophobic region in alpha M-2*.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Pharmacia Monsanto, Searle Discovery Res, St Louis, MO 63198 USA	Saint Louis University; Saint Louis University; Academia Sinica - Taiwan	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.			Ling, Thai-Yen/0000-0002-3992-883X	NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1152, DOI 10.1021/bi00055a021; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BIRKENMEIER G, 1994, METHOD ENZYMOL, V228, P264; BORTH W, 1994, ANN NY ACAD SCI, V737, P267, DOI 10.1111/j.1749-6632.1994.tb44317.x; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; Cote N, 1998, CAN J VET RES, V62, P279; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; Harthun NL, 1998, J IMMUNOTHER, V21, P85, DOI 10.1097/00002371-199803000-00001; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; Huang SS, 1999, J BIOL CHEM, V274, P27754, DOI 10.1074/jbc.274.39.27754; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; HUANG SS, 1988, J BIOL CHEM, V263, P1535; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; LAMARRE J, 1990, LAB INVEST, V62, P545; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LIEBL DJ, 1993, BIOCHEM BIOPH RES CO, V193, P1255, DOI 10.1006/bbrc.1993.1760; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERWIN JR, 1991, AM J PATHOL, V138, P37; Narita M, 1997, J NEUROCHEM, V69, P1904; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHAH M, 1995, J CELL SCI, V108, P985; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1984, MOL CELL BIOCHEM, V58, P121, DOI 10.1007/BF00240611; Webb DJ, 1996, BIOCHEM J, V320, P551, DOI 10.1042/bj3200551; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473	46	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46212	46218		10.1074/jbc.M105177200	http://dx.doi.org/10.1074/jbc.M105177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583997	hybrid			2022-12-27	WOS:000172573100098
J	Xu, GM; Sikaneta, T; Sullivan, BM; Zhang, QH; Andreucci, M; Stehle, T; Drummond, L; Arnaout, MA				Xu, GM; Sikaneta, T; Sullivan, BM; Zhang, QH; Andreucci, M; Stehle, T; Drummond, L; Arnaout, MA			Polycystin-1 interacts with intermediate filaments.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKD1 GENE-PRODUCT; KIDNEY-DISEASE; IN-VITRO; PROTEIN PHOSPHATASE; MEMBRANE-FUSION; MDCK CELLS; DESMOSOMES; DOMAIN; IDENTIFICATION; MICE	Polycystin-1, the protein defective in a majority of patients with autosomal dominant polycystic kidney disease, is a ubiquitously expressed multi-span transmembrane protein of unknown function. Subcellular localization studies found this protein to be a component of various cell junctional complexes and to be associated with the cytoskeleton, but the specificity and nature of such associations are not known. To identify proteins that interact with the polycystin-1 C-tail (P1CT), this segment was used as bait in a yeast two-hybrid screening of a kidney epithelial cell library. The intermediate filament (IF) protein vimentin was identified as a strong polycystin-1-interacting partner. Cytokeratins K8 and K18 and desmin were also found to interact with P1CT. These interactions were mediated by coiled-coil motifs in polycystin-1 and IF proteins. Vimentin, cytokeratins K8 and K18, and desmin also bound directly to P1CT in GST pull-down and in in vitro filament assembly assays. Two observations confirmed these interactions in vivo: (i) a cell membrane-anchored form of recombinant P1CT decorated the IF network and was found to associate with the cytoskeleton in detergent-solubilized cells and (ii) endogenous polycystin-1 distributed with IF at desmosomal junctions. Polycystin-1 may utilize this association for structural, storage, or signaling functions.	Massachusetts Gen Hosp, Renal Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Bldg 149,13th St, Boston, MA 02129 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054711] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK54711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen E, 1996, J CELL BIOL, V133, P1367, DOI 10.1083/jcb.133.6.1367; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; BROWN D, 1998, J AM SOC NEPHROL, V9, P371; Carr CM, 2000, NATURE, V404, P347, DOI 10.1038/35006200; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Eckes B, 1998, J CELL SCI, V111, P1897; Faigle W, 2000, MOL BIOL CELL, V11, P3485, DOI 10.1091/mbc.11.10.3485; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; Fuchs E, 1997, MOL BIOL CELL, V8, P189, DOI 10.1091/mbc.8.2.189; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Herrmann H, 2000, J MOL BIOL, V298, P817, DOI 10.1006/jmbi.2000.3719; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Ho CL, 1998, J CELL SCI, V111, P1767; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; Inada H, 1998, BIOCHEM BIOPH RES CO, V253, P21, DOI 10.1006/bbrc.1998.9732; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; KELLY DE, 1981, ANAT REC, V199, P1, DOI 10.1002/ar.1091990102; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; KIM K, 1997, J AM SOC NEPHROL, V8, P375; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; Li HP, 1999, BIOCHEM BIOPH RES CO, V259, P356, DOI 10.1006/bbrc.1999.0780; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; McNutt N S, 1973, Prog Biophys Mol Biol, V26, P45; MENG JJ, 1994, J BIOL CHEM, V269, P18679; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Neophytou P, 1996, HUM GENET, V98, P437, DOI 10.1007/s004390050235; North AJ, 1999, J CELL SCI, V112, P4325; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Parnell SC, 1999, BIOCHEM BIOPH RES CO, V259, P539, DOI 10.1006/bbrc.1999.0810; Perrichot R, 2000, Hum Mutat, V15, P582, DOI 10.1002/1098-1004(200006)15:6<582::AID-HUMU20>3.3.CO;2-2; Peters DJM, 1999, J PATHOL, V188, P439, DOI 10.1002/(SICI)1096-9896(199908)188:4<439::AID-PATH367>3.0.CO;2-P; Piepenhagen PA, 1995, AM J PHYSIOL-CELL PH, V269, pC1433, DOI 10.1152/ajpcell.1995.269.6.C1433; Pritchard L, 2000, HUM MOL GENET, V9, P2617, DOI 10.1093/hmg/9.18.2617; QIAN E, 1997, J AM SOC NEPHROL, V8, P1753; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Scheffers MS, 2000, HUM MOL GENET, V9, P2743, DOI 10.1093/hmg/9.18.2743; SHEU HM, 1989, EXP CELL RES, V185, P176, DOI 10.1016/0014-4827(89)90047-5; Thormahlen M, 1998, J STRUCT BIOL, V122, P30, DOI 10.1006/jsbi.1998.3986; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PD, 1999, LAB INVEST, V79, P1311; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	74	66	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46544	46552		10.1074/jbc.M107828200	http://dx.doi.org/10.1074/jbc.M107828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581269	hybrid			2022-12-27	WOS:000172573100140
J	Christensen, M; Strange, K				Christensen, M; Strange, K			Developmental regulation of a novel outwardly rectifying mechanosensitive anion channel in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; VOLUME REGULATION; EPITHELIAL-CELLS; CL CHANNELS; NEURONS; CURRENTS; EXPRESSION; GENETICS; FAMILY; SENSITIVITY	The nematode Caenorhabditis elegans offers unique experimental advantages for defining the molecular basis of anion channel function and regulation. However, the relative inaccessibility of somatic cells in adult animals greatly limits direct electrophysiologcal studies of channel activity. We developed methods to routinely isolate and patch clamp C. elegans embryo cells and oocytes and to culture and patch clamp neurons and muscle cells. Dissociated embryonic cells express a robust outwardly rectifying anion current that is activated by membrane stretch and depolarization. This current, termed I-Cl,I-mec, is inhibited by anion and mechanosensitive channel inhibitors. I-Cl,I-mec has broad anion selectivity and the channel has a unitary conductance of 5-7 picosiemens. I-Cl,I-mec is not detectable in whole-cell or isolated patch recordings from oocytes, cultured muscle cells, and cultured neurons but is expressed in single cell and later embryos. Channel density is high, and the current is observed in >80% of membrane patches. Macroscopic currents of 40-120 pA at +100 mV are typically observed in inside-out membrane patches formed using low resistance patch pipettes. Isolated membrane patches of early embryonic cells therefore contain 60-200 I-Cl,I-mec channels. The apparent activation of I-Cl,I-mec shortly after fertilization and its down-regulation in terminally differentiated cells suggests that the channel may play important roles in embryogenesis and/or cytokinesis.	Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Anesthesiol Res Div,Med Ctr N T4202, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Strange, K (corresponding author), Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Anesthesiol Res Div,Med Ctr N T4202, Nashville, TN 37232 USA.	kevin.strange@mcmail.vanderbilt.edu			NIDDK NIH HHS [DK51610] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051610] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bamber BA, 1999, J NEUROSCI, V19, P5348; Barbier-Brygoo H, 2000, BBA-BIOMEMBRANES, V1465, P199, DOI 10.1016/S0005-2736(00)00139-5; BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; BRENNER S, 1974, GENETICS, V77, P71; Buechner M, 1999, DEV BIOL, V214, P227, DOI 10.1006/dbio.1999.9398; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; Dieudonne S, 1997, J MEMBRANE BIOL, V159, P83, DOI 10.1007/s002329900271; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Eder C, 1998, J NEUROSCI, V18, P7127; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; Eggermont J, 1998, BIOCHEM J, V331, P347; FALKE LC, 1988, FEBS LETT, V237, P141, DOI 10.1016/0014-5793(88)80188-1; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hryciw DH, 2000, CLIN EXP PHARMACOL P, V27, P892, DOI 10.1046/j.1440-1681.2000.03356.x; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Jackson M B, 1999, Adv Neurol, V79, P511; Jackson PS, 1996, AM J PHYSIOL-CELL PH, V270, pC57, DOI 10.1152/ajpcell.1996.270.1.C57; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LEWIS JA, 1995, CAENORHABDITIS ELEGA, P4; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Lockery SR, 1998, METHOD ENZYMOL, V293, P201; Machaca K, 1996, DEV BIOL, V176, P1, DOI 10.1006/dbio.1996.9999; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Majid A, 2001, J PHYSIOL-LONDON, V534, P409, DOI 10.1111/j.1469-7793.2001.00409.x; Mannella CA, 1997, J BIOENERG BIOMEMBR, V29, P525, DOI 10.1023/A:1022489832594; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Montell DJ, 1999, DEVELOPMENT, V126, P3035; Moody WJ, 1998, CURR TOP DEV BIOL, V39, P159, DOI 10.1016/S0070-2153(08)60455-X; Morris AP, 1999, ADV PHARMACOL, V46, P209, DOI 10.1016/S1054-3589(08)60472-X; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; Pierce-Shimomura JT, 2001, NATURE, V410, P694, DOI 10.1038/35070575; Robertson AP, 1997, PARASITOLOGY, V115, P183, DOI 10.1017/S0031182097001273; Rutledge E, 2001, CURR BIOL, V11, P161, DOI 10.1016/S0960-9822(01)00051-3; Schriever AM, 1999, J BIOL CHEM, V274, P34238, DOI 10.1074/jbc.274.48.34238; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Tombola F, 2000, BIOPHYS J, V79, P863, DOI 10.1016/S0006-3495(00)76342-9; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zang JH, 1998, P NATL ACAD SCI USA, V95, P13652, DOI 10.1073/pnas.95.23.13652	57	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45024	45030		10.1074/jbc.M107652200	http://dx.doi.org/10.1074/jbc.M107652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11568185	hybrid			2022-12-27	WOS:000172406700092
J	Janowski, BA; Shan, B; Russell, DW				Janowski, BA; Shan, B; Russell, DW			The hypocholesterolemic agent LY295427 reverses suppression of sterol regulatory element-binding protein processing mediated by oxysterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE SPHINGOMYELIN; LEUCINE ZIPPER PROTEIN; A REDUCTASE-ACTIVITY; HAMSTER OVARY CELLS; HUMAN FIBROBLASTS; ENDOPLASMIC-RETICULUM; CHOLESTEROL-METABOLISM; CYSTEINE PROTEASE; LDL RECEPTOR	The sterol LY295427 reduces plasma cholesterol levels in animals by increasing the expression of hepatic low density lipoprotein (LDL) receptors. Here we trace the hypocholesterolemic activity of LY295427 to an ability to reverse oxysterol-mediated suppression of sterol regulatory element-binding protein (SREBP) processing. Micromolar concentrations of LY295427 induced the metabolism of LDL in oxysterol-treated cultured cells and inhibited the stimulation of cholesteryl ester synthesis mediated by oxysterols. cDNA microarray and RNA blotting experiments revealed that LY295427 increased levels of the LDL receptor mRNA and those of other SREBP target genes. The compound stimulated the accumulation of SREBPs in the nuclei of cells grown in the presence of oxysterols within 4-6 h of addition to the medium. Induction required components of the normal SREBP-processing pathway, including the SREBP cleavage-activating protein and the Site 1 protease. LY295427 overcame the suppression of SREBP processing mediated by several oxysterols but not by LDL-derived cholesterol. We conclude that LY295427 achieves a therapeutically desirable end point by an unique mechanism of action.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Tilarik Inc, San Francisco, CA 94080 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	russell@utsw.swmed.edu		Russell, David/0000-0002-0277-403X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bensch WR, 1999, J PHARMACOL EXP THER, V289, P85; Bowling N, 1996, J LIPID RES, V37, P2586; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1974, J BIOL CHEM, V249, P7306; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DAHL NK, 1994, J LIPID RES, V35, P1839; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Gardner RG, 2001, J BIOL CHEM, V276, P8681, DOI 10.1074/jbc.M007888200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lange Y, 1999, J LIPID RES, V40, P2264; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; Lin HS, 1999, STEROIDS, V64, P735, DOI 10.1016/S0039-128X(99)00053-7; LIN HS, 1995, J MED CHEM, V38, P277, DOI 10.1021/jm00002a010; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SAMBROOK J, 2000, MOL CLONING LAB MANU; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P251, DOI 10.1016/0005-2736(90)90301-4; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; Windaus A, 1909, BER DTSCH CHEM GES, V42, P238, DOI 10.1002/cber.19090420138; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	53	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45408	45416		10.1074/jbc.M108348200	http://dx.doi.org/10.1074/jbc.M108348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577112	hybrid			2022-12-27	WOS:000172406700138
J	Maga, G; Ramunno, A; Nacci, V; Locatelli, GA; Spadari, S; Fiorini, I; Baldanti, F; Paolucci, S; Zavattoni, M; Bergamini, A; Galletti, B; Muck, S; Hubscher, U; Giorgi, G; Guiso, G; Caccia, S; Campiani, G				Maga, G; Ramunno, A; Nacci, V; Locatelli, GA; Spadari, S; Fiorini, I; Baldanti, F; Paolucci, S; Zavattoni, M; Bergamini, A; Galletti, B; Muck, S; Hubscher, U; Giorgi, G; Guiso, G; Caccia, S; Campiani, G			The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464 - A novel generation of nonnucleoside inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; P-GLYCOPROTEIN; RT INHIBITORS; INFECTION; CHEMOTHERAPY; TRANSPORTER; NEVIRAPINE; METABOLISM	The human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitor pyrrolopyridooxazepinone (PPO) derivative, (+/-)-PPO294, was shown to be active toward wild type and mutated HIV-1 RT and to act synergistically in combination with 3'-azido-3'-deoxythymidine (Campiani, G., Morelli, E., Fabbrini, M., Nacci, V., Greco, G., Novellino, E., Ramunno, A., Maga, G., Spadari, S., Caliendo, G., Bergamini, A., Faggioli, E., Uccella, I., Bolacchi, F., Marini, S., (1999) J. Med. Chant. 42, 4462-4470). The (+/-)-PPO294 racemate was resolved into its pure enantiomers, and the absolute configuration was determined by x-ray analysis. Only one enantiomer, (R)-(-)-PPO464, displayed antiviral activity against both the wild type and the K103N mutant HIV-1 RT and was found to interact exclusively with the reaction intermediate formed by RT complexed with both the DNA and the nucleotide substrates. Being the first compound of its class to display this behavior, (R)-(-)-PPO464 is the representative of a novel generation of nonnucleoside inhibitors. (R)(-)-PPO464 showed significant synergism when tested in combination with other RT inhibitors and efficiently inhibited viral replication when tested against the laboratory strain HIV-1 IIIB or against either wild type or multidrug-resistant clinical isolates. Pharmacokinetic studies in mice and rats showed a more favorable profile for (R)-(-)-PPO464 than for the corresponding racemate. (R)-(-)-PPO464 was also found to easily cross the blood-brain barrier. The coadministration of the HIV-1 protease inhibitor ritonavir increased the bioavailability of (R)-(-)-PPO464, having little effect on its plasma and brain elimination rates.	Univ Siena, Dipartimento Farm Chim Tecnol, I-53100 Siena, Italy; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, Italy; Policlin San Matteo, IRCCS, Serv Virol, I-27100 Pavia, Italy; Univ Roma Tor Vergata, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy; Ind Farmaceut Riunite Spa, Sigma Tau, I-00040 Pomezia, Italy; Univ Zurich Irchel, Inst Vet Biochem, CH-8050 Zurich, Switzerland; Univ Siena, Ctr Interdipartimentale Anal & Determinaz Struttu, I-53100 Siena, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy	University of Siena; Consiglio Nazionale delle Ricerche (CNR); University of Salerno; IRCCS Fondazione San Matteo; University of Pavia; University of Rome Tor Vergata; University of Zurich; University of Siena; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Campiani, G (corresponding author), Univ Siena, Dipartimento Farm Chim Tecnol, Via Laterina 8, I-53100 Siena, Italy.	campiani@unisi.it	Paolucci, Stefania/J-4055-2018; Maga, Giovanni/C-5409-2009; Baldanti, Fausto/J-4924-2018; Ramunno, Anna/ABD-7912-2021	Paolucci, Stefania/0000-0001-8447-8586; Maga, Giovanni/0000-0001-8092-1552; Baldanti, Fausto/0000-0002-3358-8969; Zavattoni, Maurizio/0000-0002-5199-0038; Campiani, Giuseppe/0000-0001-5295-9529; GIORGI, GIANLUCA/0000-0002-8817-7745				Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014; Arion D, 1996, MOL PHARMACOL, V50, P1057; Barnard J, 1997, BIOCHEMISTRY-US, V36, P7786, DOI 10.1021/bi970140u; Blake M, 2000, CLIN INFECT DIS, V30, pS96, DOI 10.1086/313859; Caccia S, 1998, CLIN PHARMACOKINET, V34, P281, DOI 10.2165/00003088-199834040-00002; Campiani G, 1999, J MED CHEM, V42, P4462, DOI 10.1021/jm990150o; Cattaneo E, 1999, MICROBIOLOGICA, V22, P281; CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clotet B, 1999, INT J CLIN PRACT, P21; De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7; De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4; DECLERCQ E, 1994, ANN NY ACAD SCI, V724, P438; Drewe J, 1999, BIOCHEM PHARMACOL, V57, P1147, DOI 10.1016/S0006-2952(99)00026-X; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762; Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRECO WR, 1995, PHARMACOL REV, V47, P331; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; HUBSCHER U, 1994, PHYSIOL REV, V74, P259, DOI 10.1152/physrev.1994.74.2.259; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lin JH, 1997, PHARMACOL REV, V49, P403; Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427; Maga G, 2000, ANTIMICROB AGENTS CH, V44, P1186, DOI 10.1128/AAC.44.5.1186-1194.2000; Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1; Masters Barry R., 1994, V8, P1; O'Brien WA, 2000, CLIN INFECT DIS, V30, pS185, DOI 10.1086/313858; Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; Sheldrick G.M., 1997, SHELX 97 RELEASE 97; TATSURA T, 1992, J BIOL CHEM, V267, P2383; Telenti A, 2000, REV MED VIROL, V10, P385, DOI 10.1002/1099-1654(200011/12)10:6&lt;385::AID-RMV296&gt;3.0.CO;2-1; Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6	39	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44653	44662		10.1074/jbc.M106702200	http://dx.doi.org/10.1074/jbc.M106702200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572864	Green Accepted, hybrid			2022-12-27	WOS:000172406700044
J	Robledo, MM; Bartolome, RA; Longo, N; Rodriguez-Frade, JM; Mellado, M; Longo, I; van Muijen, GNP; Sanchez-Mateos, P; Teixido, J				Robledo, MM; Bartolome, RA; Longo, N; Rodriguez-Frade, JM; Mellado, M; Longo, I; van Muijen, GNP; Sanchez-Mateos, P; Teixido, J			Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MALIGNANT MELANOMA; T-LYMPHOCYTES; CD34(+) CELLS; RHO GTPASES; ADHESION; MIGRATION; PROTEIN; MIG; METASTASIS; INVASION	Chemokines are secreted into the tumor microenvironment by tumor-infiltrating inflammatory cells as well as by tumor cells. Chemokine receptors mediate agonist-dependent cell responses, including migration and activation of several signaling pathways. In the present study we show that several human melanoma cell lines and melanoma cells on macroscopically infiltrated lymph nodes express the chemokine receptors CXCR3 and CXCR4. Using the highly invasive melanoma cell line BLM, we demonstrate that the chemokine Mig, a ligand for CXCR3, activates the small GTPases RhoA and Rac1, induces a reorganization of the actin cytoskeleton, and triggers cell chemotaxis and modulation of integrin VIA-5- and VIA-4-dependent cell adhesion to fibronectin. Furthermore, the chemokine SDF-1 alpha, the ligand of CXCR4, triggered modulation of beta (1) integrin-dependent melanoma cell adhesion to fibronectin. Additionally, Mig and SDF-1 alpha activated MAPKs p44/42 and p38 on melanoma cells. Expression of functional CXCR3 and CXCR4 receptors on melanoma cells indicates that they might contribute to cell motility during invasion as well as to regulation of cell proliferation and survival.	Ctr Invest Biol, Dept Immunol, E-28006 Madrid, Spain; Hosp Univ Gregorio Maranon, Serv Inmunooncol, Madrid 28007, Spain; Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain; Univ Nijmegen Hosp, Dept Pathol, NL-6500 Nijmegen, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); General University Gregorio Maranon Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Radboud University Nijmegen	Teixido, J (corresponding author), Ctr Invest Biol, Dept Immunol, Velazquez 144, E-28006 Madrid, Spain.		Teixidó, Joaquin/J-8543-2014; Mellado, Mario/M-9893-2014; Sanchez-Mateos, Paloma/E-8931-2013; Frade, Jose Miguel Rodriguez/K-4266-2014; Bartolome, Ruben A/M-1873-2014	Mellado, Mario/0000-0001-6325-1630; Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Sanchez-Mateos, Paloma/0000-0001-6589-4445				Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COCHRAN AJ, 1985, PATHOLOGY, V17, P340, DOI 10.3109/00313028509063777; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; del Peso L, 1997, ONCOGENE, V15, P3047; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Elenitsas Rosalie, 1998, Current Opinion in Oncology, V10, P162, DOI 10.1097/00001622-199803000-00014; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; GOWN AM, 1986, AM J PATHOL, V123, P195; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kunz M, 1999, J PATHOL, V189, P552, DOI 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I; Lane WJ, 2000, BLOOD, V96, P4152; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; Loetscher P, 2000, Adv Immunol, V74, P127; Luca M, 1997, AM J PATHOL, V151, P1105; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOULD AP, 1994, J BIOL CHEM, V269, P27224; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1999, Adv Immunol, V71, P211; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Poncelet P, 1993, METHODS IMMUNOLOGICA, P388; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robledo MM, 1998, J BIOL CHEM, V273, P12056, DOI 10.1074/jbc.273.20.12056; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; SINGH RK, 1994, CANCER RES, V54, P3242; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348	57	203	213	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45098	45105		10.1074/jbc.M106912200	http://dx.doi.org/10.1074/jbc.M106912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571298	Green Published, hybrid			2022-12-27	WOS:000172406700100
J	Tanaka, M; Morishima, I; Akagi, T; Hashikawa, T; Nukina, N				Tanaka, M; Morishima, I; Akagi, T; Hashikawa, T; Nukina, N			Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NEURODEGENERATIVE DISEASES; HUNTINGTONS-DISEASE; CRYSTAL-STRUCTURE; PROTEIN; APOMYOGLOBIN; FLUORESCENCE; INCLUSIONS; MUTANT; INTACT	An aberrant structure of the expanded polyglutamine might be involved in the formation of aggregates in CAG repeat diseases. To elucidate structural properties of the expanded polyglutamine, we prepared sperm whale myoglobin (Mb) mutants, in which 12, 28, 35, and 50 repeats of glutamine were inserted at the corner between the C and D helices (Gln(12), Gln(28), Gln(35), and Gln(50), respectively). Circular dichroism and IR spectroscopies showed that the expanded polyglutamine, which was recognized by the monoclonal antibody 1C2 in Gln(28), Gln(35), and Gln(50) Mb forms an antiparallel beta -pleated sheet structure. Gln(50) Mb aggregates were found to comprise an intermolecular antiparallel beta -pleated sheet. Fluorescence together with H-1 NMR spectra revealed partial unfolding of the protein surface in Gln(35) and Gln(50) Mb, although the structural changes in the protein core were rather small. The present results indicate that the fluctuating beta -pleated sheet of the expanded polyglutamine exposed on the protein surface facilitates the formation of aggregates through intermolecular interactions. The present study has first established and characterized structural properties of a molecular model for polyglutamine diseases in which various lengths of polyglutamine including a pathologically expanded glutamine repeat were inserted into a structurally known protein.	RIKEN, Brain Sci Inst, Lab CAG Repeat Dis, Wako, Saitama 3510198, Japan; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Wako, Saitama 3510198, Japan	RIKEN; Kyoto University; RIKEN	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Lab CAG Repeat Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Tanaka, Motomasa/N-5064-2015; Nukina, Nobuyuki/GPP-6265-2022	Tanaka, Motomasa/0000-0002-2994-7703; 				Altschuler EL, 1997, J PEPT RES, V50, P73; Chen YW, 1999, P NATL ACAD SCI USA, V96, P1257, DOI 10.1073/pnas.96.4.1257; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Dong A, 1998, ARCH BIOCHEM BIOPHYS, V355, P275, DOI 10.1006/abbi.1998.0718; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Fink AL, 1998, FOLD DES, V3, P19, DOI 10.1016/S1359-0278(98)00005-4; HIRSCH RE, 1980, BIOCHEM BIOPH RES CO, V93, P432, DOI 10.1016/0006-291X(80)91096-7; JENNINGS PA, 1993, SCIENCE, V262, P92; LAMAR GN, 1986, J AM CHEM SOC, V108, P5568, DOI 10.1021/ja00278a033; LAMAR GN, 1980, J AM CHEM SOC, V102, P1822, DOI 10.1021/ja00526a011; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; McGowan DP, 2000, NEUROSCIENCE, V100, P677, DOI 10.1016/S0306-4522(00)00391-2; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; PARCZEL A, 1993, INT J PEPT PROT RES, V41, P223; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; POSTNIKOVA GB, 1991, EUR J BIOCHEM, V198, P223, DOI 10.1111/j.1432-1033.1991.tb16005.x; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RAJARATHNAM K, 1993, BIOCHEMISTRY-US, V32, P5670, DOI 10.1021/bi00072a024; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TOWNEND R, 1966, BIOCHEM BIOPH RES CO, V23, P163, DOI 10.1016/0006-291X(66)90522-5; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0	26	90	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45470	45475		10.1074/jbc.M107502200	http://dx.doi.org/10.1074/jbc.M107502200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584007	hybrid			2022-12-27	WOS:000172406700145
J	Wei, JPJ; Srinivasan, C; Han, H; Valentine, JS; Gralla, EB				Wei, JPJ; Srinivasan, C; Han, H; Valentine, JS; Gralla, EB			Evidence for a novel role of copper-zinc superoxide dismutase in zinc metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE LYS7 GENE; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; MOLECULAR-BIOLOGY; FREE-IRON; YEAST; MUTANTS; PROTEINS; DETOXIFICATION; HOMEOSTASIS	The LYS7 gene in Saccharomyces cerevisiae encodes a protein (yCCS) that delivers copper to the active site of copper-zinc superoxide dismutase (CuZn-SOD, a product of the SOD) gene). In yeast lacking Lys7 (lys7 Delta), the SOD1 polypeptide is present but inactive. Mutants lacking the SOD1 polypeptide (sod1 Delta) and lys7 Delta yeast show very similar phenotypes, namely poor growth in air and aerobic auxotrophies for lysine and methionine. Here, we demonstrate certain phenotypic differences between these strains: 1) lys7 Delta cells are slightly less sensitive to paraquat than sod1 Delta cells, 2) EPR-detectable or "free" iron is dramatically elevated in sod1 Delta mutants but not in lys7 Delta yeast, and 3) although sod1 Delta mutants show increased sensitivity to extracellular zinc, the lys7 Delta strain is as resistant as wild type. To restore the SOD catalytic activity but not the zinc-binding capability of the SOD1 polypeptide, we overexpressed Mn-SOD from Bacillus stearothermophilus in the cytoplasm of sod1 Delta yeast. Paraquat resistance was restored to wild-type levels, but zinc was not. Conversely, expression of a mutant CuZn-SOD that binds zinc but has no SOD activity (H46C) restored zinc resistance but not paraquat resistance. Taken together, these results strongly suggest that CuZn-SOD, in addition to its antioxidant properties, plays a role in zinc homeostasis.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Gralla, EB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM08042, GM08496] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042, T32GM008496] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; Corson LB, 1999, J BIOL CHEM, V274, P27590, DOI 10.1074/jbc.274.39.27590; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRALLA EB, 1997, OXIDATIVE STRESS MOL, P495; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Kaiser C., 1994, METHODS YEAST GENETI; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; Lu Y, 1996, INORG CHEM, V35, P1692, DOI 10.1021/ic9513189; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; NISHIDA CR, 1994, P NATL ACAD SCI USA, V91, P9906, DOI 10.1073/pnas.91.21.9906; Nishimura K, 1998, J BACTERIOL, V180, P1962, DOI 10.1128/JB.180.7.1962-1964.1998; Pearce DA, 1999, J BACTERIOL, V181, P4774, DOI 10.1128/JB.181.16.4774-4779.1999; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; [No title captured]	32	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44798	44803		10.1074/jbc.M104708200	http://dx.doi.org/10.1074/jbc.M104708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581253	hybrid			2022-12-27	WOS:000172406700063
J	Ninio, S; Rotem, D; Schuldiner, S				Ninio, S; Rotem, D; Schuldiner, S			Functional analysis of novel multidrug transporters from human pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EFFLUX PUMP; EMRE; ANTIPORTER; PROTEINS; H+; RESISTANCE; ALIGNMENT; SEQUENCES; BINDING	Proteins of the Smr family are the smallest multidrug transporters, about 110 amino acids long, that extrude various drugs in exchange with protons, thereby rendering bacteria resistant to these compounds. One of these proteins, EmrE, is an Escherichia coli protein, which has been cloned based on its ability to confer resistance to ethidium and methyl viologen and which has been extensively characterized. More than 60 genes coding for Smr proteins have been identified in several bacteria based on amino acid sequence similarity to the emrE gene. In this work we have analyzed the sequence similarity among these homologues and identified some distinct signature sequence elements and several fully conserved residues. Five of these homologues, from human pathogens Mycobacterium tuberculosis, Bordetella pertussis, and Pseudomonas aeruginosa and from Escherichia coli, were cloned into an E. coli expression system. The proteins were further characterized and show varying degrees of methyl viologen uptake into proteoliposomes and [H-3]TPP binding in solubilized membranes. The homologues can also form mixed oligomers with EmrE that exhibit intermediate binding characteristics. A comparative study of various homologous proteins provides a tool for deciphering structure-function relationship and monomer-monomer interaction in multidrug transporters and in membrane proteins in general.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.		Rotem, Dvir/G-1396-2013; Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237; Rotem, Dvir/0000-0002-1840-6530	NINDS NIH HHS [NS16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; De Rossi E, 1998, J BACTERIOL, V180, P6068, DOI 10.1128/JB.180.22.6068-6071.1998; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; Jack DL, 2000, J BACTERIOL, V182, P2311, DOI 10.1128/JB.182.8.2311-2313.2000; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Masaoka Y, 2000, J BACTERIOL, V182, P2307, DOI 10.1128/JB.182.8.2307-2310.2000; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torres J, 2000, EUR J BIOCHEM, V267, P3422, DOI 10.1046/j.1432-1327.2000.01324.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044	26	48	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48250	48256		10.1074/jbc.M108231200	http://dx.doi.org/10.1074/jbc.M108231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11574548	hybrid			2022-12-27	WOS:000172927000069
J	Ding, K; Sandgren, S; Mani, K; Belting, M; Fransson, LA				Ding, K; Sandgren, S; Mani, K; Belting, M; Fransson, LA			Modulations of glypican-1 heparan sulfate structure by inhibition of endogenous polyamine synthesis - Mapping of spermine-binding sites and heparanase, heparin lyase, and nitric oxide/nitrite cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE SYNTHASE; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; TETRASACCHARIDES; INVOLVEMENT; NUCLEI; CELLS	Cell surface heparan sulfate proteoglycans facilitate uptake of growth-promoting polyamines (Belting, M., Persson, S., and Fransson, L.-A (1999) Biochem. J. 338, 317-323; Belting, M., Borsig, L., Fuster, M. M., Brown, J. R., Persson, L., Fransson, L.-A., and Esko, J. D. (2001) Proc. Natl. Acad. Sci. U. S. A., in press). Here, we have analyzed the effect of polyamine deprivation on the structure and polyamine affinity of the heparan sulfate chains in various glypican-1 glycoforms synthesized by a transformed cell line (ECV 304). Heparan sulfate chains of glypican-1 were either cleaved with heparanase at sites embracing the highly modified regions or with nitrite at N-unsubstituted glucosamine residues. The products were separated and further degraded by heparin lyase to identify sulfated iduronic acid. Polyamine affinity was assessed by chromatography on agarose substituted with the polyamine spermine. In heparan sulfate made by cells with undisturbed endogenous polyamine synthesis, free amino groups were restricted to the unmodified, unsulfated segments, especially near the core protein. Spermine high affinity binding sites were located to the modified and highly sulfated segments that were released by heparanase. In cells with up-regulated polyamine uptake, heparan sulfate contained an increased number of clustered N-unsubstituted glucosamines and sulfated iduronic acid residues. This resulted in a greater number of NO/nitrite-sensitive cleavage sites near the potential spermine-binding sites. Endogenous degradation by heparanase and NO-derived nitrite in polyamine-deprived cells generated a separate pool of heparan sulfate oligosaccharides with an exceptionally high affinity for spermine. Spermine uptake in polyamine-deprived cells was reduced when NO/nitrite-generated degradation of heparan sulfate was inhibited. The results suggest a functional interplay between glypican recycling, NO/nitrite-generated heparan sulfate degradation, and polyamine uptake.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, SE-22184 Lund, Sweden	Lund University	Fransson, LA (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, BMC C13, SE-22184 Lund, Sweden.	Lars-Ake.Fransson@medkem.lu.se		Mani, Katrin/0000-0002-1821-0634; Belting, Mattias/0000-0003-1585-5434				Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blachier F, 1997, NITRIC OXIDE-BIOL CH, V1, P268, DOI 10.1006/niox.1997.0127; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; Colin S, 1999, MOL PHARMACOL, V55, P74, DOI 10.1124/mol.55.1.74; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; Ding K, 2001, J BIOL CHEM, V276, P3885, DOI 10.1074/jbc.M005238200; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69	32	44	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46779	46791		10.1074/jbc.M105419200	http://dx.doi.org/10.1074/jbc.M105419200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577085	hybrid			2022-12-27	WOS:000172768500016
J	Gao, M; Fan, SJ; Goldberg, ID; Laterra, J; Kitsis, RN; Rosen, EM				Gao, M; Fan, SJ; Goldberg, ID; Laterra, J; Kitsis, RN; Rosen, EM			Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT ACTIVATION; CYTOCHROME-C; SCATTER FACTOR; CASPASE ACTIVATION; FACTOR PROTECTS; SURVIVAL; RELEASE; INHIBITION; IDENTIFICATION; PROTEASE	The cytokine hepatocyte growth factor/scatter factor (HGF/SF) has been found to protect a variety of epithelial and cancer cell types against cytotoxicity and apoptosis induced by DNA damage, but the specific apoptotic signaling events and the levels at which they are blocked by HGF/SF have not been identified. We found that treatment of MDA-MB-453 human breast cancer cells with adriamycin (also known as doxorubicin, a DNA topoisomerase II alpha inhibitor) induced a series of time-dependent events, including the mitochondrial release of cytochrome c and apoptosis-inducing factor, mitochondrial membrane depolarization, activation of a set of caspases (caspase-9, -3, -7, -2, and -8), cleavage of poly(ADP-ribose) polymerase (PARP), and up-regulation of expression of the Fas ligand. All of these events were blocked by preincubation of the cells with HGF/SF. In contrast, the pan-caspase inhibitor benzyloxycarbonyl-VAD-fluoromethylketone blocked some of these events (e.g. caspase-3 activation and PARP cleavage) but did not block cytochrome c release or mitochondrial depolarization. These findings suggest that HGF/SF functions, in part, upstream of the mitochondria to block mitochondrial apoptosis signaling, prevent activation of multiple caspases, and protect breast cancer cells against apoptosis.	Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New Hyde Pk, NY 11040 USA; Kennedy Krieger Res Inst, Dept Neurol, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Neurosci, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; Kennedy Krieger Institute; Kennedy Krieger Institute; Kennedy Krieger Institute; Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rosen, EM (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	erosen@lij.edu			NIEHS NIH HHS [R01-ES 09169] Funding Source: Medline; PHS HHS [R01-80000, R01-82599] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Asselin E, 2001, CANCER RES, V61, P1862; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Gao CF, 2001, EXP CELL RES, V265, P145; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nomura M, 1999, CANCER RES, V59, P5542; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rosen EM, 1997, J UROLOGY, V157, P72, DOI 10.1016/S0022-5347(01)65286-8; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; Rosen EM, 2000, ANGIOGENESIS IN HEALTH AND DISEASE, P145; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yao Y, 1996, AM J PATHOL, V149, P1707; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47257	47265		10.1074/jbc.M106791200	http://dx.doi.org/10.1074/jbc.M106791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11571297	hybrid			2022-12-27	WOS:000172768500079
J	Hillier, W; Hendry, G; Burnap, RL; Wydrzynski, T				Hillier, W; Hendry, G; Burnap, RL; Wydrzynski, T			Substrate water exchange in photosystem II depends on the peripheral proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-STABILIZING PROTEIN; PHOTOSYNTHETIC OXYGEN-EVOLUTION; EXTRINSIC PROTEINS; 33-KDA PROTEIN; EXOGENOUS REDUCTANTS; CYTOCHROME C-550; EVOLVING COMPLEX; PROTON-TRANSFER; OXIDIZING SIDE; CORE COMPLEX	The O-18 exchange rates for the substrate water bound in the S-3 state were determined in different photosystem. II sample types using time-resolved mass spectrometry. The samples included thylakoid membranes, salt-washed Triton X-100-prepared membrane fragments, and purified core complexes from spinach and cyanobacteria. For each sample type, two kinetically distinct isotopic exchange rates could be resolved, indicating that the biphasic exchange behavior for the substrate water is inherent to the O-2-evolving catalytic site in the S3 state. However, the fast phase of exchange became somewhat slower (by a factor of similar to2) in NaCl-washed membrane fragments and core complexes from spinach in which the 16- and 23-kDa extrinsic proteins have been removed, compared with the corresponding rate for the intact samples. For CaCl2-washed membrane fragments in which the 33-kDa manganese stabilizing protein (MSP) has also been removed, the fast phase of exchange slowed down even further (by a factor of similar to3). Interestingly, the slow phase of exchange was little affected in the samples from spinach. For core complexes prepared from Synechocystis PCC 6803 and Synechococcus elongatus, the fast and slow exchange rates were variously affected. Nevertheless, within the experimental error, nearly the same exchange rates were measured for thylakoid samples made from wild type and an MSP-lacking mutant of Synechocystis PCC 6803. This result could indicate that the MSP has a slightly different function in eukaryotic organisms compared with prokaryotic organisms. In all samples, however, the differences in the exchange rates are relatively small. Such small differences are unlikely to arise from major changes in the metal-ligand structure at the catalytic site. Rather, the observed differences may reflect subtle long range effects in which the exchange reaction coordinates become slightly altered. We discuss the results in terms of solvent penetration into photosystem II and the regional dielectric around the catalytic site.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Oklahoma State Univ, Dept Microbiol & Mol Genet, Stillwater, OK 74078 USA; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 0200, Australia	Michigan State University; Oklahoma State University System; Oklahoma State University - Stillwater; Australian National University	Hillier, W (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.	Hillier@photon.cem.msu.edu	Wydrzynski, Thomas/C-9630-2009; Hillier, Warwick/D-1034-2009					AKERLUND HE, 1982, BIOCHIM BIOPHYS ACTA, V681, P1, DOI 10.1016/0005-2728(82)90271-7; Al-Khaldi SF, 2000, PLANT MOL BIOL, V43, P33, DOI 10.1023/A:1006419928712; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bricker TM, 1998, BBA-BIOENERGETICS, V1409, P50, DOI 10.1016/S0005-2728(98)00148-0; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRICKER TM, 1996, ADV PHOTOSYNTH, V4, P113; BRITT DR, 1996, OXYGENIC PHOTOSYNTHE, V4, P137; Britt RD, 2000, ANNU REV BIOPH BIOM, V29, P463, DOI 10.1146/annurev.biophys.29.1.463; Burda K, 2001, BBA-BIOENERGETICS, V1506, P47, DOI 10.1016/S0005-2728(01)00182-7; Burda K, 2001, FEBS LETT, V491, P81, DOI 10.1016/S0014-5793(01)02175-5; Burnap RL, 1996, BIOCHEMISTRY-US, V35, P874, DOI 10.1021/bi951964j; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; Campbell KA, 1998, BIOCHEMISTRY-US, V37, P5039, DOI 10.1021/bi9800552; Debus RJ, 2000, MET IONS BIOL SYST, V37, P657; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; Denisov VP, 1996, NAT STRUCT BIOL, V3, P505, DOI 10.1038/nsb0696-505; Dwyer JJ, 2000, BIOPHYS J, V79, P1610, DOI 10.1016/S0006-3495(00)76411-3; ENAMI I, 1994, BBA-BIOENERGETICS, V1185, P75, DOI 10.1016/0005-2728(94)90195-3; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; GHANOTAKIS DF, 1984, BIOCHIM BIOPHYS ACTA, V767, P524, DOI 10.1016/0005-2728(84)90051-3; Halle B, 1999, NATO ADV SCI I A-LIF, V305, P233; Halle B., 1999, BIOL MAGN RESON, V17, P419; Haumann M, 1997, PHOTOSYNTH RES, V51, P193, DOI 10.1023/A:1005861917596; Hillier W, 2000, BIOCHEMISTRY-US, V39, P4399, DOI 10.1021/bi992318d; Hillier W, 2001, BBA-BIOENERGETICS, V1503, P197, DOI 10.1016/S0005-2728(00)00225-5; Hillier W, 1998, BIOCHEMISTRY-US, V37, P16908, DOI 10.1021/bi980756z; Hoganson CW, 2000, MET IONS BIOL SYST, V37, P613; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; KUWABARA T, 1983, PLANT CELL PHYSIOL, V24, P741, DOI 10.1093/oxfordjournals.pcp.a076571; Kuzek D, 2001, BBA-BIOENERGETICS, V1503, P123, DOI 10.1016/S0005-2728(00)00218-8; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; Mulkidjanian AY, 1999, BBA-BIOENERGETICS, V1410, P1, DOI 10.1016/S0005-2728(98)00174-1; Nugent JHA, 2001, BBA-BIOENERGETICS, V1503, P138, DOI 10.1016/S0005-2728(00)00223-1; ONO T, 1984, FEBS LETT, V168, P281, DOI 10.1016/0014-5793(84)80263-X; ONO TA, 1983, FEBS LETT, V164, P255, DOI 10.1016/0014-5793(83)80297-X; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P14474, DOI 10.1021/bi970116g; Richens DT., 1997, CHEM AQUA IONS; Schlodder E, 1999, J BIOL CHEM, V274, P30387, DOI 10.1074/jbc.274.43.30387; SEIDLER A, 1997, BIOCHIM BIOPHYS ACTA, V1277, P35; SHARP RR, 1980, BIOCHIM BIOPHYS ACTA, V592, P169, DOI 10.1016/0005-2728(80)90123-1; Shen JR, 1998, BIOCHEMISTRY-US, V37, P1551, DOI 10.1021/bi971676i; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; TAMURA N, 1990, PLANT CELL PHYSIOL, V31, P469; TAMURA N, 1985, BIOCHIM BIOPHYS ACTA, V809, P245, DOI 10.1016/0005-2728(85)90068-4; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Tommos C, 1998, ACCOUNTS CHEM RES, V31, P18, DOI 10.1021/ar9600188; VANLEEUWEN PJ, 1993, PHOTOSYNTH RES, V38, P169, DOI 10.1007/BF00146416; VANLEEUWEN PJ, 1991, PHOTOSYNTH RES, V28, P149, DOI 10.1007/BF00054128; Vrettos JS, 2001, BIOCHEMISTRY-US, V40, P7937, DOI 10.1021/bi010679z; Vrettos JS, 2001, BBA-BIOENERGETICS, V1503, P229, DOI 10.1016/S0005-2728(00)00214-0; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Wydrzynski T, 1996, PHYSIOL PLANTARUM, V96, P342, DOI 10.1111/j.1399-3054.1996.tb00224.x; Zouni A, 2000, BBA-BIOENERGETICS, V1457, P103, DOI 10.1016/S0005-2728(00)00100-6; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589; Zouni A, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P925	64	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46917	46924		10.1074/jbc.M102954200	http://dx.doi.org/10.1074/jbc.M102954200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595731	hybrid			2022-12-27	WOS:000172768500034
J	Nibbelink, M; Moulin, K; Arnaud, E; Duval, C; Penicaud, L; Casteilla, L				Nibbelink, M; Moulin, K; Arnaud, E; Duval, C; Penicaud, L; Casteilla, L			Brown fat UCP1 is specifically expressed in uterine longitudinal smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; GENETIC ABLATION; LIVER; MECHANISMS; PHYSIOLOGY; OBESITY; MICE	Until now, uncoupling protein I (UCP1) was considered as unique to brown adipocytes. It supports a highly regulated uncoupling of oxidative phosphorylation that is associated with diet as well as with non-shivering thermogenesis. Here we report that UCP1 is not specific to brown adipocytes and can be expressed in longitudinal smooth muscle layers. In the uterus, this conclusion was drawn from different convergent data. A specific antibody against mouse UCP1 revealed, in mitochondrial fractions, a protein with the same molecular weight as brown fat UCP1. Sensitive and specific reverse transcriptase-polymerase chain reaction detected a mRNA whose sequence was totally homologous to that of brown fat UCP1 mRNA. Antibody against UCP1 as well as a UCP1 antisense probe specifically stained uterine longitudinal smooth muscles. UCP1 was also ex. pressed in longitudinal smooth muscle of digestive and male reproductive tracts but was never expressed in other types of smooth muscle, including those of arterial vessels. In uterine tract, UCP1 content was increased after cold exposure or beta -adrenergic agonist treatment. It was also up-regulated during the postovulatory period after sexual cycle synchronization. Its content transiently increased during gestation and decreased markedly after birth. These regulations strongly argue about a role for UCP1 in thermogenesis as well as in relaxation of longitudinal smooth muscle layers.	IFR31 Rangueil Univ Hosp, UMR 5018 CNRS, F-31403 Toulouse 4, France		Casteilla, L (corresponding author), IFR31 Rangueil Univ Hosp, UMR 5018 CNRS, F-31403 Toulouse 4, France.	casteil@rangueil.inserm.fr		Casteilla, Louis/0000-0001-9647-3248				BATHGATE B, 1992, MOL MICROBIOL, V6, P363, DOI 10.1111/j.1365-2958.1992.tb01479.x; Brauner P, 2001, PEDIATR RES, V49, P440, DOI 10.1203/00006450-200103000-00022; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Hamann A, 1998, Z ERNAHRUNGSWISS, V37, P1; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kozak LP, 2000, ANNU REV NUTR, V20, P339, DOI 10.1146/annurev.nutr.20.1.339; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Masaki T, 1999, BBA-MOL CELL BIOL L, V1440, P81, DOI 10.1016/S1388-1981(99)00104-3; MIROUX B, 1992, J BIOL CHEM, V267, P13603; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OWEN JA, 1975, AM J CLIN NUTR, V28, P333; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1992, FEBS LETT, V303, P103, DOI 10.1016/0014-5793(92)80496-4; Ricquier D, 2000, J PHYSIOL-LONDON, V529, P3, DOI 10.1111/j.1469-7793.2000.00003.x; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; Riemer RK, 1998, PEDIATR RES, V44, P615, DOI 10.1203/00006450-199811000-00001; SHINOHARA Y, 1991, FEBS LETT, V293, P173, DOI 10.1016/0014-5793(91)81179-C; WRAY S, 1993, AM J PHYSIOL, V264, pC1, DOI 10.1152/ajpcell.1993.264.1.C1; Yoshida T, 1998, AM J PHYSIOL-ENDOC M, V274, pE469, DOI 10.1152/ajpendo.1998.274.3.E469; Zorov DB, 1997, BIOSCIENCE REP, V17, P507, DOI 10.1023/A:1027304122259	25	42	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47291	47295		10.1074/jbc.M105658200	http://dx.doi.org/10.1074/jbc.M105658200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11572862	hybrid			2022-12-27	WOS:000172768500083
J	Scholich, K; Pierre, S; Patel, TB				Scholich, K; Pierre, S; Patel, TB			Protein associated with Myc (PAM) is a potent inhibitor of adenylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CRYSTAL-STRUCTURE; C-ELEGANS; KINASE-II; IN-VIVO; STIMULATION; EXPRESSION; CLONING; IDENTIFICATION; CALMODULIN	Using the yeast two-hybrid assay and the second of the two large cytosolic domains of type V adenylyl cyclase (ACV) as bait, we identified a small region (amino acids 1028-1231) in the protein associated with Myc (PAM) as an interaction site for ACV. This small region of PAM as well as purified full-length PAM inhibited the activity of ACV. Additionally, full-length PAM was a very potent inhibitor of ACI and AC activities in S49 cyc(-) cells and HeLa cells with IC50 values in the pm and low nm range. Moreover, the regulator of chromatin condensation I-like domain of PAM (amino acids 446-1062) was sufficient and as potent as full-length PAM at inhibiting the activity of ACV. Interestingly, full-length PAM did not inhibit ACII activity that was stimulated by either forskolin of G alpha (s). When endogenous levels of PAM in HeLa cells were decreased using antisense oligode-oxynucleotides, the basal cAMP content was elevated and the dose-response curve for vasoactive intestinal peptide-elicited cAMP accumulation in HeLa cells was shifted to the left. Therefore, we conclude that PAM is a very potent, novel inhibitor of specific isoforms of AC. Furthermore, the regulator of chromatin condensation I-like domain of PAM is sufficient to exert the effects of the full-length protein on AC and decreases in endogenous PAM levels in HeLa cells can modulate both basal and agonist stimulated cAMP accumulation.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Vasc Biol Ctr, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; CHEN ZT, 1995, J BIOL CHEM, V270, P27525, DOI 10.1074/jbc.270.46.27525; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KASSIS S, 1982, J BIOL CHEM, V257, P5312; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; NAIR BG, 1990, J BIOL CHEM, V265, P21317; Patel TB, 2001, GENE, V269, P13, DOI 10.1016/S0378-1119(01)00448-6; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Schaefer AM, 2000, NEURON, V26, P345, DOI 10.1016/S0896-6273(00)81168-X; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Smit Martine J., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P1; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Sun H, 1997, J BIOL CHEM, V272, P5413, DOI 10.1074/jbc.272.9.5413; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zhen M, 2000, NEURON, V26, P331, DOI 10.1016/S0896-6273(00)81167-8	48	43	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47583	47589		10.1074/jbc.M107816200	http://dx.doi.org/10.1074/jbc.M107816200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11590159	hybrid			2022-12-27	WOS:000172768500118
J	Aydemir-Koksoy, A; Abramowitz, J; Allen, JC				Aydemir-Koksoy, A; Abramowitz, J; Allen, JC			Ouabain-induced signaling and vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DIGITALIS-LIKE-FACTOR; ANGIOTENSIN-II; NA+/K+-ATPASE; INTRACELLULAR NA+; TRANSDUCTION; TRANSACTIVATION; MECHANISMS; SECRETION; ADDUCIN	The hypothesis of this study is that the sodium pump complex acts as an intracellular signal-transducing molecule in canine vascular smooth muscle cells through its interaction with other membrane and cytoskeletal proteins. We have demonstrated that 1 nM ouabain induced transactivation of the epidermal growth factor receptor (EGFR), resulting in increased proliferation and bromodeoxyuridine (BrdUrd) uptake. Immunoprecipitation and Western blotting showed that the EGFR and Src were phosphorylated within 5 min of 10(-9) M ouabain stimulation. Both ouabain-induced DNA synthesis (BrdUrd uptake) and MAPK42/44 phosphorylation were inhibited by the Src inhibitor PP2, the EGFR kinase inhibitor AG1478, the tyrosine kinase inhibitor genistein, and the MEK1 inhibitor PD98059. Ouabain concentrations higher than 1 nM had little or no stimulating effect on proliferation or BrdUrd uptake but did minimally activate ERK1/2. Thus, low concentrations of ouabain, which do not inhibit the sodium pump sufficiently to perturb the resting cellular ionic milieu, initiate a transactivational signaling cascade leading to vascular smooth muscle cell proliferation.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Cardiovasc Sci Sect, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Allen, JC (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.	juliusa@bcm.tmc.edu	Abramowitz, Joel/A-2620-2015	Allen, Jeffrey/0000-0001-9957-6664	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024585] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24585] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN JC, 1989, AM J PHYSIOL, V256, pC786, DOI 10.1152/ajpcell.1989.256.4.C786; Aydemir-Koksoy A, 2001, AM J PHYSIOL-HEART C, V280, pH1869, DOI 10.1152/ajpheart.2001.280.4.H1869; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Danto SI, 1998, AM J PHYSIOL-CELL PH, V275, pC82, DOI 10.1152/ajpcell.1998.275.1.C82; Demoliou-Mason CD, 1998, BIOL SIGNAL RECEPT, V7, P90; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; Ferrandi M, 1999, AM J PHYSIOL-HEART C, V277, pH1338, DOI 10.1152/ajpheart.1999.277.4.H1338; GESCHWIND A, 2001, ONCOGENE, V20, P1594; GOLOMB E, 1994, AM J HYPERTENS, V7, P69, DOI 10.1093/ajh/7.1.69; GOTO A, 1992, PHARMACOL REV, V44, P377; GOTO A, 1990, BIOCHEM BIOPH RES CO, V173, P1093, DOI 10.1016/S0006-291X(05)80898-8; Haas M, 2000, J BIOL CHEM, V275, P27832; Haendeler J, 2000, REGUL PEPTIDES, V95, P1, DOI 10.1016/S0167-0115(00)00133-6; Hamlyn JM, 1998, CLIN EXP HYPERTENS, V20, P523, DOI 10.3109/10641969809053230; Ishida Mari, 1997, Keio Journal of Medicine, V46, P61; Iwasaki H, 1998, J CARDIOVASC PHARM, V31, pS182, DOI 10.1097/00005344-199800001-00052; KAHN A M, 1992, Journal of the American Society of Nephrology, V3, P522; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; KRAMER HJ, 1991, AM J HYPERTENS, P481; LAREDO J, 1995, BIOCHEM BIOPH RES CO, V212, P487, DOI 10.1006/bbrc.1995.1996; Leserer M, 2000, IUBMB LIFE, V49, P405; Liu J, 2000, J BIOL CHEM, V275, P27838; LOMPRE AM, 1999, CLIN EXP PHARM PHYSL, V26, P1; NAKAGAWA Y, 1992, J BIOL CHEM, V267, P8785; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; SCHMITZ G, 1991, ATHEROSCLEROSIS, V88, P109, DOI 10.1016/0021-9150(91)90074-D; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Takahashi H, 2000, HYPERTENS RES, V23, pS1, DOI 10.1291/hypres.23.Supplement_S1; Tripodi G, 1996, J CLIN INVEST, V97, P2815, DOI 10.1172/JCI118737; Turner NA, 2001, CELL SIGNAL, V13, P269, DOI 10.1016/S0898-6568(01)00135-8; Velarde V, 1999, AM J PHYSIOL-CELL PH, V277, pC253, DOI 10.1152/ajpcell.1999.277.2.C253	32	131	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46605	46611		10.1074/jbc.M106178200	http://dx.doi.org/10.1074/jbc.M106178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11579090	hybrid			2022-12-27	WOS:000172573100147
J	Chang, HSW; Julin, DA				Chang, HSW; Julin, DA			Structure and function of the Escherichia coli RecE protein, a member of the RecB nuclease domain family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROCELLULOSE-FILTER-BINDING; EXONUCLEASE-VIII; EVOLUTIONARY RELATIONSHIPS; ENDONUCLEASE ACTIVITY; CONSENSUS SEQUENCE; STRANDED-DNA; RAC PROPHAGE; ACTIVE-SITE; ENZYME; IDENTIFICATION	The RecB subunit of the Escherichia coli RecBCD enzyme has both helicase and nuclease activities. The helicase function was localized to an N-terminal domain, whereas the nuclease activity was found in a C-terminal domain. Recent analysis has uncovered a group of proteins that have weak amino acid sequence similarity to the RecB nuclease domain and that are proposed to constitute a family of related proteins (Axavind, L., Walker, D. R., and Koonin, E. V. (1999) Nucleic Acids Res. 27,1223-1242). One is the E. coli RecE protein (exonuclease VIII), an ATP-independent exonuclease that degrades the 5 ' -terminated strand of double-stranded DNA. We have made mutations in several residues of RecE that align with the critical residues of RecB, and we find that the mutations reduce or abolish the nuclease activity of RecE but do not affect the enzyme binding to linear double-stranded DNA. Proteolysis experiments with subtilisin show that a stable 34-kilodalton C-terminal domain that contains these critical residues has nuclease activity, whereas no stable proteolytic fragments accumulate from the N-terminal portion of RecE. These results show that RecE has a nuclease domain and active site that are similar to RecB, despite the very weak sequence similarity between the two proteins. These similarities support the hypothesis that the nuclease domains of the two proteins are evolutionarily related.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Julin, DA (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	dj13@umail.umd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039777, R29GM039777] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39777] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; CAMPBELL AM, 1996, ESCHERICHIA COLI SAL, V2, P2041; CHU CC, 1989, J BACTERIOL, V171, P2101, DOI 10.1128/jb.171.4.2101-2109.1989; CLARK AJ, 1993, J BACTERIOL, V175, P7673, DOI 10.1128/JB.175.23.7673-7682.1993; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; JOSEPH JW, 1983, J BIOL CHEM, V258, P411; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KOOISTRA J, 1993, MOL MICROBIOL, V7, P915, DOI 10.1111/j.1365-2958.1993.tb01182.x; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; KORANGY F, 1992, J BIOL CHEM, V267, P1733; KORANGY F, 1992, J BIOL CHEM, V267, P1727; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KUSHNER SR, 1974, P NATL ACAD SCI USA, V71, P3593, DOI 10.1073/pnas.71.9.3593; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LUISIDELUCA C, 1988, J BACTERIOL, V170, P5797, DOI 10.1128/jb.170.12.5797-5805.1988; Luneberg E, 2001, MOL MICROBIOL, V39, P1259, DOI 10.1111/j.1365-2958.2001.02314.x; Matsuo Y, 1999, PROTEINS, V35, P70, DOI 10.1002/(SICI)1097-0134(19990401)35:1<70::AID-PROT7>3.0.CO;2-9; Moreira D, 2000, MOL MICROBIOL, V35, P1, DOI 10.1046/j.1365-2958.2000.01692.x; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Murzin AG, 1998, CURR OPIN STRUC BIOL, V8, P380, DOI 10.1016/S0959-440X(98)80073-0; Muyrers JPP, 2000, GENE DEV, V14, P1971; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; PATTERSON C, 1988, MOL BIOL EVOL, V5, P603; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Ponting CP, 2000, ADV PROTEIN CHEM, V54, P185, DOI 10.1016/S0065-3233(00)54007-8; Rost B, 1997, FOLD DES, V2, pS19, DOI 10.1016/S1359-0278(97)00059-X; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Wang JD, 2000, J BIOL CHEM, V275, P507, DOI 10.1074/jbc.275.1.507; WILLIS DK, 1985, J BACTERIOL, V162, P1166, DOI 10.1128/JB.162.3.1166-1172.1985; Wolf YI, 2000, J MOL BIOL, V299, P897, DOI 10.1006/jmbi.2000.3786; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018; Yu M, 1998, J MOL BIOL, V283, P797, DOI 10.1006/jmbi.1998.2127; Yu M, 1998, P NATL ACAD SCI USA, V95, P981, DOI 10.1073/pnas.95.3.981; Zhang XJJ, 1999, NUCLEIC ACIDS RES, V27, P4200, DOI 10.1093/nar/27.21.4200	50	15	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46004	46010		10.1074/jbc.M108627200	http://dx.doi.org/10.1074/jbc.M108627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590160	hybrid			2022-12-27	WOS:000172573100070
J	Kovacic, HN; Irani, K; Goldschmidt-Clermont, PJ				Kovacic, HN; Irani, K; Goldschmidt-Clermont, PJ			Redox regulation of human Rac1 stability by the proteasome in human aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE; SIGNAL-TRANSDUCTION; SUPEROXIDE; FIBROBLASTS; PATHWAY; PROLIFERATION; EXPRESSION; HOMOLOG; RAS	Rac1 has been shown to activate a NADPH oxidase complex producing superoxide anions in a variety of mammalian cell types. We evaluated the impact of Rac1-induced reactive oxygen species production on the turnover of Rae1 itself in human aortic endothelial cells. The concentration of a constitutively active mutant of Rae1 (Rac1(V12)) was increased by treatment of the cells with diphenylene iodinium (DPI), an inhibitor of the NADPH oxidase. Such an effect was not observed for the dominant negative form of Rae1 (Rac1(N17)). We showed a decrease in proteolytic degradation of Rac1(V12) in the presence of DPI, and showed that short term treatment with H2O2 reverses the effect of DPI. We found that proteasome inhibitors (lactacystin and MG132) increased Rac1(V12) protein level. In support of this finding, we have identified in the primary sequence of Rac1 a potential destruction box domain, which is known to be a signal for protein degradation mediated by the ubiquitin/proteasome system. We show that Rac1(V12) is ubiquitinated before degradation. By contrast Rae1(N17) induces an accumulation of the ubiquitinated form of Rac1. These results suggest that Rae1 activation of NADPH oxidase is necessary for the proteolytic degradation of Rac1 itself.	Univ Mediterranee, UMR CNRS 6032, Fac Pharm, F-13385 Marseille, France; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21287 USA; Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Johns Hopkins University; Duke University	Kovacic, HN (corresponding author), Univ Mediterranee, UMR CNRS 6032, Fac Pharm, 27 Bd J Moulin, F-13385 Marseille, France.			Irani, Kaikobad/0000-0001-9194-7387; Kovacic, Herve/0000-0001-6509-4210				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chiou SK, 1998, VIROLOGY, V244, P108, DOI 10.1006/viro.1998.9077; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Senadheera D, 2001, INT J MOL MED, V8, P127; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4	29	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45856	45861		10.1074/jbc.M107925200	http://dx.doi.org/10.1074/jbc.M107925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585836	hybrid			2022-12-27	WOS:000172573100049
J	Bogatkevich, GS; Tourkina, E; Silver, RM; Ludwicka-Bradley, A				Bogatkevich, GS; Tourkina, E; Silver, RM; Ludwicka-Bradley, A			Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH MUSCLE ACTIN; IDIOPATHIC PULMONARY-FIBROSIS; BRONCHOALVEOLAR LAVAGE FLUID; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; ALVEOLAR MYOFIBROBLASTS; BINDING-PROTEIN; MESSENGER-RNA; CYCLIN D1; PROLIFERATION	Myofibroblasts are ultrastructurally and metabolically distinctive fibroblasts that express smooth muscle (SM)-alpha actin and are associated with various fibrotic lesions. The present study was undertaken to investigate the myofibroblast phenotype that appears after activation of normal lung fibroblasts by thrombin. We demonstrate that thrombin induces smooth muscle-a actin expression and rapid collagen gel contraction by normal lung fibroblasts via the proteolytically activated receptor-1 and independent of transforming growth factor-beta pathway. Using antisense oligonucleotides we demonstrate that a decreased level of PKC epsilon abolishes SM-alpha actin expression and collagen gel contraction induced by thrombin in normal lung fibroblasts. Inhibition of PKC epsilon translocation also abolishes thrombin-induced collagen gel contraction, SM-alpha actin increase, and its organization by normal lung fibroblasts, suggesting that activation of PKC epsilon is required for these effects. In normal lung fibroblasts PKC epsilon binds to SM-alpha actin after thrombin treatment, but in activated fibroblasts derived from scleroderma lung they associate even in untreated cells. This suggests that SM-alpha actin may serve as a substrate for PKC epsilon in lung fibroblasts when activated by thrombin. We propose that thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via a PKC-dependent pathway. Thrombin-induced differentiation of normal lung fibroblasts to a myofibroblast phenotype resembles the phenotype observed in scleroderma lung fibroblasts. Therefore, we conclude that chronic exposure to thrombin after microvascular injury leads to activation of normal lung fibroblasts and to the appearance of a myofibroblast phenotype in vivo. Our study provides novel, compelling evidence that thrombin is an important mediator of the interstitial lung fibrosis associated with scleroderma.	Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Ludwicka-Bradley, A (corresponding author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 912,POB 250623, Charleston, SC 29425 USA.	bradleyh@musc.edu		Ludwicka-Bradley, Anna/0000-0002-3122-4678	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001070] Funding Source: NIH RePORTER; NCRR NIH HHS [RR1070-1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Bachhuber BG, 1997, J VASC RES, V34, P41, DOI 10.1159/000159200; BIWAS P, 1995, FEBS LETT, V373, P146; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRETSCHNEIDER E, 1995, BIOCHEM PHARMACOL, V49, P33, DOI 10.1016/0006-2952(94)00404-A; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Byeon MK, 2000, MOL BIOL CELL, V11, p332A; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dabbagh K, 1998, THROMB HAEMOSTASIS, V79, P405; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; DESMOULIERE A, 1995, VASCULAR SMOOTH MUSC, P329; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; GODIN D, 1995, BRIT J PHARMACOL, V115, P903, DOI 10.1111/j.1476-5381.1995.tb15895.x; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRAY AJ, 1995, AM J RESP CELL MOL, V12, P684, DOI 10.1165/ajrcmb.12.6.7766431; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Hellbert K, 2000, ADV ENZYME REGUL, V40, P49, DOI 10.1016/S0065-2571(99)00038-2; HERNANDEZRODRIGUEZ NA, 1995, LANCET, V346, P1071, DOI 10.1016/S0140-6736(95)91744-6; HEWITSON TD, 1995, AM J NEPHROL, V15, P111, DOI 10.1159/000168813; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KANG YH, 1991, J HISTOCHEM CYTOCHEM, V39, P413, DOI 10.1177/39.4.2005371; KAPANCI Y, 1995, AM J RESP CRIT CARE, V152, P2163, DOI 10.1164/ajrccm.152.6.8520791; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KOTANI I, 1995, THROMB RES, V77, P493, DOI 10.1016/0049-3848(95)00025-9; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KUHN C, 1991, AM J PATHOL, V138, P1257; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; Low RB, 1999, CURR TOPICS PATHOL, V93, P19; LUDWICKA A, 1995, J RHEUMATOL, V22, P1876; LUDWICKA A, 1992, J RHEUMATOL, V19, P1716; Ludwicka-Bradley A, 2000, AM J RESP CELL MOL, V22, P235, DOI 10.1165/ajrcmb.22.2.3642; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; MALARKEY K, 1995, BRIT J PHARMACOL, V116, P2267, DOI 10.1111/j.1476-5381.1995.tb15063.x; Maruyama N, 2000, J RHEUMATOL, V27, P2777; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MITCHELL J, 1989, LAB INVEST, V60, P643; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OHBA T, 1994, AM J RESP CELL MOL, V10, P405, DOI 10.1165/ajrcmb.10.4.7510986; Pache JC, 1998, MODERN PATHOL, V11, P1064; Papadimitriou E, 1997, AM J PHYSIOL-CELL PH, V272, pC1112, DOI 10.1152/ajpcell.1997.272.4.C1112; Phan SH, 1996, KIDNEY INT, V49, pS46; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Slater SJ, 2000, BIOCHEMISTRY-US, V39, P271, DOI 10.1021/bi9916527; Steen VD, 2000, ARTHRITIS RHEUM-US, V43, P2437, DOI 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U; STEEN VD, 1994, ARTHRITIS RHEUM, V37, P1283, DOI 10.1002/art.1780370903; TANI K, 1991, AM J RESP CELL MOL, V5, P34, DOI 10.1165/ajrcmb/5.1.34; Tourkina E, 2001, ARTHRITIS RHEUM-US, V44, P1370, DOI 10.1002/1529-0131(200106)44:6<1370::AID-ART230>3.0.CO;2-2; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; VYALOV SL, 1993, AM J PATHOL, V143, P1754; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; YANPING X, 1995, J BIOL CHEM, V270, P23887; Zhang HY, 1996, AM J PATHOL, V148, P527; Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720; ZHANG K, 1994, AM J PATHOL, V145, P114	64	158	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45184	45192		10.1074/jbc.M106441200	http://dx.doi.org/10.1074/jbc.M106441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579091	hybrid			2022-12-27	WOS:000172406700111
J	Boylan, JM; Anand, P; Gruppuso, PA				Boylan, JM; Anand, P; Gruppuso, PA			Ribosomal protein S6 phosphorylation and function during late gestation liver development in the rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA-SYNTHESIS; FETAL-RAT; PERINATAL-PERIOD; CELL-CYCLE; KINASE; RAPAMYCIN; ACTIVATION; PROLIFERATION; P70(S6K)	The phosphorylation of ribosomal protein S6 is thought to be required for biosynthesis of the cell's translational apparatus, a critical component of cell growth and proliferation. We have studied the signal transduction pathways involved in hepatic S6 phosphorylation during late gestation in the rat. This is a period during which hepatocytes show a high rate of proliferation that is, at least in part, independent of mitogenic signaling pathways that are operative in mature hepatocytes. Our initial studies demonstrated that there was low basal activity of two S6 kinases in liver, S6K1 and S6K2, on embryonic day 19 (2 days preterm). In addition, insulin- and growth factor-mediated S6K1 and S6K2 activation was markedly attenuated compared with that in adult liver. Nonetheless, two-dimensional gel electrophoresis demonstrated that fetal liver S6 itself was highly phosphorylated. To characterize the fetal hepatocyte pathway for S6 phosphorylation, we went on to study the sensitivity of hepatocyte proliferation to the S6 kinase inhibitor rapamycin. Unexpectedly, administration of rapamycin to embryonic day 19 fetuses in. situ did not affect hepatocyte DNA synthesis. This resistance to the growth inhibitory effect of rapamycin occurred even though S6K1 and S6K2 were inhibited. Furthermore, fetal hepatocyte proliferation was sustained even though rapamycin administration resulted in the dephosphorylation of ribosomal protein S6. In contrast, rapamycin blocked hepatic DNA synthesis in adult rats following partial hepatectomy coincident with S6 dephosphorylation. We conclude that hepatocyte proliferation in the late gestation fetus is supported by a rapamycin-resistant mechanism that can function independently of ribosomal protein S6 phosphorylation.	Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, Providence, RI 02903 USA; Brown Univ, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, 593 Eddy St, Providence, RI 02903 USA.				NICHD NIH HHS [HD11343, HD24455, HD35831] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011343, P01HD011343, R01HD035831] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Boylan JM, 1998, J BIOL CHEM, V273, P3784, DOI 10.1074/jbc.273.6.3784; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fausto Nelson, 1994, P1059; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Gruppuso PA, 1997, IN VITRO CELL DEV-AN, V33, P562; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; MAYOR F, 1985, BIOL NEONATE, V48, P185, DOI 10.1159/000242171; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; Slavik JM, 2001, J IMMUNOL, V166, P3201, DOI 10.4049/jimmunol.166.5.3201; TERADA N, 1993, J BIOL CHEM, V268, P12062; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Withers DJ, 1997, J BIOL CHEM, V272, P2509	37	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44457	44463		10.1074/jbc.M103457200	http://dx.doi.org/10.1074/jbc.M103457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11574531	hybrid			2022-12-27	WOS:000172406700016
J	Crowder, CM; Westover, EJ; Kumar, AS; Ostlund, RE; Covey, DF				Crowder, CM; Westover, EJ; Kumar, AS; Ostlund, RE; Covey, DF			Enantiospecificity of cholesterol function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL FATES; CAENORHABDITIS-ELEGANS; PHOSPHOLIPID STRUCTURE; STEROL-METABOLISM; LET-60; VULVAR; GENE; RAS; REQUIREMENT; STABILITY	The importance of the absolute configuration of cholesterol for its function in vivo is unknown. To directly test this question in viva, we synthesized the enantiomer of cholesterol (ent-cholesterol) and tested its ability to substitute for natural cholesterol (not-cholesterol) in the growth, viability, and behavior of Caenorhabditis elegans, a cholesterol auxotroph. First-generation animals grown on ent-cholesterol were viable with only mild behavioral defects. However, ent-cholesterol produced 100% lethality/arrest of their second generation progeny. Isotopically labeled ent-cholesterol incorporated into animals, indicating that its lethality was not secondary to cholesterol starvation. When mixed with not-cholesterol, ent-cholesterol was not inert; rather, it antagonized the activity of not-cholesterol. These results demonstrate for the first tine that the absolute configuration of cholesterol, not just its physical properties, is essential for its functions in viva.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Covey, DF (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Eulcid Ave, St Louis, MO 63110 USA.	dcovey@molecool.wustl.edu			NIGMS NIH HHS [GM47969] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047969] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1986, BIOCHIM BIOPHYS ACTA, V856, P36, DOI 10.1016/0005-2736(86)90006-4; AGARWAL K, 1986, BIOCHIM BIOPHYS ACTA, V883, P468, DOI 10.1016/0304-4165(86)90286-2; ARNETT EM, 1982, J AM CHEM SOC, V104, P636, DOI 10.1021/ja00366a054; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CHITWOOD DJ, 1984, LIPIDS, V19, P500, DOI 10.1007/BF02534482; DUTKY SR, 1967, NEMATOLOGICA, V13, P140; GHOSH D, 1971, CHEM PHYS LIPIDS, V7, P173, DOI 10.1016/0009-3084(71)90030-2; GUYER W, 1983, CHEM PHYS LIPIDS, V33, P313, DOI 10.1016/0009-3084(83)90025-7; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMETTER A, 1982, CHEM PHYS LIPIDS, V31, P283, DOI 10.1016/0009-3084(82)90063-9; HIEB WF, 1968, SCIENCE, V160, P778, DOI 10.1126/science.160.3829.778; Hoekstra D, 2000, CURR OPIN CELL BIOL, V12, P496, DOI 10.1016/S0955-0674(00)00122-8; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; Ingham PW, 2000, CURR BIOL, V10, pR180, DOI 10.1016/S0960-9822(00)00346-8; Kumar AS, 1999, TETRAHEDRON LETT, V40, P823, DOI 10.1016/S0040-4039(98)02588-X; Kuwabara PE, 2000, GENE DEV, V14, P1933; Lalitha S, 2001, CHEM COMMUN, P1192, DOI 10.1039/b104081m; Lalitha S, 2001, J SUPRAMOL CHEM, V1, P53; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; LOZANO R, 1984, COMP BIOCHEM PHYS C, V79, P21, DOI 10.1016/0742-8413(84)90156-7; LU NC, 1977, NEMATOLOGICA, V23, P57, DOI 10.1163/187529277X00228; Matyash V, 2001, MOL BIOL CELL, V12, P1725, DOI 10.1091/mbc.12.6.1725; MICKUS DE, 1992, J AM CHEM SOC, V114, P359, DOI 10.1021/ja00027a055; Ostlund RE, 1996, J MASS SPECTROM, V31, P1291, DOI 10.1002/(SICI)1096-9888(199611)31:11<1291::AID-JMS424>3.0.CO;2-5; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; SULSTON J, 1988, MONOGRAPH, V17, P587; Yochem J, 1999, DEVELOPMENT, V126, P597; Yochem J, 1997, MOL CELL BIOL, V17, P2716, DOI 10.1128/MCB.17.5.2716	31	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44369	44372		10.1074/jbc.C100535200	http://dx.doi.org/10.1074/jbc.C100535200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11598105	hybrid			2022-12-27	WOS:000172406700003
J	Fujioka, Y; Taira, T; Maeda, Y; Tanaka, S; Nishihara, H; Iguchi-Ariga, SMM; Nagashima, K; Ariga, H				Fujioka, Y; Taira, T; Maeda, Y; Tanaka, S; Nishihara, H; Iguchi-Ariga, SMM; Nagashima, K; Ariga, H			MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-DEPENDENT TRANSCRIPTION; TRANSFORMING ACTIVITY; IN-VIVO; ESSENTIAL COFACTOR; CELL-GROWTH; GENES; ASSOCIATION; EXPRESSION; INTERACTS; IDENTIFICATION	The c-myc oncogene product (c-Myc) is a transcription factor that dimerizes with Max and recognizes the E-box sequence, and it plays key functions in cell proliferation, differentiation, and apoptosis. We previously showed that MM-1 bound to myc box II within the transactivation domain of c-Myc and repressed the E-box-dependent transcriptional activity of c-Myc. Here we report that MM-1 showed features of a tumor suppressor. In an EST data base search for cDNAs homologous to MM-1, we found a frequent substitution of amino acid 157 of MM-1, from alanine to arginine (A157R), and the substitution was observed more in tumor cells than in normal cells. A survey of the A157R mutation of MM-1 in 57 cultured cancer cells and 90 tissues from cancer patients showed that the A157R was present in about 50-60% of leukemia/lymphoma cells and in more than 75% of squamous cell carcinoma of tongue cancer. Although both the A157R and the wild-type MM-1 bound to c-Myc, only A157R lost the activities to repress both the E-box-dependent transcriptional activity of c-Myc and the myc/ras cooperative transforming activity in rat 3Y1 cells. Furthermore, the wild-type MM-1, but not A157R, arrested the growth of 3Y1 cells. The human MM-1 gene was mapped at chromosome 12q12-12q13, where many chromosome abnormalities in cancer cells have been reported. The results suggest that MM-1 is a novel candidate for a tumor suppressor that controls the transcriptional activity of c-Myc.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0608012, Japan; Hokkaido Univ, Grad Sch Med, Dept Pathol, Sapporo, Hokkaido 0608012, Japan; Hokkaido Univ, Coll Med Technol, Sapporo, Hokkaido 0608012, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST)	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Ariga, Hiroyoshi/B-5895-2013; Ariga, Sanae/H-9647-2013	Ariga, Hiroyoshi/0000-0001-7384-2143; 				ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Bao JX, 1996, ONCOGENE, V12, P2171; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Guo QM, 2000, CANCER RES, V60, P5922; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Niki T, 2000, GENES CELLS, V5, P127, DOI 10.1046/j.1365-2443.2000.00311.x; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Okano HJ, 1999, GENE DEV, V13, P2087, DOI 10.1101/gad.13.16.2087; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Prendergast GC, 1999, ONCOGENE, V18, P2914, DOI 10.1038/sj.onc.1202784; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Taira T, 1997, NUCLEIC ACIDS RES, V25, P1975, DOI 10.1093/nar/25.10.1975; Takayama M, 2000, GENES CELLS, V5, P481, DOI 10.1046/j.1365-2443.2000.00338.x; Takayama M, 2000, FEBS LETT, V477, P43, DOI 10.1016/S0014-5793(00)01756-7; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403	44	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45137	45144		10.1074/jbc.M106127200	http://dx.doi.org/10.1074/jbc.M106127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11567024	hybrid			2022-12-27	WOS:000172406700105
J	Sundararajan, R; Cuconati, A; Nelson, D; White, E				Sundararajan, R; Cuconati, A; Nelson, D; White, E			Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; PORE-FORMING DOMAIN; MITOCHONDRIAL-MEMBRANE; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; DELTA-ENDOTOXIN; X-RAY; PROTEIN; OLIGOMERIZATION	Tumor necrosis factor (TNF)-alpha -mediated death signaling induces oligomerization of proapoptotic Bcl-2 family member Bax into a high molecular mass protein complex in mitochondrial membranes. Bax complex formation is associated with the release of cytochrome c, which propagates death signaling by acting as a cofactor for caspase-9 activation. The adenovirus Bcl-2 homologue E1B 19K blocks TNT-alpha -mediated apoptosis by preventing cytochrome c release, caspase-9 activation, and apoptosis of virus-infected cells. TNF-alpha induces E1B 19K-Bax interaction and inhibits Bax oligomerization. Oligomerized Bax may form a pore to release mitochondrial proteins, analogous to the homologous pore-forming domains of bacterial toxins. E1B 19K can also bind to proapoptotic Bak, but the functional significance is not known. TNF-alpha signaling induced Bak-Bax interaction and both Bak and Bax oligomerization. E1B 19K was constitutively in a complex with Bak, and blocked the Bak-Bax interaction and oligomerization of both. The TNF-alpha -mediated cytochrome c and Smac/DIABLO release from mitochondria was inhibited by E1B 19K expression in adenovirus-infected cells. Since either Bax or Bak is essential for death signaling by TNF-alpha, the interaction between E1B 19K and both Bak and Bax may be required to inhibit their cooperative or independent oligomerization to release proteins from mitochondria which promote caspase activation and cell death.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	White, E (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021; Cuconati, Andrea/GWV-4662-2022; Cuconati, Andrea/AAI-7533-2020	White, Eileen/0000-0003-2961-3065; Nelson, Deirdre/0000-0001-5527-2570; Cuconati, Andrea/0000-0001-5123-0381	NATIONAL CANCER INSTITUTE [R37CA053370, R01CA053370] Funding Source: NIH RePORTER; NCI NIH HHS [CA53370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x; MANOJ KAS, 1999, J BACTERIOL, V181, P6103; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8	38	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45120	45127		10.1074/jbc.M106386200	http://dx.doi.org/10.1074/jbc.M106386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571294	hybrid			2022-12-27	WOS:000172406700103
J	Lamarre, C; LeMay, JD; Deslauriers, N; Bourbonnais, Y				Lamarre, C; LeMay, JD; Deslauriers, N; Bourbonnais, Y			Candida albicans expresses an unusual cytoplasmic manganese-containing superoxide dismutase (SOD3 gene product) upon the entry and during the stationary phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; SACCHAROMYCES-CEREVISIAE; YEAST-CELLS; ALTERNATIVE OXIDASE; COPPER; PROTECTS; OXYGEN; ATPASE	We report here that in addition to a cytoplasmic copper-zinc-containing superoxide dismutase (SOD) and a mitochondrial manganese-containing SOD, Candida albicans expresses a third SOD gene (SOD3). The deduced amino acid sequence contains all of the motifs found in previously characterized manganese-containing SODs, except the presence of a mitochondrial transit peptide. Recombinant Sod3p expressed and purified from Escherichia coli is a homotetramer with a subunit mass of 25.4 kDa. Mass absorption spectrometry detected the presence of both iron and manganese in purified Sod3p but, as determined by metal replacement experiments, the enzyme displays activity only when bound to manganese. Overexpression of SOD3 was shown to rescue the hypersensitivity to redox cycling agents of a Saccharomyces cerevisiae mutant lacking the cytoplasmic copper-zinc-containing SOD. Northern blot analyses showed that the transcription of SOD3 is induced neither by the transition from the yeast to the mycelial form of C. albicans nor by drug-induced oxidative stress. In continuous cultures, the expression of SOD3 was strongly stimulated upon the entity and during the stationary phase, concomitantly with the repression of SOD1. We conclude that Sod3p is an atypical cytosolic manganese-containing superoxide dismutase that is involved in the protection of C. albicans against reactive oxygen species during the stationary phase.	Univ Laval, Ctr Rech, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, Dept Biochim & Microbiol, Ste Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Bourbonnais, Y (corresponding author), Univ Laval, Ctr Rech, Ste Foy, PQ G1K 7P4, Canada.	yves.bourbonnais@bcm.ulaval.ca		Bourbonnais, Yves/0000-0002-8130-6612				Agius DR, 1998, BIOCHEM MOL BIOL INT, V44, P41; Averbeck NB, 2001, MOL GEN GENET, V264, P604, DOI 10.1007/s004380000346; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; BALZAN R, 1995, P NATL ACAD SCI USA, V92, P4219, DOI 10.1073/pnas.92.10.4219; Balzan R, 1999, BIOCHEM BIOPH RES CO, V256, P63, DOI 10.1006/bbrc.1999.0285; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Borghouts C, 2001, MOL CELL BIOL, V21, P390, DOI 10.1128/MCB.21.2.390-399.2001; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; Deslauriers N, 1996, MICROBIOL-SGM, V142, P1239, DOI 10.1099/13500872-142-5-1239; Diez B, 1998, CURR GENET, V33, P387, DOI 10.1007/s002940050351; Dinant M, 2001, CURR GENET, V39, P101, DOI 10.1007/s002940000183; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GREGORY EM, 1983, ARCH BIOCHEM BIOPHYS, V220, P293, DOI 10.1016/0003-9861(83)90413-7; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; Hwang CS, 1999, BBA-GEN SUBJECTS, V1427, P245, DOI 10.1016/S0304-4165(99)00020-3; Jamieson DJ, 1996, FEMS MICROBIOL LETT, V138, P83, DOI 10.1111/j.1574-6968.1996.tb08139.x; KAISER C, 1994, LAB COURSE MANUAL ME, P201; Kirimura K, 2000, BIOSCI BIOTECH BIOCH, V64, P2034, DOI 10.1271/bbb.64.2034; Kitayama K., 1995, PLANT PHYSIOL, V108, P1748; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KUH WK, 2001, BIOCHEM J, V356, P595; Lamarre C, 2000, MOL MICROBIOL, V35, P444, DOI 10.1046/j.1365-2958.2000.01715.x; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Melov S, 2000, ANN NY ACAD SCI, V908, P219; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; Rhie GE, 1999, BBA-GEN SUBJECTS, V1426, P409, DOI 10.1016/S0304-4165(98)00161-5; Riggle PJ, 2000, J BACTERIOL, V182, P4899, DOI 10.1128/JB.182.17.4899-4905.2000; Romani L, 1996, RES IMMUNOL, V147, P512, DOI 10.1016/S0923-2494(97)85216-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santos R, 1999, J BACTERIOL, V181, P4509, DOI 10.1128/JB.181.15.4509-4516.1999; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Vazquez N, 1998, INFECT IMMUN, V66, P145; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Weissman Z, 2000, P NATL ACAD SCI USA, V97, P3520, DOI 10.1073/pnas.97.7.3520; Yukioka H, 1998, BBA-GENE STRUCT EXPR, V1442, P161, DOI 10.1016/S0167-4781(98)00159-6	42	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43784	43791		10.1074/jbc.M108095200	http://dx.doi.org/10.1074/jbc.M108095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11562375	hybrid			2022-12-27	WOS:000172297700041
J	Uversky, VN; Lee, HJ; Li, J; Fink, AL; Lee, SJ				Uversky, VN; Lee, HJ; Li, J; Fink, AL; Lee, SJ			Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; MOLTEN GLOBULE; ALZHEIMERS-DISEASE; LEWY BODIES; IN-VITRO; AGGREGATION; DEMENTIA; FIBRILLIZATION; MUTATION; PROTEINS	Aggregation of alpha -synuclein is tightly associated with many neurodegenerative diseases, such as Parkinson's disease, dementia with Lewy body, Lewy body variant of Alzheimer's disease, multiple system atrophy, and Hallervorden-Spatz disease, implicating a crucial role of aggregated forms of alpha -synuclein in the pathogenesis. Here, we examined the effect of elevated temperature on the oligomerization and structural changes of alpha -synuclein in the early stage of aggregation and show that self-assembly is crucial for the stabilization of a partially folded conformation. The efficiency of alpha -synuclein oligomerization increased proportional to the temperature increase, both in purified form and in crude cytosolic preparation. This oligomerization coincided with a small but reproducible change in the circular dichroism spectrum and an increase in the 1-anilinonaphthalene-8-sulfonic acid binding. The hydrodynamic dimensions of the dimer measured by size exclusion chromatography suggest a pre-molten globule-like structure. These data suggest that partially folded alpha -synuclein, which is unstable in the monomeric form, is stabilized by self-assembly and that these oligomers may evolve into the fibril nucleus.	Parkinsons Inst, Sunnyvale, CA 94089 USA; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142292, Moscow Region, Russia	University of California System; University of California Santa Cruz; Russian Academy of Sciences	Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Lee, Seung-Jae/0000-0002-5155-5335	NIEHS NIH HHS [ES10806] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010806] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baba M, 1998, AM J PATHOL, V152, P879; Campbell BCV, 2000, NEUROBIOL DIS, V7, P192, DOI 10.1006/nbdi.2000.0286; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Langston JW, 1998, EXP NEUROL, V154, P684, DOI 10.1006/exnr.1998.6975; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tcherkasskaya O, 2001, PROTEINS, V44, P244, DOI 10.1002/prot.1089; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; Uversky VN, 1994, INT J BIOCHROMATOGR, P103; UVERSKY VN, 2001, IN PRESS EUR J BIOCH; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	30	149	153	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43495	43498		10.1074/jbc.C100551200	http://dx.doi.org/10.1074/jbc.C100551200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11590163	hybrid			2022-12-27	WOS:000172297700003
J	Huber, TB; Kottgen, M; Schilling, B; Walz, G; Benzing, T				Huber, TB; Kottgen, M; Schilling, B; Walz, G; Benzing, T			Interaction with podocin facilitates nephrin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL NEPHROTIC SYNDROME; SLIT DIAPHRAGM; GLOMERULAR PROTEIN; FINNISH TYPE; GENE; ACTIVATION; MUTATIONS; APOPTOSIS; PATHWAY; NPHS1	Mutations of NPHS1 or NPHS2, the genes encoding for the glomerular podocyte proteins nephrin and podocin, cause steroid-resistant proteinuria. In addition, mice lacking CD2-associated protein (CD2AP) develop a nephrotic syndrome that resembles NPHS mutations suggesting that all three proteins are essential for the integrity of glomerular podocytes. Although the precise glomerular function of either protein remains unknown, it has been suggested that nephrin forms zipper-like interactions to maintain the structure of podocyte foot processes. We demonstrate now that nephrin is a signaling molecule, which stimulates mitogen-activated protein kinases. Nephrin-induced signaling is greatly enhanced by podocin, which binds to the cytoplasmic tail of nephrin. Mutational analysis suggests that abnormal or inefficient signaling through the nephrin-podocin complex contributes to the development of podocyte dysfunction and proteinuria.	Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany	University of Freiburg	Walz, G (corresponding author), Univ Hosp Freiburg, Div Renal, Hugstetterstr 55, D-79106 Freiburg, Germany.		Benzing, Thomas/X-5476-2019	Kottgen, Michael/0000-0003-2406-5039; Huber, Tobias B./0000-0001-7175-5062				Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Beltcheva O, 2001, HUM MUTAT, V17, P368, DOI 10.1002/humu.1111; BENZING T, 2000, J BIOL CHEM; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; HOLMBERG C, 1995, PEDIATR NEPHROL, V9, P87, DOI 10.1007/BF00858984; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Lenkkeri U, 1999, AM J HUM GENET, V64, P51, DOI 10.1086/302182; Patrakka J, 2000, KIDNEY INT, V58, P972, DOI 10.1046/j.1523-1755.2000.00254.x; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	20	265	303	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					41543	41546		10.1074/jbc.C100452200	http://dx.doi.org/10.1074/jbc.C100452200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11562357	hybrid			2022-12-27	WOS:000172450400002
J	Ogden, SK; Lee, KC; Wernke-Dollries, K; Stratton, SA; Aronow, B; Barton, MC				Ogden, SK; Lee, KC; Wernke-Dollries, K; Stratton, SA; Aronow, B; Barton, MC			p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IN-VIVO; P53-MEDIATED REPRESSION; SYNTHETIC NUCLEI; PROMOTER INVITRO; DNA-BINDING; ACETYLATION; ACTIVATION; ENHANCER; PROTEIN	Many of the functions ascribed to p53 tumor suppressor protein are mediated through transcription regulation. We have shown that p53 represses hepatic-specific a-fetoprotein (A-FP) gene expression by direct interaction with a composite HNF-3/p53 DNA binding element. Using solid-phase, chromatin-assembled AFP DNA templates and analysis of chromatin structure and transcription in vitro, we find that p53 binds DNA and alters chromatin structure at the AFP core promoter to regulate transcription. Chromatin assembled in the presence of hepatoma extracts is activated for AFP transcription with an open, accessible core promoter structure. Distal (-850) binding of p53 during chromatin assembly, but not post-assembly, reverses transcription activation concomitant with promoter inaccessibility to restriction enzyme digestion. Inhibition of histone deacetylase activity by trichostatin-A (TSA) addition, prior to and during chromatin assembly, activated chromatin transcription in parallel with increased core promoter accessibility. Chromatin immunoprecipitation analyses showed increased H3 and H4 acetylated histones at the core promoter in the presence of TSA, while histone acetylation remained unchanged at the site of distal p53 binding. Our data reveal that p53 targets chromatin structure alteration at the core promoter, independently of effects on histone acetylation, to establish repressed AFP gene expression.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45267 USA	University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Barton, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd,Box 117, Houston, TX 77030 USA.		Ogden, Stacey K/P-9585-2019; Aronow, Bruce J/F-8438-2012; Ogden, Stacey K/N-2528-2018	Ogden, Stacey K/0000-0001-8991-3065; Barton, Michelle/0000-0002-4042-1374	NCI NIH HHS [T32 CA59268] Funding Source: Medline; NIGMS NIH HHS [GM53683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Barton MC, 1996, METHOD ENZYMOL, V274, P299; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Cai HN, 1996, P NATL ACAD SCI USA, V93, P9309, DOI 10.1073/pnas.93.18.9309; Chou J Y, 1989, Oxf Surv Eukaryot Genes, V6, P1; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Crowe AJ, 1999, METHODS, V17, P173, DOI 10.1006/meth.1998.0728; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; GODBOUT R, 1988, GENE DEV, V2, P949, DOI 10.1101/gad.2.8.949; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Liu L, 1999, MOL CELL BIOL, V19, P1202; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Mizzen C, 1998, COLD SPRING HARB SYM, V63, P469, DOI 10.1101/sqb.1998.63.469; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Ogden SK, 2000, J BIOL CHEM, V275, P27806; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SPEAR BT, 1995, DNA CELL BIOL, V14, P635, DOI 10.1089/dna.1995.14.635; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Weiss J, 1995, Recent Results Cancer Res, V139, P137; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zaret KS, 1995, PROTEIN EXPRES PURIF, V6, P821, DOI 10.1006/prep.1995.0014; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	47	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 9	2001	276	45					42057	42062		10.1074/jbc.C100381200	http://dx.doi.org/10.1074/jbc.C100381200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	497HY	11572852	hybrid			2022-12-27	WOS:000172450400070
J	Garcia-Bermejo, ML; Leskow, FC; Fujii, T; Wang, QM; Blumberg, PM; Ohba, M; Kuroki, T; Han, KC; Lee, J; Marquez, VE; Kazanietz, MG				Garcia-Bermejo, ML; Leskow, FC; Fujii, T; Wang, QM; Blumberg, PM; Ohba, M; Kuroki, T; Han, KC; Lee, J; Marquez, VE; Kazanietz, MG			Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKC alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY CONSTRAINED ANALOGS; ESTER TUMOR PROMOTERS; PHORBOL ESTER; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; SUPPRESSES APOPTOSIS; HUMAN KERATINOCYTES; DAG-LACTONES; PHASE-II; IN-VIVO	Phorbol esters, the archetypical (PKC) activators, induce apoptosis in androgen-sensitive LNCaP prostate cancer cells. In this study we evaluate the effect of a novel class of PKC ligands, the diacylglycerol (DAG)-lactones, as inducers of apoptosis in LNCaP cells. These unique ligands were designed using novel pharmacophore- and receptor-guided approaches to achieve highly potent DAG surrogates. Two of these compounds, HK434 and HK654, induced apoptosis in LNCaP cells with much higher potency than oleoyl-acetyl-glycerol or phorbol 12,13-dibutyrate. Moreover, different PKC isozymes were found to mediate the apoptotic effect of phorbol 12-myristate 13-acetate (PMA) and HK654 in LNCaP cells. Using PKC inhibitors and dominant negative PKC isoforms, we found that both PKCalpha and PKCdelta mediated the apoptotic effect of PMA, whereas only PKCalpha was involved in the effect of the DAG-lactone. The PKCalpha selectivity of HK654 in LNCaP cells contrasts with similar potencies in vitro for binding and activation of PKCalpha and PKCdelta. Consistent with the differences in isoform dependence in intact cells, PMA and HK654 show marked differences in their abilities to translocate PKC isozymes. Both PMA and HK654 induce a marked redistribution of PKCalpha to the plasma membrane. On the other hand, unlike PMA, HK654 translocates PKCdelta predominantly to the nuclear membrane. Thus, DAG-lactones have a unique profile of activation of PKC isozymes for inducing apoptosis in LNCaP cells and represent the first example of a selective activator of a classical PKC in cellular models. An attractive hypothesis is that selective activation of PKC isozymes by pharmacological agents in cells can be achieved by differential intracellular targeting of each PKC.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; NCI, Ctr Canc Res, Lab Cellular Carcinogenesis & Tumor Promot, NIH, Bethesda, MD 20892 USA; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan; Seoul Natl Univ, Coll Pharm, Lab Med Chem, Kwanak Ku, Seoul 151742, South Korea; NCI, Ctr Canc Res, Lab Med Chem, NIH, Frederick, MD 21701 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Showa University; Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelo@spirit.gcrc.upenn.edu	Wang, Qiming Jane/B-6064-2012; Marquez, Victor/AAP-3549-2021; García-Bermejo, María Laura/E-1542-2015; Kuroki, Toshio/A-9500-2011	Wang, Qiming Jane/0000-0002-9502-4851; García-Bermejo, María Laura/0000-0002-8167-2276; Kuroki, Toshio/0000-0001-6369-4351; Lee, Jeewoo/0000-0002-7832-6719	NCI NIH HHS [R01 CA89202-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benzaria S, 1998, BIOORG MED CHEM LETT, V8, P3403, DOI 10.1016/S0960-894X(98)00614-3; BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; Bruckheimer EM, 2000, ONCOGENE, V19, P5251, DOI 10.1038/sj.onc.1203881; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garzotto M, 1998, CANCER RES, V58, P2260; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gonzalez R, 1999, MELANOMA RES, V9, P599, DOI 10.1097/00008390-199912000-00010; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Keenan C, 1999, CELL IMMUNOL, V196, P104, DOI 10.1006/cimm.1999.1549; Kiley SC, 1999, CANCER RES, V59, P3230; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; Leirdal M, 1999, BRIT J CANCER, V80, P1558, DOI 10.1038/sj.bjc.6690560; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Marquez VE, 1999, PHARMACOL THERAPEUT, V82, P251, DOI 10.1016/S0163-7258(98)00048-5; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nacro K, 2000, J MED CHEM, V43, P921, DOI 10.1021/jm9904607; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OJEDA F, 1992, INT J RADIAT BIOL, V61, P663, DOI 10.1080/09553009214551471; Okuda H, 1999, ONCOGENE, V18, P5604, DOI 10.1038/sj.onc.1202946; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; Tamamura H, 2000, J MED CHEM, V43, P3209, DOI 10.1021/jm990613q; TENG K, 1992, J AM CHEM SOC, V114, P1059, DOI 10.1021/ja00029a039; Varterasian ML, 2000, CLIN CANCER RES, V6, P825; Wan QJ, 2000, J BIOL CHEM, V275, P12136, DOI 10.1074/jbc.275.16.12136; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725	58	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 4	2002	277	1					645	655		10.1074/jbc.M107639200	http://dx.doi.org/10.1074/jbc.M107639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	508KU	11584014	hybrid			2022-12-27	WOS:000173087900085
J	Sokol, SY; Li, ZG; Sacks, DB				Sokol, SY; Li, ZG; Sacks, DB			The effect of IQGAP1 on Xenopus embryonic ectoderm requires Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASGAP-RELATED PROTEIN; SMALL GTPASES; ACTIVATING PROTEINS; CELL-ADHESION; ACTIN; RHO; CYTOKINESIS; BINDING; IDENTIFICATION; RAC1	IQGAP1 contains a number of protein recognition motifs through which it binds to targets. Several in vitro studies have documented that IQGAP1 interacts directly with calmodulin, actin, E-cadherin, beta -catenin, and the small GTPases Cdc42 and Rac. Nevertheless, direct demonstration of in vivo function of mammalian IQGAP1 is limited. Using a novel assay to evaluate in vivo function of IQGAP1, we document here that microinjection of IQGAP1 into early Xenopus embryos generates superficial ectoderm. lesions at late blastula stages. This activity was retained by the mutated variants of IQGAP1 in which the calponin homology domain or the WW domain was deleted. By contrast, deletion of the IQ (IQGAP1-Delta IQ), Ras-GAP-related (IQGAP1-Delta GRD), or C-terminal (IQGAP1-DeltaC) domains abrogated the effect of IQGAP1 on the embryos. None of the latter mutants bound Cdc42, suggesting that the binding of Cdc42 by IQGAP1 is critical for its function. Moreover, overexpression of IQGAP1, but not IQGAP1-Delta GRD, significantly increased the amount of active Cdc42 in embryonic cells. Co-injection of wild type IQGAP1 with dominant negative Cdc42, but not the dominant negative forms of Rac or Rho, blocked the effect of IQGAP1 on embryonic ectoderm. Together these data indicate that the activity of IQGAP1 in embryonic ectoderm. requires Cdc42 function.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Thorn 530, Boston, MA 02115 USA.			Sokol, Sergei/0000-0002-3963-9202; Sacks, David/0000-0003-3100-0735				Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Eng K, 1998, CURR BIOL, V8, P611, DOI 10.1016/S0960-9822(98)70248-9; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Faix J, 1996, FEBS LETT, V394, P251, DOI 10.1016/0014-5793(96)00963-5; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MERRIAM RW, 1983, J EMBRYOL EXP MORPH, V76, P51; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Sambrook J., 2002, MOL CLONING LAB MANU; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999	35	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48425	48430		10.1074/jbc.M107975200	http://dx.doi.org/10.1074/jbc.M107975200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11584017	hybrid			2022-12-27	WOS:000172927000094
J	Destoumieux-Garzon, D; Saulnier, D; Garnier, J; Jouffrey, C; Bulet, P; Bachere, E				Destoumieux-Garzon, D; Saulnier, D; Garnier, J; Jouffrey, C; Bulet, P; Bachere, E			Crustacean immunity - Antifungal peptides are generated from the C terminus of shrimp hemocyanin in response to microbial challenge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; SEQUENCE HOMOLOGY; INSECT IMMUNITY; CDNA CLONING; PENAEIDINS; HEMOLYMPH; PROTEINS; PROPHENOLOXIDASE; PURIFICATION; EXPRESSION	We report here the isolation from plasma of two penaeid shrimp species of novel peptides/polypeptides with exclusive antifungal activities. A set of three molecules was purified with molecular masses at 2.7 kDa (Penaeus vannamei), 7.9 kDa, and 8.3 kDa (Penaeus stylirostris). Primary structure determination was performed by a combination of Edman degradation and mass spectrometry. The peptides display 95-100% sequence identity with a C-terminal sequence of hemocyanin, indicating that they are cleaved fragments of the shrimp respiratory protein. Specific immunodetection of the hemocyanin-derived (poly)peptides revealed that experimental microbial infections increase their relative concentration in plasma as compared with nonstimulated animals. Thus, the production of antifungal (poly)peptides by limited proteolysis of hemocyanin could be relevant to a shrimp immune reaction that would confer a new function to the multifunctional respiratory pigment of crustaceans.	Univ Montpellier 2, UMR 5098, CNRS, IFREMER, CC 80,Pl Eugene Bataillon, F-34095 Montpellier, France; IFREMER, Ctr Oceanol Pacifique, Taravao, Tahiti, France; Inst Biol Mol & Cellulaire, UPR 9022 CNRS, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier; Ifremer; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Bachere, E (corresponding author), Univ Montpellier 2, UMR 5098, CNRS, IFREMER, CC 80,Pl Eugene Bataillon, F-34095 Montpellier, France.	evelyne.bachere@ifremer.fr	Destoumieux-Garzon, Delphine/O-3328-2014; BULET, Philippe/C-8557-2014	Destoumieux-Garzon, Delphine/0000-0002-8793-9138; BULET, Philippe/0000-0001-9016-265X; saulnier, denis/0000-0003-1422-0242				Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; Brogden KA, 1996, P NATL ACAD SCI USA, V93, P412, DOI 10.1073/pnas.93.1.412; Brogden KA, 1997, ANTIMICROB AGENTS CH, V41, P1615, DOI 10.1128/AAC.41.7.1615; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CRISP LM, 1989, MYCOLOGIA, V81, P709, DOI 10.2307/3759875; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; DEPLEDGE MH, 1989, HELGOLANDER MEERESUN, V43, P207, DOI 10.1007/BF02367900; Destoumieux D, 2000, J CELL SCI, V113, P461; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Destoumieux D, 1999, EUR J BIOCHEM, V266, P335, DOI 10.1046/j.1432-1327.1999.00855.x; Dionysius DA, 1997, J DAIRY SCI, V80, P667, DOI 10.3168/jds.S0022-0302(97)75985-X; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; Fogaca AC, 1999, J BIOL CHEM, V274, P25330, DOI 10.1074/jbc.274.36.25330; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; ISHIMARU K, 1995, INT J SYST BACTERIOL, V45, P134, DOI 10.1099/00207713-45-1-134; Iwanaga S, 1998, J BIOCHEM, V123, P1; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; Kim HS, 2000, J IMMUNOL, V165, P3268, DOI 10.4049/jimmunol.165.6.3268; Kuwata H, 1998, BBA-PROTEIN STRUCT M, V1429, P129, DOI 10.1016/S0167-4838(98)00224-6; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; LEE SY, 1995, BIOL PHARM BULL, V18, P1049, DOI 10.1248/bpb.18.1049; Lee YJ, 1996, BIOCHEM BIOPH RES CO, V218, P6, DOI 10.1006/bbrc.1996.0002; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Lightner D.V., 1983, CRC HDB MARICULTURE, P289; Michaut L, 1996, FEBS LETT, V395, P6, DOI 10.1016/0014-5793(96)00992-1; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Paul RJ, 1997, ZOOL-ANAL COMPLEX SY, V100, P298; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sellos D, 1997, FEBS LETT, V407, P153, DOI 10.1016/S0014-5793(97)00350-5; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SONG YL, 1993, B I ZOOL ACAD SINICA, V32, P217; Tasiemski A, 2000, MOL BRAIN RES, V76, P237, DOI 10.1016/S0169-328X(00)00005-X; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8	39	276	311	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47070	47077		10.1074/jbc.M103817200	http://dx.doi.org/10.1074/jbc.M103817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598107	hybrid			2022-12-27	WOS:000172768500054
J	Le Clainche, C; Didry, D; Carlier, MF; Pantaloni, D				Le Clainche, C; Didry, D; Carlier, MF; Pantaloni, D			Activation of Arp2/3 complex by Wiskott-Aldrich Syndrome protein is linked to enhanced binding of ATP to Arp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN POLYMERIZATION; F-ACTIN; N-WASP; ORGANIZATION; MOTILITY	In response to signaling, the Arp2/3 complex (actin-related proteins 2 and 3 complex) is activated by binding the C-terminal MA) domain of proteins of the Wiskott-Aldrich Syndrome family to promote the formation of a branched actin filament array, responsible for cell protrusion. The Arp2/3 complex exists in different structural/functional states: the inactive Arp2/3, the activated WA-Arp,2/3 complex, the ternary G-actin-WA-Arp2/3 complex, which branches the filaments. This work addresses the role of ATP binding in Arp2/3 function. Using photocross-linking, hydrodynamic, and fluorescence techniques, we show that in the inactive Arp2/3 complex only one rapidly exchangeable ATP is tightly bound to Arp3 with an affinity of 10(8) m(-1). Upon activation of the Arp2/3 complex by WA, ATP binds to Arp2 with high affinity (10(7) m(-1)), implying that a large structural change of Arp2 is linked to Arp2/3 activation. ATP is rapidly exchangeable on Arp2 and Arp3 in WA-Arp2/3 and G-actin-WA-Arp2/3 complexes. ATP is not hydrolyzed in inactive Arp,2/3, in WA-Arp2/3, nor in G-actin-WA-Arp2/3. Arp2 has a greater specificity than Arp3 for ATP versus ATP analogs. Using functional assays of actin polymerization in branched filaments, we show that binding of ATP to Arp2 is required for filament branching.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.		Le Clainche, Christophe/A-4782-2015	Le Clainche, Christophe/0000-0001-5659-677X				Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOCKRIN S, 1980, BIOCHEMISTRY-US, V19, P5358; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Wear MA, 2000, CURR BIOL, V10, pR891, DOI 10.1016/S0960-9822(00)00845-9; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200	20	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46689	46692		10.1074/jbc.C100476200	http://dx.doi.org/10.1074/jbc.C100476200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11598103	hybrid			2022-12-27	WOS:000172768500002
J	Hassa, PO; Covic, M; Hasan, S; Imhof, R; Hottiger, MO				Hassa, PO; Covic, M; Hasan, S; Imhof, R; Hottiger, MO			The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-DEFICIENT MICE; NITRIC-OXIDE SYNTHASE; ADP-RIBOSE POLYMERASE; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; DEPENDENT TRANSCRIPTION; GENE-EXPRESSION; CELL-DEATH; PROTEINS; DOMAIN	Poly(ADP-ribose) polymerase 1 (PARP-1)-deficient mice are protected against septic shock, diabetes type 1, stroke, and inflammation. We report that primary cells from PARP-1(-1-) animals are impaired in kappaB-dependent transcriptional activation induced by different stimuli involved in inflammatory and genotoxic stress signaling. PARP-1 was also required for p65-mediated transcriptional activation. PARP-1 enzymatic inhibitors did not inhibit the transcriptional activation of a kappaB-dependent reporter gene in wild type cells. Remarkably, neither the enzymatic activity nor the DNA binding activity of PARP-1 was required for kappaB-dependent transcriptional activation in PARP-1(-/-) cells complemented with different PARP-1 mutants. However, PARP-1 interacted in vitro directly with both subunits of NF-kappaB (p50 and p65), and mapping of the interaction domains revealed that both subunits bind to different PARP-1 domains. Furthermore, a PARP-1 mutant lacking the enzymatic and DNA binding activity interacted comparably to the wild type PARP-1 with p65 or p50. Finally, we showed that PARP-1 is activating the natural inducible nitric-oxide synthase and P-selectin promoter in a kappaB-dependent manner upon stimulation of the cells with inflammatory stimuli or cotransfection of p65. Our results provide evidence that neither the DNA binding nor the enzymatic activity of PARP-1 but its direct protein-protein interaction with both subunits of NF-kappaB is required for its coactivator function, thus expanding the role of PARP-1 as an essential and novel classical transcriptional coactivator for kappaB-dependent gene expression in vivo.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hottiger, MO (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270				Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALTHAUS FR, 1992, J CELL SCI, V102, P663; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; Desnoyers S, 1996, MOL CELL BIOCHEM, V159, P155, DOI 10.1007/BF00420918; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HEINE H, 1995, J IMMUNOL, V155, P4899; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; Kuhnle S, 1999, BIOCHEM BIOPH RES CO, V263, P433, DOI 10.1006/bbrc.1999.1393; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Soriano FG, 2001, J MOL MED, V79, P437, DOI 10.1007/s001090100236; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1996, J IMMUNOL, V156, P350	55	256	268	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45588	45597		10.1074/jbc.M106528200	http://dx.doi.org/10.1074/jbc.M106528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590148	hybrid			2022-12-27	WOS:000172573100015
J	Huber, CG; Timperio, AM; Zolla, L				Huber, CG; Timperio, AM; Zolla, L			Isoforms of photosystem II antenna proteins in different plant species revealed by liquid chromatography-electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; LIGHT-HARVESTING COMPLEX; REACTION-CENTER SUBUNITS; IDENTIFICATION; CHLOROPLAST; POLYPEPTIDES; MEMBRANES; GENES; RESOLUTION; SYSTEM	The high selectivity offered by reversed-phase highperformance liquid chromatography on-line coupled to electrospray ionization mass spectrometry has been utilized to characterize the major and minor light-harvesting proteins of photosystem II (Lhcb). Isomeric forms of the proteins, revealed either on the basis of different hydrophobicity enabling their chromatographic separation or on the basis of different molecular masses identified within one single chromatographic peak, were readily identified in a number of monocot and dicot species. The presence of several Lhcb1 isoforms (preferably in dicots) can explain the tendency of dicot Lhcb1 to form trimeric aggregates. The Lhcb1 molecular masses ranged from 24,680 to 25,014 among different species, whereas within the same species, the isoforms differed by 14-280 mass units. All Lhcb1 proteins appear to be highly conserved among different species such that they belong to a single gene group that has several different gene family members. In all species examined, the number of isoforms corresponded more or less to the genes cloned previously. Two isoforms of Lhcb3 were found in petunia and tomato. For Lhcb6, the most divergent of all light-harvesting proteins, the greatest number of isoforms was found in petunia, tobacco, tomato, and rice. Lhcb2, Lhcb4, and Lhcb5 were present in only one form. The isoforms are assumed to play an important role in the adaptation of plants to environmental changes.	Loepold Franzens Univ, Inst Analyt Chem & Radiochem, A-6020 Innsbruck, Austria; Univ Tuscia, Dept Environm Sci, I-01100 Viterbo, Italy	University of Innsbruck; Tuscia University	Huber, CG (corresponding author), Loepold Franzens Univ, Inst Analyt Chem & Radiochem, Innrain 52A, A-6020 Innsbruck, Austria.		Timperio, Anna Maria/AAN-4248-2020; Huber, Christian G./E-5445-2011	Timperio, Anna Maria/0000-0001-8457-042X; Huber, Christian G./0000-0001-8358-1880				BASSI R, 1987, J BIOL CHEM, V262, P13333; BASSI R, 1991, PLANTA, V183, P423, DOI 10.1007/BF00197742; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; BENNETT J, 1980, P NATL ACAD SCI-BIOL, V77, P5253, DOI 10.1073/pnas.77.9.5253; BERGANTINO E, 1995, J BIOL CHEM, V270, P8474, DOI 10.1074/jbc.270.15.8474; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; BROWNE CA, 1982, ANAL BIOCHEM, V124, P201, DOI 10.1016/0003-2697(82)90238-X; Corradini D, 2000, J CHROMATOGR A, V886, P111, DOI 10.1016/S0021-9673(00)00449-0; CORTES HJ, 1992, J CHROMATOGR, V626, P3, DOI 10.1016/0021-9673(92)85324-M; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; De Luca C, 1999, J PHOTOCH PHOTOBIO B, V49, P50, DOI 10.1016/S1011-1344(99)00016-0; Dekker JP, 1999, FEBS LETT, V449, P211, DOI 10.1016/S0014-5793(99)00442-1; DEMMIN DS, 1989, J MOL EVOL, V29, P266, DOI 10.1007/BF02100210; DUNSMUIR P, 1985, NUCLEIC ACIDS RES, V13, P2503, DOI 10.1093/nar/13.7.2503; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GREEN BR, 1992, FEBS LETT, V305, P18, DOI 10.1016/0014-5793(92)80646-X; GRIFFITHS WJ, 2000, EXS, P8869; HANCOCK W, 1999, ANAL CHEM, V1, P742; Huber CG, 1999, J CHROMATOGR A, V849, P161, DOI 10.1016/S0021-9673(99)00532-4; HUNER NPA, 1992, PLANT PHYSIOL, V99, P830, DOI 10.1104/pp.99.3.830; IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; JANSSON S, 1990, BIOCHIM BIOPHYS ACTA, V1019, P110, DOI 10.1016/0005-2728(90)90130-V; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P69, DOI 10.1016/0005-2728(87)90213-1; Li JX, 2000, PLANT PHYSIOL, V123, P807, DOI 10.1104/pp.123.3.807; MATOO AK, 1987, P NATL ACAD SCI USA, V84, P1497; Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; PETER GF, 1991, J BIOL CHEM, V266, P16745; PICHERSKY E, 1985, GENE, V40, P247, DOI 10.1016/0378-1119(85)90047-2; Premstaller A, 2001, ANAL CHEM, V73, P2390, DOI 10.1021/ac010046q; SCHWARTZ E, 1990, PLANT MOL BIOL, V15, P157, DOI 10.1007/BF00017734; Sharma J, 1997, J BIOL CHEM, V272, P33158, DOI 10.1074/jbc.272.52.33158; Sharma J, 1997, J BIOL CHEM, V272, P3935, DOI 10.1074/jbc.272.7.3935; Sharma J, 1997, J BIOL CHEM, V272, P33153, DOI 10.1074/jbc.272.52.33153; SIGRIST M, 1992, BIOCHIM BIOPHYS ACTA, V1098, P191, DOI 10.1016/S0005-2728(05)80336-6; STOCKINGER EJ, 1994, PLANT PHYSIOL, V104, P1475, DOI 10.1104/pp.104.4.1475; Szabo I, 2001, J BIOL CHEM, V276, P13784, DOI 10.1074/jbc.M008081200; Zolla L, 1999, PHOTOSYNTH RES, V61, P281, DOI 10.1023/A:1006397419473; Zolla L, 2000, PROTEINS, V41, P398, DOI 10.1002/1097-0134(20001115)41:3<398::AID-PROT110>3.0.CO;2-K; ZOLLA L, RECENT RES DEV BIOEN	47	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45755	45761		10.1074/jbc.M106700200	http://dx.doi.org/10.1074/jbc.M106700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581262	hybrid			2022-12-27	WOS:000172573100036
J	Lin, YH; Yang-Yen, HF				Lin, YH; Yang-Yen, HF			The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; HEMATOPOIETIC-CELLS; NEOPLASTIC TRANSFORMATION; INTERLEUKIN-3; RECEPTOR; RNA; TRANSDUCTION; EXPRESSION; APOPTOSIS	We have recently demonstrated that the gene encoding the osteopontin (OPN) protein is activated both by interleukin-3 and granulocyte-macrophage colony-stimulating factor signaling pathways and that, through binding to the cell surface receptor CD44, OPN contributes to the survival activities of interleukin (IL)-3 and GM-CSF (Lin, Y.-H., Huang, C.-J., Chao, J.-R., Chen, S.-T., Lee, S.-F., Yen, J. J.-Y., and Yang-Yen, H.-F. (2000) Mot. Cell. Biol. 20, 2734 -2742). In this report, we demonstrate that the CD44-binding domain of OPN involves a region containing amino acid residues from 121 to 140 and that both threonine and serine at positions 137 and 147, respectively, are essential for the survival stimulatory effect of OPN. Substitution of either residue with alanine results into a dominant negative mutant that overrides the survival effect of IL-3. Upon binding to the CD44 receptor, the wild-type OPN but not the inactive mutant induces activation of phosphatidylinositol 3-kinase and Akt. Last, we demonstrate that two waves of Akt activation are detected in IL-3-treated cells and that the survival promoting effect of OPN is mediated predominantly through the phosphatidylinositol 3-kinase/Akt signaling pathway. Together, our results suggest that a positive autoregulatory loop is involved in the survival pathway of IL-3.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Acad Sinica, Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Defense Medical Center	Yang-Yen, HF (corresponding author), Acad Sinica, Inst Mol Biol, 128 Yen Jiou Yuan Rd,Sect 2, Taipei 11529, Taiwan.	imbyy@ccvax.sinica.edu.tw	Yang-Yen, Hsin-Fang/ABA-5808-2021	Yang-Yen, Hsin-Fang/0000-0001-9048-4800				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BEHREND EI, 1994, CANCER RES, V54, P832; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DURONIO V, 1992, J BIOL CHEM, V267, P21856; GARDNER HAR, 1994, ONCOGENE, V9, P2321; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Liaw L, 1998, J CLIN INVEST, V101, P1468; Lin YH, 2000, MOL CELL BIOL, V20, P2734, DOI 10.1128/MCB.20.8.2734-2742.2000; Minshall C, 1996, J IMMUNOL, V156, P939; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Oates AJ, 1996, ONCOGENE, V13, P97; RODAN GA, 1995, ANN NY ACAD SCI, V760, P1, DOI 10.1111/j.1749-6632.1995.tb44614.x; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SENGER DR, 1988, CANCER RES, V48, P5770; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SINGH K, 1992, J BIOL CHEM, V267, P23847; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SU LC, 1995, ONCOGENE, V10, P2163; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	45	198	215	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46024	46030		10.1074/jbc.M105132200	http://dx.doi.org/10.1074/jbc.M105132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590166	hybrid			2022-12-27	WOS:000172573100073
J	Nemeria, N; Yan, Y; Zhang, Z; Brown, AM; Arjunan, P; Furey, W; Guest, JR; Jordan, F				Nemeria, N; Yan, Y; Zhang, Z; Brown, AM; Arjunan, P; Furey, W; Guest, JR; Jordan, F			Inhibition of the Escherichia coli pyruvate dehydrogenase complex E1 subunit and its tyrosine 177 variants by thiamin 2-thiazolone and thiamin 2-thiothiazolone diphosphates - Evidence for reversible tight-binding inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DECARBOXYLASE; ENZYMES; FLUORESCENCE; ACTIVATION; SUBSTRATE; MECHANISM; KINETICS; RESIDUES; OXIDASE	Variants of the pyruvate dehydrogenase subunit (El; EC 1.2.4.1) of the Escherichia coli pyruvate dehydrogenase multienzyme complex with Y177A and Y177F substitutions were created. Both variants displayed pyruvate dehydrogenase multienzyme complex activity at levels of 11% (Y177A El) and 7% (Y177F El) of the parental enzyme. The K-m values for thiamin diphosphate (ThDP) were 1.58 mum (parental El) and 6.65 mum (Y177A EI), whereas the Y177F El variant was not saturated at 200 mum. According to fluorescence studies, binding of ThDP was unaffected by the Tyr(117) substitutions. The ThDP analogs thiamin 2-thiazolone diphosphate (ThTDP) and thiamin 2-thiothiazolone diphosphate (ThTTDP) behaved as tight-binding inhibitors of parental El (K-i = 0.003 mum for ThTDP and K-i = 0.064 mum for ThTTDP) and the Y177A and Y177F variants. This analysis revealed that ThTDP and ThTTDP bound to parental El via a two-step mechanism, but that ThTDP bound to the Y177A variant via a one-step mechanism. Binding of ThTDP was affected and that of ThTTDP was unaffected by substitutions at Tyr(177). Addition of ThDP or ThTDP to parental El resulted in similar CD spectral changes in the near-UV region. In contrast, binding of ThTTDP to either parental El or the Y177A and Y177F variants was accompanied by the appearance of a positive band at 330 nm, indicating that ThTTDP was bound in a chiral environment. In combination with x-ray structural evidence on the location of Tyr(177), the kinetic and spectroscopic data suggest that Tyr(177) has a role in stabilization of some transition state(s) in the reaction pathway, starting with the free enzyme and culminating with the first irreversible step (decarboxylation), as well as in reductive acetylation of the dihydrolipoamide acetyltransferase component.	Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA; Rutgers State Univ, Program Cellular & Mol Biodynam, Newark, NJ 07102 USA; Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Sheffield	Jordan, F (corresponding author), Rutgers State Univ, Dept Chem, 73 Warren St, Newark, NJ 07102 USA.	frjordan@newark.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-62330, GM-13198, GM-48195, GM-50380] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BISSWANG.H, 1974, EUR J BIOCHEM, V48, P377, DOI 10.1111/j.1432-1033.1974.tb03779.x; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; FERSHT A, 1999, STRUCTURE MECH PROTE, P106; Gutowski J A, 1979, Methods Enzymol, V62, P120; GUTOWSKI JA, 1976, J BIOL CHEM, V251, P2863; Hajipour G, 1999, BIOORGAN MED CHEM, V7, P887, DOI 10.1016/S0968-0896(98)00269-7; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HENNING J, 1996, BIOCH PHYSL THIAMIN, P235; JORDAN F, 1998, BIOCHIM BIOPHYS ACTA, V1385, P187; JORDAN F, 1986, THIAMIN PYROPHOSPHAT, P79; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KLUGER R, 1984, J BIOL CHEM, V259, P8960; KOCHETOV GA, 1970, BIOCHEM BIOPH RES CO, V41, P1134, DOI 10.1016/0006-291X(70)90203-2; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; Lakowicz JR, 1983, PRINCIPLES FLUORESCE, P489; Li HJ, 1999, BIOCHEMISTRY-US, V38, P9992, DOI 10.1021/bi9902438; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; MCNALLY AJ, 1995, J BIOL CHEM, V270, P19736, DOI 10.1074/jbc.270.34.19736; MESHALKINA LE, 1979, BIOCHIM BIOPHYS ACTA, V571, P218, DOI 10.1016/0005-2744(79)90092-5; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Nemeria N, 1998, BIOCHEMISTRY-US, V37, P911, DOI 10.1021/bi9722251; OBRIEN TA, 1980, J BIOL CHEM, V255, P3302; SEGEL IH, 1993, ENZYME KINETICS BEHA, P72; SHIN W, 1977, J AM CHEM SOC, V99, P3491, DOI 10.1021/ja00452a050; SHREVE DS, 1983, J BIOL CHEM, V258, P2405; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; Tittmann K, 2000, BIOCHEMISTRY-US, V39, P10747, DOI 10.1021/bi0004089; Tripatara A, 1999, ARCH BIOCHEM BIOPHYS, V367, P39, DOI 10.1006/abbi.1999.1231; Williams J W, 1979, Methods Enzymol, V63, P437; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	36	90	96	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45969	45978		10.1074/jbc.M104116200	http://dx.doi.org/10.1074/jbc.M104116200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11583990	hybrid			2022-12-27	WOS:000172573100066
J	Xiao, KH; Chandrasekaran, A; Yu, L; Yu, CA				Xiao, KH; Chandrasekaran, A; Yu, L; Yu, CA			Evidence for the intertwined dimer of the cytochrome bc(1) complex in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; WATER-SOLUBLE FRAGMENT; BOVINE HEART; RHODOBACTER-SPHAEROIDES; ELECTRON-TRANSFER; DOMAIN MOVEMENT; BC1 COMPLEX; SUBUNIT-IV; MITOCHONDRIAL; INVOLVEMENT	To confirm that the cytochrome bc(1) complex exists as a dimer with intertwining Rieske iron-sulfur proteins in solution, four Rhodobacter sphaeroides mutants expressing His-tagged cytochrome bc(1) complexes containing two pairs of cysteine substitutions, one in the interface between the head domain of iron-sulfur protein (ISP) and cytochrome b and the other between the tail domain of ISP and cytochrome b, were generated and characterized. They are: K70C(ISP)/A185C(cytb)(.)P33C(ISP)/G89C(cytb), K70C(ISP)/A185C(cytb)(.)P33C(ISP)/M92C (cytb), K70C (ISP)/A185C(cytb)(.)L34C(ISP)/V64C(cytb), and K70C(ISP)/A185C(cytb)(.)N36C(ISP)/G89C(cytb). The K70C(ISP)/A185C(cytb) cysteine pair cross-links the head domain of ISP and cytochrome b; the P33C(ISP)/G89C(cytb), P33C(ISP)/M92C (cytb), L34C(ISP)/V64C(cytb), and N36C(ISP)/G89C(cytb) cysteine pairs cross-link the tail domain of ISP and cytochrome b. An adduct protein with an apparent molecular mass of 128 kDa containing two cytochrome b and two ISP proteins is detected in the K70C(ISP)/A185C(cytb)(.)P33C(ISP)/G89C(cytb) and K70C(ISP)/A185C(cytb)(.)N36C(ISP)/G89C(cytb) mutant complexes, confirming that the be,. complex exists as a dimer with intertwining ISPs. The loss of activity in these two double-cysteine-pair mutant complexes was attributed to the disulfide bond between the head domain of ISP and cytochrome b and not the one between the tail domain of ISP and cytochrome b.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okstate.edu	Xiao, Kunhong/AAG-4275-2020	Xiao, Kunhong/0000-0002-1069-1226	NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Jungas C, 1999, EMBO J, V18, P534, DOI 10.1093/emboj/18.3.534; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P13005, DOI 10.1021/bi00248a009; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V240, P921; Obungu VH, 2000, BBA-BIOENERGETICS, V1457, P36, DOI 10.1016/S0005-2728(99)00116-4; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tso SC, 2000, J BIOL CHEM, V275, P15287, DOI 10.1074/jbc.M907367199; VONJAGOW G, 1977, BIOCHIM BIOPHYS ACTA, V462, P549, DOI 10.1016/0005-2728(77)90100-1; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	14	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46125	46131		10.1074/jbc.M107436200	http://dx.doi.org/10.1074/jbc.M107436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11562368	hybrid			2022-12-27	WOS:000172573100087
J	Zelcer, N; Saeki, T; Reid, G; Beijnen, JH; Borst, P				Zelcer, N; Saeki, T; Reid, G; Beijnen, JH; Borst, P			Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER; GENE-TRANSFER; GLUTATHIONE; RAT; EXPRESSION; EXPORT; MRP3; LOCALIZATION; CELLS; GLYCOPROTEIN	We have characterized the substrate specificity and mechanism of transport of the human multidrug resistance-associated protein 3 (MRP3). A murine fibroblastlike cell line generated from the kidneys of mice that lack Mdr1a/b and Mrp1 was retrovirally transduced with MRP3 cDNA. Stable clones overproducing MRP3 were resistant to the epipodophyllotoxins etoposide and teniposide but not to vincristine, doxorubicin, and cisplatin, drugs suggested to be MRP3 substrates by others. The resistance to etoposide was associated with reduced cellular accumulation and enhanced efflux of this drug and was not affected by depleting cells of glutathione but was inhibited by several common organic anion transport inhibitors. Membrane vesicles from infected insect cells expressing MRP3 mediated ATP-dependent transport of estradiol 17-beta -D-glucuronide, leukotriene C-4, dinitrophenyl S-glutathione but not glutathione itself, and etoposide glucuronide, a major metabolite of etoposide in vivo. The transport of estradiol 17-beta -D-glucuronide by MRP3 was inhibited in a concentration-dependent manner by both etoposide and methotrexate. Even though etoposide glucuronide is an excellent substrate for MRP3, this compound is not involved in the etoposide resistance of our MRP3 cells, as these cells extrude unmodified etoposide rather than etoposide glucuronide.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Slotervaart Hospital	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	pborst@nki.nl	Zelcer, Noam/C-6393-2009	Reid, Glen/0000-0001-6465-5223; Zelcer, Noam/0000-0001-6935-7532				Allen JD, 2000, CANCER RES, V60, P5761; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; Grignani F, 1998, CANCER RES, V58, P14; HANDE K, 1988, CANCER RES, V48, P1829; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Jedlitschky G, 1996, CANCER RES, V56, P988; Johnson DR, 2001, CANCER RES, V61, P1469; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Klein M, 1996, J BIOL CHEM, V271, P29666, DOI 10.1074/jbc.271.47.29666; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1997, CANCER RES, V57, P3537; Loe DW, 1998, CANCER RES, V58, P5130; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ogawa K, 2000, AM J PHYSIOL-GASTR L, V278, pG438, DOI 10.1152/ajpgi.2000.278.3.G438; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Rappa G, 1997, CANCER RES, V57, P5232; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Sakamoto H, 1999, CANCER LETT, V135, P113; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Soroka CJ, 2001, HEPATOLOGY, V33, P783, DOI 10.1053/jhep.2001.23501; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; Young LC, 2001, CLIN CANCER RES, V7, P1798; Young LC, 1999, CLIN CANCER RES, V5, P673; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zeng H, 1999, CANCER RES, V59, P5964; Zeng H, 2000, CANCER RES, V60, P4779	42	220	226	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46400	46407		10.1074/jbc.M107041200	http://dx.doi.org/10.1074/jbc.M107041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581266	hybrid			2022-12-27	WOS:000172573100123
J	Leventhal, AR; Chen, WG; Tall, AR; Tabas, I				Leventhal, AR; Chen, WG; Tall, AR; Tabas, I			Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NIEMANN-PICK-DISEASE; UNESTERIFIED CHOLESTEROL; CHEMICAL-COMPOSITION; ACYL TRANSFERASE; J774 MACROPHAGES; CELLS; METABOLISM; RECEPTOR; STORAGE	Cholesterol efflux from macrophage foam cells, a key step in reverse cholesterol transport, requires trafficking of cholesterol from intracellular sites to the plasma membrane. Sphingomyelin is a cholesterol-binding molecule that transiently exists with cholesterol in endosomes and lysosomes but is rapidly hydrolyzed by lysosomal sphingomyelinase (L-SMase), a product of the acid sphingomyelinase (ASM) gene. We therefore hypothesized that sphingomyelin hydrolysis by L-SMase enables cholesterol efflux by preventing cholesterol sequestration by sphingomyelin. Macrophages from wildtype and ASM knockout mice were incubated with [H-3]cholesteryl ester-labeled acetyl-LDL and then exposed to apolipoprotein A-I or high density lipoprotein. In both cases, [H-3]cholesterol efflux was decreased substantially in the ASM knockout macrophages. Similar results were shown for ASM knockout macrophages labeled long-term with [H-3]cholesterol added directly to medium, but not for those labeled for a short period, suggesting defective efflux from intracellular stores but not from the plasma membrane. Cholesterol trafficking to acyl-coenzyme A.-cholesterol acyltransferase (ACAT) was also defective in ASM knockout macrophages. Using filipin to probe cholesterol in macrophages incubated with acetyl-LDL, we found there was modest staining in the plasma membrane of wild-type macrophages but bright, perinuclear fluorescence in ASM knockout macrophages. Last, when wild-type macrophages were incubated with excess sphingomyelin to "saturate" L-SMase, [H-3]cholesterol efflux was decreased. Thus, sphingomyelin accumulation due to L-SMase deficiency leads to defective cholesterol trafficking and efflux, which we propose is due to sequestration of cholesterol by sphingomyelin and possibly other mechanisms. This model may explain the low plasma high density lipoprotein found in ASM-deficient humans and may implicate L-SMase deficiency and/or sphingomyelin enrichment of lipoproteins as novel atherosclerosis risk factors.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Eckhardt, Erik/G-1567-2010; Tall, Alan/AAT-8528-2021		NCI NIH HHS [P30 CA13696] Funding Source: Medline; NCRR NIH HHS [S10 RR13701, S10 RR10506] Funding Source: Medline; NHLBI NIH HHS [HL-56984] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013701, S10RR010506] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Botelho RJ, 2000, J BIOL CHEM, V275, P15717, DOI 10.1074/jbc.M910068199; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jiang XC, 2000, ARTERIOSCL THROM VAS, V20, P2614, DOI 10.1161/01.ATV.20.12.2614; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LEVADE T, 1988, J INHERIT METAB DIS, V11, P151, DOI 10.1007/BF01799864; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MAOR I, 1995, ARTERIOSCL THROM VAS, V15, P1378, DOI 10.1161/01.ATV.15.9.1378; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; RAPP JH, 1983, J LIPID RES, V24, P1329; Reagan JM, 2000, J BIOL CHEM, V275, P38104, DOI 10.1074/jbc.M005296200; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; RINNINGER F, 1995, BBA-LIPID LIPID MET, V1255, P141, DOI 10.1016/0005-2760(94)00228-Q; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Rothblat GH, 1999, J LIPID RES, V40, P781; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SHIO H, 1979, LAB INVEST, V41, P160; Slotte JP, 1999, CHEM PHYS LIPIDS, V102, P13, DOI 10.1016/S0009-3084(99)00071-7; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Tall AR, 1998, EUR HEART J, V19, pA31; Tang W, 1999, BBA-MOL CELL BIOL L, V1437, P301, DOI 10.1016/S1388-1981(99)00023-2; TANGIRALA RK, 1993, J BIOL CHEM, V268, P9653; VIANA MB, 1990, J MED GENET, V27, P499, DOI 10.1136/jmg.27.8.499; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Worgall TS, 2000, CIRCULATION, V102, P30; XU XX, 1991, J BIOL CHEM, V266, P17040; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	57	91	99	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44976	44983		10.1074/jbc.M106455200	http://dx.doi.org/10.1074/jbc.M106455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579092	hybrid			2022-12-27	WOS:000172406700086
J	Pinheiro, TJT; Venning, JD; Jackson, JB				Pinheiro, TJT; Venning, JD; Jackson, JB			Fast hydride transfer in proton-translocating transhydrogenase revealed in a rapid mixing continuous flow device	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; NADP(H)-BINDING COMPONENT DIII; RHODOSPIRILLUM-RUBRUM; ESCHERICHIA-COLI; ENERGY TRANSDUCTION; CRYSTAL-STRUCTURE; DOMAIN III; BINDING; RECOMBINANT; RESOLUTION	Transhydrogenase couples the redox reaction between NAD(II) and NADP(H) to proton translocation across a membrane. Coupling is achieved through changes in protein conformation. Upon mixing, the isolated nucleotide-binding components of transhydrogenase (dI, which binds NAD(H), and dIII, which binds NADP(H)) form a catalytic dI(2)-dIII(1) complex, the structure of which was recently solved by x-ray crystallography. The fluorescence from an engineered Trp in dIII changes when bound NADP(+) is reduced. Using a continuous flow device, we have measured the Trp fluorescence change when dI(2).dIII(1) complexes catalyze reduction of NADP(+) by NADH on a sub-millisecond scale. At elevated NADH concentrations, the first-order rate constant of the reaction approaches 21,200 s(-1), which is larger than that measured for redox reactions of nicotinamide nucleotides in other, soluble enzymes. Rather high concentrations of NADH are required to saturate the reaction. The deuterium isotope effect is small. Comparison with the rate of the reverse reaction (oxidation of NADPH by NAD(+)) reveals that the equilibrium constant for the redox reaction on the complex is >36. This high value might be important in ensuring high turnover rates in the intact enzyme.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Birmingham; University of Warwick	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	j.b.jackson@bham.ac.uk						Bell R, 1980, TUNNEL EFFECT CHEM; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; Bizouarn T, 2000, BBA-BIOENERGETICS, V1457, P211, DOI 10.1016/S0005-2728(00)00103-1; Bragg PD, 2001, ARCH BIOCHEM BIOPHYS, V388, P299, DOI 10.1006/abbi.2001.2298; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; FERSHT A, 1985, ENZYME STRUCTURE MEC, P130; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; GLICKMAN MH, 1994, J AM CHEM SOC, V116, P793, DOI 10.1021/ja00081a060; GRANT KL, 1989, BIOCHEMISTRY-US, V28, P6597, DOI 10.1021/bi00442a010; Hatefi Y, 1996, FASEB J, V10, P444, DOI 10.1096/fasebj.10.4.8647343; HOEK JB, 1988, BIOCHEM J, V254, P1; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 1999, FEBS LETT, V464, P1, DOI 10.1016/S0014-5793(99)01644-0; Jeeves M, 2000, BBA-BIOENERGETICS, V1459, P248, DOI 10.1016/S0005-2728(00)00159-6; JENCKS WP, 1983, CURR TOP MEMBR TRANS, V19, P1; LEE CHUAN-PU, 1965, BIOCHIM BIOPHYS BIOPHYS ACTA, V105, P397; LITTLE JW, 1972, ANAL BIOCHEM, V48, P217, DOI 10.1016/0003-2697(72)90184-4; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; Peake SJ, 1999, BBA-BIOENERGETICS, V1413, P81, DOI 10.1016/S0005-2728(99)00084-5; PERSSON B, 1987, ARCH BIOCHEM BIOPHYS, V259, P341, DOI 10.1016/0003-9861(87)90500-5; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; Shastry MCR, 1998, BIOPHYS J, V74, P2714, DOI 10.1016/S0006-3495(98)77977-9; Venning JD, 2000, J BIOL CHEM, V275, P19490, DOI 10.1074/jbc.M000577200; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1999, BIOCHEM J, V341, P329, DOI 10.1042/0264-6021:3410329; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; VIOLA RE, 1979, ANAL BIOCHEM, V96, P334, DOI 10.1016/0003-2697(79)90590-6; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	36	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44757	44761		10.1074/jbc.M109227200	http://dx.doi.org/10.1074/jbc.M109227200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577115	hybrid			2022-12-27	WOS:000172406700057
J	Zuniga, FA; Shi, GP; Haller, JF; Rubashkin, A; Flynn, DR; Iserovich, P; Fischbarg, J				Zuniga, FA; Shi, GP; Haller, JF; Rubashkin, A; Flynn, DR; Iserovich, P; Fischbarg, J			A three-dimensional model of the human facilitative glucose transporter Glut1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; POLYTOPIC MEMBRANE-PROTEINS; SUGAR PERMEATION PATHWAY; LACTOSE PERMEASE; ESCHERICHIA-COLI; TRANSMEMBRANE SEGMENTS; CONFORMATIONAL CHANGE; HUMAN-ERYTHROCYTES; N-ETHYLMALEIMIDE; CYTOCHALASIN-B	The human facilitative transporter Glut1 is the major glucose transporter present in all human cells, has a central role in metabolism, and is an archetype of the superfamily of major protein facilitators. Here we describe a three-dimensional structure of Glut1 based on helical packing schemes proposed for lactose permease and Glut1 and predictions of secondary structure, and refined using energy minimization, molecular dynamics simulations, and quality and environmental scores. The Ramachandran scores and the stereochemical quality of the structure obtained were as good as those for the known structures of the KesA K+ channel and aquaporin 1. We found two channels in Glut1. One of them traverses the structure completely, and is lined by many residues known to be solvent-accessible. Since it is delimited by the QLS motif and by several well conserved residues, it may serve as the substrate transport pathway. To validate our structure, we determined the distance between these channels and all the residues for which mutations are known. From the locations of sugar transporter signatures, motifs, and residues important to the transport function, we find that this Glut1 structure is consistent with mutagenesis and biochemical studies. It also accounts for functional deficits in seven pathogenic mutants.	Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA	Columbia University; Columbia University	Fischbarg, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol, 630 West & 168th St, New York, NY 10032 USA.		Zuniga, Felipe/Q-8035-2019; Rubashkin, Andrey A/H-8243-2016; Zuniga, Felipe A/L-7885-2013	Rubashkin, Andrey A/0000-0002-9054-0574; Zuniga, Felipe A./0000-0003-0286-565X	NATIONAL EYE INSTITUTE [R01EY008918] Funding Source: NIH RePORTER; NEI NIH HHS [EY08918] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Barrett MP, 1999, CURR OPIN CELL BIOL, V11, P496, DOI 10.1016/S0955-0674(99)80072-6; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; DAVIES A, 1990, BIOCHEM J, V266, P799; DAVIES A, 1987, J BIOL CHEM, V262, P9347; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ducarme P, 1996, J MOL MODEL, V2, P27, DOI 10.1007/s008940050018; Dwyer DS, 2001, PROTEINS, V42, P531, DOI 10.1002/1097-0134(20010301)42:4<531::AID-PROT110>3.3.CO;2-0; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; Klepper J, 1999, NEUROCHEM RES, V24, P587, DOI 10.1023/A:1022544131826; Klepper J, 2001, HUM MOL GENET, V10, P63, DOI 10.1093/hmg/10.1.63; Klepper J, 1999, PEDIATR RES, V46, P677, DOI 10.1203/00006450-199912000-00006; KRUPKA RM, 1986, BIOCHEM CELL BIOL, V64, P1099, DOI 10.1139/o86-145; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAY JM, 1989, BIOCHIM BIOPHYS ACTA, V986, P207, DOI 10.1016/0005-2736(89)90469-0; MORI H, 1994, J BIOL CHEM, V269, P11578; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Oliveira L, 1999, PROTEIN ENG, V12, P1087, DOI 10.1093/protein/12.12.1087; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Olsowski A, 1998, BIOCHEMISTRY-US, V37, P10738, DOI 10.1021/bi980440r; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; RAMPAL AL, 1987, BIOCHIM BIOPHYS ACTA, V896, P287, DOI 10.1016/0005-2736(87)90189-1; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; Rost B, 1996, METHOD ENZYMOL, V266, P525; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; SERGEANT S, 1985, J BIOL CHEM, V260, P4677; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; STULTZ CM, 1993, PROTEIN SCI, V2, P305; TAKATA K, 1992, CELL TISSUE RES, V267, P407, DOI 10.1007/BF00319362; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang D, 2000, HUM MUTAT, V16, P224, DOI 10.1002/1098-1004(200009)16:3<224::AID-HUMU5>3.0.CO;2-P; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6; WELLNER M, 1994, BIOCHEM J, V299, P813, DOI 10.1042/bj2990813; WELLNER M, 1992, FEBS LETT, V309, P293, DOI 10.1016/0014-5793(92)80792-F; Zeng H, 1996, BIOPHYS J, V70, P14, DOI 10.1016/S0006-3495(96)79560-7; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; ZOTTOLA RJ, 1995, BIOCHEMISTRY-US, V34, P9734, DOI 10.1021/bi00030a011	63	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44970	44975		10.1074/jbc.M107350200	http://dx.doi.org/10.1074/jbc.M107350200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571301	hybrid			2022-12-27	WOS:000172406700085
J	Ahmed, S; Saini, S; Arora, S; Singh, J				Ahmed, S; Saini, S; Arora, S; Singh, J			Chromodomain protein Swi6-mediated role of DNA polymerase a in establishment of silencing in fission yeast.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWITCHING GENE SWI6; MATING-TYPE REGION; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; EPIGENETIC INHERITANCE; CHROMOSOME SEGREGATION; CHROMATIN-STRUCTURE; HISTONE H3; REPLICATION; DOMAINS	Although DNA replication has been thought to play an important role in the silencing of mating type loci in Saccharomyces cerevisiae, recent studies indicate that silencing can be decoupled from replication. In Schizo-saccharomyces pombe, mating type silencing is brought about by the trans-acting proteins, namely Swi6, Clr1-Clr4, and Rhp6, in cooperation with the cis-acting silencers. The latter contain an autonomous replication sequence, suggesting that DNA replication may be critical for silencing in S. pombe. To investigate the connection between DNA replication and silencing in S. pombe, we analyzed several temperature-sensitive mutants of DNA polymerase a. We find that one such mutant, swi7H4, exhibits silencing defects at mat, centromere, and telomere loci. This effect is independent of the checkpoint and replication defects of the mutant. Interestingly, the extent of the silencing defect in the swi7H4 mutant at the silent mat2 locus is further enhanced in absence of the cis-acting, centromere-proximal silencer. The chromodomain protein Swi6, which is required for silencing and is localized to mat and other heterochromatin loci, interacts with DNA polymerase alpha in vivo and in vitro in wild type cells. However, it does not interact with the mutant pola and is delocalized away from the silent mat loci in the mutant. Our results demonstrate a role of DNA polymerase a in the establishment of silencing. We propose a recruitment model for the coupling of DNA replication with the establishment of silencing by the chromodomain protein Swi6, which may be applicable to higher eukaryotes.	Inst Microbial Technol, Chandigarh 160036, India; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Rutgers State University New Brunswick; Rutgers State University Medical Center	Singh, J (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.	jag@imtech.res.in						Ahmed S, 2001, CURR SCI INDIA, V80, P1337; AHMED S, 2000, THESIS PANJAB U CHAN; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bhaumik D, 1998, MOL BIOL CELL, V9, P2107, DOI 10.1091/mbc.9.8.2107; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; EKWALL K, 1991, YEAST, V7, P745, DOI 10.1002/yea.320070709; EKWALL K, 1994, GENETICS, V136, P53; Ekwall K, 1996, J CELL SCI, V109, P2637; EKWALL K, 1999, CHROMOSOME STRUCTURA, P47; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Grewal SIS, 1998, GENETICS, V150, P563; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KLAR AJS, 1992, MOL CELLULAR BIOL YE, V2, P583; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; OLSSON T, 1993, NUCLEIC ACIDS RES, V21, P855; Pidoux AL, 2000, J CELL SCI, V113, P4177; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; SINGH PB, 1994, J CELL SCI, V107, P2653; Smith JS, 1999, MOL CELL BIOL, V19, P3184; THON G, 1992, GENETICS, V131, P287; THON G, 1994, GENETICS, V138, P29; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WOLFFE AP, 1991, J CELL SCI, V99, P201; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	38	32	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					47814	47821		10.1074/jbc.M109186200	http://dx.doi.org/10.1074/jbc.M109186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11581276	hybrid			2022-12-27	WOS:000172927000013
J	Yang, CL; Carrier, F				Yang, CL; Carrier, F			The UV-inducible RNA-binding protein A18 (A18 hnRNP) plays a protective role in the genotoxic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ULTRAVIOLET-LIGHT; TRANSLATION INITIATION; HUMAN THIOREDOXIN; DNA; GENES; IDENTIFICATION; CELLS; INDUCTION; DAMAGE	We have previously shown that specific RNA-binding proteins (RBP) are activated by genotoxic stress. The role and function of these stress-activated RBP are, however, poorly understood. The data presented here indicate that the RBP AIS heterogeneous ribonucleoprotein (hnRNP) is induced and translocated from the nuclei to the cytoplasm after exposure to UV radiation. Using a new in vitro system we identified potential cellular targets for A18 hnRNP. Forty-six mRNA transcripts were identified, most of which are stress- or UV-responsive genes. Two important stress-responsive transcripts, the replication protein A (RPA2) and thioredoxin, were studied in more detail. Northwestern analyses indicate that A18 hnRNP binds specifically to the 3'-untranslated region of RPA2 transcript independently of its poly(A) tail, whereas the poly(A) tail of thioredoxin mRNA reinforces binding. Overexpression of A18 hnRNP increases the mRNAs stability and consequently enhances translation in a dose-dependent manner. Moreover, cell lines expressing reduced levels of AIS hnRNP are more sensitive to UV radiation. These data suggest that A18 hnRNP plays a protective role against genotoxic stresses by translocating to the cytosol and stabilizing specific transcripts involved in cell survival.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Carrier, F (corresponding author), 108 N Greene St,Rm 330, Baltimore, MD 21201 USA.	fcarr001@umaryland.edu	Carrier, France/C-3063-2008	Carrier, France/0000-0002-5517-5284; Pfeffer, Lawrence/0000-0003-2809-1234	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057827] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 57827-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERER W, 1981, J INVEST DERMATOL, V76, P202, DOI 10.1111/1523-1747.ep12525745; Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Applegate LA, 1998, J INVEST DERMATOL, V111, P159, DOI 10.1046/j.1523-1747.1998.00254.x; BADEN HP, 1964, J INVEST DERMATOL, V43, P71, DOI 10.1038/jid.1964.117; Bae SK, 1999, CANCER RES, V59, P5989; Bertram J, 1998, EUR J CANCER, V34, P731, DOI 10.1016/S0959-8049(97)10081-8; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; Brzoska PM, 1996, GENOMICS, V36, P151, DOI 10.1006/geno.1996.0435; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; CARRIER F, 1994, P NATL ACAD SCI USA, V91, P1554, DOI 10.1073/pnas.91.4.1554; CARRIER F, 1994, AIDS RES HUM RETROV, V10, P767, DOI 10.1089/aid.1994.10.767; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Dubnau E, 1996, GENE, V170, P17, DOI 10.1016/0378-1119(95)00841-1; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Funasaka Y, 1997, PIGM CELL RES, V10, P68, DOI 10.1111/j.1600-0749.1997.tb00469.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gloe T, 1999, J BIOL CHEM, V274, P15996, DOI 10.1074/jbc.274.23.15996; Graumann P, 1996, J BACTERIOL, V178, P4611, DOI 10.1128/jb.178.15.4611-4619.1996; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Katoh K, 1998, MOL BIOL CELL, V9, P1919, DOI 10.1091/mbc.9.7.1919; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lewis BC, 2000, CANCER RES, V60, P6178; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; Melander Y, 1997, J BIOL CHEM, V272, P3254, DOI 10.1074/jbc.272.6.3254; Mendez-Alvarez S, 2000, BIOCHEM BIOPH RES CO, V267, P953, DOI 10.1006/bbrc.1999.2070; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Paunesku T, 2000, INT J RADIAT BIOL, V76, P189, DOI 10.1080/095530000138844; Peyruchaud O, 2000, CELL MOL LIFE SCI, V57, P1109; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Scott JM, 2000, J BACTERIOL, V182, P2771, DOI 10.1128/JB.182.10.2771-2777.2000; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; Toninello A, 2000, J BIOL INORG CHEM, V5, P612, DOI 10.1007/s007750000144; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Yamamoto M, 1997, EXP EYE RES, V65, P645, DOI 10.1006/exer.1997.0370; YOKOMIZO A, 1995, CANCER RES, V55, P4293; Zhang SY, 2001, J BACTERIOL, V183, P2316, DOI 10.1128/JB.183.7.2316-2321.2001	57	194	214	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47277	47284		10.1074/jbc.M105396200	http://dx.doi.org/10.1074/jbc.M105396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11574538	hybrid			2022-12-27	WOS:000172768500081
J	Greasley, PJ; Fanelli, F; Scheer, A; Abuin, L; Nenniger-Tosato, M; DeBenedetti, PG; Cotecchia, S				Greasley, PJ; Fanelli, F; Scheer, A; Abuin, L; Nenniger-Tosato, M; DeBenedetti, PG; Cotecchia, S			Mutational and computational analysis of the alpha(1b)-adrenergic receptor. Involvement of basic and hydrophobic residues in receptor activation and G protein coupling.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND INTRACELLULAR LOOP; AMINO-ACID; HORMONE RECEPTOR; ALPHA-SUBUNITS; BINDING-SITES; RHODOPSIN; MECHANISMS; SELECTIVITY; RECOGNITION; SEQUENCE	To investigate their role in receptor coupling to G(q), we mutated all basic amino acids and some conserved hydrophobic residues of the cytosolic surface of the alpha (1b)-adrenergic receptor (AR). The wild type and mutated receptors were expressed in COS-7 cells and characterized for their ligand binding properties and ability to increase inositol phosphate accumulation. The experimental results have been interpreted in the context of both an ab initio model of the alpha (1b)-AR and of a new homology model built on the recently solved crystal structure of rhodopsin. Among the twenty-three basic amino acids mutated only mutations of three, Arg(254) and Lys(258) in the third intracellular loop and Lys(291) at the cytosolic extension of helix 6, markedly impaired the receptor-mediated inositol phosphate production. Additionally, mutations of two conserved hydrophobic residues, Val(147) and Leu(151) in the second intracellular loop had significant effects on receptor function. The functional analysis of the receptor mutants in conjunction with the predictions of molecular modeling supports the hypothesis that Arg(254), Lys(258), as well as Leu(151) are directly involved in receptor-G protein interaction and/or receptor-mediated activation of the G protein. In contrast, the residues belonging to the cytosolic extensions of helices 3 and 6 play a predominant role in the activation process of the alpha (1b)-AR. These findings contribute to the delineation of the molecular determinants of the alpha (1b)-Ar/G(q) interface.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Modena, Dipartimento Chim, I-41100 Modena, Italy	University of Lausanne; Universita di Modena e Reggio Emilia	Cotecchia, S (corresponding author), Fac Med, Inst Pharmacol & Toxicol, 27 Rue du Bugnon, CH-1005 Lausanne, Switzerland.		Fanelli, Francesca/O-8807-2014	Fanelli, Francesca/0000-0002-7620-6895				ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Damaj BB, 1996, FASEB J, V10, P1426, DOI 10.1096/fasebj.10.12.8903513; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Fanelli F, 1998, METHODS, V14, P302, DOI 10.1006/meth.1998.0586; Fanelli F, 1999, PROTEINS, V37, P145, DOI 10.1002/(SICI)1097-0134(19991101)37:2<145::AID-PROT1>3.0.CO;2-R; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; HOGGER P, 1995, J BIOL CHEM, V270, P7405; Horn F, 2000, PROTEINS, V41, P448, DOI 10.1002/1097-0134(20001201)41:4<448::AID-PROT30>3.0.CO;2-C; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Jin H, 1998, BBA-MOL CELL RES, V1402, P165, DOI 10.1016/S0167-4889(97)00159-6; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Lee NH, 1996, MOL PHARMACOL, V50, P140; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Loewen MC, 2001, P NATL ACAD SCI USA, V98, P4888, DOI 10.1073/pnas.051633098; Mathi SK, 1997, MOL ENDOCRINOL, V11, P424, DOI 10.1210/me.11.4.424; MORO O, 1993, J BIOL CHEM, V268, P22273; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; Oliveira L, 1999, PROTEIN ENG, V12, P1087, DOI 10.1093/protein/12.12.1087; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 2000, MOL PHARMACOL, V57, P219; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; Wade SM, 1996, MOL PHARMACOL, V50, P351; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1992, J BIOL CHEM, V267, P25798	42	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46485	46494		10.1074/jbc.M105791200	http://dx.doi.org/10.1074/jbc.M105791200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585821	hybrid			2022-12-27	WOS:000172573100134
J	Saka, A; Abe, M; Okano, H; Minemura, M; Qadota, H; Utsugi, T; Mino, A; Tanaka, K; Takai, Y; Ohya, Y				Saka, A; Abe, M; Okano, H; Minemura, M; Qadota, H; Utsugi, T; Mino, A; Tanaka, K; Takai, Y; Ohya, Y			Complementing yeast rho1 mutation groups with distinct functional defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; 1,3-BETA-D-GLUCAN SYNTHASE; ACTIN CYTOSKELETON; CRYSTAL-STRUCTURE; CELL-CYCLE; PKC1; GENE; HOMOLOG	Saccharomyces cerevisiae is a multifunctional molecular switch involved in establishment of cell morphogenesis. We systematically characterized isolated temperature-sensitive mutations in the RHO1 gene and identified two groups of rho1 mutations (rho1A and rho1B) possessing distinct functional defects. Biochemical and cytological analyses demonstrated that mutant cells of the rho1A and rho1B groups have defects in activation of the Rho1p effectors Pkc1p kinase and 1,3-beta -glucan synthase, respectively. Heteroallelic diploid strains with rho1A and rho1B mutations were able to grow even at the restrictive temperature of the corresponding homoallelic diploid strains, showing intragenic complementation. The ability to activate both of the essential Rho1p effector proteins was restored in the heteroallelic diploid. Thus, each of the complementing rho1 mutation groups abolishes a distinct function of Rho1p, activation of Pkc1p kinase or 1,3-beta -glucan synthase activity.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan; Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Suita, Osaka 5650871, Japan; Hokkaido Univ, Sch Med, Inst Canc, Div Biochem,Kita Ku, Sapporo, Hokkaido 0608638, Japan	University of Tokyo; University of Tokyo; Osaka University; Hokkaido University	Ohya, Y (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bldg FSB-101,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	ohya@k.u-tokyo.ac.jp	Abe, Mitsuhiro/C-3602-2017; Tanaka, Kazuma/A-4240-2012					Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; Drgonova J, 1999, J CELL BIOL, V146, P373, DOI 10.1083/jcb.146.2.373; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FINK GR, 1966, GENETICS, V53, P445; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Haarer BK, 1996, GENETICS, V144, P495; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; OHYA Y, 1994, GENETICS, V138, P1041; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIKORSKI RS, 1989, GENETICS, V122, P19; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	39	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46165	46171		10.1074/jbc.M103805200	http://dx.doi.org/10.1074/jbc.M103805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11574532	hybrid			2022-12-27	WOS:000172573100092
J	Velarde, G; Ford, RC; Rosenberg, MF; Powis, SJ				Velarde, G; Ford, RC; Rosenberg, MF; Powis, SJ			Three-dimensional structure of transporter associated with antigen processing (TAP) obtained by single particle image analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; MAJOR HISTOCOMPATIBILITY COMPLEX; PUTATIVE PEPTIDE TRANSPORTER; MHC-LINKED TRANSPORTER; ABC TRANSPORTER; ELECTRON-MICROSCOPY; NUCLEOTIDE-BINDING; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	dThe transporter associated with antigen processing (TAP) is an ATP binding cassette transporter responsible for peptide translocation into the lumen of the endoplasmic reticulum for assembly with major histocompatibility complex class I molecules. Immunoaffinity-purified TAP particles comprising TAP1 and TAP2 polypeptides, and TAP2 particles alone were characterized after detergent solubilization and studied by electron microscopy. Projection structures of TAP1+2 particles reveal a molecule similar to 10 nm across with a deeply staining central region, whereas TAP2 molecules are smaller in projection. A three-dimensional structure of TAP reveals it is isolated as a single heterodimeric complex, with the TAP1 and TAP2 subunits combining to create a central 3-nm-diameter pocket on the predicted endoplasmic reticulum-lumenal side, Its structural similarity to other ABC transporters demonstrates a common tertiary structure for this diverse family of membrane proteins.	Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee, Scotland; UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Dundee; University of Manchester	Powis, SJ (corresponding author), Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee, Scotland.			Ford, Robert/0000-0002-0958-1505; Powis, Simon/0000-0003-4218-2984				Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; Armandola EA, 1996, EUR J IMMUNOL, V26, P1748, DOI 10.1002/eji.1830260813; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Burgess SA, 1997, J CELL BIOL, V139, P675, DOI 10.1083/jcb.139.3.675; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Deverson EV, 1998, J IMMUNOL, V160, P2767; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Deverson EV, 2001, GENES IMMUN, V2, P48, DOI 10.1038/sj.gene.6363727; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gileadi U, 1997, J BIOL CHEM, V272, P11103; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Katayama E, 1998, ADV EXP MED BIOL, V453, P37; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kitmitto A, 1998, J BIOL CHEM, V273, P29592, DOI 10.1074/jbc.273.45.29592; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Knittler MR, 1998, J IMMUNOL, V161, P5967; Lacaille VG, 1998, J BIOL CHEM, V273, P17386, DOI 10.1074/jbc.273.28.17386; Lapinski PE, 2000, J BIOL CHEM, V275, P6831, DOI 10.1074/jbc.275.10.6831; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; Momburg F, 1996, J IMMUNOL, V156, P1756; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Newitt S, 1999, TRANSPL P, V31, P1519, DOI 10.1016/S0041-1345(99)00024-X; NIGGINS CF, 1992, ANN REV CELL BIOL, V8, P67; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; Tsiotis G, 1997, BBA-BIOENERGETICS, V1322, P163, DOI 10.1016/S0005-2728(97)00073-X; Uebel S, 1997, FEBS LETT, V416, P359, DOI 10.1016/S0014-5793(97)01222-2; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	66	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46054	46063		10.1074/jbc.M108435200	http://dx.doi.org/10.1074/jbc.M108435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11595746	hybrid			2022-12-27	WOS:000172573100077
J	Jiang, W; Zhou, L; Breyer, B; Feng, T; Cheng, HW; Haydon, R; Ishikawa, A; He, TC				Jiang, W; Zhou, L; Breyer, B; Feng, T; Cheng, HW; Haydon, R; Ishikawa, A; He, TC			Tetracycline-regulated gene expression mediated by a novel chimeric repressor that recruits histone deacetylases in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TN10 TET REPRESSOR; MAMMARY-TUMOR VIRUS; INDUCIBLE GENE; TRANSGENIC MICE; TRANSCRIPTIONAL REGULATION; IN-VIVO; TRANSACTIVATOR SYSTEM; HUMAN CYTOMEGALOVIRUS; CULTURED-CELLS; PROMOTER	Regulated gene expression will provide important platforms from which gene functions can be investigated and safer means of gene therapy may be developed. Histone deacetylases have recently been shown to play an important role in regulating gene expression. Here we investigated whether a more tightly controlled expression could be achieved by using a novel chimeric repressor that recruits histone deacetylases to a tetracycline-responsive promoter. This chimeric repressor was engineered by fusing the tetracycline repressor (TetR) with an mSin3-interacting domain of human Mad1 and was shown to bind the tetO(2) element with high affinity, and its binding was efficiently abrogated by doxycycline. The chimeric repressor was shown to directly interact with mSin3 of the historic deacetylase complex. This inducible system was further simplified by using a single vector that contained both a chimeric repressor expression cassette and a tetracycline-responsive promoter. When transiently introduced into mammalian cells, the chimeric repressor system exhibited a significantly lower basal level of luciferase activity (up to 25-fold) than that of the TetR control. When stably transfected into HEK 293 cells, the chimeric repressor system was shown to exert a tight control of green fluorescent protein expression in a doxycycline dose- and time-dependent fashion. Therefore, this novel chimeric repressor provides an effective means for more tightly regulated gene expression, and the simplified inducible system may be used for a broad range of basic and clinical studies.	Univ Chicago, Med Ctr, Oncol Mol Lab, Dept Surg, Chicago, IL 60637 USA; Chongqing Univ Med Sci, Dept Biochem & Mol Biol, Chongqing 400046, Peoples R China; Yamagata Univ, Sch Med, Dept Orthopaed Surg, Yamagata 9909585, Japan	University of Chicago; University of Chicago Medical Center; Chongqing Medical University; Yamagata University	He, TC (corresponding author), Univ Chicago, Med Ctr, Oncol Mol Lab, Dept Surg, 5841 S Maryland Ave,MC 3079,Rm J-611, Chicago, IL 60637 USA.							Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Akagi K, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e23; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Bello B, 1998, DEVELOPMENT, V125, P2193; Berens C, 1997, J BIOL CHEM, V272, P6936, DOI 10.1074/jbc.272.11.6936; BERENS C, 1995, MOL MICROBIOL, V18, P437, DOI 10.1111/j.1365-2958.1995.mmi_18030437.x; Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; EVGENEV M, 1979, MOL GEN GENET, V176, P275, DOI 10.1007/BF00273222; FINCATO G, 1991, BLOOD, V77, P579; GATZ C, 1988, P NATL ACAD SCI USA, V85, P1394, DOI 10.1073/pnas.85.5.1394; GAZIT G, 1995, CANCER RES, V55, P1660; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gschwend JE, 1997, PROSTATE, V33, P166; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; Hoppe UC, 2000, MOL THER, V1, P159, DOI 10.1006/mthe.1999.0023; HU MCT, 1990, MOL CELL BIOL, V10, P6141, DOI 10.1128/MCB.10.12.6141; HYNES NE, 1981, P NATL ACAD SCI-BIOL, V78, P2038, DOI 10.1073/pnas.78.4.2038; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kaszycki P, 1996, J PROTEIN CHEM, V15, P607, DOI 10.1007/BF01886743; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim HJ, 1998, ARCH PHARM RES, V21, P320, DOI 10.1007/BF02975295; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KO MSH, 1989, DNA-J MOLEC CELL BIO, V8, P127, DOI 10.1089/dna.1.1989.8.127; KOTHARY R, 1989, DEVELOPMENT, V105, P707; Kringstein AM, 1998, P NATL ACAD SCI USA, V95, P13670, DOI 10.1073/pnas.95.23.13670; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee AV, 1997, BIOTECHNIQUES, V23, P1062, DOI 10.2144/97236st02; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MIKULITS W, 1995, NUCLEIC ACIDS RES, V23, P2342, DOI 10.1093/nar/23.12.2342; NATZLE JE, 1992, DEV GENET, V13, P331, DOI 10.1002/dvg.1020130504; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Orth P, 1998, J MOL BIOL, V279, P439, DOI 10.1006/jmbi.1998.1775; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rossi FMV, 2000, MOL CELL, V6, P723, DOI 10.1016/S1097-2765(00)00070-8; Rossi FMV, 1998, CURR OPIN BIOTECH, V9, P451, DOI 10.1016/S0958-1669(98)80028-1; Rossi FMV, 1998, NAT GENET, V20, P389, DOI 10.1038/3871; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHWEINFEST CW, 1988, GENE, V71, P207, DOI 10.1016/0378-1119(88)90093-5; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SIZEMORE C, 1990, NUCLEIC ACIDS RES, V18, P2875, DOI 10.1093/nar/18.10.2875; SMITH LD, 1988, J MOL BIOL, V203, P949, DOI 10.1016/0022-2836(88)90120-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAKAHASHI M, 1991, ANAL BIOCHEM, V199, P197, DOI 10.1016/0003-2697(91)90089-C; TAKEKOSHI M, 1993, J GEN VIROL, V74, P1649, DOI 10.1099/0022-1317-74-8-1649; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wheeler GN, 2000, CURR BIOL, V10, P849, DOI 10.1016/S0960-9822(00)00596-0; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939; ZERNIK J, 1991, BIOCHEM BIOPH RES CO, V176, P1149, DOI 10.1016/0006-291X(91)90405-V	66	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45168	45174		10.1074/jbc.M106924200	http://dx.doi.org/10.1074/jbc.M106924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581265	hybrid			2022-12-27	WOS:000172406700109
J	Ng, CJ; Wadleigh, DJ; Gangopadhyay, A; Hama, S; Grijalva, VR; Navab, M; Fogelman, AM; Reddy, ST				Ng, CJ; Wadleigh, DJ; Gangopadhyay, A; Hama, S; Grijalva, VR; Navab, M; Fogelman, AM; Reddy, ST			Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; INHIBITS 3 STEPS; PLASMA-LIPOPROTEINS; DIABETES-MELLITUS; GENETIC-VARIATION; POLYMORPHISMS; ASSOCIATION; PON2; ASSAY	The oxidation of apolipoprotein B-containing lipoproteins and cell membrane lipids is believed to play an integral role in the development of fatty streak lesions, an initial step in atherogenesis. We have previously shown that two antioxidant-like enzymes, paraoxonase (PON)-1 and PON3, are high density lipoprotein-associated proteins capable of preventing the oxidative modification of low density lipoprotein (LDL) (Reddy, S. T., Wadleigh, D. J., Grijalva, V., Ng, C., Hama, S., Gango-padhyay, A., Shih, D. M., Lusis, A. J., Navab, M., and Fogelman, A. M. (2001) Arterioscler. Thromb. Vase. Biol. 21, 542-547). In the present study, we demonstrate that PON2 (i) is not associated with high density lipoprotein; (ii) has antioxidant properties; and (iii) prevents LDL lipid peroxidation, reverses the oxidation of mildly oxidized LDL (MM-LDL), and inhibits the ability of MM-LDL to induce monocyte chemotaxis. The PON2 protein was overexpressed in HeLa cells using the tetracycline-inducible ("Tet-On") system, and its antioxidant capacity was measured in a fluorometric assay. Cells that overexpressed PON2 showed significantly less intracellular oxidative stress following treatment with hydrogen peroxide or oxidized phospholipid. Moreover, cells that overexpressed PON2 were also less effective in oxidizing and modifying LDL and, in fact, were able to reverse the effects of preformed MM-LDL. Our results suggest that PON2 possesses antioxidant properties similar to those of PON1 and PON3. However, in contrast to PON1 and PON3, PON2 may exert its antioxidant functions at the cellular level, joining the host of intracellular antioxidant enzymes that protect cells from oxidative stress.	Univ Calif Los Angeles, Dept Med, Atherosclerosis Res Unit, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Reddy, ST (corresponding author), Univ Calif Los Angeles, Dept Med, Atherosclerosis Res Unit, A8-131 CHS,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R01HL071776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568, R01 HL071776] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH BJ, 1992, ANAL BIOCHEM, V201, P375, DOI 10.1016/0003-2697(92)90354-A; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Boright AP, 1998, ATHEROSCLEROSIS, V139, P131, DOI 10.1016/S0021-9150(98)00071-9; Busch CP, 1999, PHARMACOGENETICS, V9, P351, DOI 10.1097/00008571-199906000-00010; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; DURRINGTON RN, 2001, ARTERIOSCLEROSIS, V21, P473; Fanella S, 2000, CLIN CHEM LAB MED, V38, P413, DOI 10.1515/CCLM.2000.060; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hegele RA, 1998, CLIN GENET, V54, P394; Imai Y, 2000, ATHEROSCLEROSIS, V149, P435, DOI 10.1016/S0021-9150(99)00340-8; Kobayashi M, 1998, P NATL ACAD SCI USA, V95, P12787, DOI 10.1073/pnas.95.22.12787; La Du BN, 2001, ARTERIOSCL THROM VAS, V21, P467, DOI 10.1161/01.ATV.21.4.467; La Du BN, 1992, PHARMACOGENETICS DRU, P51; Mackness B, 2000, CLIN SCI, V98, P355, DOI 10.1042/CS19990239; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 1997, LANCET, V349, P851, DOI 10.1016/S0140-6736(05)61755-2; MAIER JAM, 1994, EUR J BIOCHEM, V221, P35, DOI 10.1111/j.1432-1033.1994.tb18712.x; Mochizuki H, 1998, GENE, V213, P149, DOI 10.1016/S0378-1119(98)00193-0; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Navab M, 2001, ARTERIOSCL THROM VAS, V21, P481, DOI 10.1161/01.ATV.21.4.481; Odawara M, 1997, J CLIN ENDOCR METAB, V82, P2257, DOI 10.1210/jc.82.7.2257; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PrimoParmo SL, 1996, GENOMICS, V33, P498, DOI 10.1006/geno.1996.0225; Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sanghera DK, 1998, AM J HUM GENET, V62, P36, DOI 10.1086/301669; SHIH D, IN PRESS PARAOXONASE; Suehiro T, 1996, INT J CARDIOL, V57, P69, DOI 10.1016/S0167-5273(96)02779-9; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597	34	373	404	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44444	44449		10.1074/jbc.M105660200	http://dx.doi.org/10.1074/jbc.M105660200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579088	hybrid			2022-12-27	WOS:000172406700014
J	Jung, YW; Mikata, Y; Lippard, SJ				Jung, YW; Mikata, Y; Lippard, SJ			Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-DOMAIN PROTEIN; MOBILITY GROUP PROTEIN-1; HUMAN CELL-EXTRACTS; DAMAGED DNA; TRANSLESION SYNTHESIS; CRYSTAL-STRUCTURE; SEQUENCE CONTEXT; CANCER-PATIENTS; TRANS ISOMER; CROSS-LINKS	The TATA-binding protein (TBP) recognizes the TATA box element of transcriptional promoters and recruits other initiation factors. This essential protein binds selectively to cisplatin-damaged DNA. Electrophoretic mobility shift assays were performed to study the kinetics of TBP binding both to the TATA box and to cisplatin-damaged DNA in different sequence contexts. TBP binds with high affinity (K-d = 0.3 nM) to DNA containing site-specific cisplatin 1,2-intrastrand d(GpG) cross-links. The k(on) and k(off) values for the formation of these TBP complexes are 1-3 x 10(5) m(-1) s(-1) and similar to1-5 x 10(-4) S-1, respectively, similar to the corresponding values for the formation of a TBP-TATA box complex. In electrophoretic mobility shift assay competition assays, cisplatin-damaged DNA extensively sequesters TBP from its natural binding site, the TATA box. Nine DNA probes were prepared to determine the flanking sequence dependence of TBP binding to cisplatin-modified DNA. TBP clearly displays sequence context selectivity for platinated DNA, very similar to but not as dramatic as that of the high mobility group protein HMGB1. When TBP was added to an in vitro nucleotide excision repair assay, it specifically shielded cisplatin-modified 1,2(GpG) intrastrand cross-links from repair. These results indicate that TBP is likely to be a key protein in mediating the cytotoxicity of cisplatin.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu	Jung, Yongwon/G-7634-2012					Balasubramanian B, 1998, P NATL ACAD SCI USA, V95, P9738, DOI 10.1073/pnas.95.17.9738; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; Burstyn JN, 2000, NUCLEIC ACIDS RES, V28, P4237, DOI 10.1093/nar/28.21.4237; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P8259, DOI 10.1021/bi0004495; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Coin F, 1998, MOL CELL BIOL, V18, P3907, DOI 10.1128/MCB.18.7.3907; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; Das D, 2001, J BIOL CHEM, V276, P32597, DOI 10.1074/jbc.M011792200; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; FICHTINGERSCHEPMAN AMJ, 1987, CANCER RES, V47, P3000; GE H, 1994, J BIOL CHEM, V269, P17136; Grove A, 1998, J MOL BIOL, V282, P731, DOI 10.1006/jmbi.1998.2058; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; Hey T, 2001, BIOCHEMISTRY-US, V40, P2901, DOI 10.1021/bi002166i; Hoffmann JS, 1997, J MOL BIOL, V270, P539, DOI 10.1006/jmbi.1997.1143; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; Jamieson ER, 2000, BIOCHEMISTRY-US, V39, P8426, DOI 10.1021/bi000342h; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jamieson ER, 1999, J BIOL CHEM, V274, P12346, DOI 10.1074/jbc.274.18.12346; Jordan P, 1998, NUCLEIC ACIDS RES, V26, P2831, DOI 10.1093/nar/26.12.2831; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; KATO K, 1994, NUCLEIC ACIDS RES, V22, P1179, DOI 10.1093/nar/22.7.1179; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; Lu W, 2000, J BIOL CHEM, V275, P35006, DOI 10.1074/jbc.M004735200; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; McANulty MM, 1996, BIOCHEMISTRY-US, V35, P6089, DOI 10.1021/bi952877u; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Ohndorf UM, 1997, BIOCHEMISTRY-US, V36, P14807, DOI 10.1021/bi9717643; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; Pastor N, 2000, J MOL BIOL, V304, P55, DOI 10.1006/jmbi.2000.4173; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Patrick SM, 1999, J BIOL CHEM, V274, P14972, DOI 10.1074/jbc.274.21.14972; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Petri V, 1998, BIOCHEMISTRY-US, V37, P15842, DOI 10.1021/bi981072u; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Pilch DS, 2000, J MOL BIOL, V296, P803, DOI 10.1006/jmbi.2000.3496; REED E, 1986, J CLIN INVEST, V77, P545, DOI 10.1172/JCI112335; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000; Wolner BS, 2001, J BIOL CHEM, V276, P6260, DOI 10.1074/jbc.M008273200; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	72	30	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43589	43596		10.1074/jbc.M108299200	http://dx.doi.org/10.1074/jbc.M108299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11568187	hybrid			2022-12-27	WOS:000172297700016
J	Cabart, P; Murphy, S				Cabart, P; Murphy, S			BRFU, a TFIIB-like factor, is directly recruited to the TATA-box of polymerase III small nuclear RNA gene promoters through its interaction with TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-TFIIIB; PROXIMAL SEQUENCE ELEMENT; HUMAN U6 GENE; IN-VIVO; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; SNRNA GENES; DNA-BINDING; TBP; INITIATION	The human snRNA genes transcribed by RNA polymerase II (pol II) and III (pol III) have different core promoter elements. Both gene types contain similar proximal sequence elements (PSEs) but differ in the absence (pol II) or presence (pol III) of a TATA-box, which, together with the PSE, determines the assembly of a pol III-specific pre-initiation complex. BRFU is a factor exclusively required for transcription of the pol III-type snRNA genes. We report that recruitment of BRFU to the TATA-box of these promoters is TATA-binding protein (TBP)-dependent. BRFU in turn stabilizes TBP on TATA-containing template and extends the TBP footprint both upstream and downstream of the TATA element. The core domain of TBP is sufficient for BRFU.TBP.DNA complex formation and for interaction with BRFU off the template. We have mapped amino acid residues within TBP and domains of BRFU that mediate this interaction. BRFU has no specificity for sequences flanking the TATA-box and also forms a stable complex on the TATA-box of the pol II-specific adenovirus major late promoter (AdMLP). Furthermore, pol III-type transcription can initiate from an snRNA gene promoter containing an AdMLP TATA-box and flanking sequences. Therefore, the polymerase recruitment is not simply determined by the sequence of the TATA-box and immediate flanking sequences.	Univ Oxford, Sir William Dunn Sch Pathol, Chem Pathol Unit, Oxford OX1 3RE, England	University of Oxford	Cabart, P (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Chem Pathol Unit, S Parks Rd, Oxford OX1 3RE, England.			Cabart, Pavel/0000-0003-0065-367X				BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BOYD DC, 1995, J MOL BIOL, V253, P677, DOI 10.1006/jmbi.1995.0582; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; Hahn S, 2000, GENE DEV, V14, P719; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; MURPHY S, 1986, NUCLEIC ACIDS RES, V14, P9243, DOI 10.1093/nar/14.23.9243; Murphy S, 1997, NUCLEIC ACIDS RES, V25, P2068, DOI 10.1093/nar/25.11.2068; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Tansey WP, 1997, SCIENCE, V275, P829, DOI 10.1126/science.275.5301.829; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Yoon JB, 1996, MOL CELL BIOL, V16, P1; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	46	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43056	43064		10.1074/jbc.M108515200	http://dx.doi.org/10.1074/jbc.M108515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11564744	hybrid			2022-12-27	WOS:000172169300057
J	Saburi, S; Nadano, D; Akama, TO; Hirama, K; Yamanouchi, K; Naito, K; Tojo, H; Tachi, C; Fukuda, MN				Saburi, S; Nadano, D; Akama, TO; Hirama, K; Yamanouchi, K; Naito, K; Tojo, H; Tachi, C; Fukuda, MN			The trophinin gene encodes a novel group of MAGE proteins, magphinins, and regulates cell proliferation during gametogenesis in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; EMBRYO IMPLANTATION; NECDIN GENE; GERM-CELLS; EXPRESSION; IDENTIFICATION; TROPHOBLAST; INTERACTS; ADHESION; ANTIGEN	Trophinin is a membrane protein that mediates apical cell adhesion between trophoblastic cells and luminal epithelial cells of the endometrium and is implicated in the initial attachment during the process of human embryo implantation. The present study identified novel trophinin gene transcripts, which encode proteins structurally distinct from trophinin protein in the mouse. We designated these proteins "magphinins," because they share consensus amino acid sequences with MAGE (melanoma-associated antigen) superfamily proteins. Among many MAGE proteins, magphinins are closely related to NRAGE, which mediates p75 neurotrophin receptor-dependent apoptosis, and necdin, which is a strong suppressor of cell proliferation in post-mitotic neurons. There are three major forms of magphinins, i.e. magphinin-alpha, -beta, and -gamma, in the mouse, which are formed due to alternative usage of different exons. Northern blot analysis revealed that magphinins are expressed in brain, ovary, testis, and epididymis. In addition, Western blot analysis and in vitro translation experiments showed that magphinins expressed in the mouse ovary and testis are translation products utilizing the second initiation AUG codon and contain an active nuclear localization signal. Ectopic expression of magphinins in mammalian cells resulted in nuclear localization of magphinin and suppressed cell proliferation. Immunohistochemistry of the mouse ovary and testis showed that magphinin proteins are distributed in the cytoplasm of the male and female germ cells, whereas these proteins are translocated to the nucleus at a specific stage of gametogenesis. These results strongly suggest that magphinins regulate cell proliferation during gametogenesis in the mouse.	Burnham Inst, Dept Glycobiol, La Jolla, CA 92037 USA; Univ Tokyo, Inst Med Sci, Microbiol Lab, Tokyo 1088639, Japan; Univ Tokyo, Lab Appl Genet, Dept Anim Resource Sci, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Azabu Univ, Lab Dev & Reprod Biotechnol, Sch Vet Med & Life Sci, Kanagawa 2298501, Japan	Sanford Burnham Prebys Medical Discovery Institute; University of Tokyo; University of Tokyo; Azabu University	Fukuda, MN (corresponding author), Burnham Inst, Dept Glycobiol, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034108] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34108] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; CAO G, 1991, EXP CELL RES, V193, P405, DOI 10.1016/0014-4827(91)90113-9; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Chomez P, 2001, CANCER RES, V61, P5544; CHOMEZ P, 1995, IMMUNOGENETICS, V43, P97; De Plaen E, 1999, GENOMICS, V55, P176, DOI 10.1006/geno.1998.5638; DEBACKER O, 1995, GENOMICS, V28, P74, DOI 10.1006/geno.1995.1108; FUKUDA MN, 1995, GENE DEV, V9, P1199, DOI 10.1101/gad.9.10.1199; Fukuda MN, 1999, EMBRYO IMPLANTATION, P132; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; Jurk M, 1998, INT J CANCER, V75, P762, DOI 10.1002/(SICI)1097-0215(19980302)75:5<762::AID-IJC16>3.0.CO;2-8; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; KOCHER T, 1995, CANCER RES, V55, P2236; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lucas S, 1999, CANCER RES, V59, P4100; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mertineit C, 1998, DEVELOPMENT, V125, P889; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; Osterlund C, 2000, CANCER RES, V60, P1054; Pack SD, 1997, CYTOGENET CELL GENET, V79, P123, DOI 10.1159/000134698; Pold M, 1999, GENOMICS, V59, P161, DOI 10.1006/geno.1999.5870; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; SHULTZTHATER E, 1994, INT J CANCER, V59, P435; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P5027, DOI 10.1073/pnas.95.9.5027; Suzuki N, 1999, BIOL REPROD, V60, P621, DOI 10.1095/biolreprod60.3.621; Suzuki N, 2000, ENDOCRINOLOGY, V141, P4247, DOI 10.1210/en.141.11.4247; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tsai TF, 1999, HUM MOL GENET, V8, P1357, DOI 10.1093/hmg/8.8.1357; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032	39	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49378	49389		10.1074/jbc.M108584200	http://dx.doi.org/10.1074/jbc.M108584200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11590179	hybrid			2022-12-27	WOS:000173922100099
J	Tulla, M; Pentikainen, OT; Viitasalo, T; Kapyla, J; Impola, U; Nykvist, P; Nissinen, L; Johnson, MS; Heino, J				Tulla, M; Pentikainen, OT; Viitasalo, T; Kapyla, J; Impola, U; Nykvist, P; Nissinen, L; Johnson, MS; Heino, J			Selective binding of collagen subtypes by integrin alpha I-1, alpha I-2, and alpha I-10 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; CHONDROCYTE ADHESION; CRYSTAL-STRUCTURE; ALPHA-2-BETA-1; ALPHA-1-BETA-1; EXPRESSION; GENE; LOCALIZATION; CLONING; ALPHA(1)BETA(1)	Four integrins, namely alpha (1)beta (1), alpha (2)beta (1), alpha (10)beta (1), and alpha (11)beta (1), form a special subclass of cell adhesion receptors. They are all collagen receptors, and they recognize their ligands with an inserted domain (I domain) in their a subunit. We have produced the human integrin alpha I-10 domain as a recombinant protein to reveal its ligand binding specificity. In general, alpha I-10 did recognize collagen types I-VI and laminin-1 in a Mg2+-dependent manner, whereas its binding to tenascin was only slightly better than to albumin. When alpha I-10 was tested together with the alpha I-1 and alpha I-2 domains, all three I domains seemed to have their own collagen binding preferences. The integrin alpha I-2 domain bound much better to fibrillar collagens (I-III) than to basement membrane type IV collagen or to beaded filament-forming type VI collagen. Integrin all had the opposite binding pattern. The integrin alpha I-10 domain was similar to the all domain in that it bound very well to collagen types IV and VI. Based on the previously published atomic structures of the all and alpha I-2 domains, we modeled the structure of the alpha I-10 domain. The comparison of the three I domains revealed similarities and differences that could potentially explain their functional differences. Mutations were introduced into the al domains, and their binding to types I , IV, and VI collagen was tested. In the alpha I-2 domain, Asp-219 is one of the amino acids previously suggested to interact directly with type I collagen. The corresponding amino acid in both the alpha I-1 and alpha I-10 domains is oppositely charged (Arg-218). The mutation D219R in the alpha I-2 domain changed the ligand binding pattern to resemble that of the alpha I-1 and alpha I-10 domains and, vice versa, the R218D mutation in the all and alpha I-10 domains created an alpha I-2 domain-like ligand binding pattern. Thus, all three collagen receptors appear to differ in their ability to recognize distinct collagen subtypes. The relatively small structural differences on their collagen binding surfaces may explain the functional specifics.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland	University of Jyvaskyla; University of Turku; University of Turku; Abo Akademi University	Heino, J (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35, FIN-40351 Jyvaskyla, Finland.	jyrki.heino@utu.fi	Pentikäinen, Olli T/E-1980-2012; Impola, Ulla/T-5008-2018	Pentikäinen, Olli T/0000-0001-7188-4016; Impola, Ulla/0000-0003-3769-2648; Kapyla, Jarmo/0000-0003-3036-713X; Nissinen, Liisa/0000-0002-6743-6736				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Gardner H, 1999, J CELL SCI, V112, P263; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P270, DOI 10.1002/art.1780400211; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Meharra EJ, 2000, CELL IMMUNOL, V201, P1, DOI 10.1006/cimm.2000.1630; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Muller WEG, 1998, NATURWISSENSCHAFTEN, V85, P11, DOI 10.1007/s001140050444; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi M, 1998, J CELL BIOL, V142, P587; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; Setty S, 1998, J BIOL CHEM, V273, P12244, DOI 10.1074/jbc.273.20.12244; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; ZUTTER MM, 1990, AM J PATHOL, V137, P113	45	200	205	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48206	48212		10.1074/jbc.M104058200	http://dx.doi.org/10.1074/jbc.M104058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	505QL	11572855	hybrid			2022-12-27	WOS:000172927000063
J	Flaishon, L; Lantner, F; Hershkoviz, R; Levo, Y; Shachar, I				Flaishon, L; Lantner, F; Hershkoviz, R; Levo, Y; Shachar, I			Low levels of IFN-gamma down-regulate the integrin-dependent adhesion of B cells by activating a pathway that interferes with cytoskeleton rearrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; HEAT-STABLE ANTIGEN(HI); PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; LYMPHOCYTE RECIRCULATION; LEUKOCYTE TRAFFICKING; MIGRATION; MATURATION; PHOSPHORYLATION; ROLES	In order to fully mature and participate in the humoral immune response, immature B cells must first migrate into specific areas in the spleen where they differentiate into mature cells. However, before their maturation in the spleen, immature B cells must be excluded from non-splenic secondary lymphoid organs where any antigen encounter would lead to the death of the cells because of the negative selection process. We have recently shown that immature B cells can actively exclude themselves from antigen-enriched sites by down-regulating their integrin-mediated adhesion in a process mediated by interferon-gamma (IFN-gamma). In this study, we followed the pathway by which IFN-gamma regulates the homing of B cells. We show here that the inhibitory signal of IFN-gamma is transmitted through the IFN-gamma receptor whose engagement leads to the activation of PI3K. This PI3K activation subsequently leads to the inhibition of PKC alpha phosphorylation and cytoskeleton rearrangement required for promoting integrin-mediated adhesion and migration of B cells.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Sourasky Med Ctr, IL-64239 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, Herzel St, IL-76100 Rehovot, Israel.							ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Bowman EP, 2000, J EXP MED, V191, P1303, DOI 10.1084/jem.191.8.1303; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Coffer PJ, 1998, BIOCHEM J, V335, P1; Flaishon L, 2000, J EXP MED, V192, P1381, DOI 10.1084/jem.192.9.1381; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Harakawa N, 1997, J LEUKOCYTE BIOL, V61, P500, DOI 10.1002/jlb.61.4.500; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; HOGG N, 1995, IMMUNOL TODAY, V16, P327, DOI 10.1016/0167-5699(95)80147-2; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LORTAN JE, 1987, EUR J IMMUNOL, V17, P1311, DOI 10.1002/eji.1830170914; MACKAY CR, 1993, IMMUNOL TODAY, V14, P99, DOI 10.1016/0167-5699(93)90205-Y; MYERS MG, 1994, J BIOL CHEM, V269, P28783; PAIGE CJ, 1978, J IMMUNOL, V121, P641; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Shachar I, 1996, SCIENCE, V274, P106, DOI 10.1126/science.274.5284.106; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Wu DQ, 2000, J CELL SCI, V113, P2935	40	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46701	46706		10.1074/jbc.M103484200	http://dx.doi.org/10.1074/jbc.M103484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585817	hybrid			2022-12-27	WOS:000172768500005
J	Kao, HY; Verdel, A; Tsai, CC; Simon, C; Juguilon, H; Khochbin, S				Kao, HY; Verdel, A; Tsai, CC; Simon, C; Juguilon, H; Khochbin, S			Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE ENHANCER FACTOR-2; MEF2 TRANSCRIPTION FACTOR; MADS BOX; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; N-COR; REPRESSION; ACTIVATION; BINDING; COMPLEX	Here we show that HDAC7, a member of the class II histone deacetylases, specifically targets several members of myocyte enhancer factors, MEF2A, -2C, and -2D, and inhibits their transcriptional activity. Furthermore, we demonstrate that DNA-bound MEF2C is capable of recruiting HDAC7, demonstrating that the HDAC7-dependent repression of transcription is not due to the inhibition of the MEF2 DNA binding activity. The data also suggest that the promoter bound MEF2 is potentially capable of remodeling adjacent nucleosomes via the recruitment of HDAC7. We have also observed a nucleocytoplasmic shuttling of HDAC7 and dissected the mechanism involved. In NIH3T3 cells, HDAC7 was primarily localized in the cytoplasm, essentially due to an active CRM1-dependent export of the protein from the nucleus. Interestingly, in HeLa cells, HDAC7 was predominantly nuclear. In these cells we could restore the cytoplasmic localization of HDAC7 by expressing CaMK I. This CaMK I-induced nuclear export of HDAC7 was abolished when three critical serines, Ser-178, Ser-344, and Ser-479, of HDAC7 were mutated. We show that these serines are involved in the direct interaction of HDAC7 with 14-3-3. Mutations of these serine residues weakened the association with 14-3-3 and dramatically enhanced the repression activity of HDAC7 in NIH3T3 cells, but not in HeLa cells. Data presented in this work clearly show that the signal dependent subcellular localization of HDAC7 is essential in controlling its activities. The data also show that the cellular concentration of factors such as 14-3-3, CaMK I, and other yet unknown molecules may determine the subcellular localization of an individual HDAC member in a cell type and HDAC-specific manner.	Case Western Reserve Univ, Dept Biochem, Sch Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Fac Med, Equipe Chromatine & Express Genes, INSERM U309, Inst Albert Bonniot, F-38706 La Tronche, France; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Howard Hughes Medical Institute; Salk Institute	Kao, HY (corresponding author), Case Western Reserve Univ, Dept Biochem, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Verdel, André/M-5201-2013; Khochbin, Saadi/M-8090-2013	Khochbin, Saadi/0000-0002-0455-0857; VERDEL, Andre/0000-0001-6048-3794	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54418] Funding Source: Medline; NICHD NIH HHS [HD 27183] Funding Source: Medline; NIGMS NIH HHS [GM 26444] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang EY, 2000, GENE DEV, V14, P45; Kao HY, 2000, GENE DEV, V14, P55; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taylor JM, 1997, MOL CELL BIOL, V17, P5550, DOI 10.1128/MCB.17.9.5550; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	64	196	202	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47496	47507		10.1074/jbc.M107631200	http://dx.doi.org/10.1074/jbc.M107631200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11585834	hybrid			2022-12-27	WOS:000172768500107
J	Miura, T; Ouchida, R; Yoshikawa, N; Okamoto, K; Makino, Y; Nakamura, T; Morimoto, C; Makino, I; Tanaka, H				Miura, T; Ouchida, R; Yoshikawa, N; Okamoto, K; Makino, Y; Nakamura, T; Morimoto, C; Makino, I; Tanaka, H			Functional modulation of the glucocorticoid receptor and suppression of NF-kappa B-dependent transcription by ursodeoxycholic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BILIARY-CIRRHOSIS; GENE-EXPRESSION; NUCLEAR RECEPTOR; IMMUNE-RESPONSES; LIGAND-BINDING; CROSS-TALK; BILE-ACIDS; TRANSACTIVATION; TRANSREPRESSION; DOMAIN	Ursodeoxycholic acid (UDCA) is the current mainstay of treatment for various liver diseases including primary biliary cirrhosis. UDCA acts as a bile secretagogue, cytoprotective agent, immunomodulator, and inhibitor of cellular apoptosis. Despite this cumulative evidence of the cytoprotective and immunosuppressive effects of UDCA, both the target molecule and pathway of UDCA action remain unknown. We previously described that, in the absence of glucocorticoid ligand, UDCA activates the glucocorticoid receptor (GR) into DNA binding species but does not elicit its transactivational function in a transient transfection assay. Here we further studied the molecular mechanism of UDCA action and revealed that the ligand binding domain of the GR is responsible for UDCA-dependent nuclear translocation of the GR. Indeed, we demonstrated that UDCA acts on the distinct region of the ligand binding domain when compared with the classical GR agonist dexamethasone, resulting in loss of coactivator recruitment and differential regulation of gene expression by the GR. Our data clearly indicated that UDCA, at least in part via activation of the GR, suppresses NF-kappaB-dependent transcription through the intervention of GR-p65 interaction. Together with the established clinical safety of UDCA, we may propose that UDCA could be a prototypical compound for development of a novel and selective GR modifier.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 0788510, Japan	University of Tokyo; Asahikawa Medical College	Tanaka, H (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hirotnk@ims.u-tokyo.ac.jp						Adcock IM, 1999, BRIT J PHARMACOL, V127, P1003, DOI 10.1038/sj.bjp.0702613; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; BOTLA R, 1995, J PHARMACOL EXP THER, V272, P930; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BOUSCAREL B, 1993, AM J PHYSIOL, V264, pG243, DOI 10.1152/ajpgi.1993.264.2.G243; CALMUS Y, 1992, HEPATOLOGY, V16, P719, DOI 10.1002/hep.1840160317; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; EVANS RM, 1989, RECENT PROG HORM RES, V45, P1; EWERTH S, 1985, GASTROENTEROLOGY, V88, P126, DOI 10.1016/S0016-5085(85)80144-X; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Gershwin ME, 2000, IMMUNOL REV, V174, P210, DOI 10.1034/j.1600-0528.2002.017402.x; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Gustafsson J A, 1990, Princess Takamatsu Symp, V21, P137; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; Heathcote EJ, 2000, HEPATOLOGY, V31, P1005, DOI 10.1053/he.2000.5984; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirano F, 1996, J GASTROENTEROL, V31, P55, DOI 10.1007/BF01211187; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; LACAILLE F, 1993, HEPATOLOGY, V18, P165, DOI 10.1002/hep.1840180125; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; LIANIDOU ES, 1989, ANAL BIOCHEM, V179, P341, DOI 10.1016/0003-2697(89)90140-1; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Makino I, 1998, J GASTROEN HEPATOL, V13, P659, DOI 10.1111/j.1440-1746.1998.tb00707.x; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nishigaki Y, 1996, DIGEST DIS SCI, V41, P1487, DOI 10.1007/BF02088577; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OZAKI S, 1979, J LIPID RES, V20, P240; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; Poupon R, 1999, J HEPATOL, V30, P408, DOI 10.1016/S0168-8278(99)80098-1; Prima V, 2000, J STEROID BIOCHEM, V72, P1, DOI 10.1016/S0960-0760(99)00146-6; Reichardt HM, 2000, ADV PHARMACOL, V47, P1; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Roux S, 1999, J BIOL CHEM, V274, P10059, DOI 10.1074/jbc.274.15.10059; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Tanaka H, 1996, J IMMUNOL, V156, P1601; Tu H, 2000, TRENDS CARDIOVAS MED, V10, P30, DOI 10.1016/S1050-1738(00)00043-8; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wan YH, 2001, MOL ENDOCRINOL, V15, P17, DOI 10.1210/me.15.1.17; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Yamazaki K, 1999, HEPATOLOGY, V30, P71, DOI 10.1002/hep.510300121; YOSHIKAWA M, 1992, HEPATOLOGY, V16, P358, DOI 10.1002/hep.1840160213	62	113	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47371	47378		10.1074/jbc.M107098200	http://dx.doi.org/10.1074/jbc.M107098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11577102	hybrid, Green Submitted			2022-12-27	WOS:000172768500092
J	Corvi, MM; Soltys, CLM; Berthiaume, LG				Corvi, MM; Soltys, CLM; Berthiaume, LG			Regulation of mitochondrial carbamoyl-phosphate synthetase 1 activity by active site fatty acylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ACID OXIDATION; CARBAMYLPHOSPHATE SYNTHETASE; NITROGEN-METABOLISM; SIGNALING PROTEINS; PALMITOYL-COA; BOVINE LIVER; COENZYME-A; CHAIN; DEHYDROGENASE	In addition to its role in reversible membrane localization of signal-transducing proteins, protein fatty acylation could play a role in the regulation of mitochondrial metabolism. Previous studies have shown that several acylated proteins exist in mitochondria isolated from COS-7 cells and rat liver. Here, a prominent fatty-acylated 165-kDa protein from rat liver mitochondria was identified as carbamoyl-phosphate synthetase 1 (CPS 1). Covalently attached palmitate was linked to CPS 1 via a thioester bond resulting in an inhibition of CPS I activity at physiological concentrations of palmitoyl-CoA. This inhibition corresponds to irreversible inactivation of CPS 1 and occurred in a time- and concentration-dependent manner. Fatty acylation of CPS 1 was prevented by preincubation with N-ethylmaleimide and 5'-p-fluorosulfonylbenzoyladenosine, an ATP analog that reacts with CPS 1 active site cysteine residues. Our results suggest that fatty acylation of CPS 1 is specific for long-chain fatty acyl-CoA and very likely occurs on at least one of the essential cysteine residues inhibiting the catalytic activity of CPS 1. Inhibition of CPS 1 by long-chain fatty acyl-CoAs could reduce amino acid degradation and urea secretion, thereby contributing to nitrogen sparing during starvation.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Fac Med & Dent, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Berthiaume, LG (corresponding author), Univ Alberta, Dept Cell Biol, 555 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	Luc.Berthiaume@ualberta.ca		Berthiaume, Luc/0000-0003-0926-059X; Corvi, Maria/0000-0002-6192-5029				ALLAND L, 1994, J BIOL CHEM, V269, P16701; Aoki T T, 1975, Adv Enzyme Regul, V13, P329, DOI 10.1016/0065-2571(75)90023-0; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P455; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS EP, 1988, BIOCHEM J, V250, P819, DOI 10.1042/bj2500819; Cahill G F Jr, 1981, Curr Top Cell Regul, V18, P389; CAHILL GF, 1976, CLIN ENDOCRINOL META, V5, P397, DOI 10.1016/S0300-595X(76)80028-X; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CLARKE S, 1976, J BIOL CHEM, V251, P950; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DEICHAITE I, 1993, J BIOL CHEM, V268, P13738; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; ELLIOTT KRF, 1974, BIOCHEM J, V141, P807, DOI 10.1042/bj1410807; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FAHIEN LA, 1984, ARCH BIOCHEM BIOPHYS, V230, P213, DOI 10.1016/0003-9861(84)90102-4; GLUTHOHRLEIN G, 1968, EUR J BIOCHEM, V7, P119; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; Ishikawa E, 1976, Adv Enzyme Regul, V14, P117, DOI 10.1016/0065-2571(76)90010-8; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; KAWAGUCHI A, 1976, J BIOL CHEM, V251, P1406; Krebs H A, 1973, Adv Enzyme Regul, V11, P361, DOI 10.1016/0065-2571(73)90024-1; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MADDAIAH VT, 1989, PEDIATR RES, V25, P119, DOI 10.1203/00006450-198902000-00003; MADDAIAH VT, 1985, BIOCHEM BIOPH RES CO, V127, P565, DOI 10.1016/S0006-291X(85)80197-2; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; MCILHINNEY RAJ, 1995, LIPID MODIFICATIONS; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MILLER T, 1995, BYTE, V20, P18; MOORE KH, 1992, INT J BIOCHEM, V24, P809, DOI 10.1016/0020-711X(92)90017-U; MORAN LA, 1996, BIOCHEMISTRY; MOREL F, 1974, FEBS LETT, V39, P133, DOI 10.1016/0014-5793(74)80035-9; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; PARSONS DF, 1967, METHOD ENZYMOL, V10, P443; PIERSON DL, 1980, J BIOL CHEM, V255, P7891; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWELL GL, 1981, J BIOL CHEM, V256, P2740; POWERS SG, 1981, J BIOL CHEM, V256, P1160; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; RAIJMAN L, 1976, ARCH BIOCHEM BIOPHYS, V175, P270, DOI 10.1016/0003-9861(76)90508-7; RATNER S, 1973, ADV ENZYMOL RAMB, V39, P1; Roe C. R., 1995, METABOLIC MOL BASES, P1501; Saudubray J, 1995, METABOLIC MOL BASES, P327; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; TABIBANA M, 1976, UREA CYCLE, P301; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; VANCE JE, 1990, J BIOL CHEM, V265, P7248	55	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45704	45712		10.1074/jbc.M102766200	http://dx.doi.org/10.1074/jbc.M102766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577071	hybrid			2022-12-27	WOS:000172573100029
J	Griffin, TJ; Aebersold, R				Griffin, TJ; Aebersold, R			Advances in proteome analysis by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							IMMOBILIZED PH GRADIENTS; GEL-SEPARATED PROTEINS; COMPLEX PEPTIDE MIXTURES; GENE-EXPRESSION; 2-DIMENSIONAL ELECTROPHORESIS; ELECTROSPRAY-IONIZATION; QUANTITATIVE-ANALYSIS; POLYACRYLAMIDE GELS; SEQUENCE-ANALYSIS; ACCURATE MASS		Inst Syst Biol, Seattle, WA 98105 USA	Institute for Systems Biology (ISB)	Griffin, TJ (corresponding author), Inst Syst Biol, 4225 Roosevelt Way N,Suite 200, Seattle, WA 98105 USA.			Griffin, Timothy/0000-0001-6801-2559	NCI NIH HHS [1R33CA84698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA084698] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Banks JF, 1996, METHOD ENZYMOL, V270, P486; BEAVIS RC, 2000, PROTEOMICS TRENDS GU, P22; BLACKSTOCK W, 2000, PROTEOMICS TRENDS GU, P12; Bruce JE, 1999, ANAL CHEM, V71, P2595, DOI 10.1021/ac990231s; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; Conrads TP, 2000, ANAL CHEM, V72, P3349, DOI 10.1021/ac0002386; Corthals GL, 1997, ELECTROPHORESIS, V18, P317, DOI 10.1002/elps.1150180304; Courchesne PL, 1998, ELECTROPHORESIS, V19, P956, DOI 10.1002/elps.1150190611; Cravatt BF, 2000, CURR OPIN CHEM BIOL, V4, P663, DOI 10.1016/S1367-5931(00)00147-2; DAVIS MT, 1995, ANAL CHEM, V67, P4549, DOI 10.1021/ac00120a019; DELEENHEER AP, 1992, MASS SPECTROM REV, V11, P249, DOI 10.1002/mas.1280110402; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Dunn MJ, 1996, METHOD ENZYMOL, V271, P177; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; Figeys D, 1997, ELECTROPHORESIS, V18, P360, DOI 10.1002/elps.1150180310; Gatlin CL, 2000, ANAL CHEM, V72, P757, DOI 10.1021/ac991025n; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Goodlett DR, 2000, ANAL CHEM, V72, P1112, DOI 10.1021/ac9913210; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Griffin TJ, 2001, ANAL CHEM, V73, P978, DOI 10.1021/ac001169y; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Haynes PA, 1998, ELECTROPHORESIS, V19, P939, DOI 10.1002/elps.1150190609; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HumpherySmith I, 1997, ELECTROPHORESIS, V18, P1217, DOI 10.1002/elps.1150180804; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ji JY, 2000, J CHROMATOGR B, V745, P197, DOI 10.1016/S0378-4347(00)00192-4; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kenyon G L, 1977, Methods Enzymol, V47, P407; KLOSE J, 1975, HUMANGENETIK, V26, P231; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; LIN CS, 1988, MOL CELL BIOL, V8, P4659, DOI 10.1128/MCB.8.11.4659; LIN Y, 1999, P NATL ACAD SCI USA, V96, P14694; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Loboda AV, 2000, RAPID COMMUN MASS SP, V14, P1047, DOI 10.1002/1097-0231(20000630)14:12<1047::AID-RCM990>3.0.CO;2-E; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Lopez MF, 2000, ELECTROPHORESIS, V21, P1082, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1082::AID-ELPS1082>3.3.CO;2-5; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Medzihradszky KF, 2000, ANAL CHEM, V72, P552, DOI 10.1021/ac990809y; Munchbach M, 2000, ANAL CHEM, V72, P4047, DOI 10.1021/ac000265w; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; Pasa-Tolic L, 1999, J AM CHEM SOC, V121, P7949, DOI 10.1021/ja991063o; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1791, DOI 10.1002/elps.11501601299; Rabilloud T, 1997, ELECTROPHORESIS, V18, P307, DOI 10.1002/elps.1150180303; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Shabanowitz J, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P163; Shevchenko A, 2000, ANAL CHEM, V72, P2132, DOI 10.1021/ac9913659; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spahr CS, 2000, ELECTROPHORESIS, V21, P1635, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1635::AID-ELPS1635>3.0.CO;2-1; Steinberg TH, 2000, ELECTROPHORESIS, V21, P486, DOI 10.1002/(SICI)1522-2683(20000201)21:3<486::AID-ELPS486>3.0.CO;2-Q; Washburn M. P., 2000, PROTEOMICS TREND GUI, P27; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wildgruber R, 2000, ELECTROPHORESIS, V21, P2610, DOI 10.1002/1522-2683(20000701)21:13<2610::AID-ELPS2610>3.0.CO;2-H; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yates JR, 2000, TRENDS GENET, V16, P5, DOI 10.1016/S0168-9525(99)01879-X; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	78	123	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45497	45500		10.1074/jbc.R100014200	http://dx.doi.org/10.1074/jbc.R100014200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585843	hybrid			2022-12-27	WOS:000172573100001
J	Morris-Desbois, C; Rety, S; Ferro, M; Garin, J; Jalinot, P				Morris-Desbois, C; Rety, S; Ferro, M; Garin, J; Jalinot, P			The human protein HSPC021 interacts with Int-6 and is associated with eukaryotic translation initiation factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNCHBACK MESSENGER-RNA; MAMMARY-TUMOR VIRUS; RET FINGER PROTEIN; PML NUCLEAR-BODIES; FACTOR EIF3; IN-VIVO; SUBUNIT; BINDING; PUMILIO; DOMAIN	The Int-6 protein has been shown to be a subunit of eukaryotic translation initiation factor 3 (eIF3) and to play a role in the control of cell growth. By immunoprecipitation experiments and mass spectrometry analyses, we identified a human protein previously known as HSPC021 that is associated with Int-6. Exposure of Jurkat cells to the phosphatase inhibitor H2O2 triggers a marked phosphorylation on tyrosine of HSPC021. Several experiments were performed to evaluate whether this protein is associated with eIF3. It was observed that HSPC021 coelutes with Int-6 and eIF3 in gel filtration, coimmunoprecipitates with eIF3, and is incorporated into eIF3 both in rabbit reticulocyte lysates and in COS7 cells. A direct protein-protein interaction occurs between HSPC021 and Int-6, but the analysis of different mutants of HSPC021 indicated that a larger region of the protein is necessary for incorporation into eIF3 as compared with binding to Int-6. Taken together, our results establish that HSPC021 is tightly associated with the mammalian translation initiation factor eIF3. Analysis of the primary sequence of HSPC021 from different species revealed the presence of a tetratricopeptide repeat, a proteasome-COP9 (constitutive photomorphogenesis 9) signalosome-initiation factor 3 domain along with a Pumilio FBF repeat. These protein motifs are also present in subunits of eIF3, of the lid of the 26 S proteasome, and of the COP9 signalosome.	Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, UMR 5665, CNRS, F-69364 Lyon 07, France; Commissariat Energie Atom Grenoble, Lab Chim Prot, F-38054 Grenoble, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CEA	Jalinot, P (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol & Cellulaire, UMR 5665, CNRS, 46 Allee Italie, F-69364 Lyon 07, France.		Rety, Stephane/L-9870-2019; Morris, Christelle/M-8168-2014; FERRO, Myriam/O-6588-2014	Rety, Stephane/0000-0002-2089-6727; Morris, Christelle/0000-0003-1575-4609; FERRO, Myriam/0000-0002-4222-6847				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BUBECK P, 1993, NUCLEIC ACIDS RES, V21, P3601, DOI 10.1093/nar/21.15.3601; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Cao TY, 1998, J CELL SCI, V111, P1319; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Edwards TA, 2001, CELL, V105, P281, DOI 10.1016/S0092-8674(01)00318-X; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jin YJ, 1998, J IMMUNOL, V161, P1743; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MacDonald JIS, 1999, J MOL NEUROSCI, V13, P141, DOI 10.1385/JMN:13:1-2:141; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Miyazaki S, 1999, GENE, V233, P241, DOI 10.1016/S0378-1119(99)00130-4; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Wreden C, 1997, DEVELOPMENT, V124, P3015; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; Zamore PD, 1997, RNA, V3, P1421	39	25	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45988	45995		10.1074/jbc.M104966200	http://dx.doi.org/10.1074/jbc.M104966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11590142	hybrid			2022-12-27	WOS:000172573100068
J	Bellu, AR; Komori, M; van der Klei, IJ; Kiel, JAKW; Veenhuis, M				Bellu, AR; Komori, M; van der Klei, IJ; Kiel, JAKW; Veenhuis, M			Peroxisome biogenesis and selective degradation converge at Pex14p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICHIA-PASTORIS REQUIRES; HANSENULA-POLYMORPHA; DEFICIENT MUTANTS; TARGETING SIGNAL; ALCOHOL OXIDASE; YEAST; AUTOPHAGY; PROTEIN; IMPORT; GENE	We have analyzed the function of Hansenula polymorpha Pex14p in selective peroxisome degradation. Previously, we showed that Pex14p was involved in peroxisome biogenesis and functions in peroxisome matrix protein import. Evidence for the additional function of HpPex14p in selective peroxisome degradation (pexophagy) came from cells defective in HpPex14p synthesis. The suggestion that the absence of HpPex14p interfered with pexophagy was further analyzed by mutational analysis. These studies indicated that deletions at the C terminus of up to 124 amino acids of HpPex14p did not affect peroxisome degradation. Conversely, short deletions of the N terminus (31 and 64 amino acids, respectively) of the protein fully impaired pexophagy. Peroxisomes present in these cells remained intact for at least 6 h of incubation in the presence of excess glucose, conditions that led to the rapid turnover of the organelles in wild-type control cells. We conclude that the N terminus of HpPex14p contains essential information to control pexophagy in H. polymorpha and thus, that organelle development and turnover converge at Pex14p.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands; Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Dept Vet Sci, Cellular & Mol Biol Lab, Osaka 5998531, Japan	University of Groningen; Osaka Metropolitan University	Veenhuis, M (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.	M.Veenhuis@biol.rug.nl	van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; Bellu AR, 2001, FEMS YEAST RES, V1, P23, DOI 10.1111/j.1567-1364.2001.tb00010.x; DIDION T, 1992, FEBS LETT, V303, P113, DOI 10.1016/0014-5793(92)80500-G; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Gunkel K, 1999, FEBS LETT, V451, P1, DOI 10.1016/S0014-5793(99)00513-X; HANSEN H, 1992, MOL GEN GENET, V235, P269, DOI 10.1007/BF00279370; Kiel JAKW, 1999, YEAST, V15, P741, DOI 10.1002/(SICI)1097-0061(19990630)15:9<741::AID-YEA416>3.0.CO;2-O; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Komori M, 1999, FEBS LETT, V457, P397, DOI 10.1016/S0014-5793(99)01087-X; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Sakai Y, 2000, CELL BIOCHEM BIOPHYS, V32, P51, DOI 10.1385/CBB:32:1-3:51; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Sepulveda J., 1992, FEMS MICROBIOL LETT, V91, P207; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; TUTTLE DL, 1993, EUR J CELL BIOL, V60, P283; TUTTLE DL, 1995, J CELL SCI, V108, P25; VANDERKLEI IJ, 1991, YEAST, V7, P813, DOI 10.1002/yea.320070806; VANDERKLEI IJ, 1991, ARCH MICROBIOL, V156, P15, DOI 10.1007/BF00418181; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; Veenhuis M, 1996, FEBS LETT, V383, P114, DOI 10.1016/0014-5793(96)00220-7; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Will GK, 1999, MOL CELL BIOL, V19, P2265; Yuan WP, 1997, J CELL SCI, V110, P1935; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	32	95	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44570	44574		10.1074/jbc.M107599200	http://dx.doi.org/10.1074/jbc.M107599200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11564741	hybrid, Green Published			2022-12-27	WOS:000172406700032
J	Bubulya, A; Chen, SY; Fisher, CJ; Zheng, Z; Shen, XQ; Shemshedini, L				Bubulya, A; Chen, SY; Fisher, CJ; Zheng, Z; Shen, XQ; Shemshedini, L			c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; ACTIVATION FUNCTION-2; NUCLEAR RECEPTORS; IN-VIVO; COACTIVATOR; PROTEIN; TRANSACTIVATION; TRANSCRIPTION; IDENTIFICATION	The transactivation functions of the human androgen receptor (hAR) are regulated by several accessory factors that can be either positive or negative. One factor that has been previously shown to mediate hAR transactivation is the proto-oncoprotein c-Jun. The positive effect is a primary one, can be exerted by both endogenous and exogenous c-Jun, and requires multiple regions of c-Jun. However, the exact mechanism by which c-Jun exerts its enhancing function is unknown. In this study, we have used a mammalian two-hybrid system to ask if c-Jun influences the ligand-dependent amino- to carboxyl-terminal (N-to-C) interaction of hAR, which is thought to be responsible for the homodimerization of this receptor. Our results show that e-Jun enhances both hAR N-to-C terminal interaction and DNA binding in vitro. We have also tested a panel of c-Jun and c-Fos mutants for their activities on the N-to-C interaction, and the data demonstrate that the activities of these mutants parallel their activities on hAR transactivation. A mutation in the hAR activation function-2 (AF-2) abrogates N-to-C interaction, DNA binding, and transactivation, and these activities are not rescued by exogenous c-Jun. Interestingly, the p160 coactivator TIF2 can stimulate hAR N-to-C interaction, a finding consistent with the effect on hAR transactivation. These data strongly suggest that the hAR N-to-C interaction is the target of c-Jun action, and this activity requires a functional receptor AF-2.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft, Toledo, OH 43528 USA.		CHEN, Shaoyong/ABF-3357-2021					Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barthold JS, 2000, J UROLOGY, V164, P497, DOI 10.1016/S0022-5347(05)67411-3; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kelly C, 1996, CHILD PSYCHOL PSYCHI, V1, P59; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Park JJ, 2000, CANCER RES, V60, P5946; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SEMINTAL JA, 1991, J BIOL CHEM, V266, P510; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; THOLE HH, 1994, J STEROID BIOCHEM, V48, P463, DOI 10.1016/0960-0760(94)90194-5; THUMMEL C, 1995, CELL, V83, P571; Tillman K, 1998, ENDOCRINE, V9, P193, DOI 10.1385/ENDO:9:2:193; Wilson J D, 1981, Recent Prog Horm Res, V37, P1; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	51	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44704	44711		10.1074/jbc.M107346200	http://dx.doi.org/10.1074/jbc.M107346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577103	hybrid			2022-12-27	WOS:000172406700050
J	Lee, JH; Voo, KS; Skalnik, DG				Lee, JH; Voo, KS; Skalnik, DG			Identification and characterization of the DNA binding domain of CpG-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO METHYLATION; MAMMALIAN DEVELOPMENT; METHYLTRANSFERASE GENE; DROSOPHILA-TRITHORAX; CXXC DOMAIN; ALL-1 GENE; ACTIVATION; REPRESSOR; PROMOTER; ISLAND	CpG-binding protein is a transcriptional activator that exhibits a unique DNA binding specificity for unmethylated CpG motifs. CpG-binding protein contains a cysteine-rich CXXC domain that is conserved in DNA methyltransferase 1, methyl binding domain protein 1, and human trithorax. In vitro DNA binding assays reveal that CpG-binding protein contains a single DNA binding domain comprised of the CXXC domain and a short carboxyl extension. Specific mutation to alanine of individual conserved cysteine residues within the CXXC domain abolishes DNA binding activity. Denaturation/renaturation experiments in the presence of various metal cations demonstrate that the CXXC domain requires zinc for efficient DNA binding activity. Ligand selection of high affinity binding sites from a pool of degenerate oligonucleotides reveals that CpG-binding protein interacts with a variety of sequences that contains the CpG dinucleotide with a consensus binding site of (A/C)CpG(A/C). Mutation of the CpG motif(s) present within ligand-selected oligonucleotides ablates the interaction with CpG-binding protein, and mutation to thymine of the nucleotides flanking the CpG motifs reduces the affinity of CpG-binding protein. Hence, a CpG motif is necessary and sufficient to comprise a binding site for CpG-binding protein, although the immediate flanking sequence affects binding affinity.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Sect Pediat Hematol Oncol, Canc Res Bldg,1044 W Walnut St,Rm 472, Indianapolis, IN 46202 USA.				NATIONAL CANCER INSTITUTE [R29CA058947, R01CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Fujino T, 2000, BIOCHEM BIOPH RES CO, V271, P305, DOI 10.1006/bbrc.2000.2614; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Sambrook J., 2002, MOL CLONING LAB MANU; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	35	118	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44669	44676		10.1074/jbc.M107179200	http://dx.doi.org/10.1074/jbc.M107179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572867	hybrid			2022-12-27	WOS:000172406700046
J	Liu, A; Prenger, MS; Norton, DD; Mei, L; Kusiak, JW; Bai, G				Liu, A; Prenger, MS; Norton, DD; Mei, L; Kusiak, JW; Bai, G			Nerve growth factor uses Ras/ERK and phosphatidylinositol 3-kinase cascades to up-regulate the N-methyl-D-aspartate receptor 1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR INDUCES TRANSCRIPTION; PC12 CELLS; DNA-BINDING; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; SP1 PHOSPHORYLATION; SUBUNIT-1 PROMOTER; NMDA RECEPTOR; RAT-BRAIN	We reported previously that nerve growth factor (NGF) up-regulates activity of the N-methyl-D-aspartate receptor 1 (NR1) promoter. We have explored the pathways and nuclear targets of NGF signaling in regulating the NR1 promoter. PD98059 and wortmannin, but not rapamycin, significantly attenuated NGF-induced transcriptional activity from an NR1 promoter-luciferase construct. Coexpressing constitutively active forms of Ras, Raf, or MAPK/ERK kinase 1 (MEK1) increased promoter activity dramatically. The MEK1-induced increase was largely prevented by mutations of the tandem GC boxes in the promoter. Promoter activity was also increased significantly by coexpressed GC box-binding proteins (Sp1, 3, or 4) in nonstimulated PC12 cells. Either an extracellular signal-regulated kinase-1 (ERK1)- or Sp1-specific antibody coprecipitated Spl with ERKs, and the coprecipitation was enhanced significantly by NGF treatment of PC12 cells. ERK2 also incorporated radioactivity of [gamma P-32]ATP into recombinant Sp1. However, ERK2-treated Sp1 and PC12 nuclear extracts or nuclear extracts from NGF-treated cells exhibited reduced binding to the promoter or a consensus GC box. Our results suggest that NGF utilizes both the Ras/ERK and phosphatidylinositol 3-kinase pathways to up-regulate NR1 promoter activity and that Sp1 is a novel substrate of NGF-activated ERKs. NGF-increased NR1 promoter activity may involve a complicated mechanism of Sp1 phosphorylation and possible transcription factor exchange.	Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, Baltimore, MD 21201 USA; Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA; NIA, Mol Neurobiol Unit, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bai, G (corresponding author), Univ Maryland, Sch Dent, Dept Oral & Craniofacial Biol Sci, 666 W Baltimore St, Baltimore, MD 21201 USA.	GNB001@dental.umaryland.edu	Mei, Lin/G-8755-2012		NINDS NIH HHS [NS34062, NS38077] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062, R01NS038077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000500] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AZIZ N, 1993, ONCOGENE, V8, P2259; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOONSTRA J, 1985, BIOCHIMIE, V67, P1177, DOI 10.1016/S0300-9084(85)80117-6; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT RP, 1992, ONCOGENE, V7, P2281; Freeland K, 2000, BIOCHEM J, V345, P233, DOI 10.1042/0264-6021:3450233; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Groot M, 2000, EUR J CELL BIOL, V79, P924, DOI 10.1078/0171-9335-00126; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Hashimoto K, 2000, J NEUROCHEM, V74, P92, DOI 10.1046/j.1471-4159.2000.0740092.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KIM SJ, 1994, J BIOL CHEM, V269, P3739; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; Kumahara E, 1999, J BIOCHEM, V125, P541, DOI 10.1093/oxfordjournals.jbchem.a022319; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; PUJIC Z, 1993, NEUROSCI LETT, V162, P67, DOI 10.1016/0304-3940(93)90561-X; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; Rockow S, 1996, ONCOGENE, V12, P2351; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Si JT, 1997, J BIOL CHEM, V272, P10367; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WATANABE M, 1993, ANN NY ACAD SCI, V707, P463, DOI 10.1111/j.1749-6632.1993.tb38099.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zhang SY, 1997, ARCH BIOCHEM BIOPHYS, V338, P227, DOI 10.1006/abbi.1996.9809; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200; Zhong J, 1996, MOL PHARMACOL, V50, P631	67	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45372	45379		10.1074/jbc.M105399200	http://dx.doi.org/10.1074/jbc.M105399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571288	hybrid			2022-12-27	WOS:000172406700133
J	Liu, LD; Komori, K; Ishino, S; Bocquier, AA; Cann, IKO; Kohda, D; Ishino, Y				Liu, LD; Komori, K; Ishino, S; Bocquier, AA; Cann, IKO; Kohda, D; Ishino, Y			The archaeal DNA primase - Biochemical characterization of the p41-p46 complex from Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON; ESCHERICHIA-COLI; REPLICATION FORK; POLYMERASE; EXPRESSION; SEQUENCE; CLONING; GENE	We characterized the primase complex of the hyperthermophilic archaeon, Pyrococcus furiosus. The two proteins, Pfup41 and Pfup46, have similar sequences to the p48 and p58 subunits, respectively, of the eukaryotic DNA polymerase alpha -primase complex. Unlike previously reported primases, the Pfup41 preferentially utilizes deoxyribonucleotides for its de novo synthesis, and moreover, it synthesizes up to several kilobases in length in a template-dependent manner (Bocquier, A., Liu, L., Cann, I., Komori, K., Kohda, D., and Ishino, Y. (2001) Curr. Biol. 11, 452-456). The p41-p46 complex showed higher DNA binding activity than the catalytic p41 subunit alone. In addition, the amount of DNA synthesized by the p41-p46 complex was much more abundant and shorter in length than that by Pfup41 alone. The activity for RNA primer synthesis, which was not detected with Pfup41, was observed from the reaction using the p41-p46 complex in vitro. The in vitro replication of M13 single-stranded DNA by the P. furiosus proteins was stimulated by ATP. Observation of the labeled primers by using [gamma-P-32]ATP in the substrates suggests ATP as the preferable initiating nucleotide for the p41-p46 complex. These results show that the primer synthesis activity of Pfup41 is regulated by Pfup46, and the p41-p46 complex may function as the primase in the DNA replication machinery of P. furiosus, in a similar fashion to the eukaryotic polymerase alpha -primase complex.	Binomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; Binomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan		Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Mol Biol, 6-2-3 Furuedai, Osaka 5650874, Japan.		Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776; Ishino, Yoshizumi/0000-0001-9419-0826; Ishino, Sonoko/0000-0002-1833-1735				Arezi B, 1999, BIOCHEMISTRY-US, V38, P12899, DOI 10.1021/bi9908991; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Bocquier AA, 2001, CURR BIOL, V11, P452, DOI 10.1016/S0960-9822(01)00119-1; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Copeland WC, 1997, PROTEIN EXPRES PURIF, V9, P1, DOI 10.1006/prep.1996.0665; Desogus G, 1999, NUCLEIC ACIDS RES, V27, P4444, DOI 10.1093/nar/27.22.4444; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Imamura M, 1995, BIOL PHARM BULL, V18, P1647; Ishino Y, 2001, METHOD ENZYMOL, V334, P249; Ishino Y, 1998, GENES GENET SYST, V73, P323, DOI 10.1266/ggs.73.323; Kirk BW, 1999, BIOCHEMISTRY-US, V38, P7727, DOI 10.1021/bi990247c; Komori K, 2000, PROTEIN ENG, V13, P41, DOI 10.1093/protein/13.1.41; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; Kornberg A., 1992, DNA REPLICATION; Leipe DD, 1999, NUCLEIC ACIDS RES, V27, P3389, DOI 10.1093/nar/27.17.3389; SHEAFF RJ, 1994, BIOCHEMISTRY-US, V33, P2247, DOI 10.1021/bi00174a035; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; UEMORI T, 1993, NUCLEIC ACIDS RES, V21, P259, DOI 10.1093/nar/21.2.259; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WANG TSF, 1996, DNA REPLICATION EUKA, P461; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	27	61	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45484	45490		10.1074/jbc.M106391200	http://dx.doi.org/10.1074/jbc.M106391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584001	hybrid			2022-12-27	WOS:000172406700147
J	Perkins, S; Walsh, EJ; Deivanayagam, CCS; Narayana, SVL; Foster, TJ; Hook, M				Perkins, S; Walsh, EJ; Deivanayagam, CCS; Narayana, SVL; Foster, TJ; Hook, M			Structural organization of the fibrinogen-binding region of the clumping factor B MSCRAMM of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; DOMAIN; FIBRONECTIN; IDENTIFICATION; PATHOGENESIS; ADHERENCE; CLEAVAGE; CLFA	The clumping factor B (ClfB) of Staphylococcus aureus is a surface protein that binds to fibrinogen (Ni Eidhin, D., Perkins, S., Francois, P., Vaudaux, P., Hook, M., and Foster, T. J., 1998 Mol. Microbiol. 30, 245-257). The ligand-binding activity is located in the similar to 500-residue A-region (residues 44-542), which represents the N-terminal half of the MSCRAMM protein. We now hypothesize that the ClfB A-region is composed of three subdomains, which we have named N1, N2, and N3, respectively. To examine this hypothesis, we expressed recombinant forms of the individual putative subdomains, the tandem motifs N12 and N23, and the full-length A-region N123. Far UV circular dichroism spectra showed that each subdomain is composed mainly of beta -sheets with little or no discernible alpha -helices. Heat-induced unfolding of individual subdomains occurred with a single state transition and was reversible, indicating that the subdomains can fold as discreet units. Gel permeation chromatography indicated that N2, N3, and N23 are globular. In contrast, domain Nl appeared to be elongated and conferred a somewhat elongated structure on segments containing this subdomain (i.e. N12 or N123). N123, N12, and N23 all bound to fibrinogen, but N23 had a higher affinity for fibrinogen than that observed for the full-length A-region; N123 or for N12. However, an extended N terminus of N23 was required for ligand binding. A form of N23 that was generated by proteolytic processing and lacked the N-terminal extension was unable to bind fibrinogen. Recombinant forms of individual subdomains did not bind fibrinogen. The addition of recombinant N23 effectively inhibited ClfB-mediated bacterial adherence to fibrinogen, and N123 caused some reduction in bacterial attachment, whereas N12 was essentially inactive. Antibodies raised against the central N2 domain of the A-region were the most effective at inhibiting bacterial adhesion to immobilized fibrinogen, although anti-N3 or anti-N1 antibodies also caused some reduction in ClfB-mediated adherence to fibrinogen.	Texas Med Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Univ Alabama Birmingham, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35205 USA	Baylor College of Medicine; Trinity College Dublin; University of Alabama System; University of Alabama Birmingham	Hook, M (corresponding author), Texas Med Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.			Deivanayagam, Champion/0000-0003-2972-1824	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERS GK, 1967, J BIOL CHEM, V242, P3026; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Deivanayagam CCS, 1999, ACTA CRYSTALLOGR D, V55, P554, DOI 10.1107/S0907444998012426; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Entenza JM, 2000, INFECT IMMUN, V68, P5443, DOI 10.1128/IAI.68.9.5443-5446.2000; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; HATT J, 1992, STRATEGIES, V5, P81; Josefsson E, 1998, MICROBIOL-UK, V144, P3387, DOI 10.1099/00221287-144-12-3387; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; McAleese FM, 2001, J BIOL CHEM, V276, P29969, DOI 10.1074/jbc.M102389200; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; McGavin MJ, 1997, INFECT IMMUN, V65, P2621, DOI 10.1128/IAI.65.7.2621-2628.1997; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; OWEN P, 1985, ENTEROBACTERIAL SURF, P207; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633; VAUDAUX PE, 1995, INFECT IMMUN, V63, P585, DOI 10.1128/IAI.63.2.585-590.1995; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; Wolz C, 1996, INFECT IMMUN, V64, P3142, DOI 10.1128/IAI.64.8.3142-3147.1996; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44721	44728		10.1074/jbc.M106741200	http://dx.doi.org/10.1074/jbc.M106741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11568183	hybrid			2022-12-27	WOS:000172406700052
J	Rockman, SP; Currie, SA; Ciavarella, M; Vincan, E; Dow, C; Thomas, RJS; Phillips, WA				Rockman, SP; Currie, SA; Ciavarella, M; Vincan, E; Dow, C; Thomas, RJS; Phillips, WA			Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; RETINOBLASTOMA PROTEIN; PANCREATIC-CANCER; PROMOTER ACTIVITY; TUMORS; EXPRESSION; MUTATIONS; SEQUENCE; MOUSE	Activation of beta -catenin/T cell factor (TCF) transcription as a result of mutations in the adenomatous polyposis coli (APC) and/or beta -catenin genes occurs in the majority of colon tumors. An increasing number of genes, including c-myc and cyclin D1, have been implicated as targets of this pathway. We now report that the dominant negative helix-loop-helix regulator Id2 is also a target of the beta -catenin/TCF transcription pathway in colon adenocarcinoma. Investigation of the mechanism for the overexpression of Id2 in colon carcinoma cells demonstrated that the Id2 promoter is activated, and the Id2 protein is up-regulated by beta -catenin. Conversely, reducing free beta -catenin blocked this induction of promoter activity. We have also used an electrophoretic mobility shift assay and supershift to identify a motif in the Id2 promoter that binds to TCF4 protein. Site-directed mutagenesis of this motif abolished promoter reporter activity. Both transfection of Id2 into SW480 cells and induction of Id2 in HT29 colon cells was found to increase anchorage-independent survival of these cells. Growing evidence associates disruption to Id2 expression with tumorigenesis, and our findings suggest that this dysregulation of Id2 expression is due to the activation of the beta -catenin/TCF pathway.	Peter MacCallum Canc Inst, Surg Oncol Res Lab, Melbourne, Vic 3002, Australia; Western Hosp, Dept Anat Pathol, Footscray, Vic 3011, Australia	Peter Maccallum Cancer Center; Western Hospital	Phillips, WA (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, Locked Bag 1 ABeckett St, Melbourne, Vic 8006, Australia.	w.phillips@pmci.unimelb.edu.au	Phillips, Wayne A/H-8070-2013; rockman, steve/AAT-5105-2021	Phillips, Wayne A/0000-0002-7961-638X; Vincan, Elizabeth/0000-0002-8607-4849				Atherton GT, 1996, CELL GROWTH DIFFER, V7, P1059; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAND K, 2001, DNA MICROARRAYS MOL; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Gerdes B, 1999, DIGESTION, V60, P544, DOI 10.1159/000007704; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hulsken J, 2000, J CELL SCI, V113, P3545; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Israel MA, 1999, CANCER RES, V59, p1726S; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kleeff J, 1998, CANCER RES, V58, P3769; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KURABAYASHI M, 1995, GENE, V156, P311, DOI 10.1016/0378-1119(95)00017-Z; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Mariadason JM, 2001, CANCER RES, V61, P3465; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Norton JD, 2000, J CELL SCI, V113, P3897; Pagliuca A, 2000, CANCER RES, V60, P1376; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Ramsay R G, 1995, Methods Mol Biol, V37, P369; Ramsay RG, 2000, CANCER RES, V60, P1805; ROCZO N, 2000, GI CANCER, V3, P259; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310	31	118	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45113	45119		10.1074/jbc.M107742200	http://dx.doi.org/10.1074/jbc.M107742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572874	hybrid			2022-12-27	WOS:000172406700102
J	Tornaletti, S; Maeda, LS; Lloyd, DR; Reines, D; Hanawalt, PC				Tornaletti, S; Maeda, LS; Lloyd, DR; Reines, D; Hanawalt, PC			Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMER; DNA-BASE DAMAGES; COUPLED REPAIR; ESCHERICHIA-COLI; COCKAYNE-SYNDROME; UREA RESIDUES; HUMAN-CELLS; DUPLEX DNA; STRAND; GENE	Thymine glycols are formed in DNA by exposure to ionizing radiation or oxidative stress. Although these lesions are repaired by the base excision repair pathway, they have been shown also to be subject to transcription-coupled repair. A current model for transcription-coupled repair proposes that RNA polymerase II arrested at a DNA lesion provides a signal for recruitment of the repair enzymes to the lesion site. Here we report the effect of thymine glycol on transcription elongation by T7 RNA polymerase and RNA polymerase II from rat liver. DNA substrates containing a single thymine glycol located either in the transcribed or nontranscribed strand were used to carry out in vitro transcription. We found that thymine glycol in the transcribed strand blocked transcription elongation by T7 RNA polymerise similar to 50% of the time but did not block RNA polymerise It. Thymine glycol in the nontranscribed strand did not affect transcription by either polymerase. These results suggest that arrest of RNA polymerase elongation by thymine glycol is not necessary for transcription-coupled repair of this lesion. Additional factors that recognize and bind thymine glycol in DNA may be required to ensure RNA polymerise arrest and the initiation of transcription-coupled repair in vivo.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Stanford University; Emory University	Hanawalt, PC (corresponding author), Stanford Univ, Dept Biol Sci, 385 Serra Mall, Stanford, CA 94305 USA.	hanawalt@stanford.edu	excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Lloyd, Daniel/0000-0002-4888-6790; Maeda, Lauren/0000-0001-9215-2965	NCI NIH HHS [CA-77712, R56 CA077712, R01 CA077712] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077712, R56CA077712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHEY PM, 1983, RADIAT RES, V93, P609, DOI 10.2307/3576040; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5404, DOI 10.1021/bi00391a028; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5398, DOI 10.1021/bi00391a027; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANAWALT PC, 1993, ALFRED BENZON SYMP S, V35, P231; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; HTUN H, 1992, METHOD ENZYMOL, V212, P272; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; KAO JY, 1993, J BIOL CHEM, V268, P17787; Kung HC, 1997, J BIOL CHEM, V272, P9227; LASPIA MF, 1988, J BACTERIOL, V170, P3359, DOI 10.1128/jb.170.8.3359-3366.1988; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1995, MUTAT RES-DNA REPAIR, V337, P169, DOI 10.1016/0921-8777(95)00021-B; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MORAN E, 1985, MUTAT RES, V146, P229, DOI 10.1016/0167-8817(85)90063-X; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; REINES D, 1991, J BIOL CHEM, V266, P10510; ROUET P, 1985, CANCER RES, V45, P6113; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SHI YB, 1988, J BIOL CHEM, V263, P527; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Tornaletti S, 1997, J BIOL CHEM, V272, P31719, DOI 10.1074/jbc.272.50.31719; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660	42	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45367	45371		10.1074/jbc.M105282200	http://dx.doi.org/10.1074/jbc.M105282200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11571287	Green Accepted, hybrid			2022-12-27	WOS:000172406700132
J	Volk, KA; Snyder, PM; Stokes, JB				Volk, KA; Snyder, PM; Stokes, JB			Regulation of epithelial sodium channel activity through a region of the carboxyl terminus of the alpha-subunit - Evidence for intracellular kinase-mediated reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME; NA+ CHANNEL; PROTEIN-KINASE; BETA-SUBUNIT; PSEUDOHYPOALDOSTERONISM TYPE-1; MISSENSE MUTATION; MEMBRANE TOPOLOGY; CELL-SURFACE; WW DOMAINS; PY MOTIF	The epithelial sodium channel (ENaC) is a heteromultimer composed of three subunits, each having two membrane-spanning domains with intracellular amino and carboxyl termini. Several hormones and proteins regulate channel activity, but the molecular nature of this regulation is unknown. We conducted experiments to determine a possible new site within the carboxyl terminus of the a-subunit involved in enhanced channel activity through endogenous kinases. When an alpha -subunit that was truncated to remove a PY motif was expressed in Xenopus oocytes with wild type human beta- and gamma -ENaC subunits, channel activity was greatly enhanced. The removal of the entire intracellular carboxyl terminus of the alpha -subunit eliminated this enhanced basal activity. Using several point mutations, we localized this site to two amino acid residues (Pro(595)-Gly(596)) near the second membrane-spanning domain. The nonspecific kinase inhibitor staurosporine inhibits basal channel activity of wild type ENaC but was ineffective in inhibiting channels mutated at this site. The major effect of these mutations was not on channel kinetics but was largely, if not entirely, on the number of active channels on the cell surface. This region is potentially important in effecting kinase-mediated increases in ENaC activity.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52246 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52246 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Stokes, JB (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, E300 GH, Iowa City, IA 52246 USA.	john-stokes@uiowa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, P50DK052617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55006] Funding Source: Medline; NIDDK NIH HHS [DK52617, DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chalfant ML, 1996, AM J PHYSIOL-RENAL, V271, pF861, DOI 10.1152/ajprenal.1996.271.4.F861; Chalfant ML, 1996, J MEMBRANE BIOL, V152, P207, DOI 10.1007/s002329900098; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHEN L, 1991, AM J PHYSIOL, V261, pF126, DOI 10.1152/ajprenal.1991.261.1.F126; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FRINDT G, 1995, AM J PHYSIOL-RENAL, V268, pF480, DOI 10.1152/ajprenal.1995.268.3.F480; Frindt G, 1996, AM J PHYSIOL-RENAL, V270, pF371, DOI 10.1152/ajprenal.1996.270.2.F371; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Grunder S, 1997, J HYPERTENS, V15, P173, DOI 10.1097/00004872-199715020-00008; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HASSON JH, 1995, P NATL ACAD SCI USA, V92, P11495; Husted RF, 1996, AM J PHYSIOL-RENAL, V271, pF433, DOI 10.1152/ajprenal.1996.271.2.F433; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; Jeunemaitre X, 1997, J HYPERTENS, V15, P1091, DOI 10.1097/00004872-199715100-00007; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Lang F, 2000, P NATL ACAD SCI USA, V97, P8157, DOI 10.1073/pnas.97.14.8157; Melander O, 1998, HYPERTENSION, V31, P1118, DOI 10.1161/01.HYP.31.5.1118; NAGY E, 1994, AM J PHYSIOL-RENAL, V267, pF831, DOI 10.1152/ajprenal.1994.267.5.F831; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; RENARD S, 1994, J BIOL CHEM, V269, P12981; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Stockando JD, 2000, J BIOL CHEM, V275, P25760, DOI 10.1074/jbc.M003615200; Stokes JB, 1999, KIDNEY INT, V56, P2318, DOI 10.1046/j.1523-1755.1999.00803.x; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Volk KA, 2000, AM J PHYSIOL-CELL PH, V278, pC1047, DOI 10.1152/ajpcell.2000.278.5.C1047	49	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43887	43893		10.1074/jbc.M108714200	http://dx.doi.org/10.1074/jbc.M108714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571309	hybrid			2022-12-27	WOS:000172297700054
J	Luo, YJ; Goss, DJ				Luo, YJ; Goss, DJ			Homeostasis in mRNA initiation - Wheat germ poly(A)-binding protein lowers the activation energy barrier to initiation complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) TAIL; BINDING-PROTEIN; TRANSLATION; CAP; EFFICIENCY; SUBUNITS; ANALOGS	Previous kinetic binding studies of wheat germ protein synthesis eukaryotic initiation factor iso4F (eIFiso4F) and its subunit, eIF4E, with m(7)GTP and mRNA analogues indicated that binding occurred by a two-step process with the first step being too fast to measure by stopped-flow techniques (1). Further equilibrium studies showed that poly(A)-binding protein (PABP) enhanced the cap binding of eIFiso4F about 40-fold. The kinetic effects of PABP on cap binding and the temperature dependence of this reaction were measured and compared. Fluorescence stopped-flow studies of the PABP.eIFiso4F protein complex with cap show a concentration-independent conformational change. PABP did not significantly increase the rate of the conformational change, and because the initial second-order binding is essentially diffusion-controlled, the enhancement of cap affinity must reside in the dissociation rate. The dissociation rate was more than 5-fold slower in the presence of PABP. The temperature dependence of the cap binding reaction was markedly reduced in the presence of PABP. The reduced energy barrier for formation of a cap.eIFiso4F complex suggests a more stable platform for fm-ther initiation complex formation and a possible means of adapting to varying temperature conditions.	CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA; CUNY, Grad Ctr, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System	Goss, DJ (corresponding author), CUNY Hunter Coll, Dept Chem, 695 Pk Ave, New York, NY 10021 USA.				NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BALASTA ML, 1993, J BIOL CHEM, V268, P18599; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1989, BIOCHEMISTRY-US, V28, P4771, DOI 10.1021/bi00437a038; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; OLSEN K, 1993, BIOCHEMISTRY-US, V32, P9686, DOI 10.1021/bi00088a021; Ren JH, 1996, NUCLEIC ACIDS RES, V24, P3629, DOI 10.1093/nar/24.18.3629; SHA M, 1995, J BIOL CHEM, V270, P29904; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570	17	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43083	43086		10.1074/jbc.M104970200	http://dx.doi.org/10.1074/jbc.M104970200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11571283	hybrid			2022-12-27	WOS:000172169300060
J	Zhang, Y; Repa, JJ; Gauthier, K; Mangelsdorf, DJ				Zhang, Y; Repa, JJ; Gauthier, K; Mangelsdorf, DJ			Regulation of lipoprotein lipase by the oxysterol receptors, LXR alpha and LXR beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; TUMOR NECROSIS FACTOR; MESSENGER-RNA LEVELS; GENE-EXPRESSION; NUCLEAR RECEPTOR; TRANSGENIC MICE; X-RECEPTOR; FATTY-ACID; DEVELOPMENTAL REGULATION; CHOLESTEROL EFFLUX	Lipoprotein lipase (LPL) is a key enzyme for lipoprotein metabolism and is responsible for hydrolysis of triglycerides in circulating lipoproteins, releasing free fatty acids to peripheral tissues. In liver, LPL is also believed to promote uptake of high density lipoprotein (HDL)-cholesterol and thereby facilitate reverse cholesterol transport. In this study we show that the Lpl gene is a direct target of the oxysterol liver X receptor, LXR alpha. Alice fed diets containing high cholesterol or an LXR-selective agonist exhibited a significant increase in LPL expression in the liver and macrophages, but not in other tissues (e.g. adipose and muscle). Studies in Lxr-deficient mice confirmed that this response was dependent more on the presence of LXR alpha than LXR beta. Analysis of the Lpl gene revealed the presence of a functional DR4 LXR response element in the intronic region between exons 1 and 2. This response element directly binds rexinoid receptor (RXR)/LXR heterodimers and is sufficient for rexinoid- and LXR agonist-induced transcription of the Lpl gene. Together, these studies further distinguish the roles of LXR alpha and beta and support a growing body of evidence that LXRs function as key regulators of lipid metabolism and are anti-atherogenic.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Mangelsdorf, David/0000-0002-4355-0796; Repa, Joyce/0000-0001-5740-1954				Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BURGAYA F, 1989, BIOCHEM J, V259, P159, DOI 10.1042/bj2590159; CAMPS L, 1991, J LIPID RES, V32, P1877; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1001, P316, DOI 10.1016/0005-2760(89)90116-1; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; Costet P, 2000, J BIOL CHEM, V275, P28240; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; ENERBACK S, 1988, GENE, V64, P97, DOI 10.1016/0378-1119(88)90484-2; Goldberg IJ, 1996, J LIPID RES, V37, P693; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUA XX, 1991, GENE, V107, P247, DOI 10.1016/0378-1119(91)90325-6; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LINDQVIST P, 1983, J BIOL CHEM, V258, P9086; LOWE ME, 1989, J BIOL CHEM, V264, P20042; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rinninger F, 1998, J LIPID RES, V39, P1335; Sartippour MR, 2000, ARTERIOSCL THROM VAS, V20, P104, DOI 10.1161/01.ATV.20.1.104; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Strauss JG, 2001, J BIOL CHEM, V276, P36083, DOI 10.1074/jbc.M104430200; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; VILARO S, 1988, BIOCHEM J, V249, P549, DOI 10.1042/bj2490549; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; Yang WS, 1998, J LIPID RES, V39, P2054; Zhang Z, 2001, J LIPID RES, V42, P649	51	243	255	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					43018	43024		10.1074/jbc.M107823200	http://dx.doi.org/10.1074/jbc.M107823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11562371	hybrid			2022-12-27	WOS:000172169300052
J	Fiaschi, T; Chiarugi, P; Buricchi, F; Giannoni, E; Taddei, ML; Talini, D; Cozzi, G; Zecchi-Orlandini, S; Raugei, G; Ramponi, G				Fiaschi, T; Chiarugi, P; Buricchi, F; Giannoni, E; Taddei, ML; Talini, D; Cozzi, G; Zecchi-Orlandini, S; Raugei, G; Ramponi, G			Low molecular weight protein-tyrosine phosphatase is involved in growth inhibition during cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; EXPRESSION; PHOSPHORYLATION; SRC; IDENTIFICATION; GENE	Low molecular weight protein-tyrosine phosphatase (LMW-PTP) is an enzyme involved in mitogenic signaling and cytoskeletal rearrangement after platelet-derived growth factor (PDGF) stimulation. Recently, we demonstrated that LMW-PTP is regulated by a redox mechanism involving the two cysteine residues of the catalytic site, which turn reversibly from reduced to oxidized state after PDGF stimulation. Since recent findings showed a decrease of intracellular reactive oxygen species in contact inhibited cells and a lower tyrosine phosphorylation level in dense cultures in comparison to sparse ones, we studied if the level of endogenous LMW-PTP is regulated by growth inhibition conditions, such as cell confluence and differentiation. Results show that both cell confluence and cell differentiation up-regulate LMW-PTP expression in C2C12 and PC12 cells. We demonstrate that during myogenesis LMW-PTP is regulated at translational level and that the protein accumulates at the plasma membrane. Furthermore, we showed that both myogenesis and cell-cell contact lead to a dramatical decrease of tyrosine phosphorylation level of PDGF receptor. In addition, we observed an increased association of the receptor with LMW-PTP during myogenesis. Herein, we demonstrate that myogenesis decreases the intracellular level of reactive oxygen species, as observed in dense cultures. As a consequence, LMW-PTP turns from oxidized to reduced form during muscle differentiation, increasing its activity in growth inhibition conditions such as differentiation. These data suggest that LMW-PTP plays a crucial role in physiological processes, which require cell growth arrest such as confluence and differentiation.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Dipartimento Anat Istol & Med Legale, I-50134 Florence, Italy	University of Florence; University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@scibio.unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098; raugei, giovanni/0000-0003-1294-786X				Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; CHIARUGI P, 2001, 27 M FED EUR BIOCH S; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kong WH, 2000, AM J PHYSIOL-GASTR L, V279, pG613, DOI 10.1152/ajpgi.2000.279.3.G613; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kume T, 1996, J BIOL CHEM, V271, P30916, DOI 10.1074/jbc.271.48.30916; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; MABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623; Magherini F, 1998, FEBS LETT, V437, P263, DOI 10.1016/S0014-5793(98)01241-1; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sorby M, 1996, J BIOL CHEM, V271, P10963; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; YablonkaReuveni Z, 1997, GROWTH FACTORS, V15, P1, DOI 10.3109/08977199709002109; YEE AS, 1998, FRONT BIOSCI, V3, P532	33	37	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49156	49163		10.1074/jbc.M107538200	http://dx.doi.org/10.1074/jbc.M107538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595742	hybrid			2022-12-27	WOS:000173922100071
J	Gaughan, L; Brady, ME; Cook, S; Neal, DE; Robson, CN				Gaughan, L; Brady, ME; Cook, S; Neal, DE; Robson, CN			Tip60 is a co-activator specific for class I nuclear hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLASE COMPLEX; LIGAND-BINDING DOMAIN; ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; COACTIVATOR; ACETYLTRANSFERASE; PROTEIN; TRANSCRIPTION; CBP	The nuclear hormone receptor superfamily is composed of a group of hormone-dependent transcription factors that play prominent roles in homeostatic events in vertebrates. A prerequisite for steroid hormone receptor activity is the binding of co-activator molecules to the activation function-2 domain of the receptor. The LXXLL motif/nuclear receptor box, contained within a number of co-activator molecules, mediates the interaction with nuclear hormone receptors. Tip60 (Tat-interactive protein 60 kDa), previously shown to bind to and enhance androgen receptor (AR)-mediated transactivation, contains a single nuclear receptor box at its extreme C terminus. We demonstrate that unlike members of the p160 co-activator family that interact predominantly with the N terminus of the AR in an LXXLL motif-independent manner, the LXXLL motif of Tip60 is required and is sufficient for AR interaction. Furthermore, by using the mammalian two-hybrid system and transient transfection experiments, we show that Tip60 preferentially interacts with and up-regulates class I nuclear receptors, suggesting that Tip60 is a steroid hormone receptor-specific co-activator. We conclude that Tip60 may specifically regulate a subset of nuclear hormone receptors, giving an indication to how regulated nuclear receptor activation can be achieved.	Univ Newcastle Upon Tyne, Sch Med, Prostate Res Grp, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Prostate Res Grp, Sch Surg Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086				Alen P, 1999, MOL CELL BIOL, V19, P6085; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gnanapragasam VJ, 2000, BJU INT, V86, P1001, DOI 10.1046/j.1464-410x.2000.00943.x; HARD T, 1993, ACCOUNTS CHEM RES, V26, P644; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Li DS, 1999, MOL CELL BIOL, V19, P7191; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thompson J, 2001, MOL ENDOCRINOL, V15, P923, DOI 10.1210/me.15.6.923; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	44	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46841	46848		10.1074/jbc.M103710200	http://dx.doi.org/10.1074/jbc.M103710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591700	hybrid			2022-12-27	WOS:000172768500024
J	Gruz, P; Pisani, FM; Shimizu, M; Yamada, M; Hayashi, I; Morikawa, K; Nohmi, T				Gruz, P; Pisani, FM; Shimizu, M; Yamada, M; Hayashi, I; Morikawa, K; Nohmi, T			Synthetic activity of Sso DNA polymerase Y1, an archaeal DinB-like DNA polymerase, is stimulated by processivity factors proliferating cell nuclear antigen and replication factor C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SULFOLOBUS-SOLFATARICUS; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; DOMAIN ORGANIZATION; GENE ENCODES; MUTAGENESIS; FAMILY; COMPLEX; BYPASS	DNA replication efficiency is dictated by DNA polymerases (pol) and their associated proteins. The recent discovery of DNA polymerase Y family (DinB/UmuC/RAD30/REV1 superfamily) raises a question of whether the DNA polymerase activities are modified by accessory proteins such as proliferating cell nuclear antigen (PCNA). In fact, the activity of DNA pol IV (DinB) of Escherichia coli is enhanced upon interaction with the beta subunit, the processivity factor of DNA pol III. Here, we report the activity of Sso DNA pol Y1 encoded by the dbh gene of the archaeon Sulfolobus solfataricus is greatly enhanced by the presence of PCNA and replication factor C (RFC). Sso pol Y1 per se was a distributive enzyme but a substantial increase in the processivity was observed on poly(dA)-oligo(dT) in the presence of PCNA (039p or 048p) and RFC. The length of the synthesized DNA product reached at least 200 nucleotides. Sso pol Y1 displayed a higher affinity for DNA compared with pol IV of E. coli, suggesting that the two DNA polymerases have distinct reason(s) to require the processivity factors for efficient DNA synthesis. The abilities of pol Y1 and pol IV to bypass DNA lesions and their sensitive sites to protease are also discussed.	Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, Tokyo 1588501, Japan; CNR, Ist Biochim Prot & Enzimol, I-80125 Naples, Italy; Biomol Engn Res Inst, Dept Struct Biol, Osaka 5650874, Japan	National Institute of Health Sciences - Japan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Nohmi, T (corresponding author), Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.		Pisani, Francesca M./AAX-4025-2020	Yamada, Masami/0000-0002-8758-3979				Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bridges B, 2000, BIOESSAYS, V22, P933; Bruck I, 1996, J BIOL CHEM, V271, P10767, DOI 10.1074/jbc.271.18.10767; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; Edgell DR, 1997, J BACTERIOL, V179, P2632, DOI 10.1128/jb.179.8.2632-2640.1997; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Garcia PL, 2000, BACTERIAL STRESS RESPONSES, P369; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kim SR, 2001, MOL GENET GENOMICS, V266, P207; KORNBERG A, 1992, DNA REPLICATION, P169; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; Lasken RS, 1996, J BIOL CHEM, V271, P17692, DOI 10.1074/jbc.271.30.17692; Leipe DD, 1999, NUCLEIC ACIDS RES, V27, P3389, DOI 10.1093/nar/27.17.3389; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; PETIT MA, 1994, J BIOL CHEM, V269, P23824; Pisani FM, 1998, BIOCHEMISTRY-US, V37, P15005, DOI 10.1021/bi981127s; PISANI FM, 1992, NUCLEIC ACIDS RES, V20, P2711, DOI 10.1093/nar/20.11.2711; Pisani FM, 1998, EXTREMOPHILES, V2, P171, DOI 10.1007/s007920050057; Pisani FM, 1996, BIOCHEMISTRY-US, V35, P9158, DOI 10.1021/bi960446l; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; Sarov-Blat L, 1998, J BIOL CHEM, V273, P5520, DOI 10.1074/jbc.273.10.5520; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tissier A, 2000, GENE DEV, V14, P1642; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wagner J, 2000, J BACTERIOL, V182, P4587, DOI 10.1128/JB.182.16.4587-4595.2000; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2000, EMBO REP, V1, P484; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	51	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47394	47401		10.1074/jbc.M107213200	http://dx.doi.org/10.1074/jbc.M107213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11581267	hybrid			2022-12-27	WOS:000172768500095
J	Smisterova, J; Wagenaar, A; Stuart, MCA; Polushkin, E; ten Brinke, G; Hulst, R; Engberts, JBFN; Hoekstra, D				Smisterova, J; Wagenaar, A; Stuart, MCA; Polushkin, E; ten Brinke, G; Hulst, R; Engberts, JBFN; Hoekstra, D			Molecular shape of the cationic lipid controls the structure of cationic lipid/dioleylphosphatidylethanolamine-DNA complexes and the efficiency of gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOSOME COMPLEXES; TRANSFECTION ACTIVITY; ELECTRON-MICROSCOPY; PLASMID DNA; MECHANISM; RELEASE; CELLS; AMPHIPHILES; PARTICLES; MEMBRANES	Pyridinium amphiphiles, abbreviated as SAINT, are highly efficient vectors for delivery of DNA into cells. Within a group of structurally related compounds that differ in transfection capacity, we have investigated the role of the shape and structure of the pyridinium molecule on the stability of bilayers formed from a given SAINT and dioleoylphosphatidylethanolamine (DOPE) and on the polymorphism of SAINT/DOPE-DNA complexes. Using electron microscopy and small angle x-ray scattering, a relationship was established between the structure, stability, and morphology of the lipoplexes and their transfection efficiency. The structure with the lowest ratio of the cross-sectional area occupied by polar over hydrophobic domains (SAINT-2) formed the most unstable bilayers when mixed with DOPE and tended to convert into the hexagonal structure. In SAINT-2-containing lipoplexes, a hexagonal topology was apparent, provided that DOPE was present and complex assembly occurred in 150 mM NaCl. If not, a lamellar phase was obtained, as for lipoplexes prepared from geometrically more balanced SAINT structures. The hexagonal topology strongly promotes transfection efficiency, whereas a strongly reduced activity is seen for complexes displaying the lamellar topology. We conclude that in the DOPE-containing complexes the molecular shape and the nonbilayer preferences of the cationic lipid control the topology of the lipoplex and thereby the transfection efficiency.	Univ Groningen, Fac Med Sci, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands; Biomade Technol Fdn, NL-9747 AG Groningen, Netherlands; Univ Groningen, Stratingh Inst, Phys Irgan Chem Unit, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biophys Chem, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Polymer Chem, NL-9747 AG Groningen, Netherlands; Dutch Polymer Inst, Polymer Chem Lab, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; Dutch Polymer Institute	Hoekstra, D (corresponding author), Univ Groningen, Fac Med Sci, Dept Membrane Cell Biol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	d.hoekstra@med.rug.nl	Stuart, Marc/B-6274-2008	Stuart, Marc/0000-0003-0667-6338				Balasubramaniam RP, 1996, GENE THER, V3, P163; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; Bennett MJ, 1997, J MED CHEM, V40, P4069, DOI 10.1021/jm970155q; Bhattacharya S, 1998, BIOCHEMISTRY-US, V37, P7764, DOI 10.1021/bi971772j; Blessing T, 1998, P NATL ACAD SCI USA, V95, P1427, DOI 10.1073/pnas.95.4.1427; Boukhnikachvili T, 1997, FEBS LETT, V409, P188, DOI 10.1016/S0014-5793(97)00505-X; Byk G, 1998, J MED CHEM, V41, P224, DOI 10.1021/jm9704964; Chesnoy S, 2000, ANNU REV BIOPH BIOM, V29, P27, DOI 10.1146/annurev.biophys.29.1.27; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Gao X, 1995, GENE THER, V2, P710; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; Hagstrom JE, 1996, BBA-BIOMEMBRANES, V1284, P47, DOI 10.1016/0005-2736(96)00106-X; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; Hui SW, 1996, BIOPHYS J, V71, P590, DOI 10.1016/S0006-3495(96)79309-8; ISRAELACHVILI JN, 1975, BIOCHIM BIOPHYS ACTA, V389, P13, DOI 10.1016/0005-2736(75)90381-8; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; LabatMoleur F, 1996, GENE THER, V3, P1010; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; Lewis RNAH, 2000, BIOPHYS J, V79, P1455, DOI 10.1016/S0006-3495(00)76397-1; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Meekel AAP, 2000, EUR J ORG CHEM, V2000, P665; Miller AD, 1998, ANGEW CHEM INT EDIT, V37, P1769; Mui B, 2000, BBA-BIOMEMBRANES, V1467, P281, DOI 10.1016/S0005-2736(00)00226-1; Oberle V, 2000, BIOPHYS J, V79, P1447, DOI 10.1016/S0006-3495(00)76396-X; Pitard B, 1999, P NATL ACAD SCI USA, V96, P2621, DOI 10.1073/pnas.96.6.2621; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Regelin AE, 2000, BBA-BIOMEMBRANES, V1464, P151, DOI 10.1016/S0005-2736(00)00126-7; REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021; Ren T, 2000, GENE THER, V7, P764, DOI 10.1038/sj.gt.3301153; SMYTHTEMPLETON N, 1997, NAT BIOTECHNOL, V15, P647; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; VANDERWOUDE I, 1995, BBA-BIOMEMBRANES, V1240, P34, DOI 10.1016/0005-2736(95)00161-1; VanDerWoude I, 1997, P NATL ACAD SCI USA, V94, P1160, DOI 10.1073/pnas.94.4.1160; Wang JK, 1998, J MED CHEM, V41, P2207, DOI 10.1021/jm950802i; Wheeler JJ, 1999, GENE THER, V6, P271, DOI 10.1038/sj.gt.3300821; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; Yoshikawa Y, 1996, FEBS LETT, V396, P71, DOI 10.1016/0014-5793(96)01057-5	38	154	168	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					47615	47622		10.1074/jbc.M106199200	http://dx.doi.org/10.1074/jbc.M106199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11583999	hybrid			2022-12-27	WOS:000172768500122
J	Van Dort, HM; Knowles, DW; Chasis, JA; Lee, G; Mohandas, N; Low, PS				Van Dort, HM; Knowles, DW; Chasis, JA; Lee, G; Mohandas, N; Low, PS			Analysis of integral membrane protein contributions to the deformability and stability of the human erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING; CELL DEFORMABILITY; ANION-EXCHANGER; BAND-3 PROTEIN; SPECTRIN; SKELETON; PHOSPHATIDYLSERINE; SPHEROCYTOSIS; TRANSMEMBRANE; DEFICIENCY	Three major hypotheses have been proposed to explain the role of membrane-spanning proteins in establishing/maintaining membrane stability. These hypotheses ascribe the essential contribution of integral membrane proteins to (i) their ability to anchor the membrane skeleton to the lipid bilayer, (ii) their capacity to bind and stabilize membrane lipids, and (iii) their ability to influence and regulate local membrane curvature. In an effort to test these hypotheses in greater detail, we have modified both the membrane skeletal and lipid binding interactions of band 3 (the major membrane-spanning and skeletal binding protein of the human erythrocyte membrane) and have examined the impact of these modifications on erythrocyte membrane morphology., deformability, and stability. The desired changes in membrane skeletal and protein-lipid interactions were induced by 1) reaction of the cells with 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS), an inhibitor of band 3-mediated anion transport that dissociates band 3 into dimers (increasing its surface area in contact with lipid) and severs band 3 linkages to the membrane skeleton; 2) a fragment of ankyrin that ruptures the same ankyrin-band 3 bridge to the membrane skeleton, but drives the band 3 subunit equilibrium toward the tetramer (i.e. decreasing the band 3 surface area in contact with lipid); and 3) an antibody to the ankyrin-binding site on band 3 that promotes the same changes in band 3 skeletal and lipid interactions as the ankyrin fragment. We observed that although DIDS induced echinocytic morphological changes in the treated erythrocytes, it had little impact on either membrane deformability or stability. In contrast, resealing of either the ankyrin fragment or anti-band 3 IgG into erythrocytes caused spontaneous membrane fragmentation and loss of deformability/stability. Because these and other new observations cannot all be reconciled with any single hypothesis on membrane stability, we suggest that more than one hypothesis may be operative and provide an explanation of how each might individually contribute to net membrane stability.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.			Low, Philip/0000-0001-9042-5528	NHLBI NIH HHS [HL 31579] Funding Source: Medline; NIDDK NIH HHS [DK 26263] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08296, GM 24417] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, R01DK026263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008296, R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BESSIS M, 1975, BLOOD CELLS, V1, P307; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; Chang SH, 2001, J BIOL CHEM, V276, P22223, DOI 10.1074/jbc.M100604200; COHEN AM, 1986, BLOOD, V68, P920; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; Discher DE, 1996, BIOPHYS J, V71, P1680, DOI 10.1016/S0006-3495(96)79424-9; DISCHER DE, 1994, SCIENCE, V266, P1032, DOI 10.1126/science.7973655; EVANS E, 1984, J CLIN INVEST, V73, P477, DOI 10.1172/JCI111234; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GOLAN DE, 1986, J CELL BIOL, V103, P819, DOI 10.1083/jcb.103.3.819; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOW PS, 1991, BLOOD, V77, P1581; MAKSYMIW R, 1987, BIOCHEMISTRY-US, V26, P2983, DOI 10.1021/bi00385a005; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MOHANDAS N, 1983, SEMIN HEMATOL, V20, P225; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORROW JS, 1997, HDB PHYSIOL 14, P485; NIGG EA, 1979, BIOCHEMISTRY-US, V18, P3457, DOI 10.1021/bi00583a004; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; REID ME, 1987, BLOOD, V69, P1068; RYBICKI AC, 1988, J CLIN INVEST, V81, P255, DOI 10.1172/JCI113303; Sinard J. H., 1994, Molecular Biology of the Cell, V5, p421A; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; TANNER MJA, 1976, BIOCHEM J, V153, P271, DOI 10.1042/bj1530271; Van Dort HM, 1998, J BIOL CHEM, V273, P14819, DOI 10.1074/jbc.273.24.14819; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; Yi SJ, 1997, BIOCHEMISTRY-US, V36, P9596, DOI 10.1021/bi9704966	37	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46968	46974		10.1074/jbc.M107855200	http://dx.doi.org/10.1074/jbc.M107855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11595743	hybrid			2022-12-27	WOS:000172768500041
J	Bosoy, D; Lue, NF				Bosoy, D; Lue, NF			Functional analysis of conserved residues in the putative "finger" domain of telomerase reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; TEMPLATE RNA COMPONENT; TETRAHYMENA TELOMERASE; YEAST TELOMERASE; SACCHAROMYCES-CEREVISIAE; IN-VITRO; MAMMALIAN TELOMERASE; PROTEIN; COMPLEX; VIVO	Telomerase is a ribonucleoprotein reverse transcriptase (RT) responsible for the maintenance of one strand of telomere terminal repeats. The catalytic protein subunit of telomerase, known generically as telomerase reverse transcriptase (TERT), exhibits significant homology to RTs encoded by retroviruses and retroelements. The polymerization mechanisms of telomerase may therefore be similar to those of the "conventional" RTs. In this study, we explored the extent of mechanistic conservation by analyzing mutations of conserved residues within the putative "finger" domain of TERT. Previous analysis has implicated this domain of retroviral RTs in nucleotide and RNA binding and in processivity control. Our results demonstrate that residues conserved between TERT and human immunodeficiency virus-1 RT are more likely than TERT-specific residues to be required for enzyme activity. In addition, residues presumed to make direct contact with either the RNA or nucleotide substrate appear to be functionally more important. Furthermore, distinct biochemical defects can be observed for alterations in the putative RNA- and nucleotide-binding TERT residues in a manner that can be rationalized by their postulated mechanisms of action. This study thus supports a high degree of mechanistic conservation between telomerase and retroviral RTs and underscores the roles of distinct aspects of telomerase biochemistry in telomere length maintenance.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, William Randolph Hearst Microbiol Res Ctr, New York, NY 10021 USA	Cornell University	Lue, NF (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, William Randolph Hearst Microbiol Res Ctr, 1300 York Ave, New York, NY 10021 USA.		Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062631] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM62631-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bhattacharyya A, 1997, P NATL ACAD SCI USA, V94, P2823, DOI 10.1073/pnas.94.7.2823; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Eickbush TH, 1997, SCIENCE, V277, P911, DOI 10.1126/science.277.5328.911; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1495, DOI 10.1093/nar/26.6.1495; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1487, DOI 10.1093/nar/26.6.1487; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	49	36	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46305	46312		10.1074/jbc.M108168200	http://dx.doi.org/10.1074/jbc.M108168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11581271	hybrid			2022-12-27	WOS:000172573100111
J	Mishra, SK; Agostinelli, NR; Brett, TJ; Mizukami, I; Ross, TS; Traub, LM				Mishra, SK; Agostinelli, NR; Brett, TJ; Mizukami, I; Ross, TS; Traub, LM			Clathrin- and AP-2-binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; SACCHAROMYCES-CEREVISIAE; ARRESTIN/CLATHRIN INTERACTION; MEDIATED ENDOCYTOSIS; APPENDAGE DOMAIN; BINDING PROTEIN; ADAPTER COMPLEX; TERMINAL DOMAIN; YEAST; AP-2	Clathrin-mediated endocytosis is a major pathway for the internalization of macromolecules into the cytoplasm of eukaryotic cells. The principle coat components, clathrin and the AP-2 adaptor complex, assemble a polyhedral lattice at plasma membrane bud sites with the aid of several endocytic accessory proteins. Here, we show that huntingtin-interacting protein 1 (HIP1), a binding partner of huntingtin, copurifies with brain clathrin-coated vesicles and associates directly with both AP-2 and clathrin. The discrete interaction sequences within HIP1 that facilitate binding are analogous to motifs present in other accessory proteins, including AP180, amphiphysin, and epsin. Bound to a phosphoinositide-containing membrane surface via an epsin N-terminal homology (ENTH) domain, HIP1 associates with AP-2 to provide coincident clathrin-binding sites that together efficiently recruit clathrin to the bilayer. Our data implicate HIP1 in endocytosis, and the similar modular architecture and function of HIP1, epsin, and AP180 suggest a common role in lipid-regulated clathrin lattice biogenesis.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); University of Michigan System; University of Michigan	Traub, LM (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, 3500 Terrace St,S325BST, Pittsburgh, PA 15261 USA.		Mishra, Santosh/S-7516-2017; Brett, Thomas/AAC-9147-2019	Mishra, Santosh/0000-0001-8616-2606; Brett, Thomas/0000-0002-6871-6676; Ross, Theodora/0000-0002-9166-1802; Traub, Linton/0000-0002-1303-0298	NATIONAL CANCER INSTITUTE [K08CA076025, R01CA082363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053249] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82363-01A1, KO8 CA76025-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK53249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 2001, J CELL SCI, V114, P1041; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kim M, 1999, NEUROSCIENCE, V89, P1159, DOI 10.1016/S0306-4522(98)00400-X; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McCann RO, 1999, BIOCHEM BIOPH RES CO, V266, P135, DOI 10.1006/bbrc.1999.1776; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Morgan JR, 2000, J NEUROSCI, V20, P8667; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; ter Haar E, 2000, P NATL ACAD SCI USA, V97, P1096, DOI 10.1073/pnas.97.3.1096; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; Yeung BG, 1999, MOL BIOL CELL, V10, P3643, DOI 10.1091/mbc.10.11.3643; Zhu YX, 1999, P NATL ACAD SCI USA, V96, P5013, DOI 10.1073/pnas.96.9.5013	48	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46230	46236		10.1074/jbc.M108177200	http://dx.doi.org/10.1074/jbc.M108177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11577110	hybrid			2022-12-27	WOS:000172573100101
J	Opresko, PL; Laine, JP; Brosh, RM; Seidman, MM; Bohr, VA				Opresko, PL; Laine, JP; Brosh, RM; Seidman, MM; Bohr, VA			Coordinate action of the helicase and 3 ' to 5 ' exonuclease of Werner syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SYNDROME FIBROBLASTS; SYNDROME CELLS; WRN PROTEIN; REPLICATION; REPAIR; KU; BINDING; DAMAGE; 3'->5'-EXONUCLEASE	Werner syndrome is a human disorder characterized by premature aging, genomic instability, and abnormal telomere metabolism. The Werner syndrome protein (WRN) is the only known member of the RecQ DNA helicase family that contains a 3' --> 5'-exonuclease. However, it is not known whether both activities coordinate in a biological pathway. Here, we describe DNA structures, forked duplexes containing telomeric repeats, that are substrates for the simultaneous action of both WRN activities. We used these substrates to study the interactions between the WRN helicase and exonuclease on a single DNA molecule. WRN helicase unwinds at the forked end of the substrate, whereas the WRN exonuclease acts at the blunt end. Progression of the WRN exonuclease is inhibited by the action of WRN helicase converting duplex DNA to single strand DNA on forks of various duplex lengths. The WRN helicase and exonuclease act in concert to remove a DNA strand from a long forked duplex that is not completely unwound by the helicase. We analyzed the simultaneous action of WRN activities on the long forked duplex in the presence of the WRN protein partners, replication protein A (RPA), and the Ku70/80 heterodimer. RPA stimulated the WRN helicase, whereas Ku stimulated the WRN exonuclease. In the presence of both RPA and Ku, the WRN helicase activity dominated the exonuclease activity.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Brosh, Robert/AAR-6124-2020; Bohr, Vilhelm/AAP-5931-2020	Opresko, Patricia/0000-0002-6470-2189	NATIONAL INSTITUTE ON AGING [Z01AG000726, Z01AG000741, ZIAAG000741, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hisama FM, 2000, CANCER RES, V60, P2372; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin GM, 1997, FASEB J, V11, pA1449; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN GM, 1970, LAB INVEST, V23, P86; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Oshima J, 2000, BIOESSAYS, V22, P894, DOI 10.1002/1521-1878(200010)22:10<894::AID-BIES4>3.0.CO;2-B; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Schulz VP, 1996, HUM GENET, V97, P750; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Smith J, 2000, BIOCHIMIE, V82, P71, DOI 10.1016/S0300-9084(00)00183-8; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Watt PM, 1996, GENETICS, V144, P935; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	45	83	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44677	44687		10.1074/jbc.M107548200	http://dx.doi.org/10.1074/jbc.M107548200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11572872	hybrid			2022-12-27	WOS:000172406700047
J	Prall, OWJ; Carroll, JS; Sutherland, RL				Prall, OWJ; Carroll, JS; Sutherland, RL			A low abundance pool of nascent p21(WAF1/Cip1) is targeted by estrogen to activate cyclin E-Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; DEPENDENT KINASES; CDK INHIBITORS; PHASE-TRANSITION; D1 EXPRESSION; S-PHASE; C-MYC; P27(KIP1); RECEPTOR	Estrogens regulate cell proliferation in target tissues, including breast cancer by stimulating G(1)-S phase transition. Activation of cyclin E-Cdk2 through abrogation of the ability of p21(WAF1/Cip1) to bind to and inhibit cyclin-CDKs is a pivotal event in this process in MCF-7 breast cancer cells. A proposed mechanism is p21 sequestration into cyclin D1.Cdk4/6 complexes driven by estrogen-induced transcriptional activation of cyclin D1 gene expression. However, we now show that some E-2-induced cyclin E.Cdk2 activation occurs in the absence of increased cyclin D1 levels and requires decreased p21 protein synthesis. Both mechanisms operate in the absence of major changes in total p21 protein levels and instead target a low abundance subset of newly synthesized p21. E2-induced activation of cyclin E-Cdk2 is mimicked by targeted inhibition of nascent p21 expression by antisense p21 oligonucleotides. Cyclin E-Cdk2 activation is completely inhibited by a combination of antisense cyclin D1 oligonucleotide transfection and elimination of the decrease in nascent p21 by infection with adenoviral-p21. These findings strongly support a central role for p21 in the early phase of E-2-induced mitogenesis and highlight a major functional role for newly synthesized CDK inhibitory proteins.	St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), St Vincents Hosp, Canc Res Program, Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008	Carroll, Jason/0000-0003-3643-0080				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Altucci L, 1996, ONCOGENE, V12, P2315; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FALCKPEDERSEN E, 1998, CELLS LAB MANUAL; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Geng Y, 1996, ONCOGENE, V12, P1173; GREENBERG ME, 1999, CURRENT PROTOCOLS MO; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KEYOMARSI K, 1994, CANCER RES, V54, P380; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Liu JB, 2000, ONCOGENE, V19, P661, DOI 10.1038/sj.onc.1203373; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; WIMMEL A, 1994, ONCOGENE, V9, P995; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	60	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45433	45442		10.1074/jbc.M104752200	http://dx.doi.org/10.1074/jbc.M104752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11581254	hybrid			2022-12-27	WOS:000172406700141
J	Yabuta, Y; Takagi, H; Inouye, M; Shinde, U				Yabuta, Y; Takagi, H; Inouye, M; Shinde, U			Folding pathway mediated by an intramolecular chaperone - Propeptide release modulates activation precision of pro-subtilisin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; CRYSTAL-STRUCTURE; PRECURSOR; SEQUENCE; COMPLEX; BPN'	Propeptides of several proteases directly catalyze the protein folding reaction. Uncatalyzed folding traps these proteases into inactive molten-globule-like conformers that switch into active enzymes only when their cognate propeptides are added in trans. Although tight binding and proteolytic susceptibility forces propeptides to function as single turnover catalysts, the significance of their inhibitory function and the mechanism of activation remain unclear. Using pro-subtilisin as a model, we establish that precursor activation is a highly coordinated process that involves synchronized folding, autoprocessing, propeptide release, and protease activation. Our results demonstrate that activation is controlled by release of the first free active protease molecule. This triggers an exponential cascade that selectively targets the inhibitory propeptide in the autoprocessed complex as its substrate. However, a mutant precursor that enhances propeptide release can drastically reduce the folding efficiency by altering the synergy between individual stages. Our results represent the first demonstration that propeptide release, not precursor folding, is the rate-determining step and provides the basis for the proposed model for precise spatial and temporal activation that allows proteases to function as regulators of biological function.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Fukui Prefectural Univ, Dept Biosci, Fukui 9101195, Japan; Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Oregon Health & Science University; Fukui Prefectural University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Shinde, U (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, MRB631,3181 SW Sam Jackson Pk Rd,Mail Code L224, Portland, OR 97201 USA.	shindeu@ohsu.edu						Anderson DE, 1999, BIOCHEMISTRY-US, V38, P4728, DOI 10.1021/bi982165e; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; Herszenyi L, 1999, CANCER, V86, P1135, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2; Inouye M, 2001, NAT STRUCT BIOL, V8, P321, DOI 10.1038/86194; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; JOHNSON WJ, 1982, SCIENCE, V218, P574, DOI 10.1126/science.6289443; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Kojima S, 1998, J MOL BIOL, V277, P1007, DOI 10.1006/jmbi.1998.1671; LI YY, 1994, J BIOL CHEM, V269, P4169; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMITH SM, 1989, J BIOL CHEM, V264, P20487; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; WELLS JA, 1988, TRENDS BIOCHEM SCI, V13, P291, DOI 10.1016/0968-0004(88)90121-1; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	33	89	92	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44427	44434		10.1074/jbc.M107573200	http://dx.doi.org/10.1074/jbc.M107573200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577106	hybrid			2022-12-27	WOS:000172406700012
J	Ishimi, Y; Komamura-Kohno, Y; Arai, K; Masai, H				Ishimi, Y; Komamura-Kohno, Y; Arai, K; Masai, H			Biochemical activities associated with mouse Mcm2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME-MAINTENANCE PROTEINS; HUMAN CDC7-RELATED KINASE; IN-VITRO PHOSPHORYLATION; DNA HELICASE ACTIVITY; S-PHASE CHECKPOINT; FISSION YEAST; CELL-CYCLE; HETEROHEXAMERIC COMPLEXES; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE	Mcm2, a member of the Mcm2-7 protein family essential for the initiation of DNA replication, has several biochemical activities including the ability to inhibit the Mcm4,6,7 helicase. In this study, we characterized the activities associated with Mcm2 and determined the region required for them. It was found that Mcm2 deleted at an amino-terminal portion is able to bind to an Mcm4,6,7 hexameric complex and to inhibit its DNA helicase activity. The same deletion mutant of Mcm2 and the carboxyl-terminal half of Mcm2 were both able to bind to Mcm4, suggesting that the carboxyl-half of Mcm2 binds to Mcm4 to disassemble the Mcm4,6,7 hexamer. Phosphorylation of Mcm2,4,6,7 complexes with Cdc7 kinase showed that the amino-terminal region of Mcm2 is required for the phosphorylation, and it contains major Cdc7-mediated phosphorylation sites. We also found that Mcm2 itself can assemble a nucleosome-like structure in vitro in the presence of H3/H4 histones. The amino-terminal region of Mcm2 was required for the activity where a histone-binding domain is located. Finally, we identified a region required for the nuclear localization of Mcm2. The function of Mcm2 is discussed based on these biochemical characteristics.	Mitsubishi Kagaku Inst Life Sci, Tokyo 1948511, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Minato Ku, Tokyo 1088639, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Tokyo	Ishimi, Y (corresponding author), Mitsubishi Kagaku Inst Life Sci, 11 Minamiooya, Tokyo 1948511, Japan.	yukio@libra.ls.m-kagaku.co.jp						Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BINASTEIN M, 1977, CELL, V11, P609, DOI 10.1016/0092-8674(77)90078-2; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; ISHIMI Y, 1984, EUR J BIOCHEM, V162, P19; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H., 1999, FRONT BIOSCI, V4, pD834; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sclafani RA, 2000, J CELL SCI, V113, P2111; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WAHLE E, 1989, J BIOL CHEM, V264, P2469; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; You ZY, 1999, MOL CELL BIOL, V19, P8003; Young MR, 1997, GENES CELLS, V2, P631, DOI 10.1046/j.1365-2443.1997.1510349.x; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	57	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2001	276	46					42744	42752		10.1074/jbc.M106861200	http://dx.doi.org/10.1074/jbc.M106861200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	492LF	11568184	hybrid			2022-12-27	WOS:000172169300016
J	Lane, S; Birse, C; Zhou, S; Matson, R; Liu, HP				Lane, S; Birse, C; Zhou, S; Matson, R; Liu, HP			DNA array studies demonstrate convergent regulation of virulence factors by Cph1, Cph2, and Efg1 in Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTOUS-GROWTH; HYPHAL DEVELOPMENT; MORPHOLOGICAL DEVELOPMENT; PROTEINASE EXPRESSION; BINDING PROTEIN; MAP KINASE; GENE; TRANSCRIPTION; MORPHOGENESIS; CONTRIBUTES	Candida albicans, normally a human commensal, can cause fatal systemic infections under certain circumstances. Its unique ability to switch from yeast to hyphal growth in response to various environmental signals is inherent to its pathogenicity. Filamentation is regulated by multiple pathways including a Cph1-mediated mitogen-activated protein kinase pathway, an Efg1-mediated cAmP/PKA pathway, and a Cph2 pathway. To gain a general picture of how these various signaling pathways regulate differential gene expression during filamentation, we have constructed a partial C. albicans DNA array of 7,000 genes and used it to study the gene expression profiles using various mutants and growth conditions. By combining this novel technology with a new liquid medium in which cph1/cph1 is defective in filamentation, previously identified differentially expressed genes (ECE1, HWP1, HYR1, RBT1, SAPs5-6, and RBT4) are found to be regulated by all three pathways. In addition, two novel genes, DDR48 and YPL184, have been found to be differentially regulated during hyphal development and by all three pathways. This suggests that distinct filamentation signaling pathways converge to regulate a common set of differentially expressed genes. As one of the mechanisms for the observed convergence, we find that the transcription of a key regulator, TEC1, is regulated by Efg1 and Cph2. Importantly, most of the genes regulated by multiple filamentation pathways encode known virulence factors. Perhaps, C. albicans utilizes converging pathways to regulate its vital virulence factors to ensure its survival and pathogenicity in various host environments.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Beckman Coulter Inc, Ctr Adv Technol, Fullerton, CA 92834 USA	University of California System; University of California Irvine; Beckman Coulter Inc.	Liu, HP (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	h4liu@uci.edu			NIGMS NIH HHS [GM55155] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055155] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey DA, 1996, J BACTERIOL, V178, P5353, DOI 10.1128/jb.178.18.5353-5360.1996; BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; Bockmuhl DP, 2001, GENETICS, V157, P1523; Braun BR, 2000, GENETICS, V156, P31; Braun BR, 2000, GENETICS, V155, P57; Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105; Brown AJP, 1999, TRENDS MICROBIOL, V7, P333, DOI 10.1016/S0966-842X(99)01556-5; Brown D. H. Jr., 1999, Molecular Microbiology, V34, P651, DOI 10.1046/j.1365-2958.1999.01619.x; Bubert A, 1999, MOL GEN GENET, V261, P323, DOI 10.1007/s004380050973; Buckman J, 1998, BIOCHEMISTRY-US, V37, P14326, DOI 10.1021/bi981106y; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Csank C, 1998, INFECT IMMUN, V66, P2713, DOI 10.1128/IAI.66.6.2713-2721.1998; Davis D, 2000, MOL CELL BIOL, V20, P971, DOI 10.1128/MCB.20.3.971-978.2000; DELBRUCK S, 1993, MOL MICROBIOL, V10, P859, DOI 10.1111/j.1365-2958.1993.tb00956.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El Barkani A, 2000, MOL CELL BIOL, V20, P4635, DOI 10.1128/MCB.20.13.4635-4647.2000; FONZI WA, 1993, GENETICS, V134, P717; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; Hoyer LL, 1998, CURR GENET, V33, P451, DOI 10.1007/s002940050359; HUBE B, 1994, MOL MICROBIOL, V14, P87, DOI 10.1111/j.1365-2958.1994.tb01269.x; Kadosh D, 2001, MOL CELL BIOL, V21, P2496, DOI 10.1128/MCB.21.7.2496-2505.2001; Khalaf RA, 2001, GENETICS, V157, P1503; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Lane S, 2001, MOL CELL BIOL, V21, P6418, DOI 10.1128/MCB.21.19.6418-6428.2001; Leberer E, 1997, CURR BIOL, V7, P539, DOI 10.1016/S0960-9822(06)00252-1; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; Leng P, 2001, J BACTERIOL, V183, P4090, DOI 10.1128/JB.183.13.4090-4093.2001; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Marcus SL, 2000, MICROBES INFECT, V2, P145, DOI 10.1016/S1286-4579(00)00273-2; MILLER KY, 1992, GENE DEV, V6, P1770, DOI 10.1101/gad.6.9.1770; Murad AMA, 2001, EMBO J, V20, P4742, DOI 10.1093/emboj/20.17.4742; Naglik JR, 1999, INFECT IMMUN, V67, P2482, DOI 10.1128/IAI.67.5.2482-2490.1999; Olson KA, 2000, MOL CELL BIOL, V20, P4199, DOI 10.1128/MCB.20.12.4199-4209.2000; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Pi HW, 1997, MOL CELL BIOL, V17, P6410, DOI 10.1128/MCB.17.11.6410; Powderly WG, 1999, AIDS RES HUM RETROV, V15, P1405, DOI 10.1089/088922299309900; Ramon AM, 1999, J BACTERIOL, V181, P7524, DOI 10.1128/JB.181.24.7524-7530.1999; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Schaller M, 1999, MOL MICROBIOL, V34, P169, DOI 10.1046/j.1365-2958.1999.01590.x; Schroppel K, 2000, INFECT IMMUN, V68, P7159, DOI 10.1128/IAI.68.12.7159-7161.2000; Schweizer A, 2000, MOL MICROBIOL, V38, P435, DOI 10.1046/j.1365-2958.2000.02132.x; Sharkey LL, 1999, J BACTERIOL, V181, P5273, DOI 10.1128/JB.181.17.5273-5279.1999; Sonneborn A, 2000, MOL MICROBIOL, V35, P386, DOI 10.1046/j.1365-2958.2000.01705.x; Sonneborn A, 1999, INFECT IMMUN, V67, P4655, DOI 10.1128/IAI.67.9.4655-4660.1999; SRIKANTHA T, 1995, MOL GEN GENET, V246, P342, DOI 10.1007/BF00288607; Staab JF, 1998, YEAST, V14, P681, DOI 10.1002/(SICI)1097-0061(199805)14:7&lt;681::AID-YEA256&gt;3.0.CO;2-8; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999	53	172	194	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					48988	48996		10.1074/jbc.M104484200	http://dx.doi.org/10.1074/jbc.M104484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595734	hybrid			2022-12-27	WOS:000173922100050
J	Wilson, KA; Maerz, AL; Poumbourios, P				Wilson, KA; Maerz, AL; Poumbourios, P			Evidence that the transmembrane domain proximal region of the human T-cell leukemia virus type 1 fusion glycoprotein gp21 has distinct roles in the prefusion and fusion-activated states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED MEMBRANE-FUSION; MALTOSE-BINDING PROTEIN; DODECYL-SULFATE MICELLE; AMINO-TERMINAL REGION; INFLUENZA HEMAGGLUTININ; ENVELOPE GLYCOPROTEIN; IMMUNODEFICIENCY-VIRUS; SYNCYTIUM FORMATION; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE	To investigate the structural context of the fusion peptide region in human T-cell leukemia virus type 1 gp21, maltose-binding protein (MBP) was used as an N-terminal solubilization partner for the entire gp21 ectodomain (residues 313-445) and C-terminally truncated ectodomain fragments. The bacterial expression of the MBP/gp21 chimeras resulted in soluble trimers containing intramonomer disulfide bonds. Detergents blocked the proteolytic cleavage of fusion peptide residues in the NIBP/gp21-(313-425) chimera, indicating that the fusion peptide is available for interaction with detergent despite the presence of an N-terminal MBP domain. Limited proteolysis experiments indicated that the transmembrane domain proximal sequence Thr(425)-Ala(439) protects fusion peptide residues from chymotrypsin. MBP/gp21 chimera stability therefore depends on a functional interaction between N-terminal and transmembrane domain proximal regions in a gp21 helical hairpin structure. In addition, thermal aggregation experiments indicated that the Thr(425)-Ser(436) sequence confers stability to the fusion peptide-containing MBP/gp21 chimeras. The functional role of the transmembrane domain proximal sequence was assessed by alanine-scanning mutagenesis of the full-length envelope glycoprotein, with 11 of 12 single alanine substitutions resulting in 1.5- to 4.5-fold enhancements in cell-cell fusion activity. By contrast, single alanine substitutions in MBP/gp21 did not significantly alter chimera stability, indicating that multiple residues within the transmembrane domain proximal region and the fusion peptide and adjacent glycine-rich segment contribute to stability, thereby mitigating the potential effects of the substitutions. The fusion-enhancing effects of the substitutions are therefore likely to be caused by alteration of the prefusion complex. Our observations suggest that the function of the transmembrane domain proximal sequence in the prefusion envelope glycoprotein is distinct from its role in stabilizing the fusion peptide region in the fusion-activated helical hairpin conformation of gp21.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Poumbourios, P (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	apoum@ariel.ucs.unimelb.edu.au						ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chang DK, 2000, J BIOL CHEM, V275, P19150, DOI 10.1074/jbc.M907148199; Chang DK, 1999, J BIOL CHEM, V274, P5299, DOI 10.1074/jbc.274.9.5299; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; Chen J, 1998, BIOCHEMISTRY-US, V37, P13643, DOI 10.1021/bi981098l; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; Colotto A, 1996, BIOCHEMISTRY-US, V35, P980, DOI 10.1021/bi951991+; Colotto A, 1997, BIOCHEMISTRY-US, V36, P7644, DOI 10.1021/bi970382u; Daenke S, 1999, J GEN VIROL, V80, P1429, DOI 10.1099/0022-1317-80-6-1429; Damico R, 2000, J VIROL, V74, P6469, DOI 10.1128/JVI.74.14.6469-6475.2000; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; Delamarre L, 1997, J VIROL, V71, P259, DOI 10.1128/JVI.71.1.259-266.1997; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; FAN N, 1992, J CLIN MICROBIOL, V30, P905, DOI 10.1128/JCM.30.4.905-910.1992; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Hildreth JEK, 1998, J VIROL, V72, P9544, DOI 10.1128/JVI.72.12.9544-9552.1998; Jassal SR, 2001, J VIROL, V75, P8317, DOI 10.1128/JVI.75.17.8317-8328.2001; Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; Maerz AL, 2000, J VIROL, V74, P6614, DOI 10.1128/JVI.74.14.6614-6621.2000; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Manns A, 1999, LANCET, V353, P1951, DOI 10.1016/S0140-6736(98)09460-4; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Pique C, 2000, VIROLOGY, V276, P455, DOI 10.1006/viro.2000.0538; PIQUE C, 1992, J VIROL, V66, P906, DOI 10.1128/JVI.66.2.906-913.1992; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; Rosenberg JR, 1997, J VIROL, V71, P7180, DOI 10.1128/JVI.71.10.7180-7186.1997; Sagara Y, 1998, J VIROL, V72, P535, DOI 10.1128/JVI.72.1.535-541.1998; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	52	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 28	2001	276	52					49466	49475		10.1074/jbc.M108449200	http://dx.doi.org/10.1074/jbc.M108449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	522XK	11595747	hybrid			2022-12-27	WOS:000173922100109
J	Logan-Smith, MJ; Lockyer, PJ; East, JM; Lee, AG				Logan-Smith, MJ; Lockyer, PJ; East, JM; Lee, AG			Curcumin, a molecule that inhibits the Ca2+-ATPase of sarcoplasmic reticulum but increases the rate of accumulation of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; INOSITOL 1,4,5-TRISPHOSPHATE; ADENOSINE-TRIPHOSPHATASE; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; CA-2+ RELEASE; THAPSIGARGIN; VESICLES; MUSCLE; TRANSPORT	Curcumin, an important inhibitor of carcinogenesis, is an inhibitor of the ATPase activity of the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum (SR). Inhibition by curcumin is structurally specific, requiring the presence of a pair of -OH groups at the 4-position of the rings. Inhibition is not competitive with ATP. Unexpectedly, addition of curcumin to SR vesicles leads to an increase in the rate of accumulation of Ca2+, unlike other inhibitors of the Ca2+-ATPase that result in a reduced rate of accumulation. An increase in the rate of accumulation of Ca2+ is seen in the presence of phosphate ion, which lowers the concentration of free Ca2+ within the lumen of the SR, showing that the effect is not passive leak across the SR membrane. Rather, simulations suggest that the effect is to reduce the rate of slippage on the ATPase, a process in which a Ca2+ bound, phosphorylated intermediate releases its bound Ca2+ on the cytoplasmic rather than on the lumenal side of the membrane. The structural specificity of the effects of curcumin on ATPase activity and on Ca2+ accumulation is the same, and the apparent dissociation constants for the two effects are similar, suggesting that the two effects of curcumin could follow from binding to a single site on the ATPase.	Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Southampton; University of Bristol	Lee, AG (corresponding author), Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England.	agl@soton.ac.uk						ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANTONIU B, 1985, BIOCHIM BIOPHYS ACTA, V816, P9, DOI 10.1016/0005-2736(85)90387-6; BIGELOW DJ, 1987, J BIOL CHEM, V262, P13449; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; BROWN GR, 1994, BBA-BIOMEMBRANES, V1195, P252, DOI 10.1016/0005-2736(94)90264-X; CHAMBERLAIN BK, 1984, J BIOL CHEM, V259, P7547; CHRISTENSEN SB, 1993, FEBS LETT, V335, P345, DOI 10.1016/0014-5793(93)80416-R; Coll KE, 1999, BIOCHEMISTRY-US, V38, P2444, DOI 10.1021/bi9823028; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; de Meis L, 1998, BIOCHEM BIOPH RES CO, V243, P598, DOI 10.1006/bbrc.1997.8028; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, SARCOPLASMIC RETICUL, P1; DUGGAN PF, 1970, J GEN PHYSIOL, V56, P147, DOI 10.1085/jgp.56.2.147; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GODT RE, 1974, J GEN PHYSIOL, V63, P722, DOI 10.1085/jgp.63.6.722; GOULD GW, 1987, BIOCHEM J, V245, P739, DOI 10.1042/bj2450739; GOULD GW, 1987, J BIOL CHEM, V262, P7676; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; HARDWICKE PM, 1974, EUR J BIOCHEM, V42, P183; HASSELBACH W, 1974, MEMBRANE PROTEINS TR, P103; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1983, J BIOL CHEM, V258, P4804; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JONES OT, 1986, PESTIC BIOCHEM PHYS, V25, P420, DOI 10.1016/0048-3575(86)90017-9; KHAN YM, 1995, BIOCHEMISTRY-US, V34, P14385, DOI 10.1021/bi00044a015; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUTSCHABSKY L, 1986, CRYST RES TECHNOL, V21, P627, DOI 10.1002/crat.2170210513; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; Logan-Smith MJ, 2000, FASEB J, V14, pA1574; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; Manson MM, 2000, BIOCHEM SOC T, V28, P7, DOI 10.1042/bst0280007; MARTINEZAZORIN F, 1992, J BIOL CHEM, V267, P11923; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MATHIESON AM, 1968, ACTA CRYSTALL B-STRU, VB 24, P1456, DOI 10.1107/S0567740868004474; MCWHIRTER JM, 1987, BIOCHEM J, V245, P731, DOI 10.1042/bj2450731; MCWHIRTER JM, 1987, BIOCHEM J, V245, P713, DOI 10.1042/bj2450713; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELGUNOV VI, 1988, FEBS LETT, V227, P157, DOI 10.1016/0014-5793(88)80888-3; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3091, DOI 10.1021/bi00464a028; MIKOS GJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P256, DOI 10.1016/0167-4889(87)90142-X; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; PAPP B, 1991, J BIOL CHEM, V266, P14593; PATIL AO, 1984, J CHEM SOC PERK T 2, P1107, DOI 10.1039/p29840001107; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAITO K, 1984, J BIOCHEM, V95, P1297, DOI 10.1093/oxfordjournals.jbchem.a134735; SCHERER NM, 1985, BIOCHEM BIOPH RES CO, V128, P1064, DOI 10.1016/0006-291X(85)91048-4; SOKOLOVE PM, 1986, FEBS LETT, V203, P121, DOI 10.1016/0014-5793(86)80726-8; STARLING AP, 1994, BIOCHEMISTRY-US, V33, P3023, DOI 10.1021/bi00176a035; STEFANOVA HI, 1991, BIOCHIM BIOPHYS ACTA, V1064, P321, DOI 10.1016/0005-2736(91)90318-3; STONER GD, 1995, J CELL BIOCHEM, P169; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WICTOME M, 1995, BIOCHEM J, V310, P859, DOI 10.1042/bj3100859; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; WICTOME M, 1994, BIOCHEM BIOPH RES CO, V199, P916, DOI 10.1006/bbrc.1994.1316; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397	64	76	92	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46905	46911		10.1074/jbc.M108778200	http://dx.doi.org/10.1074/jbc.M108778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11592968	hybrid			2022-12-27	WOS:000172768500032
J	St John, RJ; Carpenter, JF; Balny, C; Randolph, TW				St John, RJ; Carpenter, JF; Balny, C; Randolph, TW			High pressure refolding of recombinant human growth hormone from insoluble aggregates - Structural transformations, kinetic barriers, and energetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH HYDROSTATIC-PRESSURE; PROTEIN AGGREGATION; CRYSTAL-STRUCTURE; DENATURATION; STATE; UREA; STABILIZATION; INTERMEDIATE; TEMPERATURE; DEPENDENCE	Two different types of insoluble, non-native aggregates of recombinant human growth hormone were formed by agitation in buffer or buffer containing 0.75 m guanidine HCl (GdnHCl) and characterized by infrared and second derivative UV spectroseopies. The degree of secondary structural perturbation was greater in the aggregates formed in 0.75 m GdnHCl. Both aggregate types were dissolved and refolded using high hydrostatic pressures in combination with either elevated temperature or non-denaturing levels of guanidine HCl or urea. The effects of a range of temperature, pressure, and chaotrope concentrations were tested and led to optimal conditions that approached 100%, yield of native protein. The aggregates formed in 0.75 m GdnHCl required higher concentrations of urea or GdnHCl, or higher temperature or pressure for a yield equivalent to that for aggregates formed in buffer alone. Investigation of the effects of pressure, temperature, and chaotrope on unfolding of rhGH documented that under conditions used for optimal high pressure disaggregation and refolding, the native state is greatly favored thermodynamically (e.g. 25 kJ/mol at 2000 bar and 0.75 m GdnHCl). Dissolution of aggregates under pressure is a kinetically limited process. Comparison of refolding yields in GdnHCl and urea solutions suggest that pressure effects on electrostatic interactions do not dominate pressure effects on disaggregation. We suggest that non-native hydrogen bonds between protein molecules within aggregates of recombinant human growth hormone are responsible for the rate-limiting kinetic barrier in pressure-induced disaggregation.	Univ Colorado, Dept Chem Engn, Ctr Engn, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA; INSERM, U128, IFR 24, F-34293 Montpellier 05, France	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Institut National de la Sante et de la Recherche Medicale (Inserm)	Randolph, TW (corresponding author), Univ Colorado, Dept Chem Engn, Ctr Engn, ECCH 111, Boulder, CO 80309 USA.	randolph@pressure.colorado.edu						ARAKAWA T, 1984, BIOCHEMISTRY-US, V23, P5924, DOI 10.1021/bi00320a005; BALNY C, 1993, FOOD REV INT, V9, P611, DOI 10.1080/87559129309540980; Bam NB, 1998, J PHARM SCI, V87, P1554, DOI 10.1021/js980175v; Bam NB, 1996, BIOTECHNOL PROGR, V12, P801, DOI 10.1021/bp960068b; Carpenter JF, 1999, METHOD ENZYMOL, V309, P236; Cioni P, 1996, J MOL BIOL, V263, P789, DOI 10.1006/jmbi.1996.0616; Clark ED, 2001, CURR OPIN BIOTECH, V12, P202, DOI 10.1016/S0958-1669(00)00200-7; Clark EDB, 1998, CURR OPIN BIOTECH, V9, P157; CLELAND JL, 1993, ACS SYM SER, V516, P151; CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong AC, 1997, ARCH BIOCHEM BIOPHYS, V347, P213, DOI 10.1006/abbi.1997.0349; FIELDS GB, 1992, J PHYS CHEM-US, V96, P3974, DOI 10.1021/j100189a013; GEKKO K, 1989, J PHYS CHEM-US, V93, P426, DOI 10.1021/j100338a082; Gorovits BM, 1998, BIOCHEMISTRY-US, V37, P6132, DOI 10.1021/bi9730137; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; Gupta R, 1999, BIOCHEMISTRY-US, V38, P2471, DOI 10.1021/bi982078m; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; Kendrick BS, 1998, P NATL ACAD SCI USA, V95, P14142, DOI 10.1073/pnas.95.24.14142; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; Lange R, 1996, EUR BIOPHYS J BIOPHY, V24, P277; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEACH SJ, 1960, J AM CHEM SOC, V82, P4790, DOI 10.1021/ja01503a008; LI TM, 1976, BIOCHEMISTRY-US, V15, P5571, DOI 10.1021/bi00670a023; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Mohana-Borges R, 1999, J BIOL CHEM, V274, P7732, DOI 10.1074/jbc.274.12.7732; MOORE WV, 1980, J CLIN ENDOCR METAB, V51, P691, DOI 10.1210/jcem-51-4-691; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; NOWICKI C, 1981, INT J PEPT PROT RES, V18, P52; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RATNER RE, 1990, DIABETES, V39, P728, DOI 10.2337/diabetes.39.6.728; Rick SW, 2000, J PHYS CHEM B, V104, P6884, DOI 10.1021/jp000841s; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; Rudolph R, 1995, PROTEIN ENG PRINCIPL, P283; Speed MA, 1997, BIOTECHNOL BIOENG, V54, P333; SPEED MA, 1995, PROTEIN SCI, V4, P900; St John RJ, 1999, P NATL ACAD SCI USA, V96, P13029, DOI 10.1073/pnas.96.23.13029; TANFORD C, 1964, J AM CHEM SOC, V86, P2050, DOI 10.1021/ja01064a028; THORNTON CA, 1993, ARCH NEUROL-CHICAGO, V50, P135, DOI 10.1001/archneur.1993.00540020013009; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; VANELDIK R, 1989, CHEM REV, V89, P549, DOI 10.1021/cr00093a005; Volkin DB, 1997, MOL BIOTECHNOL, V8, P105, DOI 10.1007/BF02752255; Webb JN, 2001, P NATL ACAD SCI USA, V98, P7259, DOI 10.1073/pnas.131194798; YANARI S, 1960, J BIOL CHEM, V235, P2818; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; Zhang ZY, 2001, BIOPHYS CHEM, V89, P145, DOI 10.1016/S0301-4622(00)00227-1; Zou Q, 1998, PROTEINS, V31, P107, DOI 10.1002/(SICI)1097-0134(19980501)31:2<107::AID-PROT1>3.0.CO;2-J	51	73	82	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 14	2001	276	50					46856	46863		10.1074/jbc.M107671200	http://dx.doi.org/10.1074/jbc.M107671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	502XR	11591710	hybrid			2022-12-27	WOS:000172768500026
J	Gross, I; Bassit, B; Benezra, M; Licht, JD				Gross, I; Bassit, B; Benezra, M; Licht, JD			Mammalian Sprouty proteins inhibit cell growth and differentiation by preventing Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; DROSOPHILA SPROUTY; SIGNALING PATHWAY; KINASE ACTIVATION; PC12 CELLS; RECEPTOR; FGF; EXPRESSION; PATTERN; IDENTIFICATION	Sprouty was genetically identified as an antagonist of fibroblast growth factor signaling during tracheal branching in Drosophila. In this study, we provide a functional characterization of mammalian Sprouty1 and Sprouty2. Sprouty1 and Sprouty2 inhibited events downstream of multiple receptor tyrosine kinases and regulated both cell proliferation and differentiation. Using NIH3T3 cell lines conditionally expressing Sprouty1 or Sprouty2, we found that these proteins specifically inhibit the Ras/Raf/MAP kinase pathway by preventing Ras activation. In contrast, activation of the phosphatidylinositol 3-kinase pathway was not affected by Sprouty1 or Sprouty2. We further showed that Sprouty1 and Sprouty2 do no prevent the formation of a SNT.Grb2.Sos complex upon fibroblast growth factor stimulation, yet block Ras activation. Taken together, these results establish mammalian Sprouty proteins as important negative regulators of growth factor signaling and suggest that Sprouty proteins act downstream of the Grb2.Sos complex to selectively uncouple growth factor signals from Ras activation and the MAP Kinase pathway.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Gross, Isabelle/P-9859-2019; Licht, Jonathan/L-4239-2019; Gross, Isabelle/I-4972-2016	Gross, Isabelle/0000-0002-2783-8773; Gross, Isabelle/0000-0002-2783-8773; Licht, Jonathan/0000-0002-3942-1369	NCI NIH HHS [CA59998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Green DR, 2000, METHOD ENZYMOL, V322, P15; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Reich A, 1999, DEVELOPMENT, V126, P4139; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Taguchi A, 2000, GENETICS, V154, P1639; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Wang JK, 1996, ONCOGENE, V13, P721; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	36	215	221	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					46460	46468		10.1074/jbc.M108234200	http://dx.doi.org/10.1074/jbc.M108234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11585837	hybrid			2022-12-27	WOS:000172573100131
J	Santaguida, M; Ding, QM; Berube, G; Truscott, M; Whyte, P; Nepveu, A				Santaguida, M; Ding, QM; Berube, G; Truscott, M; Whyte, P; Nepveu, A			Phosphorylation of the CCAAT displacement protein (CDP)/Cux transcription factor by cyclin A-cdk1 modulates its DNA binding activity in G(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUT HOMEODOMAIN PROTEIN; FACTOR HINF-D; DEPENDENT-KINASE INHIBITOR; HISTONE GENE PROMOTER; CELL-CYCLE; CDK INHIBITORS; DROSOPHILA-MELANOGASTER; DOCKING SITE; S-PHASE; A CDK2	Stable DNA binding by the mammalian CCAAT displacement protein (CDP)/Cux transcription factor was previously found to be up-regulated at the G(1)/S transition as the result of two events, dephosphorylation by the Cdc25A phosphatase and proteolytic processing, to generate an amino-truncated isoform of 110 kDa. In S phase, CDP/Cux was shown to interact with and repress the core promoter of the p21(WAF1) gene. Here we demonstrate that DNA binding by p110 CDP/Cux is down-modulated as cells progress into G(2). Accordingly, cyclin A-Cdk1 was found to bind to CDP/Cux and modulate its DNA binding activity in vitro and in vivo. Interaction with CDP/Cux required the presence of both cyclin A and a cyclin-dependent kinase (Cdk)-activating kinase-activated Cdk1 and involved the Cut homeodomain and a downstream Cy motif. Phosphorylation of serines 1237 and 1270 caused inhibition of DNA binding in vitro. In cotransfection studies, cyclin A-Cdk1 inhibited CDP/ Cux stable DNA binding and prevented repression of the p21(WAF1) reporter. In contrast, mutant CDP/Cux proteins in which serines 1237 and 1270 were replaced with alanines were not affected by cyclin A-Cdk1. In summary, our results suggest that the phosphorylation of CDP/ Cux by cyclin A-Cdk1 contributes to down-modulate CDP/Cux activity as cells progress into the G2 phase of the cell cycle.	McGill Univ, Hlth Ctr, Mol Oncol Grp, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McGill Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McGill Univ, Dept Oncol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McGill University; McGill University; McMaster University; McGill University; McMaster University; McMaster University	Nepveu, A (corresponding author), 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		/AAB-8315-2020	Truscott, Mary/0000-0002-2324-6383				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLTHUIS J, 1990, SCIENCE, V247, P1454, DOI 10.1126/science.2321007; JACK JW, 1985, CELL, V42, P869, DOI 10.1016/0092-8674(85)90283-1; KATO J, 1993, GENE DEV, V7, P331; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LIU S, 1991, GENETICS, V127, P151; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Moon NS, 2001, MOL CELL BIOL, V21, P6332, DOI 10.1128/MCB.21.18.6332-6345.2001; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; Stunkel W, 2000, J VIROL, V74, P2489, DOI 10.1128/JVI.74.6.2489-2501.2000; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANDENENT FMI, 1994, J CELL PHYSIOL, V159, P515, DOI 10.1002/jcp.1041590316; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANWIJNEN AJ, 1989, J BIOL CHEM, V264, P15034; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Wang ZY, 1999, MOL CELL BIOL, V19, P284; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	70	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45780	45790		10.1074/jbc.M107978200	http://dx.doi.org/10.1074/jbc.M107978200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11584018	hybrid			2022-12-27	WOS:000172573100039
J	Warnmark, A; Wikstrom, A; Wright, APH; Gustafsson, JA; Hard, T				Warnmark, A; Wikstrom, A; Wright, APH; Gustafsson, JA; Hard, T			The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION DOMAIN; HUMAN GLUCOCORTICOID RECEPTOR; KAPPA-B P65; TRANSACTIVATION DOMAIN; TATA-BOX; FUNCTIONAL-ANALYSIS; PROMOTER-CONTEXT; FUNCTION AF-1; PROTEIN; DNA	The N-terminal regions of the estrogen receptor ve (ER alpha -N) and beta (ER beta -N) were expressed and purified to homogeneity. Using NAM and circular dichroism spectroscopy, we conclude that both ER alpha -N and ER beta -N are unstructured in solution. The TATA box-binding protein (TBP) has been shown previously to interact with ERa-N in vitro and to potentiate ER-activated transcription. We used surface plasmon resonance and circular dichroism spectroscopy to confirm and further characterize the ER-N-TBP interaction. Our results show that the intrinsically unstructured ERa-N interacts with TBP, and suggest that structural changes are induced in ERa-N upon TBP interaction. Conformational changes upon target factor interaction have not previously been demonstrated for any N-terminal region of nuclear receptors. In addition, no binding of ER beta -N to TBP was detected. This difference in TBP binding could imply differential recruitment of target proteins by ERa-N and ER beta -N. The affinity of the ER alpha -N-TBP interaction was determined to be in the micromolar range (K-D = 10(-6) to 10(-5) m). Our results support models of TBP as a target protein for the N-terminal activation domain of ER alpha. Further, our results suggest that target proteins can induce and/or stabilize ordered structure in N-terminal regions of nuclear receptors upon interaction.	Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Royal Inst Technol, Dept Biotechnol, SE-10691 Stockholm, Sweden; Sodertorns Hogskola, Dept Nat Sci, SE-14104 Huddinge, Sweden	Karolinska Institutet; Royal Institute of Technology; Sodertorn University	Warnmark, A (corresponding author), Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden.		; Wright, Anthony/J-8187-2015	Hard, Torleif/0000-0001-9813-9913; Wright, Anthony/0000-0003-1029-9969				Alen P, 1999, MOL CELL BIOL, V19, P6085; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bhat RA, 1998, J STEROID BIOCHEM, V67, P233, DOI 10.1016/S0960-0760(98)00115-0; BIRNBAUMER M, 1983, J BIOL CHEM, V258, P7331; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Delaunay F, 2000, MOL PHARMACOL, V58, P584, DOI 10.1124/mol.58.3.584; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hermann S, 2001, J BIOL CHEM, V276, P40127, DOI 10.1074/jbc.M103793200; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Metivier R, 2000, MOL ENDOCRINOL, V14, P1849, DOI 10.1210/me.14.11.1849; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4827; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	50	101	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 7	2001	276	49					45939	45944		10.1074/jbc.M107875200	http://dx.doi.org/10.1074/jbc.M107875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	499LR	11595744	hybrid			2022-12-27	WOS:000172573100062
J	Angata, T; Hingorani, R; Varki, NM; Varki, A				Angata, T; Hingorani, R; Varki, NM; Varki, A			Cloning and characterization of a novel mouse Siglec, mSiglec-F - Differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; ACID-BINDING-SITE; MYELIN-ASSOCIATED GLYCOPROTEIN; MOLECULAR-CLONING; NEGATIVE REGULATOR; SIALIC ACIDS; IDENTIFICATION; SIALOADHESIN; RECEPTOR; CELLS	A novel mouse Siglec (mSiglec-F) belonging to the subfamily of Siglec-3-related Siglecs has been cloned and characterized. Unlike most human Siglec-3 (hSiglec-3)-related Siglecs with promiscuous linkage specificity, mSiglec-F shows a strong preference for alpha2-3-linked sialic acids. It is predominantly expressed in immature cells of the myelomonocytic lineage and in a subset of CD11b (Mac-1)-positive cells in some tissues. As with previously cloned Siglec-3-related mSiglecs, the lack of strong sequence similarity to a singular hSiglec made identification of the human ortholog difficult. We therefore conducted a comprehensive comparison of Siglecs between the human and mouse genomes. The mouse genome contains eight Siglec genes, whereas the human genome contains 11 Siglec genes and a Siglec-like gene. Although a one-to-one orthologous correspondence between human and mouse Siglecs 1, 2, and 4 is confirmed, the Siglec-3-related Siglecs showed marked differences between human and mouse. We found only four Siglec genes and two pseudogenes in the mouse chromosome 7 region syntenic to the Siglec-3-related gene cluster on human chromosome 19, which, in contrast, contains seven Siglec genes, a Siglec-like gene, and thirteen pseudogenes. Although analysis of gene maps and exon structures allows tentative assignments of mouse-human Siglec ortholog pairs, the possibility of unequal genetic recombination makes the assignments inconclusive. We therefore support a temporary lettered nomenclature for additional mouse Siglecs. Current information suggests that mSiglec-F is likely a hSiglec-5 ortholog. The previously reported mSiglec-3/CD33 and mSiglec-E/MIS are likely orthologs of hSiglec-3 and hSiglec-9, respectively. The other Siglec-3-like gene in the cluster (mSiglec-G) is probably a hSiglec-10 ortholog. Another mouse gene (mSiglec-H), without an apparent human ortholog, lies outside of the cluster. Thus, although some duplications of Siglec-3-related genes predated separation of the primate and rodent lineages (about 80-100 million years ago), this gene cluster underwent extensive duplications in the primate lineage thereafter.	Univ Calif San Diego, Sch Med 0687, Dept Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; BD Biosci Pharmingen, Res Immunocytometry, San Diego, CA 92121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Sch Med 0687, Dept Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NHLBI NIH HHS [P01-HL57345] Funding Source: Medline; NIGMS NIH HHS [R37-GM32373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Biermann H, 1999, J LEUKOCYTE BIOL, V65, P217, DOI 10.1002/jlb.65.2.217; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Eichler EE, 1996, HUM MOL GENET, V5, P899, DOI 10.1093/hmg/5.7.899; FUJITA N, 1989, BIOCHEM BIOPH RES CO, V165, P1162, DOI 10.1016/0006-291X(89)92724-1; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Kim J, 2001, GENOMICS, V74, P129, DOI 10.1006/geno.2001.6521; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W. H, 1997, MOL EVOLUTION; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Martini R, 1997, GLIA, V19, P298; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Page R.D.M., 1998, MOL EVOLUTION PHYLOG; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PEIPER SC, 1988, BLOOD, V72, P314; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; TCHILIAN EZ, 1994, BLOOD, V83, P3188; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Ulyanova T, 2001, J BIOL CHEM, V276, P14451, DOI 10.1074/jbc.M011650200; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200	42	79	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					45128	45136		10.1074/jbc.M108573200	http://dx.doi.org/10.1074/jbc.M108573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11579105	hybrid			2022-12-27	WOS:000172406700104
J	Robert, SJ; Zugaza, JL; Fischmeister, R; Gardier, AM; Lezoualc'h, F				Robert, SJ; Zugaza, JL; Fischmeister, R; Gardier, AM; Lezoualc'h, F			The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; KINASE-C; ALZHEIMERS-DISEASE; APP CLEAVAGE; ACTIVATION; RELEASE; EXPRESSION; ALPHA; CELLS; IDENTIFICATION	The serotonin 5-HT4 receptor has recently gained a lot of attention for its functional roles in central processes such as memory and cognition. In this study, we show that activation of the human 5-HT4 (h5-HT4) receptor stimulates the secretion of the non-amyloidogenic soluble form of the amyloid precursor protein (sAPP alpha). 5-HT enhanced the level of secreted sAPP alpha in a time- and dose-dependent manner in Chinese hamster ovary cells stably expressing the h5-HT4(e) receptor isoform. The increase was inhibited by the selective 5-HT4 receptor antagonist, GR113808. The 5-HT4 selective agonists, prucalopride and renzapride, also increased secreted sAPP alpha in IMR32 human neuroblastoma cells. The stimulatory effect of 5-HT was mimicked by forskolin, a direct activator of adenylyl cyclase, and 8-bromo-cAMP, a membrane-permeant cAMP analogue. On the contrary, inhibition of protein kinase A (PKA) by H89 potentiated the 5-HT-induced increase in both secreted and cellular sAPP alpha. This phenomenon involves a novel PKA-independent stimulatory process that overcomes a PKA-dependent inhibitory one. Finally, activation of the h5-HT4(e) receptor did not modify extracellular amyloid beta -protein in Chinese hamster ovary cells transfected with the human APP695. Given the neuroprotective and enhancing memory effects of sAPP alpha, our results may open a new avenue for the treatment of Alzheimer's disease.	Univ Paris Sud, Fac Pharm, INSERM,U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France; Univ Paris Sud, Fac Pharm, INSERM,U461, Lab Neuropharmacol,UPRES EAD 2707, F-92296 Chatenay Malabry, France; Univ Paris Sud, Fac Pharm, Inst Sinalisat & Innovat Therapeut IFR 75ISIT, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Lezoualc'h, F (corresponding author), Univ Paris Sud, Fac Pharm, INSERM,U446, Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France.	Frank.Lezoualch@cep.u-psud.fr	Bustelo, Xose R./A-9526-2010; Lezoualc'h, Frank/E-5031-2016; Fischmeister, Rodolphe/L-6061-2018	Bustelo, Xose R./0000-0001-9398-6072; Fischmeister, Rodolphe/0000-0003-2086-9865; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bender E, 2000, J NEUROCHEM, V74, P478, DOI 10.1046/j.1471-4159.2000.740478.x; Blondel O, 1998, J NEUROCHEM, V70, P2252; Bonaventure P, 2000, SYNAPSE, V36, P35, DOI 10.1002/(SICI)1098-2396(200004)36:1<35::AID-SYN4>3.0.CO;2-Y; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Claeysen S, 1999, MOL PHARMACOL, V55, P910; CONSOLO S, 1994, NEUROREPORT, V5, P1230, DOI 10.1097/00001756-199406020-00018; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; De Strooper B, 2000, NATURE, V405, P627, DOI 10.1038/35015193; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Efthimiopoulos S, 1996, J NEUROCHEM, V67, P872; EGLEN RM, 1995, TRENDS PHARMACOL SCI, V16, P391, DOI 10.1016/S0165-6147(00)89081-1; FAGNI L, 1992, BRIT J PHARMACOL, V105, P973, DOI 10.1111/j.1476-5381.1992.tb09087.x; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; Gandy S, 1999, TRENDS ENDOCRIN MET, V10, P273, DOI 10.1016/S1043-2760(99)00166-6; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jolly-Tornetta C, 1998, J BIOL CHEM, V273, P14015, DOI 10.1074/jbc.273.22.14015; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; Lee RKK, 1997, J NEUROCHEM, V68, P1830; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Lezoualc'h F, 2000, MOL ENDOCRINOL, V14, P147, DOI 10.1210/me.14.1.147; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Marambaud P, 1998, MOL MED, V4, P715, DOI 10.1007/BF03401766; Marambaud P, 1996, J NEUROCHEM, V67, P2616; Marchetti E, 2000, NEUROPHARMACOLOGY, V39, P2017, DOI 10.1016/S0028-3908(00)00038-1; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mialet J, 2000, BRIT J PHARMACOL, V129, P771, DOI 10.1038/sj.bjp.0703101; Mialet J, 2000, BRIT J PHARMACOL, V131, P827, DOI 10.1038/sj.bjp.0703641; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Racchi M, 1999, TRENDS PHARMACOL SCI, V20, P418, DOI 10.1016/S0165-6147(99)01380-2; REYNOLDS GP, 1995, BRIT J PHARMACOL, V114, P993, DOI 10.1111/j.1476-5381.1995.tb13303.x; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Xie EZ, 1996, GENOMICS, V35, P551, DOI 10.1006/geno.1996.0397; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	58	105	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44881	44888		10.1074/jbc.M109008200	http://dx.doi.org/10.1074/jbc.M109008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11584021	hybrid, Green Submitted			2022-12-27	WOS:000172406700074
J	Wang, XQ; Sun, P; Paller, AS				Wang, XQ; Sun, P; Paller, AS			Inhibition of integrin-linked kinase/protein kinase B/Akt signaling - Mechanism for ganglioside-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-CYCLE PROGRESSION; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; GD3 GANGLIOSIDE; TYROSINE PHOSPHORYLATION; KERATINOCYTE ADHESION; MEDIATED MODULATION; SURVIVAL SIGNALS; EXPRESSION	Ganglioside GT1b inhibits keratinocyte attachment to and migration on a fibronectin matrix by binding to alpha (5)beta (1) and preventing alpha (5)beta (1) interaction with fibronectin. The role of gangliosides in triggering keratinocyte apoptosis, however, is unknown. Addition of GT1b to keratinocyte-derived SCC12 cells, grown in serum-free medium but exposed to fibronectin, suppressed Bad phosphorylation, activated caspase-9, and inhibited cyclin D and E expression, resulting in cell cycle arrest at G(1) phase and initiation of apoptosis. The mechanism of GT1b activation of caspase-9 involved inhibition of beta (1) integrin serine/threonine phosphorylation and decreased phosphorylation of both integrin-linked kinase and protein kinase B/Akt at its Ser-473 site, leading to cytochrome c release from mitochondria. Consistently, blockade of GT1b function with anti-GT1b antibody specifically activated the Ser-473 site of Akt, markedly suppressing apoptosis. The ganglioside-induced inhibition of Akt phosphorylation was GT1b-specific and was not observed when cells were treated with other keratinocyte gangliosides, including GD3. These studies suggest that the modulation of keratinocyte cell cycle and survival by GT1b is mediated by its direct interaction with alpha (5)beta (1) and resultant inhibition of the integrin/integrin-linked kinase/protein kinase B/Akt signaling pathway.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol 107, 2300 Childrens Plaza, Chicago, IL 60614 USA.			Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [R01 AR44619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044619] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BREMER EG, 1994, CURR TOP MEMBR, V40, P387, DOI 10.1016/S0070-2161(08)60989-2; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cavallini L, 1999, ARCH BIOCHEM BIOPHYS, V370, P156, DOI 10.1006/abbi.1999.1378; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Colell Anna, 2001, FASEB Journal, V15, P1068; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANAI N, 1988, J BIOL CHEM, V263, P10915; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Ilic D, 1998, J CELL BIOL, V143, P547; Iwabuchi K, 2000, J BIOL CHEM, V275, P15174, DOI 10.1074/jbc.275.20.15174; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Li FG, 1999, J CELL SCI, V112, P4589; MERZAK A, 1995, MOL CHEM NEUROPATHOL, V24, P121, DOI 10.1007/BF02962138; Nakatsuji Y, 2001, EXP NEUROL, V168, P290, DOI 10.1006/exnr.2000.7602; Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603; Okazaki T, 1998, CELL SIGNAL, V10, P685, DOI 10.1016/S0898-6568(98)00035-7; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PALLER AS, 1992, J INVEST DERMATOL, V98, P226, DOI 10.1111/1523-1747.ep12555896; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Ryu BR, 1999, J PHARMACOL EXP THER, V290, P811; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SPADARI S, 1995, MOL PHARMACOL, V47, P1231; Sung CC, 1998, EXP CELL RES, V239, P311, DOI 10.1006/excr.1997.3897; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Usuki S, 1999, NEUROCHEM RES, V24, P281, DOI 10.1023/A:1022522306946; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yoshida S, 2001, CANCER RES, V61, P4244; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	52	59	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 30	2001	276	48					44504	44511		10.1074/jbc.M106563200	http://dx.doi.org/10.1074/jbc.M106563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	496QD	11577096	hybrid			2022-12-27	WOS:000172406700023
J	Williams, EJ; Williams, G; Howell, FV; Skaper, SD; Walsh, FS; Doherty, P				Williams, EJ; Williams, G; Howell, FV; Skaper, SD; Walsh, FS; Doherty, P			Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CRYSTAL-STRUCTURE; AMINO-ACIDS; HAV MOTIF; IN-VIVO; FGF; OUTGROWTH; EXPRESSION; ACTIVATION; COMPLEX	In this study, we show that the neurite outgrowth response stimulated by N-cadherin is inhibited by a recently developed and highly specific fibroblast growth factor receptor (FGFR) antagonist. To test whether the N-cadherin response also requires FGF function, we developed peptide mimetics of the receptor binding sites on FGFs. Most mimetics inhibit the neurite outgrowth response stimulated by FGF in the absence of any effect on the N-cadherin response. The exceptions to this result were two mimetics of a short FGF1 sequence, which has been shown to interact with the region of the FGFR containing the histidine-alanine-valine motif. These peptides inhibited FGF and N-cadherin responses with similar efficacy. The histidine-alanine-valine region of the FGFR has previously been implicated in the N-cadherin response, and a candidate interaction site has been identified in extracellular domain 4 of N-cadherin. We now show that antibodies directed to this site on N-cadherin inhibit the neurite outgrowth response stimulated by N-cadherin, and peptide mimetics of the site inhibit N-cadherin and FGF responses. Thus, we can conclude that N-cadherin contains a novel motility motif in extracellular domain 4, and that peptide mimetics of this motif can interact with the FGFR.	Kings Coll London, MRC, Ctr Dev Neurobiol, Mol Neurobiol Grp, London SE1 1UL, England; GlaxoSmithKline Inc, Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of London; King's College London; GlaxoSmithKline	Doherty, P (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, Mol Neurobiol Grp, London SE1 1UL, England.	patrick.doherty@kcl.ac.uk	Doherty, Patrick/A-8752-2008; Williams, Gareth/B-3202-2010	Williams, Gareth/0000-0001-9205-4943; Doherty, Patrick/0000-0002-0407-5689				Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; BALSAMO J, 1990, J BIOL CHEM, V265, P2923; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Hamby JM, 1997, J MED CHEM, V40, P2296, DOI 10.1021/jm970367n; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; Lom B, 1998, J NEUROBIOL, V37, P633, DOI 10.1002/(SICI)1097-4695(199812)37:4<633::AID-NEU11>3.0.CO;2-L; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Peluso JJ, 2000, BIOL SIGNAL RECEPT, V9, P115; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Riehl R, 1996, NEURON, V17, P837, DOI 10.1016/S0896-6273(00)80216-0; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shan WS, 1999, BIOPHYS CHEM, V82, P157, DOI 10.1016/S0301-4622(99)00115-5; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Skaper SD, 2000, J NEUROCHEM, V75, P1520, DOI 10.1046/j.1471-4159.2000.0751520.x; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1231; Williams EJ, 2000, MOL CELL NEUROSCI, V15, P456, DOI 10.1006/mcne.2000.0847	42	116	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 23	2001	276	47					43879	43886		10.1074/jbc.M105876200	http://dx.doi.org/10.1074/jbc.M105876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	494QQ	11571292	hybrid			2022-12-27	WOS:000172297700053
